<SEC-DOCUMENT>0001564590-21-008081.txt : 20210224
<SEC-HEADER>0001564590-21-008081.hdr.sgml : 20210224
<ACCEPTANCE-DATETIME>20210224160724
ACCESSION NUMBER:		0001564590-21-008081
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		110
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210224
DATE AS OF CHANGE:		20210224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CytomX Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001501989
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273521219
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37587
		FILM NUMBER:		21673103

	BUSINESS ADDRESS:	
		STREET 1:		151 OYSTER POINT BLVD.
		STREET 2:		SUITE 400
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650.515.3185

	MAIL ADDRESS:	
		STREET 1:		151 OYSTER POINT BLVD.
		STREET 2:		SUITE 400
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ctmx-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-24T20:40:34.0269736+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 19fb4f4ba39c4e5496fc22bf5dabd4ad -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ctmx="http://cytomx.com/20201231" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
ctmx-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:AmendmentFlag" contextRef="C_0001501989_20200101_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001501989_20200101_20201231">FY</ix:nonNumeric>
			<ix:nonNumeric id="F_000007" name="dei:EntityCentralIndexKey" contextRef="C_0001501989_20200101_20201231">0001501989</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001501989_20200101_20201231">--12-31</ix:nonNumeric>
			<ix:nonNumeric id="F_000395" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000397" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201704Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000398" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201704Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000400" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000401" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000403" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000404" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000406" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000407" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000409" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201908Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000410" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201908Member_20201231">true</ix:nonNumeric>
			<ix:nonNumeric id="F_000412" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000413" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000529" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180401_20180630">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000536" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTimingOfTransferOfGoodOrServiceAxis_us-gaapTransferredOverTimeMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000540" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20200101_20201231">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000541" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20190101_20191231">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000542" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180101_20181231">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000580" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200101_20201231">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000581" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20190101_20191231">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000582" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20180101_20181231">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000641" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000642" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000643" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000658" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000789" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001501989_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231" decimals="INF">0.0208</ix:nonFraction>
			<ix:nonNumeric id="F_000833" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxEarlyExerciseOfEmployeeOptionsMember_20200101_20201231">P36M</ix:nonNumeric>
			<ix:nonNumeric id="F_001012" name="us-gaap:OpenTaxYear" contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2010 2011 2012 2013 2014 2015 2016 2017 2018</ix:nonNumeric>
			<ix:nonNumeric id="F_001013" name="us-gaap:OpenTaxYear" contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2010 2011 2012 2013 2014 2015 2016 2017 2018</ix:nonNumeric>
			<ix:nonNumeric id="F_000554" name="ctmx:LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171001_20171031">P6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000610" name="ctmx:CollaborationTargetResearchTerm" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707">P2Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000789_2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001501989_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231" decimals="INF">0.0208</ix:nonFraction>
			<ix:nonNumeric id="F_000893" name="ctmx:NetOperatingLossCarrybackPeriod" contextRef="C_0001501989_20200327_20200327">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000108" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_20190101_20191231">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000109" name="us-gaap:TypeOfRevenueExtensibleList" contextRef="C_0001501989_20180101_20181231">us-gaap:LicenseAndServiceMember</ix:nonNumeric>
			<ix:nonNumeric id="F_000158" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_0001501989_20180101_20181231">us-gaap:AccountingStandardsUpdate201409Member</ix:nonNumeric>
			<ix:nonNumeric id="F_000182" name="us-gaap:AccountingStandardsUpdateExtensibleList" contextRef="C_0001501989_20190101_20191231">us-gaap:AccountingStandardsUpdate201802Member</ix:nonNumeric>
			<ix:nonNumeric id="F_000744" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001501989_20201231">P5Y9M</ix:nonNumeric>
			<ix:nonNumeric id="F_000745" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001501989_20191231">P6Y10M6D</ix:nonNumeric>
			<ix:nonNumeric id="F_000741" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_0001501989_20191231">us-gaap:OtherLiabilitiesCurrent</ix:nonNumeric>
			<ix:nonNumeric id="F_000818" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001501989_20200101_20201231">P6Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000819" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001501989_20200101_20201231">P4Y8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_000820" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_0001501989_20200101_20201231">P6Y4M24D</ix:nonNumeric>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000860" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="3">0.644</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000875" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="3">0.733</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000861" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="3">0.644</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000876" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="3">0.686</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000862" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="3">0.656</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000877" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="3">0.693</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000863" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231" decimals="3">0.473</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000878" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231" decimals="3">1.221</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000864" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231" decimals="3">0.608</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000879" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231" decimals="3">0.719</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000865" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231" decimals="3">0.464</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000880" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231" decimals="3">0.705</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000866" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF">0.002</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000881" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF">0.013</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000867" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF">0.014</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000882" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="INF">0.025</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000868" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="INF">0.025</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000883" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="INF">0.030</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000869" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF">0.001</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000884" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF">0.002</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000870" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231" decimals="INF">0.016</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000885" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231" decimals="INF">0.024</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000871" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231" decimals="INF">0.021</ix:nonFraction>
			<ix:nonFraction unitRef="U_xbrlipure" id="F_000886" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231" decimals="INF">0.026</ix:nonFraction>
			<ix:nonNumeric id="F_000887" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P4Y8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_000888" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P4Y10M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000889" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">P4Y8M12D</ix:nonNumeric>
			<ix:nonNumeric id="F_000890" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">P4Y10M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000891" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000892" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">P4Y10M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000872" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231">P6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000873" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231">P6M</ix:nonNumeric>
			<ix:nonNumeric id="F_000874" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231">P6M</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000073" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001501989_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000074" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001501989_20191231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000075" name="us-gaap:PreferredStockValue" contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000076" name="us-gaap:PreferredStockValue" contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" xsi:nil="true"></ix:nonFraction>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="ctmx-20201231.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001501989_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001501989_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001501989_20210202">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-02</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001501989_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ctmxActivity">
				<xbrli:measure>ctmx:Activity</xbrli:measure>
			</xbrli:unit>
			<xbrli:unit id="U_ctmxSegment">
				<xbrli:measure>ctmx:Segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_ctmxComputerEquipmentAndSoftwareMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ctmx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20180101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_ctmxProbodyTechnologyMember_20190101_20190131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctmx:ProbodyTechnologyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_ctmxProbodyTechnologyMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctmx:ProbodyTechnologyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-01-01</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201704Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201704Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201813Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201815Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201908Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201908Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ctmx:OptionsAndESPPToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ctmx:OptionsAndESPPToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ctmx:OptionsAndESPPToPurchaseCommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFairValueByAssetClassAxis_ctmxMoneyMarketFundsIncludedInRestrictedCashMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ctmx:MoneyMarketFundsIncludedInRestrictedCashMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFairValueByAssetClassAxis_ctmxMoneyMarketFundsIncludedInRestrictedCashMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ctmx:MoneyMarketFundsIncludedInRestrictedCashMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:PfizerIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ctmxAgreement">
				<xbrli:measure>ctmx:Agreement</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20160401_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-01</xbrli:startDate>
					<xbrli:endDate>2016-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-01</xbrli:startDate>
					<xbrli:endDate>2016-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-01</xbrli:startDate>
					<xbrli:endDate>2016-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20170701_20170731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-07-01</xbrli:startDate>
					<xbrli:endDate>2017-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20180501_20180531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-05-01</xbrli:startDate>
					<xbrli:endDate>2018-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20170701_20170731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SeattleGeneticsAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-07-01</xbrli:startDate>
					<xbrli:endDate>2017-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20180501_20180531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SeattleGeneticsAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-05-01</xbrli:startDate>
					<xbrli:endDate>2018-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ctmxTarget">
				<xbrli:measure>ctmx:Target</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20170331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160401_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-01</xbrli:startDate>
					<xbrli:endDate>2016-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:SecondTargetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-01</xbrli:startDate>
					<xbrli:endDate>2019-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_ctmxDevelopmentRegulatoryAndCommercialMilestonePaymentsMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ctmx:DevelopmentRegulatoryAndCommercialMilestonePaymentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160401_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-01</xbrli:startDate>
					<xbrli:endDate>2016-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20160401_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SeattleGeneticsAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-01</xbrli:startDate>
					<xbrli:endDate>2016-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ctmxAccountingUnit">
				<xbrli:measure>ctmx:AccountingUnit</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-01</xbrli:startDate>
					<xbrli:endDate>2016-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160401_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-04-01</xbrli:startDate>
					<xbrli:endDate>2016-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2016-04-01_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
							<us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2016-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
						</xbrldi:typedMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20180531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180401_20180630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-04-01</xbrli:startDate>
					<xbrli:endDate>2018-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:SecondTargetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:SecondTargetMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-01</xbrli:startDate>
					<xbrli:endDate>2019-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTimingOfTransferOfGoodOrServiceAxis_us-gaapTransferredOverTimeMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171001_20171031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2017-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-10-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-09-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-09-29</xbrli:startDate>
					<xbrli:endDate>2017-09-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenProductsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-09-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-09-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-09-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxRegentsOfTheUniversityOfCaliforniaMember_us-gaapTypeOfArrangementAxis_ctmxSublicenseAgreementMember_20170929_20170929">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SublicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-09-29</xbrli:startDate>
					<xbrli:endDate>2017-09-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxRegentsOfTheUniversityOfCaliforniaMember_us-gaapTypeOfArrangementAxis_ctmxSublicenseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SublicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxRegentsOfTheUniversityOfCaliforniaMember_us-gaapTypeOfArrangementAxis_ctmxSublicenseAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SublicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-09-29</xbrli:startDate>
					<xbrli:endDate>2017-09-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-09-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenOtherProductsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-09-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200401_20200630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-04-01</xbrli:startDate>
					<xbrli:endDate>2020-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20190401_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-04-01</xbrli:startDate>
					<xbrli:endDate>2019-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenOtherProductsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-09-29</xbrli:startDate>
					<xbrli:endDate>2017-09-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenOtherProductsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenOtherProductsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-23</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-23</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-23</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-23</xbrli:startDate>
					<xbrli:endDate>2020-03-23</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapContingentConsiderationByTypeAxis_ctmxAdditionalContingentPaymentsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ctmx:AdditionalContingentPaymentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-23</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-07-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2014-07-06</xbrli:startDate>
					<xbrli:endDate>2014-07-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-07-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2014-07-06</xbrli:startDate>
					<xbrli:endDate>2014-07-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ctmxTerm">
				<xbrli:measure>ctmx:Term</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_ctmxAchievingAdditionalTargetsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ctmx:AchievingAdditionalTargetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-07-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20160131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxPreClinicalCandidateMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20161231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:PreClinicalCandidateMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxDrugApplicationForCTLA4Member_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20171130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:DrugApplicationForCTLA4Member</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170317">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-03-17</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170425_20170425">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-04-25</xbrli:startDate>
					<xbrli:endDate>2017-04-25</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170425">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-04-25</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170425">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2017-04-25</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxThirdAndFourthTargetsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:ThirdAndFourthTargetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxAcceleratedRecognitionOfDeferredRevenueMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AcceleratedRecognitionOfDeferredRevenueMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxThirdAndFourthTargetsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:ThirdAndFourthTargetsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-02-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-28</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140101_20140131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2014-01-01</xbrli:startDate>
					<xbrli:endDate>2014-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-02-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130501_20130531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:PfizerIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2013-05-01</xbrli:startDate>
					<xbrli:endDate>2013-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141201_20141231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:PfizerIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2014-12-01</xbrli:startDate>
					<xbrli:endDate>2014-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:PfizerIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxFirstTargetUnderDiscoveryAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:FirstTargetUnderDiscoveryAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSecondTargetUnderDiscoveryAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SecondTargetUnderDiscoveryAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenOtherProductsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxFirstTargetUnderDiscoveryAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:FirstTargetUnderDiscoveryAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSecondTargetUnderDiscoveryAgreementMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SecondTargetUnderDiscoveryAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenOtherProductsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20131231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2013-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-04-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-04-01</xbrli:startDate>
					<xbrli:endDate>2019-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeStatementLocationAxis_ctmxSublicenseAndMaintenanceFeesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ctmx:SublicenseAndMaintenanceFeesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-04-01</xbrli:startDate>
					<xbrli:endDate>2019-04-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-04-01</xbrli:startDate>
					<xbrli:endDate>2019-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:SecondTargetMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-01</xbrli:startDate>
					<xbrli:endDate>2019-06-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200201_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-01</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200301_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304_20200304">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ctmx:PatentInfringementLawsuitMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-04</xbrli:startDate>
					<xbrli:endDate>2020-03-04</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ctmx:PatentInfringementLawsuitMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ctmx:PatentInfringementLawsuitMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-04</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_ctmxDefendant">
				<xbrli:measure>ctmx:Defendant</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001501989_srtLitigationCaseAxis_ctmxSecuritiesClassActionLawsuitMember_20200521_20200521">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ctmx:SecuritiesClassActionLawsuitMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-21</xbrli:startDate>
					<xbrli:endDate>2020-05-21</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151210">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-12-10</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_us-gaapLeaseContractualTermAxis_ctmxFirstYearOfLeaseTermMember_20151209_20151210">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ctmx:FirstYearOfLeaseTermMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-12-09</xbrli:startDate>
					<xbrli:endDate>2015-12-10</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_us-gaapLeaseContractualTermAxis_ctmxSecondTwelveMonthsOfLeaseTermMember_20151209_20151210">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ctmx:SecondTwelveMonthsOfLeaseTermMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-12-09</xbrli:startDate>
					<xbrli:endDate>2015-12-10</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_us-gaapLeaseContractualTermAxis_ctmxTenthYearOfLeaseTermMember_20151209_20151210">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ctmx:TenthYearOfLeaseTermMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-12-09</xbrli:startDate>
					<xbrli:endDate>2015-12-10</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151209_20151210">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-12-09</xbrli:startDate>
					<xbrli:endDate>2015-12-10</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_20151014">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-10-14</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20180730_20180731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ctmx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-07-30</xbrli:startDate>
					<xbrli:endDate>2018-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20180731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ctmx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2018-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20180730_20180731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-07-30</xbrli:startDate>
					<xbrli:endDate>2018-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180730_20180731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-07-30</xbrli:startDate>
					<xbrli:endDate>2018-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:JefferiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-02-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_srtRangeAxis_srtMaximumMember_20200201_20200229">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:JefferiesMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-02-01</xbrli:startDate>
					<xbrli:endDate>2020-02-29</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:JefferiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:JefferiesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20160101_20160101">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-01-01</xbrli:startDate>
					<xbrli:endDate>2016-01-01</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20190930">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-09-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPlanNameAxis_ctmxEarlyExerciseOfEmployeeOptionsMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:EarlyExerciseOfEmployeeOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapPlanNameAxis_ctmxEarlyExerciseOfEmployeeOptionsMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:EarlyExerciseOfEmployeeOptionsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAwardTypeAxis_ctmxNonEmployeesMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:NonEmployeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAwardTypeAxis_ctmxNonEmployeesMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:NonEmployeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapAwardTypeAxis_ctmxNonEmployeesMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:NonEmployeesMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-01-01</xbrli:startDate>
					<xbrli:endDate>2019-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2018-01-01</xbrli:startDate>
					<xbrli:endDate>2018-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_20200327_20200327">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-03-27</xbrli:startDate>
					<xbrli:endDate>2020-03-27</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtRangeAxis_srtMinimumMember_20170101_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-01-01</xbrli:startDate>
					<xbrli:endDate>2017-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210101_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ctmx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ctmx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-01-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210101_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ctmx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20210201_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-01</xbrli:startDate>
					<xbrli:endDate>2021-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210201_20210228">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ctmx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-02-01</xbrli:startDate>
					<xbrli:endDate>2021-02-28</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20210101_20210131">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001501989</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-01-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="text-align:center;border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549</p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM <ix:nonNumeric id="F_000000" name="dei:DocumentType" contextRef="C_0001501989_20200101_20201231">10-K</ix:nonNumeric></p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Mark One)</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;width:4.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000030" name="dei:DocumentAnnualReport" contextRef="C_0001501989_20200101_20201231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;width:95.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended <ix:nonNumeric id="F_000002" name="dei:DocumentPeriodEndDate" contextRef="C_0001501989_20200101_20201231" format="ixt:datemonthdayyearen">December 31, <ix:nonNumeric id="F_000003" name="dei:DocumentFiscalYearFocus" contextRef="C_0001501989_20200101_20201231">2020</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OR</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;width:4.78%;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000031" name="dei:DocumentTransitionReport" contextRef="C_0001501989_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;width:95.22%;">
<p style="margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number <ix:nonNumeric id="F_000017" name="dei:EntityFileNumber" contextRef="C_0001501989_20200101_20201231">001-37587</ix:nonNumeric></p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000006" name="dei:EntityRegistrantName" contextRef="C_0001501989_20200101_20201231">CytomX Therapeutics, Inc.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact Name of Registrant as Specified in Its Charter)</p>
<p style="margin-bottom:4pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001501989_20200101_20201231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000018" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001501989_20200101_20201231">27-3521219</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom" style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000019" name="dei:EntityAddressAddressLine1" contextRef="C_0001501989_20200101_20201231">151 Oyster Point Boulevard,</ix:nonNumeric> <ix:nonNumeric id="F_000020" name="dei:EntityAddressAddressLine2" contextRef="C_0001501989_20200101_20201231">Suite 400</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000021" name="dei:EntityAddressCityOrTown" contextRef="C_0001501989_20200101_20201231">South San Francisco</ix:nonNumeric>, <ix:nonNumeric id="F_000022" name="dei:EntityAddressStateOrProvince" contextRef="C_0001501989_20200101_20201231" format="ixt-sec:stateprovnameen">California</ix:nonNumeric></p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000023" name="dei:EntityAddressPostalZipCode" contextRef="C_0001501989_20200101_20201231">94080</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom" style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonNumeric id="F_000024" name="dei:CityAreaCode" contextRef="C_0001501989_20200101_20201231">650</ix:nonNumeric>) <ix:nonNumeric id="F_000025" name="dei:LocalPhoneNumber" contextRef="C_0001501989_20200101_20201231">515-3185</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:30%;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:37.78%;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading Symbol(s)</p></td>
<td valign="top" style="width:2.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:27.78%;">
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:30%;"><ix:nonNumeric id="F_000027" name="dei:Security12bTitle" contextRef="C_0001501989_20200101_20201231"><p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, <span style="font-size:10pt;">$0.00001 </span>par value</p></ix:nonNumeric></td>
<td valign="bottom" style="width:2.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="width:37.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000005" name="dei:TradingSymbol" contextRef="C_0001501989_20200101_20201231">CTMX</ix:nonNumeric></p></td>
<td valign="top" style="width:2.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:27.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:SecurityExchangeName" contextRef="C_0001501989_20200101_20201231" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act:</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">None<span style="font-size:6pt;font-weight:normal;">&#160;</span></p>
<p style="text-align:center;border-bottom:Solid 1pt #000000;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:42.11%;margin-right:42.04%;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160; <span style="font-family:Segoe UI Symbol;">&#9744;</span> &#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000009" name="dei:EntityWellKnownSeasonedIssuer" contextRef="C_0001501989_20200101_20201231">No</ix:nonNumeric>&#160;&#160; <span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160; <span style="font-family:Segoe UI Symbol;">&#9744;</span> &#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000010" name="dei:EntityVoluntaryFilers" contextRef="C_0001501989_20200101_20201231">No</ix:nonNumeric>&#160;&#160; <span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the issuer (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000011" name="dei:EntityCurrentReportingStatus" contextRef="C_0001501989_20200101_20201231">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000026" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001501989_20200101_20201231">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr style="height:14.75pt;">
<td valign="bottom" style="width:21.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="bottom" style="width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:47.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom" style="width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:26.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000012" name="dei:EntityFilerCategory" contextRef="C_0001501989_20200101_20201231" format="ixt-sec:entityfilercategoryen">Accelerated&#160;filer</ix:nonNumeric></p></td>
<td valign="bottom" style="width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
</tr>
<tr style="height:12.95pt;">
<td valign="bottom" style="width:21.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="bottom" style="width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:47.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="bottom" style="width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom" style="width:26.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom" style="width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000013" name="dei:EntitySmallBusiness" contextRef="C_0001501989_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="top" style="width:21.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:47.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:26.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top" style="width:0.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:2.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000014" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001501989_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p></td>
</tr>
</table></div>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<span style="font-size:10pt;"> </span><span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000015" name="dei:IcfrAuditorAttestationFlag" contextRef="C_0001501989_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange&#160;Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000016" name="dei:EntityShellCompany" contextRef="C_0001501989_20200101_20201231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of June 30, 2020, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000032" name="dei:EntityPublicFloat" contextRef="C_0001501989_20200630" decimals="-5" scale="6">379.4</ix:nonFraction> million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Select Market on June 30, 2020 of $8.33 per share. Shares of the registrant&#8217;s common stock held by each officer and director and each person known to the registrant to own 10% or more of the outstanding common stock of the registrant have been excluded in that such persons may be deemed affiliates. This determination of affiliate status is not a determination for other purposes.</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 2, 2021, <ix:nonFraction unitRef="U_xbrlishares" id="F_000033" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001501989_20210202" decimals="INF" format="ixt:numdotdecimal">64,784,355</ix:nonFraction> shares of the registrant&#8217;s common stock, $0.00001 par value per share, were outstanding.</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&#160;</p>
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p><ix:nonNumeric id="F_000298" name="dei:DocumentsIncorporatedByReferenceTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant&#8217;s definitive proxy statement to be filed for its 2021 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</p></ix:nonNumeric>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CYTOMX THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT ON FORM 10-K</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Page</span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><span style="text-decoration:underline;">PART&#160;I</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><span style="text-decoration:underline;">Business</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1A.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;1B.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="text-decoration:underline;">Unresolved Staff Comments</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;2.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><span style="text-decoration:underline;">Properties</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;3.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;4.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><span style="text-decoration:underline;">PART&#160;II</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr style="height:10.7pt;">
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;5.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;6.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><span style="text-decoration:underline;">Selected Financial Data</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;7.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;7A.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;8.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="text-decoration:underline;">Financial Statements and Supplementary Data</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;9.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="text-decoration:underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM 9A.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM 9B.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><span style="text-decoration:underline;">Other Information</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><span style="text-decoration:underline;">PART&#160;III</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;10.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><span style="text-decoration:underline;">Directors, Executive Officers of the Registrant and Corporate Governance Matters</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;11.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><span style="text-decoration:underline;">Executive Compensation</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;12.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><span style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;13.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><span style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;14.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTANT_FEES_SERVIC"><span style="text-decoration:underline;">Principal Accounting Fees and Services</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><span style="text-decoration:underline;">PART&#160;IV</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:6pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;15.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS"><span style="text-decoration:underline;">Exhibits and Financial Statement Schedules</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ITEM&#160;16.</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><span style="text-decoration:underline;">Form 10-K Summary</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:10%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:82%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">Signatures</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Forward-Looking Statements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains certain forward-looking statements that involve risks and uncertainties. These forward-looking statements reflect our current views with respect to, among other things, future events and our financial performance. These statements are often, but not always, made through the use of words or phrases such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;continue,&#8221; &#8220;will,&#8221; &#8220;anticipate,&#8221; &#8220;seek,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;projection,&#8221; &#8220;would,&#8221; &#8220;annualized&#8221; and &#8220;outlook,&#8221; or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These forward-looking statements are not historical facts, and are based on current expectations, estimates and projections about our industry, management&#8217;s beliefs and certain assumptions made by management, many of which, by their nature, are inherently uncertain and beyond our control. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, estimates and uncertainties that are difficult to predict. Although we believe that the expectations reflected in these forward-looking statements are reasonable as of the date made, actual results may prove to be materially different from the results expressed or implied by the forward-looking statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A number of important factors could cause our actual results to differ materially from those indicated in these forward-looking statements, including those factors identified in &#8220;Risk Factors&#8221; or &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; or the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the extent to which the COVID-19 pandemic and related governmental regulations and restrictions may impact our business, including our research, clinical trials, manufacturing and financial condition&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations regarding the potential benefits, activity, effectiveness and safety of our product candidates and therapeutics developed utilizing our Probody&#174; platform technology&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the initiation, timing, progress and results of our ongoing clinical trials, research and development programs, preclinical studies, and Investigational New Drug application (&#8220;IND&#8221;), Clinical Trial Application, New Drug Application (&#8220;NDA&#8221;), Biologics License Application (&#8220;BLA&#8221;)&#59; and other regulatory submissions&#894;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of the completion of our ongoing clinical trials and the timing and availability of clinical data from such clinical trials&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to identify and develop additional product candidates&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our dependence on collaborators for developing, obtaining regulatory approval for and commercializing product candidates in the collaboration&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our or a collaborator&#8217;s ability to obtain and maintain regulatory approval of any of our product candidates&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our receipt and timing of any milestone payments or royalties under any research collaboration and license agreements or arrangements&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our expectations and beliefs regarding the evolution of the market for cancer therapies and development of the immuno-oncology industry&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the rate and degree of market acceptance of any approved product candidates&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the commercialization of any approved product candidates&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to establish and maintain collaborations and retain commercial rights for our product candidates in such collaborations&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the implementation of our business model and strategic plans for our business, technologies and product candidates&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our estimates of our expenses, ongoing losses, future revenue and capital requirements&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to obtain additional funds for our operations&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our or any collaborator&#8217;s ability to obtain and maintain intellectual property protection for our technologies and product candidates and our ability to operate our business without infringing the intellectual property rights of others&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our reliance on third parties to conduct our preclinical studies or any future clinical trials&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our reliance on third-party supply and manufacturing partners to supply the materials and components for, and manufacture, our research and development, preclinical and clinical trial product supplies&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to attract and retain qualified key management and technical personnel&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to secure and maintain licenses of intellectual property to protect our technologies and product candidates&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our financial performance&#59; and</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developments relating to our competitors or our industry.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any forward-looking statements in this Annual Report on Form 10-K reflect our current views with respect to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Part I, Item&#160;1A. Risk Factors and discussed elsewhere in this Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs and therapeutic biologics, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained these industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which these data are derived. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except where the context otherwise requires, in this Annual Report on Form 10-K, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Company&#8221; refer to CytomX Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trademarks</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this Annual Report on Form 10-K are the property of their respective owners. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I">PART I</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1_BUSINESS"><span style="font-style:italic;">Business</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We aim to build a commercial stage enterprise to maximize our impact on the treatment of cancer. We are advancing potential first-in-class and best-in-class antibody-based therapeutics created using our Probody&#174; therapeutic technology platform that could meaningfully improve outcomes for cancer patients. Our proprietary and unique Probody technology platform is designed to enable &#8220;conditional activation&#8221; of antibody-based drugs within the tumor while minimizing drug activity in healthy tissues and circulation. Our platform is built on a strong foundation of tumor biology expertise including deep knowledge of tumor-associated enzymes known as proteases. Proteases are tightly controlled in normal tissues but often poorly regulated and active in tumor microenvironments where they play important roles in cancer cell migration, invasion and metastasis. Leveraging our deep scientific knowledge, we conceived of and constructed our Probody therapeutic platform which allows us to genetically engineer therapeutic antibodies to contain protease-cleavable masks. Our masking strategy is designed to reduce antibody binding to targets until the mask is removed by proteases in the tumor microenvironment, providing more selective targeting of the tumor. We believe this innovative approach has the potential to improve cancer treatment in three ways: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Enhancing a potential product&#8217;s &#8220;therapeutic window,&#8221; the balance between tolerability and activity&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Allowing the pursuit of high potential targets that were previously considered &#8220;undruggable&#8221; due to their ubiquitous expression on normal tissues&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3)</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Enabling the development of new combination therapies that are otherwise poorly tolerated. </span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into multiple partnerships with some of the world&#8217;s leading biotech and pharmaceutical companies, including AbbVie Inc., (&#8220;AbbVie&#8221;), Amgen, Inc. (&#8220;Amgen&#8221;), Astellas Pharma Inc. (&#8220;Astellas&#8221;), and Bristol Myers Squibb Company (&#8220;Bristol Myers Squibb&#8221;), which allow us to broaden the application of our technology and potentially expedite the development of Probody therapeutics. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have utilized our Probody platform to build a promising pipeline of conditional Probody therapeutics that encompasses five novel product candidates, four of which are in Phase 2 clinical studies. These investigational products include the conditionally activated antibody-drug conjugates (&#8220;ADCs&#8221;) praluzatamab ravtansine (CX-2009, targeting CD166) and CX-2029 (targeting CD71), and the Probody immune checkpoint inhibitors pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4). We also have two preclinical agents in investigational new drug (&#8220;IND&#8221;)-enabling studies - a conditionally activated ADC targeting EpCAM/Trop-1 (CX-2043) and a conditionally activated T-cell engaging bispecific antibody targeting EGFR and CD3 (CX-904). </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzkk5j0cumnd000001.jpg" title="" alt="" style="width:720px;height:316px;" /></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">CytomX Pipeline of Conditionally Activated Probody Therapeutics</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, we focused our internal clinical development efforts on advancing praluzatamab ravtansine (CX-2009) and CX-2029, two of our conditionally activated ADCs, into Phase 2 clinical studies. The Phase 2 clinical study of praluzatamab ravtansine is focused on breast cancer, evaluating both monotherapy and the combination with pacmilimab, our wholly-owned anti-PD-L1 conditionally activated checkpoint inhibitor. CX-2029 is being evaluated as monotherapy in a Phase 2 clinical study in four different cancer types, including squamous non-small cell lung cancer (&#8220;sqNSCLC&#8221;), head and neck squamous cell carcinoma (&#8220;HNSCC&#8221;), esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma (&#8220;DLBCL&#8221;). Our partner, Bristol Myers Squibb is continuing the clinical development of two Probodies, BMS-986249 and BMS-986288, directed against the checkpoint target CTLA-4. In a Phase 1/2 clinical trial, BMS-986249 is being evaluated in a randomized fashion in patients with previously-untreated metastatic melanoma. In addition, the trial has been modified to include three additional single-arm cohorts: advanced hepatocellular carcinoma, metastatic castration-resistant prostate cancer and unresectable locally advanced or metastatic triple-negative breast cancer (&#8220;TNBC&#8221;). BMS-986288 continues to be evaluated in a Phase 1 clinical study. Our conditionally activated ADC, CX-2043, targets Trop-1 or epithelial cell adhesion molecule (&#8220;EpCAM&#8221;) and we are working towards a potential IND filing in late 2021. Additionally, our collaboration with Amgen has advanced our first T-cell-engaging bispecific antibody targeting the CD3 receptor on T cells and the epidermal growth factor receptor (&#8220;EGFR&#8221;) on tumor cells. We are working towards a potential IND filing for CX-904 in late 2021.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Praluzatamab ravtansine (CX-2009)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our wholly-owned lead product candidate, praluzatamab ravtansine, is a potential first-in-class conditionally activated ADC directed against CD166, a tumor target previously considered undruggable due to its high expression on normal tissues. Because praluzatamab ravtansine is designed to remain masked in circulation, in order to minimize its binding to normal tissues, we believe we can address this new target that is poorly suited for conventional ADCs because of its widespread presence on normal cells and tissues. We have completed and previously reported data from a Phase 1 dose-finding, multi-cohort study involving heavily-pretreated patients in which we observed encouraging anti-cancer activity in patients with TNBC and hormone receptor-positive (&#8220;HR+&#8221;), human epidermal growth factor receptor 2 (&#8220;HER2&#8221;)-non-amplified breast cancer, among others. In December 2020, we initiated a new three-arm Phase 2 study in these two breast cancer subtypes, using 7 mg/kg administered every three weeks as the recommended dose. The first two arms, Arms A and B, will evaluate praluzatamab ravtansine as monotherapy&#59; Arm A in patients with HR+, HER2-non-amplified breast cancer and Arm B in patients with TNBC. Arm C will study praluzatamab ravtansine in combination with pacmilimab (CX-072) in patients with TNBC. We expect initial data to be available in the fourth quarter of 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">CX-2029</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our second lead conditionally activated ADC is CX-2029 which we are advancing in a global co-development collaboration with our partner AbbVie. This program is intended to open a therapeutic window for targeting CD71, also known as the transferrin receptor 1 (&#8220;TfR1&#8221;). CD71 is a cell surface protein essential for iron uptake in dividing cells and is highly expressed in a number of solid and hematologic cancers. However, given its central role in iron metabolism, CD71 is present on most healthy cells and is thought to be undruggable with conventional ADCs. In 2020, we completed the Phase 1 dose-escalation phase of our ongoing Phase 1/2 study of CX-2029, for which we received a $40 million milestone payment from AbbVie. In November 2020, we expanded this study into a four-cohort Phase 2 cohort expansions evaluating CX-2029 as a monotherapy at the dose of 3 mg/kg administered every three weeks in patients with sqNSCLC, HNSCC, esophageal and gastro-esophageal junction cancers, and DLBCL. Initial data are expected in the fourth quarter of 2021.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">BMS-986249 and BMS-986288 </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In collaboration with our partner, Bristol Myers Squibb, we are studying two CTLA-4-directed Probody therapeutics generated with our Probody platform. BMS-986249, a Probody version of ipilimumab, was advanced in February 2020 into a randomized Phase 2 study in combination with the PD-1 inhibitor nivolumab in patients with previously-untreated metastatic melanoma, triggering a $10.0 million milestone payment to us. This study has been modified to include three additional single-arm cohorts: advanced hepatocellular carcinoma, metastatic castration-resistant prostate cancer, and unresectable locally advanced or metastatic TNBC. The second anti-CTLA-4 antibody BMS-986288, a Probody version of non-fucosylated ipilimumab, is being examined in a Phase 1 study as monotherapy and in combination with nivolumab in patients with selected advanced solid tumors. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical programs</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are working towards submitting INDs during 2021 for two of our preclinical programs, CX-2043 and CX-904.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CX-2043 is our third conditionally activated ADC and is <span style="color:#333333;">directed against Trop-1 or EpCAM, another target that is highly expressed on a wide variety of tumor types but is considered difficult to drug due to its wide expression on normal tissues</span>. <span style="color:#333333;">This program was originally developed by ImmunoGen, Inc. (&#8220;ImmunoGen&#8221;), utilizing our Probody technology and ImmunoGen&#8217;s next-generation linker chemistry and novel maytansinoid payload, DM-21. We in-licensed exclusive worldwide development and commercialization rights to CX-2043 from ImmunoGen in 2019.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CX-904 is our most advanced program in the new and promising modality of T-cell engaging bispecific antibodies (&#8220;TCBs&#8221;). CX-904 is a conditionally activated epidermal growth factor receptor-CD3 (&#8220;EGFR-CD3&#8221;) TCB which we have partnered with Amgen. While TCBs are designed to direct the activity of cytotoxic T cells to tumors and are highly potent, their development for solid tumor indications has been challenging due to significant on-target, off-tumor toxicities. We believe such toxicity could be reduced using our Probody platform by localizing the activity of TCBs to the tumor microenvironment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The successful development of our product candidates involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. This is due to the numerous risks and uncertainties associated with the development of product candidates. If our Probody therapeutic technology and product candidates generally prove to be ineffective, unsafe or commercially unviable, it would have a material and adverse effect on our business, financial condition, results of operations and prospects.<span style="font-size:8pt;">&#160;&#160;</span>See &#8220;Risk Factors&#8221; for a discussion of the risks and uncertainties associated with our product candidates and our research and development projects.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Corporate Strategy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are utilizing our industry-leading, proprietary, and differentiated Probody platform to develop a robust pipeline of antibody-based therapies to improve the lives of people with cancer and to build a long-term, multi-product, commercial-stage biopharmaceutical company. We aim to achieve this goal by:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Advancing potentially first-in-class therapies against high potential, novel targets that have not yet been drugged because of broad expression in healthy tissue. Our conditionally activated ADCs, praluzatamab ravtansine (CX-2009) and CX-2029, targeting CD166 and CD71, respectively, are our most advanced programs in this class.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Developing novel and improved combination therapies based on validated immuno-oncology targets and pathways that have the potential to improve outcomes for cancer patients. Our partner, Bristol Myers Squibb, is progressing two Probody anti-CTLA-4 inhibitors, BMS-986249 and BMS-986288, in combination with nivolumab, a PD-1 inhibitor. We are studying our conditionally activated anti-PD-L1 therapeutic candidate, pacmilimab (CX-072), in combination with praluzatamab ravtansine in patients with TNBC.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Positioning ourselves at the cutting edge of anti-cancer research and development by creating new potent therapeutic antibody formats. We are working towards filing an IND in late 2021 for CX-904, our conditionally activated version of an EGFR-CD3 T-cell engaging bispecific that we have partnered with Amgen.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Partnering with leading global biopharmaceutical companies to access capital, additional resources and expertise, as well as increase the number of Probody therapeutic candidates being advanced into clinical studies. To date, we have formed several strategic alliances with major multinational drug companies, including AbbVie, Amgen, Bristol Myers Squibb, and most recently in 2020, Astellas. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Continuing to access technologies or programs that complement our Probody platform and our pipeline through licenses or acquisitions.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Fostering a unique, patient-focused culture of execution, alignment and accountability centered around our vision, mission and values.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our </span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Platform</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Localization of therapeutic antibody activity within disease tissue is of increasing interest in the biopharmaceutical industry due to the desire to maximize the activity of antibody-based biologics while reducing their toxicities. At CytomX, we call our approach to therapeutic antibody localization our Probody platform. A Probody therapeutic consists of three components: an active anti-cancer antibody, a mask for the antibody, and a protease-cleavable linker which connects the mask to the antibody. The mask is a peptide designed to disguise the active binding site of the antibody to prevent the therapeutic from binding to the target present on healthy tissue. Probody therapeutics are produced as a single protein by standard antibody production methodology. The following graphic depicts the three components of a Probody therapeutic:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gzkk5j0cumnd000002.jpg" title="" alt="" style="width:594px;height:320px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Depiction of the structure of a Probody therapeutic and a protease interacting with the Probody to cleave the linker and activate the molecule</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">When a Probody therapeutic enters a tumor, it encounters proteases, which are enzymes that cleave proteins and have increased activity in the tumor microenvironment. The proteases in the tumor cleave the linker, releasing the mask and allowing the antibody to bind to the target on the tumor. The following graphic depicts the activation of a Probody therapeutic by proteases:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gzkk5j0cumnd000003.jpg" title="" alt="" style="width:664px;height:148px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Depiction of how a Probody therapeutic is designed to enter the tumor microenvironment (left), be activated by protease cleavage to remove the mask (middle), thereby enabling the released antibody to bind to the tumor target (right)</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proteases play an essential role in many aspects of normal physiology, such as digestion of food in the gastrointestinal tract, wound healing and metabolic function. However, uncontrolled protease activity can lead to destruction of essential proteins and tissues. Therefore, proteases are normally very tightly regulated by multiple mechanisms, with only small amounts of extracellular protease activity being detectable in healthy tissues. In contrast, it has been well documented that proteases are not only present, but also activated, in virtually all types of tumors, playing a key role in tumor growth, invasion and metastasis. Probody therapeutics are designed to be activated in this protease-rich tumor microenvironment, but not in healthy tissue where proteases are under tight control. Consequently, toxicities that arise from the binding of an antibody to a target in healthy tissues can be minimized, while </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">biological activity against the tumor where it is desired can be preserved. We and our partners have demonstrated the potential applicability of our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> platform across multiple modalities, including ADCs, cancer immunotherapy, and TCBs. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Key Advantages of Our Probody Platform</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our Probody platform provides the following key advantages:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">A novel therapeutic antibody class enabled by our proprietary platform.</span><span style="color:#000000;"> We believe we have a differentiated technology platform that gives us a substantial competitive advantage supported by more than a decade of research and a strong intellectual property portfolio.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Potential to improve the therapeutic window of antibody-based therapeutics.</span><span style="color:#000000;"> By engineering our therapeutics to selectively activate in the tumor microenvironment, our Probody product candidates have the potential to improve safety and tolerability.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Ability to combine more effectively with other therapies.</span><span style="color:#000000;"> We believe the therapeutic window and tumor specificity of our candidates have the potential to reduce the dose-limiting toxicities observed in combination therapies and thus enable new combinations with other cancer therapies that are difficult or impossible to use.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Applicability across many molecular targets.</span><span style="color:#000000;"> We believe that our technology addresses many different molecular targets expressed by many different kinds of tumors&#8212;including targets that are difficult to address because they are also expressed on healthy cells&#8212;because Probody therapeutics are designed to have limited interaction with non-cancerous tissues.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span><span style="font-weight:bold;font-style:italic;color:#000000;">Versatility across antibody modalities.</span><span style="color:#000000;"> We believe that our technology can be applied to most antibody-based therapies, including novel potent modalities like ADCs and TCBs.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Lead Product Candidates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are leveraging our Probody platform to build a robust pipeline of potential first-in-class anti-cancer therapies. We currently retain worldwide development and commercialization rights to two of our most advanced Probody therapeutics in the clinic, praluzatamab ravtansine (CX-2009) and pacmilimab (CX-072). Additionally, we are advancing multiple partnered development programs in the clinic, including CX-2029, an anti-CD71 conditionally activated ADC in collaboration with AbbVie, as well as BMS-986249 and BMS-986288, our anti-CTLA-4 Probody programs partnered with Bristol Myers Squibb.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Praluzatamab Ravtansine (CX-2009: CD166-Directed Conditional ADC) Program</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although there are several ADCs approved for the treatment of cancer in the United States and elsewhere, conventional ADCs have been restricted to targeting proteins that are expressed highly in tumors, but are absent or poorly expressed in healthy tissues, in order to avoid undesirable toxicities. However, few cancer-associated proteins have this desirable profile, thereby limiting the utility of conventional ADCs. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a broad research program at CytomX aimed at discovering and validating a new class of ADCs taking advantage of the fact that Probody therapeutics are designed to reduce binding of potent anti-cancer therapy to targets in healthy tissues while increasing binding to target in tumor tissue. We believe this unique, conditional approach can open up new classes of ADC targets that were previously deemed unsuitable because of expression on normal tissues. Our therapeutic strategy with conditional ADCs is to leverage targets to achieve binding to tumor cells, and to effect cancer cell killing via a cytotoxic payload conjugated to the antibody. We do not mask the cytotoxic payload in our conditional ADCs and therefore some payload-related toxicities are expected. However, our Probody platform is designed to minimize on target toxicities that otherwise may occur with traditional ADCs. While payload toxicities are still anticipated, they may offer an indication that therapeutically active levels of the drug conjugate are being achieved.&#160;&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate is praluzatamab ravtansine, a wholly-owned conditionally activated ADC directed against CD166, a novel cell surface target that we have validated at CytomX. CD166 is highly and homogenously expressed in multiple different tumor types but its high expression on normal tissues makes this a difficult target to drug with a traditional ADC therapy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the first ADC that targets CD166, praluzatamab ravtansine is made up of a humanized, conditionally activated antibody that recognizes CD166 and is conjugated with the potent microtubule inhibiting payload DM4, licensed from ImmunoGen. In May 2020 at the American Society of Clinical Oncology annual meeting (ASCO), we reported data from an ongoing Phase 1 dose-finding, multi-cohort study, in which 96 heavily-pretreated patients were enrolled to receive praluzatamab ravtansine at escalating doses of 0.25 - 10 mg/kg every 3 weeks, or 4 - 6 mg/kg every 2 weeks. Seven tumor types with high CD166 expression were included in this study: breast carcinoma, epithelial ovarian carcinoma, NSCLC, HNSCC, cholangiocarcinoma, endometrial carcinoma, and castration-resistant prostate carcinoma. Praluzatamab ravtansine was generally well tolerated at doses up to 7 mg/kg administered every three </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">weeks, with</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> no dose-limiting toxicities reported at doses up to 7 mg/kg</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> DM4-related toxicities, including ocular, neuropathic, and hepatic were higher in frequency at dose equivalents greater than 7 mg/kg dosed at every three weeks compared to 7 mg/kg or lower. The occurrence and severity of ocular adverse events were dose dependent: 20% of patients dosed at &#8805;8 mg/kg experienced Grade 3+ ocular adverse events&#59; one patient treated at doses &#8804; 7 mg/kg had a Grade 3+ ocular adverse event. Preliminary pharmacokinetic (&#8220;PK&#8221;) data showed that </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">praluzatamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ravtansine</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> circulates predominantly intact at all doses and PK is not strongly influenced by target-mediated drug disposition or anti-drug antibodies.&#160;&#160;Evidence of anti-cancer activity for CX-2009 was observed in patients with several tumor types including breast cancer, ovarian cancer and NSCLC.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These results were updated at the 2020 San Antonio Breast Cancer Symposium with particular focus on our clinical experience with CX-2009 in breast cancer. At the time of data cutoff in August 2020, 32 patients with HER2&#8211; breast cancer who received &#8805;4 mg/kg of praluzatamab ravtansine were response evaluable. Two confirmed partial responses were observed in patients with HR+, HER2&#8211; subtype, while three unconfirmed responses were observed in patients with TNBC. Clinical benefit rates of 41% and 28% were observed at 16 and 24 weeks (&#8220;CBR16&#8221; and &#8220;CBR 24&#8221;), respectively, with all four patients with TNBC who achieved CBR16 maintaining it at CBR24. Adverse events were consistent with data previously reported.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gzkk5j0cumnd000004.jpg" title="" alt="" style="width:710px;height:394px;" /></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Observed Clinical Activity in Breast Cancer with Praluzatamab Ravtansine (CX-2009) at Doses &#8805;4 mg/kg Q3W</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Importantly, responses were durable with some patients having their responses extended to almost one year, as shown in the spider plot below.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzkk5j0cumnd000005.jpg" title="" alt="" style="width:678px;height:396px;" /></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Observed Responses and Durability in Breast Cancer with Praluzatamab Ravtansine (CX-2009) at Doses &#8805;4 mg/kg Q3W</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on these encouraging early data, we have launched a new three-arm Phase 2 study in HER2-non amplified breast cancer. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:3pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gzkk5j0cumnd000006.jpg" title="" alt="" style="width:702px;height:256px;" />&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Design of the Praluzatamab Ravtansine (CX-2009) Phase 2 study</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial data are expected in the fourth quarter of 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">According to the American Cancer Society, an estimated 284,200 new cases of breast cancer are expected in the United States in 2021, making it the most frequently diagnosed cancer in women. HR+/HER2&#8210; and TNBC subtypes, collectively HER2-non-amplified, is the largest segment of breast cancer, accounting for greater than 80% of patients with advanced breast cancer. Patients with HR+ breast cancer are treated with hormone-based therapy, which can be single-agent or combination therapy (including CDK4/6 or mTOR </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">inhibition).</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the cancer progresses, patients may require more aggressive cytotoxic chemotherapy.&#160;The patients that progress despite these therapies represent a significant unmet need for more efficacious treatment options.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CX-2029 (anti-CD71 Conditional ADC) Program in Collaboration with AbbVie </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are collaborating with AbbVie on the development of CX-2029, a CD71-directed conditionally activated ADC. CD71, also known as TfR1, is a cell surface protein that is essential for iron uptake in dividing cells. CD71 is highly expressed in a number of solid and hematologic cancers and has attractive molecular properties for efficient internalization of ADCs and cytotoxic payloads to tumor cells. However, CD71 is present on most healthy cells, and is thought to be an undruggable target with conventional ADCs. Our preclinical work has shown that conventional ADC to CD71 is lethal at sub-therapeutic doses, rendering it an undevelopable drug.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We used our Probody platform to design and construct CX-2029, a conditionally activated anti-CD71 ADC conjugated with the tubulin inhibitor, monomethyl auristatin E (&#8220;MMAE&#8221;), as the payload. In preclinical studies, CX-2029 demonstrated potent anticancer effects in various animal tumor models. For CX-2029 to be effective in patients, we believe we need to achieve dose levels in the 2 - 4 mg/kg range in cancer patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2020, we completed the dose-escalation phase of an ongoing Phase 1/2 clinical study, for which we received a $40 million milestone payment from AbbVie. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we disclosed preliminary data from the Phase 1/2 study that forty-five patients with advanced solid tumors had been enrolled into the Phase 1 study to receive CX-2029 intravenously at 8 escalating dose cohorts ranging from 0.1 mg/kg to 5 mg/kg every three weeks. At doses of 0.25 &#8211; 5 mg/kg, more than 90 percent of CX-2029 circulated predominantly as the intact species. CX-2029 was generally well tolerated at doses up to 3 mg/kg, with infusion related reactions, anemia, and neutropenia/leukopenia as the most common treatment related adverse events. Anemia and neutropenia are commonly observed with the MMAE payload, and anemia was managed with transfusions and supportive care.&#160;&#160;The etiology of anemia is under investigation and is likely multifactorial, including MMAE-related and CD71 expression on red blood cell precursors. No CX-2029 treatment related deaths were reported, and no patient withdrew from the trial due to anemia.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Evidence of target lesion reduction was observed principally in patients with tumors of squamous histology, including confirmed partial responses in two patients with </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sqNSCLC</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and in one patient with HNSCC among 21 response-evaluable patients treated at doses &#8805;2 mg/kg of CX-2029.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gzkk5j0cumnd000007.jpg" title="" alt="" style="width:720px;height:442px;" />&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Observed Clinical Activity with CX-2029 at Doses &#8805;2 mg/kg Q3W</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Durable responses were seen with CX-2029 in responding patients who received doses at &#8805;2 mg/kg every three weeks, extending their responses to almost six months.</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzkk5j0cumnd000008.jpg" title="" alt="" style="width:720px;height:534px;" /></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Observed Responses and Durability with CX-2029 at Doses &#8805;2 mg/kg Q3W</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Best responses in patients with sqNSCLC and HNSCC who received CX-2029 at doses &#8805;2 mg/kg every three weeks are shown in the waterfall plot below. One patient with sqNSCLC who was dosed at 1 mg/kg and one patient with HNSCC came off study without a post-baseline assessment are excluded from the plot.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzkk5j0cumnd000009.jpg" title="" alt="" style="width:720px;height:348px;" /></p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Observed Clinical Activity in sqNSCLC and HNSCC with CX-2029 at Doses &#8805;2 mg/kg Q3W</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The spider plot demonstrating responses and durability for patients with sqNSCLC and HNSCC who received CX-2029 at doses &#8805;2 mg/kg every three weeks is shown below. CX-2029 showed clinical activity in patients with heavily-pretreated sqNSCLC and HNSCC, with 3 of 4 sqNSCLC patients achieving at least stable disease, including two confirmed partial responses (3 mg/kg, n&#61;1&#59; 5 mg/kg, n&#61;1), and 7 of 8 HNSCC patients achieving at least stable disease, including one confirmed partial response at 3 mg/kg and one prolonged stable disease ongoing at ~25 weeks as of data cut off. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gzkk5j0cumnd000010.jpg" title="" alt="" style="width:642px;height:418px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Observed Responses and Durability in sqNSCLC and HNSCC with CX-2029 at Doses &#8805;2 mg/kg Q3W</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This study has now expanded into a four-cohort Phase 2 clinical study, evaluating CX-2029 as a monotherapy at the dose of 3 mg/kg, administered every three weeks, in patients with sqNSCLC, HNSCC, esophageal and gastro-esophageal junction cancers, and DLBCL. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><img src="gzkk5j0cumnd000011.jpg" title="" alt="" style="width:720px;height:252px;" /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Design of the CX-2029 Phase 2 expansion study</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial results are expected in the fourth quarter of 2021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lung cancer is the leading cause of death from all cancers globally, resulting in more than 1.8 million deaths per year. Greater than 80% of lung cancers are NSCLC and the main subtypes of NSCLC are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, with squamous cell representing approximately 30%. Head and neck cancers include cancers in the larynx, throat, lips, mouth, nose, and salivary glands, and represent the 6<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> most common cancer worldwide, resulting in 350,000 deaths annually, whereas it is the 8<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> most commonly diagnosed cancer in the United States, accounting for approximately 11,500 deaths annually. The most common types of esophageal cancer are adenocarcinoma and squamous cell carcinoma, with squamous cell accounting for about 90% of the global annual incidence of 456,000. DLBCL is the most common aggressive subtype of non-Hodgkin lymphoma, constituting up to 40% of cases globally and more than 18,000 people diagnosed with the malignancy each year in the United States. Despite recent advances in cancer treatment, including the advent of immuno-oncology therapy, significant unmet need remains for these four cancer types.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Pacmilimab (CX-072: conditionally activated PD-L1 therapeutic) Program</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most advanced wholly-owned immuno-oncology product candidate is pacmilimab, a conditionally activated therapeutic against PD-L1, a clinically and commercially validated cancer target. The PD pathway consists principally of two targets: PD-1, which is typically expressed on T-cells, and PD-L1, which is typically expressed on the tumor cells as well as on healthy tissue. In healthy tissue, PD-1 and PD-L1 work together to negatively regulate immune response and maintain tolerance between the immune system and healthy tissue. Tumors, however, upregulate PD-L1 to evade immune surveillance by the host&#8217;s immune system. Therefore, development of antibodies against PD-1 and PD-L1 have become a key focal point in cancer drug development, with three PD-1 antibodies nivolumab (Opdivo&#174;), pembrolizumab (Keytruda&#174;), and cemiplimab (Libtayo&#174;) and three PD-L1 antibodies atezolizumab (Tecentriq&#174;), durvalumab (Imfinzi&#174;), and avelumab (Bavencio&#174;) approved by the FDA as of January 2021, with many other PD pathway inhibitors in clinical development. In addition to assessment as single agents, PD-1 and PD-L1 antibodies have been studied extensively as the centerpiece of oncology combination therapies.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While inhibitors of the PD-L1 and/or PD-1 pathway offer the potential for clinical benefit in patients with a wide-variety of cancer types, there are a number of risks imposed by administration of these agents. According to U.S. labels for Opdivo, Keytruda, Tecentriq, Bavencio, and Imfinzi, the most common side effects (defined as either &#62;15% or &#62;20%, depending upon the agent) that were observed with commercially available anti-PD-L1 and anti-PD-1 agents include: fatigue, decreased appetite, nausea, vomiting, diarrhea, dyspnea, constipation, cough, musculoskeletal pain, back pain, abdominal pain, arthralgia, urinary tract infection, upper respiratory tract infection, peripheral edema, infusion-related reaction, rash, asthenia, pruritus, headache, and pyrexia.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Combining a PD pathway inhibitor with another anti-cancer agent often results in significantly greater toxicity than monotherapy alone. One example is the combination of atezolizumab and paclitaxel protein-bound, or nab-paclitaxel, which was approved in the United States for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumors express &#8805; 1% of PD-L1, as determined by an FDA approved test. According to data reported in 2018 in <span style="font-style:italic;">The New England Journal of Medicine</span>, the combination of atezolizumab at a dose of 840 mg and nab-paclitaxel at a dose of 100 mg per square meter of body-surface resulted in Grade 3/4 treatment related adverse events (&#8220;TRAEs&#8221;) in 48.7% of the patients treated versus 42.2% in the placebo-nab-paclitaxel group, and drug discontinuations in 6.4% of the patients treated, compared to 1.4% in the placebo group.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that a locally activated Probody therapeutic targeting PD-L1 has the potential to maintain the anti-tumor activity of the PD pathway blockade while reducing the autoimmunity that results from blocking such pathway systemically. As such, we believe that pacmilimab has the potential to enable combination therapies that cannot be appropriately dosed because of synergistic toxicity, and ultimately that pacmilimab may have the potential to play an important role in combination therapy. Pacmilimab may also ultimately prove to be a safer monotherapy than existing PD inhibitors which could have specific applications in certain clinical settings. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our Phase 1/2 study of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pacmilimab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as monotherapy in patients with heavily-pretreated cancers we reported in May 2020 that a total of 114 patients with seven different tumor types were enrolled to receive </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pacmilimab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at the 10 mg/kg dose. As of an April 20, 2020 data cutoff, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pacmilimab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> monotherapy continued to demonstrate durable anti-tumor activity in patients with IO-sensitive tumors such as TNBC, anal squamous cell carcinoma, cutaneous squamous cell carcinoma, and tumors with high mutational burden. This conditionally</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activ</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutic was generally well tolerated by patients, with Grade 3/4 TRAEs of 10% and 5.9% for patients who received </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pacmilimab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> monotherapy &#60; 6 months and &#8805; 6 months, respectively. Long term patients experienced fewer (~21%) immune-related adverse events (&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">irAEs</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) and had no grade 3+ </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">irAEs</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> suggesting that tolerability can impact duration of treatment.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzkk5j0cumnd000012.jpg" title="" alt="" style="width:720px;height:308px;" /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:9pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Activity and Durability Observed in IO-Responsive Tumors with Pacmilimab Monotherapy at 10 mg/kg Dose</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on this potentially differentiated profile of a favorable tolerability and clear evidence of anti-cancer activity, we are studying pacmilimab in combination with praluzatamab ravtansine in a Phase 2 study in TNBC.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2019, we initiated <span style="Background-color:#FFFFFF;color:#000000;">PROCLAIM-CX-072-002, a Phase 2 clinical study evaluating the conditionally activated anti-PD-L1 pacmilimab in combination with ipilimumab. In March 2020, we made the strategic decision to terminate this study. The decision followed a re-evaluation of the evolving clinical, competitive and commercial landscapes in immuno-oncology, along with impact of the COVID-19 pandemic. This decision allowed for resources to be redirected towards our potential first-in-class assets, including the combination of pacmilimab and praluzatamab ravtansine (CX-2009) in TNBC.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BMS-986249 and BMS-986288 (anti-CTLA-4 Probody Therapeutics) Programs in Collaboration with Bristol Myers Squibb</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In collaboration with our partner, Bristol Myers Squibb, we are developing BMS-986249 and BMS-986288, Probody versions of ipilimumab. Ipilimumab, sold under the brand name Yervoy&#174;, is a monoclonal antibody that targets CTLA-4, a checkpoint protein receptor that downregulates the immune system. In the United States, ipilimumab has been approved by the FDA to treat melanoma as a single agent and in combination with nivolumab, an anti-PD-1 antibody, for colorectal cancer, hepatocellular carcinoma, malignant pleural mesothelioma, NSCLC, and renal cell carcinoma. While treatment with ipilimumab as a monotherapy or in combination with nivolumab has resulted in clinically meaningful anti-tumor activity in these malignancies, ipilimumab has a narrow therapeutic window and the FDA approved label has a black box warning about potential severe and fatal immune-related adverse events. We believe our CTLA-4-targeting Probody therapeutic may be able to effectively localize the anti-CTLA-4 antibody activity to the tumor microenvironment, thereby limiting systemic toxicities normally seen with ipilimumab, which could improve the benefit/risk profile of anti-CTLA-4 containing treatment regimens.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In an ongoing Phase 1/2 study conducted by Bristol Myers Squibb in patients with advanced cancers, Bristol Myers Squibb reported at ASCO 2020 preliminary data indicating that escalating doses of BMS-986249 ranging from 240 mg to 2400 mg (approximately 3 to 30 mg/kg of ipilimumab) were found to be generally well tolerated, either as a single agent or in combination with nivolumab. In February 2020, Bristol Myers Squibb initiated a randomized Phase 2 study cohort expansion in combination with nivolumab in patients with previously-untreated unresectable stage III-IV melanoma and we received a $10.0 million milestone payment from them. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This study has been </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">modified</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to include three additional single-arm cohorts: </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">advanced hepatocellular carcinoma, metastatic castration-resistant prostate cancer, and unresectable locally advanced or metastatic TNBC</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For BMS-986288, a Probody version of non-fuscosylated ipilimumab, Bristol Myers Squibb is evaluating its <span style="Background-color:#FFFFFF;">safety and efficacy alone and in combination with nivolumab </span>in an ongoing Phase 1/2a study in patients with selected advanced solid tumors. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Preclinical Product Candidates and Research</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are actively broadening the application of our Probody platform technology to multiple other product candidates, including additional potential first-in-class conditionally activated ADC product candidates and investigational TCB product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Anti-Trop-1 (EpCAM) Conditionally Activated ADC Program</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Trop-1 or epithelial cell adhesion molecule (&#8220;EpCAM&#8221;) is a target that is highly expressed on a wide variety of tumor types. It has been, however, a difficult target to drug as it is also expressed widely on normal tissues. An EpCAM-targeting conditional ADC program was initially developed by ImmunoGen utilizing our Probody technology and ImmunoGen&#8217;s next-generation linker chemistry and novel maytansinoid payload, DM-21. At the 2018 European Antibody Congress and the 2019 American Association for Cancer Research Annual Meeting, ImmunoGen reported pre-clinical data from this program showing CX-2043 elicited potent tumor regression in multiple tumor models, while minimizing on-target toxicities outside the tumor microenvironment<span style="Background-color:#FFFFFF;">. In late</span> 2019, we obtained a worldwide, exclusive, sublicensable license from ImmunoGen to this anti-EpCAM ADC program, for which w<span style="Background-color:#FFFFFF;">e are working towards submitting an IND in late 2021</span>. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Conditionally Activated TCB Platform</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also extended our Probody platform to the new and promising modality of T-cell engaging bispecific antibodies (&#8220;TCBs&#8221;).&#160;&#160;Conventional TCBs are a highly potent therapeutic modality designed to direct the activity of cytotoxic T cells to tumors. TCBs such as the BiTE, Blincyto&#174;, a CD19-directed TCB commercialized by Amgen, have shown clinical activity in hematologic malignancies, but development of TCBs for solid tumor indications is proving challenging. Due to their high potency, TCBs can target normal tissues with low antigen expression, resulting in significant on-target, off-tumor toxicity that limits dosing to low levels. We are exploring the potential of our Probody technology to improve the therapeutic window for TCBs in solid tumors. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our most advanced program in this modality is CX-904, a conditionally activated epidermal growth factor receptor-CD3 (&#8220;EGFR-CD3&#8221;) TCB, which we partnered with Amgen.&#160;&#160;In <span style="font-style:italic;">in vitro</span> preclinical studies, CX-904 was shown to reduce cytotoxicity up to 100,000-fold as compared to an unmasked EGFR-CD3 TCB. CX-904 also induced tumor regressions and demonstrated significant anti-tumor activity in established tumor models. Additionally, CX-904 is predicted to be tolerated at efficacious doses in humans. We are working towards submission of an IND in late 2021. </p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pre-clinical Research</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continue to conduct extensive research to create future generations of product candidates based on our Probody technology. Our broad Probody therapeutic technology platform and lead product candidates are supported by more than a decade of thorough scientific research and strong intellectual property. We have established a broad worldwide patent estate of at least 150 issued, owned and co-owned patents and at least 325 pending, owned and co-owned patent applications. We also have an exclusive license from University of California, Santa Barbara (&#8220;UCSB&#8221;) to three patent families covering screening tools to identify masks and substrates.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Collaborations<span style="font-style:italic;font-weight:normal;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that the Probody platform has broad applicability across a number of targets and antibody formats. We have leveraged strategic partnering to (a) extend the reach of our therapeutic opportunity, and (b) bring in significant non-dilutive capital into the Company. Since 2013, we have entered into collaborations with AbbVie, Amgen, Astellas, Bristol Myers Squibb and ImmunoGen, among others, to enable development of certain Probody therapeutics. In constructing each of these collaborations, our primary objectives were to collaborate with leading biopharmaceutical players to realize the potential of Probody therapeutics&#59; gain meaningful near-term funding and/or technology access to enable advancement of our wholly-owned Probody therapeutics pipeline&#59; broaden the number of Probody therapeutics that ultimately reach the clinic&#59; and retain significant milestones, royalties, and in some cases product rights, for long-term upside. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">AbbVie Ireland Unlimited Company</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, we entered into two agreements with AbbVie, a CD71 Co-Development and Licensing Agreement (the &#8220;CD71 Agreement&#8221;) and the Discovery Agreement (the Discovery Agreement, together with the CD71 Agreement are collectively referred to as the &#8220;AbbVie Agreements&#8221;). Under the terms of the CD71 Agreement, we and AbbVie are co-developing CX-2029, a conditionally activated antibody-drug conjugate (&#8220;ADC against CD71, and we are responsible for pre-clinical and early clinical development. AbbVie will be responsible for later development and commercialization, with global late-stage development costs shared between the two companies. We will assume 35% of the net profits or net losses related to later development unless we opt-out. If we opt-out from participation of co-development of CX-2029, AbbVie will have sole right and responsibility for the further development, manufacturing and commercialization of CX-2029. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the CD71 Agreement, we received an upfront payment of $20.0 million in April 2016, and a milestone payment of $40.0 million in May 2020 for completion of the dose-escalation phase of the ongoing Phase 1/2 study. We are currently eligible to receive up to $430.0 million in development, regulatory and commercial milestone payments and royalties on ex-US sales in the high teens to low twenties if we participate in the co-development of CX-2029 subject to a reduction in such royalties if we opt-out from the co-development of the CD71 conditionally activated ADC. Our share of later stage co-development costs for CX-2029 is capped, provided that AbbVie may offset our co-development cost above the capped amounts from future payments such as milestone payments and royalties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Discovery Agreement, AbbVie received exclusive worldwide rights to develop and commercialize conditionally activated ADCs against up to two targets, one of which was selected in March 2017 and the second of which was selected in July 2019. We shall perform research services to discover the Probody therapeutics and create conditionally activated ADCs for the nominated collaboration targets. From that point, AbbVie shall have sole right and responsibility for development and commercialization of products comprising or containing such conditionally activated ADCs (&#8220;Discovery Licensed Products&#8221;). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Discovery Agreement, we received an upfront payment of $10.0 million in April 2016 and we received an additional upfront payment of $10.0 million in July 2019 upon the selection by AbbVie of the second target and the satisfaction of certain performance conditions under the CD71 Agreement. We are also eligible to receive up to $265.0 million for each target in development, regulatory and commercial milestone payments as well as royalties in the high single to low teens from commercial sales of any resulting conditionally activated ADCs.&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Amgen, Inc. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2017, we entered into a Collaboration and License Agreement (the &#8220;Amgen Agreement&#8221;) with Amgen. Pursuant to the Amgen Agreement, we received an upfront payment of $40.0 million in October 2017. Concurrent with the entry into the Amgen Agreement, Amgen purchased <span style="color:#000000;">1,156,069 shares of our common stock for $20.0 million</span>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Amgen Agreement, we and Amgen are co-developing a conditionally activated T-cell engaging bi-specific therapeutic targeting EGFR (&#8220;EGFR Products&#8221;). We are responsible for early-stage development of EGFR Products and all related costs (up to certain pre-set costs and certain limits based on clinical study size). Amgen will be responsible for late-stage development, commercialization, and all related costs of EGFR Products. Following early-stage development, we will have the right to elect to participate financially in the global co-development of EGFR Products with Amgen, during which we would bear certain of the worldwide development costs for EGFR Products and Amgen would bear the rest of such costs (the &#8220;EGFR Co-Development Option&#8221;). If we exercise our EGFR Co-Development Option, we will share in somewhat less than 50% of the profit and losses from sales of such EGFR Products in the U.S., subject to certain caps, offsets, and deferrals. If we choose not to exercise our EGFR Co-Development Option, we will not bear any costs of later stage development. We are eligible to receive up to $455.0 million in development, regulatory, and commercial milestone payments for EGFR Products, and royalties in the low-double digit to mid-teen percentage of worldwide commercial sales, provided that if we exercise our EGFR Co-Development option, we shall only receive royalties in the low-double digit to mid-teen percentage of commercial sales outside of the United States.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amgen also has the right to select a total of up to three targets, including the two additional targets discussed below. We and Amgen will collaborate in the research and development of conditionally activated T-cell engaging bi-specifics products directed against such targets. Amgen has selected one such target (the &#8220;Amgen Other Product&#8221;). If Amgen exercises its option within a specified period of time, it can select two such additional targets (the &#8220;Amgen Option Products&#8221; and, together with the Amgen Other Product, the &#8220;Amgen Products&#8221;). Except with respect to preclinical activities to be conducted by us, Amgen will be responsible, at its expense, for the development, manufacture, and commercialization of all Amgen Products. If Amgen exercises all of its options and advances all three of the Amgen Products, we are eligible to receive up to $950.0 million in upfront, development, regulatory, and commercial milestones and tiered high single-digit to low-teen percentage royalties. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have the option to select, from programs specified in the Amgen Agreement, an existing pre-clinical stage T-cell engaging bispecific product from the Amgen pre-clinical pipeline.&#160;&#160;We will be responsible, at our expense, for converting this program to a conditionally</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activ</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> T-cell engaging bispecific product, and thereafter, be responsible for development, manufacturing, and commercialization of the product (&#8220;CytomX Product&#8221;). Amgen is eligible to receive up to $203.0 million in development, regulatory, and commercial milestone payments for the CytomX Product, and tiered mid-single digit to low double-digit percentage royalties.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, we entered into a Collaboration and License Agreement (the &#8220;Astellas Agreement&#8221;) with Astellas, pursuant to which we and Astellas will collaborate on the research, development and commercialization of T-cell engaging bi-specific antibody products (&#8220;Products&#8221;) directed to CD3 and selected tumor antigen targets using our Probody&#174; platform and other proprietary technology. Under the Astellas Agreement, we granted Astellas an exclusive, worldwide, royalty-bearing license to develop and commercialize Products in all fields. Astellas may select up to four targets to develop, with an option to expand to six targets. We will lead preclinical research and discovery activities up to clinical candidate selection for Products directed against up to four targets. Astellas will lead preclinical and clinical development of and obtaining regulatory approval for all Products. Astellas will be responsible for commercializing each Product, provided that we will have the option to elect to co-commercialize certain Products with Astellas in the United States, subject to the terms of a separate commercialization agreement to be entered into between Astellas and us.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Astellas Agreement, we received an upfront payment of $80 million, and Astellas will be responsible for funding the cost of preclinical research and discovery activities of both parties for all Products and for funding the cost of development and commercialization of all Products worldwide. If Astellas exercises its option to expand to six targets, we will be eligible to receive future preclinical, clinical and commercial milestones of approximately $2.5 billion. Astellas will pay us tiered royalties on global net sales of Products from high single digit to mid-teens percentages, subject to certain reductions. Astellas&#8217; royalty obligations continue with respect to each country and each Product until the later of (i) the date on which such Product is no longer covered by certain intellectual property rights, (ii) the 10th anniversary of the first commercial sale of such product in such country, and (iii) the loss of regulatory exclusivity for such Product in such country.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, for a specified number of targets, at a pre-specified time prior to the initiation of the first pivotal study of a Product directed against such target, we will have an option to elect to co-fund certain subsequently initiated clinical trials for such Product. If we opt in, we would be responsible for a pre-determined portion of the costs of such trials, subject to specified caps, deferrals and offsets. We would then have the option to elect to co-commercialize such Products in the United States. For any such Products, in lieu of royalties in the United States, we will receive less than 40% of the profits for such Products in the United States and tiered low double digit to mid-teens percentage royalties on net sales of such Products outside of the United States, subject to certain reductions. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Bristol Myers Squibb Company</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, we and Bristol Myers Squibb entered into a Collaboration and License Agreement (the &#8220;BMS Agreement&#8221;) to discover and develop compounds for use in human therapeutics aimed at multiple immuno-oncology targets using our Probody therapeutic technology. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the BMS Agreement, we granted Bristol Myers Squibb exclusive worldwide rights to develop and commercialize Probody therapeutics for up to four oncology targets, two of which were selected upon the execution of the BMS Agreement.&#160;&#160;Pursuant to the BMS Agreement, we received an upfront payment of $50.0 million and were initially entitled to receive contingent payments of up to an aggregate of $1,217.0 million in development, regulatory and commercial milestone payments, which can be reduced by any such payments received or by any termination of targets being pursued. We are entitled to royalty payments in the mid-single digit to low double digits percentage from potential future sales. We also receive research and development service fees.&#160;&#160;Bristol Myers Squibb has terminated certain targets from the BMS Agreement, as described below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, Bristol Myers Squibb selected the third target pursuant to the BMS Agreement and paid us $10.0 million. In December 2016, Bristol Myers Squibb selected the fourth and its final target pursuant to the BMS Agreement and paid us $15.0 million.&#160;&#160;In December 2016, Bristol Myers Squibb selected BMS-986249, a CTLA-4 Probody therapeutic, as a clinical candidate pursuant to the BMS Agreement, which triggered a $2.0 million pre-clinical milestone payment to us. In November 2017, Bristol Myers Squibb received acceptance of the IND for BMS-986249 from the FDA, which triggered a $10.0 million milestone payment to us. Bristol Myers Squibb recently advanced BMS-986249 into a randomized Phase 2 cohort expansion in patients with metastatic melanoma in combination with the PD-1 inhibitor <span style="Background-color:#FFFFFF;">nivolumab as part of the larger clinical trial, triggering, in February 2020, a $10.0 million milestone payment from </span>Bristol Myers Squibb<span style="Background-color:#FFFFFF;"> to us. This study has been modified to include three additional single-arm cohorts: advanced hepatocellular carcinoma, metastatic castration-resistant prostate cancer, and unresectable locally advanced or metastatic TNBC.&#160;&#160;</span></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In September 2019, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol Myers Squibb</span><span style="Background-color:#FFFFFF;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">initiated the dose escalation phase of a Phase 1/2a clinical</span><span style="Background-color:#FFFFFF;"> trial of a second anti-CTLA-4-directed therapeutic, BMS-986288, based on a modified version of ipilimumab, administered as monotherapy and in combination with nivolumab in patients with selected advanced solid tumors</span><span style="Background-color:#FFFFFF;">. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, we and Bristol Myers Squibb entered into Amendment Number 1 to Extend Collaboration and License Agreement (&#8220;Amendment 1&#8221;). Amendment 1 granted Bristol Myers Squibb exclusive worldwide rights to develop and commercialize Probody therapeutics for up to six additional oncology targets and two non-oncology targets. Under the terms of Amendment 1, we continued to collaborate with Bristol Myers Squibb to discover and conduct preclinical development of Probody therapeutics against targets selected by Bristol Myers Squibb. Pursuant to Amendment 1, we received an upfront payment of $200.0 million and were eligible to receive contingent payments for development, regulatory and sales milestones. We were also entitled to tiered mid-single to low double-digit percentage of royalties from potential future sales</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, we and Bristol Myers Squibb entered into Amendment Number 2 to amend the Collaboration and License Agreement (&#8220;Amendment 2&#8221;), as amended by Amendment 1. Subsequent to Amendment 2, Bristol Myers Squibb has the exclusive worldwide rights to develop and commercialize Probody therapeutics for up to five oncology targets. Under the terms of Amendment 2, the period for target selection has been extended and we will continue to collaborate with Bristol Myers Squibb to discover and conduct preclinical development of Probody therapeutics against targets selected by Bristol Myers Squibb. Pursuant to Amendment 2, we are eligible to receive contingent payments for development, regulatory and sales milestones of up to an aggregate of $1,779.0 million. We are also entitled to tiered mid-single to low double-digit percentage of royalties from potential future sales.&#160;&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ImmunoGen, Inc<span style="font-weight:bold;">. </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2014, CytomX and ImmunoGen entered into the Research Collaboration Agreement (the &#8220;ImmunoGen Research Agreement&#8221;). The ImmunoGen Research Agreement provides us with the right to use ImmunoGen&#8217;s ADC technology in combination with our Probody therapeutic technology to create a conditionally activated ADC directed at one specified target under a research license, and to subsequently obtain an exclusive, worldwide development and commercialization license to use ImmunoGen&#8217;s ADC technology to develop and commercialize such conditionally activated ADCs. Under the agreement, we provided ImmunoGen with the rights to our Probody therapeutic technology to create conditionally activated ADCs directed at two targets under the research license and to subsequently obtain exclusive, worldwide development and commercialization licenses to develop and commercialize such conditionally activated ADCs.<span style="color:#000000;"> In February 2016, we exercised our option to obtain a development and commercialization license for</span> <span style="color:#000000;">praluzatamab ravtansine (CX-2009) pursuant to the terms of the ImmunoGen Research Agreement (the &#8220;CX-2009 License&#8221;).</span>&#160;&#160;In February 2017, ImmunoGen exercised its option to obtain a development and commercialization license for the first of its two targets. ImmunoGen discontinued this program in July 2017 and substitution rights for this program terminated in February 2017. <span style="color:#000000;">ImmunoGen exercised its second option to obtain a development and commercialization license pursuant to the ImmunoGen Research Agreement (the &#8220;ImmunoGen 2017 License&#8221;) for a target, EpCAM, in December 2017. At the end of 2019, as a result of a strategic restructuring by ImmunoGen and its decision to out-license certain programs, we obtained a </span>worldwide, exclusive, sublicensable license <span style="color:#000000;">to the EpCAM conditionally activated ADC program from ImmunoGen (the &#8220;ImmunoGen 2019 License&#8221;) and the ImmunoGen 2017 license ended.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the ImmunoGen Research Agreement, both we and ImmunoGen were required to perform research activities on behalf of the other party for no monetary consideration. Each party was solely responsible for the development, manufacturing and commercialization of any products resulting from the exclusive development and commercialization license obtained by such party under the agreement. In consideration for the <span style="color:#000000;">praluzatamab ravtansine License</span>, ImmunoGen is entitled to receive up to $60.0 million in development and regulatory milestone payments, up to $100.0 million in sales milestone payments and royalties in the mid to high single digits percentage on the commercial sales of any resulting product. In August 2017, we made a milestone payment of $1.0 million to ImmunoGen for the first patient dosing with praluzatamab ravtansine <span style="Background-color:#FFFFFF;">and in February 2020, we triggered a $3.0 million milestone payment to ImmunoGen for the first dosing of a patient in the praluzatamab ravtansine Phase 2 clinical trial.&#160;&#160;</span><span style="Background-color:#FFFFFF;color:#000000;">Under the ImmunoGen 2019 License, we gained rights to the EpCAM conditionally activated ADC program and, in return, we made an upfront payment, and we will pay certain </span><span style="Background-color:#FFFFFF;">clinical development, approval and commercialization </span><span style="Background-color:#FFFFFF;color:#000000;">milestone payments if achieved and royalties on product sales.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Probody therapeutic candidates are designed to be produced as fully recombinant antibody prodrugs. Our Probody therapeutic candidates are also designed to maintain the manufacturability benefits of antibodies and leverage well established technologies used for antibody production. We conduct cell line development and process development both in-house and in collaboration with contract development and manufacturing organizations (&#8220;CMO&#8221;). CMOs are responsible for manufacturing of drug substance and clinical drug product materials. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our preferred cell line has been successfully used for manufacturing several antibodies and requires minimal process optimization to establish a process to support early phase manufacturing. We utilize well established production steps typically part of a platform manufacturing process for antibodies. The CMO we have selected has a strong track record in manufacturing therapeutic biologics, including antibodies. Similarly, for our conditionally</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activ</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ADC projects we have selected CMOs with strong expertise in clinical/commercial drug conjugate manufacturing and with capabilities for toxin conjugation and fill-finish. Furthermore, our two lead </span><span style="color:#000000;">conditionally</span><span style="color:#000000;"> </span><span style="color:#000000;">activ</span><span style="color:#000000;">at</span><span style="color:#000000;">e</span><span style="color:#000000;">d</span><span style="color:#000000;"> A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DC programs incorporate toxin payloads that have an established clinical and regulatory history.&#160;&#160;</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have generally been able to successfully manufacture praluzatamab ravtansine (CX-2009), CX-2029, and pacmilimab (CX-072) for our ongoing early-stage clinical trials with contract manufacturers.&#160;&#160;Our partner, Bristol Myers Squibb, has also been successful in independently manufacturing drug product for BMS-986249 and BMS-986288.&#160;&#160;However, in November 2019, we encountered a production failure at one of our CMOs that manufactures pacmilimab for our Phase 2 clinical trial. While we contracted with alternative suppliers that were able to timely deliver clinical trial drug product for the then ongoing trial, a failure to do so would have required us to temporarily suspend our ongoing trial for new and ongoing patients.&#160;&#160;Furthermore, in order to conduct later-stage clinical trials of our product candidates, including praluzatamab ravtansine, CX-2029, and pacmilimab, and eventually, if approved, commercial products, we will need to manufacture them in larger quantities.&#160;&#160;We, or any manufacturing partners, may be unable to successfully increase the manufacturing scale and capacity for any of our product candidates in a timely or cost-effective manner, or at all.&#160;&#160;For example, we are currently working with our CMOs to change our manufacturing processes and formulations, scaling up for large drug manufacturing capability for praluzatamab ravtansine and pacmilimab and increasing the term of stability for pacmilimab drug product for late-stage clinical trials and commercialization.&#160;&#160;However, we may have to start late-stage trials with our early clinical trial drug product and switch to the late-stage or commercial drug product mid trial. In such event, the FDA will require us to complete bridging studies to compare the earlier stage material with the late-stage or commercial material to assure comparability between the earlier trial material and the late-stage or commercial material.&#160;&#160;Changing the formulation and scale up process is a complicated and difficult task.&#160;&#160; While we believe we can complete the process successfully, there can be no assurances that the changes we make to the drug product and manufacturing process will be successful or completed in a timely manner or that the FDA will not require additional development steps or studies from those we believe are necessary.&#160;&#160;If we are unable scale up our manufacturing capabilities with respect to praluzatamab ravtansine, pacmilimab or any of our other product candidates, increase the life of drug stability of pacmilimab or such other product candidates, or successfully complete the FDA&#8217;s bridging requirements, we may not be able to successfully obtain FDA approval and commercialize pacmilimab or such other product candidates in a timely manner or at all. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The supply chain for the manufacturing of our product candidates is complicated and can involve many parties. We do not own manufacturing facilities for producing such supplies and rely on third-party contract manufacturers to manufacture our clinical trial and preclinical study product supplies. Our clinical trial manufacturing contractors and suppliers are our sole source for their respective manufacturing and supplies. Failure of any of these contractors could affect our ability to have clinical trial material available when needed. This could result in a substantial delay of our clinical trials. For example, for each of praluzatamab ravtansine, CX-2029, and pacmilimab, our manufacturing supply chain includes several contract manufacturers, and failure by any of these manufacturers could result in interruptions of our clinical studies. We do not have any long-term contracts and we do not currently have an alternative to any of our third-party contract manufacturers. Consequently, there can be no assurance that our preclinical and clinical development product supplies will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of any of our third-party contract manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In addition, we may encounter issues with transferring technology to a new third-party manufacturer, and we may encounter regulatory delays if we need to move the manufacturing of our products from one third-party manufacturer to another. For example, we were dependent on ImmunoGen under our collaboration for certain steps in the manufacturing of clinical quantities of praluzatamab ravtansine. At the end of 2018, ImmunoGen closed their clinical manufacturing facility in Norwood, Massachusetts provided clinical manufacturing support for the praluzatamab ravtansine program.&#160;&#160;We recently completed the transfer of the drug substance manufacturing process from ImmunoGen to a contract manufacturer, where we have an existing relationship and with expertise in the manufacture of antibody drug conjugates at a clinical and commercial scale.&#160;&#160;While the manufacturing transfer process has been completed, there can be no assurance that we will not experience a disruption in the supply of praluzatamab ravtansine as a result of such transfer or that we will not experience any other disruption in the manufacturing of praluzatamab ravtansine. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">In-Licenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">License from UCSB</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2010, we entered into an agreement with UCSB, that grants us an exclusive license, with the right to sublicense, under the patent rights owned by UCSB covering mask and screening technologies relating to the identification and discovery of pro-protein biologics, including masks and substrates, for the identification of pro-proteins, for use in the fields of therapeutics, in vivo diagnostics, and prophylactics (the &#8220;UCSB Agreement&#8221;). The UCSB Agreement also grants us an exclusive license, with the right to </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sublicense, under UCSB&#8217;s interest in certain patent rights we co-own with UCSB covering </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> antibodies and other pro-proteins in the fields of therapeutics, in vivo diagnostics and prophylactics.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We had no upfront payment obligations under the agreement.&#160;&#160;In April 2019, we amended the UCSB Agreement and in connection with the amendment, we paid UCSB $1.0 million and issued 150,000 shares of our common stock to UCSB.&#160;&#160;We are obligated to pay to UCSB royalties on net sales of licensed products in the low single digit percentages, subject to annual minimum amounts as well as certain reductions.&#160;&#160;We are required to make milestone payments to UCSB on the accomplishment of certain milestones totaling up to $1,075 million for each of the first two indications for each licensed product consisting of a molecule or compound covered by the licensed patent rights. We were also obligated to make a payment to UCSB upon the first occurrence of an IPO or change of control. If the Company sublicenses its rights under the UCSB Agreement, it must pay UCSB a percentage of our total sublicense revenues ranging from the mid-single to mid-teen percentages, which total amount would be first reduced by the aggregate amount of certain research and development related expenses incurred by the Company and other permitted deductions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Licenses from ImmunoGen</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, we exercised our option to obtain a worldwide, exclusive, sublicensable license from ImmunoGen for development and commercialization of products directed against the target selected by us under our research collaboration agreement with ImmunoGen. Additionally, in December 2019, we obtained a worldwide, exclusive, sublicensable license to ImmunoGen&#8217;s EpCAM conditionally activated ADC program. See the description of the license agreements set forth under the caption &#8220;Our Collaborations&#8212;ImmunoGen, Inc.&#8221; in this Item 1 of this Annual Report on Form 10-K.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Competition </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CytomX is pioneering a new class of antibody therapeutics &#8211; the Probody therapeutic platform. The biotechnology and biopharmaceutical industries, including the ADC and immuno-oncology subsectors, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. Any product candidates that we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. While we believe that our proprietary Probody platform and scientific expertise in the field of biologics and immuno-oncology provide us with competitive advantages, a wide variety of institutions, including large biopharmaceutical companies, specialty biotechnology companies, academic research departments and public and private research institutions, are actively developing potentially competitive products and technologies. We face substantial competition from biotechnology and biopharmaceutical companies developing biopharmaceutical products, particularly with respect to ADC and immuno-oncology therapeutics, where competition is intense and rapidly evolving. These competitors generally fall within the following categories:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Masking and conditional activation: <span style="font-weight:normal;">Several companies, including AbbVie, Adagene, Amgen, Amunix, BioAtla, Halozyme, Harpoon, Maverick Therapeutics, Pandion Therapeutics, Revitope, Roche, Seagen, Werewolf, and Xilio are exploring antibody masking and/or conditional activation strategies, which could compete with our Probody Platform.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Antibody-drug conjugates:<span style="font-weight:normal;"> Several large pharmaceutical companies, such as AbbVie, Daiichi Sankyo, Gilead, Pfizer, Roche, and Takeda are developing ADCs. Two mid-sized companies, ImmunoGen and Seagen are also leaders in this space. In addition, numerous smaller companies have ongoing efforts in the space.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cancer immunotherapies:<span style="font-weight:normal;"> Cancer immunotherapy is one of the most competitive and fastest growing segments of the pharmaceutical industry. Almost every large pharmaceutical company is developing cancer immunotherapies, including Amgen, AstraZeneca PLC, Bristol Myers Squibb, Celgene, GlaxoSmithKline plc, Merck &#38; Co., Inc., Novartis AG, Pfizer, Roche Holding Ltd and Sanofi SA. In addition, many large and mid-sized biotech companies such as BeiGene, Incyte, Nektar, and Alkermes have ongoing efforts in cancer immunotherapy. Numerous smaller companies are also working in this space.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">T-cell engaging bispecifics: <span style="font-weight:normal;">Several large pharmaceutics companies, such as Amgen, Novartis, and Roche, have on-going efforts in the field of TCBs. In additional, several mid-sized biotech companies such as Macrogenics and Xencor, as well as numerous smaller companies, have ongoing efforts in TCBs. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical and human resources than we do. Accordingly, our competitors may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Accelerated merger and acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical study sites and patient registration for clinical studies and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunity could be substantially limited in the event that our competitors develop and commercialize products that are more effective, safer, less toxic, more convenient or less expensive than our comparable products. In geographies that are critical to our commercial success, competitors may also obtain regulatory approvals </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">before us, resulting in our competitors building a strong market position in advance of our products&#8217; entry. We believe the factors determining the success of our programs will be the efficacy, safety and convenience of our product candidates.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Intellectual Property</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to our business, including seeking, maintaining, and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and product candidates that are important to the development and implementation of our business. Our patent portfolio is intended to cover, but is not limited to, our technology platforms, our product candidates and components thereof, their methods of use and processes for their manufacture, our proprietary reagents and assays, and any other inventions that are commercially important to our business. We also rely on trade secret protection of our confidential information and know-how relating to our proprietary technology, platforms and product candidates, continuing innovation, and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in our Probody platform and product candidates. We expect to rely on data exclusivity, market exclusivity, patent term adjustment and patent term extensions when available. Our commercial success may depend in part on our ability to obtain and maintain patent and other proprietary protection for our technology, inventions, and improvements&#59; to preserve the confidentiality of our trade secrets&#59; to maintain our licenses to use intellectual property owned or controlled by third parties&#59; to defend and enforce our proprietary rights, including our patents&#59; to defend against and challenge the assertion by third parties of their purported intellectual property rights&#59; and to operate without the unauthorized infringement of valid and enforceable patents and other proprietary rights of third parties.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that we have a strong global intellectual property position and substantial know-how and trade secrets relating to our Probody therapeutic technology, platform and product candidates. Our patent portfolio as of February 20, 2021 contains at least 150 issued patents (some of which are co-owned with a third party) and at least 325 pending patent applications (some of which are co-owned with a third party). We have exclusively licensed UCSB&#8217;s interest in the co-owned patent family covering Probody and other pro-protein technology in the fields of therapeutics, <span style="font-style:italic;">in vivo</span> diagnostics and prophylactics.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These patents and patent applications include claims directed to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Probody platform and PDC platform&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Other pro-protein platforms&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Probody conjugates and conjugation methods to produce PDCs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Bispecific and other multispecific Probody therapeutics, including T-cell-recruiting bispecific Probody therapeutics&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Protease-cleavable linkers, e.g., serine protease- and/or MMP-cleavable linkers&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Improved display systems for peptide display, e.g., to identify masks, substrates, and other proteins&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Cancer immunotherapy Probody therapeutics, e.g., PD-L1, PD-1, and CTLA-4 Probody therapeutics, as well as related novel antibodies and combination therapies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Probody drug conjugates, e.g., CD-166, CD71 (transferrin receptor), CD49c (integrin alpha 3), and CD147 PDCs, as well as related Probody therapeutics, novel antibodies and ADCs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Probody therapeutics to other targets, e.g., EGFR, Jagged, and IL6R Probody therapeutics, as well as related PDCs, novel antibodies and ADCs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Antibodies that bind Probody therapeutics, e.g., anti-mask and anti-Probody antibodies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Antibodies that bind key targets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Antibodies that bind the active site of uPA protease&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Compositions and methods to discriminate between intact Probody therapeutics and activated versions thereof, as well as other translation assays&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Methods to produce intact Probody therapeutics&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.53%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Methods to use any of the above-referenced compounds and compositions.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have exclusively licensed a patent portfolio of patent families from UCSB patents and patent applications that cover compositions and methods related to screening for and identification of masks and protease-cleavable linkers that we incorporate into our Probody therapeutics.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As for the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> platform, product candidates and processes we develop and commercialize, in the normal course of business, we intend to pursue, where appropriate, patent protection or trade secret protection relating to compositions, methods of manufacture, assay methods, methods of use, treatment of indications, dosing and formulations. We may also pursue patent protection with respect to product development processes and technology.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We continually assess and refine our intellectual property strategy as we develop new platform technologies and product candidates. To that end, we are prepared to file additional patent applications if our intellectual property strategy requires such filings, or where we seek to adapt to competition or seize business opportunities. Further, we are prepared to file patent applications, as we consider appropriate under the circumstances, relating to the new technologies that we develop. In addition to filing and prosecuting patent applications in the United States, we often file counterpart patent applications in the European Union and in additional countries where we believe such foreign filing is likely to be beneficial.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our currently issued patents will likely expire on dates ranging from 2028 to 2037, unless we receive patent term extension or adjustment as might be available under applicable law. If patents are issued on our pending patent applications, the resulting patents are projected to expire on dates ranging from 2028 to 2041, unless we receive patent term extension or adjustment. However, the actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country, and the validity and enforceability of the patent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our patents and patent applications are subject to risks and uncertainties under U.S. and foreign law. We also rely on trademark registration to protect our trademarks.&#160;&#160;For a more comprehensive discussion of risks related to our proprietary technology, inventions, improvements, platforms and product candidates, please see the section entitled &#8220;Risk Factors&#8212;Risks Related to Intellectual Property.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also rely on trade secret protection for our confidential and proprietary information. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result of the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation and Product Approval</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Governmental authorities in the U.S., at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing and export and import of products such as those we are developing. Our product candidates are subject to regulation in the U.S. as biologics, which must be approved by the FDA through the BLA process before they may be legally marketed in the U.S. and will be subject to similar requirements in other countries prior to marketing in those countries. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. Government Regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the U.S., the FDA regulates biologics under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and the Public Health Service Act (&#8220;PHSA&#8221;), and their respective implementing regulations. Failure to comply with the applicable U.S. requirements at any time during the product development or approval process, or after approval, may subject an applicant to administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal to approve pending applications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">withdrawal of an approval&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">imposition of a clinical hold&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">warning or untitled letters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seizures or administrative detention of product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">total or partial suspension of production or distribution&#59; or</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injunctions, fines, disgorgement, or civil or criminal penalties.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">BLA Approval Process</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process required by the FDA before a biologic may be marketed in the U.S. generally involves the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">completion of nonclinical laboratory tests, animal studies and formulation studies conducted according to good laboratory practices (&#8220;GLPs&#8221;), and other applicable regulations&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">submission to the FDA of an IND, which must become effective before human clinical trials may begin&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">performance of adequate and well-controlled human clinical trials according to good clinical practices (&#8220;GCPs&#8221;), to establish the safety, purity and potency of the product candidate for its intended use&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">submission to the FDA of a BLA&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the product candidate is produced to assess compliance with current good manufacturing practices (&#8220;cGMPs&#8221;) to assure that the facilities, methods and controls are adequate to preserve the product candidate&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">FDA review and approval of the BLA to permit commercial marketing of the product for its particular labeled uses in the United States.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preclinical and Clinical Studies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a biologic product candidate is identified for development, it enters the preclinical or nonclinical testing stage. Nonclinical tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the nonclinical tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some nonclinical testing may continue even after the IND is submitted. In addition to including the results of the nonclinical studies, the IND will also include a protocol detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated if the first phase lends itself to an efficacy evaluation. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time during the life of an IND and may affect one or more specific studies or all studies conducted under the IND.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All clinical trials must be conducted under the supervision of one or more qualified investigators in accordance with GCPs. They must be conducted under protocols detailing the objectives of the trial, dosing procedures, research subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol, and any subsequent material amendment to the protocol, must be submitted to the FDA as part of the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors also must report to the FDA serious and unexpected adverse reactions in a timely manner, any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigation brochure or any findings from other studies or animal or <span style="font-style:italic;">in vitro</span> testing that suggest a significant risk in humans exposed to the product candidate. An institutional review board (&#8220;IRB&#8221;) at each institution participating in the clinical trial must review and approve the protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each research subject or the subject&#8217;s legal representative, monitor the study until completed and otherwise comply with IRB regulations. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Phase 1&#8212;The product candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and elimination. In the case of some therapeutic candidates for severe or life-threatening diseases, such as cancer, especially when the product candidate may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Phase 2&#8212;Clinical trials are performed on a limited patient population intended to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Phase 3&#8212;Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product approval.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A pivotal study is a clinical study that is designed to meet regulatory agency requirements for the evaluation of a product candidate&#8217;s efficacy and safety such that it can be used to justify the approval of the product. Generally, pivotal studies are also Phase 3 studies but may</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">consist of Phase 2 studies if the trial design for such Phase 2 provides a reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need. Human clinical trials are inherently uncertain, and Phase 1, Phase 2 and Phase 3 testing may not be successfully completed. The FDA or the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the development of a new biologic product candidate, sponsors are given opportunities to meet with the FDA at certain points&#59; specifically, prior to the submission of an IND, at the end of Phase 2 and before a BLA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide advice on the next phase of development. Sponsors typically use the meeting at the end of Phase 2 to discuss their Phase 2 clinical results and present their plans for the pivotal Phase 3 clinical trial that they believe will support the approval of the new therapeutic. If a Phase 3 clinical trial is the subject of discussion at the end of Phase 2 meeting with the FDA, a sponsor may be able to request a Special Protocol Assessment (&#8220;SPA&#8221;), the purpose of which is to reach agreement with the FDA on the Phase 3 clinical trial protocol design and analysis that will form the primary basis of an efficacy claim. If a written agreement is reached, it will be binding on the FDA and may not be changed by the sponsor or the FDA after the trial begins except with the written agreement of the sponsor and the FDA or if the FDA determines that a substantial scientific issue essential to determining the safety or efficacy of the product candidate was identified after the testing began. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post-approval trials, sometimes referred to as &#8220;Phase 4&#8221; clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may mandate the performance of such &#8220;Phase 4&#8221; clinical trials as a condition of approval for a BLA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, sponsors usually complete additional animal safety studies, develop additional information about the chemistry and physical characteristics of the product candidate and finalize a process for manufacturing commercial quantities of the product candidate in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and the manufacturer must develop methods for testing the safety, purity and potency of the product candidate. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biologic product candidate does not undergo unacceptable deterioration over its shelf life. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Submission of a BLA to the FDA</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of product development, nonclinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests and other control mechanisms, proposed labeling and other relevant information are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for marketed products. Fee waivers or reductions are available in certain circumstances, such as where a waiver is necessary to protect the public health, where the fee would present a significant barrier to innovation, or where the applicant is a small business submitting its first human therapeutic application for review.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Within 60 days following submission of the application, the FDA reviews a BLA to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews a BLA to determine, among other things, whether the proposed product is safe, pure and potent for its intended use, and whether the facility in which it is being manufactured, processed, packaged, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency in accordance with cGMP. The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with GCP requirements. To assure cGMP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval of the application. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product receives regulatory approval, the approval may be significantly limited to specific indications and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a condition of BLA approval, the FDA may require a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) to ensure that the benefits of the drug outweigh its risks. If the FDA determines a REMS is necessary prior to or during review of the application, the sponsor must submit a REMS as part of its application, and the FDA will not approve a BLA without a REMS, if required. A REMS program may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate healthcare providers of the product&#8217;s risks, or other elements to assure safe use, such as limitations on who may prescribe or dispense the drug, dispensing only under certain circumstances, special monitoring and the use of patient registries.&#160;&#160;In addition, all REMS programs must include a timetable to periodically assess the strategy following implementation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, product approval may require substantial post-approval testing and surveillance to monitor the product&#8217;s safety and efficacy, and the FDA has the authority to prevent or limit further marketing of a product based on the results of these post-marketing programs. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing. Moreover, changes to the conditions established in an approved application, including changes in indications, labeling or manufacturing processes or facilities may require submission and FDA approval of a new supplement before the changes can be implemented.&#160;&#160;A supplement for a new indication typically requires clinical data similar to that supporting the original approval, and the FDA uses similar procedures in reviewing supplements as it does in reviewing original applications.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Companion Diagnostics</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our product candidates may require use of an in vitro diagnostic to identify appropriate patient populations. These diagnostics, often referred to as companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, pre-clinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import, and post-market surveillance. Unless an exemption applies, companion diagnostic tests require marketing clearance or approval from the FDA prior to commercial distribution. The two primary types of FDA marketing authorization applicable to a medical device are premarket notification, also called 510(k) clearance, and premarket approval (&#8220;PMA&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If use of companion diagnostic is essential to safe and effective use of a biologic product, then the FDA generally will require approval or clearance of the diagnostic contemporaneously with the approval of the biologic product. According to FDA guidance, for novel product candidates such as drugs and therapeutic biologics, a companion diagnostic device and its corresponding product candidate should be approved or cleared contemporaneously by FDA for the use indicated in the product labeling. The guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a product candidate generally will be considered an investigational device unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#8217;s Investigational Device Exemption (&#8220;IDE&#8221;) regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a drug or biologic product candidate are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA generally requires companion diagnostics intended to select the patients who will respond to cancer treatment to obtain approval of a PMA for that diagnostic contemporaneously with approval of the therapeutic product. The PMA process, including the gathering of clinical and pre-clinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the applicant must prepare and provide the FDA with reasonable assurance of the device&#8217;s </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are also subject to an application fee. In addition, PMAs for certain devices must generally include the results from extensive pre-clinical and adequate and well-controlled clinical trials to establish the safety and effectiveness of the device for each indication for which FDA approval is sought. In particular, for a diagnostic, the applicant must demonstrate that the diagnostic produces reproducible results when the same sample is tested multiple times by multiple users at multiple laboratories. In addition, as part of the PMA review, the FDA will typically inspect the manufacturer&#8217;s facilities for compliance with the Quality System Regulation (&#8220;QSR&#8221;) which imposes elaborate testing, control, documentation and other quality assurance requirements.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PMA approval is not guaranteed, and the FDA may ultimately respond to a PMA submission with a not approvable determination based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming to generate and that can substantially delay approval. If the FDA&#8217;s evaluation of the PMA application is favorable, the FDA typically issues an approvable letter requiring the applicant&#8217;s agreement to specific conditions, such as changes in labeling, or specific additional information, such as submission of final labeling, in order to secure final approval of the PMA. If the FDA&#8217;s evaluation of the PMA or manufacturing facilities is not favorable, the FDA will deny approval of the PMA or issue a not approvable letter. A not approvable letter will outline the deficiencies in the application and, where practical, will identify what is necessary to make the PMA approvable. The FDA may also determine that additional clinical trials are necessary, in which case the PMA approval may be delayed for several months or years while the trials are conducted and then the data submitted in an amendment to the PMA. If the FDA concludes that the applicable criteria have been met, the FDA will issue a PMA for the approved indications, which can be more limited than those originally sought by the applicant. The PMA can include post-approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device, including, among other things, restrictions on labeling, promotion, sale and distribution. Once granted, PMA approval may be withdrawn by the FDA if compliance with post approval requirements, conditions of approval or other regulatory standards are not maintained or problems are identified following initial marketing. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After a device is placed on the market, it remains subject to significant regulatory requirements. Medical devices may be marketed only for the uses and indications for which they are cleared or approved. Device manufacturers must also establish registration and device listings with the FDA. A medical device manufacturer&#8217;s manufacturing processes and those of its suppliers are required to comply with the applicable portions of the QSR, which cover the methods and documentation of the design, testing, production, processes, controls, quality assurance, labeling, packaging and shipping of medical devices. Domestic facility records and manufacturing processes are subject to periodic unscheduled inspections by the FDA. The FDA also may inspect foreign facilities that export products to the United States. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expedited Development and Review Programs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA offers a number of expedited development and review programs for qualifying product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product candidate may be eligible for fast track designation if it is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product candidate and the specific indication for which it is being studied. The sponsor of a fast track product candidate has opportunities for frequent interactions with the review team during product development and, once a BLA is submitted, the product candidate may be eligible for priority review. A fast track product candidate may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product candidate intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product candidate can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product candidate may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product candidate, including involvement of senior managers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After a BLA is submitted for a product candidate, including a product candidate with a fast track designation and/or breakthrough therapy designation, the BLA may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product candidate is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. Priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date, compared to ten months under standard review.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, product candidates studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Patent Term Restoration and Marketing Exclusivity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending upon the timing, duration and specifics of FDA approval of the use of our therapeutic candidates, some of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product candidate&#8217;s approval date. The patent term restoration period is generally one half of the time between the effective date of an IND and the submission date of a BLA, plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved product candidate is eligible for the extension and the application for extension must be made prior to expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we intend to apply for restorations of patent term for some of our currently owned or licensed patents to add patent life beyond their current expiration date, depending on the expected length of clinical trials and other factors involved in the submission of the relevant BLA.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Biosimilars and Exclusivity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Affordable Care Act, signed into law in 2010, includes the Biologics Price Competition and Innovation Act (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. The FDA has issued several guidance documents outlining an approach to review and approval of biosimilars. Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical study or studies. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued &#8220;Written Request&#8221; for such a study.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Orphan Drug Designation</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant Orphan Drug Designation to therapeutic candidates intended to treat a rare disease or condition, which is generally a disease or condition that affects either (1) fewer than 200,000 individuals in the U.S., or (2) more than 200,000 individuals in the U.S. and for which there is no reasonable expectation that the cost of developing and making available in the U.S. a product candidate for this type of disease or condition will be recovered from sales in the U.S. for that product candidate. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drug designation entitles the applicant to incentives such as grant funding towards clinical study costs, tax advantages, and waivers of FDA user fees.&#160;&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan Drug Designation must be requested before submitting a BLA. After the FDA grants Orphan Drug Designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product candidate that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product candidate is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same product candidate for the same indication, except under limited circumstances, for seven years. Orphan drug exclusivity, however, could also block the approval of one of our therapeutic candidates for seven years if a competitor obtains approval of the same product candidate as defined by the FDA or if our product candidate is determined to be contained within the competitor&#8217;s product candidate for the same indication or disease. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Pediatric Studies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Pediatric Research Equity Act (&#8220;PREA&#8221;), requires a sponsor to conduct pediatric studies for most therapeutic candidates and biologics, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original BLAs and supplements thereto must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must assess the safety and effectiveness of the product candidate for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product candidate is safe and effective. The sponsor or FDA may request a deferral of pediatric studies for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the product candidate or biologic is ready for approval for use in adults before pediatric studies are complete or that additional safety or effectiveness data needs to be collected before the pediatric studies begin. The law requires the FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. It further requires the FDA to post the PREA Non- Compliance letter and sponsor&#8217;s response.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Post-Approval Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a BLA approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the biologic product reaches the market. Later discovery of previously unknown problems with a product candidate may result in restrictions on the product candidate or even complete withdrawal of the product candidate from the market. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval. In addition, the FDA may under some circumstances require testing and surveillance programs to monitor the effect of approved product that have been commercialized, and the FDA under some circumstances has the power to prevent or limit further marketing of a product candidate based on the results of these post-marketing programs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any biologic products manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">record-keeping requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reporting of adverse experiences with the product candidate&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">providing the FDA with updated safety and efficacy information&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product sampling and distribution requirements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">notifying the FDA and gaining its approval of specified manufacturing or labeling changes&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">complying with FDA promotion and advertising requirements, which include, among other things, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in-patient populations that are not described in the product&#8217;s approved labeling, limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biologic manufacturers and other entities involved in the manufacture and distribution of approved therapeutic products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMPs and other laws. The FDA periodically inspects manufacturing facilities to </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">assess compliance with cGMP, which imposes extensive procedural, substantive and record-keeping requirements. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations would also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use if our product candidates are approved. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">New Legislation and Regulations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations changed or what the effect of such changes, if any, may be.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Regulation Outside of the U.S.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the U.S., we will be subject to regulations of other jurisdictions governing any clinical trials and commercial sales and distribution of our therapeutic candidates. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the U.S. before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or areas. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under European Union regulatory systems, a company can consider applying for marketing authorization in several European Union member states by submitting its marketing authorization application(s) under a centralized, decentralized or mutual recognition procedure. The centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. The centralized procedure is compulsory for medicines derived from biotechnology, orphan medicinal products, or those medicines with an active substance not authorized in the European Union on or before May 20, 2004 intended to treat acquired immune deficiency syndrome (&#8220;AIDS&#8221;), cancer, neurodegenerative disorders or diabetes and optional for those medicines containing a new active substance not authorized in the European Union on or before May 20, 2004, medicines which are highly innovative, or medicines to which the granting of a marketing authorization under the centralized procedure would be in the interest of patients at the European Union-level. The decentralized procedure provides for recognition by European Union national authorities of a first assessment performed by one of the member states. Under this procedure, an identical application for marketing authorization is submitted simultaneously to the national authorities of several European Union member states, one of them being chosen as the &#8220;Reference Member State&#8221;, and the remaining being the &#8220;Concerned Member States&#8221;. The Reference Member State must prepare and send drafts of an assessment report, summary of product characteristics and the labelling and package leaflet within 120 days after receipt of a valid marketing authorization application to the Concerned Member States, which must decide within 90 days whether to recognize approval. If any Concerned Member State does not recognize the marketing authorization on the grounds of potential serious risk to public health, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states. The mutual recognition procedure is similar to the decentralized procedure except that a medicine must have already received a marketing authorization in at least one of the member states, and that member state acts as the Reference Member State.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As in the U.S., we may apply for designation of a product candidate as an orphan drug for the treatment of a specific indication in the European Union before the application for marketing authorization is made.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Orphan drugs in the European Union enjoy economic and marketing benefits, including up to ten years of market exclusivity for the approved indication unless another applicant can show that its product is safer, more effective or otherwise clinically superior to the orphan-designated product, the marketing authorization holder is unable to supply sufficient quantity of the medicinal product or the marketing authorization holder has given its consent.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Coverage and Reimbursement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly reducing reimbursements for medical products and services. Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of therapeutics have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">revenue and results. If these third- party payors do not consider our products to be cost-effective compared to other therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our products on a profitable basis.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare Reform</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (together, the &#8220;ACA&#8221;) has had a significant impact on the health care industry. The ACA expanded coverage for the uninsured while at the same time containing overall healthcare costs. With regard to biopharmaceutical products, the ACA, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts, which, through subsequent legislative amendments, will be increased to 70% starting in 2019, off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, as well as efforts by the former presidential administration to modify, repeal, or otherwise invalidate all, or certain provisions of, the ACA. By way of example, the Tax Cuts and Jobs Act was enacted, which, among other things, removes penalties for not complying with the ACA&#8217;s individual mandate to carry health insurance.<span style="font-size:9.5pt;">&#160;&#160;</span>The U.S. Supreme Court is currently reviewing the constitutionality of the ACA in its entirety. <span style="color:#000000;"> It is unclear how these challenges, subsequent appeals, and other efforts to challenge, repeal, or replace the ACA will impact the ACA, particularly in light of presidential and congressional elections of 2020.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted that impact payment methodologies and reimbursement amounts. On August 2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress, which led to aggregate reductions to Medicare payments to providers of 2% per fiscal year starting in April 2013, and, due to subsequent legislative amendments, will stay in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. On January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012 (the &#8220;ATRA&#8221;) which among other things, also reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recently, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, the 21st Century Cures Act changed the reimbursement methodology for infusion drugs and biologics furnished through durable medical equipment in an attempt to remedy over- and underpayment of certain products. Furthermore, with the new Presidential administration and both houses of Congress potentially under the control of one party, which has promoted substantial changes to the healthcare system and drug pricing rules, some changes are likely.&#160;&#160;Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.&#160;&#160;We cannot predict the extent of the impact of any changes to any of these laws on us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finally, in some foreign countries, the proposed pricing for a product candidate must be approved before it may be lawfully marketed. The requirements governing therapeutic pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, therapeutic candidates launched in the European Union do not follow price structures of the U.S. and generally tend to be significantly lower.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Healthcare Laws</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to healthcare regulation and enforcement by the federal government and the states and foreign governments where we may market our product candidates, if approved. These laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, physician and other health care provider payment and drug pricing transparency laws and regulations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal Anti-Kickback Statute prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. The Anti-Kickback Statute is subject to evolving interpretations. In the past, the government has enforced the Anti-Kickback Statute to reach large settlements with healthcare companies based on sham consulting and other financial arrangements with physicians. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The majority of states also have anti-kickback laws, which establish similar prohibitions and, in some cases, may apply to items or services reimbursed by any third-party payor, including commercial insurers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the civil False Claims Act prohibits knowingly presenting or causing the presentation of a false, fictitious or fraudulent claim for payment to the U.S. government, knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the U.S. government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. government. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act. Actions under the False Claims Act may be brought by the Attorney General or as a qui tam action by a private individual in the name of the government. The federal government is using the False Claims Act, and the accompanying threat of significant liability, in its investigation and prosecution of pharmaceutical and biotechnology companies throughout the U.S., for example, in connection with the promotion of products for unapproved uses and other sales and marketing practices. The government has obtained multi-million and multi-billion-dollar settlements under the False Claims Act in addition to individual criminal convictions under applicable criminal statutes. Given the significant size of actual and potential settlements, it is expected that the government will continue to devote substantial resources to investigating healthcare providers&#8217; and manufacturers&#8217; compliance with applicable fraud and abuse laws.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), created new federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There has also been a recent trend of increased federal and state regulation of payments made to physicians and other healthcare providers. The ACA, among other things, imposes new reporting requirements on drug manufacturers for payments made by them to physicians (as defined by statute), teaching hospitals and, beginning in 2022, certain other health care professionals, as well as ownership and investment interests held by physicians and their immediate family members. Certain states also mandate implementation of compliance programs and compliance with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, impose restrictions on drug manufacturer marketing practices and/or require the tracking and reporting of pricing and marketing information as well as gifts, compensation and other remuneration or items of value provided to physicians and other healthcare professionals and entities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Penalties for violating any of such laws or any other governmental regulations that apply include, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, exclusion from participation in federal and state healthcare programs, integrity oversight and reporting obligations to resolve allegations of non-compliance and imprisonment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Data Privacy and Security Laws</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;) and their respective implementing regulations, including the final omnibus rule published on January 25, 2013, imposes specified requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; defined as independent contractors or agents of covered entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state laws and non-US laws and regulations (particularly EU laws regarding personal data relating to individuals based in Europe) govern the privacy and security of health information in certain circumstances, many of which differ </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from each other in significant ways, thus complicating compliance efforts.&#160;&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, California recently enacted legislation, the California Consumer Privacy Act, or CCPA, which went into effect January 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Although the law includes limited exceptions, including for &#8220;protected health information&#8221; maintained by a covered entity or business associate, it may regulate or impact our processing of personal information depending on the context.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Environment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our third-party manufacturers are subject to inspections by the FDA for compliance with cGMP and other U.S. regulatory requirements, including U.S. federal, state and local regulations regarding environmental protection and hazardous and controlled substance controls, among others. Environmental laws and regulations are complex, change frequently and have tended to become more stringent over time. We have incurred, and may continue to incur, significant expenditures to ensure we are in compliance with these laws and regulations. We would be subject to significant penalties for failure to comply with these laws and regulations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Our Company Origins and Team</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Probody platform technology has its origins in work performed at the University of California, Santa Barbara (&#8220;UCSB&#8221;), by our scientific founder Professor Patrick Daugherty. Since our inception, we have continued developing and adding to this technology and aspire to design a pipeline of Probody therapeutics that will better the lives of cancer patients. We have assembled an experienced and talented group of individuals dedicated to the advancement of cancer care. Our president and chief executive officer, Dr. Sean McCarthy, leads a team that draws on robust experience in all phases of product discovery, clinical development and commercialization. Our clinical development team is led by Dr. Amy Peterson, chief development officer, and Dr. Alison Hannah, chief medical officer. Our research and preclinical development team is led by Dr. Marcia Belvin, head of research, and includes renowned and established researchers. Our management team members have significant experience in oncology with previous experience at BeiGene, Chiron, Genentech, Maxygen, Medivation, Millennium, Novartis, SGX and other companies. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Human Capital</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 144 full-time employees and 2 part-time employees. Of these employees, 109 were primarily engaged in research and development activities. None of our employees are represented by a labor union or covered by collective bargaining agreements and we consider our employee relations to be good. Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees, consultants and directors through the granting of stock-based compensation awards and cash-based performance bonus awards.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations commenced in February 2008 when our predecessor entity was formed. We were incorporated in Delaware in September 2010. We maintain our executive offices at 151 Oyster Point Blvd., Suite 400, South San Francisco, California 94080, and our main telephone number is (650)&#160;515-3185.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We view our operations and measure our business as one reportable segment operating in the United States. See Note 2 to our audited financial statement included elsewhere in this Annual Report on Form 10-K for additional information. Additional information required by this item is incorporated herein by reference to PART II. Item 6 of this Annual Report on Form 10-K.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development expenses were $112.9 million, $131.6 million and $103.9 million for the years ended December 31, 2020, 2019 and 2018, respectively. Please see &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations-Research and Development Expenses&#8221; for additional detail regarding our research and development activities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain a website at <span style="font-style:italic;">www.cytomx.com</span>, which contains information about us. The information in, or that can be accessed through, our website is not part of this Annual Report on Form&#160;10-K. Our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q and current reports on Form&#160;8-K and amendments to those reports are available, free of charge, on or through our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements and other information regarding our filings at <span style="font-style:italic;">www.sec.gov</span>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART II &#8211; OTHER INFORMATION</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1A_RISK_FACTORS">Risk Factors</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk Factors Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are providing the following summary of risk factors contained in this Annual Report on Form 10-K to enhance the readability and accessibility of our risk factor disclosures in accordance with SEC rules. Please carefully review the full risk factors pertaining to this summary and to additional general risk factors contained in this Annual Report on Form 10-K in their entirety for additional information regarding the material factors that make an investment in our securities speculative or risky. These risks and uncertainties include, but are not limited to, the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The COVID-19 pandemic or any future pandemic could adversely impact our business, including our research, clinical trials, and financial condition.&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We are a clinical-stage biopharmaceutical company with a limited operating history and have not generated any revenue from product sales.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We expect that we will need to raise substantial additional funds to advance development of our product candidates and we cannot guarantee that this additional funding will be available on acceptable terms or at all. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our product candidates are in early stages of development and may fail or suffer delays that materially and adversely affect their commercial viability.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Interim, &#8220;top-line,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our product candidates may cause undesirable side effects at any time during or after the clinical trial process that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including withdrawal from the market.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our approach to the discovery and development of our therapeutic treatments is based on novel technologies that are unproven and may not result in marketable products.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The market may not be receptive to our product candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We have entered, and may in the future seek to enter, into collaborations with third parties for the development and commercialization of our product candidates using our Probody platform. If we fail to enter into such collaborations, or such collaborations are not successful, we may not be able to capitalize on the market potential of our Probody platform and resulting product candidates.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of any of our product candidates may be delayed, and our business will be harmed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expense and present significant distractions to our management. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We rely on third parties to conduct all of our clinical trials and certain of our preclinical studies and intend to continue to do so, and if such third parties do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development programs could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Because we have no long-term contracts with and rely on third-party manufacturing and supply partners, most of which are sole source suppliers, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">We, or third-party manufacturers, may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our stock price may be volatile and purchasers of our common stock could incur substantial losses.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risk Factors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should consider carefully the risks and uncertainties described below, together with all of the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. The risks described below are not the only risks facing the Company. Risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, results of operations and/or prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The COVID-19 pandemic or any future pandemic could adversely impact our business, including our research, clinical trials, and financial condition.&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, a novel strain of coronavirus, COVID-19, was reported to have surfaced in Wuhan, China. Since then, the COVID-19 coronavirus has spread to multiple countries, including the United States and European and Asia-Pacific countries, including countries in which we have planned or active clinical trial sites, including for praluzatamab ravtansine (CX-2009). As the COVID-19 coronavirus continues to spread around the globe, we will likely continue to experience disruptions that could severely impact our business, research, including research for our partners or research of our partners, and clinical trials, including ongoing or planned clinical trials for praluzatamab ravtansine, CX-2029 and clinical trials of our partners, including Bristol Myers Squibb. These disruptions and impacts may include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays or difficulties in enrolling patients in our clinical trials or the clinical trials of our partners&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays or difficulties in clinical site initiation for praluzatamab ravtansine, CX-2029 or any other clinical trials we or our partners decide to initiate, including difficulties in recruiting clinical site investigators and clinical site staff&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our or our partners&#8217; clinical trial sites and hospital staff supporting the conduct of our or our partners&#8217; clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">difficulty in interpreting clinical data due to patients being infected by COVID-19&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">limitations in employee resources that would otherwise be focused on the conduct of our clinical trials or the clinical trials of our partners, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in receiving approval from local regulatory authorities to initiate our or our partners&#8217; planned clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in clinical sites receiving the supplies and materials needed to conduct our or our partners&#8217; clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">interruption in manufacturing or global shipping that may affect the timely delivery or transport of research materials or clinical trial materials, such as investigational drug product used in our or our partners&#8217; clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in local regulations as part of a response to the COVID-19 coronavirus outbreak which may require us or our partners to change the ways in which clinical trials are conducted, which may result in unexpected costs, or cause us or our partners to discontinue the clinical trials altogether&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in necessary interactions with local regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government employees&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal of the FDA to accept data from clinical trials in affected geographies outside the United States.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2020, we announced the temporary pause in new patient enrollment and new site activation in our Phase 2 clinical trial of praluzatamab ravtansine as a result of the COVID-19 pandemic, primarily due to delays in patient enrollment and clinical site initiations, and the termination of the Phase 2 clinical trial of pacmilimab (CX-072) after a re-evaluation of the evolving clinical, competitive and commercial landscapes in immuno-oncology, taken together with impact of the COVID-19 pandemic. Since then, we have revised our strategy for developing praluzatamab ravtansine, including redesigning the study. While we have initiated our Phase 2 clinical trial for praluzatamab ravtansine and the Phase 2 expansion cohorts for CX-2029, we cannot be certain of the impact of the COVID-19 pandemic on clinical trial planning, or that site initiation, patient recruitment or other clinical trial activities will not be delayed, discontinued or otherwise impacted.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, the COVID-19 pandemic and government limitations on activities may continue to impact our ability to conduct research, including limiting our ability to obtain research materials and equipment, limiting access to our laboratories to conduct research, limiting the ability or willingness of employees to work at our facilities and limiting our ability to complete research and experiments in a timely basis or at all. For example, in March 2020 we initiated a mandatory work-from-home program, limiting onsite activity to a substantially reduced level of laboratory research activities. Although we have gradually increased levels of such laboratory research activities, there can be no assurance that we will be able to continue to increase or maintain current levels of such activity. The COVID-19 pandemic and government limitations could further impact our ability to conduct business generally, including making timely payments, filing timely governmental and other business reports and filings, and otherwise comply with our obligations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the potential business, research and clinical impacts arising as a result of the COVID-19 pandemic could cause us to default on our obligations to our collaborative partners, including our specific research and development obligations, potentially resulting in termination of one or more collaborations, and could materially and adversely affect our business, financial condition, results of operation and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the spread of COVID-19 coronavirus may negatively impact the trading price of shares of our common stock and could further severely impact our ability to raise additional capital on a timely basis or at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The global outbreak of the COVID-19 coronavirus continues to rapidly evolve, including with the discovery of&#160;&#160;new variants/mutations of the virus. The extent to which the COVID-19 coronavirus may impact our business, including our clinical trials, research and financial condition will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company with a limited operating history and have not generated any revenue from product sales.&#160;&#160;We have a history of losses, expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could result in a decline in the market value of our common stock.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company with a limited operating history, developing a novel class of therapeutic antibody product candidates, based on our proprietary biologic Probody technology platform. Since our inception, we have devoted our resources to the development of Probody therapeutics. We have had significant operating losses since our inception. As of December 31, 2020 and December 31, 2019, we had an accumulated deficit of $450.1 million and $417.2 million, respectively. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Though we have developed our Probody platform, our technologies and product candidates are in early stages of development, and we are subject to the risks of failure inherent in the development of product candidates based on novel technologies. We have not yet demonstrated our ability to successfully complete any clinical trials, including large-scale, pivotal clinical trials, obtain regulatory approvals, arrange for a third party to manufacture a commercial-scale product candidate, or conduct sales and marketing activities necessary for successful commercialization. Typically, it takes many years to develop one product candidate from the time it enters initial preclinical studies to when it is available for treating patients. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a longer operating history. We will need to transition from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we have never generated any revenue from product sales, and have not obtained regulatory approval for any of our product candidates. We also do not expect to generate any revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies and clinical trials and the regulatory approval process for our product candidates. We expect our net losses to increase substantially as we continue clinical development of our lead programs and advance additional programs into clinical development. In particular, we expect our losses to increase substantially as we enroll patients in our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 2 clinical trial of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">praluzatamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ravtansine</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (CX-2009)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditionally</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activ</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DC candidate directed against CD166, as monotherapy or in combination with </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pacmilimab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(CX-072) </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in patients with breast cancer, as we enroll patients in our Phase 2 expansion trial of CX-2029, our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditionally</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activ</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DC candidate directed against CD71 in collaboration with AbbVie Inc., and as we advance into later trials and new trials for these and other programs. However, the amount of our future losses is uncertain. Our ability to achieve profitability, if ever, will depend on, among other things, our, or our collaborators, successfully developing product candidates, obtaining regulatory approvals to market and commercialize product candidates, manufacturing any approved products on commercially reasonable terms, establishing a sales and marketing organization or suitable third-party alternatives for any approved product and raising sufficient funds to finance business activities. If we, or our collaborators, are unable to develop our technologies and commercialize one or more of our product candidates or if sales revenue from any product candidate that receives approval is insufficient, we will not achieve profitability, which could have a material and adverse effect on our business, financial condition, results of operations and prospects.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We expect that we will need to raise substantial additional funds to advance development of our product candidates and we cannot guarantee that this additional funding will be available on acceptable terms or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development and commercialization of our current or future product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development of biopharmaceutical product candidates is capital-intensive. To date, we have used substantial funds to develop our technology and product candidates and will require significant funds to conduct our ongoing clinical trials as well as to further our research and development, preclinical testing and future clinical trials of additional product candidates, to seek regulatory approvals for our product candidates and to manufacture and market any products that are approved for commercial sale. In addition, we have incurred and will continue to incur additional costs associated with operating as a public company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had $316.1 million in cash, cash equivalents and short-term investments. We believe that our existing capital resources will be sufficient to fund our planned operations at least for the next twelve months from the date the financial statements included in this report are issued. Our future capital requirements and the period for which we expect our existing resources to support our operations may vary significantly from what we expect. Our monthly spending levels vary based on our ongoing clinical trials, new and ongoing research and development and other corporate activities. For example, we expect our monthly spending to increase substantially as we enroll patients in our Phase 2 clinical trial of praluzatamab ravtansine<span style="color:#000000;"> (CX-2009)</span> as monotherapy or in combination with pacmilimab (CX-072) in patients with breast cancer, and as we enroll patients in our Phase 2 expansion trial of CX-2029. Because the length of time and activities associated with conducting our clinical trials and successfully researching and developing our product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and, once any product candidate is approved, any subsequent marketing and commercialization activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timing and amount of our operating expenditures will depend largely on:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the scope, timing and progress of our ongoing clinical trials as well as any other preclinical and clinical development activities which may be affected by, among other things, the COVID-19 pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number, size and type of clinical trials and preclinical studies that we may be required to complete for our product candidates, as well as the cost and time of such studies and trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the number, scope and prioritization of preclinical and clinical programs we decide to pursue&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the time and cost necessary to produce clinical supplies of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the time and cost necessary to scale our manufacturing capabilities following regulatory approval and commercial launch of any product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the progress of the development efforts of parties with whom we have entered or may in the future enter into collaborations and research and development agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing and amount of payments we may receive or are obligated to pay under our collaboration agreements and license agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to maintain our current licenses and research and development programs and to establish new collaboration arrangements&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">the costs involved in prosecuting and enforcing patent and other intellectual property claims, including our ongoing litigation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost of any existing or future litigation to which we are or may become a party&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the cost and timing of regulatory approvals&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our efforts to enhance operational systems and hire additional personnel, including personnel to support development and commercialization of our product candidates and satisfy our obligations as a public company.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to obtain funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and preclinical studies or clinical trials, limit strategic opportunities or undergo reductions in our workforce or other corporate restructuring activities. We also could be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our technologies or product candidates that we would otherwise pursue on our own. We do not expect to realize revenue from sales of products or royalties from licensed products in the foreseeable future, if at all, and unless and until our product candidates are clinically tested, approved for commercialization and successfully marketed. To date, we have financed our operations primarily through sales of our common stock, sale of our convertible preferred securities prior to our IPO and payments received under our collaboration agreements, including, most recently, the Collaboration and License Agreement that we entered into with Astellas in March 2020. We will be required to seek additional funding in the future and currently intend to do so through additional collaborations, public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control, including the COVID-19 pandemic. Additional funds may not be available to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with all oncology drugs, our product candidates in clinical development or preclinical development go through a long process and have a high risk of failure or termination for strategic reasons. For example, in 2017, we initiated Phase 1/2 clinical trials of pacmilimab (CX-072), which expanded to a Phase 2 trial in 2019 evaluating the anti-PD-L1 conditionally activated therapeutic in combination with ipilimumab in melanoma. In March 2020, we made the strategic decision to terminate that trial. In 2017, we initiated a Phase 1/2 clinical trial of praluzatamab ravtansine (CX-2009) and in 2019, we initiated a Phase 2 expansion trial of praluzatamab ravtansine in patients with hormone receptor (&#8220;HR&#8221;)-positive, HER2- negative breast cancer. That Phase 2 expansion trial was paused in early 2020 due to COVID-19.&#160;&#160;In 2020, we revised our strategy for developing praluzatamab ravtansine and initiated a new Phase 2 clinical trial of praluzatamab ravtansine alone or in combination with pacmilimab in patients with triple-negative breast cancer. In 2020, we initiated our Phase 2 clinical trial expansion cohorts of CX-2029, our conditionally activated ADC candidate directed against CD71 in collaboration with AbbVie, for the treatment of four types of cancer.&#160;&#160;In addition, in 2019, Bristol Myers Squibb initiated enrollment in a randomized Phase 2 cohort expansion in its ongoing Phase 1/2 clinical trial for BMS-986249, an anti-CTLA-4 Probody, and initiated a Phase 1/2 trial for BMS-986288, a second anti-CTLA-4 Probody, both of which are underway. It is impossible to predict when or if any of our or our partner&#8217;s product candidates will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we or our partners must complete extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Commencement of clinical trials for programs beyond praluzatamab ravtansine, CX-2029, BMS-986249, BMS-986288, and pacmilimab is subject to finalizing the trial design and filing an IND or similar filing with the FDA or similar foreign regulatory authority. In addition, even if we file our IND or comparable submissions in other jurisdictions for these or other product candidates, including CX-2043 and CX-904, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence our clinical trials or disagree with our study design, which may require us to complete additional preclinical studies or amend our protocols or impose stricter conditions on the commencement of clinical trials and may delay our ability to begin Phase 1 clinical trials, causing an increase in the amount of time and expense required to develop our product candidates including CX-2043 and CX904. As a result of the foregoing, the research and development, preclinical studies and clinical testing of any product candidate is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the development process. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, we or our collaborators may also experience delays in completing ongoing clinical trials, completing preclinical studies or initiating further clinical trials of our product candidates, including, for example, among other things, as a result of the COVID-19 pandemic. We do not know whether our or our collaborators&#8217; ongoing clinical trials or preclinical studies will be completed on schedule or at all, or whether planned clinical trials or preclinical studies will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. We or our collaborators may have insufficient internal resources to complete ongoing clinical trials or initiate clinical trials for our other product candidates. The development programs for our product candidates may also be delayed for a variety of reasons, including delays related to:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">recruiting suitable patients to participate in a clinical trial, particularly in light of the COVID-19 pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developing and validating any companion diagnostic to be used in a clinical trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the FDA or other regulatory authorities requiring us to submit additional data or imposing other requirements before permitting us to initiate a clinical trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining regulatory clearance to commence a clinical trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">reaching agreement on acceptable terms with prospective contract research organization (&#8220;CROs&#8221;) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">obtaining institutional review board (&#8220;IRB&#8221;) approval at each clinical trial site&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">having patients complete a clinical trial or return for post-treatment follow-up&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">clinical trial sites deviating from trial protocol or dropping out of a trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adding new clinical trial sites&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">manufacturing our product candidates in sufficient quality and quantity for use in clinical trials&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators electing to not pursue development and commercialization of our product candidates.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or safety profiles, notwithstanding promising results in earlier trials.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates are in early stages of development and may fail or suffer delays that materially and adversely affect their commercial viability. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize such product candidates, or experience significant delays in doing so, our business will be materially harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are very early in our development efforts, with only three product candidates, praluzatamab ravtansine (CX-2009), CX-2029, and pacmilimab (CX-72), currently in early-stage clinical development. In addition, Bristol Myers Squibb is currently evaluating BMS-986249, a CTLA-4-directed Probody therapeutic in a randomized cohort expansion trial of a Phase 1/2 clinical trial that it initiated in January 2018, and BMS-986288, a second anti-CTLA-4 Probody, in a Phase 1/2 trial it initiated in 2019. We have no products on the market and our ability to achieve and sustain profitability depends on obtaining regulatory approvals for and successfully commercializing our product candidates, either alone or with third parties. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or our collaborator must conduct extensive preclinical tests and clinical trials to demonstrate sufficient safety and efficacy of our product candidates in patients. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, we may not have the financial resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">negative or inconclusive results from our clinical trials, the clinical trials of our collaborators or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product-related side effects experienced by participants in our clinical trials, the clinical trials of our collaborators or by individuals using drugs or therapeutic biologics similar to our product candidates&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">delays in submitting INDs or comparable foreign applications or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays in enrolling research subjects in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">high drop-out rates of research subjects&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our or our collaborators&#8217; clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">greater than anticipated clinical trial costs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delay in the development or approval of companion diagnostic tests for our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">unfavorable FDA or other regulatory agency inspection and review of a clinical trial site&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our technology in particular&#59; or</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">varying interpretations of data by the FDA and similar foreign regulatory agencies.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could find that the therapeutics we or our collaborators pursue are not safe or efficacious. Further, a clinical trial may be suspended or terminated by us, our collaborators, the IRBs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we expect to rely on our collaborators, CROs and clinical trial sites to ensure proper and timely conduct of our clinical trials and while we expect to enter into agreements governing their committed activities, we have limited influence over their actual performance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our collaborators experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues or receive royalties from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenues. Furthermore, if one or more of our product candidates or our Probody therapeutic technology generally prove to be ineffective, unsafe or commercially unviable, the development of our entire platform and pipeline could be delayed, potentially permanently. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2020, we made the strategic decision to terminate our Phase 2 clinical trial evaluating pacmilimab in combination ipilimumab in melanoma. This decision followed a re-evaluation of the evolving clinical, competitive and commercial landscapes in immuno-oncology, taken together with impact of the COVID-19 pandemic.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interim, &#8220;top-line,&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose preliminary or top-line data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. For example, we have reported preliminary data from our clinical trials of praluzatamab ravtansine (CX-2009), CX-2029, and pacmilimab (CX-072) at various meetings and at our CytomX 2019 R&#38;D Day. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Further, as a result of the COVID-19 or for other reasons, we may not be able to collect accurate or complete data at the time we collect such preliminary data, including as a result of the inability of sites to properly record data due to staffing limitations or the inability of patients to visit sites at scheduled times, the inability of CROs to access site data or for other reasons. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, top-line data should be viewed with caution until the final data are available.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates may cause undesirable side effects at any time during or after the clinical trial process that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including withdrawal from the market.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Undesirable side effects caused by our product candidates could cause us, our collaborators or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. As is the case with all oncology drugs, there may be immediate or late side effects associated with the use of our product candidates (e.g., praluzatamab ravtansine [CX-2009], CX-2029, and pacmilimab [CX-072]). There can be no assurance that unexpected adverse events will not occur in our ongoing trials or in future trials involving our product candidates or the product candidates of our collaborators. Undesirable side effects may appear in later trials that were not observed in our earlier trials or may be more severe in later trials than earlier trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we reported that the administration of monotherapy pacmilimab has been generally well tolerated with the majority of treatment-related adverse events (&#8220;TRAEs&#8221;) as Grade 1/2. At that time, we also reported that of the 114 monotherapy patients treated with 10 mg/kg every two weeks and who were evaluable for safety, ten (9%) patients experienced a grade &#8805;3 TRAE, and two (2%) experienced grade &#8805;3 immune-related adverse events (&#8220;irAEs&#8221;), with two (2%) TRAEs leading to treatment discontinuation. In June 2019, we also reported that at the 10 mg/kg dose, the anti-drug antibody (&#8220;ADA&#8221;) rate was approximately 62%. While we do not believe this ADA is impacting our ability to reach targeted drug exposures, we cannot provide assurance that the rate will not change or that it will not later limit drug exposure or cause severe adverse events. We also cannot provide assurance that the rates and the types of adverse events will not increase with time as more patients are treated in ongoing or future studies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Administration of pacmilimab in combination with ipilimumab has been generally well tolerated with the majority of TRAEs as Grade 1/2. In October 2019, we reported that of the 27 patients treated across all combination doses, Grade 3/4 TRAEs were reported in nine (33%) patients and Grade 3/4 irAEs were reported in six (22%) patients. Of the 20 patients treated with ipilimumab at 3 mg/kg at varying doses of pacmilimab, Grade 3/4 TRAEs were reported in five (25%) patients and Grade 3/4 irAEs were reported in three (15%) patients. We cannot provide assurance that these rates and the types of adverse events will not increase over time with more patients being treated in future studies of our product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Administration of praluzatamab ravtansine has also been generally well tolerated with most reported TRAEs being Grade 1/2. In May 2020, we announced that 34/92 (37%) patients experienced a Grade 3/4 TRAE. The most common adverse event observed was ocular toxicity, an anticipated toxicity associated with the DM4 payload. Other Grade 3/4 TRAEs included liver function test abnormalities, gastrointestinal disorders and nervous system disorders. We cannot guarantee that these rates and the types of adverse events will not increase over time with more patients being treated in ongoing or future studies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of our or our collaborators&#8217; future clinical trials could reveal a high and unacceptable severity of adverse side effects, including immune system related adverse events or increased toxicity, and it is possible that patients enrolled in such clinical trials could respond in unexpected ways or otherwise have unexpected adverse events. For example, in October 2019, we announced the initiation of our first Phase 2 clinical trial of pacmilimab at a dose level of 10 mg/kg in combination with ipilimumab at a dose level of 3 mg/kg. This dose of ipilimumab in combination with another PD agent, Opdivo&#174; (nivolumab), is often not tolerated by patients.&#160;&#160;While we believe our Phase 1 clinical data supports this combination, only further clinical testing will determine whether such a combination is tolerable for patients. However, in March 2020, we made the strategic decision to terminate the Phase 2 study evaluating pacmilimab in combination with ipilimumab. This decision followed a re-evaluation of the evolving clinical, competitive and commercial landscapes in immuno-oncology, taken together with impact of the COVID-19 pandemic.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, we announced that CX-2029 was generally well tolerated at doses up to 3 mg/kg with the most common TRAEs being infusion related reactions, anemia and neutropenia/leukopenia. Grade 3 or greater hematologic TRAEs, anemia and neutropenia, were dose dependent, with anemia being managed with transfusions and supportive care. The etiology of anemia is under investigation and is likely to be multi-factorial, including MMAE-related and CD71 expression on red blood cell precursors. While we believe these TRAEs are manageable, there can be no assurance that the rate or severity of any of these side effects will not increase over time with more patients being treated in ongoing or future studies.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Phase 2 clinical trial of BMS-986249 being conducted by Bristol Myers Squibb includes the administration of the product candidate at relatively high dosage levels, which could further exacerbate such risks. In our Phase 2 clinical trial with praluzatamab ravtansine and CX-2029, we are targeting CD166 and CD71, respectively, targets that are broadly expressed on normal tissue, which could create unacceptable toxicity or fail to result in anti-tumor activity. For instance, CD71 is a metabolic protein with high levels of expression in healthy tissues, and the consequences of targeting such protein in humans are unknown. Any future clinical trials of our product candidates could face similar or heightened risks depending on the modality.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that our clinical trials or the clinical trials of our collaborators reveal severe adverse side effects, our or our collaborators&#8217; clinical trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could impose a clinical hold, order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. For example, in our Phase 1/2 clinical trial of praluzatamab ravtansine, some patients stopped treatment due to ocular toxicity. While we are using ocular toxicity prophylactic measures in our Phase 2 clinical trial, we cannot be assured that such measures will be effective. In addition, any of these occurrences with respect to one of our product candidates could negatively affect our or any collaborator&#8217;s ability to enroll patients and seek regulatory approval for other product candidates that we have developed using our Probody platform, which could also result in a collaborator terminating any program utilizing our Probody platform and the termination of such collaborative relationship. Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects. Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event that any of our product candidates receives regulatory approval and we, our collaborators or others identify undesirable side effects caused by such product or any other Probody therapeutics, any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely affect our results of operations and business:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may withdraw their approval of the product or seize the product&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we or our collaborators may be required to recall the product or change the way the product is administered to patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be subject to fines, injunctions or the imposition of civil or criminal penalties&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we may be required to create a Medication Guide outlining the risks of such side effects for distribution to patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">we could be sued and held liable for harm caused to patients&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the product may become less competitive&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our reputation may suffer.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, adverse side effects caused by any drugs of other companies utilizing the same or similar antibodies of our product candidates, or that are similar in nature to our product candidates could delay or prevent regulatory approval of our product candidates, limit the commercial profile of an approved label for our product candidates, or result in significant negative consequences following marketing approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of these events could prevent us from achieving or maintaining market acceptance of our product candidates and could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside the United States. Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ongoing COVID-19 pandemic&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the size and nature of the target patient population&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the eligibility criteria for the clinical trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the design of the clinical trial&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the availability of an appropriate genomic screening test&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the perceived risks and benefits of the product candidate under study&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the efforts to facilitate timely enrollment in clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the patient referral practices of physicians&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the ability to monitor patients adequately during and after treatment&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the proximity and availability of clinical trial sites for prospective patients.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2020, we announced a temporary pause in new patient enrollment and new site activation in our Phase 2 clinical trial of praluzatamab ravtansine as a result of the COVID-19 pandemic. Since then, we have revised our strategy for praluzatamab ravtansine and have initiated a new Phase 2 clinical trial of praluzatamab ravtansine, however, there can be no assurances that the COVID-19 pandemic will not continue to have a significant impact on our ability to complete our ongoing clinical trials and enroll patients in any planned or future clinical trials.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, competing clinical trials and clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs or therapeutic biologics that may be approved for the indications we are investigating, could affect our ability to enroll a sufficient number of eligible patients in our clinical trials. There are currently several PD-1 and/or PD-L1 agents approved for a growing list of cancer types along with thousands of clinical trials exploring the use of PD-1 and PD-L1 agents. There can be no assurance that further trials with pacmilimab (CX-072) or our other drug candidates will not be adversely affected by a limited patient population. Our clinical trials of praluzatamab ravtansine and CX-2029 study patients who have one or a select number of specific tumor types rather than patients suffering from any cancer, which limits the rate of enrollment of the trial. In addition, some of our clinical trials seek to treat indications with small population sizes which could be particularly difficult to enroll. Our clinical trials of praluzatamab ravtansine and CX-2029 are also competing with thousands of clinical trials with alternative anti-cancer drugs in a similar class (e.g. antibody-drug conjugates), and certain arms of the clinical trials may be difficult to enroll due to the emerging standard of care for such indications in certain jurisdictions, including the United States.&#160;Any clinical trials of our product candidates initiated by our collaborators, including Bristol Myers Squibb&#8217;s ongoing Phase 2 clinical trial, face similar and additional risks relating to enrollment. We or our collaborators could also encounter delays in the development of any of our product candidates if prescribing physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Any delays relating to patient enrollment could cause significant delays in the timing of our or our collaborators&#8217; clinical trials, which may materially and adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our approach to the discovery and development of our therapeutic treatments is based on novel technologies that are unproven and may not result in marketable products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to continue to develop a pipeline of product candidates using our proprietary Probody platform. We believe that product candidates (including cancer immunotherapies, conditionally activated ADCs and bispecific antibodies) identified with our product discovery platform may offer an improved therapeutic approach by taking advantage of unique conditions in the tumor microenvironment, thereby reducing the dose-limiting toxic effects associated with traditional antibody products, which can also attack healthy tissue. However, the scientific research that forms the basis of our efforts to develop product candidates based on our Probody platform is ongoing, including the research resulting from our ongoing clinical trials for praluzatamab ravtansine (CX-2009), CX-2029, and pacmilimab (CX-072). </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may ultimately discover that our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> platform and any product candidates resulting from it do not possess certain properties required for therapeutic effectiveness or protection from toxicity. For example, when </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutics are administered to human subjects, protease levels in tumors may not be sufficient and the peptide mask may not be cleaved, which would limit the potential efficacy of the antibody. In addition, if the peptide mask is inappropriately released, for example, due to an inflammatory disease, it may reduce the potential to limit toxicity of the anti-cancer agent or result in unforeseen events when administered in humans. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Binding of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">peptide mask to the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">antigen-binding domain of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may not be constant, which could lead to intermittent periods when the antigen-binding domain or antibody portion is unmasked. Furthermore, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> product candidates may not remain stable in the human body for the period of time required for the drug to reach and to bind to the target tissue. In addition, product candidates based on our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> platform may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies. Although our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> platform and certain product candidates have demonstrated successful results in animal studies, they may not demonstrate the same chemical and pharmacological properties in humans and may interact with human biological systems in unforeseen, ineffective or harmful ways. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our understanding of the molecular pharmacology of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutics, that is, the precise manner and sequence in which they are activated and behave in vivo, is incomplete. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutics are complex biological&#160;molecules and we are evaluating the performance of this new technology in cancer patients for the first time.&#160;Many specific elements of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutic function may contribute to their overall safety and efficacy profile including, but not limited to, the removal of only one mask from the dually-masked antibody, the removal of both masks from the dually-masked antibody, the binding strength of masks for the underlying antibody, and the binding strength of the underlying antibody for its target.&#160;We have limited structural evidence for how masks interact with antibodies.&#160;It may take many years before we develop a full understanding of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> pharmacology, and we may never know precisely how they function in vivo.</span><span style="font-style:italic;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As with any new biologic or product developed on a novel platform, we have a limited understanding of the immunogenicity profile of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutics</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. As a result, our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates may trigger immune responses, such as</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> anti-drug antibody (&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADA</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, that may inhibit the ability of the antibody to reach the target tissue, inhibit the ability of the antibody to bind to its target, cause adverse side effects in humans or cause hypersensitivity reactions</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we reported in February 2019 that in our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pacmilimab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> trial at the 10 mg/kg dose, the ADA rate was approximately 62%. We do not believe the ADA rate is impacting our ability to reach targeted drug exposures. However, we cannot provide assurance that it will not later limit drug exposure or cause severe adverse events. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Problems that are specific to our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> platform may have an unfavorable impact on all of our product candidates. As a result, we may never succeed in developing a marketable product and we may never become profitable, which would cause the value of our common stock to decline.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the scientific evidence to support the feasibility of developing product candidates against novel, difficult to drug targets,&#160;is both preliminary and limited.&#160;For example, our understanding of the expression of CD166 and CD71 in both healthy and diseased tissues is still developing. As a result, we cannot provide any assurance that we will be able to successfully identify and advance any product candidates to target novel, difficult-to-drug targets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe the only clinical experience that the FDA and foreign regulatory authorities have with Probody-based therapeutics in oncology comes from praluzatamab ravtansine, CX-2029, BMS-986249, and pacmilimab. We believe that the FDA and foreign regulatory authorities, have no clinical experience in other disease areas, and such limited experience may increase the complexity, uncertainty and length of the regulatory approval process for our product candidates and may keep us from commencing first-in-human trials in certain countries. As there is limited historical precedent for the regulatory clearance of Probody-based therapeutics in oncology, there is a higher degree of risk that the FDA or other regulatory authorities could disagree that we or our collaborators have satisfied their requirements to commence clinical trials for some product candidates or disagree with our study designs, which may require us to complete additional preclinical studies or amend our protocols or impose stricter conditions on the commencement of clinical trials. In addition, local clinical practice in other countries may affect whether we or our collaborators are able to initiate a clinical trial there. As a result, we and our collaborators may never receive approval to market and commercialize any product candidate. Even if we or our collaborators obtain regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we or they intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or our collaborators may be required to perform additional or unanticipated clinical trials to obtain approval or be subject to post-marketing testing requirements to maintain regulatory approval. If one or more of our product candidates or our Probody technology generally prove to be ineffective, unsafe or commercially unviable, our entire platform and pipeline may have little, if any, value, which would have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The market may not be receptive to our product candidates based on a novel therapeutic modality, and we may not generate any future revenue from the sale or licensing of product candidates.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if regulatory approval is obtained for a product candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether the product can be sold at a competitive cost and whether it will otherwise be accepted in the market. The product candidates that we are developing are based on our Probody platform, which is a new technology and therapeutic approach. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors, may not adopt a product or treatment based on our Probody platform and technologies, and we may not be able to convince the medical community and third-party payors to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our collaborators. This may be particularly true for any of our product candidates (including BMS-986249, BMS-986288, and pacmilimab [CX-072]) for which there are existing approved therapies, such as approved agents targeting PD-L1, PD-1, or CTLA-4. Market acceptance of our product candidates will depend on, among other factors:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the timing of our receipt of any marketing and commercialization approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the terms of any approvals and the countries in which approvals are obtained&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the safety and efficacy of our product candidates, including those being developed by our collaborators&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the prevalence and severity of any adverse side effects associated with our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the availability of effective companion diagnostics&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">relative convenience and ease of administration of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the willingness of patients to accept any new methods of administration&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success of our physician education programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the availability of coverage and adequate reimbursement from government and third-party payors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the pricing of our products, particularly as compared to alternative treatments&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any product candidate we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We have entered, and may in the future seek to enter, into collaborations with third parties for the development and commercialization of our product candidates using our Probody platform. If we fail to enter into such collaborations, or such collaborations are not successful, we may not be able to capitalize on the market potential of our Probody platform and resulting product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since 2013, we have entered into collaborations with AbbVie, Amgen, Astellas, Bristol Myers Squibb, ImmunoGen, Pfizer and others to develop certain Probody therapeutics. We may in the future seek third-party collaborators for development and commercialization of other therapeutic technologies or product candidates. Biopharmaceutical companies are our prior and likely future collaborators for any marketing, distribution, development, licensing or broader collaboration arrangements. With respect to our existing collaboration agreements, and what we expect will be the case with any future collaboration agreements, we have and would expect to have limited control over whether such collaborations pursue the development of our product candidates or the amount and timing of resources that such collaborators dedicate to the development or commercialization of our product candidates. For instance, in March 2018, Pfizer terminated the collaboration agreement we had entered into with them in May 2013. Such collaboration agreement had entitled Pfizer to nominate up to four research targets and since 2013, we had collaborated with Pfizer on three of such targets. However, no program was ever advanced beyond the lead optimization stage pursuant to the agreement, and Pfizer had previously elected not to select a fourth target and had decided to discontinue its epidermal growth factor receptor conditionally activated ADC. In July 2017, ImmunoGen discontinued the preclinical evaluation of one of its two programs being developed under our collaboration and in December 2019, licensed the other program to us, terminating their license agreement from us. In addition, in January 2019, Bristol Myers Squibb terminated its programs for three targets it had selected under our agreement with them. As a result, there can be no assurances that any of the programs covered by our existing or future collaborations will be developed further. Further, our ability to generate revenues from our existing and future arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. Additionally, some of our collaborations may require us to share in certain development and commercialization expenses. If we cannot afford to share such expenses when required, our rights under such collaborations may be adversely affected, including potentially that our collaborators may terminate the relevant agreement.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Overall, collaborations involving our product candidates currently pose, and will continue to pose, the following risks to us:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations, including, with respect to Bristol Myers Squibb, BMS-986249 and BMS-986288&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on preclinical or clinical trial results, changes in the collaborators&#8217; strategic focus or available funding or resources, or external factors such as an acquisition that diverts resources or creates competing priorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators have significant discretion in designing any clinical trials they operate pursuant to our collaboration agreements, including Bristol Myers Squibb&#8217;s ongoing Phase 2 cohort expansion of BMS-986249 and its Phase 1/2 clinical trial of BMS-986288, and may release data from such clinical trials, including with respect to our Probody therapeutics, without consulting us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing and are not necessarily required to give us information about their clinical data&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators may independently develop, or develop with third parties, products that compete directly or indirectly with our product candidate if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to litigation or potential liability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidate or that result in costly litigation or arbitration that diverts management attention and resources&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the foregoing, our current and any future collaboration agreements may not lead to development or commercialization of our product candidates in the most efficient manner or at all and may not result in the realization of the benefits we expected to achieve upon our entry into such agreements. Any failure to successfully develop or commercialize our product candidates pursuant to our current or any future collaboration agreements could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our collaborators cease development efforts under our collaboration agreements, or if any of those agreements are terminated, these collaborations may fail to lead to commercial products and we may never receive milestone payments or future royalties under these agreements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of our revenue to date has been derived from our existing collaboration agreements, including, most recently, the agreement that we entered into with Astellas in March 2020, and a significant portion of our future revenue and cash resources is expected to be derived from these agreements or other similar agreements we may enter into in the future. Revenue from research and development collaborations depend upon continuation of the collaborations, reimbursement of development costs, the achievement of milestones and royalties, if any, derived from future products developed from our research. If our development partners do not select additional targets and we are unable to successfully advance the development of our product candidates or achieve milestones, revenue and cash resources from milestone payments under our collaboration agreements will be substantially less than expected.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, to the extent that any of our collaborators were to terminate a collaboration agreement, we may decide to independently develop these product candidates to the extent we retain development rights. Such development could include funding preclinical or clinical trials, assuming marketing and distribution costs and defending intellectual property rights. Alternatively, in certain instances, we may choose to abandon product candidates altogether. For instance, in March 2018, Pfizer terminated our 2013 collaboration agreement with them, and in January 2019, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol Myers Squibb</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> terminated its programs for three targets that it had selected under our agreement with them. The termination of any of our collaboration agreements or individual programs within a collaboration agreement could result in a change to our business plan and may have a material adverse effect on our business, financial condition, results of operations and prospects. If a collaboration is terminated, we would not be eligible to receive the milestone, royalty or other payments that would have been payable under the collaboration agreement. For example, as a result of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen&#8217;s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> decision to out-license the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EpCAM</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> program and our licensing of the program from them in 2019, their license for the program from us ended and we will not receive milestone or other payments from them.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the commercialization of any of our product candidates may be delayed, and our business will be harmed.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For planning purposes, we sometimes estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the submission of regulatory filings, or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of marketing approval, or a commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which may cause the timing of achievement of the milestones to vary considerably from our estimates, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our available capital resources or capital constraints we experience&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the rate of progress, costs and results of our clinical trials and research and development activities, including the extent of scheduling conflicts with participating clinicians and collaborators&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to identify and enroll patients who meet clinical trial eligibility criteria&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our receipt of approvals by the FDA and other regulatory authorities and the timing thereof&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">other actions, decisions or rules issued by regulators&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to access sufficient, reliable and affordable supplies of materials used in the manufacture of our product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to manufacture and supply clinical trial materials to our clinical sites on a timely basis&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the efforts of our collaborators with respect to the commercialization of our products&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing activities.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, in March 2020, we announced the temporary pause in new patient enrollment and new site activation in our Phase 2 clinical trial of praluzatamab ravtansine (CX-2009) as a result of the COVID-19 pandemic and the termination of the Phase 2 clinical trial of pacmilimab (CX-072) in combination with ipilimumab after a re-evaluation of the evolving clinical, competitive and commercial landscapes in immuno-oncology, taken together with impact of the COVID-19 pandemic.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to achieve announced milestones in the timeframes we expect, the commercialization of any of our product candidates may be delayed, and our business and results of operations may be harmed. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not successfully engage in strategic transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize product candidates, impact our cash position, increase our expense and present significant distractions to our management. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since commencing operations, we have entered into several collaboration agreements, including the agreement that we entered into with Astellas in March 2020. From time to time, we may consider strategic transactions, such as additional collaborations, acquisitions of companies, asset purchases and out- or in-licensing of product candidates or technologies. In particular, we will evaluate and, if strategically attractive, seek to enter into additional collaborations, including with major biotechnology or biopharmaceutical companies. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">collaborator terminates the collaboration. Any such collaboration, or other strategic transaction, may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees of any acquired business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material and adverse effect on our business, financial condition, results of operations and prospects. The termination by a collaborator of a collaboration may cause a decrease in the price of our stock. Conversely, any failure to enter any additional collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches market.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to successfully develop companion diagnostic tests for certain of our product candidates, or experience significant delays in doing so, we may not realize the full commercial potential of our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we are focused on precision medicine, in which predictive biomarkers will be used to identify the right patients for our product candidates, we believe that our success may depend, in part, on the development of companion diagnostic tests. To successfully develop a companion diagnostic test, we would need to address a number of scientific, technical and logistical challenges. However, we have little experience in the development of companion diagnostic tests and may not be successful in developing appropriate tests to pair with any of our product candidates. Companion diagnostic tests are subject to regulation by the FDA and similar regulatory authorities outside the United States as medical devices and require separate regulatory approval prior to commercialization. Given our limited experience in developing companion diagnostic tests, we could seek to rely on third parties to design, manufacture, obtain regulatory approval for any companion diagnostic tests for our product candidates. However, we and such collaborators may encounter difficulties in developing and obtaining approval for the companion diagnostic tests, including issues relating to selectivity/specificity, analytical validation, reproducibility, or clinical validation. Any delay or failure by us or our collaborators to develop or obtain regulatory approval of the companion diagnostic tests could delay or prevent approval of our product candidates. As a result, our business would be harmed, possibly materially.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We rely on third parties to conduct all of our clinical trials and certain of our preclinical studies and intend to continue to do so, and if such third parties do not perform as contractually required, fail to satisfy regulatory or legal requirements or miss expected deadlines, our development programs could be delayed with material and adverse effects on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have the ability to independently conduct clinical trials. As such, we currently rely and intend to continue to rely on third-party clinical investigators, CROs, clinical data management organizations and consultants to help us design, conduct, supervise and monitor clinical trials of our product candidates. As a result, we will have less control over the timing, quality and other aspects of our clinical trials than we would have had we conducted them on our own. These investigators, CROs and consultants are not our employees and we have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful. Furthermore, our third-party contractors, including CROs are being and may continue to be impacted in their ability to conduct our work as a result of the COVID-19 pandemic.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we cannot contract with acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties, satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical development programs could be delayed and otherwise adversely affected. In all events, we will be responsible for ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the trial. The FDA requires preclinical studies to be conducted in accordance with good laboratory practices (&#8220;GLPs&#8221;) and clinical trials to be conducted in accordance with good clinical practices (&#8220;GCPs&#8221;), including for designing, conducting, recording and reporting the results of preclinical studies and clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our clinical trials could have a material and adverse effect on our business, financial condition, results of operations and prospects.<span style="font-weight:bold;font-style:italic;"> </span></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We are currently conducting </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">and will continue to conduct clinical trials and will contract with third-party manufacturers in foreign countries, which could expose us to risks that could have a material adverse effect on the success of our business.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have enrolled or are planning to enroll patients in our clinical trials outside the United States, including in Europe, Australia and South Korea. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, such clinical trials must be conducted in accordance with GCPs, and the FDA must be able to validate the data through an on-site inspection if deemed necessary. Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with additional foreign regulatory requirements&#59; foreign exchange fluctuations&#59; patient monitoring and compliance&#59; compliance with foreign manufacturing, customs, shipment and storage requirements&#59; the severity of the COVID-19 pandemic in such jurisdictions&#59; and cultural differences in medical practice and clinical research. We are also subject to risks associated with doing business globally, including commercial, political, and financial risks. In addition, we are subject to potential disruption caused by military conflicts&#59; potentially unstable governments or legal systems&#59; civil or political upheaval or unrest&#59; local labor policies and conditions&#59; possible expropriation, nationalization, or confiscation of assets&#59; problems with repatriation of foreign earnings&#59; economic or trade sanctions&#59; closure of markets to imports&#59; anti-American sentiment&#59; terrorism or other types of violence in or outside the United States&#59; health pandemics&#59; and a significant reduction in global travel. For example, pandemics and public health emergencies, such as the COVID-19 pandemic, have disrupted and delayed and could in the future disrupt or delay enrollment in our clinical trials in Europe, South Korea and elsewhere. Our success will depend, in part, on our ability to overcome the challenges we encounter with respect to these risks and other factors affecting U.S. companies with global operations. If our global clinical trials or foreign third-party suppliers were to experience significant disruption due to these risks or for other reasons, it could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we have no long-term contracts with and rely on third-party manufacturing and supply partners, most of which are sole source suppliers, our supply of research and development, preclinical and clinical development materials may become limited or interrupted or may not be of satisfactory quantity or quality.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on third-party contract manufacturers to manufacture our clinical trial and preclinical study product supplies which, in addition to having other issues, could be adversely impacted by the COVID-19 pandemic. Most of our clinical trial manufacturing contractors and suppliers are our sole source for their respective manufacturing and supplies. Failure of any of these contractors could put our ability to have clinical trial material available when needed. This could result in a substantial delay of our clinical trials. For each of praluzatamab ravtansine (CX-2009), CX-2029, and pacmilimab (CX-072), our manufacturing supply chain includes several contract manufacturers, and failure by any of these manufacturers could result in interruptions of our clinical studies. For example, in November 2019, one of our contract manufacturers that manufactures pacmilimab experienced a production failure. If we had not been able to assure sufficient supplies of clinical trial drug product after the production failure, we may have been required to suspend any ongoing trials and postpone future trials. Although we have taken sufficient steps to assure our current supply of pacmilimab clinical trial drug product for our ongoing clinical trial and planned clinical trials, there can be no assurance that we will not have future production failures, which could affect our ability to conduct our trials for praluzatamab ravtansine, CX-2029, pacmilimab or any other clinical trial drug candidates on our planned timeline or at all. We do not own manufacturing facilities for producing such supplies and do not have any long-term contracts and we do not currently have an alternative to any of our third-party contract manufacturers. There can be no assurance that our preclinical and clinical development product supplies will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of any of our third-party contract manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In addition, we may encounter issues with transferring technology to a new third-party manufacturer, and we may encounter regulatory delays if we need to move the manufacturing of our products from one third-party manufacturer to another. For example, we were dependent on ImmunoGen under our collaboration for certain steps in the manufacturing of clinical quantities of praluzatamab ravtansine. At the end of 2018, ImmunoGen closed their clinical manufacturing facility in Norwood, MA. This site provided clinical manufacturing support for the praluzatamab ravtansine program. We completed transfer of the drug substance manufacturing process from ImmunoGen to a CMO, where we have an existing relationship and which has expertise in the manufacture of antibody-drug conjugates at a clinical and commercial scale. While the manufacturing transfer process has been completed, there can be no assurance that we will not experience a disruption in the supply of praluzatamab ravtansine as a result of such transfer or that we will not experience any other disruption in the manufacture of praluzatamab ravtansine. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacturing process for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as current Good Manufacturing Practices (&#8220;cGMPs&#8221;). In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, such as the pacmilimab manufacturing production failure our contract manufacturer experienced in November 2019, or if our supply of components or other materials becomes limited or interrupted for other reasons, such as one of our manufacturers going out of business, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the original manufacturer and we may have difficulty transferring such skills or technology to another third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to rely on third-party manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future, manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able to develop and commercialize our product candidates successfully. We may find that our third-party manufacturer is unable to scale up the process in order to produce commercial quantities of our products. Our or a third party&#8217;s failure to execute on our manufacturing requirements and comply with cGMPs could adversely affect our business in a number of ways, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an inability to initiate or continue clinical trials of product candidates under development&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">loss of the cooperation of a collaborator&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">requirements to cease distribution or to recall batches of our product candidates&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The supply chain for the manufacturing of our product candidates is complicated and can involve many parties. This is especially the case for our clinical-stage conditionally activated ADCs, praluzatamab ravtansine and CX-2029. If we were to experience any supply chain issues, our product supply could be seriously disrupted. In addition, we expect the logistical challenges associated with our supply chain to grow more complex as additional product candidates commence any clinical trials.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We, or third-party manufacturers, may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing our product candidates and commercializing approved products, if any. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It may prove more challenging than we anticipate to manufacture products that incorporate our Probody therapeutic technology. In order to conduct clinical trials of our product candidates, including our clinical trials for praluzatamab ravtansine (CX-2009), CX-2029, and pacmilimab (CX-072), we will need to manufacture them in large quantities. To date, we have generally been able to successfully manufacture praluzatamab ravtansine, CX-2029, and pacmilimab for our ongoing early-stage clinical trials. However, in November 2019, we had a production failure at one of our contract manufacturers that manufactured pacmilimab for our Phase 1/2 clinical trial and for our future trials. If we had not been able to assure sufficient supplies of clinical trial drug product after the production failure, we may have been required to suspend any ongoing trials and postpone future trials. Although we have taken sufficient steps to assure our current supply of pacmilimab clinical trial drug product for our planned clinical trials, there can be no assurance that we will not have future production failures, which could affect our ability to conduct our trials for praluzatamab ravtansine, CX-2029, pacmilimab or any other clinical trial drug candidates on our planned timeline or at all. Furthermore, in order to conduct later stage clinical trials of our product candidates, such as our Phase 2 clinical trial for praluzatamab ravtansine, and eventually, if approved, commercial products, we will need to manufacture them in larger quantities. We, or any manufacturing partners, may be unable to successfully increase the manufacturing scale and capacity for any of our product candidates in a timely or cost-effective manner, or at all. For example, we are currently working with our CMOs to change our manufacturing processes and formulations as well as scaling up for larger drug manufacturing capability, including praluzatamab ravtansine drug product for late-stage clinical trials and commercialization. However, we may have to start late-stage trials with our early clinical trial drug product and switch to late-stage or commercial drug product mid trial. In such event, the FDA will require us to complete bridging studies to compare the earlier stage material with late-stage or commercial material to assure comparability between the earlier trial material and the late- stage or commercial material. Changing formulation and scaling up the process is a complicated and difficult task. While we believe we can complete this process successfully, there can be no assurances that the changes we make to the drug product and manufacturing process will be successful or completed in a timely manner or that the FDA will not require additional development steps or studies from those we believe are necessary. If we are not able to scale up our manufacturing capabilities with respect to praluzatamab ravtansine, pacmilimab or any of our other product candidates, increase the life of drug stability of product candidates, or successfully complete the FDA&#8217;s bridging requirements, we may not be able to successfully obtain FDA approval and commercialize product candidates in a timely manner or at all. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we were dependent on </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> under our collaboration for certain steps in the manufacturing of clinical quantities of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">praluzatamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ravtansine</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. At the end of</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 2018, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> closed their clinical manufacturing facility in Norwood, Massachusetts, which provided clinical manufacturing support for the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">praluzatamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ravtansine</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> program. We completed the transfer of the drug substance manufacturing process from </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to a contract manufacturer, where we have an existing relationship and with expertise in the manufacture of antibody drug conjugates at a clinical and commercial scale. While the manufacturing transfer process has been completed, there can be no assurance that we will not experience a disruption in the supply of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">praluzatamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ravtansine</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in connection with such transfer or that we will not experience any other disruption in the manufacturing of </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">praluzatamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ravtansine</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, for CX-2029, the manufacturing of additional clinical quantities could be particularly difficult because we are relying on three different parties to manufacture supplies. If we, or any manufacturing partners, are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the development, testing, and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may expend our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we focus on specific product candidates and indications, including praluzatamab ravtansine (CX-2009), CX-2029, and pacmilimab (CX-072). As a result, we may forgo or delay pursuit of opportunities with those products in other indications or with other product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs, including CX-2043 and CX-904, and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may experience difficulties in managing our growth and expanding our operations successfully.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will need to grow our organization substantially to continue development and pursue the potential commercialization of praluzatamab ravtansine (CX-2009), CX-2029, and pacmilimab (CX-072) and our other product candidates, including CX-2043 and CX-904, as well as function as a public company. As we increase the number of our product candidates entering and advancing through preclinical studies and clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with additional organizations to provide these capabilities for us. In addition, we expect our collaborations to require greater resources as the development of our product candidates under such agreements progresses. In the future, we expect to also have to manage additional relationships with collaborators or partners, suppliers and other organizations. In particular, if the third parties on which we currently rely are not capable of delivering services or supplies in a manner that is sufficient to meet our requirements as we expand our operations, we could be required to contract with new third parties and there can be no assurances that the services or supplies of such third parties will be available on commercially reasonable terms, or at all. Furthermore, our ability to manage our operations and future growth will require us to continue to increase headcount as well as improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face competition from entities that have developed or may develop product candidates for cancer, including companies developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of drugs and therapeutic biologics is highly competitive. We compete with a variety of multinational biopharmaceutical companies and specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors have developed, are developing or will develop product candidates and processes competitive with our product candidates. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that enter the market. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop product candidates. Additionally, there is intense and rapidly evolving competition in the biotechnology, biopharmaceutical and antibody and immunoregulatory therapeutics fields, and our competitors include larger and better funded biopharmaceutical, biotechnological and therapeutics companies. In addition, these companies compete with us in recruiting scientific and managerial talent.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that while our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> platform, its associated intellectual property and our scientific and technical know-how, give us a competitive advantage in this space, competition from many sources remains. The clinical development pipeline for cancer includes small molecules, antibodies and therapies from a variety of groups. In addition, numerous compounds are in clinical development for cancer treatment. As a result, our success will partially depend on our ability to develop and protect therapeutics that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated if competing products that are safer, more effective, or less expensive than the therapeutics we develop or if we are unable to utilize our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutic technology to differentiate our </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutics from the products of our competitors. For instance, if any of our lead product candidates, including, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">praluzatamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ravtansine</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and CX-2029 are approved, they will compete with a range of therapeutic treatments that are either in development or currently marketed. A variety of oncology drugs and therapeutic biologics are currently on the market or in clinical development. The market for immunotherapies like </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pacmilimab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (CX-072)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> is, in particular, highly competitive and the field is changing quickly. In</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> March 2020,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> we made the strategic decision to terminate our Phase 2 study evaluating </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pacmilimab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in combination ipilimumab. This decision followed a re-evaluation of the evolving clinical, competitive and commercial landscapes in immuno-oncology, taken together with impact of the COVID-19 pandemic. Given the amount of time required to successfully develop and obtain regulatory approval for each of our product candidates, it is therefore possible that by the time we obtain any such approval, if ever, and commence sales, we may no longer be able to differentiate such product candidate from those of our competitors. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face substantial competition from pharmaceutical companies developing products in immuno-oncology, including companies such as Amgen, AstraZeneca PLC, Bristol Myers Squibb, GlaxoSmithKline plc, Merck &#38; Co., Inc. Novartis AG, Pfizer, Roche Holding Ltd. and Sanofi SA. Many large and mid-sized biotech companies, including BeiGene, Incyte, Nektar, and Alkermes have ongoing efforts in cancer immunotherapy. Finally, numerous small companies are also working in the space. Several companies, including Xilio, Amgen, Amunix, BioAtla, Halozyme, Maverick Therapeutics, Pandion Therapeutics, Revitope, Roche, and Seagen are exploring antibody masking and/or conditional activation strategies, which could compete with our Probody platform. We are also aware of several companies that are developing ADCs, such as AbbVie, Gilead, ImmunoGen, Seagen, Pfizer, Roche Holding Ltd. and Takeda. Furthermore, several large pharmaceutical companies, including Amgen, Novartis AG and Roche Holding Ltd., are developing T-cell engaging immunotherapies, and we are aware of several mid-sized biotech companies, such as Macrogenics and Xencor, and small companies with ongoing efforts to develop T-cell engaging immunotherapies. Any of these companies may be well capitalized and may have significant clinical experience. In addition, these companies include our collaborators.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop less differentiated or noncompetitive before we recover the expense of developing and commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Any inability to attract and retain qualified key management and technical personnel would impair our ability to implement our business plan.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success largely depends on the continued service of key management, advisors and other specialized personnel, including Sean A. McCarthy, D.Phil., our president and chief executive officer, and Amy C. Peterson, M.D., our chief development officer. The loss of one or more members of our management team or other key employees or advisors could delay our research and development programs and have a material and adverse effect on our business, financial condition, results of operations and prospects. The relationships that our key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent on the continued service of our technical personnel because of the highly technical nature of our product candidates and technologies and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide us with continued service, they could terminate their employment with us at any time without penalty. Our future success will depend in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition for personnel from other companies, universities, public and private research institutions, government entities and other organizations, especially as job opportunities in the biotechnology industry have recently increased significantly in the San Francisco Bay Area.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If any of our product candidates are approved for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to commercialize successfully any such future products.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no sales, marketing or distribution capabilities or experience. If any of our product candidates is approved, we will need to develop internal sales, marketing and distribution capabilities to commercialize such products, which would be expensive and time-consuming, or enter into collaborations with third parties to perform these services. If we decide to market our products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market our products or decide to co-promote products with collaborators, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and there can be no assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance of any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Price controls imposed in foreign markets may adversely affect our future profitability. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or future collaborators may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our Probody therapeutic candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected. We currently do not know how the exit of the United Kingdom from the European Union will affect the pricing of prescription drugs, either in the United Kingdom or in the remaining European Union member states.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments, including as a result of the clinical testing of praluzatamab ravtansine (CX-2009), CX-2029, BMS-986249, BMS-986288, pacmilimab (CX-072) and any of our other product candidates or those of our collaborators. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing product candidates, such claims could result in an FDA investigation of the safety and effectiveness of our product candidates, our manufacturing processes and facilities (or the manufacturing processes and facilities of our third-party manufacturers) or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. We currently have insurance that we believe is appropriate for our stage of development and may need to obtain higher levels of insurance prior to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our employees and independent contractors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of fraud or other misconduct by our employees or independent contractors. Misconduct by these parties could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state data privacy, security, fraud and abuse, and other healthcare laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our current operations are concentrated in one location, and we or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current operations are located in our facilities in South San Francisco, California. Any unplanned event, such as flood, fire, explosion, earthquake, extreme weather condition, medical epidemics, power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Earthquakes or other natural disasters could further disrupt our operations and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. For example, in March 2020, the COVID-19 pandemic caused us to restrict access to our facility and initiate a work-from-home program limiting onsite activity to a substantially reduced level of laboratory research activities. Although we have gradually increased levels of our laboratory research activities, there can be no assurance that we will be able to continue to increase or maintain current levels of such activity or that the COVID-19 pandemic will not continue to impact our ability to conduct business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material and adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure you that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities, or the manufacturing facilities of our third-party contract manufacturers, are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the U.S.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We prepare our financial statements in conformity with accounting principles generally accepted in the U.S. These accounting principles are subject to interpretation by the Financial Accounting Standards Board (&#8220;FASB&#8221;) and the SEC. A change in these policies or interpretations could have a significant effect on our reported financial results, may retroactively affect previously reported results, could cause unexpected financial reporting fluctuations, and may require us to make costly changes to our operational processes and accounting systems. For example, in May 2014, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) 2014-09, <span style="font-style:italic;">Revenue from Contracts with Customers (Topic 606), </span>which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The ASU replaced most existing revenue recognition guidance in the U.S. GAAP when it became effective. The new standard was effective at the beginning of our fiscal year 2018 with early adoption permitted for our fiscal year 2017. We evaluated the impact of ASU 2014-09 on our financial statements and adoption of the standard had a significant impact on our financial statements and retroactively affected the accounting treatment of transactions completed before adoption. Additionally, for the purpose of revenue recognition, we are required to estimate research service periods as well as the related cost to completion, of our research development program. Such estimates are inherently uncertain and may result in changes in estimates to financial statements in subsequent periods.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;IRC&#8221;), if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage points change (by value) in the ownership of its equity over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income and taxes may be limited. California has similar rules. For example, we performed an IRC Section 382 analysis in 2017 and determined there was an ownership change that resulted in Section 382 limitations. The ownership change limited our ability to utilize net operating losses against taxable income in 2018 for both federal and California tax purposes. The remaining net operating losses and credit will be available in future years before expiration during their respective carryforward periods. We may experience ownership changes in the future as a result of shifts in our stock ownership, some of which are outside our control, and our ability to utilize net operating loss carryforwards could be limited by an &#8220;ownership change&#8221; as described above, which could result in additional increased tax liability to the Company. </p>
<p style="Background-color:#FFFFFF;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Intellectual Property</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are not able to obtain and enforce patent protection for our technologies or product candidates, development and commercialization of our product candidates may be adversely affected.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends in part on our ability to obtain and maintain patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others, for our product candidates, methods used to manufacture our product candidates and methods for treating patients using our product candidates, as well as our ability to preserve our trade secrets, to prevent third parties from infringing upon our proprietary rights and to operate without infringing upon the proprietary rights of others. We have a substantial number of issued patents and pending patent applications, some of which are co-owned with a third party, covering our Probody platforms and products as well as methods of use and production thereof&#59; we have exclusively licensed UCSB&#8217;s interest in the patent family co-owned with UCSB that covers Probody and other pro-protein technology in the fields of therapeutics, <span style="font-style:italic;">in vivo</span> diagnostics and prophylactics. In addition, we have exclusively licensed a patent portfolio of three patent families from UCSB that includes patents and patent applications that cover compositions and methods related to the screening for and identification of the masks and protease-cleavable linkers that we incorporate into our Probody candidates. We may not be able to apply for patents on certain aspects of our product candidates in a timely fashion or at all. Our existing issued and granted patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and technology. There is no guarantee that any of our pending patent applications will result in issued or granted patents, that any of our issued or granted patents will not later be found to be invalid or unenforceable or that any issued or granted patents will include claims that are sufficiently broad to cover our product candidates or to provide meaningful protection from our competitors. Moreover, the patent position of biotechnology and biopharmaceutical companies can be highly uncertain because it involves complex legal and factual questions. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our current and future proprietary technology and product candidates are covered by valid and enforceable patents or are effectively maintained as trade secrets. If third parties disclose or misappropriate our proprietary rights, it may materially and adversely affect our position in the market.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. Patent and Trademark Office (&#8220;USPTO&#8221;) and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. The standards applied by the USPTO and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and biopharmaceutical patents. As such, we do not know the degree of future protection that we will have on our proprietary products and technology. While we will endeavor to try to protect our product candidates with intellectual property rights such as patents, as appropriate, the process of obtaining patents is time-consuming, expensive and sometimes unpredictable.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, there are numerous recent changes to the patent laws and proposed changes to the rules of the USPTO that may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, the America Invents Act (&#8220;AIA&#8221;) enacted within the last several years involves significant changes in patent legislation. The Supreme Court has ruled on several patent cases in recent years, some of which cases either narrow the scope of patent protection available in certain circumstances or weaken the rights of patent owners in certain situations. The recent decision by the Supreme Court in <span style="font-style:italic;">Association for Molecular Pathology v. Myriad Genetics, Inc</span>. precludes a claim to a nucleic acid having a stated nucleotide sequence that is identical to a sequence found in nature and has not been modified. We currently are not aware of an immediate impact of this decision on our patents or patent applications because we are developing product candidates that contain modifications, such as our Probody substrates and masks, that we believe are not found in nature. However, this decision has yet to be clearly interpreted by courts and by the USPTO. We cannot assure you that the interpretations of this decision or subsequent rulings will not adversely impact our patents or patent applications. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once granted, patents may remain open to opposition, interference, re-examination, post-grant review, inter </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">partes</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> review, nullification or derivation action in court or before patent offices or similar proceedings for a given period after allowance or grant, during which time third parties can raise objections against such initial grant. In the course of such proceedings, which may continue for a protracted period of time, the patent owner may be compelled to limit the scope of the allowed or granted claims thus attacked, or may lose the allowed or granted claims altogether. In addition, there can be no assurance that:</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Others will not or may not be able to make, use or sell compounds that are the same as or similar to our product candidates but that are not covered by the claims of the patents that we own or license.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We or our licensors, or our collaborators are the first to make the inventions covered by each of our issued patents and pending patent applications that we own or license.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We or our licensors, or our collaborators are the first to file patent applications covering certain aspects of our inventions.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Others will not independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating or otherwise violating our intellectual property rights.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">A third party may not challenge our patents and, if challenged, a court would hold that our patents are valid, enforceable and infringed.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Any issued patents that we own or have licensed will provide us with any competitive advantages, or will not be challenged by third parties.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">We may develop additional proprietary technologies that are patentable.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The patents of others will not have a material or adverse effect on our business, financial condition, results of operations and prospects.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Our competitors do not conduct research and development activities in countries where we do not have enforceable patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other companies or organizations may challenge our or our licensors&#8217; patent rights or may assert patent rights that prevent us from developing and commercializing our products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody therapeutics are a relatively new scientific field. We have obtained grants and issuances of Probody therapeutic patents and have licensed one patent family comprising several of these patents from a third party on an exclusive basis for therapeutics applications. The issued patents and pending patent applications in the United States and in key markets around the world that we own or license claim many different methods, compositions and processes relating to the discovery, development, manufacture and commercialization of antibody and immunoregulatory therapeutics. Specifically, we own and have licensed a portfolio of patents, patent applications and other intellectual property covering Probody compositions of matter as well as their methods of manufacturing and use.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As the field of antibody and immunoregulatory therapeutics matures, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when, to whom, and with what claims. In addition, third parties may attempt to invalidate our intellectual property rights. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our rights are not directly challenged, disputes could lead to the weakening of our intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management and could have a material and adverse effect on our business, financial condition, results of operations and prospects or our ability to successfully compete.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are many issued and pending patents that claim aspects of our product candidates and modifications that we may need to apply to our product candidates. There are also many issued patents that claim antibodies or portions of antibodies that may be relevant for Probody products we wish to develop. Thus, it is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent rights on reasonable terms, we may not be able to market products or perform research and development or other activities covered by these patents.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining a valid and enforceable issued or granted patent covering our technology in the U.S. and worldwide can be extremely costly. In jurisdictions where we have not obtained patent protection, competitors may use our technology to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but where it is more difficult to enforce a patent as compared to the U.S. Competitor products may compete with our future products in jurisdictions where we do not have issued or granted patents or where our issued or granted patent claims or other intellectual property rights are not sufficient to prevent competitor activities in these jurisdictions. The legal systems of certain countries, particularly certain developing countries, make it difficult to enforce patents and such countries may not recognize other types of intellectual property protection, particularly that relating to biopharmaceuticals. This could make it difficult for us to prevent the infringement of our patents or marketing of competing products in violation of our proprietary rights generally in certain jurisdictions. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We generally file a provisional patent application first (a priority filing) at the USPTO. An international application under the Patent Cooperation Treaty (&#8220;PCT&#8221;) is usually filed within twelve months after the priority filing. Based on the PCT filing, national and regional patent applications may be filed in the United States, Europe, Japan, Australia and Canada and, depending on the individual case, also in any or all of, <span style="font-style:italic;">inter alia</span>, Brazil, China, Hong Kong, India, Indonesia, Israel, Malaysia, Mexico, New Zealand, Russia or Eurasian Patent Organization, Singapore, South Africa, South Korea and other jurisdictions. We have so far not filed for patent protection in all national and regional jurisdictions where such protection may be available. In addition, we may decide to abandon national and regional patent applications before grant. Finally, the grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant registration authorities, while granted by others. It is also quite common that depending on the country, various scopes of patent protection may be granted on the same product candidate or technology.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws in the U.S., and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition from others in those jurisdictions. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business and results of operations may be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We or our licensors, or any future strategic partners may become subject to third party claims or litigation alleging infringement of patents or other proprietary rights or seeking to invalidate patents or other proprietary rights, and we may need to resort to litigation to protect or enforce our patents or other proprietary rights, all of which could be costly, time consuming, delay or prevent the development and commercialization of our product candidates, or put our patents and other proprietary rights at risk.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We or our licensors, or any future strategic partners may be subject to third-party claims for infringement or misappropriation of patent or other proprietary rights. We are generally obligated under our license or collaboration agreements to indemnify and hold harmless our licensors or collaborators for damages arising from intellectual property infringement by us. For example, in March 2020, Vytacera Bio, LLC filed a patent infringement lawsuit against the Company in the U.S. District Court for the District of Delaware. The lawsuit alleges that the Company&#8217;s use, offers to sell, and/or sales of the Probody technology platform for basic research applications constitutes infringement.&#160;The complaint seeks unspecified monetary damages.&#160;The Company believes that the lawsuit is without merit and intends to vigorously defend itself. However, there can be no assurance that a court might not rule against us in these proceedings. Even if we are successful in defending against such claim, this litigation could divert management&#8217;s attention, as well as our resources, from our business and any claims paid out of our cash reserves would harm our financial condition and operating results.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or our licensors, or any future strategic partners are found to infringe a third-party patent or other intellectual property rights, we could be required to pay damages, potentially including treble damages, if we are found to have willfully infringed. In addition, we or our licensors, or any future strategic partners may choose to seek, or be required to seek, a license from a third party, which may not be available on acceptable terms, if at all. Even if a license can be obtained on acceptable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us. If we fail to obtain a required license, we or our collaborators may be unable to effectively market product candidates based on our technology, which could limit our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations. In addition, we may find it necessary to pursue claims or initiate lawsuits to protect or enforce our patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to patent or other proprietary rights, even if resolved in our favor, could be substantial, and litigation would divert our management&#8217;s attention. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and limit our ability to continue our operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we were to initiate legal proceedings against a third party to enforce a patent covering one of our products or our technology, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on one or more of our products or certain aspects of our platform technology. Such a loss of patent protection could have a material and adverse effect on our business, financial condition, results of operations and prospects. Patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without legally infringing,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">misappropriating or otherwise violating our patents or other intellectual property rights.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property rights of third parties could adversely affect our ability to commercialize our product candidates, and we might be required to litigate or obtain licenses from third parties in order to develop or market our product candidates. Such litigation or licenses could be costly or not available on commercially reasonable terms.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because the antibody landscape is still evolving, including the masked antibody landscape, it is difficult to conclusively assess our freedom to operate without infringing on third-party rights. There are numerous companies that have pending patent applications and issued patents broadly covering antibodies generally or covering antibodies directed against the same targets as, or targets similar to, those we are pursuing. There are many issued patents and patent applications covering antibodies targeted against PD-1 and PD-L1, and the intellectual property covering PD-1 and PD-L1 antibodies has been the subject of litigation and licensing, especially regarding how broadly certain claims should be construed. If the claims were to be construed broadly by the courts, we may need to obtain a license to some of such intellectual property, covering PD-1 and/or PD-L1 antibodies, which would decrease the profits we would realize from the sale of such products. An increasing number of third parties are filing masked antibody patent applications, several of which contain claims that are patterned after our own patent claims. Our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our products or product candidates or elements thereof, or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize products or product candidates unless we successfully pursue litigation to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may be issued patents of which we are not aware, held by third parties that, if found to be valid and enforceable, could be alleged to be infringed by our Probody therapeutic technologies. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be alleged to be infringed by our Probody therapeutic technologies. If such an infringement claim should be brought and be successful, we may be required to pay substantial damages, be forced to abandon our product candidates or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is also possible that we have failed to identify relevant third-party patents or applications. For example, U.S. applications filed before November 29, 2000 and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our products or platform technology could have been filed by others without our knowledge. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our products or the use of our products. Third-party intellectual property right holders may also actively bring infringement claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our products. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our product candidates that are held to be infringing. We might, if possible, also be forced to redesign product candidates so that we no longer infringe the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Litigation, including the ongoing patent infringement lawsuit brought by Vytacera Bio, LLC (&#8220;Vytacera&#8221;) against us, or other legal proceedings relating to intellectual property claims, with or without merit, is unpredictable and generally expensive and time consuming and is likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon, misappropriating or otherwise violating or from successfully challenging our intellectual property rights. For example, although we believe the Vytacera lawsuit is without merit and we intend to vigorously defend ourselves, we cannot provide any assurance that we will be successful. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material and adverse effect on our ability to compete in the marketplace.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose our rights to intellectual property rights that are necessary for developing and protecting our product candidates or we could lose certain rights to grant sublicenses.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our licenses from Amgen, ImmunoGen and UCSB impose, and any future licenses we enter into are likely to impose, various development, commercialization, funding, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations on us, including various payment obligations such as milestone and royalty payments and payments based on sublicensing revenues. Our rights under our agreements with our licensors or collaborators may be limited or modified according to their terms. Additionally, if we breach any of these obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. Moreover, our licensors and collaborators may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing, misappropriating or otherwise violating the licensor&#8217;s rights. In addition, while we cannot currently determine the amount of the royalty or sublicense revenue payment obligations we would be required to pay on development or sales of future products, if any, the amounts may be significant. The amount of our future royalty or sublicense revenue payment obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our intellectual property agreements with our licensors, collaborators and third parties may be subject to disagreements over contract interpretation, which could narrow the scope of, or result in termination of, our rights to the relevant intellectual property or technology or increase our financial or other obligations to such third parties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. For example, we may disagree with our licensors or collaborators regarding whether, when and to what extent various obligations under these agreements apply to certain of our product candidates and products, including various payment, development, commercialization, funding, diligence, sublicensing, insurance, patent prosecution and enforcement and/or other obligations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement. In either case, such disagreement could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self&#8209;executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to seeking patent protection for certain aspects of our product candidates, we also consider trade secrets, including confidential and unpatented know-how, important to the maintenance of our competitive position. We protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign their inventions to us.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the U.S. and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets of our employees&#8217; or consultants&#8217; former employers or their clients. These claims may be costly to defend and if we do not successfully do so, we may be required to pay monetary damages and may lose valuable intellectual property rights or personnel.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of our employees were previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper our ability to commercialize, or prevent us from commercializing, our product candidates, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Government Regulation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may be unable to obtain or be delayed in obtaining U.S. or foreign regulatory approval and, as a result, be unable or delayed in being able to commercialize our product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates that we are currently developing are regulated as therapeutic biologics that are subject to requirements for review and approval of a BLA by the FDA&#8217;s Center for Drug Evaluation and Research (&#8220;CDER&#8221;). Therefore, our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs and therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug or therapeutic biologic can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. For example, at this time it is impossible to predict whether the COVID-19 pandemic will cause regulatory delays in the U.S. or foreign jurisdictions. It is possible that none of the product candidates we may develop will obtain the regulatory approvals necessary for us or our existing or future collaborators to begin selling them.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a company, we have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating us require judgment and can change, which makes it difficult to predict with certainty how they will be applied. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. Further, government shutdowns, such as the partial U.S. federal government shutdown in late 2018 or the uncertain impact of the United Kingdom&#8217;s departure from the European Union may impact our ability to access government agencies in a timely manner or otherwise impact our ability to move our product candidates through the regulatory process. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, the FDA may respond to our submissions by defining requirements we may not have anticipated. Such responses could lead to significant delays in the clinical development of our product candidates. In addition, because there may be approved treatments for some of the diseases for which we may seek approval, in order to receive regulatory approval, we may need to demonstrate through clinical trials that the product candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or more effective than existing products. Furthermore, in recent years, there has been increased public and political pressure on the FDA with respect to the approval process for new drugs and therapeutic biologics, and the FDA&#8217;s standards, especially regarding product safety, appear to have become more stringent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any delay or failure in obtaining required approvals could have a material and adverse effect on our ability to generate revenues from the particular product candidate for which we are seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations on the approved uses for which we may market the product or the labeling or other restrictions. In addition, the FDA has the authority to require a REMS as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may limit the size of the market for the product and affect reimbursement by third-party payors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities outside the U.S. and vice versa.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any regulatory approvals that we or our collaborators obtain for our product candidates may also be subject to limitations on the approved indicated uses for which a product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including &#8220;Phase 4&#8221; clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. In addition, if the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and good clinical practices for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fines, warning letters or holds on clinical trials&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic partners&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">suspension or revocation of product license approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">product seizure or detention or refusal to permit the import or export of products&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injunctions or the imposition of civil or criminal penalties.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, the results of the 2020 U.S. Presidential Election may impact our business and industry. Namely, the Trump administration took several executive actions, including the issuance of a number of executive orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict whether or how these executive actions will be implemented, or whether they will be rescinded and replaced under the Biden administration. The policies and priorities of a new administration are unknown and could materially impact the regulations governing our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action, and we may not achieve or sustain profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Affordable Care Act includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (&#8220;BPCIA&#8221;), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a highly similar or &#8220;biosimilar&#8221; product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Disruptions at the&#160;FDA&#160;and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the&#160;FDA&#160;to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is inherently fluid and unpredictable. Disruptions at the&#160;FDA&#160;and other agencies may also slow the time necessary for therapeutic biologics or modifications to approved therapeutic biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the&#160;FDA, have had to furlough&#160;FDA&#160;employees and stop critical activities. &#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Separately, in response to the global pandemic of COVID-19, on March 10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Healthcare legislative reform measures may have a material and adverse effect on our business and results of operations.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (together, the &#8220;ACA&#8221;), was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, subjected therapeutic biologics to potential competition by lower-cost biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and therapeutic biologics that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs and therapeutic biologics, and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts, which, through subsequent legislative amendments, was increased to 70% starting in 2019, off negotiated prices of applicable brand drugs and therapeutic biologics to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs and therapeutic biologics to be covered under Medicare Part D.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA. By way of example, the Tax Cuts and Jobs Act of 2017 includes a provision repealing the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221;  On December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Cuts and Jobs Act, the remaining provisions of the ACA are invalid as well. On December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court's decision that the individual mandate was unconstitutional but remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court is currently reviewing the case, and its ruling may impact the application and effect of ACA. In addition, there may be other efforts to challenge, repeal, or replace the ACA. We are continuing to monitor any changes to the ACA that, in turn, may potentially impact our business in the future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted to reduce healthcare expenditures. The Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 2, 2020 through March 31, 2021, unless additional Congressional action is taken. On January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. If federal spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA or the National Institutes of Health to continue to function at current levels. Amounts allocated to federal grants and contracts may be reduced or eliminated. These reductions may also impact the ability of relevant agencies to timely review and approve research and development, manufacturing, and marketing activities, which may delay our ability to develop, market and sell any products we may develop.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, payment methodologies, including payment for companion diagnostics, may be subject to changes in healthcare legislation and regulatory initiatives. For example, the Centers for Medicare &#38; Medicaid Services (&#8220;CMS&#8221;) has begun bundling the Medicare payments for certain laboratory tests ordered while a patient received services in a hospital outpatient setting. Additionally, CMS significantly altered the payment methodology under the Medicare Clinical Laboratory Fee Schedule (CLFS). Effective 2018, the CFLS is based on a weighted average of reported prices that private payors, Medicare Advantage plans, and Medicaid Managed Care plans pay for laboratory services. Further, in March 2018, CMS finalized a national coverage determination extending coverage under the Medicare program for certain diagnostic laboratory tests using next generation sequencing (&#8220;NGS&#8221;) that are approved by the FDA as a companion <span style="font-style:italic;">in vitro</span> diagnostic and used in a cancer with an FDA-approved companion diagnostic indication. Under the national coverage determination, diagnostic tests that meet these criteria are covered only in patients with recurrent, metastatic, relapsed, refractory or stages III or IV cancer if the test has an FDA-approved or cleared indication for use in that patient&#8217;s cancer and results are provided to the treating physician for management of the patient using a report template to specify treatment options. Although the Medicare program increasingly is used as a model for how private payors and other governmental payors develop their coverage and </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reimbursement policies, it is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for any companion diagnostics associated with our product candidates.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, the 21st Century Cures Act changed the reimbursement methodology for infusion drugs and biologics furnished through durable medical equipment in an attempt to remedy over- and underpayment of certain products. Furthermore, with the new Presidential administration and both houses of Congress under the control of one party, which has promoted substantial changes to the healthcare system and drug pricing rules, some changes are likely. If certain of these changes are implemented, it could have a materially adverse impact on the ability of biotechnology and pharmaceutical companies, like us, to obtain capital to further their research or develop their product candidates make it economically unfeasible for such companies to continue to develop needed new innovative therapies.&#160;&#160;Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or companion diagnostics or additional pricing pressures.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we or our collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we do not currently have any products on the market, once we begin commercializing our product candidates, we will be subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind to induce or reward either the referral of an individual for, or the purchase, or order or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the U.S. federal False Claims Act, which imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services&#59; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the U.S. federal legislation commonly referred to as Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the CMS information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), teaching hospitals and, beginning in 2022, certain other health care professionals, as well as ownership and investment interests held by the physicians described above and their immediate family members&#59; and</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">analogous state laws and regulations, such as state anti-kickback and false claims laws that may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers&#59; </span><span style="color:#000000;">and </span><span style="color:#000000;">state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug and therapeutic biologics manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures and pricing information.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our future business arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any such requirements, we may be subject to penalties, including civil or criminal penalties, monetary damages, the curtailment or restructuring of our operations, loss of eligibility to obtain approvals from the FDA, or exclusion from participation in government contracting, healthcare reimbursement or other government programs, including Medicare and Medicaid, any of which could adversely our financial results. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we or future collaborators, manufacturers or service providers fail to comply with applicable federal, state or foreign laws or regulations, we could be subject to enforcement actions, which could affect our ability to develop, market and sell our products successfully and could harm our reputation and lead to reduced acceptance of our products by the market. These enforcement actions include, among others:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">adverse regulatory inspection findings&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">warning letters&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">voluntary or mandatory product recalls or public notification or medical product safety alerts to healthcare professionals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions on, or prohibitions against, marketing our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">restrictions on, or prohibitions against, importation or exportation of our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">suspension of review or refusal to approve pending applications or supplements to approved applications&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">exclusion from participation in government-funded healthcare programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">exclusion from eligibility for the award of government contracts for our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">suspension or withdrawal of product approvals&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">seizures or administrative detention of products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">injunctions&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">civil and criminal penalties and fines.</span></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we receive marketing and commercialization approval of a product candidate, we will be subject to continuing regulatory requirements, including in relation to adverse patient experiences with the product and clinical results that are reported after a product is made commercially available, both in the U.S. and any foreign jurisdiction in which we seek regulatory approval. The FDA has significant post-market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. The FDA also has the authority to require a REMS plan after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or therapeutic biologic. The manufacturer and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer or facility, including withdrawal of the product from the market. If we rely on third-party manufacturers, we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. If we or our collaborators, manufacturers or service providers fail to </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, delay of approval or refusal by the FDA to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We face regulation and potential liability related to the privacy, data protection and information security which may require significant resources and may adversely affect our business, operations and financial performance.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulatory environment surrounding information security, data collection and privacy is increasingly demanding. We are subject to numerous U.S. federal and state laws and non-U.S. regulations governing the protection of personal and confidential information of our clinical subjects, clinical investigators, employees and vendors/business contacts, including in relation to medical records, credit card data and financial information. For example, on May 25, 2018, the European Union General Data Protection Regulation, or GDPR, became effective, implementing more stringent requirements in relation to our use of personal data relating to individuals located in the E.U. (and E.E.A.). The GDPR is directly applicable in all E.U. and E.E.A. member states. The GDPR significantly increased fining levels to up to 4% total worldwide annual turnover or up to &#8364;20 million (whichever is higher) for non-compliance with its requirements. Further, following the withdrawal of the United Kingdom from the E.U. and the expiry of the transition period, from January 1, 2021, we have to comply with the GDPR and separately the GDPR as implemented in the United Kingdom, with each regime having the ability to issue substantial fines. The relationship between the United Kingdom and the E.U. in relation to certain aspects of data protection law remains unclear, including how data transfers between E.U. member states and the United Kingdom will be treated. These changes may lead to additional compliance costs and could increase our overall risk.  We will be subject to the GDPR where we have an E.U. presence or &#8220;establishment&#8221; (<span style="font-style:italic;">e.g</span>., E.U. based subsidiary or operations), when conducting clinical trials with E.U. based data subjects (whether the trials are conducted directly by us or through a clinical vendor or collaborator) or offering approved products or services (if relevant) to E.U. and E.E.A. based data subjects (regardless of whether involving our E.U. based subsidiary or operations). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The GDPR sets out a number of requirements that must be complied with when handling the personal data of such data subjects within the E.U. and the E.E.A. including: providing expanded disclosures about how their personal data will be used&#59; higher standards for organizations to demonstrate that they have obtained valid consent or have another legal basis in place to justify their data processing activities&#59; the obligation to appoint data protection officers in certain circumstances&#59; new rights for individuals to be &#8220;forgotten&#8221; and rights to data portability, as well as enhanced current rights (e.g., access requests)&#59; the principal of accountability and demonstrating compliance through policies, procedures, training and audit&#59; the new mandatory data breach regime. In particular, medical or health data, genetic data and biometric data where the latter is used to uniquely identify an individual (even, in certain situations, where such data is key coded) are all classified as &#8220;special category&#8221; data under GDPR and afford greater protection and require additional compliance obligations. Further, E.U. and EEA member states have a broad right to impose additional conditions &#8211; including restrictions &#8211; on these data categories. This is because the GDPR allows E.U. and E.E.A. member states to derogate from the requirements of the GDPR mainly in regard to specific processing situations (including special category data and processing for scientific or statistical purposes).&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will also be subject to evolving E.U. laws on data export, where we transfer data outside the E.U. (or E.E.A.) to group companies or third parties. Recent legal developments in Europe have created complexity and uncertainty regarding transfers of personal data from the E.E.A. to the United States. For example, on July 16, 2020, the Court of Justice of the European Union (CJEU) invalidated the EU-US Privacy Shield Framework (Privacy Shield) under which personal data could be transferred from the E.E.A. to United States entities which had self-certified under the Privacy Shield scheme. While the CJEU upheld the adequacy of the standard contractual clauses (a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism, and potential alternative to the Privacy Shield), it made clear that reliance on them alone may not necessarily be sufficient in all circumstances. Use of the standard contractual clauses must now be assessed on a case-by-case basis taking into account the legal regime applicable in the destination country, in particular applicable surveillance laws and rights of individuals and additional measures and/or contractual provisions may need to be put in place, however, the nature of these additional measures is currently uncertain. These recent developments will require us to review and amend the legal mechanisms by which we transfer personal data from the E.E.A. to the United States. As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the standard contractual clauses cannot be used, or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Where we rely on third parties to carry out a number of services for us, including processing personal data on our behalf, we are required under GDPR to enter into contractual arrangements to help ensure that these third parties only process such data according to our instructions and have sufficient security measures in place. Any security breach or non-compliance with our contractual terms or </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">breach of applicable law by such third parties could result in enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have an adverse impact on our reputation and business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In recent years, U.S. and European lawmakers and regulators have expressed concern over electronic marketing and the use of third-party cookies, web beacons and similar technology for online behavioral advertising. In the E.U., marketing is defined broadly to include any promotional material and the rules specifically on e-marketing are currently set out in the ePrivacy Directive which will be replaced by a new ePrivacy Regulation. While the ePrivacy Regulation was originally intended to be adopted on May 25, 2018 (alongside the GDPR), it is still going through the European legislative process. The current draft of the ePrivacy Regulation imposes strict opt-in e-marketing rules with limited exceptions to business to business communications and significantly increases fining powers to the same levels as GDPR (see above).&#160;&#160;Regulation of cookies and web beacons may lead to broader restrictions on our online activities, including efforts to understand followers&#8217; internet usage and promote ourselves to them.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may find it necessary or desirable to join self-regulatory bodies or other privacy-related organizations, particularly relating to biopharmacy and/or scientific research, that require compliance with their rules pertaining to privacy and data security.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, California enacted the California Consumer Privacy Act (&#8220;CCPA&#8221;) on June 28, 2018, which went into effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability. Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any person, including any of our employees, clinical vendors or collaborators or those with whom we share such information, negligently disregards or intentionally breaches our established controls with respect to our clinical subject, clinical investigator or employee data, or otherwise mismanages or misappropriates that data, we could be subject to significant monetary damages, regulatory enforcement actions, fines and/or criminal prosecution in one or more jurisdictions. As above, under the GDPR there are significant new punishments for non-compliance which could result in a penalty of up to 4% of a firm&#8217;s global annual revenue. In addition, a data breach could result in negative publicity which could damage our reputation and have an adverse effect on our business, financial condition or results of operations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to comply with these and other data privacy and security restrictions that may be enacted could require us to modify our data processing practices and policies and increase the cost of our operations. We strive to comply with all applicable laws, but they may conflict with each other, and by complying with the laws or regulations of one jurisdiction, we may find that we are violating the laws or regulations of another jurisdiction. Despite our efforts, we may not have fully complied in the past and may not in the future. If we become liable under laws or regulations applicable to us, we could be required to pay significant fines and penalties, our reputation may be harmed and we may be forced to change the way we operate. That could require us to incur significant expenses or to discontinue certain services, which could negatively affect our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Even if we are able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern regulatory approvals, pricing and reimbursement for new drugs and therapeutic biologics vary widely from country to country. Some countries require approval of the sale price of a drug or therapeutic biologic before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription biopharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and reimbursement for these products and related treatments will be available from government authorities, private health insurers and other organizations. Even if we succeed in bringing one or more products to the market, these products may not be considered cost-effective, and the amount reimbursed for any products may be insufficient to allow us to sell our products on a competitive basis. Because our programs are in the early stages of development, we are unable at this time to determine their cost effectiveness or the likely level or method of reimbursement. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices, and are seeking to reduce the prices charged or the amounts reimbursed for biopharmaceutical products. If the price we are able to charge for any products we develop, or the reimbursement provided for such products, is inadequate in light of our development and other costs, our return on investment could be adversely affected. There may be significant delays in obtaining reimbursement for </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">newly-approved drugs or therapeutic biologics, and coverage may be more limited than the purposes for which the drug or therapeutic biologic is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for reimbursement does not imply that any drug or therapeutic biologic will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs or therapeutic biologics, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may be based on payments allowed for lower-cost drugs or therapeutic biologics that are already reimbursed, may be incorporated into existing payments for other services and may reflect budgetary constraints or imperfections in Medicare data. Net prices for drugs or therapeutic biologics may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs or therapeutic biologics from countries where they may be sold at lower prices than in the U.S. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement rates. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for new drugs or therapeutic biologics that we develop and for which we obtain regulatory approval could have a material and adverse effect on our operating results, our ability to raise capital needed to commercialize products and our financial condition.</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may seek and fail to obtain fast track or breakthrough therapy designations for our current or future product candidates. If we are successful, these programs may not lead to a faster development or regulatory review process, and they do not guarantee we will receive approval for any product candidate. We may also seek to obtain accelerated approval for one or more of our product candidates but the FDA may disagree that we have met the requirements for such approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for fast track designation. Fast track designation provides increased opportunities for sponsor meetings with the FDA during preclinical and clinical development, in addition to the potential for rolling review of a BLA, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive fast track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the fast track designation if it believes that the designation is no longer supported by data from our clinical development program.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also seek breakthrough therapy designation for any product candidate that we develop. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Like fast track designation, breakthrough therapy designation is within the discretion of the FDA. Accordingly, even if we believe a product candidate we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of breakthrough therapy designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if a product candidate we develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Product candidates may also be eligible for accelerated approval if the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical studies to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. Products receiving accelerated approval may be subject to expedited withdrawal procedures if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA requires pre-approval of promotional materials for accelerated approval products, once approved. We cannot guarantee that the FDA will agree any of our product candidates has met the criteria to receive accelerated approval, which would require us to conduct additional clinical testing prior to seeking FDA approval. Even if any of our product candidates received approval through this pathway, the product may fail required post-approval confirmatory clinical trials, and we may be required to remove the product from the market or amend the product label in a way that adversely impacts its marketing. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may seek Orphan Drug Designation for some of our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of our business strategy, we may seek Orphan Drug Designation for our product candidates, and we may be unsuccessful. Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs and therapeutic biologics for relatively small patient populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a drug or therapeutic biologic as an orphan drug if it is a drug or therapeutic biologic intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug or therapeutic biologic will be recovered </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from sales in the United States. In the United States, Orphan Drug Designation entitles a party to financial incentives such as opportunities for grant funding toward clinical trial costs, tax advantages and user-fee waivers. In addition, if a product that has Orphan Drug Designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same product for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or where the manufacturer is unable to assure sufficient product quantity.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain Orphan Drug Designation for our product candidates in specific indications, we may not be the first to obtain marketing approval of these product candidates for the orphan-designated indication due to the uncertainties associated with developing pharmaceutical products. In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different biologics can be approved for the same condition. Even after an orphan product is approved, the FDA can subsequently approve the same drug or therapeutic biologic for the same condition if the FDA concludes that the later drug or therapeutic biologic is safer, more effective or makes a major contribution to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug or therapeutic biologic nor gives the drug or therapeutic biologic any advantage in the regulatory review or approval process. In addition, while we may seek Orphan Drug Designation for our product candidates, we may never receive such designations.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax reform legislation passed in 2017 reduced the amount of the qualified clinical research costs for a designated orphan product that a sponsor may claim as a credit from 50% to 25%. Thus, further limiting the advantage and may impact our future business strategy of seeking the Orphan Drug Designation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Ownership of Our Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">variations in the level of expense related to the ongoing development of our Probody platform, our product candidates or future development programs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">results of clinical trials, or the addition or termination of clinical trials or funding support by us, or existing or future collaborators or licensing partners&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our execution of any additional collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under existing or future arrangements or the termination or modification of any such existing or future arrangements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any intellectual property infringement lawsuit or opposition, interference or cancellation proceeding in which we may become involved, including the ongoing patent infringement lawsuit brought by Vytacera against us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">additions and departures of key personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory developments affecting our product candidates or those of our competitors&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in general market and economic conditions.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our stock price may be volatile and purchasers of our common stock could incur substantial losses.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price is volatile. Since our initial public offering (&#8220;IPO&#8221;), our stock had low and high sales prices in the range of $3.60 and $35.00 per share. The market price for our common stock may be influenced by many factors, including the other risks described in this section titled &#8220;Risk Factors&#8221; and the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">results of clinical trials and preclinical studies of our product candidates, or those of our competitors or our collaborators&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">regulatory or legal developments in the U.S. and other countries, especially changes in laws or regulations applicable to our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success of competitive products or technologies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">introductions and announcements of new products by us, our future commercialization partners, or our competitors, and the timing of these introductions or announcements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">actions taken by regulatory agencies with respect to our products, clinical studies, manufacturing process or sales and marketing terms&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the extent to which the COVID-19 pandemic and related governmental regulations and restrictions may impact our business, including our research, clinical trials, manufacturing and financial condition, as well as the impact of other pandemics, natural disasters and other calamities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the success of our efforts to acquire or in-license additional technologies, products or product candidates&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developments concerning any existing or future collaborations, including but not limited to those with our sources of manufacturing supply and our commercialization partners&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">market conditions in the pharmaceutical and biotechnology sectors&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures or capital commitments&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability or inability to raise additional capital and the terms on which we raise it&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the recruitment or departure of key personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in the structure of healthcare payment systems&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or our industry generally&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">fluctuations in the valuation of companies perceived by investors to be comparable to us&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">announcement and expectation of additional financing efforts&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">speculation in the press or investment community&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">trading volume of our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">sales of our common stock by us or our stockholders&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the concentrated ownership of our common stock&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">changes in accounting principles&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">terrorist acts, acts of war or periods of widespread civil unrest&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">natural disasters and other calamities&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">general economic, industry and market conditions.</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility, including as a result of the COVID-19 pandemic, that has been often unrelated to the operating performance of the issuer. These broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the spread of COVID-19 coronavirus may negatively impact the trading price of shares of our common stock and could further severely impact our ability to raise additional capital on a timely basis or at all.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The future issuance of equity or of debt securities that are convertible into equity will dilute our share capital.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may choose to raise additional capital in the future, depending on market conditions, strategic considerations and operational requirements. To the extent that additional capital is raised through the issuance of shares or other securities convertible into shares, our stockholders will be diluted. On February 27, 2020, we entered into an Open Market Sale Agreement (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), to sell shares of our common stock, par value $0.00001 per share, with aggregate gross sales proceeds of up to $75,000,000, from time to time, through an at the market offering under which Jefferies will act as sales agent. We have issued securities under the Sales Agreement and may do so in the future. In January and February 2021, we sold 16,428,571 shares of our common stock at $7.00 per share in an underwritten public offering. Future issuances of our common stock or other equity securities pursuant to the Sales Agreement or otherwise, or the perception that such sales may occur, could adversely affect the trading price of our common stock and impair our ability to raise capital through future offerings of shares or equity securities. No prediction can be made as to the effect, if any, that future sales of common stock or the availability of common stock for future sales will have on the trading price of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The employment agreements with our executive officers may require us to pay severance benefits to officers in connection with termination of employment or upon a change of control of us, which could harm our financial condition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each of our executive officers is entitled to receive a lump sum payment equal to one year or more of his or her base salary as well as continued medical and dental coverage for a period of one year or more plus a prorated portion of his or her target annual bonus for the calendar year in which his or her employment is terminated following his or her termination of employment due to good reason or without cause. In the event of a change in control and a termination of employment without cause or due to good reason, each of our executive officers would similarly receive one year or more of his or her base salary as well as continued medical and dental coverage for a period of one year or more, as well as an additional lump sum payment equal to 100% or more of his or her target annual bonus for the calendar year in which his or her employment is terminated and full vesting of his or her outstanding option awards. The accelerated vesting of options could result in dilution to our existing stockholders and harm the market price of our common stock. Furthermore, the payment of these severance benefits could harm our financial condition. In addition, these potential severance payments may discourage or prevent third parties from seeking a business combination with us.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">An active market for our common stock may not be maintained.</p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our IPO in October 2015, there had been no public market for shares of our common stock. Our stock began trading on the Nasdaq Global Select Market in 2015, and we can provide no assurance that we will be able to maintain an active trading market on The Nasdaq Global Select Market or any other exchange in the future. If an active market for our common stock is not maintained, it may be difficult for our stockholders to sell shares without depressing the market price for the shares or at all. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire other businesses, applications or technologies using our shares as consideration.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, our executive officers, directors, holders of 5% or more of our capital stock based on publicly available filings made with the SEC and their respective affiliates beneficially owned approximately 38% of our outstanding common stock. Therefore, these stockholders have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that our stockholders may feel are in their best interest.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and our amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a prohibition on actions by our stockholders by written consent&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a requirement that special meetings of stockholders, which our company is not obligated to call more than once per calendar year, be called only by the chairman of our board of directors, our chief executive officer, our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors, or, subject to certain conditions, by our secretary at the request of the stockholders holding of record, in the aggregate, shares entitled to cast not less than ten percent of the votes at a meeting of the stockholders (assuming all shares entitled to vote at such meeting were present and voted)&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">advance notice requirements for election to our board of directors and for proposing matters that can be acted upon at stockholder meetings&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">division of our board of directors into three classes, serving staggered terms of three years each&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the authority of the board of directors to issue preferred stock with such terms as the board of directors may determine.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, as amended, which prohibits a person who owns in excess of 15 percent of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15 percent of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions would apply even if the proposed merger or acquisition could be considered beneficial by some stockholders.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a public company, we incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel need to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors. However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act of 2002 in a timely manner or with adequate compliance, we may be subject to sanctions by regulatory authorities.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 404 of the Sarbanes-Oxley Act of 2002 requires that we evaluate and determine the effectiveness of our internal controls over financial reporting and provide a management report on the internal control over financial reporting. If we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated.&#160;&#160;We evaluate our internal controls systems to allow management to report on the effectiveness of the operation of our internal controls. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, if we are not able to comply with the requirements of Section 404, or if we or our independent registered public accounting firm identify deficiencies in our internal controls that are deemed to be material weaknesses, we could be subject to sanctions or investigations by The Nasdaq Global Select Market, the SEC or other regulatory authorities, which would entail expenditure of additional financial and management resources and could materially adversely affect our stock price. Deficient internal controls could also cause us to fail to meet our reporting obligations or cause investors to lose confidence in our reported financial information, which could have a negative effect on our stock price.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may incur significant costs from class action litigation due to our expected stock volatility.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price may fluctuate for many reasons, including as a result of public announcements regarding the progress of our development efforts or the development efforts of future collaborators or competitors, the addition or departure of our key personnel, variations in our quarterly operating results and changes in market valuations of biopharmaceutical and biotechnology companies.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This risk is especially relevant to us because biopharmaceutical and biotechnology companies have experienced significant stock price volatility in recent years. When the market price of a stock has been volatile as our stock price may be, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock. For example, in May 2020, a putative securities class action lawsuit was brought against us (&#8220;Class Action Lawsuit&#8221;). While the Class Action Lawsuit was voluntarily dismissed without prejudice by the plaintiff and his attorneys in January 2021, a similar lawsuit or another lawsuit could be filed in the future. Stockholder lawsuits of this type against us, even if it is without merit, could cause us to incur substantial costs defending the lawsuit. The lawsuit could also divert the time and attention of our management.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our amended and restated bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that, subject to limited exceptions, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers or other employees to us or our stockholders, any action asserting a claim against us arising pursuant to any provision of the Delaware General Corporation Law, as amended, our amended and restated certificate of incorporation or our amended and restated bylaws, any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws or any other action asserting a claim against us that is governed by the internal affairs doctrine. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated certificate of incorporation described above. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and employees. Alternatively, if a court were to find these provisions of our amended and restated certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General Risk Factors</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We may acquire assets or form strategic alliances in the future, and we may not realize the benefits of such acquisitions<span style="font-weight:normal;font-style:normal;">.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As we continue to mature our Probody platform and our clinical stage pipeline, we may seek to acquire and/or in-license other oncology products, product candidates, programs or companies that we consider complimentary to our efforts. Such efforts may never result in a transaction and any future growth through acquisition or in-licensing will depend upon the availability of suitable products, product candidates, programs or companies for acquisition or in-licensing on acceptable prices, terms and conditions. Even if appropriate opportunities are available, we may not be able to acquire rights to them on acceptable terms, or at all. The competition to acquire or in-license rights to promising products, product candidates, programs and companies is fierce, and many of our competitors are large, multinational pharmaceutical and biotechnology companies with considerably more financial, development and commercialization resources, personnel, and experience than we have. In order to compete successfully in the current business climate, we may have to pay higher prices for assets than may have been paid historically, which may make it more difficult for us to realize an adequate return on any acquisition. In addition, even if we succeed in identifying promising products, product candidates, programs or companies, we may not have the ability to develop, obtain regulatory approval for and commercialize such opportunities, or the financial resources necessary to pursue them. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are able to successfully identify and acquire or in-license new products, product candidates, programs or companies, we may not be able to successfully manage the risks associated with integrating any products, product candidates, programs or companies into our business or the risks arising from anticipated and unanticipated problems in connection with an acquisition or in-licensing. Further, while we seek to mitigate risks and liabilities of potential acquisitions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. Any failure in identifying and managing these risks and uncertainties effectively would have a material adverse effect on our business. In any event, we may not be able to realize the anticipated benefits of any acquisition or in-licensing for a variety of reasons, including the possibility that a product candidate fails to advance to clinical development, proves not to be safe or effective in clinical trials, or fails to reach its forecasted commercial potential or that the integration of a product, product candidate, program or company gives rise to unforeseen difficulties and expenditures. Any failure in identifying and managing these risks and uncertainties would have a material adverse effect on our business.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, acquisitions create other uncertainties and risks, particularly when the acquisition takes the form of a merger or other business consolidation. We may encounter unexpected difficulties, or incur unexpected costs, in connection with transition activities and integration efforts, which include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">high acquisition costs&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the need to incur substantial debt or engage in dilutive issuances of equity securities to pay for acquisitions&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the potential disruption of our historical business and our activities under our collaboration agreements&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the strain on, and need to expand, our existing operational, technical, financial and administrative infrastructure&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our lack of experience in late-stage product development and commercialization&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the difficulties in assimilating employees and corporate cultures&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the difficulties in hiring qualified personnel and establishing necessary development and/or commercialization capabilities&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the failure to retain key management and other personnel&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the challenges in controlling additional costs and expenses in connection with and as a result of the acquisition&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the need to write down assets or recognize impairment charges&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the diversion of our management&#8217;s attention to integration of operations and corporate and administrative infrastructures&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">any unanticipated liabilities for activities of or related to the acquired business or its operations, products or product candidates.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to integrate or otherwise manage an acquired business successfully and in a timely manner, resulting operating inefficiencies could increase our costs more than we planned, could negatively impact the market price of our common stock and could otherwise distract us from execution of our strategy. Failure to maintain effective financial controls and reporting systems and procedures could also impact our ability to produce timely and accurate financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our future growth may depend, in part, on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future growth may depend, in part, on our ability to develop and commercialize our product candidates in foreign markets for which we may rely on collaboration with third parties. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our product candidates. To obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our product candidates and ultimately commercialize our product candidates in foreign markets, we would be subject to the risks and uncertainties, including the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of intellectual property rights in some foreign countries. We may need to rely on third parties to market, distribute and sell our products in foreign markets.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our information technology systems, or those of our CROs or other contractors or consultants we may utilize, may fail, suffer disruptions or suffer security breaches, which could result in a material disruption of our product development programs.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our information technology and other internal infrastructure systems and those of our CROs and contractors and consultants, including corporate firewalls, servers, leased lines and connection to the Internet, face the risk of systemic failure and may be vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions of our operations. For instance, the loss of data from any current or future clinical trial or data from any preclinical studies involving our product candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. These challenges have been made more difficult by the COVID-19 pandemic and resulting shelter-in-place and stay-at-home restrictions, which are driving greater dependency on remote working technology and electronic monitoring of clinical trial sites. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could incur liability, recovery of our data could take a prolonged period of time, and the development of our research or product candidates could be delayed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cybersecurity breaches and other disruptions could compromise our information, including the theft of our intellectual property, and could expose us to liability, which could cause our business and reputation to suffer. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect and store confidential and sensitive electronic information on our networks and in our data centers. This information includes, among other things, our intellectual property and proprietary information, the confidential information of our collaborators and licensees, and the personally identifiable information of our employees. It is important to our operations and business strategy that this electronic information remains secure and is perceived to be secure. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, and the volume of data we retain, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches and other cyber-attacks. Information security risks have significantly increased in recent years in part due to the proliferation of new technologies and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign private parties and state actors. A security breach or privacy violation that leads to disclosure or modification of or prevents access to personally identifiable information or other protected information could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, require us to verify the correctness of database contents and otherwise subject us to liability under laws and regulations that protect personal data, resulting in increased costs or loss of revenue. Similarly, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Additionally, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy. If we are unable to prevent such security breaches or privacy violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial loss and other regulatory penalties because of lost or misappropriated information. In addition, these breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. Moreover, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information, trade secrets or other intellectual property. As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities. While we have implemented security measures to protect our data security and information technology systems, such measures may not prevent such events. Significant disruptions of our information technology systems or breaches of data security could have a material adverse effect on our business, financial condition and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development activities involve the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic chemicals in our facilities in South San Francisco, California that are required for our research and development activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing these materials in our South San Francisco facilities comply with the relevant guidelines of South San Francisco, the state of California and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Changes in </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. or foreign tax laws </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> regulations </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">that are applied adversely to us </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">may have a material adverse effect on our business, </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">cash flow, </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">financial condition </span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">or</span><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"> results of operations.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business and financial condition. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act (the &#8220;Tax Act&#8221;), enacted many significant changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform legislation could have a material impact on the value of our deferred tax assets, could result in significant one-time charges, and could increase our future tax expense. Recent presidential candidate proposals for U.S. tax legislation could have a material adverse effect on our future business, financial condition and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading opinions regarding our stock, our stock price and trading volume could decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if our target studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><span style="font-style:italic;">Unresolved Staff Comments</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_2_PROPERTIES"><span style="font-style:italic;">Properties</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal executive office is currently located in South San Francisco, California, and consists of approximately 76,000 square feet of office and research and development space, all of which is located in a single building, under a lease that expires in October 2026. We believe that our existing facilities are sufficient for our current needs.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_3_LEGAL_PROCEEDINGS">Legal Proceedings</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 4, 2020, Vytacera Bio, LLC filed a patent infringement lawsuit against us in the U.S. District Court for the District of Delaware.&#160;&#160;The lawsuit alleges that our use, offers to sell, and/or sales of the Probody&#174; technology platform for basic research applications constitutes infringement.&#160;&#160;The complaint seeks unspecified monetary damages.&#160;&#160;We filed an Answer, Affirmative Defenses, and Counterclaims on May 26, 2020.&#160;&#160;Vytacera Bio, LLC filed its Answer to CytomX Therapeutics Inc.&#8217;s Counterclaims on June 5, 2020.&#160;&#160;The parties have agreed to a case schedule, which is pending Court approval.&#160;&#160;Discovery is in the initial phases. We believe that the lawsuit is without merit and intend to vigorously defend ourselves.&#160;&#160;Accordingly, we cannot reasonably estimate any range of potential future charges, and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</p>
<p style="Background-color:#FFFFFF;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 21, 2020, a putative securities class action lawsuit was commenced in the U.S. District Court for the Northern District of California naming as defendants us and three current and former officers. The complaint alleged that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to the product candidates praluzatamab ravtansine<span style="color:#000000;"> (CX-2009)</span> and pacmilimab (CX-072).  On January 14, 2021, the class action was dismissed without prejudice.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Mine Safety Disclosures</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_II">PART II</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><span style="font-style:italic;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information for Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock has been listed on the Nasdaq Global Select Market under the symbol &#8220;CTMX&#8221; since our initial public offering in October 2015. Prior to that time, there was no public market for our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders of Record</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of January 31, 2021, there were approximately 28 stockholders of record of our common stock. The actual number of stockholders is greater than this number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently intend to retain future earnings, if any, for use in operation of our business and to fund future growth. We have never declared or paid any cash dividends on our capital stock and do not anticipate paying any cash dividends in the foreseeable future. Payment of cash dividends, if any, in the future will be at the discretion of our board of directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant.&#160;&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock Performance Graph</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following graph shows the total stockholder&#8217;s return on an investment of $100 in cash at market close on October 8, 2015 (the first day of trading of our common stock), through December&#160;31, 2020 for (i)&#160;our common stock, (ii)&#160;the Nasdaq Composite Index and (iii)&#160;the Nasdaq Biotechnology Index. Pursuant to applicable Securities and Exchange Commission rules, all values assume reinvestment of pre-tax amount of all dividends&#59; however, no dividends have been declared on our common stock to date. The stockholder return shown on the graph below is not necessarily indicative of future performance, and we do not make or endorse any predictions as to future stockholder return. This graph shall not be deemed &#8220;soliciting material&#8221; or be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934 as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. </p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gzkk5j0cumnd000013.jpg" title="" alt="" style="width:720px;height:344px;" /></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$100 investment in stock or index</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">October<span style="font-family:Calibri;">&#160;</span>8,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CytomX (CTMX)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161.78</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85.19</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163.64</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117.05</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64.42</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50.78</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Composite Index</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; (IXIC)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104.09</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111.90</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143.50</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137.92</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">186.51</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267.90</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Biotech Index (&#94;NBI)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100.00</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110.25</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86.34</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104.52</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94.77</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117.91</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148.19</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Securities Authorized for Issuance Under Equity Compensation Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item regarding equity compensation plans is incorporated by reference to the information set forth in PART III. Item&#160;12 of this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds from Registered Securities </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Sales of Unregistered Equity Securities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.<span style="font-weight:bold;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Issuer Purchases of Equity Securities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_6_SELECTED_FINANCIAL_DATA"><span style="font-style:italic;">Selected Financial Data</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:10.27%;text-indent:-10.27%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registrants may voluntarily include selected financial data required by Form 10-K under Item 6. We have elected not to include such selected financial data.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Discussion and Analysis of</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> Financial Condition and Results of Operations</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion should be read in conjunction with the attached financial statements and notes thereto. This Annual Report on Form 10-K, including the following sections, contains forward-looking statements within the meaning of the federal securities laws. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those expressed or implied by such forward-looking statements. For a detailed discussion of these risks and uncertainties, see the &#8220;Risk Factors&#8221; section in Item&#160;1A of this Annual Report on Form 10-K. We caution the reader not to place undue reliance on these forward-looking statements, which reflect management&#8217;s analysis only as of the date of this Form 10-K. We undertake no obligation to update forward-looking statements, which reflect events or circumstances occurring after the date of this Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are advancing a robust pipeline of novel, potential first-in-class antibody-based therapeutics created using our Probody&#174; technology platform<span style="color:#000000;">. </span>These Probody therapeutics are designed to be conditionally activated in the tumor microenvironment, effectively enabling them to target cancer tissues more specifically, while minimizing deleterious activity in healthy tissues and circulation. We achieve this &#8220;conditional activation&#8221; by modifying our Probody therapeutics with a mask that is designed to block binding to target until the mask is removed by proteases. Proteases are enzymes that are more abundant in the tumor microenvironment than in normal tissue, leading to potentially an enrichment of therapeutic activity in the tumor. We believe this innovative approach has the potential to improve cancer treatments in three ways by: (1) enhancing a product candidate&#8217;s therapeutic window, the balance between tolerability and activity&#59; (2) allowing the pursuit of targets that were previously considered &#8220;undruggable,&#8221; due to their presence on normal tissues&#59; and (3) improving combination therapies that are, otherwise, poorly tolerated.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidates, praluzatamab ravtansine (CX-2009) and CX-2029, are two conditionally activated antibody-drug conjugates (&#8220;ADCs&#8221;) against the previously undruggable targets CD166 and CD71, respectively. These cancer targets were considered inaccessible to conventional ADCs due to their ubiquitous expression in many healthy tissues, but which we believe are potentially addressable with our Probody technology. After demonstrating favorable tolerability and encouraging anti-tumor activity in separate dose-escalation Phase 1 studies, praluzatamab ravtansine, our wholly-owned conditional ADC, and CX-2029, a conditionally activated ADC partnered with AbbVie, are currently in Phase 2 clinical studies. Our clinical-stage pipeline also includes cancer immunotherapeutic candidates against validated targets such as our wholly-owned PD-L1 inhibitor, pacmilimab (CX-072), being studied in combination with praluzatamab ravtansine. Our partner, Bristol Myers Squibb is conducting clinical studies with CTLA-4-targeting Probody therapeutics, BMS-986249, currently in a randomized Phase 2 study, and BMS-986288, currently in a Phase 1/2a study.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have two preclinical agents in investigational new drug application (&#8220;IND&#8221;)-enabling studies, including<span style="color:#000000;"> CX-2043, our third conditionally activated ADC targeting the epithelial cell adhesion molecule (&#8220;EpCAM&#8221;), a widely expressed tumor antigen. CX-2043 has demonstrated potent anti-tumor activity across multiple cancer types and superior tolerability in animal models compared to the corresponding, unmasked ADC</span>. <span style="color:#000000;">Pursuant to</span> our<span style="color:#000000;"> partnership with Amgen, we have also recently advanced CX-904, a conditionally activated T-cell engaging bispecific antibody candidate against the epidermal growth factor receptor (&#8220;EGFR&#8221;) on tumor cells and CD3 on T cells, into IND-enabling studies. We intend to file INDs for both CX-2043 and CX-904 in late 2021.&#160;&#160;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, a strain of novel coronavirus-caused disease (now commonly known as COVID-19) was reported to have surfaced in Wuhan, China. COVID-19 has since spread rapidly throughout many countries and has been declared to be a pandemic. In an effort to contain and mitigate the spread of COVID-19, many countries, including the United States, Canada and countries in Europe and Asia, have imposed unprecedented restrictions on travel, business operations and public gatherings, and there have been business closures and limitations on business operations, which have resulted in a substantial reduction in economic activity.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020, in assessing the evolving COVID-19 pandemic and related governmental restrictions, the emerging challenges for clinical trial execution within our studies and across the industry, and the need of healthcare facilities and providers to prioritize resources for management of the pandemic, we made the decision to temporarily pause new patient enrollment and new site activation in the PROCLAIM-CX-2009-001 study of praluzatamab ravtansine. This study included a Phase 2 expansion designed to evaluate praluzatamab ravtansine in patients with various cancers, including hormone receptor-positive (&#8220;HR+&#8221;), human epidermal growth factor receptor 2 (&#8220;HER2&#8221;)-non-amplified breast cancer. Since then, we have revised our strategy for praluzatamab ravtansine to also include patients with triple-negative breast cancer (&#8220;TNBC&#8221;). A new three-arm study, CX-2009-002, was initiated in the fourth quarter of 2020 targeting investigators who treat breast cancer. Arms A and B will evaluate praluzatamab ravtansine monotherapy at 7 mg/kg administered every three weeks in patients with HR+/HER2-non-amplified breast cancer and TNBC, respectively. Arm C will evaluate praluzatamab ravtansine in combination with pacmilimab in patients with TNBC. Approximately 40 evaluable patients will be enrolled into each arm of the study.</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also made the strategic decision, in March 2020, to terminate the PROCLAIM-CX-072-002 study evaluating pacmilimab in combination with ipilimumab in melanoma. This decision followed a re-evaluation of the evolving clinical, competitive and commercial landscapes in immuno-oncology, along with the impact of the COVID-19 pandemic, and allowed for resources to be redirected towards our potential first-in-class assets, including a combination of praluzatamab ravtansine and pacmilimab, and to the generation of additional clinical candidates for advancement to the filing of INDs and human testing.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="Background-color:#FFFFFF;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">continue to work with our partner, AbbVie, o</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the clinical development of CX-2029</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and, in the fourth quarter of 2020, we dosed the first patient in the Phase 2 expansion study in patients with </span><span style="Background-color:#FFFFFF;color:#000000;">squamous non-small&#160;cell lung cancer</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, h</span><span style="Background-color:#FFFFFF;color:#000000;">ead and neck squamous cell cancer</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, esophageal cancer and diffuse large B-cell lymphoma. In addition, Bristol Myers Squibb initiated a randomized Phase 2 study evaluating BMS-986249, a </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> version of ipilimumab, </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as monotherapy or in combination with its anti PD-1 antibody, nivolumab, in patients with metastatic melanoma</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. This study has been </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">modified</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to include three additional single-arm cohorts: advanced hepatocellular carcinoma, metastatic castration-resistant prostate cancer, and unresectable locally advanced or metastatic TNBC. Bristol Myers Squibb</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> continues its Phase 1 dose-escalation study of BMS-986288, a</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> version of non-</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fucosylated</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ipilimumab.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 27, 2020, we entered into an Open Market Sale Agreement (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), to sell shares of our common stock, par value $0.00001 per share, with aggregate gross sales proceeds of up to $75,000,000, from time to time, through an at the market offering under which Jefferies will act as sales agent. During the year ended December 31, 2020, we sold 1,535,217 shares of our common stock for aggregate gross proceeds of $11.7 million under the Sales Agreement. Pursuant to the Sales Agreement, Jefferies, as sales agent, received a commission of 3.0% of the gross sales price for shares of common stock sold under the Sales Agreement. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any product candidates approved for sale, and we continue to incur significant research and development and general administrative expenses related to our operations. We are not profitable and have incurred losses in each year since our founding in 2008. Our net loss was $32.9 million, $102.2 million and $84.6 million for 2020, 2019 and 2018, respectively. As of December 31, 2020 and 2019, we had an accumulated deficit of $450.1 million and $ 417.2 million, respectively. We expect to continue to incur significant losses for the foreseeable future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 outbreak and any preventative or protective actions that we or our collaboration partners may take in respect of this virus may result in a period of further disruption for our clinical trials, manufacturing, research, financial reporting capabilities and operations generally and could potentially impact our patients, partners, employees and third parties. Any resulting financial impact cannot be reasonably estimated at this time but may materially affect the business and our financial condition and results of operations. The extent to which the COVID-19<span style="font-weight:bold;"> </span>pandemic impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of COVID-19<span style="font-weight:bold;"> </span>and the actions necessary to contain the virus or treat its impact, among others. Although our operations have been modified, they are continuing at a reduced operational rate. Currently, it is not possible to predict how long the pandemic will last or the time that it will take for economic activity to return to its prior levels. We do not yet know the full extent of any impact or delay on our business or our operations, including clinical trial activity, however, we will continue to monitor the COVID-19 situation closely and operate in accordance with all relevant health and safety guidelines as they evolve.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory agencies, including the FDA, regulate many aspects of a product candidate&#8217;s life cycle, including research and development and preclinical and clinical testing. We will need to commit significant time, resources, and funding to develop our wholly-owned and partnered product candidates in clinical trials, including praluzatamab ravtansine, CX-2029, and pacmilimab, as well as any additional product candidates for which we initiate clinical studies in the future. We are unable to provide the nature, timing, and estimated costs of the efforts necessary to complete the development of our product candidates because, among other reasons, of regulatory uncertainty, manufacturing limitations, and the pace of enrollment of our clinical trials, which is a function of many factors, including the availability and proximity of patients with the relevant condition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no manufacturing capabilities and do not intend to establish any such capabilities in the near term. As such, we are dependent on third parties to supply our product candidates according to our specifications, in sufficient quantities, on time, in compliance with appropriate regulatory standards and at competitive prices.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of Results of Operations</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenue to date has been primarily derived from non-refundable license payments, milestone payments and reimbursements for research and development expenses under our research, collaboration, and license agreements. We recognize revenue from upfront payments over the term of our estimated period of performance under the agreement using a cost-based input method or a common measure of progress for the entire performance obligation. In addition to receiving upfront payments, we may also be entitled to milestone and other contingent payments upon achieving predefined objectives. Revenue from milestones and other contingent payments, when it is probable that there will not be a significant revenue reversal, is also recognized over the performance period based on a similar method. Reimbursements from Astellas and <span style="letter-spacing:-0.1pt;">Bristol Myers Squibb</span> for research and development costs when incurred under our research, collaboration and license agreements with them are classified as revenue.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the foreseeable future, we do not expect to generate any revenue from the sale of products unless and until such time as our product candidates have advanced through clinical development and obtained regulatory approval. We expect that any revenue we generate in the foreseeable future will fluctuate from year to year as a result of the timing and amount of milestones and other payments from our collaboration agreements with AbbVie, Amgen, Astellas, Bristol Myers Squibb and any other collaboration partners, and as a result of the fluctuations in the research and development expenses we incur in the performance of assigned activities under these agreements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;color:#000000;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie, one of our collaboration partners, entered into a license agreement with Seattle Genetics, Inc. (&#8220;SGEN&#8221;) to license certain intellectual property rights. As part of our collaboration agreement with AbbVie, we received a sublicense to these intellectual property rights and therefore pay SGEN sublicense fees. These sublicense fees are treated as reductions to the transaction price and combined with the performance obligation to which they relate. Milestone payments, when considered probable of being reached and when a significant revenue reversal would not be probable of occurring, are also recorded net of the associated sublicense fees and included in the transaction price.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development expenses consist primarily of costs incurred to conduct research, such as the discovery and development of our product candidates, clinical development including activities with third parties, such as contract research organizations (&#8220;CRO&#8221;) and <span style="color:#000000;">contract development and manufacturing organizations</span> (&#8220;CMO&#8221;), the manufacture of drug products used in clinical trials, as well as the development of product candidates pursuant to our research, collaboration and license agreements. Research and development expenses include personnel costs, including stock-based compensation expense, contractor services, laboratory materials and supplies, depreciation and maintenance of research equipment, and an allocation of related facilities costs. We expense research and development costs as incurred.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expenses to increase substantially in absolute dollars in the future as we advance our product candidates through clinical trials, initiate additional clinical trials, and pursue regulatory approval of our product candidates. Examples include our Phase 2 clinical trials for praluzatamab ravtansine (CX-2009) and CX-2029 and potential future clinical trials for CX-2029 and for praluzatamab ravtansine in combination with pacmilimab (CX-072).  The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: the safety and efficacy of our product candidates, early clinical data, investment in our clinical program, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. We may never succeed in achieving regulatory approval for any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses include personnel costs, expenses for outside professional services and other allocated expenses. Personnel costs consist of salaries, bonuses, benefits and stock-based compensation. Outside professional services consist of accounting and audit services, legal and other consulting fees. Allocated expenses primarily consist of rent expense related to our office and information technology related costs. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest Income</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="S169793997">Interest income primarily consists of interest income from our cash equivalents and short-term investments, and accretion of discounts or amortization of premiums on our short-term investments.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Income (Expense), Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense), net consists primarily of income (expense) resulting from changes to currency exchange rates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provision for (Benefit from) Income Taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="S171274771">Income taxes are recorded in accordance with&#160;ASC 740,&#160;Accounting for Income Taxes, or&#160;ASC 740, which provides for deferred taxes using an asset and liability approach. We recognize deferred tax assets and liabilities for the expected future tax consequences of events that have been included in our financial statements or tax returns. We determine our deferred tax assets and liabilities based on differences between the financial reporting and tax bases of assets and liabilities, which are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also account for uncertain tax positions in accordance with the provisions of&#160;ASC 740. When uncertain tax positions exist, we recognize the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic.&#160;&#160;<span style="color:#000000;">The tax relief measures under the CARES Act for businesses include a five-year net operating loss carryback, suspension of annual deduction limitation of 80% of taxable income from net operating losses generated in a tax year beginning after December 31, 2017, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property.&#160;&#160;</span>We record the effect of an enacted change in a tax law in the period that includes the enactment date in accordance with ASC 740.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Comparison of Years Ended December&#160;31, 2020 and 2019</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,362</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,489</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,873</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our revenue by collaboration partner during the respective periods:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,192</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,878</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,314</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amgen</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,609</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,871</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,738</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,931</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,931</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol Myers Squibb</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,630</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,740</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,110</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,362</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,489</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,873</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in revenue of $42.9 million for 2020 compared to 2019 was primarily due to: </p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an increase in revenue of $32.3 million from AbbVie primarily due to (a) $28.9 million of revenue recognized related to the $40.0 million milestone payment earned in the first quarter of 2020 for satisfying the CD71 dose escalation success criteria milestone under the CD71 Co-Development and Licensing Agreement with AbbVie (the &#8220;CD71 Agreement&#8221;), reflecting the percentage completed to-date of the project for of 2020, (b) a $1.0 million increase in revenue recognized related to the $10.0 million upfront payment earned for the second target selected by AbbVie in June 2019 under the Discovery Collaboration and Licensing Agreement (the &#8220;Discovery Agreement&#8221;), which amount is being recognized as revenue over the estimated research service period of five years and (c) a higher percentage of completion progress under the CD71 Agreement in 2020 compared to 2019 as a result of additional FTE hours incurred&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an increase in revenue of $4.7 million from Amgen primarily due to an increase in the percentage of completion progress for 2020 as a result of additional FTE hours incurred, and the completion of the clinical candidate characterization phase and moving to the IND-enabling phase earlier than planned in the second quarter of 2020 which resulted in a reduction of the estimated FTE hours-to-completion of the Amgen EGFR program under the Collaboration and License Agreement with Amgen (the &#8220;Amgen Agreement&#8221;)&#59; </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">an increase in revenue of $</span><span style="color:#000000;">13.9</span><span style="color:#000000;"> million from Astellas due to the recognition of revenue</span><span style="color:#000000;"> of $12.4 million</span><span style="color:#000000;"> related to the $80.0 million upfront payment being recognized over the estimated research service period of five years, as well as service revenue </span><span style="color:#000000;">of $1.5 million </span><span style="color:#000000;">representing research and development services provided to Astellas under the </span><span style="color:#000000;">Collaboration and License Agreement (the &#8220;Astellas Agreement&#8221;)</span><span style="color:#000000;"> entered into in March </span><span style="color:#000000;">2020&#59; </span><span style="color:#000000;">and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease in revenue of $8.1 million from Bristol Myers Squibb primarily due to the recognition of revenue of $18.1 million related to certain targets terminated under the Collaboration and License Agreement with Bristol Myers Squibb (the &#8220;BMS Agreement&#8221;) in the first quarter of 2019&#59; partially offset by the recognition in full of the $10.0 million milestone payment earned for achieving the dosing of first patient in the Part 2 cohort expansion of the ongoing CTLA-4 program by Bristol Myers Squibb in February 2020.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Costs and Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses<span style="font-style:normal;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,936</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,619</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,683</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses decreased by $18.7 million during 2020 compared to 2019. The decrease was attributable to the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease of $10.4 million in clinical trial related expenses resulting from decreased clinical activities primarily due to the COVID-19 pandemic and revision of our development strategies&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease due to a $5.0 million charge for acquiring the technical know-how related to drug conjugate linker-toxin and CD3-based bispecific technologies during the first quarter of 2019&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease of $2.3 million in laboratory contracts services and supplies related expenses due to timing of manufacturing and other research activities&#59;&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease of $1.0 million in consulting expenses primarily due to shifting of more previously outsourced research and development work in house&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease of $1.1 million in travel related expenses due to a decrease in business travel activities as a result of the pandemic.</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above decreases were offset by the following:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a net increase of $0.7 million in personnel related expenses primarily due to an increase of $1.8 million as a result of merit increase and increase in new hires of senior positions, and an increase of $1.0 million related to severance payments during 2020, partially offset by a decrease of $2.1 million in stock-based compensation driven primarily by increased cancellations of stock options due to employee departures as well as decreases in the grant date fair values of new option grants resulting from decreases in prices of our common stock during the current year&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an increase of $0.5 million in allocation of information technology and facilities related expenses resulting from an increase in the ratio of headcount in the research and development function relative to that for the general and administrative function.</span></p></td></tr></table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses by program incurred during the respective periods presented:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">External costs incurred by product candidate (target):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Praluzatamab ravtansine, CX-2009 (CD166)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,191</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,014</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,177</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CX-2029 (CD71)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,978</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,376</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,398</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pacmilimab, CX-072 (PD-L1)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,642</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,054</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,412</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other wholly owned and partnered programs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,255</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,591</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,664</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,016</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,568</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,552</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,082</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,603</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.72%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,521</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Internal Costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,854</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,016</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">838</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,936</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,619</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.72%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,683</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The decrease in research and development expenses for 2020 compared to 2019 was attributable to the following changes by project:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The increase in praluzatamab ravtansine (CX-2009) expenses was primarily due to a $3.0 million licensing payment to ImmunoGen for achieving the milestone of the first dosing of a patient in the praluzatamab ravtansine Phase 2 clinical trial during the first quarter of 2020, offset by a $0.7 million decrease in clinical trial related expenses and a $0.4 million decrease in laboratory contract services due to the pause in clinical activity related to the COVID-19 pandemic.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The decrease in CX-2029 expenses was primarily due to a decrease of $4.5 million in laboratory contract services resulting from the timing of manufacturing and other research activities, partially offset by a $1.4 million increase in sublicense fee expense to UCSB related to the $40.0 million milestone payment earned in March 2020 for satisfying the CD71 dose escalation success criteria under the CD71 Agreement.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The decrease in pacmilimab (CX-072) expenses was primarily due to $9.2 million decrease in clinical trial related expenses and a $7.3 million decrease in laboratory contract services as a result of the timing of manufacturing and other research activities in the pacmilimab study and the termination in March 2020 of the CX-072-002 study to evaluate the conditionally activated anti-PD-L1 pacmilimab in combination with ipilimumab in melanoma.&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The increase in &#8220;Other wholly owned and partnered programs&#8221; was primarily due to a $6.0 million sublicense fee payment to UCSB related to the $80.0 million upfront payment under the Astellas Agreement during the first quarter of 2020, an increase of $6.3 million in laboratory contract services related to the Amgen EGFR project as it ramped up during the IND-enabling phase, and an increase of $2.5 million in laboratory contract services largely related to the EpCAM program that began in December 2019, partially offset by the $7.5 million of upfront license fee paid for the EpCAM program we entered into with Immunogen in the fourth quarter of 2019 (the &#8220;ImmunoGen 2019 License&#8221;).</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The decrease in general research and development expenses was primarily due to a $5.0 million charge for acquiring technical know-how related to drug conjugate linker-toxin and CD3-based bispecific technologies during the first quarter of 2019, and the $3.4 million sublicense and maintenance fees associated with entering into Amendment No.3 to the UCSB Agreement in the second quarter of 2019.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The increase in internal costs was primarily due to increase in personnel-related expenses.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,031</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,765</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(734</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses decreased by $0.7 million during 2020 compared to that in 2019. The decrease was attributable to the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease of $2.3 million in personnel-related expense primarily due to a decrease in stock-based compensation driven primarily by increased cancellations of stock options due to employee departures as well as decreases in the grant date fair values of new option grants resulting from decreases in prices of our common stock during the current year&#59; and</span></p></td></tr></table></div>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease of $0.5 million in travel related expenses due to decrease in business travel activities&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:9.07%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The above decreases were offset by the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an increase of $1.2 million in outside professional services primarily related to legal services for new patent filings and maintenance, business development and other legal matters&#59; </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an increase of $0.5 million in dues and subscriptions primarily due to increase in software application hosting projects to improve operational processes&#59; and</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an increase of $0.4 million in business insurance premium expenses.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest Income and Other Expense, Net</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,836</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,365</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,529</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(135</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total interest income and other expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,809</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,230</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,421</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Interest Income</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income decreased by $6.5 million for 2020 compared to 2019. The decrease was primarily attributable to lower average cash, cash equivalents and short-term investments during 2020 and lower interest rates as we experienced a sharp decrease in interest rates starting in March 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Other Expense, net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net decreased by $0.1 million for 2020 compared to 2019.  The decrease was primarily attributable to a decrease in foreign currency losses resulting from the strengthening of the U.S. dollar against the Euro and British Pound Sterling.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Provision for (Benefit from) Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for (benefit from) income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,911</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(427</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,484</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit increased by $13.5 million for 2020 compared to 2019.&#160; The income tax benefit of $13.9 million for 2020 was generated due to the recognition of net operating loss carrybacks under the CARES Act, which generated<span style="color:#000000;"> a tax refund of taxes paid for 2018.&#160;&#160;</span>The income tax benefit of $0.4 million for 2019 was primarily due to a true-up of 2018 federal income tax expense and an unrealized gain on the available-for-sale securities recorded in other comprehensive income for 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discussion of 2018 items and the year-to-year comparisons between 2019 and 2018 that are not included in this Form 10-K can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2019 filed on February 27, 2020. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Sources of Liquidity</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had cash, cash equivalents and short-term investments of $316.1 million and an accumulated deficit of $450.1 million, compared to cash, cash equivalents and short-term investments of $296.1 million and an accumulated deficit of $417.2 million as of December 31, 2019.  Additionally, in January and February 2021 in an underwritten public offering of our common stock, we raised an aggregate net proceeds of approximately $107.7 million.&#160;&#160;To date, we have financed our operations primarily through sales of our common stock in conjunction with the IPO, subsequent stock offerings and through our at-the-market offering, sales of our convertible preferred securities prior to our IPO and payments received under our collaboration agreements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="P260244544">Based upon our current operating plan, we expect our existing capital resources will be sufficient to fund operations for a period of at least twelve months from the date the financial statements included in this report are issued.  However, if the anticipated operating results and future financing are not achieved in future periods, our planned expenditures may need to be reduced in order to extend the time period over which the then-available resources would be able to fund the operations. The amounts and timing of our actual expenditures depend on numerous factors, including the progress of our preclinical and clinical development efforts, the results of any clinical trials and other studies, our operating costs and expenditures and other factors described under the caption &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. The cost and timing of developing our products, including praluzatamab ravtansine (CX-2009), CX-2029, and pacmilimab (CX-072) are highly uncertain, are subject to substantial risks and many changes. As such, we may alter our expenditures as a result of contingencies such as the failure of one or all of our product candidates currently in clinical development, the acceleration of one or all of our product candidates in clinical development, the initiating of clinical trials for additional product candidates, the identification of more promising product candidates in our research efforts or unexpected operating costs and expenditures. <span style="color:#000000;"> We will need to raise additional funds in the future.&#160;&#160;There can be no assurance, however, that such efforts will be successful or that, in the event that they are successful, the terms and conditions of such financing will be favorable to us.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Summary Statement of Cash Flows</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our cash flows for the periods presented:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,259</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(140,480</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75,521</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) by investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,718</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,701</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,926</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,893</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,627</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,624</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,434</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(59,152</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,029</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash Flows from Operating Activities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">2020</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, cash provided by operating activities was $5.3 million, which consisted of a net loss of $32.9 million, adjusted by non-cash charges of $20.1 million and a net increase of $18.1 million relating to the change of our net operating assets and liabilities. The non-cash charges primarily consisted of $14.8 million in stock-based compensation, $2.9 million in non-cash lease expense and $2.6 million in depreciation and amortization, which amounts were partially offset by $0.2 million in accretion of discounts on our short-term investments. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The change of our net operating assets and liabilities was primarily due to:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a net increase of $30.9 million in deferred revenue resulting primarily from the $80.0 million upfront payment from Astellas as well as the $40.0 million milestone payment from AbbVie, partially offset by the continued recognition of deferred revenue from other existing customers&#59;&#160;&#160;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an increase of $0.1 million in cash flows from prepaid expenses and other current assets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease of $0.2 million in cash flows from other assets&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease of $11.0 million in accrued liabilities primarily due to payment of $7.5 million for the ImmunoGen 2019 License and $2.8 million for lease liabilities&#59;&#160;&#160;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></span><span style="color:#000000;"></span><span style="color:#000000;">a decrease in cashflow of $</span><span style="color:#000000;">0.8</span><span style="color:#000000;"> million from accounts receivable primarily related to research and development service fees due from Astellas pursuant to the Astellas Agreement&#59; and </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease in cashflow of $0.9 million from accounts payable.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">2019</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2019, cash used in operating activities was $140.5 million, which consisted of a net loss of $102.2 million, adjusted by non-cash charges of $23.8 million and a net decrease of $62.1 million relating to the change in our net operating assets and liabilities. The non-cash charges primarily consisted of $19.1 million in stock-based compensation&#59; $1.6 million of common stock issued in connection with our entry into Amendment No.3 to the UCSB Agreement, $2.7 million in non-cash lease expense and $2.6 million in depreciation and amortization expense&#59; which amounts were partially offset by $2.2 million in accretion of discounts on our short-term investments. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The change in our net operating assets and liabilities was primarily due to: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease of $47.7 million in deferred revenue resulting from continued recognition of deferred revenue from existing customers and the accelerated recognition of revenue of $17.4 million related to the termination of certain targets under the BMS Agreement in the first quarter of 2019, partially offset by the additional $10.0 million milestone payment due from AbbVie in June 2019, which payment was triggered by its selection of the second target under the Discovery Collaboration and Licensing Agreement with AbbVie (as amended, the &#8220;Discovery Agreement&#8221;)&#59;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease of $15.4 million in accrued liabilities and income tax payable primarily due to the net payment of $13.1 million for our 2018 income tax liability and $3.8 million in sublicense fees, partially offset by $1.5 million increase in other liabilities during 2019&#59;&#160;&#160;</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">a decrease of $1.0 million in cashflow with $0.4 million from accounts payable and $0.6 million from other assets&#59; and</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.07%;text-indent:-4.54%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">an increase of $2.0 million in cash flows from prepaid expenses and other current assets.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash Flows from Investing Activities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, cash used in investing activities was $18.7 million, which consisted of $199.1 million used in the purchase of short-term investments and $2.3 million of capital expenditures used to purchase property and equipment, partially offset by $182.7 million in proceeds received upon the maturity of marketable securities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2019, cash provided by investing activities was $79.7 million, which consisted of $258.2 million in proceeds received upon the maturity of marketable securities, partially offset by $175.0 million used in the purchases of short-term investments and $3.5 million of capital expenditures used to purchase property and equipment.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cash Flows from Financing Activities</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2020, cash provided by financing activities was $16.9 million, which primarily consisted of proceeds from our common stock issuance of $11.3 million under the Open Market Sales Agreement (net of underwriting discounts and stock issuance costs of $0.4 million) and $5.6 million from the exercise of stock options and employee stock purchases under the employee stock purchase plan (&#8220;ESPP&#8221;).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2019, cash provided by financing activities was $1.6 million, primarily consisted of proceeds from the exercise of stock options and employee stock purchases under the employee stock purchase plan.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our contractual obligations as of December 31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="22" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:62.26%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments Due by Period<sup style="font-size:85%;line-height:120%;vertical-align:top">(4)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2025+</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,129</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,273</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,420</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,572</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,116</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,510</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty obligations<sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License maintenance fees<sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">750</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,875</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,875</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total contractual obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,029</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,023</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,170</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,322</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,991</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,535</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We lease our current facility under a long-term operating lease, which expires in 2026. The lease provides us with one option to extend the lease term for a period of five years at the then fair market rental value. </p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(2)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have royalty obligations under the terms of certain exclusive licensed patent rights. The royalty obligations are cancellable any time by giving notice to the licensor, with the termination being effective 60 days after giving notice. See </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Part II. Item 8. Financial Statements and Supplementary Data,</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Note</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;1</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> -</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License Agreement</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">" in the accompanying Notes to the financial statements for more information</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(3)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have annual license maintenance fees under the terms of certain license agreement with UCSB. See Part II. Item 8. Financial Statements and Supplementary Data, Note&#160;10 -&#160;&#8220;License Agreement&#8221; in the accompanying Notes to the financial statements for more information.</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">(</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">4</sup></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><sup style="font-size:85%;line-height:120%;vertical-align:top">)</sup></span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This table does not include any milestone payments or royalty payments to third parties as the amounts, timing and likelihood of such payments are not known. See Part II. Item 8. Financial Statements and Supplementary Data, Note&#160;9 -&#160;&#8220;Research and Collaboration Agreements&#8221; in the accompanying Notes to the financial statements for more information.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into agreements in the normal course of business with CROs for clinical trials and with vendors for pre-clinical studies and other services and products for operating purposes, which are cancelable at any time by us, generally upon 30 to 60 days prior written notice. These payments are not included in the above table of contractual obligations. The above table also excludes unrecognized tax benefits of $6.5 million as of December 31, 2020 because these uncertain tax positions, if recognized, would be an adjustment to our deferred tax assets, which are subject to a valuation allowance.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment Information</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have one primary business activity and operate as one reportable segment.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#auto;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and<span style="letter-spacing:0.05pt;"> </span>Estimates</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is<span style="letter-spacing:0.4pt;"> </span>based on our financial statements, which have been prepared in accordance with United States generally<span style="letter-spacing:0.35pt;"> </span>accepted accounting principles (&#8220;U.S. GAAP&#8221;). The preparation of these financial statements requires our management<span style="letter-spacing:0.55pt;"> </span>to make judgments and estimates that affect the reported amounts of assets and liabilities and the disclosure<span style="letter-spacing:0.6pt;"> </span>of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue<span style="letter-spacing:0.5pt;"> </span>generated and expenses incurred during the reporting periods. Our estimates are based on our historical experience and<span style="letter-spacing:0.4pt;"> </span>on various other factors that we believe are reasonable under the circumstances, the results of which form the<span style="letter-spacing:0.45pt;"> </span>basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from<span style="letter-spacing:0.5pt;"> </span>other sources. Actual results may differ from these judgments and estimates under different assumptions or<span style="letter-spacing:0.55pt;"> </span>conditions and any such differences may be material. We believe that the accounting policies discussed below are critical<span style="letter-spacing:0.5pt;"> </span>to understanding our historical and future performance, as these policies relate to the more significant<span style="letter-spacing:0.55pt;"> </span>areas involving management&#8217;s judgments and<span style="letter-spacing:0.2pt;"> </span>estimates.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize revenue when our customer obtains control of the promised goods or services, in an amount that reflects the consideration which we have received or expect to receive in exchange for those goods or services.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenues are primarily derived through our license, research, development and commercialization agreements. The terms of these types of agreements may include (i) licenses for our technology or programs, (ii) research and development services, and (iii) services or obligations in connection with participation in research or steering committees. Payments to us under these arrangements typically include one or more of the following: nonrefundable upfront and license fees, research funding, milestone and other contingent payments to us for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products.&#160;&#160;We assess whether the promises in its arrangements with customers are considered as distinct performance obligations that should be accounted for separately. Judgment is required to determine whether the license to our intellectual property is distinct from the research and development services or participation on steering committees.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaboration and license agreements may include contingent payments related to specified research, development and regulatory milestones. Such milestone payments are typically payable under the collaborations when the collaboration partner claims or selects a target, or initiates or advances a covered product candidate in preclinical or clinical development, upon submission for marketing approval of a covered product with regulatory authorities&#59; or upon receipt of actual marketing approvals of a covered product or for additional indications. Milestone payments that are not within the control of us or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.&#160;&#160;At each reporting date, we re-evaluate whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price by using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price in such period of determination.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaboration and license agreements may also include contingent payments related to sales-based milestones. Sales-based milestones are typically payable when annual sales of a covered product reach specified levels. Sales-based milestones are recognized at the later of when the associated performance obligation has been satisfied or when the sales occur. Unlike other contingency payments, such as regulatory milestones, sales-based milestones are not included in the transaction price based on estimates at the inception of the contract, but rather, are included when the sales or usage occur.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price in each arrangement is allocated to the identified performance obligations based on the relative standalone selling price (<span style="color:#000000;">&#8220;</span>SSP<span style="color:#000000;">&#8221;</span>) of each distinct performance obligation, which requires judgment. In instances where SSP is not directly observable, such as when a license or service is not sold separately, SSP is determined using information that may include market conditions and other observable inputs. Due to the early stage of our licensed technology, the license of such technology is typically combined with research and development services and steering committee participation as one performance obligation.&#160;&#160;In the event that we receive non-cash consideration such as consideration in the form of a research license and research support services from the counterparty, the transaction price of a non-monetary exchange that has commercial substance is estimated based on the fair value of the non-cash consideration received, which may be determined through a valuation analysis.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain cases, our performance creates an asset that does not have an alternative use to the customer and we have an enforceable right to payment at all times for performance completed to date.&#160;&#160;In these cases, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary, we adjust the measure of performance and related revenue recognition. There have been changes in estimates of research service periods and the related estimated FTE hours-to-completion, of certain of our research development programs in 2020, 2019 and 2018.&#160;&#160;Such adjustments have impacted and may continue to impact the amounts and timing of our revenue recognized.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accrued liabilities for estimated costs of research, preclinical and clinical studies and contract manufacturing activities, which are a significant component of research and development expenses. A substantial portion of our ongoing research and development activities is conducted by third-party service providers, including CROs. Our contracts with CROs generally include pass-through costs, such as regulatory expenses, investigator fees, travel costs and other miscellaneous costs. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payments that do not match the periods over which materials or services are provided to us under such contracts. We accrue the costs incurred under agreements with these third parties based on actual work completed in accordance with the respective agreements. In the event we make advance payments, they are recorded as prepaid expenses and recognized as the services are performed. We determine the estimated costs through discussions with internal personnel and external service providers as to the progress of stage of completion of the services and the agreed-upon fees to be paid for such services.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We make significant judgments and estimates in determining the accrual balance in each reporting period. As actual costs become known, we adjust our accruals. Although we do not expect our estimates to be materially different than the actual amounts incurred, such estimates for the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in us reporting amounts that are too high or too low in any one period. Our accrual is dependent, in part, upon the receipt of timely and accurate reporting from CROs and other third-party vendors. Variations in the assumptions used to estimate accruals including, but not limited to, the number of patients enrolled, the rate of patient enrollment and the actual services performed, may vary from our estimates, resulting in adjustments to clinical trial expenses in future periods. Changes in these estimates that result in material changes to our accruals could materially affect our financial condition and results of operations.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We account for income taxes using an asset and liability approach. Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. We record a valuation allowance to reduce our deferred tax assets to reflect the net amount that we believe is more likely than not to be realized. Realization of our deferred tax assets is dependent on the generation of future taxable income, the amount and timing of which are uncertain. The valuation allowance requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Based upon the weight of available evidence at December 31, 2020, we continue to maintain a full valuation allowance against all of our deferred tax assets after management considered all available evidence, both positive and negative, including but not limited to our historical operating results, income or loss in recent periods, cumulative income in recent years, forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize the tax effects of an uncertain tax position only if it is more likely than not that it will be sustained based solely on its technical merits as of the reporting date and only in an amount more likely than not that it will be sustained upon review by the tax authorities. We evaluate uncertain tax positions on a quarterly basis and adjust the liability for changes in facts and circumstances, such as new regulations or interpretations by the taxing authorities, including the 2017 Tax Cuts and Jobs Act (&#8220;Tax Act&#8221;), new information obtained during a tax examination, significant amendment to an existing tax law, or resolution of an examination. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the income tax provision in the period in which such determination is made. The resolution of our uncertain income tax positions is dependent on uncontrollable factors such as law changes, new case law, and the willingness of the income tax authorities to settle, including the timing thereof and other factors. Although we do not anticipate significant changes to our uncertain income tax positions in the next twelve months, items outside of our control could cause our uncertain income tax positions to change in the future, which would be recorded in our statements of operations. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS">Quantitative and Qualitative Disclosures about Market Risk</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate risks. We had cash, cash equivalents and short-term investments of $316.1 million and $296.1 as of December 31, 2020 and 2019, respectively, which consists of bank deposits, money market funds and U.S. government bonds. Such interest-bearing instruments carry a degree of interest rate risk&#59; however, historical fluctuations of interest income have not been significant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not enter into investments for trading or speculative purposes and have not used any derivative financial instruments to manage our interest rate exposure. We have not historically been exposed to material risks due to changes in interest rates. Based on our investment positions as of December 31, 2020, a hypothetical 100 basis point change in interest rates would not have material effect in the fair value of the portfolio. Any changes would only be realized if we sold the investments prior to maturity.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><span style="font-style:italic;">Financial Statements and Supplementary Data</span></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CYTOMX THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT ON FORM 10-K </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO AUDITED FINANCIAL STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:94.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="padding-left:0.7pt;padding-Right:0.7pt;padding-Top:0pt;padding-Bottom:0pt;width:3.4%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="text-decoration:underline;">Page</span></p></td>
</tr>
<tr>
<td valign="bottom" style="width:94.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><span style="text-decoration:underline;">Reports of Independent Registered Public Accounting Firm</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p></td>
</tr>
<tr>
<td valign="bottom" style="width:94.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:94.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial Statements</p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:94.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BALANCE_SHEETS"><span style="text-decoration:underline;">Balance Sheets</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr>
<td valign="bottom" style="width:94.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_OPERATIONS_COMPREHENSIVE_LOSS"><span style="text-decoration:underline;">Statements of Operations and Comprehensive Loss</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:-12pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:3.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="bottom" style="width:94.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_STOCKHOLDERS_EQUITY"><span style="text-decoration:underline;">Statements of Stockholders&#8217; Equity</span></a><span style="text-decoration:underline;"> </span></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p></td>
</tr>
<tr style="height:12.15pt;">
<td valign="bottom" style="width:94.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_STATEMENTS_CASH_FLOWS"><span style="text-decoration:underline;">Statements of Cash Flows</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p></td>
</tr>
<tr>
<td valign="bottom" style="width:94.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:23.1pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#N1_DESCRIPTION__BUSINESS"><span style="text-decoration:underline;">Notes to Financial Statements</span></a></p></td>
<td valign="bottom" style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="width:3.4%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC">Report of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and the Board of Directors of CytomX Therapeutics, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying balance sheets of CytomX Therapeutics, Inc. (the Company) as of December 31, 2020 and 2019, the related statements of operations and comprehensive loss, stockholders' equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:6.67%;font-size:5pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Audit Matter</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:6.67%;font-size:5pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:5pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:3.33%;width:96.66%;">
<tr>
<td style="width:17.02%;"></td>
<td style="width:2.58%;"></td>
<td style="width:77.06%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:18pt;;margin-right:0.56%;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:6pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounting for revenue and collaboration agreements</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Description of the Matter</p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:18pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recorded revenue from collaboration agreements of $100.4 million for the year ended December 31, 2020. As described in Note 2, the terms of the Company&#8217;s collaboration agreements may include licenses for the Company&#8217;s technology or programs, research and development services, and services or obligations in connection with participation in research or steering committees. Amounts received under these arrangements typically include nonrefundable upfront payments and license fees, research funding, milestone and other contingent payments for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:18pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Auditing the Company&#8217;s accounting for revenues from collaboration arrangements was complex and required significant judgments primarily in identifying which elements represent revenue producing performance obligations, determining the measurement and allocation of arrangement consideration, and evaluating estimates of the total expected inputs under the input method for revenue recognized over time.</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:18pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">How We Addressed the Matter in Our Audit</p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:18pt;;margin-right:0.56%;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:18pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To test the accounting treatment for revenue from collaboration arrangements, we evaluated, among other things, whether the identified performance obligations were properly determined, and the transaction price was properly measured and allocated to the identified performance obligations. To test the measurement of efforts toward satisfying the performance obligation, our audit procedures included, among others, reviewing management&#8217;s analysis for accuracy and completeness by agreeing data to the underlying contract, inspecting communications with the collaborative partner, evaluating the application of the input method for the recognition of revenue and testing the estimated total inputs and actual inputs incurred.</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &#38; Young LLP</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2017. </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redwood City, California</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CYTOMX THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="BALANCE_SHEETS">BALANCE SHEETS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">191,859</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">188,425</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">124,260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">107,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001501989_20201231" decimals="-3" scale="3">798</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001501989_20191231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,096</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,177</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:AssetsCurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">324,013</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:AssetsCurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">303,335</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,950</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets, net</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,167</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:Goodwill" contextRef="C_0001501989_20201231" decimals="-3" scale="3">949</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:Goodwill" contextRef="C_0001501989_20191231" decimals="-3" scale="3">949</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001501989_20201231" decimals="-3" scale="3">917</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001501989_20191231" decimals="-3" scale="3">917</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use asset</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,382</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,172</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,015</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:Assets" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">358,663</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:Assets" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">341,282</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders' Equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,996</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,158</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,059</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues, current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">74,869</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:ContractWithCustomerLiabilityCurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,381</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">100,924</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">85,590</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, net of current portion</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">186,261</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000067" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">178,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities - long term</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000068" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000069" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000070" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="C_0001501989_20191231" decimals="-3" scale="3">850</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000071" name="us-gaap:Liabilities" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">308,860</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000072" name="us-gaap:Liabilities" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">290,169</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 11)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000073">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000074">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000089" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000090" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF">0.00001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000091" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000092" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;<ix:nonFraction unitRef="U_xbrlishares" id="F_000093" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000094" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000095" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_xbrlishares" id="F_000096" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2020 and 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000075">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000076">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000097" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001501989_20201231" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000098" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001501989_20191231" decimals="INF">0.00001</ix:nonFraction></ix:nonFraction> par value&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000099" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001501989_20201231" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000100" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001501989_20191231" decimals="INF" format="ixt:numdotdecimal">75,000,000</ix:nonFraction> shares authorized at</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; December 31, 2020 and 2019, respectively&#59; <ix:nonFraction unitRef="U_xbrlishares" id="F_000101" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001501989_20201231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000103" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001501989_20201231" decimals="INF" format="ixt:numdotdecimal">48,251,819</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000102" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001501989_20191231" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_xbrlishares" id="F_000104" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001501989_20191231" decimals="INF" format="ixt:numdotdecimal">45,523,088</ix:nonFraction></ix:nonFraction> shares issued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; and outstanding at December 31, 2020 and 2019, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000077" name="us-gaap:CommonStockValue" contextRef="C_0001501989_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000078" name="us-gaap:CommonStockValue" contextRef="C_0001501989_20191231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000079" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">499,964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000080" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">468,285</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income (loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000081" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001501989_20201231" decimals="-3" sign="-" scale="3">47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000082" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_0001501989_20191231" decimals="-3" scale="3">57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001501989_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">450,115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001501989_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">417,230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">358,663</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">341,282</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to financial statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CYTOMX THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_OPERATIONS_COMPREHENSIVE_LOSS">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">100,362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">57,489</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,502</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">112,936</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">131,619</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">103,866</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,031</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">36,765</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">33,510</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:OperatingExpenses" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">148,967</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:OperatingExpenses" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">168,384</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:OperatingExpenses" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">137,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">48,605</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">110,895</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001501989_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">77,874</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,836</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,365</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,641</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" scale="3">27</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" scale="3">135</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="C_0001501989_20180101_20181231" decimals="-3" sign="-" scale="3">68</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">46,796</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">102,665</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="C_0001501989_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">70,301</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for (benefit from) income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,911</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" scale="3">427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000133" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:NetIncomeLoss" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">32,885</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:NetIncomeLoss" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">102,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:NetIncomeLoss" contextRef="C_0001501989_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">84,604</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000137" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="C_0001501989_20200101_20201231" decimals="2" sign="-">0.71</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000138" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="C_0001501989_20190101_20191231" decimals="2" sign="-">2.26</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000139" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" contextRef="C_0001501989_20180101_20181231" decimals="2" sign="-">2.03</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used to compute net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000140" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001501989_20200101_20201231" decimals="0" format="ixt:numdotdecimal">46,145,563</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000141" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001501989_20190101_20191231" decimals="0" format="ixt:numdotdecimal">45,335,927</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000142" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001501989_20180101_20181231" decimals="0" format="ixt:numdotdecimal">41,664,382</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income (loss):</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain (loss) on short-term investments, net of tax</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" scale="3">104</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000144" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001501989_20190101_20191231" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001501989_20180101_20181231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of adoption of new accounting pronouncement</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" contextRef="C_0001501989_20190101_20191231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total comprehensive loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">32,989</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">102,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="C_0001501989_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">84,603</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to financial statements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CYTOMX THERAPEUTIC, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="STATEMENTS_STOCKHOLDERS_EQUITY">Statements of Stockholders&#8217; Equity </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income/(Loss)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2017</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000150" name="us-gaap:SharesIssued" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="INF" format="ixt:numdotdecimal">38,478,560</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000151" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">289,454</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231" decimals="-3" sign="-" scale="3">94</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">219,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">69,896</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of adoption of new accounting pronouncement - ASC 606</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000156" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">10,912</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">10,912</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock in follow-on offering, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000159" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">5,867,347</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">134,596</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000161" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">134,596</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000162" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">673,382</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,156</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,156</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under the Employee Stock Purchase Plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000165" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" format="ixt:numdotdecimal">63,920</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" scale="3">872</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001501989_20180101_20181231" decimals="-3" scale="3">872</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001501989_20180101_20181231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000172" name="us-gaap:NetIncomeLoss" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">84,604</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:NetIncomeLoss" contextRef="C_0001501989_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">84,604</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2018</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000174" name="us-gaap:SharesIssued" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" format="ixt:numdotdecimal">45,083,209</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">445,956</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000177" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" sign="-" scale="3">93</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000178" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">314,981</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000179" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">130,883</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Impact of adoption of new accounting pronouncement - ASU 2018-02</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000180" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000181" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" sign="-" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000183" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">146,930</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000184" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">633</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000185" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001501989_20190101_20191231" decimals="-3" scale="3">633</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under the Employee Stock Purchase Plan</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000186" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">142,949</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000187" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" scale="3">994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000188" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001501989_20190101_20191231" decimals="-3" scale="3">994</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock to UCSB</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000189" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">150,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000190" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000191" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000192" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000193" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000194" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000195" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001501989_20190101_20191231" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000196" name="us-gaap:NetIncomeLoss" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">102,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000197" name="us-gaap:NetIncomeLoss" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">102,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000198" name="us-gaap:SharesIssued" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal">45,523,088</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000199" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000200" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">468,285</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000201" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231" decimals="-3" scale="3">57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000202" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">417,230</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000203" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,113</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000204" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,064,830</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000205" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000206" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,876</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under the Employee Stock Purchase Plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000207" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">128,684</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" scale="3">729</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_0001501989_20200101_20201231" decimals="-3" scale="3">729</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under the Open Market Sale Agreement,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; net of issuance cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000210" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,535,217</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000213" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000214" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other comprehensive loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000215" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231" decimals="-3" sign="-" scale="3">104</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000216" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" scale="3">104</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000217" name="us-gaap:NetIncomeLoss" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">32,885</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000218" name="us-gaap:NetIncomeLoss" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">32,885</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000219" name="us-gaap:SharesIssued" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal">48,251,819</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000220" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000221" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">499,964</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000222" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231" decimals="-3" sign="-" scale="3">47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000223" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">450,115</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="us-gaap:StockholdersEquity" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">49,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to financial statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CYTOMX THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_STATEMENTS_CASH_FLOWS">STATEMENTS OF CASH FLOWS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.2%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="us-gaap:ProfitLoss" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">32,885</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="us-gaap:ProfitLoss" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">102,238</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="us-gaap:ProfitLoss" contextRef="C_0001501989_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">84,604</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001501989_20200101_20201231" decimals="-3" scale="3">146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001501989_20190101_20191231" decimals="-3" scale="3">146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001501989_20180101_20181231" decimals="-3" scale="3">146</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="ctmx:DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="ctmx:DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,459</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="ctmx:DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,738</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accretion of discount on investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001501989_20200101_20201231" decimals="-3" scale="3">236</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,228</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,701</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:ShareBasedCompensation" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000238" name="us-gaap:ShareBasedCompensation" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000239" name="us-gaap:ShareBasedCompensation" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-cash lease expense</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000240" name="ctmx:NoncashLeaseExpense" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,887</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="ctmx:NoncashLeaseExpense" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,672</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock in connection with UCSB sublicense fee</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,602</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000243" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001501989_20200101_20201231" decimals="-3" scale="3">785</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">84</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000245" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="C_0001501989_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">10,042</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">81</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">2,074</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,899</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0001501989_20200101_20201231" decimals="-3" scale="3">157</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0001501989_20190101_20191231" decimals="-3" scale="3">640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="C_0001501989_20180101_20181231" decimals="-3" scale="3">20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" scale="3">857</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" scale="3">374</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001501989_20180101_20181231" decimals="-3" scale="3">261</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities, income tax payable and other long-term liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="ctmx:IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">11,039</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="ctmx:IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">15,396</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="ctmx:IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,833</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000258" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,891</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000259" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">47,741</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000260" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="C_0001501989_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">38,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000261" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,259</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">140,480</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001501989_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">75,521</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,309</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,497</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000266" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,788</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of short-term investments</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">199,108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">174,992</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">204,601</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of short-term investments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">182,699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">258,190</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">214,315</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">18,718</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">79,701</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,926</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock, net of issuance costs</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000276" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,288</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">134,596</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from employee stock purchase plan and exercise of stock options</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,605</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,028</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000281" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,893</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,627</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">139,624</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash, cash equivalents and restricted cash</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,434</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">59,152</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">70,029</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash, beginning of year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">189,342</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">248,494</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001501989_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">178,465</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.2%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents and restricted cash, end of year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">192,776</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">189,342</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">248,494</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of cash flow information:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for income taxes</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="us-gaap:IncomeTaxesPaidNet" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,061</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosures of noncash investing items:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment in accounts payable and accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001501989_20200101_20201231" decimals="-3" scale="3">122</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001501989_20190101_20191231" decimals="-3" scale="3">428</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,027</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right of use assets obtained in exchange for operating lease obligations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000297" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">28,054</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.52%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying notes to financial statements</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<ix:nonNumeric id="F_000299" name="us-gaap:NatureOfOperations" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N1_DESCRIPTION__BUSINESS">1. Description of the Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CytomX Therapeutics, Inc. (the <span style="color:#000000;">&#8220;</span>Company<span style="color:#000000;">&#8221;</span>) is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are advancing potential first-in-class antibody-based therapeutics created using our Probody&#174; technology platform that could meaningfully improve patient outcomes in a disease where significant unmet need remains. Our proprietary and unique Probody technology platform is designed to enable &#8220;conditional activation&#8221; of antibody-based drugs within the tumor while minimizing drug activity in healthy tissues and circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000300" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000300_dcnt_743c340d-5e3b-44a4-a972-7716cc9d5fce">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Basis of Presentation and Summary of Significant Accounting Policies</p><ix:nonNumeric id="F_000316" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (<span style="color:#000000;">&#8220;</span>U.S. GAAP&#8221;). </p></ix:nonNumeric><ix:nonNumeric id="F_000317" name="us-gaap:UseOfEstimates" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric id="F_000318" name="us-gaap:ConcentrationRiskCreditRisk" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products, and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all the Company&#8217;s cash is held by one financial institution. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents and short-term investments in highly rated money market funds and its short-term investments in U.S. Government Bonds.</p><ix:nonNumeric id="F_000334" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customers and collaboration partners who represent 10% or more of the Company&#8217;s total revenue during each period presented or accounts receivable balance at each respective balance sheet date are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable, net</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie Ireland Unlimited Company</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,192</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000358" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000361" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc.</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000364" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20201231" decimals="-3" scale="3">798</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol-Myers Squibb Company</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000356" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000359" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">47,740</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000362" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,780</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000366" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20191231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue from customers who represent 10% or more</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of the Company's total revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000357" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">91,753</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000360" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">53,618</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000363" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">51,777</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000365" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20201231" decimals="-3" scale="3">798</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000367" name="us-gaap:AccountsReceivableNetCurrent" contextRef="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20191231" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s customers are located in the United States of America, Ireland and Japan.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000319" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000319_dcnt_4fddafad-77b7-499b-b3ea-0f5d4f89fa9b">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has determined that it has <ix:nonFraction unitRef="U_ctmxActivity" id="F_000368" name="ctmx:NumberOfBusinessActivities" contextRef="C_0001501989_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> business activity and operates as <ix:nonFraction unitRef="U_ctmxSegment" id="F_000369" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001501989_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment as it only reports financial information on an aggregate basis to its chief executive officer and chief financial officer, who are the Company&#8217;s chief operating decision makers. All long-lived assets are maintained in the United States of America.</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000300_dcnt_743c340d-5e3b-44a4-a972-7716cc9d5fce" continuedAt="F_000300_dcnt_633a5a9c-a1d7-4784-bba0-219eeba4ca77"><ix:continuation id="F_000319_dcnt_4fddafad-77b7-499b-b3ea-0f5d4f89fa9b">
</ix:continuation><ix:nonNumeric id="F_000320" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000321" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash represents a standby letter of credit issued pursuant to an office lease entered in December 2015. </p><ix:nonNumeric id="F_000335" name="ctmx:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the amounts shown in the statement of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000370" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">191,859</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000371" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">188,425</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000372" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001501989_20201231" decimals="-3" scale="3">917</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000373" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001501989_20191231" decimals="-3" scale="3">917</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000374" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">192,776</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000375" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">189,342</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000322" name="us-gaap:MarketableSecuritiesPolicy" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Short-term Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All investments have been classified as available-for-sale (&#8220;AFS&#8221;) and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Generally, those investments with contractual maturities less than 12 months are considered short-term investments. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses impairment of its AFS debt securities investments at each reporting period.&#160;&#160;Unrealized gains resulting from the excess of the fair value over the amortized cost basis of an investment are reported as a component of accumulated other comprehensive income (loss), net of tax.&#160;&#160;Unrealized losses or impairments resulting from the fair value of the AFS debt security being below the amortized cost basis are evaluated, using the discounted cash flow model, for identification of credit losses and non-credit related losses.&#160;&#160;Any credit losses are charged to earnings against the allowance for credit losses of the security, limited to the difference between the fair value and the amortized cost basis of the security.&#160;&#160;Any difference between the fair value of the security and the amortized cost basis, less the allowance for credit losses, are reported in other comprehensive income (loss).&#160;&#160;Expected cash inflows due to improvements in credit are recognized through a reversal of the allowance for credit losses subject to the total allowance previously recognized.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of impairment of any security, if management (i) has the intent to sell such security or (ii) will more-likely-than-not be required to sell such security before recovery of its amortized cost basis, such AFS debt security&#8217;s amortized cost basis will be written down to its fair value through earnings along with any existing allowance for credit losses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000323" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000323_dcnt_678c29cd-5ea7-458f-8eb0-b4cf3eba2801">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment, net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost net of accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the respective assets. <ix:nonNumeric id="F_000336" name="ctmx:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000336_cnt_1">The useful lives of property and equipment are as follows:</ix:nonNumeric></p><ix:continuation id="F_000336_cnt_1">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000376" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231" format="ixt-sec:duryear">5</ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000377" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_ctmxComputerEquipmentAndSoftwareMember_20200101_20201231" format="ixt-sec:duryear">3</ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000378" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231" format="ixt-sec:duryear">3</ix:nonNumeric> years</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000379" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" contextRef="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">Shorter of remaining lease term or estimated life of the assets</ix:nonNumeric></p></td>
</tr>
</table></div></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintenance and repairs that do not extend the life or improve the asset are expensed when incurred.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000300_dcnt_633a5a9c-a1d7-4784-bba0-219eeba4ca77" continuedAt="F_000300_dcnt_08c359b2-2c21-4669-922f-b6101ce2bdba"><ix:continuation id="F_000323_dcnt_678c29cd-5ea7-458f-8eb0-b4cf3eba2801">
</ix:continuation><ix:nonNumeric id="F_000324" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Goodwill and Intangible Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the purchase price paid over the fair value of tangible and identifiable intangible assets acquired in business combinations. Goodwill and other intangible assets with indefinite lives are not amortized, but are assigned to reporting units and tested for impairment annually, or whenever there is an impairment indicator. Intangible assets are comprised of in-process research and development. The Company assesses impairment indicators annually as of December 31 or more frequently, if a change in circumstances or the occurrence of events suggests the remaining value may not be recoverable. Intangible assets that are not deemed to have an indefinite life are amortized over their estimated useful lives. There was <ix:nonFraction unitRef="U_iso4217USD" id="F_000380" name="us-gaap:GoodwillImpairmentLoss" contextRef="C_0001501989_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000381" name="us-gaap:GoodwillImpairmentLoss" contextRef="C_0001501989_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000382" name="us-gaap:GoodwillImpairmentLoss" contextRef="C_0001501989_20180101_20181231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000383" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="C_0001501989_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000384" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="C_0001501989_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="C_0001501989_20180101_20181231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of goodwill or intangible assets identified during the years ended December 31, 2020, 2019 and 2018.</p></ix:nonNumeric><ix:nonNumeric id="F_000325" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable and prior to any goodwill impairment test. An impairment loss is recognized when the total of estimated undiscounted future cash flows expected to result from the use of the asset (or asset group) and its eventual disposition is less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. There was <ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="C_0001501989_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="C_0001501989_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="C_0001501989_20180101_20181231" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of long-lived assets during the years ended December 31, 2020, 2019 and 2018.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000326" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000326_dcnt_86293da3-18ec-41ca-ad06-e2e3b3937cb4">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 1, 2018, the Company adopted Accounting Standards Update No. 2014-09, <span style="font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span>, which supersedes the revenue recognition requirements in Accounting Standards Codification (ASC) Topic 605, <span style="font-style:italic;">Revenue Recognition (ASC 605)</span>, using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2018. The impact of the adoption of ASC 606 was an increase in the balance of deferred revenue and an increase in the accumulated deficit balance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20180101" decimals="-5" sign="-" scale="6">10.9</ix:nonFraction> million on January 1, 2018 in the Company&#8217;s Balance Sheet.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s revenues are primarily derived through its license, research, development and commercialization agreements. The terms of these types of agreements may include (i) licenses for the Company<span style="color:#000000;">&#8217;</span>s technology or programs, (ii) research and development services, and (iii) services or obligations in connection with participation in research or steering committees. Payments to the Company under these arrangements typically include one or more of the following: nonrefundable upfront and license fees, research funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses whether the promises in its arrangements with customers are considered as distinct performance obligations that should be accounted for separately. Judgment is required to determine whether the license to the Company<span style="color:#000000;">&#8217;</span>s intellectual property is distinct from the research and development services or participation on steering committees.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s collaboration and license agreements may include contingent payments related to specified research, development and regulatory milestones. Such milestone payments are typically payable under the collaborations when the collaboration partner claims or selects a target, or initiates or advances a covered product candidate in preclinical or clinical development, upon submission for marketing approval of a covered product with regulatory authorities&#59; or upon receipt of actual marketing approvals of a covered product or for additional indications. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.&#160;&#160;At each reporting date, the Company re-evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price by using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price in such period of determination.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s collaboration and license agreements may also include contingent payments related to sales-based milestones. Sales-based milestones are typically payable when annual sales of a covered product reach specified levels. Sales-based milestones are recognized at the later of when the associated performance obligation has been satisfied or when the sales occur. Unlike other contingency payments, such as regulatory milestones, sales-based milestones are not included in the transaction price based on estimates at the inception of the contract, but rather, are included when the sales or usage occur.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000300_dcnt_08c359b2-2c21-4669-922f-b6101ce2bdba" continuedAt="F_000300_dcnt_54b7a778-cfc7-49b8-99ca-d78f277547d7"><ix:continuation id="F_000326_dcnt_86293da3-18ec-41ca-ad06-e2e3b3937cb4">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price in each arrangement is allocated to the identified performance obligations based on the relative standalone selling price (<span style="color:#000000;">&#8220;</span>SSP<span style="color:#000000;">&#8221;</span>) of each distinct performance obligation, which requires judgment. In instances where SSP is not directly observable, such as when a license or service is not sold separately, SSP is determined using information that may include market conditions and other observable inputs. Due to the early stage of the Company<span style="color:#000000;">&#8217;</span>s licensed technology, the license of such technology is typically combined with research and development services and steering committee participation as one performance obligation.&#160;&#160;In the event that the Company receives non-cash consideration such as consideration in the form of a research license and research support services from the counterparty, the transaction price of a non-monetary exchange that has commercial substance is estimated based on the fair value of the non-cash consideration received, which may be determined through a valuation analysis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain cases, the Company&#8217;s performance creates an asset that does not have an alternative use to the customer and the Company has an enforceable right to payment at all times for performance completed to date.&#160;&#160;In these cases, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie Ireland Unlimited Company (<span style="color:#000000;">&#8220;</span>AbbVie<span style="color:#000000;">&#8221;</span>), one of the Company<span style="color:#000000;">&#8217;</span>s collaboration partners, entered into a license agreement with Seattle Genetics, Inc. (<span style="color:#000000;">&#8220;</span>SGEN<span style="color:#000000;">&#8221;</span>) to license certain intellectual property rights. As part of the Company<span style="color:#000000;">&#8217;</span>s collaboration agreement with AbbVie, the Company is required to pay SGEN sublicense fees for certain milestone achievements and annual maintenance fee. These sublicense fees are treated as reductions to the transaction price and combined with the performance obligation to which they relate.</p></ix:continuation><ix:nonNumeric id="F_000327" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss represents all changes in stockholders&#8217; equity except those resulting from distributions to stockholders. The Company&#8217;s non-credit related unrealized gains and losses on short-term investments and impact of adoption of new accounting pronouncements during the period represent the components of other comprehensive income (loss) that is excluded from the reported net loss.</p></ix:nonNumeric><ix:nonNumeric id="F_000328" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Balances </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company satisfies its performance obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company<span style="color:#000000;">&#8217;</span>s right to consideration is unconditional.</p></ix:nonNumeric><ix:nonNumeric id="F_000329" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000329_dcnt_c6e0dd82-b5a9-4e9c-97e4-1d57c15bfb5e">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its stock-based awards made to employees based on the fair values of the awards as of the grant date using the Black-Scholes option-pricing model. Stock-based compensation expense is recognized over the requisite service period using the ratable method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest.&#160;&#160;Forfeitures are recognized as they occur.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 2019, the Company adopted ASU No. 2018-07, <span style="font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.</span> Under this new standard, stock options granted to non-employees as consideration for<span style="letter-spacing:0.4pt;"> </span>services received are measured on the date of grant using the Black-Scholes option-pricing model.&#160;&#160;The<span style="letter-spacing:0.4pt;"> related </span>grant date fair values of stock options are expensed on a straight-line basis over the period, generally the vesting period, during which<span style="letter-spacing:0.3pt;"> </span>the non-employee is required to provide service in exchange for the award.&#160;&#160;<span style="font-style:italic;">&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the adoption of ASU 2018-07, such stock-based compensation expense was measured on the date of performance at the fair value of the consideration received or the fair value<span style="letter-spacing:0.4pt;"> </span>of the equity instruments issued, using the Black-Scholes option-pricing model, whichever can be more<span style="letter-spacing:0.45pt;"> </span>reliably measured. Stock-based compensation expense for options granted to non-employees was periodically remeasured as the underlying options<span style="letter-spacing:0.1pt;"> </span>vest.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000300_dcnt_54b7a778-cfc7-49b8-99ca-d78f277547d7" continuedAt="F_000300_dcnt_1439a104-25fe-4b59-a835-59102b3fe406"><ix:continuation id="F_000329_dcnt_c6e0dd82-b5a9-4e9c-97e4-1d57c15bfb5e">
</ix:continuation><ix:nonNumeric id="F_000330" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using an asset and liability approach. Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company records a valuation allowance to reduce its deferred tax assets to reflect the net amount that it believes as more likely than not to be realized. Realization of the deferred tax assets is dependent on the generation of future taxable income, the amount and timing of which are uncertain. The valuation allowance requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Based upon the weight of available evidence at December 31, 2020, the Company continues to maintain a full valuation allowance against all of its deferred tax assets after management considered all available evidence, both positive and negative, including but not limited to its historical operating results, income or loss in recent periods, cumulative income in recent years, forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the tax effects of an uncertain tax position only if it is more likely than not that it will be sustained based solely on its technical merits as of the reporting date and only in an amount more likely than not that it will be sustained upon review by the tax authorities. The Company evaluates uncertain tax positions on a quarterly basis and adjust the liability for changes in facts and circumstances, such as new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, significant amendment to an existing tax law, or resolution of an examination. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the income tax provision in the period in which such determination is made. The resolution of its uncertain income tax positions is dependent on uncontrollable factors such as law changes, new case law, and the willingness of the income tax authorities to settle, including the timing thereof and other factors. Although the Company does not anticipate significant changes to its uncertain income tax positions in the next twelve months, items outside of its control could cause its uncertain income tax positions to change in the future, which would be recorded in its statements of operations. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense. </p></ix:nonNumeric><ix:nonNumeric id="F_000331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000331_dcnt_b5836bf7-fe67-4099-bc72-ab4f9e5a482d">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company <span style="color:#000000;">records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced, and includes these costs in accrued liabilities in the balance sheets and within research and development expense in the statements of operations. These costs are a significant component of the Company&#8217;s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status and timing of actual services performed may vary from the Company&#8217;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. All costs associated with research and development are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, the Company acquired certain technology know-how that is complementary to the Company&#8217;s proprietary Probody technology from a third party for $<ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_ctmxProbodyTechnologyMember_20190101_20190131" decimals="-5" scale="6">5.0</ix:nonFraction> million.&#160;&#160;The Company plans to use this technology in certain of the Company&#8217;s discovery stage projects, and has concluded that the technology acquired does not have an alternative future use.&#160;&#160;Accordingly, the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_ctmxProbodyTechnologyMember_20190101_20191231" decimals="-5" scale="6">5.0</ix:nonFraction> million has been recorded as research and development expense for 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000300_dcnt_1439a104-25fe-4b59-a835-59102b3fe406"><ix:continuation id="F_000331_dcnt_b5836bf7-fe67-4099-bc72-ab4f9e5a482d">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000332" name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted the Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-02, <span style="font-style:italic;">Leases (Topic 842)</span> on January 1, 2019, using the modified retrospective approach.  As a result of the adoption of ASC 842, the Company recorded a right-of-use asset of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000392" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101" decimals="-5" scale="6">28.0</ix:nonFraction> million and a lease liability $<ix:nonFraction unitRef="U_iso4217USD" id="F_000393" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101" decimals="-5" scale="6">30.1</ix:nonFraction> million on January 1, 2019.&#160;&#160;There was no impact on the Company&#8217;s accumulated deficit as of the adoption date.&#160;&#160;The Company determines if an arrangement is or contains a lease at inception.&#160;&#160;Operating leases are recorded as operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the Company&#8217;s balance sheet.&#160;&#160;ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term.&#160;&#160;The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments.&#160;&#160;The operating lease ROU assets also include any lease prepayments made and reduced by lease incentives. The Company&#8217;s lease terms may include options to extend the lease when it is reasonably certain that such option will be exercised. Lease expenses are recognized on a straight-line basis over the lease term.&#160;&#160;The Company elected the short-term lease recognition exemption<span style="Background-color:#FFFFFF;color:#000000;">.</span> The Company&#8217;s operating lease arrangement includes lease and non-lease components which are generally accounted for separately.</p></ix:nonNumeric></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000301" name="ctmx:AdoptedAndRecentAccountingPronouncementsTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000301_dcnt_af2405f5-b665-4a06-8772-a3b908b430a5">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Adopted and Recent Accounting Pronouncements</p><ix:nonNumeric id="F_000333" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000333_dcnt_adeec6d0-b882-4445-88d8-b066ff9fbe49">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#263238;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Adopted Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;" id="S170363231">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financial Instruments - Credit Losses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. <span style="color:#000000;">This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the previous other-than-temporary-impairment model. </span>The Company adopted this standard on <ix:nonNumeric id="F_000394" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric> using a modified retrospective approach.&#160;&#160;There was no impact on the Company&#8217;s accumulated deficit as of January 1, 2020 as there was no incremental impairment loss to be recognized upon the adoption of this ASU.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Simplification of the Test for Goodwill Impairment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, the FASB issued ASU No. 2017-04, <span style="font-style:italic;">Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span>. The new standard simplifies the measurement of goodwill by eliminating the Step 2 impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill with the carrying amount of that goodwill. The new guidance requires an entity to compare the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. The Company adopted this standard on <ix:nonNumeric id="F_000396" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201704Member_20201231" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric> and there was no material impact on its financial statement.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair Value Measurement Disclosure Requirements Modification</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No. 2018-13, <span style="font-style:italic;">Fair Value Measurement (Topic 820)</span>. The amendments in this ASU modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. Various disclosure requirements have been removed, including the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels, the valuation processes for Level 3 fair value measurements held at the end of the reporting period. The ASU also modified various disclosure requirements and added some disclosure requirements for Level 3 fair value measurements. The amendments in this ASU were effective for the Company on <ix:nonNumeric id="F_000399" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric> and there was no material impact on its financial statements upon adoption of this ASU. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000301_dcnt_af2405f5-b665-4a06-8772-a3b908b430a5"><ix:continuation id="F_000333_dcnt_adeec6d0-b882-4445-88d8-b066ff9fbe49">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Internal Use Software Guidance for Cloud Computing Arrangement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No. 2018-15, <span style="font-style:italic;">Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40)</span>. The amendments in this ASU on the accounting for implementation, setup and other upfront costs (collectively &#8220;implementation costs&#8221;) apply to entities that are a customer in a hosting arrangement. The amendments under this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. Accordingly, the amendments in this ASU require an entity in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to expense. They also require an entity to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. The Company adopted this standard on <ix:nonNumeric id="F_000402" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric> and there was no material impact on its financial statement upon adoption of this ASU.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Collaborative Arrangements and Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued&#160;ASU No. 2018-18, <span style="font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the interaction between Topic 808 and Topic 606</span>.&#160;&#160;The amendments in&#160;this ASU targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In addition, unit-of-account guidance in Topic 808 was aligned with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606.&#160;The ASU&#160;was effective for the Company on <ix:nonNumeric id="F_000405" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric>, and there was no material impact on its financial statements upon adoption of this ASU.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Share-Based Payment to Customer</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2019, the FASB issued ASU 2019-08,</span><span style="font-style:italic;Background-color:#FFFFFF;"> Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Codification Improvements &#8211; Share-Based Consideration Payable to a Customer. </span><span style="color:#000000;">The amendments in this ASU require that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in Topic 718. Under ASC 606, these awards are considered a reduction of the transaction price, unless the awards are payment for a distinct good or service received from the customer and should be recorded as a reduction of the transaction price.&#160;&#160;However, the ASU requires these awards to be measured on the basis of the grant-date fair value of the share-based payment award in accordance with Topic 718 and should be recognized at the later of when the award is promised and when the entity recognizes revenue for the transfer of the related goods or services in accordance with ASC 606.&#160;&#160;The ASU&#160;is effective for the Company on <ix:nonNumeric id="F_000408" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201908Member_20201231" format="ixt:datemonthdayyearen">January 1, 2020</ix:nonNumeric>, and there was no material impact on its financial statements upon adoption of this ASU.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span>. The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles of ASC 740 in order to reduce cost and complexity of its application.&#160;&#160;The ASU removes the exception related to the incremental approach for intraperiod tax allocation as well as two exceptions related to accounting for outside basis differences of equity method investments and foreign subsidiaries.&#160;&#160;The ASU also amends the scope of ASC 740 related to a franchise tax (or similar tax) that is partially based on income&#59; clarifies when a step-up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction&#59; specifies that an entity is not required to allocate income tax expense to a legal entity that is both not subject to tax and disregarded by the taxing authority&#59; and&#160;&#160;clarifies that all tax effects, both deferred and current, should be accounted for in the interim period that includes the enactment date.&#160;&#160;The ASU&#160;is effective for the Company on <ix:nonNumeric id="F_000411" name="us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231" format="ixt:datemonthdayyearen">January 1, 2021</ix:nonNumeric>, and interim periods within those fiscal years.&#160;&#160;The Company does not expect the adoption of this ASU will have a material impact on its financial statements.</p></ix:continuation>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000302" name="us-gaap:EarningsPerShareTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000302_dcnt_2652a435-e564-4327-a667-8b666d1f7ae7">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Net Loss Per Share </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period.&#160;&#160;Diluted net loss per share is calculated using the weighted-average number of common shares outstanding, plus potential dilutive common stock during the period.&#160;&#160;Diluted net loss per share is the same as basic net loss per share since the effect of the potentially dilutive securities is anti-dilutive.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000302_dcnt_2652a435-e564-4327-a667-8b666d1f7ae7">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000337" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following weighted-average outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented, because including them would have been anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and ESPP to purchase common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000414" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20200101_20201231" decimals="0" format="ixt:numdotdecimal">11,388,691</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000415" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20190101_20191231" decimals="0" format="ixt:numdotdecimal">9,687,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000416" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20180101_20181231" decimals="0" format="ixt:numdotdecimal">7,478,755</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000303" name="us-gaap:FairValueDisclosuresTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000303_dcnt_0f5095be-972b-4469-9577-239698e14a20">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Fair Value Measurements and Short-Term Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 820-10, Fair Value Measurements and Disclosures, the Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level I: Inputs which include quoted prices in active markets for identical assets and liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level II: Inputs other than Level I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities&#59; quoted prices in markets that are not active&#59; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">Level III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s financial instruments, including restricted cash, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. The Company&#8217;s financial instruments consist of Level I assets which consist primarily of highly liquid money market funds, some of which are included in restricted cash and U.S. government bonds that are included in short-term investments. </p><ix:nonNumeric id="F_000338" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth the fair value of the Company&#8217;s short-term investments subject to fair value measurements on a recurring basis and the level of inputs used in such measurements:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Allowance for Credit Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000420" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">131,121</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000421" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">131,121</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (money market funds)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000422" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_ctmxMoneyMarketFundsIncludedInRestrictedCashMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" scale="3">917</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000423" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_ctmxMoneyMarketFundsIncludedInRestrictedCashMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" scale="3">917</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government bonds</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000424" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">124,254</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000425" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000426" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">124,260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total Securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000417" name="ctmx:CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">256,292</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000418" name="ctmx:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001501989_20201231" decimals="-3" scale="3">6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000419" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">256,298</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Allowance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Credit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000430" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">170,757</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000431" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">170,757</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (money market funds)</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000432" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_ctmxMoneyMarketFundsIncludedInRestrictedCashMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" scale="3">917</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000433" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_ctmxMoneyMarketFundsIncludedInRestrictedCashMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" scale="3">917</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government bonds</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000434" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">107,610</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000435" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" scale="3">110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000436" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">107,720</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total securities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000427" name="ctmx:CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">279,284</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000428" name="ctmx:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" contextRef="C_0001501989_20191231" decimals="-3" scale="3">110</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000429" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">279,394</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000437" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="C_0001501989_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">No</ix:nonFraction> securities have contractual maturities of greater than twelve months.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000303_dcnt_0f5095be-972b-4469-9577-239698e14a20">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000304" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Property and Equipment</p><ix:nonNumeric id="F_000339" name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000438" name="us-gaap:MachineryAndEquipmentGross" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,772</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000439" name="us-gaap:MachineryAndEquipmentGross" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">12,124</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000440" name="ctmx:ComputerEquipmentAndSoftwareGross" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,600</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000441" name="ctmx:ComputerEquipmentAndSoftwareGross" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,555</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000442" name="us-gaap:FurnitureAndFixturesGross" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,024</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000443" name="us-gaap:FurnitureAndFixturesGross" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,024</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000444" name="us-gaap:LeaseholdImprovementsGross" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,728</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000445" name="us-gaap:LeaseholdImprovementsGross" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,483</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000446" name="us-gaap:ConstructionInProgressGross" contextRef="C_0001501989_20201231" decimals="-3" scale="3">252</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000447" name="us-gaap:ConstructionInProgressGross" contextRef="C_0001501989_20191231" decimals="-3" scale="3">236</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000448" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,376</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000449" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,422</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000450" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">11,426</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000451" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,050</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000452" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,950</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000453" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,372</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000454" name="us-gaap:Depreciation" contextRef="C_0001501989_20200101_20201231" decimals="-5" scale="6">2.4</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000455" name="us-gaap:Depreciation" contextRef="C_0001501989_20190101_20191231" decimals="-5" scale="6">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000456" name="us-gaap:Depreciation" contextRef="C_0001501989_20180101_20181231" decimals="-5" scale="6">1.7</ix:nonFraction> million for the years ended December 31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000305" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Goodwill and Intangible Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill and in-process research and development assets resulted from a series of integrated financing transactions in 2010 that was accounted for as a business combination. The in-process research and development was related to the Company&#8217;s proprietary Probody platform and was accounted for as an indefinite-lived intangible asset until the underlying project was completed or abandoned. In connection with the collaboration agreements, the Company began amortizing the intangible asset in 2017. The intangible asset is being amortized over the estimated lives of the patents which average <ix:nonNumeric id="F_000457" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20200101_20201231" format="ixt-sec:duryear">12</ix:nonNumeric> years. The amortization expense for the years ended December 31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000458" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20200101_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000459" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20190101_20191231" decimals="-5" scale="6">0.1</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000460" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20180101_20181231" decimals="-5" scale="6">0.1</ix:nonFraction> million, respectively.</p><ix:nonNumeric id="F_000340" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill and intangible assets consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000461" name="us-gaap:Goodwill" contextRef="C_0001501989_20201231" decimals="-3" scale="3">949</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000462" name="us-gaap:Goodwill" contextRef="C_0001501989_20191231" decimals="-3" scale="3">949</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000463" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000464" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated amortization</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000465" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20201231" decimals="-3" scale="3">583</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000466" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20191231" decimals="-3" scale="3">438</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000467" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,167</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000468" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,312</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000306" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Accrued Liabilities</p><ix:nonNumeric id="F_000341" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and clinical expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000469" name="ctmx:AccruedResearchAndClinicalCurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,092</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000470" name="ctmx:AccruedResearchAndClinicalCurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,006</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000471" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000472" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,721</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal and professional expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000473" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001501989_20201231" decimals="-3" scale="3">815</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000474" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,062</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities - short term</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000475" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000476" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000477" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001501989_20201231" decimals="-3" scale="3">595</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000478" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001501989_20191231" decimals="-3" scale="3">452</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000479" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">23,059</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000480" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">30,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000307" name="ctmx:ResearchAndCollaborationAgreementsTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000307_dcnt_abda1fde-9304-4914-b5ac-57f5caebcef9">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Research and Collaboration Agreements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000342" name="us-gaap:DisaggregationOfRevenueTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the revenue by collaboration partners:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000481" name="us-gaap:Revenues" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,192</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000482" name="us-gaap:Revenues" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000483" name="us-gaap:Revenues" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">18,997</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amgen</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000484" name="us-gaap:Revenues" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,609</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000485" name="us-gaap:Revenues" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000486" name="us-gaap:Revenues" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,899</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000487" name="us-gaap:Revenues" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">13,931</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol Myers Squibb</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000488" name="us-gaap:Revenues" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">39,630</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000489" name="us-gaap:Revenues" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">47,740</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000490" name="us-gaap:Revenues" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">32,780</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000491" name="us-gaap:Revenues" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,471</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000492" name="us-gaap:Revenues" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000493" name="us-gaap:Revenues" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">100,362</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000494" name="us-gaap:Revenues" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">57,489</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000495" name="us-gaap:Revenues" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">59,502</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">AbbVie Ireland Unlimited Company</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, the Company and AbbVie entered into <ix:nonFraction unitRef="U_ctmxAgreement" id="F_000496" name="ctmx:NumberOfCollaborationAgreements" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20160430" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> agreements, a CD71 Co-Development and Licensing Agreement (the <span style="color:#000000;">&#8220;</span>CD71 Agreement<span style="color:#000000;">&#8221;</span>) and a Discovery Collaboration and Licensing Agreement (as amended and restated in June 2019, the <span style="color:#000000;">&#8220;</span>Discovery Agreement<span style="color:#000000;">&#8221;</span> and together with the CD71 Agreement the <span style="color:#000000;">&#8220;</span>AbbVie Agreements<span style="color:#000000;">&#8221;</span>). Under the terms of the CD71 Agreement, the Company and AbbVie will co-develop a conditionally activated antibody-drug conjugate (<span style="color:#000000;">&#8220;A</span>DC<span style="color:#000000;">&#8221;</span>) against CD71, with the Company responsible for preclinical and early clinical development. AbbVie will be responsible for later development and commercialization, with global late-stage development costs shared between the two companies. The Company will assume <ix:nonFraction unitRef="U_xbrlipure" id="F_000497" name="ctmx:PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20160401_20160430" decimals="2" scale="-2">35</ix:nonFraction>% of the net profits or net losses related to later development and commercialization unless it opts-out. If the Company opts-out from participation of co-development of the CD71 conditionally activated ADC, which includes CX-2029, AbbVie will have sole right and responsibility for the further development, manufacturing and commercialization of such CD71 conditionally activated ADC. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the CD71 Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000498" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430" decimals="-5" scale="6">20.0</ix:nonFraction> million in April 2016, and was eligible to initially receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000499" name="ctmx:ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160430" decimals="INF" scale="6">470.0</ix:nonFraction> million in development, regulatory and commercial milestone payments, a <ix:nonFraction unitRef="U_xbrlipure" id="F_000500" name="ctmx:ContingentPaymentsReceivableProfitSplitOnSales" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430" decimals="2" scale="-2">35</ix:nonFraction>% profit split on U.S. sales, and royalties on ex-U.S. sales at percentages in the high teens to low twenties if the Company participates in the co-development of the CD71 conditionally activated ADC subject to a reversion to a royalty on U.S. sales, and reduction in royalties on ex-U.S. sales, if the Company opts-out from the co-development of the CD71 conditionally activated ADC. The Company<span style="color:#000000;">&#8217;</span>s share of later stage co-development costs for each CD71 conditionally activated ADC is capped, provided that AbbVie may offset the Company<span style="color:#000000;">&#8217;</span>s co-development cost above the capped amounts from future payments such as milestone payments and royalties. In July 2017, the Company received a milestone payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000501" name="ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20170701_20170731" decimals="-5" scale="6">14.0</ix:nonFraction> million (net of payment of an associated sublicense fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000503" name="ctmx:PaymentsOfSublicenseFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20170701_20170731" decimals="-5" scale="6">1.0</ix:nonFraction> million to SGEN under the Seattle Genetics Agreement) from AbbVie for achieving certain milestones required to be met to begin GLP toxicology studies under the CD71 Agreement. In May 2018, the United States Food and Drug Administration (<span style="color:#000000;">&#8220;</span>FDA<span style="color:#000000;">&#8221;</span>) cleared the IND application for CX-2029. As a result, the Company achieved the IND success criteria under the CD71 Agreement and received a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000502" name="ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20180501_20180531" decimals="-5" scale="6">21.0</ix:nonFraction> million milestone payment (net of the payment of an associated sublicense fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000504" name="ctmx:PaymentsOfSublicenseFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20180501_20180531" decimals="-5" scale="6">4.0</ix:nonFraction> million to SGEN). In March 2020, the Company earned a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000505" name="ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331" decimals="-5" scale="6">40.0</ix:nonFraction> million milestone payment for satisfying the CD71 dose escalation success criteria under the CD71 Agreement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000307_dcnt_abda1fde-9304-4914-b5ac-57f5caebcef9" continuedAt="F_000307_dcnt_ce0e8c4f-bc75-4fb9-9068-b110d6f0b736">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Discovery Agreement, AbbVie receives exclusive worldwide rights to develop and commercialize conditionally activated ADCs against up to <ix:nonFraction unitRef="U_ctmxTarget" id="F_000506" name="ctmx:NumberOfTargets" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> targets, <ix:nonFraction unitRef="U_ctmxTarget" id="F_000507" name="ctmx:NumberOfTargetsSelected" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20170331" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> of which was selected in March 2017. The Company shall perform research services to discover the Probody therapeutics and create conditionally activated ADCs for the nominated collaboration targets. From that point, AbbVie shall have sole right and responsibility for development and commercialization of products comprising or containing such conditionally activated ADCs (<span style="color:#000000;">&#8220;</span>Discovery Licensed Products<span style="color:#000000;">&#8221;</span>). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Discovery Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000508" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160401_20160430" decimals="-5" scale="6">10.0</ix:nonFraction> million in April 2016 and subsequently earned an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000509" name="ctmx:MilestonePaymentReceived" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630" decimals="-5" scale="6">10.0</ix:nonFraction> million milestone payment triggered by selection of the second target by AbbVie in June 2019. The Company is also eligible to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000510" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_ctmxDevelopmentRegulatoryAndCommercialMilestonePaymentsMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430" decimals="INF" scale="6">265.0</ix:nonFraction> million for each target, in development, regulatory and commercial milestone payments and royalties at percentages in the high single to low teens from commercial sales of any resulting conditionally activated ADCs. The second target was selected under the Discovery Agreement that allows AbbVie to select a target for developing a conditionally activated ADC or a Probody.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that the AbbVie Agreements should be combined and evaluated as a single arrangement in determining revenue recognition, because both agreements were concurrently negotiated and executed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified the following performance obligations at the inception of the AbbVie Agreements: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research, development and commercialization license for CD71 Probody therapeutic, </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research services related to CD71 Probody therapeutic, </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the obligation to participate in the CD71 Agreement joint research committee, </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research services related to the first discovery target </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research, development and commercialization license for the first discovery target, and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the obligation to participate in the Discovery Agreement joint research committee. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company concluded that AbbVie<span style="color:#000000;">&#8217;</span>s option for the second discovery target was not a material right and was therefore not a performance obligation at the inception of the AbbVie Agreements. However, it was subsequently included in the total transaction price in June 2019 as a performance obligation upon AbbVie&#8217;s selection of such second target as further discussed below.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the research, development and commercialization licenses for CD71 and discovery targets are not distinct from the Company<span style="color:#000000;">&#8217;</span>s respective research services and expertise. The Company considered factors such as novelty of the Probody therapeutic and conditionally activated ADC technology and lack of other parties<span style="color:#000000;">&#8217;</span> expertise in this space, the Company<span style="color:#000000;">&#8217;</span>s rights to technology relating to a proprietary platform to enable the Probody therapeutic development and AbbVie<span style="color:#000000;">&#8217;</span>s contractual obligation to use the Company<span style="color:#000000;">&#8217;</span>s research services. The Company determined that the CD71 Agreement research, development and commercialization license, related research service and participation in the joint research committee were a combined performance obligation and were distinct from the Discovery Agreement research, development and commercialization license, related research service and participation in the joint research committee. Therefore, the Company concluded that there are two distinct performance obligations:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the CD71 Agreement performance obligation consisting of the CD71 Agreement research, development and commercialization license, related research service and participation in the joint research committee, and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Discovery Agreement performance obligation consisting of the Discovery Agreement research, development and commercialization license, related research service and participation in the joint research committee.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total transaction price for the Discovery Agreement and CD71 Agreement, collectively, upon adoption of ASC 606 on January 1, 2018 of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000511" name="ctmx:AggregateCollaborationTransactionAmount" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160430" decimals="-5" scale="6">39.8</ix:nonFraction> million consists of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000512" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160401_20160430" decimals="-5" scale="6">30.0</ix:nonFraction> million in upfront payments, and a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000513" name="ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160401_20160430" decimals="-5" scale="6">14.0</ix:nonFraction> million milestone payment received under the CD71 Agreement (net of the payment of an associated sublicense fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000514" name="ctmx:PaymentsOfSublicenseFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20160401_20160430" decimals="-5" scale="6">1.0</ix:nonFraction> million to SGEN), less $<ix:nonFraction unitRef="U_iso4217USD" id="F_000515" name="ctmx:EstimatedSublicenseFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160401_20160430" decimals="-5" scale="6">4.2</ix:nonFraction> million of estimated sublicense fees. The upfront payments under the AbbVie Agreements are allocated between the <ix:nonFraction unitRef="U_ctmxAccountingUnit" id="F_000516" name="ctmx:NumberOfAccountingUnits" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160401_20160430" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> performance obligations based on the estimated relative standalone selling prices. The $30.0 million of upfront payments is allocated $<ix:nonFraction unitRef="U_iso4217USD" id="F_000517" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430" decimals="-5" scale="6">20.0</ix:nonFraction> million to the CD71 Agreement, with the remaining $<ix:nonFraction unitRef="U_iso4217USD" id="F_000518" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160401_20160430" decimals="-5" scale="6">10.0</ix:nonFraction> million allocated to the Discovery Agreement. The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000519" name="ctmx:MilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160430" decimals="-5" scale="6">14.0</ix:nonFraction> million milestone payment received (net of the payment of an associated sublicense fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000520" name="ctmx:PaymentsOfSublicenseFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20160401_20160430" decimals="-5" scale="6">1.0</ix:nonFraction> million to SGEN) and the estimated sublicense fees of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000521" name="ctmx:EstimatedSublicenseFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430" decimals="-5" scale="6">4.2</ix:nonFraction> million are allocated to the CD71 Agreement performance obligation as they are directly related to the development of the CX-2029. </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000307_dcnt_ce0e8c4f-bc75-4fb9-9068-b110d6f0b736" continuedAt="F_000307_dcnt_9f2e6fd7-de42-465e-81d4-75959272ff1b">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therefore, of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000522" name="ctmx:AggregateCollaborationTransactionAmount" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160430" decimals="-5" scale="6">39.8</ix:nonFraction> million total initial transaction price discussed above, the Company allocated $<ix:nonFraction unitRef="U_iso4217USD" id="F_000523" name="ctmx:AggregateCollaborationTransactionAmount" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160430" decimals="-5" scale="6">29.8</ix:nonFraction> million to the CD71 Agreement performance obligation and recognized revenue using a cost-based input measure, the common measure of progress for the performance obligation. In applying the cost-based input method, revenue is recognized based on actual full-time employee (&#8220;FTE&#8221;) hours incurred as a percentage of total estimated FTE hours for completing its combined performance obligation over the estimated service period.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&#160;&#160;During 2019, as a result of ongoing dose escalation in the continued development program, there was a change in estimate of the research service period as well as an increase in the projected FTE hours-to-completion.&#160;&#160;The research service period for the CD71 Agreement performance obligation was extended from April 2021 to March 2022 in 2019.&#160;&#160;During the second quarter of 2020, the Company further increased the projected FTE hours-to-completion and extended the research service period for the CD71 Agreement performance obligation from March 2022 to September 2022 in response to the reduced rate of operation as impacted by the COVID-19 pandemic.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The remaining $10.0 million of the total initial transaction price of $39.8 million allocated to the Discovery Agreement performance obligation represents an obligation to continuously make the Company<span style="color:#000000;">&#8217;</span>s Probody therapeutic technology platform available to AbbVie. The $10.0 million was initially recognized on a straight-line basis over <ix:nonNumeric id="F_000524" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2016-04-01_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430" format="ixt-sec:durwordsen">five years</ix:nonNumeric>, which represented the estimated research service period for the first target, through April 2021 using the time-elapsed input method as the common measure of progress over the entire performance obligation.  During the fourth quarter of 2020, the Company extended the estimated research service period for this first target for an additional twelve months from April 2021 to April 2022.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2018, the Company earned a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000525" name="ctmx:MilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20180531" decimals="-5" scale="6">21.0</ix:nonFraction> million milestone payment (net of the payment of an associated sublicense fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000526" name="ctmx:PaymentsOfSublicenseFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20180501_20180531" decimals="-5" scale="6">4.0</ix:nonFraction> million to SGEN) under the CD71 Agreement. The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000527" name="ctmx:MilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180531" decimals="-5" scale="6">21.0</ix:nonFraction> million milestone payment was included as part of the transaction price in May 2018 and a revenue adjustment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000528" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180401_20180630" decimals="-5" scale="6">9.9</ix:nonFraction> million was recognized in the second quarter of 2018 reflecting the percentage completed to-date on the project related to this milestone.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company earned a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000530" name="ctmx:AggregateCollaborationTransactionAmount" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000531" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000532" name="ctmx:AggregateCollaborationTransactionAmount" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190630" decimals="-5" scale="6">10.0</ix:nonFraction></ix:nonFraction></ix:nonFraction> million milestone payment for the second target selected by AbbVie under the Discovery Agreement.&#160;&#160;It is recognized also using the time-elapse measure of progress of the related obligation and straight line over the estimated research service period of <ix:nonNumeric id="F_000533" name="ctmx:EstimatedResearchServicePeriod" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630" format="ixt-sec:durwordsen">five years</ix:nonNumeric> through June 2024.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000534" name="ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331" decimals="-5" scale="6">40.0</ix:nonFraction> million milestone payment earned in March 2020 for satisfying the CD71 dose escalation success criteria under the CD71 Agreement was included as part of the transaction price as it was unconstrained during the first quarter of 2020 and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000535" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTimingOfTransferOfGoodOrServiceAxis_us-gaapTransferredOverTimeMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331" decimals="-5" scale="6">26.6</ix:nonFraction> million was recognized as revenue related to this milestone reflecting the percentage completed to-date on the project.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the remaining potential milestone payments of both agreements are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company<span style="color:#000000;">&#8217;</span>s control. Therefore, these payments continued to be fully constrained and were not included in the transaction price as of December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000537" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20200101_20201231" decimals="-5" scale="6">38.2</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000538" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20190101_20191231" decimals="-5" scale="6">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000539" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180101_20181231" decimals="-5" scale="6">19.0</ix:nonFraction> million for the years ended December 31, 2020, 2019 and 2018, respectively, related to the AbbVie Agreements. As of December 31, 2020 and 2019, deferred revenue related to the CD71 Agreement performance obligation was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000543" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20201231" decimals="-5" scale="6">25.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000544" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20191231" decimals="-5" scale="6">20.0</ix:nonFraction> million, respectively, and deferred revenue related to the Discovery Agreement performance obligation was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000545" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20201231" decimals="-5" scale="6">8.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000546" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20191231" decimals="-5" scale="6">11.6</ix:nonFraction> million, respectively. <ix:nonFraction unitRef="U_iso4217USD" id="F_000547" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000548" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction> amounts were due from AbbVie as of December 31, 2020 and 2019. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Amgen, Inc.<span style="color:#FF0000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 29, 2017, the Company and Amgen, Inc. (<span style="color:#000000;">&#8220;</span>Amgen<span style="color:#000000;">&#8221;</span>) entered into a Collaboration and License Agreement (the <span style="color:#000000;">&#8220;</span>Amgen Agreement<span style="color:#000000;">&#8221;</span>). Pursuant to the Amgen Agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000549" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171001_20171031" decimals="-5" scale="6">40.0</ix:nonFraction> million in October 2017. Concurrent with the entry into the Amgen Agreement, the Company and Amgen entered into a Share Purchase Agreement (the <span style="color:#000000;">&#8220;</span>Purchase Agreement<span style="color:#000000;">&#8221;</span>) pursuant to which Amgen purchased <ix:nonFraction unitRef="U_xbrlishares" id="F_000550" name="ctmx:CommonStockSharesIssuableUnderAgreement" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171031" decimals="INF" format="ixt:numdotdecimal">1,156,069</ix:nonFraction> shares of the Company<span style="color:#000000;">&#8217;</span>s common stock at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000551" name="us-gaap:SharePrice" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171031" decimals="2">17.30</ix:nonFraction> per share (calculated based on a <ix:nonNumeric id="F_000553" name="ctmx:PeriodUsedToCalculateWeightedAveragePricePerShare" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171001_20171031" format="ixt-sec:durday">20</ix:nonNumeric>-day volume-weighted average price), for total proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000552" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171001_20171031" decimals="-5" scale="6">20.0</ix:nonFraction> million, which the Company received on October 6, 2017, the closing date of the transaction. The Company estimated a premium on the stock sold to Amgen of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000555" name="ctmx:EstimatedPremiumOnIssuanceOfShares" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171001_20171031" decimals="-5" scale="6">0.5</ix:nonFraction> million, which takes into account a discount due to the lack of marketability resulting from the <span style="-sec-ix-hidden:F_000554">six-month</span> lockup period.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Amgen Agreement, the Company and Amgen will co-develop a conditionally activated T-cell engaging bi-specific therapeutic targeting epidermal growth factor receptor (the <span style="color:#000000;">&#8220;</span>EGFR Products<span style="color:#000000;">&#8221;</span>). The Company is responsible for early-stage development of EGFR Products and all related costs up to certain pre-set costs and certain limits based on clinical trial size. Amgen will be responsible for late-stage development, commercialization, and all related costs of EGFR Products. Following early-stage development, the Company will have the right to elect to participate financially in the global co-development of EGFR Products with Amgen, during which the Company would bear certain of the worldwide development costs for EGFR Products and Amgen would bear the rest of such costs (the <span style="color:#000000;">&#8220;</span>EGFR Co-Development Option<span style="color:#000000;">&#8221;</span>). If the Company exercises its EGFR Co-Development Option, the Company will share in somewhat less than <ix:nonFraction unitRef="U_xbrlipure" id="F_000557" name="ctmx:ProfitShareUponExerciseOfCoDevelopmentOption" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929" decimals="INF" scale="-2">50</ix:nonFraction>% of the profit and losses from sales of such EGFR Products in the U.S., subject to certain caps, offsets, and deferrals. If the Company chooses not to exercise its EGFR Co-Development Option, the Company will not bear any costs of later stage development. The Company is eligible to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000556" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929" decimals="INF" scale="6">455.0</ix:nonFraction> million in development, regulatory, and commercial milestone payments for EGFR Products, and royalties in the low-double-digit to mid-teen percentage of worldwide commercial sales, provided that if the Company exercises its EGFR Co-Development option, it shall receive a profit and loss split of sales in the United States and royalties in the low-double-digit to mid-teen percentage of commercial sales outside of the United States.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000307_dcnt_9f2e6fd7-de42-465e-81d4-75959272ff1b" continuedAt="F_000307_dcnt_b1b4243a-d748-40fa-97ca-fd5a6f3edf34">

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amgen also has the right to select a total of up to <ix:nonFraction unitRef="U_ctmxTarget" id="F_000558" name="ctmx:NumberOfTargets" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> targets, including the two additional targets discussed below. The Company and Amgen collaborate in the research and development of conditionally activated T-cell engaging bi-specifics products directed against such targets. Amgen has selected <ix:nonFraction unitRef="U_ctmxTarget" id="F_000559" name="ctmx:NumberOfTargetsSelected" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> such target (the <span style="color:#000000;">&#8220;</span>Amgen Other Product<span style="color:#000000;">&#8221;</span>). If Amgen exercises its option within the specified period of time, it can select <ix:nonFraction unitRef="U_ctmxTarget" id="F_000560" name="ctmx:NumberOfAdditionalCollaborationTarget" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> such additional targets (the <span style="color:#000000;">&#8220;</span>Amgen Option Products<span style="color:#000000;">&#8221;</span> and, together with the Amgen Other Product, the <span style="color:#000000;">&#8220;</span>Amgen Products<span style="color:#000000;">&#8221;</span>). Except with respect to preclinical activities to be conducted by CytomX, Amgen will be responsible, at its expense, for the development, manufacture, and commercialization of all Amgen Products. If Amgen exercises all of its options and advances all three of the Amgen Products, CytomX is eligible to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000561" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929" decimals="INF" scale="6">950.0</ix:nonFraction> million in upfront, development, regulatory, and commercial milestones and tiered high single-digit to low-teen percentage royalties. The Company concluded that, at the inception of the agreement, Amgen<span style="color:#000000;">&#8217;</span>s option to select the two additional targets is not a material right and does not represent a performance obligation of the agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the initiation of the collaboration, CytomX had the option to select, from programs specified in the Amgen Agreement, an existing pre-clinical stage T-cell engaging bispecific product from the Amgen pre-clinical pipeline. In March 2018, CytomX selected the program. CytomX is responsible, at its expense, for converting this program to a conditionally activated T-cell engaging bispecific product, and thereafter, will be responsible for development, manufacturing, and commercialization of the product (<span style="color:#000000;">&#8220;</span>CytomX Product<span style="color:#000000;">&#8221;</span>). Amgen is eligible to receive up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000562" name="ctmx:ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929" decimals="INF" scale="6">203.0</ix:nonFraction> million in development, regulatory, and commercial milestone payments for the CytomX Product, and tiered mid-single digit to low double-digit percentage royalties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considered the criteria for combining contracts in ASC 606 and determined that the Amgen Agreement and the Purchase Agreement should be combined into one contract. The Company accounted for the Amgen Agreement based on the fair values of the assets and services exchanged. The Company identified the following performance obligations at the inception of the Amgen Agreement: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research, development and commercialization license, </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research and development services for the EGFR Products and the Amgen Other Product, and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the obligation to participate in the joint steering committee (&#8220;JSC&#8221;) and the joint research committee (&#8220;JRC&#8221;). </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that research, development and commercialization license and the participation in the JSC and JRC are not distinct from the research and development services and therefore those performance obligations were combined into one combined performance obligation. The Amgen Other Products are accounted for as a separate performance obligation from the EGFR Products as the nature of the services being performed is not the same and the value that Amgen can derive from one program is not dependent on the success of the other.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with the execution of the Amgen Agreement, the Company entered into a sublicense agreement whereby the Company granted Amgen a sublicense of its rights to one patent family that it co-owns with UCSB, that is exclusively licensed to the Company under the UCSB Agreement covering Probody antibodies and other pro-proteins in the fields of therapeutics, in vivo diagnostics and prophylactics. This sublicense was incremental to the patents, patent applications and know-how covering conditionally activated T-cell engaging bispecific molecules that were developed and owned by the Company and licensed to Amgen.  Under the UCSB Agreement, as amended, the Company is obligated to make a sublicense payment to UCSB equal to up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000563" name="ctmx:LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxRegentsOfTheUniversityOfCaliforniaMember_us-gaapTypeOfArrangementAxis_ctmxSublicenseAgreementMember_20170929_20170929" decimals="INF" scale="-2">7.5</ix:nonFraction>% of certain upfront and milestone payments owed to or received by the Company. There were <ix:nonFraction unitRef="U_iso4217USD" id="F_000564" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxRegentsOfTheUniversityOfCaliforniaMember_us-gaapTypeOfArrangementAxis_ctmxSublicenseAgreementMember_20201231" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000565" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxRegentsOfTheUniversityOfCaliforniaMember_us-gaapTypeOfArrangementAxis_ctmxSublicenseAgreementMember_20191231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> sublicense fees payable to UCSB as of December 31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total transaction price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000566" name="ctmx:AggregateCollaborationTransactionAmount" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929" decimals="-5" scale="6">51.2</ix:nonFraction> million, consisting of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000567" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929" decimals="-5" scale="6">40.0</ix:nonFraction> million upfront payment, an estimated fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000569" name="ctmx:EstimatedFairValueOfProducts" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929" decimals="-5" scale="6">10.7</ix:nonFraction> million for the CytomX Product and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000568" name="ctmx:PremiumOnIssuanceOfSharesAllocatedToCommonStock" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929" decimals="-5" scale="6">0.5</ix:nonFraction> million of premium on the sale of the Company<span style="color:#000000;">&#8217;</span>s common stock, was allocated between the two performance obligations based on the relative standalone selling price of each performance obligation. To determine the standalone selling price, the Company used the discounted cash flow method by calculating risk-adjusted net present values of estimated cash flows. The Company determined that the remaining potential milestone payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company<span style="color:#000000;">&#8217;</span>s control. As a result, these payments were fully constrained and were not included in the transaction price as of January 1, 2018, the adoption date of ASC 606. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000570" name="ctmx:AggregateCollaborationTransactionAmount" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929" decimals="-5" scale="6">51.2</ix:nonFraction> million total transaction price, the Company allocated $<ix:nonFraction unitRef="U_iso4217USD" id="F_000571" name="ctmx:AggregateCollaborationTransactionAmount" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929" decimals="-5" scale="6">46.4</ix:nonFraction> million to the EGFR Products performance obligation and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000572" name="ctmx:AggregateCollaborationTransactionAmount" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929" decimals="-5" scale="6">4.8</ix:nonFraction> million to the Amgen Other Product performance obligations. The transaction price of the EGFR Product performance obligation was recognized using a cost-based input measure. In applying the cost-based input method of revenue recognition, the Company uses actual FTE hours incurred relative to estimated total FTE hours expected to be incurred for the combined performance obligation over the research service period. At the end of the second quarter of 2019, the Company determined that it will undertake additional testing and assessment of the molecules being evaluated under the EGFR project.&#160;&#160;As a result, the estimated FTE hours-to-completion and research service period were increased to <ix:nonNumeric id="F_000573" name="ctmx:EstimatedResearchServicePeriod" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200401_20200630" format="ixt-sec:durwordsen">eight years</ix:nonNumeric>.&#160;&#160;In the second quarter of 2020, the Company completed the clinical candidate </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000307_dcnt_b1b4243a-d748-40fa-97ca-fd5a6f3edf34" continuedAt="F_000307_dcnt_9346f865-cf6e-4310-80de-e5899383a179">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">characterization phase and has moved into the IND-enabling phase earlier than planned</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;As a result, the estimated FTE hours-to-completion and research service period were decreased from eight to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000574" name="ctmx:EstimatedResearchServicePeriod" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20190401_20190630" format="ixt-sec:durwordsen">seven years</ix:nonNumeric></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000575" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929" decimals="-5" scale="6">4.8</ix:nonFraction> million transaction price allocated to the Amgen Other Product performance obligation represents an obligation to continuously make the Probody therapeutic technology platform available to Amgen, which is recognized over the common measure of progress for the entire performance obligation over the estimated research service period of <ix:nonNumeric id="F_000576" name="ctmx:EstimatedResearchServicePeriod" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929" format="ixt-sec:durwordsen">six years</ix:nonNumeric>.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000577" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200101_20201231" decimals="-5" scale="6">8.6</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000578" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20190101_20191231" decimals="-5" scale="6">3.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000579" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20180101_20181231" decimals="-5" scale="6">4.9</ix:nonFraction> million for the years ended December 31, 2020, 2019 and 2018, respectively, related to the Amgen Agreement.  As of December 31, 2020 and 2019, deferred revenue related to the EGFR Products performance obligation was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000585" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231" decimals="-5" scale="6">29.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000586" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20191231" decimals="-5" scale="6">37.6</ix:nonFraction> million, respectively. As of December 31, 2020 and 2019, deferred revenue related to the Amgen Other Products performance obligation was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000583" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231" decimals="-5" scale="6">2.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000584" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20191231" decimals="-5" scale="6">3.0</ix:nonFraction> million, respectively. <ix:nonFraction unitRef="U_iso4217USD" id="F_000587" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_000588" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20191231" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></ix:nonFraction> amounts were due from Amgen as of December 31, 2020 and 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Astellas Pharma Inc.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and Astellas Pharma, Inc. (&#8220;Astellas&#8221;) entered into a Collaboration and License Agreement (the &#8220;Astellas Agreement&#8221;) on March 23, 2020, the effective date, to collaborate on preclinical research activities to discover and develop certain antibody compounds for the treatment of cancer using the Company&#8217;s Probody therapeutic technology. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Astellas Agreement, the Company granted Astellas an exclusive, worldwide, rights to develop and commercialize Probody therapeutics for up to <ix:nonFraction unitRef="U_ctmxTarget" id="F_000589" name="ctmx:NumberOfTargets" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction> collaboration targets including <ix:nonFraction unitRef="U_ctmxTarget" id="F_000590" name="ctmx:NumberOfTargetsSelected" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> initial target and <ix:nonFraction unitRef="U_ctmxTarget" id="F_000591" name="ctmx:NumberOfAdditionalCollaborationTarget" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> additional targets (&#8220;Additional Targets&#8221;).&#160;&#160;In addition, Astellas has the right to expand the number of Additional Targets from <ix:nonFraction unitRef="U_ctmxTarget" id="F_000592" name="ctmx:RightToExpandNumberOfAdditionalCollaborationTarget" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> up to <ix:nonFraction unitRef="U_ctmxTarget" id="F_000593" name="ctmx:RightToExpandNumberOfAdditionalCollaborationTarget" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323" decimals="INF" format="ixt-sec:numwordsen">five</ix:nonFraction> (the &#8220;Expansion Option&#8221;) before the third anniversary of the effective date.&#160;&#160;Furthermore, for a specified number of targets, at a pre-specified time prior to the initiation of the first pivotal study of a product against such target, the Company may elect to participate in certain development costs and share in the profits generated in the United States with respect to such product (&#8220;Cost Share Option&#8221;). The Cost Share Option, if exercised, will also provide the option for the Company to co-commercialize such product in the United States.&#160;&#160;The Company does not consider the Cost Share Option as a performance obligation at the inception of the agreement as the participation is at the Company&#8217;s discretion.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Astellas Agreement, the consideration from Astellas is comprised of an upfront fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000594" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323" decimals="-5" scale="6">80.0</ix:nonFraction> million and contingent payments for development, regulatory and sales milestones of up to an aggregate of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000595" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323" decimals="-8" scale="9">1.6</ix:nonFraction> billion.&#160;&#160;If Astellas exercises its Expansion Option for the two Additional Targets, the Company would be eligible to receive additional upfront and milestone payments aggregating to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000596" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapContingentConsiderationByTypeAxis_ctmxAdditionalContingentPaymentsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323" decimals="-8" scale="9">0.9</ix:nonFraction> billion.<span style="font-size:8pt;">&#160;&#160;</span>The Company is also entitled to tiered royalties from high-single digit to mid-teen percentage royalties from potential future sales. Astellas is responsible for all preclinical research costs incurred by either party as set forth in the preclinical research plan and the Company will receive research and development service fees based on a prescribed FTE rate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified the following performance obligations at the inception of the Astellas Agreement: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the exclusive research, development and commercialization license&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research and development services&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the obligation to participate in the joint research committee.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the license, the research services and expertise related to the development of the product candidates should be combined with the research services and participation in the joint research committee as one combined performance obligation. The Company concluded, that at the inception of the agreement, Astellas&#8217; Expansion Option for two Additional Targets were not material rights and therefore not considered performance obligations.&#160;&#160;As such, each option will be accounted for as a separate arrangement upon exercise. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial transaction price of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000597" name="ctmx:AggregateCollaborationTransactionAmount" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323" decimals="-5" scale="6">90.0</ix:nonFraction> million consists of the upfront fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000598" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323" decimals="-5" scale="6">80.0</ix:nonFraction> million and research and development service fees of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000599" name="ctmx:ResearchAndDevelopmentServiceFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323" decimals="-5" scale="6">10.0</ix:nonFraction> million. The Company determined that the potential development and regulatory milestone payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company<span style="color:#000000;">&#8217;</span>s control. Therefore, the potential development and regulatory milestone payments were fully constrained and were not included in the initial transaction price and continued to be fully constrained as of December 31, 2020.&#160;&#160;The Company will re-evaluate the transaction price at each reporting date or as uncertain events are resolved or other changes in circumstances occur.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000307_dcnt_9346f865-cf6e-4310-80de-e5899383a179" continuedAt="F_000307_dcnt_4479a292-eaad-40a1-92a2-3daa98c689fd">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The upfront fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000600" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323" decimals="-5" scale="6">80.0</ix:nonFraction> million for the combined obligation to continuously make the Probody therapeutic technology platform available to Astellas is recognized on a straight-line basis for the entire performance obligation over the estimated research service period of <ix:nonNumeric id="F_000601" name="ctmx:EstimatedResearchServicePeriod" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323" format="ixt-sec:durwordsen">five years</ix:nonNumeric>, which ends in <ix:nonNumeric id="F_000602" name="ctmx:EstimatedResearchServiceTerminationMonthAndYear" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323" format="ixt:datemonthyearen">March 2025</ix:nonNumeric>.&#160;&#160;The research and development service fees, estimated to be $<ix:nonFraction unitRef="U_iso4217USD" id="F_000603" name="ctmx:ResearchAndDevelopmentServiceFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323" decimals="-5" scale="6">10.0</ix:nonFraction> million, will be recognized when services are provided based on the prescribed FTE rate. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000604" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200101_20201231" decimals="-5" scale="6">13.9</ix:nonFraction> million for the year ended December 31, 2020, which included the research and development service fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000605" name="ctmx:ResearchAndDevelopmentServiceFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200101_20201231" decimals="-5" scale="6">1.5</ix:nonFraction> million.&#160;&#160;As of December 31, 2020, deferred revenue relating to the Astellas Agreement was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000606" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231" decimals="-5" scale="6">67.6</ix:nonFraction> million. The amount due from Astellas under the Astellas Agreement was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000607" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231" decimals="-5" scale="6">0.8</ix:nonFraction> million as of December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Bristol Myers Squibb Company </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 23, 2014, the Company and Bristol Myers Squibb Company (<span style="color:#000000;">&#8220;</span>Bristol Myers Squibb<span style="color:#000000;">&#8221;</span>) entered into a Collaboration and License Agreement (the <span style="color:#000000;">&#8220;</span>BMS Agreement<span style="color:#000000;">&#8221;</span>) to discover and develop compounds for use in human therapeutics aimed at multiple immuno-oncology targets using the Company<span style="color:#000000;">&#8217;</span>s Probody therapeutic technology. The effective date of the BMS Agreement was July 7, 2014.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the BMS Agreement, the Company granted Bristol Myers Squibb exclusive worldwide rights to develop and commercialize Probody therapeutics for up to <ix:nonFraction unitRef="U_ctmxTarget" id="F_000608" name="ctmx:NumberOfOncologyTarget" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction> oncology targets. Bristol Myers Squibb had additional rights to substitute up to <ix:nonFraction unitRef="U_ctmxTarget" id="F_000609" name="ctmx:NumberOfCollaborationTarget" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> collaboration targets within three years of the effective date of the BMS Agreement. These rights expired in May 2017. <ix:nonNumeric id="F_000612" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">Each collaboration target had a <span style="-sec-ix-hidden:F_000610">two-year</span> research term and the <ix:nonFraction unitRef="U_ctmxTarget" id="F_000611" name="ctmx:NumberOfAdditionalCollaborationTarget" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> additional targets had to be nominated by Bristol Myers Squibb within <ix:nonNumeric id="F_000613" name="ctmx:PeriodOfNominationOfAdditionalTarget" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707" format="ixt-sec:durwordsen">five years</ix:nonNumeric> of the effective date of the BMS Agreement. The research term for each collaboration target could be extended in <ix:nonNumeric id="F_000614" name="ctmx:ExtensionOfResearchTermForEachCollaborationTarget" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707" format="ixt-sec:durwordsen">one year</ix:nonNumeric> increments up to <ix:nonFraction unitRef="U_ctmxTerm" id="F_000615" name="ctmx:IncrementsOfExtendedCollaborationTargetResearchTimes" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> times.</ix:nonNumeric></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the BMS Agreement, the financial consideration from Bristol Myers Squibb was comprised of an upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000616" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707" decimals="-5" scale="6">50.0</ix:nonFraction> million, and the Company was initially entitled to receive contingent payments of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000618" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_ctmxAchievingAdditionalTargetsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707" decimals="INF" scale="6">25.0</ix:nonFraction> million for additional targets and up to an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000617" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707" decimals="INF" format="ixt:numdotdecimal" scale="6">1,192.0</ix:nonFraction> million for development, regulatory and sales milestones.&#160;&#160;In addition, the Company is entitled to royalty payments in the mid-single digits to low double-digit percentages from potential future sales. The Company also receives research and development service fees based on a prescribed FTE rate that is capped.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified the following performance obligations at the inception of the BMS Agreement: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the exclusive research, development and commercialization license&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research and development services&#59; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the obligation to participate in the joint research committee. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the license, the Company<span style="color:#000000;">&#8217;</span>s research services and expertise related to the development of the product candidates should be combined with the research services and participation in the joint research committee as one combined performance obligation. The Company concluded that, at the inception of the agreement, Bristol Myers Squibb&#8217;s options for the third and fourth targets were not material rights and not performance obligations. As such, each option was accounted for as a separate arrangement upon exercise. Additionally, the Company considered whether the services performed for each target should be considered as separate performance obligations and concluded that all targets should be accounted for as one combined performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received an upfront payment of $50.0 million from Bristol Myers Squibb in July 2014. In January and December 2016, Bristol Myers Squibb selected the third and fourth targets, respectively, and paid the Company $<ix:nonFraction unitRef="U_iso4217USD" id="F_000619" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20160131" decimals="-5" scale="6">10.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000620" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20161231" decimals="-5" scale="6">15.0</ix:nonFraction> million, respectively, pursuant to the terms of the BMS Agreement. In December 2016, Bristol Myers Squibb selected a clinical candidate pursuant to the BMS Agreement, which triggered a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000621" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxPreClinicalCandidateMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20161231" decimals="-5" scale="6">2.0</ix:nonFraction> million pre-clinical milestone payment to the Company. In November 2017, the Company recognized a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000622" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxDrugApplicationForCTLA4Member_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20171130" decimals="-5" scale="6">10.0</ix:nonFraction> million milestone payment from Bristol Myers Squibb upon approval of the investigational new drug application for the CTLA-4-directed Probody therapeutic.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 17, 2017, the Company and Bristol Myers Squibb entered into Amendment Number 1 to Extend Collaboration and License Agreement (<span style="color:#000000;">&#8220;</span>Amendment 1<span style="color:#000000;">&#8221;</span>). Amendment 1 granted Bristol Myers Squibb exclusive worldwide rights to develop and commercialize Probody therapeutics for up to <ix:nonFraction unitRef="U_ctmxTarget" id="F_000623" name="ctmx:NumberOfAdditionalCollaborationTarget" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170317" decimals="INF" format="ixt-sec:numwordsen">eight</ix:nonFraction> additional targets. The effective date of Amendment 1 was April 25, 2017 (<span style="color:#000000;">&#8220;</span>Amendment Effective Date<span style="color:#000000;">&#8221;</span>). Under the terms of Amendment 1, the Company continued to have obligations to Bristol Myers Squibb to discover and conduct preclinical development of Probody therapeutics against any targets they chose to select during the research period under the terms of Amendment 1.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000307_dcnt_4479a292-eaad-40a1-92a2-3daa98c689fd" continuedAt="F_000307_dcnt_b44bd2f0-73ee-4e0a-8490-b1e6b2cdca1e">

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Amendment 1, the financial consideration from Bristol Myers Squibb was comprised of an upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000624" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170425_20170425" decimals="-5" scale="6">200.0</ix:nonFraction> million and the Company was initially eligible to receive contingent payments for development, regulatory and sales milestones of up to an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000626" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170425" decimals="-5" format="ixt:numdotdecimal" scale="6">3,586.0</ix:nonFraction> million for the <ix:nonFraction unitRef="U_ctmxTarget" id="F_000625" name="ctmx:NumberOfResearchTargetsSelected" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170425" decimals="INF" format="ixt-sec:numwordsen">eight</ix:nonFraction> targets. The Company was also entitled to tiered mid-single to low double-digit percentage royalties from potential future sales. Amendment 1 did not change the term of the Bristol Myers Squibb&#8217;s royalty obligation under the BMS Agreement. Bristol Myers Squibb<span style="color:#000000;">&#8217;</span>s royalty obligation continues on a licensed-product by licensed-product basis until the later of (i) the expiration of the last claim of the licensed patents covering the licensed products in the country, (ii) the twelfth anniversary of the first commercial sale of a licensed product in a country, or (iii) the expiration of any applicable regulatory, pediatric, orphan drug or data exclusivity with respect to such product.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial transaction price for the BMS Agreement and Amendment 1, collectively, was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000627" name="ctmx:AggregateCollaborationTransactionAmount" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707" decimals="-5" scale="6">272.8</ix:nonFraction> million consisting of the upfront fees of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000628" name="ctmx:UpfrontFeeReceived" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707" decimals="-5" scale="6">250.0</ix:nonFraction> million, research and development service fees of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000629" name="ctmx:ResearchAndDevelopmentServiceFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707" decimals="-5" scale="6">10.8</ix:nonFraction> million and milestone payments received to date of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000630" name="ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707" decimals="-5" scale="6">12.0</ix:nonFraction> million. The Company determined that the remaining potential milestone payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company<span style="color:#000000;">&#8217;</span>s control. Therefore, these payments were fully constrained and were not included in the transaction price upon the adoption of ASC 606 on January 1, 2018. The BMS Agreement represents an obligation to continuously make the Probody therapeutic technology platform available to Bristol Myers Squibb.  Therefore, the initial transaction price is recognized over the estimated research service period, which ends on <ix:nonNumeric id="F_000631" name="ctmx:EstimatedResearchServiceTerminationDate" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707" format="ixt:datemonthdayyearen">April 25, 2025</ix:nonNumeric>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter of 2019, Bristol Myers Squibb terminated pre-clinical activities on three of the first four collaboration targets selected under the original 2014 BMS Agreement.&#160;&#160;The first and second targets under the BMS Agreement were combined into a single performance obligation. The Company determined that termination of pre-clinical activities on the second target does not impact the Company&#8217;s continuing obligation to Bristol Myers Squibb for the first target, CTLA-4, as it is still being actively developed by Bristol Myers Squibb.&#160;&#160;Therefore, the Company concluded that it will continue to amortize the related deferred revenue over the original performance period. The Company has determined that upon the termination of pre-clinical activities on the third and the fourth collaboration targets selected by Bristol Myers Squibb in January and December of 2016, respectively, under the BMS Agreement, it has no further obligations.&#160;&#160;As a result of termination of three of the four collaboration targets, the Company is no longer eligible to receive up to an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000634" name="ctmx:ContingentMilestonePaymentsNoLongerEligibleToReceive" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxThirdAndFourthTargetsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190331" decimals="-5" scale="6">894.0</ix:nonFraction> million contingent payments for development, regulatory and sales milestones as well as the related royalty payments for such targets.&#160;&#160;As a result, the Company recognized $<ix:nonFraction unitRef="U_iso4217USD" id="F_000632" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxThirdAndFourthTargetsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20190331" decimals="-5" scale="6">18.1</ix:nonFraction> million of revenue for the third and fourth targets in the first quarter of 2019, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000633" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxAcceleratedRecognitionOfDeferredRevenueMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20190331" decimals="-5" scale="6">17.4</ix:nonFraction> million represented the accelerated recognition of all of the related deferred revenue upon the effective date of termination.&#160; The Company continues to be obligated to perform research work under Amendment 1 executed in March 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, Bristol Myers Squibb dosed the first patient in the Part 2 cohort expansion portion of its ongoing BMS-986249 clinical study for the CTLA-4 program,<span style="Background-color:#FFFFFF;"> which triggered a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000635" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200229" decimals="-5" scale="6">10.0</ix:nonFraction> million milestone payment to the Company </span>pursuant to the terms of the BMS Agreement.&#160;&#160;The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000636" name="ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20200331" decimals="-5" scale="6">10.0</ix:nonFraction> million milestone payment was recognized as revenue in the first quarter of 2020.&#160;&#160;The Company reevaluated the remaining potential milestone payments and determined that significant revenue reversal was still probable as the achievement of such milestones was highly dependent on factors outside the Company<span style="color:#000000;">&#8217;</span>s control. As a result, these payments continued to be fully constrained and were not included in the transaction price on December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Company and Bristol Myers Squibb entered into Amendment Number 2 to amend the Collaboration and License Agreement (&#8220;Amendment 2&#8221;), as amended by Amendment 1. Subsequent to Amendment 2, Bristol Myers Squibb has the exclusive worldwide rights to develop and commercialize Probody therapeutics for up to five oncology targets. Under the terms of Amendment 2, the period for target selection has been extended and the Company will continue to collaborate with Bristol Myers Squibb to discover and conduct preclinical development of Probody therapeutics against targets selected by Bristol Myers Squibb. Pursuant to Amendment 2, the Company is eligible to receive contingent payments for development, regulatory and sales milestones of up to an aggregate of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000637" name="ctmx:ContingentMilestonePaymentsReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210228" decimals="-5" format="ixt:numdotdecimal" scale="6">1,779.0</ix:nonFraction> million. It is also entitled to tiered mid-single to low double-digit percentage of royalties from potential future sales.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000638" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231" decimals="-5" scale="6">39.6</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000639" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231" decimals="-5" scale="6">47.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000640" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231" decimals="-5" scale="6">32.8</ix:nonFraction> million for the years ended December 31, 2020, 2019, and 2018, respectively. As of December 31, 2020 and 2019, deferred revenue relating to the BMS Agreement was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000644" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231" decimals="-5" scale="6">128.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000645" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231" decimals="-5" scale="6">158.0</ix:nonFraction> million, respectively. The amounts due from Bristol Myers Squibb under the BMS Agreement were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000646" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231" decimals="0">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000647" name="us-gaap:ContractWithCustomerAssetNet" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231" decimals="0" format="ixt:numdotdecimal">13,000</ix:nonFraction> as of December 31, 2020 and 2019, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ImmunoGen, Inc. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2014, the Company and ImmunoGen, Inc. (<span style="color:#000000;">&#8220;</span>ImmunoGen<span style="color:#000000;">&#8221;</span>) entered into the Research Collaboration Agreement (the <span style="color:#000000;">&#8220;</span>ImmunoGen Research Agreement<span style="color:#000000;">&#8221;</span>). The ImmunoGen Research Agreement provided the Company with the right to use ImmunoGen<span style="color:#000000;">&#8217;</span>s Antibody Drug Conjugate (<span style="color:#000000;">&#8220;</span>ADC<span style="color:#000000;">&#8221;</span>) technology in combination with the Company<span style="color:#000000;">&#8217;</span>s Probody therapeutic technology to create a conditionally activated ADC directed at one specified target under a research license, and to subsequently obtain an exclusive, </p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000307_dcnt_b44bd2f0-73ee-4e0a-8490-b1e6b2cdca1e" continuedAt="F_000307_dcnt_16279390-aa0b-4cbf-8fc7-75586a252dc8">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">worldwide development and commercialization license to use </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</span><span style="color:#000000;">&#8217;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ADC technology to develop and commercialize such </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditionally</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activ</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DCs. The Company made </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000648" name="ctmx:CashPaymentToExecuteAgreement" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140101_20140131" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upfront cash payment in connection with the execution of the agreement. Instead, the Company provided </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with the rights to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CytomX</span><span style="color:#000000;">&#8217;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutic technology to create </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditionally</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activ</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DCs directed at </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_ctmxTarget" id="F_000649" name="ctmx:NumberOfResearchTargetsSelected" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140131" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction></span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> targets under the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Research Agreement and to subsequently obtain exclusive, worldwide development and commercialization licenses to develop and commercialize such </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditionally</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activ</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DCs. In February 2016, the Company exercised its option to obtain a development and commercialization license for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">praluzatamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ravtansine</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (CX-2009)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> pursuant to the terms of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Research Agreement (the </span><span style="color:#000000;">&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CX-2009 License</span><span style="color:#000000;">&#8221;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).</span></p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, ImmunoGen exercised its first option to obtain a development and commercialization license for one of the two targets. Substitution rights for this first target selection program terminated in February 2017 and ImmunoGen discontinued the program in July 2017. The Company recognized the remaining deferred revenue related to the discontinued program upon the termination of the program. ImmunoGen exercised its second option to obtain a development and commercialization license pursuant to the ImmunoGen Research Agreement (the <span style="color:#000000;">&#8220;</span>ImmunoGen 2017 License<span style="color:#000000;">&#8221;</span>) for a target in December 2017.&#160;&#160;In December 2019, the parties entered into a license agreement (the &#8220;ImmunoGen 2019 License&#8221;) pursuant to which the ImmunoGen 2017 License was terminated and ImmunoGen granted a license for all of ImmunoGen&#8217;s rights under the ImmunoGen 2017 License to the Company. See Note 10. License Agreement, for more information.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the ImmunoGen Research Agreement, both the Company and ImmunoGen performed research activities on behalf of the other party for no monetary consideration through January 2018. In December 2017, the Company entered into the ImmunoGen 2017 License arrangement and extended the Company<span style="color:#000000;">&#8217;</span>s obligation to provide research services under the ImmunoGen Research Agreement to June 30, 2018. The estimated fair value of the consideration of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000650" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140131" decimals="-5" scale="6">13.2</ix:nonFraction> million for the performance obligation to ImmunoGen was recognized as revenue over the research period that ended on June 30, 2018. No further research services were provided by the Company after June 20, 2018 under the ImmunoGen 2017 License arrangement. The Company recognized revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000651" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231" decimals="-5" scale="6">1.5</ix:nonFraction> million for the year ended December 31, 2018. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company dosed the first patient in the praluzatamab ravtansine Phase 2 clinical trial and triggered a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000652" name="ctmx:MilestonePaymentPayable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200229" decimals="-5" scale="6">3.0</ix:nonFraction> million milestone payment to ImmunoGen pursuant to the CX-2009 License which continued to remain in effect following the termination of the ImmunoGen 2017 License in December 2019.&#160;&#160;The Company recorded a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000653" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20200331" decimals="-5" scale="6">3.0</ix:nonFraction> million charge to research and development expense in the first quarter of 2020, in connection with this milestone payment to ImmunoGen.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-weight:bold;font-style:italic;">Pfizer Inc.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2013, the Company and Pfizer Inc. (<span style="color:#000000;">&#8220;</span>Pfizer<span style="color:#000000;">&#8221;</span>) entered into a Research Collaboration, Option and License Agreement (the <span style="color:#000000;">&#8220;</span>Pfizer Agreement<span style="color:#000000;">&#8221;</span>) to collaborate on the discovery and preclinical research activities related to Probody therapeutics, and conditionally activated ADCs for research project targets nominated by Pfizer. Pfizer nominated <ix:nonFraction unitRef="U_ctmxTarget" id="F_000654" name="ctmx:NumberOfNominatedResearchTargets" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130501_20130531" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> research targets in 2013 and, pursuant to the Pfizer Agreement, had the option of nominating <ix:nonFraction unitRef="U_ctmxTarget" id="F_000655" name="ctmx:NumberOfAdditionalResearchTargetsWithNominationOption" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130501_20130531" decimals="INF" format="ixt-sec:numwordsen">two</ix:nonFraction> additional research targets. In December 2014, Pfizer selected an additional research target and paid the Company $<ix:nonFraction unitRef="U_iso4217USD" id="F_000656" name="ctmx:ContractWithCustomerLiabilityAdditions" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141201_20141231" decimals="-5" scale="6">1.5</ix:nonFraction> million. The option to select a fourth target lapsed in May 2016. Pfizer discontinued the epidermal growth factor receptor (<span style="color:#000000;">&#8220;</span>EGFR<span style="color:#000000;">&#8221;</span>) program and decided to terminate the remaining two targets in February and March 2018. In March 2018, Pfizer terminated the Pfizer Agreement. As such, the Company had no further performance obligations under this agreement after the first quarter of 2018.&#160;&#160;The Company recognized revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000657" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231" decimals="-5" scale="6">1.4</ix:nonFraction> million for the year ended December 31, 2018.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Liabilities </p><ix:nonNumeric id="F_000343" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents changes in the Company<span style="color:#000000;">&#8217;</span>s total contract liabilities for the year ended December 31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deductions</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000659" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">230,239</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000660" name="ctmx:ContractWithCustomerLiabilityAdditions" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">120,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000661" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">89,109</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000662" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">261,130</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000663" name="ctmx:ContractWithCustomerLiabilityAdditions" contextRef="C_0001501989_20200101_20201231" decimals="-5" scale="6">120.0</ix:nonFraction> million of additions to deferred revenue during the year ended December 31,2020.&#160;&#160;Of such amount, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000664" name="ctmx:ContractWithCustomerLiabilityAdditions" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20200101_20201231" decimals="-5" scale="6">40.0</ix:nonFraction> million was related to the milestone payment triggered by AbbVie&#8217;s CD71 dose escalation success criteria which was achieved in March 2020, and an $<ix:nonFraction unitRef="U_iso4217USD" id="F_000665" name="ctmx:ContractWithCustomerLiabilityAdditions" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_20200101_20201231" decimals="-5" scale="6">80.0</ix:nonFraction> million addition was related to the upfront fee payable under the Astellas Agreement entered into in March 2020.  Deductions of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000666" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="C_0001501989_20200101_20201231" decimals="-5" scale="6">89.1</ix:nonFraction> million related to revenue recognized included in the contract liability balance at the beginning of the period plus the revenue recognized related to the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000667" name="ctmx:ContractWithCustomerLiabilityAdditions" contextRef="C_0001501989_20200101_20201231" decimals="-5" scale="6">120.0</ix:nonFraction> million additions during the year ended December 31, 2020.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000307_dcnt_16279390-aa0b-4cbf-8fc7-75586a252dc8">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects that the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000668" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_20201231" decimals="-5" scale="6">261.1</ix:nonFraction> million of deferred revenue related to the following contracts as of December 31, 2020 will be recognized as revenue as set forth below. However, the timing of revenue recognition could differ from the estimates depending on facts and circumstances impacting the various contracts, including progress of research and development, resources assigned to the contracts by the Company or its collaboration partners or other factors outside of the Company<span style="color:#000000;">&#8217;</span>s control.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000669" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20201231" decimals="-5" scale="6">25.2</ix:nonFraction> million of deferred revenue related to the CD71 Agreement as of December 31, 2020 is expected to be recognized based on actual FTE effort and program progress until approximately <ix:nonNumeric id="F_000676" name="ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200101_20201231" format="ixt:datemonthyearen">September 2022</ix:nonNumeric>. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000670" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxFirstTargetUnderDiscoveryAgreementMember_20201231" decimals="-5" scale="6">1.0</ix:nonFraction> million of deferred revenue related to the first target under the Discovery Agreement as of December 31, 2020 is expected to be recognized ratably until approximately <ix:nonNumeric id="F_000677" name="ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxFirstTargetUnderDiscoveryAgreementMember_20200101_20201231" format="ixt:datemonthyearen">April 2022</ix:nonNumeric>.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000671" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSecondTargetUnderDiscoveryAgreementMember_20201231" decimals="-5" scale="6">7.0</ix:nonFraction> million of deferred revenue related to the second target under the Discovery Agreement as of December 31, 2020 is expected to be recognized ratably until approximately <ix:nonNumeric id="F_000678" name="ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSecondTargetUnderDiscoveryAgreementMember_20200101_20201231" format="ixt:datemonthyearen">June 2024</ix:nonNumeric>.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000672" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_20201231" decimals="-5" scale="6">29.8</ix:nonFraction> million of deferred revenue related to the Amgen EGFR Products as of December 31, 2020 is expected to be recognized based on actual FTE effort and program progress until approximately <ix:nonNumeric id="F_000679" name="ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_20200101_20201231" format="ixt:datemonthyearen">September 2024</ix:nonNumeric>.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000673" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_20201231" decimals="-5" scale="6">2.2</ix:nonFraction> million of deferred revenue related to the Amgen Other Products as of December 31, 2020 is expected to be recognized ratably until approximately <ix:nonNumeric id="F_000680" name="ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_20200101_20201231" format="ixt:datemonthyearen">September 2023</ix:nonNumeric>. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000674" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_20201231" decimals="-5" scale="6">67.6</ix:nonFraction> million of deferred revenue related to the Astellas Agreement as of December 31, 2020 is expected to be recognized ratably until approximately <ix:nonNumeric id="F_000681" name="ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_20200101_20201231" format="ixt:datemonthyearen">March 2025</ix:nonNumeric>.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">The $<ix:nonFraction unitRef="U_iso4217USD" id="F_000675" name="us-gaap:ContractWithCustomerLiability" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20201231" decimals="-5" scale="6">128.3</ix:nonFraction> million of deferred revenue related to the BMS Agreement as of December 31, 2020 is expected to be recognized ratably until approximately <ix:nonNumeric id="F_000682" name="ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20200101_20201231" format="ixt:datemonthyearen">April 2025</ix:nonNumeric>.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000308" name="ctmx:LicenseAgreementDisclosureTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000308_dcnt_ef1a4746-390e-4662-bff2-b7dff81cf969">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. License Agreement </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">UCSB</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has an exclusive, worldwide license agreement with UCSB (the <span style="color:#000000;">&#8220;</span>UCSB Agreement<span style="color:#000000;">&#8221;</span>), relating to the use of certain patents and technology relating to its core technology, including its therapeutic antibodies, and to certain patent rights the Company co-owns with UCSB covering Probody antibodies and other pro-proteins. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the UCSB Agreement, the Company is obligated to (i) make royalty payments to UCSB on net sales of its products covered under the agreement, subject to annual minimum amounts, (ii) make milestone payments to UCSB upon the occurrence of certain events, (iii) make a milestone payment to UCSB upon occurrence of an IPO or change of control, and (iv) reimburse UCSB for prosecution and maintenance of the licensed patents. If the Company sublicenses its rights under the UCSB Agreement, it is obligated to pay UCSB a percentage of the total sublicense revenue received, which total amount would be first reduced by the aggregate amount of certain research and development related expenses incurred by the Company and other permitted deductions. As part of the UCSB Agreement, the Company has annual minimum royalty obligations of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000683" name="ctmx:RoyaltyObligationsFutureMinimumPaymentsDue" contextRef="C_0001501989_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million under the terms of certain exclusive licensed patent rights.&#160;&#160;The royalty obligations are cancellable any time by giving notice to the licensor, with the termination being effective <ix:nonNumeric id="F_000684" name="ctmx:LicenseTerminationPeriod" contextRef="C_0001501989_20200101_20201231" format="ixt-sec:durday">60</ix:nonNumeric> days after giving notice.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2013, the Company amended the UCSB Agreement to reduce certain amounts due to UCSB upon receipt by the Company of upfront payments, milestone payments and royalties from sublicensees. In exchange for this amendment, the Company issued to UCSB <ix:nonFraction unitRef="U_xbrlishares" id="F_000685" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20131231" decimals="INF" format="ixt:numdotdecimal">157,332</ix:nonFraction> shares of common stock. The UCSB Agreement, as amended, will remain in effect until the expiration or abandonment of the last to expire of the licensed patents.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, the Company entered into Amendment No.3 to the UCSB Agreement to adjust and clarify certain sublicense terms (&#8220;Amendment No.3&#8221;).&#160;&#160;In connection with the amendment, the Company issued to UCSB <ix:nonFraction unitRef="U_xbrlishares" id="F_000686" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190430" decimals="INF" format="ixt:numdotdecimal">150,000</ix:nonFraction> shares of CytomX common stock with a fair value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000687" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190430" decimals="INF">10.68</ix:nonFraction> per share. Under the terms of Amendment No.3, the Company and UCSB agreed to modify the determination of sublicense revenues payable by the Company to UCSB on certain existing collaboration agreements and on collaboration agreements executed subsequent to Amendment No.3.&#160;&#160;In exchange, the Company agreed to make an upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000688" name="ctmx:PaymentOfUpfrontFees" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430" decimals="-5" scale="6">1.0</ix:nonFraction> million as well as additional annual license maintenance fees of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000689" name="ctmx:AnnualLicenseMaintenanceFees" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430" decimals="-5" scale="6">0.8</ix:nonFraction> million through <ix:nonNumeric id="F_000690" name="ctmx:LicensePaymentTerm" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430">2031</ix:nonNumeric>.&#160;&#160;In the event that the Company terminates the agreement due to material concern of the safety or efficacy of the related technology, <ix:nonFraction unitRef="U_xbrlipure" id="F_000691" name="ctmx:PercentageOfRemainingMaintenanceFeesOutstanding" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190430" decimals="2" scale="-2">50</ix:nonFraction>% of all remaining maintenance fees will become due immediately.&#160;&#160;Otherwise, all remaining maintenance fees will become due immediately upon early termination of the agreement unless there is a material breach by UCSB.&#160;&#160;Pursuant to Amendment No.3, the Company recorded in research and development expense a charge of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000692" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_ctmxSublicenseAndMaintenanceFeesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430" decimals="-5" scale="6">3.4</ix:nonFraction> million relating to sublicense and maintenance fees representing the <ix:nonFraction unitRef="U_xbrlishares" id="F_000693" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190430" decimals="INF" format="ixt:numdotdecimal">150,000</ix:nonFraction> shares issued with a fair value of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000694" name="ctmx:FairValueOfCommonStockIssued" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430" decimals="-5" scale="6">1.6</ix:nonFraction> million, the upfront payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000695" name="ctmx:PaymentOfUpfrontFees" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190630" decimals="-5" scale="6">1.0</ix:nonFraction> million and the additional annual maintenance fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000696" name="ctmx:AnnualLicenseMaintenanceFees" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190630" decimals="-5" scale="6">0.8</ix:nonFraction> million during the second quarter of 2019.&#160;&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000308_dcnt_ef1a4746-390e-4662-bff2-b7dff81cf969">

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company incurred an additional $<ix:nonFraction unitRef="U_iso4217USD" id="F_000697" name="ctmx:AdditionalSublicenseFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630" decimals="-5" scale="6">0.8</ix:nonFraction> million of sublicense fees related to the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000698" name="ctmx:MilestonePaymentReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630" decimals="-5" scale="6">10.0</ix:nonFraction> million milestone payment for the second target selected by AbbVie under the Discovery Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000699" name="ctmx:SublicenseFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200201_20200229" decimals="-5" scale="6">0.8</ix:nonFraction> million of sublicense fees triggered by the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000700" name="ctmx:MilestonePaymentReceivable" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200201_20200229" decimals="-5" scale="6">10.0</ix:nonFraction> million milestone payment from Bristol Myers Squibb&#8217;s dosing of the first patient in the Part 2 cohort expansion portion of its ongoing BMS-986249 clinical study for the CTLA-4 program.&#160;&#160;In March 2020, the Company incurred additional sublicense fees of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000701" name="ctmx:AdditionalSublicenseFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200301_20200331" decimals="-5" scale="6">6.0</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000702" name="ctmx:AdditionalSublicenseFees" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331" decimals="-5" scale="6">1.4</ix:nonFraction> million related to the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000703" name="us-gaap:ProceedsFromCollaborators" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200301_20200331" decimals="-5" scale="6">80.0</ix:nonFraction> million upfront fee received pursuant to the Astellas Agreement entered into in March 2020, and the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000704" name="ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331" decimals="-5" scale="6">40.0</ix:nonFraction> million milestone payment from AbbVie for satisfying the CD71 dose escalation success criteria under the CD71 Agreement, respectively.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020, 2019 and 2018, the Company incurred sublicense expenses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000705" name="ctmx:SublicenseFees" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20200101_20201231" decimals="-5" scale="6">9.1</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000706" name="ctmx:SublicenseFees" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190101_20191231" decimals="-5" scale="6">4.3</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000707" name="ctmx:SublicenseFees" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20180101_20181231" decimals="-5" scale="6">0.6</ix:nonFraction> million, respectively, under the provisions of the UCSB Agreement.&#160;&#160;As of December 31, 2020 and 2019, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000708" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20201231" decimals="-6" scale="6">0</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000709" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20191231" decimals="-5" scale="6">0.2</ix:nonFraction> million sublicense fee payable to UCSB, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ImmunoGen </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company entered into a License Agreement (the &#8220;ImmunoGen 2019 License&#8221;) with ImmunoGen, Inc. to obtain an exclusive license with respect to <span style="color:#000000;">epithelial cell adhesion molecule (&#8220;EPCAM&#8221;).</span>  Under the ImmunoGen 2019 License, ImmunoGen agreed to transfer its know-how, patents, intellectual property rights, and technology transfer materials and information related to its EpCAM program. The license gives the Company the sole ability to develop, manufacture, use and commercialize any licensed product that incorporates, is comprised of, or otherwise derived from a Probody that targets EpCAM in any human therapeutic field on a worldwide basis. In exchange, the Company agreed to make non-refundable and non-creditable payments including an upfront license payment of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000710" name="ctmx:UpfrontLicensePayment" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231" decimals="-5" scale="6">7.5</ix:nonFraction> million and certain clinical development, approval and commercialization milestone payments, if achieved and royalties on product sales.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The upfront license fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000711" name="ctmx:UpfrontLicensePayment" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231" decimals="-5" scale="6">7.5</ix:nonFraction> million was recorded as research and development expense in December 2019 and included in accrued liabilities as of December 31, 2019.&#160;&#160; The upfront license fee was paid in January 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000309" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. Commitments and Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Legal Proceedings </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On <ix:nonNumeric id="F_000712" name="us-gaap:LossContingencyLawsuitFilingDate" contextRef="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304_20200304">March 4, 2020</ix:nonNumeric>, <ix:nonNumeric id="F_000713" name="us-gaap:LossContingencyNameOfPlaintiff" contextRef="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200101_20201231">Vytacera Bio, LLC</ix:nonNumeric> filed a patent infringement lawsuit against the Company in the U.S. District Court for the District of Delaware.&#160; The lawsuit alleges that the Company&#8217;s use, offers to sell, and/or sales of the Probody&#174; technology platform for basic research applications constitutes infringement.&#160; The complaint seeks unspecified monetary damages.&#160; The Company filed an Answer, Affirmative Defenses, and Counterclaims on <ix:nonNumeric id="F_000714" name="ctmx:LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate" contextRef="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304_20200304" format="ixt:datemonthdayyearen">May 26, 2020</ix:nonNumeric>.&#160; Vytacera Bio, LLC filed its Answer to CytomX Therapeutics Inc.&#8217;s Counterclaims on <ix:nonNumeric id="F_000715" name="ctmx:LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate" contextRef="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304_20200304" format="ixt:datemonthdayyearen">June 5, 2020</ix:nonNumeric>.&#160; The parties have agreed to a case schedule, which is pending Court approval.&#160; Discovery is in the initial phases. The Company believes that the lawsuit is without merit and intends to vigorously defend itself and has <ix:nonFraction unitRef="U_iso4217USD" id="F_000716" name="us-gaap:LossContingencyEstimateOfPossibleLoss" contextRef="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction>t recorded any amount for claims associated with this lawsuit as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 21, 2020, a putative securities class action lawsuit was commenced in the U.S. District Court for the Northern District of California naming as defendants the Company and <ix:nonFraction unitRef="U_ctmxDefendant" id="F_000717" name="ctmx:NumberOfCurrentAndFormerOfficersNamedAsDefendants" contextRef="C_0001501989_srtLitigationCaseAxis_ctmxSecuritiesClassActionLawsuitMember_20200521_20200521" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction> current and former officers. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to the product candidates praluzatamab ravtansine (CX-2009) and pacmilimab (CX-072). The plaintiff sought to represent all persons who purchased or otherwise acquired CytomX securities between May 17, 2018, and May 13, 2020. On January 14, 2021, the class action was dismissed without prejudice.<span style="color:#000000;">&#160;</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Indemnifications</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; insurance.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000310" name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000310_dcnt_b35d637c-3393-4c45-8ead-dac38c5d5abb">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. Leases </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Lease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 10, 2015, the Company entered into a lease (the &#8220;2016 Lease&#8221;) with HCP Oyster Point III LLC (the &#8220;Landlord&#8221;) to lease approximately <ix:nonFraction unitRef="U_utrsqft" id="F_000718" name="us-gaap:AreaOfLand" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151210" decimals="INF" format="ixt:numdotdecimal">76,000</ix:nonFraction> rentable square feet of office and laboratory space located in South San Francisco, California for the Company&#8217;s new corporate headquarters.&#160;&#160;</p><ix:nonNumeric id="F_000719" name="us-gaap:LesseeOperatingLeaseDescription" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20200101_20201231"><p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the Lease commenced on October 1, 2016. The 2016 Lease has an initial term of <ix:nonNumeric id="F_000720" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151210" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the commencement date, and the Company has an option to extend the initial term for an additional <ix:nonNumeric id="F_000721" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151210" format="ixt-sec:durwordsen">five years</ix:nonNumeric> at the then fair rental value as determined pursuant to the 2016 Lease. </p></ix:nonNumeric>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Lease provided for annual base rent of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000722" name="ctmx:OperatingLeasesRentExpenseAnnualBaseRent" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_us-gaapLeaseContractualTermAxis_ctmxFirstYearOfLeaseTermMember_20151209_20151210" decimals="-5" scale="6">3.1</ix:nonFraction> million in the first year of the lease term. The annual base rent for the second twelve months was approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000723" name="ctmx:OperatingLeasesRentExpenseAnnualBaseRent" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_us-gaapLeaseContractualTermAxis_ctmxSecondTwelveMonthsOfLeaseTermMember_20151209_20151210" decimals="-5" scale="6">4.3</ix:nonFraction> million, which will increase on an annual basis beginning from the 25<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> month to approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000724" name="ctmx:OperatingLeasesRentExpenseAnnualBaseRent" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_us-gaapLeaseContractualTermAxis_ctmxTenthYearOfLeaseTermMember_20151209_20151210" decimals="-5" scale="6">5.5</ix:nonFraction> million for the tenth year of the lease. The Company utilized the full amount of the one-time improvement allowance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000725" name="ctmx:MaximumImprovementAllowance" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151209_20151210" decimals="INF" scale="6">12.6</ix:nonFraction> million, of which $<ix:nonFraction unitRef="U_iso4217USD" id="F_000726" name="ctmx:ImprovementAllowanceFromRecoverableRent" contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151209_20151210" decimals="-5" scale="6">2.3</ix:nonFraction> million is recoverable by the landlord through increased rent which continues through the expiration of the initial lease term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company obtained a standby letter of credit (the &#8220;Letter of Credit&#8221;) in an amount of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000727" name="us-gaap:LettersOfCreditOutstandingAmount" contextRef="C_0001501989_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20201231" decimals="-5" scale="6">0.9</ix:nonFraction> million, which may be drawn by the Landlord to be applied for certain purposes upon the Company&#8217;s breach of any provisions under the 2016 Lease. The Company has recorded the $<ix:nonFraction unitRef="U_iso4217USD" id="F_000728" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001501989_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20201231" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000729" name="us-gaap:RestrictedCashNoncurrent" contextRef="C_0001501989_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20191231" decimals="-5" scale="6">0.9</ix:nonFraction></ix:nonFraction> million Letter of Credit as non-current restricted cash on its balance sheet as of December 31, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense is recognized on a straight-line basis over the term of the lease and accordingly the Company records the difference between cash rent payments and the recognition of rent expense against the operating lease ROU asset.&#160;&#160;Rent expense during the years ended December 31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000730" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001501989_20200101_20201231" decimals="-5" scale="6">5.1</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000731" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001501989_20190101_20191231" decimals="-5" scale="6">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000732" name="us-gaap:OperatingLeaseExpense" contextRef="C_0001501989_20180101_20181231" decimals="-5" scale="6">4.2</ix:nonFraction> million, respectively.</p><ix:nonNumeric id="F_000344" name="ctmx:SupplementalInformationRelatedToLeasesTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental information related to leases are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:95%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000733" name="us-gaap:OperatingLeasePayments" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,990</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000734" name="us-gaap:OperatingLeasePayments" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,855</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental balance sheet information related to leases:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000735" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">22,495</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000736" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">25,382</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000737" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,195</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000738" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">2,810</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current operating lease liabilities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000739" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">21,675</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000740" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,871</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000742" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,870</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000743" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">27,681</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000744">5.75</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000745">6.85</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000746" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001501989_20201231" decimals="4" scale="-2">8.25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000747" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="C_0001501989_20191231" decimals="4" scale="-2">8.25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric><ix:nonNumeric id="F_000345" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000345_dcnt_0f0969a1-149b-468f-8bbb-52d4cad50116">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000310_dcnt_b35d637c-3393-4c45-8ead-dac38c5d5abb"><ix:continuation id="F_000345_dcnt_0f0969a1-149b-468f-8bbb-52d4cad50116">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:95%;">
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Maturity of operating lease liabilities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000748" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,129</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000749" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,273</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000750" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,420</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000751" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,572</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025 and beyond</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000752" name="ctmx:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,116</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000753" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">31,510</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000754" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,640</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000755" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">24,870</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p></ix:continuation></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000311" name="ctmx:CommonStockTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13. Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2015, the Company&#8217;s board of directors and stockholders approved the amendment and restatement of the Company&#8217;s certificate of incorporation. The Amended and Restated Certificate of Incorporation was effective as of October 14, 2015, which provided for <ix:nonFraction unitRef="U_xbrlishares" id="F_000756" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001501989_20151014" decimals="INF" format="ixt:numdotdecimal">75,000,000</ix:nonFraction> authorized shares of common stock with par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000757" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001501989_20151014" decimals="INF">0.00001</ix:nonFraction> per share and <ix:nonFraction unitRef="U_xbrlishares" id="F_000758" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001501989_20151014" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction> shares of preferred stock with a par value of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000759" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001501989_20151014" decimals="INF">0.00001</ix:nonFraction> per share.&#160;&#160;In June 2020, the board of directors and stockholders of the Company approved an increase in the authorized shares of common stock from 75,000,000 to <ix:nonFraction unitRef="U_xbrlishares" id="F_000760" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001501989_20200630" decimals="INF" format="ixt:numdotdecimal">150,000,000</ix:nonFraction>.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stockholders are entitled to dividends if and when declared by the board of directors subject to the prior rights of the preferred stockholders. As of December 31, 2020 and 2019, <ix:nonFraction unitRef="U_iso4217USD" id="F_000761" name="us-gaap:DividendsCommonStock" contextRef="C_0001501989_20200101_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_iso4217USD" id="F_000762" name="us-gaap:DividendsCommonStock" contextRef="C_0001501989_20190101_20191231" decimals="INF" format="ixt-sec:numwordsen" scale="3">no</ix:nonFraction></ix:nonFraction> dividends on common stock had been declared by the Board of Directors.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2018, the Company completed an underwritten public offering of <ix:nonFraction unitRef="U_xbrlishares" id="F_000763" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20180730_20180731" decimals="INF" format="ixt:numdotdecimal">5,867,347</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000764" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20180731" decimals="2">24.50</ix:nonFraction> per share, which included <ix:nonFraction unitRef="U_xbrlishares" id="F_000765" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20180730_20180731" decimals="INF" format="ixt:numdotdecimal">765,306</ix:nonFraction> shares issued pursuant to the underwriters<span style="color:#000000;">&#8217;</span> exercise of their option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000766" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180730_20180731" decimals="-5" scale="6">134.6</ix:nonFraction> million after deducting underwriting discounts and commissions and offering expenses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000767" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180730_20180731" decimals="-5" scale="6">9.2</ix:nonFraction> million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company entered into an Open Market Sale Agreement (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), to sell shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000768" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20200229" decimals="INF">0.00001</ix:nonFraction> per share, with aggregate gross sales proceeds of up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000769" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_srtRangeAxis_srtMaximumMember_20200201_20200229" decimals="INF" format="ixt:numdotdecimal">75,000,000</ix:nonFraction>, from time to time upon the Company&#8217;s request, through an at the market offering under which Jefferies will act as sales agent.&#160;&#160;Pursuant to the Sales Agreement, Jefferies as the sales agent will receive a commission of <ix:nonFraction unitRef="U_xbrlipure" id="F_000770" name="ctmx:PercentageOfSalesCommission" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20200229" decimals="3" scale="-2">3.0</ix:nonFraction>% of the gross sales price for shares of common stock sold under the Sales Agreement.&#160;&#160;During December 2020, the Company sold <ix:nonFraction unitRef="U_xbrlishares" id="F_000771" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20201201_20201231" decimals="INF" format="ixt:numdotdecimal">1,535,217</ix:nonFraction> shares at an average price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000772" name="ctmx:SharesIssuedAveragePricePerShare" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20201201_20201231" decimals="2">7.62</ix:nonFraction> per shares and received net proceeds of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000773" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20201201_20201231" decimals="-5" scale="6">11.3</ix:nonFraction> million after deducting the <ix:nonFraction unitRef="U_xbrlipure" id="F_000774" name="ctmx:PercentageOfSalesCommissionAndIssuanceCost" contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20201231" decimals="3" scale="-2">3.0</ix:nonFraction>% sales commission and related issuance cost.&#160;&#160;</p><ix:nonNumeric id="F_000346" name="us-gaap:ScheduleOfStockByClassTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had reserved shares of common stock for issuance, as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000775" name="ctmx:StockOptionsIssuedAndOutstanding" contextRef="C_0001501989_20201231" decimals="INF" format="ixt:numdotdecimal">10,929,530</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000776" name="ctmx:StockOptionsIssuedAndOutstanding" contextRef="C_0001501989_20191231" decimals="INF" format="ixt:numdotdecimal">9,936,168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future stock option grants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000777" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001501989_20201231" decimals="INF" format="ixt:numdotdecimal">2,903,398</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000778" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001501989_20191231" decimals="INF" format="ixt:numdotdecimal">3,145,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future employee stock purchase plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000779" name="ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan" contextRef="C_0001501989_20201231" decimals="INF" format="ixt:numdotdecimal">1,935,683</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000780" name="ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan" contextRef="C_0001501989_20191231" decimals="INF" format="ixt:numdotdecimal">1,609,137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000781" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001501989_20201231" decimals="INF" format="ixt:numdotdecimal">15,768,611</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000782" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001501989_20191231" decimals="INF" format="ixt:numdotdecimal">14,690,571</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000312" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000312_dcnt_e4517dd5-38ef-4c64-93fe-7f7751c22880">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14. Stock-based Compensation </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The 2010 Plan and 2011 Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2010, the Company adopted its 2010 Stock Incentive Plan (the &#8220;2010 Plan&#8221;) which provided for the granting of stock options to employees, directors and consultants of the Company. Options granted under the 2010 Plan were either incentive stock options (&#8220;ISOs&#8221;) or nonqualified stock options (&#8220;NSOs&#8221;).&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2012, the Company adopted its 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;). The 2011 Plan is divided into two separate equity programs, an option and stock appreciation rights grant program and a stock award program. In conjunction with adopting the 2011 Plan, the Company discontinued the 2010 Plan and released the shares reserved and still available under that plan.&#160;&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000312_dcnt_e4517dd5-38ef-4c64-93fe-7f7751c22880" continuedAt="F_000312_dcnt_ae715bc5-a7eb-4acd-9450-8a5361939237">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the consummation of the IPO in October 2015, the board of directors adopted the Company&#8217;s 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221; and collectively with the 2010 Plan and 2011 Plan, the &#8220;Plans&#8221;). In conjunction with adopting the 2015 Plan, the Company discontinued the 2011 Plan with respect to new equity awards.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The 2015 Plan</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options under the 2015 Plan may be granted for periods of up to <ix:nonNumeric id="F_000783" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric>. All options issued to date have had a <ix:nonNumeric id="F_000784" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001501989_20200101_20201231" format="ixt-sec:duryear">10</ix:nonNumeric>-year life.&#160;&#160;Under the terms of the 2015 Plan, options may be granted at an exercise price not less than the estimated fair value of the Company&#8217;s common stock on the date of grant, as determined by the Company&#8217;s board of directors. For employees holding more than <ix:nonFraction unitRef="U_xbrlipure" id="F_000785" name="ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage" contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231" decimals="INF" scale="-2">10</ix:nonFraction>% of the voting rights of all classes of stock, the exercise price of ISOs and NSOs may not be less than <ix:nonFraction unitRef="U_xbrlipure" id="F_000786" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231" decimals="INF" scale="-2">110</ix:nonFraction>% of the estimated fair value of the shares on the date of grant, as determined by the board of directors. To date, options granted under the 2015 Plan generally vest over <ix:nonNumeric id="F_000787" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231" format="ixt-sec:durwordsen">four years</ix:nonNumeric> and vest at a rate of <ix:nonFraction unitRef="U_xbrlipure" id="F_000788" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231" decimals="INF" scale="-2">25</ix:nonFraction>% upon the first anniversary of the issuance date and <span style="-sec-ix-hidden:F_000789_2">1/48</span>th per month thereafter.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial number of shares of common stock available for future issuance under the 2015 Plan was <ix:nonFraction unitRef="U_xbrlishares" id="F_000790" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20151231" decimals="INF" format="ixt:numdotdecimal">2,444,735</ix:nonFraction>. Beginning on January 1, 2016 and continuing until the expiration of the 2015 Plan, the total number of shares of common stock available for issuance under the 2015 Plan will automatically increase annually on January 1 by <ix:nonFraction unitRef="U_xbrlipure" id="F_000791" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20160101_20160101" decimals="INF" scale="-2">4</ix:nonFraction>% of the total number of issued and outstanding shares of common stock as of January 1 of the same year.  As of December 31, 2020 and 2019, <ix:nonFraction unitRef="U_xbrlishares" id="F_000792" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">2,698,798</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000793" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20191231" decimals="INF" format="ixt:numdotdecimal">1,808,066</ix:nonFraction> shares of common stock were available for future issuance under the 2015 Plan.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The 2019 Plan</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, the Board of Directors adopted the 2019 Employment Inducement Incentive Plan (the &#8220;2019 Plan&#8221;) which provides for the grant of stock options and other equity awards to any employee who has not previously been an employee or director of the Company or who is commencing employment with the Company following a bona fide period of nonemployment by the Company. Awards granted under the 2019 Plan are intended to constitute &#8220;employment inducement awards&#8221; under Nasdaq Listing Rule 5635(c)(4). Options granted under the 2019 Plan are nonqualified stock options (&#8220;NSOs&#8221;) which may be exercisable for periods of up to <ix:nonNumeric id="F_000794" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20200101_20201231" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> and the options shall be granted at an exercise price of not less than <ix:nonFraction unitRef="U_xbrlipure" id="F_000795" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20200101_20201231" decimals="INF" scale="-2">100</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the date of grant.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial number of shares of common stock available for future issuance under the 2019 Plan was <ix:nonFraction unitRef="U_xbrlishares" id="F_000796" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20190930" decimals="INF" format="ixt:numdotdecimal">1,815,000</ix:nonFraction>.&#160;&#160;As of December 31, 2020 and 2019, <ix:nonFraction unitRef="U_xbrlishares" id="F_000797" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">204,600</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000798" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20191231" decimals="INF" format="ixt:numdotdecimal">1,337,200</ix:nonFraction> shares, respectively, of common stock were available for future issuance under the 2019 Plan.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000347" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity under the Company&#8217;s stock option plans is set forth below:</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Grant</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2019</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000799" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231" decimals="INF" format="ixt:numdotdecimal">3,145,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000804" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001501989_20191231" decimals="INF" format="ixt:numdotdecimal">9,936,168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000811" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001501989_20191231" decimals="2">12.26</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options authorized</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000800" name="ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,820,923</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000801" name="ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">4,219,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000805" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001501989_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">4,219,044</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000812" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001501989_20200101_20201231" decimals="2">7.23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000806" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001501989_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">1,064,830</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000813" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001501989_20200101_20201231" decimals="2">4.58</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options cancelled</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000802" name="ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,156,253</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000807" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001501989_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">2,160,852</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000814" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001501989_20200101_20201231" decimals="2">13.75</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000803" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231" decimals="INF" format="ixt:numdotdecimal">2,903,398</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000808" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001501989_20201231" decimals="INF" format="ixt:numdotdecimal">10,929,530</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000815" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001501989_20201231" decimals="2">10.77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000818">6.4</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000821" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable&#8212;December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000809" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001501989_20201231" decimals="INF" format="ixt:numdotdecimal">6,145,652</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000816" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001501989_20201231" decimals="2">11.69</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000819">4.7</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000822" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,031</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest&#8212;December 31, 2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000810" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_0001501989_20201231" decimals="INF" format="ixt:numdotdecimal">10,929,530</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000817" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0001501989_20201231" decimals="2">10.77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000820">6.4</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000823" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,844</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the underlying common stock as of December 31, 2020.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options exercised in the years ended December 31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000824" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001501989_20200101_20201231" decimals="-5" scale="6">4.4</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000825" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001501989_20190101_20191231" decimals="-5" scale="6">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000826" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001501989_20180101_20181231" decimals="-5" scale="6">14.6</ix:nonFraction> million, respectively. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000312_dcnt_ae715bc5-a7eb-4acd-9450-8a5361939237" continuedAt="F_000312_dcnt_0c62dd7e-f421-43b2-9bbf-8e8d9ba130f3">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The options granted in the years ended December 31, 2020, 2019 and 2018 had weighted-average per share grant-date fair values of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000827" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001501989_20200101_20201231" decimals="2">3.94</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000828" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001501989_20190101_20191231" decimals="2">7.03</ix:nonFraction> and $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000829" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001501989_20180101_20181231" decimals="2">14.21</ix:nonFraction>, respectively. As of December 31, 2020, the unrecognized compensation expense with respect to options granted was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000830" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001501989_20201231" decimals="-5" scale="6">23.2</ix:nonFraction> million&#160;and is expected to be recognized over <ix:nonNumeric id="F_000831" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" format="ixt-sec:duryear">2.8</ix:nonNumeric> years.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Early Exercise of Employee Options</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain stock options granted under the Plans provide option holders the right to elect to exercise unvested options in exchange for restricted common stock. Such unvested restricted shares are subject to a repurchase right held by the Company at the original issuance price in the event the optionee&#8217;s service to the Company is terminated either voluntarily or involuntarily. The right usually lapses <ix:nonFraction unitRef="U_xbrlipure" id="F_000832" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxEarlyExerciseOfEmployeeOptionsMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231" decimals="INF" scale="-2">25</ix:nonFraction>% on the first anniversary of the vesting start date and in 36 equal monthly amounts thereafter. These repurchase terms are considered to be a forfeiture provision. The cash or full recourse notes received from employees for exercise of unvested options is treated as a refundable deposit and is classified as a liability on the balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with the completion of the IPO in October 2015, the Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;) became effective. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to <ix:nonFraction unitRef="U_xbrlipure" id="F_000834" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20201231" decimals="INF" scale="-2">15</ix:nonFraction>% of their eligible compensation, subject to any plan limitations. The ESPP generally provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at <ix:nonFraction unitRef="U_xbrlipure" id="F_000835" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231" decimals="2" scale="-2">85</ix:nonFraction>% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. The Company issued <ix:nonFraction unitRef="U_xbrlishares" id="F_000836" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001501989_20200101_20201231" decimals="INF" format="ixt:numdotdecimal">128,684</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000837" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" contextRef="C_0001501989_20190101_20191231" decimals="INF" format="ixt:numdotdecimal">142,949</ix:nonFraction> shares of common stock under the ESPP in 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future purchase under the ESPP were <ix:nonFraction unitRef="U_xbrlishares" id="F_000838" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,935,683</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000839" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20191231" decimals="INF" format="ixt:numdotdecimal">1,609,137</ix:nonFraction> shares at December 31, 2020 and 2019, respectively. The compensation expense related to the ESPP was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000840" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231" decimals="-5" scale="6">0.4</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000841" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231" decimals="-5" scale="6">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000842" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231" decimals="-5" scale="6">0.5</ix:nonFraction> million for the years ended December 31, 2020, 2019 and 2018, respectively. As of December 31, 2020, there was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000843" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20201231" decimals="-5" scale="6">0.2</ix:nonFraction> million <span style="font-size:12pt;">&#160;</span>of unrecognized compensation cost related to the ESPP, which the Company expects to recognize over <ix:nonNumeric id="F_000844" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231" format="ixt-sec:durmonth">5</ix:nonNumeric> months.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Based Compensation</p><ix:nonNumeric id="F_000348" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation recorded related to options granted to employees and non-employees and employee stock purchase plan was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000845" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,825</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000846" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,226</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000847" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,313</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000848" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,961</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000849" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">9,874</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000850" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,565</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000851" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,786</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000852" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">19,100</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000853" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,878</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for employees was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000854" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231" decimals="-5" scale="6">14.7</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000855" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231" decimals="-5" scale="6">18.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000856" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231" decimals="-5" scale="6">16.7</ix:nonFraction> million for the years ended December 31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for non-employees was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000857" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxNonEmployeesMember_20200101_20201231" decimals="-5" scale="6">0.1</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000858" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxNonEmployeesMember_20190101_20191231" decimals="-5" scale="6">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000859" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxNonEmployeesMember_20180101_20181231" decimals="-5" scale="6">0.2</ix:nonFraction> million for the years ended December 31, 2020, 2019 and 2018, respectively.</p><ix:nonNumeric id="F_000349" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of employee stock options and ESPP using the Black-Scholes valuation model based on the date of grant with the following assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000860">64.4% - 73.3%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000861">64.4% - 68.6%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000862">65.6% - 69.3%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000863">47.3% - 122.1%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000864">60.8% - 71.9%</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000865">46.4% - 70.5%</span></p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000866">0.2% - 1.3%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000867">1.4% - 2.5%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000868">2.5% - 3.0%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000869">0.1% - 0.2%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000870">1.6% - 2.4%</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000871">2.1% - 2.6%</span></p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000887">&#8212; %</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000888">&#8212; %</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000889">&#8212; %</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000890">4.7 - 4.9</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000891">4.9 - 5.0</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000892">4.7 - 4.9</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000872">0.5</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000873">0.5</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000874">0.5</span></p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000312_dcnt_0c62dd7e-f421-43b2-9bbf-8e8d9ba130f3">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected term. <span style="font-style:normal;">The expected term of stock options represents the period that the stock options are expected to remain outstanding and is based on vesting terms, exercise term and contractual lives of the options. The expected term of the ESPP shares is equal to the six-month look-back period. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility. <span style="font-style:normal;">The expected stock price volatility for the Company&#8217;s stock options is based on the historical stock price volatility which is commensurate with the estimated expected term of the stock awards. Volatility for ESPP shares is equal to the Company&#8217;s historical volatility over a six-month offering period. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate.<span style="font-style:normal;"> The risk-free interest rate is based on the U.S. Treasury yield with a maturity equal to the expected term of the stock options in effect at the time of grant.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dividend yield. <span style="font-style:normal;">The expected dividend is assumed to be zero as the Company has never paid dividends</span><span style="letter-spacing:0.2pt;font-style:normal;"> </span><span style="font-style:normal;">and has no current plan to pay any dividends on its common</span><span style="letter-spacing:0.15pt;font-style:normal;"> </span><span style="font-style:normal;">stock.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p></ix:continuation><ix:nonNumeric id="F_000313" name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000313_dcnt_a6732b46-bf49-40cd-9700-20eb7530c99d">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="N17_INCOME_TAXES">15. Income Taxes </p><ix:nonNumeric id="F_000350" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company derives its income only from the United States. The components of the provision for (benefit from) income taxes are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000904" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,912</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000905" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" scale="3">390</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000906" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,302</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000907" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001501989_20200101_20201231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000908" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="C_0001501989_20180101_20181231" decimals="-3" scale="3">1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000909" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,911</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000910" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" scale="3">390</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000911" name="us-gaap:CurrentIncomeTaxExpenseBenefit" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000912" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000913" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" scale="3">37</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for (benefit from) income taxes</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000914" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001501989_20200101_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">13,911</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000915" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001501989_20190101_20191231" decimals="-3" sign="-" scale="3">427</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000916" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000351" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s effective tax rate to the statutory U.S. federal rate is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal taxes at statutory rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000917" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001501989_20200101_20201231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000918" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001501989_20190101_20191231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000919" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="C_0001501989_20180101_20181231" decimals="INF" scale="-2">21.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax, net of federal benefit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000920" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001501989_20200101_20201231" decimals="3" scale="-2">3.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000921" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001501989_20190101_20191231" decimals="3" scale="-2">1.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000922" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="C_0001501989_20180101_20181231" decimals="3" scale="-2">0.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000923" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001501989_20200101_20201231" decimals="3" sign="-" scale="-2">2.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000924" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001501989_20190101_20191231" decimals="3" sign="-" scale="-2">1.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000925" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" contextRef="C_0001501989_20180101_20181231" decimals="3" scale="-2">1.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000926" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001501989_20200101_20201231" decimals="3" scale="-2">11.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000927" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001501989_20190101_20191231" decimals="3" scale="-2">2.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000928" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="C_0001501989_20180101_20181231" decimals="3" scale="-2">6.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000929" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001501989_20200101_20201231" decimals="3" sign="-" scale="-2">31.2</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000930" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001501989_20190101_20191231" decimals="3" sign="-" scale="-2">22.8</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000931" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="C_0001501989_20180101_20181231" decimals="3" sign="-" scale="-2">49.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryback</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000932" name="ctmx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" contextRef="C_0001501989_20200101_20201231" decimals="3" scale="-2">27.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000933" name="ctmx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" contextRef="C_0001501989_20190101_20191231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000934" name="ctmx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" contextRef="C_0001501989_20180101_20181231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Return to provision adjustment</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000935" name="ctmx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" contextRef="C_0001501989_20200101_20201231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000936" name="ctmx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" contextRef="C_0001501989_20190101_20191231" decimals="3" scale="-2">0.3</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000937" name="ctmx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" contextRef="C_0001501989_20180101_20181231" decimals="3" scale="-2">0.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000938" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001501989_20200101_20201231" decimals="3" sign="-" scale="-2">0.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000939" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001501989_20190101_20191231" decimals="3" sign="-" scale="-2">0.1</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000940" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="C_0001501989_20180101_20181231" decimals="3" sign="-" scale="-2">0.5</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000941" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001501989_20200101_20201231" decimals="3" scale="-2">29.7</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000942" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001501989_20190101_20191231" decimals="3" scale="-2">0.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlipure" id="F_000943" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="C_0001501989_20180101_20181231" decimals="3" sign="-" scale="-2">20.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000313_dcnt_a6732b46-bf49-40cd-9700-20eb7530c99d" continuedAt="F_000313_dcnt_e615b69b-4210-4dff-b5c1-0cd9bd667d82">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000352" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The types of temporary differences that give rise to significant portions of the Company&#8217;s deferred income tax assets and liabilities are set out below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000944" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">37,099</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000945" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,967</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000946" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">15,468</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000947" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">16,803</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000948" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">10,940</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000949" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,514</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000950" name="ctmx:DeferredTaxAssetsLeaseLiability" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,223</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000951" name="ctmx:DeferredTaxAssetsLeaseLiability" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,813</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000952" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,923</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000953" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,320</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000954" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">38,832</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000955" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">47,180</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000956" name="us-gaap:DeferredTaxAssetsDeferredIncome" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">56,881</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and deferred rent</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000957" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,512</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000958" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,296</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000959" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,955</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000960" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">8,578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000961" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">7,837</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000962" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,746</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000963" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001501989_20201231" decimals="-3" scale="3">20</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000964" name="us-gaap:DeferredTaxAssetsOther" contextRef="C_0001501989_20181231" decimals="-3" scale="3">39</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred income tax assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000965" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">111,990</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000966" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">115,353</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000967" name="us-gaap:DeferredTaxAssetsGross" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">87,603</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000968" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">106,448</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000969" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">109,174</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000970" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">86,466</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net of valuation allowance</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000971" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,542</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000972" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000973" name="us-gaap:DeferredTaxAssetsNet" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000974" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="C_0001501989_20201231" decimals="-3" scale="3">433</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000975" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="C_0001501989_20191231" decimals="-3" scale="3">591</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000976" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="C_0001501989_20181231" decimals="-3" scale="3">854</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000977" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,724</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000978" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,330</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000979" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" contextRef="C_0001501989_20181231" decimals="-3" scale="3">108</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000980" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="C_0001501989_20201231" decimals="-3" scale="3">385</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000981" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="C_0001501989_20191231" decimals="-3" scale="3">243</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000982" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="C_0001501989_20181231" decimals="-3" scale="3">175</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000983" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="C_0001501989_20191231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000984" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,542</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000985" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000986" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,137</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred income tax liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was enacted in response to the COVID-19 pandemic.&#160;&#160;<span style="color:#000000;">The tax relief measures under the CARES Act for businesses include a <span style="-sec-ix-hidden:F_000893">five-year</span> net operating loss carryback, suspension of annual deduction limitation of <ix:nonFraction unitRef="U_xbrlipure" id="F_000894" name="ctmx:PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation" contextRef="C_0001501989_20200327_20200327" decimals="2" scale="-2">80</ix:nonFraction>% of taxable income from net operating losses generated in a tax year beginning after December 31, 2017, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property.</span>&#160;&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized income tax benefit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000987" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="C_0001501989_20200101_20201231" decimals="-5" sign="-" scale="6">13.9</ix:nonFraction> million for the year ended December 31, 2020, through the net operating loss carryback <span style="Background-color:#FFFFFF;color:#000000;">under the CARES Act which generated a refund of income taxes paid for 2018.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has established a valuation allowance against all of its net deferred tax assets. Management considered all available evidence, both positive and negative, including but not limited to our historical operating results, income or loss in recent periods, cumulative losses in recent years, forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts, and concluded the deferred tax assets are not more likely than not to be realized. The net change in <span style="letter-spacing:-0.1pt;">the total valuation allowance for the years ended December 31, 2020, 2019 and 2018 was an increase(decrease) of $(<ix:nonFraction unitRef="U_iso4217USD" id="F_000895" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001501989_20200101_20201231" decimals="-5" sign="-" scale="6">2.7</ix:nonFraction>) million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000896" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001501989_20190101_20191231" decimals="-5" scale="6">22.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000897" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="C_0001501989_20180101_20181231" decimals="-5" scale="6">35.7</ix:nonFraction> million, respectively.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had net operating loss carryforwards for federal and state income tax purposes of approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000988" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">168.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000989" name="us-gaap:OperatingLossCarryforwards" contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-5" scale="6">24.2</ix:nonFraction> million, respectively, as of December 31, 2020, available to reduce future taxable income. Of the federal net operating loss carryforwards, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000992" name="ctmx:OperatingLossCarryforwardsAmountToExpireIfNotUsed" contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-5" scale="6">65.6</ix:nonFraction> million will begin to expire in <ix:nonNumeric id="F_000990" name="ctmx:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2034</ix:nonNumeric>, if not utilized and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000993" name="ctmx:OperatingLossCarryforwardsAmountNotSubjectToExpiration" contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-6" scale="6">103</ix:nonFraction> million will carryforward indefinitely.&#160;&#160;The state net operating loss carryforwards will begin to expire in <ix:nonNumeric id="F_000991" name="ctmx:OperatingLossCarryforwardsExpirationYear" contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2032</ix:nonNumeric>, if not utilized.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also has federal and state research and development tax credits carryforwards of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000994" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" scale="6">15.6</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000995" name="us-gaap:TaxCreditCarryforwardAmount" contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231" decimals="-5" scale="6">9.0</ix:nonFraction> million, respectively, as of December 31, 2020 available to reduce future income taxes. The federal research and development tax credits will begin to expire in <ix:nonNumeric id="F_000996" name="ctmx:TaxCreditCarryforwardExpirationYear" contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">2031</ix:nonNumeric> if not utilized. The state research and development tax credits have no expiration date.&#160;&#160;&#160;</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000313_dcnt_e615b69b-4210-4dff-b5c1-0cd9bd667d82">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal Revenue Code section 382 (&#8220;IRC Section 382&#8221;) places a limitation (the &#8220;Section 382 Limitation&#8221;) on the amount of taxable income that can be offset by net operating loss (&#8220;NOL&#8221;) carryforwards after a change in control (generally greater than <ix:nonFraction unitRef="U_xbrlipure" id="F_000997" name="ctmx:PercentageOfChangeInOwnership" contextRef="C_0001501989_srtRangeAxis_srtMinimumMember_20170101_20171231" decimals="INF" scale="-2">50</ix:nonFraction>% change in ownership) of a loss corporation. California has similar rules. The Company has performed an IRC Section 382 analysis and determined there was an ownership change in 2017 that resulted in 382 limitations. When an ownership change occurs, IRC Section 382 limits the use of NOLs and credits in subsequent periods based on the annual 382 limitations.&#160;&#160;The annual 382 limitations may limit the full use of available tax attributes in one year but the identified <span style="color:#000000;">ownership changes may not result in expiration of tax attributes for use prior to expiration of their respective carryforward periods. Accordingly, none of the tax attributes have been reduced but limited the full use in 2018.  The Company has determined that, while an ownership change has occurred, the applicable limits would not impair the value or anticipated use of the Company&#8217;s federal and state net operating losses. Although realization is not assured, management believes it is more likely than not that any limitation under IRC Section 382 will not impair the realizability of the deferred income tax assets related to federal and state net operating loss carryforwards.&#160;&#160;</span>The Company reviewed its stock ownership for the year ended December 31, 2020 and concluded no ownership changes occurred in current year which would result in a reduction of its net operating loss or in its research and development credits expiring unused. If additional ownership change occurs, the utilization of net operating loss and credit carryforwards could be significantly reduced.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000898" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001501989_20201231" decimals="-5" scale="6">6.5</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000899" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001501989_20191231" decimals="-5" scale="6">5.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000900" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001501989_20181231" decimals="-5" scale="6">3.8</ix:nonFraction> million of unrecognized tax benefits as of December 31, 2020, 2019 and 2018, respectively, and approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000901" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="C_0001501989_20201231" decimals="-6" scale="6">0</ix:nonFraction>, $<ix:nonFraction unitRef="U_iso4217USD" id="F_000902" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="C_0001501989_20191231" decimals="-5" scale="6">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000903" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" contextRef="C_0001501989_20181231" decimals="-5" scale="6">1.0</ix:nonFraction> million, respectively, would affect the Company&#8217;s effective tax rate if recognized.</p><ix:nonNumeric id="F_000353" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at the beginning of the year</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000998" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,249</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000999" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001000" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001501989_20171231" decimals="-3" format="ixt:numdotdecimal" scale="3">4,320</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to current year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001001" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001501989_20200101_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,205</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001002" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001501989_20190101_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,403</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001003" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="C_0001501989_20180101_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,166</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment based on tax positions related to prior years</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001004" name="ctmx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" contextRef="C_0001501989_20190101_20191231" decimals="-3" scale="3">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_001005" name="ctmx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" contextRef="C_0001501989_20180101_20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">1,730</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of the year</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001006" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001501989_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">6,454</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001007" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001501989_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,249</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_001008" name="us-gaap:UnrecognizedTaxBenefits" contextRef="C_0001501989_20181231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,756</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction of the provision for income taxes in the period that such determination is made. Interest and penalties have <ix:nonFraction unitRef="U_iso4217USD" id="F_001009" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001501989_20201231" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_001010" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001501989_20191231" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction unitRef="U_iso4217USD" id="F_001011" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" contextRef="C_0001501989_20181231" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t been accrued for 2020, 2019 and 2018.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the United States, including California state jurisdiction. The tax years 2010 to 2019 remains <span style="letter-spacing:-0.1pt;">open to U.S. federal and state examination to the extent of the utilization of net operating loss and credit carryovers. As of December 31, 2020</span>, the Company is under examination by the State of California.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000314" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true">
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16. Defined Contribution Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sponsors a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time U.S. employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. During the years ended December 31, 2020, 2019 and 2018, the Company made contributions to the plan of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001014" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001501989_20200101_20201231" decimals="-5" scale="6">0.8</ix:nonFraction> million, $<ix:nonFraction unitRef="U_iso4217USD" id="F_001015" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001501989_20190101_20191231" decimals="-5" scale="6">0.8</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_001016" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" contextRef="C_0001501989_20180101_20181231" decimals="-5" scale="6">0.6</ix:nonFraction> million, respectively.</p></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000315" name="us-gaap:SubsequentEventsTextBlock" contextRef="C_0001501989_20200101_20201231" escape="true" continuedAt="F_000315_dcnt_1729b70e-10bd-4853-8072-8da639e08077">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17. Subsequent Events</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Company completed an underwritten public offering of <ix:nonFraction unitRef="U_xbrlishares" id="F_001017" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210101_20210131" decimals="INF" format="ixt:numdotdecimal">14,285,714</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_001018" name="us-gaap:SharesIssuedPricePerShare" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210131" decimals="2">7.00</ix:nonFraction> per share.&#160;&#160;The aggregate net proceeds received by the Company from the offering were approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_001019" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001501989_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210101_20210131" decimals="-5" scale="6">93.6</ix:nonFraction> million, after deducting underwriting discounts and commissions and estimated offering expenses of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001021" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210101_20210131" decimals="-5" scale="6">6.4</ix:nonFraction> million.&#160;&#160;The Company also granted the underwriters the option, for <ix:nonNumeric id="F_001023" name="ctmx:OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20210101_20210131" format="ixt-sec:durday">30</ix:nonNumeric> days, to purchase up to <ix:nonFraction unitRef="U_xbrlishares" id="F_001024" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20210101_20210131" decimals="INF" format="ixt:numdotdecimal">2,142,857</ix:nonFraction> additional shares of common stock at the public offering price, less the underwriting discounts and commissions. In February 2021, the underwriters exercised the option in full which resulted in additional net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001020" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001501989_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20210201_20210228" decimals="-5" scale="6">14.1</ix:nonFraction> million to the Company, after deducting the underwriting discounts and commissions of $<ix:nonFraction unitRef="U_iso4217USD" id="F_001022" name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="C_0001501989_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210201_20210228" decimals="-5" scale="6">0.9</ix:nonFraction> million. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:continuation id="F_000315_dcnt_1729b70e-10bd-4853-8072-8da639e08077">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:continuation>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.1%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><span style="font-style:italic;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.1%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9A_CONTROLS_PROCEDURES"><span style="font-style:italic;">Controls and Procedures</span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) refers to controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their control objectives. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2020, the end of the period covered by this Annual Report on Form 10-K. Management&#8217;s assessment of internal control over financial reporting was conducted using the criteria defined in the <span style="font-style:italic;">Internal Control&#8212;Integrated Framework (2013) </span>issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;). Based upon such evaluation, our Principal Executive Officer and Principal Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f). Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets&#59; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of the financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors&#59; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements prepared for external purposes in accordance with generally accepted accounting principles.&#160;&#160;Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future&#160;periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in&#160;<span style="font-style:italic;">Internal Control &#8211; Integrated Framework (2013)&#160;</span>issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on our evaluation under the framework in&#160;<span style="font-style:italic;">Internal Control &#8211; Integrated Framework</span>, management concluded that our internal control over financial reporting was effective as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in Internal Control Over Financial Reporting</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during our fiscal quarter ended December 31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.1%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_9B_OR_INFORMATION"><span style="font-style:italic;">Other Information </span></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 25, 2021, we completed an underwritten public offering of 14,285,714 shares of common stock at a price of $7.00 per share. The aggregate net proceeds received by us from the offering were approximately $93.6 million, after deducting underwriting discounts and commissions and estimated offering expenses of $6.4 million.&#160;&#160;We also granted the underwriters the option, for 30 days, to purchase up to 2,142,857 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. In February 2021, the underwriters exercised the option in full which resulted in additional net proceeds of $14.1 million to us, after deducting the underwriting discounts and commissions of $0.9 million.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 20, 2021, &#160;Dr. Charles Fuchs informed the Company that he could not stand for re-election and that he would retire from the Board and its committees, effective April 1, 2021.&#160; Dr. Fuchs&#8217; resignation is not due to any disagreement with the Company, the Board or the management of the Company. </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_III">PART III</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO">Directors, Executive Officers and Corporate Governance</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item will be set forth in the Company&#8217;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have adopted a code of business conduct and ethics that applies to all employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. The code of business conduct and ethics is available on our website at www.cytomx.com. Amendments to, and waivers from, the code of business conduct and ethics that apply to any director, executive officer or persons performing similar functions will be disclosed at the website address provided above and, to the extent required by applicable regulations, on a Current Report on Form 8-K filed with the SEC.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_11_EXECUTIVE_COMPENSATION">Executive Compensation</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item will be set forth in the Company&#8217;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item will be set forth in the Company&#8217;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR">Certain Relationships and Related Transactions and Director Independence</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item will be set forth in the Company&#8217;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_14_PRINCIPAL_ACCOUNTANT_FEES_SERVIC">Principal Accountant Fees and Services</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item will be set forth in the Company&#8217;s proxy statement to be filed with the Securities and Exchange Commission within 120 days after the Company&#8217;s fiscal year end and is incorporated herein by reference.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IV"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> IV</span></p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.27%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;" id="ITEM_15_EXHIBITS"><span style="font-style:italic;">Exhibits and Financial Statement Schedules</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-style:italic;font-size:10pt;">Financial Statements:</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements required by Item 15(a) are filed as part of this Annual Report on Form&#160;10-K under Item&#160;8 &#8220;Financial Statements and Supplementary Data.&#8221;</p>
<p style="line-height:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:8.51%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"><span style="margin-left:36pt;"></span>&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-style:italic;font-size:10pt;">Financial Statement Schedules</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statement schedules required by Item 15(a) are omitted because they are not applicable, not required or the required information is included in the financial statements or notes thereto as filed in Item 8 of this Annual Report on Form 10-K.</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><span style="font-style:italic;font-size:10pt;">Exhibits. </span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.6%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:left;margin-top:0pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-top:0pt;text-align:center;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:29.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />Number</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description<span style="font-weight:normal;">&#160;</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br />Herewith</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;1.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459020007395/ctmx-ex11_1755.htm"><span style="text-decoration:underline;">Open Market Sale Agreement, dated as of February 27, 2020, by and between CytomX Therapeutics, Inc. and Jefferies LLC.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/27/2020</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.1(a)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000119312515347080/d78795dex31.htm"><span style="text-decoration:underline;">Amended and Restated Certificate of Incorporation.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/19/2015</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.1(b)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000119312520176532/d920733dex31.htm"><span style="text-decoration:underline;">Certificate of Amendment to Amended and Restated Certificate of Incorporation of CytomX Therapeutics, Inc.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6/23/2020</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;3.2</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000119312515347080/d78795dex32.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/19/2015</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reference is made to exhibits 3.1 through 3.2.</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.2</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000119312515329662/d948537dex41.htm"><span style="text-decoration:underline;">Specimen Common Stock Certificate.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/28/2015</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.3</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000156459017022252/ctmx-ex44_91.htm"><span style="text-decoration:underline;">Registration Rights Agreement dated as of September 29, 2017 by and between CytomX Therapeutics, Inc. and Amgen, Inc.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/7/2017</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;4.4</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459020037722/ctmx-ex44_216.htm"><span style="text-decoration:underline;">Description of Registrant&#8217;s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934.</span></a><span style="text-decoration:underline;"> </span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/6/2020</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1(a)#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000119312515307013/d948537dex103.htm"><span style="text-decoration:underline;">2010 Stock Incentive Plan adopted on September 21, 2010 (&#8220;2010 Plan&#8221;).</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/28/2015</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1(b)#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000119312515307013/d948537dex104.htm"><span style="text-decoration:underline;">Form of Stock Option Agreement under the 2010 Plan.</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/28/2015</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2(a)#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000119312515307013/d948537dex101.htm"><span style="text-decoration:underline;">2011 Stock Incentive Plan, adopted on February&#160;7, 2012, as amended (&#8220;2011 Plan&#8221;).</span></a></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/28/2015</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2(b)#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000119312515307013/d948537dex102.htm"><span style="text-decoration:underline;">Form of Restricted Stock Award Agreement and Option Exercise Agreement under the 2011 Plan.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/28/2015</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3(a)#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000119312515338434/d948537dex105.htm"><span style="text-decoration:underline;">2015 Equity Incentive Plan (&#8220;2015 Plan&#8221;).</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/6/2015</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3(b)#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000156459015010977/ctmx-ex104_591.htm"><span style="text-decoration:underline;">Form of 2015 Plan Option Agreement under the 2015 Plan.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/23/2015</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3(c)#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000156459015010977/ctmx-ex105_592.htm"><span style="text-decoration:underline;">Form of 2015 Plan Early Exercise Option Agreement</span></a><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/23/2015</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4(a)#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459019041726/ctmx-ex101_559.htm"><span style="text-decoration:underline;">2019 Employment Inducement Incentive Plan adopted on September 18, 2019 (&#8220;2019 Plan&#8221;).</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/7/2019</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4(b)#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459019041726/ctmx-ex102_564.htm"><span style="text-decoration:underline;">Form of Stock Option Agreement under the 2019 Plan.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/7/2019</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.6%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:left;margin-top:0pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-top:0pt;text-align:center;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:29.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />Number</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description<span style="font-weight:normal;">&#160;</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br />Herewith</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5#</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000119312515329662/d948537dex106.htm"><span style="text-decoration:underline;">2015 CytomX Therapeutics, Inc. Employee Stock Purchase Plan.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/28/2015</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000119312515307013/d948537dex1016.htm"><span style="text-decoration:underline;">Form of Indemnification Agreement by and between CytomX Therapeutics, Inc. and each of its directors and each of its executive officers.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/28/2015</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000119312515307013/d948537dex107.htm"><span style="text-decoration:underline;">Employment Offer Letter Agreement between CytomX Therapeutics, Inc. and Sean A. McCarthy, D. Phil, dated as of December 15, 2010.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/28/2015</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459019041726/ctmx-ex105_561.htm"><span style="text-decoration:underline;">Employment Offer Letter Agreement between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D. dated as of September 23, 2019.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/7/2019</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459020022844/ctmx-ex103_199.htm"><span style="text-decoration:underline;">Employment Offer Letter Agreement between CytomX Therapeutics, Inc. and Carlos Campoy dated as of March 9, 2020.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/7/2020</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459019017968/ctmx-ex101_193.htm"><span style="text-decoration:underline;">Amended and Restated Severance and Change of Control Agreement dated February 27, 2019, by and between CytomX Therapeutics, Inc. and Sean McCarthy. D. Phil.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/9/2019</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459019041726/ctmx-ex106_560.htm"><span style="text-decoration:underline;">Amended and Restated Severance and Change of Control Agreement effective as of October 14, 2019, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/7/2019</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459019017968/ctmx-ex102_194.htm"><span style="text-decoration:underline;">Amended and Restated Severance and Change of Control Agreement dated March 25, 2019, by and between CytomX Therapeutics, Inc. and Lloyd Rowland.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/9/2019</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13<span style="color:#000000;">&#8224;&#8224;</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459020007395/ctmx-ex1032_1585.htm"><span style="text-decoration:underline;">Severance and Change of Control Agreement effective as of February 3, 2020, by and between CytomX Therapeutics, Inc. and Alison Hannah, M.D.</span></a><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-K</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2/27/2020</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.32</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459020022844/ctmx-ex101_328.htm"><span style="text-decoration:underline;">Severance and Change of Control Agreement dated March 23, 2020, by and between CytomX Therapeutics, Inc. and Carlos Campoy.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/7/2020</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000156459015011520/ctmx-ex101_6.htm"><span style="text-decoration:underline;">Lease dated as of December 10, 2015, by and between CytomX Therapeutics, Inc. and HCP Oyster Point III LLC.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12/16/2015</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16(a)</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000119312515322694/d948537dex1021.htm"><span style="text-decoration:underline;">Exclusive License Agreement dated as of August 19, 2010, by and between The Regents of the University of California and CytomX Therapeutics, Inc., as amended by Amendment No. 1 to Exclusive Agreement effective as of May 30, 2013 and Amendment No. 2 to Exclusive Agreement effective as of November 8, 2013.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9/18/2015</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.16(b)<span style="color:#000000;">&#8224;&#8224;</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459019017968/ctmx-ex106_447.htm"><span style="text-decoration:underline;">Amendment No.3 to Exclusive License Agreement effective as of April 2, 2019, by and between CytomX Therapeutics, Inc. and The Regents of the University of California.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/9/2019</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17&#8224;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459020051302/ctmx-ex101_357.htm"><span style="text-decoration:underline;">Research Collaboration, Option and License Agreement dated as of May 30, 2013, by and between CytomX Therapeutics, Inc. and Pfizer, Inc.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/5/2020</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18(a)&#8224;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459020051302/ctmx-ex102_356.htm"><span style="text-decoration:underline;">Collaboration and License Agreement dated as of May&#160;23, 2014, by and between CytomX Therapeutics, Inc. and Bristol Myers Squibb Company.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/5/2020</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.18(b)&#8224;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000156459017008943/ctmx-ex101_883.htm"><span style="text-decoration:underline;">Amendment to Extend Collaboration and License Agreement, dated March 17, 2017, by and between the Company and Bristol Myers Squibb.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/5/2017</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19(a)&#8224;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000156459016022364/ctmx-ex101_550.htm"><span style="text-decoration:underline;">Co-Development and License Agreement, dated April 21, 2016, by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/3/2016</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.6%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:left;margin-top:0pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-top:0pt;text-align:center;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:29.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />Number</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description<span style="font-weight:normal;">&#160;</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br />Herewith</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459018027387/ctmx-ex101_175.htm"><span style="text-decoration:underline;">First Amendment to the CD71 Co-Development and License Agreement by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company, dated as of October 5, 2016.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/6/2018</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19(c)&#8224;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459018027387/ctmx-ex102_176.htm"><span style="text-decoration:underline;">Second Amendment to the CD71 Co-Development and License Agreement by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company, effective as of March 31, 2017.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/6/2018</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19(d)&#8224;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459018027387/ctmx-ex103_177.htm"><span style="text-decoration:underline;">Third Amendment to the CD71 Co-Development and License Agreement by and between CytomX Therapeutics, Inc. and AbbVie Ireland Unlimited Company, effective as of January 3, 2018.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/6/2018</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.3</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.19(e)<span style="color:#000000;">&#8224;</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459019030054/ctmx-ex101_505.htm"><span style="text-decoration:underline;">Amended and Restated Discovery Collaboration and License Agreement, dated as of June 28, 2019, by and between CytomX Therapeutics, Inc., and AbbVie Ireland Unlimited Company.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8/7/2019</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20(a)&#8224;&#8224;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000156459017022252/ctmx-ex101_92.htm"><span style="text-decoration:underline;">Collaboration and License Agreement by and between CytomX Therapeutics, Inc. and Amgen, Inc. dated as of September 29, 2017.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/7/2017</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.20(b)&#8224;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459020051302/ctmx-ex103_355.htm"><span style="text-decoration:underline;">Amendment No. 1 to the Collaboration and License Agreement, dated as of September 29, 2020, by and between CytomX Therapeutics, Inc. and Amgen, Inc.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/5/2020</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.21<span style="color:#000000;">&#8224;&#8224;</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459020022844/ctmx-ex104_330.htm"><span style="text-decoration:underline;">Collaboration and License Agreement dated as of March 23, 2020, by and between CytomX Therapeutics, Inc. and Astellas Pharma Inc.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5/7/2020</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22(a)&#8224;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001501989/000119312515336443/d948537dex1017.htm"><span style="text-decoration:underline;">Research Collaboration Agreement dated as of January&#160;8, 2014, by and between ImmunoGen, Inc. and CytomX Therapeutics, Inc., as amended by the First Amendment to Research Collaboration Agreement effective as of April 3, 2015.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10/2/2015</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22(b)&#8224;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459018027387/ctmx-ex105_179.htm"><span style="text-decoration:underline;">Second Amendment to the Research Collaboration Agreement by and between CytomX Therapeutics, Inc. and ImmunoGen Inc., dated as of February 12, 2016.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/6/2018</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.22(c)&#8224;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459018027387/ctmx-ex106_180.htm"><span style="text-decoration:underline;">Third Amendment to the Research Collaboration Agreement by and between CytomX Therapeutics, Inc. and ImmunoGen Inc., dated as of March 3, 2017.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/6/2018</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.23&#8224;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1501989/000156459018027387/ctmx-ex104_178.htm"><span style="text-decoration:underline;">License Agreement by and between CytomX Therapeutics, Inc. and ImmunoGen Inc., dated as of February 12, 2016.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11/6/2018</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.24#<span style="color:#000000;">&#8224;&#8224;</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ctmx-ex1024_991.htm"><span style="text-decoration:underline;">Consulting Agreement effective as of December 14, 2020, by and between CytomX Therapeutics, Inc and Dr. W. Michael Kavanaugh.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.25#</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ctmx-ex1025_992.htm"><span style="text-decoration:underline;">Retirement Agreement by and between CytomX Therapeutics, Inc and Dr. W. Michael Kavanaugh, dated as of December 1, 2020.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">23.1</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ctmx-ex231_6.htm"><span style="text-decoration:underline;">Consent of Independent Registered Public Accounting Firm.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_ATTORNEY"><span style="text-decoration:underline;">Power of Attorney (included on signature page)</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">31.1</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ctmx-ex311_9.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">31.2</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ctmx-ex312_8.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">32.1**</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="ctmx-ex321_7.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100.6%;">
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="text-align:left;margin-top:0pt;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-top:0pt;text-align:center;line-height:1pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td colspan="7" valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:29.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
</tr>
<tr>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br />Number</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Description<span style="font-weight:normal;">&#160;</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed<br />Herewith</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.INS</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document - <span style="color:#000000;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.SCH</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.CAL</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.DEF</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.LAB</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">101.PRE</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">104</span></p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:60.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="top" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:0.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:6.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:12pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Confidential treatment has been granted for certain information contained in this exhibit. Such information has been omitted and filed separately with the Securities and Exchange Commission.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;&#8224;</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-size:9pt;">Certain confidential portions of this exhibit have been omitted from this exhibit.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">Indicates management contract or compensatory plan.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">**</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">The certifications attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of CytomX Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;text-indent:-4.17%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:5pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_16_FORM_10K_SUMMARY">Item 16. Form 10-K Summary</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Registrants may voluntarily include a summary of information required by Form 10-K under Item 16. We have elected not to include such summary.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SIGNAT</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">URES</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:24.89%;"></td>
<td style="width:35.11%;"></td>
<td style="width:5.56%;"></td>
<td style="width:34.44%;"></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td colspan="2" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">CytomX Therapeutics, Inc.</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 24, 2021</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sean A. McCarthy</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sean A. McCarthy, D.Phil.</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carlos Campoy</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top" style=" border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Carlos Campoy</p></td>
</tr>
<tr>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="POWER_ATTORNEY">POWER OF ATTORNEY</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each person whose individual signature appears below hereby authorizes and appoints Sean A. McCarthy, D. Phil., Carlos Campoy and Lloyd Rowland and each of them, with full power of substitution and resubstitution, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this Annual Report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agents full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorney-in-fact and agents or his substitute or substitutes may lawfully do or cause to be done by virtue thereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:28.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sean A. McCarthy</p></td>
<td valign="top" style="width:0.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:11pt;;text-indent:-11pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive&#160;Officer and Director</p></td>
<td valign="top" style="width:4.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sean A. McCarthy, D.Phil.</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Matthew P. Young</p></td>
<td valign="top" style="width:0.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:4.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Matthew P. Young</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Charles S. Fuchs </p></td>
<td valign="top" style="width:0.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:4.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Charles S. Fuchs, M.D., M.P.H.</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Frederick W. Gluck</p></td>
<td valign="top" style="width:0.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:4.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frederick W. Gluck</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ John A. Scarlett</p></td>
<td valign="top" style="width:0.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:4.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">John A. Scarlett, M.D.</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Elaine V. Jones</p></td>
<td valign="top" style="width:0.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:4.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Elaine V. Jones, Ph.D.</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ James R. Meyers</p></td>
<td valign="top" style="width:0.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:4.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James R. Meyers</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Mani Mohindru</p></td>
<td valign="top" style="width:0.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:4.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mani Mohindru, Ph.D.</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Halley E. Gilbert</p></td>
<td valign="top" style="width:0.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top" style="width:4.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Halley E. Gilbert</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="width:28.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:0.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:44.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:20.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.24
<SEQUENCE>2
<FILENAME>ctmx-ex1024_991.htm
<DESCRIPTION>EX-10.24 - MK CONSULTING AGREEMENT
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ctmx-ex1024_991.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000001.jpg" title="" alt="" style="width:115px;height:65px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.24</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#333333;font-family:Verdana;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#333333;font-family:Verdana;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Certain identified information has been excluded from this exhibit because it is, both, not material, and would likely cause competitive harm to CytomX Therapeutics, Inc.</font><font style="font-family:Arial;color:#000000;"> </font><font style="Background-color:#FFFFFF;">if publicly disclosed.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;color:#333333;font-family:Times New Roman;font-size:11pt;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p>&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONSULTING AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;text-indent:7.69%;">This Consulting Agreement<font style="font-weight:normal;font-variant: normal;"> (the &#8220;</font><font style="font-variant: normal;">Agreement</font><font style="font-weight:normal;font-variant: normal;">&#8221;) is made and entered into by and between </font>CytomX Therapeutics, Inc., <font style="font-weight:normal;font-variant: normal;">a Delaware corporation, with an address at 151 Oyster Point Blvd, Suite 400, South San Francisco, CA&nbsp;&nbsp;94080,</font> <font style="font-weight:normal;font-variant: normal;">(&#8220;</font><font style="font-variant: normal;">Company</font><font style="font-weight:normal;font-variant: normal;">&#8221;) and</font><font style="font-weight:normal;"> Dr. W. Michael Kavanaugh, </font><font style="font-weight:normal;font-variant: normal;">an individual residing at [***], (&#8220;</font><font style="font-variant: normal;">Consultant</font><font style="font-weight:normal;font-variant: normal;">&#8221;), effective as of December 14, 2020 (&#8220;</font><font style="font-variant: normal;">Effective Date</font><font style="font-weight:normal;font-variant: normal;">&#8221;)</font><font style="font-variant: normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">Recitals</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, ceased to be an employee of the Company as of December 1, 2020;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-weight:bold;font-variant: small-caps;">Whereas</font>, Consultant has skills and knowledge in the Company&#8217;s field of endeavor and is well suited to advise the Company; and</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">Whereas<font style="font-weight:normal;font-variant: normal;">, the Company desires that Consultant advise and consult with the Company in Consultant&#8217;s area of expertise for a period of  six (6) months from the Effective Date and to serve on the Company&#8217;s scientific advisory board (&#8220;SAB&#8221;) for an indefinite period of time on the terms and conditions set forth herein;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">Now Therefore<font style="font-weight:normal;font-variant: normal;">, in consideration of the mutual obligations specified in this Agreement, the parties agree to the following:</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="NumberingSchemesChangeInsertionStart"></a>1.<font style="font-weight:normal;margin-left:36pt;"><a name="NumberingSchemesChangeInsertionStart"></a></font><font style="font-variant: small-caps;">Services</font><font style="font-variant: small-caps;font-weight:normal;">.</font><font style="font-weight:normal;"> The Company hereby retains the Consultant and Consultant accepts such retention upon the terms and conditions set forth in this Agreement. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consulting Services.<font style="font-weight:normal;">&nbsp;&nbsp;For a period of six (6) months from the Effective Date, unless mutually extended in writing, the Consultant shall serve as an advisor to the Company, providing consulting services to the Company on research, technical or development matters of the Company from time to time as requested (the &#8220;</font>Services<font style="font-weight:normal;">&#8221;),.&nbsp;&nbsp;The Chief Executive Officer of the Company, or his designee shall initiate requests for services, and the Consultant will perform the Services using Consultant&#8217;s highest degree of professional skill and expertise. In rendering the services, Consultant will determine the specific manner in which the services will be performed, but will accommodate the scheduling requirements and the work of the Company. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.73%;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000002.jpg" title="" alt="" style="width:624px;height:56px;"><font style="font-size:11pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110311757.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000001.jpg" title="" alt="" style="width:115px;height:65px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-weight:bold;">1.2&nbsp;&nbsp; SAB Services</font>.&nbsp;&nbsp;Consultant shall also serve on the Company&#8217;s SAB for an indefinite period, attending and preparing for SAB meetings and performing such other services in connection with the SAB as are agreed upon by the Consultant and the Company from time to time. Time spent preparing for and attending meetings of the SAB shall not be included in billings for the Services in Section 1.1 above.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consultant shall render the Services at such times and in such quantities as are mutually agreeable, provided that such Services shall not exceed fifteen (15) hours in any given month ( not including time spent preparing for and attending SAB meetings) unless otherwise specifically agreed to by Consultant and Company.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-variant: small-caps;">Compensation.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.1<font style="margin-left:36pt;">Consulting Services.</font><font style="font-weight:normal;">&nbsp;&nbsp;For a period of six (6) months from the Effective Date, Company shall pay Consultant $250.00 per hour, payable in arrears pursuant to monthly invoices (provided by Consultant) for the Services (excluding time spent preparing for and attending SAB meetings), such invoices payable within thirty (30) days from date of receipt by the Company.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;color:#auto;font-size:13pt;font-family:Cambria;font-style:normal;text-transform:none;font-variant: normal;">2.2<font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;">SAB Services.</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;">&nbsp;&nbsp;Beginning January 1, 2021, the Company will pay Consultant fees of [***] per year for serving on the SAB, payable quarterly in arrears on the last day of each quarter. Payment for any partial month will be prorated.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:7.69%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.3&nbsp;&nbsp;&nbsp;&nbsp;Stock Option.<font style="font-weight:normal;">  Effective December 14, 2020, the Company will grant to the Consultant pursuant to the Company&#8217;s 2015 Equity Incentive Plan (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Plan</font><font style="font-weight:normal;">&#8221;), an option to purchase 12,000 shares (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Shares</font><font style="font-weight:normal;">&#8221;) of the Company&#8217;s common stock at a per share exercise price equal to the closing price of the Company&#8217;s common stock as reported by the Nasdaq on the date of grant (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Option</font><font style="font-weight:normal;">&#8221;). Subject to the terms and conditions of the Plan and the Company&#8217;s standard form of stock option agreement, assuming the Consultant&#8217;s continued service to the Company hereunder as of each vesting date, the Option shall vest and become exercisable in equal monthly installments over a two (2) year period at the end of each full calendar month following the Effective Date, so that the Option shall be fully vested and exercisable with respect to all of the Shares on the last day of the twenty-fourth (24<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) month after the Effective Date.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.4<font style="font-weight:normal;margin-left:36pt;"></font>Expenses.&nbsp;&nbsp;<font style="font-weight:normal;">The Company shall also reimburse Consultant for reasonable expenses incurred in performing services for the Company, including, but not limited to, reasonable airfare, lodging, meals and other transportation expenses, </font><font style="font-style:italic;font-weight:normal;">provided</font><font style="font-weight:normal;">, that any expenses in excess of $500 incurred in any one month shall require written approval of the Company prior to being incurred.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="font-variant: small-caps;">Independent Contractor Status</font><font style="font-weight:normal;">.&nbsp;&nbsp;It is understood and agreed that Consultant is an independent contractor, is not an agent or employee of the Company, and is not authorized to act on behalf of the Company.&nbsp;&nbsp;Consultant agrees not to hold himself or herself out as, or give any person any reason to believe that she is an employee, agent, joint venturer or partner of the </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000002.jpg" title="" alt="" style="width:624px;height:56px;"><font style="font-size:11pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110311757.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000001.jpg" title="" alt="" style="width:115px;height:65px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company. The Company will not make any deductions from any amounts payable to Consultant for taxes or insurance (except to the extent the Company is required by law to do so).&nbsp;&nbsp;All payroll, income and employment taxes shall be the sole responsibility of Consultant.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-variant: small-caps;">No Solicitation</font><font style="font-variant: small-caps;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;During the term of this Agreement and for one (1) year after its termination, Consultant (and its personnel performing hereunder) will not personally or through others recruit, solicit or induce any employee of the Company to terminate his or her employment with the Company.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-variant: small-caps;">Maintaining Confidential Information</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.1<font style="font-weight:normal;margin-left:36pt;"></font>Company Information<font style="font-weight:normal;">.&nbsp;&nbsp;During the term of this Agreement, Consultant may receive or otherwise be exposed to confidential and proprietary information relating to the Company&#8217;s technology, know-how, data, inventions, developments, plans, business practices, and strategies, and those of the Company&#8217;s collaborators and business associates.&nbsp;&nbsp;Such confidential and proprietary information of the Company (collectively referred to as &#8220;</font>Information<font style="font-weight:normal;">&#8221;) may include but not be limited to: (i) information supplied to Consultant with the legend &#8220;Confidential&#8221; or equivalent; (ii) the Company&#8217;s marketing and customer support strategies, financial information (including sales, costs, profits and pricing methods), internal organization, employee information, customer lists and business plans; (iii) the Company&#8217;s technology, including, but not limited to, discoveries, inventions, research and development efforts, manufacturing processes, assays, data (including without limitation preclinical, clinical and manufacturing data), software, trade secrets, processes, compounds, product, candidates, products, samples, media and/or cell lines (and procedures and formulations for producing any such samples, media and/or cell lines), vectors, viruses, assays, plasmids, formulas, methods, protocols, clinical trial designs and strategies and product know&#8209;how and show&#8209;how; (iv) all derivatives, improvements, additions, modifications, and enhancements to any of the above, including any such information or material created or developed by Consultant under this Agreement; (v) information of third parties as to which the Company has an obligation of confidentiality; and (vi) information regarding the Consulting Inventions (defined in Section 6.1).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consultant acknowledges the confidential and secret character of the Information and agrees that the Information (with the exception of information in category (v)) is the sole, exclusive and extremely valuable property of the Company.&nbsp;&nbsp;Accordingly, Consultant shall not reproduce any of the Information without the applicable prior written consent of the Company, use the Information except in the performance of this Agreement, nor disclose all or any part of the Information in any form to any third party, either during or after the term of this Agreement.&nbsp;&nbsp;Upon termination of this Agreement for any reason, including expiration of term, Consultant agrees to cease using and to return to the Company all whole and partial copies of the Information.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consultant shall not remove from the premises of Company or otherwise transfer to any third party any materials to which Company provides Consultant access, unless Consultant has express advance written consent from Company.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000002.jpg" title="" alt="" style="width:624px;height:56px;"><font style="font-size:11pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110311757.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000001.jpg" title="" alt="" style="width:115px;height:65px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.2<font style="font-weight:normal;margin-left:36pt;"></font>Employer Information<font style="font-weight:normal;">.&nbsp;&nbsp;Consultant agrees that she will not, during her engagement with the Company, improperly use or disclose any proprietary information or trade secrets of her former or current employers or companies with which she has or has had a consulting or other relationship, if any.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.3<font style="font-weight:normal;margin-left:36pt;"></font>Third Party Information<font style="font-weight:normal;">.&nbsp;&nbsp;Consultant recognizes that the Company has received and in the future will receive from third parties their confidential or proprietary information subject to a duty on the Company&#8217;s part to maintain the confidentiality of such information and, in some cases, to use it only for certain limited purposes.&nbsp;&nbsp;Consultant agrees that she owes the Company and such third parties, both during the term of her or his engagement and thereafter, a duty to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any person, firm or corporation (except in a manner that is consistent with the Company&#8217;s agreement with the third party) or use it for the benefit of anyone other than the Company or such third party (consistent with the Company&#8217;s agreement with the third party).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.4<font style="margin-left:36pt;">Statutory Immunity from Prosecution.</font><font style="font-weight:normal;"> Consultant shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that: (i) is done solely for the purpose of reporting or investigating a suspected violation of law and is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney; or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-variant: small-caps;">Inventions</font><font style="font-variant: small-caps;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.1<font style="font-weight:normal;margin-left:36pt;"></font>Disclosure of Inventions<font style="font-weight:normal;">.&nbsp;&nbsp;Consultant shall promptly and fully disclose to the Company any and all ideas, improvements, inventions, know-how, techniques and works of authorship learned, conceived or developed by Consultant (i) pursuant his performance of the Services for the Company and/or (2) as a result of his using the Information whether such use of Information occurs during or after the term of this Agreement (all of the foregoing, together with all intellectual property rights therein (including without limitation patent applications and patents), the &#8220;</font>Consulting Inventions<font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;</font>All inventions by Consultant during the term of the Services or within one (1) year thereafter and having utility in the field of protease-activated biologics shall be presumed to have been made using the Information unless Consultant is able to show conclusively that they were not<font style="font-weight:normal;">.&nbsp;&nbsp;Consultant specifically agrees that he shall not have any right to use the Information outside of performing the Services</font>. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.2<font style="font-weight:normal;margin-left:36pt;"></font>Inventions Assigned to the Company<font style="font-weight:normal;">.&nbsp;&nbsp;Consultant agrees that any and all Consulting Inventions shall be the sole and exclusive property of the Company.&nbsp;&nbsp;Accordingly, Consultant hereby assigns to the Company all her, his or its right, title and interest in and to the Consulting Inventions, and agrees to execute and deliver (during and after the term of this Agreement and for no additional consideration) all documents and take all reasonable, lawful actions to assist the Company to evidence or record such assignment or perfect, defend or enforce the Consulting Inventions.&nbsp;&nbsp;Consultant shall do so both during and after the term of this Agreement, for no additional consideration beyond the payments from Company to Consultant for the Services during the term of this Agreement.&nbsp;&nbsp;Further, if Company is unable, after making reasonable inquiry, </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000002.jpg" title="" alt="" style="width:624px;height:56px;"><font style="font-size:11pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110311757.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000001.jpg" title="" alt="" style="width:115px;height:65px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">to obtain Consultant&#8217;s signature on any such documents, Consultant hereby appoints Company as Consultant&#8217;s attorney-in-fact to execute and deliver such documents. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consultant explicitly acknowledges and agrees that all works of authorship contained in the Consulting Inventions are &#8220;works for hire&#8221; under the copyright laws of the United States, and that the Company shall own the copyright in all such works of authorship.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-variant: small-caps;">Term and Termination.</font><font style="font-weight:normal;">&nbsp;&nbsp;The initial term of this Agreement is two (2) years beginning on the Effective Date set forth above and will automatically renew for additional terms of one (1) year until terminated in accordance with this Section</font><font style="font-size:11pt;font-family:Arial;font-weight:normal;"> 7. </font><font style="font-weight:normal;"> Notwithstanding the foregoing, either the Company or Consultant may terminate this Agreement at any time with or without cause by giving thirty (30) days written notice.&nbsp;&nbsp;If this Agreement terminates, Consultant shall cease work immediately after giving or receiving such notice or termination, unless otherwise advised by the Company, shall return to the Company all Information, Consulting Inventions, and other materials belonging to the Company, and shall notify the Company of costs incurred up to the termination date.&nbsp;&nbsp;Sections 4-6 of this Agreement shall survive any termination of this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-variant: small-caps;">Compliance with Applicable Laws</font><font style="font-weight:normal;">.&nbsp;&nbsp;Consultant warrants that all work performed under this Agreement complies with or will comply with all applicable United States and foreign laws and regulations.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-variant: small-caps;">Assignment; Benefit</font><font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement is for the personal services of Consultant and may not be assigned by her, him or it.&nbsp;&nbsp;Consultant may not delegate any of his, her or its duties under this Agreement nor shall it be assignable by Consultant by operation of law, without the prior written consent of the Company.&nbsp;&nbsp;The parties&#8217; rights and obligations under this Agreement will bind and inure to the benefit of their respective successors, heirs, executors, and administrators and permitted assigns.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-variant: small-caps;">Legal and Equitable Remedies</font><font style="font-variant: small-caps;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;Consultant hereby acknowledges and agrees that if Consultant breaches this Agreement, including, without limitation, by the actual or threatened disclosure of Information or Consulting Inventions without the prior express written consent of the Company, the Company will suffer an irreparable injury, such that no remedy at law will afford it adequate protection against, or appropriate compensation for, such injury. Accordingly, Consultant hereby agrees that the Company shall be entitled to specific performance of Consultant&#8217;s obligations under this Agreement, as well as such further relief as may be granted by a court of competent jurisdiction.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-variant: small-caps;">Notices</font><font style="font-variant: small-caps;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;Any notices required or permitted hereunder shall be given to the appropriate party at the address specified below or at such other address as the party shall specify in writing.&nbsp;&nbsp;Such notice shall be deemed given upon personal delivery to the appropriate address or sent by certified or registered mail, three days after the date of mailing.&nbsp;&nbsp;Either party may update its notice address by written notice to the other party.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000002.jpg" title="" alt="" style="width:624px;height:56px;"><font style="font-size:11pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110311757.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000001.jpg" title="" alt="" style="width:115px;height:65px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:7.69%;width:102.31%;">
<tr>
<td style="width:51.15%;"></td>
<td style="width:51.15%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to the Company:</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to the Consultant:</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">CytomX Therapeutics, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151 Oyster Point Blvd, Suite 400</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">South San Francisco, CA&nbsp;&nbsp;94080</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ATTN: General Counsel</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dr. W. Michael Kavanaugh </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the address set forth above</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-variant: small-caps;">Governing Law; Severability</font><font style="font-variant: small-caps;font-weight:normal;">.</font><font style="font-weight:normal;">&nbsp;&nbsp;This Agreement shall be governed by and construed according to the laws of the State of California, without giving effect to its conflict of laws rules.&nbsp;&nbsp;If any provision of this Agreement is found by a court of competent jurisdiction to be unenforceable, that provision shall be severed and the remainder of this Agreement shall continue in full force and effect.&nbsp;&nbsp;Any disputes arising under this Agreement shall be resolved by trial to a judge as the finder of fact seated in a court of competent subject matter jurisdiction in California.&nbsp;&nbsp;Each party hereby consents to, and waives any defenses that party may have to or conflicting with, the personal jurisdiction and venue of all such courts or relating to trial to a judge (including without limitation the defense of </font><font style="font-style:italic;font-weight:normal;">forum non conveniens</font><font style="font-weight:normal;">).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-variant: small-caps;">Complete Understanding; Modification</font><font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement constitutes the final, exclusive and complete understanding and agreement of the Company and Consultant with respect to the subject matter hereof.&nbsp;&nbsp;There are no other understandings, agreements, representations or warranties between the parties with respect to that subject matter other than those set forth in this Agreement.&nbsp;&nbsp;Any waiver, modification or amendment of any provision of this Agreement shall be effective only if in writing and signed by a Company officer. This Agreement may be signed electronically or in counterparts.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="font-weight:normal;margin-left:36pt;"></font><font style="font-variant: small-caps;">Indemnification.</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;margin-left:36pt;">The Company</font><font style="font-weight:normal;"> shall indemnify and hold Consultant harmless to the fullest extent permitted by applicable law against all expense, liability, and loss (including, without limitation, attorneys&#8217; fees) actually and reasonably incurred or suffered by Consultant in connection with defending any third-party claim or lawsuit arising out of or in </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">connection with Consultant&#8217;s performance under this Agreement, except for such loss or damage</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> arising from Consultant&#8217;s or Consultant&#8217;s employees&#8217; unlawful conduct, gross negligence, </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">willful <font style="color:#auto;">misconduct, or fraud. Consultant shall promptly notify the Company in writing of such claim or lawsuit. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">In Witness Whereof<font style="font-weight:normal;font-variant: normal;">, the parties hereto have executed this Agreement as of the Effective Date.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:50.03%;"></td>
<td style="width:49.97%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">CytomX Therapeutics, Inc.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Lloyd Rowland</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Lloyd Rowland</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: SVP, General Counsel </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: <font style="text-decoration:underline;">3-December-2020</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-variant: small-caps;font-style:normal;text-transform:none;">Consultant</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Michael Kavanaugh</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Dr. W. Michael Kavanaugh</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: <font style="text-decoration:underline;">4-December-2020</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000002.jpg" title="" alt="" style="width:624px;height:56px;"><font style="font-size:11pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110311757.1</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000001.jpg" title="" alt="" style="width:115px;height:65px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="ghwd5ikruv45000002.jpg" title="" alt="" style="width:624px;height:56px;"><font style="font-size:11pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\110311757.1</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.25
<SEQUENCE>3
<FILENAME>ctmx-ex1025_992.htm
<DESCRIPTION>EX-10.25_MK RETIREMENT AGREEMENT
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ctmx-ex1025_992.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 10.25</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">RETIREMENT AGREEMENT</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.94%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.95%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Retirement Agreement (the &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) by and between W. Michael Kavanaugh, M.D. (&#8220;<font style="text-decoration:underline;">Executive</font>&#8221;), and CytomX Therapeutics, Inc., a Delaware corporation (the &#8220;<font style="text-decoration:underline;">Company</font>&#8221;), is made effective as of the twenty-fourth day following the date Executive signs this Agreement if not revoked in accordance with Section 5(c)(iii) (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;) with reference to the following facts:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Executive&#8217;s employment with the Company and status as an officer and employee of the Company and each of its affiliates ended on December 1, 2020 (the &#8220;<font style="text-decoration:underline;">Retirement Date</font>&#8221;).</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:15.87%;text-indent:-7.94%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Executive and the Company are parties to that certain Amended and Restated Severance and Change of Control Agreement dated as of March 25, 2019, as amended (the &#8220;<font style="text-decoration:underline;">Severance Agreement</font>&#8221;).</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:15.87%;text-indent:-7.94%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.94%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Executive and the Company want to end their relationship amicably and also to establish the obligations of the parties including, without limitation, all amounts due and owing to the Executive.</p></td></tr></table></div>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;text-indent:15.87%;font-size:11pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.95%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the parties agree as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Retirement Date</font><font style="color:#000000;">.&nbsp;&nbsp;Executive acknowledges and agrees that his status as an officer and employee of the Company ended effective as of the Retirement Date.&nbsp;&nbsp;Executive hereby agrees to execute such further document(s) as shall be determined by the Company as necessary or desirable to give effect to the termination of Executive&#8217;s status as an officer of the Company as of the Retirement Date; </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;">, that such documents shall not be inconsistent with any of the terms of this Agreement.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Final Paycheck; Payment of Accrued Wages and Expenses</font><font style="color:#000000;">.&nbsp;&nbsp;The Company will pay Executive all accrued but unpaid base salary and all accrued and unused vacation earned through the Retirement Date, subject to standard payroll deductions and withholdings.&nbsp;&nbsp;The Company will reimburse Executive for all outstanding expenses incurred prior to the Retirement Date which are consistent with the Company&#8217;s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company&#8217;s requirements with respect to reporting and documenting such expenses.&nbsp;&nbsp;Executive is entitled retain or be paid these payments regardless of whether Executive executes this Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Retirement Payments and Benefits</font><font style="color:#000000;">.&nbsp;&nbsp;Without admission of any liability, fact or claim, the Company hereby agrees, subject to this Agreement becoming effective and irrevocable within forty-five days following the Retirement Date and continued compliance with the terms and conditions of the Proprietary Information and Inventions Agreement entered into between Executive and the Company (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Confidentiality Agreement</font><font style="color:#000000;">&#8221;), to provide Executive the severance benefits set forth below.&nbsp;&nbsp;Specifically, the Company and Executive agree as follows: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Severance</font><font style="color:#000000;">.&nbsp;&nbsp;The Company shall pay to Executive an amount equal to $629,290.28, which constitutes twelve (12) months of Executive&#8217;s base salary as in effect on the Effective Date and Executive&#8217;s target bonus for 2020, pro-rated through the Retirement Date, such </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">payment to be made in a single lump sum</font><font style="color:#000000;">, less applicable withholdings and deductions,</font><font style="color:#000000;"> on the first payroll date following the date this Agreement becomes effective and irrevocable</font><font style="color:#000000;">.</font><font style="font-weight:bold;font-family:Calibri;color:#000000;"> </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Healthcare Continuation</font><font style="color:#000000;">.  If Executive timely elects to receive continued healthcare coverage pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="text-decoration:underline;color:#000000;">COBRA</font><font style="color:#000000;">&#8221;), the Company shall directly pay, or reimburse Executive for, the COBRA or Medicare and Medicare Supplement premiums for Executive and COBRA premiums for Executive&#8217;s covered dependents (including his spouse)  through the earlier of (i) the twelve (12)-month anniversary of the Retirement Date or (ii) the date on which Executive and/or Executive&#8217;s covered dependents, if any, become eligible for healthcare coverage under another employer&#8217;s plan(s); </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;">, that the Company will continue to pay for the COBRA. Medicare and Medicare Supplement  premiums for Executive if he is not eligible for coverage under another employer&#8217;s plan(s) and COBRA premiums for those family member(s) who are not eligible for coverage under another employers plan(s) pursuant to COBRA; </font><font style="font-style:italic;color:#000000;">provided further</font><font style="color:#000000;">, that after the Company ceases to directly pay or reimburse premiums pursuant to this Section 3(b), Executive may, if eligible, elect to continue healthcare coverage at Executive&#8217;s expense in accordance with the provisions of COBRA.&nbsp;&nbsp;Executive acknowledges that Executive shall be solely responsible for all matters relating to Executive&#8217;s continuation of coverage pursuant to COBRA and Medicare and Medicare Supplemental coverage, including, without limitation, Executive&#8217;s election of such coverage and his timely payment of premiums.&nbsp;&nbsp;Executive shall be responsible for providing documentation of Medicare and Medicare Supplemental coverage premiums to the Company, and the Company may elect to pay monthly or make a one-time payment of such premiums; provided that Executive shall be responsible for any tax consequences from the payments above.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Stock Options</font><font style="color:#000000;">.&nbsp;&nbsp;Executive acknowledges and agrees that the unvested portion of each option to purchase Company common stock held by Executive as of the Retirement Date terminated as of such date.&nbsp;&nbsp;The vested portion of each option to purchase Company common stock that is outstanding and held by Executive as of the Retirement Date shall remain eligible to be exercised through the three month anniversary of the Retirement Date. If by the three month anniversary of the Retirement Date, the Company has not received a duly executed notice of exercise and remuneration in accordance with Executive&#8217;s option agreements, Executive&#8217;s vested options shall automatically terminate and be of no further effect.&nbsp;&nbsp;Executive agrees that the agreements evidencing Executive stock options shall automatically be deemed amended to the extent necessary to reflect the terms of this Section 3(c).</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">SEC Reporting.&nbsp;&nbsp;</font><font style="color:#000000;">Executive acknowledges that to the extent required by the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Exchange Act</font><font style="color:#000000;">&#8221;), Executive will have continuing obligations under Section 16(a) and 16(b) of the Exchange Act to report any matching transactions in Company common stock for six (6) months following the Retirement Date.&nbsp;&nbsp;Executive hereby agrees not to undertake, directly or indirectly, any matching transactions until the end of such six (6) month period.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(e)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Sole Retirement Benefit</font><font style="color:#000000;">.&nbsp;&nbsp;Executive agrees that the payments provided by this Section 3 are not required under the Company&#8217;s normal policies and procedures and are provided as a severance solely in connection with this Agreement.&nbsp;&nbsp;Executive acknowledges and agrees that the payments referenced in this Section 3 constitute adequate and valuable consideration, in and of themselves, for the promises contained in this Agreement.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="text-decoration:none;Background-color:#auto;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Full Payment</font><font style="color:#000000;">.&nbsp;&nbsp;Executive acknowledges that the payment and arrangements herein shall constitute full and complete satisfaction of any and all amounts properly due and owing to Executive as a result of his employment with the Company and the termination thereof.&nbsp;&nbsp;Executive further acknowledges that, other than the Confidentiality Agreement, this Agreement shall supersede each agreement entered into between Executive and the Company regarding Executive&#8217;s employment, including, without limitation, the Severance Agreement , any offer letter, employment agreement, bonus plan or arrangement, severance and/or change in control agreement, and each such agreement shall be deemed terminated and of no further effect as of the Effective Date.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Executive&#8217;s Release of the Company</font><font style="color:#000000;">.&nbsp;&nbsp;Executive understands that by agreeing to the release provided by this Section 5, Executive is agreeing not to sue, or otherwise file any claim against, the Company or any of its directors, officers, employees, investors or other agents for any reason whatsoever based on anything that has occurred as of the date Executive signs this Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Released Claims.&nbsp;&nbsp;</font><font style="color:#000000;">On behalf of Executive and Executive&#8217;s heirs, assigns, executors, administrators, trusts, spouse and estate, Executive hereby releases and forever discharges the &#8220;</font><font style="text-decoration:underline;color:#000000;">Releasees</font><font style="color:#000000;">&#8221; hereunder, consisting of the Company and each of its owners, affiliates, subsidiaries, predecessors, successors, assigns, agents, directors, officers, partners, employees, and insurers, and all persons acting by, through, under or in concert with them, or any of them, of and from any and all manner of action or actions, cause or causes of action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims, demands, damages, loss, cost or expense, of any nature whatsoever, known or unknown, fixed or contingent (hereinafter called &#8220;</font><font style="text-decoration:underline;color:#000000;">Claims</font><font style="color:#000000;">&#8221;), which Executive now has or may hereafter have against the Releasees, or any of them, by reason of any matter, cause, or thing whatsoever from the beginning of time to the date hereof, including, without limiting the generality of the foregoing, any Claims arising out of, based upon, or relating to Executive&#8217;s hire, employment, remuneration or termination by the Releasees, or any of them, Claims arising under federal, state, or local laws relating to employment, Claims of any kind that may be brought in any court or administrative agency, including any Claims arising under Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. &#167;&#160; 2000, et seq.; Americans with Disabilities Act, as amended, 42&#160;U.S.C. &#167;&#160;12101 et seq.; the Rehabilitation Act of 1973, as amended, 29&#160;U.S.C. &#167;&#160;701 et seq.; Age Discrimination in Employment Act, as amended, 29 U.S.C. &#167;&#160;621, et seq.; Civil Rights Act of 1866, and Civil Rights Act of 1991; 42 U.S.C. &#167;&#160;1981, et seq.; Equal Pay Act, as amended, 29 U.S.C. &#167;&#160;206(d); regulations of the Office of Federal Contract Compliance, 41 C.F.R. Section 60, et seq.; The Family and Medical Leave Act, as amended, 29&#160;U.S.C.&#160;&#167;&#160;2601 et&#160;seq.; the Fair Labor Standards Act of 1938, as amended, 29&#160;U.S.C. &#167;&#160;201 et seq.; the Employee Retirement Income Security Act, as amended, 29 U.S.C. &#167;&#160;1001 et seq.; the Worker Adjustment and Retraining Notification Act, as amended, 29 U.S.C. &#160;&#167; 2101 et seq.; the California Fair Employment and Housing Act, as amended, Cal. Lab. Code &#167; 12940 et seq.; the California Equal Pay Law, as amended, Cal. Lab. Code &#167;&#167; 1197.5(a),199.5; the Moore-Brown-Roberti Family Rights Act of 1991, as amended, Cal. Gov&#8217;t Code &#167;&#167;12945.2, 19702.3; California Labor Code &#167;&#167; 1101, 1102; the California WARN Act, California Labor Code &#167;&#167; 1400 et. seq; California Labor Code &#167;&#167; 1102.5(a),(b); Claims for wages under the California Labor Code and any other federal, state or local laws of similar effect; the employment and civil rights laws of California; Claims for breach of implied or express contract; Claims arising in tort, including, without limitation, Claims of wrongful dismissal or discharge, discrimination, harassment, retaliation, fraud, misrepresentation, defamation, libel, slander, defamation, infliction of emotional distress, violation of public policy, and/or breach of the implied covenant of </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">good faith and fair dealing;</font><font style="color:#000000;"> and Claims for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney&#8217;s fees</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Unreleased Claims.&nbsp;&nbsp;</font><font style="color:#000000;">Notwithstanding the generality of the foregoing, Executive does not release the following claims:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.89%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(i)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.89%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Claims for workers&#8217; compensation insurance benefits under the terms of any worker&#8217;s compensation insurance policy or fund of the Company;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.89%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Claims to continued participation in certain of the Company&#8217;s group benefit plans pursuant to the terms and conditions of COBRA;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.89%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(iv)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Claims to any benefit entitlements vested as the date of Executive&#8217;s employment termination, pursuant to written terms of any Company employee benefit plan;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.89%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(v)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Claims for indemnification under any written indemnification agreement between Executive and the Company, the Company&#8217;s Bylaws or any applicable law; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.89%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(vi)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Executive&#8217;s right to bring to the attention of the Equal Employment Opportunity Commission claims of discrimination; </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="font-style:italic;color:#000000;">however</font><font style="color:#000000;">, that Executive does release Executive&#8217;s right to secure any damages for alleged discriminatory treatment.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Acknowledgement.&nbsp;&nbsp;</font><font style="color:#000000;">In accordance with the Older Workers Benefit Protection Act of 1990, Executive has been advised of the following:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.89%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(i)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Executive should consult with an attorney before signing this Release;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.89%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(ii)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Executive has been given at least twenty-one (21) days to consider this Agreement;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:13.89%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(iii)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Executive has twenty-four (24) days after signing this Agreement to revoke it.&nbsp;&nbsp;If Executive wishes to revoke this Agreement, Executive must deliver notice of Executive&#8217;s revocation in writing, no later than 5:00 p.m. on the 24th day following Executive&#8217;s execution of this Agreement to Lloyd Rowland, Senior Vice President, General Counsel, email: lrowland@cytomx.com. Executive understands that if he revokes this Agreement, it will be null and void in its entirety, and he will not be entitled to any payments or benefits provided in Section 3 of this Agreement.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(d)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:12pt;margin-left:11.9%;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:12pt;margin-left:11.9%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.&#8221;</font></p>
<p style="margin-top:12pt;margin-bottom:12pt;margin-left:11.9%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Non-Disparagement, Transition and Transfer of Company Property</font><font style="color:#000000;">.&nbsp;&nbsp;Executive further agrees that:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(a)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Non-Disparagement</font><font style="color:#000000;">.&nbsp;&nbsp;For a period of five years following the Retirement Date, Executive agrees that he shall not disparage, criticize or defame the Company, its affiliates and their respective affiliates, directors, officers, agents, partners, stockholders, employees, products, services, technology or business, either publicly or privately.&nbsp;&nbsp;Nothing in this Section 6(a) shall have application to any evidence or testimony required by any court, arbitrator or government agency.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(b)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Transition</font><font style="color:#000000;">.&nbsp;&nbsp;Each of the Company and Executive shall use their respective reasonable efforts to cooperate with each other in good faith to facilitate a smooth transition of Executive&#8217;s duties to other executive(s) of the Company.&nbsp;&nbsp;Without limiting the foregoing, Executive shall be available, on a non-exclusive basis, to respond to, and shall respond with reasonable promptness and completeness to, e-mail and telephone inquiries from the Company regarding transitional matters provided that such inquiries would not interfere in any significant manner with other business pursuits (including other employment) by Executive.&nbsp;&nbsp;For the avoidance of doubt, nothing in this Section 6(b) shall entitle Executive to the vesting of any stock options or otherwise prevent Executive&#8217;s unvested stock options from terminating effective as of the Retirement Date.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(c)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-style:italic;color:#000000;">Transfer of Company Property</font><font style="color:#000000;">.&nbsp;&nbsp;Executive represents and warrants that he has turned over to the Company all files, memoranda, records, and other documents, and any other physical or personal property which are the property of the Company and which he had in his possession, custody or control at or prior to the time he signed this Agreement, except as is necessary to execute any obligations under a future consulting arrangement contemplated between the parties or as otherwise mutually agreed.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Executive Representations</font><font style="color:#000000;">.&nbsp;&nbsp;Executive warrants and represents that (a) he has not filed or authorized the filing of any complaints, charges or lawsuits against the Company or any affiliate of the Company with any governmental agency or court, and that if, unbeknownst to Executive, such a complaint, charge or lawsuit has been filed on his behalf, he will immediately cause it to be withdrawn and dismissed, (b) he has reported all hours worked as of the date of this Agreement and has been paid all compensation, wages, bonuses, commissions, and/or benefits to which he may be entitled and no other compensation, wages, bonuses, commissions and/or benefits are due to her, except as provided in this Agreement, (c) he has no known workplace injuries or occupational diseases and has been provided and/or has not been denied any leave requested under the Family and Medical Leave Act or any similar state law, (d) the execution, delivery and performance of this Agreement by Executive does not and will not conflict with, breach, violate or cause a default under any agreement, contract or instrument to which Executive is a party or any judgment, order or decree to which Executive is subject, and (e) upon the execution and delivery of this Agreement by the Company and Executive, this </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">Agreement will be a valid and binding obligation of Executive, enforceable in accordance with its terms.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">No Assignment by Executive</font><font style="color:#000000;">.&nbsp;&nbsp;Executive warrants and represents that no portion of any of the matters released herein, and no portion of any recovery or settlement to which Executive might be entitled, has been assigned or transferred to any other person, firm or corporation not a party to this Agreement, in any manner, including by way of subrogation or operation of law or otherwise.&nbsp;&nbsp;If any claim, action, demand or suit should be made or instituted against the Company or any other Releasee because of any actual assignment, subrogation or transfer by Executive, Executive agrees to indemnify and hold harmless the Company and all other Releasees against such claim, action, suit or demand, including necessary expenses of investigation, attorneys&#8217; fees and costs.&nbsp;&nbsp;In the event of Executive&#8217;s death, this Agreement shall inure to the benefit of Executive and Executive&#8217;s executors, administrators, heirs, distributees, devisees, and legatees.&nbsp;&nbsp;None of Executive&#8217;s rights or obligations may be assigned or transferred by Executive, other than Executive&#8217;s rights to payments hereunder, which may be transferred only upon Executive&#8217;s death by will or operation of law.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">9.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Governing Law</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of California or, where applicable, United States federal law, in each case, without regard to any conflicts of laws provisions or those of any state other than California.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">10.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Miscellaneous</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement, together with the Confidentiality Agreement, comprises the entire agreement between the parties with regard to the subject matter hereof and supersedes, in their entirety, any other agreements between Executive and the Company with regard to the subject matter hereof, including, without limitation, the Severance Agreement.&nbsp;&nbsp;The Company and Executive acknowledge that the termination of the Executive&#8217;s employment with the Company is intended to constitute an involuntary separation from service for the purposes of Section 409A of the Code, and the related Department of Treasury regulations.&nbsp;&nbsp;Executive acknowledges that there are no other agreements, written, oral or implied, and that he may not rely on any prior negotiations, discussions, representations or agreements.&nbsp;&nbsp;This Agreement may be modified only in writing, and such writing must be signed by both parties and recited that it is intended to modify this Agreement.&nbsp;&nbsp;This Agreement may be executed in separate counterparts, each of which is deemed to be an original and all of which taken together constitute one and the same agreement.&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">11.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Company Assignment and Successors</font><font style="color:#000000;">.&nbsp;&nbsp;The Company shall assign its rights and obligations under this Agreement to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise).&nbsp;&nbsp;This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns, personnel and legal representatives.&nbsp;&nbsp;&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">12.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Maintaining Confidential Information</font><font style="color:#000000;">.</font><font style="font-weight:bold;color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">Executive reaffirms his obligations under the Confidentiality Agreement.&nbsp;&nbsp;Executive acknowledges and agrees that the payments provided in Section 3 above shall be subject to Executive&#8217;s continued compliance with Executive&#8217;s obligations under the Confidentiality Agreement.&nbsp;&nbsp;For the avoidance of doubt, nothing in this Agreement or the Confidentiality Agreement will be construed to prohibit Executive from filing a charge with, reporting possible violations to, or participating or cooperating with any governmental agency or entity, including but not limited to the EEOC, the Department of Justice, the Securities and Exchange Commission, Congress, or any agency Inspector General, or making other disclosures that are protected under the whistleblower, anti-discrimination, or anti-retaliation provisions of federal, state or local law or regulation. Executive does not need </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="color:#000000;">the prior authorization of the Company to make any such reports or disclosures, and Executive is not required to notify the Company that Executive has made such reports or disclosures.</font><font style="color:#000000;"> </font><font style="color:#000000;">F</font><font style="color:#000000;">urthermore, in accordance with 18 U.S.C. &#167; 1833, notwithstanding anything to the contrary in </font><font style="color:#000000;">the Confidentiality Agreement or </font><font style="color:#000000;">this Agreement: (</font><font style="color:#000000;">i</font><font style="color:#000000;">) </font><font style="color:#000000;">Executive </font><font style="color:#000000;">shall not be in breach of </font><font style="color:#000000;">the Confidentiality Agreement or </font><font style="color:#000000;">this Agreement, and shall not be held criminally or civilly liable under any federal or state trade secret law (x) for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (y) for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (ii) if </font><font style="color:#000000;">Executive </font><font style="color:#000000;">file</font><font style="color:#000000;">s</font><font style="color:#000000;"> a lawsuit for retaliation by the Company for reporting a suspected violation of law, </font><font style="color:#000000;">Executive </font><font style="color:#000000;">may</font><font style="color:#000000;"> disclose the trade secret to Executive&#8217;s</font><font style="color:#000000;"> attorney, and may use the trade secret information in the court proceeding, if </font><font style="color:#000000;">Executive </font><font style="color:#000000;">file</font><font style="color:#000000;">s</font><font style="color:#000000;"> any document containing the trade secret under seal, and do</font><font style="color:#000000;">es</font><font style="color:#000000;"> not disclose the trade secret, except pursuant to court orde</font><font style="color:#000000;">r.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.95%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">13.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:11pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Executive&#8217;s Cooperation</font><font style="color:#000000;">.&#160; After the Retirement Date, Executive shall cooperate with the Company and its affiliates, upon the Company&#8217;s reasonable request, with respect to any internal investigation or administrative, regulatory or judicial proceeding involving matters within the scope of Executive&#8217;s duties and responsibilities to the Company or its affiliates during his employment with the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company&#8217;s reasonable request to give testimony without requiring service of a subpoena or other legal process, and turning over to the Company all relevant Company documents which are or may have come into Executive&#8217;s possession during his employment); </font><font style="font-style:italic;color:#000000;">provided</font><font style="color:#000000;">, </font><font style="font-style:italic;color:#000000;">however</font><font style="color:#000000;">, that any such request by the Company shall not be unduly burdensome or interfere with Executive&#8217;s personal schedule&#160;or ability to engage in gainful employment.&#160;&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Signature page(s) follow)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.94%;">IN WITNESS WHEREOF, the undersigned have caused this Retirement Agreement to be duly executed and delivered as of the date indicated next to their respective signatures below.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DATED: 11-December-2020</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:47.62%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Michael Kavanaugh</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:47.62%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">W. Michael Kavanaugh, M.D.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:47.62%;text-indent:-47.62%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:-47.62%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:47.62%;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CYTOMX THERAPEUTICS, INC.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DATED:&nbsp;&nbsp;1-December-2020</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:47.62%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: /<font style="text-decoration:underline;">s/ Lloyd Rowland</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:47.62%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name: Lloyd Rowland </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:47.62%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;Senior Vice President, General Counsel</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:-7.94%;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Signature page to Retirement Agreement]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Courier;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ctmx-ex231_6.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ctmx-ex231_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1 </p>
<p style="text-align:center;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-216567 and 333-228203) and Form S-8 (Nos. 333-207694, 333-209992, 333-215795, 333-223491, 333-229916 and 333-236711) of CytomX Therapeutics, Inc. of our report dated February 24, 2021, with respect to the financial statements of CytomX Therapeutics, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2020.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Ernst &amp; Young LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redwood City, California </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 24, 2021</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ctmx-ex311_9.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ctmx-ex311_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="FIS_CERTIFICATION"></a><a name="FIS_CERTIFICATION"></a>Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Sean A. McCarthy, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.21%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of CytomX Therapeutics, Inc. for the year ended December&#160;31, 2020;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.21%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.21%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.21%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.25%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.25%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.25%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.21%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.25%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.25%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 24, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:59.97%;width:194.6pt;;">
<tr>
<td style="width:194.6pt;"></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sean A. McCarthy</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sean A. McCarthy, D.Phil.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"><a name="eolPage126"></a><a name="D657912DEX312_HTM"></a><a name="FIS_EXHIBIT_31_2"></a>&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ctmx-ex312_8.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ctmx-ex312_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="FIS_CERTIFICATION_2"></a><a name="FIS_CERTIFICATION_2"></a>Exhibit 31.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATIONS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Carlos Campoy, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.21%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of CytomX Therapeutics, Inc. for the year ended December&#160;31, 2020;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.21%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.21%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.21%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.25%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.25%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;&nbsp;&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.25%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.25%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.21%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.04%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.25%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.25%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.12%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: February 24, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:59.97%;width:194.6pt;;">
<tr>
<td style="width:194.6pt;"></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" >
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carlos Campoy</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carlos Campoy</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;"><a name="eolPage127"></a><a name="D657912DEX321_HTM"></a><a name="FIS_EXHIBIT_32"></a>&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ctmx-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
ctmx-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="FIS_CERTIFICATION_3"></a><a name="FIS_CERTIFICATION_3"></a>Exhibit 32.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 1350 CERTIFICATIONS*</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:3.99%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section&#160;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167; 1350), Sean A. McCarthy, D.Phil., President and Chief Executive Officer of CytomX Therapeutics, Inc. (the &#8220;Company&#8221;) and Carlos Campoy, Chief Financial Officer of the Company, each hereby certify that, to the best of his knowledge:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.99%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. The Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020 to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;), fully complies with the requirements of Section&#160;13(a) or 15(d) of the Exchange Act; and</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:3.99%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the period covered by the Annual Report.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: February&#160;24, 2021</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  style="width:48.22%;">
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:2%;">
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.12%;">
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="middle"  style="width:48%;">
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Sean A. McCarthy</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="bottom"  style="width:1.12%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carlos Campoy</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sean A. McCarthy, D.Phil.</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Carlos Campoy</p></td>
</tr>
<tr>
<td valign="top"  style="width:48.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">President and Chief&#160;Executive&#160;Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
<td valign="bottom"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;line-height:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer and Principal Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt #000000;padding-bottom:0pt;margin-top:0pt;margin-right:89.93%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;line-height:2pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.25%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;">This certification accompanies the Annual Report on Form 10-K, to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>ghwd5ikruv45000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ghwd5ikruv45000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #- 6@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Y#Q!X_L-)9[>S N[I>#@_(A]
MSW^@K#\<>,W:632=,E*HORSS(>6/=0?3U->?1123RB.)"[MT K>G2OK(^?S#
M-W&3I8??O_D;NH^--=U)COO6AC/_ "S@^0?X_K6;I\TLVLV;2RNY\].68G^(
M5I6OAP8#74AS_<3_ !K9T_2;&*^MRMNN1*I!))/45KS16QY<:&(JR4JDOO9Z
MM7CFIRR1ZU>E'93Y[\J<=S7L=<!J&FV<M]<%H%W&1B2"1WKR,7%R2L?3XVFY
MQ5C$LO%&KV+#9=M(H_@E^8?XUV>C>-+/4&6"[ MISP"3\C'Z]OQKD;G05P6M
MI"#_ '7_ ,:Q98I()#'*A5AU!KDC5JTGY'!&M7H/75'M]%<!X3\4O%(FG7\F
MZ)OEBE8_=/H?:NOUC5H-&L&N9N6Z1H#R[>E>C"M&<.8]6GB(3AS_ 'DNH:E:
M:7;F>[F$:]AU+'T KAM3\>7D[,EA&MO'V=AN<_T%<[J6IW.JW;7%U(68_=7L
MH]!3K+2Y[P!_]7%_>8=?H*X:F)G-VAHCSJN,J59<M/1$=QJ=]=DFXNYI,_WG
M.*[GX?$G2[K/_/?_ -E%846BV<8^96D/JQ_PKK_"\$5O93+#&$!DR0/I58:$
MO:79>$HS552DS=HHHKT3U0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "N:\;:Z=$T)O);%U<'RXB.J^
MK?@/YBNEKR+XDWYN?$@M0?DM8@N/]IN3_2M*<>:1Y^9XAT,,Y1W>B./1'ED5
M%!9V. /4UV&G:?'808&#*P^=_7V^E8_AVV$ES)<,.(QA?J?_ *U=+71-]#YW
M T4H^T>X5-:?\?L'_71?YU#4UI_Q^P?]=%_G69Z,=T>E5Q5W_P ?D_\ UT;^
M==K7%7?_ !^3_P#71OYUY^(V1[5?9$-5;ZQCO8=K8$@^XWI_]:K5%<K5]&<K
M2:LSBG1XI&1QM93@BK>H:K=ZF+<7,FX01A%_Q/O5O7K<+-'.H^^-K?4?_6_E
M60 6( ZDX%<KO%N)YDTX-P-+2=/%TYFE'[E#T_O'_"ND P,#@"HK:!;:VCA7
MHHQ]3WJ6NB$>5'H4J:A&P5T7AW_CUF_W_P"E<[71>'?^/6;_ '_Z5O1^,Z:/
MQ&S1117:=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7A?B]R_BW4B?^>Q'Y "O=*\3\=6QMO%][D<
M2%9%]\J/ZYK:A\1X>?)^PB_/]&2>' !I\A[F4_R%;%8?AJ4&">'/(8./QX_I
M6Y6DMSAPK3HQL%36G_'[!_UT7^=0U-:?\?L'_71?YU)TQW1Z57%7?_'Y/_UT
M;^==K7%7?_'Y/_UT;^=>?B-D>U7V1#1117*<QF:Z =/!])!_6L*R :_MP>GF
M+_.MG7Y0+>*+NS;OP _^O6'!)Y5Q')_<<-^1KGJ/WS@KM>U.SHH!!&1T/2BN
M@[PKHO#O_'K-_O\ ]*YVNB\._P#'K-_O_P!*UH_&:T?B-FBBBNTZPHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "O._B?I+/%:ZK&N=G[F7 ['E3_,?B*]$JO?64.HV,UI<+NBE4JPJH
M2Y7<YL9AUB*,J??\SP/3;S[%>I*?N'Y7'M79JP=0RD%2,@CN*Y37=%N=!U.2
MSN 2!S')CAU[$4_2M8:SQ#-EH,\$=4_^M75)<RNCY'#U70DZ573]#J:FM/\
MC]@_ZZ+_ #JM#-%<1B2%U=3W!JS:?\?L'_71?YUF>K!IM-'I5<5=_P#'Y/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQJWG3D]U!Y_,X'XTOC;_ )''4O\ KH/_ $$5NM-#G>NI[+H/_(NZ9_UZ1?\
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M0]+31M&M;!,$Q)AV'\3=2?SJY2T,XPM(T*\*\;?\CCJ7_70?^@BO=:\T\1>
M-7U;Q!>7UO-:"*9PRAW8'H!S\OM2@[,J:;6AW>@_\B[IG_7I%_Z *OD@#).
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gzkk5j0cumnd000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkk5j0cumnd000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /#",H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #O11WHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB1XSC^WVMXFDV;\QQD<D=CT-2G=Z="K65V>STUW6-&=V"JHR2>U>,#Q9XP\
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MOMLUIYH\Z%=T@]!4NGZA;ZG9I=6K[X7Y5O6O#CJ_B?R_$6K^18XD81N<MQC
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MD0MM#KGTS0SHOWF4?4T .HHSD9%-9U099@OU.* '44BLKC*L"/8TM !1110
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M20!ZYH5E895@1[&@!:*0D 9)P*:LL;'"NI/L: 'T444 %%%% !1110 4444
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MFCU+Q#_R+U__ -<6KYSTW2WD^&4>L0+^_P!/U#S,CKC*9_E7T9XA_P"1>O\
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M)L?1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -?\
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MI6$D23,N.?0&MS4_!7@?1/$%A:7E]?2WKN#%&)6?!]\M6J7+**_IF;?,G?\
MX8E^)FMZS:^.-)@T>X9&GC"@9XYR,TGB#PCXLTC0YM=C\27#W<">:Z[C@CKC
MK3_&RJ/BKX>5?NB,8S^->B^-?^1'U7_KU;^59/W:/,M[LO>HHOLCG=(\>O\
M\*Q_M^[^:X2,@_[39Q7,:%H'BSQU8C6K[7)K6*?YH88R0%';O67:6<UY\"G\
ME2QC8N0/3<:]+^&6JVFH>"-/$$BEHHPKJ#]T@5JTG*;[6_$A.T8KU_ Y+PWX
MAU_PKXVC\+:_=M>0SC,$S=>V!^M/\4>(M=\2^-#X7\/W9M(X1FXF7K_GD52\
M5W46M?&C1;>Q82M:$-*5[<K3?#,R:)\9M6AOV$;7*CRBW\73I^53#W^7F\_G
M;8J7NJ5O+Y7+&H^&/&7A&2WU#2]7GOU\P":!R3D9&>];OC#4O%5Y!IEAHL3V
MTEVH,\XS^[Z?XUTGC#Q99^%-*%W.%D=W"I%GEB3_ /7KSWQ=XTU?5=<TO0-,
M<6'VV-7:0CD9 /'YTOBM'?7^D&VOD,UOP1X@T72)-4B\4SB[B7>0\G#?K6YX
M<\47VN_"FZU"XD/VN.%U,@ZDA>M<_P"(_  TOP[=7^M>);R?;'E5:5@"?3&:
M/AX5_P"%,ZEM.1LEQ_WS2D_<FNR'%>]%^9G^!=)\3^-=(-U+KD]O!%(5C",1
MGD]>:V_$NNZ]>^(K;P=H=\\4L: 7-SD[JV?@H/\ BA4_Z[/_ .A&N=M9DT3X
MZ7S7Q$:WB@0LW0_YQ6LDO:J'3];$)ODE+JO\R74_"?C+PM'%J>EZU<7KJX\V
M!F)WC\ZL_$C6]2BT70IP[VT\LB^:H..<<UWOBSQ19^%]%:_N-K\@(F?O&O-/
MBAJ1U;0] O?),0EF5@I[=:A-MI?WD5;KY,E^*6M:KIO_  CYTZ=DFEP,9X)/
MK3M0\%^+3HLFL/XDG%\D9EV!CM&!G'6H?B8,ZAX4S_?6O5=4_P"1:N_^O9OY
M4GI3E+K=C6LXKR1Q7@CQQ<77@*ZU/5&WSV082-_>P2*YO0['Q5\1A+JL^L2V
M5@S'R8HR1QZ]:H^%+26]^%OB*& $R%WP!WY-=M\'=4M;GP9;V:.HN+8;)$[@
MU=E*3;[+\2/ABDN[.=LM8\1> ?&%KH^L7S7VG7AVQ2.3E3^?O4/Q UG7(_B+
MI]CH]TT37,>T<\#/>I?BE=PZKXW\/:79L)+F&</(%ZJ,BDUZ/9\8M#5NJQC^
ME3#WN2_=_=9E2]WFMV7YE/Q;HWBKP9IL6OQZ_//*KCS49C@_K6C::%XL\9Z&
MNLW&N2VK2)OAAC) '''>NB^,?_(A3?[Z_P Q6YX*_P"1&T[_ *]E_P#014W]
MR;[;?<#T<?,Y;X7>*-4U#2=3M-0D:YN=/D,88]6Q6;::%XQ\97=U=:EJ<^G6
MJN1' A(X]>M4/ASJ)TF/QA?A=Q@N&8#UZ4GAK3_$/Q&@EU2XU^6R@+D"&W..
M/P(JW[TK^2%\-UYA97VN^"?B!8Z//K+7]C=G 5GSM/'O[U[@IRH/J*^<-3T:
MQT+XI:):6^H2WDXD7S6DD+8.1ZDU]'1_ZI?H*$[TT_43TG;T'4444AA1110
M4444 %%%% !1110 4444 >*Z7_R7N^_W#_6O8=0_Y!\_^X:\>TO_ )+W??[A
M_K7L.H?\@^?_ '#42_@+T?YLK_EZ_5'SS\/M(\0:]=:I:6&HM8V*W#&1DR&8
M\<=:Z!)_$/@#QS8:?<ZK+>Z?>$*%D)."<>_O6I\$A_H^L?\ 7VW]*B^*7_(\
M>&O^NX_FM:[3@N]OR)>JGY7)/%6I7_AOXE:7>FXD_LZ] 5DS\H_SBNH^(_B)
MM&\'O+;R;;BYQ'"0><DC_&J?Q2T,ZKX*-Q$O^D6@$J$=>*\]AUA_B!K/AW2P
M2T=L@DN!Z,,]?R%9Q7,O9^?X;E-\K]IY?B:/BJYU?P_\,]*G%U+]L=U=B3R2
M<<58_P"$5\6ZGX;_ +:N/$,\=R(A)'&C$*!^=:GQHB6+PUI\2C"K.HQ^(KM8
MN/ Z_P#7H/Y4Y/W9S7?]!16L(OM^IY5X0N/%WQ!T]H)M6>UM[4^6SH2&D8>I
MS6CX1U'7/#?Q$D\+ZCJ#WEN\?F1LY)Q_G-7O@A_R!+__ *^6_I5*_&?V@(!_
MTZ_T%7M4275?H1O"7E_F&LZ]K_C3QE-H&A7C65G;<32KG)_SFJ^O:/XL^']N
MFLVFM37=K&P\^&0DY&?K2?#^YBT7XE:W87S".:>3='N_BZ5V/Q8U6TL?!%W#
M-(OFS@+&G=CFLV^6G&4=V:I<U1Q>Q@^/_%D]W\+[?6;"5HI)&0G:>^.16?9^
M%_%NO^&TU>YU^:&;RM\42$@#'XUDZ_9RV?P-LDF4AFD1L'T(->OZ*,>";?'_
M #Z_TJII151KH_T(3?N?UU/)O!U[XP\=6TFFRZL]O!:'8\RD[I#]<UH^'[W7
M?"/Q)C\.7VI27MI<)O4N2<=/\:M_!/\ U6K?]?+?TJ'Q+_R772_^N(_]EJEI
M.'GO]PFO=GY;?>:OBO\ X2W7O%"Z1I<TEAIR+F2=<C?7,>+-$\0> [)-8M/$
MLLGEN/,BDDY89'O5O4]:USQCX[N?#UC?_P!G6UL.70?,W3_&L/XD>#+?P[X9
M:>_UVZO+QV 1)93@\C/&:R3M%277\=32UY<K/<?#>I/JWA^RO9/ORQ*S?4BM
M6N9^'YSX*TS'_/!?Y"NFK:HK2:,8.\4PHHHJ"PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***K3ZC96K[+B
M[@B;KMDD"G]: +-%4?[:TK_H)6?_ '_7_&C^VM*_Z"5G_P!_U_QH O451_MK
M2O\ H)6?_?\ 7_&C^VM*_P"@E9_]_P!?\: +U%4?[:TK_H)6?_?]?\:/[:TK
M_H)6?_?]?\: +U07EI#?6DMK.@>*52K*>X-0?VUI7_02L_\ O^O^-']M:5_T
M$K/_ +_K_C2:35F"=CSP?!J"WGD-AK=[:6[L6\B,C:/TJTOPATJ'5=.U&VN9
MHKFT;<S@Y,IYZY^M=S_;6E?]!*S_ ._Z_P"-']M:5_T$K/\ [_K_ (TT[; ]
M2CXD\*Z7XIL/LNHP+(!]UNZFN ;X(1!\0^(M1BA_YYJXQ_*O3?[:TK_H)6?_
M '_7_&C^VM*_Z"5G_P!_U_QI))#N8GA/P)I/A-&:U0R7#_?F?EFK2\1>&]/\
M3::]EJ$*NA^Z>ZGU%6?[:TK_ *"5G_W_ %_QH_MK2O\ H)6?_?\ 7_&G+WMQ
M+38\M/P=U&T9HM.\2WD5N3PA(X'MQ72^$/AEIOAFY-]+*][?-_RWFY(KK?[:
MTK_H)6?_ '_7_&C^VM*_Z"5G_P!_U_QIIM":N2:CIUKJEC)9W<2RPR##*PKR
MVX^#4MI<O)HFNW5G$YSY2D;1].*]._MK2O\ H)6?_?\ 7_&C^VM*_P"@E9_]
M_P!?\:FVMRKZ6."\/?".ST_4EU+5KV;4KE3E?..0I]J]*4!5"J, =!5+^VM*
M_P"@E9_]_P!?\:/[:TK_ *"5G_W_ %_QJKZ6)MU+U%4?[:TK_H)6?_?]?\:/
M[:TK_H)6?_?]?\:0R]15'^VM*_Z"5G_W_7_&C^VM*_Z"5G_W_7_&@"]15'^V
MM*_Z"5G_ -_U_P :/[:TK_H)6?\ W_7_ !H O451_MK2O^@E9_\ ?]?\:/[:
MTK_H)6?_ '_7_&@"]13%EC>,2)(K1D9# Y&/K50ZSI8.#J5H"/\ ILO^- %Z
MBJ/]M:5_T$K/_O\ K_C1_;6E?]!*S_[_ *_XT 7J*H_VUI7_ $$K/_O^O^-'
M]M:5_P!!*S_[_K_C0!>HJC_;6E?]!*S_ ._Z_P"-']M:5_T$K/\ [_K_ (T
M7J*H_P!M:5_T$K/_ +_K_C1_;6E?]!*S_P"_Z_XT 7J*H_VUI7_02L_^_P"O
M^-']M:5_T$K/_O\ K_C0!>HJC_;6E?\ 02L_^_Z_XT?VUI7_ $$K/_O^O^-
M$&O^'[#Q)IKV5_")(VZ$]0?6N 'P7M]X1]<OGM ?^/<L-N/3I7HW]M:5_P!!
M*S_[_K_C1_;6E?\ 02L_^_Z_XTDDG<=]+$5CH&G6&C+I4-L@M FTIC@BN!U'
MX*Z9/=O/INHW6G!SDK V!^M>A_VUI7_02L_^_P"O^-']M:5_T$K/_O\ K_C3
M>KN):*QPVA_!_2],ODN[Z[GU*6,Y0W!S@UZ&\$4D!@9 8RNTKCC%5?[:TK_H
M)6?_ '_7_&C^VM*_Z"5G_P!_U_QIMW5@ZW/.M6^#L#ZC)?:)J=QISN<F.(_*
M3^51Z?\ !L2WT=UKNKW&H",Y$4A^7^5>D_VUI7_02L_^_P"O^-']M:5_T$K/
M_O\ K_C26FP/4L06L-M;+;Q1JL2KM"@<8KSSQ'\([+4M2;4=+O)M-N6.6\DX
M#'WKN_[:TK_H)6?_ '_7_&C^VM*_Z"5G_P!_U_QH:N[@M%8\Q@^#<]Y<HVM:
M]=7<*'/E$C:WUXKU'3=-M=)L8[.SB6*&,855%,_MK2O^@E9_]_U_QH_MK2O^
M@E9_]_U_QIWTL*VMR]15'^VM*_Z"5G_W_7_&C^VM*_Z"5G_W_7_&D,O451_M
MK2O^@E9_]_U_QH_MK2O^@E9_]_U_QH O451_MK2O^@E9_P#?]?\ &C^VM*_Z
M"5G_ -_U_P : +U%4?[:TK_H)6?_ '_7_&C^VM*_Z"5G_P!_U_QH O451_MK
M2O\ H)6?_?\ 7_&C^VM*_P"@E9_]_P!?\: +U%4?[:TK_H)6?_?]?\:/[:TK
M_H)6?_?]?\: +U%4X]5TZ:01Q7]L[GHJRJ2?UJ>>ZM[5-]Q/'$I_BD8*/UH
MEHJC_;6E?]!*S_[_ *_XT?VUI7_02L_^_P"O^- %ZBJ/]M:5_P!!*S_[_K_C
M1_;6E?\ 02L_^_Z_XT 7J*H_VUI7_02L_P#O^O\ C1_;6E?]!*S_ ._Z_P"-
M %ZBJ/\ ;6E?]!*S_P"_Z_XT?VUI7_02L_\ O^O^- %ZBJ/]M:5_T$K/_O\
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M %ZBJ/\ ;6E?]!*S_P"_Z_XT?VUI7_02L_\ O^O^- %ZBJ/]M:5_T$K/_O\
MK_C1_;6E?]!*S_[_ *_XT 7JI:KI=IK.GR6-]$);>3[RGO2?VUI7_02L_P#O
M^O\ C1_;6E?]!*S_ ._Z_P"-#5]P3L.TS3+71[".RLHA'!&,*H[52B\+Z3#K
M\NMI;*+^4;6ER<D?Y%6_[:TK_H)6?_?]?\:/[:TK_H)6?_?]?\:=W>_4.EBZ
MRAE*GH1@UCZ/X7TG0;FZN-/M5BDNGWRD$_,?\FK?]M:5_P!!*S_[_K_C1_;6
ME?\ 02L_^_Z_XTO,.EBS<01W5O)!*NZ.1=K#U%9^A>'=-\.6;6NF6XAA9BQ4
M$]34_P#;6E?]!*S_ ._Z_P"-']M:5_T$K/\ [_K_ (T 9UOX-T.UU]];BLD6
M_<$&7G-3ZUX8TKQ!);R:C;+,UNVZ,DGY35K^VM*_Z"5G_P!_U_QH_MK2O^@E
M9_\ ?]?\:.WD'F4?$'A'1_$]M#;ZK:+/'"<H"3Q^7TKGQ\'_  8/^86O_?;?
MXUUW]M:5_P!!*S_[_K_C1_;6E?\ 02L_^_Z_XT6L!0T3PAHGA[)TZQCB8_Q#
MD_K6[5'^VM*_Z"5G_P!_U_QH_MK2O^@E9_\ ?]?\:=[A8O451_MK2O\ H)6?
M_?\ 7_&C^VM*_P"@E9_]_P!?\:0%ZBJ/]M:5_P!!*S_[_K_C1_;6E?\ 02L_
M^_Z_XT 7J*H_VUI7_02L_P#O^O\ C1_;6E?]!*S_ ._Z_P"- %ZBJ/\ ;6E?
M]!*S_P"_Z_XT?VUI7_02L_\ O^O^- %ZBJ/]M:5_T$K/_O\ K_C1_;6E?]!*
MS_[_ *_XT 7J*H_VUI7_ $$K/_O^O^-']M:5_P!!*S_[_K_C0!>HI@EC:/S%
MD4QXSN!XQ]:J?VUI8ZZE:?\ ?Y?\: +U%4?[:TK_ *"5G_W_ %_QH_MK2O\
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M]X8TK4M7@U2YME>[@&(W)/%0ZYX.T/Q$ROJ-DDKJ,!N0?TK0_MK2O^@E9_\
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M76HZE=:B(CE$G((!_ "MCQ9\.],\4>1(7>UN8!B.:+AE%='_ &UI7_02L_\
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MP.,5KVFFI::.FGJY*I%Y>X]>F*/[:TK_ *"5G_W_ %_QH_MK2O\ H)6?_?\
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M_P"$5T;_ )\HO^^16S10!C?\(KHW_/E%_P!\BC_A%=&_Y\HO^^16S10!C?\
M"*Z-_P ^47_?(H_X171O^?*+_OD5LT4 8W_"*Z-_SY1?]\BC_A%=&_Y\HO\
MOD5LT4 8W_"*Z-_SY1?]\BJNI^&-(CTJ\=;.(,L#D$*.#M-='5/5O^0-??\
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M^16S10!C?\(KHW_/E%_WR*/^$5T;_GRB_P"^16S10!C?\(KHW_/E%_WR*/\
MA%=&_P"?*+_OD5LT4 8W_"*Z-_SY1?\ ?(H_X171O^?*+_OD5LT4 8W_  BN
MC?\ /E%_WR*/^$5T;_GRB_[Y%;-% &-_PBNC?\^47_?(H_X171O^?*+_ +Y%
M;-% &-_PBNC?\^47_?(H_P"$5T;_ )\HO^^16S10!C?\(KHW_/E%_P!\BC_A
M%=&_Y\HO^^16S10!Y[XSTFSTJ70IK*%89&U%%)08R-K<5/X[ EU+PO;R',4M
MTX=<\-\G>IOB)]W0/^PFG_H+52^(1(U7PCC_ )_'_P#0* .H'A71L?\ 'E%_
MWR*7_A%=&_Y\HO\ OD5L+]T?2EH QO\ A%=&_P"?*+_OD4?\(KHW_/E%_P!\
MBMFB@#&_X171O^?*+_OD4?\ "*Z-_P ^47_?(K9HH QO^$5T;_GRB_[Y%'_"
M*Z-_SY1?]\BMFB@#&_X171O^?*+_ +Y%'_"*Z-_SY1?]\BMFB@#&_P"$5T;_
M )\HO^^11_PBNC?\^47_ 'R*V:* ,;_A%=&_Y\HO^^11_P (KHW_ #Y1?]\B
MMFB@#&_X171O^?*+_OD4?\(KHW_/E%_WR*V:* ,;_A%=&_Y\HO\ OD4?\(KH
MW_/E%_WR*V:* ,;_ (171O\ GRB_[Y%'_"*Z-_SY1?\ ?(K9HH QO^$5T;_G
MRB_[Y%'_  BNC?\ /E%_WR*V:* ,;_A%=&_Y\HO^^11_PBNC?\^47_?(K9HH
M QO^$5T;_GRB_P"^11_PBNC?\^47_?(K9HH QO\ A%=&_P"?*+_OD4?\(KHW
M_/E%_P!\BMFB@#&_X171O^?*+_OD4?\ "*Z-_P ^47_?(K9HH QO^$5T;_GR
MB_[Y%'_"*Z-_SY1?]\BMFB@#&_X171O^?*+_ +Y%'_"*Z-_SY1?]\BMFB@#&
M_P"$5T;_ )\HO^^11_PBNC?\^47_ 'R*V:* ,;_A%=&_Y\HO^^17-^&H$LOB
M/KEI -D"V\3*@Z DO7>UPVB?\E4U[_KUA_F] $&AZ?:ZOXQ\1?;(Q-Y4D03=
MSM^6NG_X171O^?*+_OD5RW@,D^,?%F3_ ,O$?_H)KT*@#&_X171O^?*+_OD4
M?\(KHW_/E%_WR*V:* ,;_A%=&_Y\HO\ OD4?\(KHW_/E%_WR*V:* ,;_ (17
M1O\ GRB_[Y%'_"*Z-_SY1?\ ?(K9HH QO^$5T;_GRB_[Y%'_  BNC?\ /E%_
MWR*V:* ,;_A%=&_Y\HO^^11_PBNC?\^47_?(K9HH QO^$5T;_GRB_P"^11_P
MBNC?\^47_?(K9HH QO\ A%=&_P"?*+_OD4?\(KHW_/E%_P!\BMFB@#&_X171
MO^?*+_OD4?\ "*Z-_P ^47_?(K9HH QO^$5T;_GRB_[Y%'_"*Z-_SY1?]\BM
MFB@#&_X171O^?*+_ +Y%'_"*Z-_SY1?]\BMFB@#&_P"$5T;_ )\HO^^11_PB
MNC?\^47_ 'R*V:* ,;_A%=&_Y\HO^^11_P (KHW_ #Y1?]\BMFB@#&_X171O
M^?*+_OD4?\(KHW_/E%_WR*V:* ,;_A%=&_Y\HO\ OD4?\(KHW_/E%_WR*V:*
M ,;_ (171O\ GRB_[Y%'_"*Z-_SY1?\ ?(K9HH QO^$5T;_GRB_[Y%'_  BN
MC?\ /E%_WR*V:* ,;_A%=&_Y\HO^^11_PBNC?\^47_?(K9HH QO^$5T;_GRB
M_P"^16?K?AG28M#O9$LXU986((4<<5U-9NO_ /(OZA_UP;^5 '*V$\B_"R:0
MR,&6)L-GD?-5GPGX>TJ\\,6,\MK'([Q@EB,YK)<D?!B^(X/D-_Z'70?#DD^
M=().3Y H T/^$5T;_GRB_P"^11_PBNC?\^47_?(K0OK^UTVT>ZO)1% @RSGM
M6*/'GAHC(U-2/^N3_P"% %K_ (171O\ GRB_[Y%'_"*Z-_SY1?\ ?(J&W\:>
M'KJYCMX=11I9#A%*,,_F*WZ ,;_A%=&_Y\HO^^11_P (KHW_ #Y1?]\BMFB@
M#&_X171O^?*+_OD4?\(KHW_/E%_WR*V:* ,;_A%=&_Y\HO\ OD4?\(KHW_/E
M%_WR*V:* ,;_ (171O\ GRB_[Y%'_"*Z-_SY1?\ ?(K9HH QO^$5T;_GRB_[
MY%'_  BNC?\ /E%_WR*V:* ,;_A%=&_Y\HO^^11_PBNC?\^47_?(K9HH QO^
M$5T;_GRB_P"^11_PBNC?\^47_?(K9HH QO\ A%=&_P"?*+_OD4?\(KHW_/E%
M_P!\BMFB@#&_X171O^?*+_OD4?\ "*Z-_P ^47_?(K9HH QO^$5T;_GRB_[Y
M%'_"*Z-_SY1?]\BMFB@#&_X171O^?*+_ +Y%'_"*Z-_SY1?]\BMFB@#&_P"$
M5T;_ )\HO^^11_PBNC?\^47_ 'R*V:* ,;_A%=&_Y\HO^^11_P (KHW_ #Y1
M?]\BMFB@#&_X171O^?*+_OD4?\(KHW_/E%_WR*V:* ,;_A%=&_Y\HO\ OD4?
M\(KHW_/E%_WR*V:* ,;_ (171O\ GRB_[Y%'_"*Z-_SY1?\ ?(K9HH \\\7:
M79Z3J.@264*PL]V58IQD;35CQJJSZ]X=MICF&5Y-RD\-]VI?'_\ Q^>'?^OT
M_P#H)K/\?DCQ1X3P<?O7_P#9: .L'A;1MH_T*+I_=%+_ ,(KHW_/E%_WR*V%
M^XOTI: ,;_A%=&_Y\HO^^11_PBNC?\^47_?(K9HH QO^$5T;_GRB_P"^11_P
MBNC?\^47_?(K9HH QO\ A%=&_P"?*+_OD4?\(KHW_/E%_P!\BMFB@#&_X171
MO^?*+_OD4?\ "*Z-_P ^47_?(K9HH QO^$5T;_GRB_[Y%'_"*Z-_SY1?]\BM
MFB@#&_X171O^?*+_ +Y%'_"*Z-_SY1?]\BMFB@#&_P"$5T;_ )\HO^^11_PB
MNC?\^47_ 'R*V:* ,;_A%=&_Y\HO^^11_P (KHW_ #Y1?]\BMFB@#&_X171O
M^?*+_OD4?\(KHW_/E%_WR*V:* ,;_A%=&_Y\HO\ OD4?\(KHW_/E%_WR*V:*
M ,;_ (171O\ GRB_[Y%'_"*Z-_SY1?\ ?(K9HH QO^$5T;_GRB_[Y%'_  BN
MC?\ /E%_WR*V:* ,;_A%=&_Y\HO^^11_PBNC?\^47_?(K9HH QO^$5T;_GRB
M_P"^11_PBNC?\^47_?(K9HH QO\ A%=&_P"?*+_OD4?\(KHW_/E%_P!\BMFB
M@#&_X171O^?*+_OD4?\ "*Z-_P ^47_?(K9HH QO^$5T;_GRB_[Y%'_"*Z-_
MSY1?]\BMFB@#&_X171O^?*+_ +Y%<_X7@2S\<Z]:P#9 BPE4'094UW-<5H/_
M "43Q!_N0_\ H)H H>&]/M=7\5^)C>QB?RKI53?SM&Q:ZO\ X171O^?*+_OD
M5S'@ Y\3>*_^OP?^@+7H% &-_P (KHW_ #Y1?]\BC_A%=&_Y\HO^^16S10!C
M?\(KHW_/E%_WR*/^$5T;_GRB_P"^16S10!C?\(KHW_/E%_WR*/\ A%=&_P"?
M*+_OD5LT4 8W_"*Z-_SY1?\ ?(H_X171O^?*+_OD5LT4 8W_  BNC?\ /E%_
MWR*/^$5T;_GRB_[Y%;-% &-_PBNC?\^47_?(H_X171O^?*+_ +Y%;-% &-_P
MBNC?\^47_?(H_P"$5T;_ )\HO^^16S10!C?\(KHW_/E%_P!\BC_A%=&_Y\HO
M^^16S10!C?\ "*Z-_P ^47_?(H_X171O^?*+_OD5LT4 8W_"*Z-_SY1?]\BC
M_A%=&_Y\HO\ OD5LT4 8W_"*Z-_SY1?]\BC_ (171O\ GRB_[Y%;-% &-_PB
MNC?\^47_ 'R*/^$5T;_GRB_[Y%;-% &-_P (KHW_ #Y1?]\BC_A%=&_Y\HO^
M^16S10!C?\(KHW_/E%_WR*/^$5T;_GRB_P"^16S10!C?\(KHW_/E%_WR*/\
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MQ$3VL$K;GB5CZD5PNE1I%\8-;6-0J_9+?@?[IKOZX/3O^2QZW_UZ6_\ Z":
M.\HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M='TI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:]6JD<=2/+*P4444$!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[":?^@M5+XA_\A7PC_U^/_Z!5WXB?=T#_L)I_P"@M5+XA_\ (5\(_P#7X_\
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M^NW\!F\V-0KK@Y SFNIKS3PCJ7A[P_JLFCV\\\UP[;6FDR02.V:]*!R,CO0
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M^N2_SKU6K6QY-;XV%%%%,R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKW_7K#_-Z[FN&T3_ )*IKW_7K#_-Z *O@/\ Y''Q9_U\1_\ H)KT.O// ?\
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MT'3XG@L(8G^\J@&O.4C\5^$6CN]0U#[?:%PLBD?=!_*O2K:9;BWCF7[KC(H
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MG_\ 9:T?'_\ Q^>'?^OT_P#H)K.^('_(T>$_^NS_ /LM 'HR_<7Z5P?Q4_Y
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M]A-/_06JE\0_^0KX1_Z_'_\ 0* /05^Z/I2TB_='TI: "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *XK0?^2B>(/\ <A_]!-=K7%:#_P E$\0?[D/_ *": *?P_P#^
M1F\5_P#7X/\ T!:]!KS[X?\ _(S>*_\ K\'_ * M>@T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5F>(?^1?OO^N1K3K,\0_\B_??]<C0!G>!/^12L_\ =_K7
M25S?@3_D4K/_ '?ZUTE !1110 4444 %(0#U&:6HKFXCM+:2XE.V.-=S'VI-
MV5V"U(I-.LI3F2VB8^ZTZ*PM(#F*WC0^RUY)J?Q+UV\EFETFTVV,+X:5ESWQ
MUK:MOB%=6FLV%IJ$!^S742;9=N/F/O\ E3CJ#T/2:*16#*&'0C(I: "BBB@
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M^U-/_P"?VW_[^"@"W144-S!< F"9) ."48'%2T %%%% !1110 4444 %%%%
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M?Q11@C^=<CX<U!-3^+&M7$<4L2FU@&V5<'A37HQC1CDJ"?<5PFF*%^,6MA0
M/LEOT_W32&=[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 53U;_D#7W_7O)_Z":N53U;_ ) U]_U[R?\ H)H
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M._\ R1>^_P"N#?\ H==!\./^1 TC_K@*Y]_^2+WW_7!O_0ZZ#X<?\B!I'_7
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M_9: /1E^XOTK@_BI_P @6R_Z^!_2N\7[B_2N#^*G_(%LO^O@?TH*C\2,J/\
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M1;5?^O>:M_X9_P#)/M*_ZYG_ -"-8%M_R1;5?^O>:M_X9_\ )/M*_P"N9_\
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M^&O_ "4!_P#KA_0UKFW^[/Y%YA_ 9[K1117RA\\%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5FZ_\
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M !1110 5Q6@_\E$\0?[D/_H)KM:XK0?^2B>(/]R'_P!!- %/X?\ _(S>*_\
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M_B+_ )*U<?\ 8-B_]">N+,?]UF:T/XB*?BS_ )%+5?\ KV?^59/@'_D'W/\
MOK_Z"*UO%G_(I:K_ ->S_P JR? /_(/N?]]?_017SE/_ '*?JCO?\5>A=\3_
M /'SHW_7['_Z$M>V+]T?2O"?'5V;"SLKP#/D3B7'KM(/]*ZJP\>:Y?6,-S'9
M1!)4##)[$5ZF5UJ=+#WF[:G-B(2E/0]-HKA_#_C*^U#Q+_9%[;*A-OYZLO\
MO8KN*]J$XSCS1=T<K33LPHHHJA!1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %4]6_Y U]_U[R?^@FKE4]6_Y U]_P!>\G_H)H \_MO^2+:K_P!>
M\U;_ ,,_^2?:5_US/_H1K MO^2+:K_U[S5O_  S_ .2?:5_US/\ Z$: .L)
M&2< 55.JZ>"0;VWR.#^\%.U$XTR[(_YXO_Z":^?M&T^VN;6:69-[F>3)/^\:
MY,7BXX:"G)7.G"X:6(GRIV/?O[5T_P#Y_;?_ +^"K$,\-Q'YD,J2)_>1LBO"
M)=(LA"Y$(^Z:[KX/9_X0Z1<DA;N0#/IQ66#S".)DU%6L:XK RPZ3;O<]!HHH
MKT#A"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** .*^(GW= _P"PFG_H+52^(?\ R%?"/_7X_P#Z
M!5WXB?=T#_L)I_Z"U4OB'_R%?"/_ %^/_P"@4 >@K]T?2N6^)7_).M;_ .N'
M_LPKJ5^Z/I7+?$K_ ))UK?\ UP_]F% 'D=E_QYQ?[HJ>H++_ (\XO]T5/0!U
MGP;Z^(/^OM?_ $ 5ZG7@'A?Q5-X4T_5)X(A))<:FD(![?NL_TKIO^%E:U_SZ
M14 >LT5Y*_Q,UE$9C:1<#-=]X0UQ_$?AJUU.2,1O,#E1VP2/Z4 ;E%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5PVB?\E4U[_KUA_F]=S7#:)_R537O^O6'^;T 5? ?_(X^+/\ KXC_
M /037H=>>> _^1Q\6?\ 7Q'_ .@FO0Z /)/C7_K_  __ -=)?Y+7"=J[OXU_
MZ_P__P!=)?Y+7"=J^FR;^ _4][+/X3]0KH?AK_R4!_\ KA_0USU=#\-?^2@/
M_P!</Z&M<V_W9_(O,/X#/=:***^4/G@HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LW7_\ D7]0_P"N
M#?RK2K-U_P#Y%_4/^N#?RH X=_\ DB]]_P!<&_\ 0ZZ#X<?\B!I'_7 5S[_\
MD7OO^N#?^AUT'PX_Y$#2/^N H 9\2O\ D2+W_/8UEZ;_ ,@VV_ZYC^5:GQ*_
MY$B]_P ]C67IO_(-MO\ KF/Y5I X\7T.7^('_'E;_P"Y-_Z!6KX/_P"17L?^
MN2_RK*^('_'E;_[DW_H%:O@__D5['_KDO\JI?$8R_A+U*OCW_D5Y_J/YBCP1
M_P @J;_KLW]*/'O_ "*\_P!1_,4>"/\ D%3?]=F_I1]H/^7/S-#Q3_R*VI?]
M<&KFOA]_Q^ZU_P!=U_\ 0%KI?%/_ "*VI?\ 7!JYKX??\?NM?]=U_P#0%H?Q
M((_PI';7?_'G-_N'^5><^!O^1@F_X'_Z%7HUW_QYS?[A_E7G/@;_ )&";_@?
M_H5#W04_@D>F56^&_P#Q\ZY_U^R?SJS5;X;_ /'SKG_7[)_.E/8O"?$ST"BB
MBLCO"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH XGQ__ ,?GAW_K]/\ Z":SOB!_R-'A/_KL_P#[+6CX_P#^/SP[_P!?I_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNDO\EKA.U=U\:2&N/#X4@D22YQ]%KA>U?39._P!R_4]W+/X3]0KH?AK_ ,E
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MBD!RH/J*6D:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <3X_\
M^/SP[_U^G_T$UG?$#_D:/"?_ %V?_P!EK1\?_P#'YX=_Z_3_ .@FL[X@$#Q1
MX2R?^6S_ /LM 'HR_<7Z5P?Q4_Y ME_U\#^E=RDB;5^=>F.M<)\4V5M%L]K
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MC_OD5K>+/^12U7_KV?\ E63X!_Y!]S_OK_Z"*^>IR?U.>O5'<TO:KT(?B/\
MN= &SC)8G\JW?#4:MX<TYB.?(0_H*POB7_R %^K?RK?\,_\ (M:?_P!>Z?\
MH(J)R?U2.O5C27M6<KXP8IXHLX5.$^R@X_[:5W:PQ[!\O;%<'XR_Y&ZS_P"O
M0?\ HRO0%^Z*K%2?L*6O1_F*FESR/,=+'F_$DVS\P^7*=IZ9W"N]O=/M5L+@
MB%01$V./:N"TC_DJC?\ 7*7_ -"%>CW_ /R#KG_KDW\C58NI-3A9]$%))IG,
M^!?%6I-H%I86MO"RV\$9+.,DG_(K?U#QCJ^E0I<SVMNT?FC("\Y]:XWX9?\
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M_K\?_P! H [E;*# /EC.[=^-<M\2+.!?AWK+",96'</KN%=BOW1]*Y;XE?\
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M[L<D$_A5BB@"O]AM^?W8Y;=^-+]C@_YYC[Q;\:GHH KBRMUQB,<$D?C0+*W
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MHV7PQJ!+D@0-D>M<WX 1C?:T0V/WX_\ 0%I/XAQ_A2.ZN_\ CSF_W#_*O.?
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M]\><4 6J*J_9Y>?WQY(-'V:7_GL?O9_2@"U157[/+Q^^/#$T"VE&W]\>,YH
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M,\0_\B_??]<C0!F^ P%\(V0'0+_6NEKF_ G_ "*5G_N_UKI* "BBB@ HHHH
M*SM>OGTW0KR\3[T,185HU4U.R34M-N+.3[LR%#^-3._*[#C:ZN?/5Z?$5SIB
M:X]^_DSS;  ?NUIKI&K:1KFCOJ.IN]K<R*R.K<$Y'%=58^ M43P[JFD7$@:,
MMNM3GIT/^-8-EX3\7:IJ6GVFI_+:6+@J2V> 1_A5PLI*WE]UA2V=_/\ X![?
M'CRUP<C YIU,B3RXD3^ZH%/I,2V"BBB@84444 %%%% !17+:UJU^_B.VT33W
M6)WC:221AG &*D\+:S=W\^H6%\5:XLI0A=1@,",BA:_U\@>ATM<'IW_)8];_
M .O2W_\ 0370:EK=[979BATMYT'\8?']*X"QUV^7XJ:O<#27,CVT ,>_IA3[
M4 >MUY/XB_Y*U<?]@V+_ -">NP_X2;4O^@')_P!_/_K5P.NOKLWCF36(]#D:
M)[1(=H?N"Q]/>N7&TY5,/*,5=LTHM1FFQWBS_D4M5_Z]G_E63X!_Y!]S_OK_
M .@BIM:DU_4M%O+)- E5IXF0$OTR/I53P[;>(=$MYH9-"E?>P((?T 'I7APP
M5=864''5M'6ZL/:)W$^)?_( 7ZM_*M_PS_R+6G_]>Z?^@BN=\567B+Q!IRVL
M6A2QD9Y+^WTK1TF77]/TJUM'T"5FBC5"0_7 QZ5,L#B'AHPY=;L:JP]HW<Q?
M&7_(W6?_ %Z#_P!&5Z OW17 ZYIGB+5=:AODT21%B@$>TMU._/I72#4-= Q_
MPCTW_??_ -:JQ&"KRHTXJ.J3O]X0JP4I-LXO2/\ DJC?]<I?_0A7H]__ ,@Z
MY_ZY-_(UP%EHGB2U\7_VRVB2&,HZ[-W/)!]/:NHN+W7IK66(>'Y@70J#O]1]
M*,5@J\YQ<8[)!3JP2=V<[\,O^/1O^N$?]:W/'/\ R+C_ .^/Y&L7PIIGB/P_
M"4ET223,2KPV.F?:M#Q GB#6-,-I'H,J,6!R7_\ K5I7P=>6,]HHZ7)A5@J5
MFRSX!_Y$W3_]P_S-9'Q!_P"0EH_TE_D*N^&X_$&BZ%;6$F@RNT2D%@_7DGTJ
MEXDT[Q%KEW92QZ'(@MP^06ZY ]O:BA@Z\<8ZCCI=_J$ZL'2Y;ZG:6 _XE]O_
M -<U_E7*VGBBZ\.>/[F.S@CEEO3Y0W]!@9_I6I;7NO0VT41\/S$H@4_/Z#Z5
MS%QHWB2;Q=!K(T201QR%BF[DY7'I4X3"8BE4E/EZ.PZM2$HI7/23XT\2@9^P
MV?Y'_&NF\%^(I?$_A]-0GB6*0R.C*O3Y6(_I7G9U'72"/^$>F_[[_P#K56\(
M>.+SPI8MH5QH<LETDCRL ^,!F+#M[UZ.#JXA<SQ.B,*L8:>S/;Z*\QG^+<UM
M"99?#TZH.I\S_P"M4=G\86OXVDMM F=%<H3YG<=>U=WMZ=N;F5C'DE>UCU*B
MO*[WXR?V<L;7>@S1K(VU3YG?\JL0?%B:XA66+P_.489!\S_ZU'MZ5K\RL')+
M:QZ917E5Q\9TM;@03:',LK,JA?,ZENG:KG_"TKG_ *%Z?_OY_P#6H=:FDFY+
M4.23Z'I-%>4P_&F.XO'M(M$F:=&*LOF="/PJU-\5YH(7ED\/SA$&2?,[?E0Z
MU-.SD@Y)=CTRJ>K?\@:^_P"O>3_T$US.G>-;S4K&*[@T24QR#*_O/_K4NI>)
M-1;2KQ3HD@!@<$^9T^4^U:DF);?\D6U7_KWFK?\ AG_R3[2O^N9_]"-<_9L6
M^">IL1@FVF./2D^'^OW]MX)TV&/2'E14(#A\9^8^U 'HNH_\@N[_ .N+_P#H
M)KPCP_\ \>$G_7Q)_P"A&O4KOQ%J<UE/$-#DR\;*/WGJ/I7E6G67B&Q@DB;0
MY6)E=LA_4D^E>7FM"I6I*--7=ST<LK0I56YNVAK2_P"ID_W37'^'O^/^W_ZZ
M2_R%=(X\0-&R_P!@R\@C[_\ ]:L73=!\26,L,S:-(V'=B WJ![5YN%P5>%.H
MI1W1Z&)Q=&52#C+9G4URGB;_ )"]I_US/]:WO^*@_P"@!+_WW_\ 6K(U/1?$
M>I7\,RZ+(BQH0<MUZ^U1@\#B(5E*4="\7C*$Z+C&6IKZ/_R"+7_KF*36?^0-
M=_\ 7,U!8P>(;6RA@;09244 G?\ _6HO[?Q#=6,T"Z#*#(N =_\ ]:LO[/Q/
MM;\O4U^O8?V=N;H8/@W_ (_;G_=_K798'I7+Z)H/B32+B5WT61PZXX;_ .M6
MY_Q4'_0 E_[[_P#K5>*P.(G4;C$SPV-H0II2D<OKX!U"<=C/'G_OFNLBM8/*
M7]TO3TKGM0T#Q)?3RSKHTBYD5@"WH,>E;:#Q J*/[!EX']__ .M6V)P>(E3I
MJ,=D9X?%4(U)N3W95URWB2TA98P#]HCY'UKWG3O^09:_]<E_E7@^H6?B&^AC
MB70Y5Q*KDE_0_2NKLOB[M@%LFAS.UN!&Q$G<<>E>AEL)8>B_;::]3AS"4:]5
M.CKIT/5Z*\Q_X6W)_P! "?\ [^?_ %JJGXV0@QJ-$F+N[(%\SN#@]J]!5J;V
MDC@=&HMT>L45Y=_PMV7_ *%Z;_OY_P#6IK?&01RHDNA3)O#$'S/09/:E'$4I
M.RDARH5(J[BSU.BO+(/C']IB$L6A3,AZ'S/_ *U2'XNNJDG0)L 9/[S_ .M0
M\123MS(%0JM7Y6>GT5Y3'\:H9GB2+19F:2,2 >9V/X>U6/\ A;<G_0 F_P"_
MG_UJ<JU.+M*20HTJDE=)GIU%>5R_&9(!-YNB3*8HO-(\SMG'IZFG)\8))$#+
MX>G((R/WG_UJ'7II)N2LP5&HW9(]2HKRJX^,K6UO)/+X?F6-!N8^9T'Y4Y?C
M(DES+!'HDSO$0'Q)TR ?3WH5>FUS*2L#HU$^5K4]3HKS'_A;DG_0 G_[^?\
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M 7:RO$?_ " ;K_<-:/V3Q%_T I?^^O\ ZU4]4TCQ)?Z=-;+HDBLZX!W?_6H
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M3]-AM6T"5FC4 G?_ /6IVT,8U8*JW<Z6L35O^0]I/^[<?^BZ?]NUW_H7IO\
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MQVFL0M<V$KVN/G5G//Z4_4?%?Q#&HSBUTE1;[OW8(R<4P/8:*\5_X2OXE?\
M0+3_ +YH_P"$K^)7_0+3_OF@#VJBO%D\5_$GS(\Z4FW>-WR]L\UK:[XN\<Q3
MPC2M%01[!OWC=S^5 'J=%>+_ /"9_$W_ *!$'_?NC_A,_B;_ - B#_OW0![1
M17BQ\9_$[!QI$&?^N=;DGQ)U70M!MKK7]%832-L)1L#//M0!Z;17DW_"[K7_
M *!+?]_O_K4?\+NMO^@2W_?[_P"M2N@/6:*\F_X7=;?] EO^_P!_]:KUC\6A
M?V%U>0Z-*8K;.\^9Z?A3 ]+HKRA/C5%(@==&;!Z?O_\ ZU._X7.G_0&;_O\
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M5>A3^)@ T[3L ?\ 'V/Y&NF\/JO]A6? _P!6.U<U\3/^0=IW_7V/Y&NF\/\
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M@_\ 12U<VCT'Y54D_P"1IO?^N,'_ **6KE %5@/[>T3@?\?\7_H55=& VW7
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MO)P'^\5O7_,\[!_QJOJ/P/04EL!_PD>B<#_C\'_H)IU);?\ (QZ)_P!?@_\
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M^ZOY4*302P\).[/GOPO%J>DWOFW6@WY4HPXB!ZMGUKK_ .W9?^A?U'_OR/\
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M_P"@FNUKBM!_Y*)X@_W(?_030!3\  'Q-XKR/^7P?^@+7H&T>@_*O/\ X?\
M_(S>*_\ K\'_ * M>@T )M4_PC\J38O]T?E3J* &[%_NC\J-B_W1^5.HH 3:
MO]T?E2;%_NC\J=10 W8O]T?E1L7^Z/RIU% ";5_NC\J38O\ ='Y4ZB@!NQ?[
MH_*C8O\ ='Y4ZB@!-B_W1^5&Q?[H_*EHH ;L7^Z/RHV+_='Y4ZB@!NQ?[H_*
MEV+_ '1^5+10 W8G]U?RHV)_=7\J=10 W8G]U?RJO>:=9ZA$(KNWCE0'(5E!
M&:M44 8__"*Z'_T#;?\ [X%'_"*Z'_T#;?\ [X%;%% &/_PBNA_] VW_ .^!
M4Z:#ID=I+:QV<212C#JJ@9K1HH YL>!=!48%F@'TH_X0;0O^?-:Z2B@#F_\
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MW9E@U%X4/\  KD_#5I/9?%;6H;BX,\@M8#O(_P!DTAGI-%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5G7>A:;?3F>YM(Y)",;BHS6C10!C-X6T8
MJ1]AB]OE%>?V7A+7])FO8K:")H9;J25.<8#'(KUFBL:U"G6CR36A49N+NCPK
MQOX7U^[T9;FYACCALW$SD'L./ZUL>'_^0%:?]<Q7=^//^1&U?_KA_45PGA__
M ) 5I_US%>%FM&%&$805D=F&DY-MG&^+/^1NL?\ KYM_YUZ'_#^%>>>+/^1N
ML?\ KYM_YUZ'_#^%<6+_ (5+T-J7Q2]3S;P[_P E%U3_ *^'_E7=ZW_R [W_
M *XM_*N$\._\E%U3_KX?^5=WK?\ R [W_KBW\J,5_&AZ(5/X7\SM_ G_ ")V
MG_[A_F:U]6_Y U]_U[R?^@FLCP)_R)VG_P"X?YFM?5O^0-??]>\G_H)KZ];'
MF'G]M_R1;5?^O>:M_P"&?_)/M*_ZYG_T(U@6W_)%M5_Z]YJW_AG_ ,D^TK_K
MF?\ T(TP.MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J&N?\B_
MJ7_7K+_Z":OU0US_ ) &I?\ 7K+_ .@F@#PWPU_R X/I6G/_ ,>\G^X?Y5SV
MA:SI]KHL:S72(R#D'K5Q/$>EW5D[I=(,J1M/6OB:M&HZDGRO<^PI5::II76Q
MC:!_R%[+_L'Q_P VKLJXSP^<ZM8D=#I\?\VKLZWS3_>/DC'+?X'S9S'B/_67
M_P#V#Q_Z.6M^Q_X\H?\ =%8'B/\ UE__ -@\?^CEK?L?^/*'_=%/$_[K2^8L
M/_O-7Y%+Q+_R+6H_]<&JGH?_ "'M8_ZZ)_Z+2KGB7_D6M1_ZX-5/0_\ D/:Q
M_P!=$_\ 1:4Z/^XU/5"K?[[3]&=#7*:E_P ?=[_V$;3_ -%M75URFI?\?=[_
M -A&T_\ 1;4LL_B2_P +'F/\./\ B1U2_<'TK)\0_P#'M9?]?T'_ *&*UE^X
M/I63XA_X]K+_ *_H/_0Q7-@_]XAZHZ,7_ GZ,B\,?\>=U_U]S?\ H;5MGH:Q
M/#'_ !YW7_7W-_Z&U;9Z&GC?]XGZL6$_W>'HCD['_C_L?^OZ]_\ 9:ZVN2L?
M^/\ L?\ K^O?_9:ZVNC,_P")#_"C#+O@E_B96M?^1]\-_P#7>3_T6:]SKPRU
M_P"1]\-_]=Y/_19KW.O<RG_=8_,\;-/]Y?R.*^(GW= _[":?^@M5+XA_\A7P
MC_U^/_Z!5WXB?=T#_L)I_P"@M5+XA_\ (5\(_P#7X_\ Z!7I'GGH*_='TI:1
M?NCZ4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'^+
M_ T7BC4K.^:X>&2VC,8VG&03FNPHH \U_P"%5_\ 42F_[Z/^-17'PCCNH&AD
MU&8HPP1N->GT4 ?/VK6JV7CO5K53E85B0$^T:BG5-XD_Y*5KW^]'_P"@+4-
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MUMKVERZ?=Y\F3&<'!X.?Z5SH^'.GJ !=76!_TU;_ !JHRL85J3J6L<#\1O\
M46WT-='X9_Y %K_N4_Q/\/-,M]"O+\RSR2V\+,F^0D9_.F^&^-!M1_LU<7=G
M/6@X4TF4O&G_ ""+7_K^M_\ T,5ZI:?\></^X/Y5Y7XT_P"01:_]?UO_ .AB
MO5+3_CSA_P!P?RJ9[FV%^ X_Q_\ \?GAW_K]/_H)K.^('_(T>$_^NS_^RUH^
M/_\ C\\._P#7Z?\ T$UG?$#_ )&CPG_UV?\ ]EJ#I/1E^XOTI:1?N+]*6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "N*T'_DHGB#_<A_]!-=K7%:#_R43Q!_
MN0_^@F@"G\/_ /D9O%?_ %^#_P! 6O0:\^^'_P#R,WBO_K\'_H"UZ#0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !69XA_Y%^^_P"N1K3K,\0_\B_??]<C0!G>
M!/\ D4K/_=_K725S?@3_ )%*S_W?ZUTE !1110 4444 %9GB&:XM_#]]+:@F
M=(B4QZUIUG:]=M8:%>W2)O:*(L%]:F?PLJ'Q(\9\-^"KGQ3:27]QJS1R,YRF
M[D5TEA\+&M-0M[C^UY&\J17V[NN#FN0\/>'O%&L1S:CIMP;>*60G"MBNET[P
MGXUAU*VDGU)FB212XWGD9Y[UHM&NA#Z]3UQ1A0/04M(N0@!ZXI:D:V"BBB@
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M> 5S\F?3_"O)Q65K$574<K'IX;,70IJ"C<J^()$DDORC!L:>.A_Z:K70V/\
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MJOF>/F=_K+N<A\0W0_V H92?[33C/^RU4_B(<:KX1S_S^/\ ^@5-X_LH8I-
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MSJ$V<1))'4Y-'V.+.<?Q;OQH X37/AM'JWB.[U:/598'N2-R*1C@ >GM5/\
MX56__0=G_,?X5Z.+*($$#H<T@LHAMP/NYQ^- 'G=M\*TBU.RNY=9FE%M,LP0
MD8.#GTKSK1Q@78_Z>)/_ $(U]$_8HAVZ K^=?.^DG/VOVN)!_P"/&@#2K)N/
M^0I?>^D7/\EK6K(NANU6\S_#I-RP_): +FF?\@Z#_<%6ZJ::<Z="?]D5;H Q
MY/\ D"ZP._\ :5IQ_P !>M:/_5K]*R9/^03J\G\0U"T7\-KUK1_ZM?I0 2?Z
MMOH:[_X.LH\#\L!BZGZG_IHU< _^K;Z&NZ^$5M'-X)9G'+7,X/\ WV: /1=Z
M?WE_.N'T-E;XIZ\5(/\ HL/0^[UV)LHF# C[PP:XOP] D'Q2U]8Q@&VA/ZO0
M!!X$8+XQ\69('[^/J?\ 9->A;U_O#\Z\Y\$P)/XP\6!QUGC'_CIKOS91'=D?
M>ZT 3[U_O#\Z-Z_WA^=0&RB))(ZD&E^QQ>G\6[\: )MZ_P!X?G1O7^\/SJ#[
M%%QQT.:/L40QP>,X_&@"?>G]Y?SHWK_>'YU!]BBXX/ (H^Q1>G\.W\* )]Z?
MWE_.C>G]Y?SJ V41SQU 'Y4&RB.[(^]C- $^]?[P_.C>O]X?G4)LXB2<=6W4
M"SB!SC^+=^- $V]?[P_.C>G]Y?SJ 640(('0Y%"V42XP.@(% $^]/[R_G1O7
M^\/SJ#[%%CH?NE?PH^Q18/'5=M $^]/[R_G1O7^\/SJ#[%$<\=0 ?PI?L<7/
M'4@_E0!-O3^\OYUPOBGX<6GB;7O[5.HRV\IB6(A",$#/M[UV?V*+GCJVZE^Q
MQ>G\1;\:J,Y0?-'<J,G%W1YG_P *>M_^@W<_]]#_  H_X4];_P#0;N?^^A_A
M7I8LHAMP.A)'XT"RB 48/RC K?ZW7_F9I]9J_P S/'O&/@ZV\)?#VYC@NGN&
MFO8G9G(SRXKD4^XOTKU_XE:!=:GX1-OIL/F7"RQ$+G'"L":\>N4O;$.L\=NL
MD8RR>>-WY5Z.5XJ%-3=1[G=@*\8<W.]R2I]&_P"1PTGZO_(5E6TVIM+LN;-;
M?<N]#,^P%?QKHO#>@ZM?:_87JVT;6D.XM(DH8=JZ\9C:-3#RC&6K.C$XJG.C
M))F%:@B:]R/^7J7_ -#-6:@MW9Y[W/:ZE'_CYJ>N[!N7U>'HCKPU_8Q]"MJ'
M_(.N?^N3?RK0UT'S?#IP<"P/\Q5"_8KI]P1VC8_I6CK<C*WA^,?=:Q+'ZY%<
M6,O]:I'+B;_6*96HHHKU;R['H:CK$'_A'?%O!Y5,>_ J*'_4)]*L6,K?\([X
MI_Z9JNW\A5>$DPH?:O*P-_K%:W?_ #//PE_;5/4?26P/_"1Z)QTO!_(TN:6U
M<KXAT8#^*[ /Y&NO&N7U>?H=.*O[&7H?2,3KY2?,.GK6?X@D0>'K_+KS W?V
MJS#91+%'@'A<"L[Q#I\#>'K[*YVP-C\J^./F3D7_ .2+WW_7!O\ T.N@^''_
M "(&D?\ 7 5SS +\%KT#H(&_]#K;^'5S&O@+2%.[/V<'I0!V%%5OML.,_-]W
M=]WM2_;(L$_-P,]* +%%5S>PC/WN,9^7UH^V1<_>X('3UH L457^VP_[7WMO
MW:7[9%Q][DD=/2@">BJXO83C&[G../2C[9$0#\W(R.* +%%5OML.,_-]W=]W
MM2M>PJ"3NX&?NT 6**KF\B7=G=QUXH-Y$"0=W#;>E %BBJ_VR+./FY;;T[T?
M;8B1][DX'% %BBJXO8CC[W.>WI1]MB_VN1GI0!8HJO\ ;8O]KIGI0;V(9^]P
M >GK0!8HJN;V(9^]QUXH^V1 D?-P=O2@"Q15<7D1./F^]MZ=Z!>1'&-W)P.*
M +%%5UO86 (W<C/2D^VPXS\WW=WW>U %FBJ_VV+!/S<#/2@WL0S][C&?E]:
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MZ/\ $O\ Y)WK/_7)?_0UKSBQ_P"/*'_=%?/YY]CYGN9-]OY%+Q+_ ,BUJ/\
MUP:J>A_\A[6/^NB?^BTJYXE_Y%K4?^N#53T/_D/:Q_UT3_T6E<5'_<:GJCLK
M?[[3]&=#7*:E_P ?=[_V$;3_ -%M75URFI?\?=[_ -A&T_\ 1;4LL_B2_P +
M'F/\./\ B1U2_<'TK)\0_P#'M9?]?T'_ *&*UE^X/I63XA_X]K+_ *_H/_0Q
M7-@_]XAZHZ,7_ GZ,B\,?\>=U_U]S?\ H;5MGH:Q/#'_ !YW7_7W-_Z&U;9Z
M&GC?]XGZL6$_W>'HCD['_C_L?^OZ]_\ 9:ZVN2L?^/\ L?\ K^O?_9:ZVNC,
M_P")#_"C#+O@E_B96M?^1]\-_P#7>3_T6:]SKPRU_P"1]\-_]=Y/_19KW.O<
MRG_=8_,\;-/]Y?R.*^(GW= _[":?^@M5+XA_\A7PC_U^/_Z!5WXB?=T#_L)I
M_P"@M5+XA_\ (5\(_P#7X_\ Z!7I'GGH*_='TI:1?NCZ4M !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7S=I'_+Y
M_P!?,G_H1KZ1KQ.'X=>);2:Y$;6S1O,[KD'."2?7WH S*R;C_D*7_P#V![G^
M2UU__""^*/\ IU_(_P"-9]_X(US3K;5M6OV@$,6F3QX0'.2!_A0!EZ9_R#H/
M]P5;JIIG_(.@_P!P5;H QY/^0)K'_82M/_07K6C_ -6OTK)D_P"0)K'_ &$K
M3_T%ZUH_]6OTH )/]6WT->@?!S_D1O\ MZG_ /1C5Y_)_JV^AKT#X.?\B-_V
M]3_^C&H ]!KAM$_Y*IKW_7K#_-Z[FN&T3_DJFO?]>L/\WH J^ _^1Q\6?]?$
M?_H)KT.O// ?_(X^+/\ KXC_ /037H= !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 =>M>3_ !.T_3M/O;2]L;42ZU*^V. #(D'?
M(_*O6*I-I=I)?_;9(E><<*S#I0!XWXEEUF6?2H?$.E10:;*P626!>5'8=!CG
M%>O:9IMCIFCK!81JL(3Y<=^*N75G;WD)BN(ED0]B*;';):6)@B&$1"%'H* /
MFFV_X^+[_K[F_P#0S5FJUM_Q\7W_ %]S?^AFK-?:8/\ W>'HCZC#?P8^A6U#
M_D&W/_7)OY5H:[_KO#G_ %X'^8K/U#_D&W/_ %R;^5:&N_Z[PY_UX'^8KBQO
M^]T3EQ7^\4R"BBBO6/1%L?\ D7?%W^ZG\A44/^H3Z5+8_P#(N^+O]U/Y"HH?
M]0GTKR<!_O%;U_S/.P?\:KZDE);?\C'HG_7X/_032TEM_P C'HG_ %^#_P!!
M-=F._P!WGZ'3B_X$O0^E(O\ 5+]*H:__ ,B_J'_7!OY5?B_U2_2J&O\ _(OZ
MA_UP;^5?&'S!P[_\D7OO^N#?^AUO?#A%/@'2"0/]0*P7_P"2+WW_ %P;_P!#
MKH/AQ_R(&D?]<!0!U'EI_='Y4>6G]T?E3J* &^6G]T?E1Y:?W13J* &^6G]T
M?E1Y:_W13J* &^6G]T?E1Y:?W1^5.HH ;Y:?W1TQTH\M/[H_*G44 -\M/[H_
M*CRT_NCUZ4ZB@!OEI_='KTH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NC
M\J/+3^Z/RIU% #?+3^Z/RH\M/[H_*G44 -\M/[H]>E'EI_='Y4ZB@!OEH/X1
M^5'EI_='ITIU% #?+3^Z/RH\M/[H_*G44 -\M/[H_*CRT_NC\J=10 WRT_NB
MCRT_NC\J=10 WRT_NC\J/+3^Z.F.E.HH PO%ZJ/".JD  _9VKCO#B@Z';9'\
M/]:[/QA_R)^J_P#7NU<;X;_Y 5M_NU<-SDQ?PHI>,OETFV*\'[=!_P"ABO4K
M1%^R0_*/N _I7EOC3_D$6O\ U_6__H8KU2T_X\X?]P?RHGN5A?@.,\?1(+_P
MZP4!OMA&<?[)JC\0/^1H\)_]=G_]EK1\?_\ 'YX=_P"OT_\ H)K.^('_ "-'
MA/\ Z[/_ .RU!TGHR_<7Z4M(OW%^E+0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7%:#_ ,E$\0?[D/\ Z":[6N*T'_DHGB#_ '(?_030!3^'_P#R,WBO_K\'
M_H"UZ#7GWP__ .1F\5_]?@_] 6O0: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *S/$/\ R+]]_P!<C6G69XA_Y%^^_P"N1H SO G_ "*5G_N_UKI*YOP)_P B
ME9_[O]:Z2@ HHHH **** "L[7;%M2T.\LT.&FB*BM&J&M7%Q::-=W%JNZ>.,
ML@]34SMRNY4;\RL>0^&/&[>"89M(U2R<;'.UL8S1J.NW'Q%\2:;!8VC);6TH
M=G(]QGG\*Z+PAJECXPAN?[;M[;[5%)MPRC)KN;"PTK3AMLXH(R>/E R:TZIR
MZ$]U$OPIY<*)_=4"GT45(!1110 4444 %%%&10 4444 %<'IW_)8];_Z]+?_
M -!-=Y7!Z=_R6/6_^O2W_P#030!WE%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!Y_P#%AUCT73'=@JKJ,!))X'S5SI\2Z0+P
M6GVZ'S"F[.\8_.NK^(F@W^J:>MQ9W"!(/GDAD4%6Q^'%>6B3P8/#KSR++]M$
MF\R!> X^7;UZ5Y^,P$<5)2;M8WI5G35K%#PS(DWQ!U*2-PZ-.Y#*<@\5WVM_
M\@.]_P"N+?RKC])TJZT_QE;27#1 3VXE58AP <UV&M_\@.]_ZXM_*O#Q\.3$
MQCVL==%WIMG;^!/^1.T__</\S6OJW_(&OO\ KWD_]!-9'@3_ )$[3_\ </\
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MW%^E+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]<S_ .A&L"V_Y(MJO_7O-6_\,_\ DGVE?]<S_P"A&F!UM%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!RGQ*!;X>:P%!)\I>
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M@5Z1YYZ"OW1]*6D7[H^E+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_P#&'_D3K?\ Z_X?
M_9J\^C_U:_2O0?C#_P B=;_]?\/_ +-7GT?^K7Z4 $G^K;Z&O0/@Y_R(W_;U
M/_Z,:O/Y/]6WT->@?!S_ )$;_MZG_P#1C4 >@UPVB?\ )5->_P"O6'^;UW-<
M-HG_ "537O\ KUA_F] %7P'_ ,CCXL_Z^(__ $$UZ'7GG@/_ )''Q9_U\1_^
M@FO0Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-?\ ^1?U#_K@W\J^-/F3AW_Y(O??]<&_]#KH/AQ_R(&D?]<!7/O_ ,D7OO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KBM!_Y*)X@_P!R'_T$UVM<5H/_ "43Q!_N0_\ H)H I_#_ /Y&;Q7_
M -?@_P#0%KT&O/OA_P#\C-XK_P"OP?\ H"UZ#0 4444 %%%% !1110 4444
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M3_=- '>T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6OTKT'XP_P#(G6__ %_P_P#LU>?1_P"K7Z4 $G^K;Z&O0/@Y_P B-_V]3_\
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MY*IKW_7K#_-Z *O@/_D<?%G_ %\1_P#H)KT.O// ?_(X^+/^OB/_ -!->AT
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M-%=LX[QPEA^=<CX<U&'5/BQK5S LJH;6 8E3:>%/:D!Z11110 4444 %%%%
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M0/\ L)I_Z"U4OB'_ ,A7PC_U^/\ ^@4 >@K]T?2EI%^Z/I2T %%%% !1110
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M>(;37M)LTLDF=VO(&QY9P '&:]KM/^/.'_<'\J)[CPR:A9G'^/\ _C\\._\
M7Z?_ $$UG?$#_D:/"?\ UV?_ -EK1\?_ /'YX=_Z_3_Z":SOB!_R-'A/_KL_
M_LM0=!Z,OW%^E+2+]Q?I2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 5Q6@_\E$\0?[D/_H)KM:XK0/\
MDHGB#_<A_P#030!3^'__ ",WBO\ Z_!_Z M>@UP?@=!'XJ\5@?\ /XO_ * M
M=Y0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !69XA_Y%^^_P"N1K3K,\0_\B_?
M?]<C0!G>!/\ D4K/_=_K725S?@3_ )%*S_W?ZUTE !1110 4444 %9GB&..7
MP_?)*"4,)R!UK3JIJ<ZVVF7$[1^8J(6*'O4S^%E1^)'@_A'QO/X2:[MQ9O-!
M)(6&>HKM+#XN+>W]O;?V7(OFR*F[)XR<>E8DGQ&TY9&!\-Q'!QG8:GTOXA:=
M=ZK;6R>'XD=Y%4-MY&3UK2.K5R6K7/8E.Y0?44M(IRH/3(I:D$%%%% !1110
M 4444 %%%% !7-ZEX0@OM9EU2.[N+:XE14<Q.5W!1@=*Z2B@#EO^$/D_Z#6H
M?]_F_P :/^$/D_Z#6H?]_F_QKJ:* .6_X0^3_H-:A_W^;_&C_A#Y/^@UJ'_?
MYO\ &NIHH Y;_A#Y/^@UJ'_?YO\ &C_A#Y/^@UJ'_?YO\:ZFB@#EO^$/D_Z#
M6H?]_F_QH_X0^3_H-:A_W^;_ !KJ:* .6_X0^3_H-:A_W^;_ !H_X0^3_H-:
MA_W^;_&NIHH Y;_A#Y/^@UJ'_?YO\:/^$/D_Z#6H?]_F_P :ZFB@#EO^$/D_
MZ#6H?]_F_P :/^$/D_Z#6H?]_F_QKJ:* .6_X0^3_H-:A_W^;_&C_A#Y/^@U
MJ'_?YO\ &NIHH Y;_A#Y/^@UJ'_?YO\ &C_A#Y/^@UJ'_?YO\:ZFB@#EO^$/
MD_Z#6H?]_F_QH_X0^3_H-:A_W^;_ !KJ:* .6_X0^3_H-:A_W^;_ !H_X0^3
M_H-:A_W^;_&NIHH Y;_A#Y/^@UJ'_?YO\:/^$/D_Z#6H?]_F_P :ZFB@#EO^
M$/D_Z#6H?]_F_P :/^$/D_Z#6H?]_F_QKJ:* .6_X0^3_H-:A_W^;_&FR>#&
MEC:-]8ORK@J1YS<@_C75T4 9=IH-I9Z$=)0$VY0HV>ISUK&@\#K;1"*#5KZ.
M-?NJLK8'ZUUM% '+?\(?)_T&M0_[_-_C1_PA\G_0:U#_ +_-_C74T4 <M_PA
M\G_0:U#_ +_-_C1_PA\G_0:U#_O\W^-=310!RW_"'R?]!K4/^_S?XT?\(?)_
MT&M0_P"_S?XUU-% '+?\(?)_T&M0_P"_S?XT?\(?)_T&M0_[_-_C74T4 <M_
MPA\G_0:U#_O\W^-'_"'R?]!K4/\ O\W^-=310!RW_"'R?]!K4/\ O\W^-'_"
M'R?]!K4/^_S?XUU-% '+?\(?)_T&M0_[_-_C1_PA\G_0:U#_ +_-_C74T4 <
MM_PA\G_0:U#_ +_-_C1_PA\G_0:U#_O\W^-=310!RW_"'R?]!K4/^_S?XT?\
M(?)_T&M0_P"_S?XUU-% '+?\(?)_T&M0_P"_S?XT?\(?)_T&M0_[_-_C74T4
M <M_PA\G_0:U#_O\W^-'_"'R?]!K4/\ O\W^-=310!RW_"'R?]!K4/\ O\W^
M-'_"'R?]!K4/^_S?XUU-% '+?\(?)_T&M0_[_-_C1_PA\G_0:U#_ +_-_C74
MT4 <M_PA\G_0:U#_ +_-_C1_PA\G_0:U#_O\W^-=310!RW_"'R?]!K4/^_S?
MXT?\(?)_T&M0_P"_S?XUU-% '+?\(?)_T&M0_P"_S?XT?\(?)_T&M0_[_-_C
M74T4 <M_PA\G_0:U#_O\W^-'_"'R?]!K4/\ O\W^-=310!RW_"'R?]!K4/\
MO\W^-'_"'R?]!K4/^_S?XUU-% '*#P1#)=6TUUJ%W<BWD$J))(2-P[\GWK2U
M[P[;:]':B:22-[9R\3QM@J2,5LT4 <M_PA\G_0:U#_O\W^-'_"'R?]!K4/\
MO\W^-=310!RW_"'R?]!K4/\ O\W^-'_"'R?]!K4/^_S?XUU-% '+?\(?)_T&
MM0_[_-_C1_PA\G_0:U#_ +_-_C74T4 <M_PA\G_0:U#_ +_-_C1_PA\G_0:U
M#_O\W^-=310!RW_"'R?]!K4/^_S?XT?\(?)_T&M0_P"_S?XUU-% '+?\(?)_
MT&M0_P"_S?XT?\(?)_T&M0_[_-_C74T4 <M_PA\G_0:U#_O\W^-'_"'R?]!K
M4/\ O\W^-=310!RW_"'R?]!K4/\ O\W^-'_"'R?]!K4/^_S?XUU-% '+?\(?
M)_T&M0_[_-_C1_PA\G_0:U#_ +_-_C74T4 <M_PA\G_0:U#_ +_-_C1_PA\G
M_0:U#_O\W^-=310!RW_"'R?]!K4/^_S?XT?\(?)_T&M0_P"_S?XUU-% '+?\
M(?)_T&M0_P"_S?XT?\(?)_T&M0_[_-_C74T4 <M_PA\G_0:U#_O\W^-'_"'R
M?]!K4/\ O\W^-=310!RW_"'R?]!K4/\ O\W^-'_"'R?]!K4/^_S?XUU-% '+
M?\(?)_T&M0_[_-_C1_PA\G_0:U#_ +_-_C74T4 <M_PA\G_0:U#_ +_-_C1_
MPA\G_0:U#_O\W^-=310!RW_"'R?]!K4/^_S?XT?\(?)_T&M0_P"_S?XUU-%
M'+?\(?)_T&M0_P"_S?XT?\(?)_T&M0_[_-_C74T4 <M_PA\G_0:U#_O\W^-6
M]$\+V^BWMQ>K/-/<7"A7DE8L2!G'7ZUO44 <S=>#H)M3N+Z"]N;:2XQY@BD*
M@X&!TIG_  A\G_0:U#_O\W^-=310!RW_  A\G_0:U#_O\W^-'_"'R?\ 0:U#
M_O\ -_C74T4 <M_PA\G_ $&M0_[_ #?XT?\ "'R?]!K4/^_S?XUU-% '+?\
M"'R?]!K4/^_S?XT?\(?)_P!!K4/^_P W^-=310!RW_"'R?\ 0:U#_O\ -_C1
M_P (?)_T&M0_[_-_C74T4 <M_P (?)_T&M0_[_-_C1_PA\G_ $&M0_[_ #?X
MUU-% '+?\(?)_P!!K4/^_P W^-'_  A\G_0:U#_O\W^-=310!RW_  A\G_0:
MU#_O\W^-'_"'R?\ 0:U#_O\ -_C74T4 <M_PA\G_ $&M0_[_ #?XT?\ "'R?
M]!K4/^_S?XUU-% '+?\ "'R?]!K4/^_S?XT?\(?)_P!!K4/^_P W^-=310!R
MW_"'R?\ 0:U#_O\ -_C1_P (?)_T&M0_[_-_C74T4 <M_P (?)_T&M0_[_-_
MC1_PA\G_ $&M0_[_ #?XUU-% '+?\(?)_P!!K4/^_P W^-'_  A\G_0:U#_O
M\W^-=310!RW_  A\G_0:U#_O\W^-'_"'R?\ 0:U#_O\ -_C74T4 <M_PA\G_
M $&M0_[_ #?XT?\ "'R?]!K4/^_S?XUU-% '+?\ "'R?]!K4/^_S?XT?\(?)
M_P!!K4/^_P W^-=310!RW_"'R?\ 0:U#_O\ -_C1_P (?)_T&M0_[_-_C74T
M4 <M_P (?)_T&M0_[_-_C1_PA\G_ $&M0_[_ #?XUU-% '+?\(?)_P!!K4/^
M_P W^-,F\%&>%XI-8OV1QA@9FY'YUUE% &9!H=I!H?\ 9*@FW*;#GJ:Q;?P.
MMK"L,&K7T<:C"J)FP/UKK:* .6_X0^3_ *#6H?\ ?YO\:/\ A#Y/^@UJ'_?Y
MO\:ZFB@#EO\ A#Y/^@UJ'_?YO\:/^$/D_P"@UJ'_ '^;_&NIHH Y;_A#Y/\
MH-:A_P!_F_QH_P"$/D_Z#6H?]_F_QKJ:* .6_P"$/D_Z#6H?]_F_QH_X0^3_
M *#6H?\ ?YO\:ZFB@#EO^$/D_P"@UJ'_ '^;_&C_ (0^3_H-:A_W^;_&NIHH
M Y;_ (0^3_H-:A_W^;_&C_A#Y/\ H-:A_P!_F_QKJ:* .6_X0^3_ *#6H?\
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M_O\ -_C74T4 <M_PA\G_ $&M0_[_ #?XT?\ "'R?]!K4/^_S?XUU-% '+?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#"0+_SX77_ 'R/\:/^$@7_ )\+K_OD?XUL8'H*,#T% &/_ ,) O_/A=?\
M?(_QH_X2!?\ GPNO^^1_C6Q@>@HP/04 8_\ PD"_\^%U_P!\C_&C_A(%_P"?
M"Z_[Y'^-;&!Z"C ]!0!C_P#"0+_SX77_ 'R/\:/^$@7_ )\+K_OD?XUL8'H*
M,#T% &/_ ,) O_/A=?\ ?(_QH_X2!?\ GPNO^^1_C6Q@>@HP/04 8_\ PD"_
M\^%U_P!\C_&C_A(%_P"?"Z_[Y'^-;&!Z"C ]!0!C_P#"0+_SX77_ 'R/\:/^
M$@7_ )\+K_OD?XUL8'H*,#T% &/_ ,) O_/A=?\ ?(_QH_X2!?\ GPNO^^1_
MC6Q@>@HP/04 8_\ PD"_\^%U_P!\C_&C_A(%_P"?"Z_[Y'^-;&!Z"C ]!0!C
M_P#"0+_SX77_ 'R/\:/^$@7_ )\+K_OD?XUL8'H*,#T% &/_ ,) O_/A=?\
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MP/04 8__  D"_P#/A=?]\C_&C_A(%_Y\+K_OD?XUL8'H*,#T% &/_P ) O\
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ML8'H*,#T% &/_P ) O\ SX77_?(_QH_X2!?^?"Z_[Y'^-;&!Z"C ]!0!C_\
M"0+_ ,^%U_WR/\:-+\2VFJZI<Z?''+'<6Z*[JX'0YQ_*MC ]!7#Z)_R5/7O^
MO6'^;T ;?_"56K:C=6,5O/++;$"38!@9&1WJ7_A(%_Y\+K_OD?XUSO@V99_&
M/BC ^[-$.?\ =-=U@>@H Q_^$@7_ )\+K_OD?XT?\) O_/A=?]\C_&MC ]!1
M@>@H Q_^$@7_ )\+K_OD?XT?\) O_/A=?]\C_&MC ]!1@>@H Q_^$@7_ )\+
MK_OD?XT?\) O_/A=?]\C_&MC ]!1@>@H Q_^$@7_ )\+K_OD?XT?\) O_/A=
M?]\C_&MC ]!1@>@H Q_^$@7_ )\+K_OD?XT?\) O_/A=?]\C_&MC ]!1@>@H
M Q_^$@7_ )\+K_OD?XT?\) O_/A=?]\C_&MC ]!1@>@H Q_^$@7_ )\+K_OD
M?XT?\) O_/A=?]\C_&MC ]!1@>@H Q_^$@7_ )\+K_OD?XT?\) O_/A=?]\C
M_&MC ]!1@>@H Q_^$@7_ )\+K_OD?XT?\) O_/A=?]\C_&MC ]!1@>@H Q_^
M$@7_ )\+K_OD?XT?\) O_/A=?]\C_&MC ]!1@>@H Q_^$@7_ )\+K_OD?XT?
M\) O_/A=?]\C_&MC ]!1@>@H Q_^$@7_ )\+K_OD?XT?\) O_/A=?]\C_&MC
M ]!1@>@H Q_^$@7_ )\+K_OD?XT?\) O_/A=?]\C_&MC ]!1@>@H Q_^$@7_
M )\+K_OD?XT?\) O_/A=?]\C_&MC ]!1@>@H Q_^$@7_ )\+K_OD?XT?\) O
M_/A=?]\C_&MC ]!1@>@H Q_^$@7_ )\+K_OD?XT?\) O_/A=?]\C_&MC ]!1
M@>@H Q_^$@7_ )\+K_OD?XT?\) O_/A=?]\C_&MC ]!1@>@H Q_^$@7_ )\+
MK_OD?XU'/XFBMX'FDL;H(B[F.T=/SK<P/05G:^!_PC]_P/\ 4-_*@!D.OVD^
MA-JZ[OLX4L<]>N*JVOBJ"\MDN(+*Z:-QE2%'/ZUS=M,+?X1W,K#(6)B?^^ZZ
M#P+*EQX,TR51PT((S0!:_P"$@7_GPNO^^1_C1_PD"_\ /A=?]\C_ !K8P/04
M8'H* ,?_ (2!?^?"Z_[Y'^-'_"0+_P ^%U_WR/\ &MC ]!1@>@H Q_\ A(%_
MY\+K_OD?XT?\) O_ #X77_?(_P :V,#T%&!Z"@#'_P"$@7_GPNO^^1_C1_PD
M"_\ /A=?]\C_ !K8P/048'H* ,?_ (2!?^?"Z_[Y'^-'_"0+_P ^%U_WR/\
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M"_\ /A=?]\C_ !K8P/048'H* ,?_ (2!?^?"Z_[Y'^-'_"0+_P ^%U_WR/\
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M]=/4-W!]JM)8,X\Q2N?2HFFXNQ479G$?"-0O@:!!T#,!^=6+^/P[X4N;J\N
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M/^N#?RH X=_^2+WW_7!O_0ZZ#X<?\B!I'_7 5S[_ /)%[[_K@W_H==!\./\
MD0-(_P"N H ZJBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .)\?_P#'YX=_
MZ_3_ .@FL[X@?\C1X3_Z[/\ ^RUH^/\ _C\\._\ 7Z?_ $$UG?$#_D:/"?\
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MX^+/^OB/_P!!->AT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9_\ V6M'Q_\ \?GAW_K]/_H)K.^('_(T>$_^NS_^RT >C+]Q?I2TB_<7Z4M
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MYJW_ (9_\D^TK_KF?_0C0!UM%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <
M5\1/NZ!_V$T_]!:J7Q#_ .0KX1_Z_'_] J[\1/NZ!_V$T_\ 06JE\0_^0KX1
M_P"OQ_\ T"@#T%?NCZ4M(OW1]*6@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MN&T3_DJFO?\ 7K#_ #>NYKAM$_Y*IKW_ %ZP_P WH J^ _\ D<?%G_7Q'_Z"
M:]#KSSP'_P CCXL_Z^(__037H= !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9
MNO\ _(OZA_UP;^5:59NO_P#(OZA_UP;^5 '#O_R1>^_ZX-_Z'70?#C_D0-(_
MZX"N??\ Y(O??]<&_P#0ZZ#X<?\ (@:1_P!<!0!U5%%% !4=Q_J']Q4E13_=
M4>K 4">P]/N+]*=0.E% PHI P;.#TI: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XGQ__ ,?GAW_K
M]/\ Z":SOB!_R-'A/_KL_P#[+6CX_P#^/SP[_P!?I_\ 036=\0/^1H\)_P#7
M9_\ V6@#T9?N+]*6D7[B_2EH **** "BBB@ HHIDC;(V;T% $*_O;LMV08%6
M:AMDVQ9/5N34U WN%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KBM!_Y*)X@_P!R'_T$UVM<5H/_ "43Q!_N
M0_\ H)H I_#_ /Y&;Q7_ -?@_P#0%KT&O/OA_P#\C-XK_P"OP?\ H"UZ#0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !69XA_Y%^^_ZY&M.LSQ#_R+]]_UR- &
M=X$_Y%*S_P!W^M=)7-^!/^12L_\ =_K724 %%%% !1110 50UM;9]%O%NSBW
M,1\P^U7ZS/$,,=QX?OHIF*QM$0Q'85,_A94/B1XMX;\>3>'TGLK:R^TVRR'8
MP7G%=/8?%&YN]0M[<Z0R"614+8Z9./2L+PAXN\/Z':2V6HV>]D<[9 H)85UE
MEX^\(W-[!##:$2R.%0[!P2>*T6ZZD/KT/15.5!]12TBD%01T(I:D:"BBB@ [
M5XO=7<<GCO5UU*"?48%_U7DY81]>/K7L[#<A7U&*\YL=#USPMJ^HRV5I!?6]
MY*909,[E)).*7VOD/[)#\,;V=K?6-\C+%'*3#;R-\T8P:B\%Z7%XQ@U'5M69
MY7DG9(U+<(,#I6UX4\,7UMK.I:QJ02*2\&!!']U1C']*I:;I/B'PA/?6VF6T
M5U9W$IDBWD@H33ZZ]OQ%WMW)/AW?7$>J:WHDLK2164^(BQR0I)X_2NZO;N.Q
MM)+F579$&2$7)_*N8\$^&KG1OMU_J# WU]*9) .B\D@?K76D!A@@$>AIO97W
MLA=7;8YO_A-M._Y]K[_OP:YSPYJ,6J?%C6KF%)%0VL Q(NT\*>U>B>1#_P \
MD_[Y%<-IBJGQBUL*H ^R6_ '^R:0SO:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>K?\@:^_P"O>3_T$U<J
MGJW_ "!K[_KWD_\ 030!Y_;?\D6U7_KWFK?^&?\ R3[2O^N9_P#0C6!;?\D6
MU7_KWFK?^&?_ "3[2O\ KF?_ $(T =;1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% '%?$3[N@?]A-/_ $%JI?$/_D*^$?\ K\?_ - J[\1/NZ!_V$T_]!:J
M7Q#_ .0KX1_Z_'_] H ]!7[H^E+2+]T?2EH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KAM$_Y*IKW_7K#_-Z[FN&T3_DJFO?]>L/\WH J^ _^1Q\6?\ 7Q'_
M .@FO0Z\\\!_\CCXL_Z^(_\ T$UZ'0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !6;K_\ R+^H?]<&_E6E6;K_ /R+^H?]<&_E0!P[_P#)%[[_ *X-_P"AUT'P
MX_Y$#2/^N KGW_Y(O??]<&_]#KH/AQ_R(&D?]<!0!U5%%% !4,G,T:_C4U0G
MYKD?[(H0F35'*^U..IX%25"G[R4O_".!0#'QIL3'?O3Z**!A1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 <3X_\ ^/SP[_U^G_T$UG?$#_D:/"?_ %V?_P!EK1\?_P#'YX=_Z_3_ .@F
ML[X@?\C1X3_Z[/\ ^RT >C+]Q?I2TB_<7Z4M !1110 4444 %5[GYV2(=SDU
M8JM%^\N)).P^44#7<L 8&*6BB@04444 %%%12R[!A>6/04 /WKOV9^:G5%#%
ML^9CECU-2T#84444""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M* "BBB@ HHHH **** "BBD) &3Q0 M%0F<$X0%C^E34E)/8+!5/5O^0-??\
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M * M>@UY]\/_ /D9O%?_ %^#_P! 6O0: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *S/$/_(OWW_7(UIUF>(?^1?OO^N1H SO G_(I6?^[_6NDKF_ G_(I6?^
M[_6NDH **** "BBB@ KB9/%:ZMXEN_"I@V;HB#*#SV_QKMJ^?];O-3L?B==S
M:2A>Z"X 'IQ4Z.:B]G<K[+:WT.Q?X.VC.S?;Y>3GK6AHWPKTS3-0CNY9'G:,
MY4,>AKD_^$I\??\ /K)^56M-\2^.)=2MH[BV<0M*H<X[9YJX[Z$O;4]@
MZ"EI%R44GKCFEI %%%% #77?&R?W@17E&BV3>#/$&KK>Z5+=0W4S2Q31J#P2
M3CFO6:1D5OO*#]:2T=_D/I8\Z\%Z5>3:_K.JM;/9V=U\L4#?0#/Z54\-7=YX
M'_M#2[K3;B>,S-)!)$!A@0..37J   P!BD9%;[R@_44]MNUA;[^IPWP^TF\B
MO-6UJ]A,+W\VY8VZJN3C^==Q+$D\;1R*&1NH/>G]**?D'6Y1_L;3O^?2/\JX
MS1[>*V^+VMQPH$3[) <#_=->@UP>G?\ )8];_P"O2W_]!-(#O**** "BBB@
MHIDDHCVY[]*<K!AD=*5U>P6%HHHI@%%%% !1110 4444 %%%% !1110 444C
M,%&2<4 +2$@#).*A,S/Q&N?<TH@+',C;O:HYK_".W<#.2<1KN]^U((6<YD;/
MM4P  P!BEHY;_$%^PBJ%& ,4M%%6(*IZM_R!K[_KWD_]!-7*IZM_R!K[_KWD
M_P#030!Y_;?\D6U7_KWFK?\ AG_R3[2O^N9_]"-8%M_R1;5?^O>:M_X9_P#)
M/M*_ZYG_ -"- '6T444 %%%% !1110 4444 %&<#)HJG([74GE1G$8^\WK[5
M,I6*BK@Q:[DVKQ$IY/K5M5"J !@"D15C4(N !VIU$8VU>X2=]%L%%%%42%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q7Q$
M^[H'_833_P!!:J7Q#_Y"OA'_ *_'_P#0*N_$3[N@?]A-/_06JE\0_P#D*^$?
M^OQ__0* /05^Z/I2TB_='TI: "BBB@ JIJ#D0!$^\[ 8]N]6ZI.?.U-4[0KN
M_$\4 6XT$<:H.@&*=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7#:)_P E4U[_ *]8?YO7<UPV
MB?\ )5->_P"O6'^;T 5? ?\ R./BS_KXC_\ 037H=>>> _\ D<?%G_7Q'_Z"
M:]#H **** "BBB@ K.M/](OY[@]%_=I[CUJQ?3FWLY'7[V,*/4TMC +>TCC]
M!S5K2+?<M:1N6****@@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "LW7_P#D7]0_ZX-_*M*LW7_^1?U#_K@W
M\J .'?\ Y(O??]<&_P#0ZZ#X<?\ (@:1_P!<!7/O_P D7OO^N#?^AUT'PX_Y
M$#2/^N H ZJBBB@!'.$8^@K,O6VP1J/XOFK0F;;$??BLZ8;[Z*+LH%5$RJ[6
M-*+_ %2_2GT@& !2U)J@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B?'_ /Q^>'?^OT_^@FL[
MX@?\C1X3_P"NS_\ LM:/C_\ X_/#O_7Z?_036=\0/^1H\)_]=G_]EH ]&7[B
M_2EI%^XOTI: "BBB@ HHJ&Y;;"0.K?**!K4;;_.[RG^(\58ID2[(U7VI] /<
M*CFE6&,NWX4]F"*68X K%N;@W$N<XC7H*"H1YF68[G+;\9=OTJW%&2WF2<L>
M@]*KV$.5\QEQZ"K] 3>MD%%%-=U1<L:"!U%0(7E?>?E0=!ZU/0-JP4444""B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N*T'_ )*)X@_W
M(?\ T$UVM<5H/_)1/$'^Y#_Z": *?P__ .1F\5_]?@_] 6O0:\^^'_\ R,WB
MO_K\'_H"UZ#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %("#T.:@N)3D11_?;OZ5+%&(XPHH ?1110 444
M4 %%%% !69XA_P"1?OO^N1K3K,\0_P#(OWW_ %R- &=X$_Y%*S_W?ZUTE<WX
M$_Y%*S_W?ZUTE !1110 4444 %>?V7A"]A^(\VMR!3;.A _2O0**%I+F#I89
MY4?]Q?RI?+0?P+^5(98U.#(@/NPH$T1.!*A_X$* 'T444 %%%% !7->+_%<?
MAVP<0KYU\RDQPCK]3[5T4V_R9/+_ -9M.W/KVKR:?1O%=LVJZC=VEM<RRHX5
MV)^1,'@"HDV5$[7P-XANO$/A6+4[Y529BX8*.!@D?TK'L_$OB#Q+=7LFB>3%
M9VTAC5I%!,A%4OA/_:C^$G@N;=([<M)L89R3N-1> -6M/#%IJ6EZM)]FGBN&
M8;P?G&!R*TE;G?H1'X?G_F=5X/\ $\FO1W5O=QB.^LY#',HZ=<9_2NDEFC@B
M:25U1%Y+,< 5Y[\.8);C6M>UCRV2VNY_W61C< 3S^M>@7-O'=V[P2KN1Q@BA
M[*_9#ZM(J_VWI?\ S_V__?8KC=&N(;KXO:W+!*LB&T@&Y3D?=-=/_P (MI?_
M #P'YFN5T&RAL/BWK4%NNV,6L!Q_P$T@/1**** "BBD8[5)]!0!2N7+3[1S@
M8'X\&KB*$15'852M/WTQD/3[WXFK]84=;S[ERTT"BBBMR HHHH **** "BBB
M@ HHHH 1F"C).!2,ZJ,DXS52\D+2I G4G)J=( .6.X^]9J;<FH]"K65V(97?
MB->/4TJP9.7)8U-TZ44^6^XK]A  !P*6BBK$%%%% !1110 53U;_ ) U]_U[
MR?\ H)JY5/5O^0-??]>\G_H)H \_MO\ DBVJ_P#7O-6_\,_^2?:5_P!<S_Z$
M:P+;_DBVJ_\ 7O-6_P##/_DGVE?]<S_Z$: .MHHHH **** "F22+$A=S@"GU
M3/\ I5WC_EG$>?<U,I66FY45?<F6YB(Y;;]>*D5U<95@?I2&&-CRHJC<1B23
MR8"0W\1!Z5,I2BM=1J,9,FED:=_)B/ ^\U6(XUB0*HX%5H[-H%Q%(1ZY[T__
M $F/IA_K2C=.\EJ-V>D6-5C+?M@_+&NTCU)YJW5>TB:*([_OL235BJ@G:[ZD
MSM>R"BD#!NASBEJR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .*^(GW= _[":?^@M5+XA_\A7PC_U^/_Z!5WXB?=T#_L)I
M_P"@M5+XA_\ (5\(_P#7X_\ Z!0!Z"OW1]*6D7[H^E+0 4444 (3A2?053L/
MG$D__/1B5^E27\ACM6VGYVX6I($6*%8U_A'2@"6BBB@ HHHH *,\XJK-<G=Y
M4(W/W/85);PF)268LYY)H FHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KAM$_Y*IKW_7K#_-Z[FN&T3_DJFO?]>L/
M\WH J^ _^1Q\6?\ 7Q'_ .@FO0Z\\\!_\CCXL_Z^(_\ T$UZ'0 4444 %%%(
MQ"J6)P!R: ,^Z_TC48(!]U/WC?7T_6M&L_3096FNF',C<#V'%:%7/3W>Q4NP
M4445!(4444 %%("&&0<TM !1110 4444 %%%% !1110 4444 %%%% !1110
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M ",WBO\ Z_!_Z M>@UY]\/\ _D9O%?\ U^#_ - 6O0: "BBB@ HHHH ****
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M@=W#!%;QB.%%1!T %25S'@_Q/)KT=U;W<8COK.0QS*.G7&?TKIZ; *X/3O\
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M3[N@?]A-/_06JE\0_P#D*^$?^OQ__0*N_$3[N@?]A-/_ $%JI?$/_D*^$?\
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M_H)KT.O// ?_ "./BS_KXC_]!->AT %%%% !5+4Y"MKY:_>E(3\#UJ[6<?\
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M@"J;%#GYWY4+U]*#8HV[YW^;'?TJU10!5-BA+'>W+9ZTOV)-V=S?>W=:LT4
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MY^=^6W=?:E^Q)_?;[Q;K5FB@"JMBB[?G?@D]?6@6* *-[_*,=:M44 5!8(%
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M5A9(1G<_*XZTIL4.?G?D =?2K5% RJ;%#N^=^2.]!LD))WMRV[K5JB@"L+)
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M6$494EWY<_I4M%%4DDK(384444P"BBB@ HHHH **** "BBB@ JGJW_(&OO\
MKWD_]!-7*IZM_P @:^_Z]Y/_ $$T >?VW_)%M5_Z]YJW_AG_ ,D^TK_KF?\
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M;+L.[4W[ #UD;\Z!I\><[W_.N5R71F%UW+8 48  'M2TBC:H'I2UD9A1110
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M4 %%%% !1110 5Q6@_\ )1/$'^Y#_P"@FNUKBM!_Y*)X@_W(?_030!3^'_\
MR,WBO_K\'_H"UZ#7GWP__P"1F\5_]?@_] 6O0: "BBB@!"0HR3@"J<NI0H=J
M'>_;'2J^IZ9/>R;X[EHU QM'>LT:/+!]XLQ]JEMC-&2YDE_ULGE)Z#_&F-<0
MP194C/J&Y-,A@9?X%?'8DU.MB\TN]T5 .@%+4"FLK?ZYIVW'H,=*#=7;?<#G
M\*V([&%#DKDU.$51@*!^%.S P@E](/GD95]A3XXI(CD98^K+FMO ]*,#T%'*
M%S+%[<KP(/Q IWVZ7'1MWIMK2P/04;5_NC\J=A&47N)>C,I]J<ME+(<NS?\
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MAU_$>E2U6%NT=UYD9PK?>6@"S1110 4444 %%%% !1110 4444 %%%&<#)H
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MOUK&M&Z370J+Z$\+&-S"W;[I]15BJ4<D<T2EG D4[<Y[T\,#C%QUZ<TX-I;
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M!4\'GUJK;72Q2M;2./E/RG/6@#0HJ%[J&-2S2  ''7O5-KZ27YX-NP'H>K4
M:5%5X+V&>,,KCGMFI!/$1D..F>O:@"2HI8(Y1R.?44IGB SO' SU[4>?%S\X
MXZ\T 5]L]M]T^8GH>HJ:*YCEX^ZW]TTXSQ#.7'!QUJ*5;:7[Q&<XSGO0!9I,
MCU%4MB\ W)(S@<TOE6YQNDSGWH N;E_O#\Z-R_WA^=4_)M..1S[T>1:>HZ9Z
MT 7-P]1^=+5+RK4?=<#C/6@J%SBZ( ]Z +M(2!U-4R",C[6>#CK1Y<3'$LV_
MG')[T 6FD11DL *1)XI#A7!-5MME'R67Z9I@O82<6Z D]&H T,XZU!)=1H<
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M?%_?'3/6@"2BH_/B&?G''7FCSX\D;QP<=: )**C\^/.-XZXZ]Z!/$<8<<^]
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M1;>>;8H!Z5HQVOB+3M=TD:GJ4GV6XD5E8-P>1Q5PO="ELSWE<[%SUQ2TU/\
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M+#_<'7/XU2U>T@;1;T% 0(9&_'::TZIZM_R!K[_KWD_]!- 'G]J,?!75 /\
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M$D?C4U% $/V6$8^0<9Q1]EAX^0<#'X5-10!#]EA_N#IC\*#:PG.4'(P:FHH
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M-344 0_98LYV=\_C0+6$$'9T.:FHH A%K",80<=*!:PC'R=!BIJ* (?LL/\
M<'3%'V6'GY.HQ4U% $/V6'GY.N,T?98>?DZG-344 0_98?[G?- M81_!T.:F
MHH A%K",?(..E M80  @X&*FHH A^RPD8V#IC\*#:PG/R#D8-344 0FUA.<H
M.:/LT7]WOFIJ* (?LL/]P=<T?98N/D''2IJ* (?LL/'R#CI1]EAX^3H,5-10
M!#]EA_N#IB@VL)SE!R,&IJ* (?LL))^0<\FC[+#G.P=<_C4U% $(M80<A.AS
M0+6$8P@XZ5-10!"+6$?P#@8K,\16D!\/WN4'$1%;-9GB'_D7[[_KD: ,WP&
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MA_\ (5\(_P#7X_\ Z!0!Z"OW1]*6D7[H^E+0 4444 %%%% #?+3.=HS3J**
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5Q6@_\E$\0?[D/_H)KM:XK0?\ DHGB#_<A_P#030!3^'__ ",WBO\
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M^M6:HO\ Z+?A^D<O!]C5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5F>(?\
MD7[[_KD:TZS/$/\ R+]]_P!<C0!G>!/^12L_]W^M=)7-^!/^12L_]W^M=)0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5Q6@_P#)1/$'^Y#_ .@FNUKBM!_Y*)X@_P!R'_T$T 4_A_\ \C-XK_Z_!_Z
MM>@UY]\/_P#D9O%?_7X/_0%KT&@ HHHH **** "BBB@ HHHH **** "BBB@
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M<?%G_7Q'_P"@FO0Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S=?_P"1?U#_
M *X-_*M*LW7_ /D7]0_ZX-_*@#AW_P"2+WW_ %P;_P!#KH/AQ_R(&D?]<!7/
MO_R1>^_ZX-_Z'70?#C_D0-(_ZX"@#JJ*** "BBB@ HHHH **** "BBB@ J&4
M;'$@^AJ:D(!!![T":N .1D4M0Q$JQC;MTJ:@$[A1110,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** .)\?_\ 'YX=_P"OT_\ H)K.
M^('_ "-'A/\ Z[/_ .RUH^/_ /C\\._]?I_]!-9WQ _Y&CPG_P!=G_\ 9: /
M1E^XOTI:1?N+]*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N*T'_DHGB#_<
MA_\ 037:UQ6@_P#)1/$'^Y#_ .@F@"G\/_\ D9O%?_7X/_0%KT&O/OA__P C
M-XK_ .OP?^@+7H- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9GB'_D7[[_KD
M:TZS/$/_ "+]]_UR- &=X$_Y%*S_ -W^M=)7-^!/^12L_P#=_K724 %%%% !
M1110 4444 %%%% !1110 5S7BKQ'=:- 8[&PDN+AD+!A]U?KS4&KZ3XFN=1>
M6PU7R;<_=3GC]:V+J&9- F29O,G$)#,.YQ43;Y&RH_$D8_P_UV\U_P *Q:A?
MD><Q.[';%95OK6N>*M;U"#2;H6=I9.8M^,[V!(/KZ5/\+8)$\$1Q2QO&Q+##
M*0:R/"^H1^#M:UJQU2.9%EN&GBD6,L&!)/:M9)>TMY?CH0K\OS_S-_PGXGN[
MN]U'2-4 ^V6)Y<?QKC.:S-.U?Q!XOGOKG2[L6=G;R&./C/F$?@:B\'VL^K>*
M]>U[R7BMKD".+>I!8!0,\_2JW@O5H?!\&HZ3JL4T<D<[.C+&6#C ]!4KIS;V
M_$I];=_Z_$Z;P7XEN-9%[8WR@7MC*8Y"/XN2 ?TKJ+BYAM(&GG<)&@RS'M7
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M_(5\(_\ 7X__ *!0!Z"OW1]*6D7[H^E+0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 1W$9F@>,,5W#&15#2
MM!L-(1Q;0*))#F1R.6/O6G10!D+X>LH-7_M*UC$,S#$FWC>/>M>BB@ HHHH
M**** "N&T3_DJFO?]>L/\WKN:X;1/^2J:]_UZP_S>@"KX#_Y''Q9_P!?$?\
MZ":]#KSSP'_R./BS_KXC_P#037H= !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%9NO_P#(OZA_UP;^5:59NO\ _(OZA_UP;^5 '#O_ ,D7OO\ K@W_ *'70?#C
M_D0-(_ZX"N??_DB]]_UP;_T.N@^''_(@:1_UP% '54444 %%%% !1110 444
M4 %%%% !1110!%,IP'7[RTHF0C.:DI-B^@H%8;YJ?WJ/-3^]3MB^@HV+Z"@-
M1OFI_>H\U/[U.V+Z"C8OH* U&^:G]ZCS4_O4[8OH*-B^@H#4;YJ?WJ/-3^]3
MMB^@HV+Z"@-1OFI_>H\U/[U.V+Z"C8OH* U&^:G]ZCS4_O4[8OH*-B^@H#4;
MYJ?WJ/-3^]3MB^@HV+Z"@-1OFI_>IK7,"G#2J#Z$U)L7T%<1\0=#,]@VK0WY
MM'M4+,"<*X]Z U-9/&>E/XC.C+,/."YW_P .?3-= LB.<*ZL?8UX&VOZ,GA>
M.<:)<B;?D7>TXW],].F*],\!Z&]EIZW\U^UW)<#<#NRH^E SLJ*** "BBB@#
MB?'_ /Q^>'?^OT_^@FL[X@?\C1X3_P"NS_\ LM:/C_\ X_/#O_7Z?_036=\0
M/^1H\)_]=G_]EH ]&7[B_2EI%^XOTI: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *XK0?^2B>(/\ <A_]!-=K7%:#_P E$\0?[D/_ *": *?P_P#^1F\5_P#7
MX/\ T!:]!KS[X?\ _(S>*_\ K\'_ * M>@T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5F>(?^1?OO^N1K3K,\0_\B_??]<C0!G>!/^12L_\ =_K725S?@3_D
M4K/_ '?ZUTE !1110 4444 %%%% !1110 4444 %! (P1D444 -1$C7:B*J^
MBC%13V=M<G,T$;D=V4&IZ* &1Q1Q($C144=E&!44UC:W#!I;>)V'=D!-6**
M&HB1J%1551T"C IU%% !7#Z8@/Q<UY^XM;8?^.FNXKF=1\)?:M=FU:VNWMYY
MT5)-O<*,"@#IJ*Y*?PIJ,L#QKK,JEA@$8X_2LS_A =7_ .ADN/T_PH ] HKQ
M_P *:!K>OV]]))X@G3[/>2VXQCD(Q7/3VKH/^$!U?_H9+C]/\* /0**\_P#^
M$!U?_H9+C]/\*/\ A =7_P"ADN/T_P * /0**\__ .$!U?\ Z&2X_3_"C_A
M=7_Z&2X_3_"@#T"BO/\ _A =7_Z&2X_3_"LGQ-X6UG1/#UUJ*>(;AVAVX4XY
MRP'I[T >K45YQ9>"-8N;*&8^([@%U!QQ_A4__" ZO_T,EQ^G^% 'H%%>?_\
M" ZO_P!#)<?I_A1_P@.K_P#0R7'Z?X4 >@45Y_\ \(#J_P#T,EQ^G^%'_" Z
MO_T,EQ^G^% 'H%%>?_\ " ZO_P!#)<?I_A6!J7A_6K+Q3IVE+X@G*74;.6XX
MP<>E 'K]%>?_ /" ZO\ ]#)<?I_A1_P@.K_]#)<?I_A0!Z!17G__  @.K_\
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M%>1>$_#FM>(-%2^D\07",S,N!CLQ'I[5N_\ " ZO_P!#)<?I_A0!Z!17G_\
MP@.K_P#0R7'Z?X4?\(#J_P#T,EQ^G^% 'H%%>?\ _" ZO_T,EQ^G^%'_  @.
MK_\ 0R7'Z?X4 >@45Y__ ,(#J_\ T,EQ^G^%'_" ZO\ ]#)<?I_A0!Z!17D%
MQX?UJ'QK::(/$$Y2:U><OQP0P&.GO6__ ,(#J_\ T,EQ^G^% 'H%%>?_ /"
MZO\ ]#)<?I_A1_P@.K_]#)<?I_A0!Z!17G__  @.K_\ 0R7'Z?X4?\(#J_\
MT,EQ^G^% 'H%%>?_ /" ZO\ ]#)<?I_A1_P@.K_]#)<?I_A0!Z!17E'BCPOK
M.A>&[[4H_$-P[6\1<*<<X'TJ_8>"=8N]/M[@^(K@&6-7(XXR,^E 'I%%>?\
M_" ZO_T,EQ^G^%'_  @.K_\ 0R7'Z?X4 >@45Y__ ,(#J_\ T,EQ^G^%'_"
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M$!U?_H9+C]/\*/\ A =7_P"ADN/T_P * /0**\__ .$!U?\ Z&2X_3_"C_A
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MI025&..2/2M?_A =7_Z&2X_3_"@#T"BO/_\ A =7_P"ADN/T_P */^$!U?\
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M2X_3_"@#T"BO/_\ A =7_P"ADN/T_P */^$!U?\ Z&2X_3_"@#T"BO/_ /A
M=7_Z&2X_3_"C_A =7_Z&2X_3_"@#T"BO/_\ A =7_P"ADN/T_P *Q/%?AO6M
M T0WT?B"X=O.CCP<?Q,%]/>@#UNBO.K;P+J\UM'*?$=P"Z@]O\*E_P"$!U?_
M *&2X_3_  H ] K*UO18M=@2UN6/V;.YT!^][?2N4_X0'5_^ADN/T_PH_P"$
M!U?_ *&2X_3_  H Z]M"TU]+.G-:1?9BNW9M%-T71X]$MC:6[L;<'**3]WVK
MDO\ A =7_P"ADN/T_P */^$!U?\ Z&2X_3_"@#T"BO/_ /A =7_Z&2X_3_"C
M_A =7_Z&2X_3_"@#T"BO/_\ A =7_P"ADN/T_P *OVGA#4K>'8^MS2'U./\
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M#)<?I_A0!Z!17G__  @.K_\ 0R7'Z?X4?\(#J_\ T,EQ^G^% 'H%%>?_ /"
MZO\ ]#)<?I_A1_P@.K_]#)<?I_A0!Z!17G__  @.K_\ 0R7'Z?X5FZ_X2UG2
M=&GO4\0W#-&!@<?X4 >I45YGI/@W6-0TNWNF\17"F5 Q''<?2M2T\$:I;R[W
M\03N,=#C_"@#N*XK0?\ DHGB#_<A_P#035S_ (1C4/\ H+R_I_A5K0?#2:->
M75XT[37%SMWNWMP* ,+P-&(_%/BL#_G\7_T!:[RN4E\';=4N[ZSO7MVNG#R
M=S@#^E._X1C4/^@O+^G^% '4T5P]YX)U2YEWIK\\8QT&/\*K_P#" ZO_ -#)
M<?I_A0!Z!17D&F^']:O?$NH:8WB"<+; 8;CGD^WM6_\ \(#J_P#T,EQ^G^%
M'H%%>?\ _" ZO_T,EQ^G^%'_  @.K_\ 0R7'Z?X4 >@45Y__ ,(#J_\ T,EQ
M^G^%'_" ZO\ ]#)<?I_A0!Z!17D.@^'M:U74-2MW\03J+6=H@>.<''I6]_P@
M.K_]#)<?I_A0!Z!17G__  @.K_\ 0R7'Z?X4?\(#J_\ T,EQ^G^% 'H%%>?_
M /" ZO\ ]#)<?I_A39/ >KI&S?\ "1W' )[?X4 >A45Y%X8\.:UKEM=2OX@G
M0PW#Q#&.<''I6[_P@.K_ /0R7'Z?X4 >@45Y_P#\(#J__0R7'Z?X4?\ " ZO
M_P!#)<?I_A0!Z!17G_\ P@.K_P#0R7'Z?X5%=>!M7@LYYAXCN"8XV<#CL,^E
M 'HM%>3>&?#.M:WI0NW\07"$L1@8[?A6S_P@.K_]#)<?I_A0!Z!17G__  @.
MK_\ 0R7'Z?X4?\(#J_\ T,EQ^G^% 'H%%>?_ /" ZO\ ]#)<?I_A1_P@.K_]
M#)<?I_A0!Z!17G__  @.K_\ 0R7'Z?X4?\(#J_\ T,EQ^G^% 'H%%>7ZWX0U
MC2]&NKU?$5PS0QEP..<#Z4[1O!VL:EI%K>-XBN%::,.1QQD?2@#TZBO/_P#A
M =7_ .ADN/T_PH_X0'5_^ADN/T_PH ] HKS_ /X0'5_^ADN/T_PI1X!U8,#_
M ,)'<<'V_P * ._K,\0_\B_??]<C6.GA;4%4 ZQ*<=^/\*;/X1O+B!X9-6E*
M.,,/\B@"SX$_Y%*S_P!W^M=)5+2=-BTC38;*'.R,8&:NT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@^%] .@6]Y&7W_:
M+N6X^F]BW]:WJ** "BBB@ HHHH *RO$>E'6]!N=.#;3-MY],,#_2M6B@""S@
M^S6<4.<[% S4]%% !1110 4444 %86HZ";WQ-I^JA\"UC*;?7)S6[10 4444
M %%%% !1110 4444 %%%% !1110 4444 8GA;0SX?T9+$OO*LS9^I)_K6W11
M0 4444 %%%% !1110!A7&@F;QC:ZWOP(;5X-OKE@?Z5NT44 %%%% !1110 4
M444 97B723KOAZ]TT/L-Q&4W>F15VQM_LEA;VY.?*C5,_08JQ10 4444 %%%
M% !1110 5AZ/H1TS5]4O2^X7KHP'I@8K<HH **** "BBB@ HHHH **** "BB
MB@ HHHH BNHO/M)H<X\R-DS]1BLWPWHYT/25LR^XABV?K6O10 4444 %%%%
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MS6G3SZ;X_ATW2+R6[LF3_2-QR$/U_*K/C>\\32:A%IVG64S:?M'G2Q-AFX'
M_6KGA*1=/F2UA\/3VYD_UD[MG)]^**>]_7YA+:QWE%%% !1110!E:]KMMH5@
MT\QW2'B.,=6/I7G/A_4M;G^)>-1N&6.>W\Q8,\)R:Z_Q+X*'B'4[>^^WS0/
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M54T:TM=/U&>=(YT/EECA0#UKH/$7AC5+KP-#807+S7$1#MN/WQCI0_@:7?\
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M@ HHHH **** "BBB@ I,#.<"EHH **** "BBB@ HHHH **** "BBB@ HHHH
M0@'J,TM%% !1110 4444 %%%% !1110 F .@%+110 4444 %%%% !2  =!BE
MHH **** "D  Z#%+10 4444 %%%% !1110 A /49I>G2BB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?3+-_/DD=HXU;HOOTJY?'R+M<E?#S/N?3=%?._C%OB%X4LUUBYU$M$6&Y0>
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M=!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&1RK"/\ ]!%>SP_!_P *0:@MW'9!61PZ@8X(.?2M?4OA[X;U?45O[VP62X4
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M";_DG6E?]<J[>J6E:5::-I\5C8Q"*WB&$4=A5VJG+FDV3!65@HHHJ2@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<_MC:&E;,)D&05VCIGWS63:7T-MX2F>& /%)?D)N'"\CDT1@K>MOQ')Z_/\
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M",DAOI6_81)!X_O4B4(AB0X48'2I=.*T]?P#F>_I^)T>HZK::7$)+J3:&.
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M<Q.P[*X)I:C!;"T2V^SK @AZ[ .*233K.5HVDMT9H_N$CI2B_M#)Y8N8M_\
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M;:(QPP(B-U '6N<T'QE%JNM7>F2IY<L+E5)Z-BGZEXJ:QNM4A$6?L<0D'OD
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M]Y;1HKO/&JMT8L,&FG4+-8A*;F(1GHV\8-+4-!JZ;9+"(5MHQ&#N"X[U*UK
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M0IY";L @CD_RJ3P"D<5]KD4,K21)<@*2<_PBH=>TT6VHQ(;"::!(PJ2Q'YN
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M_A[3]2U"WOIX@9X#E&%:4ZBCRI[+_,F46[_UT.#T+2[J]O\ 5V@U!K=1<$$
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MF$K*T;XP2AQD5)_PC6G?8(K/RSY<<@D'^\*M559?(GD=S$\+_P#(SZQ]8_\
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M=\47ENU[+#;I%&V$/<KFK]D3SGH%&<]*\PCUW41ID6G"X/F27AM_./4#!/\
M2MXV=UX=,]RNHO-&(&;RY#D[@">*3A97;&I7=OZ['8Y&<4F1ZUY#'JFIS6!U
M.*2Z:Z)WJO\ !CTK>M_MVM^*?(ENI8(EMUD9$..<BJ=)K=BYT>@UDZYX@M-
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MW"*>Y4&K=*VK9/.>@YJH;Y1J/V/8V=N[=VKB=*L[[7;"34WU*2&0/^[4'Y0
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MI'B6UU:=[;8\-P@R8W&#BL/P>B3ZYK,MP UP)@!NY(&!7126^FKJX;Y$O73
MQP<<U+44K>0[MMVZ&K6>NK0-J[:=SYJIO/TJ33[22SA9))FE)<MENV>U<7J&
MFRZEX_DC2Y>!1!EBAP3R*48IRL-NT;GH&1ZT5Y;J.IZC96-_IBW3L\%RB)-G
MG!8"KFN7%WH=C8V<=S-(]X07?/(]<?G5>S\]Q<QZ-UZ4F1G&:\XTC4+^SU7R
ME:<VLD1+-/\ PGUK,U#4WAM!>PZA=2W0D7)'^K(R/>CV6NXN?0];SBJE]J5M
MI_E?:'"F5MJ>YK@-8O;^6^AEN'N%LV@1@T'8E1G/2JNKJNIZ;H;B^>7%SL+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BLO6];AT6".252QD;:JCN:K
M:?XHM;RZ%K(CP3L,JKC&:I1;5T)M+<W:*B-U LGEF50Y[9JJVL62ZE]@:4"?
M&=M))L=R_141NH!((S*H<]!FI:0!140N8"Y02KN'49I_F)MW;A@]Z '450.L
M60U(V!E'V@*&V^U6GN8(W"/*JL>@)IV87):*P==\0_V7<VUK!&LLTYX!/05!
M!XEFNM:-A%;J1&/WK9Z&FH-JXG)(Z6BD5@XRI!^E<]J7BI-.G8/:R&%#AY,<
M"DDV[(;=E<Z*BL*_\36UJ(5A1IY95W*B^E6M&UJ#6+=I(@59&VNAZ@T^5VN+
MF1IT5!>74=E:27,IPD8R:IZ+K=MK=F;BW) !P0>U))M7'>QIT5%]I@WA/-7<
M>@S2O/%&</(J_4T@)**9+*(H6E()"C/%<_!XLB?4H[.>W>$R_P"K9AUIJ+>P
MFTMSHZ*YV_\ %<%I=2010O-Y/^M*C[M2S>)8OL4-S:PO.)5W#:*?*[7"ZO8W
M:*PK7Q38W&D2Z@252(D.IZ@CM4>G^*H;N^2UEA>%I!F,L/O4<DM@YEN=#111
M4C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *VH64>HZ?/
M:2_<F0H?QKDW\#W$T,$$^IN\%NX:-/3]*[6BJC)QV$TGN8VGZ"MC?W]T)2WV
MOJ/2LW_A"HQI_DK<%9UN&GCE'523FNKHHYV%D<C;>#KA=4-_=ZBT\IA,7/8'
M\*FA\()%8Z7;?:"?L+E@?[U=113]I(7*C%?P]%)K=S?R/N6>(1-'[8Q60O@J
MXC0VT6I,MENSY6/?..E=C124VAM)F)9^'DM->EU)92=\"P[#[$_XUFW'@Z9;
MJXDTZ_-M'<$M(@'<]>U=;11SN]PLCG)/"B.FEJ)V_P!!E,F3_$<$?UJU=: M
MSKG]HM*1^Y,)3Z@C^M;-%#DW_7<$DCD+?P6\,$=NU\6ABNA<1KCIR3CI[T'P
M9-%=W<EK?F.*Z.9$(SVQZ>U=?13]I(7*CD1X(5?#:Z2MTP*3"9)/0@@C^5/N
M/",[727EO?F*[V!)'Q]_ ^GM75T4>TD'*CEQX.C?2I+:>X:2=G\P3'J&_P B
MHK?PA=#6+74+S4GG:W!"J??\*ZVBA5))W!Q35C'\4HTGA?4$4$L82 !7-:-X
M3N;O2K);N_=K1</Y!^OTKO&574JP!4]0:%4*H50 !T HC-Q3L-J]CG#X1MY'
MU'S'W)> #;_=QG_&JUMX0NDF@%QJ326\!RD>/_K5UM%"G) XIG,-X-MY(M02
M24M]JF\X'^X>/\*9;>$IS>6\VH:@UTEN<QH>Q[=JZJBA3DA.*9SUKX86VTJ_
ML1.2+MB=W]W)HN/#"SZ386/GD"T<,&]<'-=#12YY?E^ [+\_Q.:O_"\LFI/?
M:?>M:RR*%DQT;%0#P3"+**+[03*)_/DD/5S@BNLHIJ<EL#BF<-XFTVYO?%>E
M);RO"RJV) .G!JZ/!OFV=\MU=M-=7<?EF8]AC%=48T+ARH+#H<=*=1SM))!;
M6YA7_AQ;W2+2Q,Q46[ [O7%5V\(P2MJ/FR%ENVWX_ND<BNEHI<["R.7L?"UU
M%>V\UYJ+SQV_^K3T].U:&C)?+<WWVIRT?F_N<_W<"MBBAS;W%RHQM?T!-:BB
M99##<0MNCE7J*R5\*ZC>W$)U74FG@A8,(QWQZ\5U]%$9N.PW%/<QK+04L]>N
M=364GSD";/3&/\*BO/#:S:]!JUO,8)4&V0#^,>];U%"DT[A9/0Y2Y\+7<&H2
MW>D7QM3,<NG8GUJ?2_#$MB+FXEO&EOK@8,Q[5TE%'.[6"RO<@LH9+>TCBFE,
MLBKAG/>L"_\ "\TFI2WNGWS6K3#$H'\5=-12YG>X6TL<I)X+3[/;&WNGCNX.
M1/W-">#3)'>/>7C3W5S$8S*?X1@C^M=715<\@Y4<O<>$21:2VEVT%U;QB,2C
MN*C7P6&M+M;BZ:6ZN2-\Q] 0?Z5UE%'/(7*C%U'P[#J.C0V$CD-#M*2>A'0U
M2L?"UQ'>QSWNH-<"-=J+C _E73T4N=ZARHY ^#9XS)!;:B\5D[[C"/Y=*LOX
M3QJR7EO=-&GE")T_O #%=-13YY#Y4<5_P@LXLYK$:B1:2$G9CGDY]*TM-\+#
M3[^UNOM!<P0"''KC//ZUT=%'M)"Y49FN:-'K5D(78HZ,'1QU4BL9?!\MQYG]
MHZ@]P6C\M/\ 9'Y5UE%)2:5D-J^IQ$G@.XGL(K*;4B8(F5D '3!SZ>U;NF:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gzkk5j0cumnd000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkk5j0cumnd000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 32"*T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO^?J/\Z+,#<HK#_X2O2O^?J/\Z/^$KTK_GZC_.BS W**P_\ A*]*_P"?J/\
M.C_A*]*_Y^H_SHLP-RBL/_A*]*_Y^H_SH_X2O2O^?J/\Z+,#<HK#_P"$KTK_
M )^H_P Z/^$KTK_GZC_.BS W**P_^$KTK_GZC_.C_A*]*_Y^H_SHLP-RBL/_
M (2O2O\ GZC_ #H_X2O2O^?J/\Z+,#<HK#_X2O2O^?J/\Z/^$KTK_GZC_.BS
M W**P_\ A*]*_P"?J/\ .C_A*]*_Y^H_SHLP-RBL/_A*]*_Y^H_SH_X2O2O^
M?J/\Z+,#<HK#_P"$KTK_ )^H_P Z/^$KTK_GZC_.BS W**P_^$KTK_GZC_.C
M_A*]*_Y^H_SHLP-RBL/_ (2O2O\ GZC_ #H_X2O2O^?J/\Z+,#<HK#_X2O2O
M^?J/\Z/^$KTK_GZC_.BS W**P_\ A*]*_P"?J/\ .C_A*]*_Y^H_SHLP-RBL
M/_A*]*_Y^H_SH_X2O2O^?J/\Z+,#<HK#_P"$KTK_ )^H_P Z/^$KTK_GZC_.
MBS W**P_^$KTK_GZC_.C_A*]*_Y^H_SHLP-RBL/_ (2O2O\ GZC_ #H_X2O2
MO^?J/\Z+,#<HK#_X2O2O^?J/\Z/^$KTK_GZC_.BS W**P_\ A*]*_P"?J/\
M.C_A*]*_Y^H_SHLP-RBL/_A*]*_Y^H_SH_X2O2O^?J/\Z+,#<HK#_P"$KTK_
M )^H_P Z/^$KTK_GZC_.BS W**P_^$KTK_GZC_.C_A*]*_Y^H_SHLP-RBL/_
M (2O2O\ GZC_ #H_X2O2O^?J/\Z+,#<HK#_X2O2O^?J/\Z/^$KTK_GZC_.BS
M W**P_\ A*]*_P"?J/\ .C_A*]*_Y^H_SHLP-RBL/_A*]*_Y^H_SH_X2O2O^
M?J/\Z+,#<HK#_P"$KTK_ )^H_P Z/^$KTK_GZC_.BS W**P_^$KTK_GZC_.C
M_A*]*_Y^H_SHLP-RBL/_ (2O2O\ GZC_ #H_X2O2O^?J/\Z+,#<HK#_X2O2O
M^?J/\Z/^$KTK_GZC_.BS W**P_\ A*]*_P"?J/\ .C_A*]*_Y^H_SHLP-RBL
M/_A*]*_Y^H_SH_X2O2O^?J/\Z+,#<HK#_P"$KTK_ )^H_P Z/^$KTK_GZC_.
MBS W**P_^$KTK_GZC_.C_A*]*_Y^H_SHLP-RBL/_ (2O2O\ GZC_ #H_X2O2
MO^?J/\Z+,#<HK#_X2O2O^?J/\Z/^$KTK_GZC_.BS W**P_\ A*]*_P"?J/\
M.C_A*]*_Y^H_SHLP-RBL/_A*]*_Y^H_SH_X2O2O^?J/\Z+,#<HK#_P"$KTK_
M )^H_P Z/^$KTK_GZC_.BS W**P_^$KTK_GZC_.C_A*]*_Y^H_SHLP-RBL/_
M (2O2O\ GZC_ #H_X2O2O^?J/\Z+,#<HK#_X2O2O^?J/\Z/^$KTK_GZC_.BS
M W**P_\ A*]*_P"?J/\ .C_A*]*_Y^H_SHLP-RBL/_A*]*_Y^H_SH_X2O2O^
M?J/\Z+,#<HK#_P"$KTK_ )^H_P Z/^$KTK_GZC_.BS W**P_^$KTK_GZC_.C
M_A*]*_Y^H_SHLP-RBL/_ (2O2O\ GZC_ #H_X2O2O^?J/\Z+,#<HK#_X2O2O
M^?J/\Z/^$KTK_GZC_.BS W**P_\ A*]*_P"?J/\ .C_A*]*_Y^H_SHLP-RBL
M/_A*]*_Y^H_SH_X2O2O^?J/\Z+,#<HK#_P"$KTK_ )^H_P Z/^$KTK_GZC_.
MBS W**P_^$KTK_GZC_.C_A*]*_Y^H_SHLP-RBL/_ (2O2O\ GZC_ #H_X2O2
MO^?J/\Z+,#<HK#_X2O2O^?J/\Z/^$KTK_GZC_.BS W**P_\ A*]*_P"?J/\
M.C_A*]*_Y^H_SHLP-RBL/_A*]*_Y^H_SH_X2O2O^?J/\Z+,#<HK#_P"$KTK_
M )^H_P Z/^$KTK_GZC_.BS W**P_^$KTK_GZC_.C_A*]*_Y^H_SHLP-RBL/_
M (2O2O\ GZC_ #H_X2O2O^?J/\Z+,#<HK#_X2O2O^?J/\Z/^$KTK_GZC_.BS
M W**P_\ A*]*_P"?J/\ .C_A*]*_Y^H_SHLP-RBL/_A*]*_Y^H_SH_X2O2O^
M?J/\Z+,#<HK#_P"$KTK_ )^H_P Z/^$KTK_GZC_.BS W**P_^$KTK_GZC_.C
M_A*]*_Y^H_SHLP-RBL/_ (2O2O\ GZC_ #H_X2O2O^?J/\Z+,#<HK#_X2O2O
M^?J/\Z/^$KTK_GZC_.BS W**P_\ A*]*_P"?J/\ .C_A*]*_Y^H_SHLP-RBL
M/_A*]*_Y^H_SH_X2O2O^?J/\Z+,#<HK#_P"$KTK_ )^H_P Z/^$KTK_GZC_.
MBS W**P_^$KTK_GZC_.C_A*]*_Y^H_SHLP-RBL/_ (2O2O\ GZC_ #H_X2O2
MO^?J/\Z+,#<HK#_X2O2O^?J/\Z/^$KTK_GZC_.BS W**P_\ A*]*_P"?J/\
M.C_A*]*_Y^H_SHLP-RBL/_A*]*_Y^H_SH_X2O2O^?J/\Z+,#<HK#_P"$KTK_
M )^H_P Z/^$KTK_GZC_.BS W**P_^$KTK_GZC_.C_A*]*_Y^H_SHLP-RBL/_
M (2O2O\ GZC_ #H_X2O2O^?J/\Z+,#<HK#_X2O2O^?J/\Z/^$KTK_GZC_.BS
M W**P_\ A*]*_P"?J/\ .C_A*]*_Y^H_SHLP-RBL/_A*]*_Y^H_SH_X2O2O^
M?J/\Z+,#<HK#_P"$KTK_ )^H_P Z/^$KTK_GZC_.BS W**P_^$KTK_GZC_.C
M_A*]*_Y^H_SHLP-RBL/_ (2O2O\ GZC_ #H_X2O2O^?J/\Z+,#<HK#_X2O2O
M^?J/\Z/^$KTK_GZC_.BS W**P_\ A*]*_P"?J/\ .C_A*]*_Y^H_SHLP-RBL
M/_A*]*_Y^H_SH_X2O2O^?J/\Z+,#<HK#_P"$KTK_ )^H_P Z/^$KTK_GZC_.
MBS W**P_^$KTK_GZC_.C_A*]*_Y^H_SHLP-RBL/_ (2O2O\ GZC_ #H_X2O2
MO^?J/\Z+,#<HK#_X2O2O^?J/\Z/^$KTK_GZC_.BS W**P_\ A*]*_P"?J/\
M.C_A*]*_Y^H_SHLP-RBL/_A*]*_Y^H_SH_X2O2O^?J/\Z+,#<HK#_P"$KTK_
M )^H_P Z/^$KTK_GZC_.BS W**P_^$KTK_GZC_.C_A*]*_Y^H_SHLP-RBL/_
M (2O2O\ GZC_ #H_X2O2O^?J/\Z+,#<HK#_X2O2O^?J/\Z/^$KTK_GZC_.BS
M W**P_\ A*]*_P"?J/\ .C_A*]*_Y^H_SHLP-RBL/_A*]*_Y^H_SH_X2O2O^
M?J/\Z+,#<HK#_P"$KTK_ )^H_P Z/^$KTK_GZC_.BS W**P_^$KTK_GZC_.C
M_A*]*_Y^H_SHLP-RBL/_ (2O2O\ GZC_ #H_X2O2O^?J/\Z+,#<HK#_X2O2O
M^?J/\Z/^$KTK_GZC_.BS W**P_\ A*]*_P"?J/\ .C_A*]*_Y^H_SHLP-RBL
M/_A*]*_Y^H_SH_X2O2O^?J/\Z+,#<HK#_P"$KTK_ )^H_P Z/^$KTK_GZC_.
MBS W**P_^$KTK_GZC_.C_A*]*_Y^H_SHLP-RBL/_ (2O2O\ GZC_ #H_X2O2
MO^?J/\Z+,#<HK#_X2O2O^?J/\Z/^$KTK_GZC_.BS W**P_\ A*]*_P"?J/\
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M_" 6?_/63\Z[*BB["QQO_" 6?_/63\Z/^$ L_P#GK)^==E11=A8XW_A +/\
MYZR?G1_P@%G_ ,]9/SKLJ*+L+'&_\(!9_P#/63\Z/^$ L_\ GK)^==E11=A8
MXW_A +/_ )ZR?G1_P@%G_P ]9/SKLJ*+L+'&_P#" 6?_ #UD_.C_ (0"S_YZ
MR?G7944786.-_P"$ L_^>LGYT?\ " 6?_/63\Z[*BB["QQO_  @%G_SUD_.C
M_A +/_GK)^==E11=A8XW_A +/_GK)^='_" 6?_/63\Z[*BB["QQO_" 6?_/6
M3\Z/^$ L_P#GK)^==E11=A8XW_A +/\ YZR?G1_P@%G_ ,]9/SKLJ*+L+'&_
M\(!9_P#/63\Z/^$ L_\ GK)^==E11=A8XW_A +/_ )ZR?G1_P@%G_P ]9/SK
MLJ*+L+'&_P#" 6?_ #UD_.C_ (0"S_YZR?G7944786.-_P"$ L_^>LGYT?\
M" 6?_/63\Z[*BB["QQO_  @%G_SUD_.C_A +/_GK)^==E11=A8XW_A +/_GK
M)^='_" 6?_/63\Z[*BB["QQO_" 6?_/63\Z/^$ L_P#GK)^==E11=A8XW_A
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M=A8XW_A +/\ YZR?G1_P@%G_ ,]9/SKLJ*+L+'&_\(!9_P#/63\Z/^$ L_\
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M=E11=A8XW_A +/\ YZR?G1_P@%G_ ,]9/SKLJ*+L+'&_\(!9_P#/63\Z/^$
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M786/-M!L1IOC=;='8J W4UZ57 6?_)0A_P "_I7?T,2"BBBD,**** "BBB@
MHHHH **** "BBB@ HHHH *:44G)4$_2G44 ,>&*3[\:M]1FF+:VZG*PQ@^H4
M5-10 QX8Y/OQJWU%. "C   ]J6B@ HHHH *YOQG_ ,@@?4UTE<WXS_Y! ^II
MK<"QX4_Y T?T%;E8?A3_ ) T?T%;E)@@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MXWXF?\BDW_75:[*N-^)G_(I-_P!=5IK<Y\7_  )^AXM1116A\F%%%% !1110
M 4444 %%%% ';?"__D9V_P"N+5[+7C7PO_Y&=O\ KBU>RU$MSZ/*_P#=_FPH
MHHJ3T0HHHH RO$O_ "+=_P#]<C7D7PR_Y'O_ +9/7KOB7_D6[_\ ZY&O(/AO
M+'#XXWRR*B^6_+' JX[,B6Z/=**K?VA9?\_=O_W\'^-']H67_/W;_P#?P?XU
M!9D^-/\ D5+W_=KS7X3_ /(U77_7(_SKT/QC>VK^%KQ4N868KP!(":\\^$__
M "-5U_UR-6OA9#^)'LL__'O)_N'^5?..F1K-XSBC<95KL@C\37T=/_Q[R?[A
M_E7SIH__ ".\'_7X?YFB'4)[H]Z_X1S3/^?9?R%'_".:9_S[+^0K5HJ+EV.*
M\3>!=-O-,EDMXMDZ@L#GCBO-?!&IS:1XGAMR6\MY-K#/:O;-:U.UT_3+AYY5
M&4*@9&<D5X7X:MY-3\86[1+E?-R3Z5I'5:F<M'H?0J.'17'0C-.ID*>7"B'^
M$8I]9FAC^(]?B\.Z>+N6%I5+8VJ<5!X8\40^)[>2:&W>$1D ACG-8_Q/_P"1
M;7_KI6?\)/\ D%W7^\O\JJWNW)N^:QZ/1114E&9X@NOL>A7D^[!2,D5YO\-+
M4WFNW&JD9&YAGZUT'Q0U'['H<<(;!G)0@?2K7PYTT6/A_<5P92'Z52TB0]9'
M/?&3_CVTW_?;^5;GPP_Y%MO^NE8?QD_X]M-_WV_E6M\-+NVB\.,LEQ$C>9T9
MP*?V07Q'>456_M"R_P"?NW_[^#_&C^T++_G[M_\ OX/\:@L\M^,?_'YIG^X?
MYUU_PZ_Y%.+_ 'VKC/B]/#/=Z:898Y,(<[&!QS79_#K_ )%.+_?:K?PD+XCK
M**S]9U:#1]/DNIV "]!W->0:GXVUK7[YH=.#QKG ,>:E1;*<DCV^BO"VMO&E
MJGVA[F=E'.-Y-;OA7XAW"W<>GZJNTD[0YSG\:?*+F/5Z*;'(LL:R(<JPR#7C
MOC#7[[3O&4BK>3) K_<4\4DKC;L>R5'/*L,#R,0 H)R:\4FUGQ-XFD#:>\L4
M:#&5)&<5T_@RTUV[\^WU61S$AVDLW)I\MA<USAM0GN?%OBWR=QVF3R_8 '&:
M]<TKP3I6G6D<9A#R ?,WJ:KZ;X T_3-4-_%/(7)SM(&*ZVB4NP1CW.#\7^!]
M/N-)FN;:/RYHE+=>M<A\-M7FL->.G2,3&P)(SWKU/Q/>PV6@73RL!F,X]Z\>
M\"6\FH>,?-B7Y2&;-4M5J2]'H>\@Y&:*0#"@>@I:S- HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *0]*6D/2@#@;/_DH0_X%_2N_
MK@+/_DH0_P"!?TKOZ;$@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KF_&?_(('U-=)7-^,_P#D$#ZFFMP+'A3_ ) T?T%;
ME8?A3_D#1_05N4F""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0M/^?B/_ +ZH_M"T_P"?B/\ [ZH LT56_M"T_P"?B/\ [ZH_M"T_Y^(_^^J
M+-%5O[0M/^?B/_OJG)>VTC;4F0GT!H GHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7&_$S_D4F_ZZK795QOQ,_Y%)O\ KJM-;G/B_P"!/T/%J***
MT/DPHHHH **** "BBB@ HHHH [;X7_\ (SM_UQ:O9:\:^%__ ",[?]<6KV6H
MEN?1Y7_N_P V%%%%2>B%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !2'I2TAZ4 <#9_\ )0A_P+^E=_7 6?\ R4(?\"_I7?TV)!1112&%%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#TI:0]*
M.!L_^2A#_@7]*[^N L_^2A#_ (%_2N_IL2"BBBD,**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "N;\9_\@@?4UTE<WXS_ .00/J::
MW L>%/\ D#1_05N5A^%/^0-']!6Y28(0_=/TKQ?X@_\ (9;ZU[0?NGZ5XO\
M$'_D,M]:J.YQ9A_N[.-HHHJSY<****!A1110 5TG@K_D/1_2N;KI/!7_ "'H
M_I0SJP7^\1/=E^Z/I2TB_='TI:R/J@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !2'I2TAZ4 <#9_\ )0A_P+^E=_7
M6?\ R4(?\"_I7?TV)!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4AZ4M(>E ' V?_)0A_P "_I7?UP%G_P E"'_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7+>/O\ D6V_ZZ+74URWC[_D6V_ZZ+7/B_X$_0ZL#_O,/5'E
M5%%%?*'VX4444 %%%% !1110 4444 >G_#S_ ) <G_74UU]<A\//^0')_P!=
M377U]5@_]WCZ'Q68?[U/U"BBBNDXPHHHH *9+_J9/]TT^F2_ZF3_ '30!\\^
M(_\ D<)O]ZO?-(_Y ]I_UR7^5>!^(_\ D<)O]ZO?-(_Y ]I_UR7^57/9$0W9
M=KG?&O\ R+L_^Z?Y5T5<[XU_Y%V?_=/\JE;E/8\L^'-I%?:A);S+N1NH_"J6
MN:;<^$?$OFQY\L/O5AT/M6K\+/\ D-?C7HGC?PZFMZ.Y5?WT0+*0.36C=I&:
M5T7/"VO0ZYI,<RL#(H <9[T[Q?\ \BCJ?_7$UX]X/UV?PUKOV6XR(BV'!]:]
M>\52K-X,U"1""K6^<@_2H:LRT[H\Q^%'_(P_\ ;^5>P:I_R#9_\ =KQ_X4?\
MC#_P!OY5[!JG_(-G_P!VG+XA0V/!-&N(;;Q?))/(L:"4Y9OK7MP\5Z#@?\36
MV_[ZKP1-.;4_$,]LIP6D/\ZZ_P#X5/??W_\ QX54DNI,6^AZ-=>,]"MX2ZW\
M,I_NJW->3^*=8G\::Y#%:0LR1':F!GBM"3X4:B$)C8%NP+"L#R=4\$ZHK30#
M<#USQ2270;;ZGM_AK2O['T2&U)R<;C^-<?\ %>^:+3DM0V!(-V/QKJ?"WB*'
MQ!I:3I@..&7Z5P_Q>4F2U..!&?YU*^(I_#H3?"6Q5(I[LJ"77&2/>O4*\^^%
M7_($_/\ G7H-$MPCL%07=I#>V[03KNC88(J>BI*,33/"FE:1*LMI"RLO0ELU
MMT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>E+2'I0!P-G_R4(?\
M"_I7?UP%G_R4(?\  OZ5W]-B04444AA1110 4444 <F?!,%WJ\M[J,OGJS$H
M@)&T>E=':Z?:V<*Q0PHJKTX%6 RMG!!QUP:6G=BL-V)_<7\J:\$3J5:-"#_L
MBO/M3U_6=;U673]%1 (B59G.WD56_M3Q+X6F235A$]LQ^8JVX@4^47,=1JO@
MG3;\;XD\J?.0X-;.DV<FGZ9!:RRB5XUP7'>I[6<7-I%.O21 P_&IJ5V.R"BB
MBD,**** "BBB@ HHHH **** "N;\9_\ (('U-=)7-^,_^00/J::W L>%/^0-
M']!6Y6'X4_Y T?T%;E)@A#]T_2O%_B#_ ,AEOK7M!^Z?I7B_Q!_Y#+?6JCN<
M68?[NSC:***L^7"BBB@84444 %=)X*_Y#T?TKFZZ3P5_R'H_I0SJP7^\1/=E
M^Z/I2TB_='TI:R/J@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *Y;Q]_R+;?]=%KJ:Y;Q]_R+;?]=%KGQ?\  GZ'5@?]
MYAZH\JHHHKY0^W"BBB@ HHHH **** "BBB@#T_X>?\@.3_KJ:Z^N0^'G_(#D
M_P"NIKKZ^JP?^[Q]#XK,/]ZGZA11172<84444 %,E_U,G^Z:?3)?]3)_NF@#
MYY\1_P#(X3?[U>^:1_R![3_KDO\ *O _$?\ R.$W^]7OFD?\@>T_ZY+_ "JY
M[(B&[+M<[XU_Y%V?_=/\JZ*N=\:_\B[/_NG^52MRGL>:?"S_ )#7XU[;UZUX
ME\+/^0U^->VTY[DPV/(OB5X6:VF_M:U3"YS(0.^:AT3Q2+OP3JFFW<N)(X#M
M)/WN1Q7K&HV,6HV,EM*H*N.A]:^>_$^BW'A[59K8EA&W<=#FJB[Z"DK.YT?P
MH_Y&'_@#?RKV#5/^0;/_ +M>/_"C_D8?^ -_*O8-4_Y!L_\ NTI?$.&QX3X?
M_P"1T?\ ZZG^=?0(Z"OG?2KJ*S\6R33'""4Y_.O8AX[T7'^N-.:%!G3UPWQ.
MLX)/#4MPVT2Q@;?6M%O'NBJI8RMP/2O./''C1/$++:6(<P]#D8)J8IW*DU8T
M/A#/(=1NH2#Y8CR/3K71?%#37N=#-RB[FCP,"HOACH,NGV#7DR[6DRN#Z5W-
M_9QWUG);R %6'>FW[UQ)>[8\P^$^IQK)<64KA2%^4'N<UZQ7S_JVF:CX-U_S
MXE;8K[@1T->B:#\2=.O+94NRR3@8/'%$E?5!%VT9WE4-8U!--TR>X9PI5#M)
M]<<5FS^,]'MXR[3@@=E(->7^+_&DWB*;[%8JWDY[ Y)I*+8W)(W/"7CK5M8U
MR&SF):-VP6QP*]5'3FO/?ASX3?2[;[==(!)* 5!ZBO0J)6OH$;VU"BBBI*"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *0]*6D/2@#@;/\ Y*$/^!?TKOZX"S_Y
M*$/^!?TKOZ;$@HHHI#"BBB@ HHHH X+4AXDT749[JV\RZM7?<8P,;16KHWC6
MPU%_(G98+D<&,GG-7M8\2:;I7[NY=68C[@.37)7,WAOQ++MB+6MPQ^5E(3FJ
MW)V*\UKK7AG5Y[VQM7N;:>0N=O'6F7\NO^,9/LKZ=);6QX<DY %63_;OA=E#
M+]LLNO +G%=+HGBK3-1&U0+>4]5?"FGYB\C<L8#;6$$!_P"6<87\A5BD!! (
M.0:6H+"BBB@ HHHH **0D#J:-P]10 M%(2!U- (/0T +1110 5S?C/\ Y! ^
MIKI*YOQG_P @@?4TUN!8\*?\@:/Z"MRL/PI_R!H_H*W*3!"'[I^E>+_$'_D,
MM]:]H/W3]*\7^(/_ "&6^M5'<XLP_P!W9QM%%%6?+A1110,**** "ND\%?\
M(>C^E<W72>"O^0]']*&=6"_WB)[LOW1]*6D7[H^E+61]4%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+>/O^1;;_KHM
M=37+>/O^1;;_ *Z+7/B_X$_0ZL#_ +S#U1Y51117RA]N%%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+%PHQC+<^5QLXSQ$Y1=TV%%%%=!RA1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4AZ4M(>E ' V?_ "4(?\"_I7?UP%G_ ,E"'_ OZ5W]-B04
M444AA1110 4444 <'JVF:]I%]-?Z9,]Q%(V]HF; %0VWQ*$4GE:G:&!EX.U2
M:]!(!&",UG7VA:=J(Q<6ZGZ "JNNI-GT,:/XB^'I$W?:)..O[NJ%Y\3=+13]
MB#S-V!0UJ?\ "!:!G_CV?G_;JU:>$M'LG5H;;D=-W-'NA[QR2:AXD\52XAA-
MG:G@LC<X^AKO-)L6TW2X+1I6E,:X+MU-6DC2-<(BJ/88I])L:04444AA1110
M!F:XLKV+)&,EABG:1;M#IX1AAB*T" >HS2].E '(WUQJNE7SM$IFC8\;C5_0
M+*=&:ZN%VNY)Q]:WBJMU4'ZBE  Z"G< HHHI %<WXS_Y! ^IKI*YOQG_ ,@@
M?4TUN!8\*?\ (&C^@K<K#\*?\@:/Z"MRDP0A^Z?I7B_Q!_Y#+?6O:#]T_2O%
M_B#_ ,AEOK51W.+,/]W9QM%%%6?+A1110,**** "ND\%?\AZ/Z5S==)X*_Y#
MT?TH9U8+_>(GNR_='TI:1?NCZ4M9'U04444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%(>E+2'I0!P-G_R4(?\  OZ5W]<!9_\ )0A_P+^E=_38D%%%%(84444 %%%%
M !117,^*?%MOH$011YMR_"H#R#1N#=CIJ*\?E\;^)([ZV,L4D$$TB@;@.02*
MZ6[\9W&F>*_L-W$PM7("2$\57*R>9'=T4R*02Q+(OW6&13ZDH**** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1'Y!JMB=ST;1\_V-9YZ^2N?RJ[3(8EA@2)?NHH I]9F@4444 %%%% !1110
M4444 %%%% !7-^,_^00/J:Z2N;\9_P#(('U--;@6/"G_ "!H_H*W*P_"G_(&
MC^@K<I,$(?NGZ5XO\0?^0RWUKV@_=/TKQ?X@_P#(9;ZU4=SBS#_=V<;1115G
MRX4444#"BBB@ KI/!7_(>C^E<W72>"O^0]']*&=6"_WB)[LOW1]*6D7[H^E+
M61]4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "BBB@ I#TI:0]* .!L_\ DH0_X%_2N_K@+/\
MY*$/^!?TKOZ;$@HHHI#"BBB@ HHHH B6XA:3RUD4N/X<\UR,OAYH_&\FL/>0
MK&VW]V?O<4[3/#VJ6OC";49KEVM6+80MQSTJAXE\*:UJ>MRW5I>21PL!A0P
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M \/^Z*V*@]E;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %(>E+2'I0!P-G_R4(?\"_I7?UP%G_R4(?\  OZ5W]-B04444AA1110
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M%_K$<$K@JP/:O5%.5!]J35CII58U(\T=A:***1H%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M(>E+2'I0!P-G_P E"'_ OZ5W]<!9_P#)0A_P+^E=_38D%%%%(84444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%.O210P_&I:@T"BBB@ HHHH **** "BBB@ HHHH *YOQG_R"!]3725S?C/\
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M74:%'GAN>GT445ZYX(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJH[G%F'^[LXVBBBK/EPHHHH&%%%% !2CI24HZ4&M#^()11109!1110 4444
M% ZT4#K05#XD!ZT4'K10.K\;"BBB@@**** "BBB@0M)2TE!M6^(****#(***
M* "BBB@!>U)2]J2@UG\$0HHHH,@HHHH **** %7[X^M;,7^J6L9?OCZULQ?Z
MI:\;.?@B?<\&;U!]%%%> ?>!1110 4444 %=?X&_Y"3?05R%=?X&_P"0DWT%
M>CEG\<\O./\ =OF>GT445]$?)!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[9XJE<G0]8LH6MK*"%VW-&@4GUP*GJ*UF%S:Q3CI(H;\ZEK,T"BBB@ HHHH
M**** "BBB@ HHHH *YOQG_R"!]3725S?C/\ Y! ^IIK<"QX4_P"0-']!6Y6'
MX4_Y T?T%;E)@A#]T_2O%_B#_P AEOK7M!^Z?I7B_P 0?^0RWUJH[G%F'^[L
MXVBBBK/EPHHHH&%%%% !2CI24HZ4&M#^()11109!1110 4444 % ZT4#K05#
MXD!ZT4'K10.K\;"BBB@@**** "BBB@0M)2TE!M6^(****#(**** "BBB@!>U
M)2]J2@UG\$0HHHH,@HHHH **** %7[X^M;,7^J6L9?OCZULQ?ZI:\;.?@B?<
M\&;U!]%%%> ?>!1110 4444 %=?X&_Y"3?05R%=?X&_Y"3?05Z.6?QSR\X_W
M;YGI]%%%?1'R04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>E+2'I0!
MP-G_ ,E"'_ OZ5W]<!9_\E"'_ OZ5W]-B04444AA1110 4444 %>5ZG-#8?$
M\W%V0L+LH#-T'6O5*P/$7AK3=;C4W;+"R\^9P#^M-,35SS_6KA?%'CBUCMG$
ML40!^7IP0:U/B9=V\EK;Z?$RM<$%=J]5J]HL?AGPY>[(K@RSD[0Q [\>M7I/
M#NE7_BB2]EN=TZL#Y3$8JKZDVT.BTA2FC6:GJ(5!_*KM-10B*J\ # IU06%%
M%% !1110 A( R:175ONL#6)K\EXRI!: @N<%AVK$B2_T:^B\V=I$<9(9NF:=
M@.U:1$^\P%*KJX^5@:XG5Y7OM6\D7;0QY[-BNDT:T-M!C[09AZDYHL!J445#
M<W*6L)ED.%'6D!-7-^,_^00/J:1O&VE*Q4R-D?[-8GB7Q3I]_IXAA=BQ)ZBF
MD[BN=)X4_P"0-']!6Y6'X4_Y L7T%;E)C0A^Z?I7B_Q!_P"0RWUKV@_=/TKQ
M?X@_\AEOK51W.+,/]W9QM%%%6?+A1110,**** "E'2DI1TH-:'\02BBB@R"B
MBB@ HHHH *!UHH'6@J'Q(#UHH/6B@=7XV%%%%! 4444 %%%% A:2EI*#:M\0
M4444&04444 %%%% "]J2E[4E!K/X(A11109!1110 4444 *OWQ]:V8O]4M8R
M_?'UK9B_U2UXV<_!$^YX,WJ#Z***\ ^\"BBB@ HHHH *Z_P-_P A)OH*Y"NN
M\$,JZBQ9E' ZFO1RS^.>7G'^[?,]0HJ/SXO^>J?]]"CSXO\ GJG_ 'T*^B/D
MB2BH_/B_YZI_WT*//B_YZI_WT* )**C\^+_GJG_?0H\^+_GJG_?0H DHJ/SX
MO^>J?]]"E$L;'"R*?H: 'T444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(>E+2'I0!P-G_ ,E"
M'_ OZ5W]<!9_\E"'_ OZ5W]-B04444AA1110 4444 %>9>,+Z^UCQ(GA^UD,
M:!@'8>A%>FUY5XG>;0?'B:N\;&VD8!B!G  -5'<F6QC^(_#$?AZ]T\+(6D:6
M/<V3_>%;/C2QGT/68=>@F/SG<RCM@52\:>(++5[FPGMW^59(RP/;YA5OQEK,
M/B22TTK3PTC'Y7(&0.*K4G0]-T^8W&G6\QZO&K'\15FJNFQ&#3+6(]4B53^5
M6JS- HHHH **** *]W/#:PM-,0 HSS7-6RRZYJ)N'!6WCR 3T-3>*;:_NUC2
MU V@\CUJMI4FL0LD#P1+%C!(%,1/-X8M+^]>9Y0WL,\4OAQGM[J6U+[D4G%1
M7]CJUK=&:P*LK]F/2M/0]-EM5,UQCS7Y.*.@&U4-U;1W<+12#*D<U-12&<RW
M@;2&8L8>3[UB>)?"FFZ?IXF@BVN"><UZ#7-^,_\ D$#ZFFF[BL6/"G_(%B_W
M16Y6'X4_Y T?T%;E)C0A^Z?I7B_Q!_Y#+?6O:#]T_2O%_B#_ ,AEOK51W.+,
M/]W9QM%%%6?+A1110,**** "E'2DI1TH-:'\02BBB@R"BBB@ HHHH *!UHH'
M6@J'Q(#UHH/6B@=7XV%%%%! 4444 %%%% A:2EI*#:M\04444&04444 %%%%
M "]J2E[4E!K/X(A11109!1110 4444 *OWQ]:V8O]4M8R_?'UK9B_P!4M>-G
M/P1/N>#-Z@^BBBO /O HHHH **** "JAU"XLYR89"IJW63=_ZXUZV4+]\_0^
M:XJJ2IX)2B[.YH?\))J?_/P:/^$DU/\ Y^#6117T5D?G'URO_,:__"2:G_S\
M&C_A)-3_ .?@UD4460?7*_\ ,:__  DFI_\ /P:/^$DU/_GX-9%%%D'URO\
MS&O_ ,))J?\ S\&NG\%ZQ>W6JJLLQ92>E<#77^ _^0NGUI-:'5@L35G6492T
M/:U^Z/I2TB_<7Z4M9GT(4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4AZ4M(>E ' V?_)0A_P+^E=_
M7 6?_)0A_P "_I7?TV)!1112&%%%% !1110 52U+2[35;<PW<2R)Z&KM% '
MS?"[3))2R%44G[N*O6FC^'_!<8N;AHXV//F$5V%>?_%3_D"K]#5)MZ$M):G>
MPRI/"DL;;D<!E/J*?5#1?^0)8_\ 7!?Y5?J2@HHHH **** "BBB@ HHHH **
M** "N;\:?\@C\3725S?C/_D$?B::W 7PO=)'HT88\X%;/VZ+UK'\+VZ/HT>1
MV%;7V.+THT%J,^W1$'FO-?%^A76J:DTL )4GM7IIM(@#Q7E_C/6+K3M3:. @
M*#3CN<V,Y?8OGV.>_P"$-U'^ZU'_  ANH_W6J'_A*=0_OBC_ (2G4/[XJSP;
MX7S)O^$-U'^ZU'_"&ZC_ '6J'_A*=0_OBC_A*=0_OB@+X7S)O^$-U'^ZU'_"
M&ZC_ '6J'_A*=0_OBC_A*=0_OB@+X7S)O^$-U'^ZU \':C_=:H?^$IU#^^*!
MXIU#^^*#2B\-SZ7)O^$-U'^ZU'_"&ZC_ '6J'_A*=0_O"C_A*=0_OB@SOA?,
MF_X0W4?[K4?\(;J/]UJA_P"$IU#^^*/^$IU#^^* OA?,F_X0W4?[K4?\(;J/
M]UJA_P"$IU#^^*/^$IU#^^* OA?,F_X0W4?[K4?\(=J/]UJA_P"$IU#^^*/^
M$IU#/WQ05!X7F5KDQ\':C_=:C_A#=1_NM4)\4ZAG[PH_X2G4/[XH'4>%YW>Y
M-_PANH_W6H_X0W4?[K5#_P )3J']\4?\)3J']\4$7POF3?\ "&ZC_=:C_A#=
M1_NM4/\ PE.H?WQ1_P )3J']\4!?"^9-_P (;J/]UJ/^$-U'^ZU0_P#"4ZA_
M?%'_  E.H?WQ0%\+V9-_PAVH_P!UJ/\ A#=1_NM4/_"4ZA_?%'_"4ZA_?%!I
M5>&YM;DW_"&ZC_=:C_A#=1_NM4/_  E.H?WQ1_PE.H?WQ09WPOF3?\(;J/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYT6"Z-BBLE?$FENP5;N,DG YK41UD0.IRIZ&@8ZBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>M%!ZT4"G\3"BBB@D**** "BBB@#1L?]75RJ=C_JZN5\GC_]XD?L63_[C3]
MHHHKC/3"BBB@ HHHH IWCLARIQ5/[1+_ 'S^=6K^J%?5Y=_N\3\OXHG)8]V?
M0E^T2_WS^='VB7^^?SJ*BNT^=]I/N2_:)?[Y_.C[1+_?/YU%10'M)]R7[1+_
M 'S^='VB7^^?SJ*B@/:3[ENVO)([F-V=L*P)KU*R^(%A!9QQL)"RCGY#7D:_
M?'UK9C_U:UP8_%/#I-*]SZWAK"?7(S4I;'I7_"QM/_NR?]\&C_A8VG_W9/\
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M "H[O[#I_P S-[_A/M:_O+_WQ1_PGVM?WE_[XK!Q1BC^UY_RH/[#I_S,WO\
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M_P!\4?\ "?:U_>7_ +XK!Q1BO)_M>?\ *CZO^PZ?\S-[_A/M:_O+_P!\4?\
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M6-JW_/1/^^:/^%C:M_ST3_OFN)HHL@_M:IV.V_X6-JW_ #T3_OFC_A8VK?\
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M*YV6/-O[<\6_\\#_ -^Z/[<\6_\ / _]^Z])\M/[HH\M/[HHN%CS;^W/%O\
MSP/_ '[H_MSQ;C_4'_OW7I/EI_=%(8TQ]T47"QYAX6GO+CQFCWJ[9<-D8Q7J
M5<!9@#XA# Q][^E=_28(****0PHHHH **** "L+5]+T,RF[U((K-U9C6[7D_
MBI+K7?' TA9W2!6&X XX--(39TOE>"_^?B#_ +Z_^M3)%\%1QES<08'^U_\
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MT<3_ #GD?_"$ZKZ'_OFC_A"=5]#_ -\UZY11]2H?RA_:.)_G/(_^$)U7T/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1110 4444 :.B?\ (7MO]\5]!67_ !Y0_P"Z*^?=$_Y"]M_OBOH*R_X\H?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %8OBK_D7[CZ5M5FZ[9R7VDS6\>-S=,T(4E='SU/_ *]_J:CKM9/A
MWJ;R,P9.3Z4S_A7.J?WT_*M+H^;EEU=MNQQM%=E_PKG5/[Z?E1_PKG5/[Z?E
M1="_L[$=CC:*[+_A7.J?WT_*C_A7.J?WT_*BZ#^SL1V.-HKLO^%<ZI_?3\J#
M\.M4 )WIP/2BZ!9=B+[''&DK0O=)N;.X:%T)*G' JK]DN/\ GDWY4S.O1J>T
M>A#14WV2X_YY-^5'V2X_YY-^5!C[&I_*R&BIOLEQ_P \F_*C[)<?\\F_*@/8
MU/Y60T5-]DN/^>3?E1]DN/\ GDWY4![&I_*R+M25(\4D0^="OUJ.@NNFN5/L
M%%%%!@%%%% !1110 HI.]**3O0;2_A(****#$**** "BBB@ K4LO]2*RZU++
M_4BO.S7_ '?YGU?"'^^/T+-%%%?,'Z4%%%% !1110 5 ?]=4]0'_ %U=&'W?
MH<V)VCZD]%%%<YTL**** "BBB@ J"Z_U)J>H+K_4FM\-_&CZG+CO]VJ>C,GN
M:*.YHK[$_%9?$PHHHH$%%%% !1110"W-6T_U-6*KVG^IJQ7Q^+_C2]3]HR[_
M '2GZ(****YSM"BBB@ HHHH S[[[PJE5V^^\*I5];@/]WB?D_$G_ ",)A111
M76>$%%%% !1110!HZ)_R%[;_ 'Q7T%9?\>4/^Z*^?=$_Y"]M_OBOH*R_X\H?
M]T5,CZ#*OX3+%%%%0>H%%%% !2'I2TAZ4 <#9_\ )0A_P+^E=_7 6?\ R4(?
M\"_I7?TV)!1112&%%%% !1110!Q>@^&[S3_%-[?RJ!#-(64Y]:[2BBFW<25@
MHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "N;\9_\@@?4UTE<WXS_ .00
M/J::W L>%/\ D#1_05N5A^%/^0-']!6Y28(**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >8?%#_6
M1_A7F9ZUZ9\4/]9'^%>9GK6D=CYS-/X_R"BBBF><%%%% !1110 HI.]**3O0
M;2_A(****#$**** "BBB@ K4LO\ 4BLNM2R_U(KSLU_W?YGU?"'^^/T+-%%%
M?,'Z4%%%% !1110 5 ?]=4]0'_75T8?=^AS8G:/J3T445SG2PHHHH **** "
MH+K_ %)J>H+K_4FM\-_&CZG+CO\ =JGHS)[FBCN:*^Q/Q67Q,****!!1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!YE\3D9I(]JD].@KS7R9/[C?E7
MT5>Z39:@0;J!9,>M4_\ A%=&_P"?)*I2L>?B< J\^=NQX#Y,O]QORH\F7^XW
MY5[]_P (KHW_ #Y)1_PBNC?\^24^8Y_[(C_,> ^3+_<;\J/)E_N-^5>_?\(K
MHW_/DE'_  BNC?\ /DE',']D1_F/ ?)E_N-^5'DR_P!QORKW[_A%=&_Y\DH_
MX171O^?)*.8/[(C_ #'@/E2#DHP_"HSUKVOQ)X=TNVT>:2*U56 X(KQB<!9F
M Z TT[G)C<,L/",4[D=%%%,\X**** "BBB@ K4LO]2*RZU++_4BO.S7_ '?Y
MGU?"'^^/T+-%%%?,'Z4%%%% !1110 5 ?]=4]0'_ %U=&'W?H<V)VCZD]%%%
M<YTL**** "BBB@ J"Z_U)J>H+K_4FM\-_&CZG+CO]VJ>C,GN:*.YHK[$_%9?
M$PHHHH$%%%% !1110"W-6T_U-6*KVG^IJQ7Q^+_C2]3]HR[_ '2GZ(****YS
MM"BBB@ HHHH S[[[PJE5V^^\*I5];@/]WB?D_$G_ ",)A11176>$%%%% !11
M10!HZ)_R%[;_ 'Q7T%9?\>4/^Z*^?=$_Y"]M_OBOH*R_X\H?]T5,CZ#*OX3+
M%%%%0>H%%%% !2'I2TAZ4 <#9_\ )0A_P+^E=_7 6?\ R4(?\"_I7?TV)!11
M12&%%%% !1110!GPZ+90:@U['$!.V<MCUJ*\\/:??7+7$\*M(W4D"M6BBX6,
M+_A$M)_Y]U_[Y%'_  B6D_\ /NO_ 'R*W:*=V*R&QQK%&L:#"J, 4ZBBD,**
M** "BBL?6-3O[$K]DLEN,]<MC% $6O6MY>^7!"VV,GYB.#BL)M.;0]0A,,TC
M%@-P9R:Z,:P\.F_:;R$0OCA,YK,T^WFU6\:_NCB, [1[4Q&3J\MM=ZSMNYI$
M0'HCXKJM$M[2&WS:RLZG^\V:I'2-)OKR1V"._<$5!X=7R+Z:&,_NP3@4^@'5
M5!=74=I 99/NBIZAN;:*ZB,4JAE/4&I&<\WCK2U8J=_%8OB/Q9I^HV AAW;L
MFNB;P=HS')LX_P JP_$_AK3+#3A+;VR(^3R!5*PM3?\ "G_(%B_W16Y6'X4_
MY L7^Z*W*3&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/Q7_ ,@*?_=KP6Y_
MX^'^IKWKQ7_R I_]VO!;G_CX?ZFKCL>+F_V2*BBBJ/%"BBB@ HHHH *U++_4
MBLNM2R_U(KSLU_W?YGU?"'^^/T+-%%%?,'Z4%%%% !1110 5 ?\ 75/4!_UU
M=&'W?H<V)VCZD]%%%<YTL**** "BBB@ J"Z_U)J>H+K_ %)K?#?QH^IRX[_=
MJGHS)[FBCN:*^Q/Q67Q,****!!1110 4444 MS5M/]35BJ]I_J:L5\?B_P"-
M+U/VC+O]TI^B"BBBN<[0HHHH **** ,^^^\*I5=OOO"J5?6X#_=XGY/Q)_R,
M)A11176>$%%%% !1110!HZ)_R%[;_?%?05E_QY0_[HKY]T3_ )"]M_OBOH*R
M_P"/*'_=%3(^@RK^$RQ1114'J!1110 4AZ4M(>E ' V?_)0A_P "_I7?UP%G
M_P E"'_ OZ5W]-B04444AA1110 4444 %<SXH\70:!&(E1I;J3A%7L:Z:O+-
M1$,WQ2\J[ :,,NP-TSS32%)E*;QWXIAOK82QK#!-(H >+D@D5TMYXSNM,\5?
M8;N(BT<@(^W'ZUF?$9574--5  HECP!_O"IOB<D(TZU90!<%?E(ZYQ5:,C5'
MHL4@EB21?NL,BGU2T?/]C6>[KY*Y_*KM0:!1110 4A4'J ?J*6B@#G/$6C7>
MI;/LTJIM.0".*JZ?INOV\J++<P&$#!"IBNMHIW"QR^HZ!?-<F:PN%C+?>W9-
M:FCZ5_9\69&#2MRQ%:E%%P"BBBD 5S?C/_D$#ZFNDKF_&?\ R"!]336X%CPI
M_P @:/Z"MRN=\+W,4>CQAB>@[5M?;8/[Q_*AH2+%%5_ML']X_E1]M@_O'\J5
MAEBBJ_VV#^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@_O'\J+ 6**K_ &V#^\?R
MH^VP?WC^5%@+%%5_ML']X_E1]M@_O'\J+ 6**K_;8/[Q_*C[;!_>/Y46 L45
M7^VP?WC^5'VV#^\?RHL!8HJO]M@_O'\J/ML']X_E18"Q15?[;!_>/Y4?;8/[
MQ_*BP%BBJ_VV#^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@_O'\J+ 6**K_ &V#
M^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@_O'\J+ 6**K_;8/[Q_*C[;!_>/Y46
M L457^VP?WC^5'VV#^\?RHL!8HJO]M@_O'\J/ML']X_E18"Q15?[;!_>/Y4?
M;8/[Q_*BP%BBJ_VV#^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@_O'\J+ 6**K_
M &V#^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@_O'\J+ 6**K_;8/[Q_*C[;!_>
M/Y46 L457^VP?WC^5'VV#^\?RHL!8HJO]M@_O'\J/ML']X_E18"Q15?[;!_>
M/Y4?;8/[Q_*BP%BBJ_VV#^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@_O'\J+ 6
M**K_ &V#^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@_O'\J+ 6**K_;8/[Q_*C[
M;!_>/Y46 L457^VP?WC^5'VV#^\?RHL!8HJO]M@_O'\J/ML']X_E18"Q15?[
M;!_>/Y4?;8/[Q_*BP%BBJ_VV#^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@_O'\
MJ+ 6**K_ &V#^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@_O'\J+ 6**K_;8/[Q
M_*C[;!_>/Y46 L457^VP?WC^5'VV#^\?RHL!8HJO]M@_O'\J/ML']X_E18"Q
M15?[;!_>/Y4?;8/[Q_*BP%BBJ_VV#^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@
M_O'\J+ 6**K_ &V#^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@_O'\J+ 6**K_;
M8/[Q_*C[;!_>/Y46 L457^VP?WC^5'VV#^\?RHL!8HJO]M@_O'\J/ML']X_E
M18"Q15?[;!_>/Y4?;8/[Q_*BP%BBJ_VV#^\?RH^VP?WC^5%@+%%5_ML']X_E
M1]M@_O'\J+ 6**K_ &V#^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@_O'\J+ 6*
M*K_;8/[Q_*C[;!_>/Y46 L457^VP?WC^5'VV#^\?RHL!8HJO]M@_O'\J/ML'
M]X_E18"Q15?[;!_>/Y4?;8/[Q_*BP%BBJ_VV#^\?RH^VP?WC^5%@+%%5_ML'
M]X_E1]M@_O'\J+ 6**K_ &V#^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@_O'\J
M+ 6**K_;8/[Q_*C[;!_>/Y46 L457^VP?WC^5'VV#^\?RHL!8HJO]M@_O'\J
M/ML']X_E18"Q15?[;!_>/Y4?;8/[Q_*BP%BBJ_VV#^\?RH^VP?WC^5%@+%%5
M_ML']X_E1]M@_O'\J+ 6**K_ &V#^\?RH^VP?WC^5%@+%%5_ML']X_E1]M@_
MO'\J+ 6**K_;8/[Q_*C[;!_>/Y46 L457^VP?WC^5'VV#^\?RHL!8HJO]M@_
MO'\J/ML']X_E18"Q15?[;!_>/Y4?;8/[Q_*BP%BBJ_VV#^\?RH^VP?WC^5%@
M+%%5_ML']X_E1]M@_O'\J+ 6**K_ &V#^\?RH^VP?WC^5%@+%%5_ML']X_E1
M]M@_O'\J+ 6**K_;8/[Q_*C[;!_>/Y46 L457^VP?WC^5'VV#^\?RHL!8HJO
M]M@_O'\J/ML']X_E18"Q15?[;!_>/Y4?;8/[Q_*BP%BBJ_VV#^\?RH^VP?WC
M^5%@+%%5_ML']X_E1]M@_O'\J+ 6**K_ &V#^\?RH^VP?WC^5%@+%%5_ML']
MX_E1]M@_O'\J+ 6**K_;8/[Q_*C[;!_>/Y46 L457^VP?WC^5'VV#^\?RHL!
M8HJO]M@_O'\J/ML']X_E18"Q15?[;!_>/Y4?;8/[Q_*BP%BBJ_VV#^\?RH^V
MP?WC^5%@+%%5_ML']X_E1]M@_O'\J+ 6**K_ &V#^\?RH^VP?WC^5%@+%%5_
MML']X_E1]M@_O'\J+ 6**K_;8/[Q_*C[;!_>/Y46 L457^VP?WC^5'VV#^\?
MRHL!8HJO]M@_O'\J/ML']X_E18#+\5_\@*?_ ':\&N0?M#\=S7T%J'V;4+1X
M'<@,,=*Y)O NFLQ8S/R<_=%7%V.#&X5XBUGL>2X-&#7K/_"":9_SV?\ [Y%'
M_"":9_SV?_OD4[GG_P!DS_F/)L&C!KUG_A!-,_Y[/_WR*/\ A!-,_P">S_\
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MED:<J]JEK6ZDO_"4:G_SU7_OFC_A*-3_ .>J_P#?-8^Q_P#GF_\ WR:-C_\
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MJS11<+%;[#!Z'\Z#90@'Y3^=6:0]*=PL>?V"+'\0 %Z?-_2O0:X"S_Y*$/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM:LH98(2IZ$(*7[);?\ /O%_WP*=UV%9]Q+*5YK&"608=T!8>AQ4](  , 8
MI:DH**** "BBB@ HHHH **** "BBB@ KF_&?_(('U-=)7-^,_P#D$#ZFFMP+
M'A3_ ) T?T%;E8?A3_D#1_05N4F""BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK<K#\*?\@:/Z"MRDP04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7G7Q#_X^H_]T5Z+7G7Q#_X^H_\
M=%<^*_@R]#JP7^\1]3AJ***^4/MV%%%% !1110 5!=?ZDU/4%U_J36^&_C1]
M3EQW^[5/1F3W-%'<T5]B?BLOB84444""BBB@ HHHH!;FK:?ZFK%5[3_4U8KX
M_%_QI>I^T9=_NE/T04445SG:%%%% !1110!GWWWA5*KM]]X52KZW ?[O$_)^
M)/\ D83"BBBNL\(**** "BBB@#1T3_D+VW^^*^@K+_CRA_W17S[HG_(7MO\
M?%?05E_QY0_[HJ9'T&5?PF6****@]0**** "D/2EI#TH X&S_P"2A#_@7]*[
M^N L_P#DH0_X%_2N_IL2"BBBD,**** "BBB@ KRZ\CC/Q58W &W*[-WKS7J-
M<5XM\(3ZI=QZA8S"*X0[CQG-5$F1F_$-/L]_87B 862-=P]-PIOQ"^SI9V>I
MP$+,@W!AU/%;^O>'IM8\+06C.!=1A6W$=2*X:+PMXDUBZM[/4MRVL;8#,O %
M-6$[GJ^E2&72;21NK1*3^57*AM(!:V<, .1&@7/TJ:H+"BBB@ HHHH ****
M"BBB@ HHHH *YOQG_P @@?4UTE<WXS_Y! ^IIK<"QX4_Y T?T%;E8?A3_D#1
M_05N4F""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *\Z^(?_'U'_NBO1:\Z^(?_ !]1_P"Z*Y\5_!EZ
M'5@O]XCZG#4445\H?;L**** "BBB@ J"Z_U)J>H;K_4FM\-_&CZG+CO]VJ>C
M,CN:*.YHK[$_%9?$PHHHH$%%%% !1110"W-6T_U-6*KVG^IJQ7Q^+_C2]3]H
MR[_=*?H@HHHKG.T**** "BBB@#/OOO"J57;[[PJE7UN _P!WB?D_$G_(PF%%
M%%=9X04444 %%%% &CHG_(7MO]\5]!67_'E#_NBOGW1/^0O;?[XKZ"LO^/*'
M_=%3(^@RK^$RQ1114'J!1110 4AZ4M(>E ' V?\ R4(?\"_I7?UP%G_R4(?\
M"_I7?TV)!1112&%%%% !1110 5Q/BWQN^AW2V=G$);DG&TC-=M7ENJPQ0?$Y
M+B\4"*1U$9/3.#51)DR,>/?%9&1I28/^PW^%'_">>+/^@5'_ -\-_A7J2"(H
M"H7:1QQ3MJ?W5_*BZ[!9]R*REDGLH)95VR.@9AZ'%3T45)04444 %%%5[B]M
M[7'G2!,^M %36]2DTVT\R)0SGH#67I6JZY=S W%O L)&<@\T[Q''/J5M#]A!
M?!/(K/L[S4]+E6&]W&-D.,]J8BYJ_B*\M[HP6$*R,OWMPK3T35SJ</[Q=LHX
M88K-T(+-?32'G.*713MU>=1TR: .GHHJGJ7VC[&_V;/F8XQ2&6\CU%<YXS(_
MLCKW-<T[>,/,;;YNW/'%9NL'Q*;9?MQD\G/<520KG?\ A3_D#1_05N5A^%/^
M0+%_NBMRI8T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4444 %(>E+2'I0!P-G_R4(?\"_I7?UP%G_R4(?\  OZ5W]-B04444AA1110
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M WUIZ(J+M48%%P'4444AB;5]!7-^,P!I X'4UTM<WXS_ .00/J::W L>%/\
MD#1_05N5A^%/^0-']!6Y28(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MYGQM_P @23_=-=-7,^-O^0))_NFFMR*GPL\.F_UK?6HZDF_UK?6HZT/CY;L*
M***!!1110 4444 MS5M/]35BJ]I_J:L5\?B_XTO4_:,N_P!TI^B"BBBN<[0H
MHHH **** ,^^^\*I5=OOO"J5?6X#_=XGY/Q)_P C"84445UGA!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "H[C_CVE_W#_*I*CN/^/:7_</\J /$=4_Y"4WUJG5S
M5/\ D)3?6J=?*8K^-+U/M\%_N\/0****YSJ"BBB@ HHHH S[[[PJE5V^^\*I
M5];@/]WB?D_$G_(PF%%%%=9X04444 %%%% &CHG_ "%[;_?%?05E_P >4/\
MNBOGW1/^0O;?[XKZ"LO^/*'_ '14R/H,J_A,L4445!Z@4444 %(>E+2'I0!P
M-G_R4(?\"_I7?UP%G_R4(?\  OZ5W]-B04444AA1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M .00/J::W L>%/\ D#1_05N5A^%/^0-']!6Y28(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"!?TKOZ;$@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KF_&?_(('U-=)7-^,_P#D$#ZFFMP+'A3_ ) T?T%;E8?A3_D#
M1_05N4F""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /*/B1_Q]K]*\[KT3XD?\?:_2O.ZT
M6Q\UF?\ '"BBBF< 4444 %%%% &CHG_(7MO]\5]!67_'E#_NBOGW1/\ D+VW
M^^*^@K+_ (\H?]T5,CZ#*OX3+%%%%0>H%%%% !2'I2TAZ4 <#9_\E"'_  +^
ME=_7 6?_ "4(?\"_I7?TV)!1112&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7-^,_^00/J:Z2N;\9_\@@?4TUN!8\*?\@:/Z"M
MRL/PI_R!H_H*W*3!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E'Q(_X^U^E>=UZ)\2/^
M/M?I7G=:+8^:S/\ CA1113. **** "BBB@#1T3_D+VW^^*^@K+_CRA_W17S[
MHG_(7MO]\5]!67_'E#_NBID?095_"98HHHJ#U HHHH *0]*6D/2@#@;/_DH0
M_P"!?TKOZX"S_P"2A#_@7]*[^FQ(****0PHHHH **** "BBB@ HHHH ****
M"BBB@ HI"0H))P!U-<U<>*!_;*65O@@YR<9H Z:BLC6M5DT^U3R1F:3A>,\U
MDZ;KVIK>+%J2KM<94JN.*=@.MHKD]5US4S=M!I@4[>I9<YK3T+5I-0B*W"XF
M4X/&*+ ;-%%%( KF_&?_ ""!]371[AZUS?C,C^R!SW--;@6?"G_(&C^@K<K#
M\*?\@:/Z"MRDP04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Y1\2/^/M?I7G=>B?$C_C[7
MZ5YW6BV/FLS_ (X4444S@"BBB@ HHHH$:.B?\A>V_P!\5]!67_'E#_NBOGW1
M/^0O;?[]?05E_P >4/\ NBID?0Y5_"98HHHJ#U HHHH *0]*6D/2@#@;/_DH
M0_X%_2N_K@+/_DH0_P"!?TKOZ;$@HHHI#"BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2N_K@+/_ )*$/^!?TKOZ;$@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M"FE%)R5!-.HH 0J",$9%-2*./[B ?2GT4 ,>*.3[Z@_6G!0HP!@4M% !1110
M 5S?C/\ Y! ^IKI*YOQG_P @@?4TUN!8\*?\@:/Z"MRL/PI_R!H_H*W*3!!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4AZ4M(>E ' V?_)0A_P+^E=_7 6?_)0A_P "_I7?TV)!1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7-^,_^00/J:Z2N;\9
M_P#(('U--;@6/"G_ "!H_H*W*P_"G_(&C^@K<I,$%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2'I2TAZ4 <#9_\E"'_
M  +^E=_7 6?_ "4(?\"_I7?TV)!1112&%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7-^-.-'SZ9KI*JW]A#J%OY,RAE]#0@./\
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MY_.C_A.-)_OG\ZB_X0+1_P#G@GY4?\(%H_\ SP3\J- U)?\ A.-)_OG\Z/\
MA.-)_OG\ZB_X0+1_^>"?E1_P@6C_ //!/RHT#4E_X3C2?[Y_.C_A.-)_OG\Z
MB_X0+1_^>"?E1_P@6C_\\$_*C0-27_A.-)_OG\Z/^$XTG^^?SJ+_ (0+1_\
MG@GY4?\ "!:/_P \$_*C0-27_A.-)_OG\Z/^$XTG^^?SJ+_A M'_ .>"?E1_
MP@6C_P#/!/RHT#4E_P"$XTG^^?SH_P"$XTG^^?SJ+_A M'_YX)^5'_"!:/\
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MTG^^?SJ+_A M'_YX)^5'_"!:/_SP3\J- U)?^$XTG^^?SH_X3C2?[Y_.HO\
MA M'_P">"?E1_P (%H__ #P3\J- U)?^$XTG^^?SH_X3C2?[Y_.HO^$"T?\
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M3\J- U)?^$XTG^^?SH_X3C2?[Y_.HO\ A M'_P">"?E1_P (%H__ #P3\J-
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MHT#4E_X3C2?[Y_.C_A.-)_OG\ZB_X0+1_P#G@GY4?\(%H_\ SP3\J- U)?\
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M(%H__/!/RHT#4E_X3C2?[Y_.C_A.-)_OG\ZB_P"$"T?_ )X)^5'_  @6C_\
M/!/RHT#4E_X3C2?[Y_.C_A.-)_OG\ZB_X0+1_P#G@GY4?\(%H_\ SP3\J- U
M)?\ A.-)_OG\Z/\ A.-)_OG\ZB_X0+1_^>"?E1_P@6C_ //!/RHT#4E_X3C2
M?[Y_.C_A.-)_OG\ZB_X0+1_^>"?E1_P@6C_\\$_*C0-27_A.-)_OG\Z/^$XT
MG^^?SJ+_ (0+1_\ G@GY4?\ "!:/_P \$_*C0-27_A.-)_OG\Z/^$XTG^^?S
MJ+_A M'_ .>"?E1_P@6C_P#/!/RHT#4E_P"$XTG^^?SH_P"$XTG^^?SJ+_A
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV D]J[FI:LRD[HI7NDV6HD&YA#D>M<CXX\/:99^$KV>"W"R*O!KNZY?XA?\
M(E7_ /NBA;@UH8G@'0=.OO#BS7%N'?>1FNTLM'L=.):VA"$\FN>^&W_(JK_U
MT-=1?)/)9R);D"4C S3>XEL4;WQ+H^G.4N[Z.)AV8U#;>+]!NY D&I0NQ.
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M_HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAE2[B^QK)N9,G)%3>Z*M9GHU9?B+_D W?^Y6I5/5;1[[3)[:,@-(N 34HIG
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
A10 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>ghwd5ikruv45000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ghwd5ikruv45000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #;"6<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***Y[7?&.EZ&&1Y/.N.T49R?Q]*:3>QG4JPIQYINR.AK*U+Q'I.E
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M117M'OA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5#=W4-E:R7-PX2*-=S,:
MFKR3X@^)SJ%X=+M7_P!&A/[P@_?;_ 548\S.7&8J.&I<[WZ&-XJ\3S^(;\G)
M2TC.(H\_J?>N?HHKI2LK'QE2I*K-SF[MA116YHV@O>$3W *0=AW;_P"M2;2'
M3IRJ2Y8F?8:9<ZC)B%/E'5ST%=78>';2T >4>?+ZL.!]!6K%#'!&L<2!$7H
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M6\N9+B9RTCG+$UKB:_(N6.YOC,3[-<D=V1LS2.7=B6)R2>])117F'C!0 20
M,D] *?##)/((XQN8UTMAIL=HH9@&E[MZ?2JC!R-*=)S?D9MGHCR /<$HO]T=
M36U!;0VZ[8HPOOWJ:BNB,5'8[X4HPV"BBBJ- I!]XTM(/O&@!:*** .[HHHK
MTCT HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHI"<#- ',^-]?\ [$T5EB;%S<92
M/U'J:\3)+,23DGDFNA\::R=8\03,K9@A/EQCM@=3^=<[71"-D?'YEB?;UG;9
M:(***NZ78-J%ZL0^X.7/H*MG#&+D^5%_0=&^V.+B=?W*G@?WC79*H50 , <
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHHJ3V!&^Z?I7#-]X_6NY;[I^E<,WWC]:YL1T.>OT$HHHKF.<**** "BBB@
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M$4"(.BJ!4E%%=AZVP4444 %%%% !1110 4@^\:6D'WC0 M%%% '=T445Z1Z
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MC,8YXP?:KM%%P*FI:;;ZK9M:W(8QL0?E.""*?8V4.GV<=K;@B*,8&3DU8HH
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M&>.*OT4786*5AI=OIK7#6^_,\GF/N.>?:G2Z;;S:E#?ON\Z%2BX/&#[5;HI
M%4CI=LVKKJ9W_:%C\H<\8^E7:* "J4.EV\&J7.HIO\^X55?)XP!@8'X5=HH
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M@GEAEEB5WA):-C_"3Z5-3 ****0!69%H5E%K,FJJK_:9!@Y;Y1TY ]>*TZ*
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M=6.[#3NN5DU%%%:G2%%%% !1110 4@^\:6D'WC0 M%%% '=T445Z1Z 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %&*** .>UGP9H^L[GD@\F<_\
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2RSUKD<6G8X)1<79A1112$?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gzkk5j0cumnd000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkk5j0cumnd000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1 ",H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **0G R:Q9O%6FPRM&\AW
MX- &W16!_P )?I?_ #T-'_"7Z7_ST-.P&_16!_PE^E_\]#1_PE^E_P#/0T6
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MOTO_ )Z&BP&_16!_PE^E_P#/0T?\)?I?_/0T6 WZ*P/^$OTO_GH:/^$OTO\
MYZ&BP&_16!_PE^E_\]#1_P )?I?_ #T-%@-^BL#_ (2_2_\ GH:/^$OTO_GH
M:+ ;]%8'_"7Z7_ST-'_"7Z7_ ,]#18#?HK _X2_2_P#GH:/^$OTO_GH:+ ;]
M%8'_  E^E_\ /0T?\)?I?_/0T6 WZ*P/^$OTO_GH:/\ A+]+_P">AHL!OT5@
M?\)?I?\ ST-'_"7Z7_ST-%@-^BL#_A+]+_YZ&C_A+]+_ .>AHL!OT5@?\)?I
M?_/0T?\ "7Z7_P ]#18#?HK _P"$OTO_ )Z&C_A+]+_YZ&BP&_16!_PE^E_\
M]#1_PE^E_P#/0T6 WZ*P/^$OTO\ YZ&C_A+]+_YZ&BP&_16!_P )?I?_ #T-
M'_"7Z7_ST-%@-^BL#_A+]+_YZ&C_ (2_2_\ GH:+ ;]%8'_"7Z7_ ,]#1_PE
M^E_\]#18#?HK _X2_2_^>AH_X2_2_P#GH:+ ;]%8'_"7Z7_ST-'_  E^E_\
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MH:/^$OTO_GH:+ ;]%8'_  E^E_\ /0T?\)?I?_/0T6 WZ*P/^$OTO_GH:/\
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MOTO_ )Z&C_A+]+_YZ&BP&_16!_PE^E_\]#1_PE^E_P#/0T6 WZ*P/^$OTO\
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M7_ST-'_"7Z7_ ,]#18#?HK _X2_2_P#GH:/^$OTO_GH:+ ;]%8'_  E^E_\
M/0T?\)?I?_/0T6 WZ*P/^$OTO_GH:/\ A+]+_P">AHL!OT5@?\)?I?\ ST-'
M_"7Z7_ST-%@-^BL#_A+]+_YZ&C_A+]+_ .>AHL!OT5@?\)?I?_/0T?\ "7Z7
M_P ]#18#?HK _P"$OTO_ )Z&C_A+]+_YZ&BP&_16!_PE^E_\]#1_PE^E_P#/
M0T6 WZ*P/^$OTO\ YZ&C_A+]+_YZ&BP&_16!_P )?I?_ #T-'_"7Z7_ST-%@
M-^BL#_A+]+_YZ&C_ (2_2_\ GH:+ ;]%8'_"7Z7_ ,]#1_PE^E_\]#18#?HK
M _X2_2_^>AH_X2_2_P#GH:+ ;]%8'_"7Z7_ST-'_  E^E_\ /0T6 WZ*P/\
MA+]+_P">AH_X2_2_^>AHL!OT5@?\)?I?_/0T?\)?I?\ ST-%@-^BL#_A+]+_
M .>AH_X2_2_^>AHL!OT5@?\ "7Z7_P ]#1_PE^E_\]#18#?HK _X2_2_^>AH
M_P"$OTO_ )Z&BP&_16!_PE^E_P#/0T?\)?I?_/0T6 WZ*P/^$OTO_GH:/^$O
MTO\ YZ&BP&_16!_PE^E_\]#1_P )?I?_ #T-%@-^BL#_ (2_2_\ GH:/^$OT
MO_GH:+ ;]%8'_"7Z7_ST-'_"7Z7_ ,]#18#?HK _X2_2_P#GH:/^$OTO_GH:
M+ ;]%8'_  E^E_\ /0T?\)?I?_/0T6 WZ*P/^$OTO_GH:/\ A+]+_P">AHL!
MOT5@?\)?I?\ ST-'_"7Z7_ST-%@-^BL#_A+]+_YZ&C_A+]+_ .>AHL!OT5@?
M\)?I?_/0T?\ "7Z7_P ]#18#?HK _P"$OTO_ )Z&C_A+]+_YZ&BP&_16!_PE
M^E_\]#1_PE^E_P#/0T6 WZ*P/^$OTO\ YZ&C_A+]+_YZ&BP&_16!_P )?I?_
M #T-6;+Q#87\XA@<ESVI6 UJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_SZ_P#CU=#11=@<]_PA.A_\^O\ X]1_PA.A_P#/K_X]70T478'/?\(3H?\
MSZ_^/4?\(3H?_/K_ ./5T-%%V!SW_"$Z'_SZ_P#CU'_"$Z'_ ,^O_CU=#11=
M@<]_PA.A_P#/K_X]1_PA.A_\^O\ X]70T478'/?\(3H?_/K_ ./4?\(3H?\
MSZ_^/5T-%%V!SW_"$Z'_ ,^O_CU'_"$Z'_SZ_P#CU=#11=@<]_PA.A_\^O\
MX]1_PA.A_P#/K_X]70T478'/?\(3H?\ SZ_^/4?\(3H?_/K_ ./5T-%%V!SW
M_"$Z'_SZ_P#CU'_"$Z'_ ,^O_CU=#11=@<]_PA.A_P#/K_X]1_PA.A_\^O\
MX]70T478'/?\(3H?_/K_ ./4?\(3H?\ SZ_^/5T-%%V!SW_"$Z'_ ,^O_CU'
M_"$Z'_SZ_P#CU=#11=@<]_PA.A_\^O\ X]1_PA.A_P#/K_X]70T478'/?\(3
MH?\ SZ_^/4?\(3H?_/K_ ./5T-%%V!SW_"$Z'_SZ_P#CU'_"$Z'_ ,^O_CU=
M#11=@<]_PA.A_P#/K_X]1_PA.A_\^O\ X]70T478'/?\(3H?_/K_ ./4?\(3
MH?\ SZ_^/5T-%%V!SW_"$Z'_ ,^O_CU'_"$Z'_SZ_P#CU=#11=@<]_PA.A_\
M^O\ X]1_PA.A_P#/K_X]70T478'/?\(3H?\ SZ_^/4?\(3H?_/K_ ./5T-%%
MV!SW_"$Z'_SZ_P#CU'_"$Z'_ ,^O_CU=#11=@<]_PA.A_P#/K_X]1_PA.A_\
M^O\ X]70T478'/?\(3H?_/K_ ./4?\(3H?\ SZ_^/5T-%%V!SW_"$Z'_ ,^O
M_CU'_"$Z'_SZ_P#CU=#11=@<]_PA.A_\^O\ X]1_PA.A_P#/K_X]70T478'/
M?\(3H?\ SZ_^/4?\(3H?_/K_ ./5T-%%V!SW_"$Z'_SZ_P#CU'_"$Z'_ ,^O
M_CU=#11=@<]_PA.A_P#/K_X]1_PA.A_\^O\ X]70T478'/?\(3H?_/K_ ./4
M?\(3H?\ SZ_^/5T-%%V!SW_"$Z'_ ,^O_CU'_"$Z'_SZ_P#CU=#11=@<]_PA
M.A_\^O\ X]1_PA.A_P#/K_X]70T478'/?\(3H?\ SZ_^/4?\(3H?_/K_ ./5
MT-%%V!SW_"$Z'_SZ_P#CU'_"$Z'_ ,^O_CU=#11=@<]_PA.A_P#/K_X]1_PA
M.A_\^O\ X]70T478'/?\(3H?_/K_ ./4?\(3H?\ SZ_^/5T-%%V!SW_"$Z'_
M ,^O_CU'_"$Z'_SZ_P#CU=#11=@<]_PA.A_\^O\ X]1_PA.A_P#/K_X]70T4
M78'/?\(3H?\ SZ_^/4?\(3H?_/K_ ./5T-%%V!SW_"$Z'_SZ_P#CU'_"$Z'_
M ,^O_CU=#11=@<]_PA.A_P#/K_X]1_PA.A_\^O\ X]70T478'/?\(3H?_/K_
M ./4?\(3H?\ SZ_^/5T-%%V!SW_"$Z'_ ,^O_CU'_"$Z'_SZ_P#CU=#11=@<
M]_PA.A_\^O\ X]1_PA.A_P#/K_X]70T478'/?\(3H?\ SZ_^/4?\(3H?_/K_
M ./5T-%%V!SW_"$Z'_SZ_P#CU'_"$Z'_ ,^O_CU=#11=@<]_PA.A_P#/K_X]
M1_PA.A_\^O\ X]70T478'/?\(3H?_/K_ ./4?\(3H?\ SZ_^/5T-%%V!SW_"
M$Z'_ ,^O_CU'_"$Z'_SZ_P#CU=#11=@<]_PA.A_\^O\ X]1_PA.A_P#/K_X]
M70T478'/?\(3H?\ SZ_^/4?\(3H?_/K_ ./5T-%%V!SW_"$Z'_SZ_P#CU'_"
M$Z'_ ,^O_CU=#11=@<]_PA.A_P#/K_X]1_PA.A_\^O\ X]70T478'/?\(3H?
M_/K_ ./4?\(3H?\ SZ_^/5T-%%V!SW_"$Z'_ ,^O_CU'_"$Z'_SZ_P#CU=#1
M1=@<]_PA.A_\^O\ X]1_PA.A_P#/K_X]70T478'/?\(3H?\ SZ_^/4?\(3H?
M_/K_ ./5T-%%V!SW_"$Z'_SZ_P#CU'_"$Z'_ ,^O_CU=#11=@<]_PA.A_P#/
MK_X]1_PA.A_\^O\ X]70T478'/?\(3H?_/K_ ./4?\(3H?\ SZ_^/5T-%%V!
MSW_"$Z'_ ,^O_CU'_"$Z'_SZ_P#CU=#11=@<]_PA.A_\^O\ X]1_PA.A_P#/
MK_X]70T478'/?\(3H?\ SZ_^/4?\(3H?_/K_ ./5T-%%V!SW_"$Z'_SZ_P#C
MU'_"$Z'_ ,^O_CU=#11=@<]_PA.A_P#/K_X]1_PA.A_\^O\ X]70T478'/?\
M(3H?_/K_ ./4?\(3H?\ SZ_^/5T-%%V!SW_"$Z'_ ,^O_CU'_"$Z'_SZ_P#C
MU=#11=@<]_PA.A_\^O\ X]1_PA.A_P#/K_X]70T478'/?\(3H?\ SZ_^/4?\
M(3H?_/K_ ./5T-%%V!SW_"$Z'_SZ_P#CU'_"$Z'_ ,^O_CU=#11=@<]_PA.A
M_P#/K_X]1_PA.A_\^O\ X]70T478'/?\(3H?_/K_ ./4?\(3H?\ SZ_^/5T-
M%%V!SW_"$Z'_ ,^O_CU'_"$Z'_SZ_P#CU=#11=@<]_PA.A_\^O\ X]1_PA.A
M_P#/K_X]70T478'/?\(3H?\ SZ_^/4?\(3H?_/K_ ./5T-%%V!SW_"$Z'_SZ
M_P#CU'_"$Z'_ ,^O_CU=#11=@<]_PA.A_P#/K_X]1_PA.A_\^O\ X]70T478
M'/?\(3H?_/K_ ./4?\(3H?\ SZ_^/5T-%%V!SW_"$Z'_ ,^O_CU'_"$Z'_SZ
M_P#CU=#11=@<]_PA.A_\^O\ X]1_PA.A_P#/K_X]70T478'/?\(3H?\ SZ_^
M/4?\(3H?_/K_ ./5T-%%V!SW_"$Z'_SZ_P#CU'_"$Z'_ ,^O_CU=#11=@<]_
MPA.A_P#/K_X]1_PA.A_\^O\ X]70T478'/?\(3H?_/K_ ./4?\(3H?\ SZ_^
M/5T-%%V!SW_"$Z'_ ,^O_CU'_"$Z'_SZ_P#CU=#11=@<]_PA.A_\^O\ X]1_
MPA.A_P#/K_X]70T478'/?\(3H?\ SZ_^/4?\(3H?_/K_ ./5T-%%V!SW_"$Z
M'_SZ_P#CU'_"$Z'_ ,^O_CU=#11=@<]_PA.A_P#/K_X]1_PA.A_\^O\ X]70
MT478'/?\(3H?_/K_ ./4?\(3H?\ SZ_^/5T-%%V!SW_"$Z'_ ,^O_CU<MI]C
M!I_CJ.&V79'\W&:]*KSY/^2@Q_\  OZ4T(] '04M(.@I:D84444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!SOB32I[B2
M.]MN98A@*!R:S+F;5=:CCLVL98%!P[N!@BNUHIW Y+5M$N(+2TFM,M-:IL
MZ\U4G?5=<DM[>2SEMXXV!9G'!KN**+BL16T(M[:.$=$&*K7&D65U+YDT09O6
MKU%(9DR:!IPC;]P.E<IX'18]8NT084,^/S-=]+_JF^E<'X*_Y#=Y_O/_ #-4
MMA'?T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O/D_P"2@Q_\"_I7H->?)_R4&/\ X%_2FA,] '04M(.@I:0PHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!DO\ JF^E<'X*_P"0W>?[S_S-=Y+_ *IOI7!^"O\ D-WG^\_\S36P
MCOZ***0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M/D_Y*#'_ ,"_I7H->?)_R4&/_@7]*:$ST =!2T@Z"EI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *%_JL&GD"7N/
M6J)\56 (W';GIDUJ7-E:W0W7$*R8'\5<7<V%IJWB);2VMD6&W(=BO>FA'8R:
MG;16:W,DBK&PR,FJMMXAL;F;RA(JL>F3UK#UV))-9L-, _T<QG*=N#3O$>E6
MEE:VMQ;0K%(C9)4=>*+ =A1532YC<:9;S-U=,FK#2QJ<,Z@^YI#"7_5-]*X/
MP5_R&[S_ 'G_ )FNXEGB\IOWB]/6N'\$G.M7A']Y_P"9IK81W]%%%(84444
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M>A45Y[_PL:?_ )\8_P#OHT?\+&G_ .?&/_OHT?6*?</KM'N>A45Y[_PL:?\
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MZXMC%;((F)P^3FNWH:L"=PHHHI#"BBB@ HHHH **** "BBB@ KSY/^2@Q_\
M OZ5Z#7GR?\ )08_^!?TIH3/0!T%+2#H*6D,**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH JZC/]GL99/\ 9(_2L'P;
M;?Z$]X_,DC,"?QKH[BWCN83%(H*GJ#3;6UBLX!#"H5 <X%,#E_$8^R:_97K
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M-4M[#3SYJ"122.W-))W&[6-KQ%87FN^#()H\M(J$E1WK+T;QO!I-NEGJ.F,
M@VD^6!_2NIU'5YO!^@6P%OY^U?FR<8JK%JGA+6[437<4/F,,L".AHZ!U#1!X
M9U36/[0M6,5T2"$WX!/TKEOB!?BX\3VT$[$6Z#)&<9P15/R+0>-[5=!.(Q*,
M[!C'6M'QUI+VFKVE_<0^?;[0)=W3)--;B>QT5IXR\.VMJD*P)@#N!_A7%W>J
MV<7C.WN]+RJR9W@'C)(KK;2/P%<6RR?9+;..>#67;7_AZ7Q%'9:9H-O* 3^]
M&>,4(&>IPMN@C8]U!_2E?[C?2B/_ %:X&.!QZ4/]QOI69H>1)_R4EO\ @/\
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MG$)0?EBO'=%M-(T?7+FS\06<;!CA&<>]"=[@]+'6:IXL\.:AI\MN\*C*G&W
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MH]CS7_A7NH_\_$-'_"O=1_Y^(:]*HH^K4P^H4>QYK_PKW4?^?B&C_A7NH_\
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M\*ZU+_GXAH_X5UJ7_/Q#7IM%']FX?M^(?VQBNZ^X\R_X5UJ7_/Q#2K\.]1#
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M?T444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,$55[$VN=%:J4M(4/54 /Y5-114%A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !4<T,=Q$T<J*Z,,$,,U)10!QUS\-]%N9C*6G0DY(1R!6
MQHWAC3M$!^S1Y8_Q/R?SK9HIW8K(****0S!O?"6G7^NKJ\OF?:5  PW'%;%S
M;I=6[0R9VL,'%3447"QAZ)X6L-!EDDM/,W2$D[FSUJSK6AVFNVAMKO?L(Q\I
MQ6G13N*QE;;7P]I)"H[PQKR.IP*Y%+#PKXP=KS>]NYY(#[#7?7$"7,#Q2+E7
M!!!KA+KX91&Y:6PO?L@8_=5::8F8?BW2=#T;1Q!8R&:X=P!E]QYKIO#OAV+4
MO UI8WWF*-I!"G%0:?\ #6&"Z6>^N_M94Y&Y:[J*)(8UCC&%'04-@D1V5I%8
M6<5M",1QJ%%9^O>'++Q%;I#>[]J'(V-BM>BI**]G9Q6-C%:19\N)=BY]*PY_
M!.ESZR-4S*DX(.$; X]JZ2BBXK'%ZUJNA7EZNC:A&ZL>!(W'3WJHO@[PM8 W
MGVMV5!NVF;(/X5L>(O!=EKSB4[8Y@.'QS7/_ /"L;AOEDUAWC_N%>U6FB6GV
M,CP9;K<>.KJ[M4Q:B4[>.V!7KU9&A>'K/0;416Z*&/WF ZFM>I;NRHJR"BBB
MD,**** "BBB@ HHHH **** "O/D_Y*#'_P "_I7H->?)_P E!C_X%_2FA,]
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M?T444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?
M)_R4&/\ X%_2O0:\^3_DH,?_  +^E-"9Z .@I:0=!2TAA1110 4444 %%%%
M!4%]_P @^YQ_SR;^1J>F2()(GC/1E(_.@#S;X9QPO/>22*IF&>6ZCFL3QM<M
MKGC&UM4.1%\I ^HJ[JWASQ'H6J3SZ")&27@A%JSX,\(ZC_;1U;6$99.<JXY.
M:TTW,]=CM;ZUM[7PK+$RJ$$/0_05S7PN8FWU3'W!.-OTQ5?QFGB/4=7;3M/2
M0V9 !*C@ UU7A/0O["TE83_K' +_ %J>A74WZ***DH**** "BBB@ HHHH **
M** "BBB@#A?&,<LNN6<:-MRG7..XJ74M%.EVL=]%=2NZ#<59N#6YKVC?VG"&
MC8).F-K8K'_LW6=0:.WNYB(4/.1]X528BM+<&YUO1[B08WP$G\ZU_%I']EP^
MI/'Y4NK^'VFM(/LCB.:!=J'':L\:5J^I30I>RD0PL#@CK0!T>BY&BVN>HCK!
MUGQ/>Z??&"*U9U SD(37511K#$L:C"J,"E,:$Y*@_A2&<$_C342C#[$_3_GD
M?\*A^'\S3ZC<RL,,Q8D8]Z] EBC\IOD7IZ5PO@D8UN\Q_>?^9I]!'?T445(P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7GR?\E!C_X%_2O0:\^3_DH,?_ OZ4T)
MGH Z"EI!T%+2&%%%% !1110 4444 %176TVDP;[OEMGZ8J6FR(LL;1M]U@5/
MT- 'B^D>*;;PQKUT(COM)#C)'(YYXKME^*/ALH-T\P;O^[J27X<>&?FEDMY
M.I)DK/?PAX%C;:[JI]#+_P#6J_=9"4D7?^%H>&?^>\W_ '[K=T+Q'I_B*&67
M3W=EB;:VY<<USUO\/_"%U_J(S)C^[)71:)X>T[P]#)%I\3(LC;FRV>:3MT&K
M]35HHHJ2@HHHH **** "BBB@ HHHH **** "BJ.JZG'I5F;B12P! P#UK(A\
M5R32(HTJY 8XW9&*+ =+16=?:Q!I]FL\P(9AD)GFLZV\6137"Q36LEOO.%9R
M,&G8#HJ*0$$9!R#2T@&2_P"J;Z5P?@K_ )#=Y_O/_,UWDO\ JF^E<'X*_P"0
MW>?[S_S--;"._HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *\^3_DH,?\ P+^E>@UY\G_)08_^!?TIH3/0!T%+2#H*6D,****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNP V!_Z5UFEZ;#I=E';0+A4&/K2TL/6Y=HHHJ2@HHHH **** "BBB@ HHHH
M**** (KB=+:!I9#A0*\^;5KV]\3V\FYDM6D"J.QK3\6:G*+R&S\F9H&&YBBG
MJ#6'>:S;?VO8^5;3(J."04P>E4D)G3>)KNXDOK?3;>4Q^<N2P]C5#4-,N-"^
MS7<%TV&8;P!U%2ZK*&\2Z;<D%8VB)^;MS5[Q9(G]FP+N&6; _*@#>LI_M-G%
M,/XUS4]4-&4IHUJIZA*PM9B\1-?$V+0B''&[K2&=3+_JF^E<'X*_Y#=Y_O/_
M #-*\'BW8<M;XQ4'@ 2#4K@38\S+;L>N:=M!'HM%%%2,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KSY/^2@Q_\"_I7H->?)_R4&/_
M (%_2FA,] '04M(.@I:0PHHHH **** "BBB@ I"0JDGH!DTM07I(L+@CJ(FQ
M^1H X#Q3XWNA??V;HJL\X.-R&N0OKOQ7875O+J$LT8D=3AO<UT_PV@@N+Z]N
M)PKSG^_U'-2?$T 3V0']Y?\ T*M%H[&;U5S8\9ZCJ>G:+87=AO.W#3;?3 K5
M\*ZZNO:4D_\ &H ?GO4VJ)&_AB02A2OV<=?H*Y7X7?\ 'OJBC[@G 7Z8J>A7
M4]!HHHJ2@HHHH **** "BBB@ HHHH **** &-#&YRR@UBWWAY+O4H;H,%\M@
MV,=:W:* ,G6=%35( H81R+]U\=*RXO"]W+<1-?WQN(XB"JD=*ZJBG<!J($0*
MHP!TIU%%(!DO^J;Z5P?@K_D-WG^\_P#,UWDO^J;Z5P?@K_D-WG^\_P#,TUL(
M[^BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY_O/_,TUL([^BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^/M/*, DW(_YY&LWP%,+C5+F5<X8L1GZU5M!'H=%%%2,**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>?)_R4&/\ X%_2O0:\^3_DH,?_  +^E-"9Z .@I:0=!2TAA1110 44
M44 %%%% !2,P52S'"@9)J"^FFM[&66",22JN50GJ:\NU#XH:I&;BTDT=!PR$
MY;CC%-)L3:1ZA:ZA:7V?LMPDN.NTYQ5FO _#/C:[\/K*(+!9]^<YSQS70_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX_UJ_P!._LT6.UV&PL,Y_E7=_#W1;C2=)D>Y&'N"'KI$TFQ2<S+;IO/^R*N
M # & .PH;[ EKJ+1114E!2$A1DD #UI:Y_QK>26/A:[N(CAU'!H0,AU+QOH%
M@YBNIV)'! 7-9/\ PG/@LOOP=WKY7_UZPO!_@6TUJT:^U4M*'8X 8@UU'_"L
M/#/_ #[3?]_*OW41[S&I\2O"T:[4GD4>@CKJ-,U*VU:PCO;1BT,@RI(Q7,_\
M*P\,_P#/M-_W\KIM,TVVTFPCLK12L,8PH)R:EVZ%*_4MT444AA1110 4444
M%%5KV_@L(3+.X4#U-9UKXELKF819V,3@;CUH VJ*.M% #)?]4WTK@_!7_(;O
M/]Y_YFN\E_U3?2N#\%?\AN\_WG_F::V$=_1112&%%%% !3)?]4_^Z:?3)?\
M5/\ [IH \5UO_D/7-4JNZW_R'KFJ5>=B/XC/ Q?\9A1116!S!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !3H?^/ZU_P"NJ_SIM.A_X_K7
M_KJO\ZUH?Q$;8;^+$]RM?^/9/I4U0VO_ ![)]*FKTSZ(**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KSY/^2@Q_\"_I7H->?)_R4&/_ (%_2FA,] '04M(.@I:0
MPHHHH **** "BBB@#!\:_P#(G:G_ -<3_.N6^&VJV=GH4B32A6+CBNI\:_\
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MOR?]]FC^PX?[\G_?9H_MC#>8?4*QZ1_PD>F?\]Z/^$CTS_GO7F_]AP_WY/\
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MC1]9IA_:%,]H_P"$CTS_ )^!1_PD>F?\_ KQ?RC_ ,]'_P"^C1Y1_P">C_\
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M )^!7B_E'_GH_P#WT:/*/_/1_P#OHT?6:8?VA3/:/^$CTS_GX%'_  D>F?\
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M_?1IRQ$(NS'+'4XNS/:/^$CTS_GX%'_"1Z9_S\"O%_*/_/1_^^C1Y1_YZ/\
M]]&E]9ID_P!H4SVC_A(],_Y^!1_PD>F?\_ KQ?RC_P ]'_[Z-'E'_GH__?1H
M^LTP_M"F>T?\)'IG_/P*/^$CTS_GX%>+^4?^>C_]]&CRC_ST?_OHT?6:8?VA
M3/:/^$CTS_GX%'_"1Z9_S\"O%_*/_/1_^^C1Y1_YZ/\ ]]&CZS3#^T*9[1_P
MD>F?\_ H_P"$CTS_ )^!7B_E'_GH_P#WT:/*/_/1_P#OHT?6:8?VA3/:/^$C
MTS_GX%'_  D>F?\ /P*\7\H_\]'_ .^C1Y1_YZ/_ -]&CZS3#^T*9[1_PD>F
M?\_ H_X2/3/^?@5XOY1_YZ/_ -]&CRC_ ,]'_P"^C1]9IA_:%,]H_P"$CTS_
M )^!1_PD>F?\_ KQ?RC_ ,]'_P"^C1Y1_P">C_\ ?1H^LTP_M"F>T?\ "1Z9
M_P _ H_X2/3/^?@5XOY1_P">C_\ ?1H\H_\ /1_^^C1]9IA_:%,]H_X2/3/^
M?@4?\)'IG_/P*\7\H_\ /1_^^C1Y1_YZ/_WT:/K-,/[0IGM'_"1Z9_S\"C_A
M)-+_ .?@5XOY1_YZ/_WT:(82]ZD9D?:1_>-'UFG9LUHXJ%::A'=GM/\ PD>F
M?\]Z/^$CTS_GO7F_]B08^_)_WV:/[$@_OR?]]FN'^V,-YGK_ %"J>D?\)'IG
M_/>C_A(],_Y[UYO_ &)!_?D_[[-']B0?WY/^^S1_;&&\P^H53TC_ (2/3/\
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M /?1H\H_\]'_ .^C1]9IA_:%,]H_X2/3/^?@4?\ "1Z9_P _ KQ?RC_ST?\
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M /?1HV-_ST?_ +Z-']IT/,/[&Q/D>V?\)'IG_/P*/^$CTS_GX%>)[&_YZ/\
M]]&C8W_/1_\ OHT?VG0\P_L;$^1[9_PD>F?\_ H_X232_P#GX%>)[&_YZ/\
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M_P#?1H^LTP_M"F>T?\)'IG_/P*/^$CTS_GX%>+^4?^>C_P#?1H\H_P#/1_\
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M<Q_PM?2O^?*Z_*J5[$NUSF?[,^)/_/>X_P"^Q_A1_9GQ)_Y[W'_?8_PKIO\
MA:^E?\^5U^5'_"U]*_Y\KK\JK7L3IW.9_LSXD_\ />X_[['^%>G>&8]1BT"V
M3569KP#]X6.37+_\+7TK_GRNORKL='U2+6=,AOH49(Y1D*W45+N5&W0O4445
M)04444 %%%% $%U9P7L1BN(UD0]C5*V\/:9:3>;%:QJ_8@5J44 %%%% #)?]
M4WTK@_!7_(;O/]Y_YFN\E_U3?2N#\%?\AN\_WG_F::V$=_1112&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH^HX;^1!]9J_S'F_]A:[_P \#^=']A:[_P \#^=>D44?4<-_(@^LU?YCS?\
ML+7?^>!_.C^PM=_YX'\Z](HH^HX;^1!]9J_S'F_]A:[_ ,\#^=']A:[_ ,\#
M^=>D44?4<-_(@^LU?YCS?^PM=_YX'\Z/["UW_G@?SKTBBCZCAOY$'UFK_,>;
M'0==*D>0>1ZUEKX)UDNS&$C/O7KM%:0PU&G\,;&-9NLK5-3R;_A"M8_YY'\Z
M/^$*UC_GD?SKUFBK]E#L<WU6C_*>3?\ "%:Q_P \C^='_"%:Q_SR/YUZS11[
M*'8/JM'^4\F_X0K6/^>1_.C_ (0K6/\ GD?SKUFBCV4.P?5:/\IY-_PA6L?\
M\C^='_"%:Q_SR/YUZS11[*'8/JM'^4\F_P"$*UC_ )Y'\Z/^$*UC_GD?SKUF
MBCV4.P?5:/\ *>3?\(5K'_/(_G1_PA6L?\\C^=>LT4>RAV#ZK1_E/)O^$*UC
M_GD?SH_X0K6/^>1_.O6:*/90[!]5H_RGDW_"%:Q_SR/YT?\ "%:Q_P \C^=>
MLT4>RAV#ZK1_E/)O^$*UC_GD?SH_X0K6/^>1_.O6:*/90[!]5H_RGDW_  A6
ML?\ /(_G1_PA6L?\\C^=>LT4>RAV#ZK1_E/)O^$*UC_GD?SH_P"$*UC_ )Y'
M\Z]9HH]E#L'U6C_*>'ZSH-[I95KE" 2*JUW?Q&_U,?\ O"N$KEQ22:2/.QT(
MPDE$****Y3@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MD?[AI:1_N&FMQK<AM?\ 5GZFIZ@M?]6?J:GJZOQLTK?Q&%%%%9F04444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 46W_ "$X_I11;?\ (3C^
ME/[,O1G=EO\ O,3L.P^E%'8?2BOES] "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@""]_X\WKD;?[K_[QKKKW_CS>N1M_NO\ [QKV
MLM_@R]4?-\0_!$EHHHKM/E0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH J2_\?2_2IZ@E_P"/I?I4]<>/^*/H?I'#7^Y?,****X#Z
M$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *CF_P!2U25'
M-_J6K2C_ !(^IE6_A2]&/M_]54M16_\ JJEKV9_$S\?J_P 1A1114F84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56_Y?%^E6:K?\OB_2
MM:77T-J/7T+-%%%9&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[S_>?^9IK81W]%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX\WKD;?[K_[QKKKW_CS>N1M_NO\ [QKVLM_@R]4?-\0_!$EHHHKM/E0HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J2_\?2_2IZ@E
M_P"/I?I4]<>/^*/H?I'#7^Y?,****X#Z$**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *CF_P!2U25'-_J6K2C_ !(^IE6_A2]&/M_]54M1
M6_\ JJEKV9_$S\?J_P 1A1114F84444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 56_Y?%^E6:K?\OB_2M:77T-J/7T+-%%%9&(4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <5\1_\ D$)^-<GH'@'^V['[3]M\OGIMKOO%VB76
MMV"PVI0,,_>.*G\+Z3<:/IGV>X*E\C[IS57T%;4\JUKPY_PC^IPQ?:/-RV,X
MK?\ &7_((TW_ *YK_.MSQ3X5O]9U**>V,816R=S8I?$'A6_U.PLX8#'NA0!L
MM[T[BL<UJ'AZ27P]!JUJ/WL9+.0.@ KG[;47U#4[,N/F08)]>:]CTK2FM]"%
MA=8.00V*XI_A[?Q:X;FW,0M]^0"W.*$PL=KJ5UIEMI,0U1T6"1 OS=#Q7!7/
M@.TU!)K_ $F]#0D[DB4=!7>ZQHD>KZ2MK+]Y%^7ZXK@/^$!\20LR6UX$A[ 2
MXXI(;&>#M3O5:]TEV9HU1@%]Z3PG<1Z=XKE@N6",7[UUGA'PA_8@:XNVWW;Y
M#8.1BH/$W@@ZC,UWI[>7=$YSNP,T[H1T^I:I;Z;8-=3. H&5SW-<['K\?BGP
M[>+;H%E5?F0'I7,'P#XEF*I<W:O%GD&7/%=YX>\.V^A69BCY9Q\^>]+1#U.)
M^']Y#:ZI/;2N%DW-P:[S7=<M]#L'N)2"^,HA/WJY7Q!X"FN+DW6DR>7,QR<M
MBLE/A_K]S,BW]T'A!^;][DT:/4-3T#0=;AUVQ^TPX !P0#T-:M9NBZ/!HMB+
M>#.#R<^M:52,**** "BBB@ HHHH **** ,GQ+_R ;CZ5Q?PW_P"/VX^K?SKT
MAT612KJ&4]014<-I;VY)A@CC)Z[5Q3OH!Q_Q''_$HZ?PFL-?^2?G_KK7ILUO
M#<+MFB20>C#--^QVWE>5Y$?E_P!W;Q1<5CA_ EI'>Z!+;RC*.N"#7"^(-%ET
M;6_*=2%=]R_3->Z0V\-NNV&)(QZ*,4V:RM;APTUO'(PZ%ES34M0L86G+=-X,
MVV3%;DI^[(Z@UQ=OXZU31I);758GNGR1\QQQ7JR(D:!44*HZ "J\FFV,K;I+
M2%F/<H*5PL>3:)#+K_C"+4;2S,4,;AF4= *V/&6@7MIJ2ZK8*Q Y<J/>O18+
M2WML^1!''GKM7%2/&DB[74,I[$4^8+'EI^)TZV36XLR)@NT2;NAJUX'L]6GU
M"74+@NMO<$LV>C9'6N^_LG3O^?*#_O@59CBCA0)&BHHZ #%%T%CRWQ%I%_H&
MN?VI9HQ@R"Q'>DO/B;<7-BUO!:F*9A@2!J]3EACF7;*BNOHPS5;^R=._Y\H/
M^^!1?N%CC_A_I^J6PDFN]ZPR98*?4\YKO*145%"JH '0"EI-W&%%%%(#@/B-
M_J8_]X5PE=W\1O\ 4Q_[PKA*XL7NCR,Q^-!1117(><%%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %(_P!PTM(_W#36XUN0VO\ JS]34]06
MO^K/U-3U=7XV:5OXC"BBBLS(**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *+;_ )"<?THHMO\ D)Q_2G]F7HSNRW_>8G8=A]**.P^E%?+G
MZ %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%[_Q
MYO7(V_W7_P!XUUU[_P >;UR-O]U_]XU[66_P9>J/F^(?@B2T445VGRH4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5)?^/I?I4]02
M_P#'TOTJ>N/'_%'T/TCAK_<OF%%%%<!]"%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %1S?ZEJDJ.;_4M6E'^)'U,JW\*7HQ]O_JJEJ*W_
M -54M>S/XF?C]7^(PHHHJ3,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MBBV_Y"<?TI_9EZ,[LM_WF)V'8?2BCL/I17RY^@!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!!>_\>;UR-O\ =?\ WC777O\ QYO7
M(V_W7_WC7M9;_!EZH^;XA^")+1117:?*A1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!4E_P"/I?I4]02_\?2_2IZX\?\ %'T/TCAK
M_<OF%%%%<!]"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%1S?ZEJDJ.;_ %+5I1_B1]3*M_"EZ,?;_P"JJ6HK?_55+7LS^)GX_5_B,***
M*DS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JW_+XOTJ
MS5;_ )?%^E:TNOH;4>OH6:***R,0HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &#XB\._V[$J^
M:$P0<D5SW_"N3_S]I^1KOZ*&D]R90C+=' ?\*Y/_ #]I^1H_X5R?^?M/R-=_
M12Y8]B?90[' ?\*Y/_/VGY&C_A7)_P"?M/R-=_11RQ[![*'8X#_A7)_Y^T_(
MT?\ "N3_ ,_:?D:[^BCECV#V4.QP'_"N3_S]I^1H_P"%<G_G[3\C7>/-%%_K
M)$3_ 'F I4=9%W(P8>H.:.5=@]E#L<%_PKD_\_:?D:/^%<G_ )^T_(UW9GA5
MMK2QAO0L,T_( R2,>M'*NP>RAV.!_P"%<G_G[3\C1_PKD_\ /VGY&NY^UVP.
M#<0_]]BI597&58,/4'-'*NP>RAV.!_X5R?\ G[3\C1_PKD_\_:?D:[UY(XQF
M1U4>K'%1B\MB<"XA_P"^Q1RKL'LH=CAO^%<G_G[3\C1_PKD_\_:?D:[XLH7<
M6 7US34FBD.$E1CZ*P-'*NP>RAV.#_X5R?\ G[3\C1_PKD_\_:?D:[^D+!1E
MB /4FCECV#V4.QP/_"N3_P _:?D:/^%<G_G[3\C7<?;+7_GYA_[[%2JZN,HP
M8>H.:.5=@]E#L<%_PKD_\_:?D:BN?AZ8K=W^U(<#/0UZ)4%Y&TMK(B]2"!1R
MQ[![*'8\(BC\HNF<[6(J2MN7PAK7GR%(8RI8D?-[TS_A$==_YXQ_]]5QU,/.
M4VT>55PE64VTC'HK8_X1'7?^>,?_ 'U1_P (CKO_ #QC_P"^JCZM4,_J5;L8
M]%;'_"(Z[_SQC_[ZH_X1'7?^>,?_ 'U1]6J!]2K=C'HK8_X1'7?^>,?_ 'U1
M_P (CKO_ #QC_P"^J/JU0/J5;L8]%;'_  B.N_\ /&/_ +ZH_P"$1UW_ )XQ
M_P#?5'U:H'U*MV,>BMC_ (1'7?\ GC'_ -]4?\(CKO\ SQC_ .^J/JU0/J5;
ML8]%;'_"(Z[_ ,\8_P#OJC_A$==_YXQ_]]4?5J@?4JW8QZ*V/^$1UW_GC'_W
MU1_PB.N_\\8_^^J/JU0/J5;L8]%;'_"(Z[_SQC_[ZH_X1'7?^>,?_?5'U:H'
MU*MV,>BMC_A$==_YXQ_]]4?\(CKO_/&/_OJCZM4#ZE6[&/16Q_PB.N_\\8_^
M^J/^$1UW_GC'_P!]4?5J@?4JW8QZ6V_Y"<?TK7_X1'7?^>,?_?55'TB^TW4X
MQ=HJDCC!S2E0G&$F^S.O X6I3Q$921T?8?2BCL/I17R)]P%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% $%[_QYO7(V_W7_P!XUUU[
M_P >;UR-O]U_]XU[66_P9>J/F^(?@B2T445VGRH4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 5)?^/I?I4]02_P#'TOTJ>N/'_%'T
M/TCAK_<OF%%%%<!]"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %1S?ZEJDJ.;_4M6E'^)'U,JW\*7HQ]O_JJEJ*W_ -54M>S/XF?C]7^(
MPHHHJ3,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K?\
M+XOTJS5;_E\7Z5K2Z^AM1Z^A9HHHK(Q"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!DO^J;Z5[!X3_P"0+']!7C\O^J;Z5[!X3_Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,E
ME2&-I)&"HHR2>U/JGJMJU[I=Q;I]Z1<"@#C[SXG65K=20K9R2!&QN5A@UM^'
M_%UGKX(C4Q.!]QCS7G4MG?>%KE_M6DPW2N<J6R>/PKJ?#VOZ/<V3%+..UU#'
M*(G ].:II"N:6O\ CJQT.Z6#RS<-CYMC?=/I6</B=9&*-A9R;G.-NX9%<WH-
MG#JOC:87F'7<WRM4OCK2[.PU&%K6-(\L 544[+85V7O']\UU865U&6C$D>X#
M/3FI/AWXC+EM.N9<!1E2QZD]JH^+>=#TD?\ 3$?SK/OM)FTV"UUFU&U<@$+[
M"CH'4O\ B"20>,E =@-YX!KK?&&JS:7X;A>$X:10A/X5YR-375-;M9LYD/W_
M *UZOJ^F6VK:+';W$BI\@*DD=<4F,\PL/#%]K.G-J$&H;Y ,F)2<UVO@V75K
M2TEBU*&14C!(9AUQ7(3^&O$>B1S364Y6T'.Y).HK?\*>)+G4]/N["Y^:5(F.
MXGFFQ(R]9U34?%&N-IMFY2WW;<CM4&I^!]4T:S6]6^,Q0@[5SD58\"E8_$$R
MR$!RPQFO4+MK=+61[G;Y04EL^E#=@M<XG1-5U#4?"=TUVC@+'\LG0-]*H_#Z
M1VU><,['ENIKIY;[3KSPM<'3<" )PH&,5RWP\_Y"\_U:ET&>FUYUXT\279O4
MTS3R<OPV*]%KR&Z_=^.<R\ L<9^HI1!DO_"O-5:Q:Z^W?/C=Y?.36EX$U/5!
MJ+:;<([11DAG(X4CM7HD;+Y*MN&W:.<UDZ=J&CS7\\-D%%P'_>8&,FG<+&S1
M114C$P/048'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:Q]2\3Z9I5PL%U(ZNQP %S
M0!KX'H*,#T%-CF26!9E/R,NX?2LE?%.EOJPTP2O]I+;=NWC- &Q@>@HP/05A
M7?C'1[&]6TGF<2L=H 7BMIIXU@,V[,8&<B@!^!Z"C ]!61I_B;3-3OFL[:1V
MF7.05QTJWJ.J6FE0&:ZDVH/3K0!<P/048'H*YF+Q_H$TJQI<2;F.!E*Z1)$D
MC$BL"I&0<T .P/048'H*Q-3\7:1I$RQ74Y#'^Z,U%8>-=%U&X$-O.Q<_WEQ3
MLP.@P/048'H*-ZA=VX;?7-<_?^-=%TVY-O<3MY@&?E7(I =!@>@HP/05B:9X
MMTC5IO*M9R6SCYABMR@!,#T%&!Z"EHH 3 ]!7!>-?^0O!_NBN^K@?&O_ "%X
M/]T5EB/X4O0NE\:*=%%%?"GT84444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 07O_'F]<C;_=?_ 'C777O_ !YO7(V_W7_WC7M9;_!E
MZH^;XA^")+1117:?*A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<X%'M_(/[/Z<ZOZ].YV0.>E%5K&&2"U5))"[]235FM$<,DD[(****!!1110
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M_$CZF5;^%+T8^W_U52U%;_ZJI:]F?Q,_'ZO\1A1114F84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 56_Y?%^E6:K?\OB_2M:77T-J/7T+
M-%%%9&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1_PB^N_\_$/_ 'S7HM%'U/#_ ,B#V]7^9GG7_"+Z[_S\0_\ ?-'_  B^N_\
M/Q#_ -\UZ+11]3P_\B#V]7^9GG7_  B^N_\ /Q#_ -\T?\(OKO\ S\0_]\UZ
M+11]3P_\B#V]7^9GG7_"+Z[_ ,_$/_?-'_"+Z[_S\0_]\UZ+11]3P_\ (@]O
M5_F9YU_PB^N_\_$/_?-'_"+Z[_S\0_\ ?->BT4?4\/\ R(/;U?YF>=?\(OKO
M_/Q#_P!\T?\ "+Z[_P _$/\ WS7HM%'U/#_R(/;U?YF>=?\ "+Z[_P _$/\
MWS1_PB^N_P#/Q#_WS7HM%'U/#_R(/;U?YF>97WAO6HK.1Y+B(J!R M<="I0.
MIZAB#7M^M?\ (*F^E>)C_62_]=&_G45J5.G3]Q6/-S.<ITUS.XM%%%<9X@44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 5)?\ CZ7Z
M5/4$O_'TOTJ>N/'_ !1]#](X:_W+YA1117 ?0A1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !4<W^I:I*CF_P!2U:4?XD?4RK?PI>C'V_\
MJJEJ*W_U52U[,_B9^/U?XC"BBBI,PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ JM_R^+]*LU6_P"7Q?I6M+KZ&U'KZ%FBBBLC$**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &2_P"J;Z5[!X3_
M .0+']!7C\O^J;Z5[!X3_P"0+']!7=A?A9ZV7?"S=HHHKJ/2"BBB@ KSY/\
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M'^5 '$^&?%FI:KK=Q:7)C\N/IM7!ZUTWB34)]+T6:ZM]OF(1C<,BO(=+UYM
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M=\+-VBDW#UHW#UKJ/2%HI-P]:-P]: %KSY/^2@Q_\"_I7H&X>M>?I_R4&/\
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M5ZBBX6*/V)_[Y_.C[$_]\_G5ZBBX6*/V)_[Y_.C[$_\ ?/YU>HHN%BC]B?\
MOG\Z/L3_ -\_G5ZBBX6*/V)_[Y_.C[$_]\_G5ZBBX6*/V)_[Y_.C[$_]\_G5
MZBBX6*/V)_[Y_.C[$_\ ?/YU>HHN%BC]B?\ OG\Z/L3_ -\_G5ZBBX6*/V)_
M[Y_.C[$_]\_G5ZBBX6*/V)_[Y_.C[$_]\_G5ZBBX6*/V)_[Y_.C[$_\ ?/YU
M>HHN%BC]B?\ OG\Z/L3_ -\_G5ZBBX6*/V)_[Y_.C[$_]\_G5ZBBX6*/V)_[
MY_.C[$_]\_G5ZBBX6*/V)_[Y_.C[$_\ ?/YU>HHN%BC]B?\ OG\Z/L3_ -\_
MG5ZBBX6*/V)_[Y_.C[$_]\_G5ZBBX6*/V)_[Y_.C[$_]\_G5ZBBX6*/V)_[Y
M_.C[$_\ ?/YU>HHN%BC]B?\ OG\Z/L3_ -\_G5ZBBX6*/V)_[Y_.C[$_]\_G
M5ZBBX6*/V)_[Y_.C[$_]\_G5ZBBX6*/V)_[Y_.C[$_\ ?/YU>HHN%BC]B?\
MOG\Z/L3_ -\_G5ZBBX6*/V)_[Y_.C[$_]\_G5ZBBX6*/V)_[Y_.C[$_]\_G5
MZBBX6*/V)_[Y_.C[$_\ ?/YU>HHN%BC]B?\ OG\Z/L3_ -\_G5ZBBX6*/V)_
M[Y_.C[$_]\_G5ZBBX6*/V)_[Y_.C[$_]\_G5ZBBX6*/V)_[Y_.C[$_\ ?/YU
M>HHN%BC]B?\ OG\Z/L3_ -\_G5ZBBX6*/V)_[Y_.C[$_]\_G5ZBBX6*/V)_[
MY_.C[$_]\_G5ZBBX6*/V)_[Y_.C[$_\ ?/YU>HHN%BC]B?\ OG\Z/L3_ -\_
MG5ZBBX6*/V)_[Y_.C[$_]\_G5ZBBX6*/V)_[Y_.C[$_]\_G5ZBBX6*/V)_[Y
M_.C[$_\ ?/YU>HHN%BC]B?\ OG\Z/L3_ -\_G5ZBBX6*/V)_[Y_.C[$_]\_G
M5ZBBX6*/V)_[Y_.C[$_]\_G5ZBBX6*/V)_[Y_.C[$_\ ?/YU>HHN%BC]B?\
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M_P!\"C_A(H?^?=/^^!7.T4>VF'UFIW.B_P"$BA_Y]T_[X%'_  D4/_/NG_?
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M7-%U5YM'220$Y#(*M>'O&.HQ:K)I^KEGDR02W&WVIB-?QEXJGLI/[.L0#-*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYFFMA'?T444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-N;673]0",5C1=^1WR*9K7C<ZMH@M8;>0-MQ(Q'&*%Y 2>'_ /D1+[_KJO\
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M2O8/"?\ R!8_H*\?E_U3?2O8/"?_ "!8_H*[L+\+/6R[X6;M%%%=1Z04444
M%>?)_P E!C_X%_2O0:\^3_DH,?\ P+^E-"9Z .@I:0=!2TAA1110 4444 %%
M%% !1110 44A( R3@57.H6@;:;B,-TQNH LT4TR(NW+ ;NGO3J "BBB@#C/B
M183WNAPM I9H9-Y K@+_ ,;SW/A-M&ELMF%"^9S7N+(KC#J&'H1FL/Q#X>@U
M;1I[.""".23HVP#%4FNI+3Z'G'A_XAR:3IBVHL1( >O-:O\ PM>7_H&C_P >
MKLM!\/0:7IJV\\$$C@_>* UJ?V?9?\^=O_WZ'^%#:$D^YYS_ ,+7E_Z!H_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)O\ K[+_ 'U_]"K1:.QF]5<U?&S:G'H-C=:>SAH 'D*^F!6EX.UXZ[I"R/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "O)_'7_(?A_W37K%>3^.O^0_#_NFHJ? S#$_PI'.T445Y1\\
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)?]4WT
MKV#PG_R!8_H*\?E_U3?2O8/"?_(%C^@KNPOPL];+OA9NT445U'I!1110 5Y\
MG_)08_\ @7]*]!KSY/\ DH,?_ OZ4T)GH Z"EI!T%+2&%%%% !1110 4444
M%-D021LAZ,"#3J;(XBB>1ONHI8_A0!Y'XA\.:OX>UEM2T@.8F.6V5S6O>*+_
M %-H5O(F\R,@Y)ZX->GR_$;06+1R*[8.""M5&\;>$W.6LD)]XA6B;ZHS:71G
M+3ZUK_BU(K&UMY(H<!7P<\8KTOPMH2Z%I2P?\M& +\=ZPHO'_AJ YB@*?[J
M5H6GQ T:\D"*[*2<?-Q2=^PU8ZJBF0S1SQB2)U=3T(.:?4%A1110 4444 %%
M%% !1110 4444 %%%-$B$X# GZT .HI"0!DG%(LB,?E8'Z&@!U%%% #)?]4W
MTK@_!7_(;O/]Y_YFN\E_U3?2N#\%?\AN\_WG_F::V$=_1112&%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5Y/XZ_Y#\/\ NFO6*\G\=?\ (?A_W345/@9AB?X4
MCG:***\H^>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!DO\ JF^E>P>$_P#D"Q_05X_+_JF^E>P>$_\ D"Q_05W87X6>MEWPLW:*
M**ZCT@HHHH *\^3_ )*#'_P+^E>@UY\G_)08_P#@7]*:$ST =!2T@Z"EI#"B
MBB@ HHHH **** "HKDJ+28N,J$;(]1BI:AO%+V5PHZF-@/RH \7T_P +V_B?
MQ!.;.+R+5#D]P>>:[^U^'&@10;9K1)7_ +U<IX)UF'0-8N["_P QECA21[]Z
M]134;-T#"ZAP?^F@JY-D12/-/$_PVMX+*2ZL,+Y8+% *S_#OA"QU_1YG0"&Y
MM^&/?.,UW?BOQ/I]AI-Q%YRR2R(0H0AN:Q/AX&L]#U&\N<1K,V\$\=J+NP65
MQ/ASJ-RMS<Z/.Y;R 6 /U_\ K5Z+7E_P_;[3XOU*[0?NFCV@^X)KU"E+<<=@
MHHHJ2@HHHH **** "BBB@ HH[5@:AXFBL;IH&@G8CNL9(H /$>J2VJI:VY*S
M2<@CL.]8ABU"VGADMM0-PY.7C4=J@\2.VI:G8NF^-73J>".:O:MHJ:=91WD-
MQ)YB#=RW7BJ$6=<U*\/V6RA8PW$Z;B?3FJ5W;ZGH36]R;XRQNP#KCM4<D[3Z
MSH]Q+QO@).?K6QXM8?V9",\EN/RH W;6<7-K',.CC-350T4%=%M0>HCK UK3
MO$,]^7L7C$..,OBE89U<O^J;Z5P?@K_D-WG^\_\ ,TCZ1XM"',D6,?\ /2HO
MA^LB:C<+,<R MN^N:=M!'HM%%%2,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]*X/P5_R&[S_ 'G_ )FN\E_U3?2N#\%?\AN\_P!Y_P"9IK81W]%%%(84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %>3^.O^0_#_ +IKUBO)_'7_ "'X?]TU%3X&88G^%(YVBBBO*/G@HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9+_ *IOI7L'A/\
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M3O"^@1^'],6!#EV +G'>AV2!7;-RBBBH+"BBB@ HHHH **** "BBB@ K"O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?_ OZ5Z#7GR?\E!C_P"!?TIH3/0!T%+2#H*6D,**** "BBB@ HHHH HZQ?\
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M08_^!?TKT&O/D_Y*#'_P+^E-"9Z .@I:0=!2TAA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16-KNMC2X@J(9)G^Z
M@/-9D.MZE:NCWMO)Y4AZD8VT[ =916%K&OBSMHS;H999AE%4\D5F1Z_J5G<0
M_;K>3RI6 #'  HL!V%%-C=9(U=3D$9%.I ,E_P!4WTK@_!7_ "&[S_>?^9KO
M)?\ 5-]*X/P5_P AN\_WG_F::V$=_1112&%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110!C^)O^0)<?[A_E7D?AO1]<U-)3I4_EA<;_GVU[!X
M@@EN-(FCB0NY4@ 5S'PYTN]TV&Z%Y;/"6QC<.M4G9">YQOB+0O$.FZ>)M4N#
M) 6  \S=S6W<_P#),[7_ *Y&NE^(5A=:CH"0VD#S2"4':O7%8]QI&H-\/[:T
M%K(;A8R#'CD4[BL<Y!H/VGPJ=0M@?M,4HX'H*S=3UE]3M+.&4DS1$[B:]/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:/\ A+M(_P">[?\ ?-0_\(1HO_/.7_OY1_PA&B_\\Y?^_E&@:DW_  EVD?\
M/=O^^:/^$NTC_GNW_?-0_P#"$:+_ ,\Y?^_E'_"$:+_SSE_[^4:!J3?\)=I'
M_/=O^^:/^$NTC_GNW_?-0_\ "$:+_P \Y?\ OY1_PA&B_P#/.7_OY1H&I-_P
MEVD?\]V_[YH_X2[2/^>[?]\U#_PA&B_\\Y?^_E'_  A&B_\ /.7_ +^4:!J3
M?\)=I'_/=O\ OFC_ (2[2/\ GNW_ 'S4/_"$:+_SSE_[^4?\(1HO_/.7_OY1
MH&I-_P )=I'_ #W;_OFC_A+M(_Y[M_WS4/\ PA&B_P#/.7_OY1_PA&B_\\Y?
M^_E&@:DW_"7:1_SW;_OFC_A+M(_Y[M_WS4/_  A&B_\ /.7_ +^4?\(1HO\
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MSW;_ +YH_P"$NTC_ )[M_P!\U#_PA&B_\\Y?^_E'_"$:+_SSE_[^4:!J3?\
M"7:1_P ]V_[YH_X2[2/^>[?]\U#_ ,(1HO\ SSE_[^4?\(1HO_/.7_OY1H&I
M-_PEVD?\]V_[YH_X2[2/^>[?]\U#_P (1HO_ #SE_P"_E'_"$:+_ ,\Y?^_E
M&@:DW_"7:1_SW;_OFC_A+M(_Y[M_WS4/_"$:+_SSE_[^4?\ "$:+_P \Y?\
MOY1H&I-_PEVD?\]V_P"^:/\ A+M(_P">[?\ ?-0_\(1HO_/.7_OY1_PA&B_\
M\Y?^_E&@:DW_  EVD?\ /=O^^:/^$NTC_GNW_?-0_P#"$:+_ ,\Y?^_E'_"$
M:+_SSE_[^4:!J3?\)=I'_/=O^^:/^$NTC_GNW_?-0_\ "$:+_P \Y?\ OY1_
MPA&B_P#/.7_OY1H&I-_PEVD?\]V_[YH_X2[2/^>[?]\U#_PA&B_\\Y?^_E'_
M  A&B_\ /.7_ +^4:!J3?\)=I'_/=O\ OFC_ (2[2/\ GNW_ 'S4/_"$:+_S
MSE_[^4?\(1HO_/.7_OY1H&I-_P )=I'_ #W;_OFC_A+M(_Y[M_WS4/\ PA&B
M_P#/.7_OY1_PA&B_\\Y?^_E&@:DW_"7:1_SW;_OFC_A+M(_Y[M_WS4/_  A&
MB_\ /.7_ +^4?\(1HO\ SSE_[^4:!J3?\)=I'_/=O^^:/^$NTC_GNW_?-0_\
M(1HO_/.7_OY1_P (1HO_ #SE_P"_E&@:DW_"7:1_SW;_ +YH_P"$NTC_ )[M
M_P!\U#_PA&B_\\Y?^_E'_"$:+_SSE_[^4:!J3?\ "7:1_P ]V_[YH_X2[2/^
M>[?]\U#_ ,(1HO\ SSE_[^4?\(1HO_/.7_OY1H&I-_PEVD?\]V_[YH_X2[2/
M^>[?]\U#_P (1HO_ #SE_P"_E'_"$:+_ ,\Y?^_E&@:DW_"7:1_SW;_OFC_A
M+M(_Y[M_WS4/_"$:+_SSE_[^4?\ "$:+_P \Y?\ OY1H&I-_PEVD?\]V_P"^
M:/\ A+M(_P">[?\ ?-0_\(1HO_/.7_OY1_PA&B_\\Y?^_E&@:DW_  EVD?\
M/=O^^:/^$NTC_GNW_?-0_P#"$:+_ ,\Y?^_E'_"$:+_SSE_[^4:!J3?\)=I'
M_/=O^^:/^$NTC_GNW_?-0_\ "$:+_P \Y?\ OY1_PA&B_P#/.7_OY1H&I-_P
MEVD?\]V_[YH_X2[2/^>[?]\U#_PA&B_\\Y?^_E'_  A&B_\ /.7_ +^4:!J3
M?\)=I'_/=O\ OFC_ (2[2/\ GNW_ 'S4/_"$:+_SSE_[^4?\(1HO_/.7_OY1
MH&I-_P )=I'_ #W;_OFC_A+M(_Y[M_WS4/\ PA&B_P#/.7_OY1_PA&B_\\Y?
M^_E&@:DW_"7:1_SW;_OFC_A+M(_Y[M_WS4/_  A&B_\ /.7_ +^4?\(1HO\
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MSW;_ +YH_P"$NTC_ )[M_P!\U#_PA&B_\\Y?^_E'_"$:+_SSE_[^4:!J3?\
M"7:1_P ]V_[YH_X2[2/^>[?]\U#_ ,(1HO\ SSE_[^4?\(1HO_/.7_OY1H&I
M-_PEVD?\]V_[YH_X2[2/^>[?]\U#_P (1HO_ #SE_P"_E'_"$:+_ ,\Y?^_E
M&@:DW_"7:1_SW;_OFC_A+M(_Y[M_WS4/_"$:+_SSE_[^4?\ "$:+_P \Y?\
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M:/\ A+M(_P">[?\ ?-0_\(1HO_/.7_OY1_PA&B_\\Y?^_E&@:DW_  EVD?\
M/=O^^:/^$NTC_GNW_?-0_P#"$:+_ ,\Y?^_E'_"$:+_SSE_[^4:!J3?\)=I'
M_/=O^^:/^$NTC_GNW_?-0_\ "$:+_P \Y?\ OY1_PA&B_P#/.7_OY1H&I-_P
MEVD?\]V_[YH_X2[2/^>[?]\U#_PA&B_\\Y?^_E'_  A&B_\ /.7_ +^4:!J3
M?\)=I'_/=O\ OFC_ (2[2/\ GNW_ 'S4/_"$:+_SSE_[^4?\(1HO_/.7_OY1
MH&I-_P )=I'_ #W;_OFC_A+M(_Y[M_WS4/\ PA&B_P#/.7_OY1_PA&B_\\Y?
M^_E&@:DW_"7:1_SW;_OFC_A+M(_Y[M_WS4/_  A&B_\ /.7_ +^4?\(1HO\
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MSW;_ +YH_P"$NTC_ )[M_P!\U#_PA&B_\\Y?^_E'_"$:+_SSE_[^4:!J3?\
M"7:1_P ]V_[YH_X2[2/^>[?]\U#_ ,(1HO\ SSE_[^4?\(1HO_/.7_OY1H&I
M-_PEVD?\]V_[YH_X2[2/^>[?]\U#_P (1HO_ #SE_P"_E'_"$:+_ ,\Y?^_E
M&@:DW_"7:1_SW;_OFC_A+M(_Y[M_WS4/_"$:+_SSE_[^4?\ "$:+_P \Y?\
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M:/\ A+M(_P">[?\ ?-0_\(1HO_/.7_OY1_PA&B_\\Y?^_E&@:DW_  EVD?\
M/=O^^:/^$NTC_GNW_?-0_P#"$:+_ ,\Y?^_E'_"$:+_SSE_[^4:!J3?\)=I'
M_/=O^^:/^$NTC_GNW_?-0_\ "$:+_P \Y?\ OY1_PA&B_P#/.7_OY1H&I-_P
MEVD?\]V_[YH_X2[2/^>[?]\U#_PA&B_\\Y?^_E'_  A&B_\ /.7_ +^4:!J3
M?\)=I'_/=O\ OFC_ (2[2/\ GNW_ 'S4/_"$:+_SSE_[^4?\(1HO_/.7_OY1
MH&I-_P )=I'_ #W;_OFC_A+M(_Y[M_WS4/\ PA&B_P#/.7_OY1_PA&B_\\Y?
M^_E&@:DW_"7:1_SW;_OFC_A+M(_Y[M_WS4/_  A&B_\ /.7_ +^4?\(1HO\
MSSE_[^4:!J3?\)=I'_/=O^^:/^$NTC_GNW_?-0_\(1HO_/.7_OY1_P (1HO_
M #SE_P"_E&@:DW_"7:1_SW;_ +YH_P"$NTC_ )[M_P!\U#_PA&B_\\Y?^_E'
M_"$:+_SSE_[^4:!J3?\ "7:1_P ]V_[YKD[&\AOO'<<L!+)\W.*Z;_A"-%_Y
MYR_]_*M6'A?3--N!/;QN)!W+9HT#4V!T%+112&%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<QXYN)K;0&>
M&1HVSU4XH0,Z>BO"O#FG>)/$<4CVVHS83KF7%;;^"O%Z*6749"1SCSJKE\R>
M;R/6J*\DT'Q5JF@ZVNF:P=RLVUF)S7K$4BS1+(GW6&12:L-.X^BBBD,****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVK&^T^/#%YXD<+C.SR^:H>.=-O\ 3/$$>J10F6,<\<]ZV--^*-KL2/4(FBP
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M::1=ZQHLEM9H&D*D $XIG@;1KS1-&:WO4"2%\X!S2O[H[>\6O&G_ ")^I_\
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M[OZ"NU\26,^HZ1+;VZAI&! !.*Y_X>^'=1T"VN$OXU1G QALU2^$E_$<8_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gzkk5j0cumnd000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkk5j0cumnd000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,@")(# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR\65%8NF1VEQ=.]_.%4<_,?O&MZ^82M"-*UY:Z[(SIX57DY[+L=+;:_8W+A
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[X67+72OJM]&T8Y*Q$L6]LD"GI>Y"6*5'ZOR>5_(N_"FQDBTZZO7!"ROM3W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* ,S6;*YO(8Q;/M=22?FQ6;8^')1<K+>.I"G.T'.?QKI:*XZF!HU:OM9ZO\
M WAB:D(<D0' P*S]9LY;ZP,,.W?N!^8XK0HKIJ4U4@X2V9E"3A)270RM"T^?
M3[>5)]N6;(VG/:M6BBIHTHT8*G'9#J3<Y.3"BBBM2 HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH X?QYX5U+Q%<6CV AQ$A#>8^WO6_X6TRXTCP_;65UL\Z,?-L.1
M6S13OH81P\(U756["BBBD;A1110 4444 %%%% !1110 4444 %%%% !1110
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M /G^N?\ OZW^-'*']KQ_D_$^D:*^;O[3O_\ G^N?^_K?XT?VG?\ _/\ 7/\
MW];_ !HY0_M>/\GXGTC17S=_:=__ ,_US_W];_&C^T[_ /Y_KG_OZW^-'*']
MKQ_D_$^D:*^;O[3O_P#G^N?^_K?XT?VG?_\ /]<_]_6_QHY0_M>/\GXGTC17
MS=_:=_\ \_US_P!_6_QH_M.__P"?ZY_[^M_C1RA_:\?Y/Q/I&BOF[^T[_P#Y
M_KG_ +^M_C1_:=__ ,_US_W];_&CE#^UX_R?B?2-%?-W]IW_ /S_ %S_ -_6
M_P :/[3O_P#G^N?^_K?XT<H?VO'^3\3Z1HKYN_M._P#^?ZY_[^M_C1_:=_\
M\_US_P!_6_QHY0_M>/\ )^)](T5\W?VG?_\ /]<_]_6_QI5U34%8,+ZYR/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!0S#HQ'T-3)=2K_ !9^M044!<O)>J>'&/<595U<95@?I613E9D.
M5)!I<HU(UZ*I17O:3\ZN*P89!R*EJQ2=Q:***0PHHHH **** "BBB@ HHHH
M9*2(7(_NFLSS9/\ GHWYUIS?ZE_]TUDU429#_-D_YZ-^='FR?\]&_.F451(_
MS9/^>C?G1YLG_/1OSIE% #_-D_YZ-^='FR?\]&_.F44 /\V3_GHWYT>;)_ST
M;\Z910 _S9/^>C?G7G7Q&TJYEN(M40-)$$\N0]=N.G\Z]"I&574JP!4]0:##
M$456IN#/GZBO;F\-Z*[%FTRV+'J3&*;_ ,(SH?\ T"[7_OV*9Y7]E5/YD>)T
M5[9_PC.A_P#0+M?^_8H_X1G0_P#H%VO_ '[% ?V54_F1XG17MG_",Z'_ - N
MU_[]BC_A&=#_ .@7:_\ ?L4!_953^9'B=%>V?\(SH?\ T"[7_OV*/^$9T/\
MZ!=K_P!^Q0']E5/YD>)T5[9_PC.A_P#0+M?^_8H_X1G0_P#H%VO_ '[% ?V5
M4_F1XG17MG_",Z'_ - NU_[]BC_A&=#_ .@7:_\ ?L4!_953^9'B=%>V?\(S
MH?\ T"[7_OV*/^$9T/\ Z!=K_P!^Q0']E5/YD>)T5[9_PC.A_P#0+M?^_8H_
MX1G0_P#H%VO_ '[% ?V54_F1XG17MG_",Z'_ - NU_[]BC_A&=#_ .@7:_\
M?L4!_953^9'B=%>V?\(SH?\ T"[7_OV*/^$9T/\ Z!=K_P!^Q0']E5/YD>)T
M5[9_PC.A_P#0+M?^_8H_X1G0_P#H%VO_ '[% ?V54_F1XG17MG_",Z'_ - N
MU_[]BC_A&=#_ .@7:_\ ?L4!_953^9'B=%>V?\(SH?\ T"[7_OV*/^$9T/\
MZ!=K_P!^Q0']E5/YD>)T5[9_PC.A_P#0+M?^_8H_X1G0_P#H%VO_ '[% ?V5
M4_F1XG17MG_",Z'_ - NU_[]BC_A&=#_ .@7:_\ ?L4!_953^9'B=%>V?\(S
MH?\ T"[7_OV*/^$9T/\ Z!=K_P!^Q0']E5/YD>)T5[9_PC.A_P#0+M?^_8H_
MX1G0_P#H%VO_ '[% ?V54_F1XG17MG_",Z'_ - NU_[]BC_A&=#_ .@7:_\
M?L4!_953^9'B=%>V?\(SH?\ T"[7_OV*/^$9T/\ Z!=K_P!^Q0']E5/YD>)T
M5[9_PC.A_P#0+M?^_8H_X1G0_P#H%VO_ '[% ?V54_F1XG17MG_",Z'_ - N
MU_[]BC_A&=#_ .@7:_\ ?L4!_953^9'B=%>V?\(SH?\ T"[7_OV*/^$9T/\
MZ!=K_P!^Q0']E5/YD>)T5[9_PC.A_P#0+M?^_8H_X1G0_P#H%VO_ '[% ?V5
M4_F1XG17MG_",Z'_ - NU_[]BC_A&=#_ .@7:_\ ?L4!_953^9'B=%>V?\(S
MH?\ T"[7_OV*/^$9T/\ Z!=K_P!^Q0']E5/YD>)T5[9_PC.A_P#0+M?^_8H_
MX1G0_P#H%VO_ '[% ?V54_F1XG17MG_",Z'_ - NU_[]BC_A&=#_ .@7:_\
M?L4!_953^9'B=%>V?\(SH?\ T"[7_OV*/^$9T/\ Z!=K_P!^Q0']E5/YD>)T
M5[9_PC.A_P#0+M?^_8I1X:T13D:7; _]<Q0']E5/YD<)\/\ 2IY=874=K+#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I(IGB;(/'I4
M=% &K%,LJY'7N*DK(5V1MRG!%:,$XF7T8=14M6+3N34445(PHHHH **** "B
MBB@!DW^I?_=-9-:TW^I?_=-9-5$F044451(4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFQC5E,RJ2P'4"N\\/?\ (O6/_7(4/8%N:=%%%24%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !5NP^^_TJI5NP^^_TI/8:W+U%%%06%%%% !1110 4444 (2 ,FLZXG,K
M8'W1TJ6\F_Y9J?K5.KBB6PHHHIDA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4CJ^F!MIU&T!'&#.O
M^-5?$^I_V3X?N[H'$@0K'_O'I7AQL+AM,.I$'R?-\O/O@G^E-(39]#@@@$$$
M'D$4M<]X*U3^U/#5N[-F6+]V_/<5KW^I6>EP">]N$@C)QN;IF@"U16.WBG0T
MMTN&U* 12$A6R><=:=-XFT6W@AFFU"%(YL^6QSAL8S_,4 :U%9=QXBT>UACE
MGU"%$D&Y"3U%36NL:=>V[7%M>121(,LP;@4 7J*QX_%.ARW @34X#*3@+DUL
M @C(.0: "BBLSQ!J*Z7H5W=DX*H0OU/ H G;5]-5RC:A:!@<$&9<@_G5M65U
M#*0RD9!!R#7SS]BN;BPFU0@F,2[6;_:/->P> ]5_M+PS"KMF6W_=-]!T_3%-
MH29T]%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4Y'*,&4X(IM% &K#*)4W#KW%25EP2F*0'L>
MM:8((!'0U#5BT[BT444AA1110 4444 ,F_U+_P"Z:R:UIO\ 4O\ [IK)JHDR
M"BBBJ)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JW8???Z54JW8???Z4GL-;EZBBBH+"BBB@ HHHH *9-)Y<9;\J?5"\D
MW2;!T%-*XF[%8DL23U-)115D!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-=Q'&SMT4$F@#S;XHZ
MINDM=+C;I^\DQ^@K7C\-@?#DZ>R#SC#YQXY#_>_I7GU]]N\5>*KEK*,RS.Y\
ML @?*O Y/L*W?[(^(>,>=>8]/M:__%51([X9ZF;75;C396PLRY4'^\/_ -?Z
M5T/Q-_Y%M/\ KJ*\Y1+_ ,->(X'O$:*YC<.P+ Y!ZG(_&O0OB-,EQX3MYXSE
M)'5U^AYHZAT.5\'^#D\26TL]U<RQ01G:HCQG/XU9^(6F0:/9:)8V^3'&LOS-
MU/W>373?#/\ Y%EO^NIK'^+'^MTK_=E_]EHZAT)?#/@JPU+PXE_J)DFGG0E#
MO(\L#(&/RKC/#VG2ZEKT>E+/(D4S$2A6QN5>3_*O6O"'_(EV/_7)O_0C7G'@
M7_D?;?\ [:_^@-0!;\>>&=/T&.SEL%>/>2K L3DCOS7>>";R2]\*6<DI+2*"
MA8GK@G'Z8KG/BK_QY6'^^W\JV?A[_P BC;_[S?SHZ!U.JKSCXHZKB.UTN-N6
M/FR ?D/Y_I7HY( R3@#O7ANKR7?BCQ=-]B0RR,Y6)<@8 ]S0@9W^F^&Q_P *
M\:P9?WT\9E.>S'H?RQ7+_#74C9ZY+I\IVK.I ![,*<-'^(2H$$MV% P!]K7I
M_P!]5SDT.I>&]=AEO8VCNHW$IRP;=SGJ* /?**@L[E+RSAN(SE)$# U/4E!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !5ZRER/+)Z=*HTZ-RD@8=J&K@F:]%("& (Z&EK,T"B
MBB@ HHHH 9-_J7_W3636M-_J7_W36351)D%%%%42%%%07%[:V84W-S#!N^[Y
ML@7/TS0!/15'^VM*_P"@G9?]_P!?\:M0W$-PF^":.5?5&##]*8B2BBFR2)%&
MTDCJB*,LS'  ]S2&.HJ&WO+:[5FMKB&8*<$Q.&Q^534 %%%% !1110 4444
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M HHHI#"BFF1!((RZAR,A<\D?2G4 %%%% !1110 4444 %%%% !1110 4444
M%%%% !5JQ_UC?2JM6K'_ %C?2D]@6Y?HHHJ#0**** "BBB@"I?\ W4^IJC5Z
M^^ZGU-4JM;$/<2BEHIB$HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
M $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
M $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
M $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:*
M $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $JW8???Z55J
MW8_??Z4GL-;EVBBBH+"BBB@ HHHH 1FVJ6/85D,Q9B3W-:%XVV CU.*SJN)$
M@HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!<+:1"Z=7GV_.5& 34U% !1112&%%%% !1110 4444 %%%% !1110 5:L?\
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MHYVAXV) ^N:]$5@ZAE.5(R#18$[BT444 %%%% !1110 4444 %%%% !1110
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M&!91DBET'U.[\V/_ )Z)_P!]"L#Q?IVIZOI:6FFNBJ[@RL7QE?3_ #Z5@?\
M"J;'_H)W'_?"TOB^]NO#^G:3HEC<M&LHV-/G!P"!^'6@#7M_"?ARPTU([JWA
M+!<22.YR3W[US/A(0V'C^ZLM/GWV3*V,-D'C/Z5KP?#K3#$D]_>37!V[F9GP
M/SK$\+1V4/Q'EBT['V5%=4P<]%/>F(D\86CW_P 0+.T1V3SD56*GG'?]*V_$
M?A#1K?PS<O;V@CE@CW)("<Y'K534_P#DK6E_]<S_ .@-74>*/^18U'_KB: .
M/\"Z!;:QIGV_5 UTRGRXED8X11QTJ*>QBT#XE6*:>#%#./FC!XY!S6Y\-O\
MD54_ZZ-_,UF^(?\ DI>D_3^AHZAT(?B-%+-K>DQ0L5D?*JP[9(KHH/ FAQZ<
M+66U$LA7YIBQW$^M87CZY6S\1Z+</]V-B3^8KOH[B&6V6X253"R[@^>,>M(?
M4X+P5--H_B2_\/2RL\*9,63W!_PKT*O.O#6-6^(6HZE <V\0;#]FR<"O1:&"
M.)^)EVT.@PVZG'VB7!]\<UU.D6HLM(M+;&/+B5<8]JX[XI1EM-T^0=$F.?Q
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MU5")P*YWPRGB0ZWJ@TZ6!;@./M1=5P>3TS^-,1N^.T$OBG0(F.%:10?^^Z]
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M[6+E5_=?9W&?<G(_E2&+\-?^1HO?]QOYFKMCKVJR?$>2P>^E-H+AU$1/&!G
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M=D-2TRXLS)Y8F0KNQG'X5;HH R/#FAKX>TL6*W!G 8MO*;>I],FJVH>&%O\
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M:YX)MM<U>/49;N:)T  15!!Q5CQ-X2M_$P@\^YEA\G.-@!S^==#11<+'GO\
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M)12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4
M)12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )5JS^\
MWTJM5FS^\WTI/8%N6Z***@L**** "BBB@!DR;XF7VK)K9K,N8_+F(['D5429
M$-%%%42%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1161XEU?^Q-"N+T &11M0'NQZ4Q$VI:YIND &]NXXB>
MBDY;\NM9D/CSP[/*(UOL$G&7C91^9%87A'PQ'JT']MZUFZEG.Y$DY 'K73WO
MA/1;VV:%[&),CAD&"M&@:FO%+'-$LD3K)&PRK*<@UE0^)]*FU9M+6X9;P$KL
M>-EY'N16'X/TC6M#U&ZL[@%M-W$Q.S?D<5'X\\/231IK6G@B\MB&;;U8#O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,C/YK4OC.^B\2:OI^B:>XGQ+ND:,Y ]>?85H_$'3)'T.UNX$+/9.I( _A_\
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M%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%%
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M<0"5<CAATIIB:N9E%*RE3@C!%)5D!1110 4444 %%%% !1110 4444 %%%%
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M1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@
MHHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ HHQ1B@ JS9_ZQOI5;%6;/[[?2D]@6Y<H
MHHJ"PHHHH **** *]WT6JM6KKHM5JM;$O<2BEHH$)12T4 )12T4 )12T4 )1
M7*>//$%]X?TVWGL#&'DD*MO3=QBK7@W7IM?T7S[K:+J-RD@48^G%.P7UL=#1
M69XBU3^Q]#N;U<>8BXC!&<L>@KG_  'XDU+7_M@U$Q[H2  B;<4!<[.BEHI
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M:* $HI:* $HI:* $HI:* $JQ:_>;Z5!5BU^\WTH>PT6:***@H**** "BBB@
MHHHH **** (9[=91GHWK6<Z-&VUA@UKTR2-9%PPIIB:N9-%6)K5X^1\RU7JR
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *.M/CB>4X4?C5^&V6+D\MZT-V&E<BM[7H\@^@JY114-W*2L%%%%(84444
M%%%% !1110 R7_5/]#6=6C+_ *I_H:SJJ)+"BBBJ$%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MSMKOF:X7MTX_6FMX6E2**[\.:_/+<@@D3SAE;U[<5H:_J.CC^S=+UFS+PW2
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M70692HK06RC'7)J98HTZ(*.8.4SDMY'Z+QZFK4=DJ\N<GTJU14\S*20@4*,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5/;?>;Z5!4]M]YOI2>PT6:***DH**** "BBB@ HHHH **** "BBB@
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M[3Q[HMU=);LUQ;NYPOVB+8"?SHLQ71T]% Y (.0>E% PHHHH **** "BBB@
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MTF1ZBN)\-Z_J>J^%KV.$"XU2U8Q(VX8;T.?SJ&U\"V]Q8+<^(KR<WT@)<F?
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MKSP\VL%_+AC!\Q3U5AVKE/\ A8NKW\LIT?0_/@CY8E68@>^*L_$58HO"<:6
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MTK(T[PEH>DS":ST]$D'1F)8CZ9)K;I,:04444#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *FM_O-]*AJ:WZM2>P(L4445)04444 %%%% !1110 444C,%4DG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME>3:Z-9T:^2UNRN'$@)4_E534?!VMZY:2)JVLQR.!F*.)2L8;U(Q0K"=QOB
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MJ+!<[.BHX9DN((YHSE)%#*?8U)2&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 20-MG0^^*U:QU.'!]ZUQT%3(J(M%
M%%24%%%% #7_ -6WTJE5U_\ 5M]*I52$PHHHIB"BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK+^'U_\ :O#4=N_$MJQC93V]/TKJZYNUT.ZTSQ7-?600V-V"9XRV"K>H'UH
MCNO#MY-XZM];62$6T<00J6._//;&._K732J7B=1U92!3J* .:\%^'[OP[ILU
MO=O$[O)N!B)(QCW KI:** "BBBD,*Y71O#=YI_BN_P!4EDA,%P/D56.X?7BN
MJHIB*>J:;;ZMI\ME<KF.08..H]ZXN+PGXITV-K33=8B%F3QO8A@/88->@44
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%<EXW\6W/A:.R:WMHIOM!<-YA/&W'I]:$K@W8ZVBO(O^%NZG_T#;3_OIO\
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MS.7U/PWI?B+7;JXTC5VM=5A_URH#U]__ *V:I-J?BCP?JMC;ZM=QW]G<OL#
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M!A5 Z"I:**0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(<%<D9%<]X>/C+Q/;1SP:LUO;0L$9WD(,A[]!S2ZK:RVGPAM(YE*L75\'T+
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M_P"%1:7_ -!&\_)?\*N:5\,]/TG4X+Z&_NFDA.5#!<=,>E=Q13YF+E1R-MX
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M"7XE-R# &W;,<_2JC;J3*_0ZT$$ CD'I2T*H50HX &!2U)0E%+10!YS\7?\
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MPJ"<<8K'FT?[7\4=0M+G4KNQ:<!XI;>387^4<9_2M[4/ 5I#92/J/BK55M>
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MU 67T/<46"YHT444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTQ^==!X?\.6/ART:&S4EI#F25OO.?>MBBG=A8*Y35? ]O>ZHVI6-]<:;>/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% "-]T_2JU66^Z?I5>FA,2BEH
MIB$KBOB-;%-/L=5C'[RRN <_[)Z_RKMJJZEI\&JZ=-8W()AF7:VTX/X4('L<
M!HEL/%TWB34F0%;E/LT6>V%X(K%T&XD\0ZEX?TEP=NG%FE![;?NUZAH>A6?A
M[3_L5EYACW%B9&R23^%5]*\*Z;HVIW6H6@D\ZYSNWL"!DYXXXJKDV.7\:?\
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M 4FQI#J*6BD,2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH
M2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH 2BEHH
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MHHH **** "BBB@ HHHH *44E** %HHHI %%%% !1110 4444 %%%% !1110
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M **** "BBB@!&^Z?I5>K#?=/TJ"FA,2BEHI@)12T4 )12T4 )12T4 )12T4
M)12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4
M)12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4
M)12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4
M)12T4 )12T4 )12T4 )4D74TRGQ=328$M%%%(84444 %%%% "&B@T4 %%%%
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M>)+6&"YFEB6*02 Q8R2/J*FU30;#6-,%A?1>;$J@*3P5([@T)V!JYS,OP_\
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MMD].PJ.K2(;"BBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "K$-RT9PW*U7HH UT=9%W*<BG5E12M$V5/U%:44JRI
MN7\14-6+3N/HHHI#"BBB@ HHHH **** $;[I^E05.WW3]*AIH3$HI:* $HI:
M* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:
M* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:
M* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:
M* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $I\74TVGQ]30!)1112&%%%
M% !1110 4444 %%%% !1110 4444 %%%% !17)^/O$5]X;T>*ZL!%YC2;3YB
M[AC\ZO\ A/Q%%XDT6.Z&%G4;9HQ_"W^%.SM<5];&[17(^.O$E_X=@L'L1%F>
M;8_F+GCCIS750.9+>-VZL@)Q]*+!<DHHHI#"BBB@ HHHH ***YBY\331^.[?
MP^D*B-H?->0GDYZ "F%SIZ*P;VZUY/%=I;VUJC:0T0,TQ7E6R>,Y],=JWJ0!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<EIWB.^NOB!J>B2
M"+[);*ICPOS<J#R<^],5SK:***0PHKF_&^N7?A_P^+VR\OSO/2/]XN1@YS3=
M7U#Q -,TF?1[5)Y)RIN<KD*I&21R*=A7.FHI%SL&[KCFEI#"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@!KN$4LQX%9DTIE?)Z=A4EU-YC[1]T57JTB&PHHHIB"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *HZIJ]EHUJ+F_F\J(MM!VDY/T%7J\L^)FH-=:K:Z5$<^7AB
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M:S>6^T_=-:-0U8M.X4444AA1110 4444 (WW3]*AJ8_=-0TT)A1110 4444
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M^=4^Y*[%K^Q_$'A76K.33;N]U33YGVSQSG>R#N<]JYZ]\-+)\3DTXZEJ"B6
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M=$CMHHX@1&J!5SUP!Q28T2T445)04444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5!=2^7'@?>:IZR[B3S)2>PX%-(39%1115D!1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIEVMTD<T\R'*M<2;]OTKIZ**5QVL%%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#W9CUK/7QYHWV:>9S-'Y4ABV,HW.1Z &@#IZ*Y6R^(&C7EVMNPN+9F.%,Z
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M#>6MR2(+F&4CJ$<-_*@":BHFN[9)Q ]Q$LS=(RX#'\*?+-%!'YDTJ1H.K.P
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M*J:)X?T[P];/;Z;$T<;MN8,Y;G\:TZ3=W<:5E8\3^'VL6WA/Q!J-GJK?9Q(
MF]Q@ J3U^N:[>7XF:3_;4>GVL4EVKD*)H3D$GT%;.L>$-#UV;SK^R5Y<8+J2
MK'ZD4FD>#M"T.;SK&Q591T=R78?0GI5-IZDI-:'F?CPY^*-B?4V__H5>LZY_
MR [W_KBU4M1\'Z+JNKQZI=V[O=Q[=KB5@/E.1P#BMFX@CNK>2"49CD7:PSCB
MDWL-+<\G^#?_ !^:E_US7^=9'AJ_M='^(UQ/J$RV\2O("S\ &O6=#\*Z1X=>
M5]-@>)I1A]TC-G\S5;4_ OA[5[YKR[LMT[G+,DC+N/O@\T^97%RNR/+_ !_;
M0OXN@U"=G;3;Q%82Q=QR#CWJQ-HGP[ACC?\ MN_??_"C(2OU^7BO6+GP_I=W
MI<>G7%HDEK&,(K#[OT-8\'PW\+P3"5=/+,#G#RLP_(G%'-H'*[G,^(K#3M/^
M%1ATJ>6:T:4.KRD;CEAZ 5M_"O\ Y$Q?^N[_ ,A72ZEH>GZMIG]G74&;7C$:
M$IC'3I3M'T:RT*Q^Q:?&T< 8MM+%N3[GZ4KZ6';6YY)XN_Y*S#_UUA_D*L?$
M74YSXTMK"[N)HM,01EA&<9!QN/O7HE[X.T74-975KBW=KQ2K!Q*P&1TXSCM4
M^M>&-(\0!/[1M!*R?=8$JP_$<T^9"Y6>0^-IO"\=A;6GAZ-'<-OEF0D]N 2:
M]*\.ZI;:5\/+*_N2WD10DL4&3U-3)X"\.)I\EDNG@12$%CO.\X_VNM7D\,Z9
M'H+:*(I#8D$>696) //7.:&TU8$FG<- \1V'B2VDN-/,ICC;:WF)M.:UZR]$
M\/Z=X>MY(--A:..1MS!G+<_C6I4OR+04444@"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH RI_\ 7O\ [QJ.I;@8G?ZU%6B,V%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>>?%'I
MHW_75_\ V6O0Z\\^*/31O^NK_P#LM-;B>QWMI_QYP_\ 7-?Y5ROQ)_Y%8_\
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M-IR]: '4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=:N:UHT7@7Q#I%[I$DL5K<3B.6$R%@?7]*T/A[_R-?BG_KI'_-Z?\4.N@_\
M7X?Y"B^M@MI<;XKNK[7?%MIX7M;E[:W*"6X9#@D8SBC5_AU9:=ICWNB2W%O?
MVZ[PXE8[\>O-0Z_,?#WQ'L=;N4;[#/$(GD R$^7%;_B3Q?I5GH$\D%[#/--&
M5BCC;<6)XZ=J6NEAZ:W.(U/6)M1T+0/%1_X^K*?RYV ZX/'YUN_$RY?4-.T[
M2[1@S7;^9QW4 FF:1X8G/PJGLYXR+B9&F1".0>=O]*SO =S+XA\26<\W*Z59
M>6">[$;3_.GY]A>1MZ5K_D_"R2[=@);:-H#GNPX_K7+ZSIC:;\++ L")[B<3
MN3W+'@_EBJUZEQ%KEUX1C4^7/J"3*0.-N#G_ #[5UWQ0B6#PE:0I]V.5%'T&
M!1LPW0MK\/;+5M)2[U6XN9]3G0/YYE;]VQYP!G&!4WPSOKJ?3+ZQNIFE-G/L
M5F.3@Y[_ (5V&G?\@VV_ZYK_ "KA_AE_K]?_ .OE?_9JF]TRK6:/0:***DH*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"*X3?"P[CFLNMFL
MN>/RY2.W45463(BHHHJB0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C
MGGBMH'FGD6.-!EF8X J2O.O'-U/JGB"Q\/0.5C=E,N/?_ 4Q,T[CXCZ:D[16
M=K<7FWJ8QC^=2:?\0M*N[D6]S'+92$X'G=/S[5T&FZ19Z59I;6T"*JCDXY)]
M36?XF\,V^OZ>T85([I1^ZE(Z'W]J- U->ZN&@LI+B*%IRB[@B$9;Z5D>'?%5
MIXB,R11O!-$?FBD(SCUJUX?T^ZTO1X;.\N%GDC& XST["N)\5Z9<>&=<B\0Z
M:N(6?$R+V/\ @: /2'=8T9W(55&23VK T;Q7!KFISVMG:RM#"3NN"1M/_P"N
MN8\0^*I/$$5II.B[C)=J#,1_#_LUVF@:)!H.EQVD6"V,R/\ WF[T :E(S!%+
M,0% R2:6L_7+.YU#1[BTM)4BEE7;O;. /PH YZ\^(FFP7;V]I;SWK(<$PCBK
MFB>-M-UFZ^RX>VN#TCE[U8\+^'8] TI;=UB>X))ED49W'\:Y3XA0P6VM:5<6
MP5+QI!G9U(R,4] U/0KNZALK62YN)!'%&,LQ/2N.?XEV =C%874L*G!E  %5
M_B%=RO9:5IP8[KE\RCZ8_P 379V6F6MEI\=G'"GEH@4C;UXY-("/1]:L]<LQ
M<V<FY>C*>JGT-,UO7;+0;03WDF-QPB#JQ]JXW1 -"^)%UID(VV]RI*IV'\0_
ME272#7_B@+2<;X+-,[#TXP?ZBBP7-"'XE:>TJ"XL;JWB<\2N,CZ\5V5O/%=6
MZ3PN'C<;E8="*I:MI%MJFES6<D2;60A3C[I[&N0\!:E,OAC4H&8[[(,4R>G!
M/]* -K6_'&FZ-=?9 KW-R#AHXNWXU'I7CO3M1O%M)HI;.=CA5FXS^-8_PYTV
M&Y2\U>X427#3%%+<E>Y_G6C\0]-MY?#[7H14N+=@4<#!QZ4Q:G8T5D>%[^34
MO#EE<R\R-& Q]2.]:](844C'"DCL*Y7PAK]]K5SJ,=X8RL$FU-JXXH ZNBBB
MD,;)(D4;22.J(HRS,< "N1N_B+I<-PT-I#/>LO7RAQ6?\0K^>XO+'0;5R#<L
M/,Q[G %=;HVB6>C6"6]O"H( WL1RQ]Z8C"L_B+I<]R(+N&>R8]#*./\ ZU=5
M)/BT:>%//^3<BH1\_I@UF>(/#UKKNG20/&BS8_=R8Y4TGAC2KS1M(6RO+E9V
M0_(5SP/3F@"#0/%UIKUU-:B&2VN(O^64I&3ZUT!( ))P!R:\[\:://I&I1>)
M-,!#*^9U7^?T/3\:;KOC-M7TNTL-)#&\O%Q*%ZIVQ18+G2Z=XM@U76Y=.LK6
M65(B=]P"-@KHJQ/#'A^+P_I:0+AIW^:5_5JVZ "N5U;QWIVF7K6<44MY.IPZ
MP_PGTK9UZ\;3]!O;I?O1Q$BN9^'&FQC1&U*5 \]S(QWMR< X_F* -/0_&FG:
MW<_90KV]UVBEZFK'B/Q)'X=C@>2TEN/-) $9'&,?XUS/Q$LTT^;3];ME"3),
M%8KQGO\ TKN[9UNK."8A6WH&Y&>HH XK_A9UM_T"+S\Q5C3OB+:ZCJ<-BNG7
M,<DK;068<5N>(=3MM#T>:\=$+@8C7 ^9NU<_X$T5W637[\;KNZ)*;A]T'O\
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M E%+10 E%+10 E%+10 E*O6BE%(!:*** "BBB@ HHHH **** "BBB@ HHHH
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M&#]:?12&( %    '0"EHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+(--T]1F%6QN/3G\:?*+F/0[>_L[LD6UW!,1U$<@;'Y5QVL^*G@\>Z;IL=]
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MM:HY8EE7!_ TT[":N95%/DB:)L,/H:95D!1110 4444 %%%% !1110 4444
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M8BG>Z58:CC[9:0SXZ;US2V6EV.G BSM(H >OEKBK=% !1112&%%%% !1110
M50N]$TN^??=6$$S>KH#5^BF(I6>CZ=IYS9V4,)]40"IKNSMK^W,%U"DT3=4<
M9!J>B@""TLK:P@$%I D,0.0B# J>BBD,HR:+IDM\+U[&!KH$$2E/FR.G-7J*
M*8@JG>Z3I^I8^VV<,^.GF+G%7**!E6STZRT]"EG:Q0*>R+BK1 (((R#UHHH
MJ6>EV.GO(]I:Q0M(<N47&[ZU;HHH R[CPYHUW<//<:;;2S.<L[("2:C_ .$3
MT#_H$6G_ '[%;%% BE8Z1I^F%C8V<-N7^]Y:XS5VBB@ HHHI#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ I\<;2N%6B.-I&PHK2BB6)<#KW-)NPTKBQ
MQB- HI]%%06%%%% !1110 4444 %)2TE !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 9)&LB[6%4)K9HN1ROK6E133
ML)JYC45H2V:ORGRFJ<D+QGYE/UJT[D-6(Z*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***>D3R'Y5/UH 94T-N\IST7UJU%9JO
M+_,?2K/0<5+D4HC(XUB7"BGT45)04444 %%%% !1110 4444 %)2T4 )12T4
M )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4
M )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4
M )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4
M )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 )12T4 %%%% !1110
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M=H,UZMY#'N0^2Y889NV/6G8+FQ17"^"=?CU;PBT%UJL9U-Q,S[I/G09.&QV
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MA6XC3>\1<;E7U(]* +E%9EKXAT>]N/L]KJ=K--_<20$UI.ZQH7=@J@9))Z4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ%CIES='_EE&6KSWP)X?L_$5I<:[K42WMQ<2MA91N50/8UZ'J-J+[3KBU/\
MRUC*UYWX,U^V\*6]QH6NEK.2&5BDKJ=K@TEMH-[ZFS;>%9/#.N76K:;,D>F^
M0S26F3R0I/';K61X+T"V\3_:O$&M(+R269DCCEY50/;\:N6VK7_B[Q/-'I\T
MR:&D#1R,5P)"5(X_&J/A/7HO![W6A:Z&ME68R13E25(/O^ IZV%I<;XDTV+P
M5X@TW5M('D0W$OESP*<*1]/QJ+5])CUOXNO9SLPMVMT:55.-P"Y _,"I=<U
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MGWQ(_P"0MX9_Z^9/_9*]!I/9#6["BBBI*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
-HHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gzkk5j0cumnd000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkk5j0cumnd000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 5F",H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
M"?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>
M_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y[_PGUW_SZO\ ]\4?\)]=
M_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\ "?7?_/J__?%'*PN>A45Y
M[_PGUW_SZO\ ]\4?\)]=_P#/J_\ WQ1RL+GH5%>>_P#"?7?_ #ZO_P!\4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[FY17#_\)M<VT;27EI*JD94[,5T6AZN-7TU;K&-RYZ46"XZ\UN"SO?LK$&3
M./:C3=:@U*YN((B-T#;6KFK,_P!J>([R[89C2(H/J*C\)7$=MJ>LRRL%42#D
MGVHL*YWM%<SIOB635=1:*VB;R5."Y7@_C3M<\4)ILZVT$;2W![*,XHL.YTE%
M<.WCB:UC O+:1'/0E,"NLTN\_M#38;K&/,7-%@+E%%%(""\_X\IO]PUYUX1_
MY&JY_P"NG]*]%O/^/*;_ '#7G7A'_D:KG_KI_2J6PF>F4445(PHHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(^ C';2ZEM($:XIKS^(WT][1O*$:H1OV]1CUJCX8MKA-)U2.'YI64;2.<T=
M-WPM&UYJMUJ#<[7:,'VKFO$45_/XMN(K L)&?'%=_P"'-/;3].V./G<[C]:R
M(]*N1XSDO"O[DOD'%%]0*O@.2VC$T$D:I>ACN/<U'JBBX\<V<<W*+)P#5K6]
M#N;76(]2TT8)(5U'<9YI?$&G->O;7EO*D=]'RJL<9/TH VO$-M!+HDRR*"JH
M2N?I6/\ #[_D#+]*R-3F\07NFO#<&..-%Y.W&<5L_#]"NAH3T*\4= ZG7444
M5(PHHHH R_$'_(&N/]QOY5\]/]XU]$:W$\VE3H@RQ0@#\*\0/AC5,_\ 'M)_
MWR:N)XF:PE*<;(Q*4=:V?^$7U3_GUD_[Y-*/#&IY_P"/63_ODU5SR?95/Y6>
MS^%_^0)!_NC^5:=U-Y%N\@&=HZ50\/0/;Z1#'(I#!1D&M0@,,$ CWK,^MI?P
MT>2IK F\027>HQEU0D(K=L'BEF\31/XJAO1'\J/G%>HG3[0G)MHCG_8%<G/H
M!;Q=#<+ GV</DC9Q3NB['6V=R+NV68# 89K-\5_\BY=_[M;"(J*%4  =@*S?
M$-M)=Z)<0Q#+LO%+J,R?!-O&FAN0HR7.:R-&MXCX[U E!E)1M]JZ3PO9366D
MF*88;<36;I>EW$/BV^NW7]W)("#BF(J^.$7[;8OCYO.3G\:AU8"Y\7:=%/S&
M&. :T_%FF7-_/:M ,A)5)X]#3/$ND_:3;S03)'>19V!CC)H0&SKEO#)H<RNH
M*K&2OMQ7-^!YUM=!EE)^55%5-0F\0W>FO#.8TC1#EMN,@5'H=M<2^#IHK<9>
M1!@T6T V?"$#2_:KY_O&1U!]LUR&K0ZA<>)=0BL=W+_-BO3-&L?L.EK%CYB,
MGZUAZ7I5Q%XIO;F1?W4CY'%%PL-\"RVGV-XDC5+E6(<=SZU2A5;CX@3B89\N
M7Y,U9OM%NM,U]+[3Q^[<@.OUZTW7--E;4X]0TZ5%NU)+(QZGZ4 :7C6W@ET-
MC(!\O(S3O __ "*ME_USKE-??7-0TT_;2D<2^@P2:Z[P6I3PO9 C^"CH'4Z"
MBBBI&%%%% &/XE_Y \OT->,GK7M.OPO/IDB1J2Q!X%>6'P_?Y_X]Y/\ OFO#
MS.$I5%9'TF35(1I24G;4R:D@_P!:OUK1_P"$?U#_ )]Y/^^:DBT"_$BG[._7
M^[7FJE4OL>NZ]*WQ(]<L/^/"#_KFO\JG<@(=QP,5%9*4LH588(0 _E4LB"1"
MI[BOK(_"CX:?Q,YK3_#FC37<MRJ),Q8YX[UC>+M-MM*N+>]LHQ%*.?E[TYM/
MUCPY?RRV1\V"0D[6^8Y-/ATW5/$.HQ7&HA4@C/" 8)K0@[2R<R64#MU,:D_E
M6%XW_P"1<N/I711H(XU0=%  K%\56<M]HDT,(R[#BDMQD'AFWBB\.810 P)-
M8GA."+_A)=3.P924;?;BNFT2UEMM%$,@P^*RO#FEW-IKFHSRKA)) 5XIB,[Q
M:H'B6R<#YBZ#-$X6Y\?1)/\ ,J.0H-7_ !)I5S>:W:31+E$=2>*3Q+I;2ZA#
M>6,R)>1YPI/4_2@#3\56T$NARB10=JDKGZ5A^';O[%X*$^?NH*SM9EUZ_P!,
M=+HQQQ1KSQC.*DL+.YO/!UO;0#B1!GBCH!M>%K0Q:'<S./GD=VS[$UP5Q;ZC
M<7VIBSW&$2#S0*]<@M?(TI8%'/E@'ZXKGO#.DS6NH:FUP@V3."N1[4)A8L^$
MKBSDT?%JBHZY# >HZUC:(BW'C34'F&727Y<]N*L0Z1>:)XB:2T!-K+]Y>N">
MM,U;3I[?6CJ&E2Q^>6S)&3G)^E %OQ[;P/I4;N!N#\&M?PO_ ,BW9?\ 7.N$
M\1'6;^TCDORB1AL!0,$FN\\-*5\/68/7RZ'L'4UJ***D9!>?\>4W^X:\Z\(_
M\C5<_P#73^E>BWG_ !Y3?[AKSKPC_P C5<_]=/Z52V$STRBBBI&%%%% !111
M0 4444 %%%% !1110 4F :BN;J&TB,DSJJCN37.MXYTS[6MNH9F9MH(Z46 Z
MBBLU-;LVOC:&0"4'&":TNHR* "BBB@ HHHH **** ,[4]%L]6"B[A63;TS7*
M>(?#^A:38EOLD7F/\J#'>N\/ S7 7A.O^,%@!)AA ;';(IH3+G@[1%TG3&O9
M%VO(N[;_ ':SM$TU/$VIW%Y?CS8E=D56Z<&NXOX\:=(B#&!P!7,> "/L5R._
MGO\ S-._4#/UC3X_#&LVMU9?NXG)+HO2N_@?S;>.3^\H/Z5Q_C['E6Z_Q'I^
M==78 C3[?/\ SS7^5)[ 6<XZTFY?[P_.L[78+FYTJ6.T;;,1\IK@3X>\3$G_
M $K_ ,>-"0'IS,NT_,.GK7F,'_([MC_/-)_PCWB8#_CZ'_?1K/\ #\%Q;^*=
MERVZ08R?QJD@/8:***@84444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5E:[I(U>P> /L<CY6 Z5JT4 <&NF>)HHOLJ7,IBQM#>U
M;_AW01I$3/(^^>0?.Q')K=HIW%8****0PK"\1Z&^K0*T,ICFCY4@=ZW:* .#
M_LOQ+-&+62YE6+[I;U%=1H6CQZ/8K"IW-CYFQUK4HIW ****0!1110 4444
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M>V,S1SQ]-HZUT]% '!OHOB#4RL%[<2K"#SGG-=CIUC'IMC%:Q?=C&!5NBG<
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** (+S_CRF_P!PUYUX1_Y&JY_ZZ?TKT6\_X\IO
M]PUYUX1_Y&JY_P"NG]*I;"9Z91114C"BBB@ HHHH **** "BBB@ HHK!UOQ+
M#HUS'#(C,7(Z>] '._$&#4+EH8[9&9#G.*YBWF\56\8C268*.@S7>:SXNL]-
MAMY)H"_G#(^4&L?_ (6/IO\ SYG_ +X%6KV$S%@OO%?G+NEF(SZUZM9ES9PF
M3[Y0;OKBN'B^(>FR2!1:$9/]P5W5O*)K>.11@,H(I,$2T445(PHHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M110 4444 (WW3]*\P@_Y'=O\]Z]/;[I^E>80?\CNW^>]4A,]0HHHJ1A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<]3&I/Y5Q_CMQ(UK;J<N_05U]DNRQMU/:-?Y4GL'4=<7,5K"TLS;47J:S/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O/\ CRF_W#7G7A'_ )&J
MY_ZZ?TKT6\_X\IO]PUYUX1_Y&JY_ZZ?TJEL)GIE%%%2,**** "BBB@ HHHH
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M155/EL8U\&J4.>YZK17)_P#"?Z7Z-_WU1_PG^E^C?]]5[%F>?SQ[G645R?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M["O//L$/]Z3_ +[-'V"'^])_WV:\O^VJ/\K/IO[/J=ST/^V[#_GL*/[;L/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY&JY_P"NG]*]%O/^/*;_ '#7G7A'_D:KG_KI_2J6PF>F4445(PHHHH ****
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MHHY4']J5O(]'_P"%J7'_ #Y1_P#?1H_X6I<?\^4?_?1KSBBCE0?VI6\CT?\
MX6I<?\^4?_?1H_X6I<?\^4?_ 'T:\XHHY4']J5O(]'_X6I<?\^4?_?1I?^%J
M7'_/E'_WT:\WH'6CE0XYG6<DM#Z,T:_;4M,ANF4*9%#8%7Z\5T_Q]J&G64=M
M&5VHN!\M6_\ A9>J>J?]\5/*SUWC**T<CU^BO(/^%EZIZI_WQ1_PLO5/5/\
MOBCE8?7:'\QZ_17D'_"R]4]4_P"^*/\ A9>J>J?]\4<K#Z[0_F/7Z*\@_P"%
MEZIZI_WQ1_PLO5/5/^^*.5A]=H?S'K]%>0?\++U3U3_OBC_A9>J>J?\ ?%'*
MP^NT/YCU^BO(/^%EZIZI_P!\5IZ%X\U#4=4AMY"NUV .%HY65#%49OEC+4],
MHH'2BI.@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA\*"BBBLR@HHHH **** "BBB@ KE/%?^M7\*ZNN4\5_ZU?PKT\H_WI'FYO\
M[G,YFBBBOL3\V"BBB@84444 %%%% !1110 5V_AK_D'CZFN(KM_#7_(/'U->
M3G7^[?,^DX:_CR]#:HHHKY$^V"BBB@ HHHH **** "BBB@#+U[_CP/X5A+]T
M?2MW7O\ CP/X5A+]T?2O=P/^[KU9\CQ!_&CZ"T445U'SX4444 %%%% !1110
M 4444 9-_P#ZZJE6[_\ UU5*]FC_  T1BOC7H%%%%:',%%%% !1110 4444
M% ZT4#K053^-"GK24IZTE!5;^(PHHHH,@HHHH **** "BBB@ KH/!W_(P6O^
M^*Y^N@\'?\C!:_[XH9V8#_>(GO0Z4M(.E+61]2%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 07G_'E-_N&
MO.O"/_(U7/\ UT_I7HMY_P >4W^X:\Z\(_\ (U7/_73^E4MA,],HHHJ1A111
M0 4444 %%%% !1110 4444 <MXF\06-BZ6MY$LD<G#;A6>O@33-31;J&5HT<
M9"JM9OQ+:,20 1DR'.#69I?CR^LK589%W!1@86J2=M!'H.C^%K#2"'C0/(.C
MD<UNUYI%\1;AY ODMR?2O1;64SVT<I&-Z@TFGU!$U%%%(84444 %%%% $%U:
MPWD#0SH'1NH-<\?!%AYNX-A"<[,<5U%%%P*UE86]A (;>-44#' K-U3PS9:G
M)YKJ$D_O <UMT4 8NE>&K+2Y/-10\O\ ?(YK:HHH **** $;[I^E>80?\CNW
M^>]>GM]T_2O,(/\ D=V_SWJD)GJ%%%%2,\*\<?\ (S7G_70US-=-XX_Y&:\_
MZZ&N9K5'R^8?[Q(****#C"BBB@ HHHH **** "GQ?ZY/K3*?%_KD^M)[&E#^
M+'U/1K'_ (\(?]VK%5['_CPA_P!VK%? 5?XDO5GZI#X4%%%%9E!1110 4444
M %%%% !7*>*_]:OX5U=<IXK_ -:OX5Z>4?[TCS<W_P!SF<S1117V)^;!1110
M,**** "BBB@ HHHH *[?PU_R#Q]37$5V_AK_ )!X^IKR<Z_W;YGTG#7\>7H;
M5%%%?(GVP4444 %%%% !1110 4444 9>O?\ '@?PK"7[H^E;NO?\>!_"L)?N
MCZ5[N!_W=>K/D>(/XT?06BBBNH^?"BBB@ HHHH **** "BBB@#)O_P#754JW
M?_ZZJE>S1_AHC%?&O0****T.8**** "BBB@ HHHH *!UHH'6@JG\:%/6DI3U
MI*"JW\1A11109A1110 4444 %%%% !70>#O^1@M?]\5S]=!X._Y&"U_WQ0SK
MP/\ O$3WH=*6D'2EK(^I"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]T4^B@!GE1_W11Y4?]T4^B@!GE1_W11Y4?\ =%/HH 9Y4?\ =%'E1_W13Z*
M&>5'_=%'E1_W13Z* &>5'_=%'E1_W13Z* &>5'_=%'E1_P!T4^B@!GE1_P!T
M4>5'_=%/HH 9Y4?]T4>5'_=%/HH 9Y4?]T4>5'_=%/HH 9Y4?]T4>5'_ '13
MZ* &>5'_ '11Y4?]T4^B@!GE1_W11Y4?]T4^B@!GE1_W11Y4?]T4^B@!GE1_
MW11Y4?\ =%/HH 9Y4?\ =%'E1_W13Z* &>5'_=%'E1_W13Z* &>5'_=%'E1_
MW13Z* &>5'_=%'E1_P!T4^B@!GE1_P!T4>5'_=%/HH 9Y4?]T4>5'_=%/HH
M9Y4?]T4>5'_=%/HH 9Y4?]T4>5'_ '13Z* &>5'_ '11Y4?]T4^B@!GE1_W1
M1Y4?]T4^B@!GE1_W11Y4?]T4^B@!GE1_W11Y4?\ =%/HH 9Y4?\ =%'E1_W1
M3Z* &>5'_=%'E1_W13Z* &>5'_=%'E1_W13Z* &>5'_=%'E1_P!T4^B@!GE1
M_P!T4>5'_=%/HH 9Y4?]T4>5'_=%/HH 9Y4?]T4>5'_=%/HH 9Y4?]T4>5'_
M '13Z* &>5'_ '11Y4?]T4^B@!GE1_W11Y4?]T4^B@!GE1_W11Y4?]T4^B@!
MGE1_W11Y4?\ =%/HH 9Y4?\ =%'E1_W13Z* &>5'_=%'E1_W13Z* &>5'_=%
M'E1_W13Z* &>5'_=%'E1_P!T4^B@!GE1_P!T4>5'_=%/HH 9Y4?]T4>5'_=%
M/HH 9Y4?]T4>5'_=%/HH 9Y4?]T4>5'_ '13Z* &>5'_ '11Y4?]T4^B@!GE
M1_W11Y4?]T4^B@"K>1)]CF^4?<->>>$0!XJN<?\ /3^E>C7G_'E-_N&O.O"/
M_(U7/_73^E4MA,],HHHJ1A1110 4444 %%%% !1110 4444 8^OZMI^FVO\
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MA6$OW1]*]W _[NO5GR/$'\:/H+11174?/A1110 4444 %%%% !1110!DW_\
MKJJ5;O\ _754KV:/\-$8KXUZ!1116AS!1110 4444 %%%% !0.M% ZT%4_C0
MIZTE*>M)056_B,****#,**** "BBB@ HHHH *Z#P=_R,%K_OBN?KH/!W_(P6
MO^^*&=>!_P!XB>]#I2T@Z4M9'U(4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>_X\#^%82_='TKW<#_NZ]6?(\0?QH^@M%%%=1\^%%%% !1110 4444 %%%%
M&3?_ .NJI5N__P!=52O9H_PT1BOC7H%%%%:',%%%% !1110 4444 % ZT4#K
M053^-"GK24IZTE!5;^(PHHHH,PHHHH **** "BBB@ KH/!W_ ",%K_OBN?KH
M/!W_ ",%K_OBAG7@?]XB>]#I2T@Z4M9'U(4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M44 %=OX:_P"0>/J:XBNW\-?\@\?4UY.=?[M\SZ3AK^/+T-JBBBOD3[8****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY]I/^^:/^$)U7_GVD_[YHN@_LJKW1R]%=1_PA.J_\^TG_?-'_"$ZK_S[2?\
M?-%T']E5>Z.7HKJ/^$)U7_GVD_[YH_X0G5?^?:3_ +YHN@_LJKW1R] ZUU'_
M  A.J_\ /M)_WS1_PA.J_P#/M)_WS1=#CE=123NCF#UI*ZC_ (0G5?\ GV?_
M +YH_P"$)U7_ )]I/^^:+H=3+*DI.2:.7HKJ/^$)U7_GVD_[YH_X0G5?^?:3
M_OFBZ)_LJKW1R]%=1_PA.J_\^TG_ 'S1_P (3JO_ #[2?]\T70?V55[HY>BN
MH_X0G5?^?:3_ +YH_P"$)U7_ )]I/^^:+H/[*J]T<O174?\ "$ZK_P ^TG_?
M-'_"$ZK_ ,^TG_?-%T']E5>Z.7J>U_UR_6NA_P"$)U7_ )]I/^^:5?!>K(<B
MW?/^[4RU31I1RVI"?,V5_P :/QJ]_P (IK?_ #P?_OFC_A%-;_YX/_WS7G_5
M)=R_[/J=RC^-'XU>_P"$4UO_ )X/_P!\T?\ "*:W_P \'_[YH^J2[A_9]3N4
M?QH_&KW_  BFM_\ /!_^^:/^$4UO_G@__?-'U27</[/J=RC^-'XU>_X136_^
M>#_]\T?\(IK?_/!_^^:/JDNX?V?4[E'\:/QJ]_PBFM_\\'_[YH_X136_^>#_
M /?-'U27</[/J=RCV/-5X/\ 7/6M_P (IK?_ #P?_OFFCPCK2DD0/S_LU<<+
M))JY<<%-1:ON4_QH_&KW_"*:W_SP?_OFC_A%-;_YX/\ ]\U'U27<C^SZG<H_
MC1^-7O\ A%-;_P">#_\ ?-'_  BFM_\ /!_^^:/JDNX?V?4[E'\:/QJ]_P (
MIK?_ #P?_OFC_A%-;_YX/_WS1]4EW#^SZG<H_C1^-7O^$4UO_G@__?-'_"*:
MW_SP?_OFCZI+N']GU.Y1_&C\:O?\(IK?_/!_^^:/^$4UO_G@_P#WS1]4EW#^
MSZG<H?QQ_P"^O\Z]KT=E&F0_,.GK7D7_  BFMY!\A^#G[M:\4'BV&,1H&"CI
M\G_UZZ:-)PC9L[L+1E1BTSU3>O\ >'YT;U_O#\Z\NV^+_P#:_P"^/_KT;?%_
M^U_WQ_\ 7K:QU7/4=Z_WA^=&]?[P_.O+MOB__:_[X_\ KT;?%_\ M?\ ?'_U
MZ+!<]1WK_>'YT;U_O#\Z\NV^+_\ :_[X_P#KT;?%_P#M?]\?_7HL%SU'>O\
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MC/<-Z_WA^=&]?[P_.O#_ /A*=>_Y[C_OFC_A*=>_Y[C_ +YH]M2_F0?5J_\
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M0?\ ([M_GO7I[?=/TKS"#_D=V_SWJD)GJ%%%%2,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG_?(H_L;#^8?7ZIYE_:"?\\Y?^^#1_:"?\\Y?^^#7IOV.W_YY)_WR*/L=O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHH *0@'J*6D+*O4XH -J^E&U?2L35O$UKI-Q%#(I8R="#TK7BN(Y8DD###
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M9?PXBT445F9!1110 4444 %%%% !1110!V/P^_Y"<O\ N5Z37FWP^_Y"<O\
MN5Z37JT_@1]%A_X42"\_X\IO]PUYUX1_Y&JY_P"NG]*]%O/^/*;_ '#7G7A'
M_D:KG_KI_2M5L:L],HHHJ1A1110 4444 %%%% !1110 5C^([*YO--9;25HY
M5Y&TXK8HH \$U6UUA+B,7ID=_P"$YS6K%9>*3$A260+@8^?M7H_B*?2[&$7-
M[&K.HRJ]":Y&+X@/-?0PPVY2-G"#('2KO<DQT\-^(-4N8TNV9U!_B;I7KEA;
M_9;**$]50 _E7/?\)=;0ZXVGRQ[<-C?QBNI1@Z*RG((R*EMC0M%%%(84444
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M(,9).>]>P-]T_2O,(/\ D=V_SWJD[BL>H4445 PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWG_'E-_N&O.O"/\ R-5S_P!=/Z5JMC5GIE%%%2,**** "BBB@ HHHH ****
M"BBB@#S3QXQFUFUAF8K#DBH=?LK&TETPVHC&7CR5_"NN\5>&TUVURI"S(/E:
MO.KOPOKRR*@BED5#\I JT2S6\>16L5S;S6[#[0Q);;ZUZ)HY=M+MR_7RU_E7
MG^B>#;Z[O4N=2)"J<E&'6O2XHQ%$L:CA0 *3&A]%%%2,**** "BBB@ HHHH
M**** "BBB@ HHHH 1ONGZ5YA!_R.[?Y[UZ>WW3]*\P@_Y'=O\]ZI"9ZA1114
MC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD_Y^X_R-'_"NI/\ G[C_ "-'U67</[/J=SA**[O_ (5U)_S]Q_D:/^%=2?\
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M]/;[I^E>80?\CNW^>]4A,]0HHHJ1A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT6\_X\IO]PUYUX1_Y&JY_P"NG]*U6QJSTRBBBI&%%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >8O
M_P A6X_WC4E1O_R%;C_>-25\?F?^]2/=PG\%!1117 =(4444 %%%% !1110
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M10 C?=/TIMK]TTYONGZ4VU^Z:]+ _!+Y'R7%G\&'J3T445TGP84444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M &?-HEA/(7DMXV8]25J/_A'M-_Y]8_\ OFM2B@#+_P"$>TW_ )]8_P#OFC_A
M'M-_Y]8_^^:U** ,O_A'M-_Y]8_^^:/^$>TW_GUC_P"^:U** ,O_ (1[3?\
MGUC_ .^:/^$>TW_GUC_[YK4HH R_^$>TW_GUC_[YH_X1[3?^?6/_ +YK4HH
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M %T_I7HMY_QY3?[AKSKPC_R-5S_UT_I6JV-6>F4445(PHHHH **** "BBB@
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MWQ0!/14'VN'^^*/M</\ ?% $]%0?:X?[XH^UP_WQ0!/14'VN'^^*/M</]\4
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MM</]\4 3T5!]KA_OBC[7#_?% $]%0?:X?[XH^UP_WQ0!/14'VN'^^*/M</\
M?% $]%0?:X?[XH^UP_WQ0!/6%XO_ .1;N_\ <K6^UP_WQ69KZ+J.CSVL4@#N
MN!3$]CQ\=**WCX0OL\2C_OFC_A$;_P#YZC_OFO/>&J-GBRP55NY@T5O?\(C?
M_P#/4?\ ?-'_  B-_P#\]1_WS2^JU!?4:Q@T5O?\(C?_ //4?]\T?\(C?_\
M/4?]\T?5:@?4:Q@T5O?\(C?_ //4?]\T?\(C?_\ /4?]\T?5:@?4:Q@T5O?\
M(C?_ //4?]\T?\(C?_\ /4?]\T?5:@?4:Q@U6D_X^5^M=/\ \(C?_P#/4?\
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M^[_E1R2[![*?8SJ*T?[#O_\ GW?\J/[#O_\ GW?\J.278/93[&=16C_8=_\
M\^[_ )4?V'?_ //N_P"5')+L'LI]C'NONK]:F7[HJY<:#J+!<6[]?2I5T._V
MC_1W_*M'"7(M#65.?LUH9]%:/]AW_P#S[O\ E1_8=_\ \^[_ )5GR2[&7LI]
MC.HK1_L._P#^?=_RH_L._P#^?=_RHY)=@]E/L9U%:/\ 8=__ ,^[_E1_8=__
M ,^[_E1R2[![*?8SJ*T?[#O_ /GW?\J/[#O_ /GW?\J.278/93[&=16C_8=_
M_P ^[_E1_8=__P ^[_E1R2[![*?8Z#X??\A.7_<KTFO/?!5G/8:A(]RA12F
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M_P"$LN?^>:5SU%'UVO\ S!_9^&_D.A_X2RY_YYI1_P )9<_\\TKGJ*/KM?\
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M%%% !1110 4444 077W5^M3+]T5#=?=7ZU,OW16DO@1K+^'$6BBBLS(****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP/L<W ^X:\4O_P#D(W'^]2J8>G2IOD5KGE9MBJM>DO:.]BO1117(?.A1110
M4444 %%%% !1110!!=?=7ZU,OW14-U]U?K4R_=%:2^!&LOX<1:***S,@HHHH
M **** "BBB@ HHHH ['X??\ (3E_W*])KS;X??\ (3E_W*])KU:?P(^BP_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@_Y'=O\ />O3V^Z?I7F$'_([M_GO5(3/4****D84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH Y7QY_P @5/\ ?KR_M7J'CS_D"I_OUY?V
MKCQ?0\K,=XA1117&>8%%%% !1110 4444 %%%% '8_#[_D)R_P"Y7I->;?#[
M_D)R_P"Y7I->K3^!'T6'_A1(+S_CRF_W#7G7A'_D:KG_ *Z?TKT6\_X\IO\
M<->=>$?^1JN?^NG]*U6QJSTRBBBI&%%%% !1110 4444 %%%% !1110!R'BW
MQ)>:+-"EM )-^<Y4FN9_X6!JW_/FO_?!KTB]M;*=E-TJDCIFJG]F:/\ \\TJ
MDT(X.'XAZB\ZQM;)DGIM.:].M)3-:Q2,,%E!(_"O-O%D>F:3J-K<687?DEE'
M>O1=.F$]A#(!C*#^5#!%JBBBI&%%%% !137<(A8]!7/2>--)CE:-KA RG!YH
M F\779M/#UPZMAL<8KE](\-6M[9+/=:DZ2.<X\P5O:Y:'Q-HZ_8Y1Y<B]1SF
ML]? [+8_-<YF5>#@U2V$=!I6F0Z-:2>7.TJD9RQS7)6%K-XKU6>:>>1+=&*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .5\>?\@5/]^O+^U>
MH>//^0*G^_7E_:N/%]#RLQWB%%%%<9Y@4444 %%%% !1110 4444 =C\/O\
MD)R_[E>DUYM\/O\ D)R_[E>DUZM/X$?18?\ A1(+S_CRF_W#7G7A'_D:KG_K
MI_2O1;S_ (\IO]PUYUX1_P"1JN?^NG]*U6QJSTRBBBI&%%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4=.L962WC%SM[JU"38-I'>T5Y8/C)%G_ )!;_P#?8K?T;XC:;JMPL+X@=C@
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M-9LUN;2577^+'8^E7ZDH*PO&,LD'A+498G9)%BR&4X(K=KG_ !O_ ,B;J?\
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <%K7P_\
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MGQ1-)JUYI<D8>/S 2-PP170#P=:OIX+32F4IG=GOBK'BC1I+ZV2:T'[^$?(
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MD5Z;);12VQMY%#1E=I'M4.R>A:NUJ?-WAS4_[%UR&[;(V<'CUKWRT\3:9<6
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M2 3VIK<3V/G7P[<06VM0R7(!C!YR*]WN/$VE:;HZW"31;0O"(P)Z>E>4ZO\
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M'.ES!=V<XH@PFF>Z:+_R!;/_ *Y"O//C)_QZZ;_OM_*O1M*B>#2K6*12KI&
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M/NOCO4*5F6XW1YSX6^(TFD6ZVMV-T(Z$#) KK9OBSHGDMY*S^9CC*<5PU_\
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M>?\ 'E-_N&O.O"/_ "-5S_UT_I6JV-6>F4445(PHHHH **** "BBB@ HHHH
M*3 /:EHH 3 ]*-H]*9--'!&9)6"H.I-8;>,=(%TL"W4;.S;0,]Z -_:/2EJF
MFJ6CW1MA,OG XVU<H **** "BBB@ HHHH **R=:UV'1E0S ?-TYK%_X3^Q]!
M^=.P'845A:-XFM=:D9(,94\X-)JWBJRTN;R2ZO+UVYHL!O45@Z1XILM5F\E7
M5)O[F>:WJ0!1110 C?=/TKS"#_D=V_SWKT]ONGZ5YA!_R.[?Y[U2$SU"BBBI
M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!ROCS_
M ) J?[]>7]J]0\>?\@5/]^O+^U<>+Z'E9CO$****XSS HHHH **** "BBB@
MHHHH ['X??\ (3E_W*])KS;X??\ (3E_W*])KU:?P(^BP_\ "B07G_'E-_N&
MO.O"/_(U7/\ UT_I7HMY_P >4W^X:\Z\(_\ (U7/_73^E:K8U9Z91114C"BB
MB@ HHHH **** "BBB@ HHHH YSQ'XHM=#9([A"PD[;<URDOC+P],VY[(9_ZY
M5;^("V]U=VUKL!F;(#>E7;#X?:;]C0S*KNR@YQ5:6%J9]O\ $#1K4 0VI3'I
M'BM[2?'&FZI*(E+(YZ;ABN*UCPY8Z'K<"SJKV\Q/!Z"G^(="MM'GL[NSPJLR
MD*/>G9"NSUKKTHJEI,S3Z9!*QR67)J[4%!1110 4FU?[HI:* (IPWD,$ZXXK
MF?"6D3V,EQ-< ;WD8@^Q-=711<!& 92#WKA+G2=4T+5)+K3 K12=5;U-=Y13
M3 X6STK5-:U>*]U,*L41X4?X5W*J$15'0# I:*&P$(##!&13/)B_YYK^5244
M@(FABVG]VO3TKS.W 'C=@!C_ /77J#?=/TKS"#_D=V_SWJD)GJ%%%%2,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 <KX\_Y J?[]>7]J]0\>?\@5/]^O+^U<>+Z'E9CO$*
M***XSS HHHH **** "BBB@ HHHH ['X??\A.7_<KTFO-OA]_R$Y?]RO2:]6G
M\"/HL/\ PHD%Y_QY3?[AKSKPC_R-5S_UT_I7HMY_QY3?[AKSKPC_ ,C5<_\
M73^E:K8U9Z91114C"BBB@ HHHH **** "BBB@ HHHH RM9U+3]-A\V]56] 0
M":YH^.=!!Q]E_P#(8K,\>*UWK5K;.^U"2*R-9\-PZ=?V8!!AE" G'K5)(5SI
MSXYT8D+%:_,>G[L5W%M()K:.0# 900*\IUO0;/P_?VETNV2!SDK7J5A(DMC"
MT8PI08'X4,$6:***D84444 ,EW>6=GWNU<?+#XJ\]]C6^S<<9/:NSHH X#Q1
M+?)I]G;73[6D7]X4/%=!;Z#IO]D*OE1G=&"7(&>E6]<T6+6;-H7P&Q\K8Z5S
M T7Q''&;5+Z7R>@..U4(A\/%TO\ 4]/C<O C;5YS@8JWX#E6..ZMV(#B=S@^
MF36SX?\ #R:/ Q9M\TGWWQU-9.H^&+RWU%KW29VB9OO*HH 9X[<226MLA!=^
MPKK[)=EC IZB-?Y5RNF>&;R;4DO]5G:5T.55ATKL    .@I,#-UU;I]*E%F<
M38^6N!-KXHR?G_4UZC10G8+'EAM?%&/O_J:H>'EN4\48NCF3C/YU["WW3]*\
MP@_Y'=O\]ZI.X6/4****@84444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** (+S_CRF_W#7G7A'_D:KG_KI_2O1;S_ (\IO]PUYUX1_P"1
MJN?^NG]*I;"9Z91114C"BBB@ HHHH **** "BBB@ K.UG6+?1[-IYC]![UHU
MYG\1)7FU2"T)_=MMXII78F;_ (8\52Z[=3*R8C!^4[<5K>(=4?2=.-Q&NYLX
M'&:@\+Z/:Z=I<+11@2,OS,.]:]U:0WD)BG0.I[&C2X')^&O&T>J3"VN@%F/
MXP*[,'(R*\>\1:?'H7B2.2T 0%^ .U>LV+F2Q@8]3&"?RH:!%BBBBD,****
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M<GX_SJKZ"MJ9'_" Z[_S_G_OZ:/^$!UW_G_/_?TUZ?14\S'8\P_X0'7?^?\
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M?\_]_37I]%',PL>8?\(#KO\ S_G_ +^FC_A ==_Y_P _]_37I]%',PL>8?\
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M7I]%+F86/,/^$!UW_G_/_?TT?\(#KO\ S_G_ +^FO3Z*.9A8\P_X0'7?^?\
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M8F ]*?10!YOX7TZZ@\974TD3+&6?!(KTBDV@'.*6FW< HHHI %%%% !1110
M4444 %<UXUMY;G1G2)"S;3P!72TA (YH YWP7;RVVC;)4*MD<$5T=( !TI:
M"BBB@ HHHH **** "BBB@ KSKQ!87,OC""9(F,8DSD#BO1:0J"<D4T[ 1VX(
MMXP>RU+112 **** "BBB@ HHHH **** *U^I>PG51DF-@/RKA_ %A<VE_?-/
M$R!L8R,=Z]!I H'04[@+1112 **** "BBB@ HHHH **** .-\?6DUW81K#&S
MD2*>!GO6WX:B>'0;:.12K <@UK$ ]12@8'%.^@!1112 **** "BBB@ HHHH
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M="*:0'<Z=J4.IPM+!G:#CFKM4M+TZ'3+)((5  ')'>K;2*I 8@$]*0#J***
M"BBB@ HHHH **** "LV]UNTL;J*WD;,DAP #TJ/7M;@T:Q>61AN(PH]ZY7PQ
MIK:[>G6;X[^=T:GM32$=\C!T##H1FG4@ 5<#@"D617)"D$BD,=1110 4444
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M!WFG:I;:G&SV[ A3@\U=KBOAU;"'3;GVD'/X5VA900"0,TF-"T444@"BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!IF"O&RY!H V8)H[B)9(V#*PSQ4E<EX#N)I=,E20DJDK*I/H#Q76U+&%%%%
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M7-^*LW7B;3K:4_NO.Z>O!KOJYKQ3H<FH1QW5KD7,!W+CJ333$=!;QK#;I&@
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M!0QBT444@"BBB@#F?$_AI]<:,JP !&03VK7TK2X-*LDMX5 VC&>YJ_13N A
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MA7%4(W;N:PM($U&Y"B0H.N,]*YX^,M0O)6-A:2&+L6CS5.\$GB7Q&MBA/V2
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M:"( )"BX]% J6BBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M** "D=%=2K %3U!%+10 R.*.(8C15'^R,4^BB@ HHHH **** "BBB@ HHHH
M**** ,7Q#KIT6T\T0NY_V1FN9M?%6N:C'YMG&A0^L>:[F[M(;V!HIT#*1T-<
M3<V.H>%;HW-ENDLLY:/H *:L)CVU'Q5<#RPD2Y[F.K_A[PW/;7;:AJ#A[ECG
M@\ UOZ9?KJ%FLX&,CD>E7*+@%%%%(84444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<9I:* &+%&GW$5?H,4^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&57&&4,/0BEH
MH 0 *,  #T%+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4UXTD4JZAE/8C-.HH 9'
M&D2[44*/0#%/HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** # ]**** "BBB@ HHHH **** "BBB@ HHHH 0@,,$9!KGY_!
MFE7&H->LL@D8Y(#8'Y5T-% #8T6.-47HHP*=110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?#K/M%X<_P"[6[8ZE:ZC");64.IIV8KHMT444AA1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\,;#H5%*Z'9C/#5SJ5UI:S:GM$S8("KC KS/Q&S:1\3DU2=&-NLH;(^E>R
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M$%Y:17ULT$P.QA@X-9FA^%].\/O*UBL@,GWMS9K:HHN%@HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** .>U3P9I&K2F2XB8,>\9VU0C^&N@QON N&]FE)%=A13NQ6
M15L=/MM.@$5O&%4>U6J**0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"2WFC#AE(&>QJM"=626=];7\(EMI5D4_W3FK-<CX7\/7?AZ:9#*SVSG(!_A
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M^K>,YX;<D21AI1C_ &>:]!\"^)FU"V.GWCG[7 ,,6ZFFXZ:$J6NIJZ]XMM-
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M&Y6,A&16AX;\6IK3M;W$2P7:<-&.<&G9BNCIZI:MJ4>D:9/?2JS)"NXA>IK
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MK>F^+[34]7FTZ*&19(FVEB>#6Y=?\>LO^Z:\;TS5)M.\87WV2 3W32?NXR<
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M*4P0F3>8D+_WBHS4E% !1110!')!#-CS8D?'3<H-,%E: Y%K"".XC%3T4 (
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M3GU9 :6."&'_ %42)G^ZH%244 ,DBCE7;)&KCT89J,65JK K;0@CH1&*GHH
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M9B#)&K$=,TLL$4RA9$# =C1R2[A]:H/>FM=_^!V.-2^N[.;[;-81/9G[J)"
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MLGW;>(9]$%.%O"$*"&,(>JA1BI** &I&D:[8T5!Z*,4K(KJ5=0RGJ",BEHH
M@^Q6@.1:PY_ZYBI&BC=-C1JR^A&13Z* &>3%LV>4FW^[M&*5(XXEVQHJ#T48
MIU% #&AB=@SQ(S#H2H)IS*&&& (/8BEHH @^Q6F<_98<_P#7,5,JJJ[54 #L
M!2T4 ,2&*-BR1(K'J0H%$D4<O^LC1\?WE!I]% "8&W;@8]*:D,4;%DB12>I"
M@9I]% $+VEM(VY[>)CZE :!:6P4J+>(*>H"#!J:B@#,UG$.DS1Q6V\NI5511
MP:H^#]/EL=$A\]=LK+\RXQBNAHIWT%;4****0R,6\(?>(8PW][:,U)110 A
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M+*[XNY'UJIK;:IX0GM[]-;FU&-3EX96&#^5/E%S'J%%5=.O5O["&Y  \Q Q
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M!Y3#A)%+'^=:L>@:JOAJ.VAN9+6ZC .(SUQVJ&TU'QM;6RQ/HT$Q7^-ICDT
M'@SQ9>ZC?S:5JJ9O4+$.J[1M'M7<5Q7A+PQ=V>IS:QJ1*W4A8"/.0 ?>NUJ7
M:^A4;VU/+;P&/XD1^=D9CXW?6O3V*+%F3&P#G/2N5\6>%Y=5FCU"S<K>18VX
M[@=JS;B7QI=Z8]@^EPQ[UV^<)?F'O3W%L5/B->VUQHBQV$D)43KN\L=#GO4N
M@V?C"31H&LM3L4@(^53%DC]:UK+P/:QZ UG.=\TIWLY'(:LS3;7Q9X;:2TL[
M-+ZT7B-I9,8_*G?2R%;6[*&J>']9N=8M9M6UJP65'4A0A4D U%XKX\;Z>/\
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M 4444 %%%% !1110 444=.M !13%EC9MJR(6] PI] !13#+&&VF10WIGFGY
M&2>* "BHC<P X,\8_P"!BG)+')]QU;_=.: 'T44QYHHSAY$7ZL!0 ^BHQ<0L
M<+-&3Z!A4E !1110 44C,JC+$ >I-(LB/]QU;Z'- #JBN!*UNX@8+*1\I(X!
MJ6FK(CDA75B.H!S0!C^'M%?2%NVE=7EN)?,8CUK:HHH **** "BBB@ HHHH
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MX)T*[GOKG7KY/*\X[XE'<8K!T:YU2V\;WKZ5:1W,Q4@J[;0!DT^]A=KG<_\
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MHZ?2ELA[LX_6O!9TNW^VZ'+.)X^TDA?/X5N>$-:N=5TX+>QLMRF0Q(P#71D
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MN]CO[/5K#4"1:7<4Q']PYJ6YO+>RC\RYF2)/5C7F#Q#P]X]@@L?W<,J,3&O
MZBMK6](U+5?$</VB15TM2"59Q\PQR,46"YTP\3Z(Q &IVY).!\U2:O*LFA74
MD3Y!CX937">(G\&VUK):10(ETG*O%'GD>].\(ZC->>$;Z.65I-D9QN^HHMU"
M_07X?32R6VJ[Y';#OC+$XX-+\.II9/$FL!Y'8!!@,Q..:C^'G_'KJW^^_P#(
MTOPW_P"1EUG_ '!_Z%3?42Z'IE,FFCMX6EE<)&@RS'H*?7G7B_4+G5/$=GH$
M4K0P-)MF*'[RD=ZE*Y3=CKQXFT0L%&IVY8G &ZM1'610R$%3T(KF+KP+I#Z7
MY$-K&EPB_+,%^8D=*Y^:_P!<\,^%[B&_XDVD12;LGK3LGL*[6YV\_B#2;:4Q
MSZA!&XZJS59M-1L[]2UI<1S =2AS7#^%?#6GW&G_ &W5S#<S7'S@RL"1FLR]
M/_"*^++8V,X%G<2;3$C#:!BBR"[)O'LTJ>+].5)'52HR Q ZBCX@32QW^DA)
M'7,G.&(SQ4'CF43>*M*E'1D4_J*D^(?_ "$-(_ZZ?^RU2Z$OJ>C:82=,MB3D
M^6*H^+&9/"NHLI(81'!!J]I?_(+MO^N8K/\ %W_(IZE_UR/\ZA;E]#"^'%QC
MP_/)/*<+)RSG..*Z^TU"TO@3:W"2@==IS7GWA#_D2+_ZG^1J7X6?\>MQ_GO3
M:W8D]D=W=:C9V3*MS<QQ%C@!CUI;F_M+-5:YN$B5_NECUKSSXE_\A"P_ZZQ_
M^A"I/BAN_L>PVG#=ORHL#EN=K)XBT>$@2:C I(R,M5NTOK6^C\RUG25/53FN
M5T'PCIDGAZ&2\@2YEEBW;Y!RO':L'PK))I7C"[TN*1C; @*IZ"BR"[/1KS4;
M.P3==W$<*^KG%54\1Z-("4U& @=<-TK@H8V\7>,)K>ZD8VD#,ICZ@D5H>-_"
M%C%H$MSI\*VS0(6;RQ]_ZT6079W5M=V]Y'YEM,LJ#NIJ>N,^&V?^$?;/7>*[
M%RP0E!ENPI-68T[HIWFL:=I\HCN[R*%R,A7..*;:ZYI=[)Y=M?0RN>RM7F6G
MWFG3>)[H>) 9G\UDB65<@#M772>#]*?4(+O3KI;-D;=LA(^:FTD*[9UDDB1(
M7D8*HY)-9J^)-%=PBZE;EB< !JX[QU?WB7]GH\$[J) N]@>2,@&MO_A!]*71
MC!%;H+DK\LX7Y@?6BRZA=]#?@U6PNI3%!=1R.!DJIYI8]4L9;DV\=U&TR]4!
MY%>5^!()+;Q7>02.6,:2*">_%6/#_P#R4&Z_WA1RAS'J5Q<P6D7FW$JQI_>8
M\46]S#=0K-!(LD;=&4\&N;\?_P#(M/\ [XK/T(7[?#A%TX#[04.PEL8-*VEQ
MWU.GG\0:1;2&.;4($<=0S5-9:K8:B6%G=1SE/O;#G%<3I^DZ1I&DO=>)$AN)
MW?)9B&(SVXKFX]7L;3QM:R:&[PVLL@$D07:"*?*+F/6[G4[*SD$=S<QQ.1D!
MC55_$NBQMM?4K<,.Q:O//B(KW>O:>(SCS F<>A(KI-5\(:3#X7N,VT;7 CSY
MY7YLT6079TTVLZ;;Q++->1)&W(8G@T6FLZ;?N4M;R*9AV1LUYWX T9=8CFEU
M%C=6\#F)8I.0/2F:O;1>'?&UB^G((8Y9<-$O (Q19;!S/<]1GN(K:,R32*B#
MJ6K-'B;1&;:-3MR?3=7#>+-4N-7UZTTNWE9(757D"_7D5TT_@?2'TA[>*TC2
M=EXF"_,#ZT674+OH=,)4:+S0P*$9W=L5!:ZC9WLCI;7$<K)]X*>E<%X.UFZ_
MXF&BW+F4PK($=CR  >*C^&G_ "'-9^@_G1RAS'HEU>VUC$);J9(D)P&8X&:7
M[7;_ &;[1YJ^3C._/%<=\4/^19B_Z^8_YUC:[/=1>#;!87=86!\W8.U"5P;.
MZ/B?1 VTZG;@CMNK1M[F&[A6:"19(VZ,IX-<3H5GX2UO20(K: S!-CNXP0V.
MO6M[PYH2Z' T45^]S"?NJ<87Z8I-(:;-VH;FZ@LXC+<2K'&O)9CP*FKS379I
M]>\:?V*9F2UC?$BCHP-"5P;L=LGB3197")J5NS$X #=:U>HKD=6\#Z=)I8CT
M^UCANH\%95&"2*H20>+%\*_9<!;L*1YQDYHL@NSJ)/$FC12-')J5NKJ<$%NA
MJW9ZC9WZEK2XCF ZE#FN*&F^&=!TI)=:2*>XDP9'QN;<?I6!X?U.WB\=K!I<
MLB64T@ C*[1CZ4^45SU&;5]/MIO)FNXDDQG:QYQ3;76],O9/+MKV&5_[JM7E
MWBNW-UX]MH@Y4%1NQW&>17:ZSIFF^']%GU.RM(X)8$W90=:+(+LV[K7-,L9?
M*NKV&)\9VLV#4MEJ=CJ.[['<QS;>NPYQ7#>#] M]<CDU35E%T[,0JR#( -6I
MO#6H:1XDAO-#C"VCOF:$'"XHL@NS8%CH7]M^<+MOMF/N>:<?E6K+JUA!/Y$M
MW$DO383S7F,)8_$-2XPQ0Y'IS4?B6U>^^(<%JDA0R28W#M3Y17/2O^$ET42;
M/[2M]V<8W=ZTHY$FC#QL&4]"*Y35O!FDG1)&6VCCN(HR_FJOS$@9K)\$ZY/%
MX7GFG8R?9TR-QI6TT'?74[>\U?3]/<)=W<4+$9 <XIMIK6FWTFRUO8I6]%;-
M<#X0T[_A*-0NM4U0?:85=HUCDY ]*=XRT>/PX$U32!]F\O+,D? -%E>P7>YZ
M'=7]K8J&NITB!. 6.,FJ<GB/1H7*2:C K#J"U>=^,]0;5O"ME,#AR\8)]ZZ+
MP_X/TVZT")[VW2:YD7YI7'-%E;4+N^AU/]L:=]E^T_;(O(SC?GC-1V^O:5=S
M+#;W\,DC' 56Y->8>%-*:^\076G33NUC&[$0G[N0:TO'>EVFA/8WNEPK:RQD
MG,8QFCE5[!S.USTUF5$+L0%49)/:LH^)]$4X.IVX/^]6#X@36M2T&QCL6""0
M(992^"0>HJM-:>$?#UE;1:G;0RS./O*N\D_@:$@N=M:WEM>Q>;;3)*F<;E/%
M3UY5\/M1#>*KFSMII#9L'=8R, ?A7JM)JS&G=!1112&%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M')=F%EW!OM)P165X?@\.#Q$\6G65V\T8YF,NY>M:2^ ;B*$01>(+V.!1A8U
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MV\D49 (W_6O1K&\@_L6&X$BF-(5W,#P, 5'J.A66H:;]A>)5B PN!]VN=M_
M,MN/+77;O[/G)AP-I'I1=-!9IG/>&+B.[\>ZG/$P:-Y25([\"F:3_P E$N/]
MT?S-=?HW@>TT74Y;R"X<^8<^7M&!3[7P9;VNO/JJW,A=QC80,4[H5F<?>$:]
M\0FT_4)I%MHW955'*DBN@U;1-#\,:%=RQH=TL953*VXD_C5_7/!5MJ]]'>PW
M#V5P@.7B RQ]:J_\($9T*7^L75Y'CY4E PI]:+H+,YOP.0WA34B.Y'\JN_"_
MI=?[[_SKHM'\&P:/97EK'=2.ERV>0/EXQQ4_ASPM#X=\SRKAY=[$G<,=30V@
M2>AT%<;\1[.:[T!?*4L(V+-CTKLJ9+$DT312*&1AAE/<5*=F4U='G/A/POX?
MUG1(9?,N3,B@2A;@C:?I46I:7X5TO68+7[->7-SN& )\[??FMR3P"([J:73M
M5N+!)FW-'"!BKFC^#;;3;LW5Q.][<$?ZR4<BJN38X[Q-/!8^*M)=@8XE0C#'
MD<UZ2^H00Z3]K$B[%CSG/M7G'CBV2[\7Z?#(,JRM_.MR+P#*\"(^O7C0$9,1
M VX/:AVL@5[F+X0CEO\ Q+JNI*,PLY(;L?EIWP]_Y&W4O]T_^A&O0M-TBUTN
MP%K;1A%VX) ZUEZ%X1@T/5+B^CN7D:88*L.!SFE<=CD]+_Y*?/\ ]=&_D*9X
M[_Y&ZP_ZZK73ZGX(COM5&H6^H36<V<DQ <TEYX'BOKNVN9[^9Y(&#9('S8IW
M0K,Z)?\ D&'_ *YG^5>9>$(GG_MJ*,9=D< ?\"->IB$"W\G/&W;FL/0/"L.@
MW4\\5P\AE))##IDYI)Z#:///!VA:7?:C>V.IM.EVLF$5)2F>.>*Z#Q!X9\+Z
M):"6Z6\DW' C^T')K<UCP9;:E?K?6UP]C<@',D(&3FJL/@,&Z2:_U6XOE0Y"
M3 8S3N*QE:M'9I\.)&LK:6WA8J565LFH['_DF$O_  /^E=KK&AP:MHS:9N,,
M1QC8.F*J0^%88?#C:.+AS&V?GQSS2N.VIQ&BV<E]\/+J&)2S94X'MFNA^&VH
MPRZ%]BW#SXI&W+W S6[X?\/0Z!8-:1RM*K=2PK)O/ D3ZE)>:=J$VG&0898%
M&#1=,$FC&^)5S'</;64)\R9B/E7J.:H>-;;[)8:/$?\ GHI_05UVD^"K>PNS
M=75U)?39R'F R*L^(?"L&OFW,D[Q>2^X!1UIIH339Q?C""9=*TB]1"8HHP&.
M.GS5Z)I6H6]WI$-S'(IC" %L\# YIW]E6[Z4NGSH)80NWYAUKF/^$ DC5HK?
M7+N"W8D^2@&WFE=-#LT8>F7D-W\3P86#*I<9!^E>HUR>D>!+32-5AU".Y=Y(
MU(.5'S9[FNLI-CBF><_$:-X]5T^]*GR8EVL?3)KN[*[@ETV*=)5,0098'@<4
MM]I]KJ-NT%U"LB,.C#I7)#X?SQQ/##X@O8X&)/EJ!@9IZ-"U3*^O^(4\0V%]
MI=C;2NT3X,@.5X%9'@CP[HFL:<T=P]P+Q';>B3E<#/I7?Z+X?M-%M/)B4.S#
MYY".7^M9%[X%ADU&2\T^_FTYY!AA HYHNM@L]S!\0:)X4T26*.>&\N)7(*QB
MX)/7WIGCV.*/P]HRP1/%'YY(5SDC@5TFG^!X;:^6[OKV6_D7[OG <5>\2>&8
M/$5O:PR3/"MN^]=HSGBG?45M#C/&/_(FZ?\ [B_SKM?"?_(OV]5]5\)0:KI,
M%@]PZ+$  P R<&M?3+!=,L4M4<NJ=S2;T&EJ3W'_ ![2_P"X?Y5YU\//^0_J
M7T/_ *$:])90R,IZ$8KD?^$%6+5FOK35+BVW?>CC P:2>@VM3F;X+:_$JWDE
M.Q6#<GOR*[CQ5=P6WA:[,LBKOA(3)^\:@UKPA;:S#%OG>*XC&!.H^:L]O )G
M@:&]UFZNHRN%60#Y?<4[IBLS \-G=X%O3ZL/Y&MKX9?\@$_]='_G6K8>$+>P
MT:;34N'9)2"6(&15OP]X?B\/67V:*9I1N+988ZT-H$F</XH_Y'[3_P#<;^8K
MN/$/_(J7G_7O574O",&HZW!J;W+J\((" <&MB^L5OM,ELF<JLB;"PZBAO8$M
MSRVPM7O/AW>Q1@EA*C8'L#77_#R_AN?#<<*NOG1LVY.XK3T+PY;Z)8R6BR-,
MCG)WBLJZ\!QG4I;O3M2GT\2  QP*,4-I@DT87Q%FCO=2L[*W/F2Y!(7M@U5\
M;1"&\TA%&,.O_H-=CHW@RVTRY:YN+A[VX)R))@,BGZ[X2@UR[MYY+AXC"VX!
M1UIIH5F;&E_\@RW_ -P5;J&" 6]JL"L<*N :XRV:\3QO/;+J$TL**K%#]T9S
M4VN5>QW-9VJ3Z6T7V74)8E$ORA7ZGZ5HUSFMZ?I>NSO92R>5=1#<),<KGT)I
M72W*492ORJYE:AX T86$L]E)-"Y&X-YQV_E67X&U&\>SU#3IIA+! A*-[Y]:
M='HD,MY_9@\4WY89&TH-N![UN6*:'H"_V2DA,\ORF4+USZFCVD;;E_5:W-;D
M>U_D<YX!_P"1EU#_ *ZG^5;?COPT;RT.IV>$NK?YS_M>U)9V&D>$]4>X>]ED
M>X;<%"@@9X[5TFHZSIUG:J]U)NBD'11NS0ZD;WN$<-5:7NO78\8TS5'U+Q/8
M>:K++$A1]W<Y%>@>(_$&JZ'JU@0Z#3I&"OE>V.>:K-X5T2WO1XA6^D6-CN$:
MJ._M^%=)<R:-KNAF2;;) H."X^8>^*;J1N2L/6M?E>]OF:EK<VFJ6JRQ^7+&
MPSR,UY]\1+;3UN[$6H5;XR_=3@CCCBI=-\.V]S'.^F^)+VWA1N8PH7'TS5SP
M[I>C/JDTDU[)?W48'SW*@;?H:2G%:W*EAZVJ<7IOY%;Q5H=S?>$[.X16>>!%
MRO?@Y-;O@?68-3T.-!(OVB/(>//*XXK1CU[3)KTZ<KGS,$$%<+CZUR>I:-I$
M.N%+'4Y].GF(!%N@VGZFCVD6MQ_5:RE91>U_EW.QUC5[?2+&2>>15('R@GOV
MKF?"FL:[KUO>3R.BQLI%NQ3@'/?UK.U#P_86MU"NK:]=WBMC$;(&4\^U=I#<
M:9I-O;VT&U(Y#A%CYYHYXK2XO85='RNSV,%M.\<%SMUBQ"]OW!_QI/[.\=?]
M!BP_[\'_ !KL@<C([TM.YE8XWQ/%?Q>#)EU&:.:;<,LBX'>I/AP ?!EN" 07
M;@UO:UI2:SIKV<DC1JQSN4<U'H&BQZ!I,=A%*TJHQ.YA@\T7T"VIY[XQTFY\
M/:M_;5@"(F4B0#U-1?#.0:CJ^KL 5\R%1S]:]0U+3X=3LGM9P"C^U8/A;P5;
M>%[NYG@N9)3.,$, ,<YJN;0GEU.3\*2KI7C:[MKE@GF2,5+=Z[CQ=>V]IX9O
M#+(JEXB$!/WC[5#KOA"TUEQ*LC6MP.DL8^:L]/ )DN(7O]8N;V*)LB*4#::5
MT]1V:T.=TNUDM_A_>221L@FD#KGN,&M[X9_\BZO^\W\ZZ74=&@O])_LY3Y,.
M,#8.@J'P]H$7A^P%K%,TJ@DY88H;N@2LSB_'?_(X:;_N?U%=5>^$-+U:5;JY
M-SYC*,[)BHZ>E+K7A2#6=5M[^2X>-H5P%4<'G-= J[45?08HN%M3 L/"^D:#
M-]LB>=2H()EF+#'TJK<>&O#?B2X-TK>8XZM ^W^5=-/!'<0M%*H9&&"#7(/X
M",=R\ECK%U9H_P#RSB P*28-'*:C:S^$/%5M_9UVS+)QY;L6."0.]7=78M\1
M=.8]3(I/Y&NETWP/!::@MY>7LM_(HPIF XJS=^$8+OQ!#JQN'5XF#! .#BJN
MA69-XN_Y%Z?_ #VK&^&G_(NK_O-_.NIU33TU2Q>U=RBMW%5?#V@1>'[ 6L4S
M2J"3EABIOH5;4X/Q%Q\0K,_],S_,5#J;_P!L^/AIUW+)';@KM17*DY%=K?>$
M(+[78=4:Y=7C7:$ &#46N>";;6+R*\CN9+2ZC.?-B R:JZ)LRCJN@Z%X8T>X
MG1#N8$ RON.2/>N?\$$'PWJA'0QG'YUTR>!#(Y_M#5[F]B*D>7,!C/K5G1_!
M=OH]I=6\=U(Z7"[<$#Y><\475@L[G-?#S_CUU;_??^1I?AO_ ,C+K/\ N#_T
M*NKT+PG!H4=RD=P\GGDD[ATR*- \*0:!J%W=Q7#R-<@ JPZ<YI-K4:3T.AKS
M'7P=.^(=G>7 V02S !ST& :].K-UK1+37+)K>Y0;L?))C)0^HI)V&U<M37L$
M-F;II%\H+N#9ZUYIXLUC_A*M$D>SM95CMP69SR#VK</@"=HEA?Q!>M N/W9
MQCTKIK'1+*PT_P"Q)"IB(PP(^]35D)W9Q7ACPMX>UC2(9!)=&95 D"W!X/TJ
MOJ&E^%M+UVWLA:WES=%\ "?.T_C6V_@$1W,DMAJUS9*YR4A Q6AHWA"VTR\:
M\N)WO;IL?O91\PIW%8XOQJJIXFTE44JHC7"MU'(J;XA_\A#2/^NG_LM==KGA
M&#6]5M[^2Y>-H0 %4#!YS2:[X1@UV>UEDN7C-NV0%'7C%":!IFSI?_(+MO\
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M73K6^D,TKA%=RTQ*YZ]#7,K<VT_Q5A%KL,:S#!0<&NGA\ W%NGEQ>(+U8?\
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M HTWPO!87;2EF=0<H&8G!K?HH]G%= >-KN]Y;A1115G*%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% &'JOA+2M9N5N+F.19 ,9B?9_*JUIX&T6RNH
M[B-)W>,Y422EA^1KI:*=V*R$ "@   #H!2T44AA1110 4444 8]CX:TW3M2D
MU"WC<7$F=Q+9'-;%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gzkk5j0cumnd000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkk5j0cumnd000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,4",H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***CFGBMTWS2*B^IH"]B2BJ']MZ9_S^P_G1_;>F?\_L/YU/-'
MN1[2'<OT5235]/D8*EW$S'H :L3W4%L@>:544]"QIW0U*+5[DM%06U[;7F[[
M/,DFWKM/2HYM3L8'V2W,:-Z$T76X<T;7N6Z*9'*DR;XV#*>XI],H**** "BJ
MUQ?VEJ<3SI'_ +QJ2"YAN5W0R*Z^JFE=;"YE>Q+15/\ M:P\TQ?:H]X."N>:
MN @C(Z&A-/8%)/8***AGNH+5=T\JQCU8TQMVW)J*KV]]:W?^HG23_=-,FU.R
MMY?+FN8T<?PDTKK<GFC:]RW147VB'R/.\Q?*QG=VJ&'4K*XE\J&YC>3^Z#S1
M=#YEW+=%!.!DU''/%*[(CAF7J!VICN24444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%0/>VT;%7F0,.H)J92C'XG8:3>
MQ/14"7MM(P5)D+'L#4]$91E\+N#36X44450@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ***9)-'"NZ1PH]32;25V"5Q]%5O[0M/^?A/SH_M"T_Y^$_.
MH]M3_F7WE<DNQ9HJL+^T8X$Z$GWJS51G&7PNXG%K<****H04444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !15.YU:PLWV7-W'$WHQJO\
M\)'H_P#T$8/^^J"'4@M&S4HK+_X2/1_^@C!_WU5JUU*SO21;7$<N/[IH!5(M
MV3+5%%%!84444 %%%,DECA0O(P51U)H ?15&'6=-N)/+AO(G?T!J]0)23V84
M444#"BBB@ HHHH **K7>H6EB%-U<)$&Z;CUIUK>VUZA>VF251U*F@7,KVOJ3
MT444#"BBB@ HJ(7,+7#0"13*HR4[@5+0%[A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ),<@5-4GJ)W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MF*[3)GK2>"_#%W=:C]ONXV1<[@6'4T)6'B*L<5.$:6MC3^*O^HLOJ:N?#?\
MY =U]?Z53^*O^HLOJ:N?#?\ Y =U]?Z4?9-(_P"_OT_0X'6_^1I7_KJ/YU[-
M$ -".!_!7C.M?\C2G_74?SKV:/\ Y 1_W*&3@/CJ'BK?\C;)_P!=*]-\7 GP
M6GT6O,G_ .1MD_ZZ5ZQK]K+=^$ECA0LVP' ^E#Z&>$3<*J1P_P +/^0_=?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"%C'_GQ'_?5'_"QC_SXC_OJCZQ3[A]=H]SOJ*X'_A8Q_Y\1_WU1_PL8_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO_"%W_\ STCH_P"$+O\ _GI'1["IV#ZM5_E.:HKI?^$+O_\ GI'1_P (7?\
M_/2.CV%3L'U:K_*<U172_P#"%W__ #TCH_X0N_\ ^>D='L*G8/JU7^4YJBNE
M_P"$+O\ _GI'1_PA=_\ \](Z/85.P?5JO\IS5%=+_P (7?\ _/2.C_A"[_\
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M_O&CS7_O&F44 /\ -?\ O&CS7_O&F44 /\U_[QH\U_[QIE% #_-?^\:/-?\
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M['_A76J?\]H?SH_X5UJG_/:'\Z ^IU_Y6<=178_\*ZU3_GM#^='_  KK5/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "GQ?ZU?K
M3*?%_K5^M &M11169H%%%% !1110 5'+*(U]Z61PBY-9LLAD;)II7$W8))6D
M/)J.BBK("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ H!P<BBB@"[;W.?E8U<K&Z&KUK/D;6/-2T4
MF6Z***DH**** "BBB@ JE??>7Z5=JE??>7Z4UN*6Q3HHHJR HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "KECU:J=7+'JU)[#6Y=HHHJ"PHHHH **** "JE]]Q?K5NJE]]Q
M?K36XGL4:***L@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ I\7^M7ZTRGQ?ZU?K0!K4445F:!1110 4=J*
MBG?9&30!4NI=S;1VJM2DY.:2M$9L**** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **;YL>[;O7=Z9IU !1110 4444 %%%% !1110 4444
M%%-\R,'!=<^F:=0 4444 %%%% !1110 4444 %%%% !133)&K;2ZAO0FG4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4^
M+_6K]:93XO\ 6K]: -:BBBLS0**** "J5Z_.VKM9ERVZ6G'<4MB&BBBK("BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KA_&WBN;2D^S6I*ROD;P?NUW%<+XU\+OJK++:NIE&259@*:$SF&O_
M !I':K=O)<>00"&[$5V'@SQ0^KHUM<9,R DL3S7("W\2>&U6ZO(_/MD&/*9\
MK6UX7\407]Q-$UC!;2&,X,8Y--B0_P 7^,I[:[-A8,5E4XW*:QX-4\86<:WU
MS]H>U R<]#6;*H;QS&MQ]TRC=FO6[Y+==&92%,(7C/2C8-SSGPSXGU>^U[RI
M[N1HSD[#VJM\0%,FOE1U(6JWA?'_  ELFW[NYL?G5WQQ_P C*O\ P&GU%T,?
M0=0G\/ZM%+)E8BV6'K74^/KM+VP@GC(PZ TNO>'Q?>%K2\A0!X8\MCO7$3ZG
M-)9&TFYVG R>E&X;'J7PV_Y%9?\ KHU<9XV@FL?%CWSQDQ,^5]Z['X<L$\*;
MCT$C$U/J&M>'=4N?[,N#FX<[5+)T-+J/H8UCXKTS6]"ET^_=+/: J[CG=5_P
MKX:@TRY?4;:^%Q%M. !6=JOPUMUM)9[*X=YNJJ< 5A^#]4O++5WL7<LN&0J3
MQGI1Z!ZC/$]PVK>,5@)_=LRJ%KU31M,ATNPCAC0*0,''>O)M71K#QM$THQM=
M6->QV=TEY:I,A!##/%#!&#XB\(6^O2)(6$;K_%CM5YM-MM*\.W%M;1A$$+9
M[G'6I]2UJQTE UW+M!.!CFDO+F*ZT2YEA8,K0L0?PI#/)_ __(='^]7M->+>
M!_\ D.C_ 'J]IIL2V*&L7?V/39I,9^4@?E7E'A&P_MSQ%,UP-_EG=S]37J6O
MVSW6DS(@Y"D_I7FG@"\6Q\07"R<;QM&?J:%L#W/6UAC2$1*H" 8 KE?^$#LF
MUP7\A5HN28B.I]:Z[(QG/%93^(M-CU%;%IL3L,@=J0S450B*JC"J, 4M("&
M(.0:6D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT.@H8T+1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7^Z/RIW%8XWPKKNL:Q.T.I0;(RI!_=[:Q?$O@ZZM+YM1T[A!\P4'FO30H'0
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MTXZ G/%5]1M]0\'ZV;U8BT$C8!_O5ZU#;PVZ;(8UC7KA1BDGMH+E0L\22 =
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M5@GQ[:$ XQ'7K0Z"H'LK6242O;QM(.C%>:L4KC"BBBD,**** "BBB@ HHHH
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MF]!_X6!IQQ_$:[RHS;0F42F)#(O1L<BI* .$\8@_VSI_'_+=:[>:&.XA:*9
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M"J%'H!BEI:I7>K6-A(D=S<)&SG"@]Z +E%9'_"4Z+YOE?;XM^<8S6A/>V]M
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MV"ZACCVY$;Q_-_.LSQVH;Q%: CNG\Q7H7_+B/^N8_E5".;\+>))M1>2TO?\
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MEMXAL9-&+1Y)W@)MJ[XDLWU+Q5IL6]@3 "2._2F^)[VSN?$=BEI$J"$D,RJ
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M.*YKPL7TY=58L=T<.0?QKK8_$-B=!\PRJ&$6TJ6&<X]*Y+PX3J*:N$4@R0X
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MUM]KM6A\UHL_Q+7.^ O^0''_ +HK1\5R31:'(T 8ON ^7KBEU#H8\EOX<T&
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M'<?[AKC;/49;'P&@A.V1XN&!Y%=EXG_Y =Q_N&N+MK&6[\!(\(W-'%G ZFA
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MT_NC\J/+3^Z/RHWI_>%'F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT
M'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>
M'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='
MF)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?W
MA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1
MYB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]
MT?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4
M>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_
M='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT
M'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>
M'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='
MF)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?W
MA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1
MYB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]
MT?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4
M>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_
M='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT
M'EI_='Y4>6G]T?E1YB?WA^='F)_>'YT 'EI_='Y4;%_NBCS$_O#\Z/,3^\/S
MH 7 '04M-WK_ 'A2Y!Z&@!:*** "BBB@ HHHH **** "BBB@ JI>?>7Z5;JI
M>?>7Z4UN)[%6BBBK("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *M6?5JJU:L^K4GL-;ENB
MBBH+"BBB@ HHHH *K7GW5^M6:K7GW5^M-;B>Q3HHHJR HHHH **** "BBB@
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M_)0+S_KC_C7:BPM5N//$""7&-^.:([&UBN&N(X$69A@N!R13N*QR/Q Z6/\
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M2S2F1ZBJTB&PHHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1114%A1110 4444 %4;N7)VBK<C;4)K+=MS$^M5%$R8VBBBJ)"BBB@ HHHH
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ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
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M/_ZY+_.NZB_Y%Y?^O;_V6D%PL-:L=2=TMI=Q3[WM5"Z\9:+9W4EO-<D21G#
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MFN-\3_\ (W6_^\E1ZY,VG^*FN;V"6>UWY4*A<"BP7.NL/%6DZE<+!;3EI&Z
MC%;5<;9_V!XDN5N[=C:R6_R[>(R?PKL8U"QJH.0!@&D-"U'//';0M+*VU%ZF
MI:S=9TVVU*S:&YG:*,C!(?;0!FOXYT)'96N6RIP?EK4TS6++5X?-LY=Z>M<Q
M=ZMX>T6/["+4W+%" \<6_P#,BL'PC<A9M2>#>L8A=E5N,=>U.PKG=ZAXHTK3
M)C%<SE7!P0!FN3UOQ)]L\0Z>--NW\ED.]1QGFK?@:SBOHYK^Y43/,,XD&['T
MS65XBTI-.\66DD8 60%L#M0A.YW]WJUKI>GQW%Y+M4@#/4YJC:^,=&NYUABN
M"78X *XKB;W6K>?Q%&;])Y+=(@ D2EN1[58US7M)O;$)9Z==13IRC+;E>?RH
ML%SO]0U:STR+S;J78A&<UER>-M#C*AKD_-T^6N,U>YN+KP;;K.KB01<[@0:Z
M_2M"LD\-INB5V>'<6902#BBP[LW+*_M]0MQ/;/NC/>LV^\5Z1IURT%Q<$2*<
M$!<UQ6@Z@]EI=]$C-QYF.>G6M[P1I<-QI*ZC=(LTEPO/F#=_.BP7.BTO6K'6
M$=[.7>$.#D8HU/6K'2(O,O)=BYQP,UQ>I0MX=\66[VQVQS@NR \?E1ID8\0>
M*=]V2T:H<)GC(]J+!<ZBS\7:/?SB&"X)<] 5Q5S4M;L=)56NY=@;I@9JI?\
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MN;:ZM%EM558V&< 8H8(MU%<DK;N0<$"I:ANO^/:3Z4AGG&D6FHZ]J5\#K%S
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M)X.UBZFEDTZ]):9"Q#$\D"NQKBO!NE70NI-4N0!YA;:/8]*[6DQK8*P/$GB
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MW-TZUD>'G5O"%T.C?O#M]*[JV\,:-9R^;!8QH^",@=JFAT/38(GBBM45'SN
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MHHH HWBX.?6JE:-VFZ/Z5G5:V(>X4444Q!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !12$X!/I7!2ZQJ7B'67LM/F>UC3(,B<\BF([ZBN#U*SU[0HH[W^
MU)KM%.7C(QQ74:%K46MZ='<IA7899!_#0!J45YTMUJNM^(9K2VU.2WC1BIVU
MLIX:UM7!/B&8@'D8_P#K46"YUE%8M]=W^DV<*0P-?3$X)S@URL'BC43JK(BM
M+<;N;3/3VHL%ST2BJ.EWD][;&2XMS X.-A-7J "BBBD,**** "BBB@ HHHH
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M&_\ S\V7_?-:4$NM6>ESRZE)"\P^X8QQ18=S>HKS_2-3\6ZY#-<6D]JL:2%
M'7G@U/>W/C'3(?M%Q+:O$O+!$YQ185SN:*PM*\117FB_;9 047+BL2WU7Q)K
M9GFTMX(X(G*XE7DT6'<[BBN-T;Q+?+JK:;J^TS 9W(N!7946"X45S7B[7Y-&
MT\R6TL8FXP&K2T;4TU"PCE::-G*@MM/3CFBP7-.BJC:I8(VUKR$$=BXJ6"ZM
M[D$P3))CKM;-(":BJK:C9)G==1#!P<N.*D%Y;-#YHGC,?][=Q0!-150:I8-]
MV\A/T<5/'/%,NZ*17 [J<T 2455?4K&)MLEW"K>A<5(EU;R1&5)D:,<E@W%
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M5ST2BH;83"!?M!!D[E>E34AA3H_]8OUIM.3_ %B_6@9?HHHJ"@HHHH ****
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ML%S4HK+U_5/[*TV25?\ 6[3LSZUS?A#Q=>:G=/;ZECS';]UM7%%@N=Q12T4
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MA,;9'2H*UW0.N"*SIK=HSGM5ID-$-%%%,04444 %%%% !1110 4444 %%%%
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M1110 4444 %%%% !1110 4444 %%%% !5BV_BJO5BV_BI/8:+%%%%24%%%%
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M<5BI_95L-/\ L2*$C*[3M&,\8S4>CZ+;Z+:BWMV8J"3\U:5%(9C_ /".VO\
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MTT>5)_=- #**?Y4G]TT>5)_=- #**?Y4G]TT>5)_=- #**?Y4G]TT>5)_=-
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M'L:6B@#FX?"5GI\MS=02S!W5B5!XR11X/AFCTYFD>1AYC8\PG/6NDI H484
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J]QU6K%
M07'5::$RO12T50A**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6
MB@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6
MB@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6
MB@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6B@!**6
MB@!*GM_XJAJ>WZM2>P(GHHHJ2@HHHH **** "H+C[H^M3U#<?=%-"96HHHJA
M!1110 4444 %%%% !535!G2KH#_GF:MTUT61&1AE6&#0!P?@AX_L]Q TBK(R
M@!2>:K^%;N+3O$&HP73"(O.2I<X!KKH/"^E6]]]LBM]L^<[LTW4/"ND:G.)K
MJVWN.^<4[DV9Q7BG4(;SQ1;"$[U!3YAR.HJWJ'_(Z0_[RUU$7A+1H0H2UQM;
M<.>]7)-$L);U;MX<S+C#9HN%F<M\2O\ D$_\!-=)I_\ R+$/_7M_[+4^I:19
MZM%Y5Y%YB8QBK,=O%%:BW1<1!=@'M1?0=M3RW1;&2^T&Z$7+1R2-CUYKJ?!V
MM6HT2&TN)%@FA7YED.VM_3]'LM+5EM(M@8DG\:HWO@_1=0NY+JXM=TKG+$'&
M:+BLT<I"7UOQLMPBDV]MN0MC@U8\,#'C"8>B-7:6&E6FF0F*UB"(>HJ.VT:Q
MM+QKN&';,P(+47"QH5R7Q"_Y%NX_W*ZVJFH:;:ZI;-;W<>^-A@BDAM',6>NV
MFDZ#:K=V[RHRJ,A<@5#XBTWP_?6KWJSJD^S*+"X4YQQP*ZE]'L9+ 63P@P#H
MM9:^!M!60.+3Y@<CYJ=Q694\ M<-HL8FWX"_*7SFM[6_^05-]*N001VT*Q1+
MM1>@HFACN(FBD&5/44NH['(_#C_D"7/_ %\O_,UTFL?\@>Z_ZYFG:=I=II4#
M0V<?EHS%B/<U9FB2>%HI!E'&"*.H6T."\+?\@K4/PJ7P#>VMO::@LUQ'&QN"
M0&8#UKJ[71;&SBDC@AVK)]X>M9C^!M DD9VM/F8Y/S4[BLS7_M73_P#G]@_[
M^"L+QG/%/X:N6BD5U\L\J<U)_P ('X?_ .?0_P#?5:">'-,2P-D(/W!&TKGM
M1H/4SO"5G;2>'[??;Q,3&,DH,USNLZ>WA+6EU2RB!MW(5P5SC)YKT"SLX+&W
M6"W3;&HP!27MA;ZC 8;F/?&>U%PL9,_BFSCT3[<CCE>%SSFN3TM(O$5__:&I
MWD2P@YCC\S''N*ZW_A#M%^S^1]E_=CMFH!X"\/#I9X_X%1H*S-JTGL2BP6TT
M+ #&U&!K(\56$3:/+Y5K&7(/W8QFK>F^&=+TF?SK. H_KFM? /44AV.9\%V$
M2>%;(3VJ"4+SOC&:Z4 *,*  .@%*  , 8HH"P4444#"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "G)]]?K3:<GWU^M %VBBBH*"BBB@ HHHH **** "BBB@ I"0.IJ&6Y
M5.!R:I/.[]^*:0FR^UPB^]0->C^&J5%5RHGF+1O'[8IOVR3VJO13LA798^V2
M^U'VR7VJO119!=EC[9+[4?;)?:J]%%D%V6/MDOM1]LE]JKT460798^V2^U'V
MR7VJO119!=EC[9+[4?;)?:J]%%D%V6/MDOM1]LE]JKT460798^V2^U'VR7VJ
MO119!=EC[9+[4?;)?:J]%%D%V6/MDOM1]LE]JKT460798^V2^U'VR7VJO119
M!=EC[9+[4?;)?:J]%%D%V6/MDOM1]LE]JKT460798^V2^U'VR7VJO119!=EC
M[9+[4?;)?:J]%%D%V6/MDOM1]LE]JKT460798^V2^U'VR7VJO119!=EC[9+[
M4?;)?:J]%%D%V6/MDOM1]LE]JKT460798^V2^U'VR7VJO119!=EC[9+[4?;)
M?:J]%%D%V6/MDOM1]LE]JKT460798^V2^U'VR7VJO119!=EC[9+[4?;)?:J]
M%%D%V6/MDOM1]LE]JKT460798^V2^U'VR7VJO119!=EC[9+[4?;)?:J]%%D%
MV6/MDOM1]LE]JKT460798^V2^U'VR7VJO119!=EC[9+[4?;)?:J]%%D%V6/M
MDOM1]LE]JKT460798^V2^U'VR7VJO119!=EC[9+[4?;)?:J]%%D%V6/MDOM1
M]LE]JKT46079:%X_?%2+>K_$*HT4K(=V:B3H_0XJ7.>E8V2*FCN73OQ2<1J1
MIT5#%<+(/0U-4E!1110 4444 %%%% !4%QU6IZ@N.HIH3(****H04444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]B@":BF&6,)O,B!?4L,4Q;NV8X6XB)] XH FHI,C&<\>M1?;+8G'VB'/IO%
M$U%,6:)\[9$;'7##BF&ZMQUGB'_ Q0!-13/.B";S(FWUW#%,%W;,<+<1$GH
MXH FHI&=57<S +ZDU%]LM<X^TPY]-XH FHI-R[=VX;?7-0_;+4=;F'_OL4 3
MT56O))EM2]J8R_8L>*BTJ6\EL]]]Y7F[C_JFR,4 7J*A:ZMT;:UQ$I'8N!4B
M2)(,HZL/4'- #J*B-S;K]Z>(?5Q0EQ!(<)-&Q]%8&@"6BBD9U09=@H]2<4#%
MHJ#[9:_\_,/_ '\%,N[V&VLWN#(FU1D'(YH$6J*X"P\5:YJ=W<&V%F+:)L9=
MP":TO#'BBXU:YDANS"A1B/E(YQ3L%SK:*8\T40_>2HF?[S 4U+B"0XCFC8^B
ML#2 EHICRQQG#R*I]VQ34N()&VI-&Q]%8&@"6BBHGN8(SAYXU/H7 H&2T5$E
MS!(<1S1L?16!KE]3\4S6>O162&$Q,X!8D<4".MHI%974,K!E/0@YKG_%>N7&
MB6*S6ZJS%U7YO<T =#156PN6N;&.>3 +*"?2I/MEMG'VF'/^^* )J*0$$9!!
M![BHC=VRG#7$0/H7% $U%,CFBE_U<J/_ +K TU[B",X>:-3_ +3 4 2T5&D\
M,GW)4;_=8&N7O/%,MOXG_LY&A,&T'=N'4T =912*P=0RD$'N#06"C+$ >IH&
M+14/VRVSC[3#GTWBI=Z[=VX;?7/% A:*A-W; 9-Q$,],N*?'-%*,QR(_^ZP-
M #Z*8\T47^LD1/\ >8"FI<02'"31L?16!H EHHHH&%%%% !1110 4444 %.3
M[X^M-IR??'UH N4445!04444 %%%% !1110 A.!DU3GN<_*M)<SY.U:J521+
M8$D]:***HD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** %!*G(-7;>YS\K51H!Q0U<$[&S152VN,_(
MWX5;J&K&B84444@"BBB@ J"?J*GJ"?J*:$R&BBBF(**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M90XV/-\I]:2&SH/'S,GA.X*L5.Y>0<5RNMR2_P#"!VI21@YG0 Y^E=)\0;J
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MJV6OZC9W/[N3@*#WI#,#Q=X?&BW,*VC/]G?E@[;CUKU.P_Y!UM_UR7^5</\
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M.3_>_J:Z+X?$_P#"/7@SQA_Y&N=\&_\ (QR?[W]30'8[_P =7_V709H1UE3
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M/ZVW^^?Y5T7@/_D#+]!7._$_K;?[Y_E72>!4*Z*A/=13Z"ZG54445)04444
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M\3S \A3GBM3PM>SZCX>M;JY;?*ZY8URGC/PM9V>EI-I\*P.#AB@ZBNC\$_\
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MI8)+G KJ8/BA:10)&;&4[1C.X5V=QX=TBZG::>QB>1SEF(Y-1?\ "*Z'_P!
MV'\JJZ)LSEX_BC:22*GV"4;CC[PJ7Q)JNM_8(;_3"1"^2R[<[1[UT@\+Z(K
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MQ[_R!(O\]JW;GP_875Y'=2HQEC 52#V%3:EI%KJMNL%TK%!TP<4KCL9F@_\
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MXED-WXDM[(3RVUG)"K H=O7M4WB"ST;1?#'D($GD8$+( &;/O76ZMX<T_6E
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M*** "HIN@J6HYN@H!D%%+15$B44M% "44M% "44M% "44M% "44M% "44M%
M"44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M%
M"44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M%
M"44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M%
M"44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5)%WJ.I(N])C1+1112&%%%% !1110 5'-T%25'-T% ,AHHHJB0HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !3X^],I\?>@"2BBBD,**** "BBB@ J.7H*DIDG2A 0XHQ2
MT50A,48I:* /$_$EQ':^,5FE;:BL<FN[7X@^'DLE47G[Q8\ ;>^*EU;X?Z5K
M%V;BX>8.?[K50_X53H>?]9/_ -]55TR+-')Z/'-XH\;G48D)2-@Y/M2>,)DM
M_%JRR'"*YR:]7T?1+/1+-;:U08'\1'S'\:Q]9\!Z7K=T;BY>4.3GY31?4+:%
M>S^('AV*SA1[W#*H!&VEU3Q%INM:'="QG\PB-B>*J?\ "J=#_P">EQ_WU6GI
M_@73-.MY887E*R*5.3ZT:#U/-O ]]X>L_M']M)&V0-FY<UN>(M6\&SZ--'I\
M<(N3]W:F#6U_PJG0_P#GI<?]]4#X5:&&!\R?@_WJ=U<FSL8'@O2I]1\-W2DL
MMOERH]3S5/PGX@'A?49K74%\M#QD_6O7+&P@TZU6W@0+&!C&.M8^N>#=,UXJ
M;A3&5.<Q\$TKCMV.;\3_ !#L7TYX=)G+RN/O 8(JSX>U/4-2\+W,EXAX! 8G
MGH:GM?ACHEK<+,K3,5/1CD5U9TZW^Q&T5 D97!VC%%UT&D^IX[X&URPT37+N
M6^F\M&R <>YKT/\ X6'X;_Y_?_':SW^%>B/(SF2?+$D_-2?\*IT/_GI<?]]4
M.S$KH[6VN(KRVCN(6W1R#<I]14N*@L;2.PLH;6(DQQ+M7-6*DH3%&*6B@8F*
M,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )
MBC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M%
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M^:*R!(W]X_G3A.X[T<H<QJT5GK>..N*L1W2-P>M*S'=%BBD!!Z&EI#"BBB@
MHHHH **** "F2=J?3'ZT 1XHQ2T4Q"8HQ2T4 )BC%+10 F*,4M% "8HQ2T4
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M<U?A=WB5G38QZCTH ?12T4 )12T4 )12T4 )12UE>(-:CT+2Y;M@&9!D(>]
M&I17$1>-M3-J+J;13';GI)NXKIM$U3^U]/6Z\OR\DC%.S%=&C12T4AB44M%
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M/[2NCG;^[)^7FMKPK NAZ!+J;7<LA(8+&Y^7(J:[_P"1!B^B53:)Y? 2[ Q
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M:*DH2BEHH 2BEHH 2BEHH 2E'WA12CJ* ):***0PHHHH **** "BBD9MJY-
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MK5FLVZ?=*1Z4UN)[$%%%%60%%%% !1110 4444 %%%% !1110 4444 %%%%
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M]X_]T?RIL2)****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%VENOAWQO:V5M(PMYY.0S9J6_F9?B);'>VT0L<9X[46"YZ(\T<*!I9$0'NS
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MSW5O&VV2XB1AV9P*Y"X\6W2>*[?38O*:"0$EAR>*SO#F@)XJ@;5M8:1_/&Y
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M/B&>2!A#+>A!D]Q7,7=A>^#-6M([;46,-P?]2!@8KJ]1\$6M]=?:(;N:TD(
M)B&,T6'@J"TO([FXOI[QHSE1-SBE=#:.+-I9GQ?;#6X%,,T9;+],\8KLKGPK
MX3L[<3SV,"1$9W&M36_#MGK5J(9!Y3C&V11\RUAK\/T\R,RZQ>2QH0?+?H?:
MBX6,/Q/!IBV&G7>CJGV2%BQ*=,5VVG:C;?\ ".PW+2 1^5R?2K4NCV4M@UF(
M$2(C& .E<V?A]%N8#5;H0G_ED/NBBZ86:,GP'.MQKUTZ'*EWP?Q->D5SV@>$
M;7P_,TL$SR$YSN'K714F]1K82BEHI#$HI:* $HI:* $HI:* $HI:* $HI:*
M$H'6EH'6@"2BBBD,**** "BBB@!DO^J;Z5DG@UKN,H1[5E2##D5429#:***H
MD**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M ***HZKJ#:=:^>L#3 =0O84 7J*S](U:'5[)+B+@L,E,\BM"@ HHHH ****
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M]R[AVIK<3V*%%%%60%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %'2BHYO]2_TH 8;VU!8&XB!
M7[WS#BF#4K$G NX2?3>*\NAM9M0\975J)"(7DPX]:Z'Q#X1TZQT5KBTC\NY0
M@A\T["N=T"",CD&BN6\,:Y)-X:-U=ON>-BBC^]CH*@/C.]"%_P"P+K8/XLBB
MP7.PK(\1WUQI^EM+;(7D)V@!<]:9;^*=*EMDDENXH9&&6C8\J?2KFFZ@FIP/
M*L>%#8&>_O0!R&D>%7UB#[;J<UPDCD_*DA7'X57G-UX*UB)(I6DM+IN0[%B
M/K7H;,L:%F(50,D^E>;:_>MXA\2VUG:@O'"Y!<=*8CJO$E^8_"YNE)7?C&/>
ML#P]X3MM4TW[5=7%WYC.?NRL!5KQ?;:A)H<-A:P/(,+G:.XJ+3=&\31Z<##J
M8@ '$93F@#;L/"-CIUPLT4URS YP\I(K,\27NKV\<[O+"MDIY4<.1[5'HWB6
M\M]4_LS5=SS$[5<\9-;&O>'Y-:NK=C,JVZ##QD?>I#.;\.:CJ]S%NL98_L^_
M#++R]>A+G:,]<<US5AX6?3=66YM9U2 )M,>.IKINU#!!1112&%%%% !1110
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MH=+BN'N+J9?ED8X-9_B3_D>M'_Z[_P!#5;QQ9^=XLT^.YEDCA=#\Z'&.:-[
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M8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ)W7C<D9R ?:NLH8(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%%
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M7D;>[XZFK&K6,^H6;00W!AW<,<=10W=B2LCCM'@_MKQC>7P_U,3!HR>]:_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2@$G IR1,YX
M%7H;8)R>30W8:5R.WM_XFJYTHHJ&[EI6"BBBD 4444 %(:6B@!**,48H *JZ
MC%<S64D=HZI,PP&8<5:Q1B@#S/3_  5XHTNZDGM=0M=SL3ETW=3]:W;&P\9I
M>PM=ZE:/;AOG58\$C\ZZ_%&*KF%RG+>)O"KZK+'=V,BPWD8^1VZ5D_\ ")>(
M-1FB36KZ":VCP=L:D'(Z=Z[_ !1BE<+(XWQ/X6U/5;2&UL+F.&&(Y 852LM!
M\::?;);V^I62QH,#]U_]>N_Q1BG<.5&+H5OKL"/_ &Q=0SL3\OEKCBK&N:=)
MJ>FR6T;!68$9-:6*,4KA8QO"^D2Z'H,-A,ZO)'G)7I6S1BC% PHHQ1BD 448
MHQ0 448HQ0 448HQ0 448HQ0 448HQ0 448HQ0 448HQ0 448HQ0 448HQ0
M448HQ0 448HQ0 448HQ0 448HQ0 448HQ0 448HQ0 448HQ0 448HQ0 448H
MQ0 448HQ0 448HQ0 448HQ0 448HQ0 448HQ0 448HQ0 448HQ0 448HQ0 4
M48HQ0 448HQ0 448HQ0 448HQ0 448HQ0 4"C%+0 4444 %%%% !1110 4AI
M:0T )1113 **** "BBB@ HHHH *KWUS]DL9I^,HA8 GK5BL;Q/IL6I:+,LKR
M*(U+#8Q&:!%3POXD?74D,R1QE1D!6KH?.B'61./]H5Y9X&T*!HYKOSIP\8#
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 ZBBBD 4444
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M*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&*** #%&***
M#%&*** #%%%% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% "4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 A&5(]16-8>&K73]5?4(Y',C @@].:VJ*8!1112 **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gzkk5j0cumnd000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkk5j0cumnd000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '/"!L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ J.=BL+$'!J2HKG_4-0!2\^7^^://E_OFHZ
M*HDD\^7^^://E_OFHZ* )//E_OFCSY?[YJ.B@"3SY?[YH\^7^^:CIK_=H &N
MIMW$C4GVJ?\ YZM4?:FT 6/M,W_/1J47,W_/0U"*<* )Q<3?\]#2^?+_ 'S4
M(I<T 2?:)<_?-+Y\O]\U#WIU $GGR_WS1Y\O]\U'10!)Y\O]\T>?+_?-1T4
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M\O\ ?-'GR_WS4=% $GGR_P!\T>?+_?-1T4 2>?+_ 'S1Y\O]\U'10!)Y\O\
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M1144DNPX YH EHJ#S"WM3ADT 2T5'@^M"MC@F@"2BD!!Z&EH **** "BBB@
MHHHH GM/]?\ A5^J%I_K_P *OTF-!1112&%%%% !1110 4444 %%%% !1110
M 4444 4+O_7?A4%3W?\ KOPJ"J$%%%% @HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "HY%[U)1C/6@"OTHS4K1@]*;Y9H 3-.7DT@B]34@  XH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ JO-)SM'XU.S!5)-4<DMF@!XJ5340IP- $P/-/S
M4(-/W4 *::>E!-,)H 5#AZGJH3@U90[E!H =1110 4444 %%%% !1110 5HV
MW^H6LZM&V_U"TF-$M%%%(84444 %%%% !1110 4444 %%%% !5*]^^OTJ[5*
M]^^OTIH&5J***9(4444 %%%% !1110 4UVVCBG5 [;FH ,GUI*6B@ HHI:
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M6.Q\#VOE:7),PYE?<#[8KJ:H:-;?9-'M8,8*)@U?J3TZ4>6"04444&@4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5#+][GI4U13#Y<T 0FE%-IPI@/%/
M!IF>* :0$N:3.#3<T#YC0!+1110 4444 %%%% %^T_U/XU/4%I_J?QJ>I*"B
MBB@ J*Y_U#5+45S_ *AJ ,ZBBBJ)"BBB@ HHHH **** "BBB@ HHHH ****
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M"T_U/XU/4E!1110 5%<_ZAJEJ*Y_U#4 9U%%%42%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!#.^!M'>HTP*27_ %AS35-
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MT*V%KHUL@ZE Q^I%)FN%7-5<NQHT444CT@HHHH **** "BBB@ HHHH ****
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!/:?Z_\*OU0M/\
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M@ HHHH *T;;_ %"UG5HVW^H6DQHEHHHI#"BBB@ HHHH **** "BBB@ HHHH
M*I7OWU^E7:I7OWU^E- RM1113)"BBB@ HHHH **** #J*B*$&I:* (#D4VK)
M&>M1F,=J (J!3C&PI,$=10 N*;3LT;2>U #:4<T\1>IJ0*!TH :J8ZT^BB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6C;?ZA:SJT;;_4+28T2T444AA114 GQ*4;\#0!/1110 4444 %%%%
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ME7FFL_=:O2]%_P"01;?[@_E29K@_XDB_1112/1"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** +]
MI_J?QJ>H+3_4_C4]24%%%% !45S_ *AJEJ*Y_P!0U &=1115$A1110 4444
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M5!_QZ_A7*V'W%KJH/^/7\*;,:)R6M]7KL/ __(N+_P!=&_I7'ZWU>NP\#_\
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M%)2B@!U&*!2T )3@:,4E #J*!10 4444 %%%% !1110 4444 %%%% !1110
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M[U=[%'*10MM(!ZFENSKC-4*"9OZEXTLK1MEL//;U7I4&G^.;>XN5AN8C%N.
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MYESR<(O]T>E)'76ERTE3>YIZ9_K!5K6?^/>I+"T$2!FZU2UJY784!IF.T-3
MTS_D:]-_Z[BO2-<_Y ]Q_NG^5>;:,&E\5Z>5&=LP)]A7I6MJSZ1<!02=A/'T
MI,UPG\*1Y[8?=6NLA_X]?PKCK&3  /:NML95EA"YIF%%G+:V/OUVWA#_ )%^
M'ZUSFM:>2C,HZU!X6\0-I5S]@NV_T=V^5C_":&71DJ=7WNI-XTOY9=3CLPQ6
M)1\P]31IFG0O!G@DBKGC/1I)634[<;@B_.!Z>M9&CZAY;!2>*$35359\PFHZ
M88B<+Q2>']:DT2_$4Q)M9#@_[/O7421QW<'8Y%<MJ>G[&(*\4$M.G+GB>F12
MI-&LD;!E89!%/K@/"_B$V4RZ?>/B)CB-V/0^E=^#D9%2>G1JJI&Z"BBB@U"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***LV]ON^9AQV% !;V^X[F''I5WI1TH
MJ2@JE>_?7Z5=JE>_?7Z4T#*U%%%,D**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\W\1?\C+)_
MN#^M>D5YOXB_Y&63_<']::.3&? O4TM'[TNL=*-'Z4FL=*?4Y/L&1X>_Y&JW
M^O\ 0UU/C7_D"K_UT%<MX>_Y&JW^O]#74^-?^0*O_704NIK1_P!WD<MIW5*Z
MB3_CT_"N7T[JE=1)_P >GX4V94MCBM8^XU>EZ+_R"+;_ '!_*O--8^XU>EZ+
M_P @BV_W!_*DS7!_Q)%^BBBD>B%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7[3_4_C4]06G^I
M_&IZDH**** "HKG_ %#5+45S_J&H S'&5J"K-0$?-5$C:*<:;0 [-&:;10 Z
MES3<TN: %S129IR#)S0!(HP*6BB@ HHHH **** "BBB@ JI>7]G; QW$RKN!
MR">U6Z\SN1]LU6Y%UNWAB%#'MVKHP]%56[O8Y,7B7AXII7N9]P;=]2NC;_ZK
MS#MY[4B2-;RB0$D=Q5>ZMFL+G(^X:>)/.&R-2S-P *^;QV$E1J.G/9[>A]GE
MV,I8W#*I'T?DSK[34$>V# CI4,]R7Y)P*9I_AG4(]+64\2DD^4>N.U6K;P[>
MW,G^E?N8QU]37B2RK$N?*HZ'/+$T(-ZWL4(DGOI?)MD+$]3V'XUT-OIMCHEO
M]HN2))^Y/7\!3Y;NST:W-O9H&EQC/OZGUK"EEFNWW2L78]NPKMYL/EBLO>J?
MD<W+5Q;N](F?K6N7FISM;Q@Q6X., \M3-.T<N02O%:L.F*91(XXK2:2&UCXP
M*]W+\:L52YNJW/GL=@W1K/F=UT$@MHK2/H.*HWVIA 50U2OM5+9 .!67!!>:
MM<>3:QEO5NPKO.*4_LQ$N;R2>39&&=ST &370Z%X29RMUJ7?E8L_SK:T7PW;
M:7&'<"2X/)<]OI6Y2;.JCA?M5!L<:1($C4*HZ "G444CM"BBB@ J*Y@2YMY(
M7 *L".:EHH#<\FEMY-*U66T?.$;"GU%=/I5SO3833O&VF;XH]1B7YH^'Q_=K
M"TR[VLIS5'DRC[*HXFEKEEO0N!2>#=1^S7;Z=*WRR'*9]?2M9U%S:^N17&WR
M2V%ZMQ%P\;;E- .7LYJ:-+Q+8'3-9$J+B&;D8[&M/2+H21!":T+V.+Q%X:66
M/[X7<#WR.U<EIERT$^QN&!P10BJBY*EULS8UFTW*7 K"T:_;1]=CD)/E2'8P
M^O&:[!PMS;>N17&ZM:%7;L1TH,ZEXR4T>K*P=0RG*D9!I:YSP?JOV_2Q!(W[
MZ'Y2/;M71U)ZU.:G%204444%!1110 4444 %%%% !1110 4444 %%%% !111
M0 44F1ZTC.%]Z '45&)03TQ4E !1110 4444 %%%% !14D,8DDVGTJQ]C7UI
M#*=%7/L:^M'V-?6BX6*=%3SP")00:@IB"BBB@ J2*(R-@=*(HFD; Z>M:"((
MUP*0P1!&N!3J**0PHHHH **** *%W_KOPJ"I[O\ UWX5!5""BBB@04C,%I:A
M<Y:@!QDXX%,W$]3110 44M**  #!IP8T8HQ0 X'-+3*<#F@!:*** "BBB@ H
MHHH **** "BBB@ HHI&8*I9C@#J: &33);PM+(P5%&237G6LZM)KEZ1'D6R'
M"#^][U;\2ZXVHW'V.U8^0A^9A_$:9I.F#"LR\"FD>=B*KJ/DCL6-*TX*H=A5
MZ]NTMXBH/-27,Z6L/&!Q7(ZCJ#.Q.>O2F92DH*R(;^[>67:N6=C@ 5U_AS18
MM&L6U&^(\XC=S_"/2J?A/0#_ ,A2_4 8S&K=O>JGB+6VU2Y^QVQ(MT.&(_B-
M(JG%4X^UGOT15U?59M<O^,BW0X1?7WK6TK3PBAV%5=)TP<,PX%;-S.EK"0.P
MIDQ3;YYD=_>+;Q%5/-<=>W4D\VQ,L['  J?4=0+L>22>@KHO"7APJ1J5ZOSM
MS&A[>]&PDI5I\L2_X6\.C3(/M-P ;J0<_P"S[5TC ,I4C((P12T5)ZD(*$>5
M' ^)-#;3KC[9; ^2Y^91_":K:?>%"I!XKT.:%+B%HI%#*PP0:\\U?2Y=&O"5
M!-NY^4^GM33.'$4>1\\=CH5*7<&#@Y%<IK>E%&+J/<$5HZ??%6'/%;,T4=Y;
M]CD4S)I5(F=X1\0B5/[*OR"P&(RW<>E4?$6C-I%W]IMU)MI#GC^$UE:IITEK
M/YD9*LIRK#M77^'M:AU_3FL+[:9U&"#W'K2*@_:Q]E/=;,S-)U,8",>*UKNV
M2ZBR!VKF=4TV;0[_ &<F!CE&_I6SI6H"1 C&F3%M/DD<]J-@R-P,$'(-=1X2
M\0&91I]VW[U!A&)^\/2EU"R6>,LHYKDKNWDMIA+&2LB'((HW%&4J,^9'K=%<
M_P"&?$":M:B*4A;J,88?WO>N@J3U834X\R"BBB@H**** "BBB@ HHIDDL<*[
MI'"CU)H&E<?16==:[IMD%,]TJ[NF.:NP31W,"31-NC<94^HJ5*+=DRG3G%7:
MT)****H@**** "BBB@ HHHH **** "BBB@ HHHH ***LQ6PDC#9ZT 5J*N?8
MU]:/L:^M*X[%.BKGV-?6JTB;'*TP&4444""BBK-O;[CN8<=A0 6]ON^9NG85
M=Z4=**DH**** "J5[]]?I5VJ5[]]?I30,K4444R0HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKS?Q%_R,LG^X/ZUZ17F_B+_D99/]P?UIHY,9\"]33T?I2:QTI='Z4FL=*?4Y
M?L&1X>_Y&JW^O]#74^-?^0*O_705RWA[_D:K?Z_T-=3XU_Y J_\ 704NII1_
MW>1RVG=4KJ)/^/3\*Y?3NJ5U$G_'I^%-F5+8XK6/N-7I>B_\@BV_W!_*O--8
M^XU>EZ+_ ,@BV_W!_*DS7!_Q)%^BBBD>B%%%% !1110 4444 %%%% !1110
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MG((KTYTZ>(@FUZ>1X=*O6P55QOIU\T>FUD>(+Z2SLT6,X:5MN[TH\/:RFK6
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M+D#YH_\ "N=.CQBU(88.*YBZ,FGW0EMY"KH<@@T['+&O4I.\G='LE>;^(O\
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M-C$'+NN7.<G-?08-UG9?91PYC2PM*+Y?C?F;%%%%>D>*%%%% !1110 4444
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MO5Y5H^J3Z#J 89-NYQ(E>GVUS%=VZ30L&1AD5+._#UO:QUW1-1110= 4444
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M12V3!/WF)R358BK34'!?\ 6$PU9U?;5']^[+]%%%>:>P%%%% !1110 4444
M%%%% ",,J152KE5Y5P_UH CI11BDI@/!I<TS-&:0#\TN:9FES0 [-&:;FG(-
MS4 2H,#-.HHH **** )[3_7_ (5?JA:?Z_\ "K])C04444AA1110 4444 %%
M%% !1110 4444 %%%% %"[_UWX5!4]W_ *[\*@JA!1110(1ONFH14],,8)H
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MHXM*LX;[[9%"J38P2HQ5VBBO422V/522V"BBBF,**** "BBB@ HHHH ****
M"BBB@ HHHH **** ,?Q!HHUBT 5@LT?*$UQ3Z'JL;[&M&)]01S7IM%<U7#0J
M/F>YS5L+"J^9Z,Y/P[X;EMK@7EZ,2 85/2NLHHK6G3C3CRQ-:5*-./+$****
MT- HHHH **** "BBB@ HHHH *YKQ)JU[;3+:66%8C+L1GCVKI:R-;TN2]59;
M?:)@,'/<5M0<5-<^QSXI5'2?L]SC#;-(_FWDS2-U^8]*:;Q%<0VT9D<\ **V
M+3PK>7;[[^;RX^R)U_'-=-8Z18Z<N+:W1#W8#DUW5,53AHM3RJ.7U*CYJFGY
MG+V7AF]OB)+U_)B//ECK^==38Z39Z>H$$(##^(]?SJ[17#4KSJ;['JT<+3HK
MW4%%%%8G0%%%% !1110 4444 %%%% !1110 5'*I/(J2B@"L<XZ4RKF*C:$'
MIQ0!7I0*>86I,%>HH ;THS3Q&S4]81W- $:J6/%3JH4<4H  XI: "BBB@ HH
MHH GM/\ 7_A5^J%I_K_PJ_28T%%%%(84444 %%%% !1110 4444 %%%% !11
M10!0N_\ 7?A4%3W?^N_"H*H04444""BBB@ I" >HI:* &&,4GEGUJ2B@!H0#
MM3J** "BBB@ HHHH **** "BBB@ HHHH *",C!HHH Y37_"WGN;W3<1W"\L@
MZ/\ _7KG8;@3@V]RFR5>"&KTVL/7?#L.JQ^9%B*Z7[L@[^U=M#%6]V>W<\[%
MX%5/>I[_ )G*V=_=:'.&C8O;$_,E=_9W27MG%<QC"2KN%>>_V-KDW^BO;,!N
MP9,<8]:[_3K3[!IT%KNW>4@7/K3QGLVDUN3ET:T;QGL6J***X3TPHHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH ***R]0U^RTYBDC[Y!U1>HJ9245>3)E*,5>3-2BL.R\5
M:?>2B/<T3-P!)QFMRB,XS5XL(3C-7B[A1115%!1110 4444 %%%% !6C;?ZA
M:SJT;;_4+28T2T444AA1110 4444 %%%% !1110 4444 %4KW[Z_2KM4KW[Z
M_2F@96IDAPOUI]0ORU,D93A3:<* %IXIHIPH =BDI:0T .HI!TI: "BBB@ H
MHHH **** "BBB@ HHHH **** "N4UY&&I!FSM8?*:ZNJU[917L)20<]CZ5Q9
MAAGB:#IQ>IT8:JJ5129S]M&D<>[BJ]W<[CM4TV[BN--8QR@^6?NOV-9_FM+(
M(XE+R,< #J:^(J4:L)^R<=3W(2@U[2^@[RY+J=;>$9=CU]*Z-OL_AW3 J -<
M/^9/^%):6L6AV+75Q@SL/R]JPIII;ZZ:>4DD]!Z"O:CRY90N]:DOP.)\V,J6
M^RBA+%/>WS33'<[G/TKH+*T6WBR>M-M;8 ;F%1ZC>&*(JO6NS+<W51*G7=GW
M/,QN6J$G4HZKL5=7U((I16KFK>VN-:OUM;?/)^9NRBFSM/?W:VT(+2N< "O2
M/#F@Q:)9!?O3OR[>]?07/%ITY5YZ[(MZ3I<&DV*6\"XP/F/<FK]%%2>JDHJR
M"BBB@85B:MI$)L[I[:R66YF[\9!QUK;HJ914E9DS@IJS//+3PIJ-Q.BW$?DQ
M@@L2<YKOX(5MX$A3[J# J2BLZ5"-+X3.C0A2^$*:Z+(C(X!5A@@TZBMC8\V\
M1Z))H][]I@4_99#GC^$T:;?[&'/%>AW5K%>6SP3*&1Q@@UYCJNFS:%J!C;)@
M8YC8^E-,\S$472ESQV.O^2[@['(KE]3TMEFR@QSP?2KVEWK #G(-;,B+<1Y[
MUY>89G##)QCK+^MSNPF >)M.>D1NA:D;B#^S[_#<85CW%9]_ISZ7<D=87.58
M?RJ*>%HGRI*LIR".U;MA=Q:S9M9W0'G*.,]_0UY-*M',J3HU=)K9GMRIO"24
MZ?PF;:7.T[2>*M7$:RQ[JRKJ&33KDPR@@9^5CW%.^V,RB),LQX '>O#G2J4Y
MNE):G<G&:52+(G7$\8')WC'YUWR;MB[OO8YK"TK1"CK<W7+]0GI6_7UN3X.I
MAZ3=3=]#R,;7C5G[O0****]@X@HHHH **** ,+Q+K!TVU$<)_?R_=]AWKSVY
MWW),DSL[GG)-=%XP+'5HPW0*=M8%>/BJCE4:Z(\;%S<JC3V1K> K> :A<32D
M*Z<+DX%=^EY;R7!@256D R5!KR5HL$LC%3[5J>#&E;Q:"SLP,+Y)_"M,-B.6
MU-(O"XCDY:26[/3:***]0]8**** "BBB@ HHHH **** "BBB@"_:?ZG\:GJ"
MT_U/XU/4E!1110 5%<_ZAJEJ*Y_U#4 9U%%%42%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%5-0O196QDQECPH]ZYHZMJ"R>9O'TQQ7G
MXO,J&%DH3W.FCA:E5<T3L**Q++Q#%+A+E3&W][L:V5D1UW*P*GOFNFCB:5>/
M-3=S*I2G3=I(=13$ECD^XZMCT-/K9-/8@****8@HHHH **** "BBJUW>Q6:9
M?DGL*B<XPCS2=D5&+D[(LT5BS:^@B)BB;=[U(FOVQ12^Y6QR,=*YEC\,W;G1
MJ\-52ORFM144%Q'<Q"6)MRGO4M=:::NC%JVC"BBBF(**** "BBB@ HHHH **
M** "BBH'NX(Y5C>50[=!FDVEN-)O8GHJO<WD%JFZ5P/:N>OM<GN"4MAY:>O>
MN3%8ZCAE[[U[=3:CAZE5^ZCJ:*XJ.;4(CYJSR-CLQ)%=5IUZM[:+)_'CYAZ&
MLL%F5+%MQBK,JOA9T5=ZHMT445Z)S!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% $]I_K_PJ_5"T_U_X5?I,:"BBBD,**** "BBB@ HHHH
M**** "BBB@ HHHH H7?^N_"H*GN_]=^%050@HHHH$%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 45#<W"VUNTK= *Y:;5[^1S(K!5[#%<.+S"CA
M;*INSHH8:=;6)U]%<_9>(APEVF#_ 'QTK<BGBG0/&X8'TK7#XNCB%>G*Y%2C
M.F[21)13!+&SE ZEAU&:?70FGL9A1113$%%%% !1110 444A('4XH 6BH9;N
M"''F2 9JO+JMM'LPVX,<<=JRG7IP^*21I&G.6R+U%0+>6['B5?SJ<'(R*N,H
MRV9#BUN%%%%4(**** "BBB@ HHHH **** "BBH9KJ&WQYL@7)P,TFTE=C2;V
M)J*BDN88HO,>0!<9SFL&_P!?=\QV@P.[FN;$XRCAXWJ,UI4*E5VBCHZ*XA9;
M]FWK<29ZXW'%=)H^HF\A*2\3)]X5S8/-*6*GR)69K7PDZ2YGJ:=%%%>F<@44
M44 %%%% !1110!6U"=K;3YID4LR+D #)->72-.\SO<12HY.?G4C/YUZT1D8-
M<)XPN9VODC-LRQ(,!\9W5Q8V%X\U]CAQT+QYK['-R\)N!P1R#7HWA>\>\T.!
MI#EE&TD]Z\YBM[O4IA;VL#LS'DD8 %>H:/IXTO3(;4$%D4!B.YK' QES-]#'
M 1ESM]"_1117IGJ!1110 4444 %%%% !6C;?ZA:SJT;;_4+28T2T444AA111
M0 4444 %%%% !1110 4444 %4KW[Z_2KM4KW[Z_2F@96J*3AJEID@R,TR2&G
M"FTM #Z7-,S2YH ?FC--S0.3B@!ZTZBB@ HHHH **** "BBB@ HHHH ****
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M\OW1_=%;MOH]A:OOBMHPW9MHS5ZE0PGLY<TG=DT,'[.7/)W84445VG<%%%%
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M>(8Y"$N%V-ZBMM'610R,&4]P:AIHU4E+8=1112&%%%% !1110 4444 %%%%
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MN'8WC674ZRBL:#Q%;2<2 H?4]*TX;N"X_P!5*K?0U+31JI)[$U%%%(84444
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M[P$$9!R*6N-MM5N;5N'W+W#<UT5AJT%X N=DG]TU+BT:QJ*1H4445)84444
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M!1%N^7;TQ3!TJ*I :T2LK&#=W<D%/!J,&G T#) :=FHP:7-(!^:0FFYI,T#
MTTTN:::8AIIAIYJ,T"&T444Q!4R# J)>M3"D-#Q4@%1BI5I#'8I"*<*0T#(B
M*8:D:HS3$1M1#,8;B,ARF3RP[4K5!(NY2*BK!S@XQ=F^I5.2C)2:N=5;ZE)
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MKHVKKIER\TD;2;O0XJMJEZNH7S7"H4##H35.BG97N+F=K!2@TE%,DD!IP-1
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M(;@9SCFL6YCN&OFE,1"XP.:VJ*QKT56CRMV,JE-35C)BM)9W!D&U!U'K6J
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M_D?_ 'P:/^$*G_Y_(_\ O@T<\0]E/L<O3P:Z7_A"I_\ G\C_ .^#1_PA<_\
MS^1_]\&CGB'LY]CG0U+FNB_X0RX_Y_(_^^32_P#"&W'_ #^1_P#?)I<T0]G/
ML<YFFEJZ7_A#;C_G\C_[Y-)_PAEQ_P _D?\ WP:.:(>SGV.8)IM=1_PA<_\
MS^1_]\&C_A"I_P#G\C_[X-/GB'LY]CEZ*ZC_ (0J?_G\C_[X-'_"%3_\_D?_
M 'P:.>(>RGV.7HKJ/^$*G_Y_(_\ O@T?\(5/_P _D?\ WP:.>(>RGV.7HKJ/
M^$*G_P"?R/\ [X-'_"%3_P#/Y'_WP:.>(>RGV.7HKJ/^$*G_ .?R/_O@T?\
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M]CEZ*ZC_ (0J?_G\C_[X-'_"%3_\_D?_ 'P:.>(>RGV.7HKJ/^$*G_Y_(_\
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M 'R:7_A#Y_\ G[C_ .^31SQ'[.78YO--)KI?^$.G_P"?N/\ [Y-)_P (;/\
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M_/Y'_P!\&C_A"I_^?R/_ +X-'/$/93['+T5U'_"%3_\ /Y'_ -\&C_A"I_\
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M0]G/L<V#3P:Z+_A"[C_G\C_[X-+_ ,(;/_S^1_\ ?)I<\0]G/L<[FES71?\
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MPO90IQ5/_A"I_P#G\C_[X-:+EZF,G-[(YEW:1R['+'J:;74?\(5/_P _D?\
MWP:/^$*G_P"?R/\ [X-:<\3'V<^QR]%=1_PA4_\ S^1_]\&C_A"I_P#G\C_[
MX-'/$/93['+T\&NE_P"$*G_Y_(_^^#1_PA<__/Y'_P!\&CGB'LY]CG U.S71
M?\(9<?\ /Y'_ -\&E_X0VX_Y_(_^^32YHA[.?8YS--+5TO\ PAMQ_P _D?\
MWR:3_A#+C_G\C_[X-'-$/9S[',$TVNH_X0N?_G\C_P"^#1_PA4__ #^1_P#?
M!I\\0]G/L<O174?\(5/_ ,_D?_?!H_X0J?\ Y_(_^^#1SQ#V4^QR]%=1_P (
M5/\ \_D?_?!H_P"$*G_Y_(_^^#1SQ#V4^QR]%=1_PA4__/Y'_P!\&C_A"I_^
M?R/_ +X-'/$/93['+T5U'_"%3_\ /Y'_ -\&C_A"I_\ G\C_ .^#1SQ#V4^Q
MR]%=1_PA4_\ S^1_]\&C_A"I_P#G\C_[X-'/$/93['+T5U'_  A4_P#S^1_]
M\&C_ (0J?_G\C_[X-'/$/93['+T5U'_"%3_\_D?_ 'P:/^$*G_Y_(_\ O@T<
M\0]E/L<O174?\(5/_P _D?\ WP:/^$*G_P"?R/\ [X-'/$/93['+T5U'_"%3
M_P#/Y'_WP:/^$*G_ .?R/_O@T<\0]E/L<O174?\ "%3_ //Y'_WP:/\ A"I_
M^?R/_O@T<\0]E/L<O174?\(5/_S^1_\ ?!H_X0J?_G\C_P"^#1SQ#V4^QR]%
M=1_PA4__ #^1_P#?!H_X0J?_ )_(_P#O@T<\0]E/L<O174?\(5/_ ,_D?_?!
MH_X0J?\ Y_(_^^#1SQ#V4^QR]%=1_P (5/\ \_D?_?!H_P"$*G_Y_(_^^#1S
MQ#V4^QR]%=1_PA4__/Y'_P!\&C_A"I_^?R/_ +X-'/$/93['+T5U'_"%3_\
M/Y'_ -\&C_A"I_\ G\C_ .^#1SQ#V4^QR]%=1_PA4_\ S^1_]\&C_A"I_P#G
M\C_[X-'/$/93[',9I<UTW_"%3_\ /Y'_ -\&C_A"Y_\ G\C_ .^#1SQ#V<^Q
MS6:,UTO_  A<_P#S^1_]\&E_X0N?_G\C_P"^#1SQ#V<^QS&:3-=/_P (7/\
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M 'P:/^$*G_Y_(_\ O@T<\0]E/L<O174?\(5/_P _D?\ WP:/^$*G_P"?R/\
M[X-'/$/93[#-"U-3%]FF?#+]TGTK?ZUB#P9< Y%[&"/]DUKV&DWELNR:Z25!
MT^4YK.5MT;0YDK-&G:?ZG\:GJ.&,Q1[2<\U)69L%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gzkk5j0cumnd000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkk5j0cumnd000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /<",H# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^DHJBUVX
M8@ '!H;L)NQ>HJA]L?\ NBC[8_\ =6IYA<Z+]%4/MC_W5H^V/_=6CF#G1?HJ
MA]L?^ZM'VQ_[JT<P<Z+]%4/MC_W5H^V/_=%','.B_14<+EXPS<9I9'V1L_\
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M %J/^%IZ;_SYS?\ ?7_UJ+,+G>T5P7_"T]-_Y\YO^^O_ *U'_"T]-_Y\YO\
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M4+G>T5P7_"T]-_Y\YO\ OK_ZU'_"T]-_Y\YO^^O_ *U%F%SO:*X+_A:>F_\
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M3TW_ )\YO^^O_K4687.]HK@O^%IZ;_SYS?\ ?7_UJ/\ A:>F_P#/G-_WU_\
M6HLPN=[17!?\+3TW_GSF_P"^O_K4?\+3TW_GSF_[Z_\ K4687.]HK@O^%IZ;
M_P ^<W_?7_UJ/^%IZ;_SYS?]]?\ UJ+,+G>T5P7_  M/3?\ GSF_[Z_^M1_P
MM/3?^?.;_OK_ .M19A<[VBN"_P"%IZ;_ ,^<W_?7_P!:C_A:>F_\^<W_ 'U_
M]:BS"YWM%<%_PM/3?^?.;_OK_P"M1_PM/3?^?.;_ +Z_^M19A<[VBN"_X6GI
MO_/G-_WU_P#6H_X6GIO_ #YS?]]?_6HLPN=[17!?\+3TW_GSF_[Z_P#K4?\
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M\*.N#ZT47 **/;OZ4'C.>U%P"BC^E YZ<T7 **.^#P?2BBX!1111< HHHHN
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M(DN=/MM/NEO ,))YGR _3/H#7&#V& :Z?Q__ ,C;<?[HKF*I""BBB@04444
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MH6\ZQ4",!BHYW<\?04S3/#NFV.A?VSK[R^5*,16\;X8CZUW>G7=GJV@W6J0
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M_'M+_N'^51VO^H6I)_\ CVE_W#_*M(FZV/G.[_X_)_\ KHW\ZAJ:[_X_)_\
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M@"BBB@04444P.N\!_P#'UJ/_ %[&N1KKO ?_ !]ZC_U[&N1J0"BBBF 4444
M%%%% "@E6#*2"#D$=JN/J^I27*7+W]RT\8PDAE.Y1[&J5% R2>>6ZF::>1Y9
M6.6=SDG\:LKK&IHL2K?W(6+_ %8$I^3Z>E4J* ))9YIIVGEE=YG.6=CEB?K4
MMWJ%Y?LK7=U-.R#"F5RV![9JM10!H_V]J_E^7_:=WLQMV^<V,>G6JUI?WE@[
MO9W4T#. &,3E20.F<57HH T_^$CUO&/[6O?^_P"W^-44N9XK@7$<KK,&W"0-
MAL^N?6HJ*8$MQ<SW<QFN9I)I#U>1B2?QJ*BBD(**** "BBB@ JUIO_(3MO\
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M_P! V+]?\: /&J*]E_X1/0O^@;%^O^-'_")Z%_T#8OU_QH \:JUIO_(2MO\
MKH/YUZW_ ,(GH7_0-B_7_&I+?PMHB7$;KIT2L&!!&>/UH&>>>/N/%=QU/R+P
M!7,X]Z]VU+P[I%]>&:ZL8Y)6'+-GI^=4_P#A$M _Z!D/Z_XU*8V>*_C1^->U
M?\(EH'_0,A_7_&C_ (1+0/\ H&0_K_C3N2>*_C1^->U?\(EH'_0,A_7_ !H_
MX1+0/^@9#^O^-%P/%?QH_&O:O^$2T#_H&0_K_C1_PB6@?] R']?\:+@>*_C1
M^->U?\(EH'_0,A_7_&C_ (1+0/\ H&0_K_C1<#Q7\:/QKVK_ (1+0/\ H&0_
MK_C1_P (EH'_ $#(?U_QHN!XK^-'XU[5_P (EH'_ $#(?U_QH_X1+0/^@9#^
MO^-%P/%?QH_&O:O^$2T#_H&0_K_C1_PB6@?] R']?\:+@>*_C1^->U?\(EH'
M_0,A_7_&C_A$M _Z!D/Z_P"-%P/%?QH_&O:O^$2T#_H&0_K_ (T?\(EH'_0,
MA_7_ !HN!XK^-'XU[5_PB6@?] R']?\ &C_A$M _Z!D/Z_XT7 \5_&C\:]J_
MX1+0/^@9#^O^-'_"):!_T#(?U_QHN!XK77^ O^/[4?\ KSD_I7=_\(EH.#_Q
M+8?U_P :OZ9X?TFRDE:VL8XV=-C%<\@]12;&>#<T?E^=>[GP5X=)S_94'UYY
M_6E_X0OP[_T"8/S/^-',.QX/^7YT?E^=>\?\(7X=_P"@3!^9_P :/^$+\._]
M F#\S_C1S#L>#_E^='Y?G7O'_"%^'?\ H$P?F?\ &C_A"_#O_0)@_,_XT<P6
M/!_R_.C\OSKWC_A"_#O_ $"8/S/^-'_"%^'?^@3!^9_QHY@L>#_E^='Y?G7O
M'_"%^'?^@3!^9_QH_P"$+\._] F#\S_C1S!8\'_+\Z/R_.O>/^$+\._] F#\
MS_C1_P (7X=_Z!,'YG_&CF"QX/\ E^='Y?G7O'_"%^'?^@3!^9_QH_X0OP[_
M - F#\S_ (T<P6/!_P OSH_+\Z]X_P"$+\._] F#\S_C1_PA?AW_ *!,'YG_
M !HY@L>#_E^='Y?G7O'_  A?AW_H$P?F?\:/^$+\._\ 0)@_,_XT<P6/!_R_
M.C\OSKWC_A"_#O\ T"8/S/\ C1_PA?AW_H$P?F?\:.8+'@_Y?G1^7YU[Q_PA
M?AW_ *!,'YG_ !H_X0OP[_T"8/S/^-',%CP?\OSH_+\Z]X_X0OP[_P! F#\S
M_C1_PA?AW_H$P?F?\:.8+'@_Y?G1^7YU[Q_PA?AW_H$P?F?\:/\ A"_#O_0)
M@_,_XT<P6/!_R_.C\OSKWC_A"_#O_0)@_,_XT?\ "%^'?^@3!^9_QHY@L>#_
M )?G1^7YU[Q_PA?AW_H$P?F?\:/^$+\._P#0)@_,_P"-',%CP?\ +\Z/R_.O
M>/\ A"_#O_0)@_,_XT?\(7X=_P"@3!^9_P :.8+'@_Y?G1^7YU[Q_P (7X=_
MZ!,'YG_&C_A"_#O_ $"8/S/^-',%CP?\OSH_+\Z]X_X0OP[_ - F#\S_ (T?
M\(7X=_Z!,'YG_&CF"QX/^7YT?E^=>\?\(7X=_P"@3!^9_P :/^$+\._] F#\
MS_C1S!8\'_+\Z/R_.O>/^$+\._\ 0)@_,_XT?\(7X=_Z!,'YG_&CF"QX/^7Y
MT?E^=>\?\(7X=_Z!,'YG_&C_ (0OP[_T"8/S/^-',%CP?\OSH_+\Z]X_X0OP
M[_T"8/S/^-'_  A?AW_H$P?F?\:.8+'@_P"7YT?E^=>\?\(7X=_Z!,'YG_&C
M_A"_#O\ T"8/S/\ C1S!8\'_ "_.C\OSKWC_ (0OP[_T"8/S/^-'_"%^'?\
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M_H$P?F?\:/\ A"_#O_0)@_,_XT<P6/!_R_.C\OSKWC_A"_#O_0)@_,_XT?\
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MT+_H&Q?K_C1_PB>A?] V+]?\: /&J*]E_P"$3T+_ *!L7Z_XT?\ ")Z%_P!
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MH **** "BBB@ HHHH *JWO\ JA]:M55O?]4/K30F4!2T@I:T,PHHHH ****
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M6)A]?K=T>B_\+&LO^?*X_,4?\+&LO^?*X_,5YU11]8F'U^MW1Z+_ ,+&LO\
MGRN/S%'_  L:R_Y\KC\Q7G5%'UB8?7ZW='HO_"QK+_GRN/S%'_"QK+_GRN/S
M%>=44?6)A]?K=T>B_P#"QK+_ )\KC\Q1_P +&LO^?*X_,5YU11]8F'U^MW1Z
M+_PL:R_Y\KC\Q1_PL:R_Y\KC\Q7G5%'UB8?7ZW='HO\ PL:R_P"?*X_,4?\
M"QK+_GRN/S%>=44?6)A]?K=T>B_\+&LO^?*X_,4?\+&LO^?*X_,5YU11]8F'
MU^MW1Z+_ ,+&LO\ GRN/S%'_  L:R_Y\KC\Q7G5%'UB8?7ZW='HO_"QK+_GR
MN/S%'_"QK+_GRN/S%>=44?6)A]?K=T>B_P#"QK+_ )\KC\Q1_P +&LO^?*X_
M,5YU11]8F'U^MW1Z+_PL:R_Y\KC\Q1_PL:R_Y\KC\Q7G5%'UB8?7ZW='HO\
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M_4/3+7_4+3[C_4/6D3=?"9@Z4M(.E+^-:D!11^-'XT %%'XT?C0 44?C1^-
M!11^-'XT %%'XT?C0 44?C1^- !11^-'XT %%'XT?C0 44?C1^- !11^-'XT
M %%'XT?C0 4444 6;/J_^[_C54=*M6?5_P#=_P :JCI4K<8M%'XT?C5""BC\
M:/QH **/QH_&@ HH_&C\: "BC\:/QH **/QH_&@ HH_&C\: "BC\:/QH **/
MQH_&@ HH_&C\: "BC\:/QH *=%_K5^M-_&GQ?ZU?K0,GN?\ 7_A452W/^O\
MPJ*H*84444R0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@HHHH **** "BBBF!?M?]0M/N/\ 4/3+7_4+3[C_ %#UI$W7PF9VI:3M1U.
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M]*K44TW<<9.+NCU[0/$%OK5J&4A9E^\AZUMYKP^QO[C3[I;BW?:Z_D?:O5M
MU^WUFU4AMLZCYT/6N^C64E9[GM8;%*HN5[FU0**!70=HM%%% !1110 4444
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MS=W#=G)1_P![_O>OXU2^*.T7>G[^5P21C.>>1BJD^M^")+!HX=%E^TE<+^Z
MY]<[JKE0WB:O<[FRL-*U*S^T6=P\BDY2196S'[#G@>U6CX?LMX/EMLV\Q[CM
M)_O8[&N2^'EK>Z?HM]=M;2LC,6B@(P6XXIUYK?C&UM)K^6"QM[>+_EC*<R$>
MM'*A?6JO<ZE= L]B_-*[*?G?><N/0D\D4?V!9?, '4]4*N<Q_P"[Z?A6 _BG
M4;WP2=7L8T2ZA.)4==PP.I[=N:M_\)4/^$&_MOY1-M "XXW^F*7(/ZU5[FF^
MBZ?$!+)\B ?.))#L<CNX)P?K4%CIVE:C9BXM)9G7=Q*)&#8_NYSROM7(:Y?:
M_J?@-;VX:W6&4YDPI!QG Q5[P5+K%OX7:98(I[9%_P!&BC&')]\T^5!]9J]S
MJO[!L<N-KHA^Z@<XC/\ >7G@_2C^P+(%=PD..'4N<2>[>M<AJ'B'QCINGMJ%
MU%810YP;<G]YBM:^\4SGP2-;M%C29L##KD"CD#ZS5[FO_8%GA\/-N+?*_F'*
M>PYR%]J?_8%D7^X^PK]P.=N[^]@]#[UQR>)_%=UX?.KP6UJMO"A,A8$LX'4J
M/;ZUIQ^-0?!IUEX%,ZMY94'^*CE#ZS5[FXN@66U1F7>#\[>8V7'HW/(JEJUM
MH^CV4EW=O+%%D>6R%CY>>RXZ?A6';ZWXQN;6&^@BL+J*3YA#$W[P#WJ]XRU"
M1?"2W4]C$)7==T$Z[@I_ \T<J#ZS5[FI8:;I6H6T-[:AFMY%SM)(5C_>*]S[
MFIAH%F$ 5YBV[_6-(Q9A_=)SDCV-<S>>(+O2? .GW]E'!'(_RX$?RCD]!GBH
M)_$WBM=#76EMK5;(!0X.2Y!(P?IG'YT<J#ZS5[G7_P!@6.X@!PI^XH<XB/JG
MI^%"Z!99C)\P_P#/0%R1+_O#O61/XSB@\(0:N4_?3?*L7^T#BLF7Q/XGTVVM
M]2U.UM?L$Q'RIG<H/K2Y ^LU>YUG_"/VNTC=+OW?*XE;<@] <]/:E.@V.6_=
ML4(^YN.T'^\!V;W%7K2X2\LXKF+'ERJ&6I^:.5(%B:O<K6=E%8Q>7%N/.2SL
M6+'W)Y-6:**HRE*4G>19L^K_ .[_ (U5'2K5GU?_ '?\:JCI4K<!:0TM'-4(
MIZCJ5GI=N9KR=88STR>M8L'CWP]/*(4OMI)P"\;*/S-<OJ<!\4?$9M,N&;[+
M;9^0'KC!/\Q72:CX T2\M/*MX!:R@9$D8Y/UH$;>HZQ9:5IXO;N7_1B< H"V
M3^%8?_"Q?#><"\<DG'^H;_"L_P 7Z:ND> A9I*\JQR* S_C3_"_A?1M0\,6L
MES8Q--(I#2 ?-UHL!UFG:I9:K!YMC<+,G?!Y'UI=1U.UTNR:\O)=D*^@SG_&
MO-_#ZGP[\0I]*@8_9I&*!6'T/%/\8:7K=Y%?:AJ$^RQMY,00YZC. : /1-/U
M"VU.S6[LV+Q/T)7;6?JGBW1='N##>78$H'W$4N1]<=*H^#6:/P/"XZK&Q_$5
MQ/A36=,MI=0O=5@EN9IV(V1Q^8Q4]>N,4[ >J:=J=GJUL+BSF$T?0\]#65?>
M-=!T^X:WGO"9%."%7< ?PK(L'TBQ\*:G>Z$\I!3,@=N4/;CMU_2N9\,ZIH=C
MH=S'J<$\\MTQ\V2&/<4!]2>E%@N>KV=Y!J%LMU:R"2!APR]*DFF6"&260X2,
M;C@9K'\,6^EPZ0O]D2N]JS%AO.2#Z>U7]4_Y!-W_ -<&_P#0:0&"?B'X<!P;
MN3@X_P!0W^%:>E>)M)UHM'8W0=^A0C:WX \UPWP^T33=4M]0>_LHIRDBA3(.
M1G/^%5O%FG6_A+Q!8WNF9B5_F9!TZ\_I3L!WFK>+]'T6^-G?32+,%!(6(G]<
M5IPZA;7&GKJ$<G^C%2^['8=:\H\>1&]\911DX,EM'_(FM'3]<-K\-KZW9_WT
M#M;A3U^;_P#718+G7V'C/1=2ODL[6=S.Q.!Y3#]:W)Y8X(7GD;;&BEF8]L5X
M[X3M&L?'-G#)]_O^(-=;XYU.:\:/P_I['SYAF9A_ M#0'3Z3KMAKL<KV,ID$
M1PY9""#]:TADCFO/_A;Q8:@/21?ZUZ!2!"TZ+_6K]:;3HO\ 6K]:"BQ<_P"O
M_"HJEN?]?^%15!3"BBBF2%%%% !63XF_Y%G4A_TP:M:L[7H);K0+ZW@0O*\1
M"J.Y- 'E7A%?%QTZ0Z"\0M]_.[9D'_@56+22_L/'%K/XJCD>8X$;#;M!]>*=
MH</CCP_:F"RT@[';<=Z _P#LU7+;0/$OB+Q#;7FO0BWBA;=PH'X8S5(GJ1^*
M[0W_ ,2K>V$C(LJJK,AP2N.1^56?&4$'A+1(++2M\$5[,3.VXDC 'K5_5M%U
M"?XC6FH16CM9HJEI!@ ?+6IXW\.S:_ID)MMHNK5]\0/\6<9_D*!GG6H7>@Z?
M;VMSX?O;D:A$P,S%642>YSZFNX\0W.FZCX<T^XU;49K2)TW&.+K*>,^]9[1>
M+=5^RV3::--$;#SKE67+@=>W^35CQKX:U*ZDTVZT^,7;VPVF,\;O>@#BKZ>P
ML]6L)]!@NK6,.H=Y&;$G(SC-=#X]DN?[8L)[N&>?23 ID1&*AFYSS],5'K^F
M>*-=N+.];1A"L# "&-AO SRQ[$5U.LOXDM_LSV%E;WEF8P)+9UQ(#@=^E&@&
M!X8C\,7&L0W&E:A=6<H_Y=&?Y6/ISUK,\9Z390^-K6)(L)<!6E&X_,<G/TJ^
MOAO5=9\26EX^D1Z/! ZE]CY9L'/ZXK1\;>']3N-<L=3T^V:Z\E=C(K8;CG/Z
MT: SM;"PMM-LX[2TC\N",85=Q/ZFK-4M*N;N[T^.>^M?LL[Y+1;L[?2KM2-!
M1110 4444 'I4UO_ !?2H?2IK?\ B^E)[!T9X[JG_(6OO^N[_P#H1JI5O5/^
M0M>_]=W_ /0C55%9W5!R6P,>YKR))N9\_45ZC1V/A"PMH["YU*_2,Q#Y5WJ"
M,#G/]*S/%VF1Z?K!,,:K#.N]<# 'KQ^(KK)K;2;'P];Z9J5R8490S -@D]3V
M]:K>(H;75O# N[*43"U; 8<DCH1_+\JZG"+A9'?4HQ='EZHPD\(2G3XKR;4+
M>&*10Q+C:!Z<TL?@Z22T-RFHVXA!P7/3'UK1\1N1X-TU,G:RKG\A4F3_ ,*Y
M;:<=OU%1&$>I+A34GY(RI?!EQ%LE:]M1;D9,Y;"BLS6=#N-%FC61PZ2KQ)'P
M#^%=1KK,/ UC[A=PS4?C8?\ $KTYNIQU_"B<(\MT36HP4';I9G.>'HUEU^SC
M=$=2ZY5AGO7<:E-;65X84\--.H&=\=L"#^E<1X:S_P )#9=_W@Q7;ZO>^)H=
M09-/LUE@QPQ0?XTZ/P;%X5KV;]3 \96%G$+2>"%;>:<9>, #;QW%8VL:-)HQ
MB6259/-7=\JXQC'>NF\9P>9I5G=7D:I?, C*.ON/UKC[VRO+,I]KB>/>#M#<
M\?G45$DS+$Q7/(ETC3'U;4!:)(J$KD%AFME?!5T9)(DO+?SX\GRP?F(['':H
MO!/_ ",L/^XW\JW-%D8^/-6!). P&?\ >%.$8\EV50IPE!2?4Q#X.N?L\KI=
M6\DL8^>)>2#6=I.B76K.Z0X2.,9DD8\+74>$F+:KKFYR?KTZM3/#?[_PGJ,$
M!Q<X8D#J:;A%L:H0<H^=_P ##O\ PS/9V!O(KB*ZA4_,\1)P/>IK;PE//ID%
M^UY!%"ZY8OE0N?7/O6IX<C>S\-ZB]ZI6$@_(_':DU5W7P!9*&(5BH;WXS0X1
M0E1I<O,UTN86L>'KC1TBF:59X9>DD8[^E6;?PG<R6L4UU=06K3'Y$F/+$]A[
MUN:P0/!VGNPS\RG)J'QG;W%W<V$EHCR0LN$,?3=V'_UZ'2C<;HP6MK[:&39>
M&9!KJ6-_*L*Y!&7/[SV%;,VBV=KXMM$C:!H6.W[-]YAA#RP/6K>JNBZWX?@<
MC[0C+Y@_ ?\ UZJW2/\ \+&A?:^TX^;'!^0]*I12TMU-%"$';S*^I>%#=ZU<
MB&ZMK=V.Z*$<'&!S@5S]GH5[>:I)8!0)HCF0L?NCU]ZZ:&1V^(\NYC\N44>V
M!_\ 7K6T]HO[<UF+:KR,NY4/&X8_QI."D]B?8PJ2^9QU]X8GM;&2[@NX+N.,
MXD\H_=J2W\)23:;'?O?6\,+C.Z3(VY]S6JFJRQ:?>+;^&Q# <B5Q)@#WY'-&
MI,P\ 6HSR=O2E[.*)E1II7\K]3&MO#,EV;EUO;9;:!MOV@L=IX%1ZKX;GTR*
M&X$\5Q#+@"5.1S6QHUA;0>&Y-1-L+R;=]PD\?AZUH>(I)9_"UE)-"(G9U)C[
M#T%.--.(>PI^RYK&-)X*EAC22?4K:*.3&TOQR>U0?\(A=?VO_9\MQ$C,A:-B
M,[\=A6UXQM+F:#3)(8Y'4#!"?PGC']:?KU\=,FT9WDQ<18#]SM(P:;IQ'*A2
M3M;:QR=EH=Q=ZM)IV]8Y(LY+9/2J=Y;BUNY;<ON,;%21D#BO1[J&'2X]1UD;
M3Y\2E/7/.?Z?E7F3,SNSL26;EB?6L:L5!'/B*4:2T.GM[61O!LUP(;-D!(+F
M,^9^=1)X1F-C;WCWMO'!*@+,^5"Y''7WK4M/^2=7'^\?Z4SQ)(R^#](520KA
M=P]<+Q5\BM\CH5.-KOL8.LZ#<:,T32.DD,HXEB&!5*QLIM0O([:%07?@>@KL
M/%G/AG3B>3Q_*L'PM8PZAK<<4K$* 6P.,XJ902G8QJ44ZRBMBVW@V;9,(+^W
MFFB&6B3&X'TK.TG0KG599%3$4<6?,D?@*?2N\T:8F_O[6&P6VMXAR^/OFLK2
ME\_P_K,-L")UEDR >36LJ44=$L/'FBX^9+INA6]KX?OF=[6Z!&4F"AL>O-<G
MJ>B2:;96MT9TDBN  NW(QWKJ/#T$\'A._$R/&&SM#CD>M'AI8]<T!+&8J6MI
M@<GJ5SG_ .M1*FI-)!*C"I&,=G8YV[\-7-J;6,3*\UR?EC .?QJY_P (9,6D
MA34+9KA$R85^\.*MWWE:UXVBM'D*P0':JYZXZX_2N@TI_+U^YLH-/6"W09:7
MKO./6DJ<7<5/#PEIYV.(TKPU=:J;H"587MR ZOGD\U+<>%)X].EO(KNVN!"/
MWBQG)7'6NBT/(/B$J=K!ORX-4?"XW^%]8#\@[LY[_+25..Q*HTVE==S#TSP]
M/J=H]TTL=O;H<&20_+2ZIX;O-.\G:1<I,0(VBZ,36\ZM=> %6T!;RV'F!>OY
M53L;74+:_P!*N=3<O;%E$8)^X<\9%3R+3S(]A3LM"%?!LYQ$U];"Y*[OLY/S
M"LVQT.]OM2DL1'LDC.)&;HH]>:[/5KN2W\0+Y&BBYN-HV3[L'Z=*@T&Y:\U7
M6#)#]GNG .S=G QCK^%5[.*:+E0IJ2274=H'AR.S:[,DMM>($(^7!*'WS7"7
M0VW4W&%WD 8XKM?!EM=0?VDTJNJD8RP^\?6N5GTR]E^T7B6S?9T=LN,4JRTT
M0L13_=QY%W*,2>;*L0(!=@H)&<5TS^"IHWB66_ME,H&S?P2?05SEI_Q^P?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ7479X85Z+_?_P#K5Z0*]*BY.-Y'OX:<YPO-"T445J= 4444 %%%% !1110
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M/B.QM=.AD:),#=MYZY)^@%>@'PAX>)R=)ML^NVKUEI5AIRD6=K'"",'8,47
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MVHB7& 55<?B,4YO%&KR&0-=AA(,."@P/TK([=,>]7],TFXU:5HK<H&1=Q#G
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MP-#@TKL'2E%7DK$5%%%29W"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4.F:3-;Z4(++<"5=AD+ZG/>N&F\>>(I8#:1Z,Z71X\W!Z^PQ_6M&YLO$EWX
MN$O':2\<[@@&&V]Q[TQ'.:Q(FFV+2Q^+;BZU16R(X)28SSSQ707FLWE[\+UO
M6FD2Y^ZTJ.5)Z^E<T#YGA&32K70)OMV )YS'C(4@Y![]*V%@F;X4-"(9#*'Y
M38<_E5"*]KIVJZAX+?5I-=O4:-"R(LAP=OJ>M:NE>++N+X=S:E,WFW,4AA5F
M^@(_G4VD0RCX6S1&)Q((G&PJ<\GTK,\/:'<:G\-KRQ"-'.;EG574C)"KBE<>
MHMAH.O:OH:ZS%K-S]ND_>1P[\1D?_JK6U[7]6T/PA;_:E2+4Y3L+JP;_ (%_
M*LK3/$^I:/H"Z0NEW7]I0_)&QCRE7O$&DZYKW@R&:]1&U%'\SRD&/E]*+AJ<
M]=W,VE:7!JMKXG:YO@5>6V:XW+SVVUK>--:N9_"ND:A:S36[W#9!1BNX^]9+
M/!<V5K9Z?X54:D6"2M/;_)QWSFM?QQITUOX<TFVA@^>-OF6",X7I2&C>\,Z%
M=V[0:I=:M=W$DT6YX7?Y 2.PKJOPP/2JNFKMTRU4C!$2C'X5:HT ****0!11
M10 >E36_\7TJ'TJ:W_B^E)[!T9X]JG_(7O?^N[_^A&J?;^8JWJO_ "%K[_KN
M_P#Z$:AMTC:YB65@L>\;F/I7D25YG@3UJ-'<:+!=:3X3:ZMK9YKJ=MP0*20.
M@/TQS57QS8%UMM2",GF+Y<@8'@]1Q^=2:MXO-D;>WT>6)X5C 9RI.,<8_*F#
MQ%;ZSX;N+;4YHH[K=E,*0#Z?Y]ZZKP:Y3T)2I^R=.^I=O9+/2?#%I>K86LLS
M(N-\0YX[TL,MJOA)M4?3[5I<[@OEC'6L?7=4L[OPU86L,ZO-&/G0 \<4\:M9
M?\(0;$SK]I/\&#FE&21+J13:OT_$UM2?3[31+;5QIELT[H $*?*,]<CO63XS
ML+>!;.\@B6-I1A@@P*75]5LKCPE:6D5PK3IMW( <BF^*=4LK[3[*.VG61H_O
M  \<5,Y)Q"M*#BX^2,SPM!'<>(;=7^;;E@/<<U:\2:U?C7952YDA2!RJ -M'
MY=_QK%TZ\?3KZ&Z3),;[L#N/2NRFNO"VM.E[>2M#.."A)&?K@'-33LUN94'S
M0:B[,YC5-=NM8$ N-F(>,*/O'U)_R*-:U*UU%X3;6:P;%(8!0,GUXJ[XFU33
M[Z2&&QA CB7:9 ,$CT'M5/6H=,@:(:7,TBLIWY8G!X]JB5T]S.HI*_O7(=&M
M;.]U#[/=W(MX"I.[<!S^-=[?:1I,GANUM9M0VVJ,"D_F#YC@]^E>9YY ]QSF
MM6ZUMKK0[;33"$$#;@X.2>".GXU5.I%7N.A6A"+NBGJ5O;P7\T5M-YL2D;7!
M'/'M77Z(ME!X/GO;FUBD\MB?F7.3GC]<5P_8^W>O0?#T4)\&2QW1VQR,1U&>
M3U_K12:;=QX5.=1V10F%IKWAFYO#9Q6]Q;$G]RH&> ?ZU=TBW*:?:[-)MHX&
M/[V>ZVDD>H'7DX_.JT\EEI'AYK&PE:\>Z8AFQC';G/2K=Q+IFIP6ES<7,D#V
MF"T"\EL>GK^':MDH]SM5.2>J*6JZ#;2^,+:VC0)%-&'D5>A&3G%2W6JZ39:A
M<:=<6$"VT:[!(L>7+?6EU>_5?$MAJ5G()4$81T!Q@9)Y)XSS3YK70;F^FU2>
M<.)4(-L8SN#$<TFET8G3:^%=?P(="CL!X:U*[>S25(Y6($BC=C XS5D3Z?/X
M876I-+MA+&V BH "<XY]:J6$]O#X7U6T!\N1V8Q1$Y)4@8QC@]ZBBFC'@0V!
M<?:G?*QYY^]GGTX]:7,K6OT$HS2M;H2>(;2VN= LM4CMXX9'8*510!@U+KUK
M!!-HGDPQQEY8]Q1 ,\BHM1N89?!]G;)(&GBD7?'W'-3:[<PW,^D"&17\AT:0
M@\*!UY_I33CW!TWKIT19O;>*;Q_;QRQI(IMA\KKD=3V-2:58V;>(-61[6%HT
M^ZI08'TJO/?6S^,[:^68&V\G:9.P.3U]*ET^_M8-9U:>2=1&^0C==WT]:I2C
M?<M0:EMU_06P;3M6TZ\DGTRW1;9SM$:[<X]<52NHK;6/"$NH+9PV\T;$J8EQ
MT..?6DT.XAMM-U"":14DF+,@)^\/KTJ.QN8HO!,]J\@6X=B%C(YZ^E2I)[LG
ME;6L>C)= @(T>*2/2[?8S?O+BZ*XQZ@=:EUG3K:U\0:5<6Z)&99%#", *>:5
M)K'4M#@M[JZ>UDMCET SOQ_=]:75;NTN[S1YH)AL1U8AN-@]^PJER\JU*A3M
M%:$VM:O:6OB".SDL8)1(!YLCKE@#Z5R_BO3(]+UAD@ $4B[E [5T^H0Z+J&K
M1ZBU\5:$@,H4_/C_ #UKF/%%Y)J6JR3JC"%% 7..GK6=75-LPQ%.2A)R1I^"
M8@EMJ5UCYTC&T^F<Y_D*E\(L8]+U;4<!KE S D9YQG^=1^"Y5:UU*T/WFC!4
M>O6LWPYK8T:YFAND+0295UQT]:49*R%3DHJ+>Q6MO$>I6VH&\-R\F3\R2-\A
M]L=C]*B_MB\EUE=24K]H,@P%Z'L!C]*ZR!_"-G<M?1SAI1\PC.2 ?88K+TR[
MTB?Q#-J5V8K:%6W118)RWK_7ZT2CK?F,W%JRE+<Z_4Y)+31+B_@M3]JDC <#
MM[_K7G&G:1?:S+(+4"1T^9MS@=:Z2T\7)+KLXNV_T"4;5R,[<?\ ZS6%>7?]
MF:G-_8]^WD2'<&C)&,]OPIU91E;4NO*G.TF]$=)X9TN?3$U5+F-5G6)2-ISC
M(;_"JGA\M-X3UK>2VU7QGUVU5T'Q&8[R9=2F=XKB/8TC=1CI_,U--?Z9H^A7
MEIIUR;F2YW#./NY&*:G&V@XRARJSTU*7A/3%O=5,TJ_N;==Y],TS5]?N9=<>
M[ADV"$E8N V!]/>KF@ZE9:=H%\K7"K=3<!"#DC_)-8FD+:/JD)OI EN#N8M[
M5#?1,QD_W48Q>YU7ABWO9+N77-0E*QB,CYN"W^ J#PU=K<>++I(DS#<!MW''
M&36AJ]]I&IVR6\>N+;0*.8TB)W5D^%+2*/Q-(\,RRP6Z'Y]N,Y'!K3;0W^&<
M(IZ&!JMN+35+J!>B2D5TMA:0-X%N9V@C:1=V&*\_GUKF=4G%UJEW.#_K')_6
MN@LM5LH_!=Q9/.HN'SM3!R:RIV4G<YJ#2JROMJ:$C66G>$K"]>P@FF(4+N3
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M**5]653E%+EE:X6'ANU3Q)=I(A>VME\Q%/3/6M#P]JMK?ZC=0QV4%N8P=AC
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MH%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGVSQ_C'V6,_@*/MOC_O:1_D*]"H'7I^M',9'G^AZ?XCN/%T&J:Q;!/+C*EU
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M4)Z PHHHI6#IH%%%%,;U"BBB@6^X4444 %%%% !1110 4444 %%%% !1110
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M %.B_P!:OUIM/B_UJ_6@9/<_Z_\ "HJEN?\ 7_A4504PHHHIDA1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 >E36_\7TJ'TJ:#^*D
M]@Z,\=U3_D+7O_7=_P#T(U4K2U.SNCJMX?LTV&G<@A"<_,:J?8KO_GUG_P"_
M9KR9Q?,SP:D)<[T(**G^Q7?_ #ZS_P#?LT?8KO\ Y]9_^_9J.5D<DNQ!14_V
M*[_Y]9_^_9H^Q7?_ #ZS_P#?LT<K#DEV(**G^Q7?_/K/_P!^S1]BN_\ GUG_
M ._9HY6')+L045/]BN_^?6?_ +]FC[%=_P#/K/\ ]^S1RL.278@HJ?[%=_\
M/K/_ -^S1]BN_P#GUG_[]FCE8<DNQ!14_P!BN_\ GUG_ ._9H^Q7?_/K/_W[
M-'*PY)=B"BI_L5W_ ,^L_P#W[-'V*[_Y]9_^_9HY6')+L045/]BN_P#GUG_[
M]FC[%=_\^L__ '[-'*PY)=B"BI_L5W_SZS_]^S1]BN_^?6?_ +]FCE8<DNQ!
M14_V*[_Y]9_^_9H^Q7?_ #ZS_P#?LT<K#DEV(**G^Q7?_/K/_P!^S1]BN_\
MGUG_ ._9HY6')+L045/]BN_^?6?_ +]FC[%=_P#/K/\ ]^S1RL.278@HJ?[%
M=_\ /K/_ -^S1]BN_P#GUG_[]FCE8<DNQ!14_P!BN_\ GUG_ ._9H^Q7?_/K
M/_W[-'*PY)=B"BI_L5W_ ,^L_P#W[-'V*[_Y]9_^_9HY6')+L045/]BN_P#G
MUG_[]FC[%=_\^L__ '[-'*PY)=B"BI_L5W_SZS_]^S1]BN_^?6?_ +]FCE8<
MDNQ!14_V*[_Y]9_^_9H^Q7?_ #ZS_P#?LT<K#DEV(**G^Q7?_/K/_P!^S1]B
MN_\ GUG_ ._9HY6')+L045/]BN_^?6?_ +]FC[%=_P#/K/\ ]^S1RL.278@H
MJ?[%=_\ /K/_ -^S1]BN_P#GUG_[]FCE8<DNQ!14_P!BN_\ GUG_ ._9H^Q7
M?_/K/_W[-'*PY)=B"BI_L5W_ ,^L_P#W[-'V*[_Y]9_^_9HY6')+L045/]BN
M_P#GUG_[]FC[%=_\^L__ '[-'*PY)=B"BI_L5W_SZS_]^S1]BN_^?6?_ +]F
MCE8<DNQ!14_V*[_Y]9_^_9H^Q7?_ #ZS_P#?LT<K#DEV(**G^Q7?_/K/_P!^
MS1]BN_\ GUG_ ._9HY6')+L045/]BN_^?6?_ +]FC[%=_P#/K/\ ]^S1RL.2
M78@HJ?[%=_\ /K/_ -^S1]BN_P#GUG_[]FCE8<DNQ!14_P!BN_\ GUG_ ._9
MH^Q7?_/K/_W[-'*PY)=B"BI_L5W_ ,^L_P#W[-'V*[_Y]9_^_9HY6')+L045
M/]BN_P#GUG_[]FC[%=_\^L__ '[-'*PY)=B"BI_L5W_SZS_]^S1]BN_^?6?_
M +]FCE8<DNQ!14_V*[_Y]9_^_9H^Q7?_ #ZS_P#?LT<K#DEV(**G^Q7?_/K/
M_P!^S1]BN_\ GUG_ ._9HY6')+L045/]BN_^?6?_ +]FC[%=_P#/K/\ ]^S1
MRL.278@HJ?[%=_\ /K/_ -^S1]BN_P#GUG_[]FCE8<DNQ!14_P!BN_\ GUG_
M ._9H^Q7?_/K/_W[-'*PY)=B"BI_L5W_ ,^L_P#W[-'V*[_Y]9_^_9HY6')+
ML045/]BN_P#GUG_[]FC[%=_\^L__ '[-'*PY)=B"BI_L5W_SZS_]^S1]BN_^
M?6?_ +]FCE8<DNQ!14_V*[_Y]9_^_9H^Q7?_ #ZS_P#?LT<K#DEV(**G^Q7?
M_/K/_P!^S1]BN_\ GUG_ ._9HY6')+L045/]BN_^?6?_ +]FC[%=_P#/K/\
M]^S1RL.278@HJ?[%=_\ /K/_ -^S1]BN_P#GUG_[]FCE8<DNQ!14_P!BN_\
MGUG_ ._9H^Q7?_/K/_W[-'*PY)=B"BI_L5W_ ,^L_P#W[-'V*[_Y]9_^_9HY
M6')+L045/]BN_P#GUG_[]FC[%=_\^L__ '[-'*PY)=B"BI_L5W_SZS_]^S1]
MBN_^?6?_ +]FCE8<DNQ!14_V*[_Y]9_^_9H^Q7?_ #ZS_P#?LT<K#DEV(**G
M^Q7?_/K/_P!^S1]BN_\ GUG_ ._9HY6')+L045/]BN_^?6?_ +]FC[%=_P#/
MK/\ ]^S1RL.278@HJ?[%=_\ /K/_ -^S1]BN_P#GUG_[]FCE8<DNQ!14_P!B
MN_\ GUG_ ._9H^Q7?_/K/_W[-'*PY)=B"BI_L5W_ ,^L_P#W[-'V*[_Y]9_^
M_9HY6')+L045/]BN_P#GUG_[]FC[%=_\^L__ '[-'*PY)=B"BI_L5W_SZS_]
M^S1]BN_^?6?_ +]FCE8<DNQ!14_V*[_Y]9_^_9H^Q7?_ #ZS_P#?LT<K#DEV
M(**G^Q7?_/K/_P!^S1]BN_\ GUG_ ._9HY6')+L045/]BN_^?6?_ +]FC[%=
M_P#/K/\ ]^S1RL.278@HJ?[%=_\ /K/_ -^S1]BN_P#GUG_[]FCE8<DNQ!14
M_P!BN_\ GUG_ ._9H^Q7?_/K/_W[-'*PY)=B"BI_L5W_ ,^L_P#W[-'V*[_Y
M]9_^_9HY6')+L045/]BN_P#GUG_[]FC[%=_\^L__ '[-'*PY)=B"BI_L5W_S
MZS_]^S1]BN_^?6?_ +]FCE8<DNQ!14_V*[_Y]9_^_9H^Q77_ #[3?]^S1RL7
M)+L05U?A?PL^HR+=W:$6P^ZIXWT>%_"LE_,MS?1M' IRJ,.6KTJ.)8HEC0 *
MO  KJH4+ZR/0PF$O[TQT<:1($10J@8  IV*,48KM/66@"EHHH **** "BBB@
M HHHH **** "BBB@ HHHH *JWO\ JA]:M55O?]4/K30F4!2T@I:T,PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** -=>E%"]**R-1*X[Q7X@_X1W33="#SF9RH&<
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M,44 %%%% !112?C0 M%)^-'XT +12?C1^- "T4GXT?C0 M%)^-'XT +124M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+1115"$XI>*** #BBBB@ I*6B@!*7BBB@ XHXHHH .*.*** "BBB@ HXHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "JU[_JOQJS56]_U0^M-"90 HP*!2UH9B<4<4M% "?C1
M^-+10 GXT?C2T4 )^-'XTM% "?C1^-+10 GXT?C2T4 )^-+110 4444 %%%%
M !^-%%% "8%&!2T4 )@4<4M% "<4<4M% "<4<4M% "?C1^-+10 GXT?C2T4
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M:3M2UJ0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH *JWO^J'UJU56]_P!4/K30F4!2T@I:T,PHHHH **** "BBB@ HHHH
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ML?\ ?7\Z/-C_ +Z_G7S5N/\ >/YT;C_>/YT<H?VNOY/Q/I7S8_[Z_G1YL?\
M?7\Z^:MQ_O'\Z-Q_O'\Z.4/[77\OXGTKYL?]]?SH\V/^^OYU\U;C_>/YT;C_
M 'C^='*']KK^3\3Z5\V/^^OYT>;'_?7\Z^:MQ_O'\Z-Q_O'\Z.4/[77\OXGT
MKYL?]]?SH\V/^^OYU\U;C_>/YT;C_>/YT<H?VNOY/Q/I7S8_[Z_G1YL?]]?S
MKYJW'^\?SHW'^\?SHY0_M=?R_B?2OFQ_WU_.CS8_[Z_G7S5N/]X_G1N/]X_G
M1RA_:Z_D_$^E?-C_ +Z_G1YL?]]?SKYJW'^\?SHW'^\?SHY0_M=?R_B?2OFQ
M_P!]?SH\V/\ OK^=?-6X_P!X_G1N/]X_G1RA_:Z_D_$^E?-C_OK^='FQ_P!]
M?SKYJW'^\?SHW'^\?SHY0_M=?R_B?2OFQ_WU_.CS8_[Z_G7S5N/]X_G1N/\
M>/YT<H?VNOY?Q/I7S8_[Z_G1YL?]]?SKYJW'^\?SHW'^\?SHY0_M=?R?B?2O
MFQ_WU_.CS8_[Z_G7S5N/]X_G1N/]X_G1RA_:Z_E_$^E?-C_OK^='FQ_WU_.O
MFK<?[Q_.C<?[Q_.CE#^UU_)^)]*^;'_?7\Z/-C_OK^=?-6X_WC^=&X_WC^='
M*']KK^7\3Z5\V/\ OK^='FQ_WU_.OFK<?[Q_.C<?[Q_.CE#^UU_)^)]*^;'_
M 'U_.CS8_P"^OYU\U;C_ 'C^=&X_WC^='*']KK^7\3Z5\V/^^OYT>;'_ 'U_
M.OFK<?[Q_.C<?[Q_.CE#^UU_)^)]*^;'_?7\Z/-C_OK^=?-6X_WC^=&X_P!X
M_G1RA_:Z_E_$^E?-C_OK^='FQ_WU_.OFK<?[Q_.C<?[Q_.CE#^UU_)^)]*^;
M'_?7\Z/-C_OK^=?-6X_WC^=&X_WC^='*']KK^7\3Z5\V/^^OYT>;'_?7\Z^:
MMQ_O'\Z-Q_O'\Z.4/[77\OXGTKYL?]]?SH\V/^^OYU\U;C_>/YT;C_>/YT<H
M?VNOY/Q/I7S8_P"^OYT>;'_?7\Z^:MQ_O'\Z-Q_O'\Z.4/[77\OXGTKYL?\
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ML.XJ6K'HX?$QKHLT4E'-(Z1:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M[E>BD&,#K^-+0<[OU"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI:2EKN.@**** "BBB@ HHHH **** "BBB@ HHHH UUZ44+THK(U$-<=XIO\
M3=.LUEU.U:XA\SY4 Z'UKL36)=6]M<AEN8XY(P<XD' I/<SF<=_PLW2?^>%Q
MZ\"@?$S2<C_1[G\J-5\3>%-.G,(LX[J53AEAC4X_.J</C3PM)(%FTHP*>ADA
M7^E/3L9&YHWC;3]:U!+*".4.X+?,/2NFK-TU-(N$6\TZ.!@1PZ+R*TJSD!2U
M/5;31[)KN\=EC7N*X^7QAK6MMY7A_3&$9X,[YX]ZZ[5](M=9L'M+M6:,]U;&
M#7)R>%/$&BG?H6K.\8Z02GK[<\?G50Y; <WK>AZM'J&F#6M0:?[7<)&R+T )
M]N*],TOP_I>CQJ+*T1& ^^1DG\:\UU[6]6EOM+;6=->W-G<+([KT8 ^U>DZ7
MXBTO6$7['=HS'_EF?E/Y54K] .CM?]0M3L,J0:@M?]0M3GH?I2B;KX3)/WCC
MUH_&@_>;ZFBMB _&C\:** #\:/QHHH /QH_&BB@ _&C\:** #\:/QHHH /QH
M_&BB@ _&C\:** #\:/QHHH /QH_&BB@ _&C\:** #\:/QHHH ****!%FSZO_
M +O^-51TJU9]7_W?\:JCI4K<H7\:/QHHJA!^-'XT44 'XT?C110 ?C1^-%%
M!^-'XT44 'XT?C110 ?C1^-%% !^-'XT44 'XT?C110 ?C1^-%% !^-'XT44
M 'XT^+_6K]:93HO]:OUH&6+G_7_A452W/^O_  J*H*84444R0HHHH **9++'
M;Q-)-(L: #YG( &3[U%%>VETQ6WNH9F'58W5CCZ T 6**KSWUG:MLN+JWA9A
M]V1U4X^F:FCECFC62)U>-N5*G(/;^E #J*.]13W5O;)ON)HHDSUD<#^= $M%
M,$B/%YJNIC(W!E8;2/7-,DNH(H?-EFB2+^\S #\SQ0!-13(IHYXQ)%(DB'HR
M,"#^5/\ R_&@ HJ*:XBMXO,N)4B3."SD*,_6GQRQRQ+)%(DD;#(93N!% #J*
M#P2/3IQBB@ HHHH **** #O4T'4_2H>]30=3]*3!['S_ *S_ ,A[4,]/M,O_
M *$:JPR>3-')C)C<-M^E6M:_Y#VH?]?,O_H1JE5GRE6359V/4-?T4^,].L=1
MTR:)ITB",C-Q[C/J#FL#5/!$>C>'/MM[>B.]W#$8.4/7Y1WS7+V>HWNG,S6=
MU-;LP^8Q.1D4EWJ-[J#JUY=37#)T+N6H.F>(I3CS->\=_K=M-XC\#Z6=*#3-
M  KQ1CD\8Z4_5P--\*:)I5T5%YY\;>7GE0/_ -8_.O/K/4;W3I&:RNI;=G'S
M&-RN?K3)KZZNKK[5/<2RS_WV8DBE8IXQ6;M[S/1/&C;O'&A#.5V)D>AWFK^L
M7L%A\1-/FE*A9(=C.>QXQ7E\^IW]S<QW$]W-++$,1R.^67OP>W-)=W]WJ$BR
MWEU+.X&U6<Y(_&BPGC5K*V[1Z&GA_45^(AORC?91()?//W2,#(K5TF_AO=:\
M13VS958]@;/4@'FO+FUW5FMOLIU"Y\G9M\OS,C'YU!::C>V"2):W4T <8<(V
M,_7UHL:+&14KI;ZG1>") OC:-F/WMX))[U7\;VL\'B6ZFFB=(YI"T988##_)
MKGXYY()EGC=UD5MRN.N?6K%YJ=]J.S[;=S7'EG*F1]V*#E59.CR/N51U&<')
M'>O0O';'_A%]&))X SZ]*\[SCG."#D5;N=2O+J!(;BZEEBB^XC'(7Z51-*KR
M4Y1[EE] OH]$35RJ"T<X7#<]?3ZU0M]WGQ[6 D+#:_0*?6I6U*]-DMD;J8VP
MY$7F?+^50(XC<,4#!>=G8YI,F5I343URQN=:<6MKK&BPWT<B@)<P?,%4]VJK
MI\>EZ)\1)+2V*HL\&T1CD*_!Z_@:XNV\57%G MI;27D5L@S&B2X(/<=>E43J
MD,DPGDM&,[-NF?=T/JI]>]9N7D>Y963C)71W?AGP[J=EXXN;FXB9+8;R)3T?
M)R,?UJWH_$GC(\Y\V7Z]&KE])\82#5(VNKB95C4K&\\A<+G^\!D]ATS5*Y\2
M;;Z^,!F\F[D9YFA<@N2>P_N\XY[4<WD'L80C>,E]YW?@768M:T^*WN6_TRSZ
M,<9*'_\ 5C\*Q[;2[/5/&VK127MQ:WB2LT#1N "<^XYKC[36EL9A<6L#PW)^
M4['*@K[8YS_A2/JL+W9N6@FDF1M\<K-\S,.[?SI.;[$\D>6/-)73[GI^C6WB
MF&YDBUF6VNK Y#,^"V/PP.:S-"N=+_M[7-%@E6.&[+^6<\9P00/U-<?-XMNK
MF!K>XEO'@E!$RF<G(/91_CCK6:M];+M<6 $BGA2_R[??W[<4^=]ASC%+1IV\
MSKK?X97_ /:6VZF1;#/,B.-Q'; ]:M^#K"#3?'5_9VUP)XHXR%;T]C[BN8;Q
M;>-";=I[UK?'"M.=Q]CSC;_A56SUM=/F,MM%-;R,,3&&3! _V<?G1SOL3'#T
M8S4J;7GJ=+JWP_UV\U>YN(D@,4C[AF4 X_*M#PG#BPU7PS>2QQW9W!2&R.?_
M *]<O_PFNH\'[3=AU/RYF;!7_:]_IGK5"75H);HW$UO.SEMYD+Y<..1SZ=O7
MO1S/L+ZO2C/G@U]YT]A\-+_[7_Q,Y(HK-,DLC@LW^%<=J5O#::E-;V\QGAC<
M@.5ZX/K6I-XLN[BW,,\ES*)/EEC:8E-OM[_X5C7$L3L/(B,:+QSC)^N*:;9R
MXNA3A#]W9_,A'KGK2TE+5GF!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %+M;;NP<>N*2O0;A0?A%;MZ2CD<_QFAFU"C[5M=M3S
MZCKTKMU\$:;%H]KJ%[K#V\4RC.8QU/TJOJ?A7^P]3TR2UNC-#<N-DA09!^E*
MY;PDK<USD2K+]X$?44;6)P <^F*]+U'1X+OQK9VFL7QG#1;HU$6T2,,?*0.,
M8R?PI+W3[*/Q]&NG:@8[QCB2(096$!1C&>#1<U^I/778\T((.""#[BBNQU'1
M#J/C&ZM[[4HXU3)>=\+D#L%Z4Z]\%6/]AW&HZ7J3W"P@EA)$54X]":+F7U6;
MYG'H<;L;;NVG'KBDP:]$N0/^%3PL!C)'\Q7#Z5_R%K7C/[Q?YT[DU:7+*,4]
MRKY4O]Q_^^:0@J<$$'W%>O\ BSQG-X=O(;>&QBG#IN)9B,5B>)X+/Q!X6AU^
MVMECGW8?('/U/M_6E<Z*F$BD^65VCSJBNWL?!.FSBV@FUI3>RIEHX(_-4'U)
M[?C3]!\*6MMXOET_59 [0J)($ZB4>OMBBYE'!5+I/9G"D$=>**[7Q!HEA?>+
MS;VNHQ)O9FN/-^18N??K4G_""6-WI]Q<:7JCW#PY)#1%5)'H?\* ^J5+V6IP
MO;) ([@UV'@WQC+HDXM;QR]@YQSUB/K]*X\C!QZ4?AGL<4VKF5*M*C.\3Z4M
M9XKF!987#QN,AAT-35XKX.\92:).MI=.TEBQQN/6/W^E>Q6LT=Q"LL3AXV&5
M8'BLVK'TN&Q4:T?,L4M)2TCJ"BBB@ HHHH **** "BBB@ HHHH *J7WW!]:M
MU4OON#ZTT)E&EI*6M$9A^-'XT44 'XT?C110 ?C1^-%'X4 %%13W$=O$\LSA
M%7[Q)ZURD_C4RW!BTRQDN,?QD'!_*BP7.PHKC$\:W%NX74M,DMXR?O@<5UEI
M>0WUNL\#[XV'!HL%R?\ &BBB@ JEJ.EVNJ6S0W488=F[K[U=HH3L3.,9QY9(
M\_F\#WMO<!K&ZW)G.":Z/5=-O+JQMHH9-KQ@!SNZ\5NT4II3C9G-#!4Z:?*]
MSF].\+)#*)KR7S'Z[0.*WY;>&:'RI(QY9& N.E2T5G&C3C&R-HTX17*D<I>>
M%)!*9+*?;S]UN*WM+@EMK%(IFW2#.3FKM%*%*,970X45!\R$'2E_&BBMC0/Q
MHI&)"D@9P.E86G>)8KW5)=/FA>WG0_+O[T ;U'XTG./2L.?Q+"FM#3+:%IG[
MNO04 ;OXT?C2?H>XI: #\:/QHHH /QH_&BB@ _&BBB@#77I10O2BLC40UP7C
M_4);+P^ZP,5EGE$8QV!ZFN]->:_$U@NCVY;A5N0Q/XTGN9S-/P_X6T[2-/A5
MK9)+DH#+)(NXEL<]:U+C2-.NHC%-90,AZ_(!60?'OAO)SJ7S=\Q/_A0?'OAK
M'_(2'M^Z?_"E[U]#(Q=!@_X1[QU<:1 S&SN(_,12>$.-W'\J[ZO/K;5K+6/B
M;;W-C.)HO(;G:5_A([UZ#4ROU R]?OKW3M,:YL;0W4BD;H\=JQM,^(&E7<OD
MWFZRG/#+*>,^QKK.-W( SW(K/U+0=,U=66\M8Y#C[Q7YA^/6A6Z@62MIJ%O]
MV*XB(XR PQ6/'X/TFWU>+4K2-X)4;<51OD-8L_@RYT8M<Z)K#6P'\$TF%QZ9
M--T#QG?3ZY'H^H102NQP)X&!'Z5=F]@/2[7_ %"U8;H?I5>U_P!0M6&Z?A1$
MW6QD'[S?4T4'[S?4T5L0%%%% !1110#"BF22)%$\CD*J#<Q/85P5[\2)#=R0
MZ1I<EXJ'!<*W]!0(] HKCO#WCR+5K[[!=VQM;L\ '."?3GFI-5\7SZ-XDBL+
MVS1+*4X6<,<G\* .MHKD_$OC(:-=6UI90)=W,V"5W< 'ITKIK1YWM8VN41)B
MN75#D T 349K(\1:_#X>T[[5+&TC$X1%[FN;/CG5+18+G4M$\BQF.%E5\G\J
M .[S16%KGBBUT;1XK['FF<9BC'5JR+;QM>PZC:VNLZ4;-;G_ %;JV?SH [2B
MN;\2^*O[#E@MX+1[JZG&8XU/7TJC:^-+N'5X-/UO3/L33_ZMU?<#0!V5%<OK
MWBUM.U.+2["S-W?2 ?)G &?6C0O%K:AJ3Z7J-I]COAT3.0?QHU'<ZBBBB@ H
MHHH ****!%FSZO\ [O\ C54=*M6?5_\ =_QJJ.E2MRA:*0]*K:EJ%MI5E)=7
M3[8XQS[GTJA%JBO.'^)5]*S/9:(\MN/XR&/Z@$?K72^&/%MKXC5T6-H;F,?-
M$?Z4".BS1FO.)?B/J?V^>UMM&6<Q,1^[+,>/7 JSIWQ'9[^.VU736L]YP&YX
M^N: .^S16#J^HZ];W*+I6DQ7L!3)D:7;S[5SEWXYUVPOXK&ZT.&.XE(VH)]Q
MY^F: /0:*HWVJ6VFV!NKN18L+G83R>.@K$\)^+9/$LUVIMEA2$_(0Q)(SWH
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M4]'M[RZMC;32 EHC_#@D?TI@C1IT7^M7ZTVGQ?ZU?K043W/^O_"HJEN?]?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.QDGN""BJ>#WHZCZ'.2^+X?^$=6X0C[6X\L1]\U8\):*UE;&^NOFNIR6)/4
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M\GR",!%)8COP*E\$61LO"UK&\31R$%F5EP>3GFD W7O"T&MW\=Y=SN888CB
M=,^M<W\-%"W^K*HPH; 'IS7HDP)MW '.PUP?P]L[FUO]4-Q;S1!F)!="H;GC
M&: .KN?$>C65RUO<ZC;Q3)]Y&;!%>=>-Y+>^\6Z<R,)895C^93P02*[?4/!&
MAZG>RW-W!(TLIRY60@9^E<IK^C/#XQT:*VM)VLX3$I94+ #<.II@4+'5&TKP
MMK>ELV)5F5(E[C=G./R%0:9IXT_QSID0X9DB<CT)4&K/B+0+N3QWMCM9FMYI
M5D+JA*CZGIVK7U/3[A?B9:316TQA78/,"':!@#KTIW%8YK5[/[?XWUB#&3N<
MK^&#5V34VUCPUH>C DRRS>7(,] &X_I6E8Z;<O\ $W47DM9A#)OQ*8SM.<=^
ME4/"N@7D/CD^?;S)!;R.Z.R$*<$XP:+A8G^'T0M_%U_'D;5C(^G(HO-3L-3^
M(?F7]U%%96F5!D.!D?\ UZ-(CO=(UW7KM;.Y($3B(^6WS$D8QQS5GPKX'M-4
ML'O=;MYOM$TA."S(<4@*_@K4(-/\77FFP3)+:3Y\IE.02#Q^F:?\2F===TQH
M4WRK'\B>^34?B7PJOAZ^T^_T2WN&"OF15W.0>WZ9J7QZEY>7NDWEO8W$N(5=
MD6)C@YS@\4#)U\0^.]HVZ$C*!U\EL_\ H5=SI4MW<:;!+?1"*Y9<R1@8VFN%
M'CO7P!GPT_RXQ^[D_P *[+P_J5UJVE)=7EHUK,S$&-@1W]Z 1JTZ+_6K]:;3
MHO\ 6K]:118N?]?^%15+<_Z_\*BJ"F%%%%,D**** *.K:9#K&ESZ?<,ZQ3 ;
MC&0",$'OGTK,?P;IK^'5T5GN#;HP96+#<#]<5T/XT4!8P&\(::_AQ=#WSK:J
M<@[ANSG/7%2S>%]-N-"BT>82R6T(PC,PW#\<5M=LT4!8X_\ X5QHYM3;O->N
MN %9I02F/3C'Z5HWWA'3[_0[?299;@6]N<J0PW'\<5OT8IW8K(R+KPY87>@Q
M:/,KM;Q(J(Q;YA@8Z^M9R> ],32IM.-Q>/!*P.3(-RX],CIS7448HNRM#SGQ
MWI4>E^#K&PM/->..; W<MT/H*OV'@32;_3[2>1[D H&:!9,1Y]Q7;^WKUYI.
M3UR2/>B[%9&5JGAVQU72%TMP\-JI!58B!C'3KFA?#NGC0(]&D1I;6,;1O.2.
MO^-:V#2?CTI:@DCE+7X>Z/;W$<CR7<ZQ'<D<D@**?IBNL  4  # QQ1BB@84
M444""BBB@ [U-!U/TJ$=:F@ZGZ4F#V/G_6O^0[J'_7S+_P"A&J..P)&#D'-7
MM:_Y#VH?]?,O_H1JC^-6?*5M*LF>@:=XTTF]TJ.P\167FB%0%=1G=CCZCCWJ
M'Q!XNTI]$&DZ)8A(6^\TB8VCV'K[UPOXTN*+&KQ=9PLUH=G9^)-*U'0(M)U^
M.=1 !Y<\&"QYZ8/3BF:[XILKE;#3M,A>+3K617W-]XX]JX^BBR$\9.2T7^9V
M7B3Q+I^J>)M,O[8R^1;*HD+)@\,3P*77O%\$WB6SU33-["%<,)%QFN+I:+(4
ML54N[Z7/03XD\+)JIUQ(;HZ@4SY6/DWX]:K:-XRMX[C6+G42XDO%Q&J+D#@\
M?K7#X_6D_&BR+>+J\VAL^'=6BTGQ%#?S(6B5SN ZX-6/%E[I&I:E]MTU[@M,
M2TRRK@9[8KGZ3\:$D8NO+D<)+0Z[P1K6CZ%-/<ZCYK7#<)MCS@59UV_\*:PU
MQ=27FJ/=,I\I64;%/;''2N)I*+(UCB9J'*HJQO2W&@MX6CA2U/\ :VX%I"#C
M&?7-8/(&<_-1^-+082J2>K.J\5Z_8ZSIVEPVIDWVT>R0,N!T IUKXAL8?A_<
MZ*QD^U2/E<+\N-X/7Z"N2_&E[XI:&SQ$U+FZM6.QUCQ+87O@ZSTR#S?M,.-V
M5P./>M2S\>6;^$I-/OS(UYY+1!@F0W& <UYS^-+BG9%QQE5/F^1W'A[Q;IB:
M*-)UVV,MO']QE!.1]*LZCXOT*QT6>Q\.V9C:X!5]ZD  ]3UYXKSVCMUHL*.,
MJ*/*=MX=\8V46D_V/KMJ9[, [7')QZ8_K5Z^\8>'[#2)K30+$J\W#%TP%'XY
MS7GE)19#6,J\O+N^_4Z_PMXPCTJVDT_4;?S[*9RS=RN>O%;/_"6^%]'M+C^Q
M-/;SY1C#H0.G?)/'M7G%%%A+&5%'E'RR--,\C@99B>!@#-,H[?6DIG+)J0M%
M%% M HHI.^,\B@$T]!:*3\:* >FXM%&** WV"BBB@+,**0\=3BE[9H#0**3\
M:*!V%HI*6D(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0],?B*[31?A_)K.DP:C_:
M4<"R@G:T>>AQUS[5Q?UKUG2ETE_AM9#6G9;3/)7/7<<=*&=F"I1FWS+8YW4O
MAV=/L)[LZO!)Y2[@HCZ_^/5Q1C91N*,%SC<1Q78:S#X(72IO[(ED-X /+'S@
M=1GJ/2N@\'2P^*-$&GZA$7^R.K!]O! Z<TKFLL-"I4Y8V7XGF'EOQ\C<]..M
M*(93TB<X_P!DUZ%<ZU+J7Q*L[50R06LK1I&>"3M.36AJ'BFYM/&ZZ3'#$+5Y
M%252G+DC[V?IBBY,<+#7WMG8\J'/0$\XIS1N@!9&4'N17J]AX8TY/&6HSB&/
M9!&)$1Q\JN><_A4UP%U'3;R#6M4TF=<$VQBD7='^=.X+ M*[D>0JC.<*C'Z"
MGQ03S3B&.)C(QVJN.0:]"LW_ .$5\#1:G9JAO;IA^\9<D \]_:J9\8)JFO:7
M-#:+'=KA);AE&3GJ![?XTKB>&C&*4Y:LYK6] N=">%;ELF1<OQPOMFLSRY-F
M_P M]H[XXKUKQ/-/?^*=-T:1E^R2_/(FT') SC/6M"7]SJ9M)M0TF/2%38;1
MV4/CWS1<VE@$VTI;'B8!) 4$D],#K6[X?\,3:Z]THG\@P)N^:/.>O^%=AX>T
M?3+/6=:OX!%<16JL\(4[@.-W'KZ5;\)>)+K7WU-+Q(]T,>8V"8(!SQ^E%R*.
M%C=<SWO^!Y.PP2/2DIS_ .L:FTSSGN+1110 F.PZ&NP\&^,9-%G6SNV+V,AX
MR>8S_A7(4G0=B#V-#5S6C6E2ES(^E;>YBN8$FA<-&X!4CTJ4=*\@^'FMZA%?
M+IBQ//:,<_\ 7/WSZ5Z\F=O-9L^GPU=5X<PZBBBD= 4444 %%%% !1110 54
MOON#ZU;JI??<'UIH3*-+24M:(S"BBB@ HHHH ***2@#D/%NF3Q7,&L60)EA^
M\!WK4TGQ/8:C I:9(IE^\C'%;>,J5/*MU!K O_!VDWTAD,/ER'J4XI@6=0U_
M3M/@=Y)U8@955.3FI-$U0ZQ8_:&@:')Z'O6;:^"=(MI?->-YF!X#G-=%'&D4
M:QQJ%1>B@=* *FLC=HUWQ_RS.<5E>"L?\(^A''SFMZX@2Y@>&0$HXP1FH=/T
MVWTVU%O;*5C![T@+=<[XT_Y%R?\ WE_G7154U#3X-2M6MKA2T;')Q0!%H?\
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M%%%% !1110(**** "BBB@ HHHH ****!FNO2BA>E%9&@A[5QGC+5)-*T.:2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?OR$<DUNT4 8J#Z2$%!60M%)2TB@HHHH **** "BBB@ HHHH **** "BBB@
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M7G_?P?X4?\*MT/\ YZ7G_?P?X5W%%',P^J4?Y3A_^%6Z'_STO/\ OX/\*/\
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MJE'^4X?_ (5;H?\ STO/^_@_PH_X5;H?_/2\_P"_@_PKN**.9A]4H_RG#_\
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M_"K=#_YZ7G_?P?X4?\*MT/\ YZ7G_?P?X5W%%',P^J4?Y3A_^%6Z'_STO/\
MOX/\*/\ A5NA_P#/2\_[^#_"NXHHYF'U2C_*</\ \*MT/_GI>?\ ?P?X4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M5O%9E  S5JH9YO)7.,T 9_E2?W#1Y<G]TU9^W#^Y1]M']RK5R'8K>5)_=-'E
M2?W35G[</[E'VX?W*=V%D5O*D_NFCRI/[IJS]N']RC[</[E&H616\N3^Z:/+
MD_N&K/V[_8H^W?[%&H616\J3_GF:7RI/[AJS]N_V*/MW^Q1J%D5?*D_YYFCR
MI/[AJU]N_P!BC[<?[E&H616\J3^X:/)E_N&K'VX_W*/MQ_N478617\F7^X:/
M)E_N&K'VX_W*/MQ_N4:A9%?R9?[AH\F7^X:L?;C_ '*/MQ_N"B["R*_DR_W#
M1Y,O]PU8^WG^Y1]O/]RB["R*_DR_W#1Y,O\ <-6/MY_N4GV\_P!P47861!Y,
MO]PT>3+_ '#4_P!O/]P4?;S_ '!1=A9$'DR_W#1Y,O\ <-3_ &\_W!1]O/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !52]^X.>]6Z
MJ7W^K'UIH3*/>C\/UHI:T1 GX?K1^'ZTM% "?A^M'X?K2T4 )^'ZT?A^M+10
M F!1@4M% "8%&!2T4 )BEHHH$%%%)0 O-'-%% "8/K1@^M+1UZ4 )@^M&#ZT
M?C1^- [!@^M&#ZTM% A,'UHP?6EHH 3'M1CVI:* $Q[48]J6B@!,>U&/:EHH
M 3'M1CVI:* $Q[4M%% &NO2BA>E%9&H&LEOOM]:UC62WWV^M3(SF)1114&04
M444 %%%% !1110!?M?\ 4+4LK;8F/H*BM?\ 4+3[C_4/6L3=?"9I.3GUHI!T
MI:U("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ****!%FSZO_N_XU5'2K5GU?\ W?\ &JHZ5*W*%HHHJA!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4^+_ %J_6F4Z+_6K]:!E
MBY_U_P"%15+<_P"O_"HJ@IA1113)"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ %3VOWR?:H*GMOO&DQI:ENBH]XSUIV[W'YU%T5=
M,=13=WN/SHW>X_.BZ =13=WN/SHW>X_.BZ =13=WN/SHW>X_.BZ =13=WN/S
MHW>X_.BZ =13=WN/SHW>X_.BZ =13=WN/SHW>X_.BZ =13=WN/SHW>X_.BZ
M=13=WN/SHW>X_.BZ =13=WN/SHW>X_.BZ =13=WN/SHW>X_.BZ =13=WN/SH
MW>X_.BZ =13=WN/SHW>X_.BZ =13=WN/SHW>X_.BZ =13=WN/SHW>X_.BZ =
M13=WN/SHW>X_.BZ =13=WN/SHW>X_.BZ =13=WN/SHW>X_.BZ =13=WN/SHW
M>X_.BZ =13=WN/SHW>X_.BZ =13=P]?UHW>G\Z+KN X4M,4G.#3Z8PHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>2;:9$9]R_-R6!P?PK#UJV'@CQ+82:5+)';W! D@9RPQG!Z^U)XL<2?$G27
MX:&)O3NU 7.HU'5==A\60V=K#$VFMMWLP 89';FNGEFAAQYDJ(#TWMMKS+Q!
M_P E4L_^ <>O%)+ WB[XAW%C>.[6=L#B(.1G&/3ZT!<W=<\4WUCXLT[3K5H&
MMKDKN)7.<G!P<UVE>1ZMHT6B^/=+M[9Y#;^:AC5V)P-P]:]<I,:"BBBD,***
M* "BBB@ ]*F@&=U0^E36_P#%]*3V"VC/(=4FE_M:]_>R<3. -Q_O&JGGS?\
M/:3_ +Z-3ZI_R%KW_KN__H1JI7DSD^9G@59/G>I)Y\W_ #VD_P"^C1Y\W_/:
M3_OHU'14<S,[LD\^;_GM)_WT://F_P">TG_?1J.BCF879)Y\W_/:3_OHT>?-
M_P ]I/\ OHU'11S,+LD\^;_GM)_WT://F_Y[2?\ ?1J.BCF879)Y\W_/:3_O
MHT>?-_SVD_[Z-1T4<S"[)//F_P">TG_?1H\^;_GM)_WT:CHHYF%V2>?-_P ]
MI/\ OHT>?-_SVD_[Z-1U:L-/N-2N1;VRAI",X)Q34I-V&N9NR(?/F_Y[2?\
M?1H\^;_GM)_WT:W?^$*UP+DV\?\ W]6LO4=+NM*D6.[0(S#( 8'BJDJD=325
M*K%>\5O/F_YZR?\ ?1H\^;_GK)_WT:C[ \8)/>@'/3FHYI&6J)//F_YZR?\
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MG_(6O?\ KN__ *$:J5;U3_D+7O\ UW?_ -"-5*\>?Q,^>J_&PHHHJ2 HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV(?LT/\ SR3_ +Y%'V:'_GDG_?(J:BBR#ECV(?LT/_/)/^^11]FA_P">2?\
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M])Q;V,YG0T8KF_\ A+X?^?23_OJC_A+X?^?23_OJDJ<NQD=)BC%<W_PE\/\
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M^,G_ 'V*.1ASH["BN/\ ^$\@_P"?&7_OL4?\)Y!_SXR_]]BCD8<Z.PHKC_\
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MV*.1ASH["BN/_P"$\@_Y\9/^^Q1_PGD'_/C+_P!]BCD8<Z.PHKC_ /A/(/\
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M?\^,O_?8HY&'.CL**X__ (3R#_GQE_[[%'_">0?\^,G_ 'V*.1ASH["BN/\
M^$\@_P"?&7_OL4?\)Y!_SXR_]]BCD8<Z.PHKC_\ A/(/^?&7_OL4?\)Y!_SX
MR?\ ?8HY&'.CL**X_P#X3R#_ )\9?^^Q1_PGD'_/C+_WV*.1ASH["BN/_P"$
M\@_Y\9?^^Q1_PGD'_/C)_P!]BCD8<Z.PJI??ZM?K7-?\)Y!_SXR_]]BHI_&T
M$HP+.3_OH4*#%SHW*6N;_P"$NA_Y])/^^J/^$NA_Y])/^^JM19+DCI**YO\
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M #\3_F/\*/\ A$K/_GXG_,?X4<P<IQU%=C_PB5G_ ,_$_P"8_P */^$2L_\
MGXG_ #'^%','*<=178_\(E9_\_$_YC_"C_A$K/\ Y^)_S'^%','*<=178_\
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MO^$$L/\ GZN?S7_"C_A!+#_GZN?S7_"CVB#V;.!HKOO^$$L/^?JY_-?\*/\
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M (02P_Y^KG\U_P */:(/9LX'-%=]_P ()8?\_5S^:_X4?\()8?\ /U<_FO\
MA1[1![-G T9KOO\ A!+#_GZN?S7_  H_X02P_P"?JY_-?\*/:(/9LX&BN^_X
M02P_Y^KG\U_PH_X02P_Y^KG\U_PH]H@]FS@:,UWW_""6'_/U<_FO^%'_  @E
MA_S]7/YK_A1[1![-G T5WW_""6'_ #]7/YK_ (4?\()8?\_5S^:_X4>T0>S9
MP.:*[[_A!+#_ )^KG\U_PH_X02P_Y^KG\U_PH]H@]FS@:*[[_A!+#_GZN?S7
M_"C_ (02P_Y^KG\U_P */:(/9LX'-%=]_P ()8?\_5S^:_X4?\()8?\ /U<_
MFO\ A1[1![-G T9KOO\ A!+#_GZN?S7_  H_X02P_P"?JY_-?\*/:(/9LX&B
MN^_X02P_Y^KG\U_PH_X02P_Y^KG\U_PH]H@]FS@:,UWW_""6'_/U<_FO^%'_
M  @EA_S]7/YK_A1[1![-G T5WW_""6'_ #]7/YK_ (4?\()8?\_5S^:_X4>T
M0>S9P.:*[[_A!+#_ )^KG\U_PH_X02P_Y^KG\U_PH]H@]FS@:*[[_A!+#_GZ
MN?S7_"C_ (02P_Y^KG\U_P */:(/9LX'-%=]_P ()8?\_5S^:_X4?\()8?\
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M_P Q_A1_PB5G_P _$_YC_"CF#E..HKL?^$2L_P#GXG_,?X4?\(E9_P#/Q/\
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M%VW_ %S%7*BM85M[:.%22J* ":EKG.@*IG[QJY5(_>-8U2X!1116!H%%%%,
MHHHH **** +,/^K%)<?ZAZ6#_5"DN/\ 4/\ 2NN.R,)=3,'2EI!TI:V,KA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M 7+%GU?_ '?\:K#I5JSZO_N_XU5'2I6XQ:***H04444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %/B_UJ_6F4^+_6K]:!D]S_K_ ,*B
MJ6Y_U_X5%4%,****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9EVBJ7]JV'_/W#_WV*/[5L/^?N'_ +[%'MJ?\R^\/9S[,NT52_M6P_Y^X?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% S77I10O2BLC0*I'[QJ[5(_>-8U2X!1116)H%%%% !1110 4444 68/]
M4*2X_P!0_P!*6#_5"DN/]0_TKKCLC"74S.U+2=J6MC)!1110,**** "BBB@
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M111UT%<**3\#2]#R:+ZV"]]@HHI"<=>/PH'UL+129X[?A2\YXI-VW#6UPHH
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M4#GC@GTH^GXCTHOI=!ZA1111Z"UN%%%%%T&H444<YH]!ZA11^1^O444[2O8
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MOC=UJSX>C3_A%;\@?,5D.>O8TY8.A&4TXW5UU[CC7JRZ_@=%!J=M/I_VY7Q
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MX.E)V:U=]?0:Q%1:)]C1N?$UI;7TEFT4QE0=%7.?85%'XLL9(698KCSE;;Y
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M#US4QPU&'-..JNARK5-+NVY?\*W4]WI!DGF>5BY 9SDD9J#Q;=7-O#:"UN#
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M2WH>JB_L(WN)XO/8] 0,_A6MP#SD@==M<?X:\/VTD%OJ#R3+(A.%R /Y5V&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJF28HKCR$8],#I_*MS5M1O=.\#^'FL[J:W:3<'\IL!N:I-IKQ_#)YW5_.EN
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M^=5=6T:;1_A=%;3*?/+K(XSS\S ]/;-&HZ-<ZC\.-&FMXFD>V4DQA>6!//\
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M)=Z=X1UB_4A4D&8@#TZ@GVZU7\+76DV4^K)X@"+<LYR9QG(]O\:L>#[*YO\
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MZ5W3RZ22M)-[,YHXN+NDFM#J>.@ Q[4O.<\<9SBN4\+:S=W<TT5Y.9"5#)N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBC%)@%'/7K2<5<T_3Y;^8(@(0'YFK2G3E5DHP6
MI,YJ"NR]X>:Z%SMA&8?XL]!78"JUI9Q6D"QQK@#]:LC@5]A@\/*A34&[G@UZ
MBJ3NA:***[#$**** "BBB@ HHHH *J7WW!]:MU4OON#ZTT)E&EI*6K1F%%(<
M*,D@#UIJ.DBAD8,I[BGJ.W4?1110(**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH UUZ44+THK(U
M"J1^\:NGI5%L9.?7I6-5%P ]_4=ZYV[URZ@\9VFD+M-O+!YA/?.2*=JOC70]
M)G:*XNM\@ZI",D5S,?B+0=6\96FJ)J+0;(O*\J:':3SGKG^E3&)3DCT;')/J
M3FH+RV6^LY;:0MLF78WTJ5'29 Z,"K#*D'(Q575;EK/2KFX7K'&3]#4+XK#;
MT,+3;WPWH=_#H%AL$S_>VKT(&?F-2^(O&5IX<NHK:XM+F=Y5RIB"G^9K/\ :
M3"NDKJLZ+)?73,YD<9QD]J;KMI)-X_T>0P,\"KAFVY6K]WFLR-;:%[0_'%AK
MFH?8EMKFVFQE?. &[Z8-=1W/;M7#>.K9+"XTK6+5%CGAN45]HP&4]17;QOYB
M*_J 3^(I327PE0;ZER#_ %0I+C_4/]*6#_5"DN/]0_TKHCLC*74S.U+2#I2U
ML9(3!QQ_.JE[I=AJ6W[;9P7&W)7S(PV,_6KE%,#)_P"$8T+@C2+,'_KBM7XK
M.W@MOL\5O&L)!4QJH"X^E3T4@*-KI&G6D+Q6]E;Q1RY$D:1 !NW-+;Z786D$
MD%O9PQ1R\2(JC#?6KM% %:SL+33XS'9VL4"$Y*QH%R?PJK-H&D7$OFS:9:RR
M$YWM&"?UK3HH"Q%#!%!$L44:)&O1$7 %29.>GXTM% 6*-WH^G7[A[RQ@G8'[
MSQ@G]:M0PQP1K'"BQHHP$0;0/RJ2B@+%"ZT73+Z02W6G6TT@ZL\2L?UJU!!%
M;1B."-8XQRJH, 5+10%BA<Z)IEY/YUQ86TTI.=[Q@FI9K"SN+86\UK%);C_E
MFT8*C\*M44!8R/\ A%]!#8_LBRQ_UQ7%7K.PM-/@\JSM8K>,G.R- *LT4!8J
M7FFV6H",7EK%-Y9^7S$!VU8>..6(Q.BM&>J8XI]% 6*-KH^FV4QEM;*WBD/=
M4P:N\^F/6EHH"P4444"+-GU?_=_QJJ.E6K/J_P#N_P"-51TJ5N4+1115 %%%
M% !2<@Y![<XZTM% K&;/H6DW<OFSZ;:R.>=TD8)J[;V\-K#Y,$2Q1CD(HP/T
MJ6B@+$5Q:PW<+0W,:2QR#!610U):6EM80""SAC@A&2$C4* 3UZ5-10%C+G\.
MZ-<SO-/IEI)*YR[M""6-)'X:T2&19(M*LDD0AE<1 %2._2M6B@+%2TTVRL"[
M6EI# 9.6V(!FI9K>.YA:">)9(FZH>AJ:B@+%:TT^SL(O+M+>*W3=D+&@'\JL
M\_TZT44!8JWFFV6H;!>6L,^PY7S$#8^F:L(@1511A5& !P!3J* L%%%% !11
M10,*=%_K5^M-IT7^M7ZT 6+G_7_A452W/^O_  J*H*84444R0HHHH XWXEW4
ML'A<K&V!+*%?'OS_ $K2\(Z5:6/ANV2&*,--'ND./OY]:E\5:)_;V@RVB?ZX
M#?$?<?\ ULUPVF>,]5\,V8TN_P!+>9XAMC(RO^.::!G>V?AO2;'4FO[6S$<[
M9PP/ ]>.U<@FI:QXN\27-C9:A+8V5H2"\7!]/Z&KWA/5O$FL:M)<7<7DZ<0?
MD9<$<< 5CV3W'@;Q9>RW5M-)871W&6-<XY)_K0*YHZ5K>J:'XM&@ZG<O=12@
M-%*YR>1FN?L[:\N_B3?0V-R;:1BP>4?>"X&<5KZ;:W'BSQLNM?9I([" ?([C
M#.0,"H?#D;CXJW[E&*;'^8J1V%,18TW4]5T/QX-#O-2GO[>0<O+R1E<CK[XJ
M75-9U;7?%S:#IEXUK#"/WDL9P??^8JGJJ/\ \+<A8*^W:GS;>/N>M.OX;GPG
MXZDUDVSS:=<CYF09QG'^'ZT 3G4]6\(>*;73KZ_>_L[H@(\W++DXS^9JMXBU
M+6'\>Q:;8ZA<1I,JA0LAVC.<GT[47'F^.?%MC/;6TT>GV9!:5QC=@[OZ4^^C
M?_A;-D54A0JC.TX'7B@"IXXT"^TS0UFN]:N[Y?,"A)3\O/?K5M9M0\.?#Q+^
MVOYIGGV+&C\B <YVUM_$>RGN_#+?9T9RD@8@#)P*SM'\012>#EMX])FO?LJ*
ML\3'9D'/(R#TQ0!0TQ[[5(89M/\ &,C7W!>WNV(4'N!7I-MY_P!FC^TNK3;?
MF*'@UX]K T&]MP='L+ZVU0L-J*I"J<\_7CZ5ZEX;BO(?#UFE^2;D)\^:3&C5
MHHHI#"BBB@ J:WZM4-36_5JF6S]!QW.)O/\ C]N/^NC?SJK*I:)U')*D8JU>
M?\?MQ_UT;^=05\'6=JE[]3Z6DKTTCD/"]U!937UE<ND4IF+ N<9 _P#U5N)K
MUC)J@T]'+NPR&7E2?2F:CX=T_4G#RJT<@Y9HS@G\\T_3= L=+8O"LC.>CR,"
M1^0%>A7GA:C=:=[NQS4X55>-M#&T;:_BJ_:X.Z91B/<.,>E,M?D\4:FMN?W/
ME/NV=,UN:AH-IJ$JS/YD,HZR1-@M4EEI-KI]L\, 8>8"'=F!9OTJWC:5N=7O
M:UB5AW=)[(YWPY%&=#U&0H"[,R!B.HQ56U:0>"[I4SQ)\Q'I7566CVUA936T
M;2%)6+,21D9'TIUCH]MIUG):INDA<_.LO>G+'TG-O?5"CA6HQ7J8DL=F/ V2
M$P(L@X&=U9-]ODT71Q/DEGP-U=&OA/3O-W;IS%NSY._Y:N7VBVM_]G$A9! V
M45#Q5PQU.#]WO?\  3H3DETL5/$**GAJ1% 4!5X 'YU9\._\@*T/(;8#]:N7
M-I%=VC6TH9HV&TY8?X57TS2(=)5U@FE=7XVR/D+].*XI5XRH.FV[WN;JBU44
M[="6[U&TLWCBN92C2_* 0>?QKF)8H]%\36RV1(%P"'4\G_ZU=+J&FV^IP^3<
M*>.A!Y'TJM8>'[*PF,R&66;^%IFSBJP]:G1@[/6UK>H583G/8N".S%]N B^U
M 8/(W8^E6<_=/7%9ZZ1;KK!U$%_.(VD9X]*T0#Q@$<<XKEFX\ZL[FT$TFFCS
M[3-!36;Z^+SR0E)3G:H.>34UGIJZ1XQM+=)&DR,EF'^R:ZO3](M]-EGD@:0M
M*<MN]<TDFD6[ZO%J+O()XUVJH88/&/2O3_M&+E*+>EK(XUA':+\SG]$N8M-\
M0ZA!=.(FE/RL3@'O_6MN77K"*^AL_-#O+P&3Y@OY4[4M#LM4YG1D<?QQG!_6
MH].\-:?ITWFQ+)))V,I!Q^0%95:F'K+VDF[V_$N,:M-N$=F[F0)X[#QQ<271
MV)./D9NAX YK:N]?L+*2%'E$KR' V$,1[G%2ZEI%IJL02X3YATD4X(JE9>%=
M-LIO.422MV\U@<?D!0ZV%JI5)W4DK>3'&%:G*RU3-L'<@9>>,C-83ZCX@#L$
MT>,K[S#_ !K>QVQBBN&C54;W5SHE"4DDG8RM/N]5GN-M[IJ6\6/O"0-S5?Q=
MG^P9N>=RY_,5NU4U'3XM2LVMIBX1B,E3BM*=6*KQG;8F=.3IN%]SCK;PWI\U
MDD[ZJ$9ESLW+_C19W+-X:U*T^4I"V%8#&>:U_P#A"=,VX$MQW/WA_A6FFAV:
M:9)81AUBD^\V1D_I7JU<QHN\5)O5=#@AAYO5*UD<8K-IUE87\8Y='0@?A2FV
M,4NAN02SN'/OE\UULOAZSFTZ&R=I?*A;*,",GVZ5+<:%:W3VKN9 ;3;Y87V/
M%#S&G:_74I822_ Q=7&F7^M?9IG>TN8^DW&#4"7]WI&KV]L-36^AF<#;NW$#
M/Y"NAU/0K'5BK3*RR#^-3@XJ'3_#.GZ=<"9%DD8=/,(./TK..,H^SM)O;8IX
M:ISV2\[E2\E\2C4'%K%']E#C;N"Y_.J[VU[8:U-<Z>L-PTR?O(S( 5/4\?6N
MK)]?PK*U#P]::A=&Y9I89L<M$V-U<V&Q=./NM<JMK9;FM6A-KF3O^AS.C/+;
MPZQ=R()-BX/<'-5_[.9?#BZ@;K,>[=]GSQ]ZNWM=+M+2S^R1Q_NVZAN2WUK-
M_P"$2T_S,[I]F[/E;_EKJCF5)RUT,7A9I&'KQ%T-)G9/+AD7;M'0=*MSV\.G
M>*K 6"A \85E3@?YQ727>F6M[:"UEC 08V@?PXJKI^@6>G3F=&FDD/\ %(V=
MH]JC^T*;IMOS5O4?U>7/==;&?KVMRM<_V7IH+7#G#N/X::]K-X>\.2+:QM)=
M2G+&-2>3UJP_A&RDN&N/M%R)&;=N5P#_ "K1T[2X],5Q'-/-N//FMG%3.O1I
MTXP@[I:M=RHT:DY/FT['"W<\<3:<D5I<1F%B7WJ09"2.E;^HQ337]GJ=E&OV
MC _T:5PK'GWK9O\ 2;;4;FVFF>0/ <IM(P>GM1J6C6VIF-IS(LD9X=&Y%7+'
M4ZCB[6MN3]5E%27S1S6F"ZG\8F6X0"3:6=0<A/:NMOK47UE-:EB@E4J2!TS4
M.G:1:Z8K^0'=W/,DARU7N3TKCQF)]I5BX:*.ATX>DXP?-U//;GPY%#KMM8"X
MD99.2Y497BNTTK2TTJS^S)(TH!SN90*MF-&E\PHK.!PQ7D4_FBOCZM:"CV"A
MAXP=T<IXN >^TU#DAGQCL1D4WQ$J1ZSI0C4*$(5<#'&:W=0TFWU&:WEF>0-"
MVY0I&.OTHOM(MK^Z@N)6D5H3E0"/\*VIXJ$5!/HG<QJ4'=V,67_D?(^W[H?R
M-4+^:30M5OXU!"7293'K_P#KKJFTFW;55U$O+YRJ%'(QTQZ4W4M$MM6DBDN/
M,S'W7O6D,=252SVL*6&GRZ=[F&UG+9>!W$7$DBAW_$BI62S_ .$&/"8$600!
M][FNE>))(6A90RL,%>U8W_"*:>)=^^?R]VXPEOE)^E32QD):R=G>XYX>2>BN
MK6.>O3(?#.E>9GB48![#%:&J<>(M&)X&U.3]:W=0T6UU"&&"3>B0L"H3MBDU
M#1+74HXDE+*8^%=&PP%7#'4;Q;\_Q)^K25VM3#U9E/C&QPP..N#TXIFCH&\4
M7Y90=JDYQ6M!X8L8+J&Y62Y:5.C.X.[]*LVNC6UKJ$UY&\I>88<%A@?I3>.I
M0@XQ;^']1?5YO62ZW.=\.HF_5FVKOVL S#)I-'NEM/#&H.\8E02GY#R.@[=,
M5T=EHEM9-<F%Y29P0^6'&?PI+31+2TLYK5-TD4I)8.?6E/&TI)J6JNF..&E:
MR\SD-2CN6\/07$]Q"L9(\FWB7"X_QJYK@0MHRR?<V@MGIVK6'A#3Q$T1>X9#
MTR_W/I5BY\/6=XENDSS$0C ^89(]^*U>/I736ZN0L+4=VS*\4B-;O3F@P)1(
MI4ICIFNJ3)12>N*R+7PU96MT+C=-*R_=\QLA:V:X,7B*<U"$=;=3JH4G!MR6
MX4445Y\5I8Z=.@4444 %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** 04E+WJYI^GR7\^U 0@/S-5TZ<JLE"
M")G-05Y!8:?+?SA$&$'WFKM+6SBLX5CB7 '7CK19VL=G (HUP!W]:M5]7@L%
M&A&[^(\3$8AU'Y"4M%%>B<P4444 %%%% !1110 4444 %5+[[@^M6ZJ7WW!]
M::$RC2XI*CN+F&V0//($4D $]S6B3>B(2N[&#JVMP,U]I:HPE2!FW?A7/Z7K
M=QIFCZ='" WGS%6+>F:-0(;Q3JISD?9S@^VVLQ?^09H__7P?YBO1A22BCW:=
M"FJ:37]6/55.Y0?44M<WH.KW=[K5_:S,OE0;0N!3/%VHW]BMA%87 @DGF$99
MES7#4CR2LSQZU)TYV9TU+7%7L_B7P_"M_<7L-Y;*P\Q=F.#741ZC:>5 TDR0
MM,NY48]1BL[F5BY^-+UK"U:^EF2V;3-0MT43 2$D$-["M&[U.RL HN[M(6;[
MNYAS1<"Y167?:O9QZ5)=PW4:KM(20-D%JI>%=:74]+A\ZYBDNR"67H0!WHN%
MCH/QI:H?VUIHN?LYO8?,SC:3S6;KVI7-GJ6EPP2@)/)M?CJ*86.@_&EJGJ<[
MP:7<31D*R)D$^M<KX,\07][<M:ZG(K-*@EB('44KC2NCMJ3MG-<OXQUJZTZW
MA@T]@MW+ECQDA15WP]JOVO2;-KR=#=3)N Z%O7BG<5C;HJ&>YAM@IGE$88X!
M/?VJ"[U?3[*8)=744+M@J'?FBX6+U&*@:\MEMQ.TRB$\A\]::M]:RRM"D\?F
M*-Q"G)Q[TK@6.^*6L]-;TV6X^SI?1&7L@//YU9N[E;2SGN&_Y91EROT&:+@3
M?C1^-<59MXFURU;4;?4DM8FR8H1&#GZFMGP[JUW?64BZA'Y-Q;N4<D8# ?Q4
M7'8W/QH[XS6>FN:6\C*M[ Q3)8;\$58^VV[21Q^>F^5=R GDTQ6+'XT=LYJ&
M2[MXIXX7E19)/N*3UKFI;W4;:QUF=[R*1HMQB$8^Y@4K@=9VS25AZ9KUH]A:
M_;;R);J1.5)P34>OZG<6=_I<=O(%CGF DSTQ]:+A8Z&D_&LU=5LKT216=[$\
M^WI&W/ZU5M_[7%Y&DC%H0V69L9^E%PL;M%)G/7@TM,#77I10O2BLC0#7%^.M
M5GT_25@M'*W-Y)Y*,.H'?^==H:X#XA*\5MI^I*FY+.XWR#_9XK.12V+&B>!-
M(TVW0W5JEU=$9D>50P+'TS5O4/!VAZE;-#)IT$3=GB0 CWS6K8W]OJ-I'<VT
M@DCD4$$&II'CCC+2,%51DDG'%9\SYK#LK79QG@U[G2]6U#PY<2F1+=1);[^N
MTD?XUU]];"\L;BV.")$*\]ZX[0+E=<\=ZGJT&3:PPB%''1FX'_UZ[CIR3UI2
M:N.*NC@O!>N0Z9%)X>U.0075L[*ADX# G@YKMC>6JJ7:Z@"]V\P<5B>)/#NB
M:I$UQJ)\AE _?HP5A]:XB/P[X:DG\O\ X2O=&3C8)>OMFKM%ZDMM&QX@U%/$
M_B*PT;3F$T4$ZS7$B_= !Z5Z JA %'0#'Y5DZ#H6E:-9@:;&"'',Q.6;\:U_
MT[U$FNA<;]2U!_JA27'^H?Z4L'^J%)<?ZA_I71'9&4NIF#I2T@Z4M;&2"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****!
M%FSZO_N_XU5'2K5GU?\ W?\ &JHZ5*W*%HHHJA!1110 4444 %%%% !1110
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M0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBBBP!1UXH[<<U;T_3Y;^<*HPG\3>E73INI/EBB9SC&/,Q=/T^74)MJ<(
M/O-Z5VEG:16D CC4 #J?6EL[.*SA$40X'4^M6 ,5]9@<%'#QOU9XF(Q#JNRV
M#\*6BBO0.8**** "BBB@ HHHH **** "BBB@ JI??<'UJW52^^X/K30F4?6N
M6\=_\@FV]/M"Y_(UU-87BZQ>]T-_*&7B(D ]<5T4+<ZN:81I5HW,Z+PY<W-_
M-=AU$4]L(USU!*]:IS^%K^&UTR&,"1HYRSX/09S6_P"&M8AU/3(@&"SQKLDC
M)Y!'%;? (^G6M95IQE9G14Q=2$VFCD/#$;IXFU7>A"DC!(ZTSQR)MVE>04$I
MN1M+9ZX-=@L:*695 +8R0.M<QXRM;R;[!+9VKSF&8.RK6%6?M)79SUZOM9<S
M,_6;;Q$+/S-4>&YT^/YI8K?Y6(_2H=;%MK.I^'A;L5MYE.-O&!CI5Z^O]>UB
MT>PAT:2U64;'EE;@ ]<<4UM!N;/4O#T<2&6*U0B1QT!Q69E>XOB+3;72[;2X
M+2)8D%T#@#OQS5;41#8^)Y[K5["2ZM9%'ERB/>D=;?BBRN;O^S_(B,FRXWN!
MV'%17MYJNGZDXEL&O[%UPBH,%* *5MI>A7&EZA<64D=Q;L"X@*\1L.X!Z&J>
ME6]O8> YM1@@CCNC$090HW<G'6KVAZ1>23:I>26WV)+I=L=O^'6H=(L=0?1+
MCP]=V#Q#8P6YSE6.>.* Z#XO#>F-X0\TVR&Y,7G><5&[=ZYK/6ZDN[?PW)*Q
M9O,"DDY)P#S5Q;S78M'_ +%_LB5K@+Y7GY^3;ZXJ2?0;JT&A6\49D-M)F5AV
MX- :'2:U_P @*\_ZY&N#A#V&F:%K$0QL80RG/\+<9KO]5BDFTFYBC4L[1D!1
M6/I.B?:O"$.FWZ,FY<-@\@]:=A)Z&-*W]LZCJ^I9W6]M!Y41[9ZG%5/*-MX;
MT/5D'-LZASZ*W']:ZI="CTOPQ<6%FK.70]3DDGUJM9Z4\G@<V5TA1_);(/8@
M9%*S&0:I+_:WB33[53NCMXOM+8Z9[?RK"TN]T>62]FU6UEN9Y9F4'R"X50>@
M(%:_@6TEFM[J^NB&:0^4OLJ__KI+4:CX:N+JU&EM>P2,7A9.-I/KQ2LP,A'D
M?P7J$ 258EGQ%YBE2%[ 9K?7P\L'AB5K%<W\UOS*3\S>HIEW9:O>^%9DNT#7
M4L@81(,;16X\5[_PC_E6K".[\D%<CC('2F@9Q]G_ ,(]<6$.G7EJVG7J$?O'
MAP=WJ&KO?LZ-8BV=O-4IL+,?O+BN,U&?5-7TX:=-H3B[8@/<$C"^XX_K75QV
M4BZ(+(RE)1!L#CJ#B@1S0TC7O#PD_LF=+JTW;C;OU ]C4.J>)&U7PI.R1M;W
M'FK!,F>5Y -6;75=?T>W-C=:5->,I/ESHV 1[\57A\+7]UH>H/,JQWMU+YZI
MZ<YQ0,EUOP[IEOX0DDBMD26.,,9%7!;/J:AMQ_Q/_#? _P"/,8_*F:KJFK7/
MAJ>SETR2 QQ@2S.WR\>G%2S6U[#%H>L6=LUR((%5XE')&.U %S7#GQGHA[X<
M_P JR(^+'Q5QG]XQQZ\5?>/5-4\4:9?R:>]O:Q[L;N2,XZTQ-*OOLGB)3;N&
MN'8Q#'WN.* 'Z?X<TR3P@LDELCSF N)F4%L_6L9\ZEI/AV*Y)/\ I!1L>@.*
MU;>ZURTT)-).C2M,R;%F!^4#W%,O=!U*STW18K.+S9K=_,D(Z9SDB@";Q-I-
MEH\-A?6,"02Q3JA9%V[@:[.-M\:L?O%03^5<=?'5?$D]I9OIDEK!#('ED=LA
MB/3BNR0!5P#TXH0F.X]****HDUUZ44+THK(U ]*S;JWBNH9(9D#QN-I##K6D
M>E<EXKT?4M7B@73KW[*T;$L<=<UG-EQ.?E\ ZCIT\C>'M9>UA8Y$3NP4?3%1
M_P#"%>(]0PFL:Z6M^\<;MDBHO^$'\3XP?$3<>Q_QK#UVTU30%Q<>)&DG(^6&
M/D_SIJ[M9DL]6TG2;31K);.SC"Q+U/=CZFK4\RV\$DTA 5%+9-<!\/K'Q"UR
M;_4I9/LS)M1)#DM[UVNLQ-<Z+=0IU>)@*SE\6K+3T.#LM(G^(%Y-J6IW$B::
MDA6"$'J!T-;S?#GPX\>S[,^X#[WF'-'P^NH9O"L, ^66 LDB=P<]3768Y(].
MII.5GH"2:/.8(+OP%KUE&ER\VD7K[ '/W":]&!R!CD>M<3\0I4G_ ++TY/FN
MI;I&51_"!SFNSA!6%%/4 9_*B=K#B]2[!_JA27'^H?Z4L'^J%)<?ZA_I6\=D
M92ZF:.E%)VI:V,D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444"+-GU?_=_QJJ.E6K/J_P#N_P"-51TJ5N4+1115""BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I\7^M7ZTR
MG1?ZU?K0,L7/^O\ PJ*I;G_7_A4504PHHHIDA1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5-;]6J'_&IK;JU3+9^@UN<3>?\?MQ_
MUT;^=5V <$-T/!JQ>?\ '[<?]=&_G4%?"U-*C/IJ2O!*QQACU7PU?3M;6QN+
M69MV,9 JYI-QK>HZK]JE#6UJHP8R, _05T_X"C_.:Z7C^:'P*_<P6':E=2LC
ME&2ZT#7+BZ%K+-:W/>)=S ]3Q]:=IEE=7=[>ZM<V[0^;&RQH1@FNI&1TQ]2:
M.@/3GVH6/;:45JU9L%A4NNG8Y7P_!-%H&H(\<BLTC;5*G.-HZ"H=+TR:Z\,W
M5JZ/'*6W*'4BNP[@Y/%'/09_$TO[0FTVEN_R!81))=CC&O+^32/[(&G3&?'E
MF0K\H!]_I1JFES6MCI=JD;R-&^Y]JYP:[/ )[_GB@=,\DUHLR::Y8]V3+"Q<
M??9DZ[;27.@RQQH7?8#@'GCVJ+PU<2/IJV\EO/%)  &\Q,!OI6WCMQSU)H[
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M7GW.CVUM;Z3-$(6#2MY6-Q'H.]:&MI=-?:=/!;22%8P2-AXQ78\<9[=*#_\
M6SBM99HW)/EV(6#7\VYR4YN_$.L6F;.6"&%@S&48S@YKK  %P.W%+Z@8Q[\4
MG;T]JY,1B/:V1O2H^S=Q:***YGN;!1112 **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHQ30!125<L+"6^F5$&$'WFQ5TJ4JDK1)E
M)05V&GZ?+?S>6@P@/S-7:VEG%:0+'&  .OO1:V<5I"L<2X ZGUJS7UF P4</
M'7XCQ,1B'5>FP 8I:**[T<P4444P"BBB@ HHHH **** "BBB@ HHHH *J7WW
M!]:MU4OON#ZTT)E*D(R,8!]C12UHKF=[:F!_PBMK%JZZA:2-;MN#2(G1_K6\
M!@4M%5.=VD:U*DYV4PI,?3.?2EHJ#,.QYYS1T&!T[<]*** N XY!P<8XI,#'
M ''MU^M+BBBP7$QR*,<<\_7FEHHL%Q,>GY]Z.?7%+13L%P]QP?6CMC/THHH
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M^T(]CB**[?\ L33_ /GV7\S1_8FG_P#/LOYFC^Q:O=!_:$>QQ%%=O_8FG_\
M/LOYFC^Q-/\ ^?9?S-']BU>Z#^T(]CB**[?^Q-/_ .?9?S-']B:?_P ^R_F:
M/[%J]T']H1['$45V_P#8FG_\^R_F:/[$T_\ Y]E_,T?V+5[H/[0CV.(HKM_[
M$T__ )]E_,T?V)I__/LOYFC^Q:O=!_:$>QQ%%=O_ &)I_P#S[+^9H_L33_\
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MZ#^T(]CB**[?^Q-/_P"?9?S-']B:?_S[+^9H_L6KW0?VA'L<117;_P!B:?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7%_XNN=%DMHD2%"V[)W9X[?C75=OIWKSK0N?BUJP]8Y.G7JM>B]3\P/J/Z4
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M'_/H?^_G_P!:C_A*Q_SZ'_OY_P#6H_M/"_S?F'U.M_+^1TG%'%<W_P )6/\
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M/_?S_P"M1_PE8_Y]#_W\_P#K4?VGA?YOS#ZG6_E_(Z3BCBN;_P"$K'_/H?\
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M/_?S_P"M1_:>%_F_,/J=;^7\CI.*.*YO_A*Q_P ^A_[^?_6H_P"$K'_/H?\
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MM>,-C((%7H=!\*>(-..I02?87(RPCD'R'WS0!M>"[36K&RFM=5P8P<PR>:K
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MD/ABQO=6UJ]T1]3N5L[<,S!6^9L-CK6IX,NKG3O%>I:4UQ)+:PJ6 E.3Q_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_7I_V9B?Y0^O4NYS9Y[]>OO1Z^]=)_PBA_Y^S_WQ_P#7H_X10_\ /V?^^/\
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M +X_^O1_PBC?\_9_[X_^O1_9N)[!]=I'-T5TG_"*-_S]G_OC_P"O1_PBC?\
M/V?^^/\ Z]']FXGL'UVD<W172?\ "*-_S]G_ +X_^O1_PBC?\_9_[X_^O1_9
MN)[!]=I'-T5TG_"*-_S]G_OC_P"O1_PBC?\ /V?^^/\ Z]']FXGL'UVD<W17
M2?\ "*-_S]G_ +X_^O1_PBC?\_9_[X_^O1_9N)[!]=I'-T5TG_"*-_S]G_OC
M_P"O1_PBC?\ /V?^^/\ Z]']FXGL'UVD<W172?\ "*-_S]G_ +X_^O1_PBC?
M\_9_[X_^O1_9N)[!]=I'-T5TG_"*-_S]G_OC_P"O1_PBC?\ /V?^^/\ Z]']
MFXGL'UVD<W172?\ "*-_S]G_ +X_^O1_PBC?\_9_[X_^O1_9N)[!]=I'-T5T
MG_"*-_S]G_OC_P"O1_PBC?\ /V?^^/\ Z]']FXGL'UVD<W172?\ "*-_S]G_
M +X_^O1_PBC?\_9_[X_^O1_9N)[!]=I'-T5TG_"*-_S]G_OC_P"O1_PBC?\
M/V?^^/\ Z]']FXGL'UVD<W172?\ "*-_S]G_ +X_^O1_PBC?\_9_[X_^O1_9
MN)[!]=I'-T5TG_"*-_S]G_OC_P"O1_PBC?\ /V?^^/\ Z]']FXGL'UVD<W^(
MH_SFND_X15O^?L_]\?\ UZ5?"IRN^Z+ 'D;?_KT+*\2]&A_7J25T9.F:9)J$
MW0B$'YFKL[:VBMH1'&H"BE@M4MH5CC4 #]:F KW\%@XT(W>YY=?$2JOR$QBE
M[T<T5WZW.<6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JE]]P?6K=
M5+W[@^M-"92HI.*.*T1F+12<4<4 +12<4<4 +12<4<4 +12<4<4 +12<4M !
M1110 44G%'% "T4G%'% "T4G%'% "T4G%'% "T4G%'% "T4G%'% "T4G%'%
M"T4E+B@ HHQ2<4 +12<4<4 +12<4<4 ;"]**%Z45D:B'I5*5E16=V"@'[S'
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M%#\:6KV+7_9H_P!%_P!FBX6*-%7O]%_V:/\ 1?\ 9HN%BC3HO]:OUJY_HO\
MLTJ_9MPV[<]J+A8BN?\ 7#Z5%5U_)W?/C/O3?]'_ -FI'8J48JW_ */_ +-'
M^C_[-.X6*F**MYM_]FC,'^S1<+%2BK>8/]FC,'^S1<+%2BK>8/\ 9HS!_LT7
M"Q4HJWF#VHW0^U%PL5**M[H?:C=#[4!8J45;WP>U&^#_ "* L5**M[X/\BC?
M!_D4!8J45;WP?Y%+YD(__51<+%.BKGFP_P"11YL/^11<+%.BK?FP?Y%'FP_Y
M% 6*E6+3[S5)YL/^13XW1CA*&")****DH**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%.D:74VB31V#/M%QYF<CZ8KM+2ZBO;2*YA;='(NY33L")J=%_K5^M-S3XO\
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M)<?ZA_I2P?ZH4EQ_J'^E;QV1G+J9@Z4M)VI:V,D%%%% !1110 4444 %%%%
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MG[P'%=9U-=.%NE9HZ:,KK8***3C&:ZC86BDHH 6BBB@ HHHH **** "BBB@
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MA1115$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54OON#ZU;JI??<'U
MIH3*-+24M:(S"BBB@84444 %%%% !1110 4G/U]J6JNHSM;Z=<3+]Y(R5^M
MC-O_ !'#:W1M+>&6[N?XDC&0M0)XH>*=(M1T^>U#D!7((4DT[PG9HNE"\<9G
MN&+NU;TD:28\Q V.F1TH <I# %>589%'.*PO$ N;,PZC:R/MB/[Z$#@I5:\U
M.35[JUL=.D.UP))I4/1?2@#IOU]J,+GYAD>XK)O]':Z",M[<1F-,?(>#[UB>
M'],GU"V-Q)J-V3',5 SP<&@3L]SL=HR20,GTYR*.O; %<U?3W6J:NVE6DQA@
MA7,TPY8Y[4VZT.YTRW>\T^_N&DC7>Z2G(:A*P7TT.GQG'3([XYHY]_QK!N=3
M>[\)2WL3;)#%D8['O5?P?J$]Q:O:W;E[B/Y@6[J:$K#TZ'35FZEK$6ESPI/"
MYCE( D[ US>KZK=2^)+>.WE9;:&0(^.YKK-1L(=2L9+67E7'![@]J87)9;B.
M&!IY' B5<[ZK:3J:ZI;FXCA>./=\I;^/WKC(+J[U"YC\.RN%CCD_>2!N64=!
M7>V\,=K D42X1!A:0)DO-%'2B@84444 %%%% !1110 4444 :Z]**%Z45D:!
M5(_>-7:IG[QK&J7 2BBBL30**** "BBB@ HHHH LP?ZH4EQ_J'^E+!_JA27'
M^H?Z5UQV1A+J9@Z4M Z45L9(**** "BBB@ KEOB$COX1N-@)VLI;'I74U#=6
ML5[:R6TRAHY%PPH Q/!$L,WA.S$)4@ @@=CD_E6T+RW:X:U6:/[1U,0."!ZX
MKS]_ NNZ;<2#0M4$=N[$A7<KC/T!K1\/>"9]/OWU+4KK[1=@?*FX[<_7_P"M
M3%8/B1J5K;Z.ME)&'N+A@T>>J ?Q?Y]*Q/AQ<PZ;J5QIUY 8;R4?NV=3D@=1
M_GTK8B\(ZC?>+7U76I('A5@\<:.6Z?='2K/BKPC/JEY;ZEI31PWT3 LSG ('
M3I0%BSXD\9V_AR[AM9K228RQ>9N1@ .2,?I65J%L?'V@V^IV"-;SV\I$<<C
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "GQ?ZU?K3*=%_K5^M RQ<_Z_\*BJ6Y_U_P"%0U!3%HHHIDA1110
M4444 %%%% !S_B<=:._>BB@ YH[>M%%  ?P_ 4#IS110 9/MS[4444 %%%%
M!1110 4444 %30$#>3Z5#Z?6IH!G</6IDO==BEJT>-:I_P A>\_Z[R?^A&J=
M=E>^ ]4GO[B:.2WVRR,PW,<\DGTJ'_A7NL?\]+3_ +Z/^%?,U<)7<V^6Y]C0
MQ^&5*,7*S1R=%=9_PKW6/^>EI_WT?\*/^%>ZQ_STM/\ OH_X5G]3K_RLU_M#
M"_SHY.BNL_X5[K'_ #TM?^^C_A1_PKW6/^>EI_WT?\*/J=?^5A_:&%_G1R=%
M=9_PKW6/^>EI_P!]'_"C_A7NL?\ /2T_[Z/^%'U.O_*P_M#"_P Z.3HKK/\
MA7NL?\]+7_OH_P"%'_"O=8_YZ6G_ 'T?\*/J=?\ E8?VAA?YT<G176?\*]UC
M_GI:?]]'_"C_ (5[K'_/2U_[Z/\ A1]3K_RL/[0PO\Z.3HKK/^%>ZQ_STM?^
M^C_A1_PKW6/^>EI_WT?\*/J=?^5A_:&%_G1R=%=9_P *]UC_ )Z6G_?1_P *
M/^%>ZQ_STM/^^S_A1]3K_P K#^T,+_.CD^AS_*EXP!CI75_\*]UC_GI:_P#?
M9_PH_P"%>ZQ_STM?^^S_ (4OJ>(_E8?7\)_,CD^W]?2@_0?A76?\*]UC_GK:
M?]]G_"C_ (5[K'_/2U_[[/\ A3^J8C^5C_M'#=*B.;LKVXT^X$]K*T3C^[T_
M*KUUXFUB]MC!/>L48?-A%&?Q K6_X5[K'_/6U_[[/^%)_P *^UC_ )Z6O_?1
M_P *TCA\2HM*+,9XG U)<\I*Z.4^@QWXI?RYZUU?_"O=8_YZ6O\ WV?\*/\
MA7NL?\]+7_OH_P"%9K!XC^5FO]HX9_;.4Y^E)S^?:NL_X5[K'_/2U_[Z/^%'
M_"O=8_YZ6O\ WV?\*/J=?^5A_:.%_F1R> .,<?4TOT_#VKJ_^%?:Q_STM?\
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MO26ENT:L[L1N.!UJHX2#U;T)^LR^SN>U0:YI=R?W-] _('$@ZGI5]F5$+,<
M#)SV%>.ZIX:O?#NAS/<2PMOE0+Y3'/&?\:T/"_C"3[+-IFHR%E:-ECD<\C@]
M:F>&NKT]BEB?YCT6UUC3;Z<PVMY#-*.J(X)'X5?KR3X?G/BZ8Y_Y9O@X]Q7K
M=<]>G[-I&M&?,F%%%%9FH4444 %%%% !1110 4444 :Z]**%Z45D:A5(_>-7
M:I'[QK&J7 ****Q- HHHH **** "BBB@"S!_JA27'^H?Z4L'^J%)<?ZA_I77
M'9&$NIF=J6D'2EK8R04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %-*@]0#3J* &!%_N#\J-B_W1^5/HH"PS8G]T?E1L7^Z/RI]% #-B_W1
M^5&Q/[H_*GT4 ,V+_='Y4;%_NC\J?10 S8O]T?E1L3^Z/RI]% #-B_W1^5&Q
M?[H_*GT4 ,V+_='Y4;$_NC\J?10 S8O]T?E1L7^Z/RI]% #-B?W1^5&Q?[H_
M*GT4 ,V+_='Y4;%_NC\J?10 S8O]T?E1L7^Z/RI]% #-B_W1^5&Q?[H_*GT4
M ,V+_='Y4;%_NC\J?10 S8O]T?E1L7^Z/RI]% #-B_W1^5&Q?[H_*GT4 ,V)
M_='Y4;%_NC\J?10 S8O]T?E1L3^Z/RI]% #-B_W1^5&Q?[H_*GT4 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gzkk5j0cumnd000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkk5j0cumnd000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 4;!]D# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $H
MI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $H
MI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $H
MI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $H
MI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $H
MI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $H
MI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $H
MI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $H
MI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $H
MI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $H
MI:* $HI:* $HI:* $HI:* $HI:* $HI:* $HI:* $I:** "BDI: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@!*Y/Q!XZ@T#4/L<EE),V,[E<#^E
M=;7F/B&-9?B):(ZAE.,@CKQ30F7/^%J6_P#T"I_^_@_PH_X6I;_] J?_ +^#
M_"NV_LNP_P"?2'_O@4O]EV'_ #Z0_P#? IW069Q'_"U+?_H%3_\ ?P?X4?\
M"U+?_H%3_P#?P?X5VW]EV'_/I#_WP*/[+L/^?2'_ +X%%T%F<3_PM2W_ .@5
M/_W\'^%'_"U+?_H%3_\ ?P?X5VW]EV'_ #Z0_P#? H_LNP_Y](?^^!1=!9G$
M_P#"U+?_ *!4_P#W\'^%'_"U+?\ Z!4__?P?X5VW]EV'_/I#_P!\"C^R[#_G
MTA_[X%%T%F<3_P +4M_^@5/_ -_!_A1_PM2W_P"@5/\ ]_!_A7;?V78?\^D/
M_? H_LNP_P"?2'_O@47069Q/_"U+?_H%3_\ ?P?X4?\ "U+?_H%3_P#?P?X5
MVW]EV'_/I#_WP*/[+L/^?2'_ +X%%T%F<3_PM2W_ .@5/_W\'^%'_"U+?_H%
M3_\ ?P?X5VW]EV'_ #Z0_P#? H_LNP_Y](?^^!1=!9G$_P#"U+?_ *!4_P#W
M\'^%'_"U+?\ Z!4__?P?X5VW]EV'_/I#_P!\"C^R[#_GTA_[X%%T%F<3_P +
M4M_^@5/_ -_!_A1_PM2W_P"@5/\ ]_!_A7;?V78?\^D/_? H_LNP_P"?2'_O
M@47069Q/_"U+?_H%3_\ ?P?X4?\ "U+?_H%3_P#?P?X5VW]EV'_/I#_WP*/[
M+L/^?2'_ +X%%T%F<3_PM2W_ .@5/_W\'^%'_"U+?_H%3_\ ?P?X5VW]EV'_
M #Z0_P#? H_LNP_Y](?^^!1=!9G$_P#"U+?_ *!4_P#W\'^%'_"U+?\ Z!4_
M_?P?X5VW]EV'_/I#_P!\"C^R[#_GTA_[X%%T%F<3_P +4M_^@5/_ -_!_A1_
MPM2W_P"@5/\ ]_!_A7;?V78?\^D/_? H_LNP_P"?2'_O@47069Q/_"U+?_H%
M3_\ ?P?X4?\ "U+?_H%3_P#?P?X5VW]EV'_/I#_WP*/[+L/^?2'_ +X%%T%F
M<3_PM2W_ .@5/_W\'^%'_"U+?_H%3_\ ?P?X5VW]EV'_ #Z0_P#? H_LNP_Y
M](?^^!1=!9G$_P#"U+?_ *!4_P#W\'^%'_"U+?\ Z!4__?P?X5VW]EV'_/I#
M_P!\"C^R[#_GTA_[X%%T%F<3_P +4M_^@5/_ -_!_A1_PM2W_P"@5/\ ]_!_
MA7;?V78?\^D/_? H_LNP_P"?2'_O@47069Q/_"U+?_H%3_\ ?P?X4?\ "U+?
M_H%3_P#?P?X5VW]EV'_/I#_WP*/[+L/^?2'_ +X%%T%F<3_PM2W_ .@5/_W\
M'^%'_"U+?_H%3_\ ?P?X5VW]EV'_ #Z0_P#? H_LNP_Y](?^^!1=!9G$_P#"
MU+?_ *!4_P#W\'^%'_"U+?\ Z!4__?P?X5VW]EV'_/I#_P!\"C^R[#_GTA_[
MX%%T%F<3_P +4M_^@5/_ -_!_A1_PM2W_P"@5/\ ]_!_A7;?V78?\^D/_? H
M_LNP_P"?2'_O@47069Q/_"U+?_H%3_\ ?P?X4?\ "U+?_H%3_P#?P?X5VW]E
MV'_/I#_WP*/[+L/^?2'_ +X%%T%F<3_PM2W_ .@5/_W\'^%'_"U+?_H%3_\
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M_P"@5/\ ]_!_A7;?V78?\^D/_? H_LNP_P"?2'_O@47069Q/_"U+?_H%3_\
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MEV'_ #Z0_P#? H_LNP_Y](?^^!1=!9G$_P#"U+?_ *!4_P#W\'^%'_"U+?\
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M_/I#_P!\"C^R[#_GTA_[X%%T%F<3_P +4M_^@5/_ -_!_A1_PM2W_P"@5/\
M]_!_A7;?V78?\^D/_? H_LNP_P"?2'_O@47069Q/_"U+?_H%3_\ ?P?X4?\
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MV'_/I#_WP*/[+L/^?2'_ +X%%T%F<3_PM2W_ .@5/_W\'^%'_"U+?_H%3_\
M?P?X5VW]EV'_ #Z0_P#? H_LNP_Y](?^^!1=!9G$_P#"U+?_ *!4_P#W\'^%
M'_"U+?\ Z!4__?P?X5VW]EV'_/I#_P!\"C^R[#_GTA_[X%%T%F<3_P +4M_^
M@5/_ -_!_A1_PM2W_P"@5/\ ]_!_A7;?V78?\^D/_? H_LNP_P"?2'_O@470
M69Q/_"U+?_H%3_\ ?P?X4?\ "U+?_H%3_P#?P?X5VW]EV'_/I#_WP*/[+L/^
M?2'_ +X%%T%F<3_PM2W_ .@5/_W\'^%'_"U+?_H%3_\ ?P?X5VW]EV'_ #Z0
M_P#? H_LNP_Y](?^^!1=!9G$_P#"U+?_ *!4_P#W\'^%'_"U+?\ Z!4__?P?
MX5VW]EV'_/I#_P!\"C^R[#_GTA_[X%%T%F<3_P +4M_^@5/_ -_!_A1_PM2W
M_P"@5/\ ]_!_A7;?V78?\^D/_? H_LNP_P"?2'_O@47069Q/_"U+?_H%3_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7G?Q.^_IW^_\ UKT2O._B=]_3?]_^M-;B9W.F_P#(-MO^N:_RJW53
M3?\ D&VW_7,?RJW2&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\[^)WW]-_W_
M .M>B5YW\3OOZ;_O_P!::W$SN=-_Y!MM_P!<Q_*K=5--_P"0;;?]<Q_*K=(8
M4444 %%%% !1110 4444 %%%(S!5+$X &2: %HKS+Q'\5X[&ZDM=+MEG>-BK
M229V\>F*Y_\ X6YKO_/I;?DW^-4H-DN:/;:*\2_X6WKO_/I;?DW^-='X+\?:
MIXAUP65U;PI'L+90'/ZT.#0E-,]*HHHJ2PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "O,]>_Y*19_4?RKTRO,]>_Y*19_4
M?RIQ$STNEI*6D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH ;(XCC9VZ*,FN-D^)_AV.1D:67<I(/[L_X5UMY_QY3?
M[A_E7@G@[1[/7/&4EG>IOA)D) ..F:J*3W(DVGH>F?\ "T?#G_/:7_OV?\*T
M]-\;Z#JDHBAO460]!)\N?SK.;X8^&R.+9A_P(UR'BWX:?V5:MJ.D2R,D0W/&
M>H]Q3M%BO)'L0.>G2EKS?X8>*Y=2MGTN]<O/",QL>K+[UZ,6"C)( ]34M69:
M=T.HK+F\1:/;OLDU&V#>GF@XJ[;7=M>1^9;3QS+ZQN&_E19A=$]%)6;=:_I5
MF^R?4+=&'!7S!D4AFG15.TU.QOQFUNX9O9'!-6Z %HJM=7]I9)ONKF*%?]MP
M*J6WB'2+N3RX=0MV<]%\P<T6%=&I12 YI:!A7,_\)SH_]M?V5YC_ &G?LQL.
M,UTM>#C_ )*I_P!O/]*J*N3)V/>!2T4AJ2A:*2J-YK&G6!Q=7L$3?W6D&?RH
M OT50L]8T[4#BUO8)6_NJX)_*K4UQ#;1^9/-'$G]Z1@H_6@+HEHJ&"Z@ND+V
M\\<R@X)C<,/TJ7.!G/% "T56CU"REE\F.\MWES]Q906_+-2O*D*%Y75$'5F.
M * )**R/^$FT42^7_:=MNS_ST&*TXIHYXQ)%(LB'HRMD&@"AK>N6>@6/VR]9
MEBW!<@9ZU)I&K6NM6"7EHQ,+]"1BN2^+'_(H_P#;5?YBKGPU_P"1-M?Q_G56
MTN3?6QV%%54U"RDF\F.\MVESC8LJEORS5JI*"BBB@ HI** %HI*6@ HHHH *
M*** "BBB@ HHHH **** "BDHH 6BBB@ J"ZNH+.!I[B5(HE&2S' %3UX_P#$
M_4KF_P#$%MHD#L(U*[E'=CZ_@::5Q-V.NG^)GAR"39]H=^<95"16MH_BO1]<
M;99W:-)_<8X;\JQ-(^&FAVNGQI=0FXF907=CW[XQ7 ^--!_X0O7;6[TR1DCD
MRZC/W2,<?2JM%Z(AN2W/=:*S- U$ZOH-E?, &FB#L!V)%:50:"T5!<7=M:!3
M<7$4(8X4R.%S],U#=:M864:O<WD$:L,KND'(]J +M%4;+5K#4<_9+N&4CLK@
MG\J6\U:PT_\ X^[N&(GH&< _E18+HNT54L]2LK]=UI=13>NQP<?E5J@!:*I7
MFJV&G_\ 'W>0Q'T=P#^5-M=8TZ]1GM[V"0*,G$@X^M&HKHOTR618HGD<X5%+
M'Z"HK>\M;LL+>YAF*]?+D#8_*L/QQJ7]F>%+R53AW78OX\?UH6X-Z":+XRL-
M<>]%O'($M S.Y'! ]*GT'Q;IGB*:6*P=V:,9;<I%<M\/M+^Q^ [ZZ8?O+J.1
MC] "*Q?@[_R$K_\ ZY_U%7R[D\SNCV&BHIIX;>/S)Y4B0=6=@!^9ID%[:71(
MM[F&;'7RY V/RJ"RQ14%Q=06L1DN)XXD'\3L /UJG;^(-)NIO*AU"W:3IM$@
MYH"YIT56^WV?VCR/M4'G?\\_,&[\NM6: "BBB@ HHHH ***2@!:*2EH ****
M "BBB@ HHHH **** "BBB@ HI*6@ HHHH *JW^H6NFVS7%Y.D,8[L<59KQOQ
M]+J.O>+H=+CBG6T5@BDH0I..3_.FE<4G8[%_B?X<2;9Y\A]PAQ71Z5K5AK4'
MG6-PDJCJ >1]17.VWPUT"+3Q;R6_F2;<&4DYSZUY[8I/X-^(J6,$[-"90N,_
M>4GO[U7*GL1S-;GNM%(IRH/K14&@M%5I[ZTMI%CGNH8G;[JR2!2?H#4-YK.G
M6&/M5[!$3T#.,T!<OT53L]2LM04M:74,V.NQP2*CO-:TVP?9=7L$3?W6<9_*
MBPKHT**K6M]:WR;[6YBF7N8W#8_*K% Q:*H7FLZ;8';<WL$3?W6<9_*G6^JZ
M?=0F:"]@>-1EF$@X^OI18+EVFR.L:,[<*H)-1075O=*6MIXIE!P3&X8#\JR/
M&&H_V9X7O9P<,8]J_CQ0M78"#1O&5AK=W>06T<F+4,7<C@XJ70O&&E>(;E[>
MQD=G1=QRI'%<M\---^S>#[Z\<?/<ASD^@!%8/P@_Y#MU_P!<C_,55C/F>A[/
M144T\5O&9)I4C0=6=@!^9J."^M+IBMO=P3$<D1R!L?E4FA9HJ&>Y@M8S)<31
MQ(/XG8*/UJC!XATBYF\J+4;=I,X \P<T6"YJ456-_9B?R#=P";_GF9!N_+K5
M@4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124 +11
M10 5B:QXITK0ITAO[CRW<9 QGBMHUXCXY_XGGQ'BL%)*Y6(8['O515R9.QZ'
M_P +&\-_\_A_[Y-6]-\::)JUZEI:7.^9^@VUACX3Z%CEY\_45?T?X?:3HFI1
MWULTID3. Q&*'RB7,=;2TE+4EA15>2^M(IQ#)=0I*>B-( Q_"JUYKFF6#[+F
M^@C?^Z7&?RH%<T:*K6E]:WT7F6MQ%,O<HP-5KK7M*LY?*N+^!).ZF09%%@N:
M5%06]U!=Q^9;3QS(?XHV##]*FH&+16;=Z]I=B^RXO[='[J9!D?A4T6J6$UN;
MB.\@:$?><2# ^IHL*Z+E4M6U.'2--FOKC/EQ#) [U8AN(+E-\$T<J?WD8,/T
MK@_BOJ8@T*&P1OWUS(./]G_]>*:6H-V5S<M?&>G7'AYM:99([56V\CFM+1-<
ML]?L/MMDS-#O*988Y%<-K&G'3/A$D#+M<HK./0D<UH_";_D3?^WA_P"E-K0E
M-WL=V**@N+RVM0#<7$,(/3S'"Y_.E@N8+J/?;SQRH#C=&P89_"I+)J*J7FHV
M=@NZ[NH80>F]P,U%::UIM^2+:^@D(ZA7&:-0NC0HJO#?6ER[)!=0RNOWECD#
M$?E4] "T444 %%%% !1110 4444 %%%% !1110 5YW\3OOZ;_O\ ]:]$KSOX
MG??TW_?_ *TUN)G<Z;_R#;;_ *YC^56ZJ:;_ ,@VV_ZYC^56Z0PHHHH ****
M "BBB@ HHHH *S=?=X]!OG3(80G&*TJKWRQ/8SK.<1%"'/H,4+<'L>,_#+P[
M9ZWJ%U=WZB00' C/<GO7KBZ#I*C TZVQ_P!<Q7BFD>((O!WBB=[.=;NPD)#;
M,],\=>XKT:'XI>'I$!>22,]P5K22=[F<&K6.G_L/2O\ H'VW_?H5+!IEC:R>
M9;VD,3_WD0 US'_"SO#G_/PW_?-:&C^-='UR]^R64S-+C."*BS*NCHJ*2EI%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>9Z]_P E(L_J/Y5Z97F>O?\ )2+/\/Y4XB9Z72TE+2&%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 07G_'E-_N'^5>
M*?#;_D?W_P"VO\C7M=Y_QY3?[A_E7BOPV_Y']_\ MK_(U<=F1+='N.*BN(UF
MMI(F *NI!!J6H;J9+>UEF<@*B%B3]*@OH>(>#_\ B7_$QK:/Y4\YXP/;)_PK
M8^(GBR]GUC^PM-=T ^5RAY9CVK&\&9U/XBO=Q\IYKR@^Q/\ ]>I+!5E^+P\X
M9_TLXSZYK5[F*>EC<T_X0QSV0EU#4)5N7&2$ ('YUSEQ'K'PX\01!9V>V)!'
M/RNO<8]:]XKS+XQ*G]F6#?Q^8P_#BIC)MV94HV5T:'CKQ1+;>#+:ZL7*O>\!
MU[#O7+^$_A[:^)-*74[[4I#),2=J$$CG'.:Z/2?#R>)_AAI]G.VQQ&6B?T.3
M7&R^%O&'A=F>Q,SP@Y+0O\OY4U:UD)]V2:OX3U?P=K5O)H\EQ<1L=P*C]&QQ
M7JUYK9T_PM_:EU&4E6 ,T9_O$#C\Z\RTKXH:UITZPZQ;^='G!+)L91_6NG\?
M:G%J7@ 7EH^Z*9ASZ4--O4$TE='%:1I6K_$759KF[N7CM4;YCGA<]@*V]8^$
MYL;)KK2;Z:2>,9VO@9^A%<_X5C\8?V6S:$A-J6Y("]?QK=*?$LC!1_R2F_)B
M7H:GPS\5W-_YFD7[%YH1E';J1Z&O2:\C\#>%=?TSQ6E]?VC1Q%6WMD=3]*]<
MJ);FD-A:\&'_ "53_MY_I7O->##_ )*I_P!O/]*<.HI]#WFD-+14%G)>/?$I
M\/:&3"P%W,=L8]/4UP/AGP'=^+8CJFJWTJ12'Y3G+-^?:K'QC9SJ>FI_"(WQ
M^8JOH\?CY=(MO[.1OLA0&+ 7[M:)61DWJ)XE\"W?A"(:KI5]*T:'YCG#+^7:
MNJTZ\'COP!<0RG_2XE(/NP&0?Y5SE]8?$34;.2VNH7>%QAEP@S6_\,O#VK:%
M)?+J-LT4<BC9D@Y.>:'L"WT,CX3:B]KJ5[I$S$$DLJD_Q#@_RKT;Q+J<>D>'
M[R[<XV1D+[D\?UKR?7X9_!_Q&BO8AMBFD#J>Q4\-_6MGXJZP+BTT[3X'S]HQ
M*0#V/2AJ[N"=E8@^%-@;F^OM:N,G;D GU)R36?XGUW4?%WBC^QM.D=+<.8P%
M. V.I/M7HGAW2%T/P2L"#$C0F1SWR1G^M>,Z FM2^(9FT1=UX Q[=,C/7\*:
MLVV#NDD=Z/@Y;?8OFU*7[5C/ &W/Y9K&\.ZKJ?@SQ8NC7\S/;,X0ACD8/0BK
MVWXF?W'_ "2L74/"?C35+];N[LW>=<8;*CI^-'JQ>B.Z^*S!O!P8'@RH1^8J
M[\-O^1-MOQK.^*"LO@>)7&&#H#]>*T?AK_R)MK]3_.I^R6OB,71? FI6'C/^
MUI9HS!YKO@$YP<_XUZ524M2W<I*P4444AB5EZGK*:=(J-&S%AGBM3%<YXAL+
MJ[GC:"%G '.,5PYC4JTZ#E16IOAHPE42GL'_  E<7_/N_P"E+_PE<?\ SP?]
M*Q/[%U'_ )]'_,4?V+J/_/H_YBOFO[0S/^5_<>K]6P??\3;_ .$KC_YX/^E'
M_"5Q_P#/!_TK$_L74?\ GT?\Q1_8NH_\^C_F*/[0S/\ E?W!]6P??\3;_P"$
MKC_YX/\ I1_PE<?_ #P?]*Q/[%U'_GT?\Q1_8NH_\^C_ )BC^T,S_E?W!]6P
M??\ $V_^$KC_ .>#_I1_PE<?_/!_TK$_L74?^?1_S%']BZC_ ,^C_F*/[0S/
M^5_<'U;!]_Q-O_A*X_\ G@_Z4?\ "5Q_\\'_ $K$_L74?^?1_P Q1_8NH_\
M/H_YBC^T,S_E?W!]6P??\3;_ .$KC_YX/^E'_"5Q_P#/!_TK$_L74?\ GT?\
MQ1_8NH_\^C_F*7]H9G_*_N#ZM@^_XFW_ ,)7%_S[O^E7-.UQ-0G,2Q,IQG)K
MF?[%U'_GT?\ ,5J:#IMW:WQ>>!D7;U.*ZL'C<PG7C&I%V]#&O0PT:;<'KZG4
MT4E+7U1Y(54FTRQGG$\MI"\HYWE!G\ZMU!=74-G;O<3R!(T&68F@"221(8FD
MD8(BC))/ KPWQMJY\8>*+>RT\&2.(F-"!U)ZG]*N>*/&E_XJO1I.BK(+=FVY
M7J__ -:NT\$^!H?#T NKH+)?L,ENNSV%6ERZLS?O:(Z30]-&D:):6 .[R(PA
M/J1WK0HI:@T/+OC,2+'2L''[U_Y"LCPYX#O?%EDE_JM_-' 1B)0<G ]CP*U_
MC/\ \>.E?]=7_D*[;PD@3PKIX X\K^IK2]HF=KR/%]?TB_\  .NQ?9+MR'&^
M-P<9'3D5TFD_#^^\5VW]JZUJ,T;S_,BCGCM^%/\ B^,ZGI>>ZX_\>->F:(H7
M1+(#@"!/Y"AMVN)15VCQ)K._\">,X+=+@E"X((/#J?45Z]XIUT:'X;FOQCS"
M L8_VCTKSGXG?\CG8?[H_I6O\5O,_P"$8L0/]7O&[ZXXH>M@6ESFO#?A._\
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MQKC?^$.\0_\ 0,E_-?\ &C_A#O$/_0,E_-?\:/:5>P?7<P_E?W'9?\+0M?\
MGQG_ #7_ !H_X6A:_P#/C/\ FO\ C7&_\(=XA_Z!DOYK_C1_PAWB'_H&2_FO
M^-'M*O8/KN8?RO[CLO\ A:%K_P ^,_YK_C1_PM"U_P"?&?\ -?\ &N-_X0[Q
M#_T#)?S7_&C_ (0[Q#_T#)?S7_&CVE7L'UW,/Y7]QV7_  M"U_Y\9_S7_&C_
M (6A:_\ /C/^:_XUQO\ PAWB'_H&2_FO^-'_  AWB'_H&2_FO^-'M*O8/KN8
M?RO[CLO^%H6O_/C/^:_XT?\ "T+7_GQG_-?\:XW_ (0[Q#_T#)?S7_&C_A#O
M$/\ T#)?S7_&CVE7L'UW,/Y7]QV/_"T+7_GPG_,?XUN>&_%L/B*>>*.WDB,2
MACOQSGZ?2O,O^$.\0_\ 0,E_-?\ &NQ^'VB:EI5]>/?6CPJZ*%+$<]?2JISJ
M.6IU8/%8V=:,:B=O0] I:**ZCZ$*8T,;.':-&8="5&13Z@-W;>;Y7GQ^83@+
MO&?RH XGQ5\1X]"OI[""R>6X0??/W<FN)\&V[>*?&/\ :>H7<8D1_,*$X+'/
M05['<Z+IMW([SV4$CO\ >9D!)_&O&?'6C)X4\2076F,85D^=5!^Z1UK2+6R,
MI7OJ>ZC@8H[51T:]_M'1K2\(QYL8;%7ZS-3QCXOR/'XFTYT)#+;!A]=[5-HG
MPYN?$EBNI:OJ,R-*N8U7D@?C4'QA_P"1ET__ *]1_P"AM7K6C($T6Q4# ^SI
M_P"@BM+VBC-*\G<\%OHM3\">)9+6TN6W#[I'1@1QD?C76:=\,;C7+$:CJVI2
MK<SC>JCG&?7-9_Q- _X3JV]PF?TKV6T4+9PJ. $ 'Y4.3M<48J[1X=H;W_@[
MQY'IS3$QF4(ZY^5E/?%>F^._$A\/: TD)_TF;Y(_;WKSWQ>,?%2'_>C_ *UJ
M?&#?LT[^[\W]*-V@3LG8R_"_@6Z\71-JFJ7DR1.WRGJS?GVJ#Q7X-OO!]N;B
MRO)9;*3Y).<$9XY XKUCP@$7PEIHCQM\D8Q5;QXJ-X/OO,Q@+D9]:7,[CY5R
MW.<^$&3H5X2?^6_]!3/BUJ)^RV.DQG]Y<2!B/4=/YXI_P?\ ^0#>?]=_Z"LC
M5/\ BH?BQ!!]Z&V89'I@9_G3^U</LGH>EV']F^$([7&&2U.X>^WFO+?A9=P6
M.IWMQ<2+'$D))9C]*]EO?^0?<_\ 7)OY&OFO1=,U#6+LV5@&+.,O@X&/>B.J
M8IZ-'8Z[KNI^/M:72]+5ELU/&. ?<UZ3X;\-67A72R%PTVW=+*>IKS?X;ZPF
M@Z_-I5_&L;3-L#,.58=LUZSKQ;_A'[\Q_>\AMN/I2EV''N>.W]WJOQ \5O86
M\K):JQ"KGY54=S6]>?");:Q,UAJ,QO(UW ,  3[8YJM\(0O]JZDQ_P!9M'\S
M7KU#DT] C&ZN?//AR:[D\=6@O'=YTEV,6Z\#']*^AA7B5PD4?Q@VPXV><#QZ
M[>?UKVZB80"BBBH- HHHH 9*_E1.Y&=H)KB)?B/;QRLGV.7Y6(ZC_&NUN59[
M655&6*D ?A7D$_A37&N9673I2"Y(.1SS]:\['U:].WLE<];*Z&&JN7UAV^=C
MI_\ A95O_P ^4WYC_&E_X65;_P#/E-^8_P :Y/\ X1/7O^@;+^8_QH_X1/7O
M^@;+^8_QKS?K>._E?W'L?4,K_G7WG5_\+*M_^?*;\Q_C1_PLJW_Y\IOS'^-<
MI_PB>N_] V7\Q_C1_P (GKO_ $#9?S'^-'UO'?RO[@^H97_.OO.K_P"%E6__
M #Y3?F/\:/\ A95O_P ^4WYC_&N4_P"$3UW_ *!LOYC_ !H_X1/7?^@;+^8_
MQH^MX[^5_<'U#*_YU]YU?_"RK?\ Y\IOS'^-'_"RK?\ Y\IOS'^-<I_PB>N_
M] V7\Q_C1_PB>N_] V7\Q_C1];QW\K^X/J&5_P Z^\ZO_A95O_SY3?F/\:/^
M%E6__/E-^8_QKE/^$3UW_H&R_F/\:/\ A$]=_P"@;+^8_P :/K>._E?W!]0R
MO^=?>=7_ ,+*M_\ GRF_,?XT?\+*M_\ GRF_,?XURG_")Z[_ - V7\Q_C1_P
MB>N_] V7\Q_C1];QW\K^X/J&5_SK[SK/^%E6_P#SY3?F/\:Z_2K]=3T^*[5"
M@D&<'J*\D_X1/7?^@;+^8_QKU+PW;36FA6T%Q&8Y%7YE/;FN[ UL14FU55D>
M9F>&PE*FGAY7=^YK44E+7JGB#)&V1.WH":^=Y]5ND\<W%_9Q>=<^>QC7&><\
M&OHE\%2&QMQSFL>ST30XKXW5K;VQN!SN7!(JHNQ$E<\PO+[XAVL7VV=)EC'S
M' 4X_ 5TW@?XA'6IUTW4U6.[_@?& _\ ]>O06564JPRIZ@UX1KMJFD?$Q$L_
ME4SHZJO;)Z52M+033B[GO%+3(B3$A/4J*?69H>&_$N::#QL)(&*R*J[,>N!6
MOIOPNFUBR&H:KJ4RW,R[PHP>O(SFLWX@@-\1;52,@O$/U%>U(@1%51@ 8 K1
MNR5C)*[=SYV:75O".M7.FVETZN3Y?R]"">N*[.W^$TM[8_:K_4I1?2#<5Z@'
MT)-9'B*-9/BM&C#(,JYKV_M1)M!&*9XGX"N[S0?&QT::4F-F,;+GC/8BNU^)
M'B:;0M)2WM&VW-P<!O[H[UQ$/_)8O^WS^M6_BWN.O6(?_5^6/YFG;5!T8WPW
M\-IO$%D-2U:]FB\X;D Y8_7-9'BWPSJ'@]###=R2Z?<\?B.>1^%>X:4%&DV@
M7IY2X_*N7^*"1-X-N&?&]64I]<BI4G<;BN4B^%9/_")#)_Y:'^9KG/%?_$^^
M)ECIX.Z.$@$>G<_RK>^&DRVW@F29ONQEF/X9K#^'L#ZWXRU+7) 3&K-MSV).
M1^E/JV+=)'6?$@ >";H#@ C _.N>\":]9^'_ (>/=W;]+B3:@ZL>.!70_$G_
M )$JZ^H_K7BMEI&KZGI$\UO'(]G:Y=AG@'O@>O%$5>(2=G<ZBUM-6^)&OM/,
MTD5BC=?X5'H/>O4;IK'P;X6E>% D<"?+_M-VS^-<M\+/$<%QI_\ 8[HL=Q#R
MN!C>/\>*O?%??_PB#;<[?-7=^8I/>PUM<X/1-$U+XAZK<75Y=R);(WS-G./8
M#I6IK_PWN/#]D^HZ/?3/Y0RZDX./;%=+\)EB'A:0IC<9CO\ KBNSU(*=+N@_
MW?*;/Y4.3O8%%-7/)?A [OK]\SDDF$DY_P!X5[)7CWPEP/$NI =/*;'_ 'T*
M]BI3W'#8****DL**** "BBB@ HHHH **** "BBB@ KSOXG??TW_?_K7HE>=_
M$[[^F_[_ /6FMQ,[G3?^0;;?]<Q_*K=5--_Y!MM_US'\JMTAA1110 4444 %
M%%% !1110 5#=0"YMI(&)"R*5)'O4U(: /-F^#VG,Y;^TIADY_U8_P :3_A3
MFG?]!*?_ +]C_&I_&'Q)31[IK#3$6:X7AW/W5/I[UP4OCSQ3+=QF6]DB#L,!
M 5!&:T7,9/EN=M_PIS3O^@E/_P!^Q_C6QX;^'EIX;U07T-Y)*P4KM9,?UK/\
M>>+=3\.WNGM9#,14F56'#=*WO"/BVV\46)9<)=1_ZR+/3WI/FL4N6]CI*6DI
M:@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KS/7?^2D6?X?RKTRO,]>_Y*19_A_*JB)GI=+24M2,**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O/\ CRF_W#_*
MO /"FNVWA[Q=+?70<Q!I%(0<\Y%?0CH)$9&&588-<J_PZ\-R2,[69W,<GYJJ
M+2W(DF]C+;XM:&!Q%<D^Z#_&N6\3_$:XU^T;3M,MGCCE.';^(CTKO!\./#(.
M?L)_.M;3_#&C:6VZST^")Q_$$&:=XH5I,Y;X:^$I-&LGO[U-MU./E4_PK_G%
M<EX[TN]\/>+DUNV5O*=_-5U'W6[BO;*@O+*WO[=K>ZA26)NJL,@TE+6XW'2Q
MR&F_$W0;FP62ZG^SS ?-&P[^U>?^*M=G\<Z[;V>G0N8%.V,8ZD]S^E>A3?"W
MPU-,9/)G3)R523 _*M[1_#.DZ$F+"T2-NA<C+'ZFFFEJA.+>C..\86.K:)X.
MT]-)FFC2U7;,(R1Q_P#K-'A/XDZ<^E1V^L7!AN8A@N_1Z]%DC26-HY%#*PP0
M1P:Y.^^&WAR_F:5K5XF)SB%MH_*E=-:C::=T<%\1O$6DZ^UM;Z5&)IE?+3*O
M7C&*ZVR\,7$_PQ&FRKBX9#(JGL2<ULZ3X"T#1IA-;VF^4<J\IW$'VKI>E#DN
M@*+ZGA_@GQ8_A&[FTS58G2W9N>.485V^L_$W1;33G>PG%S<,/D1>@/O6[K/A
M#1==.^]M%,G_ #T3AOSK)M?AAX:MIA)]GEEP?NR2;A^5.\6*TEH8/PWGU_5=
M1FOKZXG:R .T.QVDG_"O4.]16UM!:0+#;Q+'$O 51@"I:ENY:5D+7SWJ%]'I
MOQ&FO)L^7%<9;'7&*^A*YB\\!>'[Z[DN9[3=+(<L<]33BTMQ23>QC_\ "VM"
M_P">5S_WP/\ &E3XL:&[JHCN<L<?<'^-:/\ PK?PS_SY'_OJE7X<>&E8,+,Y
M!R/FH]T5I&3\2M";7-"@U*U5FEMQD*!R4/7^0K(\#?$&ST_38]+U8M%Y/RI(
M1QCT->JI$D<*Q*/D48 ]JYG5/A]X>U:8S2VACD/4PMLS0FMF#3W1S/C+XD6C
MZ>UGHD[R3R=9DX"CV]ZWOAY%JQT9KO5;B:1YC^[21B<+ZU-IOP\\.Z9,)H[0
MRNO0S-NQ75*H50JC '  H;6R&D[W9Y_\5])-WH4=_&N9+5ADCK@G_P"O7 >$
M[6Y\5^+;7[2Q>. *7/HJC _4"O>[JVBO+:2WG0/%(I5E/<&LO1O"^E:#)))I
M]OY;R##'.::E96$XW=S6>-7A:+&%*[?PKPF]BOO 7C@W>PF N2I'1T)Z?RKW
MFJ.I:38ZO!Y-];),G;<,XI)V'*-]CG8OB7X<DLO/:ZV/C)B(^:N'A\1ZWXM\
M9(NFSW$%H6 *HQ "YZFNR/PK\->;O\JXQ_=\WBNETG0M.T2#RK"V2('J0.3]
M31>*%9O<Y/XJ@KX-52<D2("?Q%7OAK_R)MM^/\ZZ#5M'LM;L_LM]%YD.0V/<
M4_3=+M=)LEM+./9"O1<T7TL.VMSE]-^(5OJ/B3^QDM75][)O)XXS_A7:U@6O
M@_1K+5?[2@MMMUN+;L]SUK>%)VZ#5^HM%%%(84444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5XM\4/$\MUJATBWD9;>''F;3]XU[17-7G@+
MP_?7<EU<6A:60Y8YZFJBTGJ3)-K0\^\(^*?"_AJR!,,\EXP^>4QC\AS73_\
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M)&>X5]2U-IT'557!_G7J5%5S,GD15L+"VTVSCM;6,1Q1C  JSBEHJ2@HHHH
M3%&*6B@#@/$'PPLM4O7O+*<VDSG+ #(S6,OPFOI' N=8+Q^FP_XUZQ15<S)<
M48?AOPO8>&K,PVBYD?F20]6K<HHJ;W*M8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH 3%&*6B@ HHHH 3%+110 F*6
MBB@!,53U32[76+"2RO(]\,@P1Z>]7:* /*[CX231S,VGZHT2'H"N3_.I].^$
MT:W*3:I?M<JIR4 QG]:]-HJN9D\B(K>VBM+=(($"1H,*H["I*6BI*"DQ2T4
M%)BEHH X/Q%\,['5[Q[RSF-K.YRV!D$UAK\)K^1MMQK&Z+TV'_&O6**KF9/*
MC!\->%+#PS:M';*6E?[\C=36]114MW*2L%%%% !1110 4444 %%%% !1110
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MUK^;?XUT'@[XAWOB36A8SVD,2;"VY,Y_4TI*30XN)Z+124M0:!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;9:BD244E+2*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\SU[_DI%G]1_*O3*\SUW_DI%G^'\J<1,]+I:2EI#"BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRXKQWP?<K?\ Q.ENK48AD=F  [52;:U(:2>A[=2T45F:A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>9Z]_P E(L_J/Y5Z
M97F>O?\ )2+/ZC^5.(F>ETM)2TAA1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %><_%__D 6O_77_"O1:\Z^+_\ R +7_KK_ (4X[DRV)_ ?B#2K+PG:
M07-]#%*H.59P"*Z-_%^@QJ6;4[? ]'!KS;PO\-K37=!M[^2[E1Y!R !BJ'BS
MX;W&@VOVRTE-S OWQCYE]_I5VC<CFDD/^(7BFW\3WEO8Z:K2)$W#X^\3Z5Z=
MX<MQX>\&6ZW/R^3$9'R>F>?ZUPWPN.@7$K(]JJZD@^5G.=P]A78?$6=[?P7>
MA"1O 7([<BD^PX_S'GEWKOB'QYK36>F.\5LIX"G  ]2:L:CX$\4:):F_M=4:
MX:/YF5&.?UZUB^#_ !'J>@P3_8--^T^8PW.$)Q[<5TS?$3Q(Z%6T-L$8_P!6
MU5JM$3INS>^'OC2374;3[]A]MB&0W]\5F?$3Q5J,6I1:%I;F.23 9UZDDXQ7
M,>"K?48_'-O=-930I*Y#?(0 ":Z7XC>#]0N]036--5I'  =%/S+CN*5DI#NW
M$I+\-?$<EH)VUG$Y7<(]QZ^F<T[P/XCUG3_$1T/5&DE3<4^89V''K6=9_$7Q
M)HH6'4+8RJG'[U"I_.NR\+^.M%U^\\N6SCM;T]&9!\Q]C0[VU!6OH4_BU>W-
MEIU@UM.\1,V"5.,\&N7T:R\3^.54_;G@M(%"!B2 2./Q-=#\8QG3-.'K/_[*
M:Z_P7;1VOA2Q2-0,QACCN3S1M$=KR/+M1M_$WP_U&&?[:\]LQ^]G*M['/2O5
M=)\26NI>&EUC(6,)ND']TCJ*H?$6VCN/!=\T@&8E\Q2?4?\ ZZ\WT*]FC^&>
MLQ*3MWA?H#G/\J7Q*X7Y78DO/$/B'QSK)L=,9X;<-P$. !ZDU8U'P'XHT>T-
M];ZFT[QC<RQL<C\^M;7P@MHUTNZN,#S&?;GOQ7I9 (P1D'K3;L[(%&ZNSSSX
M>^.)M7D.E:FV;M!\DA_CQV/O67\5]2O+#7--^SW$D:^3N*JV <,:PX8ETWXL
MO#;<(MQ@ >X!/\ZT/C'_ ,AG3O\ KW/_ *$::7O$M^Z1V.D^+/'"?;6O3;6H
M&V/)P#CCH.:S)9_$?@+7(TGN'92>YW(XKVCPY MOX<TY$  -NC<#N5!K@OC"
MB_9=/?'S!R,TE*[L4XZ7.MU;Q.EEX0.MQKN+Q@HI]2*\TT;1O$GCLRZ@^J-#
M#N*@EN,^@ KN+;1?^$@^&EM8!]CM"I1CV('%>=64_BOP/+)%'!*(2V679N4^
M]"%*^ERSJMAXG\!WD-RM^\T+M@,I)4^Q!KUS1M974?#L&J2CRPT1=P1C&.O\
MJ\[L/BO!<.D&M:8CKGE@H.WWP:['Q#J-M+X%N[K3F0PO$0NP8 S2DGU'&RV/
M/=6\3:[XTUPZ;HY>*W#$ *<<#^(FI[WX?>)],M#>6^JM-+&-Q1&.?UKG_!_B
M#4=#:XEL=.^U-)PS;"<?E75_\+&\2$8_L-O^_;55FMB59ZLT_A]XWN-3F;2-
M4)-V@^21N"V.,'WK:^(%KJ=WX?6/2Q)Y_F@_NS@XP:\QT!-2E\=V^H-830"6
M<LV(R ,YKWJIE9.Z+CJK,Y?P%;:C:^&UCU,2"X\QB?,.3CC%=3245#925A:*
M**!A24M(S!%+,<*!DF@#"\6:VFB:)++N F<;8QWS7A$DC2R,[L69CDD]ZZ7Q
MQKW]LZTRQ,?L\&43T)[FN8K6*(;.N\ :\=*UE;:5\6]P0IST![&O: 0>1T-?
M-()!!!(.>HKV[P1KRZSHB+(^;F'Y7'<^AJ9(:9U-%)2U!05YM\8?^0):?]=O
MZ&O2:\V^,/\ R!;/_KM_0U4=R9[%;P'XST/1_"T-G>W9CG5V)783P3["N@N/
MB;X9AC++=O(V.%$3<_I7)>"_A_I>O^'(K^ZDE$K.RD*>.*Z)/A/H*G)>=AZ$
MTWRW)7-8\ZU6^N/'_BV,6T+(CD(H/.U<]37=?%&$6W@ZT@4 !'5?Y5V.C>&=
M*T&,K86J(QZN>6/XFN4^+O\ R+,/_74?THO=JP<MDSF?"GQ(LO#VA1:?-8SR
MNA.65@!6VWQDT_'RZ9<9]W%2> ?"VC:GX6@N;NQ269B<L2>>:/%OPSL)=/EN
M='A\FXC&[RPQ(;\Z?NWU$N:QQVN:UJWQ U"""VLG6%3A54''U)Z5[)X<TG^Q
M=#MK'.6C7YC[]Z\R^'?BX:?>KHVHI&@)*I(4 *GT)KV(8/(I3TT'#746BBBH
M- HHHH **** "O'/BC=R2^(X[4D[(8@0/][_ /57L=>4?%32W6^M]1125==C
MGT(QC^M=.$:517 \[HI*6O8$%;O@ZY>T\4V3H>K[3^/%8-=5X TR34/$L,@7
M]U!EW;T]*RK-*#N![E24M)7AC,/Q5X=B\2Z.UF[!) =T;^AKR!M+\7^#KIA;
M&X$:G[T0WJP^G->B^+/'I\,ZK'9?8_,#@'>3Q776MQ#?V45Q'M>.10P[]:I-
MHAI-GD%G\6-8LV$>H6:2$=<J5:O0/#'C?3/$B^7"WDW0ZPOU_ ]ZT]2\.Z3J
ML#17=C"P/<+M/YBO$]9T_P#X1#QQ%'8RDA'61,'D#/0_E35I"?-$[/XP_P#(
M,LO^NAKI_A]_R(VF_P"ZW_H1KE?BTYDT/37/5CD_D*ZKX??\B/IO^ZW_ *$:
M'\(+XSIJ\]^+L*OX8@EP-RW P?;!KT*O+/C!JJ?9K32T;+[_ #6 /3 Q_6E#
M<J>QM?"ER_A,*>BR'%=U7(?#:Q>R\'V_F AI3YF#Z'I77TI;A'8****10444
M4 )6;KNJQZ+I,]](K,(QT49R:TZAN+:*Z@>&9 \;C!!'6D[VT+@XJ2<MCYN\
M0>(;SQ#J#W-RY"_P1@\**R*[GQSX&ET2=KRQ1GLF.2!SY?\ ]:N&KQJL9*7O
M'Z1@*M&I03H[!74^#_%]UX<OE5BTEI(0'CZX]Q7+@$D #)/05ZEX!\ ES'JF
MJ1\=8HF'ZFJHQFY>Z8YI6H4\.U6UOT/5+2Y2[M8[B/.V10PR,&IZ:JJBA5
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MS1114&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6?U'\J],KS/7O^2D6?U'\J<1,]+I:2EI#"BBB@ HHHH **** "BBB@ HHHH
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MG/(@/W?+ S^.:'RO47O+0YKP7;W/B/QZ^ILA\M7,CMV'' _E5[XR?\AK3?\
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M')6LA*+;NSQ3X?:_#X:UFYT[4E\N.5MI9A]UAZ_E7K%WXAT6TLFNGN[<H%R
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MDJA0 H  ["GS+H'*[ZGFGQ>B;^RK%8T)"OC &:YO0_B-J6B:-;Z='IJR+""
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MC^9N<??8U[13(HHX(UCBC5$48"J, 4^I;N.*LA:***104444 %%%% !1110
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M5>F5YGKW_)2+/\/Y4XB9Z72TE+2&%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110!Q/Q%\-7_B2RM(K$(6BDW-
MN..,&NB\.V,NG:%:6D^/,BC"M@\=*TZ6G?2PK:W"BBBD,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% "4M%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5YW\3OOZ;_O_P!:]$KSOXG??TW_ '_ZTUN)
MG<Z;_P @VV_ZYC^56ZJ:;_R#;;_KF/Y5;I#"BBB@ HHHH **** "BBB@ HHI
MK,J*68X4#)- #J*I6FJV%\2+:ZBE(."%;FKE "T444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 E<;/I>JZ)K,]_I<2W$,YR\.<<UV=%.X'(6
MNF:EK6L0ZCJL2V\=N,1PYR<^M&M:/J-OKJZUI861PNUXB<;JZ[%+1<5CA;BP
MUOQ-?V_V^V6SM86W%-V=WY&NX50J!1V&*=11<84444@"O,]>_P"2D6?U'\J]
M,KS/7O\ DI%G]1_*G$3/2Z6DI:0PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M31+&SE%<%AU&: 'TE%&0.M "T4Q94?.Q@V.N#3J %HI"0!DTU)4D&48-]#0
M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.VGQYSG>X'8UTM)2UFW<M*P4444#"BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.8XD0_[*@5)BDWV!+N>46%SJWP[OY[6>QEN]-F<M&\0W8_PJ?5_&FI>)+?\
MLK1M*N4>X^1I9$("CZUZ<R*XPZ*P]",TD<,47^KC1,]=J@4^9!RLQO"6A'P]
MH4-F\ADE^\[$]S6[114E!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7G?Q.^_IO^_\ UKT2O._B
M=]_3?]_^M-;B9W.F_P#(-MO^N8_E5NJFF_\ (-MO^N8_E5ND,**** "BBB@
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MP]M8]WEWURFXDD!J:$QOA+:OB+60, >9Q4>D9;XAZB6ZA>*S?"GA]1XCOO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT5TV/<45%60E+110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *3-%4=2U2UTNV:>XE50HSC/)I-VW)E.,%
M>1;DE2*,N[!5'4DUY]XF\>JHDM--.6Z&7T^E<_X@\8WNM2&"WS%;] J]6J_X
M9\"R7XCN]0W)$3D)W:N>524WRP/"KXZKB9>RPWWF)I.@ZEXCNC)\Q7/SRO7K
M&B>';/1K95BC4R8^9R.36A9V4%C L-O&J(.P%6!6D*2CJ]SMP>70H>]+608H
MHHK4](6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G?
MQ.^_IO\ O_UKT2O._B=]_3?]_P#K36XF=SIO_(-MO^N8_E5NJFF_\@VV_P"N
M8_E5ND,**** "BBB@ HHHH **** /,?C%_R#;'_KJ?Y&O/M,TWQ3<6$<FFV]
MZ]J<[#$#MZ\X_&O0?C%_R#;'_KJ?Y&N@^&H_XH:Q^K_^A&M$[1,FKR/*O[&\
M;_\ /IJ7Y&C^Q_&W_/IJ7Y&OH+%&*7./D/GW^Q_&_P#SZZE^1KJO &G^);;Q
M$'U2"\2WV'F4'&:]8Q10Y7&H!2TE+4%A1110!Y!\7KB634;"R#?NR"<>_%=!
MX>^&NC6^FPR7\'VFX=07W?='T%4OBOI0GM[;4(I$$T!Y1FP2/4?E5WPE\0M+
MNM)A@U"X6WNHU"MO. WN#6FO+H9Z<VIM?\(%X:_Z!4'_ 'R*7_A O#7_ $"H
M/^^15L>*M#_Z"=M_W\%'_"5:'_T$[;_OX*GWBO=-&SLK>PM4MK:,1PH,*H[5
M8J&WN(KN!9H)%DC;HRG(-35)04444 %%%% !1110 4444 %%%% !1110 444
M4 %>9Z]_R4BS^H_E7IE>9Z]_R4BS^H_E3B)GI=+24M(84444 %%%% !1110
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M0QJBJ,  5/1171:Q[BBHJR$I:**!A1110 4444 %%%% !1110 4444 %%%%
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M/SN%=[X=U.35]%M[N:%H967YT88P:&AIFK1112&%%%% !1110 4444 %%%%
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M8+]ST#-)YB;MNX9],UYYXFU[5-7\1CPUH4IB8?Z^8?P^M(WPTG%N7CUFX^U
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MEHK4]$**** "BBB@ HHHH **** "BBB@ HHHH **** "BDI: "BBB@ HHHH
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MEO"HQ#$Q(^G'TJ+%7[$/@A0WC_76D_UPD8#/U.:].KS7Q)INI>&O%7_"2:5
MT\,HQ/$HSGUXJW)\4;/[+^YTV[:[(XA\L\'\J;UU0D[:,[E)+;SVC1XO.'WE
M!&[\:FK@/ NCZE-JEWXAU4.DMP?W<3$C ^E=_2:L4G<6BBBD,**** "BBB@
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MVO)99@C+@&G8+E^BD8X4FLO^T9O[@_*D.YJT54L[EYRV]<8J6YE:*$NHR0:
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MN'886I)R<DYKH,KK?!WC.X\/720RDR6;-\R_W?I7)59L;"XU*[2VMHFDD<X
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ME:,^\VL!;^\8QFI@H48  '8"J5S=R0S%%4$?2HO[0F)^X*+!=&F0",$ CWJ
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MJ6B@!NQ?[H_*G444 -V+_='Y4H51T4"EHH " 1@BF[$_NC\J=10 @51T %!
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MK#;QJB*,  5.5!Z@4M%="T/<C%15D($7^Z/RIU%% QNQ3U4?E1L7^Z/RIU%
M!3=B?W1^5.HH 0*H.0 *" 1@BEHH ;L3^Z/RI0H'0 4M% "$ ]0#2;$_NC\J
M=10 @  P!B@JI.2 :6B@!NQ/[H_*G444 -**>=H_*@(N<[1^5.HH 2DV)_='
MY4M+0 T(HY  _"E(!&",BF231Q*6D<*HY))KG-2\;Z18$J)O-<=DYJ7)+<RJ
M5Z=)7F['2;%_NC\J@FO+6T1FEE1 .3DUYCJWQ$O;H&.RC\A3T?/)K"CM=;\0
MR[MLUQ_M-G K%UUM$\JKF\+\M&/,ST'5?B#IULK+:@7$@Z>E<7J'C75M08K&
M1"A_AC']:UM-^&US*5:]F$:]2JC-=KIWA/2M.1=MLCN/XV7FE:K/?0Q]EC\5
M\3Y4>567A_6=;<,L4C*3DN_2MZ?X6-+I<DCW)^U 950O'YUZDJ*HP!@"EJOJ
M\&M3U,NPGU&JJT)/F/F/^Q+_ /M7^SOL[?:-VW;BO;/!G@VWT"R265 UXPRS
M$=/:NF.FV?VT7GD)]H QOQS5KM4TL,H.^Y]+C\YJ8J"@M%U$V+Z"C8O]T?E2
MBEKI/&"F[$_NC\J=10 @50> !00",$4M% #=B?W1^5*% Z "EHH 0@'J :38
MG]T?E3J* $  & ,4%5/4 TM% #=B?W1^5.HHH 38IZJ/RI-B_P!T?E3J* "F
M[$_NC\J=10 @50<@ 4$ C!%+10 W8G]T?E2A0.@ I:* $*@]0#2;$_NC\J=1
M0 @  P!B@JI.2H-+10 W8G]T?E3J** $*J3D@&DV+_='Y4ZB@ INQ?[H_*G4
M4 (%4'(4#\*6BB@!NQ/[H_*E"@= !110 $ CGFF[%_NC\J;)/%"NZ1PH'J:S
M+CQ#9P_=8N?:L*N*HTE><K&D*4Y_"KFN, 8 Q3'>-1\Y7CUKE+KQ-/*"L*;/
M?-9Q>_OSC,DG\J\FKGE)/EHQ<F=D,OG:\W8ZNYUBQM\C<K,.P%8]SXFE/RV\
M84>M06_AR[E(,F$!K8M/#=M#@R_O#[BN?GS+%:)<J-.7"4=WS,YJ2[O+QL,S
M-GTKEO%G@_4YHVU)4=E5<LI/3Z5['%:P0C$<:K]!4C(K*5(R#U%=6&RJ<)<]
M2;;+I9JZ,U*G%(^52""000>XI*]4\>> 6#-J.EQ CJ\2C^5<3X<\+7OB"_$*
M1LD2MB1R.E5*C*,N6Q]?0S*C5H>VO:VX>%_#EWK^I+'!N1$(+R#M7T-86OV.
MQAM]Y?8H7+=3571-#M-$L4M[:-5P/F('4UIXKT:%'V:U/C<TS%XRII\*V&[$
M_NC\J<%4'@ 44M=!Y8A (P1FDV)_='Y4ZB@!  .@ H*@]0#2T4 -V)_='Y4H
M  P!2T4 (54G)4&DV)_='Y4ZB@ INQ?[H_*G44 -V*#D*/RIU%% #=B?W1^5
M*%4'( %+10 A (P1FDV+_='Y4ZB@!  .@ H*@]0#2T4 -\M/[H_*E  & ,4M
M% "%5)R0#2;$_NC\J=10 4W8IZJ.?:G44 )L4'(4?E2]:** &[$_NC\J4*HZ
M "EHH 0@$8(S2;$_NC\J=10 @ '0 4%0>H!I:* &[$_NC\J4  8 Q2T4 (54
MG)4'\*38G]T?E3J* "F[%_NC\J=10 T(H.0H_*G=:** &[%_NC\J4*HZ "EH
MH 0@'J,TFQ/[H_*G44 ( !T %! (P1D4M% #=B?W1^5.  & *** $*@]0#2;
M$_NC\J=10 4A52<E1^5+10 @11T4?E2T44 -V+_='Y4H51T %+10 =:;L3^Z
M/RIU% "!0.@ H(!&" :6B@!NQ/[H_*E  ' Q2T4 (5#=0#2;$_NC\J=10 8P
M,"D**3DJ/RI:* &[$_NC\J=110 W8N<[1^5 10<A1^5.HH .HP:;L3^Z/RIU
M% "!5'0 4$ C! -+10 W8G]T?E2@ = !2T4 (54]0#2;$_NC\J=10   # %(
M54G)4&EHH ;L3^Z/RKSWXG??TW_?_K7HE>=_$[[^F_[_ /6FMQ,[G3?^0;;?
M]<Q_*K=5--_Y!MM_US'\JMTAA1110 4444 %%%% !1110 UY$C&78+]33&\J
MXA925>-AAAVQ7)>/] U;7;.VCTIE#H^6S)MXQ1X2T'5M*\,W=E?L#<R9V8DW
M=O6G96%=W+;>#_"I8DZ?:Y/7BC_A#_"G_0.M?RKSA_AUXP:5B)$P3D?Z0*;_
M ,*Y\8_WT_\  @5=O,B[['I/_"'^%/\ H'6OY"KFF^'M"TVZ$^GVD$<V,;D'
M.*\J_P"%<^,?[Z?^! KH_!/@_P 1:+KHNM293!L(XF#<_2DTNX)Z['IE+24M
M0:!2&EI#0!Y#\6X7BU?3KS'[L C/XBNYL-;M-<\(27%NZEO((=,\J<=*O^(M
M!MO$6E265RHYY1^ZGUKQG4O!?B;P_*ZVRS2PMQN@R<CW JU9HS=XNYT?P=_X
M_=9SZ1_S:K7Q7\06ITU=(AD#SLX9P#]T"O/;&R\361D2RM;Z(RX#A(S\WZ5U
M7AKX;ZEJ%Y'>ZV#' &W%'/S/['TJFDG<E-M61W_P^MGM?!]FK@@L"W/UKJ:C
MAB2"%(HU"H@PH'85)6;>IJM@HHHI#"BBB@ HHHH **** "BBB@ HHHH ****
M "O,]>_Y*19_4?RKTRO,]>_Y*19_4?RIQ$STNEI*6D,**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **2J&JZM:Z1:-<7+X4=NYI-V)G.,%S2>A=DD6)2[L
M HZDUY[XI\>! ]II;@OT:4'./I7/^)/&%UK4AAM]T5N> O<U?\,^!9[MTN]0
M&R$\A#U:N>524WRP/#KXZKB9^RPVW<Q=(T+4?$MYYAW%"WSRL.*]7T7PY8Z)
M"!!&/,Q\SGJ:T;6T@LX%A@C5$48  JQ6E.DHZO<[<'ET*"YI:R[B"EHHK4]$
M**** $I:** "BBB@ HHHH **** "BBB@ HHHH **** "BDJE>ZK9Z?&7N)T0
M#MGDT7L3*<8J\F7J0L%&2<5PFH_$JSBW)9PO*>S'@5QVH^+-7U9]BR,BD\(G
M6L95HH\VMFU"&D?>9ZMJ7B33-,4^?=1AP/N;N37%ZI\2G92FG0A3_??G]*P+
M#P?K6K$2LA1&/+2'G\JZ_2OAS:V[![V4S'^Z.!4<U2>VAQNOCL5_#7*CAI]8
MUO692IEFDW'A$Z?E6KI?@#4K[#W68%/7>.:]2M-+L[) L$"(!Z"K@IJA?63-
MJ>4)OFKRYCE-,\ Z38[7EC,\G??R/RKI8+2"V3;#$J*.P%3T5LHI;'J4L/2I
M*T(V$I:**HV$I:** $HI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HI*6@ HHI">* %HJO->06ZDR2*,
M>]9%QXGMTR(E+_I7+6QM"BKSD:TZ%2I\*-^H9;F&(9DD51[FN0NO$%U<'$?R
M#TJK';7U\V0';/<\5Y53/(R?+0BY'9'+VE>I*QTESXCM821&?,/M6/<^([N8
MXBPB_K4UOX8G?#32!?85L6NA6EN 2@9O4UCRYGBG[WN(N^$H[>\SE!]OOFQ^
M\DS6A;>&KB3!E;8/3O76)%'&,(@'T%/K>ED=.]ZTG)F<\PGM35C'MO#UG#@N
MID/^U6G';0PC$<:K]!4U%>M2PM&DK0BD<<ZLY_$Q,44M%=!F%%%% #74.I5A
MD'M5:TTZTL0PMH$BW'+;1U-6Z*5D-2:5DQ*6BBF(2EHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "O._B=]_3?]_^M>B5YW\3OOZ;_O\ ]::W$SN=-_Y!
MMM_US'\JMU4TW_D&VW_7,?RJW2&%%%% !1110 4444 %%%% !1110 E+249H
M *6DHH *6BB@ HHH- %:]O;?3[5[FZE6.)!DLQK)T'Q7IOB26YCL"S" C)92
M,YSZ_2N'^+E_,TUCID;$))\Q /4]OYUT'A#PM#X2TF2^EF9IY(MTH_A7BJLK
M7(N[C_%7CW3O#5P+58//NL995XV_6J&A?%6PU*]2UO+<VQ<X5R?ES[UY[I5L
MWC+QV1<DE9I2\F/[H-=)\0_!&G:-I4>I:8A@",%= Q.<]^:JRV9/,WJCU]6#
M*&!!!&013JYKP+?27_A*RDE.YU7:2>^#72UFT:H**** "BBB@ HHHH ****
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MUCW/BE1D0Q$^YKCKYAAZ/QR-Z>&JU/A1TA('6JTU_;0 EYD&.V:X^?6;VZ.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1%.Q%)8^E>V5SOA3PQ#X<LF0-OFD.7>NBKRL1452=T,****P **** "BBB@
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M;W%S$8IG0%T/8U>J2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *\[^)WW]-_P!_^M>B5YW\3OOZ;_O_ -::W$SN=-_Y!MM_US'\JMU4TW_D
M&VW_ %S'\JMTAA1110 4444 %%%% !1110 5G:["UQH=[$@RS1-BM&D.",'H
M: /&_A5K-MINH7>FW3B.29OD+>HXQ1\6"#XDTXC!^7K^(J]XR^'%Q+?/J6B
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M&4W.01WZ5GWPUSX@ZA;Q-8R6>E1N&8O_ !5H_$K3;C^Q=)ALK9Y1;S?=C'0
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M "O._B=]_3?]_P#K7HE>=_$[[^G?[_\ 6FMQ,[G3?^0;;?\ 7,?RJW533?\
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MM.C 03<#_9-5YM9TJ1LLVX^N#4_7\,OMK[REAZO\K-5;R!F"A\D].*L5SO\
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M[ I\=K#$VY$P?K4I4,I!'!IV1HJ<%T*8FLEZ!1]%J>)XI03'@XZ\4S[#;_\
M//\ 6I8H(X0?+7&>M/0:B@=TB7<_ J+[;;_W_P!*FDC65=KC(J'[#;_\\_UH
M'8F1UD4,IR#39)XX<;SC-.2-8U"J,*.E))!'-CS%SCI0,B^W6_\ ?_2IDD61
M RG(-0_8;?\ YY_J:FCC6-0J# %&@M2-[F*)MKM@_2F_;8/[_P"E/DM8I6W.
MF3ZYIGV&W'_+/]:8:F9XB\.VGB'3V@F0!L?*^.17E^C_  \F77G74&46L+_]
M]U[7BH&LX&8L8\D]3FL)T82=V>AA\RKX>FZ<'HR&S-G;1);VP55'  &*N$@
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M_P">?ZFIT18T"J,*.E $<ES%$VUVP?I31>P$XW_I3I+6*5MSKD_6F?8;<?\
M+/\ 6@"P#D9J%KR!6*E^1UXJ;'&*@:S@=BQ3D]>: %2[A=@JODGIQ4S,%4D]
M!4*6<",&5,$=.:F90RD'H>* (/MT']_]*?%<Q3$A&R14?V&W_P">?ZFGQ6T4
M+$QK@GWH%J/>18T+,< 5#]NM_P"_^E3/&LB;7&0>U0_8;?\ YY_J:!DL<R2@
ME#D"B6>.'&\XSTHCA2$81< T2P1S8\Q<XZ4 1?;K?^_^E3HZR*&4Y!J#[#;_
M ///]34Z1K&H51@"@".2ZBC;:S8(]J:+V G&_P#2G26L,K;G3)^M-^PVX/\
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MK/8YKZV@!,L\:X]6K%O_ !GI-BI_?B5AV2O+4TO7M2;_ %5S)GN[$_SK5M/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:C8<6UW+$/16K18CN=E+/7_R\C]Q[_FEKQRT^(&KV^!*RS*/7J:Z2P^)5JX
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MM@5+*5A:***!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>=_$[[^F_P"__6O1*\[^
M)WW]-_W_ .M-;B9W.F_\@VV_ZYC^56ZJ:;_R#;;_ *YC^56Z0PHHHH ****
M"BBB@ HHHH *0TM4]4N3::7<W ZQQEA0!1U;Q5H^BR>5>WB))_<!RWY5E_\
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M9V;_ &9!7167Q,90JW=KD]V4UI&O%[GH4LXP\_BT/2Z*Y*T^(.CW! =VB/\
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M,#BM27QA9P+MT_2HH_0N,UGS>*=:OOW<4C(#_#$M1==7<Y)2A)_O)N7H7H?
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MH?9,BT\.:79J!%:IQW(K32*.,81 !["I**T44MCLA2A!6BK"44M%,T$I:**
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5HUX#_HPC?\ O*345MXIQA9XOQ6MFVU:UNON2 'T->G1Q^&Q&D7J>=B,N?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "BBB@ HHHH *\SU[_DI%G]1_*O3*\SU[_DI%G]1_*G$3/2Z6DI:0PHHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>=_$[[^F_[_ /6O1*\[^)WW]-_W
M_P"M-;B9W.F_\@VV_P"N8_E5NJFF_P#(-MO^N8_E5ND,**** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]W[R-J]5CDTSQ/IO&R6-ASZBLCQ;X0BU6)KJV&RY4=OXJ\]T?6;WPWJ6"K
MX>)N*Y?@]V6J9XM&O6RRJHS?N]&;'B+PI<Z5.TULC-;=01U%7/#7C*6TD6VO
MW+0] QZBNYTK5+37]-65 K*PPR'M7(^)O!6P-=Z>#URT>/Y5P5<+.A+VN'V[
M'Z!A,RH8ZDJ6)Z[,[VVNH;N%987#HPX(ITL,<R%)$#*1R"*\@T7Q'>Z#/Y3
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M]&!P.E17-Y;V<>^XF2-?5CBN-7Q/=6-NSR8=44GFO-==\1WNMW;232$1Y^5
M>!7MY96ACTW#2QZ=?#RHNTCVR/Q-H\LFQ+Z$GI]X5J(Z2*&1@RGH0:^: [ Y
M#$'ZUWO@+Q;<0:@FG73EX)#A2QY4UZ=7!N,;Q9@>M2_ZE_\ =->->$O%<'AS
M4-66:UFF\V48\L=,9_QKV24_N7_W37G'PRBBEOM<,D:/B5?O+GUKC6Q$KW0[
M5/B39W6E75NNG7:F2)E!*G R/I2> SN^'.J'U\[_ - KL]=MH!H%^1!&#Y#\
M[!Z5QO@3_DG>J_\ ;;_T"GI86M]3C]/T:Y@\/1>(]-W"YM9SY@7NN:]"U#78
M/$'PXO+N%@6\H"1<_=;(S4?PRC2;PG-&ZAE>5E8'N#7&>);:[\%7E_:QJ7TW
M45^4?W3G/]*>[%LKG<>$K0W_ ,-8[53AI8W4?G7+:#X@U'P%;-IFIZ3*]LKD
MB9!CJ?7'-=%X>N[NQ^%JW5B@>XB1F12,Y^:K_ACQ5IWB+2(VO9+9;H?+)%(0
M,GU -(?8H#6/"?C:ZM1)*RW,39C5OE.?QZUF>/\ .H>+-%T=SFWW LOJ"1_A
M5/XAVNB6\EK)I)C74S*/EMVSD>^*N^.[6[L9-&\0["YMB!.!VZ8_K30,]*@B
M2"!(XU"JJ@  5DZCX7T[4]6MM2F1A<6^-K(<9P<\U-I>O:=JEC'<V]W$5*C(
M+@$?45R^L^,[B;Q/9:1H31S$N//<?, ._3T%19E-HS/&8;5_B%I&DN<P*-Q7
MU(R:]-CC2*-8XU"HHP /2O-O'T,VD>(])\0HI:.+$<Q Z=<G\J[NQUO3M0LU
MNH+N$QE<GYQE?K3>R$MW<JWGA?3KW6H-6D1ENH?NLAQGZUM5P5]XRNKWQ?::
M3H12:,']^^,J/Q%=[292LQ:***0PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BDHH 6BDS2T %%%)0 M%%% !129HH 6BBB@ HHHH
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M'M5%)2U!H%(:6B@#A_''C>7PO=VD,$"2F3+.&STJ_:Z3H_BW2;?4KO2DC>=
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M%+10-*P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G?Q.^_IO\
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M+I,%@DK2K$,!F&":T:S]'U./6-+@OHE*I*,@'J*T*S-$%%%% !1110 4444
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M=7$_#[Q"-0TU;">0&XB'R@]2HKMJEJPUJ%%%+0 4444 %%%% !1110 4444
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M'/0$D_XUZBI#*&!R",@TGHAK5GG_ /PAU]HGBV"]T$^78O\ Z^)F.*J>,_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7<*-V3TXJ5X(I&W.@)]Z06T"D$1J"#Q0(EJLU_ K%26R/:K-0M;09R8US]*
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MAP^()#-_8PN.#^\\H=_>MK[)X\]+_P#[Y/\ A7KNEZ)HWA8320,ENLQRQD?
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M2T/P!J6C:I%=IJ$3!3\RA#R/SKT6DQ1S,+(!TYI:**D84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5YW\3OOZ=_O_ -:]$KSOXG??T[_?_K36
MXF=SIO\ R#;;_KF/Y5;JIIO_ "#;;_KF/Y5;I#"BBB@ HHHH **** "BBB@
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M14M><?#?Q K0'2KB0[UYCW'K[5Z-3:L-"T444AA1110 4444 %%%% !1110
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MDYK0M?AG& /M5SGUV9K8MO .C0X#QM)]2:+56')F57=V.#N/'>LW P) @/\
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MFC_A#=<_Y\S1[:7\H?VIB/\ GR>T?;K7_GXB_P"^Q1]NM?\ GXB_[[%>+_\
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MV/ [[:]8MKF*[MTGA;=&XR"*UIU%-'HX/&PQ,;K?L3T4E+6AVA1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>=_$[[^F_[_ /6O1*\[^)WW]-_W_P"M-;B9W.F_\@VV_P"N8_E5NJFF_P#(
M-MO^N8_E5ND,**** "BBB@ HHHH **** "F2QK+$T;C*L""/:GTAH \,\2^&
M=6\(ZXVH:9YIMV8NCQC.WV-<_K_B:]\0WEO<7J1B2 8&P$9Z=?RKW'Q%XMT7
M0HS'?R+)(1Q"!N)_PIUGI&@ZYI]OJ']F0[9XQ( 1@C(]JT4NYDX7T1Y+J_Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F>O?\
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MS'&#C(_&M+P)XSU'4=4FT?6%'VE =K8P>.N:.4.8]&J&ZG%M:S3D9$:%R/7
MJ:N8\;1ZS)H[?V3(JX5C-N/5<'-);C>Q!X*\4W'B=K^66-8XHI L:CJ![FNM
MKP[X>Q>(7EE.E2HMN)1YX8]:Z/QQXQU70/%$-O:R9@V F/'WCBFXZDJ6FIZ?
M17E>@WGCJYUFTGNQ(MG,V6#+PJ_TJSXB\;ZG=ZW_ &'X<0-.K;7EZ\^WI1RN
MX^='I=%>37=YX]\-Q+?WDBW-NIS(O7 _"O0/#?B"#Q%I*7L(VG[KIG.TTFK
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M'+8^@*6H+(3BQMQ<D&<1KYA']['/ZU/4EA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5YW\3OOZ;_O\ ]:]$KSOXG??TW_?_ *TU
MN)G<Z;_R#;;_ *YC^56ZJ:;_ ,@VV_ZYC^56Z0PHHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2>#O'U_<75I(Z2,> .H/(Q1W#:Q[C1573KU-1T^&[C!"2H& /45:J#0****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O._B=]_3?\
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MIQ$STNEI*6D,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*C37$8'1')Q359KXD5'-JD-*]-H]PS2UY98?$F\C8+>0JZ]V7K74V?C[1KD
M-,T3'^^,5<:L'U.ZEF6'J;2L=515&UU:QO?]1<QO]#5T$'H:T33V.V,XR5TQ
M:*2EIE!1244 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6?U'\J],KS/7O^2D6?U'\J<1,]+I:2EI#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $I:** $(!ZBJ=UI=G>
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*PK'Q=I%]M"7*JQ_A;BMF.:*49CD5A[&M5)/9GH0K4ZBO%W)*6DI:9H%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KSOXG??TW_?\ ZUZ)7G?Q.^_IO^__ %IK<3.YTW_D&VW_ %S'
M\JMU4TW_ )!MM_US'\JMTAA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5YGKW_)2+/ZC^5>F5YGKO_)2+/ZC^5.(F>ETM)2TAA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 -9
M0PP15*ZT73KT8N+.&3W90:OT4FDR)0C+XE<XR\^'.E3EF@,D+'G@Y'Y5S&H_
M#O4;<LUHRS*.@SR:]:I*SE1@SAJY9AZG2QX4UEKVE-GR[J CNI(K0LO'&MV
M"22>:HZ^8,G\Z]C:)'&'4$>]8^H>%=*U$'SK< ^J\5FZ,E\+.-Y76IZT*C.9
MT[XEV[X6^@:,^J<BNIL_%&D7H'E7L98_PYYKE[WX9V[@FTN6C]F&:YF^\"ZS
M8[G1!*@[H>?RHYJL=T3]8S##_P 2/,CV*.>*491U;Z&B:9((7ED8*BC))KPR
M'4-8T63AI8SZ.#5V_P#'6IWFF264VP[Q@L!@UI3J\SM8Z\-F:K2Y'%IFHWCB
M3_A,_.$Q%CGRR,\8]:]3BD66)9$(*L,@BOFOO7I_@[QM:P:8+/4)"KQ<(W7(
MKHDK*YZ/.HJ\CTBBL%?%^CG'^E#GUJ<>)M);'^F1\^IK+GCW(6)I/[2->BLT
M:]I9/%[#_P!]5*-6L&.!=1G_ (%3YEW'[:G_ #(NT55%_:L<"="?K3Q=0GI(
MOYT717M8=R>BHO/B/\8_.G"1#_$*8^:+ZCZ*;N!Z$4N:"KBT4E% "T444 %%
M)10 M%)2T %%%% !1110 4444 %%%% !1110 4444 %%%)0 M%)2T %%%)0
MM%%5K^]BT^RENICA(U+'WH LT55L+Z'4;..Y@;*.,BH-8U2/1]/>[E4LJD9
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %>=_$[[^F_[_ /6O1*\[^)WW]-_W_P"M-;B9W.F_\@VV
M_P"N8_E5NJFF_P#(-MO^N8_E5ND,**** "BBB@ HHHH **** "BBB@ HHHH
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MP:V=>\;6=V8O+^8#'X4TK";/9*6D':EJ1A1110 4444 %%%% !1110 4444
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MFEHNPLBM965MIUJEM:Q+%"@PJJ*L48I:0PHHHH **** "BBB@ HHHH ****
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M%+24M2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^$"T'_GU_P#'C6B:6P*FHZ)6/#ZZOP+KXTC6$AF<BWG.T^Q[5Z+_ ,(%H/\
MSZ_^/&E7P)H2,&6V((.0=Q_QIN295CI5(90PY!Y%+3(HUBB6-?NJ,"GUF4%%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7G?Q.^_IO^__ %KT2O._B=]_3?\
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M^^J/MMK_ ,_$?_?5 $]%0?;;7_GXC_[ZH^VVO_/Q'_WU0!/14'VVU_Y^(_\
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MMM?^?B/_ +ZH FHJ'[;:_P#/Q'_WU1]MM?\ GXC_ .^J )J6H/MMK_S\1_\
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M>BH/MMK_ ,_$?_?5'VVU_P"?B/\ [ZH GHJ#[;:_\_$?_?5'VVU_Y^(_^^J
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MK<3.]TW_ )!MM_US'\JMU4TW_D&6W_7-?Y5;I#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KC?$?@@Z[J7VP77EG&,8KLJ*:=@/,+[X>2VEE-<?
MV@Y\M=V,=?UK$\*>&9O$D5T_VQHO(95]<YS_ (5ZWK?_ "!;O_KF:XGX4_\
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M?^@DWY?_ %Z/^%9R_P#02;\O_KUZ/11S,+'G'_"LY?\ H)-^7_UZ/^%9R_\
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M7_H)-^7_ ->C_A6<O_02;\O_ *]>CT4<S"QYQ_PK.7_H)-^7_P!>C_A6<O\
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M49QS7HU-:-&.653]133L!':@BTA!Z[!_*IJ**0!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7->.XI)O"MPD2%V)& !D]ZZ6D90PPR@CT- '-^!HI(?#,
M"2(48=0PKI:15"C"@ >U+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M!> M93 #)*'^53TF.* /.OAS:SV^IZD98G0,QP6&,\UZ-35C1.54#/7 IU-N
MX!1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#TI:* /+UM+C_ (6C%-Y+
M^7YOW]O'0UZ?3?+3=NV+N]<<TZAL!:*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **HZEJUGI,(ENY0@/0=2:S[
M+Q=I-[.(4G*N>@=2,T6 WJ*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BH;JZALX&FGD$<:C))K#3QKHSS>7Y[+DX#%#C\\4 =%13(Y$EC62-@R,,
M@CO3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOX4,#N:***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF&$\[O<T ='H'F_V%9^=GS/*7.?I6E2*H10JC  P!2TAA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 075S':6TD\K *BD\UY7KK7>IS6^JW.5B:<+ G^SZUTOC2
M2_GN[6UBLYY;,$/+Y0SG!Z5A^*=8>>UL81I=Q;)%*"N]0,X[52$SK?%%RUOX
M2;8<,Z*H/UQ4^F:%8)H44!MHSOC!8E1G.*R=;FDU+P3]H-O)"T>"4<<\'&:Z
M73+B.;1X)58%?*'/X4@.>\$N8)=2TT$[+:8A![5V%<;X-'G:IK%VO,<DYVGU
MZUV5#!!1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &)KOAV'6-DJR-#=1G*2KVK,@\(7$]RDFKZG+>I&<JA&!G\ZZZBG
M<!%4*H4# '2EHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9^K:1;:Q
M:F"X!XY5E."I]JY\>$M0D/DW.MSR6?0Q="1Z9S78447 JV-E!IUG':VZ;8T&
M *M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3&?\*M1BR'*2/??^$LT+_H)0?]]5=L=5LM2#&SN8Y@OWMISBO-/^%-_]1/\
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M4E% "T4E% "T4E% "T4E+0 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55U&W%UIUS 1D
M21LOZ5:I* /"OA_=G1O';63'"RLT!S['/]*]GUF\%AH]W=$X$<9->,>+;3^P
M/B,D\8PCR+*I]SU_G7;?$W6A!X1CAB;YKP@8]5QS_2M&KM&479,Y'X:Z5_;&
MNWM].-R(A!SW9O\ ]55O"ID\.?$C[)(<?O3"WODUW7PJT[[+X8^TLN&N'S^
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M^TO,X&/XJ]L\+3Z__8EY)K8*W"!BF0!QBO,=!_Y*<O\ U\'^=>YWW_(/N?\
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MQ1MO<LI P*UB]#*2=SW/1;%=-T>TLT&%AC"_E7%_%O2Q<Z!#?J/GMGP?H?\
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M87<_C)GBMI77:N"JDCJ:]KMLBUA!ZA!_*B6PX[LX7XM?\BJO_74?S%.^$_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M BJ[V%I(<M;0D^Z"K-% $4<$4/\ JHD3_=4"I*6B@!C(C_>16QZC-*%"KA0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
<* "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gzkk5j0cumnd000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkk5j0cumnd000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0S",H# 2(  A$! Q$!_\0
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M0W0/^?#_ ,C2?_%5NT4 87_"&Z!_SX?^1I/_ (JC_A#= _Y\/_(TG_Q5;M%
M&%_PAN@?\^'_ )&D_P#BJ/\ A#= _P"?#_R-)_\ %5NT4 87_"&Z!_SX?^1I
M/_BJ/^$-T#_GP_\ (TG_ ,56[10!A?\ "&Z!_P ^'_D:3_XJC_A#= _Y\/\
MR-)_\56[10!A?\(;H'_/A_Y&D_\ BJ/^$-T#_GP_\C2?_%5NT4 87_"&Z!_S
MX?\ D:3_ .*H_P"$-T#_ )\/_(TG_P 56[10!A?\(;H'_/A_Y&D_^*H_X0W0
M/^?#_P C2?\ Q5;M% &%_P (;H'_ #X?^1I/_BJ/^$-T#_GP_P#(TG_Q5;M%
M &%_PAN@?\^'_D:3_P"*H_X0W0/^?#_R-)_\56[10!A?\(;H'_/A_P"1I/\
MXJC_ (0W0/\ GP_\C2?_ !5;M% &%_PAN@?\^'_D:3_XJC_A#= _Y\/_ "-)
M_P#%5NT4 87_  AN@?\ /A_Y&D_^*H_X0W0/^?#_ ,C2?_%5NT4 87_"&Z!_
MSX?^1I/_ (JC_A#= _Y\/_(TG_Q5;M% &%_PAN@?\^'_ )&D_P#BJ/\ A#=
M_P"?#_R-)_\ %5NT4 87_"&Z!_SX?^1I/_BJ/^$-T#_GP_\ (TG_ ,56[10!
MA?\ "&Z!_P ^'_D:3_XJC_A#= _Y\/\ R-)_\56[10!A?\(;H'_/A_Y&D_\
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M&Z!_SX?^1I/_ (JC_A#= _Y\/_(TG_Q5;M% &%_PAN@?\^'_ )&D_P#BJ/\
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MY\/_ "-)_P#%5NT4 87_  AN@?\ /A_Y&D_^*H_X0W0/^?#_ ,C2?_%5NT4
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M !5;M% &%_PAN@?\^'_D:3_XJC_A#= _Y\/_ "-)_P#%5NT4 87_  AN@?\
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M_P#BJ/\ A#= _P"?#_R-)_\ %5NT4 87_"&Z!_SX?^1I/_BJ/^$-T#_GP_\
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M_P"$-T#_ )\/_(TG_P 56[10!A?\(;H'_/A_Y&D_^*H_X0W0/^?#_P C2?\
MQ5;M% &%_P (;H'_ #X?^1I/_BJ/^$-T#_GP_P#(TG_Q5;M% &%_PAN@?\^'
M_D:3_P"*H_X0W0/^?#_R-)_\56[10!A?\(;H'_/A_P"1I/\ XJC_ (0W0/\
MGP_\C2?_ !5;M% &%_PAN@?\^'_D:3_XJC_A#= _Y\/_ "-)_P#%5NT4 87_
M  AN@?\ /A_Y&D_^*H_X0W0/^?#_ ,C2?_%5NT4 87_"&Z!_SX?^1I/_ (JC
M_A#= _Y\/_(TG_Q5;M% &%_PAN@?\^'_ )&D_P#BJ/\ A#= _P"?#_R-)_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C&M_\A_4
M?^OJ7_T(U[/7C&M_\A_4?^OJ7_T(T >E>#?^13LO^VG_ *&U;M87@W_D4[+_
M +:?^AM6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>,:W_R']1_Z^I?_ $(U[/7C&M_\
MA_4?^OJ7_P!"- 'I7@W_ )%.R_[:?^AM6[6%X-_Y%.R_[:?^AM6[0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %>,:W_P A_4?^OJ7_ -"->SUXQK?_ "']1_Z^I?\ T(T
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M*%0[%<@ ,H("Y^D]*TJQT32[?3-,MH[:SMTV11(.%'\R2<DD\DDD\F@#'O\
MP7IK:7]GT-(] NXW,MM=:;"L1CD.W.Y5P)$;8FY&X8*,\A2*?@'QO_PEUG>V
MM[:_8M=TF7[-J=JIW(D@+#<C D%24;C)(P1R,,W85X9K=XWA#]IVQN_M$CP:
M];PPS1I$N0''DHN2>GF11N2,'&1SW /<Z*** "BBB@ HHHH **** "BBLCQ-
MK+:#H-Q?QQ>;*N%C4@E=Q. 6QT ]\9Z9R12;LKLJ$7.2C'=FO17B7_"?>)_^
M@G_Y C_^)H_X3[Q/_P!!/_R!'_\ $UC]8B>C_9-;NOQ_R/;:*\2_X3[Q/_T$
M_P#R!'_\31_PGWB?_H)_^0(__B:/K$0_LFMW7X_Y"^/1GQOJ/_;/_P!%K7.;
M1Z58O=0NM4OY+R\E\VXDQO?:%S@ #@ #H!4%<LG=MGMTHN%.,7T2$VCTH(&*
M6D/0TC0]J\ _\B3I_P#VT_\ 1C5TM>$:?XOUW2[*.SL[[RK>/.Q/)1L9))Y*
MD]2:M?\ "?>)_P#H)_\ D"/_ .)KJC7BDD>)6RRM.I*2:U;[_P"1[;17B7_"
M?>)_^@G_ .0(_P#XFC_A/O$__03_ /($?_Q-/ZQ$S_LFMW7X_P"1[;17G'@G
MQMJ6I:RFF:FZSB97,<@C"L& S@XP-N W;.2.U>CUK":DKHXJ]"="?),\$^-?
M@/2-#LM+U[PQITEAK$NIQ6Z)I^4#L48H41?NN&C7&S&2QSDX([?X3?$:'QOX
M?2WO;F,^(+1/]+CV!/,7.!*HS@@C&[&,-V *YD^*?_,E?]C78_\ L]<)\6/!
ME]X1\2I\3/#DD:"&XCFO+?[@1R0N[Y<%DD)PXSDER>0QVT8GL^M^&]%\1V_D
M:SI=I?($=$,T09HPPPVQNJ$X'*D'@>E>?_ [PWHL7P\TC6ETNT.J2O.[7C1!
MI0?,>/Y6/*C:H&!@=?4Y[#P/XSL?'7AJ/5[&.2$AS#<0/R890 2N>C## @CJ
M",X.0,/X)?\ )(="_P"WC_T?)0!Z!7SA\7_&6HI\1;34]$FWVOA>6*!W#+L^
MU2[W9,JVYE9(MC#(QL8<9Y][\2:W#X<\-:EK,_EE+.W>4(\@C$C ?*FX]"S8
M4<'DC@UY_9>![[4?@?J6FZA%(=>UE)=3N50^6TEVS"5%8. $/RQJR@ ##=.M
M 'IEA?6^IZ=;7]G)YEK=1+-"^TC<C %3@\C((ZU7UW4_[$\/:GJWD^=]AM);
MGRMVW?L0MMS@XSC&<&O+_P!GGQ)_:?@NXT-X]LFD2_*X7 :.4LXR<\L&$F>
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M=EB7;!S@,>M '445X_X;^%>G>,?"]MK_ (SN[[5=9U6T$PG-VP6U5RSH(E
M7 <$J0RA@<#'7,\&:]K7@'XJ/\/M7NY+G1;A\:;/>S'=$FP^2$9@ P(41E ,
M;Q\O0A@#W.BOGC]H>/4=,ETS&OZK/:ZGYXELI)E6!5C9&0!$50<%SRVYOE7G
MBNW^)GP^LM7\#:KJ>HW4]SK5E:274=TTDGEQE0'98X-^Q%94V="<8+%V!) /
M4**\3^$-I<^.OAS%9ZWJ5VVEZ=<262VEO,\1N4,>=L\@;<R 2A512@ 49W<
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M]_F7C/%WA3X:1^&KO4M#\56D7B2S0WD5\NLB:XNID!;YAOY=VYRH!#$$?W2
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M[^T2/!KUO##-&D2Y <>2BY)Z>9%&Y(P<9'/< ]SHHHH **** "BBB@ HHHH
M***J:I>_V?ID]UMW-&ORC&>2<#/MDBE*2BFV!;HKSQ_%.KL[,+H*"<A1&N![
M<C--_P"$GUC_ )_/_(2?X5P_VC2[/^OF1SH]%HKSK_A)]8_Y_/\ R$G^%'_"
M3ZQ_S^?^0D_PH_M&EV?]?,.="^)O^1CNO^ ?^@+63@5+<74U[<O<7#[Y7QN;
M &<#';Z5'7E5)*4W)=69O5B8%&!BEH/2H [;P9_R!YO^O@_^@K71UYC9:S?Z
M?"8;6?RXRVXC8IYZ=Q[59_X2?6/^?S_R$G^%>G1QU.%-1:>A:FDCT6BO.O\
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MJF@#Z#HKQ?XS>'_$^G68\1^%=8UR*WCWMJ-M#J<Q" G(D1-W"C+!@#A0%(4
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M55>6)?"_+@D9H X?Q5I5Y\3O%&H:?IU_/:6/AN(_9[F"8QK)JK#<N64,"L0
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M  5A509#C)VN9BZ-@X801]0 Q/B7IL.L?#S5].E:0/<I'';A" 7N#(ODIDC
M#2[%).  3R.HV/#>B0^'/#6FZ-!Y92SMTB+I&(Q(P'S/M'0LV6/)Y)Y- 'BG
M[37_ #*W_;W_ .T:]'^,%C<:A\*-?AM8_,D6))B-P&$CD21SSZ*K'WQQS5/X
ML_#:;XA:78FQO([?4+!W,(GSY4BOMWAB 2#\H((!Z$$<Y'2>&+3Q3#9PMXHU
M2QN+I(O+:.PMRB,V?ONS<LV /NJBC<PPWRD ')_ ;4H;[X5V=O$L@>PN)K>4
ML!@L7,N5YZ;9%ZXY!^M<I^T78W&IZCX-L+./S+JZEN(84W ;G8PA1D\#)(ZU
MKVOPK\2>"?%$^J_#_6+%+&ZW";3=5\SRU7'RC*Y+X)8@_*P&!ELMGI-"\#ZE
M-XQC\9>+;ZTN=:AM_L]K;:?&R6]JOS D%CND)#$_-T+MUPI !S?[1W_)/-/_
M .PK'_Z*EKT#P)_R3SPS_P!@JU_]%+7/_$3X>ZI\0(HK*3Q%!8Z9#*)H[=-.
M\QR^W;EG,HSC+XP%^]SG -;'AW0/$&@>%X]'.O6-W):Q1PV=Q)IC+L13C#JL
MPW_+A1@KC&3N- 'E'[,O_,T_]NG_ +6H^*?_ "<+X*_[<?\ TK>NO^'_ ,*=
M4^'VHSS6/BB"YM;O8+JWFTS&\*20582Y5L%@#R/FY!P*/%WPIU3Q7XRM?$O_
M  E$%C=6.P68ATS=Y821I$+;I2&8%N3@ XZ"@#U"O/YO^+DZY;"']YX-TZ5C
M<,_,6KW"\*J@?>AC89+$E'88VL%W"3Q1X/\ %_BG2WTV;QG:6%I*C).ECI!0
MS*<<,S3L0.",*1D,0<BMCP3X<OO"GA^#1KG4;2]M[5 ENT-A]F8#+$[\.P8G
M(Y !X).XDF@#R3XL>'=1\">-+7XC^&HOE:4M>(85,4,A 3+ 8.V4,P)ZAB3N
MRRX]K\.:_8^*?#]GK6FM(;2Z0LGF)M92"592/4,".,CC@D<UG^-O#E]XK\/S
MZ-;:C:65O=(4N&FL/M+$94C9EU"D8/)!/((VD UQ_@SX5^(_ KNND>-XVM)7
MWRV=QI6^)VVD9QYP*GIRI&=JYR!B@#U2N#^,\$US\)->2"*25PD3E44L0JS(
MS'CL%!)/8 FN\JO?V-OJ>G7-A>1^9:W430S)N(W(P(89'(R">E '#_!+_DD.
MA?\ ;Q_Z/DKG_P!H3PQ<:QX2LM7LX)YYM*E<RK'@A('7YW(ZG!1.G0%B1@9$
MGP<@F\(:IXA\!:C%(EW;W!U"UG92!=V[;8_,4#( ^5/XB<N1U0UZQ/!#=6\M
MO<11S02H4DCD4,KJ1@@@\$$=J .'^#NOKX@^&6E-NC\^Q3[#,J(P"F/ 3KU)
MC\LDCC)/3H.\KR.\^#^I:!JD^J?#KQ')HCNB#^SY]TD#L,J2S,6R-K$@,KX8
MG!&1MZ".R^*6H)-;WVK^&-)1DREUIUI-<2JP8<;96"8(SDG/L.X .T^W6_\
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M.KR'(#WB[HX<%4 #9'FA0=I#,.=G-_\ :._Y)YI__85C_P#14M=IX"\ Z;X
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MBAE=2,$$'@@CM7#^+_!/B/Q9<6+#Q5:6$&GWHO;5(=)WL)%/[LNS2D,5!/0
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M<,!P3D9QM/S4 ;%_?7&I_ JYO[R3S+JZ\---,^T#<[6Q+' X&23TKE_V<?\
MDGFH?]A63_T5%7>>+M"UKQ%I=WI=AK5IIUG=VY@F+:>9Y<-D-M;S%4 J=OW2
M1R0<XQQ?ASX4^*O".G26&A_$/[):R2F9D_L6*3+D $Y=R>BC\J /3-5U6QT3
M2[C4]3N8[:SMTWRRN>%'\R2<  <DD <FOGSX?:3<?$GXPZAXTNX9SI%I=F>&
M26,)N=<""+Y2/F10C'&[[@#9WY/H=S\)[OQ%<1OXU\8ZEKD$+QM%:0PI9P?*
M6SO1<@DAL;AM8#(STQZ!I6E6.B:7;Z9IEM';6=NFR*)!PH_F23DDGDDDGDT
M9_C'7U\+>#M5UIFC#VMNS1>8C,K2GY8U(7G!<J.W7J.M<'X8^$%Q:Z'#)?\
MB_Q79ZG=_P"DW\=EJ(C3SWY;. VYAP"VX[MN?8=!XV\%:[XNO+!K?Q/!IEKI
M]VE[;1II@E<3(/E9F:3#8.[ "@?-@AL UUFFQZE%;LNJ7=I<S[\J]K;- H7
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MBX=B!M*R(%4#G.<Q-GCN/P](\#^#+'P+X:CT>QDDF)<S7$[\&:4@ MCHHPH
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M<QLIY[%2"#W!!KWNO&_'^E+X/^*FA?$=;:2332_V?574,1 60Q+,V-QQM<#
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M_@?1/^$G^+GB+X@2V^VPAE:TTN17W)<,B^2TR,",KM0]BO[PX.4H ]@HHHH
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M;ZK1_E*Y48^G^&K'3;Q;F)YGD4$+YC# SQG@#MG\ZV***TA3C!6BK E8\_\
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MP;:3^Q_%"-:BX 8K!=R,&*'[Q)=T!&=H_>''"&O9* "BBB@#S_XI_P#,E?\
M8UV/_L]=Y/!#=6\MO<11S02H4DCD4,KJ1@@@\$$=JX?Q?X)\1^++BQ8>*K2P
M@T^]%[:I#I.]A(I_=EV:4ABH)Z  Y.1TQV&FQZE%;LNJ7=I<S[\J]K;- H7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH X_6?AGX:U?47U2*WGTK5VR1J.E3M;3*226;Y?E+-N8%BI)!//
M3&QH]CKMC*Z:EK<&I6HW^46L1%/RV5WNK[&POR_+&N>#QSG8HH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *>JZ58ZWI=QIFIVT=S9W";)8G'##^8(."".00".14>C:
M?<:7IR65QJ,^H+%A8I[D#SB@ XD88#MG/S8&1C.2"S:%% !1110 4444 %%%
M% !1110 4444 %8>D>&H=.U2[UFZN)+_ %B[18Y;J4 ".,?\LH5_Y9Q;LMMR
M22<LS'FMRB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KQC6_P#D/ZC_ -?4O_H1KV>O&-;_ .0_J/\ U]2_^A&@
M#TKP;_R*=E_VT_\ 0VK=K"\&_P#(IV7_ &T_]#:MV@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *\8UO_D/ZC_U]2_^A&O9Z\8UO_D/ZC_U]2_^A&@#TKP;_P BG9?]M/\
MT-JW:PO!O_(IV7_;3_T-JW: "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQC6_^0_J/_7U+
M_P"A&O9Z\8UO_D/ZC_U]2_\ H1H ]*\&_P#(IV7_ &T_]#:MVL+P;_R*=E_V
MT_\ 0VK=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "O&-;_P"0_J/_ %]2_P#H1KV>O&-;
M_P"0_J/_ %]2_P#H1H ]*\&_\BG9?]M/_0VK=K"\&_\ (IV7_;3_ -#:MV@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!(*DHW&21@CD89@#L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?]#3>_D__P 77644 <G_ ,(GJW_0TWOY/_\ %T?\(GJW_0TWOY/_ /%UUE%
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M='_")ZM_T--[^3__ !==910!R?\ PB>K?]#3>_D__P 71_PB>K?]#3>_D_\
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M-[^3_P#Q==910!R?_")ZM_T--[^3_P#Q='_")ZM_T--[^3__ !==910!R?\
MPB>K?]#3>_D__P 71_PB>K?]#3>_D_\ \77644 <G_PB>K?]#3>_D_\ \71_
MPB>K?]#3>_D__P 77644 <G_ ,(GJW_0TWOY/_\ %T?\(GJW_0TWOY/_ /%U
MUE% ')_\(GJW_0TWOY/_ /%T?\(GJW_0TWOY/_\ %UUE% ')_P#")ZM_T--[
M^3__ !='_")ZM_T--[^3_P#Q==910!R?_")ZM_T--[^3_P#Q='_")ZM_T--[
M^3__ !==910!R?\ PB>K?]#3>_D__P 71_PB>K?]#3>_D_\ \77644 <G_PB
M>K?]#3>_D_\ \71_PB>K?]#3>_D__P 77644 <G_ ,(GJW_0TWOY/_\ %T?\
M(GJW_0TWOY/_ /%UUE% ')_\(GJW_0TWOY/_ /%T?\(GJW_0TWOY/_\ %UUE
M% ')_P#")ZM_T--[^3__ !='_")ZM_T--[^3_P#Q==910!R?_")ZM_T--[^3
M_P#Q='_")ZM_T--[^3__ !==910!R?\ PB>K?]#3>_D__P 71_PB>K?]#3>_
MD_\ \77644 <G_PB>K?]#3>_D_\ \71_PB>K?]#3>_D__P 77644 <G_ ,(G
MJW_0TWOY/_\ %T?\(GJW_0TWOY/_ /%UUE% ')_\(GJW_0TWOY/_ /%T?\(G
MJW_0TWOY/_\ %UUE% ')_P#")ZM_T--[^3__ !='_")ZM_T--[^3_P#Q==91
M0!R?_")ZM_T--[^3_P#Q='_")ZM_T--[^3__ !==910!R?\ PB>K?]#3>_D_
M_P 71_PB>K?]#3>_D_\ \77644 <G_PB>K?]#3>_D_\ \71_PB>K?]#3>_D_
M_P 77644 <G_ ,(GJW_0TWOY/_\ %T?\(GJW_0TWOY/_ /%UUE% ')_\(GJW
M_0TWOY/_ /%T?\(GJW_0TWOY/_\ %UUE% ')_P#")ZM_T--[^3__ !='_")Z
MM_T--[^3_P#Q==910!R?_")ZM_T--[^3_P#Q='_")ZM_T--[^3__ !==910!
MR?\ PB>K?]#3>_D__P 71_PB>K?]#3>_D_\ \77644 <G_PB>K?]#3>_D_\
M\71_PB>K?]#3>_D__P 77644 <G_ ,(GJW_0TWOY/_\ %T?\(GJW_0TWOY/_
M /%UUE% ')_\(GJW_0TWOY/_ /%T?\(GJW_0TWOY/_\ %UUE% ')_P#")ZM_
MT--[^3__ !='_")ZM_T--[^3_P#Q==910!R?_")ZM_T--[^3_P#Q='_")ZM_
MT--[^3__ !==910!R?\ PB>K?]#3>_D__P 71_PB>K?]#3>_D_\ \77644 <
MG_PB>K?]#3>_D_\ \71_PB>K?]#3>_D__P 77644 <G_ ,(GJW_0TWOY/_\
M%T?\(GJW_0TWOY/_ /%UUE% ')_\(GJW_0TWOY/_ /%T?\(GJW_0TWOY/_\
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M10  H+MS@$Y)X&%7L** "BBB@ HHHH Y/PG_ ,A_Q)_U]?\ LTE=97)^$_\
MD/\ B3_KZ_\ 9I*ZR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *\8UO_D/ZC_U]2_^A&O9Z\8UO_D/ZC_U]2_^A&@#
MTKP;_P BG9?]M/\ T-JW:PO!O_(IV7_;3_T-JW: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y/PG_
M ,A_Q)_U]?\ LTE=97)^$_\ D/\ B3_KZ_\ 9I*ZR@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\8UO_D/ZC_U]2_^
MA&O9Z\8UO_D/ZC_U]2_^A&@#TKP;_P BG9?]M/\ T-JW:PO!O_(IV7_;3_T-
MJW: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Y/PG_ ,A_Q)_U]?\ LTE=97)^$_\ D/\ B3_KZ_\
M9I*ZR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *\8UO_D/ZC_U]2_^A&O9Z\8UO_D/ZC_U]2_^A&@#TKP;_P BG9?]
MM/\ T-JW:PO!O_(IV7_;3_T-JW: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y/PG_ ,A_Q)_U]?\
MLTE=97)^$_\ D/\ B3_KZ_\ 9I*ZR@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\8UO_D/ZC_U]2_^A&O9Z\8UO_D/
MZC_U]2_^A&@#TKP;_P BG9?]M/\ T-JW:PO!O_(IV7_;3_T-JW: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH Y/PG_ ,A_Q)_U]?\ LTE=97)^$_\ D/\ B3_KZ_\ 9I*ZR@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>ISI6"BBBK.8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\8UO_D/ZC_U]2_^A&O9Z\8UO_D/ZC_U]2_^A&@#TKP;
M_P BG9?]M/\ T-JW:PO!O_(IV7_;3_T-JW: "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y/PG_ ,A_
MQ)_U]?\ LTE=97)^$_\ D/\ B3_KZ_\ 9I*ZR@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M09/_ (F@#=HK"_X3+0/^?_\ \@R?_$T?\)EH'_/_ /\ D&3_ .)H W:*PO\
MA,M _P"?_P#\@R?_ !-'_"9:!_S_ /\ Y!D_^)H W:*PO^$RT#_G_P#_ "#)
M_P#$T?\ "9:!_P __P#Y!D_^)H W:*PO^$RT#_G_ /\ R#)_\31_PF6@?\__
M /Y!D_\ B: -VBL+_A,M _Y__P#R#)_\31_PF6@?\_\ _P"09/\ XF@#=HK"
M_P"$RT#_ )__ /R#)_\ $T?\)EH'_/\ _P#D&3_XF@#=HK"_X3+0/^?_ /\
M(,G_ ,31_P )EH'_ #__ /D&3_XF@#=HK"_X3+0/^?\ _P#(,G_Q-'_"9:!_
MS_\ _D&3_P")H W:*PO^$RT#_G__ /(,G_Q-'_"9:!_S_P#_ )!D_P#B: -V
MBL+_ (3+0/\ G_\ _(,G_P 31_PF6@?\_P#_ .09/_B: -VBL+_A,M _Y_\
M_P @R?\ Q-'_  F6@?\ /_\ ^09/_B: -VBL+_A,M _Y_P#_ ,@R?_$T?\)E
MH'_/_P#^09/_ (F@#=HK"_X3+0/^?_\ \@R?_$T?\)EH'_/_ /\ D&3_ .)H
M W:*PO\ A,M _P"?_P#\@R?_ !-'_"9:!_S_ /\ Y!D_^)H W:*PO^$RT#_G
M_P#_ "#)_P#$T?\ "9:!_P __P#Y!D_^)H W:*PO^$RT#_G_ /\ R#)_\31_
MPF6@?\__ /Y!D_\ B: -VBL+_A,M _Y__P#R#)_\31_PF6@?\_\ _P"09/\
MXF@#=HK"_P"$RT#_ )__ /R#)_\ $T?\)EH'_/\ _P#D&3_XF@#=HK"_X3+0
M/^?_ /\ (,G_ ,31_P )EH'_ #__ /D&3_XF@#=HK"_X3+0/^?\ _P#(,G_Q
M-'_"9:!_S_\ _D&3_P")H W:*PO^$RT#_G__ /(,G_Q-'_"9:!_S_P#_ )!D
M_P#B: -VBL+_ (3+0/\ G_\ _(,G_P 31_PF6@?\_P#_ .09/_B: -VBL+_A
M,M _Y_\ _P @R?\ Q-'_  F6@?\ /_\ ^09/_B: -VBL+_A,M _Y_P#_ ,@R
M?_$T?\)EH'_/_P#^09/_ (F@#=HK"_X3+0/^?_\ \@R?_$T?\)EH'_/_ /\
MD&3_ .)H W:*PO\ A,M _P"?_P#\@R?_ !-'_"9:!_S_ /\ Y!D_^)H W:*P
MO^$RT#_G_P#_ "#)_P#$T?\ "9:!_P __P#Y!D_^)H W:*PO^$RT#_G_ /\
MR#)_\31_PF6@?\__ /Y!D_\ B: -VBL+_A,M _Y__P#R#)_\31_PF6@?\_\
M_P"09/\ XF@#=HK"_P"$RT#_ )__ /R#)_\ $T?\)EH'_/\ _P#D&3_XF@#=
MHK"_X3+0/^?_ /\ (,G_ ,31_P )EH'_ #__ /D&3_XF@#=HK"_X3+0/^?\
M_P#(,G_Q-'_"9:!_S_\ _D&3_P")H W:*PO^$RT#_G__ /(,G_Q-'_"9:!_S
M_P#_ )!D_P#B: -VBL+_ (3+0/\ G_\ _(,G_P 31_PF6@?\_P#_ .09/_B:
M -VBL+_A,M _Y_\ _P @R?\ Q-'_  F6@?\ /_\ ^09/_B: -VBL+_A,M _Y
M_P#_ ,@R?_$T?\)EH'_/_P#^09/_ (F@#=HK"_X3+0/^?_\ \@R?_$T?\)EH
M'_/_ /\ D&3_ .)H W:*PO\ A,M _P"?_P#\@R?_ !-'_"9:!_S_ /\ Y!D_
M^)H W:*PO^$RT#_G_P#_ "#)_P#$T?\ "9:!_P __P#Y!D_^)H W:*PO^$RT
M#_G_ /\ R#)_\31_PF6@?\__ /Y!D_\ B: -VBL+_A,M _Y__P#R#)_\31_P
MF6@?\_\ _P"09/\ XF@#=HK"_P"$RT#_ )__ /R#)_\ $T?\)EH'_/\ _P#D
M&3_XF@#=HK"_X3+0/^?_ /\ (,G_ ,31_P )EH'_ #__ /D&3_XF@#=HK"_X
M3+0/^?\ _P#(,G_Q-'_"9:!_S_\ _D&3_P")H W:*PO^$RT#_G__ /(,G_Q-
M'_"9:!_S_P#_ )!D_P#B: -VBL+_ (3+0/\ G_\ _(,G_P 31_PF6@?\_P#_
M .09/_B: -VBL+_A,M _Y_\ _P @R?\ Q-'_  F6@?\ /_\ ^09/_B: -VBL
M+_A,M _Y_P#_ ,@R?_$T?\)EH'_/_P#^09/_ (F@#=HK"_X3+0/^?_\ \@R?
M_$T?\)EH'_/_ /\ D&3_ .)H W:*PO\ A,M _P"?_P#\@R?_ !-'_"9:!_S_
M /\ Y!D_^)H W:*PO^$RT#_G_P#_ "#)_P#$T?\ "9:!_P __P#Y!D_^)H W
M:*PO^$RT#_G_ /\ R#)_\31_PF6@?\__ /Y!D_\ B: -VBL+_A,M _Y__P#R
M#)_\31_PF6@?\_\ _P"09/\ XF@#=HK"_P"$RT#_ )__ /R#)_\ $T?\)EH'
M_/\ _P#D&3_XF@#=HK"_X3+0/^?_ /\ (,G_ ,31_P )EH'_ #__ /D&3_XF
M@#=HK"_X3+0/^?\ _P#(,G_Q-'_"9:!_S_\ _D&3_P")H W:*PO^$RT#_G__
M /(,G_Q-'_"9:!_S_P#_ )!D_P#B: -VBL+_ (3+0/\ G_\ _(,G_P 31_PF
M6@?\_P#_ .09/_B: -VBL+_A,M _Y_\ _P @R?\ Q-'_  F6@?\ /_\ ^09/
M_B: -VBL+_A,M _Y_P#_ ,@R?_$T?\)EH'_/_P#^09/_ (F@#=HK"_X3+0/^
M?_\ \@R?_$T?\)EH'_/_ /\ D&3_ .)H W:*PO\ A,M _P"?_P#\@R?_ !-'
M_"9:!_S_ /\ Y!D_^)H W:*PO^$RT#_G_P#_ "#)_P#$T?\ "9:!_P __P#Y
M!D_^)H W:*PO^$RT#_G_ /\ R#)_\31_PF6@?\__ /Y!D_\ B: -VBL+_A,M
M _Y__P#R#)_\31_PF6@?\_\ _P"09/\ XF@#=HK"_P"$RT#_ )__ /R#)_\
M$T?\)EH'_/\ _P#D&3_XF@#=HK"_X3+0/^?_ /\ (,G_ ,31_P )EH'_ #__
M /D&3_XF@#=HK"_X3+0/^?\ _P#(,G_Q-'_"9:!_S_\ _D&3_P")H W:*PO^
M$RT#_G__ /(,G_Q-'_"9:!_S_P#_ )!D_P#B: -VBL+_ (3+0/\ G_\ _(,G
M_P 31_PF6@?\_P#_ .09/_B: -VBL+_A,M _Y_\ _P @R?\ Q-'_  F6@?\
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MH W:*PO^$RT#_G__ /(,G_Q-'_"9:!_S_P#_ )!D_P#B: -VBL+_ (3+0/\
MG_\ _(,G_P 31_PF6@?\_P#_ .09/_B: -VBL+_A,M _Y_\ _P @R?\ Q-'_
M  F6@?\ /_\ ^09/_B: -VBL+_A,M _Y_P#_ ,@R?_$T?\)EH'_/_P#^09/_
M (F@#=HK"_X3+0/^?_\ \@R?_$T?\)EH'_/_ /\ D&3_ .)H W:*PO\ A,M
M_P"?_P#\@R?_ !-'_"9:!_S_ /\ Y!D_^)H W:*PO^$RT#_G_P#_ "#)_P#$
MT?\ "9:!_P __P#Y!D_^)H W:*PO^$RT#_G_ /\ R#)_\31_PF6@?\__ /Y!
MD_\ B: -VBL+_A,M _Y__P#R#)_\31_PF6@?\_\ _P"09/\ XF@#=HK"_P"$
MRT#_ )__ /R#)_\ $T?\)EH'_/\ _P#D&3_XF@#=HK"_X3+0/^?_ /\ (,G_
M ,31_P )EH'_ #__ /D&3_XF@#=HK"_X3+0/^?\ _P#(,G_Q-'_"9:!_S_\
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M;F4N02 2"QY_"O3** ,_3-$T[1_-:RM]LTV/.N)':6:;&=N^5R7? ) W$X'
MP*T*** .7M?!,&G>?!I>LZKI^F32M*=-MGB6%-WWUC)C,D2L<G".NTL2NVMS
M2M*L=$TNWTS3+:.VL[=-D42#A1_,DG))/)))/)JY10 4444 %%%% ')^$_\
MD/\ B3_KZ_\ 9I*ZRN3\)_\ (?\ $G_7U_[-)764 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7C&M_\ (?U'_KZE_P#0C7L]>,:W
M_P A_4?^OJ7_ -"- 'I7@W_D4[+_ +:?^AM6[6%X-_Y%.R_[:?\ H;5NT %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!R?A/_D/^)/^OK_V:2NLKD_"?_(?\2?]?7_LTE=90 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4%Y>6^G
MV<MW=RK%!$NYW;H/\3[=ZS_$/B&S\.Z>;FY.^5LB& '#2-_0#N>WU(!\=\0>
M);_Q#>-)<2,EONS';*QV)C./JW)Y]^PXK*I54-.IVX3!3KN[TCW-?Q7XZN-;
M;[-IYFM; +A@3M>7(P=V#]WDC&>>I[ <UINEWNKW@M;"W:>8J6V@@  =R3P!
M]?45I^&_"E_XDE8P;8;:-@))Y <#ID*/XFQSC\R,BO9-(T6PT.S6WL8%0;0'
MD(&^3&>6/<\GZ9XP*PC"51\TCTZV)I8./LZ2U_K<R/"_@RR\/Q17$JK/J6T[
MI^<)GJ$'8=LXR<GH#BNGHHKKC%15D>%4J3J2YIN["BBBF0%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7C&M_P#(?U'_ *^I?_0C7L]>,:W_ ,A_
M4?\ KZE_]"- 'I7@W_D4[+_MI_Z&U;M87@W_ )%.R_[:?^AM6[0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% ')^$_^0_XD_P"OK_V:2NLKD_"?_(?\2?\ 7U_[-)764 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-DD2&)Y975(T4LSL<!0
M.I)["@!U<?XK\=6^B+]FT\PW5^6PP)W)%@X.[!^]P1C/'4]@>?\ %?Q#>=OL
MF@SLD.W]Y=!<,^1T7(RH&>O!STQCG@K>WGNYU@MH9)IFSMCC4LQP,\ >U<U2
MMTB>QA,N_P"7E;;M_F.O+RXU"\EN[N5I9Y6W.[=3_@/;M7:>%OA[/?[+S6%D
MMK=7XMF4K)*!USW49Q[D9Z<&N@\)^ H-+\C4-2'FZ@OS+%D&.$\8^K#UZ GC
MH#7;T4Z/60\7F-E[.A]_^0V.-(8DBB14C10JHHP% Z #L*=1172>,%%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>,:W_R']1_Z^I?
M_0C7L]>,:W_R']1_Z^I?_0C0!Z5X-_Y%.R_[:?\ H;5NUA>#?^13LO\ MI_Z
M&U;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 <GX3_P"0_P")/^OK_P!FDKK*Y/PG_P A_P 2?]?7
M_LTE=90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\8UO_D/ZC_U
M]2_^A&O9Z\8UO_D/ZC_U]2_^A&@#TKP;_P BG9?]M/\ T-JW:PO!O_(IV7_;
M3_T-JW: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH Y/PG_ ,A_Q)_U]?\ LTE=97)^$_\ D/\ B3_K
MZ_\ 9I*ZR@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>,:W_R']1_Z
M^I?_ $(U[/7C&M_\A_4?^OJ7_P!"- 'I7@W_ )%.R_[:?^AM6[6%X-_Y%.R_
M[:?^AM6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% ')^$_P#D/^)/^OK_ -FDKK*Y/PG_ ,A_Q)_U
M]?\ LTE=90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]#:MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** .3\)_\ (?\ $G_7U_[-)765R?A/_D/^)/\ KZ_]
MFDKK* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M4;^WG2.TM+F\>,)AVC$DD@*@XSE<$=CD<XKG_P!GJ&XO=.\2^);RZ\ZZU/4
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M6%A;RW#S9NE=AA&W-P/F'?=Z]*W/M_C7_H$67_?8_P#CE '645R?V_QK_P!
MBR_[['_QRC[?XU_Z!%E_WV/_ (Y0!UE%<G]O\:_] BR_[['_ ,<H^W^-?^@1
M9?\ ?8_^.4 =917)_;_&O_0(LO\ OL?_ !RC[?XU_P"@19?]]C_XY0!UE%<G
M]O\ &O\ T"++_OL?_'*/M_C7_H$67_?8_P#CE '645R?V_QK_P! BR_[['_Q
MRC[?XU_Z!%E_WV/_ (Y0!UE%<G]O\:_] BR_[['_ ,<H^W^-?^@19?\ ?8_^
M.4 =917)_;_&O_0(LO\ OL?_ !RC[?XU_P"@19?]]C_XY0!UE%<G]O\ &O\
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M['_QRC[?XU_Z!%E_WV/_ (Y0!UE%<G]O\:_] BR_[['_ ,<H^W^-?^@19?\
M?8_^.4 =917)_;_&O_0(LO\ OL?_ !RC[?XU_P"@19?]]C_XY0!UE%<G]O\
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M!UE%<G]O\:_] BR_[['_ ,<H^W^-?^@19?\ ?8_^.4 =917)_;_&O_0(LO\
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MY0!UE%<G]O\ &O\ T"++_OL?_'*/M_C7_H$67_?8_P#CE '645R?V_QK_P!
MBR_[['_QRC[?XU_Z!%E_WV/_ (Y0!UE%<G]O\:_] BR_[['_ ,<H^W^-?^@1
M9?\ ?8_^.4 =917)_;_&O_0(LO\ OL?_ !RC[?XU_P"@19?]]C_XY0!UE%<G
M]O\ &O\ T"++_OL?_'*/M_C7_H$67_?8_P#CE '645R?V_QK_P! BR_[['_Q
MRC[?XU_Z!%E_WV/_ (Y0!UE%<G]O\:_] BR_[['_ ,<H^W^-?^@19?\ ?8_^
M.4 =917)_;_&O_0(LO\ OL?_ !RC[?XU_P"@19?]]C_XY0!UE%<G]O\ &O\
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MKL#;_,1L$!2<%N5SD9XJO-H\WQ(^-UCXALX)!X;T-(U34E8A+R2)W<>42N'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !7C&M_\A_4?^OJ7_T(U[/7C&M_\A_4?^OJ
M7_T(T >E>#?^13LO^VG_ *&U;M87@W_D4[+_ +:?^AM6[0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M ')^$_\ D/\ B3_KZ_\ 9I*ZRN3\)_\ (?\ $G_7U_[-)764 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7C&M_\A_4?^OJ7_P!"->SU
MXQK?_(?U'_KZE_\ 0C0!Z5X-_P"13LO^VG_H;5NUA>#?^13LO^VG_H;5NT %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!R?A/\ Y#_B3_KZ_P#9I*ZRN3\)_P#(?\2?]?7_ +-)764
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR_[:?^AM6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% ')^$_^0_XD_P"OK_V:2NLKD_"?_(?\2?\
M7U_[-)764 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%-DD2&)Y975(T4LSL<!0.
MI)["N3UOXA:1I>8[5O[0N!_#"W[L=.K\CH>V>1@XJ924=S2G1J57:"N==7-:
M[XWTC1-\7F_:KM<CR(#G:>>&;HO(P1R1GI7ENM^+-7U[*75QLMS_ ,N\/RQ]
MNHZMR,\DX/3%9-O;SW<ZP6T,DTS9VQQJ68X&> /:L)5^D3UJ.5)>]6?R_P""
M=)JWC_7-2>189_L5NW CM^& SD?/][/0'& <=*YB.-YI4BB1GD=@JHHR6)Z
M#N:[[1/AC=3XEUF?[,G_ #PA(:0]>K<J.QXW9![5Z!I?A_2M%W'3[*.%FSE^
M6<@XXW')QP.,XJ52G/61K/&X?#KEI*_IM]YYMH7PWU"_V3ZF_P!BMS@^7C,K
M#@].B\$]>01RM>@:)X3TC0</:V^^X'_+Q-\TG?H>B\'' &1US6W16\:48['E
M5\;6K:-V79!1116ARA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %>,:W_R']1_Z^I?_ $(U[/7C&M_\A_4?^OJ7
M_P!"- 'I7@W_ )%.R_[:?^AM6[6%X-_Y%.R_[:?^AM6[0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUE<JT@&6A;Y9%Z9ROH,@9&1GO7GU,/4I_$CLA6A/9FG1116)J%%%% !1110
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M1@*!T '84ZBNB,5'8\FK7J57>;N%%%%49!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7C&M_\A_4?^OJ7_P!"->SUXQK?_(?U'_KZE_\ 0C0!Z5X-_P"13LO^VG_H
M;5NUA>#?^13LO^VG_H;5NT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!15>ZO[.Q\C[9=P6_GRK!#YT@3S)&^ZBYZL<' ')JQ0 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ)*T%S)"P"705BAE1>".1AN !N4\;MH[R""&UMXK>WBCA@B0)''&H544#
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MVG_Q- '645R?_"O=)_Y^+W_OM/\ XFC_ (5[I/\ S\7O_?:?_$T =917)_\
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MZ3_S\7O_ 'VG_P 31_PKW2?^?B]_[[3_ .)H ZRBN3_X5[I/_/Q>_P#?:?\
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M:?\ Q-'_  KW2?\ GXO?^^T_^)KS)U)3=Y,[X0C!6B=917)_\*]TG_GXO?\
MOM/_ (FC_A7ND_\ /Q>_]]I_\34%'645R?\ PKW2?^?B]_[[3_XFC_A7ND_\
M_%[_ -]I_P#$T =917)_\*]TG_GXO?\ OM/_ (FC_A7ND_\ /Q>_]]I_\30!
MUE%<G_PKW2?^?B]_[[3_ .)H_P"%>Z3_ ,_%[_WVG_Q- '654OM,L=3B\N^M
M(9U *J9$!*YZX/4'W'I7/?\ "O=)_P"?B]_[[3_XFC_A7ND_\_%[_P!]I_\
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MG_Q- '645R?_  KW2?\ GXO?^^T_^)H_X5[I/_/Q>_\ ?:?_ !- '645R?\
MPKW2?^?B]_[[3_XFC_A7ND_\_%[_ -]I_P#$T =917)_\*]TG_GXO?\ OM/_
M (FC_A7ND_\ /Q>_]]I_\30!UE%<G_PKW2?^?B]_[[3_ .)H_P"%>Z3_ ,_%
M[_WVG_Q- '645R?_  KW2?\ GXO?^^T_^)H_X5[I/_/Q>_\ ?:?_ !- '645
MR?\ PKW2?^?B]_[[3_XFC_A7ND_\_%[_ -]I_P#$T =917)_\*]TG_GXO?\
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M.GVD<"G[Q499N2>6/)ZGJ>*O5R?_  KW2?\ GXO?^^T_^)H_X5[I/_/Q>_\
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MKW2?^?B]_P"^T_\ B:/^%>Z3_P _%[_WVG_Q- '645R?_"O=)_Y^+W_OM/\
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MFC_A7ND_\_%[_P!]I_\ $T =917)_P#"O=)_Y^+W_OM/_B:/^%>Z3_S\7O\
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M %]2_P#H1KV>O&-;_P"0_J/_ %]2_P#H1H ]*\&_\BG9?]M/_0VK=K"\&_\
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M/^L-).TX-?<26NJZC8Q&*TO[JWC+;BD,S("?7 /7@5/_ ,)%K?\ T&=0_P#
MI_\ &M#2;[0(V6/5M"66, #S;>>17X!Y*E\$DXZ;<<_2NXMO"_@G7+8IIK*)
M&&X&*X?S5 ."=CDX';D=_I7/4P->EN;PS?!U'L_N7^9Y]:^+-?LY3)%JUTS%
M=N)G\T?DV1GWJY_PGWB?_H)_^0(__B:[;_A5VB?\_6H?]_$_^(H_X5=HG_/U
MJ'_?Q/\ XBL?9U>YH\9@F[N/X'$_\)]XG_Z"?_D"/_XFM+_A:.M_\^NG_P#?
MM_\ XNM23X4(97,6L,L98[5:VW$#L"=PR?? IO\ PJ?_ *C?_DK_ /9T<M9
MZV7RW2^Y_P"1F_\ "T=;_P"?73_^_;__ !=6[7XK721$7>EPRR;N&AE,8QZ8
M(;GKSFFW?PJODV?8]2MYLYW^<C1X],8W9[^E5O\ A5VM_P#/UI__ '\?_P"(
MH_?(/^$^2Z?BC2_X6Q_U!/\ R:_^PJ6W^*T#3J+G29(X3G<T<X=AQV!49Y]Z
MP[CX9:]# TD;V<[#&(XY2&;GMN 'ZU2_X0'Q/_T#/_(\?_Q5'-60U1R^2T:^
M_P#X)VW_  M'1/\ GUU#_OVG_P 71_PM'1/^?74/^_:?_%UQ/_" ^)_^@9_Y
M'C_^*K/D\-:[%*\;:/?%D8J2MNS#CT(&"/<4>TJKH)8/!2VE^)ZM'\0?#3Q(
M[7[1LR@E&@DROL< C/T)IW_"?>&/^@G_ .0)/_B:\D_X1W6_^@-J'_@*_P#A
M5:[TZ^L-GVRSN+;?G9YT3)NQUQD<]11[>?8%EN&;LI/[U_D5P,T[:*1>].K
M]0:1@422/-*\LKL\CL69V.2Q/4D]S2MTKW31/">D:#A[6WWW _Y>)OFD[]#T
M7@XX R.N:N%-S>ARXK%QPZ3:NV>6Z%X(U?6]DOE?9;1L'SYQC<..57JW!R#P
M#CK7HVC> ]$TJ+][;K?3E<-)<J&';.%Z 9'N>>M=/175"E&)XE?'UJNE[+R"
MBBBM3B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDE.21N;(&>N!T'X5'%%)/((X8WDD/144DG\*[^V\+:5;X+1/,P;<&E?/X8&
M1]16O%%'!&(X8TCC'147 'X54<OG)WG+]1\CZG 6WA;5;C!:)(5*[@TKX_#
MR0?J*W;;P99QX-Q<2S$-G"@(I'H>I_6NEHKKA@J,=U?U*4$5+72["RV&WM(D
M9,[7VY89_P!H\]ZMT45U**BK)%!1113 **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "O&-;_Y#^H_]?4O_H1KV>O&-;_Y#^H_]?4O_H1H ]*\&_\
M(IV7_;3_ -#:MVL+P;_R*=E_VT_]#:MV@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3\)_P#(?\2?
M]?7_ +-)765R?A/_ )#_ (D_Z^O_ &:2NLH **** "BBB@ HHHH **** "BB
MB@ HHHH *;)(D4322.J1H"S,QP% ZDGTK!U_QAIF@LT$C-/> 9$$?;()&X]
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M0A#7=A1117.;A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<IXF\$6FM_Z1:&.TO1N+,$^64G)^;'?/
M\7)Z\'C'5T5<*DH.\63.$9JTCY^OK"[TVY:WO;>2"4?PN,9&2,CU'!Y'%=%X
M9\;W>B_Z/=B2[LCM"J7^:(# ^7/;'\/ Z<CG/J&K:-8ZU:-;WL"N,$)( -\>
M<<J>QX'UQSFO)/$?A&^\/R[\-<V9 (N40@+T&&'.TY/'/.?J!Z=.O3Q"Y)K4
MX)TIT7S0V/8;&_M-2MEN+*XCGB/\2'.#@'!]#R.#S5FO!M'US4-"N3-8S;-V
M!(C#*N <X(_J.>3@\UZSX<\76/B"+9E;:\!(-L[@ENIRIXW# YXXQ]">.OA9
M4]5JCII8B,]'HSH****Y3H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBJ-SK.FVF?.O(@0VTJIW,#[@9(J92C%7D[ 7J*Y6Z\:PA,6EK(S$'
MF4A0#VX&<_I6)=>)M5NMX^T>4C8^6(;<?0]?UKEGCJ4=M27-'H,UQ#;('GFC
MB4G :1@HSZ<UBW7B[3(4S"9+AB#@*I4 ]LDX_3-<$[M([.[%F8Y9B<DGUJS:
M:;>WY MK:209(W 84'&<$G@5R2Q]2;M3C^I'.WL;5WXRO9@5MH8[<$#YC\[
MY[9X_2L2YO[R\S]HN995+;MK,=H/L.@K;M/!M[, US-';@@_*/G8'/?''ZUM
M6OA'3(4Q,)+AB!DLQ4 ]\ 8_7-3['%5OB_'_ ""TF<)%%)/((X8WDD/144DG
M\*UK3PQJEV QA$"D$@S';WZ8Z_I7?PV\-LA2"&.)2<E8U"C/KQ4E=$,NBOC=
MRE#N<K:^"H0F;NZD9B!Q$ H![\G.?TK<MM&TVTQY-G$"&W!F&Y@?8G)%7J*Z
MX8>E#X8E**04445L,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$UK7[O6IL.?)LTP(+2,XCB4# P.F<'KC\A@51N[NXO[N2ZNI6EGE.YW;O_\
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M** .4UGP!I.IYDM5^P3GO"OR'IU3IT';'7)S7!ZWX+U;1M\OE?:K5<GSH1G
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MX69K0_Y=;#_OV_\ \77JU8U:,Z5N;J:TZL:GPA11161H%%%% !1110 4444
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XQK?\
MR']1_P"OJ7_T(U[/7C&M_P#(?U'_ *^I?_0C0!Z5X-_Y%.R_[:?^AM6[6%X-
M_P"13LO^VG_H;5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'K@=N17LFF^ = TY@YMFNY Q(:Z;>!D8QM "D?4?TKI8XTAB2*)%2-%"JBC
M4#H .PIK#M_$R)YK".E./Z'D-C\--<N=K7)M[-=^&#OO?;QE@%R#]"1T[5U>
MF_#/1K50;UYKV3:006\M.O! 7D'''WCW_#M:*UC1@C@J9A7GUMZ%:TTZQL-_
MV.SM[;?C?Y,2INQTS@<]35FBBM3C;;=V%07=W;V%I)=74JQ01#<[MV_^O[=Z
MSM?\1V.@6C23R*]QC,=LK#>^<X^B\'GV[GBO)=?\1WVOW;23R,EOG,=LK'8F
M,X^K<GGW[#BNFAAI5=7HCGK5XT].IN>*O'4VI^?8:<?*L&^5I<$/*._T4^G7
MCGJ17)6EI<7]W':VL32SRG:B+W_^M[]JT] \,:AX@F'V=-EJKA9;AONIWX'\
M1]AZC.,YKUW1- L= M&@LD;+G=)+(07?TR<#@=A_B:[IUJ>&CR0W_K<Y84YU
MWS2V,/PQX%MM(V76H".YOU?<A4G9%CI@'&3WR1QQCID]?117EU*DJCO)G?"$
M8*T0HHHJ"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH H:CHFF:LI%]90S,0%WE<. #G 8<@9]#W-<'JW
MPSN(V:32;I98P"?*N#M?@#@,!@DG/7;CCZUZ716U.O4I_"S*=&$]T?.Z]Z=3
M5I<CUKW&>2#=*^A8Y$EB62-U>-P&5E.0P/0@^E?/+'BM'2/$&IZ'+NLKEEC)
MRT+?-&W3.5]3@#(P<=ZYL3AW52L]C>A65-N_4]WHKB]$^(FGWVR'4D^Q3G W
M]8F/ Z]5Y)Z\ #K791R)+$LD;J\;@,K*<A@>A!]*\F=.=-VDCT85(S5XL=11
M14%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445
M4NM4L++>+B[B1DQN3=EAG_9'/>DY**NV!;HKG[GQ?IL.1")9SMR"J[5SZ'//
MZ&LN?QK<MM^SV<4?][S&+Y^F,8KGGBZ,>I/,CM*9++'!&9)I$CC'5G; 'XUY
MU<^(M5NLAKMXUW;@L7R8]LCG'U-9TLLD\ADFD>20]6=B2?QKFGF,?LQ)<ST6
MY\1:5:Y#7:2-MW!8OGS[9'&?J:RY_&MLNW[/9RR?WO,8)CZ8SFN/AMYKERD$
M,DK 9*QJ6./7BM.U\,ZK=;#]G\I&S\TIVX^HZ_I6/UO$5/@7X"YI/8DO/%6H
MWEL\!$,:N"K&-#D@C!')-8PZ5T4GA":WL+BXGNXPT2,X2-2P( SU.,?E7. \
M5S5U533JB=^HZGPPM<W,,"$!I7"*3TR3BH]PJWI9SK%C_P!?$?\ Z$*RBDY)
M".AM?!7W&N[SUW)$OY88_AVK:MO#NE6N"MHDC;=I:7Y\^^#QGZ"M2BO?AAJ4
M-HFRBD%%%%;C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[0,+;28XYCC:TDY=1SW 49X]ZH_\+1UO_GUT_P#[]O\ _%T?\*NUO_GZT_\
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M\AZ]'Z=!WQUP,UU=>?.G*#M)6.R,XS5XL****@H**** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM?\ XFO&;O4;Z_V?;+RXN=F=GG2L^W/7&3QT%5JM0H+:!:R96UE^'_!/>_\
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M0PHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&2?<T_\ X1W1/^@-I_\ X"I_A5K+EU948X5;J3^:_P CR'^WK7_GG-_WR/\
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M\)_\57645Y=2I*H[R9WPA&"M$Y/_ (6%I/\ S[WO_?"?_%4?\+"TG_GWO?\
MOA/_ (JNLHJ"CD_^%A:3_P ^][_WPG_Q5'_"PM)_Y][W_OA/_BJZRB@#D_\
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MAC7_ .*KCJ*I9E+K$?M#L/\ A86D_P#/O>_]\)_\51_PL+2?^?>]_P"^$_\
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M_P 51_PL+2?^?>]_[X3_ .*KK** .3_X6%I/_/O>_P#?"?\ Q5'_  L+2?\
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M:3_S[WO_ 'PG_P 51_PL+2?^?>]_[X3_ .*KK** .3_X6%I/_/O>_P#?"?\
MQ5'_  L+2?\ GWO?^^$_^*KK** .3_X6%I/_ #[WO_?"?_%4?\+"TG_GWO?^
M^$_^*KK** .3_P"%A:3_ ,^][_WPG_Q5=/:W"7=G#<QA@DT:R*&Z@$9&:EHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKI<I@($RKA/-3<=RD)&%)QR9''&"M>B/X*T%[RZN1:SQ_;)3-<P17DT<$[D
M,9(5<1ON &[*G=SG.36Y!!#:V\5O;Q1PP1($CCC4*J*!@  <  =J )**** (
M[B%;FVE@<D+*A1B.N",5@?\ "&:=_P ]KK_OM?\ XFNCHK.=&%362N)I,X'1
M-$MM2U/5[:9Y52SF\N,H0"1N8<Y'^R*Z"W\)6%M<Q3I-<EHG#J"RXR#GTJCX
M3_Y#_B3_ *^O_9I*ZRH6&HIWY0Y4%%%%;C"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!1116HPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** &2Q1SQF.:-)(SU5UR#^%5_[
M*T[_ )\+7_ORO^%6Z*EQB]T!D?\ ",:/_P ^?_D5_P#&H)O"&ERN&3SH1C&V
M-\@^_P P)K>HK-X>D_LK[A<J.:E\%V1C(AN;A).S/A@/PP/YU6_X0C_J(_\
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M1110!6OK"TU*V:WO;>.>(_PN,X.",CT/)Y'-<'K?PU^_/HT_J?LTQ^IPK?D
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M *^I?_0C0!Z5X-_Y%.R_[:?^AM6[6%X-_P"13LO^VG_H;5NT %%%% !1110
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M-*H.0LDA89]>:ZV#P5;+N^T7DLG]WRU"8^N<YJ]%X5TB.,*T#RL.KO(V3^1
M_2L/JN)J?$_O9KRR9Y[4\-E=W*%X+6:50<%HXRPSZ<5Z9%I]E!()(;.WCD'1
MDB (_'%6:TCEO\TA^S/.HO#.KR[#]EV*^/F=U&T'U&<_IFM&#P5<MN^T7D4?
M]WRU+Y^N<8KM**WC@**WU'R(YJ+P79",":YN'D[LF%!_#!_G6C%X<TB&02+9
M(6'0.S,/R)Q6I16\</2CM%%<J(X;>&V0I!#'$I.2L:A1GUXJ2BBMDK;#"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!R?A/_D/^)/\ KZ_]FDKK*Y/PG_R'_$G_ %]?^S25UE !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 <CXWZV'_;3_P!EKD\BNZ\3>&Y/$/V7R]0>S\C?G:A;=NQ_M#IC]:P/
M^%;7/_0PR_\ ?@__ !=<=7+U6FY\Z5^EF83Y^;1&)D5UG@C_ )?_ /MG_P"S
M5G?\*VN?^AAE_P"_!_\ BZW_  SX;D\/?:O,U![SS]F-R%=NW/\ M'KG]**6
M7JC-3YT[=+,(<_-JCH****[#<**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%% !1110!R?A/_D/^)/^OK_V:2NLKD_"?_(?\2?]?7_LTE=90 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\8UO_D/ZC_U]2_^A&O9Z\8UO_D/ZC_U]2_^A&@#TKP;
M_P BG9?]M/\ T-JW:PO!O_(IV7_;3_T-JW: "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y/PG_ ,A_
MQ)_U]?\ LTE=97)^$_\ D/\ B3_KZ_\ 9I*ZR@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4O\ Z$: /2O!O_(IV7_;3_T-JW:PO!O_ "*=E_VT_P#0VK=H **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% ')^$_P#D/^)/^OK_ -FDKK*Y/PG_ ,A_Q)_U]?\ LTE=
M90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHH **** .3\)_\ (?\ $G_7U_[-)765R?A/_D/^)/\ KZ_]FDKK* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNGD^&.D&)A'>7JR$':S,C 'L2-HR/Q%9TGPM<1,8]75I #M5K?:">P)W' _
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M3'R9W).$PV2C8P!DG<<\@D T_P!I#6YK3PUI.C1>8J7]P\LKK(0"L0'R,O\
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MMUNS>YMM4MT19#&1)&H.0 >R'UKO:YCP+:W%IHDT=S!+"YN68+(A4D;5YP:
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M\#_XW1]@\:_]!>R_[X'_ ,;KK** .3^P>-?^@O9?]\#_ .-T?8/&O_07LO\
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M_P!!>R_[X'_QNNLHH Y/[!XU_P"@O9?]\#_XW1]@\:_]!>R_[X'_ ,;KK**
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M#D_L'C7_ *"]E_WP/_C='V#QK_T%[+_O@?\ QNNLHH Y/[!XU_Z"]E_WP/\
MXW1]@\:_]!>R_P"^!_\ &ZZRB@#D_L'C7_H+V7_? _\ C='V#QK_ -!>R_[X
M'_QNNLHH Y/[!XU_Z"]E_P!\#_XW1]@\:_\ 07LO^^!_\;KK** .3^P>-?\
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M#D_L'C7_ *"]E_WP/_C='V#QK_T%[+_O@?\ QNNLHH Y/[!XU_Z"]E_WP/\
MXW1]@\:_]!>R_P"^!_\ &ZZRB@#D_L'C7_H+V7_? _\ C='V#QK_ -!>R_[X
M'_QNNLHH Y/[!XU_Z"]E_P!\#_XW1]@\:_\ 07LO^^!_\;KK** .3^P>-?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BJ]K?V=]Y_P!CNX+CR)6@F\F0/Y<B_>1L=&&1D'D58H ****
M"BBB@ HJ.>>&UMY;BXECA@B0O))(P544#)))X  [T03PW5O%<6\L<T$J!XY(
MV#*ZD9!!'!!'>@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **CGGAM;>6XN)8X8(D+R22,%5% R22
M>  .]$$\-U;Q7%O+'-!*@>.2-@RNI&001P01WH DHHHH **** "BBJ]U?V=C
MY'VR[@M_/E6"'SI GF2-]U%SU8X. .30!8HHHH **** "BBB@ HHHH ****
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M.O((]0:DHH ^=/']E-IGQX\'6C:IJ5]$]Q9W(%[<&01R-<;7*#@(&\L,54
MG    'T77@'Q3_Y.%\%?]N/_ *5O7O\ 0!YGK'A.^^)>LZD-3UN[M?"=NYM+
M2TT]_+:YE1@)7EW @A949 "/X,C Y?S#54\1_ 3QC;M87LE]X=O7>2*VEEPL
MR_*'5U'"RJ-F) .>.VY!]-UXG\5M-A\??$WPOX/M6D9[1);C49(R"((7V$@D
M!MK[4XW#&9(_[U 'ME>9_$)5\2^//!_@[9'+ MP=7U!7MFE"Q1 A W\.QSYB
M'.>2OKAO3*\S^'KKXE\>>,/&.^.6!;@:1I[)<M*%BB +E?X=CGRW&,\EO7+
M&QXK\+:OXSOS83:S=Z3X=B3;+%9D+/?LR,&R^2%B 91M*_,=^1@(U>4>,O"=
M]\$WT_Q)X1UN[-G+<+!<V=V^X2OM=EW!0JNA4..0"IY!R<K]#SR-#;RRI#).
MZ(66*,J&<@?=&X@9/3D@>I%>(>(OB=#:?$W3K3QIX6N["QL'\VU\RX$@1FR%
MNFC0%)"H  VD^63+@NV H![G7E_QKTVX3X?ZQJT>MZK$T7E!+:&<1P['98I$
M95 +JP;)WEL$<$ L#ZA7G_QM_P"20Z[_ -N__H^.@ ^"7_)(="_[>/\ T?)7
MH%>?_!+_ ))#H7_;Q_Z/DKK/$FMP^'/#6I:S/Y92SMWE"/((Q(P'RIN/0LV%
M'!Y(X- '#^'57Q/\:?$6OE(WM-"MTTBTD-LPW2Y+2D.W1T;>AVCE9!V.6IS>
M ;CXH?:-8\3:[?)I%Q*)-'L-/D$<:VPW>7,ZNK9D=6W=,@-@X^ZO0?"31Y-*
M^'6GS7+^;?:IG4KJ<RLYE>;Y@S%OXMFP'W!Z]3W% 'SAX:O_ !3\)/B=8^#;
MV[_M#2-0EBB@C:0[!'+(566,<^6P8MN7H<'K\KU['\1O&:^!?!UQJZQQRW;.
ML%I%)NVO*V<9QV"AFZC.W&02*\_U/38?'?[1=J]HTAL_#5O$;R="-IF21I%1
M6 89W. 0=I^20=5JA^TQ/,MOX:MUED$$CW+O&&.UF41!21T) 9L'MN/K0!W?
MA7P?I?B'P-I]]XHMH-<U+4[07$]Y=Q;I%$PWA(R23$JA\ (5 (+  DU3^&7B
MW4IM9UGP1X@FDGU31'(@NY8V22[MPVT.X.1G!C(.<L'!YP6/IE>"1SS0_M<S
M)%+(B3)LE56(#K]B#8;U&Y5.#W /:@#V_4K!M1MU@%]=VB;\R&U95:1,$%"Q
M!*@Y^\A5A@885X1\(TFA^/'BJWGO;N]>VM[FW%Q=RF25UCN(D4LQZG:HKZ#K
MP#X6?\G"^-?^W[_TK2@#W^O%_&'A"S^+OBVX2'Q;!9-I.^T2P $[ML8>;,8_
M,4Q_.WEG*\^6K9(9:]DGC::WEB2:2!W0JLL84LA(^\-P(R.O((]0:\(U_P#9
MLA*-)X<UR17" "#44#!FW<GS$ VC;T&P\CKSP =/\//@O#X$\2MK,NL1ZDXM
MVBB1K(1F)F*_.K;VP=H9>!T8\^OJE>(?"/QUX@MO%%QX"\8F=K^/>UO+=,SS
M!P-S1LW.]2NYU8GH, D%0/;Z "BBB@ HHHH **** "BBB@ HHHH **** *>I
M6#:C;K +Z[M$WYD-JRJTB8(*%B"5!S]Y"K# PPKPCX1I-#\>/%5O/>W=Z]M;
MW-N+B[E,DKK'<1(I9CU.U17T'7@'PL_Y.%\:_P#;]_Z5I0![O?WUOIFG7-_>
M2>7:VL333/M)VHH)8X')P >E>3W/P@U'QOIS:EXWU^^36YM\D-K:NIM+#< %
M14(.<;5W;6&['4D;S[!10!X!\+?$7BGPK\1V^'.O2_;(?F2,M,7^S[(=Z&-C
M_P LV11\AQC(/RG<#[_7B?@W38?&'QW\0>-;1I#I>FN+>WF!&V>;RA"2I *L
MFT,W# _/&>Y%>L>)-;A\.>&M2UF?RREG;O*$>01B1@/E3<>A9L*.#R1P: .'
M\.JOB?XT^(M?*1O::%;II%I(;9ANER6E(=NCHV]#M'*R#L<L:Q\,KOQY<37G
MB[7=2AMG<-::39,D<=HH+!=^=ZO+M8;F'0E@"R[<:GPDT>32OAUI\UR_FWVJ
M9U*ZG,K.97F^8,Q;^+9L!]P>O4]1K-]>Z?ISS:?I$^J77(2WAECCR<$@LTC
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M1MA3<$." <L6=LY(*E".]8'PRGFN?VB?&CSRR2N$O$#.Q8A5N8U4<]@H  [
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M &M7M>MVNM7=OY6C:K::<[(ZO+-9&X8$CY63]XH!')^8,#QQQSY_X'^%&M>
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MEY_BQGFMSPQX8TOPCH<.D:1!Y5O'RS-R\KGJ[GNQQ^@     !L4444 %%%%
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M6L>=D,$,D:+DDG"B? R23^-=!X4^%]_HGBBWUS7/%U]XADM(I$M$NQ(/(=P
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M:VT%F24E'_+4N) 2^>AP-HZ<DD@%SPYHVHZSXHD\:ZZD]OF(PZ1I5P%+6,+
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M6@N6#*5$KM+(2@P?E7;R0<Y48["""&UMXK>WBCA@B0)''&H544#   X  [4
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M,:W_ ,A_4?\ KZE_]"- 'I7@W_D4[+_MI_Z&U;M87@W_ )%.R_[:?^AM6[0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>,:W_R']1_Z^I?_0C7L]>,:W_R']1_Z^I?_0C0
M!Z5X-_Y%.R_[:?\ H;5NUA>#?^13LO\ MI_Z&U;M !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5XQK?_(?U'_KZE_\ 0C7L]>,:W_R']1_Z^I?_ $(T >E>#?\ D4[+_MI_
MZ&U;M87@W_D4[+_MI_Z&U;M !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!#_XT44 ']MZM_T%+W_P(?\ QH_MO5O^@I>_^!#_ .-%% !_;>K?]!2]_P#
MA_\ &C^V]6_Z"E[_ .!#_P"-%% !_;>K?]!2]_\  A_\:/[;U;_H*7O_ ($/
M_C110 ?VWJW_ $%+W_P(?_&C^V]6_P"@I>_^!#_XT44 ']MZM_T%+W_P(?\
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M!#_XT44 ']MZM_T%+W_P(?\ QH_MO5O^@I>_^!#_ .-%% !_;>K?]!2]_P#
MA_\ &C^V]6_Z"E[_ .!#_P"-%% !_;>K?]!2]_\  A_\:/[;U;_H*7O_ ($/
M_C110 ?VWJW_ $%+W_P(?_&C^V]6_P"@I>_^!#_XT44 ']MZM_T%+W_P(?\
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M!#_XT44 ']MZM_T%+W_P(?\ QH_MO5O^@I>_^!#_ .-%% !_;>K?]!2]_P#
MA_\ &C^V]6_Z"E[_ .!#_P"-%% !_;>K?]!2]_\  A_\:/[;U;_H*7O_ ($/
M_C110 ?VWJW_ $%+W_P(?_&C^V]6_P"@I>_^!#_XT44 ']MZM_T%+W_P(?\
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M!#_XT44 ']MZM_T%+W_P(?\ QH_MO5O^@I>_^!#_ .-%% !_;>K?]!2]_P#
MA_\ &C^V]6_Z"E[_ .!#_P"-%% !_;>K?]!2]_\  A_\:/[;U;_H*7O_ ($/
M_C110 ?VWJW_ $%+W_P(?_&C^V]6_P"@I>_^!#_XT44 ']MZM_T%+W_P(?\
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M!#_XT44 ']MZM_T%+W_P(?\ QH_MO5O^@I>_^!#_ .-%% !_;>K?]!2]_P#
MA_\ &C^V]6_Z"E[_ .!#_P"-%% !_;>K?]!2]_\  A_\:/[;U;_H*7O_ ($/
M_C110 ?VWJW_ $%+W_P(?_&C^V]6_P"@I>_^!#_XT44 ']MZM_T%+W_P(?\
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M!#_XT44 ']MZM_T%+W_P(?\ QH_MO5O^@I>_^!#_ .-%% !_;>K?]!2]_P#
MA_\ &C^V]6_Z"E[_ .!#_P"-%% !_;>K?]!2]_\  A_\:/[;U;_H*7O_ ($/
M_C110 ?VWJW_ $%+W_P(?_&C^V]6_P"@I>_^!#_XT44 ']MZM_T%+W_P(?\
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M!#_XT44 ']MZM_T%+W_P(?\ QH_MO5O^@I>_^!#_ .-%% !_;>K?]!2]_P#
MA_\ &C^V]6_Z"E[_ .!#_P"-%% !_;>K?]!2]_\  A_\:/[;U;_H*7O_ ($/
M_C110 ?VWJW_ $%+W_P(?_&C^V]6_P"@I>_^!#_XT44 ']MZM_T%+W_P(?\
MQH_MO5O^@I>_^!#_ .-%% !_;>K?]!2]_P# A_\ &C^V]6_Z"E[_ .!#_P"-
M%% !_;>K?]!2]_\  A_\:/[;U;_H*7O_ ($/_C110 ?VWJW_ $%+W_P(?_&C
M^V]6_P"@I>_^!#_XT44 ']MZM_T%+W_P(?\ QH_MO5O^@I>_^!#_ .-%% !_
M;>K?]!2]_P# A_\ &C^V]6_Z"E[_ .!#_P"-%% !_;>K?]!2]_\  A_\:I.[
3RR-)(S.[$LS,<DD]23110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gzkk5j0cumnd000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkk5j0cumnd000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /H!T$# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ J2#_7+4=20?ZY:0UN7:***DU,ZBBBK,0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J2#_7+4=20?ZY
M:0UN7:***DU,ZBBBK,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ J2#_7+4=20?ZY:0UN7:***DU,ZBBBK,0H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ J2#_7+4=20?ZY:0UN7:***DU,ZBBBK,0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *D@_URU'4D'^N6D-;EVBBBI-3.HHHJS$**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "I(/]<M1U)!_KEI#6Y=HHHJ34SJ***LQ"BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5)!_KEJ.I
M(/\ 7+2&MR[1114FIG44459B%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZQGN>_E?\ ****D](**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J2#_ %RU'4D'^N6D
M-;EVBBBI-3.HHHJS$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5)!_KEJ.I(/\ 7+2&
MMR[1114FIG44459B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%%( HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1112 ****8!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %4M8_Y UY_UQ;^57:I:Q_R
M!KS_ *XM_*@BI\#/ H.E;EKT%8<'W:W+7H*Z>A\?3^-FG%TK0MNM9\705H6W
M6LV>C3W-JU[5;;[IJI;=JMM]TU!W1V,NZZ&L6;[QK:NN]8LWWC5(Y:NY0GZ&
ML6[^_6U/WK%N_OUI$\W$;'0?#?\ Y&EO^N#?S%>N^M>1?#?_ )&EO^N#?S%>
MN^M93W/>RO\ @!69XB_Y%O4O^O9_Y5IUF>(O^1;U+_KV?^50MSNJ_P -^AX/
M%UK7M/NUD1=:U[3[M=/0^.C\9K0U?MOOUGP]*T+;[]9L]&F;=MVJ\>E4;:KQ
MZ5#.^&QFW7>L2X^]6W==ZQ+C[U4CGJF=/6/=_>K8GK'N_O5I$\RN=+\,_P#D
M8+G_ *X_UKU>O*/AG_R,%S_UR_K7J]8SW/?RS^ %%%%2>B%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5)!_KEJ.I(/]<M(:W+M%%%2:F=1115F(4444 %%%% !1110
M 4444 4]1U2RTBU^TW\ZPP[@NYO6JVF>)-(UB=H=/O4FD4;BJ]J\Y^*VM>;?
MP:4I^6!?,D.>I/\ ABN:\,ZA-X=\4VTDH,6'"2ANRGK^E4HZ$WU/H"LG4O$V
MCZ1<"WO[U(92NX*?2M1&#HK*<JPR#7C?Q4_Y&B+_ *X#^9I)7&SU^TO+>_M8
M[FUD66%QE74\&J^J:UI^C0I+J%RL".VQ2W<]:\U^&7B7[/<MHMU(?+E^:W)Z
M*W<?SK5^+G_(&L?^OG_V4T6UL%]#L(_$6E3:4^J1W:-9(<-*.@[51_X3OPU_
MT%(JYOP/I::U\.IM/DD,:33."P&<?,:IZM\,;/3])NKQ+^1VAC+@%,9_6G97
M"[.P_P"$[\,_]!2*K%CXLT34KM;6SOTEG?[J#O7C'A+08O$>M_8)96B3RV?<
MHSTQ7INA?#RUT/5XM0CO7D:,$;2F <_C3:2!.YM7?BW0[&]>SN;^..X1MK(>
MH-;*L'4,IRK#(->$>,O^1^OO^OA?Z5[G;?\ 'K#_ -<U_E4M6"Y+29 ZD #K
MFEKSGXF^)I[%(](M':-Y5W3.#@[?3^5)*["YT]]XUT#3Y6BGOT,BG#(G)%%A
MXTT#495A@OT$K'"H_!->>^%/AR=8L5O]0G:&&3F.-1\Q'K53Q=X#F\/HMW9R
MM<6K,%/'S*:JR%=GMF>]'?BN/^'U_J=SH;0:E!.K0$".60??4_X8K5\5ZM_8
MWAN[NU;;+MVQ?[QZ4K:E7T(Y/&OAV*=H7U.(2*VT@]C6ZK!U5E(*D9!]:^9V
M@GE@:Y9&,6[#/VR:]R\ ZR-7\,PAC^^M_P!U)SU(YS^M-QL),WM0U"UTRS>[
MO)A% A 9ST&3@55TSQ'I.LS/%87L<TB+N*@]JR/B/_R)-Y_O1_\ H8KQK1M5
MGT758+Z X:-OF'JO<?E0E<&SZ/9@JEFX &2:Q[3Q7HM_?"RMK^.2X)("#N15
MJUOX-4T7[9;.&CEA)&.QQR/PKQSP3_R/\/\ UU?^M)(&SW(_YS6%J'C'0M,F
M:&YOX_-7AD7DBN?^)'B>72K./3K1REQ< EG4\JH[?CFN5\(_#]]>M?[0O9VA
MMG)V*%^9_?/:FEH#9Z-9>-_#U_*L45^JR,<!9.":Z $$9!!!]*\:\7?#UM$M
M#?64QGM@0'1A\R^_O77?#:^U2;39+34()A'#@PRR#[P/;\,?K0TK7!,W+OQA
MH-C=R6MSJ$<<T9PZGL:A_P"$[\-?]!2*O(_%D8F\<WL1. ]PJD_4 5VT?PFL
MGB1_[1E&Y0?N?_7HL@NSIT\<>'))%1-3B+,0H'J36IJ.KV.DVRW-].L,+':K
M-W.,UQ4/PILH9XY1J$I*.& V>ASZU/\ %0!?"ULOI< ?^.FE9= NS9_X3OPS
M_P!!2*E'CGPTQP-6A'U->:>"_!EOXGL[F::Z>$PN% 5<YSGWK4UWX8II^E3W
MEI?-(T*[BC)C(^N:JRV%=GJ5M=07D"SVTJ2Q,,AE/!J:O'?A9JDT6NOI^]C;
MS1E]F> P_P#UU[%4M6&M0JCJ>L6&C0+-?W"01LV%+=S5[M7CGQ-U8:AK\6FP
MY*VP"L/5S_\ 6(H2N#/4=+U_2]:>1=/NTG:,98+VK2KP;P;J<OA_Q7")\QI*
M?*F4^_3]2*]X&#R#D=C0U9@G<R-1\4Z+I5VUI?7T<,R@$HW;/(K3M[B*ZMX[
MB!P\4BAE8="#7BWQ._Y':X_ZY1_^@"M_X8^)1AM$NG.?O6Y8_FO^?2GRZ7"Y
MWVJ:[INC",ZA=+ ),[-W?%-/B'2UTD:J;M!9%MHE[9KA?B[_ *G3?J_]*O\
MAS18_$'PUM]/EE,2M+NW 9Z4K!<W/^$[\-?]!2*C_A._#7_04BKB?$'PXM-'
MT.ZOX[YW:%-P4IP?UKG?!GAJ+Q/?7%O-,T(BC#@J,YSFJLA7=SV/3O%&C:M=
M"UL;U)IB,A1UJ)_%^A1WQLWU",7 ?R]A_O>E9OAOP';>'=76^BO'E8 KM9<=
M1CUKR[4/^1]?_K^7_P!"%))#;/<=2U>QT>W6XO[A8(F;:&;N>N*R_P#A._#7
M_04BK$^*W_(MVG_7S_[*:Y+P5X,MO$]C<SSW+Q-%(% 5<YH25KBNSTI/''AM
MV"C58 2<#)K<AFCGA66%U>-AE6!X(KR?Q-\-XM'T:?4+:]9Q -S(Z8R/8YJW
M\)]1N7>[TYW+6Z .@_NGO^=%D.[/4"P4;F( '4GM7/77CGP[9NT;Z@KNIP1&
M,XKC?B;XGG6Z_L6VD*1A=T[*?O9_AJMX9^&C:E8QWNI7!ACE&4B0<X]2>U'*
MK!<[ZR\:^']0E6*'4$$C' 5^":W@01D'(/<5X]XJ^',FCV37VGS-/#'R\;+\
MRCU]ZV/AGXHFNF?1[V8NR+N@9CSCN/YT66X7.SU'Q/H^D7/V>^O4AE(W;6]*
MJ?\ "=^&O^@I%7G'Q1_Y&I/^N(_G6QIWPOM;[2[:Z.H2(TT:N1LSC(SZT65A
M79WNG^(M(U5S'8W\,S@9VJW-6K_4;72[1KJ\E$4(."Y[5XAXE\*WWA"\AG2<
MR1%LQSJ-I4^GUKTWPKJ:>+_";Q7P$D@'DSY[^A_2AQ&F:NG>)]&U:Y^SV-]'
M--C.Q3SBM:O KVVO?!/BO]TQ+0/NC<CATKU35?&-M;>#QK%JZF29,0JW7?[_
M $H<03+UYXPT&PNI+:YU&))HSAU]#6Q!,EQ DT3;HW&5/J*\1\$Z!)XE\0-<
MW:[[>)O,F+#ASG@5[BJA$"J % P .PI-6!"T444AA1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+6/^0->?\ 7%OY
M5=JEK'_(&O/^N+?RH(J? SP*#[M;EKT%8=O]VMRUZ"NGH?'T_C9IQ=!6A;=:
MSXN@K0MNM9L]&GN;5M5MONFJEMVJVWW34'='8RKKH:QIOO&MJZZ&L:;[QJHG
M+5W,^?O6+=_?K:G[UBW?WJTB>;B#H/AO_P C2W_7!OYBO7?6O(OAO_R-+_\
M7!OYBO7:RGN>]E?\ *S/$7_(MZE_U[/_ "K3K,\1?\BWJ7_7L_\ *H6YW5?X
M<O0\'BZUKVGW:R(NM:UG]T5T]#XZ/QFO#TJ_;??JA#TJ_;?>K-GHTS;M>U7C
MTJE:]JN]JAG?#8S;KO6)<?>K;N>AK$N/O&J1SU3.GK&N_O5LSUCW?WJTB>97
M.E^&?_(P7/\ UR_K7J]>4?#/_D8+G_KE_6O5ZQGN>_E?\ ****D]$**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M &>A?%?_ )%JT_Z^?_937GOA_5?$6GV\J:*DS1,V7\N,MS7H7Q7_ .1:M/\
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M$Y*C(Z'% &9KUW>66AW%S91;[A%X7&<5G>#=4U+5-.DDU),,K81]N-PKI,4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5)!_KEJ.I(/]<M(:W+
MM%%%2:F=1115F(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %4-;_ .0)>_\ 7%OY5?JAK?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !4D'^N6HZD@_P!<M(:W+M%%%2:F=1115F(4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %4-;_P"0)>_]<6_E5^J&M_\ ($O?^N+?RH(J? SP2V^X*W+7
MH*P[;[@K<M>@KIZ'Q]/XV:<7W:T+:L^+[M:%MUK-GHTS;M>@JTWW356UZ"K3
M?=-0SNCL95UWK'F^\:V+KO6/-]XU2.6J9\_>L6[^]6U/WK%N_OUI$\W$'2?#
M7_D9)O\ K@W\Q7K->3?#3_D9)O\ K@W\Q7K-8SW/H,L_@(*R/%'_ "+&H_\
M7!OY5KUD>*?^18U'_K@W\JE'75_AR]#PN*M>TZ"LB*M:TZ"NGH?'P^,UH>E:
M-M]ZLZ'I6C;?>K-GHTC;M:NGI5.UJX>E0ST(;&;==ZP[C[QK<NN]8=Q]\TT<
MU8S;CH:P[G[YK;N.]8ES]YJV1Y5;<Z[X7?\ (9OO^N(_G7JE>5_"[_D,WW_7
M$?SKU2L)[GT>6_P$%%%%2=X4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4D'^N6HZD@
M_P!<M(:W+M%%%2:F=1115F(4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %20?ZY:CJ2#_7+2&MR[1114FIG44459B%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J2#_7+
M4=20?ZY:0UN7:***DU,ZBBBK,0HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *S?$'_(O7_P#U
MR-:59OB#_D7[[_KB:%N9U?@9X1;_ '%K;M>@K$M_NBMNUZ"NGH?(4_C-2+[M
M7[7K5"+[M7[7K6;/1I[FW;5:;[M5;6K+?=J#NCL9=UWK&F^\:V;KO6--]XU4
M3FJE"?O6)=_>-;<_>L2\^\:TB>97.G^&/_(PW'_7N?YBO5Z\H^&/_(P7'_7N
M?YBO5ZQGN?0Y;_NZ"LCQ3_R+&H_]<&_E6O61XH_Y%C4?^N#?RJ4==;^'+T/"
MXNM:UIT%9,76M>SZ"NE['QT/C-:'I6A:_>K/AZ5H6OWJS9Z-(W+6KAZ53M>M
M7#TJ#OAL9EUWK$N/O&MNZZFL2X^^:I'/6,RXZ&L2Y^\U;=QT-8ES]YJU1Y5;
M<Z[X7?\ (:OO^N(_G7JE>5_"[_D-7W_7$?SKU2L)[GT>6_P$%%%%2=X4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4D'^N6HZD@_P!<M(:W+M%%%2:F=1115F(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %9OB#_D7K_\ ZY&M*LWQ!_R+U_\ ]<C36YG5^!GA%O\
M=%;=KT%8EO\ =%;=KT%=#V/D*?QFI%]VK]KUJA%]VK]KUK-GHT]S;MNE6G^[
M56V[59?[M0=T=C+NN]8TWWC6S==ZQIOO&J1S52A/WK$O/O&MN?O6)>?>-:1/
M,KG3_#'_ )&"X_Z]S_,5ZO7E'PQ_Y&"X_P"O<_S%>KUC/<^ARW^ @K(\4?\
M(L:C_P!<&_E6O6+XL)'A;4,?\\6_E4K<ZJW\.1X=%6O9]!61#6M:=!72]CX^
M/QFM#TK1M?O5G0]*T;7[U9L]&D;EKU%7#TJG:]:N'I4'?'8S+KO6)<??-;=U
MWK$N/OFJ1SUC,N.AK$N?OM6W<=#6)<_>-:H\JMN==\+?^0S??]<1_.O5*\M^
M%O\ R%K[_KB/YUZE6$]SZ++?X""BBBI/0"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*D@_URU'4D'^N6D-;EVBBBI-3.HHHJS$**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "I(/]<M1U)!_KEI#6Y=HHHJ3
M4SJ***LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !4D'^N6HZD@_P!<M(:W+M%%%2:F=1115F(4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *D@_URU'4D'^N6D-;EVB
MBBI-3.HHHJS$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC-N.AK$N?O&MNXZ&L2Y^\U:1/+K;G8?"T'^U+XXX\D?SKU*O,?A9_P ?U_\
M]<Q_.O3JQGN?1Y;_  $%%%%2=X4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4D'^N6H
MZD@_URTAK<NT445)J9U%%%68A1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5E>)?^1;O_ /KE
M6K65XE_Y%N__ .N5"W,JW\-GA<'W16W:]!6)!]T5MVO05TO8^1I_&:D7W:T+
M2L^+[M:%I6;/1I[FU:U9?[IJM:]*LO\ =-9L[H[&5==ZQYOO&MBZ[UCS?>-:
M(Y:I0G[UB7?WC6W/WK$N_O&KB>;7.I^&'_(=NO\ KB?YBO5:\J^&'_(=NO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5)!_KEJ.I(/\ 7+2&MR[1114FIG44459B
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !4D'^N6HZD@_URTAK<NT445)J9U%%%68
MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !4D'^N6HZD@_URTAK<NT445)J9U%%%68A1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C^*
M?^18U#_KG_45L5C^*?\ D6-0_P"N?]136YE6_AL\.@Z"MNUZ"L2#H*VK7H*Z
M'L?(T_C-6+[M:%K6?#]VM"UK-GHT]S;MNE6'^Z:KVW058?[AK-G='8RKKO6/
M+]XUL77>L>7J:T1RU2A/WK$N_O&MN?O6)=_>-7$\VOL=5\+_ /D,W?\ UR_J
M*]4KROX7_P#(9N_^N7]17JE8SW/H,M_@(*P/&A"^$[XG^X:WZY_QM_R*5]_N
M4EN=5?\ A,\4A[5K6G05DP]JUK3H*Z.A\?'XS6AZ5I6GWJS8>E:5I]ZLV>E2
M-RV[5;;[IJG:]JN-]TU#/0CL9=UT-8D_WC6W==#6)/\ >-4CEK&;<=#6)<_>
M:MNX[UB7/WFK5'EUMSM?A:I^V:@W^P!^M>FUYI\+/^/G4/\ ='\Q7I=82W/I
M,N_@(****D[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "I(/\ 7+4=20?ZY:0UN7:*
M**DU,ZBBBK,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "I(/\ 7+4=20?ZY:0UN7:***DU,ZBBBK,0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK1'+5*$_>L2[^\:V[CO6)=_>-7$\RN=5\+_^0S=_]<OZBO5*\K^&'_(9N_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *D@_URU'4D'^N6D-;EVBBBI-
M3.HHHJS$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ==ZQY>IJD<M4H7'>L2[ZUM7'>L6[^]6D3S*YUOPO'_$TO#W$=>HUY=\+_\
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M9@,2Q_W3_A6$HV/I<!C%57)+=&S1114GIA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %20?ZY:CJ2#_ %RTAK<NT445)J9U%%%6
M8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA5=.2DCZ/5@RAAT(R*6L3PC>M?\ ABRFD.7";6/N*VZP9]?3ESP4@K&\6_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHI %%%%, HHHH **** "BBBD 4444P"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ J2#_ %RU'4D'^N6D-;EVBBBI-3.HHHJS$**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@Q+'W!_PK;K!JQ]3"<9Q4D%%%%!84444 %%%% !1110 4444 %%%% !1110
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MHHJ34SJ***LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KSWQ[XN\E&TFPD_>,,32*?NCT%:OC3Q4NB69MK5P
M;Z4<8_@'K7D7SRR-)(Q9V.23W-7&-SQ\PQJ@O9PW"-.YZU?MX,\FF6\.XY-:
ML$/0"MMD>'3@Y.['P09XQ6U:6V .*CM+7IQ6W;6X %9MGIT:0^W@P*N?=%
M48JO/-@5!VZ10R>? /-9%U<=:?=7'O63-*2:I(YJM09-)DFL^>7 -232XK+G
MFW'%:)'FUJA'-+N-01QRW5PD$*EY'.% IK,68*O))P .]>J>!?"8TR!=1O4_
MTR0912/]6/\ &E)V'A,-*O.W0T_"/AB+P_8!G :\E&9']/:NDHH/2L&[GU5.
MG&G'EB-=UC1G=@JJ,DGM7C_C7Q4^MW9L[5B+&)NH_P"6A]:U?'GB[S6?2+"3
MY <3R*>OM7!Q1UI")XN8XV_[N#T'11UI6\&*9;0=">M:D$.2 !6C9Y5*FV[L
M?;P;B*V[6VQCBH[2VQCBMFW@P.:S;/4HTQ\$.T<U88[11PHJI/-@&I.O1(9<
M3]>:QKJXZU)=7'6LJ60\YJDCDJU!LLE9\\V!3YY<#K67-+N)]*T2/.JU!DLI
M))J?1])N==U*.TMU."?G;LH[U6MK:XU&\CM;9"\LAP /YU[5X9\.P>'M.6)5
M#7#C,LF.I]*4Y&^"P;K2N]B[H^DVVC:='9VJ@*HY;'+'U-7Z**P9]1&*BK(*
M***!A1110 4UT62-D=0RL,$'H13J* W/'/&?A5M#N_M=LI-E*V>/X#Z5S<4G
M>O?[VS@U"SDM;E \4BX(->)>(_#\_AW4FA8%K=SF*3U'I6L)'SF8X+D?/#86
MVGR/>M*&3BN=AEP01^-:EO-D"K:.&E4MHS;AE*D5K6T_ KGHY.*O03%2.:AH
M[Z<SIXI-PQFI'4,*R[>?.*THY-PJ#MB[HSKJWZ\5A7=K@DXKKI8PXZ5E75MP
M>*:9E5IW..N(<YR*RYHMI(KI[NWP2<5D7$&0:U3/)K4K.Z(=!UNY\/ZFMS"2
M8SQ)'GAA_C7MVFZC;ZK8Q7ELVZ.09]Q[&O!)8\'%;OA#Q-)X?U 13,38RG]X
MO]T^HJ)QZG9EV-=.7)+8]IJAK&DVVM:?)9W*@JP^5NZGU%6X9H[B%)8G#QN,
MJP[U)674^B<5.-GLSP'5]*N=#U*2TN%/RGY&[,/6H8I,'(KV;Q3X=A\0Z:T1
M 6XC&8G]_3Z5XM/;SV%W);7"%)8VPPK>$KGS&.P;HRNMC7@FS@UK6ES@@9KF
M()BI]JU8)NAIM&-&K8Z^UN>G-:L;AQ7)VESTK;MKC/>LFCU:52Y?ECW+69<P
M9!XK61@PS44T084C64;G+W$&#TK/ECKI+JW]JQYX<$\5:9PU:9@W,&>:S9(_
M:NAFCK,N(,<BM%J>=4ARNZ.@\#>*SI=PNFWC$VDA^1C_  '_  KUE2&4$$$$
M9!%?.TD=>C> O%@=%TB_DPZC$#MW'I64XGKY=C?^7<ST2BBBLSW0HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *S=2UW3M)EBBO+A8GE^ZI_G3;_Q!IFFWD5K=7"I-)C"_P"-4==\)6?B&ZAN
MIIWC** =@SO7K_6@!VO^%[3Q*;>:6=XS&N%9!G<IY_K6U:VZ6MK%;QYV1*%&
M?:GQ1K##'$OW44*/H*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %20?ZY:CJ2#_7+2&MR[1114FIG
M44459B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5A^)O$4'A_36E8AKAAB*/U/^%7=7U:V
MT;3Y+RZ<!%X49Y8]@*\0UC5KG7=2DN[ACR?D3/"CL*J,;GGX[&*C&RW*]S<3
M:A>27=RQ>61LL:E@BW$<<4R*+<1BM2"# '%;['S2O4E=DD$/;%:]I:]#BH[2
MV).2*W;6WZ<5G)GHT*1);6_3BM%5"BDC0(M-DD"CK6>YZ$4HH2:7:.M95U<=
M>:?<W'7FL>XG))YJDC"K4L,GF+'K5"67WITLGO6;<3]LUHD>=5J#+B?)P#6?
M(_-.DDZUTW@KPJVM7@O+I"+*)O\ OMO3Z4Y.R,:-*5>:2-7P'X1\YEU748LH
M#F"-AU]S7IM-1%1%1% 51@ =A3JP;N?5X?#QH0Y4%<1XX\7#3(6TZR?_ $R0
M?.P_@'^-:?B[Q/%H%@40AKR4?NT]/<UXV\DMU<//.Y>5SEF/<U48W.#,,:J:
M]G#<9&F3D\DUH6\&<$BHX(=QZ<5JPP].*VV1X$(N;NQ\$.< "MBTMNG%1VEM
MSG%;=M;^U9MGIT:74DMH,8XJ\!M%(JA!44TH45!W)**&SS8'6LBZN.O-27-Q
MUYK(GFW9YJDCGJU!DTN2:H32X[T^:7WK,N)\\ U:1YU6I9$=Q-N)&>*IX>61
M8XU+.QP%'4FB63WKTCP'X1-N%U;4(_WC#,,;#[H]:)2L3A</*O.QK>"_"B:)
M:+=W #7TJY/'W!Z5UE%%8-W/JZ5*-*/+$****#0**** "BBB@ HHHH *S=;T
M:VUS37M+A<YY1NZMZUI44$SBIJS/G_4]-N=%U&2SN5PRGY3V8=C202E37L'B
MSPU%X@T\[0%O(QF)\?I7C,L,UE=26UPA26-MK*>QK>$KZ'R^-PCH3NMC:AF!
M YJ_')7/P3;2 >E:D,O'6FT94JES<MIR#@FM:WGZ<US<4E:-M/TR:S:/0IU#
MI$?<*BFB##-5[>;IS5X$,*DZT^9&#=6V0>*P[JWVD\5V-Q#D=*QKNVR#Q519
MRUJ5SD;B#.<"LV6/VKI+B#:3Q63<0<D@5JG<\JK3<7='2>!/%K6$R:5?/_HK
MG$3D_</I]*]5!!&0<Y'%?.TL=>E^!/%HNHUTF_D_TA>(I&/WQZ?6LIQ/7R[&
M_P#+N9WW-<AXW\*+K%J;RU0"]B7_ +['I7845FG8]>K2C5@XR/G4%HW:-U*L
MIP0>QJ[;S;3@FNW\>>$2^[5]/CY',\:CK_M5YW%)TKHC*Z/E,3AY4*ECHH)N
MA!K8M+GMFN5MY^@)K4@FP<YI-&E&J=C;7&1UJ^"&6N9M+G@<UMV\X.!FLFCU
M*=2Z'SP@BLFYM^O%;W#"JEQ#GM0F5.%T<K-$0:H319'2NBNK?VK*EBP3Q6B9
MY]6F<]<0[3TXJF=T<BR(=KJ<@CL:WIHLYXK+GA*D\<5>Z."47!W1ZCX*\5KK
M5H+2[D'V^,<Y/WQZUU]?/-M<SZ?>1W5LY26,Y4U[5X9\10>(-.$J86X08ECS
M]TUC*-CZ'+\8JL>26Z-RBBBH/4"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *RKKQ%I=EJ2:?/<A;A\8'89Z9I)?$FEPZLN
MF/<?Z46V[<< ^A/K5+4/!UAJ6MQZG(SJP(+H#PQ% ":SX/LM:U.*_ED=&4 ,
MJ]' KHD0(BJO10 /I3@, #T&** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *D@_URU'4D'^N6
MD-;EVBBBI-3.HHHJS$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "H;NZBLK62YG<)%&,LQ-2NP1"
MS$!0,DGM7D'C7Q6^L7;65H^+*(X)'\9_PIQC=G+BL3&A"[W,[Q1XBE\1:EO!
M9;6,D1)GMZ_6LJ*/. !38X^E:5O!C!-="5D?+3J2K3NQ]O!@#BM:UMB2#BH[
M:W+$<5NVEM@#BHDSKHTB2UMNG%:T,01>E-AB"C-2LP45FW<]*$>5"2.%%9MS
M/C/-27,_O6/<W&2>::1%2=B.XGR>M9\LGO2RR=:H3S8!JTCSZM0CN)\#K6;+
M)SDTZ63))-2Z3I5SKNI)9VP^8GYG/11ZFK;L<:C*K.R+GAGP[/XCU)4 *VL9
MS*^.WI]:]LM+2&RM([:W0)%&, "JVC:1;:+IT=I;* %'S-W8^M:%82E<^HP>
M%C0AYA65K^N6V@Z<]S.P+D8C3/+-5O4-0M],LI+NY<)'&,GGK[5XCX@UVY\0
MZFUQ*2(5.(H^RBB,;L6-Q:H1LMV5=0U"YU?4)+RZ<L[G\AZ40Q%CTIL,1) K
M3MX0HK=61\Q[U65V200XQQ6K:VV2#BH[6WW$<5N6MOC'%0V>A1I$EK;XQQ6H
MB!5IL480"G.^T5F>A&/*ALLFT=:S+FXX/-/N9\9K'N9\D\TTC*I4L,N)RQZU
MG32X'6GRR5G7$^!6B1Y]6I;49<S]@:S9)*=+)DDUN^$?#$GB&^\R8,ME$?G;
M'WO84V['-2IRK321I^!?";:A.FJ7R?Z*AS$A_C/^%>K!0  !@#H*9!#';PI#
M"@2-!A0.U25@W<^JPV'C0ARH****1TA1110 4444 %%%% !1110 4444 %<5
MXY\)C5+<ZA9IB\C'S*!_K!_C7:T=N:$[&5:C&K!QD?.J,0VU@01V-7[>?& 3
M78>/?"7EE]8L$^7K/&.WN*X&*2NB+N?*8FA*A4LSH89>.M7HY.G-85M/VK2B
MEI-&E*I<WK:?H,UK039[US$,N#G-:MM<=*AH[Z50W>&%4[F#(/%2P2@BIR R
MU.QTV4D<Q=VN<\5B7$."1BNRN;?KQ6'>6W7BK3.*M2.4N(,9(%4\O#*LL3%9
M$.58=JW9X>H(K+GAVD\<5INCS)Q<)71ZMX,\4IKMD+><A;Z(8<?WAZBNJKY[
ML[RXTR]CN[5RDL9R/0^QKVOPYX@M_$&FK/$0LJC$L?<'_"L91L?0Y?C%5CR2
MW-AE#*58 @C!![BO(_''A5M)NFU"S0_8I3E@!]QO\*]=J*YMHKNVD@G0/&XP
MP-2G9G5BL-&O"SW/GR.2M*VGR,9J;Q3X<F\.ZB0H+6DAS$_]#[UDQ28Y!K=.
MZ/E9TY49M,Z2WGVG.:V[2YZ<UR=O-D5JVTY4CFIDCKH53L+>8$8-6" PK#M;
MC('-:\,H85FT>E"2:*UQ![5CW-OU.*Z5U#"L^X@X--,FI"YR\L7M6?<0Y!XK
M?N8,'I6;+'UJTSSZE/H<]-%M.*FT?5KG0M32\MS]TX=.S#TJU<09^M9DL9R1
M5M71QIRI3NCWC2-5M]9TZ.\MFRCC!'=3Z&KU>(>%O$DWAW4@7):SDP)4]/<>
M]>U6US%=VZ3P.'C=<J0<BL)1LSZC!XI8B'FB6BBBI.P**** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHI"<4 +60OB;2VU?^S!<9NMVW&.,^F?6F
MV_B?2[O5GTR*<M<*2,;3@D=0#5=?!^FIK_\ :ZF7SMYDV9&W<>] "3^#].GU
MX:LQD$F[>4!X+5T0I*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J2#_7+4=20?ZY:0
MUN7:***DU,ZBBBK,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHKE_%&O_9(C96K_OW'SL/X1_C6&(Q$
M*$'.9=.G*I*T3G?'GB[<7TC3Y..DTBG]!7G\4=:EWIN7,J9W$Y8'O4-O <\C
M&*TP6+I8F'-39\SFM#$4ZUJOR'VT'<UJV\&XCBH[>#) Q6W:6V,<5U2D<]"D
M26EKC'%;4$&T9Q3+:# Z5<X45DV>I3@D@)"BJ5Q/C/-/GFP*R+JXZ\T)!4G9
M$=U<=>:RY9,]Z?-+DYS5&:7'>M$C@JU!D\V!UK+FF+$T^>8L<9XJF=\D@2-2
MS$X"@9)J]C@E)S=D/M[:XU"\CM;5"\TAPJBO:O"_AR#P_IRQA0URXS+)W/M]
M*S/!/A1=&M1=W2YO91T/\ ]/K785C*1]#E^#]DN>>X4R:5((GED8*B#+$] *
M<2 ,DX [UY7XZ\6F_F;2[!R($/[UP?OGT'M4I7.S$XB-"',S,\7^*)/$%[Y,
M)*V<1PH'\9]36!%'SBFQQ].*TK:#N16Z5CY2K4E6G=C[># '%:EM 6(ID$&2
M!BMJTML <5+9U4:1):VV,<5L01!5S3+># !(JT2%%9MGIPA9",VT50N9^#S4
MEQ/@'FL:ZN.O-"1-2=D,NKC.>:RY9*=++UYJA/-@=:T2//J5.XV>; -9DLI.
M2:=-*6)-)86-QJU_%9VR%I'./H/6K>B.)<U25D6M!T2Y\0ZFMM""L8YDDQPH
MKV[3=/M]+L8[2V0+&@Q]?>JGA[0K?0--6VA 9^LDG=C6M6$I7/IL%A%0A=[L
M****D[PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ;(BR(R.H96&"".*\
M@\:^%7T6[-[:J392GH/^69]/I7L-07=G!?VKVUS&)(9!AE-.,K'+BL,J\+/<
M^?XI.X-:=O/GO2^)?#T_AW4FC(+6SG,4F.H]*S8I2""*Z$[GRTXRHSLSHHI:
MO0S;36';SY YK0BD]ZAHZJ=2YT5M/TYK4AEW"N8MYB#UK6MI\XYJ&COIU+FJ
MZ!A69=6_7BM&-PPHEC#BE<UE%-'(W=M@D@5CW$&<\5V%U;Y!XK"N[;!) K1,
M\^M1.8FBP<59T/6KGP_J:7,).PG$B=F%6+B#(/%9<L?)!%4U='!&4J4[H]ZT
MS4[?5K".[M7#1N.F>5/H:N5XIX2\32^'M0\N0EK.4XD3^Z?45[/#/'<0I-$X
M>-P"K#N*PDK'U&#Q2KP\RKJ^E6^L:?):7*@JXX/=3ZBO#]8TBYT'4WL[@$XY
M1\<./45[]6'XG\.P^(--:)@%N$YBDQT/^%.,K&>.P:K1O'='C$,NTYK4@FR!
M61<6\^GWDEM<H4EC."#4T$Q4CG@UONCYI7IRLSIK6X*D#-;EK<=.:Y&&;CK6
MM:7., FLVCT:-4ZV*0.*61 PK-MKCIS6DCAA6;/0BTT9MS;YSQ6-<P8/2NIE
MC#"LNYM_:J3,:D#F98ZS;F#/(K?N(=IZ50FCR.E:)GG5:?0YV6/K76>!_%;:
M3=#3KQR;25L(Q/\ JR?Z5@W,'<"JJ6;W$F%&!W-16J0A%RD[(G!^VC62IJ[/
MH-2&4,I!4C(([TM<3X/UTQQ1Z9>2%MHQ%(W\J[;M7)0Q%.O'F@SZ^4)PMSJS
M"BBBMR0HHHH **** "BBB@ HHHH **** "BBB@ HHIKNJ(SL<*HR3Z"@!20!
MDG '.:QK#Q/I>IZE+86\Q:9,C!4@-C@X]:73?$FEZU<S6EM(6= <@@C<.AQ4
M&E^$-/TK5I=0A+M(Y)56Z)GTH 2S\':=9:XVK1M*9"Q=4)^52>I'>NAHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "I(/]<M1U)!_KEI#6Y=HHHJ34SJ***LQ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH ***H:MJD.EV;32'+GA%[L:BI.-.+E+9#C%R=D5-?UM-+MBD9#7,@^
M5?3WKS_:\TC22$L[G)8U----?W;W,Y)=SGZ"ITBXKX7,LQEB)Z;(^CP>$5.-
MWN4VAR.E57M\/D"MGRZ!;9[5QX;&U,//G@R\7@:=>GRS17LK88!K=MK? Z51
MMXC"V0,CTK9A*%!MK[?+\UIXR-MI=CX[$Y;+"RTU0\ **AGE %.FE"CK65<W
M& >:]1(Y)R2&75Q[UDS2Y)IT\Q8U0EDJTC@J5+C9I:S+B?)QFI+B?' -9LDE
M:)6//J3<G9"2/V%>B^ O"7EA-8OX_G/,$;#H/4BLKP/X2;4YUU*]3%K&?D0_
M\M#_ (5ZR ,8&!C@ 5E*1[&78'_EY,6BBN4\9^*DT.S-O;.#?2C"C^X/4UFE
M<]BK5C2CS2,KQWXN^RHVDZ>_[]QB613]T>GUKS6-.<GDT$O-*TLC%G<Y8GO5
MR"'=@FMXQLCY3%8F6(G<DMX,D$UIP0YP,4R"'I@5L6EMT.*),NC2)+2VZ<5M
MVT &.*CMK?IQ6@JA5XK-L]2G"R% VBJUQ, ,4^>7:,9K(NKCKS22*G-(CNKC
MKS63-+FG3S;B:H32X'6K2."K4&S2XS67/-N/6GSS%B0.E478L0J@DG@"M-CS
MY2<W9#E22YF2&%2\CG"J.]>Q^#_"\>@6(>50U[* 9&[K["LOP+X2&GPKJ=]&
M/M4@_=HW\"G^M=U6,I7/?R_!*FO:3W"BBBH/6"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** ,[6M'M];TV2SN5'(^1^Z'U%>(ZIIESHNHR6
M=RA!4_*W9AZBO?ZY_P 5^&XO$.G%>$NHQF)P.?I51E8\['X-5H\T=T>.PR[3
MQ6I!-D"L::":RNI+>="DD9PRFIX)MI'/%;[GS:;IRLSH8Y.E:%M/C K#@ESC
MFKT4E0T=U.H=+;S\#FM%&W"N:MKCH*V+>;/>H:.^G-,L31!EZ5D7=MD'BMT$
M,*KW$(89%),J<5)'&W5OM)XK)N8,\BNNN[;.>*PKB @FM(L\RO2.<EC]178>
M!?%O]FS+IE\Y^RR']VY_Y9GT^E<[<0<D@5GR)SD<54E='/0K2H3NCZ)!!&00
M0>XI:\^\!^+?M$:Z3?R?OE&(9&/WAZ5Z#6#5CZNA6C6AS(Y'QKX476K0W=J@
M%[$N1C_EH/2O(QNCD*."K*<$'L:^BJ\Z\>^$O,#:OI\>7 S-&HZC^]50E8\W
M,<%SKVD-SA[>?!&:U8)>]<[&_8]16A;S]C6SU1X=.;B[,ZBTN>@S6Y;3]*X^
M";&#FMFTN>G-9M'IT:ITRL&%0S19&<5#;3Y YJZ,,*SV.U6DC"NK?VK(GA*G
MI75SP@C-85ZN253D]S6&)QE+#0YZC%#!3Q$^6",-X-[8JQ%;!5X&*LQVY!YJ
MTL6!7Q.89K4Q4M_=['V&7913PL;VO+N4#$5((R"#D$5W/AK71?0BTN#BXC'!
M/\8KE&B&*K_O+:99HF*NAR"*C+LPEAJE^G4ZL7A%4CYGJV:*R="UB/5;0$D+
M.@PZ_P!:UJ^[I58U8*<=F?.3@X.S"BBBM"0HHHH **** "BBB@ HHHH ***A
MNKJ*SMI+F=PD4:EF8]@* '331V\+S2L%CC4LS'L!65IGB'3/$!N+:V<L5!#J
MPQE3QGZ4W3=;TOQ/;7,$!9EVE9(W&#M/'Y4:)X7T_0IIIK0.7DXRQS@>E #-
M&\*:?HE[-=V^]I).!N/W!Z"MZBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "I(/]<M1U)!_KEI#6Y=HHHJ34SJ***LQ"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIDLB11M)(P5%&23VI-V5V
M"5W8CO+N*QM7N)FPBC\_:O.-0OYM7O3/)]P<(OH*LZYK$FL76Q"1;1GY%]3Z
MU6ACQ7QN<9G[67LX/1'O8#!\JYY;CHHP!TJP!B@ "GJN37S<I7/:244*B9JT
MD.>U)''5M%P*PE(QJ3(_* '2J\CM 25_&KC$ 50N#D&M:%:=.:E!V9RSHJHK
M-$4MZ)%ZX/I65<3EB:=<J<Y'%4)'8#D5]_E6<1KI4ZNDCY+-<KJ4;U*>L1LL
MF*S[B?'>G7$V.]9DLN<DFOHDCY.K4Z(263J36UX3\,R^(=0#2 K91G,C^OL*
MH:'HMSK^II:PJ=@.9'[*M>WZ9IEMI-C':6J!8T'/'+'U-3.1V9?@G4?/+8L6
M]O%:P)!"@2-%VJH["I**HZMJEMH^GR7ETV(T' '5CZ"L=SZ-N,(W>R*?B7Q!
M!X?TUIVP\[<11$_>/^%>*7=U/J5])=W+EY9#DD_RJSK6L7.OZF]W<'@\(G91
MZ57BCR0 *VA&Q\QCL8ZTK+8?#%N(':M2"+&.*9!#@"M2UM]Q!Q5-F%&D]R6T
MMLD'%;EM;XQQ4=K;].*U8HPJUDV>K2IV'(@5:;+(%6G2.%'6LRYG]Z1M*5D1
MW5QUYK'N)MQI]S/DD9K/ED]ZM(X:M09++C-9EQ-V!J2XGP" :S9)#S6BT//J
MSYG9#9).M=WX#\(FX==6U"/]VIS!&>Y]365X,\+/KMY]JN5(LHCD\??/I7L4
M:)'&J(H5%&% ["LYRZ'JY=@K_O)CJ***R/>"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH XSQQX3&K6YO[- +R(98 ??'^->
M4*2CE&!#*<$'L:^BJ\U\>^$=N[5]/CXZSQK_ #%7"70\;,<%S+VD#C;>;!P3
M6G#+D"N?B?/>M"VG(P":VW1XE.;B[,WHI.F*U+:X]ZP(I>.M789<'.:S:.^G
M4.H@FSWJWPRU@VT_3FM:"7(P34-'?"5T1W,&0>*Q+RVSGBNG8!ABL^Y@R#Q0
MF34A='&W$&"1BLJXAVG(%=7>6O7BL6>'J"*UBSRJ]$P?GBE62-BK*<@CL:]>
M\&>*TURS%M<MB^B'S _QCU%>53P[2>.*CM+NXTR^CN[5RDL9R#1*-QX/%2H3
MUV/H6D8!@00"#P0>]8WAOQ!!X@TU9XR%F7B6//(/^%;58'U,)QJ1YEU/)/'/
MA0Z5<G4;)";25OG4#[C?X5R4<E?0=Q;Q75O)!,@>*1=K*1UKQ;Q7X;E\.ZCE
M1NLY3F)_3V-:PD>#F."Y'[2&Q7MI_6M.";!!!KG(I,<UIV\^0*MH\ZE4MH=5
M:7/3FMFWG&.37'V\^T]:U8)WEP,X6O)S',:6$AKK+L?1Y=A*F)=UMW-J:8RY
M1/N^M5&M?:I[?[M6=HQ7YYC<=4Q-3GFS['#X:-!6BC*: #M3-N*T9(ZJ2)S7
M+&=STZ;5K$)6H)(P15BD(S6B=C24;HHVUS/IMXMS <,.H]1Z5Z-INH0ZG9I/
M$1R/F7NI]*\^ECS3M*U.71[[S%R86XD3UKZ'*,R="7)/X6>-CL'SKFCN>ET5
M%;W$5U DT+AHW&014M?:1:DKH^?::=F%%%%4 4444 %%%% !115/4]2M])T^
M2]NB1$G7:,D^PH ??7T&FV4MW<MMBB&6(ZUFV&J:9XMTRXBCWM$P*21N,, :
M+6]TSQ?HTRJ':!\HZMPPJ;1/#]EH,#QV:M\YRS.<DT ,T3PUI^@F4V:ONE^\
MSG)QZ5L444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %20?ZY:CJ
M2#_7+2&MR[1114FIG44459B%%%% !1110 4444 %%%% !1110 4444 %%%%
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M1VUL@2*,8 %6***Q/I4DE9!1110,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ IK*KHR,H*L,$'O3J*!/4\?\;>%&T6[-]9
MH392MR,9V,?Z5R\4G3FOH*ZM8;RUDMIT#Q2+A@:\3\3^'9_#NHE,%K60YBD
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M@GBN85EAD5XV&0RG(-25:?8P::=F5-.T^VTNS2TM4VQ)T]SZU;HHIB"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *D@_P!<M1U)!_KE
MI#6Y=HHHJ34SJ***LQ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR>88V'ZFO1Z10%4*H  Z =J6L&[GU>'H1HPY8A1112-PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KCO&WA--7M6OK1 +V(9P/^6@]/K78T4)V,JM*-6/+(^=59D<HX*LIP0:
MNV\^T@$UVOCWPE]_6+!.>L\:C]17GL;UT1E<^4Q.'E0G8Z&&6KT4F#UK!MY^
MQ-:44N0*31=*I<W[:XZ5KP39QS7+PRX(K6MKCIS4-'H4IF[PRU3N8,CI4D$N
M1BI)I%5.?P%85*L*47.;LD=D*;JNT3F[VV &:S4M_GSBN@GA:5LMT]*KFVQV
MKXS,L\==NG3TC^9]'EN44Z;]I4UD9ZP\4UHRI#+PP.0?2M'R\4QX@17BQJM.
MZ/?=%.-CJ_#>NC4(?L]P0+F,8Y_C%=#7E0,EK<)/"Q5T.017H.B:O'JUIO'R
MS)Q(O]:^URG,57C[.;]Y'SN-PKI2YEL:;J'4JP!4CD'O7 ^(=&;2[G[1;J3;
M.>@_@/I7?U%/!'<P/#*H9&&"#7;C\%'%4^5[F&'Q$J,[K8\TAES5M6R*BU;2
MY-'O=G+0-S&_]*CBDR!7P&)P\J,W&2/J*%>-2-T7 <5-')5=3FG XKC:.EJZ
M-&.2I&<8JBDE.DEP.M8N.ISNGJ+(XJG*XI)):IRS8'6MX0-+\J$FDXJ.SU.V
MTF8W\X\R2/B*('EF]:R[_40F4C.Y_P"59B1-(^]R68]S7M8*BX251E0PCKKW
M]$:5YXIUR]NS<"\>+G*HG05U.F_$/R]'?[=$7O8^$VCA_<UQRV_'2@VXS7L0
MQ56#;3.BKE^'J147'8CU75+W6[MKB[D)Y^5,_*OT%9[1\5>= M57RSA$!9F.
M !U-9.3G+4[(1A3CRQT2.^^&6H32&[T]V+1QKYB9/3D#%>BUQO@'P_-I5G+=
MW:%)[@<(>RUV5?0X2,E22D?"YI.G+%2=/8****ZCS@HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"AK&DVVLZ=)9W*Y5A\IQRI[
M&O$M6T>[T35&LIU.<_(W9AZU[Y61KVB1:Q:8*@7$8S&_]*F=24(-P5V<>(P-
M/$27-H>3V5EL4,_WOY5L0Q"HFADM;AX)D*R(<$&K<)SBOS['XFM6J-U-SZW+
M\'1P]-1I(L1I@59C;;Q42=*=7E2U/825B]')5I6R*S(WYJW')6$HF$X$SID5
M3D2KH.14;KFDG8B$FC-88IC+D5:D2H",5M%G2G=%&:+(K1\/:VVF7'V:=O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFE5JPHQYI'HX+ 3K2,GPSX/NM?E6YNMT%DISR,%_85ZU9V5M86RV]K"L42C
M"BID18T5$4*JC  & *=7@XC$SK2UV/L,+A84(VCN'%(0",$ CT(I:*YCJ#
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MR$900/PI\P6/.]"U8Z-\)Y+M& E,CI%G^\>E<WX&\*0^)I[J2]:58(@,,O\
M$QS_ "KV0Z98FV%L;2'R =PCV#;GUQ4MM:6]G&4MH(XE)R0B@"CF"QQ9^%6B
M$$":X!]<CBN#\.WDGA3QP(9/NB7R) ?1N 3],YKW:J4ND:=/,9I;*!Y"<EVC
M&3^-"86/,/B1H5U;ZLNM6@D>&;#,R\[''0X], 5-8_%IH+%(;JP,D\:A=Z,
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MK6]'CU:T*\+.O,;^_H:\\FCGLIVAN$*.IQS7Q&:9;*A.\5[K/H<%C%.-GN:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 0W-K!>6[P7$:R1L,%6%>4^*/!=QHK->6 ::R)R4 RT?\
M]:O7*1E5T*LH92,$'O71A\3.C*ZV.;$X6%>-I'@5O<YQS6I;W1'>NC\6>!"I
MDU#1UQ_%) ._TKAH9V5RC@JRG!4C!!KWJ5:%>-XGR&-P$Z,M3IU9)D[53N+;
M&3CBJT%SW!J\;D-$<U=K,\MW1CSPX[5#IVIW.AZG'>6SE=K?.O9AW%6KB4&L
M^.UFU*^BL[="\DK  #M[U4DG%\VQZ."E/G7+N>_6LXN;2*=>DB!OS%357L;<
M6MA! /\ EG&%JQ7RTK<SL?<QO97"BBBI*"BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "I(/]<M1U)!_KEI#6Y=HHHJ34SJ***LQ"BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !4D'^N6HZD@_P!<M(:W+M%%%2:F=1115F(4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M)!_KEJ.I(/\ 7+2&MR[1114FIG44459B%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %20?ZY:CJ2#_ %RTAK<N
MT445)J9U%%%68A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4D'^N6HZD@_P!<M(:W+M%%%2:F=1115F(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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D9/[IH\F3^Z:**+ARH/)D_NFGPQNLH)4@444K@HENBBBD6?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gzkk5j0cumnd000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkk5j0cumnd000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" :%",H# 2(  A$! Q$!_\0
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M]IJ/^%D:?_S[35?_ .$'TG^ZU'_"#Z3_ '6HT#4H?\+(T_\ Y]IJ/^%D:?\
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M?_S[35?_ .$'TG^ZU'_"#Z3_ '6HT#4H?\+(T_\ Y]IJ/^%D:?\ \^TU7_\
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MG^ZU'_"#Z3_=:C0-2A_PLC3_ /GVFH_X61I__/M-5_\ X0?2?[K4?\(/I/\
M=:C0-2A_PLC3_P#GVFH_X61I_P#S[35?_P"$'TG^ZU'_  @^D_W6HT#4H?\
M"R-/_P"?::C_ (61I_\ S[35?_X0?2?[K4?\(/I/]UJ- U*'_"R-/_Y]IJ/^
M%D:?_P ^TU7_ /A!])_NM1_P@^D_W6HT#4H?\+(T_P#Y]IJ/^%D:?_S[35?_
M .$'TG^ZU'_"#Z3_ '6HT#4H?\+(T_\ Y]IJ/^%D:?\ \^TU7_\ A!])_NM1
M_P (/I/]UJ- U*'_  LC3_\ GVFH_P"%D:?_ ,^TU7_^$'TG^ZU'_"#Z3_=:
MC0-2A_PLC3_^?::C_A9&G_\ /M-5_P#X0?2?[K4?\(/I/]UJ- U*'_"R-/\
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M?\+(T_\ Y]IJ/^%D:?\ \^TU7_\ A!])_NM1_P (/I/]UJ- U*'_  LC3_\
MGVFH_P"%D:?_ ,^TU7_^$'TG^ZU'_"#Z3_=:C0-2A_PLC3_^?::C_A9&G_\
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M#4H?\+(T_P#Y]IJ/^%D:?_S[35?_ .$'TG^ZU'_"#Z3_ '6HT#4H?\+(T_\
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M .?::C_A9&G_ //M-5__ (0?2?[K4?\ "#Z3_=:C0-2A_P +(T__ )]IJ/\
MA9&G_P#/M-5__A!])_NM1_P@^D_W6HT#4H?\+(T__GVFH_X61I__ #[35?\
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MDCTHL[_7M&ES/%-(@/\ %18+GK=%9FBZDVI6:2M'L8C)%:=2,**** "BBB@
MHHHH **K1WUM+*8TE4L#@BK- !15:YO[6T&9YE3ZU##K6GW#[(KE&;T% %^B
MD!!&1T-0W%W!:KNFD"#WH GHK.CUS3I7VI=(36@K!AE3D4 +1110 4444 8G
MBK_D!35ROP[^_=_[]=5XJ_Y 4U<K\._OW?\ OU2V%U/1:***D84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '&?$+_D#'_>%3> O^04_UJ'XA?\ (&/^\*F\!?\ (*?ZU7074ZVBBBI&
M%%%% !1110 4444 %%%% !1110!SWB/PZNL+O#N) ,#:<5Q?V?7O#LI9$+1
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%7_("FKE?AW]^[_WZZKQ5_R IJY7X=_?N_\ ?JEL+J>BT445(PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C/B%_R!C_O"IO 7_(*?ZU#
M\0O^0,?]X5-X"_Y!3_6JZ"ZG6T445(PHHHH **** "BBB@ HHHH **** "L+
MQ39&[TB;! (3O6[61XB25]*F6+[Q6F@.,\$&RMIWAF*B11R21BN_\RR_YZQ?
M]]"O%/[(U,3&10P)]":L"UUD#&7_ #-4T3<]D$EGGB6+_OH597&..E>,VMOK
M N%W%_S->N::'&GPA_O;1FI:L-,MT444AA1110 4444 %%%% !11378(A8]
M.: '45QNK>,#%>-:V7S2#VJFGC"^M) ;]0(SZ"G9BN=]152POHK^V66(Y!&:
MPM=\5QZ?*((#F8G&,=Z5AG445Y^OB_4K=E>Z0",G' KLM+U*'4[03Q'(-.P%
MZBBBD 4444 8GBK_ ) 4U<K\._OW?^_75>*O^0%-7*_#O[]W_OU2V%U/1:**
M*D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% '&?$+_D#'_>%3> O^04_P!:
MA^(7_(&/^\*F\!?\@I_K5=!=3K:***D84444 %%%% !1110 4444 %%%% &5
MJ^MV^DC,SA>,\U&FN6L^GO<EE,:KDU4\3^'3KB8$NSC'2F6_ADPZ-)9&7.]-
MN<4]!&?_ ,)GHN?^6/Y"C_A,]%]8?R%8Y^&9)S]J_3_ZU'_"LC_S]?I_]:GH
M+4VXO&&C22!5\K)]A77VTJS6Z2)C:PR,5YS!\-VBF5_M6<>W_P!:O1+*#[-:
M10YSL7&:3L-$]%%%(84444 %%%% !1110 5!>HTEE,B?>*X%3U5U"X%K8S2_
MW5)H \[TN6#2/$,IU,*!MQEAGUK3\3ZMI%YIA@MC&TQ(P *R;'37\5ZH]P[&
M-",BK^L^#/LMK]IBFW,G8"KZDFMX:BGT_1I9)L@'E<UA:!;#5/$=[+,-P1\@
M'FM;1-2.H:%<PD8:'Y*I>"B%UC4%/7=_A2&=9JNF6T^GRCR4&$)'%<IX(N&A
MNFLR3C<3BNXO3BRF_P!PUP/A(%O$3./N\T+8#T6F22+$I9S@"GUG:U!+<:=+
M'"Q5RN 14C)/[5L_^>HH_M6S_P">HKS0^&]:S_Q\34G_  C6M_\ /S-560KG
M:>)M1M9-$E59 37/_#KE[LC^_6#J.@ZM;V;233RL@Z@UN?#8$+<@]0W-.V@N
MIZ/1114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <9\0O^0,?]X5-X"_Y
M!3_6H?B%_P @8_[PJ;P%_P @I_K5=!=3K:***D84444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '&?$+_D#'_>
M%3> O^04_P!:A^(7_(&/^\*F\!?\@I_K5=!=3K:***D84444 %%%% !1110
M4444 %%%% !6?K%^NGZ=+-GYE7(K0KF_&,,DND2E 2 G-- ><7$^J^)+F22W
M+;1\QVL15SPC'=0:[-;RLQD$1X)/H:M>#]4L[.":*X*1MLQD]Z;HVH6L7C&:
M=Y0(C'U_.J)*_P#:=_H>O9G) )) )XQFO5K"Y%U913=V7)KR?Q=?P:KJ\:V@
M5OEQE?PKT[08FBTFW#==@I,:-.BBBI&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 8GBK_ ) 4U<K\._OW?^_75>*O^0%-7*_#O[]W_OU2
MV%U/1:***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '&?$+_D#'_>%3>
MO^04_P!:A^(7_(&/^\*F\!?\@I_K5=!=3K:***D84444 %%%% !1110 4444
M %%%% !45S ES T3C*L,&I:@N[E+2V>:0_*@R: /.];\"2_:'FM7 4GA0*P%
M\(ZB)LX<$\9Q7>:?XNCO]2EA3.Q?6LCQ1XSGLKPV]DVUAWQFK39.A)X<\#FV
MG6XN7#X/0BN_C01QJBC 48%>:Z!XXNGNTBOV8[O;%>D0RK-"LB]&&14N_4:)
M****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#$\5?\
M("FKE?AW]^[_ -^NJ\5?\@*:N5^'?W[O_?JEL+J>BT445(PHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?\@*:N5^'?W[O_?JEL+J>BT445(PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%5[N[ALX&EE<* .,T7L-)MV18HKSP_$2(:SY.P>5TW9XKNK.\AO8%EB<,"
M,G':LX58SV9O6PM6BDYK<LT445H<X4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '&?$+
M_D#'_>%3> O^04_UJ'XA?\@8_P"\*F\!?\@I_K5=!=3K:***D84444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!QGQ"_P"0,?\ >%3> O\ D%/]:A^(7_(&
M/^\*F\!?\@I_K5=!=3K:***D84444 %%%% !1110 4444 %%%% !65KFIG2[
M%Y@A;"YK5K$\3^3_ &/.94W )0@.?T37K3Q-(T,]D"0.IK>7PII8?=]EC_*O
M(=,UE])OVEMLHA[5V$7Q'4( ZR$U;3Z$IGH5M8VUHNV")4'M5FO.X?B+'+*$
MV2<UWMG/]IM8YA_&N:EIE$]%%%( HHHH **** "BBB@ HHHH **** "BBB@
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M3PT^66Q+130ZL<!@<4ZM3D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <
M9\0O^0,?]X5-X"_Y!3_6H?B%_P @8_[PJ;P%_P @I_K5=!=3K:***D84444
M%%%% !1110 4444 %%%% &-K/B&VT=PLY(R,\47<UIJ6C&64GR73)^E<G\1[
M65\3*#L5.37*_P#"7W8TK[#L4+LVYSS5)"N==8^$=#U$GR-YQSUJ[_PKS3/[
MK?G7 Z#XLNM&+% 'R,?,:V_^%EWW_/&.G9BT.EB^'^FQR!P&R/>NMMX5M[=(
ME^ZHP*\RM_B-?2S*AACP:]*L9S<V<4S#!=<FI=QHL4444AA1110 4444 %%%
M% !1110 C,%4L3P!FN/U;Q@MMJ:VL#9S4WBOQ +*/[+ 09V.TCZ\5Y_/IMQ:
MZBDMSNWM\PR?6J2$V>S6TIFM8Y#U9<US&O>*Q93+;VQ)F)QTSS6W%+Y.B12>
MD8KB/#ML-2\17LLHWA'R,\TD!+_PE.KVK+)=*/+)[+79Z3JD6J6@GB/'2FZK
MI\$^GS#RDX0D<5R/@F=H;QK,DXR3BGN@/0***0D 9-2,6BF>:GK1YJ>M &/X
MJ_Y 4U<K\._OW?\ OUU'BF13H4V#7+_#O[]W_OU2V%U/1:***D84444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2FZD5HCT.BF1R)*@=&#*>A%/K4Y0HHHH **** "BBB@ HHHH **** "BBB@
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M$@@]J]?^'VHZA<0+'*,P_P!X]:[\+7;?(SY_-<OC%>VAH>@4445WGSP4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_("FKE?AW]^[_P!^J6PNIZ+1114C"BBB@ HHHH **** "BBB@ HHHH ****
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MXA?\@8_[PJ;P%_R"G^M0_$+_ ) Q_P!X5-X"_P"04_UJN@NIUM%%%2,****
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MI;"ZGHM%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P @*:N5^'?W[O\ WZZKQ5_R IJY7X=_?N_]^J6PNIZ+1114C"BBB@ HHHH
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M6ZEML[L/EU.GK+5E>VLX+2,)"@4"K%%%!Z"22L@HHHH&%%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '&?$+_D#'_>
M%3> O^04_P!:A^(7_(&/^\*F\!?\@I_K5=!=3K:***D84444 %%%% !1110
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M._OW?^_75>*O^0%-7*_#O[]W_OU2V%U/1:***D84444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BB@G S0 45C3^)-/@OEMGG4,W:M
M>.198U=#E6&0:2DGL7*G**3DMQU%%%,@**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#BO'ZA-$(']X58\!?\@I_K4/Q"_Y Q_WA4W@+_D%/]:KH+J=;1114C"BBB@
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M 'M5JBI/5HX>G25HH****#<**** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHX(XAA5%2T45W))*R.=MO<****8@HHHH **** "BBB@ HHHH **** "BBB@
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M)'E)3K2ON9&G:/=:C*JPQ,PSR17>:;H&F:'$)[^9?, ^XXK-N?$EGI<1@L(
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/5?M4'_/5/SIOVRW'_+9/SKRDWFH$?>-1M-?-U8TOK],GV]7_GVSUDWUJ/\
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M\-Q?Q8_.CZS+^9![/'/[)</CH'HCU$WC>3MNIJ^'+7'/\ZF'ARP[C]:/;O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^^?SI_6TO^79JE@EM)?<=ZFAV2?PJ?JHJRNGVB=(D_[Y%>=?\)1-_?/YT?\
M"43?WS^=/Z];_EV:)X1;31Z6MK;CI%'_ -\BG^1".D:?D*\T7Q3-_P ]#^=.
M_P"$IE_YZ'\ZK^T/[C+4L-_.CTH1QCHB_E3MJ^@KS/\ X2F7_GH?SIW_  E$
MG_/4_G1_:/\ <8U+#_\ /Q'I7%+7FG_"42?\]3^= \4/_P ]3^=+^TO[C*O0
M_P"?B/2Z*\V_X29_^>Q_.C_A)G_Y['\Z/[3_ +C'^Y_Y^(])HKS?_A)6_P">
MQ_.E_P"$E;_GL?SI?VFOY&/EH_\ /Q'H]%><#Q(Q_P"6Y_.GKXE(_P"6Y_.C
M^U%_(Q\E+_GXCT2C->>?\)-_TV_6J][XM$$#$3_-C@9I_P!J1O\ "RZ>'C4E
MRPFFRUXS\7-9YMK9@6^ZWM7F$^I74\A=II.?]HTFH7[WUY),S$[CFJE?4X50
M=-2CU.>K3E3DXR6I;AU"YAD#+-)Q_M&O2_!?B][ITL[EAN)P*\IJWIMT]I>Q
MRHQ!'I5UJ<90=T0CZ0# C(/!J&XO(;9=TKX KS+_ (2NX-LBJQSCKFLNZU:\
MN,EI7V^F:^;6+OI8Y:^,A!\L-6=]J/C*UAW+;N&;T(KC=0\13W\A)C13V*]:
MY6YU$[CCDU634'20,1GVKHCA,36C?8Y[8FMJW9'6VVFZAJ+?(&<'U-=+IW@G
M=M:ZW*?:N9T;Q<L16)HU3WKK8];DE0.KD@^]>=B)QP<K5HL[\-E$9KFO<Z2R
MT6TLE 15;'<BKCR0VR9;"J/2N+NM?DMH3(SGIZUP6L>*[V^D8),Z+TX-=V75
M%C+^S5DCJJX;V"L>QGQ#IP?89N:O0745PNZ-LBOG/^T;HG)F?/KFM72O$][8
MR@F9V7/0FO5G@VHWBS%/4]]HK@;#Q')>VZNKG)[9JW_:TW]XU\Y4S6G3DX23
MNCNC@9R5TSLZ1F"KDG@5QO\ :TW]XUSWB/Q/=VT!C3=\PZ@]*(9M2F[)&E/+
M:DY63-7QAXTCLXWM;5P9#\K>U>1W5W+=S&21B2?4TVYNI;J4R2,68^M0UE5J
MNH[L^GPF#AAH6CN=#X<\27&CW2$-E >03Q7MFB:W;ZO:K)$X+8^;ZU\Y5M:)
MKEWIUPHB=BI/W<U='$NGOL<^/RZ.(7-'21]$T9K@+76;FXMD<NRDCIFI?[2N
M/^>K?G4O.::=N5GS[RZ:T;.YW#UI"ZCO7"_VA<?\]6_.FF_N#_RU;\ZC^VX?
MRC_L^7<[OS%]:3SD]:X/[=/C_6M^=-^V3_\ /9OSI/.X_P H_P"SWW.],\8_
MBH^TQ?WJX+[9/_SU;\Z/MD__ #T;\ZG^VU_*/^SO,[O[7#_>I#?0#J]<)]KF
M_OM^='VJ7NYJ?[;?\H_[/7<[K[?;_P!^F_VE;?WZX;[3)_>-)]H?^\:EYW/^
M4?\ 9\>YW!U2T'62C^UK3_GI7#^>_J:/.;U-+^VJG\H_[/AW.V_MBS_YZ4TZ
MU9C_ ):5Q7FMZTGF&I_MJKV0_P"SX=SM#K=F!_K*;_;MG_ST_2N,WFDW&E_;
M-;LA_4*?<[,Z_: _ZRFGQ!:8XDKC:*G^V*_D/ZA3.Q_X2"W_ +]-/B"'LPKD
M>:.:EYOB"OJ-(ZP^((^Q%)_PD"^HKE<-1\PYJ?[5Q'<?U*EV.H/B _[-5YO%
MD4/WF45Y_KFM&V!BC/S5R<M[<2L2TK<^]>]E^%QN*A[2<^5,X:[H4WRI79[3
M'XOCEX1E)J7_ (2.7L%KQ!+RXC.5E;\ZZ;0]<:4^5*>>F2:>/P.-H0]I3G=(
M*$Z$Y<LHV/1V\1S=E6J>H>+)K6T:0JF165D^M8OB0M_9[X->+@L97K8B%.4M
M&SLK8>E"FY)'-ZMK5SJ-T[N[8ST#5E[CG.:2BOT6*25D>&6+>\FMI%>.1A@Y
MX->CZ!XMN;FU5&P6'O7F%=)X5*_:0'?:M>9F]*4\,W#22-L/.$9^_L>B'7+A
MNH%59;R6=OOM^=(GV,<M<"M.RN=+C(WRH?K7R$<%BZJ_>2L=[QN%I_"99AE:
M,N<X R37.W^OQ6KE$8%AZUN>-/$-K#9B*R*DDX)6O+)':1RS')->Q@>'J37/
M5=S*>8RDO<.F7Q4V[D+BMK3]9AND)#X8>E>>5+%/)"V48CZ5W8CA_"SC[BLS
M*..K1\S1UY]]^YR2,UDUTT&@7.K6?GHK$@9X[UBW6FW%I(5EC*D>M>E@FE24
M'NM#B51U+RDK,IT^)&>0!>IIR02.V%4DUU_A7PI<W-VD\\;+&I[UTSFHJ[*.
M@T?2KPZ="WEY!7BK_P#9-Y_SR%=1%&EO D28PHQ3PPSTKXZKE%.I-S;>IWQQ
M\HJUCD_['N_^>(I/['N_^>(KMT52N2HJ&; ;&,5G_8M/^9E?7Y=CCO['N_\
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M '#^=']G7_\ </YUVCJH4G:*J%AZ4EDM/^9A_:$^QRW]G7_]P_G2_P!G7_\
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MU XKG:^SH)*G%(Z4V]9;A4UL[)<(4SNSVJ&MOPWIQOM2CS@*C G-54MR/FV
MVXI-1>,$0R'\*9=VNH74!C:"0Y]J]/#:=90JI9#@=F%4;CQ)I=OD>63]*^46
M$I4Y\ZTL<LW47Q53Q>ZTZZMF/FPNH]Q5.O3-;UG3-3C91"^<8%<:^FH\A*+Q
M7MPS.E:TMP>,I1TO<QU0N< 9K8L8WMTR#@U-#IK1D%8G)]EK5ATBZN,8C8?5
M:X<9CW67)36AR8C$NJN6"*'GRG^,THFE'\1KH[;P9>S8.5 ]ZV;;P,5QYVT_
M0UYZI5&81PU:70\NU-G<Y8DC-9M>R:OX%M9+ ^1&!(H)KRJ_TJYLKAHGB?CN
M%.*^DP,OW2B]T>O1A*$%&10I0,FG^1)G[C?E6MI&CRW$PDEC81*?FR,5V2DH
MJ[-3U#P+#C2DWCY2O>MV[\/Z=>9,ENK,>YKCKC6CI=M8P6,BHI.&&>U=7INO
M07&(6;=)W(->/.3<G)%#8?">E1/N^RI6Q#;16\>R) J^E2 Y&?6EJ')O=C&>
M4G]VCRD_NT^BI  ,4THK=13J* &>4G]T4H15Z"G44 (0#UIOE)_=I]% #/*0
M'[M/HHH :45NHI/*3^Z*?10 BJ%Z#%! (P:6B@!GE)_=% B0=!3Z* "F&-2>
M13Z* &>4G]T4X*%' I:* $(##!IOE)_=%/HH 8(T!X%/HHH 88T)R11Y2?W:
M?10 @ '2@J&ZBEHH 9Y2?W12B-5.0*=10 4PQH3R*?10 SRD_NTX  8%+10
MC*&ZBF^4G]VGT4 -$:J>!3J** &>4G]VCRD_NT^B@! ,# I&16ZBG44 ,\I/
M[HI0BKT%.HH .HIGE)_=%/HH 9Y2?W:?110 THK=15*ZT>RO!^^@5OK5^BFF
MUL!SX\(:2'W?94K6M=/MK-=L$00>U6J*;G)[L!GE)_=%'E)_=I]%2 =*:45C
MDBG44 ,\I/[HIRJ%Z"EHH 0@'K3?*3^[3Z* &") <@4^BB@!IC5CR*3RD_NB
MGT4 (%"]!00",&EHH 9Y2?W10(T!X%/HH *88T/44^B@!GE)_=%.  '%+10
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M,<?WA4_@+_D%/]:A^(7_ "!C_O"IO 7_ ""G^M5T%U.MHHHJ1A1110 4444
M%%%% !1110 4444 %8GB>S%UI,P[A.*VZR?$-O/=:7-' "79<#%" X;P??V&
MGSO!<A=P&.0#7<C4],(SB/\ [Y%>4?\ "(ZZ)"XMWR>^:D_X1GQ'_<F_.K:1
M-SU1=1TTM@"//^Z*TT960%?ND<5X];>'/$23J627;]:]9TZ-XK"%),[PN#FI
M:L-,M4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &)
MXJ_Y 4U<K\._OW?^_75>*O\ D!35ROP[^_=_[]4MA=3T6BBBI&%%%% !3719
M%*L 0:=10!Q'B7PN) UQ;+\WI7GT\#12%6&"#BO=V4.I##(-<;XE\,"=6N+=
M?G ^Z!7!BL)&HKHQA.MA*GML._5=SS3D5+'*R'()S3[BV>"1D<8(.#5?I7C-
M3H.SV/<7U3.J>GNU4=!I^JJ,).>*Z&*W2\3=!@CWK@%:K]IJ4]K(&5VP.V:U
M5&A65['BSQ6-RVI[.OJCJ9;3RSAD'Y5 UE!)Q(,?05>TSQ+;7*B.[1$[9K8.
ME6UZGFVTA;OQ4_4:U/6C*YZ%/&83%JU2)R;:#;R?ZDDM[U2F\-WB9(4;?K74
MSZ9=0,2J''K4"S20MA^?8TEC)TW:M$QJY+AZNM)V.*FM)H#AE/%1[Y5'5A^-
M>AI>6\WRRV\8]\4R70]+O@=LVUCV KLIU:57X)'DU\FKT]M3AH-0N(#D2-_W
MT:U;;Q;?0$;2"/>M&Z\%R*";?<X[5B7'AZ_MR=\! %;VJ1.!PKTGU.FM?'#X
M'GE1]!6S:^,=/FX:0Y^E>72P21'# BFJS)T)%4L1-;EQQM6.Y[3!JMK<#*/U
MJX)$89##\Z\02^N(S\LKC\:T;7Q%=V^/WC-CU-;1Q2ZHZ89BOM(]@HKSFT\<
MW"8#QKCUK<M?&=M)CSG5*UC7@^IU0Q=*74ZJBLR#7M/G V3@DU>CGCE&4;-:
MJ2>QNIQELR6BBBF4%)@>@I:* $VKZ#\J38G]U?RIU% 7&^7'_<7\J3R8O^>:
M?]\BGT4K(=V1&WA/_+)/^^1339P'_EDG_?(J>BCE0^9KJ5&TVV8<Q)_WR*A;
M1;1NL8_*M&BI=.+Z%*K-;,R6\/63=5_2JT_A+3YHRI!Y'I6_14^PI]BUB:RV
MDSQ/Q;X-ETR1IK="8>YKB64J<$=*^FKNSBO(6CE0,#ZBO(O%_@R2RE:XMD+1
MGD^U<6(PW+[T3Z'+LS51>SJ[G ]:FBMY)'"A"<GTKJO"_@ZXU.X#S(RQJ<YK
MU*Q\(6%D0=BOCU6GA,.I2YJFQ>8YDJ2]G3^(XWP/X3D6=+NX3"UZDJA$"CH!
MBFQQ1PIMC0*!V I]>I.?,_(^5<G)W>X54U&QCO[1XG&<C JW14)V=Q'B>O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QGQ"_
MY Q_WA4W@+_D%/\ 6H?B%_R!C_O"IO 7_(*?ZU7074ZVBBBI&%%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOENKQVAR(R> :U_$FE7FE[5E!"MTP:Y6O9P%%.'M)K4ZJ*<H\TUJ%%%%>D=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** .,^(7_(&/^\*F\!?\@I_
MK4/Q"_Y Q_WA4W@+_D%/]:KH+J=;1114C"BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO_)3)_\ >7^9I;L-D>F:UK\&B:2+N?YCM'R@\YQ7$Z7=^*_$WG7-A??9X5;
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,<B-D[1FK](84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%,FE6&,NYP *
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M=?MC2%,\@@U+38)H]8HJEI>H1ZC91SI_$,U=J2@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#$\5?\@*:N1^'\@CDN\]WKKO%7_("FKC_
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M[]W_ +]=5XJ_Y 4U<K\._OW?^_5+874]%HHHJ1A1110 4444 %%%% !1110
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M*O\ ]EV-Q(MP84<]0V*\NMO#6I).I);\J]7T^-HK"%&^\%P:EZ#195510JC
M'04M%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B>*O
M^0%-7*_#O[]W_OUU7BK_ ) 4U<K\._OW?^_5+874]%HHHJ1A1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 (0",$9%<OXB\-QWD32Q *XYX'6NIH(R,&IE%25F9U*<:D>61XRK76DW?\
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MKT/CV5/O6^?QK?F\&63_ '(U6J,O@4-]QE%+V.-AL[C^L9?4WC82'QZK?>@
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M=/NQ**FHJ[(T48K9"!%7H,4M%%,H**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1[2/</;4^YMT5C?\)/IG_/4_E1_PD^F?\]3^5/GCW'[:GW-FBL;_ (2?3/\
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MBQHHX4?E3L#T%+15%A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOVB8$2,Q.#UHV0'7UG:S<2VVGRR1+N8+D"M&F21I*A5URIZBI&>6GQ3K /\
MQ['\Z3_A*M8_Y]C^=>D?V18_\^ZT?V18?\^ZU5T*QY9J7B/5+FR:.6W*H>IS
M6U\-R2MR3U+5T/B;3+.+1962!01WK ^'0P]V!_?I] ZGHM%%%0,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2?G7J?\ 8NG_ //LE']BZ?\ \^R4?5Y=P^HU/YCRS^T-17_EM)^=+_:FH?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7 >&_$YC*V]PW'1:[R.194#*00:ZZ=135T>C1K1JQNA]%%%6;!1110 4444
M%%%% %*]TJTU!=MS'O%4?^$2T?\ Y]JVZ* ,3_A$]'_Y]J/^$3T?_GVK;HHN
M!B?\(EH__/M5NRT6QT]]UM%L-:%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% &3<^'--NY3)-!N8G.:B_P"$3T?_ )]JVZ*+@8G_  B>C_\ /M1_PB>C
M_P#/M6W11<#$_P"$2T?_ )]JU+6SALXA'"NU0, 5/10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &)XJ_Y
M4U<K\._OW?\ OUU7BK_D!35ROP[^_=_[]4MA=3T6BBBI&%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !52^L(;Z QRJ#QQ5NBAJXFDU9GE.O:!+IT
MY9%RG7@5:\.^))+.58)V)4G'TKT.\LXKV!HI5R#7FOB#P]+I\K21K\AYXKBJ
M4W3?-$\JM0E0E[2GL>FVUS'=1+)&P(([&IJ\O\/>));&40S,=A.*])M;N*[A
M66-@0?>NBE54T=U#$1JQ\R>BBBM3H"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5^'?W[O_ 'ZI;"ZGHM%%%2,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MG^M0_$+_ ) Q_P!X5-X"_P"04_UJN@NIUM%%%2,**** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3
M)(EE0JX!!]J?10!P'B3PP4+7%LO'5JY_2M6N-*N1R0N<$&O7)(UE0JP!!]:X
MCQ+X8R6N+92<\D#M7)5HN+YX'F8C#.#]I2.HTK5H=1MU=&Y-:5>/:=J=QI-V
M.3@'!!->FZ/K$.I0*5<%NF!6E*LIJSW.C#8I5%9[FI1116YUA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,'Q!>64+L?FO1+*?[1:12_WES2=^HU8L4445(PHHHH **** "BBD)"C).!0
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M4 %%%% !1110 4444 %%%% !1110!QGQ"_Y Q_WA4W@+_D%/]:A^(7_(&/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MBMU% 'A,WAG5YI6D:U?+')IG_"*:K_SZ/7N_E)_=H\I/[M5S"L>$?\(IJO\
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M4 %%%% !1110 4444 %%%% !1110!QGQ"_Y Q_WA4W@+_D%/]:A^(7_(&/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLR2BC(/0T4R@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>M+FR:>P4444#"BBL?7M:CTBT\TD%L]#0!L45EZ+J\>K6QE0CCTK4H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***.E !16=?ZI
M%:02,I#,@R15+1?$*:E:B:0",$XHL!O44BL&&5.12T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 <9\0O^0,?]X5-X"_Y
M!3_6H?B%_P @8_[PJ;P%_P @I_K5=!=3K:***D84444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0@,,&EHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\\U_*D^RP?\ /)/RJ?JJ[B_L]=SR'[#?CC,G_?1IOV>^7C=)^9KU_P"QV_\
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M)MU)-0WFFPM8310QA2R$<5HT4 >8Z3?7'AC4'@FMV:(#ACTK3UGQ:;NT,%K
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH XSXA?\@8_[PJ;P%_R"G^M0_$+_D#'
M_>%3> O^04_UJN@NIUM%%%2,**** "BBB@ HHHH **** "BBB@# \0Z NLCD
M=L5S/_"ND_N_K7HM%.[%8\Z_X5TG]W]:/^%=)_=_6O1:*.9A8\^A^'R12!L=
M/>NZM(/L]K'%_=7%3T4-W'8****0!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% &)XJ_P"0%-7*_#O[]W_OUU7BK_D!35ROP[^_=_[]4MA=
M3T6BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !3=B?W%_*G44 -\M/[B_E1Y:?W%_*G44 -\M/[B
M_E1Y:?W%_*G44 &,=**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** .,^(7_ "!C_O"IO 7_ ""G^M0_$+_D#'_>%3>
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M>3\Z?_P@VG?\\4H_X0;3O^>*4:!J,_X3JR_O)^='_"=67]Y/SI__  @VG?\
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M^$ZLO[R?G3_^$&T[_GBE'_"#:=_SQ2C0-1G_  G5E_>3\Z/^$ZLO[R?G3_\
MA!M._P">*4?\(-IW_/%*- U&?\)U9?WD_.C_ (3JR_O)^=/_ .$&T[_GBE'_
M  @VG?\ /%*- U&?\)U9?WD_.C_A.K+^\GYT_P#X0;3O^>*4?\(-IW_/%*-
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MO^>*4:!J,_X3JR_O)^='_"=67]Y/SI__  @VG?\ /%*/^$&T[_GBE&@:C/\
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M'_"=67]Y/SI__"#:=_SQ2C_A!M._YXI1H&HS_A.K+^\GYT?\)U9?WD_.G_\
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M7:***D84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5+5?\
MD'R?2KM4M5_Y!\GTH \O\/?\C1+_ -=:]=KR+P^I'BB7@_ZVO7:J0D%%%%2,
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*X_X]Y/]VI:B
MN/\ CWD_W: /);G_ )&X_4?SKUNW_P"/:+_<'\J\DN%/_"7$X/4?SKUNW_X]
MHO\ <'\JJ0D24445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'T-9?P^_U _&M3QL"=-&/0UF?#X$0#(]:KH+J=Y1114C"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *9+&)8RC=#3Z*
M ,BWT"VM[IIU W$YZ5KT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %(PW*0>]+10!D-X?MFO/M) W?2M91M4*.PQ2T4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &3<:#;7%T
ML[ ;A[5IQ1B*-47H*?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 9E_HMO?R!Y ,@YZ5<M;9+6$1IT%3T4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#4=+AU%"LH'(]
M*DL;"*PCV1@8JW10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 5;VQCOHMDG2HM.TJ'3EVQ8_*K]% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3'ECC&7=5
M'N:<QPI/H*\]UO4[O5M633[-OE;AJ:0'=B^M6; N(R?0,*G!##(.17G5UX6O
MK"U^U1.WF(-QRQK=\):S)?0_9YS^^09:BPKG4T444AA1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %-9U09=@H]S3JX/Q7K-TUXMC;, 2^TY
MII7 [3[=:9Q]HBS_ +PJ975QE6!'M7G_ /PB%V+;S][>:!N^_P 58\):S=&\
M^P7)!;<0,>@-%A7.ZHHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.=IP<4D-GH-FQ:U0GN*GJ&U0I;HI["IJ0PHHHH **** "BBB@ HHHH ****
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M?[9:,$E#;B1WKLJ*$P/-_MVO>7Y&9<]-V*U_#7AN:"X%[>.'ESD$]:[#:O\
M='Y4M.XK!T%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% #)AN@D [J1^E<5H>D3VWB#SW!V[CV]Z[BDP/04[@,GB6>)HW&5/6N#O]$U
M'2;Z2YL92$<Y*J*] I" >HH3 \VE&N:P5@9I(TSSN':NST#1TTFR$6 6)R2*
MUMJCHH_*EHN*P4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/4S*
M+)_)SO[8JY10!Y%_9.IQZD]R%?=NR#BM3[7XA P'E_*O2-J_W1^5&U?[H_*G
M<5CG_#LM_+'_ *:6)Q_$*WO*3TIP '04M(9R7B_2I+Z/$2D_+V%;FBVQMM,@
MC8894P:T, ]12T[@%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"
M P(/0TM% '"^(?#=RM^VH6+['8Y( YJBUWKUS']G!E4]-Q%>D8!ZBDVK_='Y
M4[BL<OX;\/-IJ&><AYF.[-<GKFE:E>:NTV'94?*\5ZK2;5]!^5%PL>:Q3Z]!
M&(XVE"CH,5M>'[G5I+W%VTA3'<5V&U?[H_*C '0#\J+A8!TI:**0PHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH 88D)Y%9>O67VG2IXXU^9EP*UZ*
M .7\(Z;)8VX$BD''<5/XFT(:K:_N\+*IW9KH< =!13N!YI'/KUE&;8-*W8,!
MVK5\.>';@71OKU]\F[<,CD5VNU?[H_*EQCI1<5@HHHI#"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVOD7#K&5X^8U!XS\307$*V]LP?=P=II:W'T,_P"'5](+^2$D[0G JOX_&=>
M]0*U/A[I$D<S74BD*R<9%9?CW_D8!]!3ZBZ'9>"]-MDTLLT2LQP<D5QWQ"MH
MK:\A,2A=Q.<5WWA#_D%#Z"N'^)/_ !]V_P!3_6DMP>QU_@8DZ'!D_P -=57*
M>!?^0)!_NUU=)[C04444AA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%!..M !131(I. 13J "BBB@ HHHH **** "BBB@ HHHH **:74=30'4G /-
M#J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3(]: %HH
MHH **** "BBB@ HHHH **** "BBF>8N,YH ?12!@W0TM !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%-WKZB@!U%)O4]Z6@ HHHH **** "B
MBB@ HHHH ***0L%ZF@!:*9YB\<]:?UH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC@8S1:QO2K0JJ\&1W=U'9V[32L%4=S7FS>*I[[Q-##$Y$8?'!ZU<U_5)];U
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MW@[9_P )!<>;CS-G.?QKLM,TF*QTY;8#^'!KCM6T6_TK5Y-0T]<AS@Y]*+W
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MOK7245,HJ2LR*E.-1<LC@/\ A!;C^\GYT?\ ""W']Y*[^BL_J]/L<_U*CV.
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MH_\ 6G^!BGVRXW_?\YL9^IJ[X0TZ:VCD69< [JH7VEWVD:I]KTT*RY)()[T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5$UO"YRT:D^XJ6B@
M"#[);_\ /%/RJ18D3[J@?04^B@ IKHCC#J"/>G44 0"TMU.1"@/TJ8  8%+1
M0 QXDD&'0-]14:V=NIRL* ^PJ>B@!  !@4UX8Y/OH&^HI]% $*VENARL* ^P
MJ;I110 4UD5QAE!'O3J* (?LEO\ \\4_*D^R6_\ SQ3\JGHH 1555PH 'H*C
M>V@D.7B5OJ*EHH C2"*+[D:K]!4E%% #'BCD^^@;ZBG*JH,* !Z"EHH .M0M
M:6[G+0H3[BIJ* &)#'']Q OT%*R(XPR@_6G44 (JA1A0 *6BB@ HHHH ****
M "BBB@ HHHH **** "BBB@"-X(I#EXU8^XIOV2W_ .>*?E4U% $(M8 <B) ?
MI4V,=*** "F"&,-N"#/KBGT4 (0&&",BD2-$^XH'TIU% #6C1_O*#]:S=<LY
M;G2Y(K<LKD<;:U** /-;;5-6TQGBGLA( <!GYILL>J>(KN$/:>5"C9RM>BR6
M5O*<O$K'WIT5O%"/W:!?I57%8@LK&.VM$A*@@>HJX!@8%%%2,8T2.060$CU%
M.P,8QQ2T4 0R6\95R$ 8C&<5P6H+J^DZL9HXFGAQT8\5Z'4<D,<PQ(@8>]-,
M#SN[UG5-0MVMH-/12_4KUKI/"FC/IL#RR@B2498&MQ+&VC;<D*@^HJQTHN*P
M4444AA1110 4444 %%%% !1110 4444 %-9%<88 CWIU% $ L[8'(A3/TJ8
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MP4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%1O/&APS 4S[7!_P ]!0!/14:3
MQO\ =8&I* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **0D*"3T%8T_B6P@O?LSSH']*3DEN7"G*?P
MJYM44V.19$#*<@C-.ID!1110 45&\\<9PS &F?:X/^>@H GHIB2I)]ULTXG
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MYA8X#@T 2T4 Y&110 4444 %%%,>1(QES@4 /HJ!;R!SA9 34X.1D4 %%%%
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M@^P6 ,!/FR+E:+!<Z$W,*MM,B@^F:=YL?]\<UYW::9XAU"'[9]H0!AN4'_\
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M3JQ=$L]0MI)#>2*P/W<5M5(REJDC1V3LIP0*\TTM=6UF]N!'>E LA%>DZO\
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M<]J>K:CJFMS6-K.L:H?X^*+!<]"2XAD.$D4GV-2$@#)KS6ZM]?T<I.MPCH2
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MN P*J-V1BN3GU/4]>U"6"QN$CCC;!W^E%@N=^MS"YPLBD^QJ6O.9[#7-*47
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M-4)*C&:?3; *8\:2##J"*?12 A2U@C.4C -3444 ,$2*Q8* Q[TX@$8-+10
MQ(D3[J@9H>))!AU!%/HH @2T@C.5C -3T44 ,DB248=013$M((SE(P#4U% !
M1110 4444 %%%% !2%0PP1FEHH B^S0YSY8S4@  P!2T4 %%%% ",H88(R*@
M-C;$Y,2YJQ10 U(UC&%&!2LH88(R*6B@"'[)!_SS%*MM"IR(P*EHH  ,# I"
MH88(S2T4 -2-(QA5 IU%% !3'C20890:?10!7%E;*<B)0:G "C %+10 C*KC
M##(-1QVT,392, FI:* (I+:&4Y= WUIR0QQKA% %/HH 8L2*254#/6CR8\D[
M1D]:?10!"+2 /N$8W>M3=L444 ,\J/=NVC/K3^HQ110! UG;NVYHE)]:E2-8
MQA1@4ZB@ HHHH B:VA8Y9 2:3[) /^68J:B@!%15&%&*4C(P:** &+$BDE5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gzkk5j0cumnd000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gzkk5j0cumnd000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 36"$D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,XZT5R_C
MF\GLM#:2!BK[@ 10@.GW+ZC\Z-R^H_.O%8KKQ%-&'C2=E/0@&G>;XE_YY7'Y
M&JY17/:-R^H_.C<OJ/SKQ?S?$O\ SRN/R-'F^)?^>5Q^1HY0N>T;E]1^=&Y?
M4?G7B_F^)?\ GE<?D:/-\2_\\KC\C1RA<]HW+ZC\Z-R^H_.O%_-\2_\ /*X_
M(T>;XE_YY7'Y&CE"Y[1N7U'YT;E]1^=>+^;XE_YY7'Y&CS?$O_/*X_(T<H7/
M:-R^H_.C<OJ/SKQ?S?$O_/*X_(T>;XE_YY7'Y&CE"Y[1N7U'YT;E]1^=>+^;
MXE_YY7'Y&CS?$O\ SRN/R-'*%SVC<OJ/SHW+ZC\Z\7\WQ+_SRN/R-'F^)?\
MGE<?D:.4+GM&Y?4?G1N7U'YUXOYOB7_GE<?D:/-\2_\ /*X_(T<H7/:-R^H_
M.C<OJ/SKQ?S?$O\ SRN/R-'F^)?^>5Q^1HY0N>T;E]1^=&Y?4?G7B_F^)?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(8@6)]:U:9'&L4:QH,*HP!3Z@L**** "BBB@ HHK"UOQ!'I=Q! /F>4XP.U
M&[14<+^9 DG]Y0:YCQ#XQBTF?[+%&TLV<$*>E%@.KHKE_#GBZ'69# \;13#G
M#&MS4M1ATRS>YF/RJ.F:+ 7**\_B^(H-V-]K(("VT,2,5W-I=1WEK'/$<HXR
M*;5@N3T444@"N0^(7_(!_P"VB_SKKZY#XA?\@'_MHO\ .FMP9K^&/^0%!6Q6
M/X8_Y 4%;%)@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]T@XI .HIC2HAPS $^M.W+QSUZ4 +1110 4444 %%%% !1110 4444 %%%%
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MD2D#WR:[$NJG!8 T .HI"P5<DX%-66-QE6! H ?12 @C(.:6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"RKU8#ZFHKJ=;:VDF;HBD
MUY^ESK7B>[DDM)A#;*?ERO44T@/100>AS2UQFC:K?Z=J?]FZFX?(RK@8%=G2
M **0L!U.*:98U;:6 )[4 /HIK2*@RS #WI597&5.10 M%-9U098@#WH$B%=P
M88]: '4FY?[P_.FRR"*)I">%&:X/^TKR6SU&Z$GRQS[5^E-(#O@01D'-+6)X
M5N)+K0H996RQ)R:V0ZL< @FD ZBF/*D?WV SZTN]>.1S0 ZBBB@ HHHH ***
M* .8\=_\BY+]14_@S_D78O\ >-0>._\ D7)?J*G\&?\ (NQ?[QI]!=3H****
M0PHHHH **** //M=US6-2UN32M'1=T+%'8MMYK/F;Q7X?"W%]MEMB?GW29XJ
MUK&FZSH?B*XU33('N5N'+LL8Y'YU3NM0\2>)HUM#IL\$+-M=W P/6K1#.F?P
MYIWB72[>_C7[-)*FX/$O-89_X23PF^]@;NRSC<[Y8#Z"NZT6Q.F:-:V1.3"F
MW-7719%VNH8'L12N.Q7TZ[^W:=!=;2OFKNP1C%6J155%"J,*.@I:DH**** "
MBBB@"AJ^H#3;!YR"2!@#'>O*;B6_O]9MM0NE*QROE%)Z5Z_<VL5W'Y<R[ESG
M%<5XRB2"\TN.-0JAC@"J0F=>K^7I(D_NQ9_2N*\,6$6L:U>WUT@?# J#S77W
M)QX?<_\ 3 _RKG_  _T&1^[ 9I= ,[7[&/1O$=M=6JB-9&5"!P*M>.)FNI+.
MQ0_+.#G\ZE\>* MB_?[0M4M6/F>(](#=,&F!M7OANQ/ATHL*AUBW!@.<XJ'P
M)<N^G26SG/V<A1727 !TYU[>7_2N1\#G&H:H@Z"4?RI= .WHHKA];\=#2M0D
MMO)9MAQD$4)7&=Q7(?$+_D _]M%_G6'_ ,+.'_/L_P"8K*U[QG_;EFMKY3+E
MU.2?>FDQ7/2/#'_("@K8K'\,_P#("@K8J6,**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "FR2+%&7<@*.I-.K!\7I=R>'[@69/F;>
M !4R=E<NE#GFHMVN>6>._$C:MJ+01-^XCXQ[BN-J2<.)W$F=X8Y^M1UXDY.<
MKL^[H4HT::A'9&KH.K2Z1J4<Z,0NX;OI7T!I.I1:II\5S$0=ZY(]*^:AUKV#
MX8Q7R6,K3$^22"F1VKJP=1J7+T/)SG#PE3]KLT>AT445Z9\N%%%% !1110 4
M444 %%%% !1110 50UO_ ) E[_UQ;^57ZH:W_P @2]_ZXM_*@#QWP%_R-]I^
M->XUX=X"_P"1OM/QKW&JEN)#)?\ 4O\ [IK@_!G_ ",-_P#[O]37>2_ZE_\
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M_P#/K%^9KJ-9^'MEJ^IR7LF-[]:S_P#A56G^H_,U6AY\XXKF?*]#'_X6]/\
M\^L7YFC_ (6]/_SZQ?F:V/\ A56G^H_,T?\ "JM/]1^9HT)Y<7W,?_A;T_\
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MUL>.)XH] 8.1DNN!2&7?"TTEQH,$DK%G.<DULUA>$/\ D7+?\:W:3&%%%%(
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M9_W*8'(Z:NK>)[3>;AX8T^4%&ZD<5:\+W]Y9ZQ<:9=2M($8[68YX K0^'_\
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MTTQ%[X>Q&/1FZX\UP,_6NQJEI>G1:99+;Q#"CD_6KM)C"BBBD 4444 %%%%
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M;5X8TBQE?>NAHIW Y?7K*SN+"WM+F0QSJJA&'KCUK GT#4Q9M'=WQ^S*.OF
MYKJ_$6A#6(%V/LE0Y5JYS_A&-<N0MM<7^8!U&VFA%?PSIT]WX:D@A_BD=22>
MV:[G2[+[#I,-K_$B;31I.FQ:78K;1 8')^M7J38(YC2=!GLO$-U>N1LE0*.?
M>HM2\.SC7(M1L2%(!WC.,Y-=911<=CB]?TZWU"^40SF+4(\'J!G\:P=:T:^B
MT[S]1NRP5@H0/G-=3X@\,RWUV+VSF\JX!SG&:S(_"NJ7\Z?VE>>9$A!V[<=*
M:8CH?"B&/P_;J1ZUMU%;P);P+$@PJBI:D84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 R6,2Q/&W1A@UPMQX9U33[Z632Y<12'[I;&*[VB
MFF!RWA_PU):7+7MZYDN&&.3G%=3112 Y[Q-HTVK&U\K'[N4,>:T;FS>72#;#
M[VW%:%%%P,/POI4ND:8;>7&XR,W!]35.VT&:'Q-)J+$>423UKJ*0C((]:=P.
M#U+2DO=6DN-)N3'<@?.NX+Q6%KNDW-NT,M[<&2<NNU=V[C-=/JOA:\&HM>Z;
M<^2S\$8S3=/\)W<U^EWJEP)BG08Q3N*Q;70Y[G4[6Z?_ %405E&?:M?7;%]0
MTMK>/[Q(-:2@*H4= ,4M*XS$TO1?)\/#3KD Y!![UGZ-I%QH[74<YS9ON/7.
M!BNKJ.:)9H7C;HRD47 \_&B3M<23Z)=XB<\KO Q6<NF/:>*H(Y)C-*5#,<YQ
MS6S)X5U6PN)#IMYY<3?P[<UI:#X7>SO#>WLHFN",9Q3N(ZD=!2T45(PHHHH
M**** .8\=_\ (N2_45/X,_Y%V+_>-0>._P#D7)?J*G\&?\B[%_O&GT%U.@HH
MHI#"BBB@ HHHH ***1F"*68X ZF@!:*R)?$^CP2^5)?1J^<8-7EU"U:X\@3*
M9"H;;['I0%RS1110 4444 %%%% !6=J.CV^I2PR39S$<K6C10 U$$<:H.BC
MK&UGPS9:S\THVOZ@5MT4 8VC>'+/1AF%<L?XB.:T[JVBNX&AE4,C=014U% '
M*Q>!--CO//\ F(SG;VKIXHDAB6-  JC  I]%%P"BBB@ KD/B%_R ?^VB_P Z
MZ^N0^(7_ " ?^VB_SIK<&:_AC_D!05L5C^&/^0%!6Q28!1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB_SIK<&:_AC_ ) 4%;%8_AC_ ) 4%;%)@%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% %:_N5M;&:9CC:A(_*O ;N23Q!XD8C),K\5
MZA\1]7^Q:1Y"-B1R,CV-<=\-=)^V:M]K9?EA8&O2PJ]G2E59YF+?M:L:2/6=
M'LDL=,@A08P@S]<5?H P,"BO.;N[GI)65D%%%%(84444 %%%% !1110 4444
M %%%% !1110 50UO_D"7O_7%OY5?JAK?_($O?^N+?RH \=\!?\C?:?C7N->'
M> O^1OM/QKW&JEN)!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH(E@A6-!A5'%>ABY*$(TD>=@HNI.55DE%%%><>F%%%% !1110 4444 %%%%
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M_P#KO_2G<+&?':/X?\6V]O!*YAE<+AFS5G6WGU[Q)'ID<C)"%);:<=*DU_\
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MQKW&O#O 7_(WVGXU[C52W$@HHHJ1A1110 4444 %%%% !1110 4444 %%%%
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MHP!3JD84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <QX[_P"1<E^HJ?P9_P B[%_O&H/'?_(N2_45/X,_Y%V+
M_>-/H+J=!1112&%%%% !1110!QL?AR*W\8R:P]Z!ERQC+GC\*J^)O"L.O:L;
MQ=0$8*!=HD(Z53USPEKU[K5U<VU[*D,CY50PP!6?_P (1XE_Z"$__?0JUZD?
M(?\ \*[B_P"@I_Y%-'_"NXO^@I_Y%-1GP5XD'749A_P,4O\ PA'B7_H(3?\
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M_"J;/_H(S?\ ?(H]T-2;_A:>F?\ /G/^8H_X6GIG_/G/^8J'_A5-G_T$9O\
MOD4?\*IL_P#H(S?]\BCW0U)O^%IZ9_SYS_F*/^%IZ9_SYS_F*A_X539_]!&;
M_OD4?\*IL_\ H(S?]\BCW0U)O^%IZ9_SYS_F*/\ A:>F?\^<_P"8J'_A5-G_
M -!&;_OD4?\ "J;/_H(S?]\BCW0U)O\ A:>F?\^<_P"8H_X6GIG_ #YS_F*A
M_P"%4V?_ $$9O^^11_PJFS_Z",W_ 'R*/=#4F_X6GIG_ #YS_F*/^%IZ9_SY
MS_F*A_X539_]!&;_ +Y%'_"J;/\ Z",W_?(H]T-2;_A:>F?\^<_YBC_A:>F?
M\^<_YBH?^%4V?_01F_[Y%'_"J;/_ *",W_?(H]T-2;_A:>F?\^<_YBC_ (6G
MIG_/G/\ F*A_X539_P#01F_[Y%'_  JFS_Z",W_?(H]T-2;_ (6GIG_/G/\
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M^%4V?_01F_[Y%'_"J;/_ *",W_?(H]T-2;_A:>F?\^<_YBC_ (6GIG_/G/\
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MYS_F*/\ A:>F?\^<_P"8J'_A5-G_ -!&;_OD4?\ "J;/_H(S?]\BCW0U)O\
MA:>F?\^<_P"8H_X6GIG_ #YS_F*A_P"%4V?_ $$9O^^11_PJFS_Z",W_ 'R*
M/=#4F_X6GIG_ #YS_F*/^%IZ9_SYS_F*A_X539_]!&;_ +Y%'_"J;/\ Z",W
M_?(H]T-2;_A:>F?\^<_YBC_A:>F?\^<_YBH?^%4V?_01F_[Y%'_"J;/_ *",
MW_?(H]T-2;_A:>F?\^<_YBC_ (6GIG_/G/\ F*A_X539_P#01F_[Y%'_  JF
MS_Z",W_?(H]T-2;_ (6GIG_/G/\ F*/^%IZ9_P ^<_YBH?\ A5-G_P!!&;_O
MD4?\*IL_^@C-_P!\BCW0U)O^%IZ9_P ^<_YBC_A:>F?\^<_YBH?^%4V?_01F
M_P"^11_PJFS_ .@C-_WR*/=#4F_X6GIG_/G/^8H_X6GIG_/G/^8J'_A5-G_T
M$9O^^11_PJFS_P"@C-_WR*/=#4F_X6GIG_/G/^8H_P"%IZ9_SYS_ )BH?^%4
MV?\ T$9O^^11_P *IL_^@C-_WR*/=#4F_P"%IZ9_SYS_ )BC_A:>F?\ /G/^
M8J'_ (539_\ 01F_[Y%'_"J;/_H(S?\ ?(H]T-2;_A:>F?\ /G/^8H_X6GIG
M_/G/^8J'_A5-G_T$9O\ OD4?\*IL_P#H(S?]\BCW0U)O^%IZ9_SYS_F*/^%I
MZ9_SYS_F*A_X539_]!&;_OD4?\*IL_\ H(S?]\BCW0U)O^%IZ9_SYS_F*/\
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M **** "BBB@ HHHH ***0L!U('U- "T4WS$_OK^=*"#T(/TH 6BBB@ HHHH
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MB@ HHHH **** "BBD!!Z$&@!:*** "BBB@ HHHH **;YB?WU_.E#*>C _0T
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M(C\P46"YZ732ZJ<%@*YW2=1O4T&26]3$L0QZYXKEK&+4O$*R72Z@T1W$*@D
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MG'GP8#$'.372TAA1110!S'CO_D7)?J*G\&?\B[%_O&H/'?\ R+DOU%3^#/\
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MP<.F2ZAXHN85N!$Y+$9]*U+WP=*EJYN]118<?,6!K3U_PQ//>B_TYRDX'0'
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M_P"^36I!)X>U-]+U6*=2<9P?QKWFRN4N[2.:,@JPZUX$-%O@<B"3C_9->H>
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MRDGO+\*FPDJ5([5K:YX;GOK*U>!MMQ;G<O..<5G)HOB#4(C;W<H2(#&4?DT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU'^RTM-)C8SD8=E/2O3-<4MH]R!_SS;^5<Y\/K&*+2!-L!=QDDBJ6PBEX?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  ?]]47\A67<GTO[3_9=O]L&+G9^\&<\U;ID4J31+)&P9&&0P[T^I*"BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*@J#V"BBBM3C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"L+Q1KD>BZ5))N'FE3L'O6S/,EO \KG"J":\*\:^(6UC4V5&/D(?E&:PQ%7V
M<?,]#+L(\15UV6YZ;X-\4+KENRRL!,#P,]JZROG3P[K,NCZG'.C$ D!A[5[_
M *9J$6I6,=S"05<>M3AJW/&SW-<TP7U>IS1^%ERBBBND\H**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YCQW_R+DOU%3^#
M/^1=B_WC4'CO_D7)?J*G\&?\B[%_O&GT%U.@HHHI#"BBB@ HHHH *R]5M](1
M6N]0@A8@<LXYK4KS#QN]QJWBN'1!(4A&US^--*[$W9%Y_%?@='9#:DE3@X@S
M6CI6H^$=9?9:VT6[T=-M3VG@'1+>V6-[?<X'S-GK7)^,/"T'AYX-5TPF+8^2
MN3VJM&3JCU**-(8ECB4*BC"@=!3ZSM!NWOM"L[I^6EC#&M&H+"BBB@ HHHH
M**** "BBB@ HI-PW;<\^E+0 45&)XB^P.-WI4E !1110 5R'Q"_Y /\ VT7^
M==?7(?$+_D _]M%_G36X,U_#'_("@K8K'\,?\@*"MBDP"BBB@ HHHH ****
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MTYT)*IL>_ AE!'0TM1P1^5!''G.U0,U)7M'PSW"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .8\=_\BY+]14_@S_D78O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG==@L^Y:TF[DOM)MKJ5"DDJ!F4C&#5VF0RQS0K)$04894BGU!84444 %%%%
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M?\^RUR_CC2;*ST;S((0CB1>1]:I-"L=+X9_Y 4%:]8_AC_D!05L5#*"BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!S'CO_D7)?J*G\&?\B[%_O&H/'?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** .8\=_P#(N2_45/X,_P"1=B_WC4'CO_D7)?J*G\&?\B[%_O&GT%U.@HHH
MI#"BBB@ HHHH *KW=];649>XF2,#^\<9JQ7E7CA9]7\9Q:/YA6#:C'\::5Q-
MV.T/C+2 <?:$_P"^A1_PF>D?\_"_]]"L!?A7IH4 R D=]M+_ ,*LTS^^/^^:
M?NB]X[JVG2ZMXYXCE'&0:EJMI]FFGZ?!:1_=B7:*LU)04444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!S'CO_ )%R7ZBI_!G_ "+L7^\:@\=_\BY+
M]14_@S_D78O]XT^@NIT%%%%(84444 %%%% !7EGCV]CT_P 3Q7,",;I I8]B
M*]3K'U>PT5BUYJ5O$S 8+MUP*:=F)JZ.4@^*U@($$]E<F7'S%1QFI/\ A:^E
M_P#/C=?E5.XU_P %Q7 BBLH'R<9VFMHIX234DL)+.!9W16"[?7I5678F[[G4
M:?>IJ.GP7D:LJ3+N ;J*LU'!#'!"D4*A8U&%4= *DJ"PHHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#F/'?_ "+DOU%3^#/^1=B_WC4'CO\ Y%R7
MZBI_!G_(NQ?[QI]!=3H****0PHHHH **** "O,?&LL^J^+(=$$A2$!6;!QG-
M>G5YGXZL;VP\10Z];QEHUVA@.X%5'<F6QF>-/#5CH5K9K;*=^1N).<\UH^.=
M'2&RL=:A9EN%1-QSU 45B>+?%]KKUK;84I*F-RA3QS5[7?$ \4Q6.DZ6C.JA
M0[$$=L&JU)T/1_#EPUUX=L9W.6>($UJ50T:T:PT:UM'&&BC"FK]9LT04444
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MS8# <^I->:ZUK,^L7A.3LS\JU+K^NSZO=D!CY0. H[UL>$_#!N9%N[E?W8Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'ZT])%?[IH =13'D5/O'K3?M$?K0!+12*P89'2FM,B]30 ^BHQ.AZ&GYXS0
MM%1&>,=Z<LR.< T /HI&8(,D\5']HC]: ):*:CJ_W32-(J=30 ^BHA/&>]2
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M;F%WGW+TQBKM!.!DT7&<-XVOI--T210VUY%^6N#\":4VJZ[YDBY5?GS[U?\
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M K?M/"^DV@P+2)CZE:EXZG'X45' 59?$SP>W\/ZK=$>592L#W K>L_AYJMR
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MC-6"7T-7XU(B"GKBGT47%8SWADZ 'K2Q0R!QD&K]%%PL1S*7A91U(JA]GE
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M*1_Q[?K4!\ :'G/V?]:ZJBCVU3N+V-/^4Y7_ (5_H?\ S[_K1_PK_0_^??\
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M'^9><\&L[XFRVBZ<JN1Y^/DKEGBW2FW)W1Z>!POM'%0C:3/(Z4#)QZTV/+G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** .8\=_\BY+]14_@S_D78O\
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M_0<EQ7/15*;O*/Y&?78>!/#\FJZFLS ^3&?F-<UIMC)J%[';QJ268#CM7O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
MYCQW_P BY+]14_@S_D78O]XU!X[_ .1<E^HJ?P9_R+L7^\:?074Z"BBBD,**
M** "BBB@#S'1"!\3=4R0/W_]!7<^(W7_ (1S4/F'^I;O7$ZU\.]1O]>N]0MK
ML1"9]PVN0:I-\-=<=2K:F[*>"#,V#^M7HR-4;OPQ91H398#IWJ?XD,I\/<,#
MR>_M7,Q?#'6(%VQ:@8U]%E(_K1)\,=9F7;+J)=?1I2?ZT:7O<-;6L>@>$O\
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M[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_$^DQ_>N@*^>C=73_P#+>4Y_VS2>9='^*4_B:I9?'JR'F,ND3WV3QIHL>?\
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MQ16OXBTE])U*2(J0F?E-,T+29=6U&."-2>03QVKP7!J7+U/NU6@Z?M+Z'3^
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M+^;'/#4[_A:T_P#T"_T:K!^(^B[V":&[@'[RHN#^E:6C>,M!UB<0_8H[>0G
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MI'_/[%_WU1R3[#]I#N7!8;3G>:MQIL0+61_PE&D?\_L7_?5'_"4:1_S^Q?\
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M=!SDKJ2NFCVG3?"UUI]FB"( D9)S6=JVIQZ2QCD(,GI5>+XH7)B9)8RS$8!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZAXU3!Z$"MYUJE'W7J%KF#X4\.)H5@H/,S?>-=%117#*3D[L84$ C!Z&BBI
MYG6/!6FZM(92/*<]2B]:-'\$Z;I,HE'[UQTWKTKIJ*T]K.W+<!  !@=*6BBL
MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\\/6K,<L$&:\ '6O<O 0(\/PY_NBL\8O<3)1U5%%%>84%%%% !1110 4444
M%%%!.!F@"IJ5]'IUA+=R_<C&36,?%UJNDB_(;89/+'R]ZQ?''BJS73;S3%<>
M>1MQFN1O?$%F^@6EE$PW+,KOS^==E+#.44VNIPUL4HR:3Z?B>QV%VM]917*
MA7&1D59K+\/W$-SHUN\!!0KQBM2N62M)H[(N\4PHHHJ2@HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH YCQW_R+DOU%3^#/^1=B_WC4'CO_D7)?J*G
M\&?\B[%_O&GT%U.@HHHI#"BBB@ HHHH *X+QCX1U77M5\ZVD00A1@%\8-=[7
M!^+-<U^PUHPZ=;220; <KTS3CN*5K:F&G@/Q4B!4U)U4= )J=_P@OBS_ *"<
MG_?^F?\ "5>+?^?*:JQ\<^)%NEMC!*)F. O<U>I&AZKI-O/::3;6]RY>:- '
M8G.35VJ>E27$NEVTEVA2X9,NIZ@U<K,T"BBB@ HHHH **** "L75O$^GZ0VV
M=R6]%YK3O)/)LYI!U5"1^5>>:%H<?B;4;J]U ;XR<A3WIH1VVDZ_9:NN;=^?
M0\&K\\\=M"TLK!57J2:\YN-/_P"$6\3P_9#MAE*K@>];/CJ\D^SPV,1.;@=J
M+!<O1^-=*DO/LP=MV<9(XKHHW61 Z$%3T(K@KOP/:0Z%]HB4"Z5-Y?\ "MCP
M3?/=:.L,AR\("G-#2Z =/1112&%<A\0O^0#_ -M%_G77UR'Q"_Y /_;1?YTU
MN#-?PQ_R H*V*Q_#'_("@K8I, HHHH ANK=;NV>!QE7&#7SSJMO)HGB=CRH$
MVX?3-?1E>1?%72/+G34$7"X"D^]7!ZV(FM+GH^A74.KZ3;7A568C()'(I=<U
MVUT*U$UPV 3@ =:XKX5ZQY]F]B[?ZH **H_%JRO&V7*L3;\#;[TFM;&=:HX4
MW**/2M*U&'5].BNHCE)%SBN&\=>#!<HU]9( X'S**R/A;XEV2?V7._7 C!->
MN,JR(5894BKIU)4I71G'EQ-+4^==&U>ZT#45D0LNT_,IKV"V;3O%^E+(F!-C
M!['-<OX\\%[=^HV,?7EU KC?#GB&YT#4%(8B/.'6O2J0CB8<\-S@A*6'G[.I
M\+.EU;0[G2IV#*2F?E(YJYH/B:?39!'*Q:+OGG%=Y:7%CXFTI9!M<,O(]*X?
MQ!X7GTYVFA4O$>X'2O.O]F1O.E*G^\I['HUAJ$&H0"2%P<CIGFGW-C;W<1CF
MB1P?45Y'I.LW.E7 :-SMSR*]-T;7K;581M8"3'*YJ'%QU1U4:\:BL]SS/QK\
M/;E)FO+! 8NI4'G\J\UD@GM9MDB.C ]QBOJP@,,$9!KG=5\%:1JLZS36Z[P<
MD^M"F[W9SU\"I/F@>-:+XJU'2&4I*SJ/X6/%>H^'OB)8ZF!%<MY<W?C KG?%
M/P[2TMGNK)@%49* 5Y3ODAE.TD$&NVM.C-*R.55*V&E9GU7%-'.@>-U8'T.:
MDKY]\/>.M2TMU0RL\0ZKFO5M"\=:=JH5))%BF/\ "3S7-*A*W-'5'H4<93J:
M/1G644BL'4,IR#TJJFIVDEX]HLRF=#AD[BL#K+=%%,EF2",R2,%0=2: 'T57
ML[ZWOX3+;2"1 Q7(]15B@ HHHH **** "BBB@ J![.VD;<\",WJ14]%%P&HB
MQKM10 .PIU%% !1110 4UT208=01[TZB@#,N] TZ\7#VT8SW"US6H_#>PN26
MA=U;L!Q7<44[LQJ8>E4^*)XYJ/PXU*V!>'8R#_:YKF;O1+^S;$D$G'HIKZ)J
M":T@N!B2,,/I3YC@J953?P.Q\Z)<7=H?E>2,_E6Q9>+]3L\8E9P/[QKU>_\
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M8V3;W)Q(%/0YKT73[DW=A#.RX+H"1^% %FBBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*[7_ (5GJ7^U^54K_P $3:8@:ZF,>>F1UJ;X;R.+ZK4BK\I2L/%^J6)&V9G
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M+Y!SXOS-5?BG=AAF-,?[M3?\+5G_ .>:?]\UAM\.M9"D_9W_ "J'_A7^L_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M% !6?K6GKJ>F2VS#[PK0HIIM.Z ^<]6TR?3;V2*5",,<<=JIQ1/-($126)X
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MQ[%_PL#2_1OSH_X6!I?HWYUX[_9]W_SR?\J/[/N_^>3_ )4<J#^TL1V/8O\
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MN)/F7[N3V%<ZQ$74Y#T99=46&]O^'D>GDX7-59=0AA4M(=H'<FL?7O%NGZ/
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M=U*'[T!_"L]X7AD*2 AAU!HY4=&&Q>)G44)(=,_F3.Y_B8FNH\&>(TT.X83
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$UUIK@,Q>/N&/2O1-*U^TU.,%' ?N#Q4.+1=+$1J>IK4445)N%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2^)NHW&Y(%14[''-<M>>(=1O3F2XD&?1C73# 3?Q.QQ3S"FOA5SVS4/&NC6
M(:[0N/X<UR>I?%- "MK!]&#5YD(KJ[.0DDI^A-:]CX1U2^QLA9<_W@172L)1
MAK)G-+&5ZFD$2ZQXRU'5E*/*P0]JYXL\AR22:](T[X63/AKQP%/]UN:Z[3O
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M%]N,]1FO9-!U6/6-*ANHR#N'->:_%+PUL8:G G X; [FHOA5K<Z73V#AFC;
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M110 4444 %%%% !1110!S'CO_D7)?J*G\&?\B[%_O&H/'?\ R+DOU%3^#/\
MD78O]XT^@NIT%%%%(84444 %%%% !7EWC>Y@TKQ;#J"OF8!=Z?[(KU&N>UKP
MKI&JW1O+_>&V@$[\# IIV8I*Z*4'Q'\// C2W>R0CYEV]*D_X6+X:_Y_O_':
MH?\ "&>$O^>W_D2D/@WPBHR9P /^FE/W1>\=I:745[:1W,#;HI%W*?45-5;3
MX;>WT^"&U;= BX0YSD59J2@HHHH **** "BBB@ HHK,U37K+25S/(-W]W/-
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M[2% >I KE/\ A6EE_P ]_P#QVNZHIW8'"_\ "M++_GO_ ..T?\*TLO\ GO\
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MY 4%;%)@%%%% !1110 4444 %%%% !1110 5FZ]8KJ&CW,!&2R$"M*@C(P:
M/G+39G\/^*1U!C?8?TKZ&M)UN+2*53D,H_E7B?Q&TDZ=KPN$4@2DN3^->A?#
MO5AJ&@1QNV94SGZ5I+57,XZ.QV-%%%9F@5!=VL=Y:R6\HRCC!!J>B@-SYO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G76@Z5?
M7'VBZL899O[[#FM&B@"*"WAMHQ'!&J(.@%2T44 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ',>._P#D7)?J
M*G\&?\B[%_O&H/'?_(N2_45/X,_Y%V+_ 'C3Z"ZG04444AA1110 4444 8MU
MXJTJSNI+>:<K)&<,,5YYXDUFQ7Q;!K$$F^,[4;/8"NJU7P!8:CJ,]],Y#2MN
M/S&J*?#/29UW(^]<XSN-6K(AW9NP^.-$EB5_M!&X9Z5)_P )IHO_ #\'\JYZ
M;X;:3;1&2678@ZDL<40_#;2;B/S(9=Z'N&-*T1WD=Y;W$=U;QSQ',;C*FI:K
M:?9II]A#:)]V)=HJS4E!1110 4444 %%%%  >1@UQOB'P:;Z[-Y92-%,3D[>
M*[*BA,#D/#OA Z=<?:KQS)-T&[FN@U?3(M6L7MI?XAU]*OT4[@><1^ ;LW 2
M2X<VX;.,BN^L;..PLX[>(85!@59HH;N%@HHHI %<A\0O^0#_ -M%_G77UR'Q
M"_Y /_;1?YTUN#-?PQ_R H*V*Q_#'_("@K8I, HHHH **** "BBB@ HHHH *
M*** "BBB@ KQSXIZ/Y%ZM^B\2G:<>PKV.N:\;Z6-2\/S<9:)2R_6JB[,F2NC
M!^%^L?:M,DM9&^=& 4>V*]#KP'P-J3:1XE1)#A#E2/>O?4;<BL.XS1):A!W0
MM%%%24%(0",$9%+10!XKX[\(2IKL<EG&=DK#) [DUZ=X4TN72-"M[69RSJN#
MFMB2&.4@N@..F15+6-8MM%L7N;A@ HR%SC-.YS0H0I3=0T:*I:7J<&K68N;=
M@4/H:NTCH335T%%%% PHHHH **** "BBB@ HHHH **** "D+!1EB /4U3U#5
M+33(#+=3+& /XC7E/BGXDRW1>VT_*)T+9SFFDV)M([CQ)XWL-$C9%<23]E'(
MKQW7/%>HZY.QDD98R>$4\5EI'>:K=84/+(QZ"O1_"WPT9]ESJ7 ZB,C!K2RB
M9W<CB]"\*ZAKEPHBB(CSRS<5[%X;\#V&C1J\B"6;'5ATKH[.PMK"%8K>,*JC
M XJS4.39:BD( %  & *6BBI*,;6/#EGK$T<LZ_-'T.*UH8D@B6-  JC  I]%
M)12=T7*I*45%O1'GGQ(U-A"EA'N^<;C@>E>7^3+G[C?E7T#>:%87\HDN(MS#
MOFJW_"*:1_S[?K5J5C-H\'\F3^XWY4J12JP(1N/:O=_^$4TC_GV_6E_X132/
M^?;]:?,+E*'A:&PU'1XW:U0L@"G*]ZV_['T__GUC_*I++3[;3XS';)M4G.,U
M:J;ARQ[%'^Q]/_Y]8_RH_L?3_P#GUC_*KU%%V'+'L4?['T__ )]8_P J/['T
M_P#Y]8_RJ]11=ARQ[%'^Q]/_ .?6/\J/['T__GUC_*KU%%V'+'L4?['T_P#Y
M]8_RH_L?3_\ GUC_ "J]11=ARQ[%'^Q]/_Y]8_RH_L?3_P#GUC_*KU%%V'+'
ML4?['T__ )]8_P J/['T_P#Y]8_RJ]11=ARQ[%'^Q]/_ .?6/\J/['T__GUC
M_*KU%%V'+'L4?['T_P#Y]8_RH_L?3_\ GUC_ "J]11=ARQ[%'^Q]/_Y]8_RH
M_L?3_P#GUC_*KU%%V'+'L4?['T__ )]8_P J/['T_P#Y]8_RJ]11=ARQ[%'^
MQ]/_ .?6/\J/['T__GUC_*KU%%V'+'L4?['T_P#Y]8_RH_L?3_\ GUC_ "J]
M11=ARQ[%'^Q]/_Y]8_RH_L?3_P#GUC_*KU%%V'+'L4?['T__ )]8_P J/['T
M_P#Y]8_RJ]11=ARQ[%'^Q]/_ .?6/\J/['T__GUC_*KU%%V'+'L4?['T_P#Y
M]8_RH_L?3_\ GUC_ "J]11=ARQ[%'^Q]/_Y]8_RH_L?3_P#GUC_*KU%%V'+'
ML4?['T__ )]8_P J/['T_P#Y]8_RJ]11=ARQ[%'^Q]/_ .?6/\J/['T__GUC
M_*KU%%V'+'L4?['T_P#Y]8_RH_L?3_\ GUC_ "J]11=ARQ[%'^Q]/_Y]8_RH
M_L?3_P#GUC_*KU%%V'+'L4?['T__ )]8_P J:^BZ>Z,IM8^1CI6A12N/E2Z'
MAGCGPV=(U%I8DQ;R'Y<"N/KZ+\1Z-'K.ERP,H\S;\A]#7@USI-Q!JQLC&=V_
M:..O->3B:/)*ZV9]AEF-5:ERR>J-#PEH,FM:K&A4F%6^<^U>]6=K'9VL<$:@
M*B@<5@^#M 71=*3<H\YQ\QQ72UW8:E[.-WNSPLSQGUBK9?"@HHHKH/-"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0
MD*,DX I:9+&LT;(_W3UH X7Q/XPL[G3I8-.NW2X1B">G2IO#?C'3X=$L+>^N
MG>\9,,2,Y-<CXJ\.6<FM_P!GZ3:2K,_SO)NR.>M3>$_#UA'K<NG:E:2O/$^U
M9-V!^5:65C.[N>DZEXCT[25C:[E*B3&W SUKA+;Q3M\837$M](=/#G"YXQ]*
MZ7QAI&ER:69[NV>4QIA K8Z#BO*O^$<FBACU62VE^PO@B//.#[THI6')NY[=
MI.NV.MQ&2RD+*"0<C%>27UYK^I^.[W2['4)D_>ML4/@ #%>G>%-+TZRTY)K&
M!H@XY#-FO/-#_P"2QW/_ %T?^0H74)="W_PBGC;_ *"4O_?T53NI?&/A=UGO
M':>('O)G^E>R55U"TBO+*6*5 P*GK]*7,/E,?PIXH@\16(;(6X4?.@[5T5>*
M>%Y6T/QRUD"0LSA<?B:]2\1>(K70+%IIF!D/"IGDT-:Z GIJ;-%>4V_B#QCK
M9,^GAHK<_=)3.:DM_&NN:-J"0:[ ^UC@,0%'UHY6',CU*BJD6H02V O%<&(C
M.[->=WGC+6]6U62UT.-PJ$@M@'I22N-NQZ?17E%YKGC31H_M-X6DA'+8CQBN
MZ\+:^NOZ8+@J4<'!4T-6!.YNT5POB[QP=*N?L%BIDNLX.WL:QAJ7CLP_:<-Y
M>-VSR^<?G3Y1<QZG17$^%/&O]J3M87Z&&\0[2&/)-=M2:L-.X445YUXY\6:G
MH6JQ):R 0Y&Y<=:$K@W8]%HKRR#6?&FIA;JU5DMV(P"F<BNJU?Q,?#VA)-?-
MNNF& .AS18.8ZFBO*+7Q!XRUI6N+%6BASQE,YJYIGC;4]/U-++7HG4N=HD8
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MB@#S?QEK]]>:JNAZ62LK$JS XQ77>%M.NM,T9(+QR\Q8L23GK7%:2 ?BA?\
MF_>\X[,_05Z?5/L2M[F9KVFMJVDRVB.49^C UYE'-K?@K688KJ1I+.1P,ELX
MKV"N'^)JQ?V%$7QO#G9]<41?0)+J=E:W"7=K'.ARLBY%35C^%"3X6TTMU\D9
MK8J2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y#XA?\@'_ +:+_.NO
MKD/B%_R ?^VB_P Z:W!FOX8_Y 4%;%8_AC_D!05L4F 4444 %%%% !1110 4
M444 %%%% !1110 4R:)9X7B?[K#!I]% 'SOXGL7T;Q0[#*J9=Z_3->V^%=2&
MJ:%!/G)Q@_A7$_%71]\4>HHGW!M)^IJ/X5:Q_K;"1N%4;0?7-:/6-S-:2L>J
MT445F:!1110 5Y=\6;6]>WBFB9O(4'> :]1K/UG3(]6TR:TE (<8YIHRKT_:
M4W$\L^%WB3R)SIMP_P AR5R>]>QU\Y1Z1?:=XL6VA1MZRY&!VS7T)8"8640G
M_P!;CYJ&<V!G)Q<)="S1112.X**** "BBB@ HHHH ***SM4UNRTB!I+J=4P.
M 3UH T&94&68*/4FN,\3>/K/2$:*!A)/C [BN&\4?$:ZU!W@LB8X3QG/6N,M
MK2]U:YVQ(\LC'G%:*'<S<^Q<UCQ'J&MSLTTC;6/W >*N^'O!U_KDP(C*19Y+
M<5V_A;X:)'LN=3&3U\LC!%>E6UI#:1+%"@50,# H<K; HWU9@>'_  ;I^B0+
MA!)*!RS#FNE P,"BBL[W-$K!1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5BS^&K&
M?5EU!D&]1C&./K6U12<4]RX5)0^%V$ P,"EHHID!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!]CMO/\
M_P E/-QC?CF@6=LLYG$*"4G)?'-3T4 1S013ILE177T(IC65LUN+=H$,*\!,
M<"IZ* &1Q)"@2-0JCH!7C^A_\ECN?^NC_P A7L=>.:'_ ,ECN?\ KH_\A51Z
MDRZ'L=-D_P!4_P#NFG5DZ]K5IH^GRR7$JJQ4A03UJ2CR5E+_ !2MBO($RYQ^
M-7OB!.^H>+;*U8XC& 0._P PIO@.PFUCQ)-J<@.Q&W*Q[\U)\0[9]/\ %-E>
M8S$<%CZ<BM>IET/5=.LX;*QBAA0*H4< 5ROQ)TV.[\/M,%'FHPPW?%=1I5_!
MJ.GQ3P.&4J.17*?$O5([70C;*X\]V&%[D5"W+>Q5\#2R:KX/>PW$NJ8R?K7(
M:?J.H^"]>G\RT+HS-\VTG@UV?@:)M&\('4'B)8IDKW-7M'US3/&#RVTUH$="
M05)&3BG?<71%*T^(FAZG']FOT;+<%6CXKIX6T^+2)I].6)$$9;]WCTKE?$_@
M+1TTZ6[MT%NR#)8FL7X=27$L5]8AF>':X4^IHLK707=[,Q-&O[.7QK)?ZBVY
M!)GYAG->H?\ ":Z&$V><=N,8Q7F.D:3IJ>+Y]/UB+ \S !.,5Z0OP\\-,H86
M9((R#O-.5A1N>=:UJ%HGC&*]TUOON2<<5[7:L7M(6/5HU)_*N);P]X'LM16!
MS&ET#PA<YS7<1!5B14^X% 7Z5,F5%#Z\E^(T?G>)+6/&=SJ/TKUJO*?'W_(V
M67_71?Y41W"6QZ/HL(M]'M8P -J <5Y/\1+Q9O&,=E,Q\J,JQ'89%>O:?_QX
M0?[M>2?$&PCB\90WEW&3:RLJL?4 4X[BEL=II7BK0K#3H8$DV[5 .!7*_$/5
M])U>RADM'_?QL3D#D\5TVG>"/"VH64=Q%:EE=<\.:CU#PEX+TQ5-\BPAC@;W
M/-"M<'>Q6T_6)AX :4GYD01@_4&J7PKLXW-U=R*&D;D$]N:Z.[TK3YO"DT&D
M8,&W<-ISG -<Q\+[^*VN+JPN&$<O1%/4G-'1AU1Z1J,$=QI\\<BA@8VX/TKR
M/P5;"T\:O"O19!7K>IW45IIT\LKA%"'!/KBO)/!-T+SQJ\X.0T@I1V82W1J_
M$O\ Y"UE_OI_,5Z'I'_(+@_W:\[^)YV:C:2$?*KH?UKO_#\ZW.AVTR_=9<BA
M[#6[.$^*OW+?_?6MVUN6M/AS#,C%66+J*Y;XHZC!+>0VB,"ZLI.*ZJSM&OOA
MU! BEF:'H*?1"ZLYGX8623W]U>RJ'8LV"?J:]2GACN(6BE4,C#!!KROX9WT=
MIJ-S8S.$8,V ?J:]4FF2"%I7.%49-*6XX['+VOA>T\+V]_?6LTA9T8D$=.<U
MYOX:OK'_ (2^:_U%MR[R?F&:[VU\7KXF-]IEM9.2J$;@<YYQ7">'M*TI_%%Q
MI^KQ8/F$#+8JEYDOI8]-_P"$UT,KM,QVXQC%>97E_;P^-XKO3F^61CG'N17H
MX^'GAH@$69P?]LU030? ]IJ:P@QK=J>$+G.:2:0VFSG_ (C73W=[863,0FX$
M_B*]'T"VBM=$M4B0+^[&<=Z\\^)=D]M=V>H1J3&&ZCL *[_PU?P7^AVSPR!]
MJ -CL:3V!;G*?%/3HIM*CN-@#QDDD#K6G\._^1='U%97Q2U2&'3$M1(#(^05
M]*U?AW_R+H^HI_9#[1U]8'C&Y-MX?G8,1N!7CZ5OUA>+;1KS0)T52=JEOR%2
MMRGL<G\)H0EE<R8^^!7?:K_R";O_ *Y-_*N ^$TX>UNH<\Q@9%=_JO\ R";O
M_KDW\J<MQ1V/+/AI_P ARZ_WQ5[XHW,CS6]EN(C+J3BJ/PT_Y#EU_OBM#XHV
M<JM;WP4E%=0?PJOM$_9.S\)V4-EX=M%B0*2GS$#DTWQ;IL.H:!=>8H+1QEE^
MM-\'ZC;ZAX=M3#(&94&]1_":3QCJL.FZ!<B1@&E0JOUJ.I?0Y+X3WS"WO+.9
MB75P%';&*]-KS3X3V#+:7=W.IWNX*-[8KTNG+<4=C"\4:_%H6ER3,?WA&%'U
MKC?!.GPWUU)KFI7,)=S\@>09&#77^)?#$?B*-4D<*%&.:YH?"RW486YP/0$T
M*U@=[F3\4)X)=3L/*EC< #.U@<?,*]#\.W-N^D0(L\3-C[H<9KQ_QGX7CT&]
MMHEEW^9CG)]:[SPCX.CLA#?K-DG!VY--VL)7N=Y534LG3IL D[>U6Z*@L\=^
M'CHOCN[1AA\2<FO8J\8UF";PCXR&H!#Y,K99QT&37K.E:I;:M9I/;2*ZD=JJ
M7<F/8O5YY\52/[*C^AK0O?B)8V&JFRFCV@'!<MP*XWQCK7_"7:K;Z?IA\Q%8
MC<O(:G%.X2:L=I\-E9?#"[A_&:Z]Y$C4L[!5'<G%9NB6*:1HT41PH5 SGTXY
MKSKQ9XIO=9U5M'TC<RAMI*\[J5KL+V18\7^,WU&7^R=(W.S':S &M[P-X2&B
M6GVBX^:ZEPQ)YP:=X2\%6VCPK<W"B2[?DL>V>:[&AOH@2ZLP_%M@E]X>NE;[
MR1EE^M<G\,[\+HU]!*P#PG !/M7H=S"+FVDA/1UQ7AT]VWA[5]4MMV TI"^_
M%..JL*6CN;?A")M;\;7EZXR(@,$^Q-:OQ2L&:UAU$#_4E1G\:L?#'3S%I+7S
M##3,P_6NB\6Z>=2\/7$"KD_>_+-#?O E[IS5SKV_X<-,6R\L90'Z8J;X86/V
M?19IG7+RN&!/TKS8ZD\NB6NCH>?.92*]O\.6BV>@VD:C!\L;OK1+1!'5FK7C
M.\V/Q%+Q=7)S^)KV:O&8T.H_$9DBZH6S^!I1'(]E7E0?:EI%X4#VI:DH****
M "BBB@ HHHH YCQW_P BY+]14_@S_D78O]XU!X[_ .1<E^HJ?P9_R+L7^\:?
M074Z"BBBD,**** "BBB@#S3QII5YI6KQZ[IZEBI+2 5H:5\2],EMTCO!)'<#
M@C9@5W$L231E)%#*>H-<QJ/@#0[YO,%JJ2$Y+>M5==2;/H,N?B'HENF3([''
M&U<UQ5U?W_CS6888HF6RC<-DJ177VWPVT6*4-+ L@':NGL-+L]-B\NUA$:^U
M%TM@LWN/L+465A#;+TC7:*LT45)04444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDV\P=S(O ^M-+43.J\,?\@*"MBL?PQ_R H*V*3&%%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)I]R^Z1"<9]!7<ZHH;3+A6&05KR;X>.5^(%S$/N[9.*:U0GHSV6FNP6-F89
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MLL@^5@>15M7L2G:Y)J7C[2=.G,)WS,.OE\TRP^(>DWTXAV2PL>GFC%<]\/\
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MVB?SIJ3)L;'AG_D!05KUC^&/^0%!6Q4LH**** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKZY#XA?\@'_MHO\ .FMP9K^&/^0%!6Q6/X8_Y 4%;%)@%%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% $:00QN72)%8]2% -+)#%
M+CS(D?'3<H-/HH   !@# %-=$D7:ZJRGLPR*=10 R.&*$8BB1!_LJ!3Z** "
MCJ,&BB@"O]@LR<FT@_[]BC[!9_\ /I!_W[%6** (TMX(_P#5PQI_NJ!4E%%
M!1110!$+:!9/,6&,/_>"#/YTLD$,IS)%&Y']Y0:DHH 15"KA0 !T %,D@AF_
MUL2/C^\H-244 (JJBA54*HZ # I:** &NB2+M=593V89%)'#%$,1QH@]%4"G
MT4 (R*Z[74,/0C-,C@BA_P!5$B9_NJ!4E% ",JN,,H8>A&:@^PVF<_98,_\
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M2T4 1-;0.^]X8V?^\4!-2X & .*** (GM;>4YD@B<_[2 TB6EM&<I;Q*?54
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&5X@U9=(TUY_XAC JSIEZNH627"'(85YW\2=6W3QVD;<*"&%:GPXU7S[ V;M
MED):JMH*^IWE%%%2,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYDB4!B?6AH#HZ***0PKD/B%_R ?^VB_SKKZY#XA?\@'_ +:+_.FMP9K^&/\
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M..U<1I.E76O7X:3<5)R6-<]6J[\D-SAQ&):?LZ>XV>^U37[G:-\F3P%K9L/
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M<S(1GC!JK,FZ/2O#$K3^&=/E<Y9H036M533+3[!IEO:?\\DVU;K-FB"BBB@
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MJ;5*TX45/J>FVWC?1;E@JWD>2<#FN@CD66,.ARIZ&OE^QBNX[^W!CE7]XO\
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M -4^V:.L#-EXQDUU]>,^ -4^Q:N(6;"S$+S7LH((R.AK.2U+0M%%%(84444
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M'I=%>:?\+/'_ #R/_?-'_"SQ_P \C_WS1RL+H]+HKS3_ (6>/^>1_P"^:/\
MA9X_YY'_ +YHY6%T>ET5YI_PL\?\\C_WS1_PL\?\\C_WS1RL+H]+HKS3_A9X
M_P">1_[YH_X6>/\ GD?^^:.5A='I=%>:?\+/'_/(_P#?-'_"SQ_SR/\ WS1R
ML+H]+HKS3_A9X_YY'_OFC_A9X_YY'_OFCE871Z717FG_  L\?\\C_P!\T?\
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M]\T<K"Z/2Z*\T_X6>/\ GD?^^:/^%GC_ )Y'_OFCE871Z717FG_"SQ_SR/\
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M&2;2-L:%C@\"K?@Z-XM$174J>.#5=!=3H:***D84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q'Q$_P"0<G^\O\Z[
M>N,^($$LVGJ(T+'<.GUIK<3-?PE_R+T'XUN5B^%4>/0(%=2K#/!K:I,84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6-6!]17/WW@O3;G+(C*_^]Q7/[&</@9PO"U:;O2D10^.=.8#S&"_05,_C;2
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MM_UT->I+]T?2O,XK6X_X6*TOE-Y?F'YL<5Z8OW1]*;$A:***0PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!DD,<R[9$##T-*D:1+M10H]!3J* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.6&*88D0,/>I
M** &HBQKM0 *.PIU%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!'+!%, )$#8Z9IZJJ*%48 Z"EHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "HI;>&;'FQAL=,U+10 @ 48 P!2T44 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $4EO#*P:2-6(Z$U
M(  ,"EHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "HGMH9'#O&K,.A-2T4    P**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KF?$?B4Z#=Q;D#1,0#GMFNFKS'XHMS&,]A36
MYRXRI*G2<H[GH6GZI::G LUM*&4C\:N5\^:'XAO-$NA)#(2F?F4\U[)X>\56
M6N6Z[7"3#@H3S]:;5C+"8Z%96>C-^BBBI.\**** "BBB@ HHHH B:U@>0.T:
MEAT-2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !41M8#+YAB4O\ WJEHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"+[-!YOF
M^6N_^]4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 45S>O>,+30W\ME,LG=5/(J3
M0/%=IKIV(/+D_N$\T[,+G04444@"BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBN6UOQO9Z//Y(C,SCJ%/2BP'4T5
M@Z!XIM-=4B/Y)!U0GFMZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHK+UO6X-%MQ+*-Q)&%!Y- &I145O,)X$E
M P'4'%9&O>)K30D'F_.Y&0@/)H W**Y;0_&UGK,_D^687[!CUKJ:+ %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445!=W4
M5G;M/,P5%&230!/17#2?$FR2[\D6SE,XW[ABNOL+^'4;5+B!@RL,\4[ 6J*"
M<#)K&@\0V]QK#Z<@RZ'!.:0&S1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !15>]O8;"V:>9@JJ.]<C%\1[%[WR&@9$
MSCS"PQ3L!VU%107$=Q LL; JPSD5S>N>-[/1[@P;#-(#@A3TI6 ZFBL#0/%=
MIKN5C'ER#^ GFM^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HK,UC6H-'A627DLP4+GUJ[;3BYMUE48#"@":BN6
MUWQM9Z--Y7EF9^X4]*O:!XEM==C)B^1QU0GFG8+FW1112 **** "BBB@ HHH
MH **** "BBB@ HHHH *\M^*)'VB,=]HKU*O*_BD?],C'^R*<=SAS'_=V><58
MLKZXL+A9K>1D8'L>M5Z*T/F4VG='L7A+QU#J*+:WS".?HI['ZFNX5E=0RD$'
MN*^;[*RO+N4"TC=FS_#7M'@R/5XK$+J1( X56'-1)'OX#%U*GN37S.IHHHJ3
MU0HHHH ***R]7URWTDPB7YFE;:!F@#4HJ*&=9;99NBLNZN4U?Q_9Z9=&!(6G
M(/)1J=@.PHK(T/Q!:ZW!OA(5NZYYK7I %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 445EZYK4.B6BSRJ6!., T :E%<*/B
M59$@?97Y_P!H5U]A?QWUBMTHVH?6G9A<MT5Q^K>/[+3;LVZQ&8J<$JW2MS1=
M<MM:MO-A.&[IGD4687-2BBBD 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !16=J^L6^CVQFG8=,A<]:YW3?B'97UZ+=X&AR
M<!F8<T[,#LZ*16#*&4Y!Z&H;RZCLK62>0_*@S2 GHK.TC5XM7MS-$I"CWK1H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ J.=_+MY'_NJ3^E254U([=.G(_P">;?RH X;P_IL>O:Y=
MWEVH=1C:#R.M-U:RC\.^);:XM1LC?"D#CDFM3X?KG3I).[$_SJ'Q\N!:OW$R
M?^A"JZBZ';(<HI]13J@LV+6D9/I4]2,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH KW\ABL9G7JJY%<)X4TFVU:\O[
MJ[42,)<!6YZBO0)462)D;[I&#7E<^J3>&]=N([%_.25BS*O8U2$S0NK)-%\9
M6_V3Y4F<*R"O1E.5!KS3PY.=?\2-=WDH62/#+&>N:],I,$%%%%(84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $%Y<K:6LD[
M]$4FO(?$.IWFMW0N2I6UC<!<Y&1FO8+FW2ZA:*095A@BN)\:V4-CHT4,"!57
M _6JB)G7V3A-+A<]!&I_2N%L+$>(O%5U/<_/!;R% IZ5V6XKX=W#M /Y"O.=
M-UF\MFO;?3H6DN9I-WR]N*$#-[Q!X<^R7]G=Z9&%(D^8+TP*[:T+M:1F3[Y7
MFO/=(\2ZM8ZDEKK,3@2$!=PQBO1D970,O*D<4F"'4444AA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5R'CMKA[..VA5B)1@[177
MTUXTD^\H/U%" Y>/PGIXT+:T*F0Q9W%><XJCX#=[>:]L&8LL+!5S73:W?1:?
MI4TCL%^4A?K7.> [>1HKG4)5(^T$,,U701O^(=273=*ED)PS*0OUKSWP-/)=
M>)&GE!WNV3FM7Q'<MKGB.'38#NBC97;'ZTW1+=+3QM+!&,*CD#\J%L'4]%HH
MHJ1A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 <?XW@O+R."V@!V-(NXCTSS2:GX3L(_#DBB-1*J</CFNP(!Y(!K@/&7B>6)
MI]-CC9%/!DSQ5*XF7_"EU*WAFZR2S1%E7\!6?X5T./4I[B^U"(LSD$!UKI/"
MMI!;Z,HBD602?,Q'J:V@B1 E0%%*X'G>IV4>@^*[=[3Y$E*J5''6O1Z\[O9A
MKWC...'YHX "<>HKT2A@@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ I"0HR3@"EK!\6:JNF:1)AL2R*0GUH \^\9:N^HZY
M%'&28HI IQTSFO2+:?[-X?$W]Q,UYY=:4;7PXEY,,S3W"/GZFNWO&*>"IV':
M*J8D8'A71X=7NKN^O%$G[QE 89&*:UFN@>-+?R/EAN),;1TK;\"C&CR'U?-4
M/&(V:WI<@ZAS1U [=3N4'U%+45L<VL1]5%2U(PHHHH **** "BBB@ HHHH *
M*** "BBB@ KR?XI$_P!IQ+_L"O6*YW6_"D&MZC'<W# J@ VTT[,Y<92E5I<D
M=SQ*STR[OI1'!"Y)[[3BE>SDL-0CBNTVX8%ACM7O]AI%EIR;;>%5KA/B7H6Y
M%U.)<L,(0!VJE+4\FMESI4N>]VCJ_#=AIITN"YM8$^=<AL<UOUYU\--;\VV:
MPE?F/"Q@]Z]%J7N>QA9QG24HA1112.@**** &NP1&8G  S7D'B+5WU/Q1&%R
M8$<;?3-=[XQU?^SM*:.,_OI" H]CQ7&7.D?V?I6G32+^^EF);/IC-4A,[VXF
M:#PR'3KY6/TKF_!NAV=]I[W=TBRR2$@[AG'-=;#$DVA(DGW3%S^5>:V^NW/A
MZ]N+2R8SPCD%>W-" U]-@&D>.!;6Y_<R(S%1T%>B#I7GO@LKJFK2ZC<2@W"D
MJ$/4 UZ%28(****0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *X?QZWG/8VO9IAD5W%>:^/)YEUNW2 %I%*E0/6FMQ,Z6U\):7Y
M$>8DWXYXJ?7)$TCP],D/RY4A<>M<0VK>)]+E2\NHY!;D\@CI6[XJU)+WPU;7
M*'Y78AOR%.P!X7\-6L^F&[O(UDDN!NRPSBDT/2KG1_%%S'$#]E91CTZUBQZU
MKMSI\$>E6\GDPIM9E (-=+X2\1OJ3/:7B[;F,9.>IH=P.NHHHJ1A1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444CG"$^U 'G^M1
MMKOBZ*P8GR8G(8"K?B3PK;_8(WL(E6>,@Y4<G%8,VL/8^*=2,,9DN#)^[4=:
MDB\1>(--O4DU*"1;>1OX@.AJ]23O?#YG_L2U%R,2A/FKE/B'K1AMUL8#ER<M
MCT-=?_:<']D_;@0(BN0:\[M+5]<;4=5N 2BHRIGV-)=QLZ7P!QHWY5UU<GX#
M_P"06_X5UE)[C04444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ JIJ0W:=./\ IFW\JMU'.GF6\B?WE(_2
M@#DO !QISIW4G^=0^/FR+5.YF3_T(51T#5(?#^N7=E>N(T.-I;ZTW5=0B\1^
M);>VLV$D:88D>H-5U%T/0+-2EI&#Z5/34&U%'H*=4C"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *.LS&WTBZE4X98
MR17*>"M+@NXKF]N4$DCOD;AGJ*ZS5H#<Z5<P@9+H0*XOPGKMKI+7.GWTJQ,K
M\;CV IK8743Q!9IH_B2PNK8;!-+M95X' KOX7\R%']1FO.]6U*/Q!XFLH+,^
M9%#*&++]*]$B3RXE3T&*&"'T444AA1110 4444 %%%% !1110 4444 %%%%
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MIH@+)EY#_$W-;U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MAZJJ[:Y75? EGJ%TTZ,T9;J%.*Z^BBX&1HGA^UT6';",L>K'K6O110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIK.J_>8#ZFG @C(H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0?*Q.2W-/E%S'H%5-3M&O],N+57*&5-H8'&*MT5)1YE)\-KI(V;^T9OE!/\
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MR\V8P?)  %-I"39M^)/$=AH;1"\M//WD ?*#CGWK4AU*V_LU;QB(8<9YXQ7
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTF3E7&14E4-(TS^RK%;7[1).JC 9^HJ_4E'D6K_\E#@^G]:F\>_\C)I_^_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR##HK?[PS08T9=K(I7T(XIU% "*JHNU5"@= !BFM%&YR\:L1ZC-/HH 0  8
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K 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>23
<FILENAME>ctmx-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-24T16:43:22.0335375+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 19fb4f4ba39c4e5496fc22bf5dabd4ad -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:ctmx="http://cytomx.com/20201231" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://cytomx.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://cytomx.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ctmx-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ctmx-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ctmx-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ctmx-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS" id="Role_StatementBALANCESHEETS">
        <link:definition>100010 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical" id="Role_StatementBALANCESHEETSParenthetical">
        <link:definition>100020 - Statement - BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" id="Role_StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>100030 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY" id="Role_StatementSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>100040 - Statement - STATEMENTS OF STOCKHOLDERS&apos; EQUITY</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS" id="Role_StatementSTATEMENTSOFCASHFLOWS">
        <link:definition>100050 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness" id="Role_DisclosureDescriptionOfBusiness">
        <link:definition>100060 - Disclosure - Description of the Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncements" id="Role_DisclosureAdoptedAndRecentAccountingPronouncements">
        <link:definition>100080 - Disclosure - Adopted and Recent Accounting Pronouncements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100090 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestments" id="Role_DisclosureFairValueMeasurementsAndShortTermInvestments">
        <link:definition>100100 - Disclosure - Fair Value Measurements and Short-Term Investments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100110 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" id="Role_DisclosureGoodwillAndIntangibleAssets">
        <link:definition>100120 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilities" id="Role_DisclosureAccruedLiabilities">
        <link:definition>100130 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreements" id="Role_DisclosureResearchAndCollaborationAgreements">
        <link:definition>100140 - Disclosure - Research and Collaboration Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreement" id="Role_DisclosureLicenseAgreement">
        <link:definition>100150 - Disclosure - License Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100160 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100170 - Disclosure - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStock" id="Role_DisclosureCommonStock">
        <link:definition>100180 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100190 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100200 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan" id="Role_DisclosureDefinedContributionPlan">
        <link:definition>100210 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100220 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100230 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100240 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100250 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsTables" id="Role_DisclosureFairValueMeasurementsAndShortTermInvestmentsTables">
        <link:definition>100260 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100270 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" id="Role_DisclosureGoodwillAndIntangibleAssetsTables">
        <link:definition>100280 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables" id="Role_DisclosureAccruedLiabilitiesTables">
        <link:definition>100290 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsTables" id="Role_DisclosureResearchAndCollaborationAgreementsTables">
        <link:definition>100300 - Disclosure -  Research and Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100310 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockTables" id="Role_DisclosureCommonStockTables">
        <link:definition>100320 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100330 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100340 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails">
        <link:definition>100350 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Customers and Collaboration Partners who Represent 10% or More of Total Revenue During Each Period Presented or Net Accounts Receivable Balance (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100370 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" id="Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails">
        <link:definition>100380 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails" id="Role_DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Adopted and Recent Accounting Pronouncements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>100400 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails">
        <link:definition>100410 - Disclosure - Fair Value Measurements and Short-Term Investments - Schedule of Short-Term Investments Subject to Fair Value Measurements on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAndShortTermInvestmentsAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Fair Value Measurements and Short-Term Investments - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>100430 - Disclosure - Property and Equipment - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails">
        <link:definition>100440 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" id="Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails">
        <link:definition>100460 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill and Intangible Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" id="Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails">
        <link:definition>100470 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails" id="Role_DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails">
        <link:definition>100480 - Disclosure - Research and Collaboration Agreements - Schedule of Revenue by Collaboration Partners (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails" id="Role_DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails">
        <link:definition>100490 - Disclosure - Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1" id="Role_DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1">
        <link:definition>100500 - Disclosure - Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details 1)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1Default" id="Role_DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1Default">
        <link:definition>100500 - Disclosure - Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details 1)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails" id="Role_DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Research and Collaboration Agreements - Amgen, Inc - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails" id="Role_DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Research and Collaboration Agreements - Astellas Pharma Inc - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails" id="Role_DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails">
        <link:definition>100530 - Disclosure - Research and Collaboration Agreements - Bristol-Myers Squibb Company - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails" id="Role_DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails">
        <link:definition>100540 - Disclosure - Research and Collaboration Agreements - ImmunoGen, Inc - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails" id="Role_DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - Research and Collaboration Agreements - Pfizer Inc - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsSummaryOfContractLiabilitiesDetails" id="Role_DisclosureResearchAndCollaborationAgreementsSummaryOfContractLiabilitiesDetails">
        <link:definition>100560 - Disclosure - Research and Collaboration Agreements - Summary of Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails" id="Role_DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Research and Collaboration Agreements - Contract Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - License Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails" id="Role_DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails">
        <link:definition>100610 - Disclosure - Leases - Summary of Supplemental Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails">
        <link:definition>100620 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails2" id="Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>100630 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" id="Role_DisclosureCommonStockAdditionalInformationDetails">
        <link:definition>100640 - Disclosure - Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails" id="Role_DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails">
        <link:definition>100650 - Disclosure - Common Stock - Reserved Shares of Common Stock Issuance on Converted Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100660 - Disclosure - Stock-based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails" id="Role_DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails">
        <link:definition>100670 - Disclosure - Stock-based Compensation - Schedule of Activity Under Company&apos;s Stock Option Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails" id="Role_DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails">
        <link:definition>100680 - Disclosure - Stock-based Compensation - Total Stock-based Compensation Recognized (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails" id="Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails">
        <link:definition>100690 - Disclosure - Stock-based Compensation - Schedule of Estimated Fair Value of Employee Stock Options and ESPP Using Black-Scholes Valuation Model (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100700 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails">
        <link:definition>100710 - Disclosure - Income Taxes - Schedule of Components of Provision for (Benefit from) Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails">
        <link:definition>100720 - Disclosure - Income Taxes - Schedule of Effective Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails">
        <link:definition>100730 - Disclosure - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100740 - Disclosure - Income Taxes- Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" id="Role_DisclosureDefinedContributionPlanAdditionalInformationDetails">
        <link:definition>100750 - Disclosure - Defined Contribution Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100760 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" name="CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" name="CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" name="CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" name="DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" name="IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock" name="AdoptedAndRecentAccountingPronouncementsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ResearchAndCollaborationAgreementsTextBlock" name="ResearchAndCollaborationAgreementsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_LicenseAgreementDisclosureTextBlock" name="LicenseAgreementDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_CommonStockTextBlock" name="CommonStockTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" name="ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_SupplementalInformationRelatedToLeasesTableTextBlock" name="SupplementalInformationRelatedToLeasesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_MajorCustomerMember" name="MajorCustomerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_AbbVieIrelandUnlimitedCompanyMember" name="AbbVieIrelandUnlimitedCompanyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_BristolMyersSquibbCompanyMember" name="BristolMyersSquibbCompanyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_AstellasPharmaIncMember" name="AstellasPharmaIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_NumberOfBusinessActivities" name="NumberOfBusinessActivities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_ProbodyTechnologyMember" name="ProbodyTechnologyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_OptionsAndESPPToPurchaseCommonStockMember" name="OptionsAndESPPToPurchaseCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" name="CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_MoneyMarketFundsIncludedInRestrictedCashMember" name="MoneyMarketFundsIncludedInRestrictedCashMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_ComputerEquipmentAndSoftwareGross" name="ComputerEquipmentAndSoftwareGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_GoodwillAbstract" name="GoodwillAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_GoodwillAndIntangibleAssetsLineItems" name="GoodwillAndIntangibleAssetsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable" name="ScheduleOfGoodwillAndIntangibleAssetsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_AccruedResearchAndClinicalCurrent" name="AccruedResearchAndClinicalCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_AmgenIncMember" name="AmgenIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_ImmunoGenIncMember" name="ImmunoGenIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_PfizerIncMember" name="PfizerIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_NumberOfCollaborationAgreements" name="NumberOfCollaborationAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts" name="PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_CD71AgreementMember" name="CD71AgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_SeattleGeneticsAgreementMember" name="SeattleGeneticsAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_DiscoveryAgreementMember" name="DiscoveryAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember" name="DevelopmentRegulatoryAndCommercialMilestonePaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_SecondTargetMember" name="SecondTargetMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" name="ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_ContingentPaymentsReceivableProfitSplitOnSales" name="ContingentPaymentsReceivableProfitSplitOnSales" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" name="MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_PaymentsOfSublicenseFees" name="PaymentsOfSublicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_NumberOfTargets" name="NumberOfTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_NumberOfTargetsSelected" name="NumberOfTargetsSelected" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ContingentMilestonePaymentsReceivable" name="ContingentMilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_MilestonePaymentReceived" name="MilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_AggregateCollaborationTransactionAmount" name="AggregateCollaborationTransactionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_EstimatedSublicenseFees" name="EstimatedSublicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_NumberOfAccountingUnits" name="NumberOfAccountingUnits" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_MilestonePaymentsReceivable" name="MilestonePaymentsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_EstimatedResearchServicePeriod" name="EstimatedResearchServicePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_CommonStockSharesIssuableUnderAgreement" name="CommonStockSharesIssuableUnderAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare" name="PeriodUsedToCalculateWeightedAveragePricePerShare" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement" name="LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_EstimatedPremiumOnIssuanceOfShares" name="EstimatedPremiumOnIssuanceOfShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_EGFRProductsMember" name="EGFRProductsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_AmgenProductsMember" name="AmgenProductsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_SublicenseAgreementMember" name="SublicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_RegentsOfTheUniversityOfCaliforniaMember" name="RegentsOfTheUniversityOfCaliforniaMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_AmgenOtherProductsMember" name="AmgenOtherProductsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_ProfitShareUponExerciseOfCoDevelopmentOption" name="ProfitShareUponExerciseOfCoDevelopmentOption" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_NumberOfAdditionalCollaborationTarget" name="NumberOfAdditionalCollaborationTarget" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" name="ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds" name="LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock" name="PremiumOnIssuanceOfSharesAllocatedToCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_EstimatedFairValueOfProducts" name="EstimatedFairValueOfProducts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_RightToExpandNumberOfAdditionalCollaborationTarget" name="RightToExpandNumberOfAdditionalCollaborationTarget" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_AdditionalContingentPaymentsMember" name="AdditionalContingentPaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_ResearchAndDevelopmentServiceFees" name="ResearchAndDevelopmentServiceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_EstimatedResearchServiceTerminationMonthAndYear" name="EstimatedResearchServiceTerminationMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_NumberOfOncologyTarget" name="NumberOfOncologyTarget" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_NumberOfCollaborationTarget" name="NumberOfCollaborationTarget" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_CollaborationTargetResearchTerm" name="CollaborationTargetResearchTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_PeriodOfNominationOfAdditionalTarget" name="PeriodOfNominationOfAdditionalTarget" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ExtensionOfResearchTermForEachCollaborationTarget" name="ExtensionOfResearchTermForEachCollaborationTarget" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes" name="IncrementsOfExtendedCollaborationTargetResearchTimes" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_AchievingAdditionalTargetsMember" name="AchievingAdditionalTargetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_PreClinicalCandidateMember" name="PreClinicalCandidateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_DrugApplicationForCTLA4Member" name="DrugApplicationForCTLA4Member" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_ThirdAndFourthTargetsMember" name="ThirdAndFourthTargetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_AcceleratedRecognitionOfDeferredRevenueMember" name="AcceleratedRecognitionOfDeferredRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_NumberOfResearchTargetsSelected" name="NumberOfResearchTargetsSelected" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_UpfrontFeeReceived" name="UpfrontFeeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_EstimatedResearchServiceTerminationDate" name="EstimatedResearchServiceTerminationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive" name="ContingentMilestonePaymentsNoLongerEligibleToReceive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_CashPaymentToExecuteAgreement" name="CashPaymentToExecuteAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_MilestonePaymentPayable" name="MilestonePaymentPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_NumberOfNominatedResearchTargets" name="NumberOfNominatedResearchTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_NumberOfAdditionalResearchTargetsWithNominationOption" name="NumberOfAdditionalResearchTargetsWithNominationOption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ContractWithCustomerLiabilityAdditions" name="ContractWithCustomerLiabilityAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_FirstTargetUnderDiscoveryAgreementMember" name="FirstTargetUnderDiscoveryAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_SecondTargetUnderDiscoveryAgreementMember" name="SecondTargetUnderDiscoveryAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear" name="ContractWithCustomerLiabilityMaturityMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_RoyaltyObligationsFutureMinimumPaymentsDue" name="RoyaltyObligationsFutureMinimumPaymentsDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_LicenseTerminationPeriod" name="LicenseTerminationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_UniversityOfCaliforniaSantaBarbaraMember" name="UniversityOfCaliforniaSantaBarbaraMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_SublicenseAndMaintenanceFeesMember" name="SublicenseAndMaintenanceFeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_AbbVieMember" name="AbbVieMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_PaymentOfUpfrontFees" name="PaymentOfUpfrontFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_AnnualLicenseMaintenanceFees" name="AnnualLicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_LicensePaymentTerm" name="LicensePaymentTerm" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_PercentageOfRemainingMaintenanceFeesOutstanding" name="PercentageOfRemainingMaintenanceFeesOutstanding" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_FairValueOfCommonStockIssued" name="FairValueOfCommonStockIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_AdditionalSublicenseFees" name="AdditionalSublicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_MilestonePaymentReceivable" name="MilestonePaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_SublicenseFees" name="SublicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_UpfrontLicensePayment" name="UpfrontLicensePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate" name="LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate" name="LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_PatentInfringementLawsuitMember" name="PatentInfringementLawsuitMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_SecuritiesClassActionLawsuitMember" name="SecuritiesClassActionLawsuitMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants" name="NumberOfCurrentAndFormerOfficersNamedAsDefendants" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_FirstYearOfLeaseTermMember" name="FirstYearOfLeaseTermMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_SecondTwelveMonthsOfLeaseTermMember" name="SecondTwelveMonthsOfLeaseTermMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_TenthYearOfLeaseTermMember" name="TenthYearOfLeaseTermMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_OperatingLeasesRentExpenseAnnualBaseRent" name="OperatingLeasesRentExpenseAnnualBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_MaximumImprovementAllowance" name="MaximumImprovementAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_ImprovementAllowanceFromRecoverableRent" name="ImprovementAllowanceFromRecoverableRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract" name="SupplementalBalanceSheetInformationRelatedToLeasesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_WeightedAverageRemainingLeaseTermAbstract" name="WeightedAverageRemainingLeaseTermAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_WeightedAverageDiscountRateAbstract" name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_UnderwrittenPublicOfferingMember" name="UnderwrittenPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_JefferiesMember" name="JefferiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_PercentageOfSalesCommission" name="PercentageOfSalesCommission" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_SharesIssuedAveragePricePerShare" name="SharesIssuedAveragePricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_PercentageOfSalesCommissionAndIssuanceCost" name="PercentageOfSalesCommissionAndIssuanceCost" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_StockOptionsIssuedAndOutstanding" name="StockOptionsIssuedAndOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_TwoThousandFifteenStockIncentivePlanMember" name="TwoThousandFifteenStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_TwoThousandNineteenStockIncentivePlanMember" name="TwoThousandNineteenStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_EarlyExerciseOfEmployeeOptionsMember" name="EarlyExerciseOfEmployeeOptionsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_NonEmployeesMember" name="NonEmployeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="ctmx_NetOperatingLossCarrybackPeriod" name="NetOperatingLossCarrybackPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation" name="PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" name="EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" name="EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" name="OperatingLossCarryforwardsAmountToExpireIfNotUsed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" name="OperatingLossCarryforwardsAmountNotSubjectToExpiration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="ctmx_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_PercentageOfChangeInOwnership" name="PercentageOfChangeInOwnership" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares" name="OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>24
<FILENAME>ctmx-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-24T16:43:22.0335375+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 19fb4f4ba39c4e5496fc22bf5dabd4ad -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="ctmx-20201231.xsd#TemplateLink" roleURI="http://cytomx.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS" xlink:href="ctmx-20201231.xsd#Role_StatementBALANCESHEETS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10210.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10250.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10260.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="ctmx-20201231.xsd#Role_StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InvestmentIncomeInterest" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS" xlink:href="ctmx-20201231.xsd#Role_StatementSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NoncashLeaseExpense" xlink:type="locator" xlink:label="ctmx_NoncashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ctmx_NoncashLeaseExpense" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10170.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="10210.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ComputerEquipmentAndSoftwareGross" xlink:type="locator" xlink:label="ctmx_ComputerEquipmentAndSoftwareGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="ctmx_ComputerEquipmentAndSoftwareGross" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_FurnitureAndFixturesGross" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_LeaseholdImprovementsGross" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_ConstructionInProgressGross" order="10070.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AccruedResearchAndClinicalCurrent" xlink:type="locator" xlink:label="ctmx_AccruedResearchAndClinicalCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="ctmx_AccruedResearchAndClinicalCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:type="locator" xlink:label="ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails2" xlink:href="ctmx-20201231.xsd#Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_StockOptionsIssuedAndOutstanding" xlink:type="locator" xlink:label="ctmx_StockOptionsIssuedAndOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="ctmx_StockOptionsIssuedAndOutstanding" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan" order="10030.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:type="locator" xlink:label="ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" xlink:type="locator" xlink:label="ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DeferredTaxAssetsLeaseLiability" xlink:type="locator" xlink:label="ctmx_DeferredTaxAssetsLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="ctmx_DeferredTaxAssetsLeaseLiability" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10170.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>25
<FILENAME>ctmx-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-24T16:43:22.0335375+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 19fb4f4ba39c4e5496fc22bf5dabd4ad -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="ctmx-20201231.xsd#TemplateLink" roleURI="http://cytomx.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS" xlink:href="ctmx-20201231.xsd#Role_StatementBALANCESHEETS" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10270.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11860.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical" xlink:href="ctmx-20201231.xsd#Role_StatementBALANCESHEETSParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10460.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="ctmx-20201231.xsd#Role_StatementSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11540.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AstellasPharmaIncMember" xlink:type="locator" xlink:label="ctmx_AstellasPharmaIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_BristolMyersSquibbCompanyMember" xlink:type="locator" xlink:label="ctmx_BristolMyersSquibbCompanyMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MajorCustomerMember" xlink:type="locator" xlink:label="ctmx_MajorCustomerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ctmx_MajorCustomerMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_CounterpartyNameAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_BristolMyersSquibbCompanyMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AstellasPharmaIncMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10760.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfBusinessActivities" xlink:type="locator" xlink:label="ctmx_NumberOfBusinessActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ProbodyTechnologyMember" xlink:type="locator" xlink:label="ctmx_ProbodyTechnologyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ctmx_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ctmx_ProbodyTechnologyMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ctmx_NumberOfBusinessActivities" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10770.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="ctmx_ComputerEquipmentAndSoftwareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ctmx_ComputerEquipmentAndSoftwareMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10240.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201908Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201908Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201815Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201704Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201704Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ctmx_SummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201704Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201815Member" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201908Member" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10850.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OptionsAndESPPToPurchaseCommonStockMember" xlink:type="locator" xlink:label="ctmx_OptionsAndESPPToPurchaseCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="ctmx_OptionsAndESPPToPurchaseCommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10120.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MoneyMarketFundsIncludedInRestrictedCashMember" xlink:type="locator" xlink:label="ctmx_MoneyMarketFundsIncludedInRestrictedCashMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10090.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="ctmx_MoneyMarketFundsIncludedInRestrictedCashMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" order="11820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="11980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="12280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="12440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="12600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="12760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="12920.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_GoodwillAbstract" xlink:type="locator" xlink:label="ctmx_GoodwillAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:type="locator" xlink:label="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_GoodwillAndIntangibleAssetsLineItems" xlink:type="locator" xlink:label="ctmx_GoodwillAndIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ctmx_GoodwillAndIntangibleAssetsLineItems" xlink:to="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_GoodwillAndIntangibleAssetsLineItems" xlink:to="ctmx_GoodwillAbstract" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_GoodwillAbstract" xlink:to="us-gaap_Goodwill" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_GoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10480.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PfizerIncMember" xlink:type="locator" xlink:label="ctmx_PfizerIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ImmunoGenIncMember" xlink:type="locator" xlink:label="ctmx_ImmunoGenIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AstellasPharmaIncMember" xlink:type="locator" xlink:label="ctmx_AstellasPharmaIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_BristolMyersSquibbCompanyMember" xlink:type="locator" xlink:label="ctmx_BristolMyersSquibbCompanyMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenIncMember" xlink:type="locator" xlink:label="ctmx_AmgenIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AmgenIncMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_BristolMyersSquibbCompanyMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AstellasPharmaIncMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_ImmunoGenIncMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_PfizerIncMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedResearchServicePeriod" xlink:type="locator" xlink:label="ctmx_EstimatedResearchServicePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentsReceivable" xlink:type="locator" xlink:label="ctmx_MilestonePaymentsReceivable" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfAccountingUnits" xlink:type="locator" xlink:label="ctmx_NumberOfAccountingUnits" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedSublicenseFees" xlink:type="locator" xlink:label="ctmx_EstimatedSublicenseFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AggregateCollaborationTransactionAmount" xlink:type="locator" xlink:label="ctmx_AggregateCollaborationTransactionAmount" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentMilestonePaymentsReceivable" xlink:type="locator" xlink:label="ctmx_ContingentMilestonePaymentsReceivable" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentReceived" xlink:type="locator" xlink:label="ctmx_MilestonePaymentReceived" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargetsSelected" xlink:type="locator" xlink:label="ctmx_NumberOfTargetsSelected" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargets" xlink:type="locator" xlink:label="ctmx_NumberOfTargets" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PaymentsOfSublicenseFees" xlink:type="locator" xlink:label="ctmx_PaymentsOfSublicenseFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" xlink:type="locator" xlink:label="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentPaymentsReceivableProfitSplitOnSales" xlink:type="locator" xlink:label="ctmx_ContingentPaymentsReceivableProfitSplitOnSales" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts" xlink:type="locator" xlink:label="ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfCollaborationAgreements" xlink:type="locator" xlink:label="ctmx_NumberOfCollaborationAgreements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:type="locator" xlink:label="us-gaap_TransferredOverTimeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="locator" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="locator" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="locator" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecondTargetMember" xlink:type="locator" xlink:label="ctmx_SecondTargetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember" xlink:type="locator" xlink:label="ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_DiscoveryAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SeattleGeneticsAgreementMember" xlink:type="locator" xlink:label="ctmx_SeattleGeneticsAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CD71AgreementMember" xlink:type="locator" xlink:label="ctmx_CD71AgreementMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CD71AgreementMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_SeattleGeneticsAgreementMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_DiscoveryAgreementMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_2" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_2" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="11310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_SecondTargetMember" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="11610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceAxis" order="12720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceDomain_2" order="12730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceDomain" order="12750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="us-gaap_TransferredOverTimeMember" order="12770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfCollaborationAgreements" order="13180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts" order="13200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="13250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" order="13270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentPaymentsReceivableProfitSplitOnSales" order="13290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" order="13310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_PaymentsOfSublicenseFees" order="13350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfTargets" order="13480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfTargetsSelected" order="13520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_MilestonePaymentReceived" order="13610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentMilestonePaymentsReceivable" order="13630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_AggregateCollaborationTransactionAmount" order="13680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedSublicenseFees" order="13760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfAccountingUnits" order="13780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_MilestonePaymentsReceivable" order="13840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="14060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="14080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="14150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedResearchServicePeriod" order="14190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="14470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="14590.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_DiscoveryAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_DiscoveryAgreementMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10190.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1Default" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1Default" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1Default">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_DiscoveryAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_DiscoveryAgreementMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10080.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedResearchServicePeriod" xlink:type="locator" xlink:label="ctmx_EstimatedResearchServicePeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedFairValueOfProducts" xlink:type="locator" xlink:label="ctmx_EstimatedFairValueOfProducts" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock" xlink:type="locator" xlink:label="ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AggregateCollaborationTransactionAmount" xlink:type="locator" xlink:label="ctmx_AggregateCollaborationTransactionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds" xlink:type="locator" xlink:label="ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfAdditionalCollaborationTarget" xlink:type="locator" xlink:label="ctmx_NumberOfAdditionalCollaborationTarget" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargetsSelected" xlink:type="locator" xlink:label="ctmx_NumberOfTargetsSelected" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargets" xlink:type="locator" xlink:label="ctmx_NumberOfTargets" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ProfitShareUponExerciseOfCoDevelopmentOption" xlink:type="locator" xlink:label="ctmx_ProfitShareUponExerciseOfCoDevelopmentOption" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentMilestonePaymentsReceivable" xlink:type="locator" xlink:label="ctmx_ContingentMilestonePaymentsReceivable" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedPremiumOnIssuanceOfShares" xlink:type="locator" xlink:label="ctmx_EstimatedPremiumOnIssuanceOfShares" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement" xlink:type="locator" xlink:label="ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare" xlink:type="locator" xlink:label="ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CommonStockSharesIssuableUnderAgreement" xlink:type="locator" xlink:label="ctmx_CommonStockSharesIssuableUnderAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenOtherProductsMember" xlink:type="locator" xlink:label="ctmx_AmgenOtherProductsMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_RegentsOfTheUniversityOfCaliforniaMember" xlink:type="locator" xlink:label="ctmx_RegentsOfTheUniversityOfCaliforniaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SublicenseAgreementMember" xlink:type="locator" xlink:label="ctmx_SublicenseAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenProductsMember" xlink:type="locator" xlink:label="ctmx_AmgenProductsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EGFRProductsMember" xlink:type="locator" xlink:label="ctmx_EGFRProductsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenIncMember" xlink:type="locator" xlink:label="ctmx_AmgenIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="ctmx_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CollaborationAndLicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AmgenIncMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_EGFRProductsMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_AmgenProductsMember" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_SublicenseAgreementMember" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="11520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="11550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ctmx_RegentsOfTheUniversityOfCaliforniaMember" order="11570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_AmgenOtherProductsMember" order="12230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="12840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_CommonStockSharesIssuableUnderAgreement" order="12860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" order="12880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare" order="12920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement" order="12940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedPremiumOnIssuanceOfShares" order="12960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentMilestonePaymentsReceivable" order="13010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ProfitShareUponExerciseOfCoDevelopmentOption" order="13030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfTargets" order="13080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfTargetsSelected" order="13100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfAdditionalCollaborationTarget" order="13120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" order="13190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds" order="13240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="13260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_AggregateCollaborationTransactionAmount" order="13330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock" order="13370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedFairValueOfProducts" order="13390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedResearchServicePeriod" order="13500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="13570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="13640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="13700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="13760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="13880.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedResearchServiceTerminationMonthAndYear" xlink:type="locator" xlink:label="ctmx_EstimatedResearchServiceTerminationMonthAndYear" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedResearchServicePeriod" xlink:type="locator" xlink:label="ctmx_EstimatedResearchServicePeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ResearchAndDevelopmentServiceFees" xlink:type="locator" xlink:label="ctmx_ResearchAndDevelopmentServiceFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AggregateCollaborationTransactionAmount" xlink:type="locator" xlink:label="ctmx_AggregateCollaborationTransactionAmount" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentMilestonePaymentsReceivable" xlink:type="locator" xlink:label="ctmx_ContingentMilestonePaymentsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_RightToExpandNumberOfAdditionalCollaborationTarget" xlink:type="locator" xlink:label="ctmx_RightToExpandNumberOfAdditionalCollaborationTarget" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfAdditionalCollaborationTarget" xlink:type="locator" xlink:label="ctmx_NumberOfAdditionalCollaborationTarget" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargetsSelected" xlink:type="locator" xlink:label="ctmx_NumberOfTargetsSelected" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargets" xlink:type="locator" xlink:label="ctmx_NumberOfTargets" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AdditionalContingentPaymentsMember" xlink:type="locator" xlink:label="ctmx_AdditionalContingentPaymentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AstellasPharmaIncMember" xlink:type="locator" xlink:label="ctmx_AstellasPharmaIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="ctmx_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CollaborationAndLicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AstellasPharmaIncMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="ctmx_AdditionalContingentPaymentsMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfTargets" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfTargetsSelected" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfAdditionalCollaborationTarget" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_RightToExpandNumberOfAdditionalCollaborationTarget" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentMilestonePaymentsReceivable" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_AggregateCollaborationTransactionAmount" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ResearchAndDevelopmentServiceFees" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedResearchServicePeriod" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedResearchServiceTerminationMonthAndYear" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="11380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive" xlink:type="locator" xlink:label="ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedResearchServiceTerminationDate" xlink:type="locator" xlink:label="ctmx_EstimatedResearchServiceTerminationDate" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" xlink:type="locator" xlink:label="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ResearchAndDevelopmentServiceFees" xlink:type="locator" xlink:label="ctmx_ResearchAndDevelopmentServiceFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UpfrontFeeReceived" xlink:type="locator" xlink:label="ctmx_UpfrontFeeReceived" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AggregateCollaborationTransactionAmount" xlink:type="locator" xlink:label="ctmx_AggregateCollaborationTransactionAmount" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfResearchTargetsSelected" xlink:type="locator" xlink:label="ctmx_NumberOfResearchTargetsSelected" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentMilestonePaymentsReceivable" xlink:type="locator" xlink:label="ctmx_ContingentMilestonePaymentsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes" xlink:type="locator" xlink:label="ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ExtensionOfResearchTermForEachCollaborationTarget" xlink:type="locator" xlink:label="ctmx_ExtensionOfResearchTermForEachCollaborationTarget" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PeriodOfNominationOfAdditionalTarget" xlink:type="locator" xlink:label="ctmx_PeriodOfNominationOfAdditionalTarget" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfAdditionalCollaborationTarget" xlink:type="locator" xlink:label="ctmx_NumberOfAdditionalCollaborationTarget" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CollaborationTargetResearchTerm" xlink:type="locator" xlink:label="ctmx_CollaborationTargetResearchTerm" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfCollaborationTarget" xlink:type="locator" xlink:label="ctmx_NumberOfCollaborationTarget" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfOncologyTarget" xlink:type="locator" xlink:label="ctmx_NumberOfOncologyTarget" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AcceleratedRecognitionOfDeferredRevenueMember" xlink:type="locator" xlink:label="ctmx_AcceleratedRecognitionOfDeferredRevenueMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ThirdAndFourthTargetsMember" xlink:type="locator" xlink:label="ctmx_ThirdAndFourthTargetsMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="ctmx_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DrugApplicationForCTLA4Member" xlink:type="locator" xlink:label="ctmx_DrugApplicationForCTLA4Member" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PreClinicalCandidateMember" xlink:type="locator" xlink:label="ctmx_PreClinicalCandidateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AchievingAdditionalTargetsMember" xlink:type="locator" xlink:label="ctmx_AchievingAdditionalTargetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_BristolMyersSquibbCompanyMember" xlink:type="locator" xlink:label="ctmx_BristolMyersSquibbCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_BristolMyersSquibbCompanyMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="ctmx_AchievingAdditionalTargetsMember" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="11090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_PreClinicalCandidateMember" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_DrugApplicationForCTLA4Member" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CollaborationAndLicenseAgreementMember" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_ThirdAndFourthTargetsMember" order="11910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_AcceleratedRecognitionOfDeferredRevenueMember" order="11930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" order="12080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_2" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="12110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="12130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfOncologyTarget" order="12400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfCollaborationTarget" order="12420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_CollaborationTargetResearchTerm" order="12440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfAdditionalCollaborationTarget" order="12460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" order="12480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_PeriodOfNominationOfAdditionalTarget" order="12500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ExtensionOfResearchTermForEachCollaborationTarget" order="12520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes" order="12540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="12590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentMilestonePaymentsReceivable" order="12610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfResearchTargetsSelected" order="12900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_AggregateCollaborationTransactionAmount" order="12970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_UpfrontFeeReceived" order="12990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ResearchAndDevelopmentServiceFees" order="13010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" order="13030.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedResearchServiceTerminationDate" order="13050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="13100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive" order="13140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="13410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="13470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="13530.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentPayable" xlink:type="locator" xlink:label="ctmx_MilestonePaymentPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfResearchTargetsSelected" xlink:type="locator" xlink:label="ctmx_NumberOfResearchTargetsSelected" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashPaymentToExecuteAgreement" xlink:type="locator" xlink:label="ctmx_CashPaymentToExecuteAgreement" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ImmunoGenIncMember" xlink:type="locator" xlink:label="ctmx_ImmunoGenIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_ImmunoGenIncMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_CashPaymentToExecuteAgreement" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfResearchTargetsSelected" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_MilestonePaymentPayable" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10760.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="ctmx_ContractWithCustomerLiabilityAdditions" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfAdditionalResearchTargetsWithNominationOption" xlink:type="locator" xlink:label="ctmx_NumberOfAdditionalResearchTargetsWithNominationOption" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfNominatedResearchTargets" xlink:type="locator" xlink:label="ctmx_NumberOfNominatedResearchTargets" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PfizerIncMember" xlink:type="locator" xlink:label="ctmx_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_PfizerIncMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfNominatedResearchTargets" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfAdditionalResearchTargetsWithNominationOption" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContractWithCustomerLiabilityAdditions" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear" xlink:type="locator" xlink:label="ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="ctmx_ContractWithCustomerLiabilityAdditions" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenOtherProductsMember" xlink:type="locator" xlink:label="ctmx_AmgenOtherProductsMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EGFRProductsMember" xlink:type="locator" xlink:label="ctmx_EGFRProductsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecondTargetUnderDiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_SecondTargetUnderDiscoveryAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_FirstTargetUnderDiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_FirstTargetUnderDiscoveryAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CD71AgreementMember" xlink:type="locator" xlink:label="ctmx_CD71AgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_BristolMyersSquibbCompanyMember" xlink:type="locator" xlink:label="ctmx_BristolMyersSquibbCompanyMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenIncMember" xlink:type="locator" xlink:label="ctmx_AmgenIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AstellasPharmaIncMember" xlink:type="locator" xlink:label="ctmx_AstellasPharmaIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AstellasPharmaIncMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AmgenIncMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_BristolMyersSquibbCompanyMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CD71AgreementMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_FirstTargetUnderDiscoveryAgreementMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_SecondTargetUnderDiscoveryAgreementMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_EGFRProductsMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_AmgenOtherProductsMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContractWithCustomerLiabilityAdditions" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear" order="10790.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureLicenseAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UpfrontLicensePayment" xlink:type="locator" xlink:label="ctmx_UpfrontLicensePayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" xlink:type="locator" xlink:label="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SublicenseFees" xlink:type="locator" xlink:label="ctmx_SublicenseFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentReceivable" xlink:type="locator" xlink:label="ctmx_MilestonePaymentReceivable" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AdditionalSublicenseFees" xlink:type="locator" xlink:label="ctmx_AdditionalSublicenseFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_FairValueOfCommonStockIssued" xlink:type="locator" xlink:label="ctmx_FairValueOfCommonStockIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfRemainingMaintenanceFeesOutstanding" xlink:type="locator" xlink:label="ctmx_PercentageOfRemainingMaintenanceFeesOutstanding" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LicensePaymentTerm" xlink:type="locator" xlink:label="ctmx_LicensePaymentTerm" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AnnualLicenseMaintenanceFees" xlink:type="locator" xlink:label="ctmx_AnnualLicenseMaintenanceFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PaymentOfUpfrontFees" xlink:type="locator" xlink:label="ctmx_PaymentOfUpfrontFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LicenseTerminationPeriod" xlink:type="locator" xlink:label="ctmx_LicenseTerminationPeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_RoyaltyObligationsFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="ctmx_RoyaltyObligationsFutureMinimumPaymentsDue" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ImmunoGenIncMember" xlink:type="locator" xlink:label="ctmx_ImmunoGenIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CD71AgreementMember" xlink:type="locator" xlink:label="ctmx_CD71AgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="ctmx_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AstellasPharmaIncMember" xlink:type="locator" xlink:label="ctmx_AstellasPharmaIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_BristolMyersSquibbCompanyMember" xlink:type="locator" xlink:label="ctmx_BristolMyersSquibbCompanyMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecondTargetMember" xlink:type="locator" xlink:label="ctmx_SecondTargetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_DiscoveryAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieMember" xlink:type="locator" xlink:label="ctmx_AbbVieMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SublicenseAndMaintenanceFeesMember" xlink:type="locator" xlink:label="ctmx_SublicenseAndMaintenanceFeesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UniversityOfCaliforniaSantaBarbaraMember" xlink:type="locator" xlink:label="ctmx_UniversityOfCaliforniaSantaBarbaraMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ctmx_UniversityOfCaliforniaSantaBarbaraMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="ctmx_SublicenseAndMaintenanceFeesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_DiscoveryAgreementMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_ProductOrServiceAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_SecondTargetMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_BristolMyersSquibbCompanyMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AstellasPharmaIncMember" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CollaborationAndLicenseAgreementMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CD71AgreementMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_ImmunoGenIncMember" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_RoyaltyObligationsFutureMinimumPaymentsDue" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_LicenseTerminationPeriod" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_PaymentOfUpfrontFees" order="11280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_AnnualLicenseMaintenanceFees" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_LicensePaymentTerm" order="11320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_PercentageOfRemainingMaintenanceFeesOutstanding" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_FairValueOfCommonStockIssued" order="11400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_AdditionalSublicenseFees" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_MilestonePaymentReceivable" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_SublicenseFees" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" order="11760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_UpfrontLicensePayment" order="11980.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants" xlink:type="locator" xlink:label="ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="locator" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate" xlink:type="locator" xlink:label="ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate" xlink:type="locator" xlink:label="ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:type="locator" xlink:label="us-gaap_LossContingencyNameOfPlaintiff" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:type="locator" xlink:label="us-gaap_LossContingencyLawsuitFilingDate" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecuritiesClassActionLawsuitMember" xlink:type="locator" xlink:label="ctmx_SecuritiesClassActionLawsuitMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PatentInfringementLawsuitMember" xlink:type="locator" xlink:label="ctmx_PatentInfringementLawsuitMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:type="locator" xlink:label="srt_LitigationCaseTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:type="locator" xlink:label="srt_LitigationCaseTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:type="locator" xlink:label="srt_LitigationCaseAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_LitigationCaseAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="ctmx_PatentInfringementLawsuitMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="ctmx_SecuritiesClassActionLawsuitMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyLawsuitFilingDate" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyNameOfPlaintiff" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants" order="10390.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:type="locator" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ImprovementAllowanceFromRecoverableRent" xlink:type="locator" xlink:label="ctmx_ImprovementAllowanceFromRecoverableRent" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MaximumImprovementAllowance" xlink:type="locator" xlink:label="ctmx_MaximumImprovementAllowance" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OperatingLeasesRentExpenseAnnualBaseRent" xlink:type="locator" xlink:label="ctmx_OperatingLeasesRentExpenseAnnualBaseRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:type="locator" xlink:label="us-gaap_AreaOfLand" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_TenthYearOfLeaseTermMember" xlink:type="locator" xlink:label="ctmx_TenthYearOfLeaseTermMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecondTwelveMonthsOfLeaseTermMember" xlink:type="locator" xlink:label="ctmx_SecondTwelveMonthsOfLeaseTermMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_FirstYearOfLeaseTermMember" xlink:type="locator" xlink:label="ctmx_FirstYearOfLeaseTermMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ctmx_FirstYearOfLeaseTermMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ctmx_SecondTwelveMonthsOfLeaseTermMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ctmx_TenthYearOfLeaseTermMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_CreditFacilityAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_2" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_AreaOfLand" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="ctmx_OperatingLeasesRentExpenseAnnualBaseRent" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="ctmx_MaximumImprovementAllowance" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="ctmx_ImprovementAllowanceFromRecoverableRent" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10880.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfSalesCommissionAndIssuanceCost" xlink:type="locator" xlink:label="ctmx_PercentageOfSalesCommissionAndIssuanceCost" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SharesIssuedAveragePricePerShare" xlink:type="locator" xlink:label="ctmx_SharesIssuedAveragePricePerShare" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfSalesCommission" xlink:type="locator" xlink:label="ctmx_PercentageOfSalesCommission" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_JefferiesMember" xlink:type="locator" xlink:label="ctmx_JefferiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="ctmx_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ctmx_UnderwrittenPublicOfferingMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_JefferiesMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ctmx_PercentageOfSalesCommission" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ctmx_SharesIssuedAveragePricePerShare" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ctmx_PercentageOfSalesCommissionAndIssuanceCost" order="11130.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NonEmployeesMember" xlink:type="locator" xlink:label="ctmx_NonEmployeesMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="ctmx_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EarlyExerciseOfEmployeeOptionsMember" xlink:type="locator" xlink:label="ctmx_EarlyExerciseOfEmployeeOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_TwoThousandNineteenStockIncentivePlanMember" xlink:type="locator" xlink:label="ctmx_TwoThousandNineteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_TwoThousandFifteenStockIncentivePlanMember" xlink:type="locator" xlink:label="ctmx_TwoThousandFifteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ctmx_TwoThousandFifteenStockIncentivePlanMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ctmx_TwoThousandNineteenStockIncentivePlanMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="ctmx_EarlyExerciseOfEmployeeOptionsMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ctmx_EmployeeStockPurchasePlanMember" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ctmx_NonEmployeesMember" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="11370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="12010.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="12220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12280.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" order="10480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="12340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="12580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="13570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="14050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="14200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="14440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="14800.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationAbstract" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10260.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="ctmx_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ctmx_EmployeeStockPurchasePlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="11060.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfChangeInOwnership" xlink:type="locator" xlink:label="ctmx_PercentageOfChangeInOwnership" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="ctmx_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" xlink:type="locator" xlink:label="ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" xlink:type="locator" xlink:label="ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="ctmx_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation" xlink:type="locator" xlink:label="ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NetOperatingLossCarrybackPeriod" xlink:type="locator" xlink:label="ctmx_NetOperatingLossCarrybackPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_NetOperatingLossCarrybackPeriod" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_OperatingLossCarryforwardsExpirationYear" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" order="10990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_TaxCreditCarryforwardExpirationYear" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_PercentageOfChangeInOwnership" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="11340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" order="11430.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares" xlink:type="locator" xlink:label="ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="ctmx_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ctmx_UnderwrittenPublicOfferingMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares" order="10700.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>26
<FILENAME>ctmx-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-24T16:43:22.0345368+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 19fb4f4ba39c4e5496fc22bf5dabd4ad -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and short term investments, allowance for credit loss.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and short term investments, accumulated gross unrealized gain before tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and short term investments, accumulated gross unrealized loss before tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:type="locator" xlink:label="ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" />
    <link:label xml:lang="en-US" xlink:label="ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due year five and thereafter.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:to="ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Indefinite Lived Intangible Assets Excluding Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues, current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities - long term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 11)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued and outstanding at December 31, 2020 and 2019</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.00001 par value; 150,000,000 and 75,000,000 shares authorized at December 31, 2020 and 2019, respectively; 48,251,819 and 45,523,088 shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&apos; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Revenue [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Revenue Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provision for (benefit from) income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Per Basic And Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used to compute net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on short-term investments, net of tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impact of adoption of new accounting pronouncement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:to="us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts And Jobs Act Of2017 Reclassification From Aoci To Retained Earnings Tax Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income/(Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Period Of Adoption [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Period Of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Effect Period Of Adoption Adjustment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in follow-on offering, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in follow-on offering, net of issuance costs, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under the Employee Stock Purchase Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under the Employee Stock Purchase Plan, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to UCSB</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Issued For Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock to UCSB, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Issued For Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance, shares</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Depreciation and amortization excluding amortization of intangible assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" xlink:to="ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NoncashLeaseExpense" xlink:type="locator" xlink:label="ctmx_NoncashLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NoncashLeaseExpense" xlink:to="ctmx_NoncashLeaseExpense_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in accrued liabilities, income tax payable and other liabilities noncurrent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" xlink:to="ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization Excluding Amortization Of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accretion of discount on investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with UCSB sublicense fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Stock And Warrants For Services Or Claims</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities, income tax payable and other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities Income Tax Payable And Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of short-term investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Available For Sale Securities Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from employee stock purchase plan and exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of cash flow information:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of noncash investing items:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchases of property and equipment in accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use assets obtained in exchange for operating lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Asset Obtained In Exchange For Operating Lease Liability</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Text Block [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of the Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nature Of Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Presentation And Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock" xlink:type="locator" xlink:label="ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adopted and recent accounting pronouncements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock" xlink:to="ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adopted and Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adopted And Recent Accounting Pronouncements [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements and Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ResearchAndCollaborationAgreementsTextBlock" xlink:type="locator" xlink:label="ctmx_ResearchAndCollaborationAgreementsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ResearchAndCollaborationAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and collaboration agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ResearchAndCollaborationAgreementsTextBlock" xlink:to="ctmx_ResearchAndCollaborationAgreementsTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ResearchAndCollaborationAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Collaboration Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ResearchAndCollaborationAgreementsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Collaboration Agreements [Text Block]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LicenseAgreementDisclosureTextBlock" xlink:type="locator" xlink:label="ctmx_LicenseAgreementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ctmx_LicenseAgreementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_LicenseAgreementDisclosureTextBlock" xlink:to="ctmx_LicenseAgreementDisclosureTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_LicenseAgreementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LicenseAgreementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CommonStockTextBlock" xlink:type="locator" xlink:label="ctmx_CommonStockTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CommonStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_CommonStockTextBlock" xlink:to="ctmx_CommonStockTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CommonStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CommonStockTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill and Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Balances</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leases Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adopted Accounting Pronouncements and Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Customers and Collaboration Partners who Represent 10% or More of Total Revenue During Each Period Presented or Net Accounts Receivable Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedules Of Concentration Of Risk By Risk Factor [Text Block]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="locator" xlink:label="ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of cash, cash equivalents, and restricted cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="locator" xlink:label="ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of property plant and equipment estimated useful lives.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Useful Lives of Property and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Short-Term Investments Subject to Fair Value Measurements on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Goodwill and Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Intangible Assets And Goodwill Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue by Collaboration Partners</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disaggregation Of Revenue Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Contract Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset And Liability Table [Text Block]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SupplementalInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="ctmx_SupplementalInformationRelatedToLeasesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SupplementalInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental information related to leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_SupplementalInformationRelatedToLeasesTableTextBlock" xlink:to="ctmx_SupplementalInformationRelatedToLeasesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SupplementalInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Supplemental Information Related to Leases</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SupplementalInformationRelatedToLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Information Related To Leases Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Reserved Shares of Common Stock Issuance on Converted Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Activity Under Company&apos;s Stock Option Plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total Stock-based Compensation Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Fair Value of Employee Stock Options and ESPP Using Black-Scholes Valuation Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Provision for (Benefit from) Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Tax Rate Reconciliation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Income Tax Assets and Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Income Tax Contingencies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MajorCustomersAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Customers [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Name Of Major Customer [Domain]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MajorCustomerMember" xlink:type="locator" xlink:label="ctmx_MajorCustomerMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_MajorCustomerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Major customer [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_MajorCustomerMember" xlink:to="ctmx_MajorCustomerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_MajorCustomerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Customer</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_MajorCustomerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Customer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">AbbVie Ireland Unlimited Company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AbbVie Ireland Unlimited Company</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Abb Vie Ireland Unlimited Company [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_BristolMyersSquibbCompanyMember" xlink:type="locator" xlink:label="ctmx_BristolMyersSquibbCompanyMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_BristolMyersSquibbCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bristol-Myers Squibb Company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_BristolMyersSquibbCompanyMember" xlink:to="ctmx_BristolMyersSquibbCompanyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_BristolMyersSquibbCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bristol Myers Squibb Company</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_BristolMyersSquibbCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bristol Myers Squibb Company [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AstellasPharmaIncMember" xlink:type="locator" xlink:label="ctmx_AstellasPharmaIncMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AstellasPharmaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Astellas Pharma Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AstellasPharmaIncMember" xlink:to="ctmx_AstellasPharmaIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AstellasPharmaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Astellas Pharma Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AstellasPharmaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Astellas Pharma Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Accounts Receivable, net</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfBusinessActivities" xlink:type="locator" xlink:label="ctmx_NumberOfBusinessActivities" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfBusinessActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of business activities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NumberOfBusinessActivities" xlink:to="ctmx_NumberOfBusinessActivities_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ctmx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="ctmx_SummaryOfSignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Application Period Cumulative Effect Transition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Application Period Cumulative Effect Transition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Difference Between Revenue Guidance In Effect Before And After Topic606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 606</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201409 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ProbodyTechnologyMember" xlink:type="locator" xlink:label="ctmx_ProbodyTechnologyMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ProbodyTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Probody technology.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ProbodyTechnologyMember" xlink:to="ctmx_ProbodyTechnologyMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ProbodyTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probody technology</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ProbodyTechnologyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Probody Technology [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 842</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201602 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfBusinessActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of business activities</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfBusinessActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Business Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, cash equivalents, and restricted cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Machinery And Equipment [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="ctmx_ComputerEquipmentAndSoftwareMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ComputerEquipmentAndSoftwareMember" xlink:to="ctmx_ComputerEquipmentAndSoftwareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer equipment and software</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ComputerEquipmentAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful life of leasehold improvements, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Indefinitelived Excluding Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Long Lived Assets Held For Use</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in accumulated deficit balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired, technology know-how</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finitelived Intangible Assets Acquired1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Right-of-use asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201613 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201704Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201704Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201704Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2017-04</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201704Member" xlink:to="us-gaap_AccountingStandardsUpdate201704Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201704Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201704 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-13</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201813Member" xlink:to="us-gaap_AccountingStandardsUpdate201813Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201813 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201815Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201815Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-15</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201815Member" xlink:to="us-gaap_AccountingStandardsUpdate201815Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201815Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201815 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-18</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201818Member" xlink:to="us-gaap_AccountingStandardsUpdate201818Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201818Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201818 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201908Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201908Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201908Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-08</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201908Member" xlink:to="us-gaap_AccountingStandardsUpdate201908Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201908Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201908 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2019-12</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201912Member" xlink:to="us-gaap_AccountingStandardsUpdate201912Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201912Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201912 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instrument Risk [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Contract Type [Domain]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OptionsAndESPPToPurchaseCommonStockMember" xlink:type="locator" xlink:label="ctmx_OptionsAndESPPToPurchaseCommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_OptionsAndESPPToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options and ESPP to purchase common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_OptionsAndESPPToPurchaseCommonStockMember" xlink:to="ctmx_OptionsAndESPPToPurchaseCommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_OptionsAndESPPToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options and ESPP to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_OptionsAndESPPToPurchaseCommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options And E S P P To Purchase Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Anti-dilutive securities excluded from computation of diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash, cash equivalents and short term investments, amortized cost basis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level I</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MoneyMarketFundsIncludedInRestrictedCashMember" xlink:type="locator" xlink:label="ctmx_MoneyMarketFundsIncludedInRestrictedCashMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_MoneyMarketFundsIncludedInRestrictedCashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Money market funds included in restricted cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_MoneyMarketFundsIncludedInRestrictedCashMember" xlink:to="ctmx_MoneyMarketFundsIncludedInRestrictedCashMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_MoneyMarketFundsIncludedInRestrictedCashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash (money market funds)</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_MoneyMarketFundsIncludedInRestrictedCashMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds Included In Restricted Cash [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U. S. Government bonds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryAndGovernmentMember" xlink:to="us-gaap_USTreasuryAndGovernmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_USTreasuryAndGovernmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury And Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for Credit Losses</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments Allowance For Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Holding Gains</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized Holding Losses</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Investments, Amortized Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Allowance For Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments, Gross Unrealized Holding Gains</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Short-term Investments, Gross Unrealized Holding Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term Investments, Aggregate Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contractual maturities of greater than twelve months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Maturities Within One Year Fair Value</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ComputerEquipmentAndSoftwareGross" xlink:type="locator" xlink:label="ctmx_ComputerEquipmentAndSoftwareGross" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ComputerEquipmentAndSoftwareGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software gross.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ComputerEquipmentAndSoftwareGross" xlink:to="ctmx_ComputerEquipmentAndSoftwareGross_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentGross" xlink:to="us-gaap_MachineryAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Machinery And Equipment Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ComputerEquipmentAndSoftwareGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer equipment and software</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ComputerEquipmentAndSoftwareGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesGross" xlink:to="us-gaap_FurnitureAndFixturesGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in progress</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressGross" xlink:to="us-gaap_ConstructionInProgressGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Depreciation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPR&amp;D [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research And Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average estimated lives of patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Acquired Finite Lived Intangible Assets Weighted Average Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amortization expense of intangible assets</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_GoodwillAbstract" xlink:type="locator" xlink:label="ctmx_GoodwillAbstract" />
    <link:label xml:lang="en-US" xlink:label="ctmx_GoodwillAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Goodwill.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_GoodwillAbstract" xlink:to="ctmx_GoodwillAbstract_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_GoodwillAndIntangibleAssetsLineItems" xlink:type="locator" xlink:label="ctmx_GoodwillAndIntangibleAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="ctmx_GoodwillAndIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Goodwill and intangible assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_GoodwillAndIntangibleAssetsLineItems" xlink:to="ctmx_GoodwillAndIntangibleAssetsLineItems_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:type="locator" xlink:label="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of goodwill and intangible assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Goodwill And Intangible Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Goodwill And Intangible Assets [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_GoodwillAndIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill And Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_GoodwillAndIntangibleAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_GoodwillAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_GoodwillAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Intangible assets, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Net</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AccruedResearchAndClinicalCurrent" xlink:type="locator" xlink:label="ctmx_AccruedResearchAndClinicalCurrent" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AccruedResearchAndClinicalCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and clinical current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AccruedResearchAndClinicalCurrent" xlink:to="ctmx_AccruedResearchAndClinicalCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AccruedResearchAndClinicalCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and clinical expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AccruedResearchAndClinicalCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Clinical Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and related expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal and professional expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities - short term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">AbbVie</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenIncMember" xlink:type="locator" xlink:label="ctmx_AmgenIncMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AmgenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amgen Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AmgenIncMember" xlink:to="ctmx_AmgenIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AmgenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amgen</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AmgenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amgen Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AstellasPharmaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Astellas</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ImmunoGenIncMember" xlink:type="locator" xlink:label="ctmx_ImmunoGenIncMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ImmunoGenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ImmunoGen, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ImmunoGenIncMember" xlink:to="ctmx_ImmunoGenIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ImmunoGenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">ImmunoGen</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ImmunoGenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Immuno Gen Inc [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PfizerIncMember" xlink:type="locator" xlink:label="ctmx_PfizerIncMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PfizerIncMember" xlink:to="ctmx_PfizerIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Pfizer</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfCollaborationAgreements" xlink:type="locator" xlink:label="ctmx_NumberOfCollaborationAgreements" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfCollaborationAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of collaboration agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NumberOfCollaborationAgreements" xlink:to="ctmx_NumberOfCollaborationAgreements_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts" xlink:type="locator" xlink:label="ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of net Income or net losses related to development and commercialization costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts" xlink:to="ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" />
    <link:label xml:lang="en-US" xlink:label="country_US_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CD71AgreementMember" xlink:type="locator" xlink:label="ctmx_CD71AgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CD71AgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">CD 71 agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_CD71AgreementMember" xlink:to="ctmx_CD71AgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CD71AgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CD71 Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CD71AgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C D71 Agreement [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SeattleGeneticsAgreementMember" xlink:type="locator" xlink:label="ctmx_SeattleGeneticsAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SeattleGeneticsAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Seattle genetics agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_SeattleGeneticsAgreementMember" xlink:to="ctmx_SeattleGeneticsAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SeattleGeneticsAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Seattle Genetics Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SeattleGeneticsAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Seattle Genetics Agreement [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_DiscoveryAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_DiscoveryAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Discovery agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_DiscoveryAgreementMember" xlink:to="ctmx_DiscoveryAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_DiscoveryAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discovery Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_DiscoveryAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Discovery Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember" xlink:type="locator" xlink:label="ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development regulatory and commercial milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember" xlink:to="ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development, Regulatory and Commercial Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Regulatory And Commercial Milestone Payments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecondTargetMember" xlink:type="locator" xlink:label="ctmx_SecondTargetMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SecondTargetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second target.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_SecondTargetMember" xlink:to="ctmx_SecondTargetMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SecondTargetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Target</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SecondTargetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second Target [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="locator" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Timing of Transfer of Good or Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Timing Of Transfer Of Good Or Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="locator" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Timing of Transfer of Good or Service</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Timing Of Transfer Of Good Or Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:type="locator" xlink:label="us-gaap_TransferredOverTimeMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransferredOverTimeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred over Time</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransferredOverTimeMember" xlink:to="us-gaap_TransferredOverTimeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TransferredOverTimeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Transferred Over Time [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfCollaborationAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of collaboration agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfCollaborationAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Collaboration Agreements</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net profits or net losses related to development and commercialization costs</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Income Or Net Losses Related To Development And Commercialization Costs</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent payments receivable upon achieving development, regulatory and commercial milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" xlink:to="ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentPaymentsReceivableProfitSplitOnSales" xlink:type="locator" xlink:label="ctmx_ContingentPaymentsReceivableProfitSplitOnSales" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentPaymentsReceivableProfitSplitOnSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent payments receivable profit split on sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ContingentPaymentsReceivableProfitSplitOnSales" xlink:to="ctmx_ContingentPaymentsReceivableProfitSplitOnSales_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" xlink:type="locator" xlink:label="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" />
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments received from revenue recognized during period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" xlink:to="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PaymentsOfSublicenseFees" xlink:type="locator" xlink:label="ctmx_PaymentsOfSublicenseFees" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PaymentsOfSublicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of sublicense fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PaymentsOfSublicenseFees" xlink:to="ctmx_PaymentsOfSublicenseFees_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCollaborators" xlink:to="us-gaap_ProceedsFromCollaborators_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromCollaborators_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Collaborators</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent payments receivable upon achieving development, regulatory and commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Payments Receivable Upon Achieving Development Regulatory And Commercial Milestones</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentPaymentsReceivableProfitSplitOnSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Profit split on U.S. sales</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentPaymentsReceivableProfitSplitOnSales_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Payments Receivable Profit Split On Sales</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment received</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Received From Revenue Recognized During Period</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PaymentsOfSublicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicense fees paid</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PaymentsOfSublicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Sublicense Fees</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargets" xlink:type="locator" xlink:label="ctmx_NumberOfTargets" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of targets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NumberOfTargets" xlink:to="ctmx_NumberOfTargets_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargetsSelected" xlink:type="locator" xlink:label="ctmx_NumberOfTargetsSelected" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfTargetsSelected_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of targets selected.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NumberOfTargetsSelected" xlink:to="ctmx_NumberOfTargetsSelected_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of targets</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Targets</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfTargetsSelected_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of targets selected</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfTargetsSelected_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Targets Selected</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentMilestonePaymentsReceivable" xlink:type="locator" xlink:label="ctmx_ContingentMilestonePaymentsReceivable" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentMilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Future contingent milestone payment receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ContingentMilestonePaymentsReceivable" xlink:to="ctmx_ContingentMilestonePaymentsReceivable_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentReceived" xlink:type="locator" xlink:label="ctmx_MilestonePaymentReceived" />
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_MilestonePaymentReceived" xlink:to="ctmx_MilestonePaymentReceived_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments received</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentMilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent milestone payments receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentMilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Milestone Payments Receivable</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AggregateCollaborationTransactionAmount" xlink:type="locator" xlink:label="ctmx_AggregateCollaborationTransactionAmount" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AggregateCollaborationTransactionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate collaboration transaction amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AggregateCollaborationTransactionAmount" xlink:to="ctmx_AggregateCollaborationTransactionAmount_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedSublicenseFees" xlink:type="locator" xlink:label="ctmx_EstimatedSublicenseFees" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedSublicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated sublicense fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_EstimatedSublicenseFees" xlink:to="ctmx_EstimatedSublicenseFees_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfAccountingUnits" xlink:type="locator" xlink:label="ctmx_NumberOfAccountingUnits" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfAccountingUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of accounting units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NumberOfAccountingUnits" xlink:to="ctmx_NumberOfAccountingUnits_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentsReceivable" xlink:type="locator" xlink:label="ctmx_MilestonePaymentsReceivable" />
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_MilestonePaymentsReceivable" xlink:to="ctmx_MilestonePaymentsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AggregateCollaborationTransactionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total transaction price</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AggregateCollaborationTransactionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Collaboration Transaction Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedSublicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated sublicense fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedSublicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Sublicense Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfAccountingUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of accounting units</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfAccountingUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Accounting Units</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment received</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition upon performance obligation, service period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognized from collaborative arrangement</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedResearchServicePeriod" xlink:type="locator" xlink:label="ctmx_EstimatedResearchServicePeriod" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedResearchServicePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated research service period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_EstimatedResearchServicePeriod" xlink:to="ctmx_EstimatedResearchServicePeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue recognition upon performance obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Remaining Performance Obligation</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedResearchServicePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated research service period</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedResearchServicePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Research Service Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount due from agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNet" xlink:to="us-gaap_ContractWithCustomerAssetNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CommonStockSharesIssuableUnderAgreement" xlink:type="locator" xlink:label="ctmx_CommonStockSharesIssuableUnderAgreement" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CommonStockSharesIssuableUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock shares issuable under agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_CommonStockSharesIssuableUnderAgreement" xlink:to="ctmx_CommonStockSharesIssuableUnderAgreement_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare" xlink:type="locator" xlink:label="ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period used to calculate weighted average price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare" xlink:to="ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement" xlink:type="locator" xlink:label="ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement" />
    <link:label xml:lang="en-US" xlink:label="ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lock-up period for share transaction under collaboration and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement" xlink:to="ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedPremiumOnIssuanceOfShares" xlink:type="locator" xlink:label="ctmx_EstimatedPremiumOnIssuanceOfShares" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedPremiumOnIssuanceOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated premium on issuance of shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_EstimatedPremiumOnIssuanceOfShares" xlink:to="ctmx_EstimatedPremiumOnIssuanceOfShares_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="ctmx_CollaborationAndLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_CollaborationAndLicenseAgreementMember" xlink:to="ctmx_CollaborationAndLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AmgenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amgen Inc</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EGFRProductsMember" xlink:type="locator" xlink:label="ctmx_EGFRProductsMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EGFRProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">EGFR Products.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_EGFRProductsMember" xlink:to="ctmx_EGFRProductsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EGFRProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">EGFR Products</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EGFRProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">E G F R Products [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenProductsMember" xlink:type="locator" xlink:label="ctmx_AmgenProductsMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AmgenProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amgen products.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AmgenProductsMember" xlink:to="ctmx_AmgenProductsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AmgenProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amgen Products</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AmgenProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amgen Products [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SublicenseAgreementMember" xlink:type="locator" xlink:label="ctmx_SublicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SublicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublicense agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_SublicenseAgreementMember" xlink:to="ctmx_SublicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SublicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicense Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SublicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublicense Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_RegentsOfTheUniversityOfCaliforniaMember" xlink:type="locator" xlink:label="ctmx_RegentsOfTheUniversityOfCaliforniaMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_RegentsOfTheUniversityOfCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regents of the university of California.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_RegentsOfTheUniversityOfCaliforniaMember" xlink:to="ctmx_RegentsOfTheUniversityOfCaliforniaMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_RegentsOfTheUniversityOfCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UC Regents</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_RegentsOfTheUniversityOfCaliforniaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regents Of The University Of California [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenOtherProductsMember" xlink:type="locator" xlink:label="ctmx_AmgenOtherProductsMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AmgenOtherProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amgen other products.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AmgenOtherProductsMember" xlink:to="ctmx_AmgenOtherProductsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AmgenOtherProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amgen Other Products</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AmgenOtherProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amgen Other Products [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CommonStockSharesIssuableUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issuable under agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CommonStockSharesIssuableUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issuable Under Agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issuable under agreement, price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, value of shares issued in connection with agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period used to calculate weighted average price per share</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Used To Calculate Weighted Average Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lock-up period for share disposal</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lock Up Period For Share Transaction Under Collaboration And License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedPremiumOnIssuanceOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated premium on the stock sold</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedPremiumOnIssuanceOfShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Premium On Issuance Of Shares</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ProfitShareUponExerciseOfCoDevelopmentOption" xlink:type="locator" xlink:label="ctmx_ProfitShareUponExerciseOfCoDevelopmentOption" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ProfitShareUponExerciseOfCoDevelopmentOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit share upon exercise of co-development option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ProfitShareUponExerciseOfCoDevelopmentOption" xlink:to="ctmx_ProfitShareUponExerciseOfCoDevelopmentOption_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ProfitShareUponExerciseOfCoDevelopmentOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage share of profit and losses</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ProfitShareUponExerciseOfCoDevelopmentOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Share Upon Exercise Of Co Development Option</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfAdditionalCollaborationTarget" xlink:type="locator" xlink:label="ctmx_NumberOfAdditionalCollaborationTarget" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfAdditionalCollaborationTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional collaboration target.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NumberOfAdditionalCollaborationTarget" xlink:to="ctmx_NumberOfAdditionalCollaborationTarget_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfAdditionalCollaborationTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional collaboration target</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfAdditionalCollaborationTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Collaboration Target</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent payments payable upon achieving development regulatory and commercial milestones.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" xlink:to="ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent payments payable</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Payments Payable Upon Achieving Development Regulatory And Commercial Milestones</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds" xlink:type="locator" xlink:label="ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds" />
    <link:label xml:lang="en-US" xlink:label="ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License payment percentage equivalence to upfront and milestone proceeds.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds" xlink:to="ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicense payment percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Payment Percentage Equivalence To Upfront And Milestone Proceeds</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock" xlink:type="locator" xlink:label="ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Premium on issuance of shares allocated to common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock" xlink:to="ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedFairValueOfProducts" xlink:type="locator" xlink:label="ctmx_EstimatedFairValueOfProducts" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedFairValueOfProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated fair value of products.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_EstimatedFairValueOfProducts" xlink:to="ctmx_EstimatedFairValueOfProducts_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Portion of transaction price allocated to premium on sale of common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Premium On Issuance Of Shares Allocated To Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedFairValueOfProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of products</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedFairValueOfProducts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Fair Value Of Products</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_RightToExpandNumberOfAdditionalCollaborationTarget" xlink:type="locator" xlink:label="ctmx_RightToExpandNumberOfAdditionalCollaborationTarget" />
    <link:label xml:lang="en-US" xlink:label="ctmx_RightToExpandNumberOfAdditionalCollaborationTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Right to expand the number of additional collaboration target.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_RightToExpandNumberOfAdditionalCollaborationTarget" xlink:to="ctmx_RightToExpandNumberOfAdditionalCollaborationTarget_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AdditionalContingentPaymentsMember" xlink:type="locator" xlink:label="ctmx_AdditionalContingentPaymentsMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AdditionalContingentPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional contingent payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AdditionalContingentPaymentsMember" xlink:to="ctmx_AdditionalContingentPaymentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AdditionalContingentPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Contingent Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AdditionalContingentPaymentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Contingent Payments [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_RightToExpandNumberOfAdditionalCollaborationTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right to expand the number of additional collaboration target</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_RightToExpandNumberOfAdditionalCollaborationTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Right To Expand Number Of Additional Collaboration Target</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ResearchAndDevelopmentServiceFees" xlink:type="locator" xlink:label="ctmx_ResearchAndDevelopmentServiceFees" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ResearchAndDevelopmentServiceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development service fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ResearchAndDevelopmentServiceFees" xlink:to="ctmx_ResearchAndDevelopmentServiceFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ResearchAndDevelopmentServiceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development service fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ResearchAndDevelopmentServiceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Service Fees</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedResearchServiceTerminationMonthAndYear" xlink:type="locator" xlink:label="ctmx_EstimatedResearchServiceTerminationMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedResearchServiceTerminationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated research service termination month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_EstimatedResearchServiceTerminationMonthAndYear" xlink:to="ctmx_EstimatedResearchServiceTerminationMonthAndYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedResearchServiceTerminationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated research service termination month &amp; year</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedResearchServiceTerminationMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Research Service Termination Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerAssetNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Amount due from customer</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfOncologyTarget" xlink:type="locator" xlink:label="ctmx_NumberOfOncologyTarget" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfOncologyTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of oncology target.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NumberOfOncologyTarget" xlink:to="ctmx_NumberOfOncologyTarget_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfCollaborationTarget" xlink:type="locator" xlink:label="ctmx_NumberOfCollaborationTarget" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfCollaborationTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of collaboration target.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NumberOfCollaborationTarget" xlink:to="ctmx_NumberOfCollaborationTarget_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CollaborationTargetResearchTerm" xlink:type="locator" xlink:label="ctmx_CollaborationTargetResearchTerm" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CollaborationTargetResearchTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration target research term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_CollaborationTargetResearchTerm" xlink:to="ctmx_CollaborationTargetResearchTerm_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PeriodOfNominationOfAdditionalTarget" xlink:type="locator" xlink:label="ctmx_PeriodOfNominationOfAdditionalTarget" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PeriodOfNominationOfAdditionalTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of nomination of additional target.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PeriodOfNominationOfAdditionalTarget" xlink:to="ctmx_PeriodOfNominationOfAdditionalTarget_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ExtensionOfResearchTermForEachCollaborationTarget" xlink:type="locator" xlink:label="ctmx_ExtensionOfResearchTermForEachCollaborationTarget" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ExtensionOfResearchTermForEachCollaborationTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Extension of research term for each collaboration target.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ExtensionOfResearchTermForEachCollaborationTarget" xlink:to="ctmx_ExtensionOfResearchTermForEachCollaborationTarget_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes" xlink:type="locator" xlink:label="ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes" />
    <link:label xml:lang="en-US" xlink:label="ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increments of extended collaboration target research times.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes" xlink:to="ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AchievingAdditionalTargetsMember" xlink:type="locator" xlink:label="ctmx_AchievingAdditionalTargetsMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AchievingAdditionalTargetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Achieving additional targets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AchievingAdditionalTargetsMember" xlink:to="ctmx_AchievingAdditionalTargetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AchievingAdditionalTargetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Each Of Two Additional Targets</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AchievingAdditionalTargetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Achieving Additional Targets [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PreClinicalCandidateMember" xlink:type="locator" xlink:label="ctmx_PreClinicalCandidateMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PreClinicalCandidateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre clinical candidate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PreClinicalCandidateMember" xlink:to="ctmx_PreClinicalCandidateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PreClinicalCandidateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Clinical Candidate</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PreClinicalCandidateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Clinical Candidate [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DrugApplicationForCTLA4Member" xlink:type="locator" xlink:label="ctmx_DrugApplicationForCTLA4Member" />
    <link:label xml:lang="en-US" xlink:label="ctmx_DrugApplicationForCTLA4Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Drug application for CTLA-4.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_DrugApplicationForCTLA4Member" xlink:to="ctmx_DrugApplicationForCTLA4Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_DrugApplicationForCTLA4Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Drug Application for CTLA-4</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_DrugApplicationForCTLA4Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Drug Application For C T L A4 [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ThirdAndFourthTargetsMember" xlink:type="locator" xlink:label="ctmx_ThirdAndFourthTargetsMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ThirdAndFourthTargetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Third and fourth targets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ThirdAndFourthTargetsMember" xlink:to="ctmx_ThirdAndFourthTargetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ThirdAndFourthTargetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third And Fourth Immuno-Oncology Targets</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ThirdAndFourthTargetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Third And Fourth Targets [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AcceleratedRecognitionOfDeferredRevenueMember" xlink:type="locator" xlink:label="ctmx_AcceleratedRecognitionOfDeferredRevenueMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AcceleratedRecognitionOfDeferredRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accelerated recognition of deferred revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AcceleratedRecognitionOfDeferredRevenueMember" xlink:to="ctmx_AcceleratedRecognitionOfDeferredRevenueMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AcceleratedRecognitionOfDeferredRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accelerated Recognition of Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AcceleratedRecognitionOfDeferredRevenueMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accelerated Recognition Of Deferred Revenue [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ScenarioForecastMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfOncologyTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of oncology target</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfOncologyTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Oncology Target</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfCollaborationTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of collaboration target</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfCollaborationTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Collaboration Target</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CollaborationTargetResearchTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration target research term</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CollaborationTargetResearchTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Target Research Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Description And Terms</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PeriodOfNominationOfAdditionalTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period of nomination of additional target from effective date</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PeriodOfNominationOfAdditionalTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Period Of Nomination Of Additional Target</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ExtensionOfResearchTermForEachCollaborationTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extension of research term for each collaboration target</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ExtensionOfResearchTermForEachCollaborationTarget_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Extension Of Research Term For Each Collaboration Target</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Times of increments for extended collaboration target research time</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increments Of Extended Collaboration Target Research Times</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfResearchTargetsSelected" xlink:type="locator" xlink:label="ctmx_NumberOfResearchTargetsSelected" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfResearchTargetsSelected_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of research targets selected.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NumberOfResearchTargetsSelected" xlink:to="ctmx_NumberOfResearchTargetsSelected_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfResearchTargetsSelected_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of research targets selected</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfResearchTargetsSelected_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Research Targets Selected</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UpfrontFeeReceived" xlink:type="locator" xlink:label="ctmx_UpfrontFeeReceived" />
    <link:label xml:lang="en-US" xlink:label="ctmx_UpfrontFeeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_UpfrontFeeReceived" xlink:to="ctmx_UpfrontFeeReceived_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedResearchServiceTerminationDate" xlink:type="locator" xlink:label="ctmx_EstimatedResearchServiceTerminationDate" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedResearchServiceTerminationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated research service termination date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_EstimatedResearchServiceTerminationDate" xlink:to="ctmx_EstimatedResearchServiceTerminationDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_UpfrontFeeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_UpfrontFeeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Received</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedResearchServiceTerminationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated research service termination date</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EstimatedResearchServiceTerminationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Research Service Termination Date</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive" xlink:type="locator" xlink:label="ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent milestone payments no longer eligible to receive.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive" xlink:to="ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent milestone payments, no longer eligible to receive</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Milestone Payments No Longer Eligible To Receive</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashPaymentToExecuteAgreement" xlink:type="locator" xlink:label="ctmx_CashPaymentToExecuteAgreement" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CashPaymentToExecuteAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash payment to execute the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_CashPaymentToExecuteAgreement" xlink:to="ctmx_CashPaymentToExecuteAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ImmunoGenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Immuno Gen Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CashPaymentToExecuteAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront cash payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CashPaymentToExecuteAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Payment To Execute Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated total fair value consideration recorded as deferred revenue</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentPayable" xlink:type="locator" xlink:label="ctmx_MilestonePaymentPayable" />
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_MilestonePaymentPayable" xlink:to="ctmx_MilestonePaymentPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments payable</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Payable</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Charge to research and development expense</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfNominatedResearchTargets" xlink:type="locator" xlink:label="ctmx_NumberOfNominatedResearchTargets" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfNominatedResearchTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of nominated research targets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NumberOfNominatedResearchTargets" xlink:to="ctmx_NumberOfNominatedResearchTargets_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfAdditionalResearchTargetsWithNominationOption" xlink:type="locator" xlink:label="ctmx_NumberOfAdditionalResearchTargetsWithNominationOption" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfAdditionalResearchTargetsWithNominationOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional research targets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NumberOfAdditionalResearchTargetsWithNominationOption" xlink:to="ctmx_NumberOfAdditionalResearchTargetsWithNominationOption_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="ctmx_ContractWithCustomerLiabilityAdditions" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability additions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ContractWithCustomerLiabilityAdditions" xlink:to="ctmx_ContractWithCustomerLiabilityAdditions_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PfizerIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfNominatedResearchTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of research targets</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfNominatedResearchTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Nominated Research Targets</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfAdditionalResearchTargetsWithNominationOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nominated number of additional research targets</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfAdditionalResearchTargetsWithNominationOption_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Research Targets With Nomination Option</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional target as deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at 12/31/2019</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deductions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at 12/31/2020</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_FirstTargetUnderDiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_FirstTargetUnderDiscoveryAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_FirstTargetUnderDiscoveryAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">First target under discovery agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_FirstTargetUnderDiscoveryAgreementMember" xlink:to="ctmx_FirstTargetUnderDiscoveryAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_FirstTargetUnderDiscoveryAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">First Target under Discovery Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_FirstTargetUnderDiscoveryAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">First Target Under Discovery Agreement [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecondTargetUnderDiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_SecondTargetUnderDiscoveryAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SecondTargetUnderDiscoveryAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second target under discovery agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_SecondTargetUnderDiscoveryAgreementMember" xlink:to="ctmx_SecondTargetUnderDiscoveryAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SecondTargetUnderDiscoveryAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Second Target under Discovery Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SecondTargetUnderDiscoveryAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second Target Under Discovery Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ContractWithCustomerLiabilityAdditions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additions to deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Deductions to deferred revenue recognized during the period</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear" xlink:type="locator" xlink:label="ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract with customer liability maturity month and year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear" xlink:to="ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue recognition maturity month and year</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Maturity Month And Year</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_RoyaltyObligationsFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="ctmx_RoyaltyObligationsFutureMinimumPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="ctmx_RoyaltyObligationsFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty obligations future minimum payments due.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_RoyaltyObligationsFutureMinimumPaymentsDue" xlink:to="ctmx_RoyaltyObligationsFutureMinimumPaymentsDue_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LicenseTerminationPeriod" xlink:type="locator" xlink:label="ctmx_LicenseTerminationPeriod" />
    <link:label xml:lang="en-US" xlink:label="ctmx_LicenseTerminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Period of time to terminate license after notice date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_LicenseTerminationPeriod" xlink:to="ctmx_LicenseTerminationPeriod_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UniversityOfCaliforniaSantaBarbaraMember" xlink:type="locator" xlink:label="ctmx_UniversityOfCaliforniaSantaBarbaraMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_UniversityOfCaliforniaSantaBarbaraMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">University of California, Santa Barbara.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_UniversityOfCaliforniaSantaBarbaraMember" xlink:to="ctmx_UniversityOfCaliforniaSantaBarbaraMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_UniversityOfCaliforniaSantaBarbaraMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">UCSB</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_UniversityOfCaliforniaSantaBarbaraMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">University Of California Santa Barbara [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SublicenseAndMaintenanceFeesMember" xlink:type="locator" xlink:label="ctmx_SublicenseAndMaintenanceFeesMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SublicenseAndMaintenanceFeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublicense and maintenance fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_SublicenseAndMaintenanceFeesMember" xlink:to="ctmx_SublicenseAndMaintenanceFeesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SublicenseAndMaintenanceFeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicense and Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SublicenseAndMaintenanceFeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublicense And Maintenance Fees [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieMember" xlink:type="locator" xlink:label="ctmx_AbbVieMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AbbVieMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">AbbVie .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AbbVieMember" xlink:to="ctmx_AbbVieMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AbbVieMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">AbbVie</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AbbVieMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Abb Vie [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_RoyaltyObligationsFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual minimum royalty obligations</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_RoyaltyObligationsFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Obligations Future Minimum Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LicenseTerminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License termination period</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LicenseTerminationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Termination Period</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PaymentOfUpfrontFees" xlink:type="locator" xlink:label="ctmx_PaymentOfUpfrontFees" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PaymentOfUpfrontFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of upfront fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PaymentOfUpfrontFees" xlink:to="ctmx_PaymentOfUpfrontFees_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AnnualLicenseMaintenanceFees" xlink:type="locator" xlink:label="ctmx_AnnualLicenseMaintenanceFees" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AnnualLicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license maintenance fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AnnualLicenseMaintenanceFees" xlink:to="ctmx_AnnualLicenseMaintenanceFees_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LicensePaymentTerm" xlink:type="locator" xlink:label="ctmx_LicensePaymentTerm" />
    <link:label xml:lang="en-US" xlink:label="ctmx_LicensePaymentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License payment term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_LicensePaymentTerm" xlink:to="ctmx_LicensePaymentTerm_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfRemainingMaintenanceFeesOutstanding" xlink:type="locator" xlink:label="ctmx_PercentageOfRemainingMaintenanceFeesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfRemainingMaintenanceFeesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of remaining maintenance fees outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PercentageOfRemainingMaintenanceFeesOutstanding" xlink:to="ctmx_PercentageOfRemainingMaintenanceFeesOutstanding_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_FairValueOfCommonStockIssued" xlink:type="locator" xlink:label="ctmx_FairValueOfCommonStockIssued" />
    <link:label xml:lang="en-US" xlink:label="ctmx_FairValueOfCommonStockIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of common stock issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_FairValueOfCommonStockIssued" xlink:to="ctmx_FairValueOfCommonStockIssued_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PaymentOfUpfrontFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of upfront fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PaymentOfUpfrontFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Upfront Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AnnualLicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AnnualLicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LicensePaymentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License payment term</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LicensePaymentTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Payment Term</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfRemainingMaintenanceFeesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of remaining maintenance fees outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfRemainingMaintenanceFeesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Remaining Maintenance Fees Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_FairValueOfCommonStockIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_FairValueOfCommonStockIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Common Stock Issued</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AdditionalSublicenseFees" xlink:type="locator" xlink:label="ctmx_AdditionalSublicenseFees" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AdditionalSublicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional sublicense fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_AdditionalSublicenseFees" xlink:to="ctmx_AdditionalSublicenseFees_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentReceivable" xlink:type="locator" xlink:label="ctmx_MilestonePaymentReceivable" />
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_MilestonePaymentReceivable" xlink:to="ctmx_MilestonePaymentReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_AdditionalSublicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional sublicense fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_AdditionalSublicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Sublicense Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment receivable</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_MilestonePaymentReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment Receivable</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SublicenseFees" xlink:type="locator" xlink:label="ctmx_SublicenseFees" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SublicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublicense fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_SublicenseFees" xlink:to="ctmx_SublicenseFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SublicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublicense fees</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SublicenseFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sublicense Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Accrued liabilities</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UpfrontLicensePayment" xlink:type="locator" xlink:label="ctmx_UpfrontLicensePayment" />
    <link:label xml:lang="en-US" xlink:label="ctmx_UpfrontLicensePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront license payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_UpfrontLicensePayment" xlink:to="ctmx_UpfrontLicensePayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_UpfrontLicensePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license payment</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_UpfrontLicensePayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Payment</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate" xlink:type="locator" xlink:label="ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate" />
    <link:label xml:lang="en-US" xlink:label="ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss contingency answer, affirmative defenses and counterclaims filing date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate" xlink:to="ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate" xlink:type="locator" xlink:label="ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate" />
    <link:label xml:lang="en-US" xlink:label="ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loss contingency, answer and counterclaims by plaintiff filing date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate" xlink:to="ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:type="locator" xlink:label="srt_LitigationCaseAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_LitigationCaseAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation Case</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_LitigationCaseAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:type="locator" xlink:label="srt_LitigationCaseTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_LitigationCaseTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation Case</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_LitigationCaseTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Case Type [Domain]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PatentInfringementLawsuitMember" xlink:type="locator" xlink:label="ctmx_PatentInfringementLawsuitMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PatentInfringementLawsuitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent infringement lawsuit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PatentInfringementLawsuitMember" xlink:to="ctmx_PatentInfringementLawsuitMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PatentInfringementLawsuitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Infringement Lawsuit</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PatentInfringementLawsuitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent Infringement Lawsuit [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecuritiesClassActionLawsuitMember" xlink:type="locator" xlink:label="ctmx_SecuritiesClassActionLawsuitMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SecuritiesClassActionLawsuitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Securities class action lawsuit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_SecuritiesClassActionLawsuitMember" xlink:to="ctmx_SecuritiesClassActionLawsuitMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SecuritiesClassActionLawsuitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities Class Action Lawsuit</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SecuritiesClassActionLawsuitMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Securities Class Action Lawsuit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:type="locator" xlink:label="us-gaap_LossContingencyLawsuitFilingDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyLawsuitFilingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lawsuit filed date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyLawsuitFilingDate" xlink:to="us-gaap_LossContingencyLawsuitFilingDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyLawsuitFilingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Lawsuit Filing Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:type="locator" xlink:label="us-gaap_LossContingencyNameOfPlaintiff" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyNameOfPlaintiff_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of plaintiff</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNameOfPlaintiff" xlink:to="us-gaap_LossContingencyNameOfPlaintiff_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyNameOfPlaintiff_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Name Of Plaintiff</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss contingency, answer, affirmative defenses and counterclaims filing date</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Answer Affirmative Defenses And Counterclaims Filing Date</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss contingency, answer and counterclaims by plaintiff filing date</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Answer And Counterclaims By Plaintiff Filing Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="locator" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss contingency claim amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loss Contingency Estimate Of Possible Loss</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants" xlink:type="locator" xlink:label="ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of current and former officers named as defendants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants" xlink:to="ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of current and former officers named as defendants</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Current And Former Officers Named As Defendants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Operating Leased Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseAgreementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Lease Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAgreementsMember" xlink:to="us-gaap_LeaseAgreementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAgreementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_FirstYearOfLeaseTermMember" xlink:type="locator" xlink:label="ctmx_FirstYearOfLeaseTermMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_FirstYearOfLeaseTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">First year of lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_FirstYearOfLeaseTermMember" xlink:to="ctmx_FirstYearOfLeaseTermMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_FirstYearOfLeaseTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First year of lease term</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_FirstYearOfLeaseTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">First Year Of Lease Term [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecondTwelveMonthsOfLeaseTermMember" xlink:type="locator" xlink:label="ctmx_SecondTwelveMonthsOfLeaseTermMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SecondTwelveMonthsOfLeaseTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second twelve months of lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_SecondTwelveMonthsOfLeaseTermMember" xlink:to="ctmx_SecondTwelveMonthsOfLeaseTermMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SecondTwelveMonthsOfLeaseTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second twelve months of lease term</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SecondTwelveMonthsOfLeaseTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second Twelve Months Of Lease Term [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_TenthYearOfLeaseTermMember" xlink:type="locator" xlink:label="ctmx_TenthYearOfLeaseTermMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_TenthYearOfLeaseTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenth year of lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_TenthYearOfLeaseTermMember" xlink:to="ctmx_TenthYearOfLeaseTermMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_TenthYearOfLeaseTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenth year of lease term</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_TenthYearOfLeaseTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tenth Year Of Lease Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Letter Of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leased Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:type="locator" xlink:label="us-gaap_AreaOfLand" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfLand_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of rentable office and laboratory space</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AreaOfLand_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Area Of Land</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Description</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extended lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OperatingLeasesRentExpenseAnnualBaseRent" xlink:type="locator" xlink:label="ctmx_OperatingLeasesRentExpenseAnnualBaseRent" />
    <link:label xml:lang="en-US" xlink:label="ctmx_OperatingLeasesRentExpenseAnnualBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases rent expense annual base rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_OperatingLeasesRentExpenseAnnualBaseRent" xlink:to="ctmx_OperatingLeasesRentExpenseAnnualBaseRent_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MaximumImprovementAllowance" xlink:type="locator" xlink:label="ctmx_MaximumImprovementAllowance" />
    <link:label xml:lang="en-US" xlink:label="ctmx_MaximumImprovementAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum improvement allowance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_MaximumImprovementAllowance" xlink:to="ctmx_MaximumImprovementAllowance_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ImprovementAllowanceFromRecoverableRent" xlink:type="locator" xlink:label="ctmx_ImprovementAllowanceFromRecoverableRent" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ImprovementAllowanceFromRecoverableRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Improvement allowance from recoverable rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ImprovementAllowanceFromRecoverableRent" xlink:to="ctmx_ImprovementAllowanceFromRecoverableRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_OperatingLeasesRentExpenseAnnualBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual lease rent</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_OperatingLeasesRentExpenseAnnualBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Rent Expense Annual Base Rent</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_MaximumImprovementAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum one-time improvement allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_MaximumImprovementAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Improvement Allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ImprovementAllowanceFromRecoverableRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Improvement allowance from recoverable rent</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ImprovementAllowanceFromRecoverableRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Improvement Allowance From Recoverable Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:type="locator" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit outstanding, amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Letters Of Credit Outstanding Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in measurement of lease liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:type="locator" xlink:label="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Supplemental balance sheet information related to leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_WeightedAverageRemainingLeaseTermAbstract" xlink:type="locator" xlink:label="ctmx_WeightedAverageRemainingLeaseTermAbstract" />
    <link:label xml:lang="en-US" xlink:label="ctmx_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average remaining lease term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_WeightedAverageRemainingLeaseTermAbstract" xlink:to="ctmx_WeightedAverageRemainingLeaseTermAbstract_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_WeightedAverageDiscountRateAbstract" xlink:type="locator" xlink:label="ctmx_WeightedAverageDiscountRateAbstract" />
    <link:label xml:lang="en-US" xlink:label="ctmx_WeightedAverageDiscountRateAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average discount rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_WeightedAverageDiscountRateAbstract" xlink:to="ctmx_WeightedAverageDiscountRateAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows from operating leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental balance sheet information related to leases:</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Information Related To Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Non-current operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current Statement Of Financial Position Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average remaining lease term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_WeightedAverageRemainingLeaseTermAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_WeightedAverageDiscountRateAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average discount rate</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_WeightedAverageDiscountRateAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Discount Rate Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturity of operating lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 and beyond</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Five And Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="ctmx_UnderwrittenPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwritten public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_UnderwrittenPublicOfferingMember" xlink:to="ctmx_UnderwrittenPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwritten Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_UnderwrittenPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Underwritten Public Offering [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwriters</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Over Allotment Option [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_JefferiesMember" xlink:type="locator" xlink:label="ctmx_JefferiesMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_JefferiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Jefferies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_JefferiesMember" xlink:to="ctmx_JefferiesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_JefferiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Jefferies LLC</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_JefferiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Jefferies [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, par value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividends on common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsCommonStock" xlink:to="us-gaap_DividendsCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DividendsCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock price, per share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwriting discounts and commissions and offering expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfSalesCommission" xlink:type="locator" xlink:label="ctmx_PercentageOfSalesCommission" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfSalesCommission_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of sales commission.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PercentageOfSalesCommission" xlink:to="ctmx_PercentageOfSalesCommission_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SharesIssuedAveragePricePerShare" xlink:type="locator" xlink:label="ctmx_SharesIssuedAveragePricePerShare" />
    <link:label xml:lang="en-US" xlink:label="ctmx_SharesIssuedAveragePricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares issued average price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_SharesIssuedAveragePricePerShare" xlink:to="ctmx_SharesIssuedAveragePricePerShare_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfSalesCommissionAndIssuanceCost" xlink:type="locator" xlink:label="ctmx_PercentageOfSalesCommissionAndIssuanceCost" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfSalesCommissionAndIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of sales commission and issuance cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PercentageOfSalesCommissionAndIssuanceCost" xlink:to="ctmx_PercentageOfSalesCommissionAndIssuanceCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfSalesCommission_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Percentage of sales commission</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfSalesCommission_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Sales Commission</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SharesIssuedAveragePricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Average price</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_SharesIssuedAveragePricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Average Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfSalesCommissionAndIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of sales commission and issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfSalesCommissionAndIssuanceCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Sales Commission And Issuance Cost</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_StockOptionsIssuedAndOutstanding" xlink:type="locator" xlink:label="ctmx_StockOptionsIssuedAndOutstanding" />
    <link:label xml:lang="en-US" xlink:label="ctmx_StockOptionsIssuedAndOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options issued and outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_StockOptionsIssuedAndOutstanding" xlink:to="ctmx_StockOptionsIssuedAndOutstanding_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, number of shares available for future issuance under employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_StockOptionsIssuedAndOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_StockOptionsIssuedAndOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Issued And Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future stock option grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Future Issuance Under Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award voting rights of common stock holding percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_TwoThousandFifteenStockIncentivePlanMember" xlink:type="locator" xlink:label="ctmx_TwoThousandFifteenStockIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen stock incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_TwoThousandFifteenStockIncentivePlanMember" xlink:to="ctmx_TwoThousandFifteenStockIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Award Tranche One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting per Month After First Anniversary</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Two [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_TwoThousandNineteenStockIncentivePlanMember" xlink:type="locator" xlink:label="ctmx_TwoThousandNineteenStockIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_TwoThousandNineteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Nineteen Stock Incentive Plan Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_TwoThousandNineteenStockIncentivePlanMember" xlink:to="ctmx_TwoThousandNineteenStockIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_TwoThousandNineteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_TwoThousandNineteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Stock Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EarlyExerciseOfEmployeeOptionsMember" xlink:type="locator" xlink:label="ctmx_EarlyExerciseOfEmployeeOptionsMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EarlyExerciseOfEmployeeOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Early exercise of employee options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_EarlyExerciseOfEmployeeOptionsMember" xlink:to="ctmx_EarlyExerciseOfEmployeeOptionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EarlyExerciseOfEmployeeOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Early Exercise of Employee Options</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EarlyExerciseOfEmployeeOptionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Early Exercise Of Employee Options [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="ctmx_EmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_EmployeeStockPurchasePlanMember" xlink:to="ctmx_EmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NonEmployeesMember" xlink:type="locator" xlink:label="ctmx_NonEmployeesMember" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NonEmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-Employees Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NonEmployeesMember" xlink:to="ctmx_NonEmployeesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NonEmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-employees</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NonEmployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Employees [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option expiration period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees holding voting rights of all classes of stock, percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Voting Rights Of Common Stock Holding Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of the shares on the date of grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted generally vest period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted generally vest percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, capital shares reserved for future issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in number of shares available for issuance, as proportion of issued and outstanding shares of common stock, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant authorized.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant grants in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant exercises in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant cancelled in period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award, number of shares available for grant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances, beginning of the period</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options granted</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Grants In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercises In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options cancelled</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balances, end of the period</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options authorized.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances, beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balances, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable, end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest, end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted-Average Exercise Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balances, beginning of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balances, end of the period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable, end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest, end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding, Weighted- Average Remaining Contractual Life (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balances, end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable, end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest, end of the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options aggregate intrinsic value.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balances at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable&#8212;December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest&#8212;December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate intrinsic value of stock options exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value, options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense, options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrecognized stock-based compensation cost, period for recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan maximum percentage of eligible compensation to purchase shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of shares issued during period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Unrecognized stock-based compensation cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NetOperatingLossCarrybackPeriod" xlink:type="locator" xlink:label="ctmx_NetOperatingLossCarrybackPeriod" />
    <link:label xml:lang="en-US" xlink:label="ctmx_NetOperatingLossCarrybackPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss carryback.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_NetOperatingLossCarrybackPeriod" xlink:to="ctmx_NetOperatingLossCarrybackPeriod_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation" xlink:type="locator" xlink:label="ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of taxable income from net operating losses for suspension of annual deduction limitation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation" xlink:to="ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Tax Credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Contingency [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Contingency [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NetOperatingLossCarrybackPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryback</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_NetOperatingLossCarrybackPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss Carryback Period</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of taxable income from net operating losses for suspension of annual deduction limitation</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Taxable Income From Net Operating Losses For Suspension Of Annual Deduction Limitation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax asset, net change in total valuation allowance increase during period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits would affect company&apos;s effective tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits That Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal State And Local Tax Expense Benefit [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State And Local Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for (benefit from) income taxes</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" xlink:type="locator" xlink:label="ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation net operating loss carryback.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" xlink:to="ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:type="locator" xlink:label="ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" />
    <link:label xml:lang="en-US" xlink:label="ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation return to provision adjustments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:to="ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. federal taxes at statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State tax, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Tax Credits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryback</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Net Operating Loss Carryback</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Return to provision adjustment</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Return To Provision Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Continuing Operations</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DeferredTaxAssetsLeaseLiability" xlink:type="locator" xlink:label="ctmx_DeferredTaxAssetsLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="ctmx_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_DeferredTaxAssetsLeaseLiability" xlink:to="ctmx_DeferredTaxAssetsLeaseLiability_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets And Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_DeferredTaxAssetsLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Goodwill And Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and deferred rent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total gross deferred income tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Leasing Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Goodwill And Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Prepaid Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Net deferred income tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Income tax expense (benefit)</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="ctmx_OperatingLossCarryforwardsExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="ctmx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_OperatingLossCarryforwardsExpirationYear" xlink:to="ctmx_OperatingLossCarryforwardsExpirationYear_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" xlink:type="locator" xlink:label="ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" />
    <link:label xml:lang="en-US" xlink:label="ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards amount to expire if not used.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" xlink:to="ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed_lbl" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" xlink:type="locator" xlink:label="ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" />
    <link:label xml:lang="en-US" xlink:label="ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards amount not subject to expiration.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" xlink:to="ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards to expire if not utilized</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Amount To Expire If Not Used</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards not subject to expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Amount Not Subject To Expiration</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="ctmx_TaxCreditCarryforwardExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="ctmx_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_TaxCreditCarryforwardExpirationYear" xlink:to="ctmx_TaxCreditCarryforwardExpirationYear_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carry forwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, expiration</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_TaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfChangeInOwnership" xlink:type="locator" xlink:label="ctmx_PercentageOfChangeInOwnership" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of change in ownership.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_PercentageOfChangeInOwnership" xlink:to="ctmx_PercentageOfChangeInOwnership_lbl" />
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of change in ownership</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_PercentageOfChangeInOwnership_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Change In Ownership</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of increase decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="locator" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions based on tax positions related to current year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment based on tax positions related to prior years</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of the year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and penalties accrued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Open tax year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OpenTaxYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Open Tax Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company contributions to defined contribution plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares" xlink:type="locator" xlink:label="ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares" />
    <link:label xml:lang="en-US" xlink:label="ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Option period granted to underwriters to purchase additional shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares" xlink:to="ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriters</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Period granted to underwriters to purchase additional shares</link:label>
    <link:label xml:lang="en-US" xlink:label="ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Option Period Granted To Underwriters To Purchase Additional Shares</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>27
<FILENAME>ctmx-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-02-24T16:43:22.0345368+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 19fb4f4ba39c4e5496fc22bf5dabd4ad -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://cytomx.com/20201231/role/TemplateLink" xlink:href="ctmx-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ctmx-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS" xlink:href="ctmx-20201231.xsd#Role_StatementBALANCESHEETS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical" xlink:href="ctmx-20201231.xsd#Role_StatementBALANCESHEETSParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:href="ctmx-20201231.xsd#Role_StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" xlink:type="locator" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:to="us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:href="ctmx-20201231.xsd#Role_StatementSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdateExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:type="locator" xlink:label="us-gaap_SharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="locator" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountingStandardsUpdateExtensibleList" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssued_li0l2" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS" xlink:href="ctmx-20201231.xsd#Role_StatementSTATEMENTSOFCASHFLOWS" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NoncashLeaseExpense" xlink:type="locator" xlink:label="ctmx_NoncashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ctmx_NoncashLeaseExpense" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="11960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="12620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness" xlink:href="ctmx-20201231.xsd#Role_DisclosureDescriptionOfBusiness" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations" xlink:type="locator" xlink:label="us-gaap_NatureOfOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="ctmx-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncements" xlink:href="ctmx-20201231.xsd#Role_DisclosureAdoptedAndRecentAccountingPronouncements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncements">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock" xlink:type="locator" xlink:label="ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShare" xlink:href="ctmx-20201231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShare">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestments" xlink:href="ctmx-20201231.xsd#Role_DisclosureFairValueMeasurementsAndShortTermInvestments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="ctmx-20201231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets" xlink:href="ctmx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilities" xlink:href="ctmx-20201231.xsd#Role_DisclosureAccruedLiabilities" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilities">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreements" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreements">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ResearchAndCollaborationAgreementsTextBlock" xlink:type="locator" xlink:label="ctmx_ResearchAndCollaborationAgreementsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ctmx_ResearchAndCollaborationAgreementsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreement" xlink:href="ctmx-20201231.xsd#Role_DisclosureLicenseAgreement" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreement">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LicenseAgreementDisclosureTextBlock" xlink:type="locator" xlink:label="ctmx_LicenseAgreementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="ctmx_LicenseAgreementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="ctmx-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeases" xlink:href="ctmx-20201231.xsd#Role_DisclosureLeases" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureLeases">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStock" xlink:href="ctmx-20201231.xsd#Role_DisclosureCommonStock" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStock">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CommonStockTextBlock" xlink:type="locator" xlink:label="ctmx_CommonStockTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ctmx_CommonStockTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="ctmx-20201231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="ctmx-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan" xlink:href="ctmx-20201231.xsd#Role_DisclosureDefinedContributionPlan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="ctmx-20201231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="ctmx-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="ctmx-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:type="locator" xlink:label="ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:type="locator" xlink:label="ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables" xlink:href="ctmx-20201231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsTables" xlink:href="ctmx-20201231.xsd#Role_DisclosureFairValueMeasurementsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="ctmx-20201231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables" xlink:href="ctmx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables" xlink:href="ctmx-20201231.xsd#Role_DisclosureAccruedLiabilitiesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsTables" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesTables" xlink:href="ctmx-20201231.xsd#Role_DisclosureLeasesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SupplementalInformationRelatedToLeasesTableTextBlock" xlink:type="locator" xlink:label="ctmx_SupplementalInformationRelatedToLeasesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ctmx_SupplementalInformationRelatedToLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockTables" xlink:href="ctmx-20201231.xsd#Role_DisclosureCommonStockTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="ctmx-20201231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="ctmx-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AstellasPharmaIncMember" xlink:type="locator" xlink:label="ctmx_AstellasPharmaIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_BristolMyersSquibbCompanyMember" xlink:type="locator" xlink:label="ctmx_BristolMyersSquibbCompanyMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MajorCustomerMember" xlink:type="locator" xlink:label="ctmx_MajorCustomerMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis" xlink:type="locator" xlink:label="srt_MajorCustomersAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_MajorCustomersAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ctmx_MajorCustomerMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_CounterpartyNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_BristolMyersSquibbCompanyMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AstellasPharmaIncMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfBusinessActivities" xlink:type="locator" xlink:label="ctmx_NumberOfBusinessActivities" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201602Member" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ProbodyTechnologyMember" xlink:type="locator" xlink:label="ctmx_ProbodyTechnologyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:type="locator" xlink:label="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:type="locator" xlink:label="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ctmx_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:to="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:to="us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ctmx_ProbodyTechnologyMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ctmx_NumberOfBusinessActivities" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ComputerEquipmentAndSoftwareMember" xlink:type="locator" xlink:label="ctmx_ComputerEquipmentAndSoftwareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ctmx_ComputerEquipmentAndSoftwareMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201912Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201912Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201908Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201908Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201818Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201818Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201815Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201815Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201704Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201704Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="ctmx_SummaryOfSignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ctmx_SummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201704Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201815Member" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201818Member" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201908Member" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201912Member" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesTable" xlink:to="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OptionsAndESPPToPurchaseCommonStockMember" xlink:type="locator" xlink:label="ctmx_OptionsAndESPPToPurchaseCommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="ctmx_OptionsAndESPPToPurchaseCommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="locator" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" xlink:type="locator" xlink:label="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:type="locator" xlink:label="us-gaap_USTreasuryAndGovernmentMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MoneyMarketFundsIncludedInRestrictedCashMember" xlink:type="locator" xlink:label="ctmx_MoneyMarketFundsIncludedInRestrictedCashMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10110.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="ctmx_MoneyMarketFundsIncludedInRestrictedCashMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasuryAndGovernmentMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="12590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="12750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureFairValueMeasurementsAndShortTermInvestmentsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesGross" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ComputerEquipmentAndSoftwareGross" xlink:type="locator" xlink:label="ctmx_ComputerEquipmentAndSoftwareGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_MachineryAndEquipmentGross" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="ctmx_ComputerEquipmentAndSoftwareGross" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_FurnitureAndFixturesGross" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_LeaseholdImprovementsGross" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ConstructionInProgressGross" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:type="locator" xlink:label="us-gaap_Depreciation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="locator" xlink:label="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_GoodwillAbstract" xlink:type="locator" xlink:label="ctmx_GoodwillAbstract" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_GoodwillAndIntangibleAssetsLineItems" xlink:type="locator" xlink:label="ctmx_GoodwillAndIntangibleAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:type="locator" xlink:label="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable" xlink:to="ctmx_GoodwillAndIntangibleAssetsLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_GoodwillAndIntangibleAssetsLineItems" xlink:to="ctmx_GoodwillAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_GoodwillAbstract" xlink:to="us-gaap_Goodwill" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_GoodwillAndIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AccruedResearchAndClinicalCurrent" xlink:type="locator" xlink:label="ctmx_AccruedResearchAndClinicalCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="ctmx_AccruedResearchAndClinicalCurrent" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PfizerIncMember" xlink:type="locator" xlink:label="ctmx_PfizerIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ImmunoGenIncMember" xlink:type="locator" xlink:label="ctmx_ImmunoGenIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AstellasPharmaIncMember" xlink:type="locator" xlink:label="ctmx_AstellasPharmaIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_BristolMyersSquibbCompanyMember" xlink:type="locator" xlink:label="ctmx_BristolMyersSquibbCompanyMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenIncMember" xlink:type="locator" xlink:label="ctmx_AmgenIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AmgenIncMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_BristolMyersSquibbCompanyMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AstellasPharmaIncMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_ImmunoGenIncMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_PfizerIncMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedResearchServicePeriod" xlink:type="locator" xlink:label="ctmx_EstimatedResearchServicePeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentsReceivable" xlink:type="locator" xlink:label="ctmx_MilestonePaymentsReceivable" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfAccountingUnits" xlink:type="locator" xlink:label="ctmx_NumberOfAccountingUnits" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedSublicenseFees" xlink:type="locator" xlink:label="ctmx_EstimatedSublicenseFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AggregateCollaborationTransactionAmount" xlink:type="locator" xlink:label="ctmx_AggregateCollaborationTransactionAmount" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentMilestonePaymentsReceivable" xlink:type="locator" xlink:label="ctmx_ContingentMilestonePaymentsReceivable" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentReceived" xlink:type="locator" xlink:label="ctmx_MilestonePaymentReceived" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargetsSelected" xlink:type="locator" xlink:label="ctmx_NumberOfTargetsSelected" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargets" xlink:type="locator" xlink:label="ctmx_NumberOfTargets" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PaymentsOfSublicenseFees" xlink:type="locator" xlink:label="ctmx_PaymentsOfSublicenseFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" xlink:type="locator" xlink:label="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentPaymentsReceivableProfitSplitOnSales" xlink:type="locator" xlink:label="ctmx_ContingentPaymentsReceivableProfitSplitOnSales" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts" xlink:type="locator" xlink:label="ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfCollaborationAgreements" xlink:type="locator" xlink:label="ctmx_NumberOfCollaborationAgreements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransferredOverTimeMember" xlink:type="locator" xlink:label="us-gaap_TransferredOverTimeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="locator" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="locator" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecondTargetMember" xlink:type="locator" xlink:label="ctmx_SecondTargetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember" xlink:type="locator" xlink:label="ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_DiscoveryAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SeattleGeneticsAgreementMember" xlink:type="locator" xlink:label="ctmx_SeattleGeneticsAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CD71AgreementMember" xlink:type="locator" xlink:label="ctmx_CD71AgreementMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:type="locator" xlink:label="country_US" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CD71AgreementMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_SeattleGeneticsAgreementMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_DiscoveryAgreementMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_SecondTargetMember" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceDomain" order="12740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="us-gaap_TransferredOverTimeMember" order="12760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="13160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfCollaborationAgreements" order="13170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts" order="13190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="13240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" order="13260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentPaymentsReceivableProfitSplitOnSales" order="13280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" order="13300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_PaymentsOfSublicenseFees" order="13340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfTargets" order="13470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfTargetsSelected" order="13510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_MilestonePaymentReceived" order="13600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentMilestonePaymentsReceivable" order="13620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_AggregateCollaborationTransactionAmount" order="13670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedSublicenseFees" order="13750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfAccountingUnits" order="13770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_MilestonePaymentsReceivable" order="13830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="14050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="14070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="14140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedResearchServicePeriod" order="14180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="14460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="14580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_DiscoveryAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_DiscoveryAgreementMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedResearchServicePeriod" xlink:type="locator" xlink:label="ctmx_EstimatedResearchServicePeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedFairValueOfProducts" xlink:type="locator" xlink:label="ctmx_EstimatedFairValueOfProducts" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock" xlink:type="locator" xlink:label="ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AggregateCollaborationTransactionAmount" xlink:type="locator" xlink:label="ctmx_AggregateCollaborationTransactionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds" xlink:type="locator" xlink:label="ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" xlink:type="locator" xlink:label="ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfAdditionalCollaborationTarget" xlink:type="locator" xlink:label="ctmx_NumberOfAdditionalCollaborationTarget" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargetsSelected" xlink:type="locator" xlink:label="ctmx_NumberOfTargetsSelected" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargets" xlink:type="locator" xlink:label="ctmx_NumberOfTargets" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ProfitShareUponExerciseOfCoDevelopmentOption" xlink:type="locator" xlink:label="ctmx_ProfitShareUponExerciseOfCoDevelopmentOption" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentMilestonePaymentsReceivable" xlink:type="locator" xlink:label="ctmx_ContingentMilestonePaymentsReceivable" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedPremiumOnIssuanceOfShares" xlink:type="locator" xlink:label="ctmx_EstimatedPremiumOnIssuanceOfShares" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement" xlink:type="locator" xlink:label="ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare" xlink:type="locator" xlink:label="ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CommonStockSharesIssuableUnderAgreement" xlink:type="locator" xlink:label="ctmx_CommonStockSharesIssuableUnderAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenOtherProductsMember" xlink:type="locator" xlink:label="ctmx_AmgenOtherProductsMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_RegentsOfTheUniversityOfCaliforniaMember" xlink:type="locator" xlink:label="ctmx_RegentsOfTheUniversityOfCaliforniaMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SublicenseAgreementMember" xlink:type="locator" xlink:label="ctmx_SublicenseAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenProductsMember" xlink:type="locator" xlink:label="ctmx_AmgenProductsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EGFRProductsMember" xlink:type="locator" xlink:label="ctmx_EGFRProductsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenIncMember" xlink:type="locator" xlink:label="ctmx_AmgenIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="ctmx_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CollaborationAndLicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AmgenIncMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_EGFRProductsMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_AmgenProductsMember" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_SublicenseAgreementMember" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ctmx_RegentsOfTheUniversityOfCaliforniaMember" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_AmgenOtherProductsMember" order="12220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="12820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="12830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_CommonStockSharesIssuableUnderAgreement" order="12850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" order="12870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare" order="12910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement" order="12930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedPremiumOnIssuanceOfShares" order="12950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentMilestonePaymentsReceivable" order="13000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ProfitShareUponExerciseOfCoDevelopmentOption" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfTargets" order="13070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfTargetsSelected" order="13090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfAdditionalCollaborationTarget" order="13110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones" order="13180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds" order="13230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="13250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_AggregateCollaborationTransactionAmount" order="13320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock" order="13360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedFairValueOfProducts" order="13380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedResearchServicePeriod" order="13490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="13560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="13630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="13690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="13750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="13870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedResearchServiceTerminationMonthAndYear" xlink:type="locator" xlink:label="ctmx_EstimatedResearchServiceTerminationMonthAndYear" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedResearchServicePeriod" xlink:type="locator" xlink:label="ctmx_EstimatedResearchServicePeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ResearchAndDevelopmentServiceFees" xlink:type="locator" xlink:label="ctmx_ResearchAndDevelopmentServiceFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AggregateCollaborationTransactionAmount" xlink:type="locator" xlink:label="ctmx_AggregateCollaborationTransactionAmount" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentMilestonePaymentsReceivable" xlink:type="locator" xlink:label="ctmx_ContingentMilestonePaymentsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_RightToExpandNumberOfAdditionalCollaborationTarget" xlink:type="locator" xlink:label="ctmx_RightToExpandNumberOfAdditionalCollaborationTarget" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfAdditionalCollaborationTarget" xlink:type="locator" xlink:label="ctmx_NumberOfAdditionalCollaborationTarget" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargetsSelected" xlink:type="locator" xlink:label="ctmx_NumberOfTargetsSelected" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfTargets" xlink:type="locator" xlink:label="ctmx_NumberOfTargets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AdditionalContingentPaymentsMember" xlink:type="locator" xlink:label="ctmx_AdditionalContingentPaymentsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AstellasPharmaIncMember" xlink:type="locator" xlink:label="ctmx_AstellasPharmaIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="ctmx_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CollaborationAndLicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AstellasPharmaIncMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="ctmx_AdditionalContingentPaymentsMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfTargets" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfTargetsSelected" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfAdditionalCollaborationTarget" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_RightToExpandNumberOfAdditionalCollaborationTarget" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentMilestonePaymentsReceivable" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_AggregateCollaborationTransactionAmount" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ResearchAndDevelopmentServiceFees" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedResearchServicePeriod" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedResearchServiceTerminationMonthAndYear" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerAssetNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive" xlink:type="locator" xlink:label="ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EstimatedResearchServiceTerminationDate" xlink:type="locator" xlink:label="ctmx_EstimatedResearchServiceTerminationDate" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" xlink:type="locator" xlink:label="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ResearchAndDevelopmentServiceFees" xlink:type="locator" xlink:label="ctmx_ResearchAndDevelopmentServiceFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UpfrontFeeReceived" xlink:type="locator" xlink:label="ctmx_UpfrontFeeReceived" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AggregateCollaborationTransactionAmount" xlink:type="locator" xlink:label="ctmx_AggregateCollaborationTransactionAmount" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfResearchTargetsSelected" xlink:type="locator" xlink:label="ctmx_NumberOfResearchTargetsSelected" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContingentMilestonePaymentsReceivable" xlink:type="locator" xlink:label="ctmx_ContingentMilestonePaymentsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes" xlink:type="locator" xlink:label="ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ExtensionOfResearchTermForEachCollaborationTarget" xlink:type="locator" xlink:label="ctmx_ExtensionOfResearchTermForEachCollaborationTarget" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PeriodOfNominationOfAdditionalTarget" xlink:type="locator" xlink:label="ctmx_PeriodOfNominationOfAdditionalTarget" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfAdditionalCollaborationTarget" xlink:type="locator" xlink:label="ctmx_NumberOfAdditionalCollaborationTarget" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CollaborationTargetResearchTerm" xlink:type="locator" xlink:label="ctmx_CollaborationTargetResearchTerm" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfCollaborationTarget" xlink:type="locator" xlink:label="ctmx_NumberOfCollaborationTarget" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfOncologyTarget" xlink:type="locator" xlink:label="ctmx_NumberOfOncologyTarget" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AcceleratedRecognitionOfDeferredRevenueMember" xlink:type="locator" xlink:label="ctmx_AcceleratedRecognitionOfDeferredRevenueMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ThirdAndFourthTargetsMember" xlink:type="locator" xlink:label="ctmx_ThirdAndFourthTargetsMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="ctmx_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DrugApplicationForCTLA4Member" xlink:type="locator" xlink:label="ctmx_DrugApplicationForCTLA4Member" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PreClinicalCandidateMember" xlink:type="locator" xlink:label="ctmx_PreClinicalCandidateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AchievingAdditionalTargetsMember" xlink:type="locator" xlink:label="ctmx_AchievingAdditionalTargetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ContingentConsiderationByTypeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_BristolMyersSquibbCompanyMember" xlink:type="locator" xlink:label="ctmx_BristolMyersSquibbCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_BristolMyersSquibbCompanyMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="ctmx_AchievingAdditionalTargetsMember" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_PreClinicalCandidateMember" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_DrugApplicationForCTLA4Member" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CollaborationAndLicenseAgreementMember" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_ThirdAndFourthTargetsMember" order="11900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_AcceleratedRecognitionOfDeferredRevenueMember" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementScenarioAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="12100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="12380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfOncologyTarget" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfCollaborationTarget" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_CollaborationTargetResearchTerm" order="12430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfAdditionalCollaborationTarget" order="12450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_PeriodOfNominationOfAdditionalTarget" order="12490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ExtensionOfResearchTermForEachCollaborationTarget" order="12510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes" order="12530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="12580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentMilestonePaymentsReceivable" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfResearchTargetsSelected" order="12890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_AggregateCollaborationTransactionAmount" order="12960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_UpfrontFeeReceived" order="12980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ResearchAndDevelopmentServiceFees" order="13000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_EstimatedResearchServiceTerminationDate" order="13040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="13090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive" order="13130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="13400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="13460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNet" order="13520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentPayable" xlink:type="locator" xlink:label="ctmx_MilestonePaymentPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfResearchTargetsSelected" xlink:type="locator" xlink:label="ctmx_NumberOfResearchTargetsSelected" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashPaymentToExecuteAgreement" xlink:type="locator" xlink:label="ctmx_CashPaymentToExecuteAgreement" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ImmunoGenIncMember" xlink:type="locator" xlink:label="ctmx_ImmunoGenIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_ImmunoGenIncMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_CashPaymentToExecuteAgreement" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfResearchTargetsSelected" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_MilestonePaymentPayable" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="ctmx_ContractWithCustomerLiabilityAdditions" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfAdditionalResearchTargetsWithNominationOption" xlink:type="locator" xlink:label="ctmx_NumberOfAdditionalResearchTargetsWithNominationOption" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfNominatedResearchTargets" xlink:type="locator" xlink:label="ctmx_NumberOfNominatedResearchTargets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PfizerIncMember" xlink:type="locator" xlink:label="ctmx_PfizerIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_PfizerIncMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfNominatedResearchTargets" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_NumberOfAdditionalResearchTargetsWithNominationOption" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContractWithCustomerLiabilityAdditions" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsSummaryOfContractLiabilitiesDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsSummaryOfContractLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsSummaryOfContractLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="ctmx_ContractWithCustomerLiabilityAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="ctmx_ContractWithCustomerLiabilityAdditions" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ContractWithCustomerLiability_li0l2" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear" xlink:type="locator" xlink:label="ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ContractWithCustomerLiabilityAdditions" xlink:type="locator" xlink:label="ctmx_ContractWithCustomerLiabilityAdditions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenOtherProductsMember" xlink:type="locator" xlink:label="ctmx_AmgenOtherProductsMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EGFRProductsMember" xlink:type="locator" xlink:label="ctmx_EGFRProductsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecondTargetUnderDiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_SecondTargetUnderDiscoveryAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_FirstTargetUnderDiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_FirstTargetUnderDiscoveryAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CD71AgreementMember" xlink:type="locator" xlink:label="ctmx_CD71AgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_BristolMyersSquibbCompanyMember" xlink:type="locator" xlink:label="ctmx_BristolMyersSquibbCompanyMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AmgenIncMember" xlink:type="locator" xlink:label="ctmx_AmgenIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AstellasPharmaIncMember" xlink:type="locator" xlink:label="ctmx_AstellasPharmaIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AstellasPharmaIncMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AmgenIncMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_BristolMyersSquibbCompanyMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CD71AgreementMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_FirstTargetUnderDiscoveryAgreementMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_SecondTargetUnderDiscoveryAgreementMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_EGFRProductsMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_AmgenOtherProductsMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContractWithCustomerLiabilityAdditions" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureLicenseAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UpfrontLicensePayment" xlink:type="locator" xlink:label="ctmx_UpfrontLicensePayment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" xlink:type="locator" xlink:label="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:type="locator" xlink:label="us-gaap_ProceedsFromCollaborators" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SublicenseFees" xlink:type="locator" xlink:label="ctmx_SublicenseFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MilestonePaymentReceivable" xlink:type="locator" xlink:label="ctmx_MilestonePaymentReceivable" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AdditionalSublicenseFees" xlink:type="locator" xlink:label="ctmx_AdditionalSublicenseFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_FairValueOfCommonStockIssued" xlink:type="locator" xlink:label="ctmx_FairValueOfCommonStockIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfRemainingMaintenanceFeesOutstanding" xlink:type="locator" xlink:label="ctmx_PercentageOfRemainingMaintenanceFeesOutstanding" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LicensePaymentTerm" xlink:type="locator" xlink:label="ctmx_LicensePaymentTerm" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AnnualLicenseMaintenanceFees" xlink:type="locator" xlink:label="ctmx_AnnualLicenseMaintenanceFees" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PaymentOfUpfrontFees" xlink:type="locator" xlink:label="ctmx_PaymentOfUpfrontFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LicenseTerminationPeriod" xlink:type="locator" xlink:label="ctmx_LicenseTerminationPeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_RoyaltyObligationsFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="ctmx_RoyaltyObligationsFutureMinimumPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ImmunoGenIncMember" xlink:type="locator" xlink:label="ctmx_ImmunoGenIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CD71AgreementMember" xlink:type="locator" xlink:label="ctmx_CD71AgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="ctmx_CollaborationAndLicenseAgreementMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieIrelandUnlimitedCompanyMember" xlink:type="locator" xlink:label="ctmx_AbbVieIrelandUnlimitedCompanyMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AstellasPharmaIncMember" xlink:type="locator" xlink:label="ctmx_AstellasPharmaIncMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_BristolMyersSquibbCompanyMember" xlink:type="locator" xlink:label="ctmx_BristolMyersSquibbCompanyMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecondTargetMember" xlink:type="locator" xlink:label="ctmx_SecondTargetMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DiscoveryAgreementMember" xlink:type="locator" xlink:label="ctmx_DiscoveryAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_AbbVieMember" xlink:type="locator" xlink:label="ctmx_AbbVieMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SublicenseAndMaintenanceFeesMember" xlink:type="locator" xlink:label="ctmx_SublicenseAndMaintenanceFeesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UniversityOfCaliforniaSantaBarbaraMember" xlink:type="locator" xlink:label="ctmx_UniversityOfCaliforniaSantaBarbaraMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="ctmx_UniversityOfCaliforniaSantaBarbaraMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="ctmx_SublicenseAndMaintenanceFeesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_DiscoveryAgreementMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_ProductOrServiceAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ctmx_SecondTargetMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_BristolMyersSquibbCompanyMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AstellasPharmaIncMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_AbbVieIrelandUnlimitedCompanyMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CollaborationAndLicenseAgreementMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ctmx_CD71AgreementMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_ImmunoGenIncMember" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_RoyaltyObligationsFutureMinimumPaymentsDue" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_LicenseTerminationPeriod" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_PaymentOfUpfrontFees" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_AnnualLicenseMaintenanceFees" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_LicensePaymentTerm" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_PercentageOfRemainingMaintenanceFeesOutstanding" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_FairValueOfCommonStockIssued" order="11390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_AdditionalSublicenseFees" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_MilestonePaymentReceivable" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_SublicenseFees" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ProceedsFromCollaborators" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="ctmx_UpfrontLicensePayment" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants" xlink:type="locator" xlink:label="ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="locator" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate" xlink:type="locator" xlink:label="ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate" xlink:type="locator" xlink:label="ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyNameOfPlaintiff" xlink:type="locator" xlink:label="us-gaap_LossContingencyNameOfPlaintiff" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyLawsuitFilingDate" xlink:type="locator" xlink:label="us-gaap_LossContingencyLawsuitFilingDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:type="locator" xlink:label="us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecuritiesClassActionLawsuitMember" xlink:type="locator" xlink:label="ctmx_SecuritiesClassActionLawsuitMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PatentInfringementLawsuitMember" xlink:type="locator" xlink:label="ctmx_PatentInfringementLawsuitMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:type="locator" xlink:label="srt_LitigationCaseTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_LitigationCaseAxis" xlink:type="locator" xlink:label="srt_LitigationCaseAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingenciesTable" xlink:type="locator" xlink:label="us-gaap_LossContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LossContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="srt_LitigationCaseAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="ctmx_PatentInfringementLawsuitMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="ctmx_SecuritiesClassActionLawsuitMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesTable" xlink:to="us-gaap_LossContingenciesLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyLawsuitFilingDate" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyNameOfPlaintiff" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesLineItems" xlink:to="ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:type="locator" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ImprovementAllowanceFromRecoverableRent" xlink:type="locator" xlink:label="ctmx_ImprovementAllowanceFromRecoverableRent" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_MaximumImprovementAllowance" xlink:type="locator" xlink:label="ctmx_MaximumImprovementAllowance" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OperatingLeasesRentExpenseAnnualBaseRent" xlink:type="locator" xlink:label="ctmx_OperatingLeasesRentExpenseAnnualBaseRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AreaOfLand" xlink:type="locator" xlink:label="us-gaap_AreaOfLand" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember" xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:type="locator" xlink:label="us-gaap_CreditFacilityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:type="locator" xlink:label="us-gaap_CreditFacilityAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_TenthYearOfLeaseTermMember" xlink:type="locator" xlink:label="ctmx_TenthYearOfLeaseTermMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SecondTwelveMonthsOfLeaseTermMember" xlink:type="locator" xlink:label="ctmx_SecondTwelveMonthsOfLeaseTermMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_FirstYearOfLeaseTermMember" xlink:type="locator" xlink:label="ctmx_FirstYearOfLeaseTermMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:type="locator" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAgreementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseAgreementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_LeaseAgreementsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ctmx_FirstYearOfLeaseTermMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ctmx_SecondTwelveMonthsOfLeaseTermMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ctmx_TenthYearOfLeaseTermMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_CreditFacilityAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_AreaOfLand" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="ctmx_OperatingLeasesRentExpenseAnnualBaseRent" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="ctmx_MaximumImprovementAllowance" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="ctmx_ImprovementAllowanceFromRecoverableRent" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_WeightedAverageDiscountRateAbstract" xlink:type="locator" xlink:label="ctmx_WeightedAverageDiscountRateAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_WeightedAverageRemainingLeaseTermAbstract" xlink:type="locator" xlink:label="ctmx_WeightedAverageRemainingLeaseTermAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:type="locator" xlink:label="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="locator" xlink:label="ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ctmx_WeightedAverageRemainingLeaseTermAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_WeightedAverageRemainingLeaseTermAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="ctmx_WeightedAverageDiscountRateAbstract" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_WeightedAverageDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:type="locator" xlink:label="ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureCommonStockAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfSalesCommissionAndIssuanceCost" xlink:type="locator" xlink:label="ctmx_PercentageOfSalesCommissionAndIssuanceCost" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_SharesIssuedAveragePricePerShare" xlink:type="locator" xlink:label="ctmx_SharesIssuedAveragePricePerShare" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfSalesCommission" xlink:type="locator" xlink:label="ctmx_PercentageOfSalesCommission" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsCommonStock" xlink:type="locator" xlink:label="us-gaap_DividendsCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_JefferiesMember" xlink:type="locator" xlink:label="ctmx_JefferiesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="ctmx_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ctmx_UnderwrittenPublicOfferingMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ctmx_JefferiesMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsCommonStock" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ctmx_PercentageOfSalesCommission" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ctmx_SharesIssuedAveragePricePerShare" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ctmx_PercentageOfSalesCommissionAndIssuanceCost" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_StockOptionsIssuedAndOutstanding" xlink:type="locator" xlink:label="ctmx_StockOptionsIssuedAndOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ctmx_StockOptionsIssuedAndOutstanding" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NonEmployeesMember" xlink:type="locator" xlink:label="ctmx_NonEmployeesMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="ctmx_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EarlyExerciseOfEmployeeOptionsMember" xlink:type="locator" xlink:label="ctmx_EarlyExerciseOfEmployeeOptionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_TwoThousandNineteenStockIncentivePlanMember" xlink:type="locator" xlink:label="ctmx_TwoThousandNineteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_TwoThousandFifteenStockIncentivePlanMember" xlink:type="locator" xlink:label="ctmx_TwoThousandFifteenStockIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ctmx_TwoThousandFifteenStockIncentivePlanMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ctmx_TwoThousandNineteenStockIncentivePlanMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="ctmx_EarlyExerciseOfEmployeeOptionsMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ctmx_EmployeeStockPurchasePlanMember" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ctmx_NonEmployeesMember" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_li0l2" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:type="locator" xlink:label="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_li0l2" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="11820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="12570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" order="12690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="12810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="12930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="13170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" order="13560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="13800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="13920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="14040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" order="14190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="14430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="14550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="14670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="14790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationAbstract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="ctmx_EmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="ctmx_EmployeeStockPurchasePlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OpenTaxYear" xlink:type="locator" xlink:label="us-gaap_OpenTaxYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfChangeInOwnership" xlink:type="locator" xlink:label="ctmx_PercentageOfChangeInOwnership" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_TaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="ctmx_TaxCreditCarryforwardExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" xlink:type="locator" xlink:label="ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" xlink:type="locator" xlink:label="ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="ctmx_OperatingLossCarryforwardsExpirationYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation" xlink:type="locator" xlink:label="ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_NetOperatingLossCarrybackPeriod" xlink:type="locator" xlink:label="ctmx_NetOperatingLossCarrybackPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchMember" xlink:type="locator" xlink:label="us-gaap_ResearchMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxContingencyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_NetOperatingLossCarrybackPeriod" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_OperatingLossCarryforwardsExpirationYear" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_TaxCreditCarryforwardExpirationYear" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="ctmx_PercentageOfChangeInOwnership" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OpenTaxYear" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" xlink:type="locator" xlink:label="ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" xlink:type="locator" xlink:label="ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_DeferredTaxAssetsLeaseLiability" xlink:type="locator" xlink:label="ctmx_DeferredTaxAssetsLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="ctmx_DeferredTaxAssetsLeaseLiability" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="locator" xlink:label="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="ctmx-20201231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares" xlink:type="locator" xlink:label="ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioForecastMember" xlink:type="locator" xlink:label="srt_ScenarioForecastMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis" xlink:type="locator" xlink:label="srt_StatementScenarioAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:href="ctmx-20201231.xsd#ctmx_UnderwrittenPublicOfferingMember" xlink:type="locator" xlink:label="ctmx_UnderwrittenPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ctmx_UnderwrittenPublicOfferingMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>ctmx-10k_20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:ctmx="http://cytomx.com/20201231"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ctmx-20201231.xsd" xlink:type="simple"/>
    <context id="C_0001501989_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0001501989_20210202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
        </entity>
        <period>
            <instant>2021-02-02</instant>
        </period>
    </context>
    <context id="C_0001501989_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ctmx:MajorCustomerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_ctmxComputerEquipmentAndSoftwareMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ctmx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20180101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_ctmxProbodyTechnologyMember_20190101_20190131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctmx:ProbodyTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_ctmxProbodyTechnologyMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ctmx:ProbodyTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201704Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201704Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201813Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201815Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201818Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201908Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201908Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201912Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ctmx:OptionsAndESPPToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ctmx:OptionsAndESPPToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ctmx:OptionsAndESPPToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFairValueByAssetClassAxis_ctmxMoneyMarketFundsIncludedInRestrictedCashMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ctmx:MoneyMarketFundsIncludedInRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFairValueByAssetClassAxis_ctmxMoneyMarketFundsIncludedInRestrictedCashMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">ctmx:MoneyMarketFundsIncludedInRestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:PfizerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20160401_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20170701_20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20180501_20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20170701_20170731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SeattleGeneticsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-07-01</startDate>
            <endDate>2017-07-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20180501_20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SeattleGeneticsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20170331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160401_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:SecondTargetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_ctmxDevelopmentRegulatoryAndCommercialMilestonePaymentsMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ctmx:DevelopmentRegulatoryAndCommercialMilestonePaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160401_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20160401_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SeattleGeneticsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160401_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2016-04-01_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2016-04-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180401_20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:SecondTargetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:SecondTargetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTimingOfTransferOfGoodOrServiceAxis_us-gaapTransferredOverTimeMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171001_20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-29</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-29</startDate>
            <endDate>2017-09-29</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-29</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-29</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-29</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxRegentsOfTheUniversityOfCaliforniaMember_us-gaapTypeOfArrangementAxis_ctmxSublicenseAgreementMember_20170929_20170929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-29</startDate>
            <endDate>2017-09-29</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxRegentsOfTheUniversityOfCaliforniaMember_us-gaapTypeOfArrangementAxis_ctmxSublicenseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxRegentsOfTheUniversityOfCaliforniaMember_us-gaapTypeOfArrangementAxis_ctmxSublicenseAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:RegentsOfTheUniversityOfCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SublicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-29</startDate>
            <endDate>2017-09-29</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-29</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-29</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200401_20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20190401_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-09-29</startDate>
            <endDate>2017-09-29</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenOtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-23</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-23</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-23</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-23</startDate>
            <endDate>2020-03-23</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapContingentConsiderationByTypeAxis_ctmxAdditionalContingentPaymentsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ctmx:AdditionalContingentPaymentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-23</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-07-07</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-06</startDate>
            <endDate>2014-07-07</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-07-07</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-07-06</startDate>
            <endDate>2014-07-07</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_ctmxAchievingAdditionalTargetsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ctmx:AchievingAdditionalTargetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-07-07</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20160131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-01-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxPreClinicalCandidateMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:PreClinicalCandidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxDrugApplicationForCTLA4Member_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:DrugApplicationForCTLA4Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-17</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170425_20170425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-25</startDate>
            <endDate>2017-04-25</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-25</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-04-25</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxThirdAndFourthTargetsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:ThirdAndFourthTargetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxAcceleratedRecognitionOfDeferredRevenueMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AcceleratedRecognitionOfDeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxThirdAndFourthTargetsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:ThirdAndFourthTargetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140101_20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-01-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130501_20130531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-05-01</startDate>
            <endDate>2013-05-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141201_20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-12-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:PfizerIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxFirstTargetUnderDiscoveryAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:FirstTargetUnderDiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSecondTargetUnderDiscoveryAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SecondTargetUnderDiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CD71AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxFirstTargetUnderDiscoveryAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:FirstTargetUnderDiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSecondTargetUnderDiscoveryAgreementMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieIrelandUnlimitedCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:SecondTargetUnderDiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:EGFRProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AmgenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:AmgenOtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20131231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeStatementLocationAxis_ctmxSublicenseAndMaintenanceFeesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ctmx:SublicenseAndMaintenanceFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AbbVieMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ctmx:SecondTargetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:DiscoveryAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200201_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:BristolMyersSquibbCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200301_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:AstellasPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ctmx:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">ctmx:UniversityOfCaliforniaSantaBarbaraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:ImmunoGenIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304_20200304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ctmx:PatentInfringementLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-04</startDate>
            <endDate>2020-03-04</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ctmx:PatentInfringementLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ctmx:PatentInfringementLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-04</instant>
        </period>
    </context>
    <context id="C_0001501989_srtLitigationCaseAxis_ctmxSecuritiesClassActionLawsuitMember_20200521_20200521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ctmx:SecuritiesClassActionLawsuitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-21</startDate>
            <endDate>2020-05-21</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-10</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_us-gaapLeaseContractualTermAxis_ctmxFirstYearOfLeaseTermMember_20151209_20151210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ctmx:FirstYearOfLeaseTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-09</startDate>
            <endDate>2015-12-10</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_us-gaapLeaseContractualTermAxis_ctmxSecondTwelveMonthsOfLeaseTermMember_20151209_20151210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ctmx:SecondTwelveMonthsOfLeaseTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-09</startDate>
            <endDate>2015-12-10</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_us-gaapLeaseContractualTermAxis_ctmxTenthYearOfLeaseTermMember_20151209_20151210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ctmx:TenthYearOfLeaseTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-09</startDate>
            <endDate>2015-12-10</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151209_20151210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LeaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-12-09</startDate>
            <endDate>2015-12-10</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_20151014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
        </entity>
        <period>
            <instant>2015-10-14</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20180730_20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ctmx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-30</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ctmx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20180730_20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-30</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180730_20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-30</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_srtRangeAxis_srtMaximumMember_20200201_20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:JefferiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ctmx:JefferiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20160101_20160101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-01</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:TwoThousandNineteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPlanNameAxis_ctmxEarlyExerciseOfEmployeeOptionsMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:EarlyExerciseOfEmployeeOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapPlanNameAxis_ctmxEarlyExerciseOfEmployeeOptionsMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ctmx:EarlyExerciseOfEmployeeOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAwardTypeAxis_ctmxNonEmployeesMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAwardTypeAxis_ctmxNonEmployeesMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapAwardTypeAxis_ctmxNonEmployeesMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ctmx:NonEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_20200327_20200327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
        </entity>
        <period>
            <startDate>2020-03-27</startDate>
            <endDate>2020-03-27</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtRangeAxis_srtMinimumMember_20170101_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210101_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ctmx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ctmx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-31</instant>
        </period>
    </context>
    <context id="C_0001501989_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210101_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ctmx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20210201_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_0001501989_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210201_20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ctmx:UnderwrittenPublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20210101_20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001501989</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_ctmxActivity">
        <measure>ctmx:Activity</measure>
    </unit>
    <unit id="U_ctmxSegment">
        <measure>ctmx:Segment</measure>
    </unit>
    <unit id="U_ctmxAgreement">
        <measure>ctmx:Agreement</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <unit id="U_ctmxTarget">
        <measure>ctmx:Target</measure>
    </unit>
    <unit id="U_ctmxAccountingUnit">
        <measure>ctmx:AccountingUnit</measure>
    </unit>
    <unit id="U_ctmxTerm">
        <measure>ctmx:Term</measure>
    </unit>
    <unit id="U_ctmxDefendant">
        <measure>ctmx:Defendant</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:AmendmentFlag contextRef="C_0001501989_20200101_20201231" id="F_000001">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001501989_20200101_20201231" id="F_000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="C_0001501989_20200101_20201231" id="F_000007">0001501989</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001501989_20200101_20201231" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231"
      id="F_000395">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201704Member_20201231"
      id="F_000397">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201704Member_20201231"
      id="F_000398">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231"
      id="F_000400">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231"
      id="F_000401">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231"
      id="F_000403">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231"
      id="F_000404">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231"
      id="F_000406">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231"
      id="F_000407">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201908Member_20201231"
      id="F_000409">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201908Member_20201231"
      id="F_000410">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231"
      id="F_000412">false</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231"
      id="F_000413">false</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180401_20180630"
      id="F_000529">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTimingOfTransferOfGoodOrServiceAxis_us-gaapTransferredOverTimeMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331"
      id="F_000536">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20200101_20201231"
      id="F_000540">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20190101_20191231"
      id="F_000541">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180101_20181231"
      id="F_000542">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200101_20201231"
      id="F_000580">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20190101_20191231"
      id="F_000581">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20180101_20181231"
      id="F_000582">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231"
      id="F_000641">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231"
      id="F_000642">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231"
      id="F_000643">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231"
      id="F_000658">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001501989_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231"
      decimals="INF"
      id="F_000789"
      unitRef="U_xbrlipure">0.0208</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxEarlyExerciseOfEmployeeOptionsMember_20200101_20201231"
      id="F_000833">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:OpenTaxYear
      contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_001012">2010 2011 2012 2013 2014 2015 2016 2017 2018</us-gaap:OpenTaxYear>
    <us-gaap:OpenTaxYear
      contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231"
      id="F_001013">2010 2011 2012 2013 2014 2015 2016 2017 2018</us-gaap:OpenTaxYear>
    <ctmx:LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171001_20171031"
      id="F_000554">P6M</ctmx:LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement>
    <ctmx:CollaborationTargetResearchTerm
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707"
      id="F_000610">P2Y</ctmx:CollaborationTargetResearchTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001501989_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20200101_20201231"
      decimals="INF"
      id="F_000789_2"
      unitRef="U_xbrlipure">0.0208</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <ctmx:NetOperatingLossCarrybackPeriod contextRef="C_0001501989_20200327_20200327" id="F_000893">P5Y</ctmx:NetOperatingLossCarrybackPeriod>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0001501989_20190101_20191231" id="F_000108">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:TypeOfRevenueExtensibleList contextRef="C_0001501989_20180101_20181231" id="F_000109">us-gaap:LicenseAndServiceMember</us-gaap:TypeOfRevenueExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList contextRef="C_0001501989_20180101_20181231" id="F_000158">us-gaap:AccountingStandardsUpdate201409Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList contextRef="C_0001501989_20190101_20191231" id="F_000182">us-gaap:AccountingStandardsUpdate201802Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001501989_20201231" id="F_000744">P5Y9M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="C_0001501989_20191231" id="F_000745">P6Y10M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="C_0001501989_20191231" id="F_000741">us-gaap:OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001501989_20200101_20201231" id="F_000818">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_0001501989_20200101_20201231" id="F_000819">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="C_0001501989_20200101_20201231" id="F_000820">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="3"
      id="F_000860"
      unitRef="U_xbrlipure">0.644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="3"
      id="F_000875"
      unitRef="U_xbrlipure">0.733</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="3"
      id="F_000861"
      unitRef="U_xbrlipure">0.644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="3"
      id="F_000876"
      unitRef="U_xbrlipure">0.686</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="3"
      id="F_000862"
      unitRef="U_xbrlipure">0.656</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="3"
      id="F_000877"
      unitRef="U_xbrlipure">0.693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="3"
      id="F_000863"
      unitRef="U_xbrlipure">0.473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="3"
      id="F_000878"
      unitRef="U_xbrlipure">1.221</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="3"
      id="F_000864"
      unitRef="U_xbrlipure">0.608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="3"
      id="F_000879"
      unitRef="U_xbrlipure">0.719</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231"
      decimals="3"
      id="F_000865"
      unitRef="U_xbrlipure">0.464</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231"
      decimals="3"
      id="F_000880"
      unitRef="U_xbrlipure">0.705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000866"
      unitRef="U_xbrlipure">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000881"
      unitRef="U_xbrlipure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="INF"
      id="F_000867"
      unitRef="U_xbrlipure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="INF"
      id="F_000882"
      unitRef="U_xbrlipure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="INF"
      id="F_000868"
      unitRef="U_xbrlipure">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="INF"
      id="F_000883"
      unitRef="U_xbrlipure">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000869"
      unitRef="U_xbrlipure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000884"
      unitRef="U_xbrlipure">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="INF"
      id="F_000870"
      unitRef="U_xbrlipure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="INF"
      id="F_000885"
      unitRef="U_xbrlipure">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231"
      decimals="INF"
      id="F_000871"
      unitRef="U_xbrlipure">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231"
      decimals="INF"
      id="F_000886"
      unitRef="U_xbrlipure">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000887">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      id="F_000888">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      id="F_000889">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000890">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      id="F_000891">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      id="F_000892">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231"
      id="F_000872">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231"
      id="F_000873">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231"
      id="F_000874">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001501989_20201231"
      id="F_000073"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001501989_20191231"
      id="F_000074"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231"
      id="F_000075"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231"
      id="F_000076"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="C_0001501989_20200101_20201231" id="F_000000">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="C_0001501989_20200101_20201231" id="F_000030">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001501989_20200101_20201231" id="F_000002">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001501989_20200101_20201231" id="F_000003">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001501989_20200101_20201231" id="F_000031">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001501989_20200101_20201231" id="F_000017">001-37587</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001501989_20200101_20201231" id="F_000006">CytomX Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001501989_20200101_20201231" id="F_000029">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001501989_20200101_20201231" id="F_000018">27-3521219</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001501989_20200101_20201231" id="F_000019">151 Oyster Point Boulevard,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001501989_20200101_20201231" id="F_000020">Suite 400</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001501989_20200101_20201231" id="F_000021">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001501989_20200101_20201231" id="F_000022">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001501989_20200101_20201231" id="F_000023">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001501989_20200101_20201231" id="F_000024">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001501989_20200101_20201231" id="F_000025">515-3185</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001501989_20200101_20201231" id="F_000027">Common Stock, $0.00001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001501989_20200101_20201231" id="F_000005">CTMX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001501989_20200101_20201231" id="F_000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="C_0001501989_20200101_20201231" id="F_000009">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="C_0001501989_20200101_20201231" id="F_000010">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="C_0001501989_20200101_20201231" id="F_000011">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001501989_20200101_20201231" id="F_000026">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001501989_20200101_20201231" id="F_000012">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001501989_20200101_20201231" id="F_000013">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001501989_20200101_20201231" id="F_000014">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="C_0001501989_20200101_20201231" id="F_000015">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="C_0001501989_20200101_20201231" id="F_000016">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_0001501989_20200630"
      decimals="-5"
      id="F_000032"
      unitRef="U_iso4217USD">379400000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001501989_20210202"
      decimals="INF"
      id="F_000033"
      unitRef="U_xbrlishares">64784355</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000298">
&lt;p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Portions of the registrant&#x2019;s definitive proxy statement to be filed for its 2021 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">191859000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">188425000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">124260000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">107720000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">798000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">13000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">7096000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">7177000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">324013000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">303335000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">6950000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">7372000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">1167000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">1312000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">949000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">949000</us-gaap:Goodwill>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">917000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">917000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">22495000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000053"
      unitRef="U_iso4217USD">25382000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000054"
      unitRef="U_iso4217USD">2172000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000055"
      unitRef="U_iso4217USD">2015000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000056"
      unitRef="U_iso4217USD">358663000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">341282000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">2996000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">4158000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">23059000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">30051000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">74869000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">51381000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">100924000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">85590000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">186261000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000067"
      unitRef="U_iso4217USD">178858000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000068"
      unitRef="U_iso4217USD">21675000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000069"
      unitRef="U_iso4217USD">24871000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000070"
      unitRef="U_iso4217USD">850000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000071"
      unitRef="U_iso4217USD">308860000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000072"
      unitRef="U_iso4217USD">290169000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000089"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000090"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000091"
      unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000092"
      unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000093"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000094"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20201231"
      decimals="INF"
      id="F_000095"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001501989_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231"
      decimals="INF"
      id="F_000096"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001501989_20201231"
      decimals="INF"
      id="F_000097"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001501989_20191231"
      decimals="INF"
      id="F_000098"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001501989_20201231"
      decimals="INF"
      id="F_000099"
      unitRef="U_xbrlishares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001501989_20191231"
      decimals="INF"
      id="F_000100"
      unitRef="U_xbrlishares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001501989_20201231"
      decimals="INF"
      id="F_000101"
      unitRef="U_xbrlishares">48251819</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001501989_20201231"
      decimals="INF"
      id="F_000103"
      unitRef="U_xbrlishares">48251819</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001501989_20191231"
      decimals="INF"
      id="F_000102"
      unitRef="U_xbrlishares">45523088</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001501989_20191231"
      decimals="INF"
      id="F_000104"
      unitRef="U_xbrlishares">45523088</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000077"
      unitRef="U_iso4217USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000078"
      unitRef="U_iso4217USD">1000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000079"
      unitRef="U_iso4217USD">499964000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000080"
      unitRef="U_iso4217USD">468285000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000081"
      unitRef="U_iso4217USD">-47000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000082"
      unitRef="U_iso4217USD">57000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">-450115000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">-417230000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">49803000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">51113000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">358663000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">341282000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">100362000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">57489000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">59502000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">112936000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">131619000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">103866000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">36031000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">36765000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">33510000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">148967000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">168384000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">137376000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">-48605000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">-110895000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">-77874000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">1836000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">8365000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">7641000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">-27000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">-135000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">-68000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">-46796000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">-102665000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">-70301000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">-13911000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">-427000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000133"
      unitRef="U_iso4217USD">14303000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">-32885000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">-102238000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">-84604000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="C_0001501989_20200101_20201231"
      decimals="2"
      id="F_000137"
      unitRef="U_iso4217USD_xbrlishares">-0.71</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="C_0001501989_20190101_20191231"
      decimals="2"
      id="F_000138"
      unitRef="U_iso4217USD_xbrlishares">-2.26</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
      contextRef="C_0001501989_20180101_20181231"
      decimals="2"
      id="F_000139"
      unitRef="U_iso4217USD_xbrlishares">-2.03</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001501989_20200101_20201231"
      decimals="0"
      id="F_000140"
      unitRef="U_xbrlishares">46145563</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001501989_20190101_20191231"
      decimals="0"
      id="F_000141"
      unitRef="U_xbrlishares">45335927</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001501989_20180101_20181231"
      decimals="0"
      id="F_000142"
      unitRef="U_xbrlishares">41664382</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">-104000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000144"
      unitRef="U_iso4217USD">139000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">11000</us-gaap:TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">-32989000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">-102088000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">-84603000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesIssued
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231"
      decimals="INF"
      id="F_000150"
      unitRef="U_xbrlishares">38478560</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231"
      decimals="-3"
      id="F_000151"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">289454000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">-94000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">-219465000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_20171231"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">69896000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231"
      decimals="-3"
      id="F_000156"
      unitRef="U_iso4217USD">-10912000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_20171231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">-10912000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000159"
      unitRef="U_xbrlishares">5867347</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">134596000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000161"
      unitRef="U_iso4217USD">134596000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000162"
      unitRef="U_xbrlishares">673382</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">4156000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">4156000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231"
      decimals="INF"
      id="F_000165"
      unitRef="U_xbrlishares">63920</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">872000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">872000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">16878000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">16878000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20180101_20181231"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231"
      decimals="-3"
      id="F_000172"
      unitRef="U_iso4217USD">-84604000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">-84604000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="INF"
      id="F_000174"
      unitRef="U_xbrlishares">45083209</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">445956000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="-3"
      id="F_000177"
      unitRef="U_iso4217USD">-93000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000178"
      unitRef="U_iso4217USD">-314981000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000179"
      unitRef="U_iso4217USD">130883000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20181231"
      decimals="-3"
      id="F_000180"
      unitRef="U_iso4217USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_srtCumulativeEffectPeriodOfAdoptionAxis_srtCumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231"
      decimals="-3"
      id="F_000181"
      unitRef="U_iso4217USD">-11000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000183"
      unitRef="U_xbrlishares">146930</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000184"
      unitRef="U_iso4217USD">633000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000185"
      unitRef="U_iso4217USD">633000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000186"
      unitRef="U_xbrlishares">142949</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000187"
      unitRef="U_iso4217USD">994000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000188"
      unitRef="U_iso4217USD">994000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231"
      decimals="INF"
      id="F_000189"
      unitRef="U_xbrlishares">150000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000190"
      unitRef="U_iso4217USD">1602000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000191"
      unitRef="U_iso4217USD">1602000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231"
      decimals="-3"
      id="F_000192"
      unitRef="U_iso4217USD">19100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000193"
      unitRef="U_iso4217USD">19100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20190101_20191231"
      decimals="-3"
      id="F_000194"
      unitRef="U_iso4217USD">139000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000195"
      unitRef="U_iso4217USD">139000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231"
      decimals="-3"
      id="F_000196"
      unitRef="U_iso4217USD">-102238000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000197"
      unitRef="U_iso4217USD">-102238000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000198"
      unitRef="U_xbrlishares">45523088</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000199"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000200"
      unitRef="U_iso4217USD">468285000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20191231"
      decimals="-3"
      id="F_000201"
      unitRef="U_iso4217USD">57000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000202"
      unitRef="U_iso4217USD">-417230000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000203"
      unitRef="U_iso4217USD">51113000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000204"
      unitRef="U_xbrlishares">1064830</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000205"
      unitRef="U_iso4217USD">4876000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000206"
      unitRef="U_iso4217USD">4876000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000207"
      unitRef="U_xbrlishares">128684</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000208"
      unitRef="U_iso4217USD">729000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000209"
      unitRef="U_iso4217USD">729000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231"
      decimals="INF"
      id="F_000210"
      unitRef="U_xbrlishares">1535217</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000211"
      unitRef="U_iso4217USD">11288000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000212"
      unitRef="U_iso4217USD">11288000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231"
      decimals="-3"
      id="F_000213"
      unitRef="U_iso4217USD">14786000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000214"
      unitRef="U_iso4217USD">14786000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20200101_20201231"
      decimals="-3"
      id="F_000215"
      unitRef="U_iso4217USD">-104000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000216"
      unitRef="U_iso4217USD">-104000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231"
      decimals="-3"
      id="F_000217"
      unitRef="U_iso4217USD">-32885000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000218"
      unitRef="U_iso4217USD">-32885000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000219"
      unitRef="U_xbrlishares">48251819</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000220"
      unitRef="U_iso4217USD">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000221"
      unitRef="U_iso4217USD">499964000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20201231"
      decimals="-3"
      id="F_000222"
      unitRef="U_iso4217USD">-47000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000223"
      unitRef="U_iso4217USD">-450115000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">49803000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">-32885000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">-102238000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">-84604000</us-gaap:ProfitLoss>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">146000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">146000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">146000</us-gaap:AmortizationOfIntangibleAssets>
    <ctmx:DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">2427000</ctmx:DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets>
    <ctmx:DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">2459000</ctmx:DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets>
    <ctmx:DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">1738000</ctmx:DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">236000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">2228000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000236"
      unitRef="U_iso4217USD">1701000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000237"
      unitRef="U_iso4217USD">14786000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000238"
      unitRef="U_iso4217USD">19100000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000239"
      unitRef="U_iso4217USD">16878000</us-gaap:ShareBasedCompensation>
    <ctmx:NoncashLeaseExpense
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000240"
      unitRef="U_iso4217USD">2887000</ctmx:NoncashLeaseExpense>
    <ctmx:NoncashLeaseExpense
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000241"
      unitRef="U_iso4217USD">2672000</ctmx:NoncashLeaseExpense>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000242"
      unitRef="U_iso4217USD">1602000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000243"
      unitRef="U_iso4217USD">785000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000244"
      unitRef="U_iso4217USD">-84000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000245"
      unitRef="U_iso4217USD">-10042000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">-81000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">-2074000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">4899000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">157000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">640000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">20000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">-857000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000253"
      unitRef="U_iso4217USD">-374000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000254"
      unitRef="U_iso4217USD">261000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <ctmx:IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000255"
      unitRef="U_iso4217USD">-11039000</ctmx:IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent>
    <ctmx:IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000256"
      unitRef="U_iso4217USD">-15396000</ctmx:IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent>
    <ctmx:IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000257"
      unitRef="U_iso4217USD">24833000</ctmx:IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000258"
      unitRef="U_iso4217USD">30891000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000259"
      unitRef="U_iso4217USD">-47741000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000260"
      unitRef="U_iso4217USD">-38195000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000261"
      unitRef="U_iso4217USD">5259000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000262"
      unitRef="U_iso4217USD">-140480000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000263"
      unitRef="U_iso4217USD">-75521000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">2309000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000265"
      unitRef="U_iso4217USD">3497000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000266"
      unitRef="U_iso4217USD">3788000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000267"
      unitRef="U_iso4217USD">199108000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000268"
      unitRef="U_iso4217USD">174992000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000269"
      unitRef="U_iso4217USD">204601000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000270"
      unitRef="U_iso4217USD">182699000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000271"
      unitRef="U_iso4217USD">258190000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000272"
      unitRef="U_iso4217USD">214315000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000273"
      unitRef="U_iso4217USD">-18718000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000274"
      unitRef="U_iso4217USD">79701000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000275"
      unitRef="U_iso4217USD">5926000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000276"
      unitRef="U_iso4217USD">11288000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000277"
      unitRef="U_iso4217USD">134596000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000278"
      unitRef="U_iso4217USD">5605000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000279"
      unitRef="U_iso4217USD">1627000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000280"
      unitRef="U_iso4217USD">5028000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000281"
      unitRef="U_iso4217USD">16893000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000282"
      unitRef="U_iso4217USD">1627000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000283"
      unitRef="U_iso4217USD">139624000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000284"
      unitRef="U_iso4217USD">3434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000285"
      unitRef="U_iso4217USD">-59152000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000286"
      unitRef="U_iso4217USD">70029000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000287"
      unitRef="U_iso4217USD">189342000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000288"
      unitRef="U_iso4217USD">248494000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001501989_20171231"
      decimals="-3"
      id="F_000289"
      unitRef="U_iso4217USD">178465000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000290"
      unitRef="U_iso4217USD">192776000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000291"
      unitRef="U_iso4217USD">189342000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000292"
      unitRef="U_iso4217USD">248494000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000293"
      unitRef="U_iso4217USD">13061000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000294"
      unitRef="U_iso4217USD">122000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000295"
      unitRef="U_iso4217USD">428000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000296"
      unitRef="U_iso4217USD">1027000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000297"
      unitRef="U_iso4217USD">28054000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations contextRef="C_0001501989_20200101_20201231" id="F_000299">
&lt;p id="N1_DESCRIPTION__BUSINESS" style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1. Description of the Business&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;CytomX Therapeutics, Inc. (the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Company&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are advancing potential first-in-class antibody-based therapeutics created using our Probody&#xae; technology platform that could meaningfully improve patient outcomes in a disease where significant unmet need remains. Our proprietary and unique Probody technology platform is designed to enable &#x201c;conditional activation&#x201d; of antibody-based drugs within the tumor while minimizing drug activity in healthy tissues and circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.&#160;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000300">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2. Basis of Presentation and Summary of Significant Accounting Policies&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;U.S. GAAP&#x201d;). &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products, and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all the Company&#x2019;s cash is held by one financial institution. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents and short-term investments in highly rated money market funds and its short-term investments in U.S. Government Bonds.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customers and collaboration partners who represent 10% or more of the Company&#x2019;s total revenue during each period presented or accounts receivable balance at each respective balance sheet date are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts Receivable, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&#160;Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AbbVie Ireland Unlimited Company&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,192&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,878&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas Pharma Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bristol-Myers Squibb Company&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,740&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,780&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue from customers who represent 10% or more&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; of the Company's total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,753&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,777&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s customers are located in the United States of America, Ireland and Japan.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management has determined that it has one business activity and operates as one operating segment as it only reports financial information on an aggregate basis to its chief executive officer and chief financial officer, who are the Company&#x2019;s chief operating decision makers. All long-lived assets are maintained in the United States of America.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash represents a standby letter of credit issued pursuant to an office lease entered in December 2015. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the amounts shown in the statement of cash flows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;191,859&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;188,425&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;192,776&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189,342&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Short-term Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All investments have been classified as available-for-sale (&#x201c;AFS&#x201d;) and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Generally, those investments with contractual maturities less than 12 months are considered short-term investments. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses impairment of its AFS debt securities investments at each reporting period.&#160;&#160;Unrealized gains resulting from the excess of the fair value over the amortized cost basis of an investment are reported as a component of accumulated other comprehensive income (loss), net of tax.&#160;&#160;Unrealized losses or impairments resulting from the fair value of the AFS debt security being below the amortized cost basis are evaluated, using the discounted cash flow model, for identification of credit losses and non-credit related losses.&#160;&#160;Any credit losses are charged to earnings against the allowance for credit losses of the security, limited to the difference between the fair value and the amortized cost basis of the security.&#160;&#160;Any difference between the fair value of the security and the amortized cost basis, less the allowance for credit losses, are reported in other comprehensive income (loss).&#160;&#160;Expected cash inflows due to improvements in credit are recognized through a reversal of the allowance for credit losses subject to the total allowance previously recognized.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the event of impairment of any security, if management (i) has the intent to sell such security or (ii) will more-likely-than-not be required to sell such security before recovery of its amortized cost basis, such AFS debt security&#x2019;s amortized cost basis will be written down to its fair value through earnings along with any existing allowance for credit losses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment, net&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost net of accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the respective assets. The useful lives of property and equipment are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of remaining lease term or estimated life of the assets&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maintenance and repairs that do not extend the life or improve the asset are expensed when incurred.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Goodwill and Intangible Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill represents the excess of the purchase price paid over the fair value of tangible and identifiable intangible assets acquired in business combinations. Goodwill and other intangible assets with indefinite lives are not amortized, but are assigned to reporting units and tested for impairment annually, or whenever there is an impairment indicator. Intangible assets are comprised of in-process research and development. The Company assesses impairment indicators annually as of December 31 or more frequently, if a change in circumstances or the occurrence of events suggests the remaining value may not be recoverable. Intangible assets that are not deemed to have an indefinite life are amortized over their estimated useful lives. There was no impairment of goodwill or intangible assets identified during the years ended December 31, 2020, 2019 and 2018.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable and prior to any goodwill impairment test. An impairment loss is recognized when the total of estimated undiscounted future cash flows expected to result from the use of the asset (or asset group) and its eventual disposition is less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. There was no impairment of long-lived assets during the years ended December 31, 2020, 2019 and 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 1, 2018, the Company adopted Accounting Standards Update No. 2014-09, &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;, which supersedes the revenue recognition requirements in Accounting Standards Codification (ASC) Topic 605, &lt;span style="font-style:italic;"&gt;Revenue Recognition (ASC 605)&lt;/span&gt;, using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2018. The impact of the adoption of ASC 606 was an increase in the balance of deferred revenue and an increase in the accumulated deficit balance of $10.9 million on January 1, 2018 in the Company&#x2019;s Balance Sheet.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s revenues are primarily derived through its license, research, development and commercialization agreements. The terms of these types of agreements may include (i) licenses for the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s technology or programs, (ii) research and development services, and (iii) services or obligations in connection with participation in research or steering committees. Payments to the Company under these arrangements typically include one or more of the following: nonrefundable upfront and license fees, research funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses whether the promises in its arrangements with customers are considered as distinct performance obligations that should be accounted for separately. Judgment is required to determine whether the license to the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s intellectual property is distinct from the research and development services or participation on steering committees.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s collaboration and license agreements may include contingent payments related to specified research, development and regulatory milestones. Such milestone payments are typically payable under the collaborations when the collaboration partner claims or selects a target, or initiates or advances a covered product candidate in preclinical or clinical development, upon submission for marketing approval of a covered product with regulatory authorities; or upon receipt of actual marketing approvals of a covered product or for additional indications. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.&#160;&#160;At each reporting date, the Company re-evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price by using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price in such period of determination.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s collaboration and license agreements may also include contingent payments related to sales-based milestones. Sales-based milestones are typically payable when annual sales of a covered product reach specified levels. Sales-based milestones are recognized at the later of when the associated performance obligation has been satisfied or when the sales occur. Unlike other contingency payments, such as regulatory milestones, sales-based milestones are not included in the transaction price based on estimates at the inception of the contract, but rather, are included when the sales or usage occur.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price in each arrangement is allocated to the identified performance obligations based on the relative standalone selling price (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;SSP&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) of each distinct performance obligation, which requires judgment. In instances where SSP is not directly observable, such as when a license or service is not sold separately, SSP is determined using information that may include market conditions and other observable inputs. Due to the early stage of the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s licensed technology, the license of such technology is typically combined with research and development services and steering committee participation as one performance obligation.&#160;&#160;In the event that the Company receives non-cash consideration such as consideration in the form of a research license and research support services from the counterparty, the transaction price of a non-monetary exchange that has commercial substance is estimated based on the fair value of the non-cash consideration received, which may be determined through a valuation analysis.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In certain cases, the Company&#x2019;s performance creates an asset that does not have an alternative use to the customer and the Company has an enforceable right to payment at all times for performance completed to date.&#160;&#160;In these cases, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AbbVie Ireland Unlimited Company (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;AbbVie&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;), one of the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s collaboration partners, entered into a license agreement with Seattle Genetics, Inc. (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;SGEN&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) to license certain intellectual property rights. As part of the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s collaboration agreement with AbbVie, the Company is required to pay SGEN sublicense fees for certain milestone achievements and annual maintenance fee. These sublicense fees are treated as reductions to the transaction price and combined with the performance obligation to which they relate.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss represents all changes in stockholders&#x2019; equity except those resulting from distributions to stockholders. The Company&#x2019;s non-credit related unrealized gains and losses on short-term investments and impact of adoption of new accounting pronouncements during the period represent the components of other comprehensive income (loss) that is excluded from the reported net loss.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contract Balances &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company satisfies its performance obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s right to consideration is unconditional.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures its stock-based awards made to employees based on the fair values of the awards as of the grant date using the Black-Scholes option-pricing model. Stock-based compensation expense is recognized over the requisite service period using the ratable method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest.&#160;&#160;Forfeitures are recognized as they occur.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 2019, the Company adopted ASU No. 2018-07, &lt;span style="font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.&lt;/span&gt; Under this new standard, stock options granted to non-employees as consideration for&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;services received are measured on the date of grant using the Black-Scholes option-pricing model.&#160;&#160;The&lt;span style="letter-spacing:0.4pt;"&gt; related &lt;/span&gt;grant date fair values of stock options are expensed on a straight-line basis over the period, generally the vesting period, during which&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;the non-employee is required to provide service in exchange for the award.&#160;&#160;&lt;span style="font-style:italic;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the adoption of ASU 2018-07, such stock-based compensation expense was measured on the date of performance at the fair value of the consideration received or the fair value&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;of the equity instruments issued, using the Black-Scholes option-pricing model, whichever can be more&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;reliably measured. Stock-based compensation expense for options granted to non-employees was periodically remeasured as the underlying options&lt;span style="letter-spacing:0.1pt;"&gt; &lt;/span&gt;vest.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using an asset and liability approach. Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company records a valuation allowance to reduce its deferred tax assets to reflect the net amount that it believes as more likely than not to be realized. Realization of the deferred tax assets is dependent on the generation of future taxable income, the amount and timing of which are uncertain. The valuation allowance requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Based upon the weight of available evidence at December 31, 2020, the Company continues to maintain a full valuation allowance against all of its deferred tax assets after management considered all available evidence, both positive and negative, including but not limited to its historical operating results, income or loss in recent periods, cumulative income in recent years, forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the tax effects of an uncertain tax position only if it is more likely than not that it will be sustained based solely on its technical merits as of the reporting date and only in an amount more likely than not that it will be sustained upon review by the tax authorities. The Company evaluates uncertain tax positions on a quarterly basis and adjust the liability for changes in facts and circumstances, such as new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, significant amendment to an existing tax law, or resolution of an examination. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the income tax provision in the period in which such determination is made. The resolution of its uncertain income tax positions is dependent on uncontrollable factors such as law changes, new case law, and the willingness of the income tax authorities to settle, including the timing thereof and other factors. Although the Company does not anticipate significant changes to its uncertain income tax positions in the next twelve months, items outside of its control could cause its uncertain income tax positions to change in the future, which would be recorded in its statements of operations. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company &lt;span style="color:#000000;"&gt;records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced, and includes these costs in accrued liabilities in the balance sheets and within research and development expense in the statements of operations. These costs are a significant component of the Company&#x2019;s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status and timing of actual services performed may vary from the Company&#x2019;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the Company&#x2019;s results of operations.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. All costs associated with research and development are expensed as incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2019, the Company acquired certain technology know-how that is complementary to the Company&#x2019;s proprietary Probody technology from a third party for $5.0 million.&#160;&#160;The Company plans to use this technology in certain of the Company&#x2019;s discovery stage projects, and has concluded that the technology acquired does not have an alternative future use.&#160;&#160;Accordingly, the $5.0 million has been recorded as research and development expense for 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted the Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;span style="font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt; on January 1, 2019, using the modified retrospective approach.  As a result of the adoption of ASC 842, the Company recorded a right-of-use asset of $28.0 million and a lease liability $30.1 million on January 1, 2019.&#160;&#160;There was no impact on the Company&#x2019;s accumulated deficit as of the adoption date.&#160;&#160;The Company determines if an arrangement is or contains a lease at inception.&#160;&#160;Operating leases are recorded as operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the Company&#x2019;s balance sheet.&#160;&#160;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term.&#160;&#160;The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments.&#160;&#160;The operating lease ROU assets also include any lease prepayments made and reduced by lease incentives. The Company&#x2019;s lease terms may include options to extend the lease when it is reasonably certain that such option will be exercised. Lease expenses are recognized on a straight-line basis over the lease term.&#160;&#160;The Company elected the short-term lease recognition exemption&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;.&lt;/span&gt; The Company&#x2019;s operating lease arrangement includes lease and non-lease components which are generally accounted for separately.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000316">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;U.S. GAAP&#x201d;). &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001501989_20200101_20201231" id="F_000317">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="C_0001501989_20200101_20201231" id="F_000318">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products, and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all the Company&#x2019;s cash is held by one financial institution. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents and short-term investments in highly rated money market funds and its short-term investments in U.S. Government Bonds.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customers and collaboration partners who represent 10% or more of the Company&#x2019;s total revenue during each period presented or accounts receivable balance at each respective balance sheet date are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts Receivable, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&#160;Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AbbVie Ireland Unlimited Company&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,192&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,878&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas Pharma Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bristol-Myers Squibb Company&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,740&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,780&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue from customers who represent 10% or more&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; of the Company's total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,753&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,777&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s customers are located in the United States of America, Ireland and Japan.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000334">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customers and collaboration partners who represent 10% or more of the Company&#x2019;s total revenue during each period presented or accounts receivable balance at each respective balance sheet date are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts Receivable, net&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year&#160;Ended December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AbbVie Ireland Unlimited Company&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,192&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,878&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas Pharma Inc.&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bristol-Myers Squibb Company&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,740&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,780&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue from customers who represent 10% or more&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; of the Company's total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,753&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,618&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51,777&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;798&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231"
      decimals="-3"
      id="F_000354"
      unitRef="U_iso4217USD">38192000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20190101_20191231"
      decimals="-3"
      id="F_000358"
      unitRef="U_iso4217USD">5878000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20180101_20181231"
      decimals="-3"
      id="F_000361"
      unitRef="U_iso4217USD">18997000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231"
      decimals="-3"
      id="F_000355"
      unitRef="U_iso4217USD">13931000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20201231"
      decimals="-3"
      id="F_000364"
      unitRef="U_iso4217USD">798000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231"
      decimals="-3"
      id="F_000356"
      unitRef="U_iso4217USD">39630000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20190101_20191231"
      decimals="-3"
      id="F_000359"
      unitRef="U_iso4217USD">47740000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20180101_20181231"
      decimals="-3"
      id="F_000362"
      unitRef="U_iso4217USD">32780000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtMajorCustomersAxis_ctmxMajorCustomerMember_20191231"
      decimals="-3"
      id="F_000366"
      unitRef="U_iso4217USD">13000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231"
      decimals="-3"
      id="F_000357"
      unitRef="U_iso4217USD">91753000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20190101_20191231"
      decimals="-3"
      id="F_000360"
      unitRef="U_iso4217USD">53618000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20180101_20181231"
      decimals="-3"
      id="F_000363"
      unitRef="U_iso4217USD">51777000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20201231"
      decimals="-3"
      id="F_000365"
      unitRef="U_iso4217USD">798000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20191231"
      decimals="-3"
      id="F_000367"
      unitRef="U_iso4217USD">13000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000319">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management has determined that it has one business activity and operates as one operating segment as it only reports financial information on an aggregate basis to its chief executive officer and chief financial officer, who are the Company&#x2019;s chief operating decision makers. All long-lived assets are maintained in the United States of America.&lt;/p&gt;
</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <ctmx:NumberOfBusinessActivities
      contextRef="C_0001501989_20200101_20201231"
      decimals="INF"
      id="F_000368"
      unitRef="U_ctmxActivity">1</ctmx:NumberOfBusinessActivities>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001501989_20200101_20201231"
      decimals="INF"
      id="F_000369"
      unitRef="U_ctmxSegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000320">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="C_0001501989_20200101_20201231" id="F_000321">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Restricted Cash&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash represents a standby letter of credit issued pursuant to an office lease entered in December 2015. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the amounts shown in the statement of cash flows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;191,859&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;188,425&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;192,776&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189,342&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <ctmx:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000335">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the amounts shown in the statement of cash flows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;191,859&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;188,425&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;192,776&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;189,342&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ctmx:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000370"
      unitRef="U_iso4217USD">191859000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000371"
      unitRef="U_iso4217USD">188425000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000372"
      unitRef="U_iso4217USD">917000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000373"
      unitRef="U_iso4217USD">917000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000374"
      unitRef="U_iso4217USD">192776000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000375"
      unitRef="U_iso4217USD">189342000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:MarketableSecuritiesPolicy contextRef="C_0001501989_20200101_20201231" id="F_000322">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Short-term Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All investments have been classified as available-for-sale (&#x201c;AFS&#x201d;) and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Generally, those investments with contractual maturities less than 12 months are considered short-term investments. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses impairment of its AFS debt securities investments at each reporting period.&#160;&#160;Unrealized gains resulting from the excess of the fair value over the amortized cost basis of an investment are reported as a component of accumulated other comprehensive income (loss), net of tax.&#160;&#160;Unrealized losses or impairments resulting from the fair value of the AFS debt security being below the amortized cost basis are evaluated, using the discounted cash flow model, for identification of credit losses and non-credit related losses.&#160;&#160;Any credit losses are charged to earnings against the allowance for credit losses of the security, limited to the difference between the fair value and the amortized cost basis of the security.&#160;&#160;Any difference between the fair value of the security and the amortized cost basis, less the allowance for credit losses, are reported in other comprehensive income (loss).&#160;&#160;Expected cash inflows due to improvements in credit are recognized through a reversal of the allowance for credit losses subject to the total allowance previously recognized.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the event of impairment of any security, if management (i) has the intent to sell such security or (ii) will more-likely-than-not be required to sell such security before recovery of its amortized cost basis, such AFS debt security&#x2019;s amortized cost basis will be written down to its fair value through earnings along with any existing allowance for credit losses.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000323">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment, net&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are recorded at cost net of accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the respective assets. The useful lives of property and equipment are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of remaining lease term or estimated life of the assets&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maintenance and repairs that do not extend the life or improve the asset are expensed when incurred.&lt;/p&gt;
</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <ctmx:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000336">The useful lives of property and equipment are as follows:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3 years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shorter of remaining lease term or estimated life of the assets&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ctmx:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231"
      id="F_000376">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_ctmxComputerEquipmentAndSoftwareMember_20200101_20201231"
      id="F_000377">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20200101_20201231"
      id="F_000378">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20200101_20201231"
      id="F_000379">Shorter of remaining lease term or estimated life of the assets</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000324">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Goodwill and Intangible Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill represents the excess of the purchase price paid over the fair value of tangible and identifiable intangible assets acquired in business combinations. Goodwill and other intangible assets with indefinite lives are not amortized, but are assigned to reporting units and tested for impairment annually, or whenever there is an impairment indicator. Intangible assets are comprised of in-process research and development. The Company assesses impairment indicators annually as of December 31 or more frequently, if a change in circumstances or the occurrence of events suggests the remaining value may not be recoverable. Intangible assets that are not deemed to have an indefinite life are amortized over their estimated useful lives. There was no impairment of goodwill or intangible assets identified during the years ended December 31, 2020, 2019 and 2018.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_0001501989_20200101_20201231"
      decimals="INF"
      id="F_000380"
      unitRef="U_iso4217USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_0001501989_20190101_20191231"
      decimals="INF"
      id="F_000381"
      unitRef="U_iso4217USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_0001501989_20180101_20181231"
      decimals="INF"
      id="F_000382"
      unitRef="U_iso4217USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_0001501989_20200101_20201231"
      decimals="INF"
      id="F_000383"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_0001501989_20190101_20191231"
      decimals="INF"
      id="F_000384"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_0001501989_20180101_20181231"
      decimals="INF"
      id="F_000385"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000325">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable and prior to any goodwill impairment test. An impairment loss is recognized when the total of estimated undiscounted future cash flows expected to result from the use of the asset (or asset group) and its eventual disposition is less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. There was no impairment of long-lived assets during the years ended December 31, 2020, 2019 and 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0001501989_20200101_20201231"
      decimals="INF"
      id="F_000386"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0001501989_20190101_20191231"
      decimals="INF"
      id="F_000387"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_0001501989_20180101_20181231"
      decimals="INF"
      id="F_000388"
      unitRef="U_iso4217USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000326">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 1, 2018, the Company adopted Accounting Standards Update No. 2014-09, &lt;span style="font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606)&lt;/span&gt;, which supersedes the revenue recognition requirements in Accounting Standards Codification (ASC) Topic 605, &lt;span style="font-style:italic;"&gt;Revenue Recognition (ASC 605)&lt;/span&gt;, using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2018. The impact of the adoption of ASC 606 was an increase in the balance of deferred revenue and an increase in the accumulated deficit balance of $10.9 million on January 1, 2018 in the Company&#x2019;s Balance Sheet.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s revenues are primarily derived through its license, research, development and commercialization agreements. The terms of these types of agreements may include (i) licenses for the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s technology or programs, (ii) research and development services, and (iii) services or obligations in connection with participation in research or steering committees. Payments to the Company under these arrangements typically include one or more of the following: nonrefundable upfront and license fees, research funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company assesses whether the promises in its arrangements with customers are considered as distinct performance obligations that should be accounted for separately. Judgment is required to determine whether the license to the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s intellectual property is distinct from the research and development services or participation on steering committees.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s collaboration and license agreements may include contingent payments related to specified research, development and regulatory milestones. Such milestone payments are typically payable under the collaborations when the collaboration partner claims or selects a target, or initiates or advances a covered product candidate in preclinical or clinical development, upon submission for marketing approval of a covered product with regulatory authorities; or upon receipt of actual marketing approvals of a covered product or for additional indications. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.&#160;&#160;At each reporting date, the Company re-evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price by using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price in such period of determination.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s collaboration and license agreements may also include contingent payments related to sales-based milestones. Sales-based milestones are typically payable when annual sales of a covered product reach specified levels. Sales-based milestones are recognized at the later of when the associated performance obligation has been satisfied or when the sales occur. Unlike other contingency payments, such as regulatory milestones, sales-based milestones are not included in the transaction price based on estimates at the inception of the contract, but rather, are included when the sales or usage occur.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The transaction price in each arrangement is allocated to the identified performance obligations based on the relative standalone selling price (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;SSP&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) of each distinct performance obligation, which requires judgment. In instances where SSP is not directly observable, such as when a license or service is not sold separately, SSP is determined using information that may include market conditions and other observable inputs. Due to the early stage of the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s licensed technology, the license of such technology is typically combined with research and development services and steering committee participation as one performance obligation.&#160;&#160;In the event that the Company receives non-cash consideration such as consideration in the form of a research license and research support services from the counterparty, the transaction price of a non-monetary exchange that has commercial substance is estimated based on the fair value of the non-cash consideration received, which may be determined through a valuation analysis.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In certain cases, the Company&#x2019;s performance creates an asset that does not have an alternative use to the customer and the Company has an enforceable right to payment at all times for performance completed to date.&#160;&#160;In these cases, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AbbVie Ireland Unlimited Company (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;AbbVie&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;), one of the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s collaboration partners, entered into a license agreement with Seattle Genetics, Inc. (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;SGEN&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) to license certain intellectual property rights. As part of the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s collaboration agreement with AbbVie, the Company is required to pay SGEN sublicense fees for certain milestone achievements and annual maintenance fee. These sublicense fees are treated as reductions to the transaction price and combined with the performance obligation to which they relate.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapInitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaapDifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_20180101"
      decimals="-5"
      id="F_000389"
      unitRef="U_iso4217USD">-10900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000327">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss represents all changes in stockholders&#x2019; equity except those resulting from distributions to stockholders. The Company&#x2019;s non-credit related unrealized gains and losses on short-term investments and impact of adoption of new accounting pronouncements during the period represent the components of other comprehensive income (loss) that is excluded from the reported net loss.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000328">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contract Balances &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company satisfies its performance obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s right to consideration is unconditional.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001501989_20200101_20201231" id="F_000329">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures its stock-based awards made to employees based on the fair values of the awards as of the grant date using the Black-Scholes option-pricing model. Stock-based compensation expense is recognized over the requisite service period using the ratable method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest.&#160;&#160;Forfeitures are recognized as they occur.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On January 2019, the Company adopted ASU No. 2018-07, &lt;span style="font-style:italic;"&gt;Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.&lt;/span&gt; Under this new standard, stock options granted to non-employees as consideration for&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;services received are measured on the date of grant using the Black-Scholes option-pricing model.&#160;&#160;The&lt;span style="letter-spacing:0.4pt;"&gt; related &lt;/span&gt;grant date fair values of stock options are expensed on a straight-line basis over the period, generally the vesting period, during which&lt;span style="letter-spacing:0.3pt;"&gt; &lt;/span&gt;the non-employee is required to provide service in exchange for the award.&#160;&#160;&lt;span style="font-style:italic;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the adoption of ASU 2018-07, such stock-based compensation expense was measured on the date of performance at the fair value of the consideration received or the fair value&lt;span style="letter-spacing:0.4pt;"&gt; &lt;/span&gt;of the equity instruments issued, using the Black-Scholes option-pricing model, whichever can be more&lt;span style="letter-spacing:0.45pt;"&gt; &lt;/span&gt;reliably measured. Stock-based compensation expense for options granted to non-employees was periodically remeasured as the underlying options&lt;span style="letter-spacing:0.1pt;"&gt; &lt;/span&gt;vest.&lt;/p&gt;
</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000330">
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes using an asset and liability approach. Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company records a valuation allowance to reduce its deferred tax assets to reflect the net amount that it believes as more likely than not to be realized. Realization of the deferred tax assets is dependent on the generation of future taxable income, the amount and timing of which are uncertain. The valuation allowance requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Based upon the weight of available evidence at December 31, 2020, the Company continues to maintain a full valuation allowance against all of its deferred tax assets after management considered all available evidence, both positive and negative, including but not limited to its historical operating results, income or loss in recent periods, cumulative income in recent years, forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes the tax effects of an uncertain tax position only if it is more likely than not that it will be sustained based solely on its technical merits as of the reporting date and only in an amount more likely than not that it will be sustained upon review by the tax authorities. The Company evaluates uncertain tax positions on a quarterly basis and adjust the liability for changes in facts and circumstances, such as new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, significant amendment to an existing tax law, or resolution of an examination. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the income tax provision in the period in which such determination is made. The resolution of its uncertain income tax positions is dependent on uncontrollable factors such as law changes, new case law, and the willingness of the income tax authorities to settle, including the timing thereof and other factors. Although the Company does not anticipate significant changes to its uncertain income tax positions in the next twelve months, items outside of its control could cause its uncertain income tax positions to change in the future, which would be recorded in its statements of operations. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense. &lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001501989_20200101_20201231" id="F_000331">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company &lt;span style="color:#000000;"&gt;records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced, and includes these costs in accrued liabilities in the balance sheets and within research and development expense in the statements of operations. These costs are a significant component of the Company&#x2019;s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status and timing of actual services performed may vary from the Company&#x2019;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#x2019;s accruals could materially affect the Company&#x2019;s results of operations.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. All costs associated with research and development are expensed as incurred.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2019, the Company acquired certain technology know-how that is complementary to the Company&#x2019;s proprietary Probody technology from a third party for $5.0 million.&#160;&#160;The Company plans to use this technology in certain of the Company&#x2019;s discovery stage projects, and has concluded that the technology acquired does not have an alternative future use.&#160;&#160;Accordingly, the $5.0 million has been recorded as research and development expense for 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_ctmxProbodyTechnologyMember_20190101_20190131"
      decimals="-5"
      id="F_000390"
      unitRef="U_iso4217USD">5000000.0</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_ctmxProbodyTechnologyMember_20190101_20191231"
      decimals="-5"
      id="F_000391"
      unitRef="U_iso4217USD">5000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000332">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Leases&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company adopted the Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;span style="font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt; on January 1, 2019, using the modified retrospective approach.  As a result of the adoption of ASC 842, the Company recorded a right-of-use asset of $28.0 million and a lease liability $30.1 million on January 1, 2019.&#160;&#160;There was no impact on the Company&#x2019;s accumulated deficit as of the adoption date.&#160;&#160;The Company determines if an arrangement is or contains a lease at inception.&#160;&#160;Operating leases are recorded as operating lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the Company&#x2019;s balance sheet.&#160;&#160;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term.&#160;&#160;The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments.&#160;&#160;The operating lease ROU assets also include any lease prepayments made and reduced by lease incentives. The Company&#x2019;s lease terms may include options to extend the lease when it is reasonably certain that such option will be exercised. Lease expenses are recognized on a straight-line basis over the lease term.&#160;&#160;The Company elected the short-term lease recognition exemption&lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;.&lt;/span&gt; The Company&#x2019;s operating lease arrangement includes lease and non-lease components which are generally accounted for separately.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101"
      decimals="-5"
      id="F_000392"
      unitRef="U_iso4217USD">28000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201602Member_20190101"
      decimals="-5"
      id="F_000393"
      unitRef="U_iso4217USD">30100000</us-gaap:OperatingLeaseLiability>
    <ctmx:AdoptedAndRecentAccountingPronouncementsTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000301">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3. Adopted and Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#263238;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p id="S170363231" style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Financial Instruments - Credit Losses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. &lt;span style="color:#000000;"&gt;This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the previous other-than-temporary-impairment model. &lt;/span&gt;The Company adopted this standard on January 1, 2020 using a modified retrospective approach.&#160;&#160;There was no impact on the Company&#x2019;s accumulated deficit as of January 1, 2020 as there was no incremental impairment loss to be recognized upon the adoption of this ASU.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Simplification of the Test for Goodwill Impairment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &lt;span style="font-style:italic;"&gt;Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;. The new standard simplifies the measurement of goodwill by eliminating the Step 2 impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill with the carrying amount of that goodwill. The new guidance requires an entity to compare the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. The Company adopted this standard on January 1, 2020 and there was no material impact on its financial statement.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurement Disclosure Requirements Modification&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No. 2018-13, &lt;span style="font-style:italic;"&gt;Fair Value Measurement (Topic 820)&lt;/span&gt;. The amendments in this ASU modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. Various disclosure requirements have been removed, including the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels, the valuation processes for Level 3 fair value measurements held at the end of the reporting period. The ASU also modified various disclosure requirements and added some disclosure requirements for Level 3 fair value measurements. The amendments in this ASU were effective for the Company on January 1, 2020 and there was no material impact on its financial statements upon adoption of this ASU. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Internal Use Software Guidance for Cloud Computing Arrangement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No. 2018-15, &lt;span style="font-style:italic;"&gt;Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40)&lt;/span&gt;. The amendments in this ASU on the accounting for implementation, setup and other upfront costs (collectively &#x201c;implementation costs&#x201d;) apply to entities that are a customer in a hosting arrangement. The amendments under this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. Accordingly, the amendments in this ASU require an entity in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to expense. They also require an entity to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. The Company adopted this standard on January 1, 2020 and there was no material impact on its financial statement upon adoption of this ASU.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Collaborative Arrangements and Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the FASB issued&#160;ASU No. 2018-18, &lt;span style="font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the interaction between Topic 808 and Topic 606&lt;/span&gt;.&#160;&#160;The amendments in&#160;this ASU targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In addition, unit-of-account guidance in Topic 808 was aligned with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606.&#160;The ASU&#160;was effective for the Company on January 1, 2020, and there was no material impact on its financial statements upon adoption of this ASU.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Share-Based Payment to Customer&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In November 2019, the FASB issued ASU 2019-08,&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt; Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Codification Improvements &#x2013; Share-Based Consideration Payable to a Customer. &lt;/span&gt;&lt;span style="color:#000000;"&gt;The amendments in this ASU require that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in Topic 718. Under ASC 606, these awards are considered a reduction of the transaction price, unless the awards are payment for a distinct good or service received from the customer and should be recorded as a reduction of the transaction price.&#160;&#160;However, the ASU requires these awards to be measured on the basis of the grant-date fair value of the share-based payment award in accordance with Topic 718 and should be recognized at the later of when the award is promised and when the entity recognizes revenue for the transfer of the related goods or services in accordance with ASC 606.&#160;&#160;The ASU&#160;is effective for the Company on January 1, 2020, and there was no material impact on its financial statements upon adoption of this ASU.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;span style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;. The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles of ASC 740 in order to reduce cost and complexity of its application.&#160;&#160;The ASU removes the exception related to the incremental approach for intraperiod tax allocation as well as two exceptions related to accounting for outside basis differences of equity method investments and foreign subsidiaries.&#160;&#160;The ASU also amends the scope of ASC 740 related to a franchise tax (or similar tax) that is partially based on income; clarifies when a step-up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction; specifies that an entity is not required to allocate income tax expense to a legal entity that is both not subject to tax and disregarded by the taxing authority; and&#160;&#160;clarifies that all tax effects, both deferred and current, should be accounted for in the interim period that includes the enactment date.&#160;&#160;The ASU&#160;is effective for the Company on January 1, 2021, and interim periods within those fiscal years.&#160;&#160;The Company does not expect the adoption of this ASU will have a material impact on its financial statements.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;"&gt;&#160;&lt;/p&gt;</ctmx:AdoptedAndRecentAccountingPronouncementsTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000333">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#263238;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Adopted Accounting Pronouncements &lt;/p&gt;
&lt;p id="S170363231" style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Financial Instruments - Credit Losses&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;span style="font-style:italic;"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/span&gt;. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. &lt;span style="color:#000000;"&gt;This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the previous other-than-temporary-impairment model. &lt;/span&gt;The Company adopted this standard on January 1, 2020 using a modified retrospective approach.&#160;&#160;There was no impact on the Company&#x2019;s accumulated deficit as of January 1, 2020 as there was no incremental impairment loss to be recognized upon the adoption of this ASU.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Simplification of the Test for Goodwill Impairment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &lt;span style="font-style:italic;"&gt;Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;. The new standard simplifies the measurement of goodwill by eliminating the Step 2 impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill with the carrying amount of that goodwill. The new guidance requires an entity to compare the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. The Company adopted this standard on January 1, 2020 and there was no material impact on its financial statement.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurement Disclosure Requirements Modification&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No. 2018-13, &lt;span style="font-style:italic;"&gt;Fair Value Measurement (Topic 820)&lt;/span&gt;. The amendments in this ASU modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. Various disclosure requirements have been removed, including the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels, the valuation processes for Level 3 fair value measurements held at the end of the reporting period. The ASU also modified various disclosure requirements and added some disclosure requirements for Level 3 fair value measurements. The amendments in this ASU were effective for the Company on January 1, 2020 and there was no material impact on its financial statements upon adoption of this ASU. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Internal Use Software Guidance for Cloud Computing Arrangement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2018, the FASB issued ASU No. 2018-15, &lt;span style="font-style:italic;"&gt;Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40)&lt;/span&gt;. The amendments in this ASU on the accounting for implementation, setup and other upfront costs (collectively &#x201c;implementation costs&#x201d;) apply to entities that are a customer in a hosting arrangement. The amendments under this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. Accordingly, the amendments in this ASU require an entity in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to expense. They also require an entity to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. The Company adopted this standard on January 1, 2020 and there was no material impact on its financial statement upon adoption of this ASU.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Collaborative Arrangements and Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018, the FASB issued&#160;ASU No. 2018-18, &lt;span style="font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the interaction between Topic 808 and Topic 606&lt;/span&gt;.&#160;&#160;The amendments in&#160;this ASU targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In addition, unit-of-account guidance in Topic 808 was aligned with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606.&#160;The ASU&#160;was effective for the Company on January 1, 2020, and there was no material impact on its financial statements upon adoption of this ASU.&lt;/p&gt;
&lt;p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;Share-Based Payment to Customer&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="Background-color:#FFFFFF;"&gt;In November 2019, the FASB issued ASU 2019-08,&lt;/span&gt;&lt;span style="font-style:italic;Background-color:#FFFFFF;"&gt; Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Codification Improvements &#x2013; Share-Based Consideration Payable to a Customer. &lt;/span&gt;&lt;span style="color:#000000;"&gt;The amendments in this ASU require that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in Topic 718. Under ASC 606, these awards are considered a reduction of the transaction price, unless the awards are payment for a distinct good or service received from the customer and should be recorded as a reduction of the transaction price.&#160;&#160;However, the ASU requires these awards to be measured on the basis of the grant-date fair value of the share-based payment award in accordance with Topic 718 and should be recognized at the later of when the award is promised and when the entity recognizes revenue for the transfer of the related goods or services in accordance with ASC 606.&#160;&#160;The ASU&#160;is effective for the Company on January 1, 2020, and there was no material impact on its financial statements upon adoption of this ASU.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU 2019-12, &lt;span style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;. The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles of ASC 740 in order to reduce cost and complexity of its application.&#160;&#160;The ASU removes the exception related to the incremental approach for intraperiod tax allocation as well as two exceptions related to accounting for outside basis differences of equity method investments and foreign subsidiaries.&#160;&#160;The ASU also amends the scope of ASC 740 related to a franchise tax (or similar tax) that is partially based on income; clarifies when a step-up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction; specifies that an entity is not required to allocate income tax expense to a legal entity that is both not subject to tax and disregarded by the taxing authority; and&#160;&#160;clarifies that all tax effects, both deferred and current, should be accounted for in the interim period that includes the enactment date.&#160;&#160;The ASU&#160;is effective for the Company on January 1, 2021, and interim periods within those fiscal years.&#160;&#160;The Company does not expect the adoption of this ASU will have a material impact on its financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231"
      id="F_000394">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201704Member_20201231"
      id="F_000396">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231"
      id="F_000399">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201815Member_20201231"
      id="F_000402">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201818Member_20201231"
      id="F_000405">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201908Member_20201231"
      id="F_000408">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
      contextRef="C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201912Member_20201231"
      id="F_000411">2021-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
    <us-gaap:EarningsPerShareTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000302">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4. Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period.&#160;&#160;Diluted net loss per share is calculated using the weighted-average number of common shares outstanding, plus potential dilutive common stock during the period.&#160;&#160;Diluted net loss per share is the same as basic net loss per share since the effect of the potentially dilutive securities is anti-dilutive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following weighted-average outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented, because including them would have been anti-dilutive:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options and ESPP to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,388,691&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,687,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,478,755&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000337">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following weighted-average outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented, because including them would have been anti-dilutive:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.86%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.86%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options and ESPP to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,388,691&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,687,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,478,755&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20200101_20201231"
      decimals="0"
      id="F_000414"
      unitRef="U_xbrlishares">11388691</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20190101_20191231"
      decimals="0"
      id="F_000415"
      unitRef="U_xbrlishares">9687844</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20180101_20181231"
      decimals="0"
      id="F_000416"
      unitRef="U_xbrlishares">7478755</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000303">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5. Fair Value Measurements and Short-Term Investments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 820-10, Fair Value Measurements and Disclosures, the Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level I: Inputs which include quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level II: Inputs other than Level I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;Level III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including restricted cash, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. The Company&#x2019;s financial instruments consist of Level I assets which consist primarily of highly liquid money market funds, some of which are included in restricted cash and U.S. government bonds that are included in short-term investments. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables set forth the fair value of the Company&#x2019;s short-term investments subject to fair value measurements on a recurring basis and the level of inputs used in such measurements:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allowance for Credit Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level I&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;131,121&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;131,121&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash (money market funds)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level I&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level I&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;256,292&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;256,298&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allowance&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Credit&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level I&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;170,757&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;170,757&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash (money market funds)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level I&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level I&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,610&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,720&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;279,284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;279,394&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;No securities have contractual maturities of greater than twelve months.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000338">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following tables set forth the fair value of the Company&#x2019;s short-term investments subject to fair value measurements on a recurring basis and the level of inputs used in such measurements:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allowance for Credit Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level I&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;131,121&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;131,121&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash (money market funds)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level I&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level I&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124,254&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124,260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total Securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;256,292&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;256,298&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Hierarchy&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Allowance&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Credit&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Holding&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Losses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair&#160;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level I&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;170,757&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;170,757&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Restricted cash (money market funds)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level I&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;917&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. Government bonds&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level I&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,610&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;107,720&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total securities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;279,284&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;279,394&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000420"
      unitRef="U_iso4217USD">131121000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000421"
      unitRef="U_iso4217USD">131121000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_ctmxMoneyMarketFundsIncludedInRestrictedCashMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000422"
      unitRef="U_iso4217USD">917000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_ctmxMoneyMarketFundsIncludedInRestrictedCashMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000423"
      unitRef="U_iso4217USD">917000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000424"
      unitRef="U_iso4217USD">124254000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000425"
      unitRef="U_iso4217USD">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20201231"
      decimals="-3"
      id="F_000426"
      unitRef="U_iso4217USD">124260000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ctmx:CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000417"
      unitRef="U_iso4217USD">256292000</ctmx:CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis>
    <ctmx:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000418"
      unitRef="U_iso4217USD">6000</ctmx:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000419"
      unitRef="U_iso4217USD">256298000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231"
      decimals="-3"
      id="F_000430"
      unitRef="U_iso4217USD">170757000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231"
      decimals="-3"
      id="F_000431"
      unitRef="U_iso4217USD">170757000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_ctmxMoneyMarketFundsIncludedInRestrictedCashMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231"
      decimals="-3"
      id="F_000432"
      unitRef="U_iso4217USD">917000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_ctmxMoneyMarketFundsIncludedInRestrictedCashMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231"
      decimals="-3"
      id="F_000433"
      unitRef="U_iso4217USD">917000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231"
      decimals="-3"
      id="F_000434"
      unitRef="U_iso4217USD">107610000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231"
      decimals="-3"
      id="F_000435"
      unitRef="U_iso4217USD">110000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_0001501989_us-gaapFairValueByAssetClassAxis_us-gaapUSTreasuryAndGovernmentMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_20191231"
      decimals="-3"
      id="F_000436"
      unitRef="U_iso4217USD">107720000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ctmx:CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000427"
      unitRef="U_iso4217USD">279284000</ctmx:CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis>
    <ctmx:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000428"
      unitRef="U_iso4217USD">110000</ctmx:CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000429"
      unitRef="U_iso4217USD">279394000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="C_0001501989_20201231"
      decimals="INF"
      id="F_000437"
      unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000304">
&lt;p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6. Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,124&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,555&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;236&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,422&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,426&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,050&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,950&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization expense was $2.4 million, $2.5 million and $1.7 million for the years ended December 31, 2020, 2019 and 2018, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000339">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,772&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,124&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer equipment and software&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,600&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,555&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,728&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,483&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;252&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;236&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,376&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,422&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,426&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,050&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,950&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,372&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000438"
      unitRef="U_iso4217USD">13772000</us-gaap:MachineryAndEquipmentGross>
    <us-gaap:MachineryAndEquipmentGross
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000439"
      unitRef="U_iso4217USD">12124000</us-gaap:MachineryAndEquipmentGross>
    <ctmx:ComputerEquipmentAndSoftwareGross
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000440"
      unitRef="U_iso4217USD">1600000</ctmx:ComputerEquipmentAndSoftwareGross>
    <ctmx:ComputerEquipmentAndSoftwareGross
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000441"
      unitRef="U_iso4217USD">1555000</ctmx:ComputerEquipmentAndSoftwareGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000442"
      unitRef="U_iso4217USD">1024000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:FurnitureAndFixturesGross
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000443"
      unitRef="U_iso4217USD">1024000</us-gaap:FurnitureAndFixturesGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000444"
      unitRef="U_iso4217USD">1728000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000445"
      unitRef="U_iso4217USD">1483000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000446"
      unitRef="U_iso4217USD">252000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000447"
      unitRef="U_iso4217USD">236000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000448"
      unitRef="U_iso4217USD">18376000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000449"
      unitRef="U_iso4217USD">16422000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000450"
      unitRef="U_iso4217USD">11426000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000451"
      unitRef="U_iso4217USD">9050000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000452"
      unitRef="U_iso4217USD">6950000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000453"
      unitRef="U_iso4217USD">7372000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="C_0001501989_20200101_20201231"
      decimals="-5"
      id="F_000454"
      unitRef="U_iso4217USD">2400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001501989_20190101_20191231"
      decimals="-5"
      id="F_000455"
      unitRef="U_iso4217USD">2500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_0001501989_20180101_20181231"
      decimals="-5"
      id="F_000456"
      unitRef="U_iso4217USD">1700000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000305">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;7. Goodwill and Intangible Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill and in-process research and development assets resulted from a series of integrated financing transactions in 2010 that was accounted for as a business combination. The in-process research and development was related to the Company&#x2019;s proprietary Probody platform and was accounted for as an indefinite-lived intangible asset until the underlying project was completed or abandoned. In connection with the collaboration agreements, the Company began amortizing the intangible asset in 2017. The intangible asset is being amortized over the estimated lives of the patents which average 12 years. The amortization expense for the years ended December 31, 2020, 2019 and 2018 was $0.1 million, $0.1 million and $0.1 million, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill and intangible assets consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;949&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;949&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(583&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(438&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,312&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20200101_20201231"
      id="F_000457">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20200101_20201231"
      decimals="-5"
      id="F_000458"
      unitRef="U_iso4217USD">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20190101_20191231"
      decimals="-5"
      id="F_000459"
      unitRef="U_iso4217USD">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20180101_20181231"
      decimals="-5"
      id="F_000460"
      unitRef="U_iso4217USD">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000340">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill and intangible assets consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;949&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;949&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In-process research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated amortization&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(583&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(438&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,167&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,312&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:Goodwill
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000461"
      unitRef="U_iso4217USD">949000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000462"
      unitRef="U_iso4217USD">949000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20201231"
      decimals="-3"
      id="F_000463"
      unitRef="U_iso4217USD">1750000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20191231"
      decimals="-3"
      id="F_000464"
      unitRef="U_iso4217USD">1750000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20201231"
      decimals="-3"
      id="F_000465"
      unitRef="U_iso4217USD">583000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20191231"
      decimals="-3"
      id="F_000466"
      unitRef="U_iso4217USD">438000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20201231"
      decimals="-3"
      id="F_000467"
      unitRef="U_iso4217USD">1167000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20191231"
      decimals="-3"
      id="F_000468"
      unitRef="U_iso4217USD">1312000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000306">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;8. Accrued Liabilities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and clinical expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,092&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,721&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal and professional expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;815&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,062&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities - short term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;595&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;452&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,059&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000341">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities consisted of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and clinical expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,092&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,006&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,721&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal and professional expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;815&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,062&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease liabilities - short term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;595&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;452&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,059&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,051&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ctmx:AccruedResearchAndClinicalCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000469"
      unitRef="U_iso4217USD">10092000</ctmx:AccruedResearchAndClinicalCurrent>
    <ctmx:AccruedResearchAndClinicalCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000470"
      unitRef="U_iso4217USD">19006000</ctmx:AccruedResearchAndClinicalCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000471"
      unitRef="U_iso4217USD">8362000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000472"
      unitRef="U_iso4217USD">6721000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000473"
      unitRef="U_iso4217USD">815000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000474"
      unitRef="U_iso4217USD">1062000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000475"
      unitRef="U_iso4217USD">3195000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000476"
      unitRef="U_iso4217USD">2810000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000477"
      unitRef="U_iso4217USD">595000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000478"
      unitRef="U_iso4217USD">452000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000479"
      unitRef="U_iso4217USD">23059000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000480"
      unitRef="U_iso4217USD">30051000</us-gaap:AccruedLiabilitiesCurrent>
    <ctmx:ResearchAndCollaborationAgreementsTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000307">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;9. Research and Collaboration Agreements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the revenue by collaboration partners:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AbbVie&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,192&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,878&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amgen&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,899&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bristol Myers Squibb&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,740&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,780&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ImmunoGen&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,355&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,489&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,502&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;AbbVie Ireland Unlimited Company&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2016, the Company and AbbVie entered into two agreements, a CD71 Co-Development and Licensing Agreement (the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;CD71 Agreement&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) and a Discovery Collaboration and Licensing Agreement (as amended and restated in June 2019, the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Discovery Agreement&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt; and together with the CD71 Agreement the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;AbbVie Agreements&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;). Under the terms of the CD71 Agreement, the Company and AbbVie will co-develop a conditionally activated antibody-drug conjugate (&lt;span style="color:#000000;"&gt;&#x201c;A&lt;/span&gt;DC&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) against CD71, with the Company responsible for preclinical and early clinical development. AbbVie will be responsible for later development and commercialization, with global late-stage development costs shared between the two companies. The Company will assume 35% of the net profits or net losses related to later development and commercialization unless it opts-out. If the Company opts-out from participation of co-development of the CD71 conditionally activated ADC, which includes CX-2029, AbbVie will have sole right and responsibility for the further development, manufacturing and commercialization of such CD71 conditionally activated ADC. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the CD71 Agreement, the Company received an upfront payment of $20.0 million in April 2016, and was eligible to initially receive up to $470.0 million in development, regulatory and commercial milestone payments, a 35% profit split on U.S. sales, and royalties on ex-U.S. sales at percentages in the high teens to low twenties if the Company participates in the co-development of the CD71 conditionally activated ADC subject to a reversion to a royalty on U.S. sales, and reduction in royalties on ex-U.S. sales, if the Company opts-out from the co-development of the CD71 conditionally activated ADC. The Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s share of later stage co-development costs for each CD71 conditionally activated ADC is capped, provided that AbbVie may offset the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s co-development cost above the capped amounts from future payments such as milestone payments and royalties. In July 2017, the Company received a milestone payment of $14.0 million (net of payment of an associated sublicense fee of $1.0 million to SGEN under the Seattle Genetics Agreement) from AbbVie for achieving certain milestones required to be met to begin GLP toxicology studies under the CD71 Agreement. In May 2018, the United States Food and Drug Administration (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;FDA&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) cleared the IND application for CX-2029. As a result, the Company achieved the IND success criteria under the CD71 Agreement and received a $21.0 million milestone payment (net of the payment of an associated sublicense fee of $4.0 million to SGEN). In March 2020, the Company earned a $40.0 million milestone payment for satisfying the CD71 dose escalation success criteria under the CD71 Agreement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Discovery Agreement, AbbVie receives exclusive worldwide rights to develop and commercialize conditionally activated ADCs against up to two targets, one of which was selected in March 2017. The Company shall perform research services to discover the Probody therapeutics and create conditionally activated ADCs for the nominated collaboration targets. From that point, AbbVie shall have sole right and responsibility for development and commercialization of products comprising or containing such conditionally activated ADCs (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Discovery Licensed Products&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Discovery Agreement, the Company received an upfront payment of $10.0 million in April 2016 and subsequently earned an additional $10.0 million milestone payment triggered by selection of the second target by AbbVie in June 2019. The Company is also eligible to receive up to $265.0 million for each target, in development, regulatory and commercial milestone payments and royalties at percentages in the high single to low teens from commercial sales of any resulting conditionally activated ADCs. The second target was selected under the Discovery Agreement that allows AbbVie to select a target for developing a conditionally activated ADC or a Probody.&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has determined that the AbbVie Agreements should be combined and evaluated as a single arrangement in determining revenue recognition, because both agreements were concurrently negotiated and executed.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company identified the following performance obligations at the inception of the AbbVie Agreements: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the research, development and commercialization license for CD71 Probody therapeutic, &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the research services related to CD71 Probody therapeutic, &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the obligation to participate in the CD71 Agreement joint research committee, &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the research services related to the first discovery target &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the research, development and commercialization license for the first discovery target, and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the obligation to participate in the Discovery Agreement joint research committee. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company concluded that AbbVie&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s option for the second discovery target was not a material right and was therefore not a performance obligation at the inception of the AbbVie Agreements. However, it was subsequently included in the total transaction price in June 2019 as a performance obligation upon AbbVie&#x2019;s selection of such second target as further discussed below.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the research, development and commercialization licenses for CD71 and discovery targets are not distinct from the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s respective research services and expertise. The Company considered factors such as novelty of the Probody therapeutic and conditionally activated ADC technology and lack of other parties&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt; expertise in this space, the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s rights to technology relating to a proprietary platform to enable the Probody therapeutic development and AbbVie&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s contractual obligation to use the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s research services. The Company determined that the CD71 Agreement research, development and commercialization license, related research service and participation in the joint research committee were a combined performance obligation and were distinct from the Discovery Agreement research, development and commercialization license, related research service and participation in the joint research committee. Therefore, the Company concluded that there are two distinct performance obligations:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the CD71 Agreement performance obligation consisting of the CD71 Agreement research, development and commercialization license, related research service and participation in the joint research committee, and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the Discovery Agreement performance obligation consisting of the Discovery Agreement research, development and commercialization license, related research service and participation in the joint research committee.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total transaction price for the Discovery Agreement and CD71 Agreement, collectively, upon adoption of ASC 606 on January 1, 2018 of $39.8 million consists of $30.0 million in upfront payments, and a $14.0 million milestone payment received under the CD71 Agreement (net of the payment of an associated sublicense fee of $1.0 million to SGEN), less $4.2 million of estimated sublicense fees. The upfront payments under the AbbVie Agreements are allocated between the two performance obligations based on the estimated relative standalone selling prices. The $30.0 million of upfront payments is allocated $20.0 million to the CD71 Agreement, with the remaining $10.0 million allocated to the Discovery Agreement. The $14.0 million milestone payment received (net of the payment of an associated sublicense fee of $1.0 million to SGEN) and the estimated sublicense fees of $4.2 million are allocated to the CD71 Agreement performance obligation as they are directly related to the development of the CX-2029. &lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Therefore, of the $39.8 million total initial transaction price discussed above, the Company allocated $29.8 million to the CD71 Agreement performance obligation and recognized revenue using a cost-based input measure, the common measure of progress for the performance obligation. In applying the cost-based input method, revenue is recognized based on actual full-time employee (&#x201c;FTE&#x201d;) hours incurred as a percentage of total estimated FTE hours for completing its combined performance obligation over the estimated service period.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&#160;&#160;During 2019, as a result of ongoing dose escalation in the continued development program, there was a change in estimate of the research service period as well as an increase in the projected FTE hours-to-completion.&#160;&#160;The research service period for the CD71 Agreement performance obligation was extended from April 2021 to March 2022 in 2019.&#160;&#160;During the second quarter of 2020, the Company further increased the projected FTE hours-to-completion and extended the research service period for the CD71 Agreement performance obligation from March 2022 to September 2022 in response to the reduced rate of operation as impacted by the COVID-19 pandemic.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The remaining $10.0 million of the total initial transaction price of $39.8 million allocated to the Discovery Agreement performance obligation represents an obligation to continuously make the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s Probody therapeutic technology platform available to AbbVie. The $10.0 million was initially recognized on a straight-line basis over five years, which represented the estimated research service period for the first target, through April 2021 using the time-elapsed input method as the common measure of progress over the entire performance obligation.  During the fourth quarter of 2020, the Company extended the estimated research service period for this first target for an additional twelve months from April 2021 to April 2022.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2018, the Company earned a $21.0 million milestone payment (net of the payment of an associated sublicense fee of $4.0 million to SGEN) under the CD71 Agreement. The $21.0 million milestone payment was included as part of the transaction price in May 2018 and a revenue adjustment of $9.9 million was recognized in the second quarter of 2018 reflecting the percentage completed to-date on the project related to this milestone.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2019, the Company earned a $10.0 million milestone payment for the second target selected by AbbVie under the Discovery Agreement.&#160;&#160;It is recognized also using the time-elapse measure of progress of the related obligation and straight line over the estimated research service period of five years through June 2024.&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The $40.0 million milestone payment earned in March 2020 for satisfying the CD71 dose escalation success criteria under the CD71 Agreement was included as part of the transaction price as it was unconstrained during the first quarter of 2020 and $26.6 million was recognized as revenue related to this milestone reflecting the percentage completed to-date on the project.&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the remaining potential milestone payments of both agreements are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s control. Therefore, these payments continued to be fully constrained and were not included in the transaction price as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized revenue of $38.2 million, $5.9 million and $19.0 million for the years ended December 31, 2020, 2019 and 2018, respectively, related to the AbbVie Agreements. As of December 31, 2020 and 2019, deferred revenue related to the CD71 Agreement performance obligation was $25.2 million and $20.0 million, respectively, and deferred revenue related to the Discovery Agreement performance obligation was $8.0 million and $11.6 million, respectively. No amounts were due from AbbVie as of December 31, 2020 and 2019. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Amgen, Inc.&lt;span style="color:#FF0000;"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 29, 2017, the Company and Amgen, Inc. (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Amgen&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) entered into a Collaboration and License Agreement (the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Amgen Agreement&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;). Pursuant to the Amgen Agreement, the Company received an upfront payment of $40.0 million in October 2017. Concurrent with the entry into the Amgen Agreement, the Company and Amgen entered into a Share Purchase Agreement (the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Purchase Agreement&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) pursuant to which Amgen purchased 1,156,069 shares of the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s common stock at a price of $17.30 per share (calculated based on a 20-day volume-weighted average price), for total proceeds of $20.0 million, which the Company received on October 6, 2017, the closing date of the transaction. The Company estimated a premium on the stock sold to Amgen of $0.5 million, which takes into account a discount due to the lack of marketability resulting from the &lt;span style="-sec-ix-hidden:F_000554"&gt;six-month&lt;/span&gt; lockup period.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Amgen Agreement, the Company and Amgen will co-develop a conditionally activated T-cell engaging bi-specific therapeutic targeting epidermal growth factor receptor (the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;EGFR Products&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;). The Company is responsible for early-stage development of EGFR Products and all related costs up to certain pre-set costs and certain limits based on clinical trial size. Amgen will be responsible for late-stage development, commercialization, and all related costs of EGFR Products. Following early-stage development, the Company will have the right to elect to participate financially in the global co-development of EGFR Products with Amgen, during which the Company would bear certain of the worldwide development costs for EGFR Products and Amgen would bear the rest of such costs (the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;EGFR Co-Development Option&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;). If the Company exercises its EGFR Co-Development Option, the Company will share in somewhat less than 50% of the profit and losses from sales of such EGFR Products in the U.S., subject to certain caps, offsets, and deferrals. If the Company chooses not to exercise its EGFR Co-Development Option, the Company will not bear any costs of later stage development. The Company is eligible to receive up to $455.0 million in development, regulatory, and commercial milestone payments for EGFR Products, and royalties in the low-double-digit to mid-teen percentage of worldwide commercial sales, provided that if the Company exercises its EGFR Co-Development option, it shall receive a profit and loss split of sales in the United States and royalties in the low-double-digit to mid-teen percentage of commercial sales outside of the United States.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amgen also has the right to select a total of up to three targets, including the two additional targets discussed below. The Company and Amgen collaborate in the research and development of conditionally activated T-cell engaging bi-specifics products directed against such targets. Amgen has selected one such target (the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Amgen Other Product&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;). If Amgen exercises its option within the specified period of time, it can select two such additional targets (the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Amgen Option Products&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt; and, together with the Amgen Other Product, the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Amgen Products&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;). Except with respect to preclinical activities to be conducted by CytomX, Amgen will be responsible, at its expense, for the development, manufacture, and commercialization of all Amgen Products. If Amgen exercises all of its options and advances all three of the Amgen Products, CytomX is eligible to receive up to $950.0 million in upfront, development, regulatory, and commercial milestones and tiered high single-digit to low-teen percentage royalties. The Company concluded that, at the inception of the agreement, Amgen&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s option to select the two additional targets is not a material right and does not represent a performance obligation of the agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At the initiation of the collaboration, CytomX had the option to select, from programs specified in the Amgen Agreement, an existing pre-clinical stage T-cell engaging bispecific product from the Amgen pre-clinical pipeline. In March 2018, CytomX selected the program. CytomX is responsible, at its expense, for converting this program to a conditionally activated T-cell engaging bispecific product, and thereafter, will be responsible for development, manufacturing, and commercialization of the product (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;CytomX Product&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;). Amgen is eligible to receive up to $203.0 million in development, regulatory, and commercial milestone payments for the CytomX Product, and tiered mid-single digit to low double-digit percentage royalties.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considered the criteria for combining contracts in ASC 606 and determined that the Amgen Agreement and the Purchase Agreement should be combined into one contract. The Company accounted for the Amgen Agreement based on the fair values of the assets and services exchanged. The Company identified the following performance obligations at the inception of the Amgen Agreement: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the research, development and commercialization license, &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the research and development services for the EGFR Products and the Amgen Other Product, and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the obligation to participate in the joint steering committee (&#x201c;JSC&#x201d;) and the joint research committee (&#x201c;JRC&#x201d;). &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that research, development and commercialization license and the participation in the JSC and JRC are not distinct from the research and development services and therefore those performance obligations were combined into one combined performance obligation. The Amgen Other Products are accounted for as a separate performance obligation from the EGFR Products as the nature of the services being performed is not the same and the value that Amgen can derive from one program is not dependent on the success of the other.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concurrent with the execution of the Amgen Agreement, the Company entered into a sublicense agreement whereby the Company granted Amgen a sublicense of its rights to one patent family that it co-owns with UCSB, that is exclusively licensed to the Company under the UCSB Agreement covering Probody antibodies and other pro-proteins in the fields of therapeutics, in vivo diagnostics and prophylactics. This sublicense was incremental to the patents, patent applications and know-how covering conditionally activated T-cell engaging bispecific molecules that were developed and owned by the Company and licensed to Amgen.  Under the UCSB Agreement, as amended, the Company is obligated to make a sublicense payment to UCSB equal to up to 7.5% of certain upfront and milestone payments owed to or received by the Company. There were no sublicense fees payable to UCSB as of December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The total transaction price of $51.2 million, consisting of the $40.0 million upfront payment, an estimated fair value of $10.7 million for the CytomX Product and $0.5 million of premium on the sale of the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s common stock, was allocated between the two performance obligations based on the relative standalone selling price of each performance obligation. To determine the standalone selling price, the Company used the discounted cash flow method by calculating risk-adjusted net present values of estimated cash flows. The Company determined that the remaining potential milestone payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s control. As a result, these payments were fully constrained and were not included in the transaction price as of January 1, 2018, the adoption date of ASC 606. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Of the $51.2 million total transaction price, the Company allocated $46.4 million to the EGFR Products performance obligation and $4.8 million to the Amgen Other Product performance obligations. The transaction price of the EGFR Product performance obligation was recognized using a cost-based input measure. In applying the cost-based input method of revenue recognition, the Company uses actual FTE hours incurred relative to estimated total FTE hours expected to be incurred for the combined performance obligation over the research service period. At the end of the second quarter of 2019, the Company determined that it will undertake additional testing and assessment of the molecules being evaluated under the EGFR project.&#160;&#160;As a result, the estimated FTE hours-to-completion and research service period were increased to eight years.&#160;&#160;In the second quarter of 2020, the Company completed the clinical candidate &lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;characterization phase and has moved into the IND-enabling phase earlier than planned&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&#160;&#160;As a result, the estimated FTE hours-to-completion and research service period were decreased from eight to &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;seven years&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The $4.8 million transaction price allocated to the Amgen Other Product performance obligation represents an obligation to continuously make the Probody therapeutic technology platform available to Amgen, which is recognized over the common measure of progress for the entire performance obligation over the estimated research service period of six years.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized revenue of $8.6 million, $3.9 million and $4.9 million for the years ended December 31, 2020, 2019 and 2018, respectively, related to the Amgen Agreement.  As of December 31, 2020 and 2019, deferred revenue related to the EGFR Products performance obligation was $29.8 million and $37.6 million, respectively. As of December 31, 2020 and 2019, deferred revenue related to the Amgen Other Products performance obligation was $2.2 million and $3.0 million, respectively. No amounts were due from Amgen as of December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Astellas Pharma Inc.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company and Astellas Pharma, Inc. (&#x201c;Astellas&#x201d;) entered into a Collaboration and License Agreement (the &#x201c;Astellas Agreement&#x201d;) on March 23, 2020, the effective date, to collaborate on preclinical research activities to discover and develop certain antibody compounds for the treatment of cancer using the Company&#x2019;s Probody therapeutic technology. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Astellas Agreement, the Company granted Astellas an exclusive, worldwide, rights to develop and commercialize Probody therapeutics for up to four collaboration targets including one initial target and three additional targets (&#x201c;Additional Targets&#x201d;).&#160;&#160;In addition, Astellas has the right to expand the number of Additional Targets from three up to five (the &#x201c;Expansion Option&#x201d;) before the third anniversary of the effective date.&#160;&#160;Furthermore, for a specified number of targets, at a pre-specified time prior to the initiation of the first pivotal study of a product against such target, the Company may elect to participate in certain development costs and share in the profits generated in the United States with respect to such product (&#x201c;Cost Share Option&#x201d;). The Cost Share Option, if exercised, will also provide the option for the Company to co-commercialize such product in the United States.&#160;&#160;The Company does not consider the Cost Share Option as a performance obligation at the inception of the agreement as the participation is at the Company&#x2019;s discretion.&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the Astellas Agreement, the consideration from Astellas is comprised of an upfront fee of $80.0 million and contingent payments for development, regulatory and sales milestones of up to an aggregate of approximately $1.6 billion.&#160;&#160;If Astellas exercises its Expansion Option for the two Additional Targets, the Company would be eligible to receive additional upfront and milestone payments aggregating to approximately $0.9 billion.&lt;span style="font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;The Company is also entitled to tiered royalties from high-single digit to mid-teen percentage royalties from potential future sales. Astellas is responsible for all preclinical research costs incurred by either party as set forth in the preclinical research plan and the Company will receive research and development service fees based on a prescribed FTE rate.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company identified the following performance obligations at the inception of the Astellas Agreement: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the exclusive research, development and commercialization license; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the research and development services; and&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the obligation to participate in the joint research committee.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the license, the research services and expertise related to the development of the product candidates should be combined with the research services and participation in the joint research committee as one combined performance obligation. The Company concluded, that at the inception of the agreement, Astellas&#x2019; Expansion Option for two Additional Targets were not material rights and therefore not considered performance obligations.&#160;&#160;As such, each option will be accounted for as a separate arrangement upon exercise. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The initial transaction price of $90.0 million consists of the upfront fee of $80.0 million and research and development service fees of $10.0 million. The Company determined that the potential development and regulatory milestone payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s control. Therefore, the potential development and regulatory milestone payments were fully constrained and were not included in the initial transaction price and continued to be fully constrained as of December 31, 2020.&#160;&#160;The Company will re-evaluate the transaction price at each reporting date or as uncertain events are resolved or other changes in circumstances occur.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The upfront fee of $80.0 million for the combined obligation to continuously make the Probody therapeutic technology platform available to Astellas is recognized on a straight-line basis for the entire performance obligation over the estimated research service period of five years, which ends in March 2025.&#160;&#160;The research and development service fees, estimated to be $10.0 million, will be recognized when services are provided based on the prescribed FTE rate. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized revenue of $13.9 million for the year ended December 31, 2020, which included the research and development service fee of $1.5 million.&#160;&#160;As of December 31, 2020, deferred revenue relating to the Astellas Agreement was $67.6 million. The amount due from Astellas under the Astellas Agreement was $0.8 million as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Bristol Myers Squibb Company &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 23, 2014, the Company and Bristol Myers Squibb Company (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Bristol Myers Squibb&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) entered into a Collaboration and License Agreement (the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;BMS Agreement&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) to discover and develop compounds for use in human therapeutics aimed at multiple immuno-oncology targets using the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s Probody therapeutic technology. The effective date of the BMS Agreement was July 7, 2014.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the BMS Agreement, the Company granted Bristol Myers Squibb exclusive worldwide rights to develop and commercialize Probody therapeutics for up to four oncology targets. Bristol Myers Squibb had additional rights to substitute up to two collaboration targets within three years of the effective date of the BMS Agreement. These rights expired in May 2017. Each collaboration target had a &lt;span style="-sec-ix-hidden:F_000610"&gt;two-year&lt;/span&gt; research term and the two additional targets had to be nominated by Bristol Myers Squibb within five years of the effective date of the BMS Agreement. The research term for each collaboration target could be extended in one year increments up to three times.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the BMS Agreement, the financial consideration from Bristol Myers Squibb was comprised of an upfront payment of $50.0 million, and the Company was initially entitled to receive contingent payments of up to $25.0 million for additional targets and up to an aggregate of $1,192.0 million for development, regulatory and sales milestones.&#160;&#160;In addition, the Company is entitled to royalty payments in the mid-single digits to low double-digit percentages from potential future sales. The Company also receives research and development service fees based on a prescribed FTE rate that is capped.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company identified the following performance obligations at the inception of the BMS Agreement: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the exclusive research, development and commercialization license; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the research and development services; and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;the obligation to participate in the joint research committee. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that the license, the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s research services and expertise related to the development of the product candidates should be combined with the research services and participation in the joint research committee as one combined performance obligation. The Company concluded that, at the inception of the agreement, Bristol Myers Squibb&#x2019;s options for the third and fourth targets were not material rights and not performance obligations. As such, each option was accounted for as a separate arrangement upon exercise. Additionally, the Company considered whether the services performed for each target should be considered as separate performance obligations and concluded that all targets should be accounted for as one combined performance obligation.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company received an upfront payment of $50.0 million from Bristol Myers Squibb in July 2014. In January and December 2016, Bristol Myers Squibb selected the third and fourth targets, respectively, and paid the Company $10.0 million and $15.0 million, respectively, pursuant to the terms of the BMS Agreement. In December 2016, Bristol Myers Squibb selected a clinical candidate pursuant to the BMS Agreement, which triggered a $2.0 million pre-clinical milestone payment to the Company. In November 2017, the Company recognized a $10.0 million milestone payment from Bristol Myers Squibb upon approval of the investigational new drug application for the CTLA-4-directed Probody therapeutic.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 17, 2017, the Company and Bristol Myers Squibb entered into Amendment Number 1 to Extend Collaboration and License Agreement (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Amendment 1&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;). Amendment 1 granted Bristol Myers Squibb exclusive worldwide rights to develop and commercialize Probody therapeutics for up to eight additional targets. The effective date of Amendment 1 was April 25, 2017 (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Amendment Effective Date&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;). Under the terms of Amendment 1, the Company continued to have obligations to Bristol Myers Squibb to discover and conduct preclinical development of Probody therapeutics against any targets they chose to select during the research period under the terms of Amendment 1.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to Amendment 1, the financial consideration from Bristol Myers Squibb was comprised of an upfront payment of $200.0 million and the Company was initially eligible to receive contingent payments for development, regulatory and sales milestones of up to an aggregate of $3,586.0 million for the eight targets. The Company was also entitled to tiered mid-single to low double-digit percentage royalties from potential future sales. Amendment 1 did not change the term of the Bristol Myers Squibb&#x2019;s royalty obligation under the BMS Agreement. Bristol Myers Squibb&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s royalty obligation continues on a licensed-product by licensed-product basis until the later of (i) the expiration of the last claim of the licensed patents covering the licensed products in the country, (ii) the twelfth anniversary of the first commercial sale of a licensed product in a country, or (iii) the expiration of any applicable regulatory, pediatric, orphan drug or data exclusivity with respect to such product.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The initial transaction price for the BMS Agreement and Amendment 1, collectively, was $272.8 million consisting of the upfront fees of $250.0 million, research and development service fees of $10.8 million and milestone payments received to date of $12.0 million. The Company determined that the remaining potential milestone payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s control. Therefore, these payments were fully constrained and were not included in the transaction price upon the adoption of ASC 606 on January 1, 2018. The BMS Agreement represents an obligation to continuously make the Probody therapeutic technology platform available to Bristol Myers Squibb.  Therefore, the initial transaction price is recognized over the estimated research service period, which ends on April 25, 2025.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the first quarter of 2019, Bristol Myers Squibb terminated pre-clinical activities on three of the first four collaboration targets selected under the original 2014 BMS Agreement.&#160;&#160;The first and second targets under the BMS Agreement were combined into a single performance obligation. The Company determined that termination of pre-clinical activities on the second target does not impact the Company&#x2019;s continuing obligation to Bristol Myers Squibb for the first target, CTLA-4, as it is still being actively developed by Bristol Myers Squibb.&#160;&#160;Therefore, the Company concluded that it will continue to amortize the related deferred revenue over the original performance period. The Company has determined that upon the termination of pre-clinical activities on the third and the fourth collaboration targets selected by Bristol Myers Squibb in January and December of 2016, respectively, under the BMS Agreement, it has no further obligations.&#160;&#160;As a result of termination of three of the four collaboration targets, the Company is no longer eligible to receive up to an aggregate of $894.0 million contingent payments for development, regulatory and sales milestones as well as the related royalty payments for such targets.&#160;&#160;As a result, the Company recognized $18.1 million of revenue for the third and fourth targets in the first quarter of 2019, of which $17.4 million represented the accelerated recognition of all of the related deferred revenue upon the effective date of termination.&#160; The Company continues to be obligated to perform research work under Amendment 1 executed in March 2017.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2020, Bristol Myers Squibb dosed the first patient in the Part 2 cohort expansion portion of its ongoing BMS-986249 clinical study for the CTLA-4 program,&lt;span style="Background-color:#FFFFFF;"&gt; which triggered a $10.0 million milestone payment to the Company &lt;/span&gt;pursuant to the terms of the BMS Agreement.&#160;&#160;The $10.0 million milestone payment was recognized as revenue in the first quarter of 2020.&#160;&#160;The Company reevaluated the remaining potential milestone payments and determined that significant revenue reversal was still probable as the achievement of such milestones was highly dependent on factors outside the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s control. As a result, these payments continued to be fully constrained and were not included in the transaction price on December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2021, the Company and Bristol Myers Squibb entered into Amendment Number 2 to amend the Collaboration and License Agreement (&#x201c;Amendment 2&#x201d;), as amended by Amendment 1. Subsequent to Amendment 2, Bristol Myers Squibb has the exclusive worldwide rights to develop and commercialize Probody therapeutics for up to five oncology targets. Under the terms of Amendment 2, the period for target selection has been extended and the Company will continue to collaborate with Bristol Myers Squibb to discover and conduct preclinical development of Probody therapeutics against targets selected by Bristol Myers Squibb. Pursuant to Amendment 2, the Company is eligible to receive contingent payments for development, regulatory and sales milestones of up to an aggregate of $1,779.0 million. It is also entitled to tiered mid-single to low double-digit percentage of royalties from potential future sales.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized revenue of $39.6 million, $47.7 million and $32.8 million for the years ended December 31, 2020, 2019, and 2018, respectively. As of December 31, 2020 and 2019, deferred revenue relating to the BMS Agreement was $128.3 million and $158.0 million, respectively. The amounts due from Bristol Myers Squibb under the BMS Agreement were $0 and $13,000 as of December 31, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;ImmunoGen, Inc. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2014, the Company and ImmunoGen, Inc. (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;ImmunoGen&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) entered into the Research Collaboration Agreement (the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;ImmunoGen Research Agreement&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;). The ImmunoGen Research Agreement provided the Company with the right to use ImmunoGen&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s Antibody Drug Conjugate (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;ADC&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) technology in combination with the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s Probody therapeutic technology to create a conditionally activated ADC directed at one specified target under a research license, and to subsequently obtain an exclusive, &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;worldwide development and commercialization license to use &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ImmunoGen&lt;/span&gt;&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;s&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; ADC technology to develop and commercialize such &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;conditionally&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;activ&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;at&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;e&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;d&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; A&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;DCs. The Company made &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;no&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; upfront cash payment in connection with the execution of the agreement. Instead, the Company provided &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ImmunoGen&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; with the rights to &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;CytomX&lt;/span&gt;&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;s&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Probody&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; therapeutic technology to create &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;conditionally&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;activ&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;at&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;e&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;d&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; A&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;DCs directed at &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;two&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; targets under the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ImmunoGen&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Research Agreement and to subsequently obtain exclusive, worldwide development and commercialization licenses to develop and commercialize such &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;conditionally&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;activ&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;at&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;e&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;d&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; A&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;DCs. In February 2016, the Company exercised its option to obtain a development and commercialization license for &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;praluzatamab&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ravtansine&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; (CX-2009)&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; pursuant to the terms of the &lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ImmunoGen&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; Research Agreement (the &lt;/span&gt;&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;CX-2009 License&lt;/span&gt;&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;).&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2017, ImmunoGen exercised its first option to obtain a development and commercialization license for one of the two targets. Substitution rights for this first target selection program terminated in February 2017 and ImmunoGen discontinued the program in July 2017. The Company recognized the remaining deferred revenue related to the discontinued program upon the termination of the program. ImmunoGen exercised its second option to obtain a development and commercialization license pursuant to the ImmunoGen Research Agreement (the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;ImmunoGen 2017 License&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) for a target in December 2017.&#160;&#160;In December 2019, the parties entered into a license agreement (the &#x201c;ImmunoGen 2019 License&#x201d;) pursuant to which the ImmunoGen 2017 License was terminated and ImmunoGen granted a license for all of ImmunoGen&#x2019;s rights under the ImmunoGen 2017 License to the Company. See Note 10. License Agreement, for more information.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the ImmunoGen Research Agreement, both the Company and ImmunoGen performed research activities on behalf of the other party for no monetary consideration through January 2018. In December 2017, the Company entered into the ImmunoGen 2017 License arrangement and extended the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s obligation to provide research services under the ImmunoGen Research Agreement to June 30, 2018. The estimated fair value of the consideration of $13.2 million for the performance obligation to ImmunoGen was recognized as revenue over the research period that ended on June 30, 2018. No further research services were provided by the Company after June 20, 2018 under the ImmunoGen 2017 License arrangement. The Company recognized revenue of $1.5 million for the year ended December 31, 2018. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2020, the Company dosed the first patient in the praluzatamab ravtansine Phase 2 clinical trial and triggered a $3.0 million milestone payment to ImmunoGen pursuant to the CX-2009 License which continued to remain in effect following the termination of the ImmunoGen 2017 License in December 2019.&#160;&#160;The Company recorded a $3.0 million charge to research and development expense in the first quarter of 2020, in connection with this milestone payment to ImmunoGen.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;span style="font-weight:bold;font-style:italic;"&gt;Pfizer Inc.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2013, the Company and Pfizer Inc. (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Pfizer&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) entered into a Research Collaboration, Option and License Agreement (the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;Pfizer Agreement&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) to collaborate on the discovery and preclinical research activities related to Probody therapeutics, and conditionally activated ADCs for research project targets nominated by Pfizer. Pfizer nominated two research targets in 2013 and, pursuant to the Pfizer Agreement, had the option of nominating two additional research targets. In December 2014, Pfizer selected an additional research target and paid the Company $1.5 million. The option to select a fourth target lapsed in May 2016. Pfizer discontinued the epidermal growth factor receptor (&lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;EGFR&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;) program and decided to terminate the remaining two targets in February and March 2018. In March 2018, Pfizer terminated the Pfizer Agreement. As such, the Company had no further performance obligations under this agreement after the first quarter of 2018.&#160;&#160;The Company recognized revenue of $1.4 million for the year ended December 31, 2018.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Contract Liabilities &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents changes in the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s total contract liabilities for the year ended December 31, 2020 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12/31/2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deductions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12/31/2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,239&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;261,130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were $120.0 million of additions to deferred revenue during the year ended December 31,2020.&#160;&#160;Of such amount, $40.0 million was related to the milestone payment triggered by AbbVie&#x2019;s CD71 dose escalation success criteria which was achieved in March 2020, and an $80.0 million addition was related to the upfront fee payable under the Astellas Agreement entered into in March 2020.  Deductions of $89.1 million related to revenue recognized included in the contract liability balance at the beginning of the period plus the revenue recognized related to the $120.0 million additions during the year ended December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company expects that the $261.1 million of deferred revenue related to the following contracts as of December 31, 2020 will be recognized as revenue as set forth below. However, the timing of revenue recognition could differ from the estimates depending on facts and circumstances impacting the various contracts, including progress of research and development, resources assigned to the contracts by the Company or its collaboration partners or other factors outside of the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s control.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;The $25.2 million of deferred revenue related to the CD71 Agreement as of December 31, 2020 is expected to be recognized based on actual FTE effort and program progress until approximately September 2022. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;The $1.0 million of deferred revenue related to the first target under the Discovery Agreement as of December 31, 2020 is expected to be recognized ratably until approximately April 2022.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;The $7.0 million of deferred revenue related to the second target under the Discovery Agreement as of December 31, 2020 is expected to be recognized ratably until approximately June 2024.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;The $29.8 million of deferred revenue related to the Amgen EGFR Products as of December 31, 2020 is expected to be recognized based on actual FTE effort and program progress until approximately September 2024.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;The $2.2 million of deferred revenue related to the Amgen Other Products as of December 31, 2020 is expected to be recognized ratably until approximately September 2023. &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;The $67.6 million of deferred revenue related to the Astellas Agreement as of December 31, 2020 is expected to be recognized ratably until approximately March 2025.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="width:4.54%;white-space:nowrap" valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"&gt;&lt;span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/&gt;&lt;span style="font-size:10pt;font-family:'Times New Roman'"&gt;&#x2022;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"&gt;&lt;span style="Background-color:#auto;text-decoration:none;"/&gt;&lt;span style="color:#000000;"&gt;The $128.3 million of deferred revenue related to the BMS Agreement as of December 31, 2020 is expected to be recognized ratably until approximately April 2025.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</ctmx:ResearchAndCollaborationAgreementsTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000342">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the revenue by collaboration partners:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;AbbVie&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,192&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,878&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,997&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amgen&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,609&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,899&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Astellas&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,931&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Bristol Myers Squibb&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,630&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,740&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;32,780&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ImmunoGen&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,471&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pfizer&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,355&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100,362&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57,489&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;59,502&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20200101_20201231"
      decimals="-3"
      id="F_000481"
      unitRef="U_iso4217USD">38192000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20190101_20191231"
      decimals="-3"
      id="F_000482"
      unitRef="U_iso4217USD">5878000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180101_20181231"
      decimals="-3"
      id="F_000483"
      unitRef="U_iso4217USD">18997000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_20200101_20201231"
      decimals="-3"
      id="F_000484"
      unitRef="U_iso4217USD">8609000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_20190101_20191231"
      decimals="-3"
      id="F_000485"
      unitRef="U_iso4217USD">3871000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_20180101_20181231"
      decimals="-3"
      id="F_000486"
      unitRef="U_iso4217USD">4899000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_20200101_20201231"
      decimals="-3"
      id="F_000487"
      unitRef="U_iso4217USD">13931000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20200101_20201231"
      decimals="-3"
      id="F_000488"
      unitRef="U_iso4217USD">39630000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20190101_20191231"
      decimals="-3"
      id="F_000489"
      unitRef="U_iso4217USD">47740000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20180101_20181231"
      decimals="-3"
      id="F_000490"
      unitRef="U_iso4217USD">32780000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_20180101_20181231"
      decimals="-3"
      id="F_000491"
      unitRef="U_iso4217USD">1471000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_20180101_20181231"
      decimals="-3"
      id="F_000492"
      unitRef="U_iso4217USD">1355000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000493"
      unitRef="U_iso4217USD">100362000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000494"
      unitRef="U_iso4217USD">57489000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000495"
      unitRef="U_iso4217USD">59502000</us-gaap:Revenues>
    <ctmx:NumberOfCollaborationAgreements
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20160430"
      decimals="INF"
      id="F_000496"
      unitRef="U_ctmxAgreement">2</ctmx:NumberOfCollaborationAgreements>
    <ctmx:PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20160401_20160430"
      decimals="2"
      id="F_000497"
      unitRef="U_xbrlipure">0.35</ctmx:PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430"
      decimals="-5"
      id="F_000498"
      unitRef="U_iso4217USD">20000000.0</us-gaap:ProceedsFromCollaborators>
    <ctmx:ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160430"
      decimals="INF"
      id="F_000499"
      unitRef="U_iso4217USD">470000000.0</ctmx:ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones>
    <ctmx:ContingentPaymentsReceivableProfitSplitOnSales
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtStatementGeographicalAxis_countryUS_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430"
      decimals="2"
      id="F_000500"
      unitRef="U_xbrlipure">0.35</ctmx:ContingentPaymentsReceivableProfitSplitOnSales>
    <ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20170701_20170731"
      decimals="-5"
      id="F_000501"
      unitRef="U_iso4217USD">14000000.0</ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod>
    <ctmx:PaymentsOfSublicenseFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20170701_20170731"
      decimals="-5"
      id="F_000503"
      unitRef="U_iso4217USD">1000000.0</ctmx:PaymentsOfSublicenseFees>
    <ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20180501_20180531"
      decimals="-5"
      id="F_000502"
      unitRef="U_iso4217USD">21000000.0</ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod>
    <ctmx:PaymentsOfSublicenseFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20180501_20180531"
      decimals="-5"
      id="F_000504"
      unitRef="U_iso4217USD">4000000.0</ctmx:PaymentsOfSublicenseFees>
    <ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331"
      decimals="-5"
      id="F_000505"
      unitRef="U_iso4217USD">40000000.0</ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod>
    <ctmx:NumberOfTargets
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430"
      decimals="INF"
      id="F_000506"
      unitRef="U_ctmxTarget">2</ctmx:NumberOfTargets>
    <ctmx:NumberOfTargetsSelected
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20170331"
      decimals="INF"
      id="F_000507"
      unitRef="U_ctmxTarget">1</ctmx:NumberOfTargetsSelected>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160401_20160430"
      decimals="-5"
      id="F_000508"
      unitRef="U_iso4217USD">10000000.0</us-gaap:ProceedsFromCollaborators>
    <ctmx:MilestonePaymentReceived
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630"
      decimals="-5"
      id="F_000509"
      unitRef="U_iso4217USD">10000000.0</ctmx:MilestonePaymentReceived>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_ctmxDevelopmentRegulatoryAndCommercialMilestonePaymentsMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430"
      decimals="INF"
      id="F_000510"
      unitRef="U_iso4217USD">265000000.0</ctmx:ContingentMilestonePaymentsReceivable>
    <ctmx:AggregateCollaborationTransactionAmount
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160430"
      decimals="-5"
      id="F_000511"
      unitRef="U_iso4217USD">39800000</ctmx:AggregateCollaborationTransactionAmount>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160401_20160430"
      decimals="-5"
      id="F_000512"
      unitRef="U_iso4217USD">30000000.0</us-gaap:ProceedsFromCollaborators>
    <ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160401_20160430"
      decimals="-5"
      id="F_000513"
      unitRef="U_iso4217USD">14000000.0</ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod>
    <ctmx:PaymentsOfSublicenseFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20160401_20160430"
      decimals="-5"
      id="F_000514"
      unitRef="U_iso4217USD">1000000.0</ctmx:PaymentsOfSublicenseFees>
    <ctmx:EstimatedSublicenseFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160401_20160430"
      decimals="-5"
      id="F_000515"
      unitRef="U_iso4217USD">4200000</ctmx:EstimatedSublicenseFees>
    <ctmx:NumberOfAccountingUnits
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160401_20160430"
      decimals="INF"
      id="F_000516"
      unitRef="U_ctmxAccountingUnit">2</ctmx:NumberOfAccountingUnits>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430"
      decimals="-5"
      id="F_000517"
      unitRef="U_iso4217USD">20000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160401_20160430"
      decimals="-5"
      id="F_000518"
      unitRef="U_iso4217USD">10000000.0</us-gaap:ProceedsFromCollaborators>
    <ctmx:MilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160430"
      decimals="-5"
      id="F_000519"
      unitRef="U_iso4217USD">14000000.0</ctmx:MilestonePaymentsReceivable>
    <ctmx:PaymentsOfSublicenseFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20160401_20160430"
      decimals="-5"
      id="F_000520"
      unitRef="U_iso4217USD">1000000.0</ctmx:PaymentsOfSublicenseFees>
    <ctmx:EstimatedSublicenseFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160401_20160430"
      decimals="-5"
      id="F_000521"
      unitRef="U_iso4217USD">4200000</ctmx:EstimatedSublicenseFees>
    <ctmx:AggregateCollaborationTransactionAmount
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_20160430"
      decimals="-5"
      id="F_000522"
      unitRef="U_iso4217USD">39800000</ctmx:AggregateCollaborationTransactionAmount>
    <ctmx:AggregateCollaborationTransactionAmount
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20160430"
      decimals="-5"
      id="F_000523"
      unitRef="U_iso4217USD">29800000</ctmx:AggregateCollaborationTransactionAmount>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2016-04-01_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430"
      id="F_000524">P5Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <ctmx:MilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20180531"
      decimals="-5"
      id="F_000525"
      unitRef="U_iso4217USD">21000000.0</ctmx:MilestonePaymentsReceivable>
    <ctmx:PaymentsOfSublicenseFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSeattleGeneticsAgreementMember_20180501_20180531"
      decimals="-5"
      id="F_000526"
      unitRef="U_iso4217USD">4000000.0</ctmx:PaymentsOfSublicenseFees>
    <ctmx:MilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180531"
      decimals="-5"
      id="F_000527"
      unitRef="U_iso4217USD">21000000.0</ctmx:MilestonePaymentsReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180401_20180630"
      decimals="-5"
      id="F_000528"
      unitRef="U_iso4217USD">9900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ctmx:AggregateCollaborationTransactionAmount
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430"
      decimals="-5"
      id="F_000530"
      unitRef="U_iso4217USD">10000000.0</ctmx:AggregateCollaborationTransactionAmount>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430"
      decimals="-5"
      id="F_000531"
      unitRef="U_iso4217USD">10000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <ctmx:AggregateCollaborationTransactionAmount
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190630"
      decimals="-5"
      id="F_000532"
      unitRef="U_iso4217USD">10000000.0</ctmx:AggregateCollaborationTransactionAmount>
    <ctmx:EstimatedResearchServicePeriod
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630"
      id="F_000533">P5Y</ctmx:EstimatedResearchServicePeriod>
    <ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331"
      decimals="-5"
      id="F_000534"
      unitRef="U_iso4217USD">40000000.0</ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTimingOfTransferOfGoodOrServiceAxis_us-gaapTransferredOverTimeMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331"
      decimals="-5"
      id="F_000535"
      unitRef="U_iso4217USD">26600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20200101_20201231"
      decimals="-5"
      id="F_000537"
      unitRef="U_iso4217USD">38200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20190101_20191231"
      decimals="-5"
      id="F_000538"
      unitRef="U_iso4217USD">5900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180101_20181231"
      decimals="-5"
      id="F_000539"
      unitRef="U_iso4217USD">19000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20201231"
      decimals="-5"
      id="F_000543"
      unitRef="U_iso4217USD">25200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20191231"
      decimals="-5"
      id="F_000544"
      unitRef="U_iso4217USD">20000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20201231"
      decimals="-5"
      id="F_000545"
      unitRef="U_iso4217USD">8000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20191231"
      decimals="-5"
      id="F_000546"
      unitRef="U_iso4217USD">11600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231"
      decimals="INF"
      id="F_000547"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231"
      decimals="INF"
      id="F_000548"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171001_20171031"
      decimals="-5"
      id="F_000549"
      unitRef="U_iso4217USD">40000000.0</us-gaap:ProceedsFromCollaborators>
    <ctmx:CommonStockSharesIssuableUnderAgreement
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171031"
      decimals="INF"
      id="F_000550"
      unitRef="U_xbrlishares">1156069</ctmx:CommonStockSharesIssuableUnderAgreement>
    <us-gaap:SharePrice
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171031"
      decimals="2"
      id="F_000551"
      unitRef="U_iso4217USD_xbrlishares">17.30</us-gaap:SharePrice>
    <ctmx:PeriodUsedToCalculateWeightedAveragePricePerShare
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171001_20171031"
      id="F_000553">P20D</ctmx:PeriodUsedToCalculateWeightedAveragePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171001_20171031"
      decimals="-5"
      id="F_000552"
      unitRef="U_iso4217USD">20000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ctmx:EstimatedPremiumOnIssuanceOfShares
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20171001_20171031"
      decimals="-5"
      id="F_000555"
      unitRef="U_iso4217USD">500000</ctmx:EstimatedPremiumOnIssuanceOfShares>
    <ctmx:ProfitShareUponExerciseOfCoDevelopmentOption
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929"
      decimals="INF"
      id="F_000557"
      unitRef="U_xbrlipure">0.50</ctmx:ProfitShareUponExerciseOfCoDevelopmentOption>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929"
      decimals="INF"
      id="F_000556"
      unitRef="U_iso4217USD">455000000.0</ctmx:ContingentMilestonePaymentsReceivable>
    <ctmx:NumberOfTargets
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929"
      decimals="INF"
      id="F_000558"
      unitRef="U_ctmxTarget">3</ctmx:NumberOfTargets>
    <ctmx:NumberOfTargetsSelected
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929"
      decimals="INF"
      id="F_000559"
      unitRef="U_ctmxTarget">1</ctmx:NumberOfTargetsSelected>
    <ctmx:NumberOfAdditionalCollaborationTarget
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929"
      decimals="INF"
      id="F_000560"
      unitRef="U_ctmxTarget">2</ctmx:NumberOfAdditionalCollaborationTarget>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenProductsMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929"
      decimals="INF"
      id="F_000561"
      unitRef="U_iso4217USD">950000000.0</ctmx:ContingentMilestonePaymentsReceivable>
    <ctmx:ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929"
      decimals="INF"
      id="F_000562"
      unitRef="U_iso4217USD">203000000.0</ctmx:ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones>
    <ctmx:LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtRangeAxis_srtMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxRegentsOfTheUniversityOfCaliforniaMember_us-gaapTypeOfArrangementAxis_ctmxSublicenseAgreementMember_20170929_20170929"
      decimals="INF"
      id="F_000563"
      unitRef="U_xbrlipure">0.075</ctmx:LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxRegentsOfTheUniversityOfCaliforniaMember_us-gaapTypeOfArrangementAxis_ctmxSublicenseAgreementMember_20201231"
      decimals="0"
      id="F_000564"
      unitRef="U_iso4217USD">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxRegentsOfTheUniversityOfCaliforniaMember_us-gaapTypeOfArrangementAxis_ctmxSublicenseAgreementMember_20191231"
      decimals="0"
      id="F_000565"
      unitRef="U_iso4217USD">0</us-gaap:AccruedLiabilitiesCurrent>
    <ctmx:AggregateCollaborationTransactionAmount
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929"
      decimals="-5"
      id="F_000566"
      unitRef="U_iso4217USD">51200000</ctmx:AggregateCollaborationTransactionAmount>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929"
      decimals="-5"
      id="F_000567"
      unitRef="U_iso4217USD">40000000.0</us-gaap:ProceedsFromCollaborators>
    <ctmx:EstimatedFairValueOfProducts
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929"
      decimals="-5"
      id="F_000569"
      unitRef="U_iso4217USD">10700000</ctmx:EstimatedFairValueOfProducts>
    <ctmx:PremiumOnIssuanceOfSharesAllocatedToCommonStock
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929"
      decimals="-5"
      id="F_000568"
      unitRef="U_iso4217USD">500000</ctmx:PremiumOnIssuanceOfSharesAllocatedToCommonStock>
    <ctmx:AggregateCollaborationTransactionAmount
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929"
      decimals="-5"
      id="F_000570"
      unitRef="U_iso4217USD">51200000</ctmx:AggregateCollaborationTransactionAmount>
    <ctmx:AggregateCollaborationTransactionAmount
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929"
      decimals="-5"
      id="F_000571"
      unitRef="U_iso4217USD">46400000</ctmx:AggregateCollaborationTransactionAmount>
    <ctmx:AggregateCollaborationTransactionAmount
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929"
      decimals="-5"
      id="F_000572"
      unitRef="U_iso4217USD">4800000</ctmx:AggregateCollaborationTransactionAmount>
    <ctmx:EstimatedResearchServicePeriod
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200401_20200630"
      id="F_000573">P8Y</ctmx:EstimatedResearchServicePeriod>
    <ctmx:EstimatedResearchServicePeriod
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20190401_20190630"
      id="F_000574">P7Y</ctmx:EstimatedResearchServicePeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929"
      decimals="-5"
      id="F_000575"
      unitRef="U_iso4217USD">4800000</us-gaap:RevenueRemainingPerformanceObligation>
    <ctmx:EstimatedResearchServicePeriod
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929"
      id="F_000576">P6Y</ctmx:EstimatedResearchServicePeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000577"
      unitRef="U_iso4217USD">8600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20190101_20191231"
      decimals="-5"
      id="F_000578"
      unitRef="U_iso4217USD">3900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20180101_20181231"
      decimals="-5"
      id="F_000579"
      unitRef="U_iso4217USD">4900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231"
      decimals="-5"
      id="F_000585"
      unitRef="U_iso4217USD">29800000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20191231"
      decimals="-5"
      id="F_000586"
      unitRef="U_iso4217USD">37600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231"
      decimals="-5"
      id="F_000583"
      unitRef="U_iso4217USD">2200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20191231"
      decimals="-5"
      id="F_000584"
      unitRef="U_iso4217USD">3000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231"
      decimals="INF"
      id="F_000587"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20191231"
      decimals="INF"
      id="F_000588"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <ctmx:NumberOfTargets
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323"
      decimals="INF"
      id="F_000589"
      unitRef="U_ctmxTarget">4</ctmx:NumberOfTargets>
    <ctmx:NumberOfTargetsSelected
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323"
      decimals="INF"
      id="F_000590"
      unitRef="U_ctmxTarget">1</ctmx:NumberOfTargetsSelected>
    <ctmx:NumberOfAdditionalCollaborationTarget
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323"
      decimals="INF"
      id="F_000591"
      unitRef="U_ctmxTarget">3</ctmx:NumberOfAdditionalCollaborationTarget>
    <ctmx:RightToExpandNumberOfAdditionalCollaborationTarget
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtRangeAxis_srtMinimumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323"
      decimals="INF"
      id="F_000592"
      unitRef="U_ctmxTarget">3</ctmx:RightToExpandNumberOfAdditionalCollaborationTarget>
    <ctmx:RightToExpandNumberOfAdditionalCollaborationTarget
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323"
      decimals="INF"
      id="F_000593"
      unitRef="U_ctmxTarget">5</ctmx:RightToExpandNumberOfAdditionalCollaborationTarget>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323"
      decimals="-5"
      id="F_000594"
      unitRef="U_iso4217USD">80000000.0</us-gaap:ProceedsFromCollaborators>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323"
      decimals="-8"
      id="F_000595"
      unitRef="U_iso4217USD">1600000000</ctmx:ContingentMilestonePaymentsReceivable>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapContingentConsiderationByTypeAxis_ctmxAdditionalContingentPaymentsMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323"
      decimals="-8"
      id="F_000596"
      unitRef="U_iso4217USD">900000000</ctmx:ContingentMilestonePaymentsReceivable>
    <ctmx:AggregateCollaborationTransactionAmount
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323"
      decimals="-5"
      id="F_000597"
      unitRef="U_iso4217USD">90000000.0</ctmx:AggregateCollaborationTransactionAmount>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323"
      decimals="-5"
      id="F_000598"
      unitRef="U_iso4217USD">80000000.0</us-gaap:ProceedsFromCollaborators>
    <ctmx:ResearchAndDevelopmentServiceFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323"
      decimals="-5"
      id="F_000599"
      unitRef="U_iso4217USD">10000000.0</ctmx:ResearchAndDevelopmentServiceFees>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323"
      decimals="-5"
      id="F_000600"
      unitRef="U_iso4217USD">80000000.0</us-gaap:ProceedsFromCollaborators>
    <ctmx:EstimatedResearchServicePeriod
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323"
      id="F_000601">P5Y</ctmx:EstimatedResearchServicePeriod>
    <ctmx:EstimatedResearchServiceTerminationMonthAndYear
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323"
      id="F_000602">2025-03</ctmx:EstimatedResearchServiceTerminationMonthAndYear>
    <ctmx:ResearchAndDevelopmentServiceFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323_20200323"
      decimals="-5"
      id="F_000603"
      unitRef="U_iso4217USD">10000000.0</ctmx:ResearchAndDevelopmentServiceFees>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000604"
      unitRef="U_iso4217USD">13900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ctmx:ResearchAndDevelopmentServiceFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200101_20201231"
      decimals="-5"
      id="F_000605"
      unitRef="U_iso4217USD">1500000</ctmx:ResearchAndDevelopmentServiceFees>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231"
      decimals="-5"
      id="F_000606"
      unitRef="U_iso4217USD">67600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20201231"
      decimals="-5"
      id="F_000607"
      unitRef="U_iso4217USD">800000</us-gaap:ContractWithCustomerAssetNet>
    <ctmx:NumberOfOncologyTarget
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707"
      decimals="INF"
      id="F_000608"
      unitRef="U_ctmxTarget">4</ctmx:NumberOfOncologyTarget>
    <ctmx:NumberOfCollaborationTarget
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707"
      decimals="INF"
      id="F_000609"
      unitRef="U_ctmxTarget">2</ctmx:NumberOfCollaborationTarget>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231"
      id="F_000612">Each collaboration target had a two-year research term and the two additional targets had to be nominated by Bristol Myers Squibb within five years of the effective date of the BMS Agreement. The research term for each collaboration target could be extended in one year increments up to three times.</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms>
    <ctmx:NumberOfAdditionalCollaborationTarget
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707"
      decimals="INF"
      id="F_000611"
      unitRef="U_ctmxTarget">2</ctmx:NumberOfAdditionalCollaborationTarget>
    <ctmx:PeriodOfNominationOfAdditionalTarget
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707"
      id="F_000613">P5Y</ctmx:PeriodOfNominationOfAdditionalTarget>
    <ctmx:ExtensionOfResearchTermForEachCollaborationTarget
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707"
      id="F_000614">P1Y</ctmx:ExtensionOfResearchTermForEachCollaborationTarget>
    <ctmx:IncrementsOfExtendedCollaborationTargetResearchTimes
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707"
      decimals="INF"
      id="F_000615"
      unitRef="U_ctmxTerm">3</ctmx:IncrementsOfExtendedCollaborationTargetResearchTimes>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707"
      decimals="-5"
      id="F_000616"
      unitRef="U_iso4217USD">50000000.0</us-gaap:ProceedsFromCollaborators>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapContingentConsiderationByTypeAxis_ctmxAchievingAdditionalTargetsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707"
      decimals="INF"
      id="F_000618"
      unitRef="U_iso4217USD">25000000.0</ctmx:ContingentMilestonePaymentsReceivable>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707"
      decimals="INF"
      id="F_000617"
      unitRef="U_iso4217USD">1192000000.0</ctmx:ContingentMilestonePaymentsReceivable>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20160131"
      decimals="-5"
      id="F_000619"
      unitRef="U_iso4217USD">10000000.0</ctmx:ContingentMilestonePaymentsReceivable>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20161231"
      decimals="-5"
      id="F_000620"
      unitRef="U_iso4217USD">15000000.0</ctmx:ContingentMilestonePaymentsReceivable>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxPreClinicalCandidateMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20161231"
      decimals="-5"
      id="F_000621"
      unitRef="U_iso4217USD">2000000.0</ctmx:ContingentMilestonePaymentsReceivable>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxDrugApplicationForCTLA4Member_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20171130"
      decimals="-5"
      id="F_000622"
      unitRef="U_iso4217USD">10000000.0</ctmx:ContingentMilestonePaymentsReceivable>
    <ctmx:NumberOfAdditionalCollaborationTarget
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170317"
      decimals="INF"
      id="F_000623"
      unitRef="U_ctmxTarget">8</ctmx:NumberOfAdditionalCollaborationTarget>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170425_20170425"
      decimals="-5"
      id="F_000624"
      unitRef="U_iso4217USD">200000000.0</us-gaap:ProceedsFromCollaborators>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170425"
      decimals="-5"
      id="F_000626"
      unitRef="U_iso4217USD">3586000000.0</ctmx:ContingentMilestonePaymentsReceivable>
    <ctmx:NumberOfResearchTargetsSelected
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20170425"
      decimals="INF"
      id="F_000625"
      unitRef="U_ctmxTarget">8</ctmx:NumberOfResearchTargetsSelected>
    <ctmx:AggregateCollaborationTransactionAmount
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707"
      decimals="-5"
      id="F_000627"
      unitRef="U_iso4217USD">272800000</ctmx:AggregateCollaborationTransactionAmount>
    <ctmx:UpfrontFeeReceived
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707"
      decimals="-5"
      id="F_000628"
      unitRef="U_iso4217USD">250000000.0</ctmx:UpfrontFeeReceived>
    <ctmx:ResearchAndDevelopmentServiceFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707"
      decimals="-5"
      id="F_000629"
      unitRef="U_iso4217USD">10800000</ctmx:ResearchAndDevelopmentServiceFees>
    <ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707"
      decimals="-5"
      id="F_000630"
      unitRef="U_iso4217USD">12000000.0</ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod>
    <ctmx:EstimatedResearchServiceTerminationDate
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140706_20140707"
      id="F_000631">2025-04-25</ctmx:EstimatedResearchServiceTerminationDate>
    <ctmx:ContingentMilestonePaymentsNoLongerEligibleToReceive
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxThirdAndFourthTargetsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190331"
      decimals="-5"
      id="F_000634"
      unitRef="U_iso4217USD">894000000.0</ctmx:ContingentMilestonePaymentsNoLongerEligibleToReceive>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxThirdAndFourthTargetsMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20190331"
      decimals="-5"
      id="F_000632"
      unitRef="U_iso4217USD">18100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtProductOrServiceAxis_ctmxAcceleratedRecognitionOfDeferredRevenueMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20190331"
      decimals="-5"
      id="F_000633"
      unitRef="U_iso4217USD">17400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200229"
      decimals="-5"
      id="F_000635"
      unitRef="U_iso4217USD">10000000.0</ctmx:ContingentMilestonePaymentsReceivable>
    <ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20200331"
      decimals="-5"
      id="F_000636"
      unitRef="U_iso4217USD">10000000.0</ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod>
    <ctmx:ContingentMilestonePaymentsReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20210228"
      decimals="-5"
      id="F_000637"
      unitRef="U_iso4217USD">1779000000.0</ctmx:ContingentMilestonePaymentsReceivable>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20201231"
      decimals="-5"
      id="F_000638"
      unitRef="U_iso4217USD">39600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20190101_20191231"
      decimals="-5"
      id="F_000639"
      unitRef="U_iso4217USD">47700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231"
      decimals="-5"
      id="F_000640"
      unitRef="U_iso4217USD">32800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231"
      decimals="-5"
      id="F_000644"
      unitRef="U_iso4217USD">128300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231"
      decimals="-5"
      id="F_000645"
      unitRef="U_iso4217USD">158000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20201231"
      decimals="0"
      id="F_000646"
      unitRef="U_iso4217USD">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231"
      decimals="0"
      id="F_000647"
      unitRef="U_iso4217USD">13000</us-gaap:ContractWithCustomerAssetNet>
    <ctmx:CashPaymentToExecuteAgreement
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140101_20140131"
      decimals="INF"
      id="F_000648"
      unitRef="U_iso4217USD">0</ctmx:CashPaymentToExecuteAgreement>
    <ctmx:NumberOfResearchTargetsSelected
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140131"
      decimals="INF"
      id="F_000649"
      unitRef="U_ctmxTarget">2</ctmx:NumberOfResearchTargetsSelected>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140131"
      decimals="-5"
      id="F_000650"
      unitRef="U_iso4217USD">13200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231"
      decimals="-5"
      id="F_000651"
      unitRef="U_iso4217USD">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ctmx:MilestonePaymentPayable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200229"
      decimals="-5"
      id="F_000652"
      unitRef="U_iso4217USD">3000000.0</ctmx:MilestonePaymentPayable>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20200101_20200331"
      decimals="-5"
      id="F_000653"
      unitRef="U_iso4217USD">3000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <ctmx:NumberOfNominatedResearchTargets
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130501_20130531"
      decimals="INF"
      id="F_000654"
      unitRef="U_ctmxTarget">2</ctmx:NumberOfNominatedResearchTargets>
    <ctmx:NumberOfAdditionalResearchTargetsWithNominationOption
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130501_20130531"
      decimals="INF"
      id="F_000655"
      unitRef="U_ctmxTarget">2</ctmx:NumberOfAdditionalResearchTargetsWithNominationOption>
    <ctmx:ContractWithCustomerLiabilityAdditions
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141201_20141231"
      decimals="-5"
      id="F_000656"
      unitRef="U_iso4217USD">1500000</ctmx:ContractWithCustomerLiabilityAdditions>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20180101_20181231"
      decimals="-5"
      id="F_000657"
      unitRef="U_iso4217USD">1400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000343">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents changes in the Company&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt;s total contract liabilities for the year ended December 31, 2020 (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12/31/2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deductions&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;12/31/2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contract liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;230,239&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89,109&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;261,130&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000659"
      unitRef="U_iso4217USD">230239000</us-gaap:ContractWithCustomerLiability>
    <ctmx:ContractWithCustomerLiabilityAdditions
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000660"
      unitRef="U_iso4217USD">120000000</ctmx:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000661"
      unitRef="U_iso4217USD">89109000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000662"
      unitRef="U_iso4217USD">261130000</us-gaap:ContractWithCustomerLiability>
    <ctmx:ContractWithCustomerLiabilityAdditions
      contextRef="C_0001501989_20200101_20201231"
      decimals="-5"
      id="F_000663"
      unitRef="U_iso4217USD">120000000.0</ctmx:ContractWithCustomerLiabilityAdditions>
    <ctmx:ContractWithCustomerLiabilityAdditions
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20200101_20201231"
      decimals="-5"
      id="F_000664"
      unitRef="U_iso4217USD">40000000.0</ctmx:ContractWithCustomerLiabilityAdditions>
    <ctmx:ContractWithCustomerLiabilityAdditions
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_20200101_20201231"
      decimals="-5"
      id="F_000665"
      unitRef="U_iso4217USD">80000000.0</ctmx:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="C_0001501989_20200101_20201231"
      decimals="-5"
      id="F_000666"
      unitRef="U_iso4217USD">89100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <ctmx:ContractWithCustomerLiabilityAdditions
      contextRef="C_0001501989_20200101_20201231"
      decimals="-5"
      id="F_000667"
      unitRef="U_iso4217USD">120000000.0</ctmx:ContractWithCustomerLiabilityAdditions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_20201231"
      decimals="-5"
      id="F_000668"
      unitRef="U_iso4217USD">261100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20201231"
      decimals="-5"
      id="F_000669"
      unitRef="U_iso4217USD">25200000</us-gaap:ContractWithCustomerLiability>
    <ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200101_20201231"
      id="F_000676">2022-09</ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxFirstTargetUnderDiscoveryAgreementMember_20201231"
      decimals="-5"
      id="F_000670"
      unitRef="U_iso4217USD">1000000.0</us-gaap:ContractWithCustomerLiability>
    <ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxFirstTargetUnderDiscoveryAgreementMember_20200101_20201231"
      id="F_000677">2022-04</ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSecondTargetUnderDiscoveryAgreementMember_20201231"
      decimals="-5"
      id="F_000671"
      unitRef="U_iso4217USD">7000000.0</us-gaap:ContractWithCustomerLiability>
    <ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxSecondTargetUnderDiscoveryAgreementMember_20200101_20201231"
      id="F_000678">2024-06</ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_20201231"
      decimals="-5"
      id="F_000672"
      unitRef="U_iso4217USD">29800000</us-gaap:ContractWithCustomerLiability>
    <ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxEGFRProductsMember_20200101_20201231"
      id="F_000679">2024-09</ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_20201231"
      decimals="-5"
      id="F_000673"
      unitRef="U_iso4217USD">2200000</us-gaap:ContractWithCustomerLiability>
    <ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_srtProductOrServiceAxis_ctmxAmgenOtherProductsMember_20200101_20201231"
      id="F_000680">2023-09</ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_20201231"
      decimals="-5"
      id="F_000674"
      unitRef="U_iso4217USD">67600000</us-gaap:ContractWithCustomerLiability>
    <ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_20200101_20201231"
      id="F_000681">2025-03</ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20201231"
      decimals="-5"
      id="F_000675"
      unitRef="U_iso4217USD">128300000</us-gaap:ContractWithCustomerLiability>
    <ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_20200101_20201231"
      id="F_000682">2025-04</ctmx:ContractWithCustomerLiabilityMaturityMonthAndYear>
    <ctmx:LicenseAgreementDisclosureTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000308">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;10. License Agreement &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;UCSB&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has an exclusive, worldwide license agreement with UCSB (the &lt;span style="color:#000000;"&gt;&#x201c;&lt;/span&gt;UCSB Agreement&lt;span style="color:#000000;"&gt;&#x201d;&lt;/span&gt;), relating to the use of certain patents and technology relating to its core technology, including its therapeutic antibodies, and to certain patent rights the Company co-owns with UCSB covering Probody antibodies and other pro-proteins. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Pursuant to the UCSB Agreement, the Company is obligated to (i) make royalty payments to UCSB on net sales of its products covered under the agreement, subject to annual minimum amounts, (ii) make milestone payments to UCSB upon the occurrence of certain events, (iii) make a milestone payment to UCSB upon occurrence of an IPO or change of control, and (iv) reimburse UCSB for prosecution and maintenance of the licensed patents. If the Company sublicenses its rights under the UCSB Agreement, it is obligated to pay UCSB a percentage of the total sublicense revenue received, which total amount would be first reduced by the aggregate amount of certain research and development related expenses incurred by the Company and other permitted deductions. As part of the UCSB Agreement, the Company has annual minimum royalty obligations of $0.2 million under the terms of certain exclusive licensed patent rights.&#160;&#160;The royalty obligations are cancellable any time by giving notice to the licensor, with the termination being effective 60 days after giving notice.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2013, the Company amended the UCSB Agreement to reduce certain amounts due to UCSB upon receipt by the Company of upfront payments, milestone payments and royalties from sublicensees. In exchange for this amendment, the Company issued to UCSB 157,332 shares of common stock. The UCSB Agreement, as amended, will remain in effect until the expiration or abandonment of the last to expire of the licensed patents.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2019, the Company entered into Amendment No.3 to the UCSB Agreement to adjust and clarify certain sublicense terms (&#x201c;Amendment No.3&#x201d;).&#160;&#160;In connection with the amendment, the Company issued to UCSB 150,000 shares of CytomX common stock with a fair value of $10.68 per share. Under the terms of Amendment No.3, the Company and UCSB agreed to modify the determination of sublicense revenues payable by the Company to UCSB on certain existing collaboration agreements and on collaboration agreements executed subsequent to Amendment No.3.&#160;&#160;In exchange, the Company agreed to make an upfront payment of $1.0 million as well as additional annual license maintenance fees of $0.8 million through 2031.&#160;&#160;In the event that the Company terminates the agreement due to material concern of the safety or efficacy of the related technology, 50% of all remaining maintenance fees will become due immediately.&#160;&#160;Otherwise, all remaining maintenance fees will become due immediately upon early termination of the agreement unless there is a material breach by UCSB.&#160;&#160;Pursuant to Amendment No.3, the Company recorded in research and development expense a charge of $3.4 million relating to sublicense and maintenance fees representing the 150,000 shares issued with a fair value of $1.6 million, the upfront payment of $1.0 million and the additional annual maintenance fee of $0.8 million during the second quarter of 2019.&#160;&#160;&lt;/p&gt;

&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2019, the Company incurred an additional $0.8 million of sublicense fees related to the $10.0 million milestone payment for the second target selected by AbbVie under the Discovery Agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2020, the Company recorded $0.8 million of sublicense fees triggered by the $10.0 million milestone payment from Bristol Myers Squibb&#x2019;s dosing of the first patient in the Part 2 cohort expansion portion of its ongoing BMS-986249 clinical study for the CTLA-4 program.&#160;&#160;In March 2020, the Company incurred additional sublicense fees of $6.0 million and $1.4 million related to the $80.0 million upfront fee received pursuant to the Astellas Agreement entered into in March 2020, and the $40.0 million milestone payment from AbbVie for satisfying the CD71 dose escalation success criteria under the CD71 Agreement, respectively.  &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During the years ended December 31, 2020, 2019 and 2018, the Company incurred sublicense expenses of $9.1 million, $4.3 million and $0.6 million, respectively, under the provisions of the UCSB Agreement.&#160;&#160;As of December 31, 2020 and 2019, there was $0 and $0.2 million sublicense fee payable to UCSB, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;ImmunoGen &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the Company entered into a License Agreement (the &#x201c;ImmunoGen 2019 License&#x201d;) with ImmunoGen, Inc. to obtain an exclusive license with respect to &lt;span style="color:#000000;"&gt;epithelial cell adhesion molecule (&#x201c;EPCAM&#x201d;).&lt;/span&gt;  Under the ImmunoGen 2019 License, ImmunoGen agreed to transfer its know-how, patents, intellectual property rights, and technology transfer materials and information related to its EpCAM program. The license gives the Company the sole ability to develop, manufacture, use and commercialize any licensed product that incorporates, is comprised of, or otherwise derived from a Probody that targets EpCAM in any human therapeutic field on a worldwide basis. In exchange, the Company agreed to make non-refundable and non-creditable payments including an upfront license payment of $7.5 million and certain clinical development, approval and commercialization milestone payments, if achieved and royalties on product sales.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The upfront license fee of $7.5 million was recorded as research and development expense in December 2019 and included in accrued liabilities as of December 31, 2019.&#160;&#160; The upfront license fee was paid in January 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</ctmx:LicenseAgreementDisclosureTextBlock>
    <ctmx:RoyaltyObligationsFutureMinimumPaymentsDue
      contextRef="C_0001501989_20201231"
      decimals="-5"
      id="F_000683"
      unitRef="U_iso4217USD">200000</ctmx:RoyaltyObligationsFutureMinimumPaymentsDue>
    <ctmx:LicenseTerminationPeriod contextRef="C_0001501989_20200101_20201231" id="F_000684">P60D</ctmx:LicenseTerminationPeriod>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20131231"
      decimals="INF"
      id="F_000685"
      unitRef="U_xbrlishares">157332</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190430"
      decimals="INF"
      id="F_000686"
      unitRef="U_xbrlishares">150000</us-gaap:CommonStockSharesIssued>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190430"
      decimals="INF"
      id="F_000687"
      unitRef="U_iso4217USD_xbrlishares">10.68</us-gaap:SharesIssuedPricePerShare>
    <ctmx:PaymentOfUpfrontFees
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430"
      decimals="-5"
      id="F_000688"
      unitRef="U_iso4217USD">1000000.0</ctmx:PaymentOfUpfrontFees>
    <ctmx:AnnualLicenseMaintenanceFees
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430"
      decimals="-5"
      id="F_000689"
      unitRef="U_iso4217USD">800000</ctmx:AnnualLicenseMaintenanceFees>
    <ctmx:LicensePaymentTerm
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430"
      id="F_000690">2031</ctmx:LicensePaymentTerm>
    <ctmx:PercentageOfRemainingMaintenanceFeesOutstanding
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190430"
      decimals="2"
      id="F_000691"
      unitRef="U_xbrlipure">0.50</ctmx:PercentageOfRemainingMaintenanceFeesOutstanding>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_ctmxSublicenseAndMaintenanceFeesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430"
      decimals="-5"
      id="F_000692"
      unitRef="U_iso4217USD">3400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190430"
      decimals="INF"
      id="F_000693"
      unitRef="U_xbrlishares">150000</us-gaap:CommonStockSharesIssued>
    <ctmx:FairValueOfCommonStockIssued
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190430"
      decimals="-5"
      id="F_000694"
      unitRef="U_iso4217USD">1600000</ctmx:FairValueOfCommonStockIssued>
    <ctmx:PaymentOfUpfrontFees
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190630"
      decimals="-5"
      id="F_000695"
      unitRef="U_iso4217USD">1000000.0</ctmx:PaymentOfUpfrontFees>
    <ctmx:AnnualLicenseMaintenanceFees
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190401_20190630"
      decimals="-5"
      id="F_000696"
      unitRef="U_iso4217USD">800000</ctmx:AnnualLicenseMaintenanceFees>
    <ctmx:AdditionalSublicenseFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630"
      decimals="-5"
      id="F_000697"
      unitRef="U_iso4217USD">800000</ctmx:AdditionalSublicenseFees>
    <ctmx:MilestonePaymentReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieMember_srtProductOrServiceAxis_ctmxSecondTargetMember_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20190601_20190630"
      decimals="-5"
      id="F_000698"
      unitRef="U_iso4217USD">10000000.0</ctmx:MilestonePaymentReceivable>
    <ctmx:SublicenseFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200201_20200229"
      decimals="-5"
      id="F_000699"
      unitRef="U_iso4217USD">800000</ctmx:SublicenseFees>
    <ctmx:MilestonePaymentReceivable
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200201_20200229"
      decimals="-5"
      id="F_000700"
      unitRef="U_iso4217USD">10000000.0</ctmx:MilestonePaymentReceivable>
    <ctmx:AdditionalSublicenseFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200301_20200331"
      decimals="-5"
      id="F_000701"
      unitRef="U_iso4217USD">6000000.0</ctmx:AdditionalSublicenseFees>
    <ctmx:AdditionalSublicenseFees
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331"
      decimals="-5"
      id="F_000702"
      unitRef="U_iso4217USD">1400000</ctmx:AdditionalSublicenseFees>
    <us-gaap:ProceedsFromCollaborators
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200301_20200331"
      decimals="-5"
      id="F_000703"
      unitRef="U_iso4217USD">80000000.0</us-gaap:ProceedsFromCollaborators>
    <ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapTypeOfArrangementAxis_ctmxCD71AgreementMember_20200301_20200331"
      decimals="-5"
      id="F_000704"
      unitRef="U_iso4217USD">40000000.0</ctmx:MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod>
    <ctmx:SublicenseFees
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20200101_20201231"
      decimals="-5"
      id="F_000705"
      unitRef="U_iso4217USD">9100000</ctmx:SublicenseFees>
    <ctmx:SublicenseFees
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20190101_20191231"
      decimals="-5"
      id="F_000706"
      unitRef="U_iso4217USD">4300000</ctmx:SublicenseFees>
    <ctmx:SublicenseFees
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20180101_20181231"
      decimals="-5"
      id="F_000707"
      unitRef="U_iso4217USD">600000</ctmx:SublicenseFees>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20201231"
      decimals="-6"
      id="F_000708"
      unitRef="U_iso4217USD">0</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001501989_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ctmxUniversityOfCaliforniaSantaBarbaraMember_20191231"
      decimals="-5"
      id="F_000709"
      unitRef="U_iso4217USD">200000</us-gaap:AccruedLiabilitiesCurrent>
    <ctmx:UpfrontLicensePayment
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231"
      decimals="-5"
      id="F_000710"
      unitRef="U_iso4217USD">7500000</ctmx:UpfrontLicensePayment>
    <ctmx:UpfrontLicensePayment
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20191231"
      decimals="-5"
      id="F_000711"
      unitRef="U_iso4217USD">7500000</ctmx:UpfrontLicensePayment>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000309">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;11. Commitments and Contingencies&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Legal Proceedings &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 4, 2020, Vytacera Bio, LLC filed a patent infringement lawsuit against the Company in the U.S. District Court for the District of Delaware.&#160; The lawsuit alleges that the Company&#x2019;s use, offers to sell, and/or sales of the Probody&#xae; technology platform for basic research applications constitutes infringement.&#160; The complaint seeks unspecified monetary damages.&#160; The Company filed an Answer, Affirmative Defenses, and Counterclaims on May 26, 2020.&#160; Vytacera Bio, LLC filed its Answer to CytomX Therapeutics Inc.&#x2019;s Counterclaims on June 5, 2020.&#160; The parties have agreed to a case schedule, which is pending Court approval.&#160; Discovery is in the initial phases. The Company believes that the lawsuit is without merit and intends to vigorously defend itself and has not recorded any amount for claims associated with this lawsuit as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 21, 2020, a putative securities class action lawsuit was commenced in the U.S. District Court for the Northern District of California naming as defendants the Company and three current and former officers. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to the product candidates praluzatamab ravtansine (CX-2009) and pacmilimab (CX-072). The plaintiff sought to represent all persons who purchased or otherwise acquired CytomX securities between May 17, 2018, and May 13, 2020. On January 14, 2021, the class action was dismissed without prejudice.&lt;span style="color:#000000;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Indemnifications&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#x2019; and officers&#x2019; insurance.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyLawsuitFilingDate
      contextRef="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304_20200304"
      id="F_000712">March 4, 2020</us-gaap:LossContingencyLawsuitFilingDate>
    <us-gaap:LossContingencyNameOfPlaintiff
      contextRef="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200101_20201231"
      id="F_000713">Vytacera Bio, LLC</us-gaap:LossContingencyNameOfPlaintiff>
    <ctmx:LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate
      contextRef="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304_20200304"
      id="F_000714">2020-05-26</ctmx:LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate>
    <ctmx:LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate
      contextRef="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304_20200304"
      id="F_000715">2020-06-05</ctmx:LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304"
      decimals="INF"
      id="F_000716"
      unitRef="U_iso4217USD">0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <ctmx:NumberOfCurrentAndFormerOfficersNamedAsDefendants
      contextRef="C_0001501989_srtLitigationCaseAxis_ctmxSecuritiesClassActionLawsuitMember_20200521_20200521"
      decimals="INF"
      id="F_000717"
      unitRef="U_ctmxDefendant">3</ctmx:NumberOfCurrentAndFormerOfficersNamedAsDefendants>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000310">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;12. Leases &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Operating Lease&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 10, 2015, the Company entered into a lease (the &#x201c;2016 Lease&#x201d;) with HCP Oyster Point III LLC (the &#x201c;Landlord&#x201d;) to lease approximately 76,000 rentable square feet of office and laboratory space located in South San Francisco, California for the Company&#x2019;s new corporate headquarters.&#160;&#160;&lt;/p&gt;&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The term of the Lease commenced on October 1, 2016. The 2016 Lease has an initial term of ten years from the commencement date, and the Company has an option to extend the initial term for an additional five years at the then fair rental value as determined pursuant to the 2016 Lease. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Lease provided for annual base rent of approximately $3.1 million in the first year of the lease term. The annual base rent for the second twelve months was approximately $4.3 million, which will increase on an annual basis beginning from the 25&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;th&lt;/sup&gt; month to approximately $5.5 million for the tenth year of the lease. The Company utilized the full amount of the one-time improvement allowance of $12.6 million, of which $2.3 million is recoverable by the landlord through increased rent which continues through the expiration of the initial lease term.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In addition, the Company obtained a standby letter of credit (the &#x201c;Letter of Credit&#x201d;) in an amount of approximately $0.9 million, which may be drawn by the Landlord to be applied for certain purposes upon the Company&#x2019;s breach of any provisions under the 2016 Lease. The Company has recorded the $0.9 million Letter of Credit as non-current restricted cash on its balance sheet as of December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense is recognized on a straight-line basis over the term of the lease and accordingly the Company records the difference between cash rent payments and the recognition of rent expense against the operating lease ROU asset.&#160;&#160;Rent expense during the years ended December 31, 2020, 2019 and 2018 was $5.1 million, $4.8 million and $4.2 million, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental information related to leases are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:95%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,855&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental balance sheet information related to leases:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,495&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,870&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000744"&gt;5.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000745"&gt;6.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:95%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturity of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,420&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025 and beyond&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,510&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,640&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,870&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfLand
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151210"
      decimals="INF"
      id="F_000718"
      unitRef="U_utrsqft">76000</us-gaap:AreaOfLand>
    <us-gaap:LesseeOperatingLeaseDescription
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20200101_20201231"
      id="F_000719">The term of the Lease commenced on October 1, 2016. The 2016 Lease has an initial term of ten years from the commencement date, and the Company has an option to extend the initial term for an additional five years at the then fair rental value as determined pursuant to the 2016 Lease. </us-gaap:LesseeOperatingLeaseDescription>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151210"
      id="F_000720">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151210"
      id="F_000721">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ctmx:OperatingLeasesRentExpenseAnnualBaseRent
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_us-gaapLeaseContractualTermAxis_ctmxFirstYearOfLeaseTermMember_20151209_20151210"
      decimals="-5"
      id="F_000722"
      unitRef="U_iso4217USD">3100000</ctmx:OperatingLeasesRentExpenseAnnualBaseRent>
    <ctmx:OperatingLeasesRentExpenseAnnualBaseRent
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_us-gaapLeaseContractualTermAxis_ctmxSecondTwelveMonthsOfLeaseTermMember_20151209_20151210"
      decimals="-5"
      id="F_000723"
      unitRef="U_iso4217USD">4300000</ctmx:OperatingLeasesRentExpenseAnnualBaseRent>
    <ctmx:OperatingLeasesRentExpenseAnnualBaseRent
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_us-gaapLeaseContractualTermAxis_ctmxTenthYearOfLeaseTermMember_20151209_20151210"
      decimals="-5"
      id="F_000724"
      unitRef="U_iso4217USD">5500000</ctmx:OperatingLeasesRentExpenseAnnualBaseRent>
    <ctmx:MaximumImprovementAllowance
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151209_20151210"
      decimals="INF"
      id="F_000725"
      unitRef="U_iso4217USD">12600000</ctmx:MaximumImprovementAllowance>
    <ctmx:ImprovementAllowanceFromRecoverableRent
      contextRef="C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapLeaseAgreementsMember_20151209_20151210"
      decimals="-5"
      id="F_000726"
      unitRef="U_iso4217USD">2300000</ctmx:ImprovementAllowanceFromRecoverableRent>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_0001501989_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20201231"
      decimals="-5"
      id="F_000727"
      unitRef="U_iso4217USD">900000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001501989_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20201231"
      decimals="-5"
      id="F_000728"
      unitRef="U_iso4217USD">900000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_0001501989_us-gaapCreditFacilityAxis_us-gaapLetterOfCreditMember_20191231"
      decimals="-5"
      id="F_000729"
      unitRef="U_iso4217USD">900000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001501989_20200101_20201231"
      decimals="-5"
      id="F_000730"
      unitRef="U_iso4217USD">5100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001501989_20190101_20191231"
      decimals="-5"
      id="F_000731"
      unitRef="U_iso4217USD">4800000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="C_0001501989_20180101_20181231"
      decimals="-5"
      id="F_000732"
      unitRef="U_iso4217USD">4200000</us-gaap:OperatingLeaseExpense>
    <ctmx:SupplementalInformationRelatedToLeasesTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000344">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental information related to leases are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:95%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating cash flows from operating leases&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,855&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Supplemental balance sheet information related to leases:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,495&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;25,382&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,195&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,810&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-current operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,675&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,871&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,870&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27,681&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000744"&gt;5.75&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000745"&gt;6.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average discount rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</ctmx:SupplementalInformationRelatedToLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000733"
      unitRef="U_iso4217USD">4990000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000734"
      unitRef="U_iso4217USD">4855000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000735"
      unitRef="U_iso4217USD">22495000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000736"
      unitRef="U_iso4217USD">25382000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000737"
      unitRef="U_iso4217USD">3195000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000738"
      unitRef="U_iso4217USD">2810000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000739"
      unitRef="U_iso4217USD">21675000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000740"
      unitRef="U_iso4217USD">24871000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000742"
      unitRef="U_iso4217USD">24870000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000743"
      unitRef="U_iso4217USD">27681000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001501989_20201231"
      decimals="4"
      id="F_000746"
      unitRef="U_xbrlipure">0.0825</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_0001501989_20191231"
      decimals="4"
      id="F_000747"
      unitRef="U_xbrlipure">0.0825</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000345">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:95%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturity of operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,129&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,273&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2023&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,420&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,572&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2025 and beyond&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,116&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,510&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,640&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,870&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000748"
      unitRef="U_iso4217USD">5129000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000749"
      unitRef="U_iso4217USD">5273000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000750"
      unitRef="U_iso4217USD">5420000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000751"
      unitRef="U_iso4217USD">5572000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ctmx:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000752"
      unitRef="U_iso4217USD">10116000</ctmx:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000753"
      unitRef="U_iso4217USD">31510000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000754"
      unitRef="U_iso4217USD">6640000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000755"
      unitRef="U_iso4217USD">24870000</us-gaap:OperatingLeaseLiability>
    <ctmx:CommonStockTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000311">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;13. Common Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2015, the Company&#x2019;s board of directors and stockholders approved the amendment and restatement of the Company&#x2019;s certificate of incorporation. The Amended and Restated Certificate of Incorporation was effective as of October 14, 2015, which provided for 75,000,000 authorized shares of common stock with par value of $0.00001 per share and 10,000,000 shares of preferred stock with a par value of $0.00001 per share.&#160;&#160;In June 2020, the board of directors and stockholders of the Company approved an increase in the authorized shares of common stock from 75,000,000 to 150,000,000.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stockholders are entitled to dividends if and when declared by the board of directors subject to the prior rights of the preferred stockholders. As of December 31, 2020 and 2019, no dividends on common stock had been declared by the Board of Directors.&lt;/p&gt;
&lt;p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2018, the Company completed an underwritten public offering of 5,867,347 shares of common stock at a price of $24.50 per share, which included 765,306 shares issued pursuant to the underwriters&lt;span style="color:#000000;"&gt;&#x2019;&lt;/span&gt; exercise of their option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were approximately $134.6 million after deducting underwriting discounts and commissions and offering expenses of $9.2 million.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2020, the Company entered into an Open Market Sale Agreement (the &#x201c;Sales Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;), to sell shares of the Company&#x2019;s common stock, par value $0.00001 per share, with aggregate gross sales proceeds of up to $75,000,000, from time to time upon the Company&#x2019;s request, through an at the market offering under which Jefferies will act as sales agent.&#160;&#160;Pursuant to the Sales Agreement, Jefferies as the sales agent will receive a commission of 3.0% of the gross sales price for shares of common stock sold under the Sales Agreement.&#160;&#160;During December 2020, the Company sold 1,535,217 shares at an average price of $7.62 per shares and received net proceeds of approximately $11.3 million after deducting the 3.0% sales commission and related issuance cost.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had reserved shares of common stock for issuance, as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,929,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,936,168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future stock option grants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,903,398&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,145,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future employee stock purchase plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,935,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,609,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,768,611&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,690,571&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</ctmx:CommonStockTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001501989_20151014"
      decimals="INF"
      id="F_000756"
      unitRef="U_xbrlishares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001501989_20151014"
      decimals="INF"
      id="F_000757"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001501989_20151014"
      decimals="INF"
      id="F_000758"
      unitRef="U_xbrlishares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001501989_20151014"
      decimals="INF"
      id="F_000759"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001501989_20200630"
      decimals="INF"
      id="F_000760"
      unitRef="U_xbrlishares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:DividendsCommonStock
      contextRef="C_0001501989_20200101_20201231"
      decimals="INF"
      id="F_000761"
      unitRef="U_iso4217USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:DividendsCommonStock
      contextRef="C_0001501989_20190101_20191231"
      decimals="INF"
      id="F_000762"
      unitRef="U_iso4217USD">0</us-gaap:DividendsCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20180730_20180731"
      decimals="INF"
      id="F_000763"
      unitRef="U_xbrlishares">5867347</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20180731"
      decimals="2"
      id="F_000764"
      unitRef="U_iso4217USD_xbrlishares">24.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20180730_20180731"
      decimals="INF"
      id="F_000765"
      unitRef="U_xbrlishares">765306</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180730_20180731"
      decimals="-5"
      id="F_000766"
      unitRef="U_iso4217USD">134600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180730_20180731"
      decimals="-5"
      id="F_000767"
      unitRef="U_iso4217USD">9200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20200229"
      decimals="INF"
      id="F_000768"
      unitRef="U_iso4217USD_xbrlishares">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_srtRangeAxis_srtMaximumMember_20200201_20200229"
      decimals="INF"
      id="F_000769"
      unitRef="U_iso4217USD">75000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ctmx:PercentageOfSalesCommission
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20200229"
      decimals="3"
      id="F_000770"
      unitRef="U_xbrlipure">0.030</ctmx:PercentageOfSalesCommission>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20201201_20201231"
      decimals="INF"
      id="F_000771"
      unitRef="U_xbrlishares">1535217</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ctmx:SharesIssuedAveragePricePerShare
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20201201_20201231"
      decimals="2"
      id="F_000772"
      unitRef="U_iso4217USD_xbrlishares">7.62</ctmx:SharesIssuedAveragePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20201201_20201231"
      decimals="-5"
      id="F_000773"
      unitRef="U_iso4217USD">11300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ctmx:PercentageOfSalesCommissionAndIssuanceCost
      contextRef="C_0001501989_srtCounterpartyNameAxis_ctmxJefferiesMember_20201231"
      decimals="3"
      id="F_000774"
      unitRef="U_xbrlipure">0.030</ctmx:PercentageOfSalesCommissionAndIssuanceCost>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000346">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had reserved shares of common stock for issuance, as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,929,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,936,168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future stock option grants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,903,398&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,145,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future employee stock purchase plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,935,683&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,609,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,768,611&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,690,571&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <ctmx:StockOptionsIssuedAndOutstanding
      contextRef="C_0001501989_20201231"
      decimals="INF"
      id="F_000775"
      unitRef="U_xbrlishares">10929530</ctmx:StockOptionsIssuedAndOutstanding>
    <ctmx:StockOptionsIssuedAndOutstanding
      contextRef="C_0001501989_20191231"
      decimals="INF"
      id="F_000776"
      unitRef="U_xbrlishares">9936168</ctmx:StockOptionsIssuedAndOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001501989_20201231"
      decimals="INF"
      id="F_000777"
      unitRef="U_xbrlishares">2903398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001501989_20191231"
      decimals="INF"
      id="F_000778"
      unitRef="U_xbrlishares">3145266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan
      contextRef="C_0001501989_20201231"
      decimals="INF"
      id="F_000779"
      unitRef="U_xbrlishares">1935683</ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan>
    <ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan
      contextRef="C_0001501989_20191231"
      decimals="INF"
      id="F_000780"
      unitRef="U_xbrlishares">1609137</ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001501989_20201231"
      decimals="INF"
      id="F_000781"
      unitRef="U_xbrlishares">15768611</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001501989_20191231"
      decimals="INF"
      id="F_000782"
      unitRef="U_xbrlishares">14690571</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000312">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;14. Stock-based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;The 2010 Plan and 2011 Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2010, the Company adopted its 2010 Stock Incentive Plan (the &#x201c;2010 Plan&#x201d;) which provided for the granting of stock options to employees, directors and consultants of the Company. Options granted under the 2010 Plan were either incentive stock options (&#x201c;ISOs&#x201d;) or nonqualified stock options (&#x201c;NSOs&#x201d;).&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2012, the Company adopted its 2011 Stock Incentive Plan (the &#x201c;2011 Plan&#x201d;). The 2011 Plan is divided into two separate equity programs, an option and stock appreciation rights grant program and a stock award program. In conjunction with adopting the 2011 Plan, the Company discontinued the 2010 Plan and released the shares reserved and still available under that plan.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the consummation of the IPO in October 2015, the board of directors adopted the Company&#x2019;s 2015 Equity Incentive Plan (the &#x201c;2015 Plan&#x201d; and collectively with the 2010 Plan and 2011 Plan, the &#x201c;Plans&#x201d;). In conjunction with adopting the 2015 Plan, the Company discontinued the 2011 Plan with respect to new equity awards.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;The 2015 Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options under the 2015 Plan may be granted for periods of up to ten years. All options issued to date have had a 10-year life.&#160;&#160;Under the terms of the 2015 Plan, options may be granted at an exercise price not less than the estimated fair value of the Company&#x2019;s common stock on the date of grant, as determined by the Company&#x2019;s board of directors. For employees holding more than 10% of the voting rights of all classes of stock, the exercise price of ISOs and NSOs may not be less than 110% of the estimated fair value of the shares on the date of grant, as determined by the board of directors. To date, options granted under the 2015 Plan generally vest over four years and vest at a rate of 25% upon the first anniversary of the issuance date and &lt;span style="-sec-ix-hidden:F_000789_2"&gt;1/48&lt;/span&gt;th per month thereafter.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The initial number of shares of common stock available for future issuance under the 2015 Plan was 2,444,735. Beginning on January 1, 2016 and continuing until the expiration of the 2015 Plan, the total number of shares of common stock available for issuance under the 2015 Plan will automatically increase annually on January 1 by 4% of the total number of issued and outstanding shares of common stock as of January 1 of the same year.  As of December 31, 2020 and 2019, 2,698,798 shares and 1,808,066 shares of common stock were available for future issuance under the 2015 Plan.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;The 2019 Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2019, the Board of Directors adopted the 2019 Employment Inducement Incentive Plan (the &#x201c;2019 Plan&#x201d;) which provides for the grant of stock options and other equity awards to any employee who has not previously been an employee or director of the Company or who is commencing employment with the Company following a bona fide period of nonemployment by the Company. Awards granted under the 2019 Plan are intended to constitute &#x201c;employment inducement awards&#x201d; under Nasdaq Listing Rule 5635(c)(4). Options granted under the 2019 Plan are nonqualified stock options (&#x201c;NSOs&#x201d;) which may be exercisable for periods of up to ten years and the options shall be granted at an exercise price of not less than 100% of the fair market value of the Company&#x2019;s common stock on the date of grant.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The initial number of shares of common stock available for future issuance under the 2019 Plan was 1,815,000.&#160;&#160;As of December 31, 2020 and 2019, 204,600 shares and 1,337,200 shares, respectively, of common stock were available for future issuance under the 2019 Plan.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Activity under the Company&#x2019;s stock option plans is set forth below:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Grant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price Per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in&#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,145,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,936,168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options authorized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,820,923&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,219,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,219,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,064,830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.58&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,156,253&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,160,852&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,903,398&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,929,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000818"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Exercisable&#x2014;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,145,652&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.69&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000819"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,031&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and expected to vest&#x2014;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,929,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000820"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the underlying common stock as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic value of stock options exercised in the years ended December 31, 2020, 2019 and 2018 was $4.4 million, $0.9 million and $14.6 million, respectively. &lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The options granted in the years ended December 31, 2020, 2019 and 2018 had weighted-average per share grant-date fair values of $3.94, $7.03 and $14.21, respectively. As of December 31, 2020, the unrecognized compensation expense with respect to options granted was $23.2 million&#160;and is expected to be recognized over 2.8 years.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Early Exercise of Employee Options&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain stock options granted under the Plans provide option holders the right to elect to exercise unvested options in exchange for restricted common stock. Such unvested restricted shares are subject to a repurchase right held by the Company at the original issuance price in the event the optionee&#x2019;s service to the Company is terminated either voluntarily or involuntarily. The right usually lapses 25% on the first anniversary of the vesting start date and in 36 equal monthly amounts thereafter. These repurchase terms are considered to be a forfeiture provision. The cash or full recourse notes received from employees for exercise of unvested options is treated as a refundable deposit and is classified as a liability on the balance sheets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Concurrent with the completion of the IPO in October 2015, the Company&#x2019;s Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) became effective. The ESPP allows eligible employees to purchase shares of the Company&#x2019;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP generally provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#x2019;s common stock on the first trading day of the offering period or on the last trading day of the offering period. The Company issued 128,684 shares and 142,949 shares of common stock under the ESPP in 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares available for future purchase under the ESPP were 1,935,683 shares and 1,609,137 shares at December 31, 2020 and 2019, respectively. The compensation expense related to the ESPP was $0.4 million, $0.6 million and $0.5 million for the years ended December 31, 2020, 2019 and 2018, respectively. As of December 31, 2020, there was $0.2 million &lt;span style="font-size:12pt;"&gt;&#160;&lt;/span&gt;of unrecognized compensation cost related to the ESPP, which the Company expects to recognize over 5 months.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock Based Compensation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation recorded related to options granted to employees and non-employees and employee stock purchase plan was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.24%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,825&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,874&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,565&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,878&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense for employees was $14.7 million, $18.9 million and $16.7 million for the years ended December 31, 2020, 2019 and 2018, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense for non-employees was $0.1 million, $0.2 million and $0.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimated the fair value of employee stock options and ESPP using the Black-Scholes valuation model based on the date of grant with the following assumptions:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000860"&gt;64.4% - 73.3%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000861"&gt;64.4% - 68.6%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000862"&gt;65.6% - 69.3%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000863"&gt;47.3% - 122.1%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000864"&gt;60.8% - 71.9%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000865"&gt;46.4% - 70.5%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000866"&gt;0.2% - 1.3%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000867"&gt;1.4% - 2.5%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000868"&gt;2.5% - 3.0%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000869"&gt;0.1% - 0.2%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000870"&gt;1.6% - 2.4%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000871"&gt;2.1% - 2.6%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000887"&gt;&#x2014; %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000888"&gt;&#x2014; %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000889"&gt;&#x2014; %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014; %&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014; %&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014; %&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000890"&gt;4.7 - 4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000891"&gt;4.9 - 5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000892"&gt;4.7 - 4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000872"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000873"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000874"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected term. &lt;span style="font-style:normal;"&gt;The expected term of stock options represents the period that the stock options are expected to remain outstanding and is based on vesting terms, exercise term and contractual lives of the options. The expected term of the ESPP shares is equal to the six-month look-back period. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility. &lt;span style="font-style:normal;"&gt;The expected stock price volatility for the Company&#x2019;s stock options is based on the historical stock price volatility which is commensurate with the estimated expected term of the stock awards. Volatility for ESPP shares is equal to the Company&#x2019;s historical volatility over a six-month offering period. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate.&lt;span style="font-style:normal;"&gt; The risk-free interest rate is based on the U.S. Treasury yield with a maturity equal to the expected term of the stock options in effect at the time of grant.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield. &lt;span style="font-style:normal;"&gt;The expected dividend is assumed to be zero as the Company has never paid dividends&lt;/span&gt;&lt;span style="letter-spacing:0.2pt;font-style:normal;"&gt; &lt;/span&gt;&lt;span style="font-style:normal;"&gt;and has no current plan to pay any dividends on its common&lt;/span&gt;&lt;span style="letter-spacing:0.15pt;font-style:normal;"&gt; &lt;/span&gt;&lt;span style="font-style:normal;"&gt;stock.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231"
      id="F_000783">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="C_0001501989_20200101_20201231" id="F_000784">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage
      contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000785"
      unitRef="U_xbrlipure">0.10</ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000786"
      unitRef="U_xbrlipure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231"
      id="F_000787">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231"
      decimals="INF"
      id="F_000788"
      unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20151231"
      decimals="INF"
      id="F_000790"
      unitRef="U_xbrlishares">2444735</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20160101_20160101"
      decimals="INF"
      id="F_000791"
      unitRef="U_xbrlipure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000792"
      unitRef="U_xbrlishares">2698798</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandFifteenStockIncentivePlanMember_20191231"
      decimals="INF"
      id="F_000793"
      unitRef="U_xbrlishares">1808066</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001501989_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20200101_20201231"
      id="F_000794">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001501989_srtRangeAxis_srtMinimumMember_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20200101_20201231"
      decimals="INF"
      id="F_000795"
      unitRef="U_xbrlipure">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20190930"
      decimals="INF"
      id="F_000796"
      unitRef="U_xbrlishares">1815000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20201231"
      decimals="INF"
      id="F_000797"
      unitRef="U_xbrlishares">204600</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxTwoThousandNineteenStockIncentivePlanMember_20191231"
      decimals="INF"
      id="F_000798"
      unitRef="U_xbrlishares">1337200</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000347">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Activity under the Company&#x2019;s stock option plans is set forth below:&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;for Grant&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price Per&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Life (years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in&#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,145,266&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,936,168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12.26&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options authorized&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,820,923&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,219,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,219,044&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,064,830&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.58&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,156,253&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,160,852&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13.75&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balances at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,903,398&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,929,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000818"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Exercisable&#x2014;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,145,652&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.69&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000819"&gt;4.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,031&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and expected to vest&#x2014;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,929,530&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000820"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,844&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20191231"
      decimals="INF"
      id="F_000799"
      unitRef="U_xbrlishares">3145266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001501989_20191231"
      decimals="INF"
      id="F_000804"
      unitRef="U_xbrlishares">9936168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001501989_20191231"
      decimals="2"
      id="F_000811"
      unitRef="U_iso4217USD_xbrlishares">12.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000800"
      unitRef="U_xbrlishares">1820923</ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized>
    <ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000801"
      unitRef="U_xbrlishares">4219044</ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001501989_20200101_20201231"
      decimals="INF"
      id="F_000805"
      unitRef="U_xbrlishares">4219044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001501989_20200101_20201231"
      decimals="2"
      id="F_000812"
      unitRef="U_iso4217USD_xbrlishares">7.23</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001501989_20200101_20201231"
      decimals="INF"
      id="F_000806"
      unitRef="U_xbrlishares">1064830</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001501989_20200101_20201231"
      decimals="2"
      id="F_000813"
      unitRef="U_iso4217USD_xbrlishares">4.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="INF"
      id="F_000802"
      unitRef="U_xbrlishares">2156253</ctmx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001501989_20200101_20201231"
      decimals="INF"
      id="F_000807"
      unitRef="U_xbrlishares">2160852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001501989_20200101_20201231"
      decimals="2"
      id="F_000814"
      unitRef="U_iso4217USD_xbrlishares">13.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20201231"
      decimals="INF"
      id="F_000803"
      unitRef="U_xbrlishares">2903398</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001501989_20201231"
      decimals="INF"
      id="F_000808"
      unitRef="U_xbrlishares">10929530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001501989_20201231"
      decimals="2"
      id="F_000815"
      unitRef="U_iso4217USD_xbrlishares">10.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000821"
      unitRef="U_iso4217USD">6844000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001501989_20201231"
      decimals="INF"
      id="F_000809"
      unitRef="U_xbrlishares">6145652</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001501989_20201231"
      decimals="2"
      id="F_000816"
      unitRef="U_iso4217USD_xbrlishares">11.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000822"
      unitRef="U_iso4217USD">6031000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_0001501989_20201231"
      decimals="INF"
      id="F_000810"
      unitRef="U_xbrlishares">10929530</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0001501989_20201231"
      decimals="2"
      id="F_000817"
      unitRef="U_iso4217USD_xbrlishares">10.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000823"
      unitRef="U_iso4217USD">6844000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001501989_20200101_20201231"
      decimals="-5"
      id="F_000824"
      unitRef="U_iso4217USD">4400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001501989_20190101_20191231"
      decimals="-5"
      id="F_000825"
      unitRef="U_iso4217USD">900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001501989_20180101_20181231"
      decimals="-5"
      id="F_000826"
      unitRef="U_iso4217USD">14600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001501989_20200101_20201231"
      decimals="2"
      id="F_000827"
      unitRef="U_iso4217USD_xbrlishares">3.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001501989_20190101_20191231"
      decimals="2"
      id="F_000828"
      unitRef="U_iso4217USD_xbrlishares">7.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001501989_20180101_20181231"
      decimals="2"
      id="F_000829"
      unitRef="U_iso4217USD_xbrlishares">14.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001501989_20201231"
      decimals="-5"
      id="F_000830"
      unitRef="U_iso4217USD">23200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      id="F_000831">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="C_0001501989_us-gaapPlanNameAxis_ctmxEarlyExerciseOfEmployeeOptionsMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20200101_20201231"
      decimals="INF"
      id="F_000832"
      unitRef="U_xbrlipure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20201231"
      decimals="INF"
      id="F_000834"
      unitRef="U_xbrlipure">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="2"
      id="F_000835"
      unitRef="U_xbrlipure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001501989_20200101_20201231"
      decimals="INF"
      id="F_000836"
      unitRef="U_xbrlishares">128684</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_0001501989_20190101_20191231"
      decimals="INF"
      id="F_000837"
      unitRef="U_xbrlishares">142949</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20201231"
      decimals="INF"
      id="F_000838"
      unitRef="U_xbrlishares">1935683</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20191231"
      decimals="INF"
      id="F_000839"
      unitRef="U_xbrlishares">1609137</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231"
      decimals="-5"
      id="F_000840"
      unitRef="U_iso4217USD">400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20190101_20191231"
      decimals="-5"
      id="F_000841"
      unitRef="U_iso4217USD">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20180101_20181231"
      decimals="-5"
      id="F_000842"
      unitRef="U_iso4217USD">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20201231"
      decimals="-5"
      id="F_000843"
      unitRef="U_iso4217USD">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxEmployeeStockPurchasePlanMember_20200101_20201231"
      id="F_000844">P5M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000348">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation recorded related to options granted to employees and non-employees and employee stock purchase plan was as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.5%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.24%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,825&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,226&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,313&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,961&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,874&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,565&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,786&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19,100&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,878&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000845"
      unitRef="U_iso4217USD">6825000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000846"
      unitRef="U_iso4217USD">9226000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231"
      decimals="-3"
      id="F_000847"
      unitRef="U_iso4217USD">8313000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231"
      decimals="-3"
      id="F_000848"
      unitRef="U_iso4217USD">7961000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231"
      decimals="-3"
      id="F_000849"
      unitRef="U_iso4217USD">9874000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231"
      decimals="-3"
      id="F_000850"
      unitRef="U_iso4217USD">8565000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000851"
      unitRef="U_iso4217USD">14786000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000852"
      unitRef="U_iso4217USD">19100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000853"
      unitRef="U_iso4217USD">16878000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20200101_20201231"
      decimals="-5"
      id="F_000854"
      unitRef="U_iso4217USD">14700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20190101_20191231"
      decimals="-5"
      id="F_000855"
      unitRef="U_iso4217USD">18900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20180101_20181231"
      decimals="-5"
      id="F_000856"
      unitRef="U_iso4217USD">16700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxNonEmployeesMember_20200101_20201231"
      decimals="-5"
      id="F_000857"
      unitRef="U_iso4217USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxNonEmployeesMember_20190101_20191231"
      decimals="-5"
      id="F_000858"
      unitRef="U_iso4217USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001501989_us-gaapAwardTypeAxis_ctmxNonEmployeesMember_20180101_20181231"
      decimals="-5"
      id="F_000859"
      unitRef="U_iso4217USD">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000349">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company estimated the fair value of employee stock options and ESPP using the Black-Scholes valuation model based on the date of grant with the following assumptions:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.36%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;ESPP&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000860"&gt;64.4% - 73.3%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000861"&gt;64.4% - 68.6%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000862"&gt;65.6% - 69.3%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000863"&gt;47.3% - 122.1%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000864"&gt;60.8% - 71.9%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000865"&gt;46.4% - 70.5%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000866"&gt;0.2% - 1.3%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000867"&gt;1.4% - 2.5%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000868"&gt;2.5% - 3.0%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000869"&gt;0.1% - 0.2%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000870"&gt;1.6% - 2.4%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000871"&gt;2.1% - 2.6%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000887"&gt;&#x2014; %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000888"&gt;&#x2014; %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000889"&gt;&#x2014; %&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014; %&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014; %&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014; %&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&#160; (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000890"&gt;4.7 - 4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000891"&gt;4.9 - 5.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000892"&gt;4.7 - 4.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000872"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000873"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000874"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000313">
&lt;p id="N17_INCOME_TAXES" style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;15. Income Taxes &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company derives its income only from the United States. The components of the provision for (benefit from) income taxes are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,912&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(390&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,911&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(390&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision for (benefit from) income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,911&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(427&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the Company&#x2019;s effective tax rate to the statutory U.S. federal rate is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. federal taxes at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryback&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Return to provision adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The types of temporary differences that give rise to significant portions of the Company&#x2019;s deferred income tax assets and liabilities are set out below (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,967&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,468&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,940&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,223&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,923&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,320&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,832&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,881&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,296&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,955&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,578&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,746&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross deferred income tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111,990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,603&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(106,448&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(109,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(86,466&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,542&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(433&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,724&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,330&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(108&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(175&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,542&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred income tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#x201c;CARES Act&#x201d;) was enacted in response to the COVID-19 pandemic.&#160;&#160;&lt;span style="color:#000000;"&gt;The tax relief measures under the CARES Act for businesses include a &lt;span style="-sec-ix-hidden:F_000893"&gt;five-year&lt;/span&gt; net operating loss carryback, suspension of annual deduction limitation of 80% of taxable income from net operating losses generated in a tax year beginning after December 31, 2017, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property.&lt;/span&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognized income tax benefit of $13.9 million for the year ended December 31, 2020, through the net operating loss carryback &lt;span style="Background-color:#FFFFFF;color:#000000;"&gt;under the CARES Act which generated a refund of income taxes paid for 2018.&lt;/span&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has established a valuation allowance against all of its net deferred tax assets. Management considered all available evidence, both positive and negative, including but not limited to our historical operating results, income or loss in recent periods, cumulative losses in recent years, forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts, and concluded the deferred tax assets are not more likely than not to be realized. The net change in &lt;span style="letter-spacing:-0.1pt;"&gt;the total valuation allowance for the years ended December 31, 2020, 2019 and 2018 was an increase(decrease) of $(2.7) million, $22.7 million and $35.7 million, respectively.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had net operating loss carryforwards for federal and state income tax purposes of approximately $168.6 million and $24.2 million, respectively, as of December 31, 2020, available to reduce future taxable income. Of the federal net operating loss carryforwards, $65.6 million will begin to expire in 2034, if not utilized and $103 million will carryforward indefinitely.&#160;&#160;The state net operating loss carryforwards will begin to expire in 2032, if not utilized.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company also has federal and state research and development tax credits carryforwards of $15.6 million and $9.0 million, respectively, as of December 31, 2020 available to reduce future income taxes. The federal research and development tax credits will begin to expire in 2031 if not utilized. The state research and development tax credits have no expiration date.&#160;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Internal Revenue Code section 382 (&#x201c;IRC Section 382&#x201d;) places a limitation (the &#x201c;Section 382 Limitation&#x201d;) on the amount of taxable income that can be offset by net operating loss (&#x201c;NOL&#x201d;) carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. California has similar rules. The Company has performed an IRC Section 382 analysis and determined there was an ownership change in 2017 that resulted in 382 limitations. When an ownership change occurs, IRC Section 382 limits the use of NOLs and credits in subsequent periods based on the annual 382 limitations.&#160;&#160;The annual 382 limitations may limit the full use of available tax attributes in one year but the identified &lt;span style="color:#000000;"&gt;ownership changes may not result in expiration of tax attributes for use prior to expiration of their respective carryforward periods. Accordingly, none of the tax attributes have been reduced but limited the full use in 2018.  The Company has determined that, while an ownership change has occurred, the applicable limits would not impair the value or anticipated use of the Company&#x2019;s federal and state net operating losses. Although realization is not assured, management believes it is more likely than not that any limitation under IRC Section 382 will not impair the realizability of the deferred income tax assets related to federal and state net operating loss carryforwards.&#160;&#160;&lt;/span&gt;The Company reviewed its stock ownership for the year ended December 31, 2020 and concluded no ownership changes occurred in current year which would result in a reduction of its net operating loss or in its research and development credits expiring unused. If additional ownership change occurs, the utilization of net operating loss and credit carryforwards could be significantly reduced.  &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company had approximately $6.5 million, $5.2 million and $3.8 million of unrecognized tax benefits as of December 31, 2020, 2019 and 2018, respectively, and approximately $0, $0.9 million and $1.0 million, respectively, would affect the Company&#x2019;s effective tax rate if recognized.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at the beginning of the year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,249&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,320&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions based on tax positions related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,166&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustment based on tax positions related to prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,730&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of the year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,454&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,249&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction of the provision for income taxes in the period that such determination is made. Interest and penalties have not been accrued for 2020, 2019 and 2018.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files income tax returns in the United States, including California state jurisdiction. The tax years 2010 to 2019 remains &lt;span style="letter-spacing:-0.1pt;"&gt;open to U.S. federal and state examination to the extent of the utilization of net operating loss and credit carryovers. As of December 31, 2020&lt;/span&gt;, the Company is under examination by the State of California.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000350">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company derives its income only from the United States. The components of the provision for (benefit from) income taxes are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,912&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(390&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,302&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,911&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(390&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(37&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision for (benefit from) income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,911&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(427&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14,303&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000904"
      unitRef="U_iso4217USD">-13912000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000905"
      unitRef="U_iso4217USD">-390000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000906"
      unitRef="U_iso4217USD">14302000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000907"
      unitRef="U_iso4217USD">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000908"
      unitRef="U_iso4217USD">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000909"
      unitRef="U_iso4217USD">-13911000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000910"
      unitRef="U_iso4217USD">-390000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000911"
      unitRef="U_iso4217USD">14303000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000912"
      unitRef="U_iso4217USD">-37000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000913"
      unitRef="U_iso4217USD">-37000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_000914"
      unitRef="U_iso4217USD">-13911000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_000915"
      unitRef="U_iso4217USD">-427000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_000916"
      unitRef="U_iso4217USD">14303000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000351">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the Company&#x2019;s effective tax rate to the statutory U.S. federal rate is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Years Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. federal taxes at statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State tax, net of federal benefit&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(31.2&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(22.8&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(49.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryback&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Return to provision adjustment&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.3&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.1&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.5&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;29.7&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001501989_20200101_20201231"
      decimals="INF"
      id="F_000917"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001501989_20190101_20191231"
      decimals="INF"
      id="F_000918"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_0001501989_20180101_20181231"
      decimals="INF"
      id="F_000919"
      unitRef="U_xbrlipure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001501989_20200101_20201231"
      decimals="3"
      id="F_000920"
      unitRef="U_xbrlipure">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001501989_20190101_20191231"
      decimals="3"
      id="F_000921"
      unitRef="U_xbrlipure">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_0001501989_20180101_20181231"
      decimals="3"
      id="F_000922"
      unitRef="U_xbrlipure">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001501989_20200101_20201231"
      decimals="3"
      id="F_000923"
      unitRef="U_xbrlipure">-0.022</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001501989_20190101_20191231"
      decimals="3"
      id="F_000924"
      unitRef="U_xbrlipure">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="C_0001501989_20180101_20181231"
      decimals="3"
      id="F_000925"
      unitRef="U_xbrlipure">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001501989_20200101_20201231"
      decimals="3"
      id="F_000926"
      unitRef="U_xbrlipure">0.110</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001501989_20190101_20191231"
      decimals="3"
      id="F_000927"
      unitRef="U_xbrlipure">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="C_0001501989_20180101_20181231"
      decimals="3"
      id="F_000928"
      unitRef="U_xbrlipure">0.062</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001501989_20200101_20201231"
      decimals="3"
      id="F_000929"
      unitRef="U_xbrlipure">-0.312</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001501989_20190101_20191231"
      decimals="3"
      id="F_000930"
      unitRef="U_xbrlipure">-0.228</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_0001501989_20180101_20181231"
      decimals="3"
      id="F_000931"
      unitRef="U_xbrlipure">-0.495</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <ctmx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback
      contextRef="C_0001501989_20200101_20201231"
      decimals="3"
      id="F_000932"
      unitRef="U_xbrlipure">0.279</ctmx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback>
    <ctmx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback
      contextRef="C_0001501989_20190101_20191231"
      decimals="3"
      id="F_000933"
      unitRef="U_xbrlipure">0.000</ctmx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback>
    <ctmx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback
      contextRef="C_0001501989_20180101_20181231"
      decimals="3"
      id="F_000934"
      unitRef="U_xbrlipure">0.000</ctmx:EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback>
    <ctmx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments
      contextRef="C_0001501989_20200101_20201231"
      decimals="3"
      id="F_000935"
      unitRef="U_xbrlipure">0.000</ctmx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments>
    <ctmx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments
      contextRef="C_0001501989_20190101_20191231"
      decimals="3"
      id="F_000936"
      unitRef="U_xbrlipure">0.003</ctmx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments>
    <ctmx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments
      contextRef="C_0001501989_20180101_20181231"
      decimals="3"
      id="F_000937"
      unitRef="U_xbrlipure">0.000</ctmx:EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001501989_20200101_20201231"
      decimals="3"
      id="F_000938"
      unitRef="U_xbrlipure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001501989_20190101_20191231"
      decimals="3"
      id="F_000939"
      unitRef="U_xbrlipure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="C_0001501989_20180101_20181231"
      decimals="3"
      id="F_000940"
      unitRef="U_xbrlipure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001501989_20200101_20201231"
      decimals="3"
      id="F_000941"
      unitRef="U_xbrlipure">0.297</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001501989_20190101_20191231"
      decimals="3"
      id="F_000942"
      unitRef="U_xbrlipure">0.004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_0001501989_20180101_20181231"
      decimals="3"
      id="F_000943"
      unitRef="U_xbrlipure">-0.204</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000352">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The types of temporary differences that give rise to significant portions of the Company&#x2019;s deferred income tax assets and liabilities are set out below (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37,099&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,967&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,468&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development credits&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,803&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,940&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,514&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,223&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,813&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,923&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,320&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;38,832&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;47,180&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;56,881&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accruals and deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,512&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,296&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,955&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,578&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,837&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,746&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total gross deferred income tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;111,990&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;115,353&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,603&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(106,448&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(109,174&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(86,466&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets, net of valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,542&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(433&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(591&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(854&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Right-of-use assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,724&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,330&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(108&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(385&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(243&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(175&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,542&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,179&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,137&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred income tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000944"
      unitRef="U_iso4217USD">37099000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000945"
      unitRef="U_iso4217USD">38967000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000946"
      unitRef="U_iso4217USD">15468000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000947"
      unitRef="U_iso4217USD">16803000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000948"
      unitRef="U_iso4217USD">10940000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000949"
      unitRef="U_iso4217USD">7514000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <ctmx:DeferredTaxAssetsLeaseLiability
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000950"
      unitRef="U_iso4217USD">5223000</ctmx:DeferredTaxAssetsLeaseLiability>
    <ctmx:DeferredTaxAssetsLeaseLiability
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000951"
      unitRef="U_iso4217USD">5813000</ctmx:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000952"
      unitRef="U_iso4217USD">3923000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000953"
      unitRef="U_iso4217USD">3320000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000954"
      unitRef="U_iso4217USD">38832000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000955"
      unitRef="U_iso4217USD">47180000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000956"
      unitRef="U_iso4217USD">56881000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000957"
      unitRef="U_iso4217USD">1512000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000958"
      unitRef="U_iso4217USD">1296000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000959"
      unitRef="U_iso4217USD">1955000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000960"
      unitRef="U_iso4217USD">8578000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000961"
      unitRef="U_iso4217USD">7837000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000962"
      unitRef="U_iso4217USD">5746000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000963"
      unitRef="U_iso4217USD">20000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000964"
      unitRef="U_iso4217USD">39000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000965"
      unitRef="U_iso4217USD">111990000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000966"
      unitRef="U_iso4217USD">115353000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000967"
      unitRef="U_iso4217USD">87603000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000968"
      unitRef="U_iso4217USD">106448000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000969"
      unitRef="U_iso4217USD">109174000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000970"
      unitRef="U_iso4217USD">86466000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000971"
      unitRef="U_iso4217USD">5542000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000972"
      unitRef="U_iso4217USD">6179000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000973"
      unitRef="U_iso4217USD">1137000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000974"
      unitRef="U_iso4217USD">433000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000975"
      unitRef="U_iso4217USD">591000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000976"
      unitRef="U_iso4217USD">854000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000977"
      unitRef="U_iso4217USD">4724000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000978"
      unitRef="U_iso4217USD">5330000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000979"
      unitRef="U_iso4217USD">108000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000980"
      unitRef="U_iso4217USD">385000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000981"
      unitRef="U_iso4217USD">243000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000982"
      unitRef="U_iso4217USD">175000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000983"
      unitRef="U_iso4217USD">15000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_000984"
      unitRef="U_iso4217USD">5542000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000985"
      unitRef="U_iso4217USD">6179000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000986"
      unitRef="U_iso4217USD">1137000</us-gaap:DeferredIncomeTaxLiabilities>
    <ctmx:PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation
      contextRef="C_0001501989_20200327_20200327"
      decimals="2"
      id="F_000894"
      unitRef="U_xbrlipure">0.80</ctmx:PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_0001501989_20200101_20201231"
      decimals="-5"
      id="F_000987"
      unitRef="U_iso4217USD">-13900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001501989_20200101_20201231"
      decimals="-5"
      id="F_000895"
      unitRef="U_iso4217USD">-2700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001501989_20190101_20191231"
      decimals="-5"
      id="F_000896"
      unitRef="U_iso4217USD">22700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_0001501989_20180101_20181231"
      decimals="-5"
      id="F_000897"
      unitRef="U_iso4217USD">35700000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000988"
      unitRef="U_iso4217USD">168600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231"
      decimals="-5"
      id="F_000989"
      unitRef="U_iso4217USD">24200000</us-gaap:OperatingLossCarryforwards>
    <ctmx:OperatingLossCarryforwardsAmountToExpireIfNotUsed
      contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-5"
      id="F_000992"
      unitRef="U_iso4217USD">65600000</ctmx:OperatingLossCarryforwardsAmountToExpireIfNotUsed>
    <ctmx:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231"
      id="F_000990">2034</ctmx:OperatingLossCarryforwardsExpirationYear>
    <ctmx:OperatingLossCarryforwardsAmountNotSubjectToExpiration
      contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231"
      decimals="-6"
      id="F_000993"
      unitRef="U_iso4217USD">103000000</ctmx:OperatingLossCarryforwardsAmountNotSubjectToExpiration>
    <ctmx:OperatingLossCarryforwardsExpirationYear
      contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231"
      id="F_000991">2032</ctmx:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231"
      decimals="-5"
      id="F_000994"
      unitRef="U_iso4217USD">15600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20201231"
      decimals="-5"
      id="F_000995"
      unitRef="U_iso4217USD">9000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <ctmx:TaxCreditCarryforwardExpirationYear
      contextRef="C_0001501989_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_us-gaapTaxCreditCarryforwardAxis_us-gaapResearchMember_20200101_20201231"
      id="F_000996">2031</ctmx:TaxCreditCarryforwardExpirationYear>
    <ctmx:PercentageOfChangeInOwnership
      contextRef="C_0001501989_srtRangeAxis_srtMinimumMember_20170101_20171231"
      decimals="INF"
      id="F_000997"
      unitRef="U_xbrlipure">0.50</ctmx:PercentageOfChangeInOwnership>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001501989_20201231"
      decimals="-5"
      id="F_000898"
      unitRef="U_iso4217USD">6500000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001501989_20191231"
      decimals="-5"
      id="F_000899"
      unitRef="U_iso4217USD">5200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001501989_20181231"
      decimals="-5"
      id="F_000900"
      unitRef="U_iso4217USD">3800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_0001501989_20201231"
      decimals="-6"
      id="F_000901"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_0001501989_20191231"
      decimals="-5"
      id="F_000902"
      unitRef="U_iso4217USD">900000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="C_0001501989_20181231"
      decimals="-5"
      id="F_000903"
      unitRef="U_iso4217USD">1000000.0</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000353">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at the beginning of the year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,249&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,320&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions based on tax positions related to current year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,205&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,403&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,166&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Adjustment based on tax positions related to prior years&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;90&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,730&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of the year&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,454&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,249&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,756&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_000998"
      unitRef="U_iso4217USD">5249000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_000999"
      unitRef="U_iso4217USD">3756000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001501989_20171231"
      decimals="-3"
      id="F_001000"
      unitRef="U_iso4217USD">4320000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001501989_20200101_20201231"
      decimals="-3"
      id="F_001001"
      unitRef="U_iso4217USD">1205000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_001002"
      unitRef="U_iso4217USD">1403000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_001003"
      unitRef="U_iso4217USD">1166000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <ctmx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="C_0001501989_20190101_20191231"
      decimals="-3"
      id="F_001004"
      unitRef="U_iso4217USD">90000</ctmx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <ctmx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="C_0001501989_20180101_20181231"
      decimals="-3"
      id="F_001005"
      unitRef="U_iso4217USD">-1730000</ctmx:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001501989_20201231"
      decimals="-3"
      id="F_001006"
      unitRef="U_iso4217USD">6454000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001501989_20191231"
      decimals="-3"
      id="F_001007"
      unitRef="U_iso4217USD">5249000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_0001501989_20181231"
      decimals="-3"
      id="F_001008"
      unitRef="U_iso4217USD">3756000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001501989_20201231"
      decimals="0"
      id="F_001009"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001501989_20191231"
      decimals="0"
      id="F_001010"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="C_0001501989_20181231"
      decimals="0"
      id="F_001011"
      unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000314">
&lt;p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;16. Defined Contribution Plan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company sponsors a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time U.S. employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. During the years ended December 31, 2020, 2019 and 2018, the Company made contributions to the plan of $0.8 million, $0.8 million and $0.6 million, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001501989_20200101_20201231"
      decimals="-5"
      id="F_001014"
      unitRef="U_iso4217USD">800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001501989_20190101_20191231"
      decimals="-5"
      id="F_001015"
      unitRef="U_iso4217USD">800000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_0001501989_20180101_20181231"
      decimals="-5"
      id="F_001016"
      unitRef="U_iso4217USD">600000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="C_0001501989_20200101_20201231" id="F_000315">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;17. Subsequent Events&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2021, the Company completed an underwritten public offering of 14,285,714 shares of common stock at a price of $7.00 per share.&#160;&#160;The aggregate net proceeds received by the Company from the offering were approximately $93.6 million, after deducting underwriting discounts and commissions and estimated offering expenses of $6.4 million.&#160;&#160;The Company also granted the underwriters the option, for 30 days, to purchase up to 2,142,857 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. In February 2021, the underwriters exercised the option in full which resulted in additional net proceeds of $14.1 million to the Company, after deducting the underwriting discounts and commissions of $0.9 million. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210101_20210131"
      decimals="INF"
      id="F_001017"
      unitRef="U_xbrlishares">14285714</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210131"
      decimals="2"
      id="F_001018"
      unitRef="U_iso4217USD_xbrlishares">7.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001501989_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210101_20210131"
      decimals="-5"
      id="F_001019"
      unitRef="U_iso4217USD">93600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210101_20210131"
      decimals="-5"
      id="F_001021"
      unitRef="U_iso4217USD">6400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <ctmx:OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20210101_20210131"
      id="F_001023">P30D</ctmx:OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001501989_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20210101_20210131"
      decimals="INF"
      id="F_001024"
      unitRef="U_xbrlishares">2142857</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001501989_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20210201_20210228"
      decimals="-5"
      id="F_001020"
      unitRef="U_iso4217USD">14100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0001501989_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_ctmxUnderwrittenPublicOfferingMember_20210201_20210228"
      decimals="-5"
      id="F_001022"
      unitRef="U_iso4217USD">900000</us-gaap:PaymentsOfStockIssuanceCosts>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624082696232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 02, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CTMX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CytomX Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001501989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3521219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">151 Oyster Point Boulevard,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">515-3185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.00001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 379.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,784,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Portions of the registrant&#8217;s definitive proxy statement to be filed for its 2021 Annual Meeting of Stockholders are incorporated by reference into Part III hereof. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on Form 10-K.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089119976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 191,859<span></span>
</td>
<td class="nump">$ 188,425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">124,260<span></span>
</td>
<td class="nump">107,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">798<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,096<span></span>
</td>
<td class="nump">7,177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">324,013<span></span>
</td>
<td class="nump">303,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">6,950<span></span>
</td>
<td class="nump">7,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,167<span></span>
</td>
<td class="nump">1,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">949<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">917<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">22,495<span></span>
</td>
<td class="nump">25,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,172<span></span>
</td>
<td class="nump">2,015<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">358,663<span></span>
</td>
<td class="nump">341,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">4,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">23,059<span></span>
</td>
<td class="nump">30,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues, current portion</a></td>
<td class="nump">74,869<span></span>
</td>
<td class="nump">51,381<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">100,924<span></span>
</td>
<td class="nump">85,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">186,261<span></span>
</td>
<td class="nump">178,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long term</a></td>
<td class="nump">21,675<span></span>
</td>
<td class="nump">24,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">308,860<span></span>
</td>
<td class="nump">290,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.00001 par value; 150,000,000 and 75,000,000 shares authorized at December 31, 2020 and 2019, respectively; 48,251,819 and 45,523,088 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">499,964<span></span>
</td>
<td class="nump">468,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(47)<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(450,115)<span></span>
</td>
<td class="num">(417,230)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">49,803<span></span>
</td>
<td class="nump">51,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">358,663<span></span>
</td>
<td class="nump">341,282<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued and outstanding at December 31, 2020 and 2019</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624161581176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">48,251,819<span></span>
</td>
<td class="nump">45,523,088<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">48,251,819<span></span>
</td>
<td class="nump">45,523,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Convertible Preferred stock, par value</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Convertible Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Convertible Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089755352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 100,362<span></span>
</td>
<td class="nump">$ 57,489<span></span>
</td>
<td class="nump">$ 59,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">112,936<span></span>
</td>
<td class="nump">$ 131,619<span></span>
</td>
<td class="nump">$ 103,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">36,031<span></span>
</td>
<td class="nump">36,765<span></span>
</td>
<td class="nump">33,510<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">148,967<span></span>
</td>
<td class="nump">168,384<span></span>
</td>
<td class="nump">137,376<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(48,605)<span></span>
</td>
<td class="num">(110,895)<span></span>
</td>
<td class="num">(77,874)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">1,836<span></span>
</td>
<td class="nump">8,365<span></span>
</td>
<td class="nump">7,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(46,796)<span></span>
</td>
<td class="num">(102,665)<span></span>
</td>
<td class="num">(70,301)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="num">(13,911)<span></span>
</td>
<td class="num">(427)<span></span>
</td>
<td class="nump">14,303<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,885)<span></span>
</td>
<td class="num">$ (102,238)<span></span>
</td>
<td class="num">$ (84,604)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.71)<span></span>
</td>
<td class="num">$ (2.26)<span></span>
</td>
<td class="num">$ (2.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used to compute net loss per share, basic and diluted</a></td>
<td class="nump">46,145,563<span></span>
</td>
<td class="nump">45,335,927<span></span>
</td>
<td class="nump">41,664,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain (loss) on short-term investments, net of tax</a></td>
<td class="num">$ (104)<span></span>
</td>
<td class="nump">$ 139<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect', window );">Impact of adoption of new accounting pronouncement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (32,989)<span></span>
</td>
<td class="num">$ (102,088)<span></span>
</td>
<td class="num">$ (84,603)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accumulated other comprehensive income (AOCI) for reclassification to retained earnings of tax effect from remeasurement of deferred tax pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL116659650-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624162219304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/(Loss)</div></th>
<th class="th">
<div>Accumulated Other Comprehensive Income/(Loss) </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2017</a></td>
<td class="nump">$ 69,896<span></span>
</td>
<td class="num">$ (10,912)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 289,454<span></span>
</td>
<td class="num">$ (94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (219,465)<span></span>
</td>
<td class="num">$ (10,912)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,478,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201409Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs</a></td>
<td class="nump">$ 134,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,867,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">4,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the Employee Stock Purchase Plan</a></td>
<td class="nump">872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the Employee Stock Purchase Plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(84,604)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(84,604)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">$ 130,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">445,956<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="num">(314,981)<span></span>
</td>
<td class="num">$ (11)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,083,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201802Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs</a></td>
<td class="nump">$ 1,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the Employee Stock Purchase Plan</a></td>
<td class="nump">$ 994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the Employee Stock Purchase Plan, shares</a></td>
<td class="nump">142,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 19,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(102,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,238)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">51,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">468,285<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(417,230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,523,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs</a></td>
<td class="nump">11,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,535,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 4,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, shares</a></td>
<td class="nump">1,064,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,064,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under the Employee Stock Purchase Plan</a></td>
<td class="nump">$ 729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under the Employee Stock Purchase Plan, shares</a></td>
<td class="nump">128,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 14,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(32,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,885)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="nump">$ 49,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 499,964<span></span>
</td>
<td class="num">$ (47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (450,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,251,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624088049608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (32,885)<span></span>
</td>
<td class="num">$ (102,238)<span></span>
</td>
<td class="num">$ (84,604)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash (used in) provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets', window );">Depreciation and amortization</a></td>
<td class="nump">2,427<span></span>
</td>
<td class="nump">2,459<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount on investments</a></td>
<td class="num">(236)<span></span>
</td>
<td class="num">(2,228)<span></span>
</td>
<td class="num">(1,701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">14,786<span></span>
</td>
<td class="nump">19,100<span></span>
</td>
<td class="nump">16,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">2,887<span></span>
</td>
<td class="nump">2,672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of common stock in connection with UCSB sublicense fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(785)<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">10,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">2,074<span></span>
</td>
<td class="num">(4,899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(157)<span></span>
</td>
<td class="num">(640)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(857)<span></span>
</td>
<td class="num">(374)<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent', window );">Accrued liabilities, income tax payable and other long-term liabilities</a></td>
<td class="num">(11,039)<span></span>
</td>
<td class="num">(15,396)<span></span>
</td>
<td class="nump">24,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">30,891<span></span>
</td>
<td class="num">(47,741)<span></span>
</td>
<td class="num">(38,195)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">5,259<span></span>
</td>
<td class="num">(140,480)<span></span>
</td>
<td class="num">(75,521)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,309)<span></span>
</td>
<td class="num">(3,497)<span></span>
</td>
<td class="num">(3,788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of short-term investments</a></td>
<td class="num">(199,108)<span></span>
</td>
<td class="num">(174,992)<span></span>
</td>
<td class="num">(204,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Maturities of short-term investments</a></td>
<td class="nump">182,699<span></span>
</td>
<td class="nump">258,190<span></span>
</td>
<td class="nump">214,315<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(18,718)<span></span>
</td>
<td class="nump">79,701<span></span>
</td>
<td class="nump">5,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">11,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,596<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from employee stock purchase plan and exercise of stock options</a></td>
<td class="nump">5,605<span></span>
</td>
<td class="nump">1,627<span></span>
</td>
<td class="nump">5,028<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">16,893<span></span>
</td>
<td class="nump">1,627<span></span>
</td>
<td class="nump">139,624<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">3,434<span></span>
</td>
<td class="num">(59,152)<span></span>
</td>
<td class="nump">70,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, beginning of year</a></td>
<td class="nump">189,342<span></span>
</td>
<td class="nump">248,494<span></span>
</td>
<td class="nump">178,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents and restricted cash, end of year</a></td>
<td class="nump">192,776<span></span>
</td>
<td class="nump">189,342<span></span>
</td>
<td class="nump">248,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of noncash investing items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable and accrued liabilities</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="nump">428<span></span>
</td>
<td class="nump">$ 1,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right of use assets obtained in exchange for operating lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation and amortization excluding amortization of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued liabilities, income tax payable and other liabilities noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624162096696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of the Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Disclosure Text Block [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of the Business</a></td>
<td class="text">
<p id="N1_DESCRIPTION__BUSINESS" style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Description of the Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CytomX Therapeutics, Inc. (the <span style="color:#000000;">&#8220;</span>Company<span style="color:#000000;">&#8221;</span>) is a clinical-stage, oncology-focused biopharmaceutical company with a vision of transforming lives with safer, more effective therapies. We are advancing potential first-in-class antibody-based therapeutics created using our Probody&#174; technology platform that could meaningfully improve patient outcomes in a disease where significant unmet need remains. Our proprietary and unique Probody technology platform is designed to enable &#8220;conditional activation&#8221; of antibody-based drugs within the tumor while minimizing drug activity in healthy tissues and circulation. The Company is located in South San Francisco, California and was incorporated in the state of Delaware in September 2010.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624090588424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2. Basis of Presentation and Summary of Significant Accounting Policies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (<span style="color:#000000;">&#8220;</span>U.S. GAAP&#8221;). </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products, and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all the Company&#8217;s cash is held by one financial institution. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents and short-term investments in highly rated money market funds and its short-term investments in U.S. Government Bonds.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customers and collaboration partners who represent 10% or more of the Company&#8217;s total revenue during each period presented or accounts receivable balance at each respective balance sheet date are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie Ireland Unlimited Company</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,192</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,878</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,997</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc.</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,931</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol-Myers Squibb Company</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,740</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,780</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue from customers who represent 10% or more</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of the Company's total revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,753</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,777</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s customers are located in the United States of America, Ireland and Japan.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has determined that it has one business activity and operates as one operating segment as it only reports financial information on an aggregate basis to its chief executive officer and chief financial officer, who are the Company&#8217;s chief operating decision makers. All long-lived assets are maintained in the United States of America.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash represents a standby letter of credit issued pursuant to an office lease entered in December 2015. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the amounts shown in the statement of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,859</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,425</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,776</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,342</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Short-term Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All investments have been classified as available-for-sale (&#8220;AFS&#8221;) and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Generally, those investments with contractual maturities less than 12 months are considered short-term investments. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses impairment of its AFS debt securities investments at each reporting period.&#160;&#160;Unrealized gains resulting from the excess of the fair value over the amortized cost basis of an investment are reported as a component of accumulated other comprehensive income (loss), net of tax.&#160;&#160;Unrealized losses or impairments resulting from the fair value of the AFS debt security being below the amortized cost basis are evaluated, using the discounted cash flow model, for identification of credit losses and non-credit related losses.&#160;&#160;Any credit losses are charged to earnings against the allowance for credit losses of the security, limited to the difference between the fair value and the amortized cost basis of the security.&#160;&#160;Any difference between the fair value of the security and the amortized cost basis, less the allowance for credit losses, are reported in other comprehensive income (loss).&#160;&#160;Expected cash inflows due to improvements in credit are recognized through a reversal of the allowance for credit losses subject to the total allowance previously recognized.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of impairment of any security, if management (i) has the intent to sell such security or (ii) will more-likely-than-not be required to sell such security before recovery of its amortized cost basis, such AFS debt security&#8217;s amortized cost basis will be written down to its fair value through earnings along with any existing allowance for credit losses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment, net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost net of accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the respective assets. The useful lives of property and equipment are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of remaining lease term or estimated life of the assets</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintenance and repairs that do not extend the life or improve the asset are expensed when incurred.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Goodwill and Intangible Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the purchase price paid over the fair value of tangible and identifiable intangible assets acquired in business combinations. Goodwill and other intangible assets with indefinite lives are not amortized, but are assigned to reporting units and tested for impairment annually, or whenever there is an impairment indicator. Intangible assets are comprised of in-process research and development. The Company assesses impairment indicators annually as of December 31 or more frequently, if a change in circumstances or the occurrence of events suggests the remaining value may not be recoverable. Intangible assets that are not deemed to have an indefinite life are amortized over their estimated useful lives. There was no impairment of goodwill or intangible assets identified during the years ended December 31, 2020, 2019 and 2018.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable and prior to any goodwill impairment test. An impairment loss is recognized when the total of estimated undiscounted future cash flows expected to result from the use of the asset (or asset group) and its eventual disposition is less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. There was no impairment of long-lived assets during the years ended December 31, 2020, 2019 and 2018.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 1, 2018, the Company adopted Accounting Standards Update No. 2014-09, <span style="font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span>, which supersedes the revenue recognition requirements in Accounting Standards Codification (ASC) Topic 605, <span style="font-style:italic;">Revenue Recognition (ASC 605)</span>, using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2018. The impact of the adoption of ASC 606 was an increase in the balance of deferred revenue and an increase in the accumulated deficit balance of $10.9 million on January 1, 2018 in the Company&#8217;s Balance Sheet.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s revenues are primarily derived through its license, research, development and commercialization agreements. The terms of these types of agreements may include (i) licenses for the Company<span style="color:#000000;">&#8217;</span>s technology or programs, (ii) research and development services, and (iii) services or obligations in connection with participation in research or steering committees. Payments to the Company under these arrangements typically include one or more of the following: nonrefundable upfront and license fees, research funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses whether the promises in its arrangements with customers are considered as distinct performance obligations that should be accounted for separately. Judgment is required to determine whether the license to the Company<span style="color:#000000;">&#8217;</span>s intellectual property is distinct from the research and development services or participation on steering committees.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s collaboration and license agreements may include contingent payments related to specified research, development and regulatory milestones. Such milestone payments are typically payable under the collaborations when the collaboration partner claims or selects a target, or initiates or advances a covered product candidate in preclinical or clinical development, upon submission for marketing approval of a covered product with regulatory authorities; or upon receipt of actual marketing approvals of a covered product or for additional indications. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.&#160;&#160;At each reporting date, the Company re-evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price by using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price in such period of determination.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s collaboration and license agreements may also include contingent payments related to sales-based milestones. Sales-based milestones are typically payable when annual sales of a covered product reach specified levels. Sales-based milestones are recognized at the later of when the associated performance obligation has been satisfied or when the sales occur. Unlike other contingency payments, such as regulatory milestones, sales-based milestones are not included in the transaction price based on estimates at the inception of the contract, but rather, are included when the sales or usage occur.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price in each arrangement is allocated to the identified performance obligations based on the relative standalone selling price (<span style="color:#000000;">&#8220;</span>SSP<span style="color:#000000;">&#8221;</span>) of each distinct performance obligation, which requires judgment. In instances where SSP is not directly observable, such as when a license or service is not sold separately, SSP is determined using information that may include market conditions and other observable inputs. Due to the early stage of the Company<span style="color:#000000;">&#8217;</span>s licensed technology, the license of such technology is typically combined with research and development services and steering committee participation as one performance obligation.&#160;&#160;In the event that the Company receives non-cash consideration such as consideration in the form of a research license and research support services from the counterparty, the transaction price of a non-monetary exchange that has commercial substance is estimated based on the fair value of the non-cash consideration received, which may be determined through a valuation analysis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain cases, the Company&#8217;s performance creates an asset that does not have an alternative use to the customer and the Company has an enforceable right to payment at all times for performance completed to date.&#160;&#160;In these cases, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie Ireland Unlimited Company (<span style="color:#000000;">&#8220;</span>AbbVie<span style="color:#000000;">&#8221;</span>), one of the Company<span style="color:#000000;">&#8217;</span>s collaboration partners, entered into a license agreement with Seattle Genetics, Inc. (<span style="color:#000000;">&#8220;</span>SGEN<span style="color:#000000;">&#8221;</span>) to license certain intellectual property rights. As part of the Company<span style="color:#000000;">&#8217;</span>s collaboration agreement with AbbVie, the Company is required to pay SGEN sublicense fees for certain milestone achievements and annual maintenance fee. These sublicense fees are treated as reductions to the transaction price and combined with the performance obligation to which they relate.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss represents all changes in stockholders&#8217; equity except those resulting from distributions to stockholders. The Company&#8217;s non-credit related unrealized gains and losses on short-term investments and impact of adoption of new accounting pronouncements during the period represent the components of other comprehensive income (loss) that is excluded from the reported net loss.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Balances </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company satisfies its performance obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company<span style="color:#000000;">&#8217;</span>s right to consideration is unconditional.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its stock-based awards made to employees based on the fair values of the awards as of the grant date using the Black-Scholes option-pricing model. Stock-based compensation expense is recognized over the requisite service period using the ratable method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest.&#160;&#160;Forfeitures are recognized as they occur.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 2019, the Company adopted ASU No. 2018-07, <span style="font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.</span> Under this new standard, stock options granted to non-employees as consideration for<span style="letter-spacing:0.4pt;"> </span>services received are measured on the date of grant using the Black-Scholes option-pricing model.&#160;&#160;The<span style="letter-spacing:0.4pt;"> related </span>grant date fair values of stock options are expensed on a straight-line basis over the period, generally the vesting period, during which<span style="letter-spacing:0.3pt;"> </span>the non-employee is required to provide service in exchange for the award.&#160;&#160;<span style="font-style:italic;">&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the adoption of ASU 2018-07, such stock-based compensation expense was measured on the date of performance at the fair value of the consideration received or the fair value<span style="letter-spacing:0.4pt;"> </span>of the equity instruments issued, using the Black-Scholes option-pricing model, whichever can be more<span style="letter-spacing:0.45pt;"> </span>reliably measured. Stock-based compensation expense for options granted to non-employees was periodically remeasured as the underlying options<span style="letter-spacing:0.1pt;"> </span>vest.</p>

<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using an asset and liability approach. Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company records a valuation allowance to reduce its deferred tax assets to reflect the net amount that it believes as more likely than not to be realized. Realization of the deferred tax assets is dependent on the generation of future taxable income, the amount and timing of which are uncertain. The valuation allowance requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Based upon the weight of available evidence at December 31, 2020, the Company continues to maintain a full valuation allowance against all of its deferred tax assets after management considered all available evidence, both positive and negative, including but not limited to its historical operating results, income or loss in recent periods, cumulative income in recent years, forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the tax effects of an uncertain tax position only if it is more likely than not that it will be sustained based solely on its technical merits as of the reporting date and only in an amount more likely than not that it will be sustained upon review by the tax authorities. The Company evaluates uncertain tax positions on a quarterly basis and adjust the liability for changes in facts and circumstances, such as new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, significant amendment to an existing tax law, or resolution of an examination. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the income tax provision in the period in which such determination is made. The resolution of its uncertain income tax positions is dependent on uncontrollable factors such as law changes, new case law, and the willingness of the income tax authorities to settle, including the timing thereof and other factors. Although the Company does not anticipate significant changes to its uncertain income tax positions in the next twelve months, items outside of its control could cause its uncertain income tax positions to change in the future, which would be recorded in its statements of operations. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company <span style="color:#000000;">records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced, and includes these costs in accrued liabilities in the balance sheets and within research and development expense in the statements of operations. These costs are a significant component of the Company&#8217;s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status and timing of actual services performed may vary from the Company&#8217;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. All costs associated with research and development are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, the Company acquired certain technology know-how that is complementary to the Company&#8217;s proprietary Probody technology from a third party for $5.0 million.&#160;&#160;The Company plans to use this technology in certain of the Company&#8217;s discovery stage projects, and has concluded that the technology acquired does not have an alternative future use.&#160;&#160;Accordingly, the $5.0 million has been recorded as research and development expense for 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted the Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-02, <span style="font-style:italic;">Leases (Topic 842)</span> on January 1, 2019, using the modified retrospective approach.  As a result of the adoption of ASC 842, the Company recorded a right-of-use asset of $28.0 million and a lease liability $30.1 million on January 1, 2019.&#160;&#160;There was no impact on the Company&#8217;s accumulated deficit as of the adoption date.&#160;&#160;The Company determines if an arrangement is or contains a lease at inception.&#160;&#160;Operating leases are recorded as operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the Company&#8217;s balance sheet.&#160;&#160;ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term.&#160;&#160;The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments.&#160;&#160;The operating lease ROU assets also include any lease prepayments made and reduced by lease incentives. The Company&#8217;s lease terms may include options to extend the lease when it is reasonably certain that such option will be exercised. Lease expenses are recognized on a straight-line basis over the lease term.&#160;&#160;The Company elected the short-term lease recognition exemption<span style="Background-color:#FFFFFF;color:#000000;">.</span> The Company&#8217;s operating lease arrangement includes lease and non-lease components which are generally accounted for separately.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624168172984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Adopted and Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock', window );">Adopted and Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3. Adopted and Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#263238;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Adopted Accounting Pronouncements </p>
<p id="S170363231" style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financial Instruments - Credit Losses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. <span style="color:#000000;">This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the previous other-than-temporary-impairment model. </span>The Company adopted this standard on January 1, 2020 using a modified retrospective approach.&#160;&#160;There was no impact on the Company&#8217;s accumulated deficit as of January 1, 2020 as there was no incremental impairment loss to be recognized upon the adoption of this ASU.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Simplification of the Test for Goodwill Impairment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, the FASB issued ASU No. 2017-04, <span style="font-style:italic;">Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span>. The new standard simplifies the measurement of goodwill by eliminating the Step 2 impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill with the carrying amount of that goodwill. The new guidance requires an entity to compare the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. The Company adopted this standard on January 1, 2020 and there was no material impact on its financial statement.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair Value Measurement Disclosure Requirements Modification</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No. 2018-13, <span style="font-style:italic;">Fair Value Measurement (Topic 820)</span>. The amendments in this ASU modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. Various disclosure requirements have been removed, including the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels, the valuation processes for Level 3 fair value measurements held at the end of the reporting period. The ASU also modified various disclosure requirements and added some disclosure requirements for Level 3 fair value measurements. The amendments in this ASU were effective for the Company on January 1, 2020 and there was no material impact on its financial statements upon adoption of this ASU. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Internal Use Software Guidance for Cloud Computing Arrangement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No. 2018-15, <span style="font-style:italic;">Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40)</span>. The amendments in this ASU on the accounting for implementation, setup and other upfront costs (collectively &#8220;implementation costs&#8221;) apply to entities that are a customer in a hosting arrangement. The amendments under this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. Accordingly, the amendments in this ASU require an entity in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to expense. They also require an entity to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. The Company adopted this standard on January 1, 2020 and there was no material impact on its financial statement upon adoption of this ASU.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Collaborative Arrangements and Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued&#160;ASU No. 2018-18, <span style="font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the interaction between Topic 808 and Topic 606</span>.&#160;&#160;The amendments in&#160;this ASU targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In addition, unit-of-account guidance in Topic 808 was aligned with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606.&#160;The ASU&#160;was effective for the Company on January 1, 2020, and there was no material impact on its financial statements upon adoption of this ASU.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Share-Based Payment to Customer</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2019, the FASB issued ASU 2019-08,</span><span style="font-style:italic;Background-color:#FFFFFF;"> Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Codification Improvements &#8211; Share-Based Consideration Payable to a Customer. </span><span style="color:#000000;">The amendments in this ASU require that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in Topic 718. Under ASC 606, these awards are considered a reduction of the transaction price, unless the awards are payment for a distinct good or service received from the customer and should be recorded as a reduction of the transaction price.&#160;&#160;However, the ASU requires these awards to be measured on the basis of the grant-date fair value of the share-based payment award in accordance with Topic 718 and should be recognized at the later of when the award is promised and when the entity recognizes revenue for the transfer of the related goods or services in accordance with ASC 606.&#160;&#160;The ASU&#160;is effective for the Company on January 1, 2020, and there was no material impact on its financial statements upon adoption of this ASU.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span>. The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles of ASC 740 in order to reduce cost and complexity of its application.&#160;&#160;The ASU removes the exception related to the incremental approach for intraperiod tax allocation as well as two exceptions related to accounting for outside basis differences of equity method investments and foreign subsidiaries.&#160;&#160;The ASU also amends the scope of ASC 740 related to a franchise tax (or similar tax) that is partially based on income; clarifies when a step-up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction; specifies that an entity is not required to allocate income tax expense to a legal entity that is both not subject to tax and disregarded by the taxing authority; and&#160;&#160;clarifies that all tax effects, both deferred and current, should be accounted for in the interim period that includes the enactment date.&#160;&#160;The ASU&#160;is effective for the Company on January 1, 2021, and interim periods within those fiscal years.&#160;&#160;The Company does not expect the adoption of this ASU will have a material impact on its financial statements.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adopted and recent accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624090272008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4. Net Loss Per Share </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss by the weighted-average number of shares of common stock outstanding for the period.&#160;&#160;Diluted net loss per share is calculated using the weighted-average number of common shares outstanding, plus potential dilutive common stock during the period.&#160;&#160;Diluted net loss per share is the same as basic net loss per share since the effect of the potentially dilutive securities is anti-dilutive.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following weighted-average outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented, because including them would have been anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and ESPP to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,388,691</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,687,844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,478,755</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089275608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Short-Term Investments</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5. Fair Value Measurements and Short-Term Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 820-10, Fair Value Measurements and Disclosures, the Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level I: Inputs which include quoted prices in active markets for identical assets and liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level II: Inputs other than Level I that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">Level III: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s financial instruments, including restricted cash, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their relatively short maturities. The Company&#8217;s financial instruments consist of Level I assets which consist primarily of highly liquid money market funds, some of which are included in restricted cash and U.S. government bonds that are included in short-term investments. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth the fair value of the Company&#8217;s short-term investments subject to fair value measurements on a recurring basis and the level of inputs used in such measurements:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Allowance for Credit Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,121</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,121</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (money market funds)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,254</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,260</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total Securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256,292</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256,298</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Allowance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Credit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,757</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,757</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (money market funds)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,610</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,720</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279,284</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279,394</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No securities have contractual maturities of greater than twelve months.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624082065096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6. Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,772</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,124</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,555</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,483</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,376</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,422</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,426</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,050</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,950</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,372</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense was $2.4 million, $2.5 million and $1.7 million for the years ended December 31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624162096696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">7. Goodwill and Intangible Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill and in-process research and development assets resulted from a series of integrated financing transactions in 2010 that was accounted for as a business combination. The in-process research and development was related to the Company&#8217;s proprietary Probody platform and was accounted for as an indefinite-lived intangible asset until the underlying project was completed or abandoned. In connection with the collaboration agreements, the Company began amortizing the intangible asset in 2017. The intangible asset is being amortized over the estimated lives of the patents which average 12 years. The amortization expense for the years ended December 31, 2020, 2019 and 2018 was $0.1 million, $0.1 million and $0.1 million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill and intangible assets consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">949</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">949</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(583</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(438</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,167</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,312</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624173736200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">8. Accrued Liabilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and clinical expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,092</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,006</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,362</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,721</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal and professional expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">815</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,062</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities - short term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,195</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,810</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,059</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,051</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624172283688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ResearchAndCollaborationAgreementsTextBlock', window );">Research and Collaboration Agreements</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9. Research and Collaboration Agreements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the revenue by collaboration partners:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,192</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,878</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,997</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amgen</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,609</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,871</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,899</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,931</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol Myers Squibb</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,740</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,780</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,471</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,355</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,362</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,489</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,502</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">AbbVie Ireland Unlimited Company</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2016, the Company and AbbVie entered into two agreements, a CD71 Co-Development and Licensing Agreement (the <span style="color:#000000;">&#8220;</span>CD71 Agreement<span style="color:#000000;">&#8221;</span>) and a Discovery Collaboration and Licensing Agreement (as amended and restated in June 2019, the <span style="color:#000000;">&#8220;</span>Discovery Agreement<span style="color:#000000;">&#8221;</span> and together with the CD71 Agreement the <span style="color:#000000;">&#8220;</span>AbbVie Agreements<span style="color:#000000;">&#8221;</span>). Under the terms of the CD71 Agreement, the Company and AbbVie will co-develop a conditionally activated antibody-drug conjugate (<span style="color:#000000;">&#8220;A</span>DC<span style="color:#000000;">&#8221;</span>) against CD71, with the Company responsible for preclinical and early clinical development. AbbVie will be responsible for later development and commercialization, with global late-stage development costs shared between the two companies. The Company will assume 35% of the net profits or net losses related to later development and commercialization unless it opts-out. If the Company opts-out from participation of co-development of the CD71 conditionally activated ADC, which includes CX-2029, AbbVie will have sole right and responsibility for the further development, manufacturing and commercialization of such CD71 conditionally activated ADC. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the CD71 Agreement, the Company received an upfront payment of $20.0 million in April 2016, and was eligible to initially receive up to $470.0 million in development, regulatory and commercial milestone payments, a 35% profit split on U.S. sales, and royalties on ex-U.S. sales at percentages in the high teens to low twenties if the Company participates in the co-development of the CD71 conditionally activated ADC subject to a reversion to a royalty on U.S. sales, and reduction in royalties on ex-U.S. sales, if the Company opts-out from the co-development of the CD71 conditionally activated ADC. The Company<span style="color:#000000;">&#8217;</span>s share of later stage co-development costs for each CD71 conditionally activated ADC is capped, provided that AbbVie may offset the Company<span style="color:#000000;">&#8217;</span>s co-development cost above the capped amounts from future payments such as milestone payments and royalties. In July 2017, the Company received a milestone payment of $14.0 million (net of payment of an associated sublicense fee of $1.0 million to SGEN under the Seattle Genetics Agreement) from AbbVie for achieving certain milestones required to be met to begin GLP toxicology studies under the CD71 Agreement. In May 2018, the United States Food and Drug Administration (<span style="color:#000000;">&#8220;</span>FDA<span style="color:#000000;">&#8221;</span>) cleared the IND application for CX-2029. As a result, the Company achieved the IND success criteria under the CD71 Agreement and received a $21.0 million milestone payment (net of the payment of an associated sublicense fee of $4.0 million to SGEN). In March 2020, the Company earned a $40.0 million milestone payment for satisfying the CD71 dose escalation success criteria under the CD71 Agreement</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Discovery Agreement, AbbVie receives exclusive worldwide rights to develop and commercialize conditionally activated ADCs against up to two targets, one of which was selected in March 2017. The Company shall perform research services to discover the Probody therapeutics and create conditionally activated ADCs for the nominated collaboration targets. From that point, AbbVie shall have sole right and responsibility for development and commercialization of products comprising or containing such conditionally activated ADCs (<span style="color:#000000;">&#8220;</span>Discovery Licensed Products<span style="color:#000000;">&#8221;</span>). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Discovery Agreement, the Company received an upfront payment of $10.0 million in April 2016 and subsequently earned an additional $10.0 million milestone payment triggered by selection of the second target by AbbVie in June 2019. The Company is also eligible to receive up to $265.0 million for each target, in development, regulatory and commercial milestone payments and royalties at percentages in the high single to low teens from commercial sales of any resulting conditionally activated ADCs. The second target was selected under the Discovery Agreement that allows AbbVie to select a target for developing a conditionally activated ADC or a Probody.&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that the AbbVie Agreements should be combined and evaluated as a single arrangement in determining revenue recognition, because both agreements were concurrently negotiated and executed.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified the following performance obligations at the inception of the AbbVie Agreements: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research, development and commercialization license for CD71 Probody therapeutic, </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research services related to CD71 Probody therapeutic, </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the obligation to participate in the CD71 Agreement joint research committee, </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research services related to the first discovery target </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research, development and commercialization license for the first discovery target, and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the obligation to participate in the Discovery Agreement joint research committee. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company concluded that AbbVie<span style="color:#000000;">&#8217;</span>s option for the second discovery target was not a material right and was therefore not a performance obligation at the inception of the AbbVie Agreements. However, it was subsequently included in the total transaction price in June 2019 as a performance obligation upon AbbVie&#8217;s selection of such second target as further discussed below.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the research, development and commercialization licenses for CD71 and discovery targets are not distinct from the Company<span style="color:#000000;">&#8217;</span>s respective research services and expertise. The Company considered factors such as novelty of the Probody therapeutic and conditionally activated ADC technology and lack of other parties<span style="color:#000000;">&#8217;</span> expertise in this space, the Company<span style="color:#000000;">&#8217;</span>s rights to technology relating to a proprietary platform to enable the Probody therapeutic development and AbbVie<span style="color:#000000;">&#8217;</span>s contractual obligation to use the Company<span style="color:#000000;">&#8217;</span>s research services. The Company determined that the CD71 Agreement research, development and commercialization license, related research service and participation in the joint research committee were a combined performance obligation and were distinct from the Discovery Agreement research, development and commercialization license, related research service and participation in the joint research committee. Therefore, the Company concluded that there are two distinct performance obligations:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the CD71 Agreement performance obligation consisting of the CD71 Agreement research, development and commercialization license, related research service and participation in the joint research committee, and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Discovery Agreement performance obligation consisting of the Discovery Agreement research, development and commercialization license, related research service and participation in the joint research committee.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total transaction price for the Discovery Agreement and CD71 Agreement, collectively, upon adoption of ASC 606 on January 1, 2018 of $39.8 million consists of $30.0 million in upfront payments, and a $14.0 million milestone payment received under the CD71 Agreement (net of the payment of an associated sublicense fee of $1.0 million to SGEN), less $4.2 million of estimated sublicense fees. The upfront payments under the AbbVie Agreements are allocated between the two performance obligations based on the estimated relative standalone selling prices. The $30.0 million of upfront payments is allocated $20.0 million to the CD71 Agreement, with the remaining $10.0 million allocated to the Discovery Agreement. The $14.0 million milestone payment received (net of the payment of an associated sublicense fee of $1.0 million to SGEN) and the estimated sublicense fees of $4.2 million are allocated to the CD71 Agreement performance obligation as they are directly related to the development of the CX-2029. </p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therefore, of the $39.8 million total initial transaction price discussed above, the Company allocated $29.8 million to the CD71 Agreement performance obligation and recognized revenue using a cost-based input measure, the common measure of progress for the performance obligation. In applying the cost-based input method, revenue is recognized based on actual full-time employee (&#8220;FTE&#8221;) hours incurred as a percentage of total estimated FTE hours for completing its combined performance obligation over the estimated service period.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&#160;&#160;During 2019, as a result of ongoing dose escalation in the continued development program, there was a change in estimate of the research service period as well as an increase in the projected FTE hours-to-completion.&#160;&#160;The research service period for the CD71 Agreement performance obligation was extended from April 2021 to March 2022 in 2019.&#160;&#160;During the second quarter of 2020, the Company further increased the projected FTE hours-to-completion and extended the research service period for the CD71 Agreement performance obligation from March 2022 to September 2022 in response to the reduced rate of operation as impacted by the COVID-19 pandemic.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The remaining $10.0 million of the total initial transaction price of $39.8 million allocated to the Discovery Agreement performance obligation represents an obligation to continuously make the Company<span style="color:#000000;">&#8217;</span>s Probody therapeutic technology platform available to AbbVie. The $10.0 million was initially recognized on a straight-line basis over five years, which represented the estimated research service period for the first target, through April 2021 using the time-elapsed input method as the common measure of progress over the entire performance obligation.  During the fourth quarter of 2020, the Company extended the estimated research service period for this first target for an additional twelve months from April 2021 to April 2022.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2018, the Company earned a $21.0 million milestone payment (net of the payment of an associated sublicense fee of $4.0 million to SGEN) under the CD71 Agreement. The $21.0 million milestone payment was included as part of the transaction price in May 2018 and a revenue adjustment of $9.9 million was recognized in the second quarter of 2018 reflecting the percentage completed to-date on the project related to this milestone.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company earned a $10.0 million milestone payment for the second target selected by AbbVie under the Discovery Agreement.&#160;&#160;It is recognized also using the time-elapse measure of progress of the related obligation and straight line over the estimated research service period of five years through June 2024.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $40.0 million milestone payment earned in March 2020 for satisfying the CD71 dose escalation success criteria under the CD71 Agreement was included as part of the transaction price as it was unconstrained during the first quarter of 2020 and $26.6 million was recognized as revenue related to this milestone reflecting the percentage completed to-date on the project.&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the remaining potential milestone payments of both agreements are probable of significant revenue reversal as their achievement is highly dependent on factors outside the Company<span style="color:#000000;">&#8217;</span>s control. Therefore, these payments continued to be fully constrained and were not included in the transaction price as of December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized revenue of $38.2 million, $5.9 million and $19.0 million for the years ended December 31, 2020, 2019 and 2018, respectively, related to the AbbVie Agreements. As of December 31, 2020 and 2019, deferred revenue related to the CD71 Agreement performance obligation was $25.2 million and $20.0 million, respectively, and deferred revenue related to the Discovery Agreement performance obligation was $8.0 million and $11.6 million, respectively. No amounts were due from AbbVie as of December 31, 2020 and 2019. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Amgen, Inc.<span style="color:#FF0000;"> </span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 29, 2017, the Company and Amgen, Inc. (<span style="color:#000000;">&#8220;</span>Amgen<span style="color:#000000;">&#8221;</span>) entered into a Collaboration and License Agreement (the <span style="color:#000000;">&#8220;</span>Amgen Agreement<span style="color:#000000;">&#8221;</span>). Pursuant to the Amgen Agreement, the Company received an upfront payment of $40.0 million in October 2017. Concurrent with the entry into the Amgen Agreement, the Company and Amgen entered into a Share Purchase Agreement (the <span style="color:#000000;">&#8220;</span>Purchase Agreement<span style="color:#000000;">&#8221;</span>) pursuant to which Amgen purchased 1,156,069 shares of the Company<span style="color:#000000;">&#8217;</span>s common stock at a price of $17.30 per share (calculated based on a 20-day volume-weighted average price), for total proceeds of $20.0 million, which the Company received on October 6, 2017, the closing date of the transaction. The Company estimated a premium on the stock sold to Amgen of $0.5 million, which takes into account a discount due to the lack of marketability resulting from the <span style="-sec-ix-hidden:F_000554">six-month</span> lockup period.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Amgen Agreement, the Company and Amgen will co-develop a conditionally activated T-cell engaging bi-specific therapeutic targeting epidermal growth factor receptor (the <span style="color:#000000;">&#8220;</span>EGFR Products<span style="color:#000000;">&#8221;</span>). The Company is responsible for early-stage development of EGFR Products and all related costs up to certain pre-set costs and certain limits based on clinical trial size. Amgen will be responsible for late-stage development, commercialization, and all related costs of EGFR Products. Following early-stage development, the Company will have the right to elect to participate financially in the global co-development of EGFR Products with Amgen, during which the Company would bear certain of the worldwide development costs for EGFR Products and Amgen would bear the rest of such costs (the <span style="color:#000000;">&#8220;</span>EGFR Co-Development Option<span style="color:#000000;">&#8221;</span>). If the Company exercises its EGFR Co-Development Option, the Company will share in somewhat less than 50% of the profit and losses from sales of such EGFR Products in the U.S., subject to certain caps, offsets, and deferrals. If the Company chooses not to exercise its EGFR Co-Development Option, the Company will not bear any costs of later stage development. The Company is eligible to receive up to $455.0 million in development, regulatory, and commercial milestone payments for EGFR Products, and royalties in the low-double-digit to mid-teen percentage of worldwide commercial sales, provided that if the Company exercises its EGFR Co-Development option, it shall receive a profit and loss split of sales in the United States and royalties in the low-double-digit to mid-teen percentage of commercial sales outside of the United States.</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amgen also has the right to select a total of up to three targets, including the two additional targets discussed below. The Company and Amgen collaborate in the research and development of conditionally activated T-cell engaging bi-specifics products directed against such targets. Amgen has selected one such target (the <span style="color:#000000;">&#8220;</span>Amgen Other Product<span style="color:#000000;">&#8221;</span>). If Amgen exercises its option within the specified period of time, it can select two such additional targets (the <span style="color:#000000;">&#8220;</span>Amgen Option Products<span style="color:#000000;">&#8221;</span> and, together with the Amgen Other Product, the <span style="color:#000000;">&#8220;</span>Amgen Products<span style="color:#000000;">&#8221;</span>). Except with respect to preclinical activities to be conducted by CytomX, Amgen will be responsible, at its expense, for the development, manufacture, and commercialization of all Amgen Products. If Amgen exercises all of its options and advances all three of the Amgen Products, CytomX is eligible to receive up to $950.0 million in upfront, development, regulatory, and commercial milestones and tiered high single-digit to low-teen percentage royalties. The Company concluded that, at the inception of the agreement, Amgen<span style="color:#000000;">&#8217;</span>s option to select the two additional targets is not a material right and does not represent a performance obligation of the agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At the initiation of the collaboration, CytomX had the option to select, from programs specified in the Amgen Agreement, an existing pre-clinical stage T-cell engaging bispecific product from the Amgen pre-clinical pipeline. In March 2018, CytomX selected the program. CytomX is responsible, at its expense, for converting this program to a conditionally activated T-cell engaging bispecific product, and thereafter, will be responsible for development, manufacturing, and commercialization of the product (<span style="color:#000000;">&#8220;</span>CytomX Product<span style="color:#000000;">&#8221;</span>). Amgen is eligible to receive up to $203.0 million in development, regulatory, and commercial milestone payments for the CytomX Product, and tiered mid-single digit to low double-digit percentage royalties.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considered the criteria for combining contracts in ASC 606 and determined that the Amgen Agreement and the Purchase Agreement should be combined into one contract. The Company accounted for the Amgen Agreement based on the fair values of the assets and services exchanged. The Company identified the following performance obligations at the inception of the Amgen Agreement: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research, development and commercialization license, </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research and development services for the EGFR Products and the Amgen Other Product, and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the obligation to participate in the joint steering committee (&#8220;JSC&#8221;) and the joint research committee (&#8220;JRC&#8221;). </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that research, development and commercialization license and the participation in the JSC and JRC are not distinct from the research and development services and therefore those performance obligations were combined into one combined performance obligation. The Amgen Other Products are accounted for as a separate performance obligation from the EGFR Products as the nature of the services being performed is not the same and the value that Amgen can derive from one program is not dependent on the success of the other.&#160;&#160;The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with the execution of the Amgen Agreement, the Company entered into a sublicense agreement whereby the Company granted Amgen a sublicense of its rights to one patent family that it co-owns with UCSB, that is exclusively licensed to the Company under the UCSB Agreement covering Probody antibodies and other pro-proteins in the fields of therapeutics, in vivo diagnostics and prophylactics. This sublicense was incremental to the patents, patent applications and know-how covering conditionally activated T-cell engaging bispecific molecules that were developed and owned by the Company and licensed to Amgen.  Under the UCSB Agreement, as amended, the Company is obligated to make a sublicense payment to UCSB equal to up to 7.5% of certain upfront and milestone payments owed to or received by the Company. There were no sublicense fees payable to UCSB as of December 31, 2020 and 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total transaction price of $51.2 million, consisting of the $40.0 million upfront payment, an estimated fair value of $10.7 million for the CytomX Product and $0.5 million of premium on the sale of the Company<span style="color:#000000;">&#8217;</span>s common stock, was allocated between the two performance obligations based on the relative standalone selling price of each performance obligation. To determine the standalone selling price, the Company used the discounted cash flow method by calculating risk-adjusted net present values of estimated cash flows. The Company determined that the remaining potential milestone payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company<span style="color:#000000;">&#8217;</span>s control. As a result, these payments were fully constrained and were not included in the transaction price as of January 1, 2018, the adoption date of ASC 606. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Of the $51.2 million total transaction price, the Company allocated $46.4 million to the EGFR Products performance obligation and $4.8 million to the Amgen Other Product performance obligations. The transaction price of the EGFR Product performance obligation was recognized using a cost-based input measure. In applying the cost-based input method of revenue recognition, the Company uses actual FTE hours incurred relative to estimated total FTE hours expected to be incurred for the combined performance obligation over the research service period. At the end of the second quarter of 2019, the Company determined that it will undertake additional testing and assessment of the molecules being evaluated under the EGFR project.&#160;&#160;As a result, the estimated FTE hours-to-completion and research service period were increased to eight years.&#160;&#160;In the second quarter of 2020, the Company completed the clinical candidate </p>
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">characterization phase and has moved into the IND-enabling phase earlier than planned</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;As a result, the estimated FTE hours-to-completion and research service period were decreased from eight to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">seven years</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The $4.8 million transaction price allocated to the Amgen Other Product performance obligation represents an obligation to continuously make the Probody therapeutic technology platform available to Amgen, which is recognized over the common measure of progress for the entire performance obligation over the estimated research service period of six years.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized revenue of $8.6 million, $3.9 million and $4.9 million for the years ended December 31, 2020, 2019 and 2018, respectively, related to the Amgen Agreement.  As of December 31, 2020 and 2019, deferred revenue related to the EGFR Products performance obligation was $29.8 million and $37.6 million, respectively. As of December 31, 2020 and 2019, deferred revenue related to the Amgen Other Products performance obligation was $2.2 million and $3.0 million, respectively. No amounts were due from Amgen as of December 31, 2020 and 2019.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Astellas Pharma Inc.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and Astellas Pharma, Inc. (&#8220;Astellas&#8221;) entered into a Collaboration and License Agreement (the &#8220;Astellas Agreement&#8221;) on March 23, 2020, the effective date, to collaborate on preclinical research activities to discover and develop certain antibody compounds for the treatment of cancer using the Company&#8217;s Probody therapeutic technology. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Astellas Agreement, the Company granted Astellas an exclusive, worldwide, rights to develop and commercialize Probody therapeutics for up to four collaboration targets including one initial target and three additional targets (&#8220;Additional Targets&#8221;).&#160;&#160;In addition, Astellas has the right to expand the number of Additional Targets from three up to five (the &#8220;Expansion Option&#8221;) before the third anniversary of the effective date.&#160;&#160;Furthermore, for a specified number of targets, at a pre-specified time prior to the initiation of the first pivotal study of a product against such target, the Company may elect to participate in certain development costs and share in the profits generated in the United States with respect to such product (&#8220;Cost Share Option&#8221;). The Cost Share Option, if exercised, will also provide the option for the Company to co-commercialize such product in the United States.&#160;&#160;The Company does not consider the Cost Share Option as a performance obligation at the inception of the agreement as the participation is at the Company&#8217;s discretion.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Astellas Agreement, the consideration from Astellas is comprised of an upfront fee of $80.0 million and contingent payments for development, regulatory and sales milestones of up to an aggregate of approximately $1.6 billion.&#160;&#160;If Astellas exercises its Expansion Option for the two Additional Targets, the Company would be eligible to receive additional upfront and milestone payments aggregating to approximately $0.9 billion.<span style="font-size:8pt;">&#160;&#160;</span>The Company is also entitled to tiered royalties from high-single digit to mid-teen percentage royalties from potential future sales. Astellas is responsible for all preclinical research costs incurred by either party as set forth in the preclinical research plan and the Company will receive research and development service fees based on a prescribed FTE rate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified the following performance obligations at the inception of the Astellas Agreement: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the exclusive research, development and commercialization license; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research and development services; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the obligation to participate in the joint research committee.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the license, the research services and expertise related to the development of the product candidates should be combined with the research services and participation in the joint research committee as one combined performance obligation. The Company concluded, that at the inception of the agreement, Astellas&#8217; Expansion Option for two Additional Targets were not material rights and therefore not considered performance obligations.&#160;&#160;As such, each option will be accounted for as a separate arrangement upon exercise. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial transaction price of $90.0 million consists of the upfront fee of $80.0 million and research and development service fees of $10.0 million. The Company determined that the potential development and regulatory milestone payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company<span style="color:#000000;">&#8217;</span>s control. Therefore, the potential development and regulatory milestone payments were fully constrained and were not included in the initial transaction price and continued to be fully constrained as of December 31, 2020.&#160;&#160;The Company will re-evaluate the transaction price at each reporting date or as uncertain events are resolved or other changes in circumstances occur.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The upfront fee of $80.0 million for the combined obligation to continuously make the Probody therapeutic technology platform available to Astellas is recognized on a straight-line basis for the entire performance obligation over the estimated research service period of five years, which ends in March 2025.&#160;&#160;The research and development service fees, estimated to be $10.0 million, will be recognized when services are provided based on the prescribed FTE rate. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized revenue of $13.9 million for the year ended December 31, 2020, which included the research and development service fee of $1.5 million.&#160;&#160;As of December 31, 2020, deferred revenue relating to the Astellas Agreement was $67.6 million. The amount due from Astellas under the Astellas Agreement was $0.8 million as of December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Bristol Myers Squibb Company </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 23, 2014, the Company and Bristol Myers Squibb Company (<span style="color:#000000;">&#8220;</span>Bristol Myers Squibb<span style="color:#000000;">&#8221;</span>) entered into a Collaboration and License Agreement (the <span style="color:#000000;">&#8220;</span>BMS Agreement<span style="color:#000000;">&#8221;</span>) to discover and develop compounds for use in human therapeutics aimed at multiple immuno-oncology targets using the Company<span style="color:#000000;">&#8217;</span>s Probody therapeutic technology. The effective date of the BMS Agreement was July 7, 2014.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the BMS Agreement, the Company granted Bristol Myers Squibb exclusive worldwide rights to develop and commercialize Probody therapeutics for up to four oncology targets. Bristol Myers Squibb had additional rights to substitute up to two collaboration targets within three years of the effective date of the BMS Agreement. These rights expired in May 2017. Each collaboration target had a <span style="-sec-ix-hidden:F_000610">two-year</span> research term and the two additional targets had to be nominated by Bristol Myers Squibb within five years of the effective date of the BMS Agreement. The research term for each collaboration target could be extended in one year increments up to three times.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the BMS Agreement, the financial consideration from Bristol Myers Squibb was comprised of an upfront payment of $50.0 million, and the Company was initially entitled to receive contingent payments of up to $25.0 million for additional targets and up to an aggregate of $1,192.0 million for development, regulatory and sales milestones.&#160;&#160;In addition, the Company is entitled to royalty payments in the mid-single digits to low double-digit percentages from potential future sales. The Company also receives research and development service fees based on a prescribed FTE rate that is capped.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company identified the following performance obligations at the inception of the BMS Agreement: </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.33%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the exclusive research, development and commercialization license; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the research and development services; and </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the obligation to participate in the joint research committee. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the license, the Company<span style="color:#000000;">&#8217;</span>s research services and expertise related to the development of the product candidates should be combined with the research services and participation in the joint research committee as one combined performance obligation. The Company concluded that, at the inception of the agreement, Bristol Myers Squibb&#8217;s options for the third and fourth targets were not material rights and not performance obligations. As such, each option was accounted for as a separate arrangement upon exercise. Additionally, the Company considered whether the services performed for each target should be considered as separate performance obligations and concluded that all targets should be accounted for as one combined performance obligation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received an upfront payment of $50.0 million from Bristol Myers Squibb in July 2014. In January and December 2016, Bristol Myers Squibb selected the third and fourth targets, respectively, and paid the Company $10.0 million and $15.0 million, respectively, pursuant to the terms of the BMS Agreement. In December 2016, Bristol Myers Squibb selected a clinical candidate pursuant to the BMS Agreement, which triggered a $2.0 million pre-clinical milestone payment to the Company. In November 2017, the Company recognized a $10.0 million milestone payment from Bristol Myers Squibb upon approval of the investigational new drug application for the CTLA-4-directed Probody therapeutic.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 17, 2017, the Company and Bristol Myers Squibb entered into Amendment Number 1 to Extend Collaboration and License Agreement (<span style="color:#000000;">&#8220;</span>Amendment 1<span style="color:#000000;">&#8221;</span>). Amendment 1 granted Bristol Myers Squibb exclusive worldwide rights to develop and commercialize Probody therapeutics for up to eight additional targets. The effective date of Amendment 1 was April 25, 2017 (<span style="color:#000000;">&#8220;</span>Amendment Effective Date<span style="color:#000000;">&#8221;</span>). Under the terms of Amendment 1, the Company continued to have obligations to Bristol Myers Squibb to discover and conduct preclinical development of Probody therapeutics against any targets they chose to select during the research period under the terms of Amendment 1.</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Amendment 1, the financial consideration from Bristol Myers Squibb was comprised of an upfront payment of $200.0 million and the Company was initially eligible to receive contingent payments for development, regulatory and sales milestones of up to an aggregate of $3,586.0 million for the eight targets. The Company was also entitled to tiered mid-single to low double-digit percentage royalties from potential future sales. Amendment 1 did not change the term of the Bristol Myers Squibb&#8217;s royalty obligation under the BMS Agreement. Bristol Myers Squibb<span style="color:#000000;">&#8217;</span>s royalty obligation continues on a licensed-product by licensed-product basis until the later of (i) the expiration of the last claim of the licensed patents covering the licensed products in the country, (ii) the twelfth anniversary of the first commercial sale of a licensed product in a country, or (iii) the expiration of any applicable regulatory, pediatric, orphan drug or data exclusivity with respect to such product.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial transaction price for the BMS Agreement and Amendment 1, collectively, was $272.8 million consisting of the upfront fees of $250.0 million, research and development service fees of $10.8 million and milestone payments received to date of $12.0 million. The Company determined that the remaining potential milestone payments were probable of significant revenue reversal as their achievement was highly dependent on factors outside the Company<span style="color:#000000;">&#8217;</span>s control. Therefore, these payments were fully constrained and were not included in the transaction price upon the adoption of ASC 606 on January 1, 2018. The BMS Agreement represents an obligation to continuously make the Probody therapeutic technology platform available to Bristol Myers Squibb.  Therefore, the initial transaction price is recognized over the estimated research service period, which ends on April 25, 2025.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter of 2019, Bristol Myers Squibb terminated pre-clinical activities on three of the first four collaboration targets selected under the original 2014 BMS Agreement.&#160;&#160;The first and second targets under the BMS Agreement were combined into a single performance obligation. The Company determined that termination of pre-clinical activities on the second target does not impact the Company&#8217;s continuing obligation to Bristol Myers Squibb for the first target, CTLA-4, as it is still being actively developed by Bristol Myers Squibb.&#160;&#160;Therefore, the Company concluded that it will continue to amortize the related deferred revenue over the original performance period. The Company has determined that upon the termination of pre-clinical activities on the third and the fourth collaboration targets selected by Bristol Myers Squibb in January and December of 2016, respectively, under the BMS Agreement, it has no further obligations.&#160;&#160;As a result of termination of three of the four collaboration targets, the Company is no longer eligible to receive up to an aggregate of $894.0 million contingent payments for development, regulatory and sales milestones as well as the related royalty payments for such targets.&#160;&#160;As a result, the Company recognized $18.1 million of revenue for the third and fourth targets in the first quarter of 2019, of which $17.4 million represented the accelerated recognition of all of the related deferred revenue upon the effective date of termination.&#160; The Company continues to be obligated to perform research work under Amendment 1 executed in March 2017.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, Bristol Myers Squibb dosed the first patient in the Part 2 cohort expansion portion of its ongoing BMS-986249 clinical study for the CTLA-4 program,<span style="Background-color:#FFFFFF;"> which triggered a $10.0 million milestone payment to the Company </span>pursuant to the terms of the BMS Agreement.&#160;&#160;The $10.0 million milestone payment was recognized as revenue in the first quarter of 2020.&#160;&#160;The Company reevaluated the remaining potential milestone payments and determined that significant revenue reversal was still probable as the achievement of such milestones was highly dependent on factors outside the Company<span style="color:#000000;">&#8217;</span>s control. As a result, these payments continued to be fully constrained and were not included in the transaction price on December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2021, the Company and Bristol Myers Squibb entered into Amendment Number 2 to amend the Collaboration and License Agreement (&#8220;Amendment 2&#8221;), as amended by Amendment 1. Subsequent to Amendment 2, Bristol Myers Squibb has the exclusive worldwide rights to develop and commercialize Probody therapeutics for up to five oncology targets. Under the terms of Amendment 2, the period for target selection has been extended and the Company will continue to collaborate with Bristol Myers Squibb to discover and conduct preclinical development of Probody therapeutics against targets selected by Bristol Myers Squibb. Pursuant to Amendment 2, the Company is eligible to receive contingent payments for development, regulatory and sales milestones of up to an aggregate of $1,779.0 million. It is also entitled to tiered mid-single to low double-digit percentage of royalties from potential future sales.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized revenue of $39.6 million, $47.7 million and $32.8 million for the years ended December 31, 2020, 2019, and 2018, respectively. As of December 31, 2020 and 2019, deferred revenue relating to the BMS Agreement was $128.3 million and $158.0 million, respectively. The amounts due from Bristol Myers Squibb under the BMS Agreement were $0 and $13,000 as of December 31, 2020 and 2019, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">ImmunoGen, Inc. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2014, the Company and ImmunoGen, Inc. (<span style="color:#000000;">&#8220;</span>ImmunoGen<span style="color:#000000;">&#8221;</span>) entered into the Research Collaboration Agreement (the <span style="color:#000000;">&#8220;</span>ImmunoGen Research Agreement<span style="color:#000000;">&#8221;</span>). The ImmunoGen Research Agreement provided the Company with the right to use ImmunoGen<span style="color:#000000;">&#8217;</span>s Antibody Drug Conjugate (<span style="color:#000000;">&#8220;</span>ADC<span style="color:#000000;">&#8221;</span>) technology in combination with the Company<span style="color:#000000;">&#8217;</span>s Probody therapeutic technology to create a conditionally activated ADC directed at one specified target under a research license, and to subsequently obtain an exclusive, </p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">worldwide development and commercialization license to use </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</span><span style="color:#000000;">&#8217;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ADC technology to develop and commercialize such </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditionally</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activ</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DCs. The Company made </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upfront cash payment in connection with the execution of the agreement. Instead, the Company provided </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with the rights to </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CytomX</span><span style="color:#000000;">&#8217;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Probody</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> therapeutic technology to create </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditionally</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activ</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DCs directed at </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">two</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> targets under the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Research Agreement and to subsequently obtain exclusive, worldwide development and commercialization licenses to develop and commercialize such </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">conditionally</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">activ</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> A</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DCs. In February 2016, the Company exercised its option to obtain a development and commercialization license for </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">praluzatamab</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ravtansine</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (CX-2009)</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> pursuant to the terms of the </span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Research Agreement (the </span><span style="color:#000000;">&#8220;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">CX-2009 License</span><span style="color:#000000;">&#8221;</span><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">).</span></p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2017, ImmunoGen exercised its first option to obtain a development and commercialization license for one of the two targets. Substitution rights for this first target selection program terminated in February 2017 and ImmunoGen discontinued the program in July 2017. The Company recognized the remaining deferred revenue related to the discontinued program upon the termination of the program. ImmunoGen exercised its second option to obtain a development and commercialization license pursuant to the ImmunoGen Research Agreement (the <span style="color:#000000;">&#8220;</span>ImmunoGen 2017 License<span style="color:#000000;">&#8221;</span>) for a target in December 2017.&#160;&#160;In December 2019, the parties entered into a license agreement (the &#8220;ImmunoGen 2019 License&#8221;) pursuant to which the ImmunoGen 2017 License was terminated and ImmunoGen granted a license for all of ImmunoGen&#8217;s rights under the ImmunoGen 2017 License to the Company. See Note 10. License Agreement, for more information.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the ImmunoGen Research Agreement, both the Company and ImmunoGen performed research activities on behalf of the other party for no monetary consideration through January 2018. In December 2017, the Company entered into the ImmunoGen 2017 License arrangement and extended the Company<span style="color:#000000;">&#8217;</span>s obligation to provide research services under the ImmunoGen Research Agreement to June 30, 2018. The estimated fair value of the consideration of $13.2 million for the performance obligation to ImmunoGen was recognized as revenue over the research period that ended on June 30, 2018. No further research services were provided by the Company after June 20, 2018 under the ImmunoGen 2017 License arrangement. The Company recognized revenue of $1.5 million for the year ended December 31, 2018. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company dosed the first patient in the praluzatamab ravtansine Phase 2 clinical trial and triggered a $3.0 million milestone payment to ImmunoGen pursuant to the CX-2009 License which continued to remain in effect following the termination of the ImmunoGen 2017 License in December 2019.&#160;&#160;The Company recorded a $3.0 million charge to research and development expense in the first quarter of 2020, in connection with this milestone payment to ImmunoGen.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<span style="font-weight:bold;font-style:italic;">Pfizer Inc.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2013, the Company and Pfizer Inc. (<span style="color:#000000;">&#8220;</span>Pfizer<span style="color:#000000;">&#8221;</span>) entered into a Research Collaboration, Option and License Agreement (the <span style="color:#000000;">&#8220;</span>Pfizer Agreement<span style="color:#000000;">&#8221;</span>) to collaborate on the discovery and preclinical research activities related to Probody therapeutics, and conditionally activated ADCs for research project targets nominated by Pfizer. Pfizer nominated two research targets in 2013 and, pursuant to the Pfizer Agreement, had the option of nominating two additional research targets. In December 2014, Pfizer selected an additional research target and paid the Company $1.5 million. The option to select a fourth target lapsed in May 2016. Pfizer discontinued the epidermal growth factor receptor (<span style="color:#000000;">&#8220;</span>EGFR<span style="color:#000000;">&#8221;</span>) program and decided to terminate the remaining two targets in February and March 2018. In March 2018, Pfizer terminated the Pfizer Agreement. As such, the Company had no further performance obligations under this agreement after the first quarter of 2018.&#160;&#160;The Company recognized revenue of $1.4 million for the year ended December 31, 2018.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Liabilities </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents changes in the Company<span style="color:#000000;">&#8217;</span>s total contract liabilities for the year ended December 31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deductions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,239</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,109</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261,130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were $120.0 million of additions to deferred revenue during the year ended December 31,2020.&#160;&#160;Of such amount, $40.0 million was related to the milestone payment triggered by AbbVie&#8217;s CD71 dose escalation success criteria which was achieved in March 2020, and an $80.0 million addition was related to the upfront fee payable under the Astellas Agreement entered into in March 2020.  Deductions of $89.1 million related to revenue recognized included in the contract liability balance at the beginning of the period plus the revenue recognized related to the $120.0 million additions during the year ended December 31, 2020.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company expects that the $261.1 million of deferred revenue related to the following contracts as of December 31, 2020 will be recognized as revenue as set forth below. However, the timing of revenue recognition could differ from the estimates depending on facts and circumstances impacting the various contracts, including progress of research and development, resources assigned to the contracts by the Company or its collaboration partners or other factors outside of the Company<span style="color:#000000;">&#8217;</span>s control.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">The $25.2 million of deferred revenue related to the CD71 Agreement as of December 31, 2020 is expected to be recognized based on actual FTE effort and program progress until approximately September 2022. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">The $1.0 million of deferred revenue related to the first target under the Discovery Agreement as of December 31, 2020 is expected to be recognized ratably until approximately April 2022.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">The $7.0 million of deferred revenue related to the second target under the Discovery Agreement as of December 31, 2020 is expected to be recognized ratably until approximately June 2024.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">The $29.8 million of deferred revenue related to the Amgen EGFR Products as of December 31, 2020 is expected to be recognized based on actual FTE effort and program progress until approximately September 2024.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">The $2.2 million of deferred revenue related to the Amgen Other Products as of December 31, 2020 is expected to be recognized ratably until approximately September 2023. </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">The $67.6 million of deferred revenue related to the Astellas Agreement as of December 31, 2020 is expected to be recognized ratably until approximately March 2025.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="width:4.54%;white-space:nowrap" valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"/><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"/><span style="color:#000000;">The $128.3 million of deferred revenue related to the BMS Agreement as of December 31, 2020 is expected to be recognized ratably until approximately April 2025.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ResearchAndCollaborationAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ResearchAndCollaborationAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089427032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAbstract', window );"><strong>Research And Development [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_LicenseAgreementDisclosureTextBlock', window );">License Agreement</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">10. License Agreement </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">UCSB</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has an exclusive, worldwide license agreement with UCSB (the <span style="color:#000000;">&#8220;</span>UCSB Agreement<span style="color:#000000;">&#8221;</span>), relating to the use of certain patents and technology relating to its core technology, including its therapeutic antibodies, and to certain patent rights the Company co-owns with UCSB covering Probody antibodies and other pro-proteins. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the UCSB Agreement, the Company is obligated to (i) make royalty payments to UCSB on net sales of its products covered under the agreement, subject to annual minimum amounts, (ii) make milestone payments to UCSB upon the occurrence of certain events, (iii) make a milestone payment to UCSB upon occurrence of an IPO or change of control, and (iv) reimburse UCSB for prosecution and maintenance of the licensed patents. If the Company sublicenses its rights under the UCSB Agreement, it is obligated to pay UCSB a percentage of the total sublicense revenue received, which total amount would be first reduced by the aggregate amount of certain research and development related expenses incurred by the Company and other permitted deductions. As part of the UCSB Agreement, the Company has annual minimum royalty obligations of $0.2 million under the terms of certain exclusive licensed patent rights.&#160;&#160;The royalty obligations are cancellable any time by giving notice to the licensor, with the termination being effective 60 days after giving notice.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2013, the Company amended the UCSB Agreement to reduce certain amounts due to UCSB upon receipt by the Company of upfront payments, milestone payments and royalties from sublicensees. In exchange for this amendment, the Company issued to UCSB 157,332 shares of common stock. The UCSB Agreement, as amended, will remain in effect until the expiration or abandonment of the last to expire of the licensed patents.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2019, the Company entered into Amendment No.3 to the UCSB Agreement to adjust and clarify certain sublicense terms (&#8220;Amendment No.3&#8221;).&#160;&#160;In connection with the amendment, the Company issued to UCSB 150,000 shares of CytomX common stock with a fair value of $10.68 per share. Under the terms of Amendment No.3, the Company and UCSB agreed to modify the determination of sublicense revenues payable by the Company to UCSB on certain existing collaboration agreements and on collaboration agreements executed subsequent to Amendment No.3.&#160;&#160;In exchange, the Company agreed to make an upfront payment of $1.0 million as well as additional annual license maintenance fees of $0.8 million through 2031.&#160;&#160;In the event that the Company terminates the agreement due to material concern of the safety or efficacy of the related technology, 50% of all remaining maintenance fees will become due immediately.&#160;&#160;Otherwise, all remaining maintenance fees will become due immediately upon early termination of the agreement unless there is a material breach by UCSB.&#160;&#160;Pursuant to Amendment No.3, the Company recorded in research and development expense a charge of $3.4 million relating to sublicense and maintenance fees representing the 150,000 shares issued with a fair value of $1.6 million, the upfront payment of $1.0 million and the additional annual maintenance fee of $0.8 million during the second quarter of 2019.&#160;&#160;</p>

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2019, the Company incurred an additional $0.8 million of sublicense fees related to the $10.0 million milestone payment for the second target selected by AbbVie under the Discovery Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company recorded $0.8 million of sublicense fees triggered by the $10.0 million milestone payment from Bristol Myers Squibb&#8217;s dosing of the first patient in the Part 2 cohort expansion portion of its ongoing BMS-986249 clinical study for the CTLA-4 program.&#160;&#160;In March 2020, the Company incurred additional sublicense fees of $6.0 million and $1.4 million related to the $80.0 million upfront fee received pursuant to the Astellas Agreement entered into in March 2020, and the $40.0 million milestone payment from AbbVie for satisfying the CD71 dose escalation success criteria under the CD71 Agreement, respectively.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2020, 2019 and 2018, the Company incurred sublicense expenses of $9.1 million, $4.3 million and $0.6 million, respectively, under the provisions of the UCSB Agreement.&#160;&#160;As of December 31, 2020 and 2019, there was $0 and $0.2 million sublicense fee payable to UCSB, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ImmunoGen </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the Company entered into a License Agreement (the &#8220;ImmunoGen 2019 License&#8221;) with ImmunoGen, Inc. to obtain an exclusive license with respect to <span style="color:#000000;">epithelial cell adhesion molecule (&#8220;EPCAM&#8221;).</span>  Under the ImmunoGen 2019 License, ImmunoGen agreed to transfer its know-how, patents, intellectual property rights, and technology transfer materials and information related to its EpCAM program. The license gives the Company the sole ability to develop, manufacture, use and commercialize any licensed product that incorporates, is comprised of, or otherwise derived from a Probody that targets EpCAM in any human therapeutic field on a worldwide basis. In exchange, the Company agreed to make non-refundable and non-creditable payments including an upfront license payment of $7.5 million and certain clinical development, approval and commercialization milestone payments, if achieved and royalties on product sales.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The upfront license fee of $7.5 million was recorded as research and development expense in December 2019 and included in accrued liabilities as of December 31, 2019.&#160;&#160; The upfront license fee was paid in January 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624090530632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">11. Commitments and Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Legal Proceedings </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 4, 2020, Vytacera Bio, LLC filed a patent infringement lawsuit against the Company in the U.S. District Court for the District of Delaware.&#160; The lawsuit alleges that the Company&#8217;s use, offers to sell, and/or sales of the Probody&#174; technology platform for basic research applications constitutes infringement.&#160; The complaint seeks unspecified monetary damages.&#160; The Company filed an Answer, Affirmative Defenses, and Counterclaims on May 26, 2020.&#160; Vytacera Bio, LLC filed its Answer to CytomX Therapeutics Inc.&#8217;s Counterclaims on June 5, 2020.&#160; The parties have agreed to a case schedule, which is pending Court approval.&#160; Discovery is in the initial phases. The Company believes that the lawsuit is without merit and intends to vigorously defend itself and has not recorded any amount for claims associated with this lawsuit as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 21, 2020, a putative securities class action lawsuit was commenced in the U.S. District Court for the Northern District of California naming as defendants the Company and three current and former officers. The complaint alleges that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to the product candidates praluzatamab ravtansine (CX-2009) and pacmilimab (CX-072). The plaintiff sought to represent all persons who purchased or otherwise acquired CytomX securities between May 17, 2018, and May 13, 2020. On January 14, 2021, the class action was dismissed without prejudice.<span style="color:#000000;">&#160;</span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Indemnifications</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; insurance.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089973976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">12. Leases </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Lease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 10, 2015, the Company entered into a lease (the &#8220;2016 Lease&#8221;) with HCP Oyster Point III LLC (the &#8220;Landlord&#8221;) to lease approximately 76,000 rentable square feet of office and laboratory space located in South San Francisco, California for the Company&#8217;s new corporate headquarters.&#160;&#160;</p><p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of the Lease commenced on October 1, 2016. The 2016 Lease has an initial term of ten years from the commencement date, and the Company has an option to extend the initial term for an additional five years at the then fair rental value as determined pursuant to the 2016 Lease. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Lease provided for annual base rent of approximately $3.1 million in the first year of the lease term. The annual base rent for the second twelve months was approximately $4.3 million, which will increase on an annual basis beginning from the 25<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> month to approximately $5.5 million for the tenth year of the lease. The Company utilized the full amount of the one-time improvement allowance of $12.6 million, of which $2.3 million is recoverable by the landlord through increased rent which continues through the expiration of the initial lease term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company obtained a standby letter of credit (the &#8220;Letter of Credit&#8221;) in an amount of approximately $0.9 million, which may be drawn by the Landlord to be applied for certain purposes upon the Company&#8217;s breach of any provisions under the 2016 Lease. The Company has recorded the $0.9 million Letter of Credit as non-current restricted cash on its balance sheet as of December 31, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense is recognized on a straight-line basis over the term of the lease and accordingly the Company records the difference between cash rent payments and the recognition of rent expense against the operating lease ROU asset.&#160;&#160;Rent expense during the years ended December 31, 2020, 2019 and 2018 was $5.1 million, $4.8 million and $4.2 million, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental information related to leases are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:95%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,990</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,855</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental balance sheet information related to leases:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,495</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,382</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,195</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,810</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,675</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,871</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,870</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,681</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000744">5.75</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000745">6.85</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.25</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.25</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:95%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Maturity of operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,129</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,273</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,420</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,572</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025 and beyond</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,116</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,510</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,640</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,870</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624090130984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_CommonStockTextBlock', window );">Common Stock</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">13. Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2015, the Company&#8217;s board of directors and stockholders approved the amendment and restatement of the Company&#8217;s certificate of incorporation. The Amended and Restated Certificate of Incorporation was effective as of October 14, 2015, which provided for 75,000,000 authorized shares of common stock with par value of $0.00001 per share and 10,000,000 shares of preferred stock with a par value of $0.00001 per share.&#160;&#160;In June 2020, the board of directors and stockholders of the Company approved an increase in the authorized shares of common stock from 75,000,000 to 150,000,000.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stockholders are entitled to dividends if and when declared by the board of directors subject to the prior rights of the preferred stockholders. As of December 31, 2020 and 2019, no dividends on common stock had been declared by the Board of Directors.</p>
<p style="margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2018, the Company completed an underwritten public offering of 5,867,347 shares of common stock at a price of $24.50 per share, which included 765,306 shares issued pursuant to the underwriters<span style="color:#000000;">&#8217;</span> exercise of their option to purchase additional shares of common stock. The aggregate net proceeds received by the Company from the offering were approximately $134.6 million after deducting underwriting discounts and commissions and offering expenses of $9.2 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company entered into an Open Market Sale Agreement (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;), to sell shares of the Company&#8217;s common stock, par value $0.00001 per share, with aggregate gross sales proceeds of up to $75,000,000, from time to time upon the Company&#8217;s request, through an at the market offering under which Jefferies will act as sales agent.&#160;&#160;Pursuant to the Sales Agreement, Jefferies as the sales agent will receive a commission of 3.0% of the gross sales price for shares of common stock sold under the Sales Agreement.&#160;&#160;During December 2020, the Company sold 1,535,217 shares at an average price of $7.62 per shares and received net proceeds of approximately $11.3 million after deducting the 3.0% sales commission and related issuance cost.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had reserved shares of common stock for issuance, as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,929,530</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,936,168</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future stock option grants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,903,398</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,145,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future employee stock purchase plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,935,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,609,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,768,611</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,690,571</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624082077384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">14. Stock-based Compensation </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The 2010 Plan and 2011 Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2010, the Company adopted its 2010 Stock Incentive Plan (the &#8220;2010 Plan&#8221;) which provided for the granting of stock options to employees, directors and consultants of the Company. Options granted under the 2010 Plan were either incentive stock options (&#8220;ISOs&#8221;) or nonqualified stock options (&#8220;NSOs&#8221;).&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2012, the Company adopted its 2011 Stock Incentive Plan (the &#8220;2011 Plan&#8221;). The 2011 Plan is divided into two separate equity programs, an option and stock appreciation rights grant program and a stock award program. In conjunction with adopting the 2011 Plan, the Company discontinued the 2010 Plan and released the shares reserved and still available under that plan.&#160;&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the consummation of the IPO in October 2015, the board of directors adopted the Company&#8217;s 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221; and collectively with the 2010 Plan and 2011 Plan, the &#8220;Plans&#8221;). In conjunction with adopting the 2015 Plan, the Company discontinued the 2011 Plan with respect to new equity awards.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The 2015 Plan</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options under the 2015 Plan may be granted for periods of up to ten years. All options issued to date have had a 10-year life.&#160;&#160;Under the terms of the 2015 Plan, options may be granted at an exercise price not less than the estimated fair value of the Company&#8217;s common stock on the date of grant, as determined by the Company&#8217;s board of directors. For employees holding more than 10% of the voting rights of all classes of stock, the exercise price of ISOs and NSOs may not be less than 110% of the estimated fair value of the shares on the date of grant, as determined by the board of directors. To date, options granted under the 2015 Plan generally vest over four years and vest at a rate of 25% upon the first anniversary of the issuance date and <span style="-sec-ix-hidden:F_000789_2">1/48</span>th per month thereafter.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial number of shares of common stock available for future issuance under the 2015 Plan was 2,444,735. Beginning on January 1, 2016 and continuing until the expiration of the 2015 Plan, the total number of shares of common stock available for issuance under the 2015 Plan will automatically increase annually on January 1 by 4% of the total number of issued and outstanding shares of common stock as of January 1 of the same year.  As of December 31, 2020 and 2019, 2,698,798 shares and 1,808,066 shares of common stock were available for future issuance under the 2015 Plan.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The 2019 Plan</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2019, the Board of Directors adopted the 2019 Employment Inducement Incentive Plan (the &#8220;2019 Plan&#8221;) which provides for the grant of stock options and other equity awards to any employee who has not previously been an employee or director of the Company or who is commencing employment with the Company following a bona fide period of nonemployment by the Company. Awards granted under the 2019 Plan are intended to constitute &#8220;employment inducement awards&#8221; under Nasdaq Listing Rule 5635(c)(4). Options granted under the 2019 Plan are nonqualified stock options (&#8220;NSOs&#8221;) which may be exercisable for periods of up to ten years and the options shall be granted at an exercise price of not less than 100% of the fair market value of the Company&#8217;s common stock on the date of grant.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial number of shares of common stock available for future issuance under the 2019 Plan was 1,815,000.&#160;&#160;As of December 31, 2020 and 2019, 204,600 shares and 1,337,200 shares, respectively, of common stock were available for future issuance under the 2019 Plan.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity under the Company&#8217;s stock option plans is set forth below:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Grant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,145,266</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,936,168</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.26</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options authorized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,820,923</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,219,044</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,219,044</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.23</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,064,830</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.58</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,156,253</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,160,852</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,903,398</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,929,530</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000818">6.4</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,844</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable&#8212;December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,145,652</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.69</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000819">4.7</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,031</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest&#8212;December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,929,530</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000820">6.4</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,844</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic values of options outstanding, exercisable, vested and expected to vest were calculated as the difference between the exercise price of the options and the estimated fair value of the underlying common stock as of December 31, 2020.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic value of stock options exercised in the years ended December 31, 2020, 2019 and 2018 was $4.4 million, $0.9 million and $14.6 million, respectively. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The options granted in the years ended December 31, 2020, 2019 and 2018 had weighted-average per share grant-date fair values of $3.94, $7.03 and $14.21, respectively. As of December 31, 2020, the unrecognized compensation expense with respect to options granted was $23.2 million&#160;and is expected to be recognized over 2.8 years.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Early Exercise of Employee Options</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain stock options granted under the Plans provide option holders the right to elect to exercise unvested options in exchange for restricted common stock. Such unvested restricted shares are subject to a repurchase right held by the Company at the original issuance price in the event the optionee&#8217;s service to the Company is terminated either voluntarily or involuntarily. The right usually lapses 25% on the first anniversary of the vesting start date and in 36 equal monthly amounts thereafter. These repurchase terms are considered to be a forfeiture provision. The cash or full recourse notes received from employees for exercise of unvested options is treated as a refundable deposit and is classified as a liability on the balance sheets.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with the completion of the IPO in October 2015, the Company&#8217;s Employee Stock Purchase Plan (&#8220;ESPP&#8221;) became effective. The ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The ESPP generally provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company&#8217;s common stock on the first trading day of the offering period or on the last trading day of the offering period. The Company issued 128,684 shares and 142,949 shares of common stock under the ESPP in 2020 and 2019, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future purchase under the ESPP were 1,935,683 shares and 1,609,137 shares at December 31, 2020 and 2019, respectively. The compensation expense related to the ESPP was $0.4 million, $0.6 million and $0.5 million for the years ended December 31, 2020, 2019 and 2018, respectively. As of December 31, 2020, there was $0.2 million <span style="font-size:12pt;">&#160;</span>of unrecognized compensation cost related to the ESPP, which the Company expects to recognize over 5 months.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation recorded related to options granted to employees and non-employees and employee stock purchase plan was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.24%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,825</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,226</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,313</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,961</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,874</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,565</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,786</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,878</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for employees was $14.7 million, $18.9 million and $16.7 million for the years ended December 31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense for non-employees was $0.1 million, $0.2 million and $0.2 million for the years ended December 31, 2020, 2019 and 2018, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of employee stock options and ESPP using the Black-Scholes valuation model based on the date of grant with the following assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000860">64.4% - 73.3%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000861">64.4% - 68.6%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000862">65.6% - 69.3%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000863">47.3% - 122.1%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000864">60.8% - 71.9%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000865">46.4% - 70.5%</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000866">0.2% - 1.3%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000867">1.4% - 2.5%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000868">2.5% - 3.0%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000869">0.1% - 0.2%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000870">1.6% - 2.4%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000871">2.1% - 2.6%</span></p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000887">&#8212; %</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000888">&#8212; %</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000889">&#8212; %</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000890">4.7 - 4.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000891">4.9 - 5.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000892">4.7 - 4.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000872">0.5</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000873">0.5</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000874">0.5</span></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected term. <span style="font-style:normal;">The expected term of stock options represents the period that the stock options are expected to remain outstanding and is based on vesting terms, exercise term and contractual lives of the options. The expected term of the ESPP shares is equal to the six-month look-back period. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility. <span style="font-style:normal;">The expected stock price volatility for the Company&#8217;s stock options is based on the historical stock price volatility which is commensurate with the estimated expected term of the stock awards. Volatility for ESPP shares is equal to the Company&#8217;s historical volatility over a six-month offering period. </span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate.<span style="font-style:normal;"> The risk-free interest rate is based on the U.S. Treasury yield with a maturity equal to the expected term of the stock options in effect at the time of grant.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dividend yield. <span style="font-style:normal;">The expected dividend is assumed to be zero as the Company has never paid dividends</span><span style="letter-spacing:0.2pt;font-style:normal;"> </span><span style="font-style:normal;">and has no current plan to pay any dividends on its common</span><span style="letter-spacing:0.15pt;font-style:normal;"> </span><span style="font-style:normal;">stock.</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089932984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p id="N17_INCOME_TAXES" style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">15. Income Taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company derives its income only from the United States. The components of the provision for (benefit from) income taxes are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,912</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(390</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,911</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(390</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,303</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for (benefit from) income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,911</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(427</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,303</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s effective tax rate to the statutory U.S. federal rate is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal taxes at statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryback</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Return to provision adjustment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The types of temporary differences that give rise to significant portions of the Company&#8217;s deferred income tax assets and liabilities are set out below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,099</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,967</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,468</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,803</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,940</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,514</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,223</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,813</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,923</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,320</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,832</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,180</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,881</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and deferred rent</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,512</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,296</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,955</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,578</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,746</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred income tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,990</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,353</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,603</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106,448</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109,174</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86,466</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net of valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,542</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(433</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(591</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,724</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,330</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(108</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(385</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(243</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(175</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,542</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred income tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (&#8220;CARES Act&#8221;) was enacted in response to the COVID-19 pandemic.&#160;&#160;<span style="color:#000000;">The tax relief measures under the CARES Act for businesses include a <span style="-sec-ix-hidden:F_000893">five-year</span> net operating loss carryback, suspension of annual deduction limitation of 80% of taxable income from net operating losses generated in a tax year beginning after December 31, 2017, changes in the deductibility of interest, acceleration of alternative minimum tax credit refunds, payroll tax relief, and a technical correction to allow accelerated deductions for qualified improvement property.</span>&#160;&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognized income tax benefit of $13.9 million for the year ended December 31, 2020, through the net operating loss carryback <span style="Background-color:#FFFFFF;color:#000000;">under the CARES Act which generated a refund of income taxes paid for 2018.</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has established a valuation allowance against all of its net deferred tax assets. Management considered all available evidence, both positive and negative, including but not limited to our historical operating results, income or loss in recent periods, cumulative losses in recent years, forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts, and concluded the deferred tax assets are not more likely than not to be realized. The net change in <span style="letter-spacing:-0.1pt;">the total valuation allowance for the years ended December 31, 2020, 2019 and 2018 was an increase(decrease) of $(2.7) million, $22.7 million and $35.7 million, respectively.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had net operating loss carryforwards for federal and state income tax purposes of approximately $168.6 million and $24.2 million, respectively, as of December 31, 2020, available to reduce future taxable income. Of the federal net operating loss carryforwards, $65.6 million will begin to expire in 2034, if not utilized and $103 million will carryforward indefinitely.&#160;&#160;The state net operating loss carryforwards will begin to expire in 2032, if not utilized.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company also has federal and state research and development tax credits carryforwards of $15.6 million and $9.0 million, respectively, as of December 31, 2020 available to reduce future income taxes. The federal research and development tax credits will begin to expire in 2031 if not utilized. The state research and development tax credits have no expiration date.&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Internal Revenue Code section 382 (&#8220;IRC Section 382&#8221;) places a limitation (the &#8220;Section 382 Limitation&#8221;) on the amount of taxable income that can be offset by net operating loss (&#8220;NOL&#8221;) carryforwards after a change in control (generally greater than 50% change in ownership) of a loss corporation. California has similar rules. The Company has performed an IRC Section 382 analysis and determined there was an ownership change in 2017 that resulted in 382 limitations. When an ownership change occurs, IRC Section 382 limits the use of NOLs and credits in subsequent periods based on the annual 382 limitations.&#160;&#160;The annual 382 limitations may limit the full use of available tax attributes in one year but the identified <span style="color:#000000;">ownership changes may not result in expiration of tax attributes for use prior to expiration of their respective carryforward periods. Accordingly, none of the tax attributes have been reduced but limited the full use in 2018.  The Company has determined that, while an ownership change has occurred, the applicable limits would not impair the value or anticipated use of the Company&#8217;s federal and state net operating losses. Although realization is not assured, management believes it is more likely than not that any limitation under IRC Section 382 will not impair the realizability of the deferred income tax assets related to federal and state net operating loss carryforwards.&#160;&#160;</span>The Company reviewed its stock ownership for the year ended December 31, 2020 and concluded no ownership changes occurred in current year which would result in a reduction of its net operating loss or in its research and development credits expiring unused. If additional ownership change occurs, the utilization of net operating loss and credit carryforwards could be significantly reduced.  </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had approximately $6.5 million, $5.2 million and $3.8 million of unrecognized tax benefits as of December 31, 2020, 2019 and 2018, respectively, and approximately $0, $0.9 million and $1.0 million, respectively, would affect the Company&#8217;s effective tax rate if recognized.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at the beginning of the year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,249</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,756</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,320</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to current year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,205</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,403</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,166</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment based on tax positions related to prior years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,730</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of the year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,454</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,249</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,756</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. To the extent accrued interest and penalties do not ultimately become payable, amounts accrued will be reduced and reflected as a reduction of the provision for income taxes in the period that such determination is made. Interest and penalties have not been accrued for 2020, 2019 and 2018.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files income tax returns in the United States, including California state jurisdiction. The tax years 2010 to 2019 remains <span style="letter-spacing:-0.1pt;">open to U.S. federal and state examination to the extent of the utilization of net operating loss and credit carryovers. As of December 31, 2020</span>, the Company is under examination by the State of California.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624090492952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text">
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">16. Defined Contribution Plan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sponsors a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time U.S. employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. During the years ended December 31, 2020, 2019 and 2018, the Company made contributions to the plan of $0.8 million, $0.8 million and $0.6 million, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624090002872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">17. Subsequent Events</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Company completed an underwritten public offering of 14,285,714 shares of common stock at a price of $7.00 per share.&#160;&#160;The aggregate net proceeds received by the Company from the offering were approximately $93.6 million, after deducting underwriting discounts and commissions and estimated offering expenses of $6.4 million.&#160;&#160;The Company also granted the underwriters the option, for 30 days, to purchase up to 2,142,857 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. In February 2021, the underwriters exercised the option in full which resulted in additional net proceeds of $14.1 million to the Company, after deducting the underwriting discounts and commissions of $0.9 million. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089889432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (<span style="color:#000000;">&#8220;</span>U.S. GAAP&#8221;). </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is subject to a number of risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products, and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all the Company&#8217;s cash is held by one financial institution. Such deposits may, at times, exceed federally insured limits. The Company invests its cash equivalents and short-term investments in highly rated money market funds and its short-term investments in U.S. Government Bonds.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customers and collaboration partners who represent 10% or more of the Company&#8217;s total revenue during each period presented or accounts receivable balance at each respective balance sheet date are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie Ireland Unlimited Company</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,192</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,878</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,997</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc.</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,931</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol-Myers Squibb Company</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,740</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,780</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue from customers who represent 10% or more</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of the Company's total revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,753</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,777</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s customers are located in the United States of America, Ireland and Japan.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management has determined that it has one business activity and operates as one operating segment as it only reports financial information on an aggregate basis to its chief executive officer and chief financial officer, who are the Company&#8217;s chief operating decision makers. All long-lived assets are maintained in the United States of America.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments purchased with original maturities of three months or less at the date of purchase to be cash equivalents.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Restricted Cash</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash represents a standby letter of credit issued pursuant to an office lease entered in December 2015. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the amounts shown in the statement of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,859</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,425</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,776</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,342</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Short-term Investments</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Short-term Investments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All investments have been classified as available-for-sale (&#8220;AFS&#8221;) and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Generally, those investments with contractual maturities less than 12 months are considered short-term investments. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Dividend and interest income are recognized when earned. Realized gains and losses are included in earnings and are derived using the specific identification method for determining the cost of securities sold.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses impairment of its AFS debt securities investments at each reporting period.&#160;&#160;Unrealized gains resulting from the excess of the fair value over the amortized cost basis of an investment are reported as a component of accumulated other comprehensive income (loss), net of tax.&#160;&#160;Unrealized losses or impairments resulting from the fair value of the AFS debt security being below the amortized cost basis are evaluated, using the discounted cash flow model, for identification of credit losses and non-credit related losses.&#160;&#160;Any credit losses are charged to earnings against the allowance for credit losses of the security, limited to the difference between the fair value and the amortized cost basis of the security.&#160;&#160;Any difference between the fair value of the security and the amortized cost basis, less the allowance for credit losses, are reported in other comprehensive income (loss).&#160;&#160;Expected cash inflows due to improvements in credit are recognized through a reversal of the allowance for credit losses subject to the total allowance previously recognized.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of impairment of any security, if management (i) has the intent to sell such security or (ii) will more-likely-than-not be required to sell such security before recovery of its amortized cost basis, such AFS debt security&#8217;s amortized cost basis will be written down to its fair value through earnings along with any existing allowance for credit losses.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, net</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment, net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are recorded at cost net of accumulated depreciation and amortization. Depreciation is provided using the straight-line method over the estimated useful lives of the respective assets. The useful lives of property and equipment are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of remaining lease term or estimated life of the assets</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maintenance and repairs that do not extend the life or improve the asset are expensed when incurred.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Goodwill and Intangible Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the purchase price paid over the fair value of tangible and identifiable intangible assets acquired in business combinations. Goodwill and other intangible assets with indefinite lives are not amortized, but are assigned to reporting units and tested for impairment annually, or whenever there is an impairment indicator. Intangible assets are comprised of in-process research and development. The Company assesses impairment indicators annually as of December 31 or more frequently, if a change in circumstances or the occurrence of events suggests the remaining value may not be recoverable. Intangible assets that are not deemed to have an indefinite life are amortized over their estimated useful lives. There was no impairment of goodwill or intangible assets identified during the years ended December 31, 2020, 2019 and 2018.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset (or asset group) may not be recoverable and prior to any goodwill impairment test. An impairment loss is recognized when the total of estimated undiscounted future cash flows expected to result from the use of the asset (or asset group) and its eventual disposition is less than its carrying amount. Impairment, if any, would be assessed using discounted cash flows or other appropriate measures of fair value. There was no impairment of long-lived assets during the years ended December 31, 2020, 2019 and 2018.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 1, 2018, the Company adopted Accounting Standards Update No. 2014-09, <span style="font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span>, which supersedes the revenue recognition requirements in Accounting Standards Codification (ASC) Topic 605, <span style="font-style:italic;">Revenue Recognition (ASC 605)</span>, using the modified retrospective transition method applied to those contracts which were not completed as of January 1, 2018. The impact of the adoption of ASC 606 was an increase in the balance of deferred revenue and an increase in the accumulated deficit balance of $10.9 million on January 1, 2018 in the Company&#8217;s Balance Sheet.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s revenues are primarily derived through its license, research, development and commercialization agreements. The terms of these types of agreements may include (i) licenses for the Company<span style="color:#000000;">&#8217;</span>s technology or programs, (ii) research and development services, and (iii) services or obligations in connection with participation in research or steering committees. Payments to the Company under these arrangements typically include one or more of the following: nonrefundable upfront and license fees, research funding, milestone and other contingent payments to the Company for the achievement of defined collaboration objectives and certain preclinical, clinical, regulatory and sales-based events, as well as royalties on sales of any commercialized products.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assesses whether the promises in its arrangements with customers are considered as distinct performance obligations that should be accounted for separately. Judgment is required to determine whether the license to the Company<span style="color:#000000;">&#8217;</span>s intellectual property is distinct from the research and development services or participation on steering committees.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s collaboration and license agreements may include contingent payments related to specified research, development and regulatory milestones. Such milestone payments are typically payable under the collaborations when the collaboration partner claims or selects a target, or initiates or advances a covered product candidate in preclinical or clinical development, upon submission for marketing approval of a covered product with regulatory authorities; or upon receipt of actual marketing approvals of a covered product or for additional indications. Milestone payments that are not within the control of the Company or the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.&#160;&#160;At each reporting date, the Company re-evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price by using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price in such period of determination.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company<span style="color:#000000;">&#8217;</span>s collaboration and license agreements may also include contingent payments related to sales-based milestones. Sales-based milestones are typically payable when annual sales of a covered product reach specified levels. Sales-based milestones are recognized at the later of when the associated performance obligation has been satisfied or when the sales occur. Unlike other contingency payments, such as regulatory milestones, sales-based milestones are not included in the transaction price based on estimates at the inception of the contract, but rather, are included when the sales or usage occur.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transaction price in each arrangement is allocated to the identified performance obligations based on the relative standalone selling price (<span style="color:#000000;">&#8220;</span>SSP<span style="color:#000000;">&#8221;</span>) of each distinct performance obligation, which requires judgment. In instances where SSP is not directly observable, such as when a license or service is not sold separately, SSP is determined using information that may include market conditions and other observable inputs. Due to the early stage of the Company<span style="color:#000000;">&#8217;</span>s licensed technology, the license of such technology is typically combined with research and development services and steering committee participation as one performance obligation.&#160;&#160;In the event that the Company receives non-cash consideration such as consideration in the form of a research license and research support services from the counterparty, the transaction price of a non-monetary exchange that has commercial substance is estimated based on the fair value of the non-cash consideration received, which may be determined through a valuation analysis.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In certain cases, the Company&#8217;s performance creates an asset that does not have an alternative use to the customer and the Company has an enforceable right to payment at all times for performance completed to date.&#160;&#160;In these cases, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie Ireland Unlimited Company (<span style="color:#000000;">&#8220;</span>AbbVie<span style="color:#000000;">&#8221;</span>), one of the Company<span style="color:#000000;">&#8217;</span>s collaboration partners, entered into a license agreement with Seattle Genetics, Inc. (<span style="color:#000000;">&#8220;</span>SGEN<span style="color:#000000;">&#8221;</span>) to license certain intellectual property rights. As part of the Company<span style="color:#000000;">&#8217;</span>s collaboration agreement with AbbVie, the Company is required to pay SGEN sublicense fees for certain milestone achievements and annual maintenance fee. These sublicense fees are treated as reductions to the transaction price and combined with the performance obligation to which they relate.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss represents all changes in stockholders&#8217; equity except those resulting from distributions to stockholders. The Company&#8217;s non-credit related unrealized gains and losses on short-term investments and impact of adoption of new accounting pronouncements during the period represent the components of other comprehensive income (loss) that is excluded from the reported net loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Contract Balances</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Contract Balances </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customer payments are recorded as deferred revenue upon receipt or when due and may require deferral of revenue recognition to a future period until the Company satisfies its performance obligations under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company<span style="color:#000000;">&#8217;</span>s right to consideration is unconditional.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its stock-based awards made to employees based on the fair values of the awards as of the grant date using the Black-Scholes option-pricing model. Stock-based compensation expense is recognized over the requisite service period using the ratable method and is based on the value of the portion of stock-based payment awards that is ultimately expected to vest.&#160;&#160;Forfeitures are recognized as they occur.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 2019, the Company adopted ASU No. 2018-07, <span style="font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting.</span> Under this new standard, stock options granted to non-employees as consideration for<span style="letter-spacing:0.4pt;"> </span>services received are measured on the date of grant using the Black-Scholes option-pricing model.&#160;&#160;The<span style="letter-spacing:0.4pt;"> related </span>grant date fair values of stock options are expensed on a straight-line basis over the period, generally the vesting period, during which<span style="letter-spacing:0.3pt;"> </span>the non-employee is required to provide service in exchange for the award.&#160;&#160;<span style="font-style:italic;">&#160;&#160;</span></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the adoption of ASU 2018-07, such stock-based compensation expense was measured on the date of performance at the fair value of the consideration received or the fair value<span style="letter-spacing:0.4pt;"> </span>of the equity instruments issued, using the Black-Scholes option-pricing model, whichever can be more<span style="letter-spacing:0.45pt;"> </span>reliably measured. Stock-based compensation expense for options granted to non-employees was periodically remeasured as the underlying options<span style="letter-spacing:0.1pt;"> </span>vest.</p>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes using an asset and liability approach. Deferred tax assets and liabilities reflect the net tax effects of temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Company records a valuation allowance to reduce its deferred tax assets to reflect the net amount that it believes as more likely than not to be realized. Realization of the deferred tax assets is dependent on the generation of future taxable income, the amount and timing of which are uncertain. The valuation allowance requires an assessment of both positive and negative evidence when determining whether it is more likely than not that deferred tax assets are recoverable. Based upon the weight of available evidence at December 31, 2020, the Company continues to maintain a full valuation allowance against all of its deferred tax assets after management considered all available evidence, both positive and negative, including but not limited to its historical operating results, income or loss in recent periods, cumulative income in recent years, forecasted earnings, future taxable income, and significant risk and uncertainty related to forecasts.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the tax effects of an uncertain tax position only if it is more likely than not that it will be sustained based solely on its technical merits as of the reporting date and only in an amount more likely than not that it will be sustained upon review by the tax authorities. The Company evaluates uncertain tax positions on a quarterly basis and adjust the liability for changes in facts and circumstances, such as new regulations or interpretations by the taxing authorities, new information obtained during a tax examination, significant amendment to an existing tax law, or resolution of an examination. To the extent that the final tax outcome of these matters is different than the amounts recorded, such differences will impact the income tax provision in the period in which such determination is made. The resolution of its uncertain income tax positions is dependent on uncontrollable factors such as law changes, new case law, and the willingness of the income tax authorities to settle, including the timing thereof and other factors. Although the Company does not anticipate significant changes to its uncertain income tax positions in the next twelve months, items outside of its control could cause its uncertain income tax positions to change in the future, which would be recorded in its statements of operations. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company <span style="color:#000000;">records accrued liabilities for estimated costs of research and development activities conducted by third-party service providers, which include the conduct of preclinical and clinical studies, and contract manufacturing activities. The Company records the estimated costs of research and development activities based upon the estimated amount of services provided but not yet invoiced, and includes these costs in accrued liabilities in the balance sheets and within research and development expense in the statements of operations. These costs are a significant component of the Company&#8217;s research and development expenses. The Company accrues for these costs based on factors such as estimates of the work completed and in accordance with agreements established with its third-party service providers under the service agreements. The Company makes significant judgments and estimates in determining the accrued liabilities balance in each reporting period. As actual costs become known, the Company adjusts its accrued liabilities. The Company has not experienced any material differences between accrued costs and actual costs incurred. However, the status and timing of actual services performed may vary from the Company&#8217;s estimates, resulting in adjustments to expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect the Company&#8217;s results of operations.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, the cost of services provided by outside contractors, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services. All costs associated with research and development are expensed as incurred.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2019, the Company acquired certain technology know-how that is complementary to the Company&#8217;s proprietary Probody technology from a third party for $5.0 million.&#160;&#160;The Company plans to use this technology in certain of the Company&#8217;s discovery stage projects, and has concluded that the technology acquired does not have an alternative future use.&#160;&#160;Accordingly, the $5.0 million has been recorded as research and development expense for 2019.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Leases</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company adopted the Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-02, <span style="font-style:italic;">Leases (Topic 842)</span> on January 1, 2019, using the modified retrospective approach.  As a result of the adoption of ASC 842, the Company recorded a right-of-use asset of $28.0 million and a lease liability $30.1 million on January 1, 2019.&#160;&#160;There was no impact on the Company&#8217;s accumulated deficit as of the adoption date.&#160;&#160;The Company determines if an arrangement is or contains a lease at inception.&#160;&#160;Operating leases are recorded as operating lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the Company&#8217;s balance sheet.&#160;&#160;ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term.&#160;&#160;The Company uses an implicit rate when readily available, or its incremental borrowing rate based on the information available at lease commencement date in determining the present value of lease payments.&#160;&#160;The operating lease ROU assets also include any lease prepayments made and reduced by lease incentives. The Company&#8217;s lease terms may include options to extend the lease when it is reasonably certain that such option will be exercised. Lease expenses are recognized on a straight-line basis over the lease term.&#160;&#160;The Company elected the short-term lease recognition exemption<span style="Background-color:#FFFFFF;color:#000000;">.</span> The Company&#8217;s operating lease arrangement includes lease and non-lease components which are generally accounted for separately.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adopted Accounting Pronouncements and Recent Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#263238;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Adopted Accounting Pronouncements </p>
<p id="S170363231" style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Financial Instruments - Credit Losses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</span>. The new standard changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. <span style="color:#000000;">This new standard also requires that credit losses related to available-for-sale debt securities be recorded as an allowance through net income rather than reducing the carrying amount under the previous other-than-temporary-impairment model. </span>The Company adopted this standard on January 1, 2020 using a modified retrospective approach.&#160;&#160;There was no impact on the Company&#8217;s accumulated deficit as of January 1, 2020 as there was no incremental impairment loss to be recognized upon the adoption of this ASU.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Simplification of the Test for Goodwill Impairment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, the FASB issued ASU No. 2017-04, <span style="font-style:italic;">Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span>. The new standard simplifies the measurement of goodwill by eliminating the Step 2 impairment test. Step 2 measures a goodwill impairment loss by comparing the implied fair value of a reporting unit's goodwill with the carrying amount of that goodwill. The new guidance requires an entity to compare the fair value of a reporting unit with its carrying amount and recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit's fair value. Additionally, an entity should consider income tax effects from any tax-deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. The Company adopted this standard on January 1, 2020 and there was no material impact on its financial statement.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair Value Measurement Disclosure Requirements Modification</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No. 2018-13, <span style="font-style:italic;">Fair Value Measurement (Topic 820)</span>. The amendments in this ASU modify the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. Various disclosure requirements have been removed, including the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels, the valuation processes for Level 3 fair value measurements held at the end of the reporting period. The ASU also modified various disclosure requirements and added some disclosure requirements for Level 3 fair value measurements. The amendments in this ASU were effective for the Company on January 1, 2020 and there was no material impact on its financial statements upon adoption of this ASU. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:justify;margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Internal Use Software Guidance for Cloud Computing Arrangement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No. 2018-15, <span style="font-style:italic;">Intangibles-Goodwill and Other- Internal-Use Software (Subtopic 350-40)</span>. The amendments in this ASU on the accounting for implementation, setup and other upfront costs (collectively &#8220;implementation costs&#8221;) apply to entities that are a customer in a hosting arrangement. The amendments under this ASU align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. Accordingly, the amendments in this ASU require an entity in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to expense. They also require an entity to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. The Company adopted this standard on January 1, 2020 and there was no material impact on its financial statement upon adoption of this ASU.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Collaborative Arrangements and Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued&#160;ASU No. 2018-18, <span style="font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the interaction between Topic 808 and Topic 606</span>.&#160;&#160;The amendments in&#160;this ASU targeted improvements to generally accepted accounting principles for collaborative arrangements by clarifying that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. In addition, unit-of-account guidance in Topic 808 was aligned with the guidance in Topic 606 (that is, a distinct good or service) when an entity is assessing whether the collaborative arrangement or a part of the arrangement is within the scope of Topic 606.&#160;The ASU&#160;was effective for the Company on January 1, 2020, and there was no material impact on its financial statements upon adoption of this ASU.</p>
<p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Share-Based Payment to Customer</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">In November 2019, the FASB issued ASU 2019-08,</span><span style="font-style:italic;Background-color:#FFFFFF;"> Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Codification Improvements &#8211; Share-Based Consideration Payable to a Customer. </span><span style="color:#000000;">The amendments in this ASU require that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in Topic 718. Under ASC 606, these awards are considered a reduction of the transaction price, unless the awards are payment for a distinct good or service received from the customer and should be recorded as a reduction of the transaction price.&#160;&#160;However, the ASU requires these awards to be measured on the basis of the grant-date fair value of the share-based payment award in accordance with Topic 718 and should be recognized at the later of when the award is promised and when the entity recognizes revenue for the transfer of the related goods or services in accordance with ASC 606.&#160;&#160;The ASU&#160;is effective for the Company on January 1, 2020, and there was no material impact on its financial statements upon adoption of this ASU.</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU 2019-12, <span style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span>. The amendments in this ASU simplify the accounting for income taxes by removing certain exceptions to the general principles of ASC 740 in order to reduce cost and complexity of its application.&#160;&#160;The ASU removes the exception related to the incremental approach for intraperiod tax allocation as well as two exceptions related to accounting for outside basis differences of equity method investments and foreign subsidiaries.&#160;&#160;The ASU also amends the scope of ASC 740 related to a franchise tax (or similar tax) that is partially based on income; clarifies when a step-up in the tax basis of goodwill should be considered part of the business combination in which the book goodwill was originally recognized and when it should be considered a separate transaction; specifies that an entity is not required to allocate income tax expense to a legal entity that is both not subject to tax and disregarded by the taxing authority; and&#160;&#160;clarifies that all tax effects, both deferred and current, should be accounted for in the interim period that includes the enactment date.&#160;&#160;The ASU&#160;is effective for the Company on January 1, 2021, and interim periods within those fiscal years.&#160;&#160;The Company does not expect the adoption of this ASU will have a material impact on its financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624084729192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Customers and Collaboration Partners who Represent 10% or More of Total Revenue During Each Period Presented or Net Accounts Receivable Balance</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Customers and collaboration partners who represent 10% or more of the Company&#8217;s total revenue during each period presented or accounts receivable balance at each respective balance sheet date are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accounts Receivable, net</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year&#160;Ended December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.56%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie Ireland Unlimited Company</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,192</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,878</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,997</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas Pharma Inc.</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,931</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol-Myers Squibb Company</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,740</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,780</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue from customers who represent 10% or more</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; of the Company's total revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,753</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,618</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,777</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.3%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">798</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.56%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Schedule of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the amounts shown in the statement of cash flows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.72%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.58%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.66%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,859</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.44%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">188,425</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:64.58%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.66%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,776</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.44%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">189,342</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of Useful Lives of Property and Equipment</a></td>
<td class="text">The useful lives of property and equipment are as follows:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.44%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.84%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shorter of remaining lease term or estimated life of the assets</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property plant and equipment estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of cash, cash equivalents, and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624161655752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following weighted-average outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented, because including them would have been anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:46.86%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.74%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.86%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options and ESPP to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,388,691</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,687,844</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.74%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.96%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,478,755</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624161806616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Short-Term Investments Subject to Fair Value Measurements on a Recurring Basis</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth the fair value of the Company&#8217;s short-term investments subject to fair value measurements on a recurring basis and the level of inputs used in such measurements:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Allowance for Credit Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,121</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,121</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (money market funds)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,254</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,260</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total Securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256,292</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256,298</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:5pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Hierarchy</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Allowance</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Credit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holding</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Losses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair&#160;Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.18%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,757</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170,757</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.38%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash (money market funds)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.24%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">917</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. Government bonds</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level I</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,610</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107,720</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.38%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total securities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.24%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279,284</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.58%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">279,394</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624168166264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.12%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,772</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,124</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,600</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,555</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,728</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,483</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">252</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">236</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.78%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,376</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.06%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,422</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,426</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,050</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.78%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,950</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.06%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,372</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624090281576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill And Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Goodwill and Intangible Assets</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill and intangible assets consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">949</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">949</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In-process research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,750</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated amortization</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(583</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(438</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,167</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,312</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624082044104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consisted of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and clinical expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,092</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,006</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payroll and related expenses</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,362</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,721</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal and professional expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">815</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,062</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease liabilities - short term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,195</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,810</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other accrued expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">595</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,059</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,051</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624173249000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue by Collaboration Partners</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the revenue by collaboration partners:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">AbbVie</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,192</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,878</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,997</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amgen</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,609</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,871</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,899</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Astellas</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,931</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bristol Myers Squibb</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,630</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,740</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,780</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ImmunoGen</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,471</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,355</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100,362</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,489</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,502</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Contract Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents changes in the Company<span style="color:#000000;">&#8217;</span>s total contract liabilities for the year ended December 31, 2020 (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deductions</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance at</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="14" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:70.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contract liabilities:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.94%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">230,239</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,109</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261,130</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624161979912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SupplementalInformationRelatedToLeasesTableTextBlock', window );">Summary of Supplemental Information Related to Leases</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Supplemental information related to leases are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:95%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for amounts included in the measurement of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,990</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,855</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.58%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental balance sheet information related to leases:</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,495</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,382</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,195</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,810</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-current operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,675</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,871</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,870</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,681</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average remaining lease term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000744">5.75</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000745">6.85</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average discount rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.25</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.25</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:95%;">
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.42%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Maturity of operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,129</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,273</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,420</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,572</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025 and beyond</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,116</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.3%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.1%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.42%;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.7%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,510</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,640</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.3%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.1%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.42%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.7%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.42%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,870</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_SupplementalInformationRelatedToLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_SupplementalInformationRelatedToLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089408568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule Reserved Shares of Common Stock Issuance on Converted Basis</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had reserved shares of common stock for issuance, as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,929,530</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,936,168</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future stock option grants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,903,398</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,145,266</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares available for future employee stock purchase plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,935,683</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,609,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,768,611</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,690,571</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624082171256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Activity Under Company's Stock Option Plans</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Activity under the Company&#8217;s stock option plans is set forth below:</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.04%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">for Grant</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.12%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2019</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,145,266</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,936,168</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.26</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options authorized</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,820,923</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,219,044</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,219,044</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.23</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.34%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,064,830</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.58</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.12%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,156,253</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,160,852</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.75</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,903,398</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,929,530</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000818">6.4</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,844</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable&#8212;December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,145,652</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.69</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000819">4.7</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,031</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.34%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest&#8212;December 31, 2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.44%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,929,530</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:8.44%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000820">6.4</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.12%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,844</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Total Stock-based Compensation Recognized</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation recorded related to options granted to employees and non-employees and employee stock purchase plan was as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:46.5%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.24%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,825</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,226</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.24%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,313</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,961</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,874</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,565</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.24%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,786</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,100</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.24%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,878</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Estimated Fair Value of Employee Stock Options and ESPP Using Black-Scholes Valuation Model</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company estimated the fair value of employee stock options and ESPP using the Black-Scholes valuation model based on the date of grant with the following assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.36%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ESPP</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="5" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:16.52%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000860">64.4% - 73.3%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000861">64.4% - 68.6%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000862">65.6% - 69.3%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000863">47.3% - 122.1%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000864">60.8% - 71.9%</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000865">46.4% - 70.5%</span></p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000866">0.2% - 1.3%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000867">1.4% - 2.5%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000868">2.5% - 3.0%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000869">0.1% - 0.2%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000870">1.6% - 2.4%</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000871">2.1% - 2.6%</span></p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dividend yield</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000887">&#8212; %</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000888">&#8212; %</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000889">&#8212; %</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212; %</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.52%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160; (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000890">4.7 - 4.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000891">4.9 - 5.0</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000892">4.7 - 4.9</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000872">0.5</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000873">0.5</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.68%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.36%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000874">0.5</span></p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624078196104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Provision for (Benefit from) Income Taxes</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company derives its income only from the United States. The components of the provision for (benefit from) income taxes are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,912</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(390</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,302</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,911</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(390</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,303</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for (benefit from) income taxes</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,911</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(427</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,303</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Tax Rate Reconciliation</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the Company&#8217;s effective tax rate to the statutory U.S. federal rate is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. federal taxes at statutory rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State tax, net of federal benefit</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.3</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.7</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31.2</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22.8</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(49.5</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryback</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Return to provision adjustment</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.3</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.1</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.5</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29.7</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20.4</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Income Tax Assets and Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The types of temporary differences that give rise to significant portions of the Company&#8217;s deferred income tax assets and liabilities are set out below (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,099</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,967</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,468</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credits</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,803</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,940</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,514</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,223</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,813</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,923</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,320</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,832</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,180</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,881</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accruals and deferred rent</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,512</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,296</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,955</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,578</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,837</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,746</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total gross deferred income tax assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111,990</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,353</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,603</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: valuation allowance</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(106,448</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(109,174</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(86,466</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets, net of valuation allowance</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,542</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(433</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(591</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(854</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use assets</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,724</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,330</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(108</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(385</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(243</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(175</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,542</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,179</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,137</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred income tax liabilities</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Schedule of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at the beginning of the year</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,249</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,756</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,320</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to current year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,205</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,403</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,166</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustment based on tax positions related to prior years</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,730</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of the year</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,454</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,249</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,756</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624083873496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Customers and Collaboration Partners who Represent 10% or More of Total Revenue During Each Period Presented or Net Accounts Receivable Balance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,362<span></span>
</td>
<td class="nump">$ 57,489<span></span>
</td>
<td class="nump">$ 59,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts Receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="nump">38,200<span></span>
</td>
<td class="nump">5,900<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctmx_MajorCustomerMember', window );">Major Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,753<span></span>
</td>
<td class="nump">53,618<span></span>
</td>
<td class="nump">51,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts Receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctmx_MajorCustomerMember', window );">Major Customer | AbbVie Ireland Unlimited Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,192<span></span>
</td>
<td class="nump">5,878<span></span>
</td>
<td class="nump">18,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctmx_MajorCustomerMember', window );">Major Customer | Bristol Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,630<span></span>
</td>
<td class="nump">47,740<span></span>
</td>
<td class="nump">$ 32,780<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts Receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ctmx_MajorCustomerMember', window );">Major Customer | Astellas Pharma Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts Receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ctmx_MajorCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ctmx_MajorCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624084424056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Activity </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfBusinessActivities', window );">Number of business activities | Activity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Increase in accumulated deficit balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(450,115,000)<span></span>
</td>
<td class="num">(417,230,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,936,000<span></span>
</td>
<td class="nump">131,619,000<span></span>
</td>
<td class="nump">$ 103,866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,495,000<span></span>
</td>
<td class="nump">25,382,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,870,000<span></span>
</td>
<td class="nump">27,681,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ctmx_ProbodyTechnologyMember', window );">Probody technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Acquired, technology know-how</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member', window );">Adjustments | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Increase in accumulated deficit balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,900,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfBusinessActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of business activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfBusinessActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ctmx_ProbodyTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ctmx_ProbodyTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624085887320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash And Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 191,859<span></span>
</td>
<td class="nump">$ 188,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">917<span></span>
</td>
<td class="nump">917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 192,776<span></span>
</td>
<td class="nump">$ 189,342<span></span>
</td>
<td class="nump">$ 248,494<span></span>
</td>
<td class="nump">$ 178,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624087851512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property and equipment</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ctmx_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of property and equipment</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Estimated useful life of leasehold improvements, description</a></td>
<td class="text">Shorter of remaining lease term or estimated life of the assets<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ctmx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ctmx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624090859080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Adopted and Recent Accounting Pronouncements - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member', window );">ASU 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201704Member', window );">ASU 2017-04</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member', window );">ASU 2018-13</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member', window );">ASU 2018-15</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member', window );">ASU 2018-18</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201908Member', window );">ASU 2019-08</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member', window );">ASU 2019-12</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in accounting principle, accounting standards update, adoption date</a></td>
<td class="text">Jan.  01,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in accounting principle, accounting standards update, adopted [true false]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in accounting principle, accounting standards update, immaterial effect [true false]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201704Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201704Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201815Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201818Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201908Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201908Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201912Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624078123064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ctmx_OptionsAndESPPToPurchaseCommonStockMember', window );">Options and ESPP to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">11,388,691<span></span>
</td>
<td class="nump">9,687,844<span></span>
</td>
<td class="nump">7,478,755<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ctmx_OptionsAndESPPToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ctmx_OptionsAndESPPToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624161753160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Schedule of Short-Term Investments Subject to Fair Value Measurements on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 256,292<span></span>
</td>
<td class="nump">$ 279,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Holding Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Aggregate Fair Value</a></td>
<td class="nump">256,298<span></span>
</td>
<td class="nump">279,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">191,859<span></span>
</td>
<td class="nump">188,425<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level I | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">131,121<span></span>
</td>
<td class="nump">170,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level I | Restricted cash (money market funds)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">917<span></span>
</td>
<td class="nump">917<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level I | U. S. Government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term Investments, Amortized Cost</a></td>
<td class="nump">124,254<span></span>
</td>
<td class="nump">107,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Short-term Investments, Gross Unrealized Holding Gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term Investments, Aggregate Fair Value</a></td>
<td class="nump">$ 124,260<span></span>
</td>
<td class="nump">$ 107,720<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and short term investments, accumulated gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and short term investments, amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=ctmx_MoneyMarketFundsIncludedInRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=ctmx_MoneyMarketFundsIncludedInRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624090253512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Additional Information (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Contractual maturities of greater than twelve months</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089086952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Machinery and equipment</a></td>
<td class="nump">$ 13,772<span></span>
</td>
<td class="nump">$ 12,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ComputerEquipmentAndSoftwareGross', window );">Computer equipment and software</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Furniture and fixtures</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">1,728<span></span>
</td>
<td class="nump">1,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">18,376<span></span>
</td>
<td class="nump">16,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(11,426)<span></span>
</td>
<td class="num">(9,050)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 6,950<span></span>
</td>
<td class="nump">$ 7,372<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ComputerEquipmentAndSoftwareGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Computer equipment and software gross.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ComputerEquipmentAndSoftwareGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624082575256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624080405688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Average estimated lives of patents</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624080624072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Goodwill and Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_GoodwillAbstract', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 949<span></span>
</td>
<td class="nump">$ 949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible assets, gross</a></td>
<td class="nump">1,750<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="num">(583)<span></span>
</td>
<td class="num">(438)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">$ 1,167<span></span>
</td>
<td class="nump">$ 1,312<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_GoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_GoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624080522696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AccruedResearchAndClinicalCurrent', window );">Research and clinical expenses</a></td>
<td class="nump">$ 10,092<span></span>
</td>
<td class="nump">$ 19,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">8,362<span></span>
</td>
<td class="nump">6,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal and professional expenses</a></td>
<td class="nump">815<span></span>
</td>
<td class="nump">1,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - short term</a></td>
<td class="nump">3,195<span></span>
</td>
<td class="nump">2,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">595<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 23,059<span></span>
</td>
<td class="nump">$ 30,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_AccruedResearchAndClinicalCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and clinical current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_AccruedResearchAndClinicalCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624084269592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Agreements - Schedule of Revenue by Collaboration Partners (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 100,362<span></span>
</td>
<td class="nump">$ 57,489<span></span>
</td>
<td class="nump">$ 59,502<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">38,192<span></span>
</td>
<td class="nump">5,878<span></span>
</td>
<td class="nump">18,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AmgenIncMember', window );">Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">8,609<span></span>
</td>
<td class="nump">3,871<span></span>
</td>
<td class="nump">4,899<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember', window );">Bristol Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">39,630<span></span>
</td>
<td class="nump">$ 47,740<span></span>
</td>
<td class="nump">32,780<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember', window );">Astellas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 13,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_ImmunoGenIncMember', window );">ImmunoGen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_PfizerIncMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_ImmunoGenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_ImmunoGenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624083839496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2016 </div>
<div>USD ($) </div>
<div>Agreement </div>
<div>Target </div>
<div>AccountingUnit</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>Target</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,362,000<span></span>
</td>
<td class="nump">$ 57,489,000<span></span>
</td>
<td class="nump">$ 59,502,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,130,000<span></span>
</td>
<td class="nump">$ 230,239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_MilestonePaymentsReceivable', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="nump">$ 38,200,000<span></span>
</td>
<td class="nump">$ 5,900,000<span></span>
</td>
<td class="nump">$ 19,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AggregateCollaborationTransactionAmount', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_EstimatedSublicenseFees', window );">Estimated sublicense fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfAccountingUnits', window );">Number of accounting units | AccountingUnit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfCollaborationAgreements', window );">Number of collaboration agreements | Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts', window );">Percentage of net profits or net losses related to development and commercialization costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Amount due from agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | CD71 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod', window );">Milestone payment received</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000.0<span></span>
</td>
<td class="nump">$ 14,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_MilestonePaymentsReceivable', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,200,000<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | CD71 Agreement | Transferred over Time</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="nump">$ 26,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | CD71 Agreement | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AggregateCollaborationTransactionAmount', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_EstimatedSublicenseFees', window );">Estimated sublicense fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_MilestonePaymentsReceivable', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | CD71 Agreement | U.S</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentPaymentsReceivableProfitSplitOnSales', window );">Profit split on U.S. sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | CD71 Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones', window );">Contingent payments receivable upon achieving development, regulatory and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | Seattle Genetics Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_PaymentsOfSublicenseFees', window );">Sublicense fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | Seattle Genetics Agreement | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_PaymentsOfSublicenseFees', window );">Sublicense fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | Discovery Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfTargetsSelected', window );">Number of targets selected | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue recognition upon performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | Discovery Agreement | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AggregateCollaborationTransactionAmount', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | Discovery Agreement | Second Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_MilestonePaymentReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | Discovery Agreement | Second Target | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AggregateCollaborationTransactionAmount', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_EstimatedResearchServicePeriod', window );">Estimated research service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | Discovery Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfTargets', window );">Number of targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | Discovery Agreement | Maximum | Development, Regulatory and Commercial Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_AggregateCollaborationTransactionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate collaboration transaction amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_AggregateCollaborationTransactionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ContingentMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ContingentMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ContingentPaymentsReceivableProfitSplitOnSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payments receivable profit split on sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ContingentPaymentsReceivableProfitSplitOnSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payments receivable upon achieving development, regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_EstimatedResearchServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated research service period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_EstimatedResearchServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_EstimatedSublicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated sublicense fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_EstimatedSublicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_MilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_MilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received from revenue recognized during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfAccountingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of accounting units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfAccountingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfTargetsSelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targets selected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfTargetsSelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_PaymentsOfSublicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of sublicense fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_PaymentsOfSublicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net Income or net losses related to development and commercialization costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_CD71AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_CD71AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_SeattleGeneticsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_SeattleGeneticsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_DiscoveryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_DiscoveryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ctmx_SecondTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ctmx_SecondTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624090091960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details 1)<br></strong></div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | Discovery Agreement | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2016-04-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue recognition upon performance obligation, service period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_DiscoveryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_DiscoveryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2016-04-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2016-04-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624083430968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Agreements - Amgen, Inc - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 29, 2017 </div>
<div>USD ($) </div>
<div>Target</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock, value of shares issued in connection with agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,596,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,059,000<span></span>
</td>
<td class="nump">$ 30,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,362,000<span></span>
</td>
<td class="nump">$ 57,489,000<span></span>
</td>
<td class="nump">$ 59,502,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,130,000<span></span>
</td>
<td class="nump">$ 230,239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AmgenIncMember', window );">Amgen Inc | EGFR Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AmgenIncMember', window );">Amgen Inc | Amgen Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Amgen Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_CommonStockSharesIssuableUnderAgreement', window );">Common stock, shares issuable under agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,156,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock, shares issuable under agreement, price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Common stock, value of shares issued in connection with agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare', window );">Period used to calculate weighted average price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement', window );">Lock-up period for share disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_EstimatedPremiumOnIssuanceOfShares', window );">Estimated premium on the stock sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfTargetsSelected', window );">Number of targets selected | Target</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfAdditionalCollaborationTarget', window );">Number of additional collaboration target | Target</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AggregateCollaborationTransactionAmount', window );">Total transaction price</a></td>
<td class="nump">$ 51,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock', window );">Portion of transaction price allocated to premium on sale of common stock</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_EstimatedFairValueOfProducts', window );">Estimated fair value of products</a></td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="nump">$ 3,900,000<span></span>
</td>
<td class="nump">$ 4,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Amount due from agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Amgen Inc | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones', window );">Contingent payments payable</a></td>
<td class="nump">203,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Amgen Inc | EGFR Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AggregateCollaborationTransactionAmount', window );">Total transaction price</a></td>
<td class="nump">46,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_EstimatedResearchServicePeriod', window );">Estimated research service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,800,000<span></span>
</td>
<td class="nump">37,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Amgen Inc | EGFR Products | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="nump">$ 455,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ProfitShareUponExerciseOfCoDevelopmentOption', window );">Percentage share of profit and losses</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Amgen Inc | Amgen Products | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="nump">$ 950,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfTargets', window );">Number of targets | Target</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Amgen Inc | Amgen Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AggregateCollaborationTransactionAmount', window );">Total transaction price</a></td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_EstimatedResearchServicePeriod', window );">Estimated research service period</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue recognition upon performance obligation</a></td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ctmx_SublicenseAgreementMember', window );">Sublicense Agreement | Amgen Inc | UC Regents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ctmx_SublicenseAgreementMember', window );">Sublicense Agreement | Amgen Inc | Maximum | UC Regents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds', window );">Sublicense payment percentage</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_AggregateCollaborationTransactionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate collaboration transaction amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_AggregateCollaborationTransactionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_CommonStockSharesIssuableUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares issuable under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_CommonStockSharesIssuableUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ContingentMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ContingentMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent payments payable upon achieving development regulatory and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_EstimatedFairValueOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_EstimatedFairValueOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_EstimatedPremiumOnIssuanceOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated premium on issuance of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_EstimatedPremiumOnIssuanceOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_EstimatedResearchServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated research service period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_EstimatedResearchServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License payment percentage equivalence to upfront and milestone proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lock-up period for share transaction under collaboration and license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfAdditionalCollaborationTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional collaboration target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfAdditionalCollaborationTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfTargetsSelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targets selected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfTargetsSelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period used to calculate weighted average price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium on issuance of shares allocated to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ProfitShareUponExerciseOfCoDevelopmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profit share upon exercise of co-development option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ProfitShareUponExerciseOfCoDevelopmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ctmx_EGFRProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ctmx_EGFRProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ctmx_AmgenOtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ctmx_AmgenOtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ctmx_AmgenProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ctmx_AmgenProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_SublicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_SublicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ctmx_RegentsOfTheUniversityOfCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ctmx_RegentsOfTheUniversityOfCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624162236952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Agreements - Astellas Pharma Inc - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 23, 2020 </div>
<div>USD ($) </div>
<div>Target</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,362<span></span>
</td>
<td class="nump">$ 57,489<span></span>
</td>
<td class="nump">$ 59,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,130<span></span>
</td>
<td class="nump">$ 230,239<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember', window );">Astellas Pharma Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Astellas Pharma Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfTargetsSelected', window );">Number of targets selected | Target</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfAdditionalCollaborationTarget', window );">Number of additional collaboration target | Target</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AggregateCollaborationTransactionAmount', window );">Total transaction price</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ResearchAndDevelopmentServiceFees', window );">Research and development service fees</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_EstimatedResearchServicePeriod', window );">Estimated research service period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_EstimatedResearchServiceTerminationMonthAndYear', window );">Estimated research service termination month &amp; year</a></td>
<td class="text">2025-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Amount due from customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Astellas Pharma Inc. | Additional Contingent Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Astellas Pharma Inc. | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfTargets', window );">Number of targets | Target</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_RightToExpandNumberOfAdditionalCollaborationTarget', window );">Right to expand the number of additional collaboration target | Target</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Astellas Pharma Inc. | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_RightToExpandNumberOfAdditionalCollaborationTarget', window );">Right to expand the number of additional collaboration target | Target</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_AggregateCollaborationTransactionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate collaboration transaction amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_AggregateCollaborationTransactionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ContingentMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ContingentMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_EstimatedResearchServicePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated research service period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_EstimatedResearchServicePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_EstimatedResearchServiceTerminationMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated research service termination month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_EstimatedResearchServiceTerminationMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfAdditionalCollaborationTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional collaboration target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfAdditionalCollaborationTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfTargetsSelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of targets selected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfTargetsSelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ResearchAndDevelopmentServiceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development service fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ResearchAndDevelopmentServiceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_RightToExpandNumberOfAdditionalCollaborationTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right to expand the number of additional collaboration target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_RightToExpandNumberOfAdditionalCollaborationTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ctmx_AdditionalContingentPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ctmx_AdditionalContingentPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624087984712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Agreements - Bristol-Myers Squibb Company - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 25, 2017 </div>
<div>USD ($) </div>
<div>Target</div>
</th>
<th class="th">
<div>Jul. 07, 2014 </div>
<div>USD ($) </div>
<div>Target </div>
<div>Term</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 17, 2017 </div>
<div>Target</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,362,000<span></span>
</td>
<td class="nump">$ 57,489,000<span></span>
</td>
<td class="nump">$ 59,502,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,130,000<span></span>
</td>
<td class="nump">$ 230,239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember', window );">Bristol Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Bristol Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_CollaborationTargetResearchTerm', window );">Collaboration target research term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfAdditionalCollaborationTarget', window );">Number of additional collaboration target | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms', window );">Research terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each collaboration target had a two-year research term and the two additional targets had to be nominated by Bristol Myers Squibb within five years of the effective date of the BMS Agreement. The research term for each collaboration target could be extended in one year increments up to three times.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ExtensionOfResearchTermForEachCollaborationTarget', window );">Extension of research term for each collaboration target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfResearchTargetsSelected', window );">Number of research targets selected | Target</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AggregateCollaborationTransactionAmount', window );">Total transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_UpfrontFeeReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ResearchAndDevelopmentServiceFees', window );">Research and development service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_EstimatedResearchServiceTerminationDate', window );">Estimated research service termination date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 25,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,600,000<span></span>
</td>
<td class="nump">$ 47,700,000<span></span>
</td>
<td class="nump">$ 32,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,300,000<span></span>
</td>
<td class="nump">$ 158,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Amount due from agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Bristol Myers Squibb Company | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,779,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Bristol Myers Squibb Company | Pre Clinical Candidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Bristol Myers Squibb Company | New Drug Application for CTLA-4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Bristol Myers Squibb Company | Third And Fourth Immuno-Oncology Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive', window );">Contingent milestone payments, no longer eligible to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">894,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Bristol Myers Squibb Company | Accelerated Recognition of Deferred Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Maximum | Bristol Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfOncologyTarget', window );">Number of oncology target | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfCollaborationTarget', window );">Number of collaboration target | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_PeriodOfNominationOfAdditionalTarget', window );">Period of nomination of additional target from effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes', window );">Times of increments for extended collaboration target research time | Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="nump">$ 3,586,000,000.0<span></span>
</td>
<td class="nump">$ 1,192,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Maximum | Bristol Myers Squibb Company | Each Of Two Additional Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContingentMilestonePaymentsReceivable', window );">Contingent milestone payments receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember', window );">Collaboration and License Agreement | Maximum | Bristol Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfAdditionalCollaborationTarget', window );">Number of additional collaboration target | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_AggregateCollaborationTransactionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate collaboration transaction amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_AggregateCollaborationTransactionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_CollaborationTargetResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration target research term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_CollaborationTargetResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent milestone payments no longer eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ContingentMilestonePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future contingent milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ContingentMilestonePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_EstimatedResearchServiceTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated research service termination date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_EstimatedResearchServiceTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ExtensionOfResearchTermForEachCollaborationTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extension of research term for each collaboration target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ExtensionOfResearchTermForEachCollaborationTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increments of extended collaboration target research times.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received from revenue recognized during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfAdditionalCollaborationTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional collaboration target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfAdditionalCollaborationTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfCollaborationTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of collaboration target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfCollaborationTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfOncologyTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of oncology target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfOncologyTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfResearchTargetsSelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of research targets selected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfResearchTargetsSelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_PeriodOfNominationOfAdditionalTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of nomination of additional target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_PeriodOfNominationOfAdditionalTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ResearchAndDevelopmentServiceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development service fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ResearchAndDevelopmentServiceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_UpfrontFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fee received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_UpfrontFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ctmx_PreClinicalCandidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ctmx_PreClinicalCandidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ctmx_DrugApplicationForCTLA4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ctmx_DrugApplicationForCTLA4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ctmx_ThirdAndFourthTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ctmx_ThirdAndFourthTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ctmx_AcceleratedRecognitionOfDeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ctmx_AcceleratedRecognitionOfDeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ctmx_AchievingAdditionalTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ctmx_AchievingAdditionalTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624088438504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Agreements - ImmunoGen, Inc - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>USD ($) </div>
<div>Target</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Estimated total fair value consideration recorded as deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,130,000<span></span>
</td>
<td class="nump">$ 230,239,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,362,000<span></span>
</td>
<td class="nump">57,489,000<span></span>
</td>
<td class="nump">$ 59,502,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Charge to research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,936,000<span></span>
</td>
<td class="nump">$ 131,619,000<span></span>
</td>
<td class="nump">103,866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Immuno Gen Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_CashPaymentToExecuteAgreement', window );">Upfront cash payment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfResearchTargetsSelected', window );">Number of research targets selected | Target</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Estimated total fair value consideration recorded as deferred revenue</a></td>
<td class="nump">$ 13,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_MilestonePaymentPayable', window );">Milestone payments payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Charge to research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_CashPaymentToExecuteAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payment to execute the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_CashPaymentToExecuteAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_MilestonePaymentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_MilestonePaymentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfResearchTargetsSelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of research targets selected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfResearchTargetsSelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_ImmunoGenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_ImmunoGenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624082634376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Agreements - Pfizer Inc - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2013 </div>
<div>Target</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContractWithCustomerLiabilityAdditions', window );">Additional target as deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,362<span></span>
</td>
<td class="nump">$ 57,489<span></span>
</td>
<td class="nump">$ 59,502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement | Pfizer Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfNominatedResearchTargets', window );">Number of research targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfAdditionalResearchTargetsWithNominationOption', window );">Nominated number of additional research targets | Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContractWithCustomerLiabilityAdditions', window );">Additional target as deferred revenue</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized from collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:LicenseAndServiceMember<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfAdditionalResearchTargetsWithNominationOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional research targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfAdditionalResearchTargetsWithNominationOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfNominatedResearchTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of nominated research targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfNominatedResearchTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_PfizerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_PfizerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624078269224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Agreements - Summary of Contract Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue From Contract With Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at 12/31/2019</a></td>
<td class="nump">$ 230,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContractWithCustomerLiabilityAdditions', window );">Additions</a></td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deductions</a></td>
<td class="nump">89,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance at 12/31/2020</a></td>
<td class="nump">$ 261,130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089328568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research and Collaboration Agreements - Contract Liabilities - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContractWithCustomerLiabilityAdditions', window );">Additions to deferred revenue</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Deductions to deferred revenue recognized during the period</a></td>
<td class="nump">89,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">261,130<span></span>
</td>
<td class="nump">$ 230,239<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContractWithCustomerLiabilityAdditions', window );">Additions to deferred revenue</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | CD71 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 25,200<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear', window );">Deferred revenue recognition maturity month and year</a></td>
<td class="text">2022-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | First Target under Discovery Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear', window );">Deferred revenue recognition maturity month and year</a></td>
<td class="text">2022-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | Second Target under Discovery Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear', window );">Deferred revenue recognition maturity month and year</a></td>
<td class="text">2024-06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember', window );">Astellas Pharma Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContractWithCustomerLiabilityAdditions', window );">Additions to deferred revenue</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 67,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear', window );">Deferred revenue recognition maturity month and year</a></td>
<td class="text">2025-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AmgenIncMember', window );">Amgen Inc | EGFR Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 29,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear', window );">Deferred revenue recognition maturity month and year</a></td>
<td class="text">2024-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AmgenIncMember', window );">Amgen Inc | Amgen Other Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear', window );">Deferred revenue recognition maturity month and year</a></td>
<td class="text">2023-09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember', window );">Bristol Myers Squibb Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 128,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear', window );">Deferred revenue recognition maturity month and year</a></td>
<td class="text">2025-04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with customer liability maturity month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_CD71AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_CD71AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_FirstTargetUnderDiscoveryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_FirstTargetUnderDiscoveryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_SecondTargetUnderDiscoveryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_SecondTargetUnderDiscoveryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AmgenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AmgenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ctmx_EGFRProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ctmx_EGFRProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ctmx_AmgenOtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ctmx_AmgenOtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624083803592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 23, 2020</div></th>
<th class="th"><div>Apr. 25, 2017</div></th>
<th class="th"><div>Jul. 07, 2014</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_RoyaltyObligationsFutureMinimumPaymentsDue', window );">Annual minimum royalty obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_LicenseTerminationPeriod', window );">License termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,251,819<span></span>
</td>
<td class="nump">45,523,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,936<span></span>
</td>
<td class="nump">$ 131,619<span></span>
</td>
<td class="nump">$ 103,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,059<span></span>
</td>
<td class="nump">30,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieMember', window );">AbbVie | Discovery Agreement | Second Target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AdditionalSublicenseFees', window );">Additional sublicense fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember', window );">Bristol Myers Squibb Company | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SublicenseFees', window );">Sublicense fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember', window );">Bristol Myers Squibb Company | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember', window );">Astellas Pharma Inc. | Collaboration and License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AdditionalSublicenseFees', window );">Additional sublicense fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | Discovery Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember', window );">AbbVie Ireland Unlimited Company | CD71 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AdditionalSublicenseFees', window );">Additional sublicense fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod', window );">Milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_ImmunoGenIncMember', window );">Immuno Gen Inc | Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_UpfrontLicensePayment', window );">Upfront license payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ctmx_UniversityOfCaliforniaSantaBarbaraMember', window );">UCSB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">157,332<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Fair value of common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_PaymentOfUpfrontFees', window );">Payment of upfront fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_AnnualLicenseMaintenanceFees', window );">Annual license maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_LicensePaymentTerm', window );">License payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_PercentageOfRemainingMaintenanceFeesOutstanding', window );">Percentage of remaining maintenance fees outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_FairValueOfCommonStockIssued', window );">Fair value of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SublicenseFees', window );">Sublicense fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,100<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ctmx_UniversityOfCaliforniaSantaBarbaraMember', window );">UCSB | Sublicense and Maintenance Fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>License Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_AdditionalSublicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional sublicense fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_AdditionalSublicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_AnnualLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_AnnualLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_FairValueOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_FairValueOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_LicensePaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License payment term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_LicensePaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_LicenseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time to terminate license after notice date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_LicenseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received from revenue recognized during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_PaymentOfUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of upfront fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_PaymentOfUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_PercentageOfRemainingMaintenanceFeesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining maintenance fees outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_PercentageOfRemainingMaintenanceFeesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_RoyaltyObligationsFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty obligations future minimum payments due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_RoyaltyObligationsFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_SublicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublicense fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_SublicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_UpfrontLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront license payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_UpfrontLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AbbVieMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AbbVieMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_DiscoveryAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_DiscoveryAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ctmx_SecondTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ctmx_SecondTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_BristolMyersSquibbCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AstellasPharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_AbbVieIrelandUnlimitedCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ctmx_CD71AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ctmx_CD71AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_ImmunoGenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_ImmunoGenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ctmx_UniversityOfCaliforniaSantaBarbaraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=ctmx_UniversityOfCaliforniaSantaBarbaraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ctmx_SublicenseAndMaintenanceFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ctmx_SublicenseAndMaintenanceFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089905112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 21, 2020 </div>
<div>Defendant</div>
</th>
<th class="th">
<div>Mar. 04, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=ctmx_PatentInfringementLawsuitMember', window );">Patent Infringement Lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyLawsuitFilingDate', window );">Lawsuit filed date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">March 4, 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNameOfPlaintiff', window );">Name of plaintiff</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Vytacera Bio, LLC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate', window );">Loss contingency, answer, affirmative defenses and counterclaims filing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 26,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate', window );">Loss contingency, answer and counterclaims by plaintiff filing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  05,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency claim amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=ctmx_SecuritiesClassActionLawsuitMember', window );">Securities Class Action Lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants', window );">Number of current and former officers named as defendants | Defendant</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss contingency answer, affirmative defenses and counterclaims filing date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss contingency, answer and counterclaims by plaintiff filing date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of current and former officers named as defendants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121555522&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLawsuitFilingDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>States the date the complaint was formally filed in a court of law, in arbitration or mediation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLawsuitFilingDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNameOfPlaintiff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identifies the plaintiff in the lawsuit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNameOfPlaintiff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ctmx_PatentInfringementLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ctmx_PatentInfringementLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ctmx_SecuritiesClassActionLawsuitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ctmx_SecuritiesClassActionLawsuitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624084402184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 10, 2015 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 917,000<span></span>
</td>
<td class="nump">$ 917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit outstanding, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">New Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of rentable office and laboratory space | ft&#178;</a></td>
<td class="nump">76,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The term of the Lease commenced on October 1, 2016. The 2016 Lease has an initial term of ten years from the commencement date, and the Company has an option to extend the initial term for an additional five years at the then fair rental value as determined pursuant to the 2016 Lease. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Initial lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Extended lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_MaximumImprovementAllowance', window );">Maximum one-time improvement allowance</a></td>
<td class="nump">$ 12,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ImprovementAllowanceFromRecoverableRent', window );">Improvement allowance from recoverable rent</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">New Lease Agreement | First year of lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_OperatingLeasesRentExpenseAnnualBaseRent', window );">Annual lease rent</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">New Lease Agreement | Second twelve months of lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_OperatingLeasesRentExpenseAnnualBaseRent', window );">Annual lease rent</a></td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember', window );">New Lease Agreement | Tenth year of lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_OperatingLeasesRentExpenseAnnualBaseRent', window );">Annual lease rent</a></td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ImprovementAllowanceFromRecoverableRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Improvement allowance from recoverable rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ImprovementAllowanceFromRecoverableRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_MaximumImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum improvement allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_MaximumImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_OperatingLeasesRentExpenseAnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases rent expense annual base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_OperatingLeasesRentExpenseAnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LeaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ctmx_FirstYearOfLeaseTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ctmx_FirstYearOfLeaseTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ctmx_SecondTwelveMonthsOfLeaseTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ctmx_SecondTwelveMonthsOfLeaseTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ctmx_TenthYearOfLeaseTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ctmx_TenthYearOfLeaseTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089604632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Supplemental Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 4,990<span></span>
</td>
<td class="nump">$ 4,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract', window );"><strong>Supplemental balance sheet information related to leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">22,495<span></span>
</td>
<td class="nump">25,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">3,195<span></span>
</td>
<td class="nump">2,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">21,675<span></span>
</td>
<td class="nump">$ 24,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">us-gaap:OtherLiabilitiesCurrent<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 24,870<span></span>
</td>
<td class="nump">$ 27,681<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_WeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted-average remaining lease term (in years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease</a></td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">6 years 10 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_WeightedAverageDiscountRateAbstract', window );"><strong>Weighted-average discount rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="nump">8.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental balance sheet information related to leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_WeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_WeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_WeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_WeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624090185816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Maturity of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturity of operating lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 5,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">5,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">5,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">5,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter', window );">2025 and beyond</a></td>
<td class="nump">10,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">31,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(6,640)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 24,870<span></span>
</td>
<td class="nump">$ 27,681<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due year five and thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089754616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Oct. 14, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStock', window );">Dividends on common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,596,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_JefferiesMember', window );">Jefferies LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,535,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_PercentageOfSalesCommission', window );">Percentage of sales commission</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_SharesIssuedAveragePricePerShare', window );">Average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_PercentageOfSalesCommissionAndIssuanceCost', window );">Percentage of sales commission and issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ctmx_JefferiesMember', window );">Jefferies LLC | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,535,217<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">5,867,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 134,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts and commissions and offering expenses</a></td>
<td class="nump">$ 9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs, shares</a></td>
<td class="nump">5,867,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price, per share</a></td>
<td class="nump">$ 24.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs, shares</a></td>
<td class="nump">765,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_PercentageOfSalesCommission">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sales commission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_PercentageOfSalesCommission</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_PercentageOfSalesCommissionAndIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of sales commission and issuance cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_PercentageOfSalesCommissionAndIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_SharesIssuedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued average price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_SharesIssuedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ctmx_JefferiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ctmx_JefferiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ctmx_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ctmx_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624078145208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Reserved Shares of Common Stock Issuance on Converted Basis (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_StockOptionsIssuedAndOutstanding', window );">Options issued and outstanding</a></td>
<td class="nump">10,929,530<span></span>
</td>
<td class="nump">9,936,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future stock option grants</a></td>
<td class="nump">2,903,398<span></span>
</td>
<td class="nump">3,145,266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan', window );">Shares available for future employee stock purchase plan</a></td>
<td class="nump">1,935,683<span></span>
</td>
<td class="nump">1,609,137<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total</a></td>
<td class="nump">15,768,611<span></span>
</td>
<td class="nump">14,690,571<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, number of shares available for future issuance under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_StockOptionsIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_StockOptionsIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624090505944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2016</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,768,611<span></span>
</td>
<td class="nump">14,690,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 14,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.94<span></span>
</td>
<td class="nump">$ 7.03<span></span>
</td>
<td class="nump">$ 14.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense, options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Number of shares issued during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,684<span></span>
</td>
<td class="nump">142,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,786<span></span>
</td>
<td class="nump">$ 19,100<span></span>
</td>
<td class="nump">$ 16,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation cost, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="nump">$ 18,900<span></span>
</td>
<td class="nump">16,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ctmx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Estimated fair value of the shares on the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,935,683<span></span>
</td>
<td class="nump">1,609,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized stock-based compensation cost, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate', window );">Plan maximum percentage of eligible compensation to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ctmx_NonEmployeesMember', window );">Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Vesting per Month After First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Options granted generally vest percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctmx_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage', window );">Employees holding voting rights of all classes of stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,698,798<span></span>
</td>
<td class="nump">1,808,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,444,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Increase in number of shares available for issuance, as proportion of issued and outstanding shares of common stock, percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctmx_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Plan | Share Based Compensation Award Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options granted generally vest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Options granted generally vest percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctmx_TwoThousandNineteenStockIncentivePlanMember', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, capital shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,600<span></span>
</td>
<td class="nump">1,337,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,815,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctmx_EarlyExerciseOfEmployeeOptionsMember', window );">Early Exercise of Employee Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options granted generally vest period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ctmx_EarlyExerciseOfEmployeeOptionsMember', window );">Early Exercise of Employee Options | Share Based Compensation Award Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Options granted generally vest percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Estimated fair value of the shares on the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Estimated fair value of the shares on the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award voting rights of common stock holding percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ctmx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ctmx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ctmx_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ctmx_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ctmx_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ctmx_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ctmx_TwoThousandNineteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ctmx_TwoThousandNineteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ctmx_EarlyExerciseOfEmployeeOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ctmx_EarlyExerciseOfEmployeeOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624088804760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Activity Under Company's Stock Option Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract', window );"><strong>Options Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Balances, beginning of the period</a></td>
<td class="nump">3,145,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Balances, end of the period</a></td>
<td class="nump">2,903,398<span></span>
</td>
<td class="nump">3,145,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balances, beginning of the period</a></td>
<td class="nump">9,936,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">4,219,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(1,064,830)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options cancelled</a></td>
<td class="num">(2,160,852)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balances, end of the period</a></td>
<td class="nump">10,929,530<span></span>
</td>
<td class="nump">9,936,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options Exercisable, end of the period</a></td>
<td class="nump">6,145,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest, end of the period</a></td>
<td class="nump">10,929,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Options Outstanding, Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balances, beginning of the period</a></td>
<td class="nump">$ 12.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted</a></td>
<td class="nump">7.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised</a></td>
<td class="nump">4.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options cancelled</a></td>
<td class="nump">13.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balances, end of the period</a></td>
<td class="nump">10.77<span></span>
</td>
<td class="nump">$ 12.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options Exercisable, end of the period</a></td>
<td class="nump">11.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest, end of the period</a></td>
<td class="nump">$ 10.77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Options Outstanding, Weighted- Average Remaining Contractual Life (years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balances, end of the period</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options Exercisable, end of the period</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest, end of the period</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 14,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balances at December 31, 2020</a></td>
<td class="nump">6,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options Exercisable&#8212;December 31, 2020</a></td>
<td class="nump">6,031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest&#8212;December 31, 2020</a></td>
<td class="nump">$ 6,844<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract', window );"><strong>Options Available for Grant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Balances, beginning of the period</a></td>
<td class="nump">3,145,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized', window );">Options authorized</a></td>
<td class="nump">1,820,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod', window );">Options granted</a></td>
<td class="num">(4,219,044)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod', window );">Options cancelled</a></td>
<td class="nump">2,156,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Balances, end of the period</a></td>
<td class="nump">2,903,398<span></span>
</td>
<td class="nump">3,145,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award, number of shares available for grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for grant authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for grant cancelled in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares available for grant grants in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624289411896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Total Stock-based Compensation Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based compensation expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 14,786<span></span>
</td>
<td class="nump">$ 19,100<span></span>
</td>
<td class="nump">$ 16,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based compensation expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">6,825<span></span>
</td>
<td class="nump">9,226<span></span>
</td>
<td class="nump">8,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based compensation expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7,961<span></span>
</td>
<td class="nump">$ 9,874<span></span>
</td>
<td class="nump">$ 8,565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089983240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation - Schedule of Estimated Fair Value of Employee Stock Options and ESPP Using Black-Scholes Valuation Model (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">64.40%<span></span>
</td>
<td class="nump">64.40%<span></span>
</td>
<td class="nump">65.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">73.30%<span></span>
</td>
<td class="nump">68.60%<span></span>
</td>
<td class="nump">69.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ctmx_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">47.30%<span></span>
</td>
<td class="nump">60.80%<span></span>
</td>
<td class="nump">46.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">122.10%<span></span>
</td>
<td class="nump">71.90%<span></span>
</td>
<td class="nump">70.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ctmx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ctmx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624162010248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_NetOperatingLossCarrybackPeriod', window );">Net operating loss carryback</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation', window );">Percentage of taxable income from net operating losses for suspension of annual deduction limitation</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax asset, net change in total valuation allowance increase during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,700,000)<span></span>
</td>
<td class="nump">$ 22,700,000<span></span>
</td>
<td class="nump">$ 35,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,454,000<span></span>
</td>
<td class="nump">5,249,000<span></span>
</td>
<td class="nump">3,756,000<span></span>
</td>
<td class="nump">$ 4,320,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits would affect company's effective tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,911,000)<span></span>
</td>
<td class="num">(427,000)<span></span>
</td>
<td class="nump">14,303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_PercentageOfChangeInOwnership', window );">Percentage of change in ownership</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed', window );">Operating loss carryforwards to expire if not utilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration', window );">Operating loss carryforwards not subject to expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2010 2011 2012 2013 2014 2015 2016 2017 2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Research and Development Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward, expiration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open tax year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2010 2011 2012 2013 2014 2015 2016 2017 2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Research and Development Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_NetOperatingLossCarrybackPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss carryback.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_NetOperatingLossCarrybackPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards amount not subject to expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards amount to expire if not used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_PercentageOfChangeInOwnership">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of change in ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_PercentageOfChangeInOwnership</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of taxable income from net operating losses for suspension of annual deduction limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in CCYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624162112728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Provision for (Benefit from) Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (13,912)<span></span>
</td>
<td class="num">$ (390)<span></span>
</td>
<td class="nump">$ 14,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="num">(13,911)<span></span>
</td>
<td class="num">(390)<span></span>
</td>
<td class="nump">14,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="num">$ (13,911)<span></span>
</td>
<td class="num">$ (427)<span></span>
</td>
<td class="nump">$ 14,303<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624090244264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal taxes at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal benefit</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(2.20%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">6.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(31.20%)<span></span>
</td>
<td class="num">(22.80%)<span></span>
</td>
<td class="num">(49.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback', window );">Net operating loss carryback</a></td>
<td class="nump">27.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments', window );">Return to provision adjustment</a></td>
<td class="nump">(0.00%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">(0.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">29.70%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="num">(20.40%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation net operating loss carryback.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation return to provision adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624089982696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Components Of Deferred Tax Assets And Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 37,099<span></span>
</td>
<td class="nump">$ 38,967<span></span>
</td>
<td class="nump">$ 15,468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credits</a></td>
<td class="nump">16,803<span></span>
</td>
<td class="nump">10,940<span></span>
</td>
<td class="nump">7,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">5,223<span></span>
</td>
<td class="nump">5,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">3,923<span></span>
</td>
<td class="nump">3,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">38,832<span></span>
</td>
<td class="nump">47,180<span></span>
</td>
<td class="nump">56,881<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Accruals and deferred rent</a></td>
<td class="nump">1,512<span></span>
</td>
<td class="nump">1,296<span></span>
</td>
<td class="nump">1,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">8,578<span></span>
</td>
<td class="nump">7,837<span></span>
</td>
<td class="nump">5,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred income tax assets</a></td>
<td class="nump">111,990<span></span>
</td>
<td class="nump">115,353<span></span>
</td>
<td class="nump">87,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(106,448)<span></span>
</td>
<td class="num">(109,174)<span></span>
</td>
<td class="num">(86,466)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">5,542<span></span>
</td>
<td class="nump">6,179<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(433)<span></span>
</td>
<td class="num">(591)<span></span>
</td>
<td class="num">(854)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(4,724)<span></span>
</td>
<td class="num">(5,330)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(385)<span></span>
</td>
<td class="num">(243)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">$ (5,542)<span></span>
</td>
<td class="num">$ (6,179)<span></span>
</td>
<td class="num">$ (1,137)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624078506344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes- Schedule of Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the beginning of the year</a></td>
<td class="nump">$ 5,249<span></span>
</td>
<td class="nump">$ 3,756<span></span>
</td>
<td class="nump">$ 4,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to current year</a></td>
<td class="nump">1,205<span></span>
</td>
<td class="nump">1,403<span></span>
</td>
<td class="nump">1,166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Adjustment based on tax positions related to prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="num">(1,730)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of the year</a></td>
<td class="nump">$ 6,454<span></span>
</td>
<td class="nump">$ 5,249<span></span>
</td>
<td class="nump">$ 3,756<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624162157928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Company contributions to defined contribution plan</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140624173279352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,535,217<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">5,867,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 134,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts and commissions and offering expenses</a></td>
<td class="nump">$ 9,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs, shares</a></td>
<td class="nump">5,867,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price, per share</a></td>
<td class="nump">$ 24.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwritten Public Offering | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts and commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs, shares</a></td>
<td class="nump">765,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event | Underwritten Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,285,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock price, per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts and commissions and offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event | Underwriters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in follow-on offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,142,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares', window );">Period granted to underwriters to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option period granted to underwriters to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ctmx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ctmx_UnderwrittenPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ctmx_UnderwrittenPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>105
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MUZ94JS0DT[=Q+KDZ2I1.AK<W7V^^3^_1_.'^_L<<?9QA#IE,0)((TT_H$GU
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MVR QFJTGRF;5/6!'@37JBXA+;'FJ>G%B;*U,8[-,OZ:CP)J#K^T192]H]%F
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MCH3$^QX2>9<K1BS/M-J#=FBKYB:^5,^VYKAT/^6)M-WEED?Y"DVI>>=/2-5
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ML]W^1?O]7-!\A:T<_\VV\NS;Z\.LZ%QKUWXP*%B;6OY7CYX/R8"KDST#SOR
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M51J.U^ZT'H6E'F7%9-</5/&+94-':PQE^B+(;:6PU'T!<Z"AK)Y'@R.5F=^
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MC;2JH0=P?V%M&RYH@?A#*>__%U!+ P04    " #J@%A22PT!W-8%  !J#@
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M9WBWN.IE4PUPQL37Q-P&E%/\7.$Q2(XW8'UA;6@&;*!]7E[]"U!+ P04
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MIU089GB["DL;L+XTN([4'Z2@?0U?_P502P,$%     @ ZH!84NI!:VT; P
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MQI/%/ 3=]\5^857C>U&F+'4V/ZWH5P*U$Z#SG5+VL' &QI^3S7]02P,$%
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M--]'"V>875+6N2BKI[W_AIE8$2)81K&=BQ*7LH=+"?^-9OC?M/<DS6'$HJF
MI.J[WNU\#INP=]Z;3./1; R_7,73FRG\'$WCV>RF=[M=B[PWC:^'L]X$WAKU
M+N/I;-:[K6K8Y4G5&TWBV634^\__F(Y'XV?ZY\LRA7V513_M@;KHXQ]-.I_W
M)K/X>C+L7=[$-Y?#WF0<WTR'O7?;;9,7/\ L_ABC^!+F^[ ",92!-R=75[U/
M10WJ(L6#5 ^'\>2:^+B)+Z<S_&467PW'DM/H72DR7(U?81&W:2UP7;:[)-]'
M[V!1=F6:@?*/KF,2NWH+'Y#/PXJ)$IY*\[J(ZOLB2O1"QE$2O7I],X+'^J^!
MHJS8X>OT]-_2!1I96%^]\-$3G +9&0^?\<_1LU/_OM4O_ I+7C*U.+<>WN6@
M!)4 R[P$8J)FMRK!;H#N[(F.8A6=CX>#(9B^+$.E2EU)(/WW216)+%VGJ)S
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M)%\S/[26/ -2JL(^4(ABG1/%,8RZ2)H*8L&BWEC11W0/6HF<+9JR9 7/Q;H
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MDT/!\[F\/V,TB8?#X=%V2I\*?8>_[)BT0+EPQ<9_X/0B3=?KQG*=?KP1#^?
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MG&;TW:_LE(_]NZA86J:30FZX$QFM?R/?(D._"F9TPPO7L(HWM,O21R\(U:C
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M[U)C$LY067$4SL=1, VS>!Q\4AC4O2WW018F28KK+$[[DOY8.2207I2JM3]
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MSM4;OETKA-W0 OQ_6=>N>R !_;?O=_\'4$L#!!0    ( .J 6%(6S,:XY (
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M,K!JRV.0]MX^O0-=@B.B+\JA44Q0AG:H:L]<(''LT'"UH1*F##'E.!/B #1
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MQA2+$H*4%J451&A3!A(Q, TQ%O*@ZR1\5T/>S.!9<$)?%"](M]M:W]-16%I
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M\I$A)7+^F<1MY.YL!9<&VCKSN+K"WYGU'E% 8.4MC%M8G9-Z. OYHT5).U1
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MJ26I./G[SE"RXKB.D3Y8(L7A<,Z<P_&<;K3Y9@L QYY*J>Q9KW"N^M3OV[2
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MHX$JK> 2[C4Q95$P_3(!H3;#, EW$P]\F5LW$8T&*[:$&=BGU;W&452C9+P
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M[8\5SE/0S@'?2Z7LSG "PX1>_ %02P,$%     @ ZH!84AS2?C*N @  J 4
M !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULE51=;YLP%'WG5UAH#ZW$
M"IC0)E42*6DW;5*K1FVW/4Q[<. 2K!J;V69I__VN3<)2J8VT%_#'N>?<>^'<
MZ5;I)U,#6/+<"&EF86UM>QG'IJBA8>9,M2#QIE*Z81:W>A.;5@,K?5 C8IHD
MYW'#N SG4W^VTO.IZJS@$E::F*YIF'Y9@E#;69B&^X-[OJFM.XCGTY9MX 'L
MMW:E<1</+"5O0!JN)-%0S<)%>KD<.;P'?.>P-0=KXBI9*_7D-E_+69BXA$!
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MO@(  *T%   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;'V42V_;, R
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M8HG[%)0UP/NME.9XL &&#;WX!U!+ P04    " #J@%A2EKE8]&L%  #+#
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M%;F;0-$+3+S)Q$F]&./4S4!SI[6/F(EU3_'?H*EU8 H20 J\- ?QB47RHV!
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M$9S4='L';5^LVKI[WT)9W"+==(UKN] D@-^72MG="SGH_PBX^A]02P,$%
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M&U^+CBA/U^6-XMOB^+CB2L]%<9D0'!-A#/3ZFG-UN#$.ZO\XQO\"4$L#!!0
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MDM8@\;P;1Y[E%4<^FQB]9L:=)C0W\*%Z:R(GE,O*$@WM"K+#V9Q;89G.V<*
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MXQ-Z/DW35S03U)6OY4\:J3/PPX)Z,3#N .WG6N-FXAQTW=WL'U!+ P04
M" #J@%A2@?PC2Y@#  #D&   &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX
M;6S-F5U/VS 4AJ_9K[!RM4F4Q Z%%K65"F@:TZ8A*K8+Q(5)3EJ+Q,YL=V7_
M?G9:XC)!'&WJQPW$2<XY[QN?DT>$P4+(1S4#T.BIR+D:!C.MR[,P5,D,"JJ.
M1 G<7,F$+*@V2SD-52F!IE50D8<DBD["@C(>C ;5N6LY&HBYSAF':XG4O"BH
M_'T.N5@, QP\G[AATYFV)\+1H*13F("^+:^E685UEI05P!43'$G(AL$8GYW'
M71M0W?&=P4*M'2-KY4&(1[NX2H=!9!5!#HFV*:CY]0LN(,]M)J/CYRII4->T
M@>O'S]D_5N:-F0>JX$+D/UBJ9\.@%Z 4,CK/]8U8?(*5H4I@(G)5_42+U;U1
M@)*YTJ)8!1L%!>/+W_1I]2#6 DR>UP/(*H!4NI>%*I675-/10(H%DO9ND\T>
M5%:K:"..<;LK$RW-56;B]&B<BE)#BBA/T0TDP#4:)XF8<\WX%%U+P<UQ F8?
MM$(=-$Y39I\FS=$57_:$?;;O+T%3EJL/@U ;439UF*P$G"\%D#<$7$)RA&)\
MB$A$HI?AH?%2&R*U(5+E.W[+T.36I,(G'1PW9(OK;'&5+7XCVV39K.A;AB9L
MREG&$OK7(Q(Y2Q@H=/?%Q*(K#86Z;ZA\7%<^;O1Q,:-\"HC9QJV+E9+QA)4Y
M'*Z?5=KL'I6I0O,RI=I>M+MJ-\8N7]N3YMJ?*3]"^/#=P8%G4[JUF>Z&S9@6
MO=-R#BBCN8+[USPU2[#!#4Y.:B<G;=KKM!,=-V0[K;.=;KF]>G7EW@[;J[EV
MZ_;JUV;ZNV^O9@F>]L*1>Q]'F_/"3#MID,R\GB'+#/B\KCQJ?+;6,(/;S$VO
M^;6,W5L>DRU/#G9,P/$.9\=3O/7P8$<:O&G4M!@?CP9?HSG2X VBYA_FY[^H
M@QUV<"ONF/GI-N5SX,';)@]VZ,&[9(^G>/OY<?3!>X ?CP9/HQ'''[)7_/&H
M\=ER_"%M^=-KRK?V5\:V^4,<?\@N^>,IWGI^B.,/V0/^>#3X&LWQA^P5?SQJ
M?+8<?T@K_O0[4>/\./Z0;?.'./Z07?+'4[S]_#C^D#W@CT>#I]%BQY]XK_CC
M4>.SY?@3M^)/OX-)4S['GWC;_(G7OHGMDC^>XB_F!S?Y<?R)]X _'@U58),;
M!Z!XKP#D4?.FKW#MF[7]_O^5RBGC"N60F431T:G)*Y>?U)<++<KJ,_:#T%H4
MU>$,: K2WF"N9T+HYX7],E[_8V/T!U!+ P04    " #J@%A20CRY0+\"  #;
M!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6R-5=]/VS 0_E>L/&W2
M($V:M@&UE6@+&A*,BFK;P[0'DUP:"__(;(?"?[^S$T(+;<5+8I_ON_ON_.4R
MWBC]:$H 2YX%EV82E-96YV%HLA($-:>J HDGA=*"6MSJ=6@J#33W(,'#N-<;
MAH(R&4S'WK;4T[&J+6<2EIJ86@BJ7V; U6821,&KX9ZM2^L,X71<T36LP/ZL
MEAIW81<E9P*D84H2#<4DN(C.%P/G[QU^,=B8K35QE3PH]>@VU_DDZ#E"P"&S
M+@+%UQ/,@7,7"&G\:V,&74H'W%Z_1K_RM6,M#]3 7/'?++?E)$@#DD-!:V[O
MU>8[M/5X@IGBQC_)IO7M!22KC56B!2,#P63SIL]M'[8 T?  (&X!\7M <@#0
M;P']SP*2%I#XSC2E^#XLJ*73L58;HITW1G,+WTR/QO*9=->^LAI/&>+L] <J
MZT890Y:@R:JD&L@)634:(*H@2V5!6D8Y?R$+QFMW2V0%6:V996#(Y7/&ZQQR
M4F@ER%R)JK;4WRB"/0#/]B3YL@!+&3=?,9UQ%C,.+=;C6(59RWW6<(\/<(]B
M<JND+9&%1 J[ 4)L1->-^+4;L_AHQ 5DIZ0??2-Q+^[M(33_-#PZVP-??!Z>
M'JFFW]UMW\=+#L2[J]Q%&$)E3BY7RR6QBE2USDK\3DBFA,!;0H%ECT=R)5VN
MQ.?J'\AU@2+)C^GCZKT^[@IR2;5D<KVMBS\W&)A<6Q#F[Q%:@X[6X&@+'*V3
MCI=YXP4[NLUV=9NWNI6H6^YT6R$_K])](FT8##T#-V6?IE'43]/A630.G[;%
M\]'Q;)B.TB39]5M\]!LEHW0T&'1^32_"K<]>@%[[\6FPF%K:1O.=M9O0%WXP
MO;//<'(W@_8M3#/V;ZE>,Y00AP)#]DY'R$TWH[396%7YX?*@+(XJORSQ[P/:
M.>!YH7" M!N7H/N?3?\#4$L#!!0    ( .J 6%+CS%/0O0,  *\-   9
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M+>7A=G"8:+%-#]ASH<UQ/1UNS(T*I34P[U="Z,>)/;/G=[3)?U!+ P04
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M-PES_13V =I#O/F=19JCN&SHX8(+"71>6XNG( S3^%=0_ 902P,$%     @
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M6FX< -<76L-FXC;HNW?V!U!+ P04    " #K@%A2K--.O<("   <"   &0
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M>:-(5Y6HFW(]4;RP?6W+E>Z2=ICI>PR$"=#?=YRKEXEIE>W-&/\'4$L#!!0
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MOZJ)XGO3D<1<Z?[&#'>Z9P51&NCG&\[5VZ3<H.F"I_\#4$L#!!0    ( .N
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M\^8.'>/"PNCM-'9$V1\<YQV]FY9>>H3>HC$7,$[.($U&5_^FQZ2TEYOV<M.
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M_/&:M0L*M;Z$9[+^2Q[;L<Z$))54/&^%P8(\+9K_]'OKB(Z %P\(>*V ]T+
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MX/<EY^KY1G^*MOG>\OA_4$L#!!0    ( .N 6%)S_PQ=U@0  #46   9
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MCMLTJ>[_@.VH.H8MU,DF)2?%%KIUDO&\@GEO-N@N6T@C69RP4K^POAI9_&&
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M'R1?%-\0C[F4/"E>SAF=,*$-U.=3SN7F07_IO/V)S/G_4$L#!!0    ( .N
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MX$X!_S3GU%,&)/5G!LQ4[[J;YH:<;AOM%W7<_I;EW1>6AUMGFOL"H:FRX-)
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M!%HMC"S<$+>2!D="]YCAU$Z5/8#OUU*:W<)>T/P?,/\?4$L#!!0    ( .N
M6%*;;- _LP(  ,\'   9    >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;(V5
M;6_:,!#'OXH5]44KK4V<1Z@ :05-F]1JJ+3;:T,.L.K$F>V4\NUW-FG*1H"^
M26SG_O>[N]CGP4:J%[T&,.2M$*4>>FMCJEO?UXLU%$S?R I*_+*4JF &IVKE
MZTH!RYVH$'X8!*E?,%YZHX%;FZK10-9&\!*FBNBZ*)C:WH&0FZ%'O?>%1[Y:
M&[O@CP856\$,S',U53CS6R\Y+Z#47)9$P7+H?:6W8QI8@;/XQ6&C]\;$IC*7
M\L5.?N1#+[ 1@8"%L2X8OEYA#$)83QC'G\:IUS*M<'_\[OV;2QZ3F3,-8RE^
M\]RLAU[/(SDL62W,H]Q\AR:AQ/I;2*'=DVP:V\ CBUH;631BC*#@Y>[-WII"
M[ EH?$00-H+PLX*H$40NT5UD+JT),VPT4')#E+5&;W;@:N/4F TO[6^<&85?
M.>K,Z!ZP!II<DQEND+P60.22/#!3*VZV=ORS L4,+U?$F9)[SN9<<,-1=3D!
MP[C05ZA_GDW(Y<45N2"\)$]K66M6YGK@&PS2HOQ%$]#=+J#P2$ 36-R0B'XA
M81 &'?+QI^6T_Z_<Q]*T]0G;^H3.7W3$WWXI9%L*X4HA/DIQ@A2UI,B1XB,D
MS)=VE6NGRIS*'LK744)#3.VU@Q6WK/@<*^QB[53I/BO,HFY6TK*2<ZRHBY4<
MLF+[Q[M8:<M*S['B+E9ZR$JRL)N5M:SL'"LAN,?)'+:RS+NPV0&6!I2FW=Q>
MR^V=Y#Y)PT2S RNVQ99J.H]9[P >T80>*7"_A?=/PN]!:\*+JC:0XT$WH$";
M+GK_@'Z=IO$1.@T^NE5PDC]%'B9,7IFH7:LZ<Q*;CA,<G*$P[F4?T32=I<,L
M2WOTOZ#]O6YKK[H'IE:\U!C*$G7!388[6^UNC]W$R,HUX+DTV,[=<(TW+BAK
M@-^74IKWB>WI[1T^^@M02P,$%     @ ZX!84C1D.:KG!   J!<  !D   !X
M;"]W;W)K<VAE971S+W-H965T-C0N>&ULQ5C;;N,V$/T5PFB!72"Q1.IB>>$8
M2.Q-XD46:VR0]J'H R/1-A%)=$G*SA;[\:4NUB66& 6-6S_8NLP9#H>'9\:<
M[!E_$AM")'B.PEA<##92;C\9AO W),)BR+8D5F]6C$=8JEN^-L26$QQDH"@T
MD&FZ1H1I/)A.LF=+/IVP1(8T)DL.1!)%F/^X(B';7PS@X/#@.UUO9/K F$ZV
M>$WNB7S8+KFZ,THO 8U(+"B+ 2>KB\$E_+2P,D!F\1LE>U&[!NE4'AE[2F\6
MP<7 3",B(?%EZ@*KGQV9D3!,/:DX_BJ<#LHQ4V#]^N#].IN\FLPC%F3&PM]I
M(#<7 V\  K+"22B_L_TM*2;DI/Y\%HKL&^QSVY$R]A,A652 5001C?-?_%PD
MH@: =@< %0#4%V 5 *LOP"X =E^ 4P"<O@"W +A] :,",.H+\ J UQ<P+@#C
MC [Y^F6+/\<23R><[0%/K96W]")C4(96:T[CE.SWDJNW5.'D=,:B2''N7C+_
M"9R#RR"@*0EQ"!9QOI522GZ8$XEI*#XJDX?[.?CPR\>)(=7PJ1/#+X:ZRH="
M'4-]2<(AL. 90";T6N S/7Q._ ,<F2WPN1Y^31Z' (T[X9__W>C7O>%PW *_
MZ0]O2]WM:YF/%=SL#'ZAAW_SY1! .QO=:<(-1;>2<ZCD',K\65V<"[$0X-NJ
M8-T?=^H]6$@2B3\UWJW2NY5YM_6,%JGO,R VF!,!<"(WC-._2=!&O-RAFSE,
MJ\-N"ATS_TR,79TDO2VOCRU'3IOA;6^7BQXN&QFSRXS9;\C8%G.PPV%"VC*5
M._+JP9)STWF1I5Y6U[VL%J]9-6;LE#-VM#->JHI*."?!6VBR<(Y7ZN5"-:)Q
MRVC<MT6C6X*%^Y:$C,H01MH0YG1' Q(' B@B^#4^M"EE[FI4B^ E^746C?B\
M,C[OE10QGQ 5WHJS"% A$AS[!+!5(]@S$*OV4#TL#7PFI&B;@W<4(83(\XXV
MW4V+H64[8[=SU<?EE,;:*7TA*[7J5+'N[FZFT3UH5J7</(&NPEJK -]))^:%
MIYXLA57E@$@;PJ)CY0&-P8J%JG4_5X]8EMEXW<&'PW9O[4%0BQQ;#H*CCM"K
ML@3U=>F]*3PKQFMRV-+H$:P* M17A"7A/HFE^K>3AB)PJ%B:1JF"4NU@ZX+K
M'5I#T_Q51\)*N:%>NB]WA*=Q;3GU6TM4@1_7R^3011TIJ30:OB+2VI0 ' ?-
M)6L-33]$2Y**UO3-N.8DJRH ]66@H4G@)_B*GVF41#K?E8)#[Q3J5,DIU.OI
M>^^O>3%>?7_I^RU4*34R^RCI_7&%;3JLI!G!$R07U3KV_U=W/Z/7=3=O+5H-
MCYOEFQ8[QW-'EMTAY*@2<O3?"OD5:A%RRW9U3*N4'.F%]R$."-]S]:<^7H.
M"I\EL1297%7JE=\?5@^0YRV)1>LZ717#U6,=(UVDE; CO; W3B)^@C)P26*P
M3!Y#ZBM^YQ'J*%T).G)/L64J+45Z+3WUEKDJQN_/\$JJD;[;KC=Z>:%5[1[A
M>2RMH7A'-1?9PXYN#U62CO22WD4)PH7NH*"28>L4#;-5J;*E;YA/3H%B_,:1
M@.M8IOLB\T;M@# ]P_Z*^9JJ;1^2E0*:PY':FCP_%LYO)-MF9X:/3$H699<;
M@E7Z4P/U?L68/-RDQY#EX?ST'U!+ P04    " #K@%A2I>F#*:("  "W!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6R=55UOFS 4_2L63YNTE6\G
M5$FD-MVT/DRMFGT\3'MPR"58-9C:)FG__:X=@M*$5-5>P#;G',ZY-I?)5JI'
M70(8\ER)6D^]TICFTO=U7D+%](5LH,8GA505,SA5:U\W"MC*D2KA1T% _8KQ
MVIM-W-J]FDUD:P2OX5X1W5854R_7(.1VZH7>?N&!KTMC%_S9I&%K6(#YV=PK
MG/F]RHI74&LN:Z*@F'I7X>6<6KP#_.*PU0=C8I,LI7RTD]O5U NL(1"0&ZO
M\+:!.0AAA=#&4Z?I]:^TQ,/Q7OVKRXY9EDS#7(K??&7*J3?VR H*U@KS(+??
MH,N36KU<"NVN9-MA X_DK3:RZLCHH.+U[LZ>NSH<$,+D#"'J"-%["7%'B%W0
MG3,7ZX89-ILHN27*HE'-#EQM'!O3\-KNXL(H?,J19V9S6558S861^2/Y3!Y
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M#2L%USR=J[]*=F[U,6Q1'&A$%[JJ[@&:4V/&NR%!0]0CJ=!H*@S?*SHU@MZ
MC>_Q$.$>UT9ZH5U[G52GQMAS'@Q'?1O(:"UT$UN[YD1MYQ /QZ,>[T9OH5UP
M#U6<N(.'/QR/7^M-?,@B04:@D9M 'ZXV-? ^<S@,XQY*1K.17;,_3FQJ1W%O
M;/<9&HE&Z!U* [92<T/U-5-KP*4JRKFZT&U(!OY,%Q1\?J&$BR-;@6[$&=G%
M^< 5]P9:"$IJ( !Y=9-  4C(BZTB0T:BD;U"?L=JLP,'->MHRUK=A-YB;50=
MV57] Q>DW='_B;TY#I"]QCY?+CE=$DG!%[48TT*D<_"=9!O;R8>,XJ,/4/P:
M8[PK^('_NK3J&!6_'C3K& 2#T.\I(I Y/)#]\-AN)D D4+=/6MY++/??"]0N
MW,.HKVI'YAA!;G7[SD[Y^:<(0?2K&ZMV21_Z&':SPN:TP&ZGA64G',*R]C9V
MBATV!PBV'R!7^3IC+Y3NM6)LW0,C_-A-^ _K'^"=]H2KE!]0/^)V26V]E&,C
MU]A-KLE&KAA/_^W>U;C=PH 14D5]3QF)C?!B-^&U5+"XW9$XL5Z<L1%,[%8_
M6^O(&F.O<P)'(1KU3=XH*G;M7S@=+;C=NNANX70,[%XNWDX/-:=\6?:B53C8
MII!5 [%YV_2[S\LN[ZOW%_!T5G6M#4S51/]*N%KF F1TH2!5:::RR:N^=/4@
MV;KLU-XS*5E>?EU1DE"N!ZC?%XS)[8-VT/QW8/H?4$L#!!0    ( .N 6%)>
MJHS'T0(   P)   9    >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;+56VV[B
M,!#]%2OJ0RMMFRM)J "ID+T]5*J@W7UVDX%836S6-M#NUZ_MA#2E(4*K]H78
MSIPSEQ-F/-HQ_B1R (F>RX**L95+N;ZV;9'F4&)QQ=9 U9LEXR66:LM7MEAS
MP)D!E87M.4YHEYA0:S(R9W=\,F(;61 *=QR)35EB_C*%@NW&EFOM#^9DE4M]
M8$]&:[R"!<B']1U7.[MAR4@)5!!&$8?EV+IQKQ/7T0!C\8O 3K362*?RR-B3
MWOS,QI:C(X("4JDIL'IL809%H9E4'']J4JOQJ8'M]9[]FTE>)?.(!<Q8\9MD
M,A];L84R6.)-(>=L]P/JA ::+V6%,+]H5]LZ%DHW0K*R!JL(2D*K)WZN"]$"
MN.$1@%<#O$- < 3@UP#_5$!0 P)3F2H54X<$2SP9<;9#7%LK-KTPQ31HE3ZA
M6O>%Y.HM43@Y64B6/EWJRF5HQDKU.0EL!+E$]TSB ATUF$/*5I3\5>?G"4A,
M"G&A4 ^+!)V?7: S1"BZS]E&8)J)D2U5L-JEG=:!3:O O".!N1ZZ953F GVE
M&61O"6R599.JMT]UZO4R)I!>(=_]@CS'<SH"FIT,=X<=\.1T>-R3C=\(YQL^
M_P3ATK8N\*S7<-WC(VA\!,9'\)\^NE2M&"/#J)O.=N(&41R.[&V[U!U60]=Q
MWEHE'59A',6-U9ND!DU2@]ZDYB  \S1'ZKM4'6*K6M]:-3+94Z^PH0X_39.H
M\1%]N"858]BJ8QA[@P-)WAL-/>] M^2]4>R[?K<@<9-1W)O1=Z# 5:?1>N!,
M]3@B),=Z'/24:]B0#S]-$M=Y;:+.AXM24[:_[F@8N@>J=%@-XR@XD*7#*AZ$
M@P-=[-:8*(&OS+@5*N -E54;;4Z;D7YC!MG!^52/>C-^7FFJ>\(MYBM"!2I@
MJ2B=JTC]%WDU>JN-9&LSC!Z95*/-+'-U70&N#=3[)6-RO]$.F@O0Y!]02P,$
M%     @ ZX!84DC[P94C!   910  !D   !X;"]W;W)K<VAE971S+W-H965T
M-CDN>&ULS5A1;^(X$/XK5J23]J1M$CLA0 5(I71U*VUUJ&CW'D[WX!(#5IV8
ML\U2I/OQYS@A(=O$H8B'OD#L^/L\\WGP##/:<_$B-X0H\)JP5(Z=C5+;6\^3
MRPU)L'3YEJ3ZS8J+!"L]%&M/;@7!L0$ES$.^'WD)IJDS&9FYN9B,^$XQFI*Y
M '*7)%@<IH3Q_=B!SG'BB:XW*IOP)J,M7I,%4=^W<Z%'7LD2TX2DDO(4"+(:
M.W?P=H8,P*SX0<E>GCR#S)5GSE^RP==X[/B91821I<HHL/[Z2>X)8QF3MN/?
M@M0I]\R I\]']B_&>>W,,Y;DGK._:*PV8V?@@)BL\(ZI)[[_@Q0.]3*^)6?2
M?()]L=9WP'(G%4\*L+8@H6G^C5\+(4X *&H!H * S@4$!2 X%Q 6@- HD[MB
M=)AAA2<CP?= 9*LU6_9@Q#1H[3Y-LW-?**'?4HU3DX7BRY>;3+D8W/-$AY/$
MYD!NP$+'6+QC!/ 5>)"*:I'UHB^8"O #LUT^GVP9/Q "# _X<YMA)<!I#!X6
M\SGX+FFZ!E.&]2::CS,B#3C?XY''A(%/,Z(P9?+WD:>T1YE=WK*P?II;CUJL
MATASI&HCP4,:D[A.X&DI2CW048\ILC+.R-(% ?P,D(_\!H/NSX;#80-\=CY\
M8/$F*$\W,'QA"U_C\5AXPY(W-+Q!6]1LL"!@^C9J[H3 Z9KHBT&!Z0&<KIOC
M@YF^VV,1@[^_:4KP59%$_F,QJ%<:U+,[^KK5%XG>Y2=GVA)&U>%S]G.AR2YI
M"BL[6Q2ZH?];T^E?B)MUX'IN]"NN)D-4RA!=( -^;9/!SM8/W*!9!CLN&KQU
M)Y>A S=\NU]-AGXI0]]*]$3ER\U*Z+BGJ2*"2 6$OKRL$6%G]%W4K(0=!MOB
MP0Y#;L^JPZ#487"A#NTA86>$;1%AAS4XE.M@AP6N;]5A6.HP?/\U"/X#CTWA
M4-L!^E4>]3_&E0A/4CL\[S;09Y^ 3S0%!X)%2YZU4X4Y% Q DN=;G7EC?)!-
MH7 F%?2/7"ALXYI=Q:RZ?*B2#UT6-4T_GOH>57Z&P0>)FBJUP_!Z46.G>L]1
MWW=P]7*NQB"YBA5UN:K" W94'O4HF>_$<J./"<P9ME5:L$KI,/H@(5*E5VC/
M3^^MMCKHPGY;5ND 1KX[:,XK73M&;Q-S78LJQ4)[CGIOR=5!!Q%R88L8=F0?
MNL,6,3J ?D>Y :L\"^V)]I+"JX/2;Y7#CH-M-6@'KD'^^A_)JB) _M6KKP[*
MUC*T X?:ZM!.G/U_":IJ$72]6J2#*BJN\48=+H;.+H+F:G@G_9>$B+7I8TFP
MY+M4Y:V'<K;LE=V9#M$O\U-X.\L[7A5-WH![Q&)-4PD866E*W^WKK"3RGE8^
M4'QKNCS/7"F>F,<-P3$1V0+]?L6Y.@ZR#<K.XN1_4$L#!!0    ( .N 6%*Q
M$%F0-P4  &\6   9    >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;+58VV[C
M-A#]%<)HT2R0Q")UL;UP#.S&&S1 TP9)TSX4?: E.F97(EV2BI.B']\AI5BV
M)=/N[B8/BF3/&<Z9&9ZA-5Y)]5DO&#/HN<B%ON@MC%F^[_=UNF %U>=RR01\
M,Y>JH 8>U6-?+Q6CF0,5>9\$0=(O*!>]R=A]=JLF8UF:G MVJY NBX*JEX\L
MEZN+'NZ]?G#''Q?&?M"?C)?TD=TS\["\5?#47WO)>,&$YE(@Q>87O0_X_57H
M ,[B-\Y6>N,>62HS*3_;A^OLHA?8B%C.4F-=4/CWQ"Y9GEM/$,??M=/>>DT+
MW+Q_]7[ER .9&=7L4N:_\\PL+GK#'LK8G):YN9.K'UE-*+;^4IEK=T6KVC;H
MH;341A8U&"(HN*C^T^<Z$1L '.T!D!I =@!1O <0UH#PV!6B&A ="XAK0'PL
M(*D!B<M]E2R7Z2DU=#)6<H64M09O]L:5RZ$AP5S8SKHW"K[E@#.3:Y'*@J%?
MZ3/3Z Q]R#)N*TYS="VJOK7U/YDR0WFNWX')P_T4G7SW;MPWL+QUTD_KI3Y6
M2Y$]2]U0=8[(X!21@ 0=\$L_?,K2<Q3BO?#IT7 \ZH!_.AX^[(!?'0\?;,/[
M4+%UV<BZ;,3Y"P^6#5U*8;AX9")]07_\!';HVK!"_^E9)5RO$KI5HCVK_ S*
M!AJFJ%T Y5)KE%*E7F8T_=Q5?[^W&+TPJK0GKF@=5^3U=,M4RH0!Y4-RC@Q]
MIK.<(5[E9*YD@40K<FAOZ&=04+VL=1&@5(@26CUC65D)7<X+;ES/=_'S1S4,
MSH/@>P^]>$TO]CJ:LCE3BF66&:(0NCEUA-(%A3H#3V2D@;"?:%Y6^Y/F,"&H
M2%T28,!HAK)26>J0 RZSKMU6Q3!P,=CY\S0Y(X/ _HW[3YO[JFU(.@T_M0W#
M>,=P*Q_).A^)-Q\/0K%4/@K^3YV3&1-LSHWNHE6Y2C:"2*(X:K-JV\4D&K5)
MM>W"09RT[*Z2%ODH)/NY#];<!U_&'29VF6>(SN<PHQ%T_I**EQ\T8NX#F-;.
M&C8 Z\K2H,5J-S]MBU%7S=MF./"4?+BF/?32KO7-4F#/=L,R=%(S[YH\E\-6
M&&<X'&'<KGN'9>3:>8=8VPY'81#N939:,QL=8&:88MJ ]F2P.V'2&@[:1--4
ME:QSHXX.UFK4ZKU=-CZ++1HX: X.@9?(#1>\* N/WN&-0PA^PW&&FZF)R?\8
M'(V>RI5@2B_XLG.R^WW&AV0?-^,6^R?D%<M@9.4^7\V(Q-%;IK295=@_K/:=
M$6#8KJC*.C4:MR<%3H:)1S=P,RNP?UC\XHG%:@E7U<BT9Y'.V/SN21!&OKPU
MNH[]PNZ-T\@J5&C..1+2H-+PW(Z SH@'K6PFL3>9C0ICOPQ[@[1QZ7+VEYT_
MKP'O.SI=U@MME=RIZ?XH&T7%?DF%*(4;%7MKZL?#F3RP!W-L+\1>0GN)["6V
ME\0=VSN._MMG]T8ZB5\ZZWV._D5W3$/,Z<)-@RE[@E_Z2_C=;JI]"V? UBEG
M>\E&8<E;*BS9^%WB5T.[0.KBKKH%^72@]K75%-[.)8V4$K^4[L91AW%ZH$T/
M>(7=CWUI:M29^'\KW)O6P6S;4Z._)'[+PC:Z2OS"]R4Z3]J'8A(17WT;^21?
M(9]'R/P!]U!HXDM;HZ#DH(+ZM>D _EMI4R.FQ"^&KC._7IG"1@S#X"U?930*
M&.)OITRUK\W.'74.J_[&JS?[*O:&JD<N-,K9')#!^0!VKZK>;E8/1B[=V[B9
M-$86[G;!*,P#:P#?SZ4TKP_V!=_Z'?/D/U!+ P04    " #K@%A24LX8"^X"
M   ?"0  &0   'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6R=5MMNXC 0_14K
MZD,K;9MKN52 5,A6VX=*J+2[SR:9$*N)S=H.=/^^MA-2+B9"^P*V,^?,F?%D
M)J,MXQ\B!Y#HLRRH&#NYE.L'UQ5)#B46=VP-5#W)&"^Q5%N^<L6: TX-J"S<
MP/-Z;HD)=28C<S;GDQ&K9$$HS#D255EB_F\*!=N.'=_9';R252[U@3L9K?$*
M%B#?UW.N=F[+DI(2J"",(@[9V'GT'V+?TP!C\9O 5NRMD0YER=B'WCRG8\?3
MBJ" 1&H*K/XV,(.BT$Q*Q]^&U&E]:N#^>L?^9()7P2RQ@!DK_I!4YF-GX* 4
M,EP5\I5M?T$3T+WF2U@AS"_:-K:>@Y)*2%8V8*6@)+3^QY]-(O8 ?N\,(&@
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MF:LO&.#:0#W/&).[C7;0?A--O@!02P,$%     @ ZX!84BVMHSRJ P  .@X
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M#@+N\F .=R#M"^9Y(81^'M@)VN/B\C]02P,$%     @ ZX!84CN4Q,^,!
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MXH(UPL[5^@MV>@:.KU#"^%]8=[Y1 $5CK*H[,$50<]G^LZ?N'#8 <7X D'2
M9!N0'0"D'2!]*R#K )D_F5:*/X<9LVPRTFH-VGD3FQOXP_1HDL^E2_N-U;3*
M"6<G7V6A:H1;]H3F#&ZHJLI&(*@%S+%0LN"",Y\@LMQ)3;:EY'^Q= B8HL0%
MMP9.9F@9%^84SN#N9@8G[T[A'7 )MY5J#).E&866HG5[AD47V;2-+#D069S
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M844?$ZB= ZTOE++/$[=!_WDR^0=02P,$%     @ ZX!84AE!I@MI @  ZP4
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MVL:HG0/9-TK9O> "=/L]>0=02P,$%     @ ZX!84@1IVR&.!   D18  !D
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M:?&XHT23-POT[QO.U>/ W.C5M]"S?P%02P,$%     @ ZX!84J_Q)V!& @
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M?MNR7!B9W?\3Q/T_<+S[#U!+ P04    " #K@%A2<WQX+%$"  #[+   &@
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M]1[&KT,9KCW?:[S^3U(]GL\MU\M?EM\[)_?X!>?ZMF)X^@M02P,$%     @
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ ZH!84N&3212W!@  TQH  !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( .J 6%+3Y?;;0@8  &@9   8
M              " @?H.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " #J@%A2W3'0QZ<"  !:"0  &               @(%R%0  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ ZH!84N[":9%D!0
M$1,  !@              ("!3Q@  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( .J 6%)8<-Y;[08  "XC   8              " @>D=
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #J@%A2S,%+
MH8,'  !D'@  &               @($,)0  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ ZH!84NA@5OL2 @  I00  !@
M ("!Q2P  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .J
M6%*%MDV]U!<  #1%   8              " @0TO  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " #J@%A22PT!W-8%  !J#@  &
M        @($71P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ ZH!84NWY(,XJ P  <@<  !D              ("!(TT  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #J@%A2;R3\.JL%   9#P
M&0              @(&$4   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( .J 6%+J06MM&P,  )D&   9              " @696  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ ZH!84FP8>VR[
M P  J @  !D              ("!N%D  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " #J@%A2)G[6$J$"  "J!0  &0
M@(&J70  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .J
M6%)''9<*UAT  ,)Y   9              " @8)@  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ ZH!84E^;GO1G"   <Q8  !D
M         ("!CWX  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " #J@%A2"/OX?<(&  !,#P  &0              @($MAP  >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( .J 6%+;\79;*@8  &(.
M   9              " @2:.  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ ZH!84O)-+[" !0  ZPP  !D              ("!AY0
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #J@%A2?Q/8
M4?$-  !-*0  &0              @($^F@  >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( .J 6%(RF^KTJ L   <?   9
M  " @6:H  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MZH!84A;,QKCD @  2P8  !D              ("!1;0  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " #J@%A2H-*3K3D#  !L!P  &0
M            @(%@MP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( .J 6%(!U]ISPQL  (58   9              " @="Z  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ ZH!84@X[[!*N!
M+@L  !D              ("!RM8  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " #J@%A2"8MOC=8"  #R!0  &0              @(&O
MVP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .J 6%*6
M7I&=B@,  "8)   9              " @;S>  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ ZH!84@/D$,'5 @  Z 4  !D
M     ("!?>(  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .J 6%+]5$24O@(  *T%   9              "
M@:_R  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ ZH!8
M4I:Y6/1K!0  RPP  !D              ("!I/4  'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " #J@%A2PP(!N%L&   4$   &0
M        @(%&^P  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( .J 6%(N-",/7 0  .\0   9              " @=@! 0!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ ZH!84KPQ))"9!   ;1(
M !D              ("!:P8! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " #J@%A2DF*,"ZH"  !T!P  &0              @($["P$
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( .J 6%(7>3;7
M_ (  .D)   9              " @1P. 0!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ ZH!84H'\(TN8 P  Y!@  !D
M ("!3Q$! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #J
M@%A20CRY0+\"  #;!@  &0              @($>%0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( .J 6%+CS%/0O0,  *\-   9
M          " @108 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#
M%     @ ZH!84A TQ:40 @  %@0  !D              ("!"!P! 'AL+W=O
M<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #K@%A2G^B"0AP#  !+
M"0  &0              @(%/'@$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;%!+ 0(4 Q0    ( .N 6%*@CDL.70(  ,D%   9              " @:(A
M 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ ZX!84JS3
M3KW" @  ' @  !D              ("!-B0! 'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6Q02P$"% ,4    " #K@%A2B1LMZX<"   E!P  &0
M    @($O)P$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M .N 6%*']D[8PP(  -@'   9              " @>TI 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ ZX!84@(#DCFD P  $0\  !D
M             ("!YRP! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " #K@%A2K28,N8\(  "U-   &0              @('", $ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( .N 6%*^:@*?=P(
M %L%   9              " @8@Y 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ ZX!84G'%15G&!P  >RD  !D              ("!
M-CP! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #K@%A2
M<_\,7=8$   U%@  &0              @($S1 $ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( .N 6%)X),YS-@@  .0L   9
M      " @4!) 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ ZX!84@;Y06@'!   < X  !D              ("!K5$! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #K@%A2P!:0\*L#   A#0
M&0              @('K50$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( .N 6%+;X=Z9@0(   8&   9              " @<U9 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ ZX!84FTKR\'/
M!   51@  !D              ("!A5P! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " #K@%A2&!'G?>8&   N(P  &0
M@(&+80$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( .N
M6%('1IBG*@,  &8)   9              " @:AH 0!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ ZX!84FV:J_RG!   H1$  !D
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M=#8U+GAM;%!+ 0(4 Q0    ( .N 6%)]D:,)40<  #LG   9
M  " @==_ 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @
MZX!84NY<QSAR!0  *1@  !D              ("!7X<! 'AL+W=O<FMS:&5E
M=',O<VAE970V-RYX;6Q02P$"% ,4    " #K@%A27JJ,Q]$"   ,"0  &0
M            @($(C0$ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4
M Q0    ( .N 6%)(^\&5(P0  &44   9              " @1"0 0!X;"]W
M;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ ZX!84K$069 W!0
M;Q8  !D              ("!:I0! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX
M;6Q02P$"% ,4    " #K@%A24LX8"^X"   ?"0  &0              @('8
MF0$ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( .N 6%(M
MK:,\J@,  #H.   9              " @?V< 0!X;"]W;W)K<VAE971S+W-H
M965T-S(N>&UL4$L! A0#%     @ ZX!84CN4Q,^,!   XA   !D
M     ("!WJ ! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4
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M  """P  #0              @ %6L $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( .N 6%*7BKL<P    !,"   +              "  <>R 0!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( .N 6%++P]_FPP4  $0R   /              "
M ;"S 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #K@%A2<WQX+%$"  #[
M+   &@              @ &@N0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #K@%A2SA7,7P\"  #J*P  $P              @ $I
LO $ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     5 !4  ,7  !IO@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>299</ContextCount>
  <ElementCount>463</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical</Role>
      <ShortName>BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness</Role>
      <ShortName>Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Adopted and Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncements</Role>
      <ShortName>Adopted and Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Measurements and Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestments</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Research and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreements</Role>
      <ShortName>Research and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreement</Role>
      <ShortName>License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsTables</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestments</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure -  Research and Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsTables</Role>
      <ShortName>Research and Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cytomx.com/20201231/taxonomy/role/DisclosureLeases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStock</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Customers and Collaboration Partners who Represent 10% or More of Total Revenue During Each Period Presented or Net Accounts Receivable Balance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Customers and Collaboration Partners who Represent 10% or More of Total Revenue During Each Period Presented or Net Accounts Receivable Balance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Adopted and Recent Accounting Pronouncements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails</Role>
      <ShortName>Adopted and Recent Accounting Pronouncements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Fair Value Measurements and Short-Term Investments - Schedule of Short-Term Investments Subject to Fair Value Measurements on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Schedule of Short-Term Investments Subject to Fair Value Measurements on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Fair Value Measurements and Short-Term Investments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Property and Equipment - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill and Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Goodwill and Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Summary of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Research and Collaboration Agreements - Schedule of Revenue by Collaboration Partners (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails</Role>
      <ShortName>Research and Collaboration Agreements - Schedule of Revenue by Collaboration Partners (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails</Role>
      <ShortName>Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1</Role>
      <ShortName>Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Research and Collaboration Agreements - Amgen, Inc - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails</Role>
      <ShortName>Research and Collaboration Agreements - Amgen, Inc - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Research and Collaboration Agreements - Astellas Pharma Inc - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails</Role>
      <ShortName>Research and Collaboration Agreements - Astellas Pharma Inc - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Research and Collaboration Agreements - Bristol-Myers Squibb Company - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails</Role>
      <ShortName>Research and Collaboration Agreements - Bristol-Myers Squibb Company - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Research and Collaboration Agreements - ImmunoGen, Inc - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails</Role>
      <ShortName>Research and Collaboration Agreements - ImmunoGen, Inc - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Research and Collaboration Agreements - Pfizer Inc - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails</Role>
      <ShortName>Research and Collaboration Agreements - Pfizer Inc - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Research and Collaboration Agreements - Summary of Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsSummaryOfContractLiabilitiesDetails</Role>
      <ShortName>Research and Collaboration Agreements - Summary of Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Research and Collaboration Agreements - Contract Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Research and Collaboration Agreements - Contract Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - License Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails</Role>
      <ShortName>License Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Leases - Summary of Supplemental Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails</Role>
      <ShortName>Leases - Summary of Supplemental Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Schedule of Maturity of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails</Role>
      <ShortName>Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Common Stock - Reserved Shares of Common Stock Issuance on Converted Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails</Role>
      <ShortName>Common Stock - Reserved Shares of Common Stock Issuance on Converted Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Stock-based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Stock-based Compensation - Schedule of Activity Under Company's Stock Option Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Activity Under Company's Stock Option Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Stock-based Compensation - Total Stock-based Compensation Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails</Role>
      <ShortName>Stock-based Compensation - Total Stock-based Compensation Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Stock-based Compensation - Schedule of Estimated Fair Value of Employee Stock Options and ESPP Using Black-Scholes Valuation Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails</Role>
      <ShortName>Stock-based Compensation - Schedule of Estimated Fair Value of Employee Stock Options and ESPP Using Black-Scholes Valuation Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Income Taxes - Schedule of Components of Provision for (Benefit from) Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Provision for (Benefit from) Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Income Taxes - Schedule of Effective Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100740 - Disclosure - Income Taxes- Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes- Schedule of Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Defined Contribution Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ctmx-10k_20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="ctmx-10k_20201231.htm">ctmx-10k_20201231.htm</File>
    <File>ctmx-20201231.xsd</File>
    <File>ctmx-20201231_cal.xml</File>
    <File>ctmx-20201231_def.xml</File>
    <File>ctmx-20201231_lab.xml</File>
    <File>ctmx-20201231_pre.xml</File>
    <File>ctmx-ex1024_991.htm</File>
    <File>ctmx-ex1025_992.htm</File>
    <File>ctmx-ex231_6.htm</File>
    <File>ctmx-ex311_9.htm</File>
    <File>ctmx-ex312_8.htm</File>
    <File>ctmx-ex321_7.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>gzkk5j0cumnd000001.jpg</File>
    <File>gzkk5j0cumnd000002.jpg</File>
    <File>gzkk5j0cumnd000003.jpg</File>
    <File>gzkk5j0cumnd000004.jpg</File>
    <File>gzkk5j0cumnd000005.jpg</File>
    <File>gzkk5j0cumnd000006.jpg</File>
    <File>gzkk5j0cumnd000007.jpg</File>
    <File>gzkk5j0cumnd000008.jpg</File>
    <File>gzkk5j0cumnd000009.jpg</File>
    <File>gzkk5j0cumnd000010.jpg</File>
    <File>gzkk5j0cumnd000011.jpg</File>
    <File>gzkk5j0cumnd000012.jpg</File>
    <File>gzkk5j0cumnd000013.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>111
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ctmx-10k_20201231.htm": {
   "axisCustom": 0,
   "axisStandard": 32,
   "contextCount": 299,
   "dts": {
    "calculationLink": {
     "local": [
      "ctmx-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ctmx-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ctmx-10k_20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ctmx-20201231_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ctmx-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ctmx-20201231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 649,
   "entityCount": 1,
   "hidden": {
    "http://cytomx.com/20201231": 3,
    "http://fasb.org/us-gaap/2020-01-31": 77,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 84
   },
   "keyCustom": 98,
   "keyStandard": 365,
   "memberCustom": 45,
   "memberStandard": 42,
   "nsprefix": "ctmx",
   "nsuri": "http://cytomx.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Net Loss Per Share",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Fair Value Measurements and Short-Term Investments",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestments",
     "shortName": "Fair Value Measurements and Short-Term Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Property and Equipment",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Goodwill and Intangible Assets",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets",
     "shortName": "Goodwill and Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Accrued Liabilities",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilities",
     "shortName": "Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctmx:ResearchAndCollaborationAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Research and Collaboration Agreements",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreements",
     "shortName": "Research and Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctmx:ResearchAndCollaborationAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctmx:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - License Agreement",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreement",
     "shortName": "License Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctmx:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Commitments and Contingencies",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Leases",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctmx:CommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Common Stock",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctmx:CommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - BALANCE SHEETS",
     "role": "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS",
     "shortName": "BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Stock-based Compensation",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Income Taxes",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Defined Contribution Plan",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Subsequent Events",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsTables",
     "shortName": "Fair Value Measurements and Short-Term Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Property and Equipment (Tables)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Goodwill and Intangible Assets (Tables)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables",
     "shortName": "Goodwill and Intangible Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - BALANCE SHEETS (Parenthetical)",
     "role": "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical",
     "shortName": "BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Accrued Liabilities (Tables)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables",
     "shortName": "Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ctmx:ResearchAndCollaborationAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure -  Research and Collaboration Agreements (Tables)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsTables",
     "shortName": "Research and Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ctmx:ResearchAndCollaborationAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctmx:SupplementalInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Leases (Tables)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctmx:SupplementalInformationRelatedToLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ctmx:CommonStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Common Stock (Tables)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ctmx:CommonStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Stock-based Compensation (Tables)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Income Taxes (Tables)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Customers and Collaboration Partners who Represent 10% or More of Total Revenue During Each Period Presented or Net Accounts Receivable Balance (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Customers and Collaboration Partners who Represent 10% or More of Total Revenue During Each Period Presented or Net Accounts Receivable Balance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_srtMajorCustomersAxis_ctmxMajorCustomerMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ctmx:NumberOfBusinessActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_ctmxActivity",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ctmx:NumberOfBusinessActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_ctmxActivity",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Summary of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Useful Lives of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "role": "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ctmx:AdoptedAndRecentAccountingPronouncementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Adopted and Recent Accounting Pronouncements - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails",
     "shortName": "Adopted and Recent Accounting Pronouncements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
       "ctmx:AdoptedAndRecentAccountingPronouncementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_us-gaapDerivativeInstrumentRiskAxis_ctmxOptionsAndESPPToPurchaseCommonStockMember_20200101_20201231",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ctmx:CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Fair Value Measurements and Short-Term Investments - Schedule of Short-Term Investments Subject to Fair Value Measurements on a Recurring Basis (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements and Short-Term Investments - Schedule of Short-Term Investments Subject to Fair Value Measurements on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ctmx:CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Fair Value Measurements and Short-Term Investments - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements and Short-Term Investments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MachineryAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Property and Equipment - Summary of Property and Equipment, Net (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment - Summary of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MachineryAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Property and Equipment - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Goodwill and Intangible Assets - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20200101_20201231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Goodwill and Intangible Assets - Schedule of Goodwill and Intangible Assets (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets - Schedule of Goodwill and Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapInProcessResearchAndDevelopmentMember_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ctmx:AccruedResearchAndClinicalCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Accrued Liabilities - Summary of Accrued Liabilities (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails",
     "shortName": "Accrued Liabilities - Summary of Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ctmx:AccruedResearchAndClinicalCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ctmx:ResearchAndCollaborationAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Research and Collaboration Agreements - Schedule of Revenue by Collaboration Partners (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails",
     "shortName": "Research and Collaboration Agreements - Schedule of Revenue by Collaboration Partners (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ctmx:ResearchAndCollaborationAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20171231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
     "shortName": "Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20180531",
      "decimals": "-5",
      "lang": null,
      "name": "ctmx:MilestonePaymentsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2016-04-01_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details 1)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1",
     "shortName": "Research and Collaboration Agreements - AbbVie Ireland Unlimited Company - Additional Information (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2016-04-01_us-gaapTypeOfArrangementAxis_ctmxDiscoveryAgreementMember_20160430",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Research and Collaboration Agreements - Amgen, Inc - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
     "shortName": "Research and Collaboration Agreements - Amgen, Inc - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_srtCounterpartyNameAxis_ctmxAmgenIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20170929_20170929",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromCollaborators",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Research and Collaboration Agreements - Astellas Pharma Inc - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
     "shortName": "Research and Collaboration Agreements - Astellas Pharma Inc - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_srtCounterpartyNameAxis_ctmxAstellasPharmaIncMember_us-gaapTypeOfArrangementAxis_ctmxCollaborationAndLicenseAgreementMember_20200323",
      "decimals": "INF",
      "lang": null,
      "name": "ctmx:NumberOfTargetsSelected",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_ctmxTarget",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Research and Collaboration Agreements - Bristol-Myers Squibb Company - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
     "shortName": "Research and Collaboration Agreements - Bristol-Myers Squibb Company - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_srtCounterpartyNameAxis_ctmxBristolMyersSquibbCompanyMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140707",
      "decimals": "INF",
      "lang": null,
      "name": "ctmx:NumberOfAdditionalCollaborationTarget",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_ctmxTarget",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Research and Collaboration Agreements - ImmunoGen, Inc - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails",
     "shortName": "Research and Collaboration Agreements - ImmunoGen, Inc - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_srtCounterpartyNameAxis_ctmxImmunoGenIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20140101_20140131",
      "decimals": "INF",
      "lang": null,
      "name": "ctmx:CashPaymentToExecuteAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ctmx:ContractWithCustomerLiabilityAdditions",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Research and Collaboration Agreements - Pfizer Inc - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails",
     "shortName": "Research and Collaboration Agreements - Pfizer Inc - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_srtCounterpartyNameAxis_ctmxPfizerIncMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20130501_20130531",
      "decimals": "INF",
      "lang": null,
      "name": "ctmx:NumberOfNominatedResearchTargets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_ctmxTarget",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Research and Collaboration Agreements - Summary of Contract Liabilities (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsSummaryOfContractLiabilitiesDetails",
     "shortName": "Research and Collaboration Agreements - Summary of Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "ctmx:ContractWithCustomerLiabilityAdditions",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Research and Collaboration Agreements - Contract Liabilities - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
     "shortName": "Research and Collaboration Agreements - Contract Liabilities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_srtCounterpartyNameAxis_ctmxAbbVieIrelandUnlimitedCompanyMember_20200101_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "ctmx:ContractWithCustomerLiabilityAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ctmx:LicenseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ctmx:RoyaltyObligationsFutureMinimumPaymentsDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - License Agreement - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
     "shortName": "License Agreement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ctmx:LicenseAgreementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "ctmx:RoyaltyObligationsFutureMinimumPaymentsDue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - STATEMENTS OF CASH FLOWS",
     "role": "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304_20200304",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyLawsuitFilingDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_srtLitigationCaseAxis_ctmxPatentInfringementLawsuitMember_20200304_20200304",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyLawsuitFilingDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestrictedCashNoncurrent",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Leases - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ctmx:SupplementalInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Leases - Summary of Supplemental Information Related to Leases (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails",
     "shortName": "Leases - Summary of Supplemental Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ctmx:SupplementalInformationRelatedToLeasesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Leases - Schedule of Maturity of Operating Lease Liabilities (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Schedule of Maturity of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Common Stock - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
     "shortName": "Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ctmx:CommonStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200630",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ctmx:CommonStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ctmx:StockOptionsIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Common Stock - Reserved Shares of Common Stock Issuance on Converted Basis (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails",
     "shortName": "Common Stock - Reserved Shares of Common Stock Issuance on Converted Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ctmx:CommonStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "ctmx:StockOptionsIssuedAndOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Stock-based Compensation - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ctmx:CommonStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20191231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Stock-based Compensation - Schedule of Activity Under Company's Stock Option Plans (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails",
     "shortName": "Stock-based Compensation - Schedule of Activity Under Company's Stock Option Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Stock-based Compensation - Total Stock-based Compensation Recognized (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails",
     "shortName": "Stock-based Compensation - Total Stock-based Compensation Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Stock-based Compensation - Schedule of Estimated Fair Value of Employee Stock Options and ESPP Using Black-Scholes Valuation Model (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails",
     "shortName": "Stock-based Compensation - Schedule of Estimated Fair Value of Employee Stock Options and ESPP Using Black-Scholes Valuation Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - Description of the Business",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness",
     "shortName": "Description of the Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200327_20200327",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ctmx:PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200327_20200327",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "ctmx:PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Income Taxes - Schedule of Components of Provision for (Benefit from) Income Taxes (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails",
     "shortName": "Income Taxes - Schedule of Components of Provision for (Benefit from) Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Income Taxes - Schedule of Effective Tax Rate Reconciliation (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100740 - Disclosure - Income Taxes- Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes- Schedule of Reconciliation of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Defined Contribution Plan - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails",
     "shortName": "Defined Contribution Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_srtStatementScenarioAxis_srtScenarioForecastMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapOverAllotmentOptionMember_20210201_20210228",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctmx:AdoptedAndRecentAccountingPronouncementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Adopted and Recent Accounting Pronouncements",
     "role": "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncements",
     "shortName": "Adopted and Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "ctmx-10k_20201231.htm",
      "contextRef": "C_0001501989_20200101_20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ctmx:AdoptedAndRecentAccountingPronouncementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 87,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_AbbVieIrelandUnlimitedCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AbbVie Ireland Unlimited Company.",
        "label": "Abb Vie Ireland Unlimited Company [Member]",
        "terseLabel": "AbbVie Ireland Unlimited Company",
        "verboseLabel": "AbbVie"
       }
      }
     },
     "localname": "AbbVieIrelandUnlimitedCompanyMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_AbbVieMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AbbVie .",
        "label": "Abb Vie [Member]",
        "terseLabel": "AbbVie"
       }
      }
     },
     "localname": "AbbVieMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_AcceleratedRecognitionOfDeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated recognition of deferred revenue.",
        "label": "Accelerated Recognition Of Deferred Revenue [Member]",
        "terseLabel": "Accelerated Recognition of Deferred Revenue"
       }
      }
     },
     "localname": "AcceleratedRecognitionOfDeferredRevenueMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_AccruedResearchAndClinicalCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and clinical current.",
        "label": "Accrued Research And Clinical Current",
        "terseLabel": "Research and clinical expenses"
       }
      }
     },
     "localname": "AccruedResearchAndClinicalCurrent",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_AchievingAdditionalTargetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achieving additional targets.",
        "label": "Achieving Additional Targets [Member]",
        "terseLabel": "Each Of Two Additional Targets"
       }
      }
     },
     "localname": "AchievingAdditionalTargetsMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_AdditionalContingentPaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional contingent payments.",
        "label": "Additional Contingent Payments [Member]",
        "terseLabel": "Additional Contingent Payments"
       }
      }
     },
     "localname": "AdditionalContingentPaymentsMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_AdditionalSublicenseFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional sublicense fees.",
        "label": "Additional Sublicense Fees",
        "terseLabel": "Additional sublicense fees"
       }
      }
     },
     "localname": "AdditionalSublicenseFees",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_AdoptedAndRecentAccountingPronouncementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adopted and recent accounting pronouncements.",
        "label": "Adopted And Recent Accounting Pronouncements [Text Block]",
        "terseLabel": "Adopted and Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "AdoptedAndRecentAccountingPronouncementsTextBlock",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctmx_AggregateCollaborationTransactionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate collaboration transaction amount.",
        "label": "Aggregate Collaboration Transaction Amount",
        "terseLabel": "Total transaction price"
       }
      }
     },
     "localname": "AggregateCollaborationTransactionAmount",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_AmgenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen Inc.",
        "label": "Amgen Inc [Member]",
        "terseLabel": "Amgen Inc",
        "verboseLabel": "Amgen"
       }
      }
     },
     "localname": "AmgenIncMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_AmgenOtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen other products.",
        "label": "Amgen Other Products [Member]",
        "terseLabel": "Amgen Other Products"
       }
      }
     },
     "localname": "AmgenOtherProductsMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_AmgenProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amgen products.",
        "label": "Amgen Products [Member]",
        "terseLabel": "Amgen Products"
       }
      }
     },
     "localname": "AmgenProductsMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_AnnualLicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license maintenance fees",
        "label": "Annual License Maintenance Fees",
        "terseLabel": "Annual license maintenance fees"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFees",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_AstellasPharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Astellas Pharma Inc.",
        "label": "Astellas Pharma Inc [Member]",
        "terseLabel": "Astellas Pharma Inc.",
        "verboseLabel": "Astellas"
       }
      }
     },
     "localname": "AstellasPharmaIncMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_BristolMyersSquibbCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bristol-Myers Squibb Company.",
        "label": "Bristol Myers Squibb Company [Member]",
        "terseLabel": "Bristol Myers Squibb Company"
       }
      }
     },
     "localname": "BristolMyersSquibbCompanyMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_CD71AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CD 71 agreement.",
        "label": "C D71 Agreement [Member]",
        "terseLabel": "CD71 Agreement"
       }
      }
     },
     "localname": "CD71AgreementMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails": {
       "order": 10060.0,
       "parentTag": "ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and short term investments, accumulated gross unrealized gain before tax.",
        "label": "Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Gross Unrealized Holding Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails": {
       "order": 10070.0,
       "parentTag": "ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and short term investments, accumulated gross unrealized loss before tax.",
        "label": "Cash Cash Equivalents And Short Term Investments Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Gross Unrealized Holding Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails": {
       "order": 10050.0,
       "parentTag": "ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and short term investments, allowance for credit loss.",
        "label": "Cash Cash Equivalents And Short Term Investments Allowance For Credit Loss",
        "terseLabel": "Allowance for Credit Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAllowanceForCreditLoss",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and short term investments, amortized cost basis.",
        "label": "Cash Cash Equivalents And Short Term Investments Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in measurement of lease liabilities.",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctmx_CashPaymentToExecuteAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payment to execute the agreement.",
        "label": "Cash Payment To Execute Agreement",
        "terseLabel": "Upfront cash payment"
       }
      }
     },
     "localname": "CashPaymentToExecuteAgreement",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_CollaborationTargetResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration target research term.",
        "label": "Collaboration Target Research Term",
        "terseLabel": "Collaboration target research term"
       }
      }
     },
     "localname": "CollaborationTargetResearchTerm",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctmx_CommonStockSharesIssuableUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock shares issuable under agreement.",
        "label": "Common Stock Shares Issuable Under Agreement",
        "verboseLabel": "Common stock, shares issuable under agreement"
       }
      }
     },
     "localname": "CommonStockSharesIssuableUnderAgreement",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ctmx_CommonStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock.",
        "label": "Common Stock [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockTextBlock",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctmx_ComputerEquipmentAndSoftwareGross": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software gross.",
        "label": "Computer Equipment And Software Gross",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareGross",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_ContingentMilestonePaymentsNoLongerEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent milestone payments no longer eligible to receive.",
        "label": "Contingent Milestone Payments No Longer Eligible To Receive",
        "terseLabel": "Contingent milestone payments, no longer eligible to receive"
       }
      }
     },
     "localname": "ContingentMilestonePaymentsNoLongerEligibleToReceive",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_ContingentMilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future contingent milestone payment receivable.",
        "label": "Contingent Milestone Payments Receivable",
        "terseLabel": "Contingent milestone payments receivable"
       }
      }
     },
     "localname": "ContingentMilestonePaymentsReceivable",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent payments payable upon achieving development regulatory and commercial milestones.",
        "label": "Contingent Payments Payable Upon Achieving Development Regulatory And Commercial Milestones",
        "terseLabel": "Contingent payments payable"
       }
      }
     },
     "localname": "ContingentPaymentsPayableUponAchievingDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_ContingentPaymentsReceivableProfitSplitOnSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent payments receivable profit split on sales.",
        "label": "Contingent Payments Receivable Profit Split On Sales",
        "terseLabel": "Profit split on U.S. sales"
       }
      }
     },
     "localname": "ContingentPaymentsReceivableProfitSplitOnSales",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctmx_ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent payments receivable upon achieving development, regulatory and commercial milestones.",
        "label": "Contingent Payments Receivable Upon Achieving Development Regulatory And Commercial Milestones",
        "terseLabel": "Contingent payments receivable upon achieving development, regulatory and commercial milestones"
       }
      }
     },
     "localname": "ContingentPaymentsReceivableUponAchievingDevelopmentRegulatoryAndCommercialMilestones",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability additions.",
        "label": "Contract With Customer Liability Additions",
        "positiveLabel": "Additions",
        "terseLabel": "Additional target as deferred revenue",
        "verboseLabel": "Additions to deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsSummaryOfContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_ContractWithCustomerLiabilityMaturityMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer liability maturity month and year.",
        "label": "Contract With Customer Liability Maturity Month And Year",
        "terseLabel": "Deferred revenue recognition maturity month and year"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityMaturityMonthAndYear",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "ctmx_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10120.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets lease liability.",
        "label": "Deferred Tax Assets Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation and amortization excluding amortization of intangible assets.",
        "label": "Depreciation And Amortization Excluding Amortization Of Intangible Assets",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortizationExcludingAmortizationOfIntangibleAssets",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_DevelopmentRegulatoryAndCommercialMilestonePaymentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development regulatory and commercial milestone payments.",
        "label": "Development Regulatory And Commercial Milestone Payments [Member]",
        "terseLabel": "Development, Regulatory and Commercial Milestone Payments"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndCommercialMilestonePaymentsMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_DiscoveryAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discovery agreement.",
        "label": "Discovery Agreement [Member]",
        "terseLabel": "Discovery Agreement"
       }
      }
     },
     "localname": "DiscoveryAgreementMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_DrugApplicationForCTLA4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Drug application for CTLA-4.",
        "label": "Drug Application For C T L A4 [Member]",
        "terseLabel": "New Drug Application for CTLA-4"
       }
      }
     },
     "localname": "DrugApplicationForCTLA4Member",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_EGFRProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EGFR Products.",
        "label": "E G F R Products [Member]",
        "terseLabel": "EGFR Products"
       }
      }
     },
     "localname": "EGFRProductsMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_EarlyExerciseOfEmployeeOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early exercise of employee options.",
        "label": "Early Exercise Of Employee Options [Member]",
        "terseLabel": "Early Exercise of Employee Options"
       }
      }
     },
     "localname": "EarlyExerciseOfEmployeeOptionsMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation net operating loss carryback.",
        "label": "Effective Income Tax Rate Reconciliation Net Operating Loss Carryback",
        "terseLabel": "Net operating loss carryback"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNetOperatingLossCarryback",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctmx_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation return to provision adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Return To Provision Adjustments",
        "negatedLabel": "Return to provision adjustment"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctmx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_EstimatedFairValueOfProducts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of products.",
        "label": "Estimated Fair Value Of Products",
        "terseLabel": "Estimated fair value of products"
       }
      }
     },
     "localname": "EstimatedFairValueOfProducts",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_EstimatedPremiumOnIssuanceOfShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated premium on issuance of shares.",
        "label": "Estimated Premium On Issuance Of Shares",
        "terseLabel": "Estimated premium on the stock sold"
       }
      }
     },
     "localname": "EstimatedPremiumOnIssuanceOfShares",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_EstimatedResearchServicePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated research service period.",
        "label": "Estimated Research Service Period",
        "terseLabel": "Estimated research service period"
       }
      }
     },
     "localname": "EstimatedResearchServicePeriod",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctmx_EstimatedResearchServiceTerminationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated research service termination date.",
        "label": "Estimated Research Service Termination Date",
        "terseLabel": "Estimated research service termination date"
       }
      }
     },
     "localname": "EstimatedResearchServiceTerminationDate",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "ctmx_EstimatedResearchServiceTerminationMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated research service termination month and year.",
        "label": "Estimated Research Service Termination Month And Year",
        "terseLabel": "Estimated research service termination month &amp; year"
       }
      }
     },
     "localname": "EstimatedResearchServiceTerminationMonthAndYear",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "ctmx_EstimatedSublicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated sublicense fees.",
        "label": "Estimated Sublicense Fees",
        "terseLabel": "Estimated sublicense fees"
       }
      }
     },
     "localname": "EstimatedSublicenseFees",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_ExtensionOfResearchTermForEachCollaborationTarget": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension of research term for each collaboration target.",
        "label": "Extension Of Research Term For Each Collaboration Target",
        "terseLabel": "Extension of research term for each collaboration target"
       }
      }
     },
     "localname": "ExtensionOfResearchTermForEachCollaborationTarget",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctmx_FairValueOfCommonStockIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common stock issued.",
        "label": "Fair Value Of Common Stock Issued",
        "terseLabel": "Fair value of common stock issued"
       }
      }
     },
     "localname": "FairValueOfCommonStockIssued",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_FirstTargetUnderDiscoveryAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First target under discovery agreement.",
        "label": "First Target Under Discovery Agreement [Member]",
        "verboseLabel": "First Target under Discovery Agreement"
       }
      }
     },
     "localname": "FirstTargetUnderDiscoveryAgreementMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_FirstYearOfLeaseTermMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First year of lease term.",
        "label": "First Year Of Lease Term [Member]",
        "terseLabel": "First year of lease term"
       }
      }
     },
     "localname": "FirstYearOfLeaseTermMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_GoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill.",
        "label": "Goodwill [Abstract]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAbstract",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctmx_GoodwillAndIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets [Line Items]",
        "terseLabel": "Goodwill And Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsLineItems",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctmx_ImmunoGenIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ImmunoGen, Inc.",
        "label": "Immuno Gen Inc [Member]",
        "terseLabel": "Immuno Gen Inc",
        "verboseLabel": "ImmunoGen"
       }
      }
     },
     "localname": "ImmunoGenIncMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_ImprovementAllowanceFromRecoverableRent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Improvement allowance from recoverable rent.",
        "label": "Improvement Allowance From Recoverable Rent",
        "terseLabel": "Improvement allowance from recoverable rent"
       }
      }
     },
     "localname": "ImprovementAllowanceFromRecoverableRent",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10200.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in accrued liabilities, income tax payable and other liabilities noncurrent.",
        "label": "Increase Decrease In Accrued Liabilities Income Tax Payable And Other Liabilities Noncurrent",
        "terseLabel": "Accrued liabilities, income tax payable and other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesIncomeTaxPayableAndOtherLiabilitiesNoncurrent",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_IncrementsOfExtendedCollaborationTargetResearchTimes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increments of extended collaboration target research times.",
        "label": "Increments Of Extended Collaboration Target Research Times",
        "terseLabel": "Times of increments for extended collaboration target research time"
       }
      }
     },
     "localname": "IncrementsOfExtendedCollaborationTargetResearchTimes",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_JefferiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies.",
        "label": "Jefferies [Member]",
        "verboseLabel": "Jefferies LLC"
       }
      }
     },
     "localname": "JefferiesMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due year five and thereafter.",
        "label": "Lessee Operating Lease Liability Payments Due Year Five And Thereafter",
        "terseLabel": "2025 and beyond"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_LicenseAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement.",
        "label": "License Agreement Disclosure [Text Block]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDisclosureTextBlock",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctmx_LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License payment percentage equivalence to upfront and milestone proceeds.",
        "label": "License Payment Percentage Equivalence To Upfront And Milestone Proceeds",
        "terseLabel": "Sublicense payment percentage"
       }
      }
     },
     "localname": "LicensePaymentPercentageEquivalenceToUpfrontAndMilestoneProceeds",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctmx_LicensePaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License payment term.",
        "label": "License Payment Term",
        "terseLabel": "License payment term"
       }
      }
     },
     "localname": "LicensePaymentTerm",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "ctmx_LicenseTerminationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time to terminate license after notice date.",
        "label": "License Termination Period",
        "terseLabel": "License termination period"
       }
      }
     },
     "localname": "LicenseTerminationPeriod",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctmx_LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lock-up period for share transaction under collaboration and license agreement.",
        "label": "Lock Up Period For Share Transaction Under Collaboration And License Agreement",
        "terseLabel": "Lock-up period for share disposal"
       }
      }
     },
     "localname": "LockUpPeriodForShareTransactionUnderCollaborationAndLicenseAgreement",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctmx_LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss contingency answer, affirmative defenses and counterclaims filing date.",
        "label": "Loss Contingency Answer Affirmative Defenses And Counterclaims Filing Date",
        "terseLabel": "Loss contingency, answer, affirmative defenses and counterclaims filing date"
       }
      }
     },
     "localname": "LossContingencyAnswerAffirmativeDefensesAndCounterclaimsFilingDate",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "ctmx_LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss contingency, answer and counterclaims by plaintiff filing date.",
        "label": "Loss Contingency Answer And Counterclaims By Plaintiff Filing Date",
        "terseLabel": "Loss contingency, answer and counterclaims by plaintiff filing date"
       }
      }
     },
     "localname": "LossContingencyAnswerAndCounterclaimsByPlaintiffFilingDate",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "ctmx_MajorCustomerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Major customer [Member].",
        "label": "Major Customer [Member]",
        "terseLabel": "Major Customer"
       }
      }
     },
     "localname": "MajorCustomerMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_MaximumImprovementAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum improvement allowance.",
        "label": "Maximum Improvement Allowance",
        "terseLabel": "Maximum one-time improvement allowance"
       }
      }
     },
     "localname": "MaximumImprovementAllowance",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_MilestonePaymentPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment payable.",
        "label": "Milestone Payment Payable",
        "terseLabel": "Milestone payments payable"
       }
      }
     },
     "localname": "MilestonePaymentPayable",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_MilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment receivable.",
        "label": "Milestone Payment Receivable",
        "terseLabel": "Milestone payment receivable"
       }
      }
     },
     "localname": "MilestonePaymentReceivable",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_MilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment received.",
        "label": "Milestone Payment Received",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "localname": "MilestonePaymentReceived",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_MilestonePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments receivable.",
        "label": "Milestone Payments Receivable",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "MilestonePaymentsReceivable",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments received from revenue recognized during period.",
        "label": "Milestone Payments Received From Revenue Recognized During Period",
        "terseLabel": "Milestone payment received"
       }
      }
     },
     "localname": "MilestonePaymentsReceivedFromRevenueRecognizedDuringPeriod",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_MoneyMarketFundsIncludedInRestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money market funds included in restricted cash.",
        "label": "Money Market Funds Included In Restricted Cash [Member]",
        "terseLabel": "Restricted cash (money market funds)"
       }
      }
     },
     "localname": "MoneyMarketFundsIncludedInRestrictedCashMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_NetOperatingLossCarrybackPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net operating loss carryback.",
        "label": "Net Operating Loss Carryback Period",
        "terseLabel": "Net operating loss carryback"
       }
      }
     },
     "localname": "NetOperatingLossCarrybackPeriod",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctmx_NonEmployeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Employees Member.",
        "label": "Non Employees [Member]",
        "terseLabel": "Non-employees"
       }
      }
     },
     "localname": "NonEmployeesMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10140.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash lease expense.",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_NumberOfAccountingUnits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of accounting units.",
        "label": "Number Of Accounting Units",
        "terseLabel": "Number of accounting units"
       }
      }
     },
     "localname": "NumberOfAccountingUnits",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_NumberOfAdditionalCollaborationTarget": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional collaboration target.",
        "label": "Number Of Additional Collaboration Target",
        "terseLabel": "Number of additional collaboration target"
       }
      }
     },
     "localname": "NumberOfAdditionalCollaborationTarget",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_NumberOfAdditionalResearchTargetsWithNominationOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional research targets.",
        "label": "Number Of Additional Research Targets With Nomination Option",
        "terseLabel": "Nominated number of additional research targets"
       }
      }
     },
     "localname": "NumberOfAdditionalResearchTargetsWithNominationOption",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_NumberOfBusinessActivities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of business activities.",
        "label": "Number Of Business Activities",
        "terseLabel": "Number of business activities"
       }
      }
     },
     "localname": "NumberOfBusinessActivities",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_NumberOfCollaborationAgreements": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of collaboration agreements.",
        "label": "Number Of Collaboration Agreements",
        "terseLabel": "Number of collaboration agreements"
       }
      }
     },
     "localname": "NumberOfCollaborationAgreements",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_NumberOfCollaborationTarget": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of collaboration target.",
        "label": "Number Of Collaboration Target",
        "terseLabel": "Number of collaboration target"
       }
      }
     },
     "localname": "NumberOfCollaborationTarget",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_NumberOfCurrentAndFormerOfficersNamedAsDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of current and former officers named as defendants.",
        "label": "Number Of Current And Former Officers Named As Defendants",
        "terseLabel": "Number of current and former officers named as defendants"
       }
      }
     },
     "localname": "NumberOfCurrentAndFormerOfficersNamedAsDefendants",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_NumberOfNominatedResearchTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of nominated research targets.",
        "label": "Number Of Nominated Research Targets",
        "terseLabel": "Number of research targets"
       }
      }
     },
     "localname": "NumberOfNominatedResearchTargets",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_NumberOfOncologyTarget": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of oncology target.",
        "label": "Number Of Oncology Target",
        "terseLabel": "Number of oncology target"
       }
      }
     },
     "localname": "NumberOfOncologyTarget",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_NumberOfResearchTargetsSelected": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of research targets selected.",
        "label": "Number Of Research Targets Selected",
        "terseLabel": "Number of research targets selected"
       }
      }
     },
     "localname": "NumberOfResearchTargetsSelected",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_NumberOfTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of targets.",
        "label": "Number Of Targets",
        "terseLabel": "Number of targets"
       }
      }
     },
     "localname": "NumberOfTargets",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_NumberOfTargetsSelected": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of targets selected.",
        "label": "Number Of Targets Selected",
        "terseLabel": "Number of targets selected"
       }
      }
     },
     "localname": "NumberOfTargetsSelected",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_OperatingLeasesRentExpenseAnnualBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases rent expense annual base rent.",
        "label": "Operating Leases Rent Expense Annual Base Rent",
        "terseLabel": "Annual lease rent"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseAnnualBaseRent",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_OperatingLossCarryforwardsAmountNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards amount not subject to expiration.",
        "label": "Operating Loss Carryforwards Amount Not Subject To Expiration",
        "terseLabel": "Operating loss carryforwards not subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAmountNotSubjectToExpiration",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_OperatingLossCarryforwardsAmountToExpireIfNotUsed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards amount to expire if not used.",
        "label": "Operating Loss Carryforwards Amount To Expire If Not Used",
        "terseLabel": "Operating loss carryforwards to expire if not utilized"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsAmountToExpireIfNotUsed",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "ctmx_OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option period granted to underwriters to purchase additional shares.",
        "label": "Option Period Granted To Underwriters To Purchase Additional Shares",
        "terseLabel": "Period granted to underwriters to purchase additional shares"
       }
      }
     },
     "localname": "OptionPeriodGrantedToUnderwritersToPurchaseAdditionalShares",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctmx_OptionsAndESPPToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options and ESPP to purchase common stock.",
        "label": "Options And E S P P To Purchase Common Stock [Member]",
        "terseLabel": "Options and ESPP to purchase common stock"
       }
      }
     },
     "localname": "OptionsAndESPPToPurchaseCommonStockMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_PatentInfringementLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent infringement lawsuit.",
        "label": "Patent Infringement Lawsuit [Member]",
        "terseLabel": "Patent Infringement Lawsuit"
       }
      }
     },
     "localname": "PatentInfringementLawsuitMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_PaymentOfUpfrontFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of upfront fees.",
        "label": "Payment Of Upfront Fees",
        "terseLabel": "Payment of upfront fees"
       }
      }
     },
     "localname": "PaymentOfUpfrontFees",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_PaymentsOfSublicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of sublicense fees.",
        "label": "Payments Of Sublicense Fees",
        "terseLabel": "Sublicense fees paid"
       }
      }
     },
     "localname": "PaymentsOfSublicenseFees",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_PercentageOfChangeInOwnership": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of change in ownership.",
        "label": "Percentage Of Change In Ownership",
        "terseLabel": "Percentage of change in ownership"
       }
      }
     },
     "localname": "PercentageOfChangeInOwnership",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctmx_PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of net Income or net losses related to development and commercialization costs.",
        "label": "Percentage Of Net Income Or Net Losses Related To Development And Commercialization Costs",
        "terseLabel": "Percentage of net profits or net losses related to development and commercialization costs"
       }
      }
     },
     "localname": "PercentageOfNetIncomeOrNetLossesRelatedToDevelopmentAndCommercializationCosts",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctmx_PercentageOfRemainingMaintenanceFeesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of remaining maintenance fees outstanding.",
        "label": "Percentage Of Remaining Maintenance Fees Outstanding",
        "terseLabel": "Percentage of remaining maintenance fees outstanding"
       }
      }
     },
     "localname": "PercentageOfRemainingMaintenanceFeesOutstanding",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctmx_PercentageOfSalesCommission": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sales commission.",
        "label": "Percentage Of Sales Commission",
        "verboseLabel": "Percentage of sales commission"
       }
      }
     },
     "localname": "PercentageOfSalesCommission",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctmx_PercentageOfSalesCommissionAndIssuanceCost": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of sales commission and issuance cost.",
        "label": "Percentage Of Sales Commission And Issuance Cost",
        "terseLabel": "Percentage of sales commission and issuance cost"
       }
      }
     },
     "localname": "PercentageOfSalesCommissionAndIssuanceCost",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctmx_PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of taxable income from net operating losses for suspension of annual deduction limitation.",
        "label": "Percentage Of Taxable Income From Net Operating Losses For Suspension Of Annual Deduction Limitation",
        "terseLabel": "Percentage of taxable income from net operating losses for suspension of annual deduction limitation"
       }
      }
     },
     "localname": "PercentageOfTaxableIncomeFromNetOperatingLossesForSuspensionOfAnnualDeductionLimitation",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctmx_PeriodOfNominationOfAdditionalTarget": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of nomination of additional target.",
        "label": "Period Of Nomination Of Additional Target",
        "terseLabel": "Period of nomination of additional target from effective date"
       }
      }
     },
     "localname": "PeriodOfNominationOfAdditionalTarget",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctmx_PeriodUsedToCalculateWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period used to calculate weighted average price per share.",
        "label": "Period Used To Calculate Weighted Average Price Per Share",
        "terseLabel": "Period used to calculate weighted average price per share"
       }
      }
     },
     "localname": "PeriodUsedToCalculateWeightedAveragePricePerShare",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ctmx_PfizerIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Inc.",
        "label": "Pfizer Inc [Member]",
        "terseLabel": "Pfizer Inc",
        "verboseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerIncMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_PreClinicalCandidateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre clinical candidate.",
        "label": "Pre Clinical Candidate [Member]",
        "terseLabel": "Pre Clinical Candidate"
       }
      }
     },
     "localname": "PreClinicalCandidateMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_PremiumOnIssuanceOfSharesAllocatedToCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium on issuance of shares allocated to common stock.",
        "label": "Premium On Issuance Of Shares Allocated To Common Stock",
        "terseLabel": "Portion of transaction price allocated to premium on sale of common stock"
       }
      }
     },
     "localname": "PremiumOnIssuanceOfSharesAllocatedToCommonStock",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_ProbodyTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Probody technology.",
        "label": "Probody Technology [Member]",
        "terseLabel": "Probody technology"
       }
      }
     },
     "localname": "ProbodyTechnologyMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_ProfitShareUponExerciseOfCoDevelopmentOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit share upon exercise of co-development option.",
        "label": "Profit Share Upon Exercise Of Co Development Option",
        "terseLabel": "Percentage share of profit and losses"
       }
      }
     },
     "localname": "ProfitShareUponExerciseOfCoDevelopmentOption",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctmx_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of property plant and equipment estimated useful lives.",
        "label": "Property Plant And Equipment Estimated Useful Lives Table [Text Block]",
        "terseLabel": "Schedule of Useful Lives of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctmx_RegentsOfTheUniversityOfCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regents of the university of California.",
        "label": "Regents Of The University Of California [Member]",
        "terseLabel": "UC Regents"
       }
      }
     },
     "localname": "RegentsOfTheUniversityOfCaliforniaMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_ResearchAndCollaborationAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and collaboration agreements.",
        "label": "Research And Collaboration Agreements [Text Block]",
        "terseLabel": "Research and Collaboration Agreements"
       }
      }
     },
     "localname": "ResearchAndCollaborationAgreementsTextBlock",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctmx_ResearchAndDevelopmentServiceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development service fees.",
        "label": "Research And Development Service Fees",
        "terseLabel": "Research and development service fees"
       }
      }
     },
     "localname": "ResearchAndDevelopmentServiceFees",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_RightToExpandNumberOfAdditionalCollaborationTarget": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to expand the number of additional collaboration target.",
        "label": "Right To Expand Number Of Additional Collaboration Target",
        "terseLabel": "Right to expand the number of additional collaboration target"
       }
      }
     },
     "localname": "RightToExpandNumberOfAdditionalCollaborationTarget",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ctmx_RoyaltyObligationsFutureMinimumPaymentsDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty obligations future minimum payments due.",
        "label": "Royalty Obligations Future Minimum Payments Due",
        "terseLabel": "Annual minimum royalty obligations"
       }
      }
     },
     "localname": "RoyaltyObligationsFutureMinimumPaymentsDue",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash, cash equivalents, and restricted cash.",
        "label": "Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctmx_ScheduleOfGoodwillAndIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and intangible assets.",
        "label": "Schedule Of Goodwill And Intangible Assets [Table]",
        "terseLabel": "Schedule Of Goodwill And Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillAndIntangibleAssetsTable",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctmx_SeattleGeneticsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seattle genetics agreement.",
        "label": "Seattle Genetics Agreement [Member]",
        "terseLabel": "Seattle Genetics Agreement"
       }
      }
     },
     "localname": "SeattleGeneticsAgreementMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_SecondTargetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second target.",
        "label": "Second Target [Member]",
        "terseLabel": "Second Target"
       }
      }
     },
     "localname": "SecondTargetMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_SecondTargetUnderDiscoveryAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second target under discovery agreement.",
        "label": "Second Target Under Discovery Agreement [Member]",
        "verboseLabel": "Second Target under Discovery Agreement"
       }
      }
     },
     "localname": "SecondTargetUnderDiscoveryAgreementMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_SecondTwelveMonthsOfLeaseTermMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second twelve months of lease term.",
        "label": "Second Twelve Months Of Lease Term [Member]",
        "terseLabel": "Second twelve months of lease term"
       }
      }
     },
     "localname": "SecondTwelveMonthsOfLeaseTermMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_SecuritiesClassActionLawsuitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities class action lawsuit.",
        "label": "Securities Class Action Lawsuit [Member]",
        "terseLabel": "Securities Class Action Lawsuit"
       }
      }
     },
     "localname": "SecuritiesClassActionLawsuitMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based compensation arrangement by share-based payment award, number of shares available for future issuance under employee stock purchase plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Future Issuance Under Employee Stock Purchase Plan",
        "terseLabel": "Shares available for future employee stock purchase plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForFutureIssuanceUnderEmployeeStockPurchasePlan",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award, number of shares available for grant.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant [Abstract]",
        "terseLabel": "Options Available for Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAbstract",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant authorized.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Authorized",
        "terseLabel": "Options authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant cancelled in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled In Period",
        "terseLabel": "Options cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCancelledInPeriod",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant exercises in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercises In Period",
        "terseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercisesInPeriod",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant grants in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Grants In Period",
        "negatedLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGrantsInPeriod",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options authorized.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Authorized",
        "terseLabel": "Options authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ctmx_ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award voting rights of common stock holding percentage.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Voting Rights Of Common Stock Holding Percentage",
        "terseLabel": "Employees holding voting rights of all classes of stock, percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVotingRightsOfCommonStockHoldingPercentage",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ctmx_SharesIssuedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued average price per share.",
        "label": "Shares Issued Average Price Per Share",
        "terseLabel": "Average price"
       }
      }
     },
     "localname": "SharesIssuedAveragePricePerShare",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ctmx_StockOptionsIssuedAndOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options issued and outstanding.",
        "label": "Stock Options Issued And Outstanding",
        "terseLabel": "Options issued and outstanding"
       }
      }
     },
     "localname": "StockOptionsIssuedAndOutstanding",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ctmx_SublicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense agreement.",
        "label": "Sublicense Agreement [Member]",
        "terseLabel": "Sublicense Agreement"
       }
      }
     },
     "localname": "SublicenseAgreementMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_SublicenseAndMaintenanceFeesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense and maintenance fees.",
        "label": "Sublicense And Maintenance Fees [Member]",
        "terseLabel": "Sublicense and Maintenance Fees"
       }
      }
     },
     "localname": "SublicenseAndMaintenanceFeesMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_SublicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublicense fees.",
        "label": "Sublicense Fees",
        "terseLabel": "Sublicense fees"
       }
      }
     },
     "localname": "SublicenseFees",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctmx_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctmx_SupplementalBalanceSheetInformationRelatedToLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental balance sheet information related to leases.",
        "label": "Supplemental Balance Sheet Information Related To Leases [Abstract]",
        "terseLabel": "Supplemental balance sheet information related to leases:"
       }
      }
     },
     "localname": "SupplementalBalanceSheetInformationRelatedToLeasesAbstract",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctmx_SupplementalInformationRelatedToLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental information related to leases.",
        "label": "Supplemental Information Related To Leases Table [Text Block]",
        "terseLabel": "Summary of Supplemental Information Related to Leases"
       }
      }
     },
     "localname": "SupplementalInformationRelatedToLeasesTableTextBlock",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ctmx_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforward, expiration"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "ctmx_TenthYearOfLeaseTermMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenth year of lease term.",
        "label": "Tenth Year Of Lease Term [Member]",
        "terseLabel": "Tenth year of lease term"
       }
      }
     },
     "localname": "TenthYearOfLeaseTermMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_ThirdAndFourthTargetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third and fourth targets.",
        "label": "Third And Fourth Targets [Member]",
        "terseLabel": "Third And Fourth Immuno-Oncology Targets"
       }
      }
     },
     "localname": "ThirdAndFourthTargetsMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_TwoThousandFifteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen stock incentive plan.",
        "label": "Two Thousand Fifteen Stock Incentive Plan [Member]",
        "terseLabel": "2015 Plan"
       }
      }
     },
     "localname": "TwoThousandFifteenStockIncentivePlanMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_TwoThousandNineteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Stock Incentive Plan Member.",
        "label": "Two Thousand Nineteen Stock Incentive Plan [Member]",
        "terseLabel": "2019 Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenStockIncentivePlanMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_UnderwrittenPublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwritten public offering.",
        "label": "Underwritten Public Offering [Member]",
        "terseLabel": "Underwritten Public Offering"
       }
      }
     },
     "localname": "UnderwrittenPublicOfferingMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_UniversityOfCaliforniaSantaBarbaraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of California, Santa Barbara.",
        "label": "University Of California Santa Barbara [Member]",
        "terseLabel": "UCSB"
       }
      }
     },
     "localname": "UniversityOfCaliforniaSantaBarbaraMember",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ctmx_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions",
        "terseLabel": "Adjustment based on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_UpfrontFeeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fee received.",
        "label": "Upfront Fee Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "UpfrontFeeReceived",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_UpfrontLicensePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront license payment.",
        "label": "Upfront License Payment",
        "terseLabel": "Upfront license payment"
       }
      }
     },
     "localname": "UpfrontLicensePayment",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ctmx_WeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate.",
        "label": "Weighted Average Discount Rate [Abstract]",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "WeightedAverageDiscountRateAbstract",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ctmx_WeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term.",
        "label": "Weighted Average Remaining Lease Term [Abstract]",
        "terseLabel": "Weighted-average remaining lease term (in years)"
       }
      }
     },
     "localname": "WeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://cytomx.com/20201231",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated By Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "verboseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "verboseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well Known Seasoned Issuer",
        "verboseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r538",
      "r539",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Icfr Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r44",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r98",
      "r106",
      "r187",
      "r336",
      "r337",
      "r338",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect Period Of Adoption Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r98",
      "r106",
      "r187",
      "r336",
      "r337",
      "r338",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect Period Of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r98",
      "r106",
      "r187",
      "r336",
      "r337",
      "r338",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect Period Of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case Type [Domain]",
        "terseLabel": "Litigation Case"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r165",
      "r271",
      "r276",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major Customers [Axis]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r300",
      "r302",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r501",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r300",
      "r302",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r501",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r165",
      "r271",
      "r276",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name Of Major Customer [Domain]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r162",
      "r271",
      "r274",
      "r466",
      "r500",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r162",
      "r271",
      "r274",
      "r466",
      "r500",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r281",
      "r300",
      "r302",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r501",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r281",
      "r300",
      "r302",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r501",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario Unspecified [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r271",
      "r275",
      "r503",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r271",
      "r275",
      "r503",
      "r519",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r231",
      "r301",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update201409 [Member]",
        "terseLabel": "ASC 606"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update201602 [Member]",
        "terseLabel": "ASC 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201613Member": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.",
        "label": "Accounting Standards Update201613 [Member]",
        "terseLabel": "ASU 2016-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201613Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201704Member": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2017-04 Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment.",
        "label": "Accounting Standards Update201704 [Member]",
        "terseLabel": "ASU 2017-04"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201704Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201813Member": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-13 Fair Value Measurement (Topic 820): Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement.",
        "label": "Accounting Standards Update201813 [Member]",
        "terseLabel": "ASU 2018-13"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201813Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201815Member": {
     "auth_ref": [
      "r213",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-15 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force).",
        "label": "Accounting Standards Update201815 [Member]",
        "terseLabel": "ASU 2018-15"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201815Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201818Member": {
     "auth_ref": [
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2018-18 Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606.",
        "label": "Accounting Standards Update201818 [Member]",
        "terseLabel": "ASU 2018-18"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201818Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201908Member": {
     "auth_ref": [
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-08 Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606): Codification Improvements - Share-Based Consideration Payable to a Customer.",
        "label": "Accounting Standards Update201908 [Member]",
        "terseLabel": "ASU 2019-08"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201908Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201912Member": {
     "auth_ref": [
      "r380",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2019-12 Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.",
        "label": "Accounting Standards Update201912 [Member]",
        "terseLabel": "ASU 2019-12"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201912Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r382",
      "r383",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update Extensible List",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable And Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10130.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r2",
      "r19",
      "r166",
      "r167"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10250.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable Net Current",
        "positiveTerseLabel": "Accounts Receivable, net",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Accretion of discount on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10140.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "positiveLabel": "Accrued liabilities",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities Current [Abstract]"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r36"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Legal and professional expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r31",
      "r221"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r48",
      "r50",
      "r51",
      "r491",
      "r513",
      "r517"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r47",
      "r51",
      "r52",
      "r95",
      "r96",
      "r97",
      "r405",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income/(Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite Lived Intangible Assets Weighted Average Useful Life",
        "terseLabel": "Average estimated lives of patents"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r20",
      "r339"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r380",
      "r381",
      "r382",
      "r383",
      "r468",
      "r469",
      "r470",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r304",
      "r306",
      "r342",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r306",
      "r328",
      "r341"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r78",
      "r201",
      "r209"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization Of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization expense of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Anti-dilutive securities excluded from computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AreaOfLand": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land held.",
        "label": "Area Of Land",
        "terseLabel": "Area of rentable office and laboratory space"
       }
      }
     },
     "localname": "AreaOfLand",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r91",
      "r145",
      "r154",
      "r160",
      "r179",
      "r401",
      "r406",
      "r424",
      "r475",
      "r490"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r43",
      "r91",
      "r179",
      "r401",
      "r406",
      "r424"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10160.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Short-term Investments, Gross Unrealized Holding Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax",
        "negatedLabel": "Short-term Investments, Gross Unrealized Holding Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r172",
      "r191"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Debt Securities Amortized Cost Basis",
        "totalLabel": "Short-term Investments, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r177",
      "r178",
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities Within One Year Fair Value",
        "verboseLabel": "Contractual maturities of greater than twelve months"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r169",
      "r173",
      "r191",
      "r478"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available For Sale Securities Debt Securities",
        "terseLabel": "Short-term Investments, Aggregate Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r171",
      "r191"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10240.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Available For Sale Securities Debt Securities Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r307",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis Of Presentation And Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Purchases of property and equipment in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash And Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r28",
      "r80"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      },
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10230.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r81",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r10",
      "r81",
      "r87",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails": {
       "order": 10080.0,
       "parentTag": "ctmx_CashCashEquivalentsAndShortTermInvestmentsAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash Cash Equivalents And Short Term Investments",
        "terseLabel": "Aggregate Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r74",
      "r80",
      "r86"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of year",
        "totalLabel": "Cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r426"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r99",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r332",
      "r333",
      "r334",
      "r380",
      "r414",
      "r425",
      "r435",
      "r468",
      "r469",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change In Accounting Principle Accounting Standards Update Adopted",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r106",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r332",
      "r333",
      "r334",
      "r380",
      "r414",
      "r425",
      "r435",
      "r468",
      "r469",
      "r506",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in CCYY-MM-DD format.",
        "label": "Change In Accounting Principle Accounting Standards Update Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r100",
      "r111",
      "r188",
      "r339",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect [true false]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r90",
      "r91",
      "r112",
      "r113",
      "r114",
      "r116",
      "r117",
      "r123",
      "r124",
      "r125",
      "r179",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class Of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r39",
      "r230",
      "r479",
      "r495"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r227",
      "r228",
      "r229",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Common stock, capital shares reserved for future issuance",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.00001 par value; 150,000,000 and 75,000,000 shares authorized at December 31, 2020 and 2019, respectively; 48,251,819 and 45,523,088 shares issued and outstanding at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation And Retirement Disclosure [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components Of Deferred Tax Assets And Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r54",
      "r56",
      "r57",
      "r62",
      "r482",
      "r497"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income Policy Policy [Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r129",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk Credit Risk",
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration By Type [Axis]",
        "terseLabel": "Contingent Consideration by Type"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract With Customer Asset And Liability Table [Text Block]",
        "terseLabel": "Summary of Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r256",
      "r258",
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract With Customer Asset Net",
        "positiveLabel": "Amount due from customer",
        "terseLabel": "Amount due from agreement"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r256",
      "r257",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract With Customer Liability",
        "periodEndLabel": "Balance at 12/31/2020",
        "periodStartLabel": "Balance at 12/31/2019",
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Estimated total fair value consideration recorded as deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsSummaryOfContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r256",
      "r257",
      "r272"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10150.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract With Customer Liability Current",
        "terseLabel": "Deferred revenues, current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r256",
      "r257",
      "r272"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10100.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract With Customer Liability Revenue Recognized",
        "terseLabel": "Deductions",
        "verboseLabel": "Deductions to deferred revenue recognized during the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsSummaryOfContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal State And Local Tax Expense Benefit [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r376",
      "r387"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense Benefit",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r376",
      "r387",
      "r389"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense Benefit",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r376",
      "r387"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State And Local Tax Expense Benefit",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r174",
      "r191",
      "r192",
      "r193"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Allowance For Credit Loss",
        "terseLabel": "December 31, 2020"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r377",
      "r387"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense Benefit",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r78",
      "r92",
      "r377",
      "r387",
      "r388",
      "r389"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense Benefit",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense Benefit Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r14",
      "r15",
      "r366",
      "r476",
      "r489"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Income Tax Liabilities",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r377",
      "r387"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State And Local Income Tax Expense Benefit",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10140.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10130.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets Goodwill And Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Gross",
        "totalLabel": "Total gross deferred income tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets Net",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10100.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10170.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r372",
      "r374",
      "r375"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10110.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research",
        "terseLabel": "Research and development credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10160.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10150.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent",
        "terseLabel": "Accruals and deferred rent"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10090.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r352",
      "r369"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities",
        "negatedTotalLabel": "Net deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Liabilities Goodwill And Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities Leasing Arrangements",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10070.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities Prepaid Expenses",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities Property Plant And Equipment",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredIncomeTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan Employer Discretionary Contribution Amount",
        "terseLabel": "Company contributions to defined contribution plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r78",
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract Type [Domain]",
        "terseLabel": "Derivative Contract"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument Risk [Axis]",
        "terseLabel": "Derivative Instrument"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.",
        "label": "Difference Between Revenue Guidance In Effect Before And After Topic606 [Member]",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation Of Revenue Table [Text Block]",
        "terseLabel": "Schedule of Revenue by Collaboration Partners"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStock": {
     "auth_ref": [
      "r255",
      "r487"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends Common Stock",
        "terseLabel": "Dividends on common stock"
       }
      }
     },
     "localname": "DividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Country [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r354"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Continuing Operations",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Continuing Operations Tax Rate Reconciliation [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r354",
      "r390"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate",
        "terseLabel": "U.S. federal taxes at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r354",
      "r390"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r354",
      "r390"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r354",
      "r390"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "order": 10080.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation Other Adjustments",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r354",
      "r390"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes",
        "terseLabel": "State tax, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r354",
      "r390"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation Tax Credits",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfEffectiveTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "verboseLabel": "Unrecognized stock-based compensation cost, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "verboseLabel": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unrecognized compensation expense, options granted"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r101",
      "r108",
      "r110",
      "r122",
      "r187",
      "r248",
      "r255",
      "r336",
      "r337",
      "r338",
      "r382",
      "r383",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r415",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r296",
      "r416",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements and Short-Term Investments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r282",
      "r284",
      "r289",
      "r296",
      "r416",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level I"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r296",
      "r456",
      "r457",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r202",
      "r205",
      "r208",
      "r211",
      "r467",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r208",
      "r471"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Gross",
        "verboseLabel": "Intangible assets, gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r202",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r208",
      "r467"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite Lived Intangible Assets Net",
        "totalLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Assets Net [Abstract]",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r203"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finitelived Intangible Assets Acquired1",
        "terseLabel": "Acquired, technology know-how"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesGross": {
     "auth_ref": [
      "r220"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures Gross",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10120.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r194",
      "r196",
      "r474"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10190.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill And Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r198",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill And Intangible Assets Policy [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r78",
      "r195",
      "r197",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r78",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment Of Intangible Assets Indefinitelived Excluding Goodwill",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r78",
      "r218",
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment Of Long Lived Assets Held For Use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r216",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment Or Disposal Of Long Lived Assets Policy [Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research And Development [Member]",
        "terseLabel": "In-Process Research and Development",
        "verboseLabel": "IPR&amp;D [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsScheduleOfGoodwillAndIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r60",
      "r145",
      "r153",
      "r156",
      "r159",
      "r161",
      "r472",
      "r480",
      "r483",
      "r498"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.",
        "label": "Income Loss From Continuing Operations Per Basic And Diluted Share",
        "terseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicAndDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r359",
      "r363",
      "r365",
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r355",
      "r364",
      "r371",
      "r385",
      "r391",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r92",
      "r109",
      "r110",
      "r144",
      "r353",
      "r386",
      "r392",
      "r499"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "terseLabel": "Provision for (benefit from) income taxes",
        "totalLabel": "Provision for (benefit from) income taxes",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r58",
      "r87",
      "r350",
      "r351",
      "r364",
      "r365",
      "r370",
      "r378",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10190.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10160.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase Decrease In Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10210.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Contract With Customer Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10180.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase Decrease In Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10170.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10180.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite Lived Intangible Assets Excluding Goodwill",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Axis]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Domain]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r65",
      "r143"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10070.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10150.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance Of Stock And Warrants For Services Or Claims",
        "terseLabel": "Issuance of common stock in connection with UCSB sublicense fee"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAgreementsMember": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual agreement that stipulates the lessee pay the lessor for use of an asset.",
        "label": "Lease Agreements [Member]",
        "terseLabel": "New Lease Agreement"
       }
      }
     },
     "localname": "LeaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r6",
      "r220"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 10060.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements Gross",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee Leases Policy [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescription": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of lessee's operating lease.",
        "label": "Lessee Operating Lease Description",
        "terseLabel": "Lease term description"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescription",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r449"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Extended lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Term Of Contract",
        "terseLabel": "Initial lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter Of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters Of Credit Outstanding Amount",
        "terseLabel": "Letter of credit outstanding, amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r35",
      "r91",
      "r155",
      "r179",
      "r402",
      "r406",
      "r407",
      "r424"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r25",
      "r91",
      "r179",
      "r424",
      "r477",
      "r493"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r37",
      "r91",
      "r179",
      "r402",
      "r406",
      "r407",
      "r424"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10090.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r230",
      "r231",
      "r232",
      "r235",
      "r236",
      "r237",
      "r240",
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r234",
      "r239",
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency Estimate Of Possible Loss",
        "terseLabel": "Loss contingency claim amount"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyLawsuitFilingDate": {
     "auth_ref": [
      "r230",
      "r233",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "States the date the complaint was formally filed in a court of law, in arbitration or mediation.",
        "label": "Loss Contingency Lawsuit Filing Date",
        "terseLabel": "Lawsuit filed date"
       }
      }
     },
     "localname": "LossContingencyLawsuitFilingDate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyNameOfPlaintiff": {
     "auth_ref": [
      "r230",
      "r233",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies the plaintiff in the lawsuit.",
        "label": "Loss Contingency Name Of Plaintiff",
        "terseLabel": "Name of plaintiff"
       }
      }
     },
     "localname": "LossContingencyNameOfPlaintiff",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MachineryAndEquipmentGross": {
     "auth_ref": [
      "r6",
      "r220"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery And Equipment Gross",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery And Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities Policy",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r126",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature Of Operations",
        "terseLabel": "Description of the Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureDescriptionOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r76",
      "r79"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r53",
      "r55",
      "r61",
      "r79",
      "r91",
      "r100",
      "r104",
      "r105",
      "r106",
      "r107",
      "r109",
      "r110",
      "r115",
      "r145",
      "r153",
      "r156",
      "r159",
      "r161",
      "r179",
      "r424",
      "r481",
      "r496"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10010.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Adopted Accounting Pronouncements and Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing And Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash investing items:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in CCYY format.",
        "label": "Open Tax Year",
        "terseLabel": "Open tax year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10100.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r145",
      "r153",
      "r156",
      "r159",
      "r161"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10060.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]",
        "terseLabel": "Maturity of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "positiveLabel": "Lease liability",
        "terseLabel": "Present value of lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesScheduleOfMaturityOfOperatingLeaseLiabilitiesDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      },
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities - short term",
        "verboseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease Liability Current Statement Of Financial Position Extensible List",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r437"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10110.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "positiveLabel": "Non-current operating lease liabilities",
        "terseLabel": "Operating lease liabilities - long term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r440",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r436"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10210.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "positiveLabel": "Right-of-use asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r448",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease Weighted Average Discount Rate Percent",
        "terseLabel": "Operating lease"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r447",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Operating lease"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesSummaryOfSupplementalInformationRelatedToLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r36"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesSummaryOfAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10220.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r45",
      "r46",
      "r48"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10020.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax",
        "terseLabel": "Unrealized gain (loss) on short-term investments, net of tax",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10120.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10080.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over Allotment Option [Member]",
        "terseLabel": "Underwriters",
        "verboseLabel": "Underwriters"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "terseLabel": "Underwriting discounts and commissions and offering expenses",
        "verboseLabel": "Underwriting discounts and commissions and offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r67",
      "r69",
      "r170"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments To Acquire Available For Sale Securities Debt",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r281",
      "r283",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension And Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureDefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r307",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Convertible Preferred stock, par value",
        "verboseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Convertible Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Convertible Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Convertible Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10040.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Convertible preferred stock, $0.00001 par value; 10,000,000 shares authorized and no shares issued and outstanding at December 31, 2020 and 2019"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r26",
      "r27"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10260.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds From Collaborators",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs",
        "verboseLabel": "Common stock, value of shares issued in connection with agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r71",
      "r331"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options",
        "terseLabel": "Proceeds from employee stock purchase plan and exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r67",
      "r68",
      "r170"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds From Sale Of Available For Sale Securities Debt",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r53",
      "r55",
      "r73",
      "r91",
      "r100",
      "r109",
      "r110",
      "r145",
      "r153",
      "r156",
      "r159",
      "r161",
      "r179",
      "r400",
      "r403",
      "r404",
      "r408",
      "r409",
      "r424",
      "r483"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant And Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r31",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r226",
      "r522",
      "r523",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r87",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property Plant And Equipment Estimated Useful Lives",
        "terseLabel": "Estimated useful life of leasehold improvements, description"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r30",
      "r220"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "totalLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r222",
      "r494"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10170.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentNetDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r29",
      "r87",
      "r222",
      "r522",
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property Plant And Equipment Policy [Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosurePropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property Plant And Equipment Useful Life",
        "terseLabel": "Estimated useful life of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation Of Unrecognized Tax Benefits Excluding Amounts Pertaining To Examined Tax Returns Roll Forward"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And Development [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research And Development Arrangement Contract To Perform For Others By Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms": {
     "auth_ref": [
      "r346",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Research And Development Arrangement Contract To Perform For Others Description And Terms",
        "terseLabel": "Research terms"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersDescriptionAndTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research And Development Arrangement Contract To Perform For Others [Line Items]",
        "terseLabel": "License Agreement [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research And Development Arrangement Contract To Perform For Others Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r345",
      "r534"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10110.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "positiveTerseLabel": "Charge to research and development expense",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r87",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research [Member]",
        "terseLabel": "Research and Development Tax Credits"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r10",
      "r80",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r5",
      "r13",
      "r86",
      "r520"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
       "weight": 1.0
      },
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10200.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesSummaryOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r21",
      "r255",
      "r339",
      "r492",
      "r512",
      "r517"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit",
        "verboseLabel": "Increase in accumulated deficit balance"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r101",
      "r108",
      "r110",
      "r187",
      "r336",
      "r337",
      "r338",
      "r382",
      "r383",
      "r508",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Contract With Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r141",
      "r142",
      "r152",
      "r157",
      "r158",
      "r162",
      "r163",
      "r165",
      "r270",
      "r271",
      "r466"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10090.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "positiveTerseLabel": "Revenue",
        "terseLabel": "Revenue recognized from collaborative arrangement",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfCustomersAndCollaborationPartnersWhoRepresent10OrMoreOfTotalRevenueDuringEachPeriodPresentedOrNetAccountsReceivableBalanceDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue From Contract With Customer Policy [Text Block]",
        "terseLabel": "Contract Balances"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue Remaining Performance Obligation",
        "terseLabel": "Revenue recognition upon performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1",
        "terseLabel": "Revenue recognition upon performance obligation, service period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r59",
      "r91",
      "r141",
      "r142",
      "r152",
      "r157",
      "r158",
      "r162",
      "r163",
      "r165",
      "r179",
      "r424",
      "r483"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r446",
      "r450"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability",
        "terseLabel": "Right of use assets obtained in exchange for operating lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAccruedLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Summary of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsScheduleOfRevenueByCollaborationPartnersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]",
        "terseLabel": "Schedule of Components of Provision for (Benefit from) Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Deferred Income Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]",
        "terseLabel": "Schedule of Effective Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r306",
      "r327",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Total Stock-based Compensation Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]",
        "terseLabel": "Schedule of Short-Term Investments Subject to Fair Value Measurements on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r202",
      "r207",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule Of Finite Lived Intangible Assets [Table]",
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule Of Intangible Assets And Goodwill Table [Text Block]",
        "terseLabel": "Schedule of Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureGoodwillAndIntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule Of Operating Leased Assets [Table]",
        "terseLabel": "Schedule Of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r31",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r307",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r312",
      "r318",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Schedule of Activity Under Company's Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Estimated Fair Value of Employee Stock Options and ESPP Using Black-Scholes Valuation Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r40",
      "r90",
      "r123",
      "r124",
      "r244",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r245",
      "r246",
      "r247",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule Of Stock By Class [Text Block]",
        "terseLabel": "Schedule Reserved Shares of Common Stock Issuance on Converted Basis"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules Of Concentration Of Risk By Risk Factor [Text Block]",
        "terseLabel": "Schedule of Customers and Collaboration Partners who Represent 10% or More of Total Revenue During Each Period Presented or Net Accounts Receivable Balance"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation [Abstract]",
        "terseLabel": "Stock-based compensation expense:"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Options granted generally vest period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTotalStockBasedCompensationRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate",
        "terseLabel": "Plan maximum percentage of eligible compensation to purchase shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "periodEndLabel": "Balances, end of the period",
        "periodStartLabel": "Balances, beginning of the period",
        "terseLabel": "Shares available for future stock option grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockReservedSharesOfCommonStockIssuanceOnConvertedBasisDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Additional Disclosures [Abstract]",
        "terseLabel": "Options Outstanding, Weighted- Average Remaining Contractual Life (years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Options Exercisable, end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Options Exercisable, end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Options exercised",
        "verboseLabel": "Aggregate intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Options cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value, options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Balances at December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r314",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Balances, end of the period",
        "periodStartLabel": "Balances, beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Balances, end of the period",
        "periodStartLabel": "Balances, beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward",
        "terseLabel": "Options Outstanding, Weighted-Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest\u2014December 31, 2020"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Options vested and expected to vest, end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest, end of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum",
        "terseLabel": "Increase in number of shares available for issuance, as proportion of issued and outstanding shares of common stock, percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r305",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Options cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche One [Member]",
        "terseLabel": "Share Based Compensation Award Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share Based Compensation Award Tranche Two [Member]",
        "terseLabel": "Vesting per Month After First Anniversary"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r87",
      "r307",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Common stock, shares issuable under agreement, price per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage",
        "terseLabel": "Options granted generally vest percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Stock option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r324",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfEstimatedFairValueOfEmployeeStockOptionsAndESPPUsingBlackScholesValuationModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Options Exercisable\u2014December 31, 2020"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Options Exercisable, end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Balances, end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Options vested and expected to vest, end of the period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent",
        "terseLabel": "Estimated fair value of the shares on the date of grant"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares Issued",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued Price Per Share",
        "terseLabel": "Fair value of common stock price per share",
        "verboseLabel": "Common stock price, per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State And Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r90",
      "r91",
      "r112",
      "r113",
      "r114",
      "r116",
      "r117",
      "r123",
      "r124",
      "r125",
      "r179",
      "r248",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Statement Class Of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r42",
      "r95",
      "r96",
      "r97",
      "r101",
      "r108",
      "r110",
      "r122",
      "r187",
      "r248",
      "r255",
      "r336",
      "r337",
      "r338",
      "r382",
      "r383",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Income And Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r122",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS",
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETSParenthetical",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r17",
      "r18",
      "r248",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period Shares Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under the Employee Stock Purchase Plan, shares",
        "verboseLabel": "Number of shares issued during period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period Shares Issued For Services",
        "terseLabel": "Issuance of common stock to UCSB, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r248",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Issuance of common stock in follow-on offering, net of issuance costs, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r248",
      "r255",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Options exercised",
        "terseLabel": "Exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfActivityUnderCompanySStockOptionPlansDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r17",
      "r18",
      "r248",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period Value Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under the Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period Value Issued For Services",
        "terseLabel": "Issuance of common stock to UCSB"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r17",
      "r18",
      "r248",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock in follow-on offering, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r42",
      "r248",
      "r255"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r23",
      "r24",
      "r91",
      "r168",
      "r179",
      "r424"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r433",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r433",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r433",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r433",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r452",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureCommonStockAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r357",
      "r363",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary Of Income Tax Contingencies [Text Block]",
        "terseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward Amount",
        "terseLabel": "Tax credit carry forwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 10030.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accumulated other comprehensive income (AOCI) for reclassification to retained earnings of tax effect from remeasurement of deferred tax pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts And Jobs Act Of2017 Reclassification From Aoci To Retained Earnings Tax Effect",
        "terseLabel": "Impact of adoption of new accounting pronouncement"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ReclassificationFromAociToRetainedEarningsTaxEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "auth_ref": [
      "r271",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by timing of transfer of good or service to customer.",
        "label": "Timing Of Transfer Of Good Or Service [Axis]",
        "terseLabel": "Timing of Transfer of Good or Service"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "auth_ref": [
      "r271",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.",
        "label": "Timing Of Transfer Of Good Or Service [Domain]",
        "terseLabel": "Timing of Transfer of Good or Service"
       }
      }
     },
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransferredOverTimeMember": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with customer in which good or service is transferred over time.",
        "label": "Transferred Over Time [Member]",
        "terseLabel": "Transferred over Time"
       }
      }
     },
     "localname": "TransferredOverTimeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r103",
      "r184",
      "r185",
      "r186",
      "r187",
      "r189",
      "r190",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r380",
      "r381",
      "r382",
      "r383",
      "r468",
      "r469",
      "r470",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureAdoptedAndRecentAccountingPronouncementsAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails1",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAstellasPharmaIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsContractLiabilitiesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsImmunogenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRevenueExtensibleList": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Type Of Revenue Extensible List",
        "terseLabel": "Type of Revenue [Extensible List]"
       }
      }
     },
     "localname": "TypeOfRevenueExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAbbvieIrelandUnlimitedCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsAmgenIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsBristolMyersSquibbCompanyAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureResearchAndCollaborationAgreementsPfizerIncAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r282",
      "r484",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "U S Treasury And Government [Member]",
        "terseLabel": "U. S. Government bonds"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureFairValueMeasurementsAndShortTermInvestmentsScheduleOfShortTermInvestmentsSubjectToFairValueMeasurementsOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r349",
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at end of the year",
        "periodStartLabel": "Balance at the beginning of the year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued",
        "terseLabel": "Interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits That Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits would affect company's effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r127",
      "r128",
      "r130",
      "r131",
      "r136",
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance Deferred Tax Asset Change In Amount",
        "terseLabel": "Deferred tax asset, net change in total valuation allowance increase during period"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Shares used to compute net loss per share, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://cytomx.com/20201231/taxonomy/role/StatementSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=112272810&loc=d3e31010-122693"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL82887624-210437"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120254519-210437"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL120320025-210437"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121329188&loc=SL108377954-173880"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=68071081&loc=d3e1205-110223"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e36027-109320"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5419-128473"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=118645555&loc=SL118645700-161420"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117817908&loc=SL117819236-161440"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=120240428&loc=SL120254526-165497"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL120154346-209984"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL116659650-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r535": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r537": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r538": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r539": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r540": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r541": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r542": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r543": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>112
<FILENAME>0001564590-21-008081-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-008081-xbrl.zip
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M(V4;($O9.T4'2[;,G$P#9X[)4G"49&0_83.0R%%6R,9IDY7]!"/#UR##/U[
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M(P%Y2B,PSVB$CP'S-VJ$)$ ,(ZU-(QB>R2+/K"EE*HGI17L>CN[8QE;Z?"[
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MV,EXK[^&9_M]&I^(O_)MZ;0FG/OT]F(7+^CA%LJIGT.+D9._ #6,<;,VE!5
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M:G-*'DND Y0X)>XS&08[UI=M+U)>7CF5DKF! .^ESY\)=TI7OO^(AWWBO:S
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M,H_ K(IG"V*!\B=F2TFO)#G^:GD$!PNFJ10,D70FA+BQ!2X8\G/==9=XFAJ
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M!9!XCMI\ L;I8E0R@M]<%:<,'O$!G/9%^X'V< 0":PSDD\LEXGU/3#Q:"+N
MNEK8B=>HMIOQ$X1@$CW4A#P4L3?/1Y:#SZ+_ 0'Z]4@@G<I89L&XM830_=1B
MJ2=&B$UUT LZM7)B[JYA&_XPTYNMVT]3>!-]E@@4%2!)8;53JGQ>9VY!MN&^
MYMR""Z^G##N2$),J/3BNYJ-,G*2V>09-X#_'T644LVWBBIW,-@V?*6Z%@J+E
M.I4YUMKP06:D+>9,&?F;,4 :^?OAY&_5R-]UR=\ZFOAZ6WX0\2!BPO_N 2F2
M=JLRMH7;^XR>S0!3.?PHD(Y4P$"B@<FMM_T\]!J[*!^U@,9<$[G+RK@5M<'7
M92'<KG=BA2LXZ87%F<-&5N<3O$96?SA9O6]D]?IL9>RUI63U1.=U3(RS_7Z;
M>3K-2;=I%R(;XUZCY X5TI+V<2BS60J;J?L[M7KD2<6A1:P/P]"1&[(!: 1=
M0:?'!CKFC0E#*M;S#'1R8B_$I41$B-H,3S;*4CFI$7:5S*2CE_5V^S=&1<K*
MKO5)J4CYI=*.GW>M>K]+/9G7,KH&OTM<$N!12Q)8=^*E$]>J'T>7X_"^<Q;
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MB*I]F(00&^V8<)!HF(3>ATM+X%\"?7LH1$Z5"($;>Q3&YN,*1GC,)H;,;G)
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MU[?!ME*'S#D9&[5N+*TG-S'" *2.*PADLX$\%B:B6.*I&"5#:V34$UJ^/ &
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MG)0[^>;=W_@?I]]\+69+?4GKI>0=.W8"0[-FQX:V:TOE#94=&U@RRZL9,]C
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MC/D1[Y'3<A)Q%7_^#><GOB4+MFU(Y_R3.3"#&QQ<7"G"U(^[.N\"NR-N,4L
M$H>?Z$ZC,36*0C?:LXU>B=B3Y S*?.Z;W+U\>W1VRGT%N5<G2JQ>M6B7!T2I
M19[HV$H+:PNS(;>5G*^R"E5QR7E=E[-<!H! Y@O)%9KLI><P6<C;+)/:2C]K
M%X*@!3_R1<]!2T=NMROK"!Y51^CW\$%"YVN6!UU/Y0A4V84UP /AC\FZL-OI
M1.MB4#F[TD4OCMR1<#&RLFVXNG4\V'9;M<]1!A@7JL-]<K"<(E;&+GM ;\.,
MYDAG3T"40O/,BEJL4_YG)JOCUY$C@CB^D#E\+L,3&'42O>V01>N %$'J\22M
M1:-9Y8UP#A7)F[^C=(4GQA7N.KO?RJ;X,G)[3$9#1;U3C;K'0IK,"2XK4DF'
M[C);&B7CZ!?9M68@2Q(JV'JZ1NE22\^$NB/)BHN4XW[3W!<L>=(!5[/XXKDK
M68S*_UZ$W:SQ*2U]5^EO5SR,I=L@I)FSPK0Y#RN&45 ?Y[M\?U2V$&OR3:*<
MWV:0;'SS>?[Q%5G^)([P/4M8H:_ZZ3/?5QWGP2>>.1A($OU\=<%*ARNWF UZ
MD/<Y;&X>)SVF;=/EZ. !X@H'AKL+RW(Q& M)29)?TK'-. 1[G+R43IS2.8A1
MX;R.L\U$G@GAK6(OUF_B.2PYL4)6&GKANKZB'?*MD,;(2=$)B!$TRQ,62C>2
ME."F$%KFBY=(PVA.J2BU'<DB,W"]V=DQ;V.K-LQ2#"2(L'P\9PSY-O[/3H7]
M=D=\]/F+3#WGBD%R]Y+^3:KZV<G#;2Q%&5.YX^B1'KH&E1_WNG6YW:,7+Q]X
M8_';U^_Q"V<OTHY.?(ML37D;8P1?Q4C(O+E%\3@:I>=-59JF'FN^3O-BRTXN
M.=<SD?>2>5&#)1#>LM,3YJ<[6B UGM91<30-IBU6:?V)?K3I85K']@Z6TSER
M0-F\9^(HS7W8 CZ\CR.YUHRITO/ZTCW1NL"?S_TFN5FR=$'=O.!;D(B).C]K
M((-[RTM&" *NI</HK_2@'5%;!&; E.C?RU%;99^,BW>AG7N+X,3.IU=^RER=
M%,Z&9BL]I1"4A7@!^"MGM))%V[259?,: Y0,1 JF!FX<%OO'":01QT.&R^N]
M@G V#7-L@AIS*# !/*/T\19E[FD%4P#! '5CN%A9@?PEJ6<(L[&IXV;)?(LD
M/E@Y-F1JD+$ YP?%[%G5;/A&L'40WL)49^%< ,3PH/TSB58S*X5V3SA]=)*P
ME@8M")/&"01.&>3DBR(8W'<>G#U*E'!GRY>B"G.YNA ^8BX6WBF)O9 ?BYR#
MJ6)IO:#[1 O-+#,?Z*BDR?.TFJ95ZH3XCR\^/'<"G*T39")T!'R(83#.2)>S
M"5#3H=%H5UF*X09H*BT[[4\*-B1IOSX5 7A[,JK=CFWB9$?PM?H&S35PL8."
MNKWV5R*."::ZZ'HJ'.WA&Z1'V #-Y*[7=<2@9<@R8XOB!^$AJ8)Z^+C#(JU2
M:2MBN%8U+]1N_2K]6MTG'E+%9*)JH89"J&1YPG0;DFWZ:OHUC77 >D8>8IXO
M6X:USM)USB"D0KVP%S :"I(?'W+@LL].3A]P $%D22'="OC3$2!03?GSZ?2_
M\VQB[LEY#=&4CB%#HEC31!MC<[08Q&2.QZ/CIA@?Q8 HKCD P@1:%9JFT^-L
MO03X%8]Y(@C&*E\!E%%.?Q:4E!:11U/,U%517NAI#DY<VLP9OQ>"=YGRU-A"
M\PBKR*L8&K&TN@$E8HA>*TC*'W&YUZ(5_C)EA0LC=;,98F5^G=14MG7"W"+2
MSZ'7)^M\S<WN9!P:]!=_W)WEP2_R+0G(2.1D,L"8#0]YH  #>;_",^B (BAT
M*S?ILF%[5Y-3-3@@A7[7U&>%BUY+A G8:EF<=HW V;V'ECS9/VC)7EC)MU%U
M_Y(4#DO-Y T@H'0#?BPX>H'F8"*,]U^[OO&\$:>/69]$J@14OBDYFRR[.JH$
M\; GI[041R\#/8!U^I[-0PC'<_MN\A4$D%J _#WWIZB8$Y]Z";8Q;KO3^?K
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MOA]D&(\M],%:1PZM-4Q,#DQ"A+\8T,$_#<<>.-0PX/O3K*('B</&+0V7:L7
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M@EDOTUGFZ4OOL$QNAT6W(_<+CETDDLF?0&:$_2T7;9QFL[05=5AEYO2D-O&
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M<Q],VP9_08V&64)L#,+.]Y:X&_MD1.Z84;2FFR!G,ZNR<C'1 B3=->X;I"D
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MLXV$.K^J+=*6?A)P %U8N,2N[)9\G#R:L/A:,IV1,V!U,(N.LMOG.-A/'7"
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M#GE),R=I9;)":33UF]@HF02)BUXGF[A#QI89ZB)-W&.9QI>)]6V#N(-'4Y*
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M5D!#MCP!>8NX(O*_ 0'?A'5*N$VU,V.540_V:F/ )J&!LUB.<#WS";-[X</
M.;3@2DAQ]ES;. '<K?^(A$>(%%K'6!=+AR&OW%97&5TF=CR0%@NX@KI',&8<
MXR!;?"N!2^4;W](UY.B@5&M>,3ZEDN/HZG8BOE>O.:=I+66DS667?Y&.$\_$
M?]-.B8:&Z=]%HR'0:&4<6-+,#U;779\KT-4^0*KAMA4=?1S_;*ZQ23J"*PW
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M--?8[?K4.23<!4UJ)+IX->R. R=>IE>9,!2MLF8$-N@]M" @%V.%=%4X<,!
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M^#OG,=311FL$4<K8_D CRZ!]==!R.\HWJHAA;,4PP(A61.TQ'4$!#5@6$3<
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M$3!=,[$SKORQVD?!6R^=I92D/<@B8>IK/0X=O8D1/'A[8[Y6&+TB!;PR/H8
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M+"U0-BGR%;=5&6?C< FS,3A-D9Z-P6P,9F-PA,; L/ !X10S7UAE6/0UN.$
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MCL#]<<%[#4R4K&I(.5+[<@6#B\379R0,_F)7>DJ/5=6TPKTK]8CQFV=Y$Z;
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M#;?H)1&M91OKX.#1$%#BUNR9W>'4Q7HV"+-!F W"L1L$CAE4Z^=@Z S5O,D
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MB4_!TNTK10-E-->ZZMG340"C\^1ZN)J8M]7C.M/BN^9]Z,YB528><KD'4"@
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M+5W-Q_7RJV^:,?,"[QSQM;+WL!1*?FT-I; AM5C"$U"0<IDP&2G*,$H[7,)
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M*T*S\IV5[ZQ\CU#YYF6:N;]TTM&\VQ5HA[798\QI#;MJ.<=!UP<Q;NU'+9I
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MZ@-P1(5>L$&?8?XG_[C!G7_@;IZNR!CE+Q,X/5"E!YB*9@*&L3'8;(8U9<!
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M;I'2_NZ;W*+&\BR\7;ZCN#TQVY#T>@B ) ?'=,[UUHIC#$/3%PH5*M$;$H%
MNE@KU&ZC1 6A@P1F@)_7;J2F(62)\=!['Y"1/Q%K4/.R:[>K:O[^XT\,AH)^
M$8'(Q5=7GW+-D\6 8GT43OTFI6*]G^U)2/\;A!C)FW_YI\^__N8Y!=U[D&/
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M_)"@& %GG[/[82C1,P)Q7[L.DRL<ZH,X?PN/,@H^#?TF SG*Q!]/ACXT$GH
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M[Y,$A,!/DYQWFGYKRBK604&>;+5XZQ4[+-PT3"&8>)VQ7'FA9""A]!;.N84
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M[3H(;7?1MS@3@]$BZ]Z+9CST5.(\T?N$DG8_[:JFJSFK['O$[C$+@<:&NN(
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MPA:U2U7)VMU*F]'DNJ2"A5R;5EKI[,.,DKK1:A4-2B$Z9:'-Q_&TIT:<LJJ
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M3T?OAI\&-P;?25:6)#"A?](6T(C:<LH\#8XORM^X)A_X*C)FR\\8,P6&NW:
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M&%\O61X'&HY?#)?L5!PDBL/(OR6\OR#B!"R)$L2W]6:?5W8:0YSBZH:KVGH
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MR!H)/,LYFS$9YJ4U(<'#03J:FOR\-1F9H%9LCF.0P1O :#@R):";R/&W5<.
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ML]R[_%E>;SL)=.*"-,6.%'2M?0H"1EBB-8RM[?!\ZUK2[I( 34)(<M>+MI3
M3ZVL5/DL+YLWI-PM*AM[:$FXM3/)HY$WAN.1K*RL/5M/;C:@=W#O,+/4,NF^
ML!__'8CQOO(H)A&HL6IR:]7D+45!HC'8;4>170O,M*[LFWS<.M0Y2<S3G%;T
M.AQXLT#S+6.9CLN!+(-N']',=3\1\)"GCSTLAQ2I^#_L-'%TH15GGEO%4XMY
M[YO*H8F"S*SE[4B^63^27WOC[$TWI^W$2KH LQ$ALY8RX"H:Q>!%8\'+SS5R
MVDC/1+'0HC8LO;:9B'R>&= I*=K,H^"]W"4@B451;]&" MG6B"O*BZ(&FS7+
MZ[EE/20*'KJ&4JX1:=]*1*V7-]@.%RBXQJ7.YDEOW;-J/TR?SQZ3STM?K0H*
MMZML:;F^Z,>/:2\ 2?(IIBO2&Q]KN>'QXY=76F+X1)*.=)0NOS+PC064G$-"
MJ*'!735 4ER(%L/59NL"AR5Z -I/KJ*TH5P8RE9:>I):4NEDE'I<-(R@0D"P
MB9V VM"ZR]@'9RU)5X&Y\F*(I2DH=_2%TJ58NX/%ROA#6AB*7E(#; GJAN#'
M=,1[4HC+1#@[IR44KJKYN?!1L<M:MPI>-9G?+A98$ ]Q72SX@=$3<G](C(\8
MQ5&,P!;/9Z_)%YS5"P2NSKR7JA;1DKA1;F%M9<U;_MF"C%O%9Y"[9;J&DU0U
M\\<-8%9V0KT]E&ZC$?F.?<_D=<8 E[X/X! &\K05@#2>B(3&1@X_U92-A_+-
MAY".=HCIT-((O'U%#0"BX_CL:/$R.7N56U-X+?Y:7K12^>"+L.<DKF"Y"_++
MSV/H&9=;0XCZ)J05MEH,&H,K'D K,D99WU'+O&:-./NV*5K:B6PM5HK^Q=E\
M$C>I"$)\Y5L')L_'^-H-[06/7\NS#:Z8=':.!F0^"./,\@C\&4*.E#V>#2<B
MP<-SSI7=I7E4"9$L#^>>L@$ &'[OEIPVP2:UH]B[Z/B$:#)39<5BX[& ?&I7
M1;-1KZB=K<MZP5X]@P(;U+Q[J;];$I646Z**AG>J.*5X$P>@\2/)RHZ%CL,X
M,UB>%-,<<HR^\*RM;]PRB6/A$Y8G??J?!D]V@%1L7=3[IB"4X #Y1%OB.PMZ
M2'HIS&^PO8N+#AOR^%8[7O,A,&:+G%QA\'/#>2B8714U!!C&QM13M!< Z.&!
M]L&7*%6E21+:YT7?A0808)]+A#\!8%D+@(&S#CN]G+6Z*<;C5ILB ]@:3U6E
MIW!N+=;L(O,R:?95+;HBJ@Y<SK!&\27/9T](UQ422UA$XN_C^^56/;2G1W*I
M.=QF;>?Q_?BL_ESZ**TQ;>&6L-FPA*53Y3'VA-&R(B)J4SWH\\OPH>EVL:X9
MR2_-A^=6Y0F>/3 M',_9#UE;\I4%[BE87_I=J&[ >?'-ZJD8DD"ADA$]#YRB
M2ALE ?1 >Z:T= 9$CB]\Q"K'--(O<!".NS$E:H-GA)%N<MS\[C,WPW9WMO9[
M/]>]8]&*;&1?K;*;6B)%TC3+J _,2F1IP@K 7(VJ&U=L%HBHV7 &<)@&&IIB
M_(#(":*>E*!XI<ECK,N+<7*RI/O+Q?:='AP-VAYDO=>BW<YNX+0 SD\RSL5>
MK:B+./!?U<D/E4>/%HN8$22OH[NL/?!W-8>3K*#1CXN49+H7UD6,R.D9U$.U
M"W><&[Y0Y8>+VP+6ETBBU<;W*&=HST9!T9I6WR[<XE6LQ5 ^SNOH6O+!MM(G
M[C,._,CLE=F=!?0^3O,02*_%P^".9OA!^G#DH@JB8^S1X,ZI)R+J7D(^1JN.
M;3YO<$3FP(Y: $!X7(3:PFK8*L^[M"=LVMC8Q\0B9!SZ2LH12?/XMB;;OB@E
M<URZ:MU=D]0 LB$[HXU+085J^E^0=>P>MD,%M.9NG1B#QS(U:#QGLR;:7^3S
MRBH7ND^<R]3W@EZZ+MC*X;VB5@HT()%#*R5*A T;Q;_$7O>>HD,/E&K/J/$T
M^OT=FW;23N6+=/4.V@JN!</Q$R>% 7V<B\\=FF -J6-D!/0 6':ZHEG>@R9
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M&=,ZCQ^=U!D;A_=/K6*$'VIFU?M?G#M21ANA"1&$ID#!$I*^D /-9NVU3&Q
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MGGJ=609I-^EW?^^5>97^D;M%AR$V?<.Q1Q@C3&:0UK(K$$$4%2V>?NVV*!'
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M6!SDPD9 _=AW$U4S"#+-%N6.N]OQ5GLZR'1N\.<UN32[0F]\^L!XBJQ$K/:
MZ&&QXX=A?2@7MWAO_-L\'1-V@M?1U AB_FR[)7G*/!>A3^QR>-D:':W=I4VS
M&?\<C_&WT#DO>-P;HU&AHH=&A2Y.BEELPRV<ZWC6*(>1)$%K;V9"[#<\!>2"
M-%WR;>^<DU7PT^K:?O$S!YEU_"S8'3IR&4G,";OF5ZR<GI"CM8%F^_21Y8W&
M7;0YG<1&YFO/9[8G=('/$W>'S[:>!M5P&?)AM>4:$+A+-$L;L2I*#JXY3I:
M"CF#IX^M"D)'AN0;S$$<%JSP!29R%C< ]IXNB#:27#;E'1,]T\\^_>IW/L,?
M>4"I'GX#/;XRMZ-UJ<!Q",WA=SBQ1;4J>U1..&ST23ZX6[Z795NWZG^\V;^H
M:C63P]R))^>@@+S826@Z<*LBJ?L6.8AW&7F$XT\^N(F)-JMPT2BK>#<ST%WK
M $A=LH;,4O$/RX7F];+?R$C'.CP'QPMD!3:._-IFSMD'_AFI,/VH*+9-]C.(
MM^MFRV'3C.4S6]H:%?+ YFK)#$KSP?JJK4EL"O9TPS!AGD!9TQTEEXHT33MN
M7-@.[ID-W'#E7#G3Q)C(VH(<8.1*'4"7>TKT ZLH7YY>1?D$G.:#:)I_L>O>
M%6==]M:Q-6/_L#7>3#XAY#?0!H>#S0I7TM9/7(D T<WH/QIE;>A*XLN% Y@D
ML53A!*UL[G-\Z.9B)8)#9\Z1G7QHO\U6IHN/.7J-VY;9DN.RQFWJ&ZEY+?NF
MP;>#;Q!#14[4.+_<VS)6TAKN0SW)M ,4C.# =*QYR6]2)<MAOHW:'?OF8D?;
MJQ$O;?@N#G;'=IH5?Y0<PH6C%1\-M<,[L+IM>BF^I;?:_=.V'=\G28791/B0
MRAJ'9 <NO&$/R!N_19TU>6(BSV??.,UNC?Z>"W_DI\ '9[]&K"1FVOL()+U'
M]-2=RS8C2R8G#Z:I;RHK=D3+==]J^?6Y\\;FHR0J N@/]T<]/1.B]<AP>1.B
M=4*T3HC6(T2T<EWHNEBHU934%S3JF*:FGUD1'JD;1EE,35ZG*EF33IYT\J23
MCU(G1S@^11=M'4>H& 'DH3U)F"HQK8WZ@<^M%8IZ06MNH.8E9^P09=!EH>^7
MC&1*2[ESGCA!G^0<* "M.ZGW7F<%H,:'8XZY!NJ%6^UG8^>' I$8?\7([5KK
MM5E>;R7NHY]S0DZQ1 P0JI&OK7I.!".#UW?7](%_T.?CYT&.+R3$$7MF A/P
MZ$JS=&[9N(Z+\@+0PB8@MZ;W2].L]%^M.F/V7H/JCQ22//)O;H6.&"RRS.B"
MV!5&<_,>,*1-J@!VJYL:Z6(4>&S#1Q_B8Q3.-ES.#<6D^&ZXSLRP:7:E6Y0!
M46@R:!\^E7\R6?+3U4>3)9\L^63)C]&2YS>,:R"-CR)^#,_G?)L5MRSS/&(<
M&2G%R4?4C@3Q( 4W=@P4M$M1&ZE\ 6]V20'./(9)OY^NE$[Z?=+ODWX_0OU.
MFI(+$(<C(NEBZJX;1_%3F0E0JG7-C0 E*%K@7B< *EIQ\O%)1&$MPX\G*H_3
M%L!)=4^J>U+=1ZBZ.5<C*:.04QK1W\#/H5<2*9.5:Z"L!:/%T#_.K(CR1LO<
M^"4$KZ"8N?>E!#DE>-;SNF'P#A*( CVX=0I6\T ZA@<87&=N'UCC:Y6D^F3,
MER_MTU*^UBCI\N)3VRD/^/FS4K(\CD DWV>WW >C(!)+CEJEJY4.&C07W5[7
M $$R8,6]6RK%PJ//XXS<$(YY4X?F$>FJ )B0DW2-=E-PGDUZ*?8Z=F(+SX@U
M?I]<T3#:^FA0P]!5HSVG;5T9 CO_I0\]G_65YA^= B'#H^NTM581DW*7C!.&
MRZ98.,8S5X'W(MHIZ8<""GS'S5GH&=7-I-"5&YOL7C%41T C/.18X. 0@P#*
M CZ]WJ2ISQ-N4/F13T./?JDE^LP B*K;KAW2E@2*#_Z%]FIH;G_N<5(1-*8P
M#*XD?W/'Z=^V7T (N'O(>LLK=\M7*@O.3I"\TJ^1JF^5$<- KW(LI=^H@422
ML)UR9^?5V%+>VH[$R/K2K9G8)O!-!Z(]4-%4K=-FM-=9L\@JUYZ]>%>ZW>P*
MS=*LH>H\/_N6'NOM[$?DYU]W=.Z[V2M@MS=\M<<D[SV=B=G+!B0X?!C\UTOM
M44MR1B07]W6YA,?4=@QX_5&S>].7NLV-6^MPQ1:M'N"LP(K5?3NX:94N68$0
M)M#M )Q'OVVO(ZX P)$KSQ;",# 4@@"1+NL67=^<UHK;WP#V?I#X<2-2)/;A
MA44]5JXD 4_.0):<@FR#+65E:UP+K,G&3\3Y+%@U^=R!%=3CS*>2I6?O'?WE
M]<!7"E)E]<8=/+)%4I_#LRU90DSZ\+5R-T#2WSH=4RSYP+L>$7X(WW ?:<C/
M@A^);&.S8+>DS;Q><,W,'!I9<:GID9A:HT%1:1>7F5N# 49PW'&(H]PEZ[J&
M&2OXJ?F.Z$^E \F6XUZTXU_J6W?O+F7<\8&26U04)*G?,0 3^/@M[JV5P0)L
M+-4.53NZEG8("^J^S,!TL)+"+"Q5)TIY'NOQN7XX:HQB;BN59=X0DM 2-5)@
MGGG/Z?O0S^N^R$466^N58^](WZ96O@TY(GCZ19T7HI.*_198;2X6PA M@G8[
M99;2'A.33LLO<T,LJ5Z4AUE@*P=?HS L+BF&=2TJRCP '+GTC+^O!3ERZ_UL
M91XKBKBA5V4#G\<W PUUMOFOGUU\9C[>OM7 ;RXO+B[%WU(J*?&UK =^EN7H
MV>YB7<4:0*'L<><7_<X#N6*9T9"G.&U#_GXKJOO1^OY2!_H>K*.TV%L[4^ [
M(05817QKK!FJV%#Q>0W*O7',JJ"*VGI;L]A.R4>L779XQ8,7Y);46V7MP07I
M>_C K<O>\B,JKOWAC^@E!B*,EZ>58K+W=H3%S/S,<!W&XH?6<VZAEF>"O%*L
MS/KA7!)?\N>/T8J//VN[:^FB8@= &)% ONO!VNUM4435%W*Q>S>YL_'QZ&-K
M;]Z*7ZN"N,E-KJ*]9WA!,)")F*Z+5@BXU.N+?.!50:YK@<\5*^0T8/@<B86[
M0PP]'UP.DAMVRR*9\7(,IQ*MX18,CNHR/_<;B";3;O=XQ'/?G^E[^\;UH?DM
M$L:B*;<HQ1_*"R56BNDTPHD8-/D"P-0W2Q],B??CC\@>&51H^N56[_/9$UW7
M;F0UE5 *S=V281'G:85G1:,\0@Q<,"@DQ7_9^LFW9!4UOU76[/U6*^SLTG?*
MR"5<[,,6%9--2L-,2@7$VLD8&?6(XL .WR[6"Q]XL^*G4[/B!]NL^$U(<.:U
M:&)2BF  Z)B;15P!#AVN9R@3TKKEK1V(M-O<*"AJ@/*<-)DK,Z1]$,DX($#E
MY!D7FQ$$[/B0U0CT6?- 4ZW)P_\ >@J-K[""\2,3LBPSF"8 8K(B?\CR,N>A
M-I:!UQ6I"27N$DJ1LC2701GI7,8151N1WM6J!,5'7#?U+;QQ=AYO7%EO-U':
MU2@QSF=7<2AX]U:.\?_=M[V>%&1?<DXXQ%(6U?V4G 2AG'#G2KJVJLS*PMP!
M"]&%# ))$5^M"531IQSVO$B-J;2HEOVR8]<:XL#Y"N$O:^\@Q3;7KJIJY /$
M30S9 ,W:KYLH!HHEG<P[N0:M43V._FIEQXD! PMD]#C$$("ZZPH!:',=3KTJ
MIE%P(*SJ S/'6PKF?&9OSBE*GW+C#U!$C+YP<&KXG+F\J7I@87R@\N-(+&+5
MI8<0D_O,YTF3;'-JJ"E:9B]RVE/ Q'4EQ6<2:O6M+]Z]U\+LL[3'9S<6VG 4
ML24@S:,/<#V,5/6UJT8)V#*]A&=LUZMPOJP>.18+ES"^2!>%7@+YMB69#G;D
M$>HR)4K"8GU(PV10O*TT"%BC!5];"74]2'^0IBU 8;Q3LAK4(#IQE _>,KMM
M^Z*;W>)]]?'LWK1%QF#\F+]SM;2R)[YC9,9832P0$^"/?(ZO3<M(L1U)2LDL
M<HC?7>X9J<A2_4SZ Q1V6I<MD3@L5BO-#J)+@<YQY79\OHP)6,A_,^-&]&_#
MR6.)P>Q'/N!;%:44&V,ZKM<1DE6_H=L)/L'=UD6+,O=%QX*+8?82&Y+(SJAX
MXZ!)34Q4&A 30W&MTG%S(49N*\6>]*DY#"/O [1,7+CE_"V8)SLF[ O)B(3G
MX50M\XM[>!ERAR//9#D0.7IOMC6/K^$X-1YD\;K36K>OX2MT@ET<7-B]([-E
M18A^PX;-.G>PZ2P"UJBJ"3<0:W-G%)]&S4QI'4?3U7O4'G$$6Y*H[G/NX"P]
M^O+KF$U)JR$9Q=PW9-3@<_$9@?R$QZ6S1&=<R=V4BH*M:-2:9#RBM1%ENM-.
MRMXG'Y86Q0XE75F\]CS70RFUU2]X#Q$R7_E>.8+"IITM;D3_JKH5@+W*D%>X
M&DXLW'56KN9"9"&?!Y!3\[W0V\6&'8G&"&-).(J\)Y&@1\Y[X(MNM8VMVGE_
M:EP2M,1L\J F>81%\)[GB8P%;10W#B1]=M4N0#=^&:CFEQ&\Z)O<(2?)B[&:
MUK*<, Q2L.20AA)RE31Y#UQ<KGBN_ZG'2WDD'[+^ZA_L@9Q\=B];K;*"MC^O
MEUT#C-CLJC*GE[4#>OIVV#_R95M%&GE*>L4#6<;!J,!@2@=\GDG6@7ZG$QE\
M7E8B;>E5J<7$VT^UWS^,QDD16K]LL7./*:+XX,99[?*ZU@>04QO$%%I=]'06
M'P55TFVLI1=-O!FLKP=:6G:E0V"?MY$R_P7:>W!F8X*IB!6.L8+>B8G/I]98
MQJ[.:LP;A]E5R2(C4V\D>P#[U732UBEYBGR?F.<7;U%113"2KN;:05_I <QD
M[(?1'=*WYTQ('7$KRB@?KI%#=H;&.]&[K:],B6<6#RM1B%1;+\6>\\9PJ[ @
MZ;G#50O7B MY1WXFU[K5\08#<S^:A?><R'OHE/M)[7^-[_8>YOJ7VF;3Z*\0
M_7TK$ZE.EG!54T3&1"O<C9 EAE:%:3FDX J9"#(8N*,\Q%8$);M=TG,(?M>X
MN@'N@%1%4,7V_;'J'_WI TC"7K52FA.">B%DEA1-S^"U19WO$!IV'MK&YJ8D
M]WLI%6-2?]MBZ^@G ;  +O*84)B^]WLN\)V1Y !@IZ>XKI:2:R!-04X56#KU
M;^A^S M 9^5GZR;;^ R39"6LXF_84D5.(!*#<V;)0DE:4;R)';<4ELP8N^&"
MH0%IL@2=R[$>V5S-=&E>V _MB?GHHA<3=#"&8''55=HVQT:FP%*PCOTE;[X:
MP&R'3\! 8OC;>@<@<^:&9>?"I9]B.7NJ@35C@K=(P*'@CO)@7TGR@L,XX\A-
M$ 81IZOM= /)M DSF\&3\!/,8X;K-YIK0<Y0?4)/0IW(2[@N/>9&G=Z'+9V\
ML:T=>2%DKYJEJHI-Y+9'R<N9$$XV:_K8AN1#P=,D\>^1-F-#YHFP%\!0P'1Z
MZS-/LJOZF!MZM@(Z2XRTKSC/XTRI1$"6CQ.R"062,/4A]W49=L Q5'@)@!?F
M,NQ,8QHC7Q@74#);L=]B(1R6632*%A-9$@$4U<SW]I_F_!V7;\C=HX7$&L&;
M"5[3O6!!T]@\X4(Q410A &[(QW(7B_Z Z-&R1+?ZQI)U,E2#RLS[24]\\!+A
M'Z-CUOV<6R8A1B,82_%*89;Q7JL'F9P[/XXJQOD8_$#P>JKF./CC9]GL V$^
ML,+[9R=:>#_VA=UW?WZC 4WA!+/=4?.2ZB]#*;&-'C47@-G^V@.^.'![2?@*
M%(M<[OW8!6'ZVCH\JE_FW'!O<1*XJ#;06VK>ATNF 9Z0*V]R_!.Z/KW%9G1>
MV)!9-_4C_"0<UM\E(R+,L]M(W<0_3Y5[O'@A<6"8;!.[V>9!@>6]AJO"?F!W
M+3$BBKPY76/M&/XJ<TTTX3M^HS"@+_FN=_0,/<7!NF+(%;3&&$F!-$ONHS>=
M*WXEJ5VU/P@E 6-K)7N#:_;"TQZ;%H\5T_)"&S]S@&;CJ3W,$;B^&&7EL7,:
MQ [05@%_\$Q,(;,6'Y+:./:))2*.@P;V=,^5E!8WG%,GCNM( 9IS1G7;%F8(
M>87WA9T73H"@2IX"#\5"B<@7XD.!EB6\D( *VVS%9SQTG$"<[;L=UDQVS]]#
M,K:%T+$XL'.YV.A&\FE[;HF[=4";^K<8.;O^Z(:3NYNMN=6J*61*;%\I?J,*
MKDZAZ,$(?OA/DZM?)$OW![%';[T2)S!1-^C<Z2S<3!>+,V58R'DTDAP'T@K5
M\;D >7UKB)R-B$;H>4P'YK#/7Y<0$G91-:=!>@E@6WX.#V&)Q4+0NYP?BS[!
M^;'YZ+1'K(T\7M1B) /*@Q2K)@RM.Q.=]C'WQD^L$A.KQ,0J<82L$LB #)K;
M23%/W&NG*S"3JIU4[:1JCU#5PLVV/O]])%_N%IU )]:9#/^1*<"("5N@8):2
M@$";7+>+89B:RQZ43R8=?L*2..GP28=/.OQ(=7A(L>5%V_3;&#8=ZH,I-H>Q
M3"&;(3, I3IKO28"UF^<]+9,VOMT97#2WI/VGK3WD6IO@.V MZP$;V(.N7NW
M93(DZ<14*C-/T0%4"X-AH-GG R:%+-\45<$@/JG@K)J,_H4FQ\9->OQTI7'2
MXY,>G_3X$>IQ9BQ4/KL(,%B@"Q6'3^"[6MF^%XTXJ>C3%;1)14\J>E+11ZBB
MF64C!@<5W'/([?7L6X>&T91"%Y\'>&C2RJ<K6Y-6GK3RI)5/1"M?2R=VH*X.
MK.0,Z#2V='PH-&@,O.K?"UATT.:SS+8>TSSI\].5RDF?3_I\TN='JL\-7Q\(
M(D% =_>\B4D9GZY(3<IX4L:3,CY29;P$1Y$S]DXE02^YWVF/&\:ZI5IWH(LQ
M'Y*@#MIW)BU^NK(X:?%)BT]:_$BUN(%";ALZ;[.\OJTBRJ:&+KNNT(%<;+99
MT;"/37J_64])CE.6JTDC3QIYTLA'JI&9L[J-@-8AOQ'(-#V'M7*P1HP''LDW
M+#?>"^ 3G8[/37K])*5STNN37I_T^A'J=1#+I*1.,062M#/ZCAGH</C>9191
M.ONY\C&=%%, >77O&6Z,NG? 5'7^,*U^FOPQ3#AF7%%F$5W*Q:V\7\:9E:QF
M0A F#"S#2:]S34]%<'D>3.Q6T:A%83!.!DY+#DP&1RO/X[;$%7,;?&&C^4"-
M1H'6LAL=L[(W@RJ,, SOF+-Q7S)W-7.+N7=NV<=]6TK!BUG5H9S"8\%14 GT
M3 <F@(?AA387U ]YR.%#Q.,W]&6X(RQP+(ID.EM<X8!;]KQ?8Z-,3WPJ1\H_
MR[SC3"W+C$#@+9H;H5,\R(+EBW&^(* B%:OBP#1 (%4C*;H=F<<9Y5XC[LI%
M3VZ5.H0Z9G.<@.K41US\HL56@,<(J2<^N*](1W:%=;B.*!6RJ :RS20C<=>C
MSH MFEPHJ\ <]F.8&+O%O(1.U;Z>?]'EFYH]>$]U._)4"X>'POTQMPE'>)2]
M%$J!+4K@CA^9N:HDLUDW>-.4GUL)F.5N3.)WF##UCD<_G[WQLUM:S!@3RMC]
M*]G0=Y%A9N-JF#:-GJ=ONV32;M731M9*X6]CY*.+#J?P\N.'2X:!:V"NZT1/
ML:K/EH/Q[N-4B -NNX%TT55+(8\LEL81Q[J[6"3:>HQP4G=@B0EQ/ <*-/IF
MP90<N'4IP[Z-JK8).;:BA\6)=0-9NXWP)_["@S$_I*@B*LRA$AI2$XKVPJ/*
M_@I'-U,S8X#7NS!)3@D/^0'"5L]G7?9N'L]*9A)*VN RE8),QC/0#V&@V*IU
M6J?BX0NT$!A>W(-\L(&*)K%07FM(;KUQ_NY>D#Q[G&5:33$D6B"<]WD0 PG9
M6X<AF&&]QU9Y3VU_8*3!GY\H:?!Q>R?',:WW!4\F][.K9Q$3NWJ82NJ*2=BJ
MKAZ_>A$-=V'_5,9F")-G!3<]PXE60]5CIN$_0 6?"4LG1ER1I]M$O ;\7?VI
M4L[L=&Q4&!LCSFT\<L"3=.XS)(RU91E9\ <P>>*.C0M^II^CE*8:D^!A?VMU
MQH'?5?VW;6ML($)^<T5Z_#8K02/;NN:&QW"5B,(0;5>^^\)##]0(/>,GA.)=
M9<O "LTN 3]DL?3 ,V%R93;CF[ZL7&-,O7FV06@I W#)*O5@";TIFKZ%[%#H
M+V[5/QS'.F2FY[,*8SI$;D!MV\B AX8^U6Y(W#(AF2>3XV!Z>_@2?JX%?M@)
M]X8^FI^/<<.6+!ZHR%L0A%R6.:0-9!@FYAUEQMF,J?/\2;+JF5%4[_R\@=K[
MV:F/PS._DF]@FG*8-$(;QC["C0X&.N!$#,]8[LILYR?*#GL<(X]N53#\Q)BC
MV7B&.:<\-V$8EO, BS8!LX0Q")LL=\,Q!SH>[/&+OSU[<O;H#S.TTK.(Z-@F
MS0^TUP[3H.B@GE&LOU1+WF6[LZP[NX:C@!%/S6#\$<* O"EX<=;,>]MH_.*J
M)3L-Y*D@$+BMF[?L':5'3L2BIO6FQZXP!X.7>37<I[8PIQOO0B<>BRFDS]4N
M461[JM#/LHIUH(K+7 2 3P*/H^I%'I06-QY0HK3=.DJ8#N5*")-%B.1SCJ?
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MS5/$RL-R$%L>V.M\*D-=G8X'^-8XH%=[7@2;4_H:>34W!4^+KS7=2!Y[WMK
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M("E?"7QYRX95/4"D(A,5_P4CFY&*P?C).$DS^:K<-1H+X),$558.^@O4&GB
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M/3M%VLWNU@1Y@N5?$/I5H>7^)I'E)R4$C 1Q[X>3-HC:-Z.*^>JG<E$5H0
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MV(&8A'YS7F;(TEBP,QQ46B;P#BH=5#JHM!0JJSJ<$+%S>2\@%N\ PKP <2T
MX3X< .\ICS)$JV&:3$C+9^%$XR"L0#Z$QQ6<(=PD=*-MZ7(IH B%].A66X I
MO.FV"F[M"CI5C0 )3CH!-V"D$&:".)M_7W_Z:1YY7IRU*HA? KA!?!@.WJX+
M[?Y* R-W#Y%? @GD<&;@^/I-KXU #QU*0#JB#PS%AZ60S$]!P0&[," HS+)X
M_FJ4"H'=.+C;3Z%U<.?@SL'='L =#!/&%:*7A<Y@J]>YSQ=\<=GL/,9YZC6[
M#W>>,&JHD=.XD%N!9N%>EM.661[,Z"UJ5:30K$*I.K;I;M4B-5JMCGX3ED0
M8^8P67H !A^$^#XA,W5-ZP!,$C8^O&G\TJ[VCNN63 :FR[LP&[-PBC_F^N<)
MK&,,O-)4.M5H5@>+>RC<#A8=+#I8M!06J[X2K7?K]7O"D;MQ0D[674QJ/"#'
M*Q:XK35-DU'*)Y*>;[]>&3V]J/A2<WY8)82ZU _K5_VP? I.(SQL7BK]IBN9
M@<:&[@O?:8.@**]XB.C'7E2P^7X_MC;.J\E(Q.SMS^\^FFT[!.TP8[ \4W@L
MGU;'<_/;FX:( 8,HB(PQ74_9!W,#ZCS L8Z ET6T$$)].[V^^M40"K[AX">+
M$77$W@A?3 8BI;W)Y0XUT:!7&08,RU"A3L8P(/]WL<\[\'VQ6!"YRS J GD5
M+L<UTR;),,E3^+Y&H_8E.\7?-#N6(7;ZZ1?5O>:]E\Y7WD_5YHP"9Q0XH\!2
MHZ#JH8XVO2]XI1EP7H%R?XQXI3=+_\Q#A8W"'RLG^@M(=6.<W%7A+$CS$0+?
M'_D(O4T SR^43_<5!H=CN7[3;0Q@L $;A'(J_' 8^JI)F-DHI$W(=28!8J!Q
MA%]T*V'DBLF"OT\XX!C =^P3]J%[+A,_I&$2N!'<84>$=U>P. $MT&\)&!@:
ME\G8*8T5C8)2H/\\/RP';?LIH [:'+0Y:+,4VJK^;FB*F?I8S'0Y?M42BD0J
MDS@646,^S+NAJMX\ WC[/-BJ_EF1>]O?./56L428 7OYCTS&?4#J[<_:Y$#4
MO0HF81S*#*E]"SYFI>C!;A94DW);:%7#>D6L_$0P^XRU.,ZVKF98T4H^&49/
M<23AD2RX E;VX;20%>4EJTNZJ@8U$:"_D>)_2D+ 2% !_W#2!E';_>&?LU9S
MPSI>WT!J["#;_X+WR-["L((R -EM>SL_U?,M3NO808'-BST=)[K82B6',_80
MHL"9C@TPTVXW>Q<//V-ZW$"$FX [1QV;JA':01;[]-Y6XN04HU.,>TI7W'-P
MBM$ZLCC%N->4<HIQ[^EZ3<49G&JTCC"V1#16BIL.<AR-I-A:4NMY;J*W>,VM
MC(<?C1B<4EY/DDL>!_*E?>+@HMX/QXAGNT5D*48<4HFPZG8^KVWGVW>CR_,
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M^I?,6\3V%_U6LU6\GD_AAS@#Y)O1%??TV!7@-"A/4.F(BU&$_]*K9]57X5_
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MU2@5 EL@HX":=?[@7@J6@R0'20Z2[/8'YP&ENI=?!P)P %&+-A_HFNTNX??
M<E?;E^MS5VU( +8X([9]J3-B]?5F:[)AVV>M,L"Q23YLN]4I(]R;),1V*P&1
M,B&V%J2YZ-R?$!O&SY80>UG?7EV5$*MLM!?M2J8KO Y/3!+]$@NES-6*0Q>Q
M\"F_YB[,QC1VX)X4KYF#B5V!T1>0Z?A;TNR:J?[[^M-/I4U(";B]YTC -6^J
M&6V:C-MYQF3<'9V1L#TZ]GDK_E^>_OLT2[]*EQZA0[(QP8_4(=EJ?9Q#<@0.
MB=V2\VTWJ,YZ=8Q?DU%,/LH#<W@7LW<)+=#:   7$2+)8ENF"3*/>LVSNG&F
M@F'8!.)[&'/SFB_2C,,<,C2X )?(J*<'?_KU4VG8X#3QRV&8RHS]F8.Q 8_!
M^\IR796]C B!/?$(K="UV=!E"(XRHK'#?^7PN^I &3SF603++ U'(Y$J,S:$
MD4M8&=],"SN7L$"X;C2SRL3>H.%S*\"NNT9X&FB&H$56^X)THK&8.AF#>E2G
MF.8](0O>H\9(]%JORS8K\4'XI?WZY0-21K8[@WO9;/6^JR%_0T%#'?WO%:AG
M.7CK[ S[M*6S,YR=X>P,^^V,]GD%QE<DPB!HA;$/9@( W5<3!5W,CT&L0D>T
MFB?3[E:B*)CX@MXJX&V_VJ+I;*9B%MVYD\CY(-*I-+B1MMP2>-&N).046?+H
M'5-F974Z@8J5(>@_-NGF.3#4(9O=\NF0S2&;0[8]0+9ZAF>QQ4>NUHM6!?:6
M;O(I*&I5PN?+$_7Q.8<:#C4<:CC4<*BQAZ@Q=ZBVLP@;6QVJW9\DD8=5_-I-
MDLA\5;@;VCS>FZIP%B>%%&723%)(6"SM0E)(O]R36)H3\J)]64V:,"WB *9Y
MZH^UC"U/ C#Y"MU:&@6?(JLI<0O"+$]A,-0NGL<Q;4Y3W/O6X0.\$V:J$B66
M!PKZ<^D3\+8O1&#R?*'M?)JH44\X](AQ"1@*D/F+4,:3%#Y^C3DE]B0N' Q'
M%FE*U<)]J[FR=WD?5W;.^_4<E<=0?!57]<ZK-7R6<+Z\C_6[E0C6(UG_:=A2
M\4'G,-(,YQ'D71CSV'<(\H0(4I778;&\"RAR4:V<J3==E^?@%7*J7.\\74RK
M@TZ*$YTE<I0;L>]!>-BO),CL$X]$Y7 %.Z6LJ:%Z^@[%&X9;IJRA1,UUY"<R
MDSI)N(@?O%3B>SX?*L#NQ5>1^J&&/6HKF:*%JEH7DVF4S(30/Y6:HAS_BD?8
M- +#]53O#+_]].&#V0IVB/2-$&D-AY><X&W&VL_.*KL!A*7'CI<UK DZ2*+@
MP<RP+>6OX>L42)<#QKX?@*M,KN,J#-B'LLB8%CI,(L X8FEEN.039+^_T/P@
M_5E..BDGC>4$@>T6%#L[)2,FR27PH'SY:G>Z1;O+VP8OU;!>4;#@B0*9SU5G
MOWO>['2VO:%Z916 QY3:WR%+VW'QV9(K6;_=C>$+"G+5S0?]C2)K3TD(& G&
MN'XXZ71.++AOY*+3[&QX(?6WDIJ=T^V#RL60[$TNT&KY(-(P"?XI\V+RE8&<
M?_<:SUHUQFK4[0XHPEOP+D.?1WI]*-)\>O;RG]]#$ZO"T=_N1I*=WC0R?]7(
M-4Q_D(;?0 GN\HIJ2_%IYY+FH,IF0I1090-2]9O=A]^+==Q !NY(^RC@QH[E
MMD^;;24F3MTY=;>75 5UM_NK:YVZLU#='1,%G!K;<ZJ"&NON7(UM:B X=>?4
MG5-W3MT]2MV=.75G'5GV2-TY9]:IQ4-4B^?_9^=ZT>D[I^_V@E).W^TY53\G
M&8^<OMNA%&VW07[][EWKW?4SR)#>,_\6J0F[R=-Z7]2>I!JD\K$))NU')I@\
M&R45K!TN(1]G.CS?LF\ 03O*!=H-G5Y81Z+>1G;"O42JF 4I#N4IK )KJ';N
MM3N7UE%N=WET3L<Y:-GYLCMH<="R_U0[]SJ]K;=:';0<N(YST.*@Q0(Z.6C9
M1ZJ=>V>=EG64<]!B!QD<M#AHL8!.#EKVD6KGWGEOZSQW!RT'KN,<M#AHL8!.
M#EKVD6KMEM=N7UA'.H<M=I#!88O#%@OHY+!E'ZG6;7OG;1<2VS49;"F,<[QY
M?Q^3&8^P6G*E@.(C4_\Z.ZXMY4P&RY;]Z)6:%60@L^"X4;]]OC7D.^DX;.EP
MV."X_WC)X+"!KNEJ=^PCC9,0.\C@\,%Q_]&2P>&#PP=KZ&"EA#A\<-Q_O&1P
M^.#PP1HZ6"DA#A\<]Q\O&1P^.'RPA@Y62HC#!\?]QTL&AP]N;]H"&MA2ANX)
M[FD[)++\$OHBEH)->!AG(J:+O(?B\37JNCNN46?%E6_64-G^A/=EM#G*G'=+
M255+?'\4L0[:TNAM;VD\D<:SZXH#:PBS6[%R:&0/+1P:[3^I'!HY--IGPC@T
M<K1P:'0HI')HY-!HGPGCT,C1PJ'1H9#*H9%#HWTFC$,C1PN'1H="*H=&&U'O
MS.OWSAT>V4@:AT>.%@Z/#H54#H\V\XX<'ME*&EOJ^JU+I R2?! )UFD^(32U
MN\V>W92AFZV9#S^FW,]R^+M:^<^B"^>?D4I[)SRV)(,_]!+Y&O&.TL+8NCKP
M\QZU^#:$/&CKX\)K;7\3\!,IS,VUY5$)W6X5J ,S>VCAP,R!F0.SS<!LZ[N'
M'9@=K@)U8&8/+1R8.3!S8+8)F+5[.SM+[\#,7@7JP,P>6C@P<V#FP&P3,.MV
MMKY?V8'9X2I0!V;VT,*!F0,S!V8;U#@[\RXOVP[-;*2-0S-'"X=F#LT<FFU\
MA_2E=][=.@'U6-!,K;]9_G64^A;YI]]G'%8'O@W"V]KDZXOXB22B75EY_4-[
MNCD/$\>_ZG>;79"WVE)]5UF:BWN6ICH9&#",VPQ9R1520Q&2IJ:YX8>3U@GS
M110AO6'\Q6<]'_I<GSK0+N)3*5Z9/UXSS6.MEJY,O39[5SU\UCP_6U8U=BFK
MX8)UEJ[H#L7ZGS#LN%96=%?C>%QUTW91W10GM*K(*3W[<-(\V3P?L, G/_XN
M6"2X%"S)4^;G*>HU-@0&C\)LQD"YBI1Q%B4@KYE()RR9BI1GP.[J-8\!7_IC
M)KY.PQ1Z"F/6:74NFNSSV#0\39/;,(#?<@G<GXT9#!R:P>QHEB7P9B;B@&7%
M\]0-3!&ZA;[")&#)D W#6\%F@J>2\8P>AO_',- P9;">7T3&<.0\0BKDHLD*
MVI":6JVD*G#J0P,BK6J>=J>NB=K+R;=,$>V&P?N76J>-4S/!*1^)QB 5_$N#
M#V%^KWATQV?RA'W_,*3:?I*'K&Y7KY=3MX]6MYU'J=M[2+,;=6L-:?226C(<
M0*$Q!PV?)C,> >Y4#M!H#"*5#\@@$0U\X!8.4".^^E$N$1HB5<\\8%.>(8*1
MH2@5#"UK%.QWYF/5<U 4J'-X/&,9S)D-9FP4WB*^Q0EPI$"((FRB#I+44QAF
MAA/&U" ;"'Q%#(?"SW \%RT6@)9EI'+K+3;9)R&8903XP-.,W=PTV4TF)JS?
M9.]"+ H? J!^RF!))["H,!L ZD_Y=!K19Y[.V!N><<^RN;#?DDQ8-B:%@&W+
M1M6R;#RL8=F C.%BV:#ZG8YUHS(W2ER-4D'JP;+QG:!O@FJ;^WXR@3'-4"6C
MJI!&QP\+G2=+G8>>R"0!N AC[(/4O653:\X;2,M]'F=X.\/[H;>X'(SA;2Q,
M'L=X0CM:<?_-.FO3O,.-AE.FX+^O/_VD;+I'&5&DBK29T&(-]9=6]0NZE;YO
MOWY"E=9TRL,ICR=1'G75<1B3.CO$21V>DO\\#D'SD3H*$G@4'&[0<7Z4!\K#
MAU:$S##^/.4SI0M!%9KX0/$=Z<XPQ6 "K!JTPZ52LY,DA]\]C!2@ID5-'H5?
M1!2.$Q6FEKD_+MO!( ,.X0NHHOAI(>)R#B$^"BEX"IWCJ]>H2$&[JM!$ 1KR
MVZ/&X\++BK2=Q1#RMXA:/T.(B_878/E@E0L;0AIJJ >9G^0I[L8,V2"7(,52
M;YI<?WRO2."#;*,DLPQZB!2OT!.W(@Z25#TT346C>%!F>4!<#$\FT%7*I$AO
MP:107TW3),A]3>!R>V>:I]-$"FEV>,J(F0J89;6860[/C40,+T<1?)H"WW5;
MR$XF$#9-0VC^+@TS,+>*2-CGL9!B46"TS 8%IPX2,-V48*-!EBPMM:.B?=5G
M87T2%22D_:<X%7XRBH'$ 3SPE0U@P,,P(R/OQ47S'/5#A"+#Z:LWPA>3 2Q7
MM^WAKE8+7O!Y+FGO"?Z;Q\8RQ,9@L4(:AL?"(2M[@O5+\BB =V'!& _^R&5&
MQB,L#NZY!6(HTE2/B$LILMJ2RWSPA_#I:4Y[6TJH89F3.Z1&<X5(T'95?^/M
M*LWH@R0*3,8!S[/DP0*SK71\$B-:E)NJD_T$LEZ=5V7 %P>C4\BI(41+PPDB
M1:$V.$:B<1.7Y)[D6A!GP\.IF":IDA&I5GX5'VVAL2^?>G$W;74N6<1REK\&
M74CZ^0IP&.P*5+H?$G RM:ZN69F1 +V9-K17]:K5;)W3>IA]A+<2-#$06#JI
MN7?AW^>8,Q#S4>%*MWNO)0M"Z>=2DG8%B8$'HID,"0E03Y<V$<!/$&;FN53(
M/%(8HL$3]Y="N9Y\9S7J#3AN74&#]8Y*X\L@ DG[0 "" L)C$AI!)!IR:4 Q
M#!61B,$+#I1!*4M87C^B;IVAH$TQQ59XR9V@8F!@8)5*=JKMSG\W/S79SU=7
M'[1M^5*!L!J=@BI8&(672ZW*5/R94^9(4J/*^K&>U\<*V#CA7P3[(P]&I0$M
MC$A ]VBMT-X<F1-*^^'<E$&/0U3(JTUZ/L#T%V,SX2O('%$B\U2L']E%;6#:
M5H&?$-M6=:$&%:!Z5FNU@@5 =]^)*#+>2#&+5(#IE]\SL/J**9Z@)<"5^CK%
M\!*:HI0!%+ @3Y'@93=$?LK& 3,+!:A<7;12:@P,3EB6I*3:L.4T%,B9]VJT
MNDA 6RBY22ZUS3H$/$/SEHAYAU(0A0(#>BF.D<LD)C@KXW=^F/KY!!80>D>?
MC>92R*J2)]05^,L](SN?E]90NT/\"RY,A>\&2:[(Z?,T)<>*\I'6<)AB3FWX
MPD0"T(B,3U6&*1NFR>0AA-7V/9 !)MT$:"$CV<Q[PF? R2 (*36LY7*5V*BE
M5,]K_LTG4Z7?DO1!$EJH3*EUZTRYRJ9Q]$5P< .,R$)+P/I-]GM)9%HDX[,:
M;62P4BMN@38V6,7*4]'@^I"U S5"4T:6P5CE/#/CR(=Y!CH 18'L5!BXI^41
M_1@SHA2<I*Q('2"G68;@#@RAG0?J-HZ\#8)YFT240[ $N&KT6]]XI]9V0>JG
M,?Y66 V;./#8[,56EEO%$@@S#NO_$,OB 4;#1Z5DV4?EV#V9@W)(AM7OHO1[
M#2J!HA6Q3BX%29J 1DD&Z#1+Y<8GD0&]*6BD$*5XE #*8&#.A"D\,G)B#==*
M&:1B& F,6I"R!<42!MKXTJK]SJ04@1<?WB(ZI01'RI?6WS*51#3F@-"DT;-Q
M H*\,()G%9 #H3Y:!9KHRBA0'BG"&9"&2)"-TR0?C8D=]&Z:A^!$H4L/'KL%
M!3ZE0  J6S^9 +^@'13^I<,>1=A,V9G%'IU2P-EL*I0U5X;7$%9,#/@T?&GZ
MU>$N&$@F_'$,_M]HQBAREHQ2/@&>.PWAZ;0:5ZV.K^1-_ 6>A8>+L!JV7$DV
M R8##HTQ-0S9$TUTBBR#+:VF!0\4'2'794*0_84+@ $SA/(/E>AT7MFGQ W)
M-$4&UC_/IHA643EKRK?6L5MC8"88/T), /K%($O0G#*?IF 8Z.4W^YVX+UJ2
MB>&S\*97B::7D<6*N3NM#UA)%R+X&"&=%A%&$P@P=@72NAJS3BCH!3RC[ 43
M9P.WPD0U/5;^E8I1#H";I"K6(3F,JZ%,4N3'.=M9A?L1IJ$C>I8X!DR2*K^)
M,C#:-)%V_._O@@PY#,N.!4VYHKN(U"$%,BL4(8(;[:=3#[7"0@.<#!A8-%!,
M%;.BQD"D\>2XB",J(PA>'I*.(E=+1+,F^Y<V!<#_-)Y5@.L?")6L*&JC-@36
MD4C<"8]0J:+)"#."T60S;*D8GS$:[Q<+$J4:C^-B+^'K;ZCP5NG8PSH"<-FR
M_PB !5VN/HQC#RD14>MZL:J65V#<,@VL_!'2!!(L(/!#*&RP"G<K^K30\8!
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MZ;-?3?8?Y+DBZT1'8XNLS5PJ[6R6OZ!]"98J<(FDCV =E7.F?)8XI\-0Z E
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M.($:3TN-J9:MNU+C(<GS04/5<FS-"FHD=H3'5?*L"%RXLYD5S)B8HJX[IE1
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M_B1BY.IO;S2N:<77$[0;YSO>83F5TA0.V[^8[BF7_+',M<E;A>?:3W&<I($
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MN0)?"L[9CJY-NZ]V&W2*'G'9,A*L=_000+,!&CB 0,N!$PCT* 3:3'6NVY=
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M,:,/$X%>#C!E,&7E0P&FC!I,R4[$_UD:G:FS,4.JA&Z(GJ[&U L'B@GV?><
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M9^8%7^9Q[-F6+UIV^VO.3/NY,R/;>OM7OK]@9DX!!O[;F>N, M?XD8@M/'>
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M,FG7++B9W.N/>=6I&\9BMK#Y*\UM3[9KS7HB;=8:H*\',=$E:E3 IA#\6J(
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M1^89EL\4=\)7QQ52<>=".0IK^8OH.JDMK[<](H$"IA#L7P'=;*3&O4EW(RR
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MPM6)[[C&E:?XW6_USQOMDX@^84R*A^%$$Y2H8K#M2OIQZ2!I^[-U?(&BG#C
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M1@4C_!]3W?G.[O2 74XFS'AY4GT>Z8R6VF[EYU&AF6&U;0S:/E#  '1< IA
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MWNEG;4BRU=\_)*I)):Q75)"Y>=XMLD-,BE.W19G[NT29<P6"/PE?-D>B^X9
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M:>D5%54A'53!@U2OQ)?+P-@BU%!I.M6G*JB=\6+GK,)*$J(7U11=$.3@*\\
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M7L!3TAX!%72%ZN>).<G 1=P?B)4(6G8L^/A\@6'2=XLTP@!>'QP=+G?/"B[
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M'QK#"Q1_0C&F!ZKVV4BG[7;!:=Y#R)Z233E-TSGIJGMI5B\95CD_A?!7EU]
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M3PMTUM0MK?6;N'N:"G*Y"Y6/<@*9CAF-F,Y6N7Q%&2>OJ+'IDCO":<JTI&D
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MA+O*PL!:!!Y?F?3MGUX<]KN=T;>[=Z^RO4W];KNXM^G6CA]N A?_Y[=_+3S
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M_A: C^FCZ_J[[05O&9R0?;5_7([[JOBHQC\]$RXPNM_@PNC^2T&5T?W&';T
MY!B59'!A5-)EH,JHI$.YH\-U[FCFBN8=T\OQ.#=.F(ZZQB$]#S[092S@JA)0
M-UP EUG=UL$- 16ZT]!W7XBG79'R-4QLWXI3"7*2"74K:C^/AQ"-^>38B*BL
M_328.'+OP I_Q>!"HSX.B1L$:J7YNPIY5^G0[#R?_,"]:,?!I'%V5&>G.Y+.
M#G:7T83S8@-;X-X]A%'RE46/'X(G%B>/].MMRD5?Y&9T1Y-&=]S7IJFLSLVH
MU0I7)5S.76E?M'@P6OQR<&FT^ 6SZ4GGEA@%IZ\,-5ZI/K@P^LSH,Z//#N*5
MCG?U2E]<&GK<&DRCJB]7/1A5K0\NC*HVJMJH:N-ZGCMRC#XSN##ZS.@SH\\.
MYGI.JK8^;^9]'C(#VIN8#.BV),?)2E+5*@(\1IWESPF6$,-O7>]IN\OG[OHW
M]6[=>5)X)2>1/Q>/+/*<E[_F3+BV-]JN9OL/.Q$__8^7/'C!IX#]+[.CM%1Z
M)2<#+Q<X^<.?[W.LW(R9@^S\#.P1LT#EY3_#$ALK]9_6@_W$Z-WXQX7M6X_I
M2:UP9MU'S$Y89"4/=F ES\R'3S_"IQ_B%J)_/U0UV8*H:F=-XEN(/&M^5LZE
M#]UUVD,!QH=(WG!NW[/F%.#^O6G/X()O;/_97H*L__E8W)7#!: "R<,+%C:Q
M1LH#O7;OGZX3)/]LSP;MR6#*FI-1=]KL]X>3YF0P&C6[O<EP,F:=OMUM;RE]
M]W3VGPN'EWPN"$N]2VEXW><HG+,H67[V 66@?U$;SU'KOO-BQP_C1<2^PBG?
M^J'S?0WWMCOMCL+&#)ASCJ0< =]7P06A,-F8<M6B\FU)>5>Z';8L"1_+#EPK
M!8XDF4H@]TJF3BV0#PG:H>9"(0=9)B'2L *6(#!B+TZ8B\(Y>6"@!'P_? 9[
MZ<U>Y/'V3 :O%/8%F1O"0OO[JS9@COD^VF!PNO1G8=W1S[F#OK$72?B+L._
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M^S8Y)#XT8KQZ+@F):7%ODQTL_^/?QB!9?HEQK,X<CIS8T=("^VP:NDMK#M]
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M!Z[WIJ&[;+K1XAX_]=?B'OY@O=[DJC<2_+?;4<Z][05Q0I=I*/ 6]P"2F(=
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M9A7BT6R5 QJGZ28>Q%N3I?X*8&5)3MY7IZCY!S6.OJ4 WS@$MW6>.N$P:.P
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MH.VVC4%[;(.6;U[**=Z"R;4C+CL7;^\>6E^N-)+S5FVE\JS-C%-)U)(>X7K
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M7?$>2=B;L1>M6?N1\-VO?#F(&#[9[2"CIK/ZNWA2FEA8 6RE&/]?"Q!U0%4
MC?*$?UF +F_O;G9W4:\L3KD*R-M=GNZKW! ](#9/2,JE=Q9S<9D46[1)"NE0
MX#R<LRBUHCVX)]UDNN3G^/3?']XU.Q/PDN'LCYY35VM_+@:1&G3K%**L66M#
MO?)&SQ'5_U;1H3K\@71!0N!S$ L5T8*7PT4,KLRC_7WW^NBJ8FZE.#PM ;>?
M;,^WQ=1.KMY%6"L'*.2XW#)#J3(0&!:NO$%\-7V0VZA%0*V0E/[/W ($U6KI
M%R.9:1978.IS!KU/*8Q^^S$GG@,2@H]\FMW1)@B.*Y[O[1S>LGGQ2<&VB9)W
M0#[T=C1,FNU^$WSI?4SX+*8SW$64IC-FF(98@@R*BZLIY#+8E#A9,9JR3GCQ
MAE79IIH\1.'B_D&5R]SX(78# =!D5'B8MTN$2[_* LJ4/W!*5&\)68J0GX4H
MP5<+^9R@WO360.;JM?ENJMR,XP2T)\ <;I,\Q%6J*OVI>]9"MK0G:P_K<;H;
MK<<Y3IA\ES509[G]J3O4)':MS?:G%=OA=DO_=$<:T/7^292;"*+)!_Z-YTH-
MK*JN42DP1)&8=)'L-'"P(P67DJ1"8?,<*6]&^Q\O>;B%UX2@_G[#53%8*7^#
M*]Q!)WVU?QP:\GU)GRLGNT]:DWH,(+P50TRX9%4.#8 X8C.J5A4:4?'.A<-"
MIFS3)?<@Y]SE(^J>LMGTW!56VK6\-XW5:YM8W(N&TN?)?WOX=W;R*C1>S;%?
M\.@6UM]MFX:NU+S+FH[UOUBS"[&\LB-=8I#M[EBYSB 7&ON0%$+"M-FCTG6K
M=L]D.)'KC$)(7,8)+(H35,1QZ]PM>&QM**'7J\[0?Q'/$H1U\'+PBR/FW/*9
MW<(*:1Q Z-IN?\W8CLJDNCY6PVX&?Z]_-LT,VNQY%5:8IR[>W?_RURV=%OPP
M_PZP91B0.,-3NDJLB>)!A5 3";\=Z&:@MR<C:4:$.,ERF&$!^>]AZ.:%H/RH
M^$C$W$\@>)![CT1_W6%KN+$O13_)A%V-]_,"EVKU@I^S<)_6CQJ2"9=YF&"H
MMGH1%/!'<7,.5G,!G*:4D\"A4!X@9>8Y-I5R2J0 \<2V+^+%7B2WV?.]/3$M
MC_+Q9'-&T$($R,% X2+!64$[9U9HGDWH%R>=Q,JULI0LD,V441Z=#RF2$B.=
MZH*SDTJ3MJH$#X#B'>@)RO+UJ)6TVSYK#UPEH8I:B9UB/[U2BX->$I/D5$<(
MK$YWE<#JC5>4339V@8W^<;&)@$UGLAHV@U5QL1UU[41[Z(PE=,:KH=.9K-OD
MAT*&['6+Y[Q*@J4AIOD!*'E*)QO,AMWNA2+;BLF"-]4"2SYQ@E,-N!U0K6FW
MJ039'MG]7A'951C^Z-E\K;".9O=J$N@.5M9<[\0A_5+*_LR MDZJK.SK*K(
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M...;NKK__=2_7]0J]GJ07.@J]C47OO)5[)T=5[%K249JB':KS>EKUIU?E !
M/ TK->J%"H U%[YR =#=40!H248K<S2I=2(MG7)Q6&WT%?]HA(01$E<J)'J7
M)B3RBS?44E81.OLK]%!D)(Q%W&%[?/221%F!]%]WM^D*)"DZ^)=2 53QI2_I
MEUKKY(EQOE\\BVP'6S#%94837K9M"9!.'P \TJ@R#)>[%$]50Z/K-5 :;\0!
M8O OG&!8YP-3)WR5.[]R3Q9WO"MTF5@EGW/[:3U4S.#*R &K-@]5J$U>&1/8
MB9@&RV?2BHM.F>+>X_%%C2E^QG[,H$TA!8XT47QA8W0LPG EO9AB7R+<*QZ2
MF^]&3Q2#'\4A0KSVF6P#.R(#7D!S?V5K] _F+%;$B ICWO,MT<KNC#2G93TC
M@\JE6.)[0'_$-:(V3/VBR"U30HVRXCQ<B_,/+0XF48R*_0G-\#D0S0_?;N_>
M-L2?*'+F+V*:RB)%4C842QPBFV>*WU5"=30J!FE5[G^"PWKP#T^('.(()/ F
M_'\"K)D6H\X\YKN2<V2/#]5364_>4PA"SKX/PAA_24^"[\\?ECZ&M!U*>L+1
M%5B(P:H1'0OSCZ&0J0@-+,_E8,%MA9YC9\GX[V"A-1_"Y^PF.V1U'D,?2,$G
MS@:@\DDB7 J+V8L ?&7?F5+XI4*<4-RRK&\UT.:;^AYIAEJ>N'#_%9>;_$FT
MRBM'*W)6 OR1'LK^M>!06EM%6-F=,<QW#8N,A<C*?$X#_+_]:P'0\QD(I*_A
M-YXBOPG<K-! M+P>,0TCQW3#,91$D9*6D3-ROH9B>/_[,")]%K]=8@XG??L7
MAIFH^-,,A/RWP,,1H5ZR_#2[!14/WPL\>^,-,RF>7M3O,:KHS*2&#]FA(0=G
M(.%534=]YM0C.NFH 3=/LF((*:?P[;-YI8EN-XX3+9@K!U^!U+CE4G:OA6#G
MAO+R;*B*@>@OF@PU+ UR,YBH9+[2S*DUF @VF3B5WYN%0\"7<B,BR>:U0Z=,
MLG1;?XT7S5=OVMR>>X;'W&MRO-K6PM#;SLJ!P)1VYG4].^]]'Y9&^IW1#*9:
MM;S-#*;"*"M>+Y6.J\ARWSL2ZJ1Z*,5[>.Y_XV,_S:17K2=\5VZW&:T?.IPO
M5=EQ>.=P7.A$KIGH<2.7]'X-M1[:LB'AKIKSP:,6^4DJMI\&8UXZ\JG!]X>G
M2X^G+'G&^E=99UH7N,H5CE#P Z,Y,>VL\='4C<&#XY6(0OA3Q*4VGA5F\3TQ
M+:;Z27EG;"%7=LN!)S@AP8X?K!F60HG-LV!7RT%-^)C(B[\W>50'/HW+-V5%
M;%;ZDLF%]&F%ZM\7;$8@B_YE>Q 09T=9A'"3[:LOK4*@>^QI_\%_V<'"CI86
MV5]RT:SMBJ)8.7I(%%/53@(U5EGUN,Q=C8;149<>:FE]U9FSA5D\J?S< <B=
MTP%YRVD&Q\-)?]CJK]S?6\Y5U&0V=C-$1D?=I[AEZPYYZ:=#36N\%C,5J:DZ
M2X*KU4IWL8CC51/VE34S?*6A31-*FMQ.D9OH*7U#'0P8G4XWC55\DBP'.$-%
M/J=D@L08NL88[_NOOUD/X2*B^/A"[ \0IA%.7DFM"BY4LH]C(X23I$N%TF]+
MXWI-/C#;MUBS91$4>2)FS+I9&J]BG7!A86[1RL$5:=@]04F*A"+?2A\2XSXJ
M-=[1YA39/4VYLS1PS].&,D7G*AD/0G9^DQ;_;]$,44"9 A%4<5.LYY)\7[=S
MDLP32F'8(A]0.[-S=(P5E)H(Y6Y;+*^&?ZS=#$GF2?5JR/S:T?KEU;B,1J4V
M9;D:TKSL/ *[V/7(!+R^X2>=\Q]^LM'LDE7#3R:]_G V'@Z:SFS(FOU>I]T<
MMUW69(/Q9-(;]^S.:%);H%2-8E/V]:OS8*/V!H85-3)S:C=!L8F3*![#)YE!
M1V;\\.>[)@O 827OECZ)<P8]$MQPG[EO!Z E9"&9)G<\N X!&TGH$*IC87*"
MC&9PJ-=N_>O1;IV)T&Z;[#V.T>RKUFZ:X;:USR4A5Q,2^;I;/*1N:^\7&?G[
MG-GGGU+SW+B%%6&_-&*RM<N8S3# NJ)"M:^P(\)%["]Y;0YU4XJ2J42=<<R<
MAR#TP_LE:J\$7V393[;GRP2Q&%S+)]9Z.1<S];=$*+VJPE#Z;A@(CFH++],G
M9=JH3N/ P^L%^5 K07XT>E0(<Z4X]W[4N"I&;)YZL>_HE(M]#Q5SWG@7\'CE
M'K\=H'G*5< 'B^!ONCVXM__MP:-3;@\^&$ W73C<7P700^P;SM=UMZP]K!O>
M*$VPVY;6\7&VM&KB0:U=33Q990/NQG[CXZQSU03":^7;:(NUKR_GG,H.H_TR
MT''6=6MEN:YEH_TO^!X?9\&W5F!>;RMLNA)\APW*XZ-L4#Z<]7KXC<GCHVQ,
M/IQ%>M0-R;PA;<=:];WN1]["^=QF9F*<,(!\;'U^L.%7?#5R_6VJN\[U=)-I
MY'C^>G(EL>@;EW]-.\X+_8L;;Q,N/"_[<_KD,!W=^/_9^_+FMI$LSZ^"T';M
MVA$DBP!ON\H1LFSUN*/*=MBJWIF_*D @*:*+!%@X)&L__;Z7F;@/$B!()LF<
MB*FV)!+(S-^[\QV#3N("EBP63-;13+L.BZ/%_=%IT"YN#QQ70*?Z!)M\FGVR
M,#HJA^*UBNR.%TC<C.-CODMT/^JSCF:%RU,X$G?#/$'1VQ+)DYF![<R=RU%0
M^J(^*I0-/T=;C_+:UDX\NZ63*)B-AM-E"O0+@[.,.AI.79A6ML)OJDGX5AD'
M'[\?I=;O#[1!+86S< (WKV%276CCWL'1:(7:QSTK;C[?TN2!DF,_Z<$6CB!@
M_7[#;LRLIU#MHU2/U\=?Q(,M&0!2U,T_U'7QGSC!12U8,DE(X4,ZL=3*#7XA
M/S9ASPJ;GCU-.L^]@AEE]=%-YY1^P[<^.!_I.T\!=4YT 0D+(KI*"*&A0I@-
M!#]X@70&*/#\N2>M2WIL'IX[FXT1V9;SL-\-_K_E8B$(*Q;&N@YN6*0-S12+
MW@<N&@!KQ^7]P/5$R_.8&Z-A0'Q4/>G&G\)9*GB]3,>&ES1A7UBNYRL;ZXEF
MX'I^8-+%Z5$3[X(1/6GC9ZV_%,])Q;F,W-S-SRNE'73#F9W^,IP*Z2G@V1&7
M!MT*I\MEYW30944-QSDF=_ *A5;&94 ):Y8R?Z8];L+A&2;OB$YG8?'1>LF.
M]%&!']\_=0ZZ:1,NM:JB?91VZHD&$X2]E?F[,BMF78S*4ORW35X(^QAEVCY%
M+8BS3@:Z,BY- <MYH8D$4ZP@LQ8O!0:^=#%B%^-KX&+MIA_%E$M\BQ#_1#^J
MZ*,6K5D$SJ8UAPMT-\)JW@5I>.T\RX5$6R^(/I*)52CI,[?,E971S"4+^_VG
MN]"7-+%G\HR.JTQ,5XDFY0% >E@R0P';@'#X05-25B]-P!H=;XZ.<$J[.XV@
MG-V\4XMN@.8,R;3-NX@9*#,4-:/"XU#,LU-@[F8F 8=-Z(N&3R0L]2T-<$+R
MH'$>9W\".>) X&JVCE]]EY1HF9XJ27,S.VCCZ"35+[KD#TDJG^=*=<4TH9U"
M'47S4)/*'34L6A68 N>O^+TB&U\13\REHAZ+F7/C+(H&YF:^%Q=:+P+:HY#*
MI%Y*=63GO. LL,)X)K/4HN*K.=AY%FNJAD2@T/F,/CX"3++(BBMX#B;#1\T/
M4Q.T0S[9UD22-:N):NRIH0LFB37GR>IH,,K4M<8Q^?9&5>2,F0;3*OB/V%'Z
MS: W&/PDYU<(-7A SJ^0\RM:ZDP=79(TZ5[\O__7:/96-JH_-8ZR4;V<9M&2
M.-C:2YRQ//Q5<KWD^BOE^FL=3Y&?--%K;:A$TN48]\:3M,O195[(]?J'1<W=
MHG%B16U6V/T.=G$!,+U<'G52M&=FQD;-+;RB^8Y1 _SB%Q:.L2B=4X+Y@[O.
MEL@-N>9-['<9<IU(9U,G;TNBC861QKAO7'J$=7:F1O*^J'0C7K;Z'R^I.JP-
M(;_:"B<!5PW,T./(FQ)LG'CHO,PUJ\]@49),.]V!9Y-C=NDZ0<9,^A9G5GF+
MP[L$1TE\^]^0Y3*TK_J&;+>8;;.33F<L%K=NYR44]Z3Y*&UQCENM.N[MG5;C
ML'\V>I*XHCSSUJL/H;KK[+_EFEU:R\5T?%4<1-WJ"AY>7*E0F@3"[T:Z84^X
MLE:Q?G9L$VL,2U5V8(?)-P@CGX0%/.NLL)$1?(;-QV&CJ^EH',-RC6"-C8;1
MGG(,(W!/=:=R74W-M/-O:K933[*JIF;#X62F:S.M2W3=[ [[NMJ=:;K6'9BZ
M/IL:X^EL8=:,;5^]=;FOQ3/N]Z7%DZGMC[S%P[7925W5QRUVZ 0VU"A (MT5
M]H6?ZV#@'K6OSKBO'J&OSO%IHJI7#J8 %S?+"7LA$2S? @5:?FK:3J?V0.TZ
MNOK?X>#0WOT?^/M9'N,;-$76N L\.CQ'7FC7UT:5_5$?=K@'H*Y%)]4_& VO
M!@)N(!V-5)EW& %*")[G);$383;F,&!2M)D>>E&4DG/,D%#;&C1)E!=A#K3<
MJ&K<SV4,'[$3T#$X:K>.56IEDZ5D3Z#RED"\IU[H=NYR%[J'53>Z'*&W(T05
M\X2R4?$B1[VL,PQ/UBW.?&O6 6;</TZ#GR. 4XW)N*IU#XMXL>8/B;8/X1G'
M'?+;._:C-"@Y^:GW*SM2E82ICM%'(QT&K*$I:RC!]ZX%,*Z4WU^(ZRG?_PZL
M^3S2BF?<7N,+=K%XX3TLU&%F% ^HC\J-O]H:CM6B9/:B!VW_NAI^O7DKCSIK
M_/U[_.U:BRMMVI'JT1%X-#%A&0"RZ1X-.L!N8E1V':Q\:P/NO+5>![;3=6R#
M>?QAN7:NGT>MD/BVGA\/N<K2\ XL=3944OXK6+TH$T8X[41[&9UKV\-HY^ $
ME#0$29UC<2^00IZ+\UVCGB"G: DR[D\+&RM\X72Z5Y4WWSC=-]LV/YK]"\>B
MDJ)(:CR1Q&?B;E3#_@05^M[-0;*,VRN&=:F;R5*O&%$OF'N^Y0<^:8Q4<?.6
M]HKRSQ,N_SG?/:RDE0OF#-%[/&!7WIJUL/J^D+>I,/4B)B4_-A937TSC]M5)
MKSSLIVIY![GQ$/(/-+JRX08@A@J;.F;;$&\%TZQO]NZC3I.O\@@Q[DEK>,2[
M:_WH+BT3E, ;?IQ]BGL7,>2Z,/:243Q'-6:UN4P]7J.9HYQ^6QQ5T&D&T6+A
M5MNAT6I6&5@H%SGKE3-(.OS*;@V^+#X[81@\"<%%2+EQ IQFEPYUA5>&1=!H
M(*6L:$3%S#]\%JRJA"\S+0>_XU'40CF'8@HD&/+^.7+0KFAA@@F32AFLZ$P]
MEG>RF_Z'\TK)I72H[E/TN"^+CQRA@G.-3A]MY3-GF)I"K+A/$C;"\7KYP44R
M7;5YWY("%V@!4MM&EZ6H>4FQ@M#+.YGPC*UF,6XU%T5M.W/A-%*H=&9S];5>
MKO@>TPM84ANX_\EV!&%%?E'_DZB=20,\ID?K1]&*Y-JQ:P7-@\0+K8R5LE//
MBCWE8*)!^FA;YDJ!'8<D4=R<I@&ZD_-"]]!Z"762Z?C\ ZF;J(XZT[:A5:?'
M4'E;QR2_6UZ:R6G3D)>8LWF>*S88238=H3&,E?.LF$X D'59)Y*X^\B6IB.I
MML_8]X0+%Z^5?A]\ C,H$'VS(6;5+47;NO4" IL':?^1L@EDYP_9^4-V_I"=
M/V3G#]D#0/8 D)T_6NK\(=G^U'A)MI>M/T[>^F.;&)"]/UIR#K?V_FB2P71]
M_4+HX75VZ1=2%"B/.K&S1AV)85%\L@!VZL"! 7'60U7G$/Q]69,0I;@S"#8!
M:=85)(Z-XGQ;/WTX8<N2YR6AY<CXYP@BOD3^0KH<?D^9A#IZ!NU'R]=3&KE@
M]=H)3&C[V_#4XN?F-KL+]/)&:8^:%(P,FF470'B_$<=(2^^3@(5I0B/-9E0^
MP4^Z'>@\=!HE-L-?Q\5\!@3$QC-5,E=V9C,3)5;ZBJ5!%'TF3!2]G3CYN*]6
M5F5L;3%2_PRU_J6=X9;*EJJKGRR=;C)7N.4IK91W:O&+KD1]OR.5G'MAYLZ8
M53WYH)@>F0!O K@J#.!5\WV_NN2.G\]=>#S'I)/*.R><&A2AEVN9$H+'-TM)
MX[/S%)'&)*W4$]6%C?#4S@+/#V[P>+O9@"%,-?^]X]X]_'8[;!72B:H.^DW%
M9Q[&<JU)#38Z<0(<R5 >6/83UE<SRP9^;8-98,*N\8/AMN-92+#Y[K!K6BZ3
M!@7YZM(XJE_3@_Z'RHHS)CM6]:0*;&X!>)."SS):%169F66.[59[4Z/N)GZ9
M6J?JII=8I7H>U1/:0)ALX6--X5$G_8%:+Q>/\L(N*<5E!4M)ND#_\W;C6BM%
M&S%^:$B;'Z/7?(#7U"/4@F*@Q!ISOFW<%&RI/Z7=4/A=(85G*]#@*33*D1RK
MD@F&%!)W.+2/SJ?COBU\ ):U=#S:9889;HH9N&$E6CRNA;6!"2IWV[N^-EV#
M\V_3M5.7K:HV7?/A<&YJBWYW,B"D.R1]O3L=SOK=N4K&<\TP#5TE&((60]&?
M0R).,J\V)TT$RJC5#CX?\#@.]:0_U$;1/RH\IO[6\$1%1FW!++C#3A1L .CQ
M1L2)D+19"/=..9N#SF@ZWJ4W7'U#<E1H2$;U&WH;(^./R%9MV(<IHS#)7663
M\Q))J]79JCO/RDO8G:;%;DM8F]3(&HJ"9E5W-6&6;>*2,[:I,N&V1HT54C=J
M^9>%:MQC*;3\TL[LAE=G\Y>"W]&6@D!)8&G3FSZ\/<+=OK)>L[(SK(!-39!>
MZ6!H&BO=BDXE?*J"-[DHYJA!&]J9\5_9.Z/L8WKAXKYTX%W\9?XS62W\9='D
M;#:W.O;S*'AL<G7V!?A\/7XZ,"N\H' [U+-FX0T4WK$P[@ 9F9;NNY:!#]@
M-;!@",IOW=<CU]3R7RI'5,LH2(L]\D.YF^YJ@7HS94AANDX<!&_6'D@[9F?]
M$Y4(9^R?B5;5*XAWUT>FSO?7;];V?:REBX3^8 ^\)^0;OQT4_CQW*=72MM1J
M':ZO_E@[3E]]L<Y;K>YY53R..;J/QHA,8Q-[D+Z-+#&LB8D>%.^=^"VZ/OE
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M32EG46#C>U&?W8PB3GAWL8%H>3YK,ICLBA<Y=-PEM\O_3GZ@,P3KA(5XY.^
M2XST#K-<'ZKQS,[C#5.'SL[:#0U-]G0PD]OD7Q9_L(??$U+5>/;4)$>-USSM
MU6B: "KY&6QWJIIY[UMT^9B#%-).THM=$-+4.TIG_-_2=W"[_??X#9=PY/VJ
M$@Y_Z3K!X[+<M9GUBUP;3IKHX9S)\;S3^@,U=W&2X79JZSU1P1!V;XU$$A=F
MQ$L'DD+G B^AP+A9X6F S+)#&]#3%\2G+3W!JK0,W7@)_Q+=CB5BFMM,A4V
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MX I$WG!H S_@@GF 1.QY!==8'K_%BAM;4)9?ZR]A)$^QTD>4N'_O*<G*82]
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ML3@<9IIR@'JDAJ2^^A37)']CJ0\/#K]F1%M0C*JLTTBUY#&5U6ZOV&4B7HH
M+R\<] N\-Z>[KN:SSMEMS1S-$??7&Y 76$J/]S) IM'/&S1@^<^IA;[1 ]]Y
MR[[=I0.%-AYY$_[CK?)LF?[RS6STTUN*K>_2_YH8/[4>[5]OV#ZCA\YUXZ]'
M< ULL\N3\N[I_[WE"^BNR,*GQQ#^XAO%L-^;C!*_?,"S2O_J?7R@;$WC46_
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M;'90):.;=V@W2E4B!F+R,NK4D</<991I>0:<JZ^ Z]+899%73Q<=UI6Q=0%
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MR!= 7?E==_\"ID19IMP"F[(0U"O\'DH$K?\6_^3%?Z._5=^^9O[TOP@E(OC
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MQ7VZE[Y/SU^F4P5 K[M3D7>,VV'T/FJU\KQT%'#2:>!@XY(G"WA^A9$K8M.
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M>K513A/\I#@,^X7E>CZ8)C8H8-?3W9<P&OC$%@CTJ;N^0@U>JC!L93!6R-\
MH0+DZR\!2'WM ,Z4.<"#0_>-PHV4&1,IT@LC8SA7#UC+C52.CJRQ "H"I!GC
M>;!&1C*&[BV1FA;!:D5U4^#"PVS'!\J!'PDLVU06KK-6"#]NCS(:20BQ/%?"
M6F&E/*B*O+0 _L>(+)SBQO$L7^'*T5CIGF<MK/"3*TN?6RO+?PG/;ZZO*$-Y
M2T+\4NE?SX&B,G"V6]ASMK/43=8R[Z5CZBB44'U0;:M\#8D!6:?648VKCBI6
M%T>Z6;ES;"-P\4*)69Q("&B/K@B58)R#/GW]@NSRQ? =M&6!3T>=I!2-A&S5
M*2FO\&-:_^W'[U^_TG^J;U\#TQ@@>!2R6##3F?$*?D0!T>H\@U6W I&/!!VS
M!3!;Q(U<J_"59A>4#O\#,RBFY1G(Y/!QUPD>E\I&?W$=8$GPJ0.#WW( IVWP
M+;4E>GMQY]_U']8Z6$=&7C#W#->B;/\-^+VNS4BE>M)@#+%!:!*B>)L$5@LE
M,#U\RXVQ2OHTG92Z!YV[06I866M@6'K>"<P?B0T.&^I4;K8P&>A9/[I41L.K
M%F"C@C3?4$O:ZU#YQJT# O^$M1#=R'VPDR ?%-U41!;0$3RI-NC% ?8F:CP"
M!8V:+XL[2KT,+J;.#P5[15 DB?ZT''T%F!5D _^!1I1 ZOU%_/357"6#IC0Y
M"#"\9@2%'6GR#*:H3?E70+GM\@U&:;'MYP6@#NO7K0WR=PBX_D_T>1\"?"%S
M]"C*7BD VQSC:KNHJAY-FW;&TX)[I)#*[4;;SD?V#K#MBH#4UFT/M<YL6'!E
M%"N)%+W%KA(5/J#B\+##".HL$]*II>;IW84X>OX[Q_U)MU94]"VH)<KLU% $
M9HZ#WMHWH))<N#,AQN[T#9II;#G?"#IE!,,A]W0IG[A3=U3E5D5/G=E@!(Q4
M$ +=CY%RT4]!CJ@!RW7&_5E''>1+;Q(:-1<%+6,QYB@5Q4-=PE)'N/O."+11
M#'28BX'>@J%IX-.+C;6/; E'5[W9J_!VTP*&N:#G*8^A1D9 ^0UXPXR 82X,
M<]*3V#49H-_+&V/12:!XKWMA6.<& S1#0^[+)98>[@8B>A+[TA=<]\-2M[??
M2K2J9;*PE=]F**D"DH2YH*5"*+1VA$:#RFZ1##B.(I'949Z7EK%,14#9K0EU
MJJ/';;DP&>;<7+$O3!J*XH([$^J$WKP;Y:Y,Z!^.'#43X:FGB,6QX!(E+R5)
M/V'"2Q'-#H;Y6WAC2<Q@E8AO5U(O5PKPKR^++'TBY7H/L(/W\)F_ZGEU!&3#
M!E.CW( 4ILF<PY44Y67F575I5",MCU"PN":]#HID4O;>"F^?XA -Z"1X7S?]
MF_ G[KY%C@L-**$^TC%<Q,*&K^B5D!-X\$7O]9LCY@-E^ M3T[&8@+I=++G_
MUQNP00VR6F'Z/GC-T<^\,(#^G%KH&SWPG;>\-," +>*-TYOP'V\57C[0AY7>
MG++7Z4CM:?G"M=18N_+"M=+DP'UJ&*Z^>DTT0')JHZS*9)J)D=S!2N:N=0!(
M8 5H4_UZ@PVI3M^1;#CNC:HA"P]+9+B*>:TA;/\#?HSR,>?&G+Q:ZQA56&(@
M(%Q;;?%4C:A 2:4CM-+11- Y:H-)Q->MD@1H3'_=^N?48JT1FTBY)^7>>3,B
MWAE(N2?EWGFQ@)1G4IZ5RK/IR>79KB;#-<N]LG@#[.R P]9*.8W''RZWOQ?F
M'NFNL:17+R9Y(BMG@YFJIQI[5R[S"H"XZ'9>IQUENNM4E$*U(CODG1:B01L8
M731SU4]IRN7_MY4_]LDVG#7Y[L.C4/#^QO,/DJ5VH9"^M<T/L8CF;]@IR[!&
MO[R"\COQ*/PXSJ$PY"JJ+I Z60P<I$Z6.OGL0:NODW,56L+IY*J4]UUU\JRC
M:?E\>/$H7.ID(6"0.ED,'*1.ECKY[$&KKY-SY</BZ>2*XJM==?*T,U#S!:/B
M4?C5Z^1F]PD")"]>$BS_9 T_6!</<VW9E@=?Q!)$D:Z\&V?R7)[8%W2*]Y8[
MU*LTJT2%:M 25A?-9_7-JUR!XQ'-*R[&P;JZ30GQ0UQ$3#JS<;[_KDSA$)&*
MQ<M>DZI<$'"D*K\ J*0J/X@JS_6'$E"5MW-_,9V(/X-/JO+3BR"IR@4&1ZKR
M"X!*JO)#J/+1P;H-MJG*6[GV&(W;2P^4JOP<[D+VO9RJN@LYQ+![==";B(W,
MECY:O!OJJ2X3*XRP'>&Z:.5PQNDF56A>I95VIBDIK>!XT4Q:WX)KOU%R._<@
MZK SF8J3_5EF<I5JAJN2)Z?5#5)Q"PR.5-Q2<4O%?0#%W7Y?_W9N/=191^WW
MI>(^"[*3BEN"(Q6W5-Q2<1]/<>=FQ+2AN%NXXU#'G>ED*A5W3;)CI!52UI$F
MWI7><?Q,)S' ;W$P0W:.RVE&1!1-_- V15*@^2O;/M_O6^XHV.SJ:'Q'LVE1
MH]R@H<.,YN*_3,T(8E.BZ@]J4X>]@F%X>TQJ&QVLOTSM0]AY3)LZ[16,X=QO
M3MOH8#7]]<]AUR%MZKB"&-J8TE8A0=2+$"'I*4 -Q<C!*D_S<\8^P[?#Y3:9
M\IBO;-A+=ARL*&3'G=<8[%@Q%Z^AP#A8&NVNF]]]EF/%YEN2$N63T7+'%$]&
M*YY-GQ")WK_U5< 2CSPO6+/?/:"%]4 .-PY->-&6'#-./!] IR/.PLGHT4CT
MS$2S<"8:PDA'W 8>V/ST>^]7X#]T 1EG!1MY"D]=63LF62E,B/)AZ":\#!].
M)ZLISY;/!CZRR6CX/#V&2@Y&.U(JVK@WTDY8\'VV0;IVCK_?&T_%*K=GYWUZ
MKSC9P7PD0@?S8;\W&,OQ9RG8N*Z5/"1Y:#<>4GN3+=KFZG@([2F!QM?M91!<
M,$SG;BU<&S2"";ZT\2 GH)SM<%7&@U>#P3GP5MJHD+S5$F])0T1(Y*0A(J&I
MF2^D]693*2#K87GZ,;II)FN$FN1"R85GC>7IA[I*+I1<*+GPU*-(I<$IF>S"
ML90&Y[DB)[GP<K"4!N>Y(B<J%P[ES<_>!F?C4/3A:O!8=/IRRQXQY]C Y- G
M9Z7[ULKR7X0KA"RZB[LD#$0M(][1L#B"N!(&JE_P0C3<:M<C1M?ZT5U:)BSU
M#<OZ'_=OWHV'O>%/2E>9#'J#GW[Y&;\CW@0NR562JP2!:@>N4F.N&D][8\E5
MDJLD5^W-51IPU0BX";EJ)G65Y"K)52UPU>#FW7 "W 1<I6I:3STKMKIL]"2C
MG0U4.S#:$-17OS>EKI;:FTD^$P8\4?ELQRCM-4&U Y^-0*&->4BCWQL5\=G)
MLHBO-W3[S?+^ZBY<0A0+B9)XON+J_LD&5TOC7:QCYS:%%&4I4<:ZG5#3?']_
M5[*,9)DS1V('EIG<O%.9\M>*=;\0V$F6D2PC#,M,;]XAKP#+#'I]R3*2923+
M;&.9&>T^B"R#]MDYL<QE0R>92!0DMC/1I(^FVIB9:D/)1,) )RH3L7#H-2&Q
M Q.I:+RIC(D*$TUDFNK18?M@/5FP+%-YL<C*%.Y>05K2I[PVE?(K*;^F$\1K
MJJG:6^6L;D0O"2;),*(@L0/#3"7#G!PFR3"B(+$#P\PDPYP<)LDPXB 1L8)@
M8,A BR! 2*X0" S)%8( <87AQT*ND+F3IRM[!P);UYY!=$8;9:S/_JN\LFPV
MQNNU<%<1TER7UZBB^+>S_LV[86^B=)4ACA$]GTO42X)),HPH2.S ,"HRS P8
M9M3K2X:1#",99@O#:%+#G!PFR3"B(+%#4HZ&Z:&C<V*5RX9,,H\H2.S / /)
M/$)!)BKS7%\\=@?F&98Q#P_;_DPGB,-O<:#X+S^GQMS7LYU2Q]1XM#E= HZ\
MMVPVHWTW.'$1R;GVV9\3RVZ^SK;A4S65!V^7;KC#C?Y(NG.7Z']U]05L\(V^
M>M9?O!OEYY.@D0%#L<Q?;RAE#53M3].P_3_[QE@SS0GI+H::VAT.YEIW-I\O
MNE,R-6=S71WT%X.:5G@[:R]X);Y@=Z)@L%H^T)NQ)YDTC>WWE!2+YZGMYMW#
MDB@D^1W%6<#G'>,OQ6&#KQ67;%SBP=8\Q8=/;X"W'?CL4O?IS^D/ZV[R>0Y\
M>:U;MN($ON?K-HI>!?Y'L3QEKGOP$2"*)^+Y^'M\N]>!;Q/7L#S"5H,?1A)R
M=<,/])6RLN#CN$9\-7]I3RG<!7X"!P\KWA)6Y>$[R=_X#%@673A(NS4\>JFL
M'.>O+NH:OCDXMUCBE1!"#?%P8DJ(FQO7I0<&[09D.4D\18%7TP.\<];PM!=Z
MK3=YZV4H(0DQ?GIIP=_A40! R7.?EY:QQ.\9SGI-;"_ CA[*LP4(X0.03-8Z
MKJL0:O90_5EW3:"(?Z>76T4'V6TD%II8G/-$7$5/$(VS6 "Q -U>$,V4=%7I
M;24;RH%N\;=SE/!'[SNP+"@I0/B%%34PE'4%\ U</.X40A5X1]1F*P0 ,7R%
MBR6@%8(??82-^[UJ;*0N*:2&=-U)7>%AAM\&^'7/ YN0*H0Y4?X?<1WX59+Y
ME"7\;!/DL8UNQ5_V0N"2KUX1'PBA"[\R@/_ LM?"K6:ILNC;11]$+4-7X"A&
MX.),"66S@J_ >C?ZBX(+C%:$5&SY3$@Y]D[K4T?[+I 2>ZM43(EDMIU06WAJ
MWBC_)>4H),W"P8UBZVMX?>!U'W5]\^:3#0=-'O0?'RS/6#D@,L@#O/C]"@[D
MAIH&\-,WLOCUY@Z?H([ZZFPZ^Q,G#?75ODK_H6H#]0;TAZ%OT MP \*^">LA
MYJT?OYS9I/IX,M#FPW%WOAC.NL.^879GDWZ_J_7)?#(:](W9S&S!)DU.H*C+
MTPU]!GK2G]7)GY\^WWWY_>.?#[?__?$[>!*CGL+.68&#AI>'QGLA1J-^%J/O
MQI*8P8I\62 [P^O!5ORRB)!#2\3VR'MBDX7E/Z#'V :$96)U++C?]I 0>R:<
M+1JT*% LAH!CK\!F<9TUTY6VA<+TNP^*E!NZ1G3&H2K<N,Z3Y:&#A;;.JSD[
M:/J0U^%C?0HLFN<@YQ;.:N4\>S0GQE\Z@0<"T'O]YG3J$<,'& E"VN -"G^]
M 3HSR&K%Y6CT,P_AT)]3"WVC![[SEK<W-&"+^L8C;\)_O%5XH*??YV&>4TW]
M'DUZ0[$F_5UO/)#31&\@%B Y!2'.N"E8"5HAO]ZHP'^GC]L.L7&*G"R5A.U_
M,,M1^0CK,I4/Q"#K.9C5 [5S8A[[Z2TX^#ZA=C%NZ]G5-^W?L(L!09YS3I;G
M+*K.$14HJ7U$AB;2/IH(RD=5>Q,Y^+ FKJ<? GSEJNC4$JX1FYR+"+R#E<Q=
M2XH^*?I$G+PL19^8HD]D%I B38JTG<=8GT2D[6HX7+/H*PM P,Y.4?_. Q*7
M6V%QQRZ2WXC7>8!JI,L]>%$;/NR@68XAGR1.6W#J[V8%;,4JH?1=7,Q%Y8Z+
M"MYQW!L)@U0Q(AZ[5#'G@9-4,6<,GE0Q0L @58Q4,1(GJ6(N$;RK5S'-@I4'
MNQG8/UBI#GH3L4&X)R H])5XA?E2T9_DV*],!OU#/ 28"K]N#?V*ER'=8P$X
M5K@$ML5JA?[XT_*<H:9._OC^X28N3YKUA]GR)'X3PP5<KB"I7@F220P+EN;]
M>M,= %50&NG>8.'-6O=_O;%^P+Z#M>GX_(/P&4-'F 8W[]1!9Z9J89N,<$OB
M-:6Y-MX7KR.P5'J2\*72DTIO9Z4W:E/IJ3.N]-19I=*+-=M@UI=J330RDFI-
MJK6K)'RIUH2$I;Y6&[>JU::A5IL6:;7=/+AA9]"7'IQPI"5*NFL+Q;87%E:F
MG4M.=<.R?WWM93.)*+==NU147+D\$P.J]*WR7G!)4R=EZDQ*3!TJ/V]M\S?'
M:#MV'5LUK1DT+0ELL2IZA*&JTTH%J4S%P4(JTPN 2BK36G-CI4X2$QRIDR06
M4B=="%12)QW*P9NV[^!MB6A+!^_<J.H*$J&U26\P$AN%!\?75^$@ /&N=N0=
M^HENU&3ATSG@) N?#I-A-BNQ7TK&/!PYJ[H]"T?>R<OTLS,]<5%%LE2=YX&3
M5)T'49UJ;F#2'JI3YF9?!!5)Y2B%KE2.YX235(Z'"(NK:INZL:T,[X%4F*)1
MEB@9W@<,C0N.P >R(,":INQH?'K:%^/8KUX$B0&#K"T3%QO)(D+ (!6$I/[K
MA4$J"'&QD2PB! Q204CJOUX8I((0%YNK9Y&+2X$5OVF#[ 4L"O&+<>Q7+X/$
M@$&JZ;V+026/7#B/2 TAJ?]Z89 :HE&"II9-0@GONKDA?*1$S8E,.Q&-F&2>
MIA2M5TGXHL(@-9ST@<3!08R<1-EU5G:=%18*<>]59%.B,X%*-B62C?(N !S9
M*$]B(772A4 E=9+421< CM1)$@NIDRX$*JF3I$ZZ '#$2  ]=E#U;!JCFOQN
M_%37#])L.(=[NAU:I4B[XDRPW+'UC30\!+^XE8:'N-PGM9HX6$BM=@U82JUV
MNH3;05G"[=5EVDJ=+&3ZK53'YR#"I3J^'"RE.I9.YC5RGW@IPZ83S%=$T7K7
M%=W^ZCI/EH?V*WQ4>35GEJ>R<)WU:\6B=JGBZS^()^!]^2$@.SM.$N,2MKX.
M2X%WE3;)/\2#L9DYT@S*BS9'&D0'AMGHP*7-&#M4!D&I&K@J:=(X:" 5M%30
M4D%+!2T5]!8%/6I#0=</VP^U]N+V4@5+%2Q5L%3!9X.E5,&7JX+K:^!Q*QI8
MO'EIUZ*6&2V%I%1%=<>X?/C9___MO7ESHTBV/OQ5,MRW;U3=D&6!]JKIBE!Y
MZ?9,5=D_V]TS\Y<#0<IB"H&&Q;;>3_^>3$ ";1:R$$ER)N[MLA""S+,^9\E,
M#:@#5PWS^4O,RQ_!A+JFGHT8J;G_FD6G4L-+C6 A]\WVRG&!]_J8&H%%;T:7
MHQ$%X7NF<U6XTWQZ1T$!=-,R-2:7#VR>#S#&KY:C_\R6/Z(@]%-FB=R KA41
M1@-UNLXR[4^50XO @+@I@A!G1/PQ)>?.9*K9,UX[['[V"(V)R4H>Q 5"$M_A
M=WJ^Y@>^X\[(G_7[.AF%.^2%MY@>T3RP&Y;EO'C\G+@"A =>R<28&1[&[<@0
M_';2 '93RV*J#D9C_CDR(OQS:J"?-)CFY\B,@ I;VM2CG^(_/I/8"3:BW=A6
M*GA'*K6^:XE*PJWJ\"UU#^%72XMXB^\:RH\?$9&'CF5L=$B])8=T#B,9NF8.
M+($1  & )^QP].*[3UJ-^HX+745FUWI=VY-M_Z::ZY%+&)=!+JA.)T/JDJ92
M*[ROY!B(30P6[-XL4FU7(R"CT.L([754$9R.HARNY5%D?AY4U5@\ABZHPI9M
M+S5!TX>FK_2ZR"JE:/K0])5+!="DH4G;9M)ZA9LTD1:JB,$645:I;%2V]Q_"
M*7A%.%5;X:M.B.8G:B]N@?O;;S:!:XZFD;IN7^+^FDKUSHC*IQT;:+ Y9D-S
MS.O0M<QIX-)4;TQWN4=@E\Z @1^=]78?V]C4S?LN-;G^<37OECE5 ? H]88P
MS3+;#$BE[,.OXG$ 7:D8?$!76@X^H2O-PY7VCNU*MRP*05=:!A%#5UHX"T0U
MT>A*R\$G=*5YN-+^T5WIYM4=Z$K+(&*_OC\!GUNU2_H$/#]!EF7>:\2F/ELF
M$6?CHXVAQ-M!#W&.&'RHF)D2E0T-/"D^,TI1&_N@%&XK![;QS0%(,;^/>OLF
MS9LI<-*L'VYY*2I]T6$^NC_9[6[%-$%4-J#[V\/]K2POS\W];4ETI]V?@NY/
M/,%"]U<X"T2UNQ73!%'9@.YO#_>G'L_];4Y.I]T?\!'=GVB"=8#,-+:&[Y^9
M=O2?H%L3ML\7UT#Q*C4(1L3@0\7LDJAL0#"R?9OA]6ADY9# 7=#(#X?M6!/
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MQM<N7Z?4]BC;^,E]IM[ -F+S&-]Q!S3);1_@6ELY7.X9[8'D]@"](4I_==F
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MX9:YHX>4W 2@AT0/B7Q"#WE<#_GVMIUO>LCWG+ZIX$D=XDF1*-WM.2;%!>?
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M^CF3)7?VG1NOS>J^0&*=7KUS8&V 01]OXO>,@P/;^.; G/X.$;YGF'R8.Y-
M;=575RVNUQGP:5PRUGB'!0X G^6R*(FN=ZEU<C/B[B:6P[>$=@];V^^KJ:![
M,_E#X_/@ -PW77H]^N'X?WK4*$H<.^UMTLC.] M#:49DRH?,,4 JH98D0V-'
M,O#I<W/];P !^<T^[82_J(UF:SD="!AOQ+%/X)L<]>RIA/UF)A$ QM\'P_^
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MI3WL](>G8-8:IRUC-#H=MG7EM*$;_:'1Z72-GIJQX"T.AU+)-0&:D[8E+,I
MSVN;5^HL<@?&P@X89C' F$0%MV9/G1>FK^_.6<4ZOCXO3T\M38<1:\FB[ <6
M34:_2_R&+*JC\Y\[87%1XXYT3673'VL^ "";95V=T<@#T#R<K</.\3A_W'R;
M/SP-G,)"IY9(U3)-<AV+? @K*)8U(T^@Z3ZOLVAVULIR?Y%T6ZDLQ[FUFQ=X
MDS<VIUM<C^?Z=^QN[BO@P_>PA#IW$THW3KYUE_W[]8^K5/VXO:Y^O"" $X^&
M)XFU* IQW*D3.H8Z.6?E5,>U38TC6 \X:&DN<0,K]NG)&@>PA(D<#Q')DL3
M)<V:>:87.2>@\L2TPSP\./8H?3T?46*4;**A((15A["8S1ZYD#D8S#_'U%[[
M"$?7 U9E6!X0_[7'Y2_PF'@1$)YP>+&OA/=XP="C_PT2)0TRU#P80RRZ87?"
M\G"6@[[UMY&)-@L_AQF8 "!/-)8$L&*U"=]WS6'@A]43T.BHC!^$/V2%'C^L
M>V]M^5BF33@ !B="TK*')W!!J(_)E[-\)1O@%"CASG'9XNXQ-=T$<DQ'Q1']
MZF2@@Y"QFA-#ELP^1;]=?AN'*D-*[0A9&GS"\_I4DF*AG/3J9$4H4Z*F^356
M-;7H6DEAMW-I@=>%K3S:=&J9.F=#)"XO3F 9G&0FO,,,*S6LBL.+8&!>3=V<
M\N)3Q$A_,1[>*]?]O"X27->] 82R '6RHG)8<8I\OL=?KWFL70?&.5G4 H>L
MB^*9"8G/;EM?PF*:Q(B3L-AA<7E903@"7YII-)!%&TBJC)9(7$?5M&0E;H=)
MIVUVNI<I]+;I#H1GD[ZP]\*;/-_1?R9XNDO5?JDD"*AX54-B@> >@_T5U2VC
MZGLH#POUT4)9C34BKN(N31/&!O>:G$ ;,'ML@[B&L1\&-D@4X/UK, X&? 5O
M8#793>:.VS4>),S5<\U %M9NR5WJ?%[@=A/%5FL6*R+HF2SI&5:G>6=EI==?
MJ:S\:2_:8R 2C-I6,F]UF$Y&UU>/*7A7 72E+++/J-\J;[:W5#/V3,\T&@<9
M^%NURWIO\\!!FX+$.Y.M3][FHDRJ9+^28K'?+8C]QLK)RALH\P!>X)],Q:]!
M"W3_<C0*!P*WW,'+L\II*EF^"CKW*1DU5@[5S&$J;PEO8UM?V)["NW*J21[S
M>D.VE0RIO]##:?SU:]$,C4<6=G+R"O8HT1Y8CU,7Z])VS?8*/>Z#"3B/V<UH
MGGT[YSD/"--TDWH/,.>O%CC[; TF%&8_93DK-Z!K$R"E\%P#3E>@@V4F47>R
MH1>D$N!.B!C66Z@XWC:YJ1HYK",$0FC>Z>L$'CS!^_CIB&F-I78_MBB!+2/A
ML#M<UO';"9A\G5I6U$HU_QPM">&?4P/]I 6^\SE:% )QD*5-/?HI_N,SB=<!
M-:+3OE<VSSG2TI5W;=J_,?_ZGM4K N35A%N 63@_(B(/'<O8N+RHM[2\B"5O
MAJZ9 TM@!"P8^^U$ ;4K?C5?JU'?\>@?D=FU7M?V9!LK;Y'+E:BW\&5ZQUA^
M)P8'=C\;IMJ>1D!&H=,1F35SYZ.*X'L4Y7#;IE:&KRPJ0U=480NWEYJ4Q00>
M 7>CZ2NK+K*<(YH^-'WE4@$T:6C2MIFT7N$F3:1=XL5@BRB'TVY4MB@A(>^^
M9U\U*US9[R_5:**B3;@CCFCG@'!O)2]31#U^90>O@YL&EN*$G&IO")A]L=5!
MFJ?><1Y=NZ:VQ#F/;IN%J)0!$-50'\T_AJ1=WC0R%8I5@-SH%]$ORL"W['[Q
M,.VY^Y\'UZQUVZM+J\43/_2+0K !XT;TCP+P"?UC.?F6T3\JC0.M EE91+NS
M?VS5FNIJ&[UXXE=Y_UC,^:@YYKV59KTK-A,&T0K%Y&IIMITAWX2674XL#$VN
MJA3OI!"$-06=LU-QHR4&&T+H@L@D&S+9=17F=;1;LW?'UX\#"]BI$^>A/;SE
MVR7 W;>QT=Q[1^7=3X!7&ZMKC,632C0.0K !,^$H]=63>G2)^[C$75?S'](E
M;MN"?W>7V%JS]Z]X4HG&00@V8+2(TE]=-J!KW,<U[KHAS$%=XY837'9WC4KG
M</5A- Z"Y;_?6Y XP*ISZ9+B_PD\/]RI\<VL>+C%)C\#K*B2TOO7ILNM5Z*4
M]W99C51Q$R@&J]*- .]BE]08ZIV'RA_([HFUJ$P@YA2I7*+ZI#*EJ-$7549=
MT!<=/YYOI8Z!>".8OXC.Z4W%]+<,^Q\VV;T(V_OB]*RAHQ77<HCJ:*O("W2X
M$K *'>YN_,MZ5CUXW'8Q'G=[#GU^AOV.R?1N$QUS.23T8_'-Y=N2ZX83L)W3
MU7IUW'-BIQ5J&X?87R7'?5TKR!]1"];9M_I*,:^2^&KO!79Y]QT<AY528Z_L
MT*N3T\E7NS8A=&JM=DN8)H1-N&FCR:^4Y1!O,TX1/'*9*@?HB472)_3$Z(D7
MGK@KU39JZ(G1$V-LC!ZY7+Q$CXP>>>&1#[.QJ2@;N%7%(X<2M!2.K96U8S3M
MG_%C4.$J.Q4UYF5TBFXV8J3F_I[S6=<=G"OZN;G)$]_G.N@1DYW$0#V?GYH[
MI;9F^29-M>$'MDY=7S.7._7A@LF/)^;7Z2O\V*-U\N#PR@,,C'7Y:[KN!O"<
M#:\Q'!B@3U@5,CKQ>TCY(Z?:C'&]%AW4Z\T?]&):%MP$ S0"'3ZSY[ET9%&=
M#5>#&\.ODD<#3UWGV?38!:!28M!\^N$=O.X)?VH^\0)]#+8&QCLQ[?"(8=,C
M$\V R5VOG\98>Z8DNW7<=7O+^2G0M_$;![81#V40$B9C=K&1,J"G'M69$7T!
ML^11>P]+K^RZ%=F[Y[(:GQU\+ADV+WGG7%8\VQMSL9TUSNRM"S[H"[7G&L1T
M@(E$C3!B<DEF(ZEOL6W"'PJ>-&XCT^**/3=-+O4#UY[K^I_ ?R##O0\&QZNQ
M&ZV >6K"$H[P)MO4@ 3L#/?_!*[I&2:G(ABV<?@XOB")D:S!K".GH4LG8!\]
M\C=VD$],/XOZ( FGT7G=GTX;=85[$@?L!OOEG_7[.AE1P &:Q;D0OI2^:G.[
MXZ=L:63- M^TS/]O?O:Y3>$;L%\::^0@EN-Y_&$Z6$'3)[KFNC/GF;I>G0P\
M=G_R,%P2'D/(1OVEECS9GED\ #YP5W(XPQF_AU../6I!L/" >R9X3-I-.^ _
M>+]WYA+37W+ ?TM!@,5^P4VEM:RXH)C,[H-:WL#(W5O'\T$:3. 7O"56XPO3
MTX%N@4L?8 A?+4?_F6V?(0J <\K /^C76GS&IMC?6862Y^9DU:E]%4CIU$$R
M1J8-FG$.M[CF,. \O[4T>XMEZ)3(,'A3@"V.RR""$4U53TYU"E.-I/Z>AKZB
MU5 ^_/P8:QXW[6#IR1U]IG; GFQ0> :H%],]+QB""H/X:Q8 &?@/&066=0K0
MAH;*3B=3RYE1"KIX&?V9&@&,S*7DV;$ \6CNC.LQNQ*#D7"]I,9P%V!ATPA@
M*$/- UV%5_\'AAP;C(GV:DZ""1N#\\)P5#2MV-J$5O$IL+B:PG N CZ#N&7$
M8STD2P=GK_,9:9O!(-+2?*+Q<,H"$?\GNR]>4>E(2I-"RF0T(JC+E)FIN&,#
M!9,W#3B0W'L#L?8\K.R<?&G4>RM>EH!X6_!';9]9MH\XRVUM\CO/DHO 'A-=
M*9;G.=$MW8E+$UW-$2S8"6!NRLS!,X0G"S\G7 R:JV-=D<][L'7TOP$\\A),
MH>\=PG.2"#M08^ OWOQHZ+;_J'35_K#;H*=*8VB<MGKMYFFOT55/>X;6:?9I
M SYT,Z9&A'&]W3I9D).$]#P<DSN'%IUB'/FU3?ZN :X$MPCBHZ0]#T#]*<!M
MG@X(7=V+:P+Z!I\>#"T096<T"GTT.*$M1NMUZ%JF-P:?ZZ6LUDIA\=X'4;_V
M/)#5T'6&C=/W_*= $_[5MJQF]" .I1D6O?QO8/HS-A^@ ?!_\&IZ\4UP=>+8
M_)7?N3N>_SJMA ^S*4W^;NGKU=^:A@GTO <S>#/BC^>_9AWD?R9H>,M)>!-1
M,'H*XT&LR_!/VKI>_[C:EI_]HK1J:J]=ZRJK;4LDI#[CD\ZG#:(* V-MK1K;
M$$*GN^.(C>Q<R4J'? OY><M> NSDUZ3G8)IQZLF7;KVQVH3/\F,A9^JA(0G_
MR\"U]O0$2)(%A"P0G;J.3JG!\H<Z!8]IQ#'C/#AWG0F_,-?(%PH(5YO"+U_C
M'. >N&(EE78;C80M;6",9<W1-Z,$(W9@;=',V:!>:?#2;VY%+]H(8@?X,4^)
M KGGUI%], !=1>E5EC( XIB>%P8B\)EZ85;66# KRO)Z^X%Y=26Q=JO-F.YX
M$8%B1IU#G%Y9ZYEF;Z>^QDA&W%U1QEC+X#D.>0*_RE/X8[K@.H78CJO?U.?B
MP9*!&V ?\*N96E5TPW\3>KK?PX<_.'\FGOS@W :N/M8\.C#"S>\UZSXROV7D
M973##<3W XBD^;Y%(1$V\W$Y>VL$KJ'-3KXLEC;%80.!ZUZ-;W0448T$4_8Q
M.T!15Z)DF0'*/FS9'9RH-:6EUGKM[JK::7.IW@)3>+YC"75RX%(C%O6\M#IN
M-<*LW$2NZ-!=0KTI9::OU-5-+]+S4*U9IINEGLC+V-3'+( -+)\7X9)32/GK
M_>SY2M'G/5[7<_VYM-WK% )^T^'\9E]$GZ\< !::=V!146-14=7>9DNLM.K*
MYGQ(E.F*+/"JW]V=[7OR8F5[X3U]ZSO8\&Y;\5Z7NALC&_75)LVY2R4YIE>V
MY(T2?4- 8Q"=SQO*;Z4HQREJ*R+CV(UG.-6>Z.G0I=K/4ZX;GS3K!1S@"3DK
M(H'VMZ5252K9==24TQYC7U=G,\SG>!BA&+&6G[!;B/?/1"U'O,*L4\N*RI+S
MSU&[$O\<-T"%34JZ8UG:U*.?XC\^D[BQKA'M]+QUZ>^\"V_M-J09*5A8EBY5
MVBUL%-=@8$-!Z->CNNV&9C;&@4.0=K^19I%LKGK7#Y??'_N/YW\,?OQ^>?]X
M_>/QXOI^\/O=Y>7WRQ\/]X__O'[XXW%P?KZ.$>$031]FK@.-SL>:_12V]C#/
M>F%ZVI-+N6/R0'+],1GHW/-J[ *H?O21.67V@RO3!C]I D):%(:7:<U[T]*=
M:24MD/YP?#*83H%T;"YQ$XA4UH2[S-Y:/J YB<W)8$][DIFX1S4H@\?SFQ\/
M=S??[A]O[V[.+R_^O+N\W\6&L$JC8X78G <U$,=3[QAFH @YN 0N!_..HH79
M(QOHL*E7;+USZ6P#R8O!'ZG/F+=Q47="V!:K:N.SL9BMGISM=#[;&K]3^<RZ
M2^/&$7 N=P'K,U.:VJG2_D _\A\I;2/Z%#9<L*CO\E7G'@G\#._A4OK-5HUW
MJD["+HL/[*YH-,F;H]=^9/VM/&_GI$?HL):FQ#C9PUES"$OMN&$O:]@]PO;A
M"7MYJ<TGRK\S[3 +PKCN4@C9W/">(24131;I^^B940>=2Z>.ZWO18_RHX\YQ
M61O*Q/2]39,W>5V ^0&C%H[;\]B?7C !<6'-E5$[+WL\^X)YZ^B=O(LF;-/U
M""O(FR,SY -O2;L\YSOF=C_#*SA?V(/8_%ASRYL<CIH :?A&)_")9<)$M#!'
MNNE'[R7L@E?OIZNFZ\$D"'NVXWQ"8(-3CYJX%TR<TPF4"T(R!HN239#L-5.(
MJW5S"@B(OE(]8*T/T=SCZZ,Y1G)&(U,'Z:RQ<0)_/);!@'\9"7A3%!#2TEPR
M"FP>:7NAZ+-Z#SR.U8U@=+Q/B;/8FO&PW8OV@G_27#ZJ.1D7VLJS8R$+8N1&
M(S,6I5MVT&SB!&Z"$,G&^%!_>'%YPV]M!W[*>CS)&$;_ K!G(1)</WE7)I-C
M'5C-F] -"H#38@WX&A"*(RD-N.+RK7N8^NICDSY'$S!=XO"V+J!_I/'IT=J4
M:1!H#FLW8QB.23+P[S^!\<1O +E:HHGN>/[I,&Q\#)O\&:7'YI2]?>IXGLG&
MM&'*=7(# WB;K"MF)Y[[KM..GIN8_L:\3"GR(3<IOH56)DP4:ZYO,I6*?2_C
M\#D08P0:'JO>3:ABG,CA=XL0)?JN1L:@51&OHUPP'8U"XMDL[1P]>Q?FK6\3
M#G//B;VEHC43O/TQ]A1@B0:V'? 626;+6'AU!50@2N/T'W7R?4Z#N14".8#A
M3:+^9C/NL)Q+P#-K6YQ/-[20O&P,PX2;6'H57AYX<P'G>7%32WIJ=OU-R#=O
M[HPP3[0#.[O\Q-687+G@L5\<]R?YH#:4YD<2P4%N5Y.5[@E+4W+!O@];3MG@
M;MPGS8[ZMKV8A@^@$<:+-@M_Q?._Y$,$!<YO[F]B"% G7_EQ&<&4E1K8 A4Z
MAVRA$;N=V^;U@K/X?D5XPN4K0$SN Z-5,#L*"Z_>SR4MKG^LU7.+/E,KDJYP
MC0U0-1N2Y('&3J YQ=P,:#.#4J\1YA797Q:J4)X7'+B+Y;G$@'I!AQ#@\39K
M[D98<9EZ+#HRP<5$3IJME&"KR?AG _PZPP [ZSU'#UQZ.(8W4X@\!8I2\'P4
MP_,/QL?P<^C+=K<W$4)DN #P&[A*$"R3KN@#UYT/YD=F'<,U<W%'-GN5'3N\
M$ :'MS/TE=08@\(/K1J'=&[8$,/!K&:Z'#GPM6XA)F;\"0L8X4! 81?K\R*+
MSPRL[_WO+^W^9Q@8&]DV9\S'GWZN2^>HG1$_!ATS[MA97SHK(U+P9',GQL:V
MH*$7EX7"E)S.'L7?Q;W@$[@G-VR8UW4ZY?AUD8^+$*?%X!:;(!\>[RV:1H4S
MWI%BF/X<=PPI^R'O1>=0:\T[M0"8Z"9M\1*P"FD)[_$=-R(=NP3D>XM^"\@*
M-&%%;4X2=X%M?3I?FAC8\4#XI 'AAJRK@3NC'$\G^)EF9T@(()-EA-9;8U"4
M^3TKLL;\9*4-?,AH=%6AS,WU[BKK[0Y"%WP+_9=E:D/3,OT9H_NZAX?22)=%
M?ZW8A_=$2^_88BX^_FG@ G/IN[0BU0'TE>H:2 ['45S9QI2M(D_$LGRYVZ[D
MFP L88MS(T'F\LC%ES"DLA F,K \A\?S_Z'Z7*-8Y$13::4T'@6&C *FM>'8
MX\B>:?#28A;7]'[&\AZ!$#:T:*$P##QV(L/%_/5%#8"!1#.:O!.E17AT2%E5
M(.K@@-AI07S.UMB^.ZD,"WLQ7XUC.N[;Z&5MW58<3<H6E:Q+"C@)@+DE.5!+
M('7-7A*+C:'*[I*Z.$J.&;PY2C?MJ&::%?KS9)RB?"9;P']<CLTA HC!/J,/
MT"%!KD7^)^]9SA>%)KSBF@@A6[R6B!/6QY@'<DQ%1 .)JN,*H6_D _T/S+=P
MIMI.9&W9U+/)Q(<M"?51*J$^VI10_QC)(L/*/#\8+F1DXQB9K.6'@&]P68YN
MPXK&\/<L>Q(#*.9TN:"RS!W;+\);0(89.-.?#,CYSNK]M6S3QUIK56NM7Z6L
MM7Y]O+E[O/YQ=7/W??!P??-CAS(K7Y0/]G)1+Y&WT>(FL8"M78O:>5]HMK5K
MBY53.RZ48LMY$JMWR(Y+=@)OQY4Z;/7)41:;=.JMM<L>_DDSKG9H-C8VWL];
MOV7O]&:MS,G.Y<![=\-RH]Z?\V<9U\C6W-H6O+FUI$M\5]U%898ZH8NQJ0[)
M>^'6"4!]ER'5JT ?>U&U/]+*> %6""IIE*%C612V,TB8 '+I*;6B+. \IPGW
MOO![P^UI%M;WJZ.Y83F9Y73T.+0$A5U$4P.P.A8) :T264?"1LI'&%4GF'$
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MGJ?C%/W@Z>.">]&I465)P"I 53@M(I#&"L'1Q6 =^BU^[M7#NOE6 )H(H>6
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MW=].&B=$IY;E334=Y&?^.9(G_CDUT$]:X#N?PU^?ZHYE:5./?HK_^$PBE6H
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MP XN9LI9ARUJ[J'YJG1'60[1!"YJQNZTJB4'Q.I<$FKNI8S$A)YYE7VHB"$
MKML0@QH"PG:T$(BRBX4'514#1,9B(.,\ LS^![W*^[4>OI@D&WR7IY"B/BK=
M3L9"RCU<9A4.82HI=#2BN@_3CZHIW_GQ><UPO]DN%E,PDL)BBK1R)F!4AL64
M\HN5B&%>#EA7Q9#Q2'@4XT4AXD6LI,@5B@D]\RH[4!'Q/U92Q*"&@)@=+01"
M[&+A057% )&Q&,@XGTJ*4>5*BHR 6Y[:1_-1Z78SUCX>QJ8K<NGC[YH=:.Z,
M-'GMHX>U#XQ]L/8AK9P)&$=A[:/\8B5B8)9/4TKX7T"J30SX,."K6,"'I1"Y
M(C.A9UYE?RIB.("E$#&H(2"$1PN!B+M8>%!5,4!DG",RUAW+<3_%6^L57ABA
M'U-)Y_3H< <N:0^S+FW]I-]H-AKM5G(3KG8CZR9<O'+"MKVR#7)'/9_O@75A
M>KKS3-T9.6=GT0RC'ZZOH*0WSOI[8%.B]GBUHU_;N;I2VZF\@M43#)>P>B*M
MG D8>AU:S'IG758\Z:/UJG0HEP>"Q; 0PT(9PL)R9$0P&A-X\NA&JQ$$8,U$
M#&H("-S10B#0+A8A5%4,$!Q7I&:B-CYH\6(27%,B5>=2.6HBO!:R4A;I-E15
M;:O)LDA?S5@5V:'LD7'AR.2)VM'G9+GDGDY]RLZ!(VH?=\?"\ 9K')++F8"A
M4@XK1'B1HXOFJ]*Q%Q8Y2BU2&,=AD0-CJXK-O,H^5,00 "L<8E!#0-B.%@)1
M=K'PH*IB@,BX.A6.(6Z7)1?\+D=I8[6NH38:;:794)/;937;>RWWX.6+'TZ=
M*//MLK(N\UBN6ZB-W==Z+!=$L."!T0X6/&25,P$CIQP*'NTS9@/1?%4Z%,L!
M@>(V6!C621'6E2.C@1%7U69>91\J8@B !0\QJ"$@;$<+@2B[6'A053% 9%R5
M@H>RRQY8N!66I(NO2UP;4=5>*[$55NNQV6SDL.@C60/YSD\U5YO[U3\\G\+K
M/'([UH .6 C!* @+(5++F8 1U:'%K,T7?F =I.(16@[ M(71'D9[,D1[Y4AT
M8( E\.31C58C",!2B!C4$!"XHX5 H%TL0JBJ&" XKDHI1%WL;H4(7(Y.I'+4
M-Y:VM5+Z345M*^UFL]-J-<^,?JO7;G8-OK-5UM/2[ZA'>=4B7>M87]^(CBX/
MQ2 \T:.U4N6XGDP"V_E]OKD5^V[;*1\>T:(31^!!;.G)E>EZ?OH ]S='N7S(
M^F#JFE9TQ'H;RR@80>7D%NY/E;,!AF,8CN4./\Y4MH-6&^U7I>.['&#MQEW9
M,%C$8+%4P6(Y\B2BQW%824$_*GT<@)44,:@A('1'"X%(NUB$4%4Q0' L!CC.
MIW:"^V9A[42(M2%*KZ%VF[WN8FU(^U'I]C,63N[A,M^U*E&F8-6+-TL5F1:%
MS(LI4;4D68VYHD.7E6.(HO(Z1P?K'!C?X'(1:>5,P%CIX&*FG'58F:.'YJO2
MP5<."'13Y0P#.0SD9 WDL,J!50YTH]6- K#*(08U!$3N:"$0:!>+$*HJ!@B.
MQ0#'^50Y=*QR8)5#S"I'YQ&N9:QR/(Q-M] BQW?^FB:>A(ZA#18X))<S <,D
M+'"47ZQ$C+MR )\=C.$PAJM8#(<%#KF"+:%G7F4?*F((@-4-,:@A(&Q'"X$H
MNUAX4%4Q0&0L!C+.H[K1Q-*&5&A;GM)&ZU'I]C*6-E:/\L"5&9(Y(Q&C%BQ<
MR"=G D9 6+@HOUB)&%+E@"OQ) \,SZH6GF'A0JY02NB9"^]#<Q1W$4, @<1
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M=_Y09V*&2!R@]PC0N4$\.M5<S:?6#*3;'\.3*+FG>N":O@GC9S=>ONICS0:
M?^Y,)J;'.CKJ<P9P(W \$]"OM@40(,-0X#@B&R"1*8@0RQ8;"X8B4GX]:3"F
MCLLTVR/.**7\H.H0?:=T?>0ZD[2!6*8<ZC!Z\>,,XQ<9E#:4WVO;,'5PG!Z!
M;[4GRKTW<\HL!4:8TW8F4VI[FN^X,S*UM&*=YG&Q&JIVY53[__Y/'MU^ !#,
M,+<Y8BK._:SF^YH^#I/8<9ZZJ=85\*R:3S2=:;MFST)'.[#M )ST'65NF@
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MIU!UVK/@F%0>!^VMHNOSH/F8D.R67VXJ3QXTF4SWK:CL20[?ZQTP+8Y!Z?F
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M$<'@94UBJ8H7Y?3A12$8<EN@GOCX9 #/^D<HOIT_^"'+/*_FNK;B[\(&8NZ
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MK=WST*.7Q+?<CY2$2W:NB2W7HY.%R,D.%FK;T!:N5_M*K95V:) ;\ZO;QU;
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MD]0JFNAZ8P58(CGM+UFY</)<^YRTC=&!$:)DJ!N@4AZBUI=&@D.?\$WG1KN
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MG%P))\.VC$)N;P^BPS"I2]OA<G%[$!.%K_3UED4NJ_U['"9K95]I+G(/@J)
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MG):)9YG@M0I5%"QY?@DN$("HP2>7).2J)Z2Y>$ZF*&;K8QT\I^<:6P0XH(<
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MB!HXL3TT*2^@ENM?^H;E;U[T?!K38VZ!2!)F!Y9UUM/1<Y'=YB#K.UZV%:5
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M)OL-5:?+KR.$&J[?'3>$4) CKCC[W?).%=<&Y2I7HL7A #V'2R6X&5?1CAO
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MA*!1;<\/B@FS$\\P[FHJKN8IL\HC/%LMXL]IB9)3]%#1AI?&1BVTQ236#)R
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MHK4-CACFY5T<OJ1QZ^E\$@2QXY^A6>RF[O+"BV"'4F?C2VEC<\#$HCTZ[I_
MQ]<;Z8P%=Z*\C05WW13<J44\D <WT%F\5NJRR]6A-9(:ECR_'YJ\FP$+YFJ(
M:"D,8[VIDV#&6E/]_XJ)%\X\5Z[8LY&4#GGH"D!AY+FGS,T@2[@4%02TW@]6
MSU!%2UG0DC(:?9= UZ[>'E\.;F6;@E;N&:PH=>A0X"[!Q:TU1$S)<"53A]I
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MDM:%QEF + O=(FE1: W;R-IRFAK"-D@?&1LR)3\%P9ZS0I3HZ^!SE%[";7!
M6:>83,06 3)+O7D-49;23RBU])1^=/KF+(^\_[V#;K_@3!0ZV^>_22D.3 I<
M?#X%"93AYPS&&YA'_9(V#EOC2HN!I3!\]81?7F]@Q,=$?FB.A'STZ[LXB[+C
M!5F") &Z)DP^_P<\UKDC.IGAI/B0#>G?OAKX\NNZF/3WZ8Q*?J*K)QB??KR7
M)?8K>FR81P)3?$C8="NMT:QRW[]S-B#G Q@C0#C]Z^M*H+;\JR2L21$D82$
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M6?4GA9<FVJ0-(J0:*P<[C&><9*?DDQV(R'8OS7;^.*,NQ-A0OPN#LY@*"]Z
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MIP@A%3=2IZV/GRHO!YTJ2I;YQ.*1IVFCC$TUO#1$40%FP1PP[D! -Y_B2@%
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MY'MT"HIQ\1=1FA[R#W'5 04$&;B$(2LZ"[XY.P$4#/9+;]^<_>"'$PX9 I9
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M6DHJ<G/P/)D:Z)89*#4/4/55#TKNGO0M,H >FRM]>3"CZER H5P( ,Z/@(I
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M#Q:GBS@VT;A#VY3.HE.GZ=0F+69X_0'LL96/IZ?II2#:5::1/I$5X*SX@T(
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M2\*V45NZU:":P5S']::(N3Q@(,14K>,N!\W%KP@#-Y,$%\IF!@N!&Q]#"MR
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MI\&9KR497.0$W)!P^E<0"#>Y&T%$YM&!()L?3FW=D+ KL!9O-(TK \%.1*E
M*18+,Z)@8"@,&9WZC(;4#]!6XS-ARKOMG.Q.:$NSR3.T*P!40F+]>R:)MQ4=
M%YG2WH>A3@#PD()\4C9JZWEB [X/G^'F@.!Z>Q7%409OHA=:$2TCRH@>45YA
M1;E/E I5?3SDN3A(U<EYTV9XG#M@[$'%OR@!XU47)PV\L;[&EX,ML@^K$W]E
M6_V0+!CO8 II@PHRV5[2<OQXKU>K3Y*@/I)2#%PDW%S?WOU+L-O_[5*B+MR4
M+J@&(=;2Y"+@RGV.'RI1EJ#@R5:H M?9*OOUQYX;K8)]4O0,KI4DZ#NX[AL)
ME#?>E<M3@17KJ'<)$"*+Z#DZJR);NP1N!E3R,XR>GLE.>$5"?_ $/Z9P>T W
MT58M2]6(C\GQ@CY?!P5D. L TRS:L=,%1"1B":I[\D=O;BFM6 6VB<*2+: \
M5.*"C"UZ"VE 82U<'D %LG*0)!Y;K;=-9;A8)M8.RN#G/8Q32(T^J@8?,.:F
M.;8_8KSY%"&T>DQ9(KA,B.KYHF8&;9.0DX39@HD/.;&]*L>#&AG.>!V#-S9;
M*RH0,S6# >).38.=);;\RRN#D0&Q942C^M0RK.HH9("1]!&=,DE-(Y-GX<34
MRH,<^K[&>[/3@!AKZGDA</:=M98AA)X0:)ZU^CC>CO/'"88ZPZ&/".QU?-HZ
M^0GJ)S_F2$XWV]5J&H^ )WTFXM<0T9RCL[IJ[0++5UF;6O^E(._1>>@'F*EL
M;%0I.CE0$SBX"&[2^T=/SCZ[()0[_6PI<AEPR9V $K9>>ISZLZ)16DY@LYA5
MV;C@:WK8"7^-Z[VC];\WDM*B[RC)N=4LK_/ZQR^DU8DG@I;\JY>Z$RQ[N+G*
M7:VEKOJ7(F8 NIQK#JI[00 KN:^8AKJ2PGR&%:F]E:B[)8W]]-B.>7$P,]83
M9Q3QDEYVNEUN3KS,-+UA(CZ9'.!&.,2Y(%^*P@!='))$\M6&+"7-@\11RDZ.
M@W.NM$UT=<P4YHQ!R#G[<!(L#R%64ZC?<#5:971@E-_,6BB\,=&0RIMU;GFU
MU+:"(<@Y3CQIOMOM$3Y"> ?9_"WTIU2($PK$],/S*''[YG<;',EG_+(HX6PE
MC6^J.50>/JRL2>^ARMVJX 9R=K4FJ_-X5>[IMPG>DDT1F78"= 6U7&J,DM&+
MM@'*+LI=/ 7<E?8"2\_\21(XK*9&OT%JS$XB+T"9S>1#ZSU,R)(M?F+%.0J?
M/FKXT!@E?7B&*=OWH9(?0)0A0$*D.P4I:Q)':P;[X4R2"&(U??J-%FH"Q7B5
M4])Q+F?*GF&2>[C9&F^,D@$\@Y0=.!/E1P\L6=CS:QZ2Q NK:<]O;) (2S$;
M*:WEU"=69W;6K,HRVUO>"[*!"1XQC48O<)4D1#.\NA79?'X@AMCSUP_DIS1@
MI7Y,WOS:XV[C_:@M:=SFM=6D!**8[,"@*:CX&T 4U=?7QM8MLO-5LEVLOSSK
M0W,;GM3YW./C3Q&\IF<O\>9CC*)=1/N]XMT^B(_NG@MSML9'\+LG&%_'H?Q#
M[,ZOZ9[6ULBX.4FG+ #AX<5I>;>V\8 Z/-)L\QT2X6#!>QP(B@0)*?22#^JE
MQ$TS2,)+>OL<)+O K8)S5J8N?KW;'6+\HXZ;=WU5TR#;I)RX>\GFQ!>?'U _
M'M&-9ZIN9+,57,R=RI7 2)04_"@=#.3\ZG8;_0X3=:=J?4\3Y@8=)^[$>?CB
M2GT:QT,:\4F[=0_B+,S=QXFH2)11SV]LU9HVWI'<Z-0^L<O7I'"R/3E<E+^V
MM1V[\:WJBA/#PRZ!_9*,#,UB7TXBV!U\@?%!K7%H]1U]4 L:+E*>&&4__+2E
M7MRG E]4B6I:--[@?3C0>;EV=H?CU5,"N:-(+TQ'Z6@NI4;H.EFX<I[T-7TH
M<@5!R=:'!:TL<EA%DUI%&VXAT3?1WA-<;S_ C*SW\ ZN$_(C;^B=IRT]8.&M
M,\U$Q+L=^69$&S@S82YPJF!QEKGJ+O5M2N%F&U9*2"TZAAG@0@*<L#\A)F>9
M_I=AL!&*$;*\U*:PY)/4#R=P8WK8';A3-)A\(/I>;X75S.ISI+2 Z"&@/P5V
M$IQP0\',6/PSOX-G38AK7_)C53(,();2JY=@Y8L7RH'>QXF(_$*Y3%YUL;5;
M";HW*.JUAI5)&^10JK'Z+[_K38[5- =LB,7"H"^NR#HVU$'O%MJO T!U?QZC
M9/_\9')O]<,))2&3. RSXV)3P#-V8&7)?=(D$UR'_*GI-N2C7^\H4]D58^,+
MZEJN$7"0=D9W06G&WI^]AT%Z2#RP]&XMXTYE>*'1XLR)4K6R4),W1/E W?J*
M@>I<A5Z_S;$=83L5XHE>ZT8Y77Q\'WR.=H>=FF$VOJ2GPAH1^\:9DY_?&+LU
MC'N5X(TV44V1DQIE%&L89?U+FFH4B3@P2D[> Z/LU##N58(WVD0U14YIE'2V
M8_/;CQ _)<'^F<Y[*BO+ 0)ZZNTEZ*#.IL!A?NL=AP)+:<A+M:-J<<5W2R*;
MZ=:K]_"I.<9+O LBJ;IJ(P0T]=Y'\(LW]U$HL)2&O%1[8>Z<2\/8.2,U<T\+
M>T]A^.H)OQ#M'N(L.7*3S__0M/C\XU\K#0S>V J_K7'36G[;ON%^?'4_\SUF
M6Y&X/>3YE9:;W<</UP_O+L']P^KAW8#FY#('+B[_<E:F("BF0G=^5_,6OX.6
MD[OXBTOPE[,JC\2'&_0A"/"8>GQ3=^V8FS !)1?S3&EG0A>'OZ FL+6G!O<P
MR#($?X0QS*(PU76W,3*ZO38&R;IIE\)9@J><IU_^* D75M"?Q]#4#D=S7 J&
M-IUWBK&@L6%8<^G+* WQ"TR.NL[<3T#35OH(.G'@DIE?GCN*"I92EI<(B'Y:
MJ=^B@[H5'_5*/E]B0DRK)Q$)R$]IM($\'_?\2'.C5//U)(B9W'^/$'>1H5"P
M!#6>X/$(*%=?$A5D(<3*VO0>+C2"U#E':IZTOAX=4('D3^04B%E'JR(^H7-Y
M[UD=^(U[5E.5WF,UYEG<K53/^?I6DE7B^AU\HBT.,)F"Q13V]Q&":89C>!L<
M6:J?ZE)3GX/N2DB7HYO%JO"8(BG%:;RK +M"(K#/1?)B16ML'=@.)LNTA-JB
MN1+E!-S5[: 2!Y3R@$(@"TOK>;6 6@H0Q[\:&_^4%]:W"=X<PFR=W,/D)0J5
MLB"[OZMW@=1%RT'Q=\Z%F6#.:/Z;NT$(\)AZ?%,WJFMZG12*GNY6.N=-7P?D
MO%.U6^D! D;J;A/\8YGX ")82E%>:K]N\?Q=2,''VJKU'A(5;QZ"Y FJ7V.T
MOZI]/MXDY>BZ@K(!&>/CPZIP0/MX1#6>:;I^^\#4S)G8N'!P(S+JD':N,\R'
M:$=VJ.LM>^BUI;4%:-=FY=63$CF#9ZWCY.U;%6=*']X7;.G/E#%]?N_%E*2#
M)M90ZP*00S70U@)HZQPTRRLXVRZG?KHI2= 9>*Y6?E^.X_6?>"JH=A'XJ;F?
M3J:C!0?,14K@9OT"$R*KPA,U"2(&0/41=>!<%2M [U,!9>:),XWB@Z55YBT6
MJ W#NH#!8KWJ26IOB78U7GAK(8-"M?'4.P^0\:PLCL?# E2U$YA6]2G:'"_*
M4N/R4U^DZE!+:\1X/E0UN\@$2/_$Y2O[03Y@(!ZOU\_4"Z5=#"M-,F&[O)4L
MSN?O8 BC%]H.X^.>.%+X',$7\AL*EP[R)=\<<=?-8G8AC9NT\^HNN;A>) Y7
MR H.>QIC"VE%_SN1N;+TXJK2K6%B]Y!K55X<DN>6Q=G[/8JR=7P?($M^UD76
M@0.UV<SA&7RN BD5 Q G2:D@OIO[ / R=MRG>2T#;=TL<SYP<T7&DM>P)1_A
MISCZ'6XN#PF1BDQ^$=Y(&ZL)"TW#U6?IQ(C?MY)'<ALF2P-J,^1/3"3Z:2X3
MV#"AP)Y)Y8-%6[ 4; D>O2*X.:_U]O[PB**0]MJDS86E[;B?@&YIVAZ";JK,
M%I9'5OEIR0YLH1_Q<A0=+*6T*:JWDO@;0KA)J;%6VT:<*-VE#!#1/]7H)>K@
M5>Z>@%=-RF4\\^.0:1PB+*TU;^&H;O(9%T#9@!H?"V\J_=U"]:1,N]@_?=%Z
M1"T5EE-%)2.@0H)22J"8+.A8@Z[V(HU,I=I.X^.K^U=\N[',L<G!GH^:L0?K
M&-S;&?#<Z_-Z :O&XEQR+EO".%%SB V,R3Z#S1JY**"2!7!A )?&PE&NT[5N
M+4^HOK@EJ$;>RU],Y04ZZRT0AD'YV&HCPQ.2U-O&E-\S;!.3TW'<%H;GXGFQ
ML>E3?+/K2TTQ6AO<!J5[B&"80?ESFM[OVX&\H#<-]"#-V7EH RUD>FRAKC&?
M'*_[3CA7O;TK8*LRMZY\'QR):]?0!U5=6KGG@^C3/;@?E5_UGJ5GR457LQK7
M*X/4C&]5!J@[B9)7A^R00++'+=?\K6>-PK;9A\BIAFO[]F14PU8N38K%M/:5
M2$7 TH5'07":ZXQRQ^2#R8R"TW<+4=>9ET ,[EM3AQM7N\/HVY:6NU*;1RK.
M@VS/063[Q;@06Q<UP/914>^!PO#8Y*+KZNDI@4]!!FLY>4*SHM6.5LZ4#K;2
M]#1=7I*^DU!<\FXD9&85=Q P]CZ$9E5DL8Z&M6;T=VD6[6BJGN;=<._W-6VJ
MAYX3&RIY^7@O/ 8,EE&8T7'**F2%>DGD^QA'&B=GK>\;;N0;]!P?IP0E-W"@
M['RPB3%DFL<IG1JSF2VEM+ETL:6<>B/9N_;T9=^HLEM4W2-ZN2ZHO?[!68!J
M2X!],OJ8SKL1Y:O.:H53?Z(A< 6<K?GXG,ZZ(D*]4Z[G8T!-\:5OJ;R8Y;K/
M4IM3G.>#:)VE5ES 1SOR3[IEGN'^W?K6V,Y^V$YZ8IE60%_?\GR"+4YV 9DP
MU\19GUCX?/=YS\[=B\?#][3MX9:'T_LL2+)+XMZJ]2%L<];/O+,KB7V;S^6C
MA>9R"8$@(JAD/ &%E*!Z,"\*>@*8J(#*ZD?NI2/[PV[1_;)L#=7,;-3*6D:V
MKAN98&/S5-4PUC%/8SJ;-)J5/&>TK5P&9Q&L>+'"K(2EV>X%"\-"'$OSLA![
MB82RQ82JIEG9#%(UZ+X4$[(=F'+AC%:*#4WQ;/V8;)_#[.<H>[XXD)7=#B;O
M/H?HL"%"K.C3[I0H*_CLW*]^+UZ(A;7.\T'5>=[TMJ7<R]W!%!+?><[KMR@^
M\ALC8WH.WDG6\7%XDO-LQ"X?SK<D46N=C@^H<8JG4U+!R/HD[3Q\SCZ]+F@Z
MU9XK)YD(9YGE+![Z.0R3W>>7/3%R&4-J'6<6O,HB9F//'YQU1VFN/FZBX#%"
M4794B8XCA,PZ;?02=E&;/R^BE;^3]R/<R<&$E;3F-21"'A#E!"@K4/ ")3,/
MO(4NT;,/4"I'2(Z.76 *NO9=A5^%@0V9=MB^(9#K #>GS[3 &G&9NO)\!F;8
M81@O6BW,//E]MZ/'B#C\[?XY(()>I^F!O2R.-V1(A05([^6DZ6DGP$O1=U1/
MB/(&*64.4L8=1#E[<*#\_>I9J8HMUM&Q7CT5MC3Z2 ]"\$6 0OH&'/X,HZ=G
MLI):O< D>(*W"5^Q,1&D[4^#LFX%%E5.;DJS,"G (>7E%<-"$/ IEP0$7!2>
MQT&7V-QT?3!0?3/ 9B!H&>T-\8>/>\[Q"G-R0B8)<XYZX=%X<\,3'-3CJ!UF
MFJ9M@[D3:Z>"G1[V^481D/TP-^9:PA*/Q(TBL_$&%,DF7L5HJT:%K>-GEA!]
MF\!==-BM8S:!T,.2+9]0U(^&!TB9'@_WDG9\1+SG?&E!D"CGS IL,=X^V*8"
MCJW#XA&E:A;$'#99Q6Y!LN2T5ZHRY!TM5!<1^Q3QQ!J*70!V]2=@3>!RSC:[
ML4\Y.-0UKE77N"R6ME_MGF!\'8>N4&+T:=%NX_O3'Z_NBF9JBL&KZZNZ$V&+
ME)N)C[ !!1\?PL^ ]O&(:CS3=.UZ152SA:L41R(7UR?@1W %*H'5NYWU/02E
M/JKI6YW?U7W(T:;EYC$GBTE[C]QK" $\IAW?M-T.__9<S)G0J$M>:QY6/=_0
M78 /4-#M)=E'T4WSSNH!BU?KZG%DL)R^_$2AIV"?Q16RXP&@?MGGZO99)"^0
MI;G8#Z=*%2SNH1YPGH=RA9-U]DR@.#\^$$VHO_>PPM DI<>" "Z2M_(L$KKY
MJ_7]J20[ >6M8(:+O"!V&,KE.P%4/C\N;>T:%G:"WQ=A1*AA/ZM^^ZG,YZ$R
MGZO2?,#YD1G07,\UM%5*A59ODFJ)X2Q&5 GP7Y'(823J,"P[D:B)WQ=A1!8C
M$0]#JLU@>S8L=_")5V%^>(8?X^B%,(BRXWI[$:"(,(ZC0''_(D]0<R$MR\#)
M[B9GSBJ&/M/\EH(__:22P(<-CS*R6$O!BT"QUFCE N3,S?=$TXZBC"'<!FG5
M5V*#%5_6=K7D;/?4D,4>DZ/#3@(F)UH=!!T>(F+*S;^CQ"%8L)2VO(2@?;+(
M6-D^7W0F/^H7W>*5WJ1IGR3&/&+A3K;*^CP92_M<V$A1;8B,*>!<0<$6,+XR
MIVM.MH-,&I;!I[*G$[^EOZ:NJ+BXZ5>PJI-F\J8?.ZH.;'"_]OS!H3A_99F#
MM\;ES;I:ME593X(_NX].+P$Z"$EDS*#@!D2TJWH<0YX?^8F^)+ 8L69*A&XT
MHM?+@E[LZ%%MX)0]W4*7 H!" I"+P.V<[K%Y@#<?N#])PJ(E]&8(;Z)TC],
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M2T.K,.:AQ(<H;V01[;9/JF L#OV>UDUMZ$^&L;?9VVEJ':#6\(5&(X7E?\"
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MQ]T>? &32IKSJ7N0E;MI!'6*C5R!OD=<V"R3TPF61!&CBFID1TS,XTEXKHY
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MXZI'7&V']BE.L>MLQ_B8TS?(8S2\Y3O*+:;BH'N/*;@ EO?0!KLC\:$G\*4
MVTI]_.0^]1%F'EVYCV'%G&G%%WZ4SM,T_='ZHKU_;PSDX7*M\-9T+!@+;[?
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MC9*2<0C6XEM'20CLAZW331 KN*6LLY?1*)\XW;P^LFF8Q* #@]@O^+V#NH\
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M_ZX'YBX)%N=$)X:<G^UO>EOF<\<A%TGX@,E%XOU_[AI^Q*LI],UP(DMFP4.
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M_E"0!# XNIXAK+=%1PZ^D$R- MG/\L6NAE=88VX/PU+O5T.'K*H:*5"3(E8
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MCK;D.A8HZ-M$1ND\RC:DXH?_<%%@!?;KIL,6Y2.L>-_M,Y) WV$3-E(\%$T
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M(GLD1Y=F29-3=473G_%:K)@4)\&!5^V[]2\<)'EN]]9*H+$,F/3 \[W8,+;
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MVX*\WQ*)=H.Z;+):2BIF<TW$!]X@(BR3B[';9N,@)F16S8 JO94OR4>N;7D
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M(X@[FFJ/MF@M\&I]9NB>H-UQN]6]'7LTXVNQ[ZI>_SW6EM8"LSV338_NCI$
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M$P5MYM-NRI#^BS"RTGE_61,11E["Z(W\1BFM_A$M:?X?3MKTD<<"N5>I[Z_
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M5*^P<Z:&^2,2.V<>:=I;#]8YL\H862"D>5'M_@]IR<J\?3(_:0=JM14>5_@
MV/;2\PZH\Y/@2D\-0T-?<=2$QK9/K4#CLY[O>IAPKG2)LN;C>D(DZTW9X-LN
M(#PS%YR,'&@I(1#;%^07;1=%;HB*G'4HA^FPWM-Z/FC[":/"X% QAK.^:A#P
MJJL, 2SZ^Y[H?=\=<DF$DR]ZK\T(NIR>F$X?73I<<4:[,[2EM_8@5\$<ZX]W
M5<8#0]543I$E)FI28!C4TOM.3V0#BR94%<A_-9T>A7&7DYW'EL+<F=V;V32D
M>S*@32<L9>TWC_0V6O4KUT&YX0QR\[SIH>&TZ>S69\/I(^D*X/30;:G_46!]
M;%0^"=>?O!(R;&'T=*JJT<4[5S,JEN'$Z.%=WOT-!;$8Q$8#5]B4_=0HA!UT
M<&"9/8:ZGIXRM<_YRCJ,#&)S8?;>_O?TS*CF"EM:GVKJ8%<,-ZS0;P'^)Z/Z
M=0&_L8HT ]D(% 7]Q$\_&QV[_W[BIRJ<Q*-IYA!&B/Q%^$ 4X)6EO*N#R.@'
MT-X!-"W3YV&B?1X.KS\"L(? ,PI6KI]L]N^$ WIB_DG^GF<28G2UZX!0'2.<
M4;Y!@.+)')1TZB9P.'6S=:A@6[=[:;C2,[Y^7UM$@9-:(%^$M*GKKU]=?U,[
MN6OMY-).W/6#0BL/<I!2I2.FH],R4BYYU:6'2ZCV, >Q ><D5C.8@YBI>\O+
MFZE[J[3N[=[;&BJDZKXW=5)-G513)]74235U4DV=5%,GU=1)'6/RM*F3:NJD
MFCJI(\+3U$D]O#JIFI:MZE@GM>Y9S&#3NQK/@+48]:R2NF\9:JS%J&FBC& M
MQA,]4VP%:S&:PDM2"B^U&OUU+Q$+=Z:TXU=5N>[H3$]A!G>P88!KD-7%UE/X
MZ5!G[>B+[CM[B$($1_)K)4T6U?U"!$>F'I*R0@1'IN"1.-8B,6T,>),:TG,!
MS&/-71ACJC%%5&B#M;)J L>F?$P'J=T>6,]P-D*Z]^3V8\VM18. 7)MQPU W
M GNP'/?C4R._%:1?'Y\:\=U_^O7QJ?3TZS4.7<KT%M!CR<"^"%P"A?=]0[;"
MTU^Q.Y]?XA5Y 6Z49F)WXF+\&=EBTS.9V1/-S&XL>L(_DT8RLO-7[_$=)G\3
M7'ONDH[RC-.'M91TU@;B)E,>L'X<^O45^6ON)>.F)\1MC:D&.12IH@B6C9>^
M^V_D7,5!6@L+DC7?90A-,^JSBJ:$0HX%-TM5GTX@JS^WE><KTC4#NI:.J3DP
M^IH#M[X=I#K?;'&=*9@5GI-BB=T5X,B+$1>[*5)U@:9Q%.10T@+PVK)?N]0@
M$* L-(-43,\6]SB_BLK>+"#3?,34Z"+";1NO4&@'[CJ+G:>@@XZ*[)$UKX?1
M=# )  ")VT*G$XXRT)-?0V1&K3UXN1%D:/=S4\-#3@T/\8SM)QOY%A&A1"(@
MVPH!J=%-7_?-[8L?KI'M+ERB^H-RY!L(],9SGF.9CPU)BJ_Y6$QWMVVBL ;I
MJS!Y.:77Y55F,LU>5="Z"3"J0IP_O[J!0X[-#8Z#*->^@7PVTM"GRD -KU=!
MO#Q?KSW73LB3\WKY?'=^!F2QA8J8-AB@2_);A*1W:?D.35F&;L$F$GV=ZO8&
MTBTGNX% SSS/@FQ B""J_E90#F6M<W;U='!=J59"IJJ4#E6E:O91K>\&N(U:
MZ9@*0..M &0JCIF*8WU7'.OW'0HOU-1&R=2AZLOS:^I0F3I4I@Y52[B8J4,U
MPA@^4X=* <BF#M6 =:AXM2-3@JKWPC5ZUIW:?V T%JXYT?.DBA:NT?.P"1:N
MT;Q?[#BJW^E9/JNOZG=G>A97Z5;]KM4TS. SSP=3BNJ02E%]U?.\=RA%U>I-
M9-B9P][M^J[V)F^?[2_:X=OJ@\>MH0&L#H:^^G1[: 7F"/Q@M17T%'0PI%HB
M=QA8>DLVU67.CS6N7LN_^1I#[PJH-%5(8% !HRD9>'J?V_XUDII VRV5Y%@_
M@-L#E'%KX'2.T8G&-VU[X/D.3KL1\0PD<U+'6L3VY%3/VUII0=#=%!\&KJEE
MVQG<QE*?)V>FVE.'.I0MR7P,9;UC&,94-?CDS!36ZE8\3FYB,%L7Z:6X)K$N
M@(QU!K6Y-L6K5L(K&A2X?S27J3#N8N4P&/3FANVY9/G)1_/2456R_.23GF81
MI0IC;>6E F73*D5A8?B3KWH'L/6*=E4Q-@:L$<PJ*NZ?'AFA+(QSE]J,; 'T
MMH,/78T_K>[)T#95^ >KPG]Z9%23/I3MAMK#!?3'YBG99=\W%JHN0-8T='QD
M729.SXS.W7^7B=./"O22L;28N%VM8A\3X7KKVTJ[2D ''G\C">X9#5:)]OI]
M36,5MR$5*2Q;$))2.Y[\ U3GNO9[TV^@OWF/HX?'859YM\+7;*O2%J[(CB,6
M+\S-6PL54T=73AW=NMKQB7#_E@AW8'&YJD]-/;D#JR=G:GV96E^069E:7Z;6
MEZGU96I]#;0HIM:7 I!-K2]3ZVLT4(ZCX(Z>9;_Z*KASK*=+MEO!G:KG,D-,
M;WEXR*ES1RK<)AHZIWB,>PQCO36J<022'GTTN2T*O-E'GZ1??V\HF./I -TI
M)NGHD]YWJ=+XQ\(%6:#[V20/R<];+/S.#&;IZ:%K'+J4Z^?1QFP\+-Q_HT!U
MP 9HU/%':_!-1YFKH2; #NIPJ"%C B,@[OHF]27?+?R-P7G)26JYO*/=TE%+
M:<:)3 2'0P"I=YI)1HX%MF=#@9FN)V1")7H-E2@D*[2'Y^YW)DC"!$ETW?<F
M2*)OS<4$29@@"1,D88(D#L^&88(D3)#$ 2!H@B0.Y,2;((D^@B1.]$PM[18D
ML?=69G"9.WNT$1*G>J^-$N]]O5F/P:RW1J6X/"N7R9=A;T(G.A6ZX/$4L(YS
MQL<\7/B$*4S<?UV1(Q6E;\?BUG^*5RLKV%#-)MV,^=EW4=B74Q\PYOA=^CR3
MT293_@_//?).1I#[OU?M3=H4*RCKX] _I+TVB@ 2$?<!-\G!KUOHY 7";8^D
M:XOKI*+C4V0%T5C4%@$<Q71O^17]\L## X925*RS_!Z]GX]]09HK \P**#\L
M-CGKU[XS2MVY0N-3&APK./[X=6KHQ*3K9]^M**8[^#OY)<KG/PG#<E2U:LI&
M:S-O UW>!I,-03U?+9&?=+'*^^X"8U'K"0CQ<_WMYE&0DZI/^PHB;6]2W!))
MVD"@9YYG038@)/"U^ENA%7XB@LAW4A_)"[F; WK)XC<4;/8Z@W,N/("B$,<W
M;A!&,AGF)R@FJ:\^'XNR5OFM"0F6/]]A0H)K=LQ%X)(;V/N^(4_ I[]B=SZ_
MQ*NUY6^ NZ>5CO@=!<^2V/U,;.PP0N06#A]>+:*_"S!1][T8-_/Y;RZZ#9!G
M^<Z+[[DK-Z+=XD36BHN622S1/;'$A/<;"[PZVYP)PA]K0!]O2*Y^^/89DJMI
MP'VWD%PNS4/W0/N.$-:IE<P_9(+!*V#;>1+H'@O>#:W6UQR#3T\Q-\+T-_TR
M8A2FOVF>5= A_:W>]L? T[,$JRSP^&VZ#%'I4G-D5?VZ8@HP[#-0I:N+(P.U
M_V=@M;-G^QXZTTX0M+K(<*OGC@7CZWG1\'D^<8,_EB&DYVT"0ZC>=\YP,IKU
M:)-4S_2T3(PT@T]Z%/'([O5!:TTW11I_E!XA:Y"OKO*MI]8PO#RICE]EE9$5
MR'$UX=]W1-GP2X8^B9'=(J2'#MH&\2P2C_&R)EO<C[)QL@KGW!$8-5\KB;:R
M[2 FFYG%JE_&0<#)/ <1*=VN0W(=(2(,'.IIWKNAKLB1]I</2;(%-^1=AE"Q
M+N0=8"/DA*EO/1>(. !%AC40$8O8C.=>ND=O$.*/\-[]3,J>2->K4Q/T,@FQ
M**Q"C @B4T] +#[5<H/?+"].7E&K%?:?(FS_>1N&,:"A=S,1-3$UC8T,()$T
MC83$2C6CP*87UC(IQ4!?\T0R?"?_(%>5Y=O)\LWB*(PLGQ;"X(8=3%>(^^TK
MYAD%*VX&JSX5.S6^'UM>1FYGAOPGIY&(V,JF,YLMLNL8Q$_UQTKB]EZ)PAVF
MY_,A(("0G93\#!1^5T]$3=Y-(6C*G$!F4$NBRSFANSPKVP34+^H)"/'SB#>6
M%VUFY))8)M3"FY@\9=!W(B96\2I78JYB_ML00G(XJ5]Z_^4ONV=,H*1:^PT.
M$INI6,Z5G/&$5K.J7R/GJE5].J6R\^/(=*G-C"PG!/O.[K,3RA@G.1TR" XB
MZV+<V3%E)WF'Q#F3,3G:C,G.^8:B^84FL^_@,_M2&2TDV$T.V/ASP%HM=N14
M[#R3H7<$!RD5IXI<XGB%BE8?=Y1C:KWGWB&<A :<"U1.-)(1VC<O/E'.@]"-
M:&E(RW/)\\=WK2?+CZP+*YA;@07</?P$1_[6I#(9OM<D#3AR;"XVE%GH[I4T
MH-H<V2X+*IX;VWW4 7>04"IL,Z7!0QDXIUJ9^-I],:>7\"KMV+7VS0;+']VS
M8_NY'^2L0_F.U#WEMA\=!H/U--WS<M4(GT;5?2H9?SS/H';,]@3 L=ZW(M]#
M& .>[PPY/9,R^CW2O(4S],R8ZJV7G9Y;44;AC.EFW_=Q$W-EW7_2%ER3=3]T
MDC-/3K.>PK#_>YDGD_F+=KA*S636MXP0?YYN59S$%'*]590.^JCO!NNSO-='
M/:\$E87E/NJM-G>N!L09ALC25PV>XM65/NMYBT@ CS> N(#RJ[E1]D5C50 Y
M0TSODSM:/^+=?E&18TWK=O:2[I%O;DA."P-:[Y;@O0!=G][$8#5N< BLK7EL
M#%B]_:U] =N0XEA *[\'I-;0-F2^,DAU;T_: Z3-R<T,6NF5L/2'MBJ+O0#T
MU&@"\.,/K5O T#8*@L@]UE+4@L%K[C+P9FZN?<*@-8(7?J?5EKHI8-6\C&8O
ML#;5-"J U=2UTBNPM;M4?A5,K<'DJ$560/O9Z%^=!0"DD!T#WNQID3W=4/>P
M@/:+]$MMC4.7NCYT1;>I)&8!ZU<%9@4UI5JIHNE&N4.,8D5.*/)MLILD5FWM
M.,K0!5Q%V1?)?;Z/J5>,O #2LTS&(_MU17^R(+LQ"*ESS3D/K\CF\AV+<,23
MT2A*646^YAT.0P;IYCJ,7((B>0,]D+]PB2I)?X%GDD""8I79MFF?^^$/%"1[
M(G%_VI[EKL*+S8-'31#N8G%#)+._O"+#<R]3ER$DSHELBF0WOZ%D0X0HW.5!
MVMQ@0PVP)^G)(-LG1[S#9MRC-,!L[JP?8>Q&L.7CIZ5^1D0,[U_EX+EL4Q&M
M@44+O%--S+/"\#R))<D@@M?$:B4E6&>47(H1N:RH*IZF;@DQV$JGK]HV=P25
MU+U^:84(5A"C^7LU'$-J\51].<CY E>-J*.@JIYKC;K&=#J1@A! PH._C<2
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MV_JD5[YX:]#O?""D^_XG6A"A2!ZSP!88>]_UA@A:QX']:I7J(F?]0<G+/=K
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MA% 63N336]!]$SG[()H#[LT$/K(_[%=$6(:?.!#9<<QSY@.J3 J153'/[$T
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M:M@(:&U@4H_I%"/1](0Q:XI'8["9D\MN:?ZH1)8D8@XJ#WZUX:@,R(G8:*4
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M__VWO_WM?SOB1MM$)";O"L$[0@V'*B"]%Q3L9 CH%JC) '"H?]@1^[W]WDW
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MWWO#:%J(; )BKTH%!Y5GH@T?4EDU[ELY/)?*6G"8/COIZ$FP*G1.D7U3PZT
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M^3XG[/M<1A?N93#&U(AOQ)W;V%?')6BAYS0L*-6ME4JPD,;>UN9!0?10#^K
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ME+\)N-:=@9N ZR;@^A@!UU!/!?&"'[901N$YL!H] !5)93]L];:HK8U))7;
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M3X7/2HEUQ:@.BN0VKN9V;S8<RZ2QB;Y(A ?8BJA X9[=9B/\48<46N2F3;"
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M@H'@-CVIQV[7' "'F#,MGE=.UEY&K,5$<>B9%Y+[? (3LXQ2/<F]<:0$ QR
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M025FZLWY %DO4#OSOFJWCQ5VCWOD2.LS^PO'N/+]L;9;OJ?V+U!+ P04
M" #K@%A2^%S1UE\3 @#6W ( %@   &=Z:VLU:C!C=6UN9# P,# P,2YJ<&?L
MO 5<E%NW,#Z(@DHITC5*B91(2)=(2TL-I81T-PA#"$B7="E=,X@PE(1T2<.
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MCV2AOP9^*U.QZW/TM)D;>T67H0!.QB,VW%O!3-#;%_=7!SH&4F2#5<7Y<U&
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MCLB^!E[+"+<N/WW[K?PT\*N6S702M!=^>$/(R-(4-_3A-ZNS2N>M$?DF4*W
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M/8:LQ^C8>G*3)$0.].^_50+91GXX*%+7.#I71@X],<&0EWE@*<'Q5Z]D_!.
MJ>>A\F0_\Q,/YH^M=%#;)YWM2GBNE"-A"%,^YT]19^+?=M3/)8;8_G8!C^8U
MN)$HH#J(_ZXAW$),17H!G4)=(_+F]N8&_-\45,1(K) -IPT+ZM)R,-,1%& *
MG:T5"CR'M+%=-N1Y<I/IS.S,#) 9V1;9YO.?*C@9K&NN*YR9[UYF3)CWJU$
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M6L\[?<HHEN[D>0K=(5A2;'2P>("]*B_S7Y=9*_Z661LBSL%SRL.CHNLHP,W
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M:SV-L9JW94ON.K1TO9=\GUENGP\)KPB="PVW&(#>JXK@@&KB$KQ' 2CRH"A
MA\N1Z-ZWAC0G 4K.8Z JLXQ@2O0^\:T0!\, @=>;(@&>)5?62 ZWF16(6J5<
MF.XF+WV[21AV\Z-0Q,' \9.+3>>5]WODF0EVSD;I+8A]B(ZE-MTHCW19J9^4
M*G:*4(HZ@3X6'J^"8J\ T<J3G%1N/GV!6X^VI\M?#4"M]V$-B=>D1)FV]>)A
M5$IS\9\9ISW?T@.%9&'BDQA$YZ[*\4"<";F".]Q?'E ZML,T2V4)UDI#/@LA
MCCU,,UZK?+FH*I$8BID?[QV@P1%DXL,U1D_L2M1\;4KP:K1N.A*VD'FBYP2W
M3 '._$+#<N%97TTU_-ZX0QWC7K4AK44V;=@FLQX:'-85PHAC7%SYL^Z3.GD<
M!1T<.Z?H^I&8G.["QTH(2NNKAJ Q\]\ZHI7$/$8+C\$&_EJPJQS:PR^'IC^O
MP%4U/--[20D+6>0=;>)C0E8$ S)CXO_UFPY%GA?Y7A8CZG4HP'.1\OXD,=7!
M_T/:6T>U]7;KHJ%0*%Y:7%NTN%-<2H$"Q3UXH4AP)V@+!5H@:'%W#9K@KL4A
MP8J[NSN'W[>_L\\>]^X]QKGC_I$Q5O[(N]XU,]\ISYSS65C T<'_$2.'K^^1
M^^#R#PX0FM6+@:P9=+.M#995[2443FYW&R-?[2!>K=M%+4L6APH>UY67M#L?
M#&?Y.%GR[[D?2=&%F*#&=EOO))\!OW9\/$[ X8UR"=WDF\76]RX,^/@>G3)Z
MR!781*!(FP#11ZTKK>1QBFPP"RXQ<K3_7&U:,@-"O>0!+,[;P]W6/B%]PHGD
M7 S8UU-T!1NK+4B%Z!!A4."F'M>L7)QJJS@^<%6WWOGO :A276W=1L-KLUM;
M5;Z* 8PIN%*S%#O\G;Z=(AA<ICZE5%.K=H+A#*;7T7F!C84RK9WH%9,R/A.>
MO]@D+T.HHU?W/PP$_U]C@9G8%ZT[Q!E.#UG;\?^^V-5-*?\Q2,7LA<#[[0\!
M68!;NQW.!0!>48*%%L<289RVN*G"A)68+YF2WSKUB.F'CE_]RET$%5E>D.(L
M:%"MO7QV[V*85DVKWQ&^0V6&80_.&XPVB-D#WVSQ;AGC.:S6L7!P?(HJ6BL'
M>00T<7[US9$NF@=#'*O\]FM393%JE<_'K\K(.)O>NSTO^_LURE23:R#UHGB!
MH"J^MR/,TC6;^>FT6)!]CN!52<*@;Z2,+Z$)IM%L)"$AF8$C*Y^].SVAD:HI
M]1%J2H*>VZ@?C&8?R%@P66)$@*AHE(\Q0LK*EFJ07^IM@L4-UGNIP\5 AP%G
M8?>,FYJWMBC$YAU_*(G81P WIW)\TC&&X8=H]XL$+WEO"Y9.YR9K.XVOGX'H
M\;#O#]N0/F19"W]'2GK],6OU)KZQR4FG>TV(X4UU&5';E+RPI:N+6%H1"L_D
M'/<:&PR,,0R^>D;8, F_LO@PUA"UE)X#+ETDW4YFS/ F3L@%$C>QGPK&93C4
M8$+]L;:3A\,8&SW8ZU[SR?4S!$]%O9*\VWTO6S'EVFRDI'#X(?Y@O1XE7^MO
MQLKA@Q+EV %ES)YK7Q9PRP_[EN$ACR&TWV.(EB U>E0'N[0F['GJJZWH!<SH
MHTM[70Q!\>;=BF/<FO*55GQT7U&]$<I><T:3!9.V+>\,4/]$J8]<Z1;77X$X
M7)A[G87JJLM+[HS)L"XAAFE_B-U*XU%+=+%"[CSI).UM)%VY2A%_.7I"GJXG
MM8!W']_6@1HY6'6MOE<J/61;:?),9%ZEG9@X6N8A"2O E V54MOW(:%T5YRP
MML9;IB:F;XR 7-)G+ !_%1G*^7(MP2QM$B^,J/255=0"V\]' #^R&C!]\P^]
M9D'\9L<,_>#?>"5HAH^F5W?D3SB$&ELC5\:V)A3U392#H\BMUN++;?*@1T P
MGX@GNV%!F)7K' ^7>-/8$/5R'T>/92@,VY=)"@DG-4_9KS*!0=_2KZ'N]B[+
MUF9V6R^SLELI\8+PM 8A;\7DFEW%^9 <YS0XTU(V)"GT(M+?.M??X$3 6MX@
M#NV;""P+.C&2P*\8KP)QPO&LFKQ#Z!NQ"^6MP4O-0N=VROJ?_HH[L$$0Y,MP
M>==&_116"!9VH4 %.U_X=.P1/W*WA6J<X^Y]SGT:T2;L _FKS@VA$6JX2A<Q
M]=NI+P':B.S:B$64+#F*EI: ?\F[]I@^"3:$F=1BC3G@9<[.VVU$$B([EC/Q
MIB[1N&=GA#MJ_72RW!/Y:9S?CO=C:/_?=*OV!1Z>5$XQ\+:6F]8Q1[T9>BS_
M;^[\<WR/C0!H!,SES9.084?S9\D)(;;VZ_1-T>89670WVE!U1&FL$F*_5*WS
MA8:U^#UH'RW^OR^W]1.'OBM^J28?/1/Q&P#[!V-6]R,T=]F7Q):A>@1 _VUS
MY,_(;M2/4_^9W?5[^BIG_]LIU>(;%K,$EO'Z[E.TD>:%W_%DW7W^J;A]+NA^
M@/O!<-+_@:?5-&O_!4^'9N83JLGP?/C'+H6[7F87[KYWUK6:2HC:/WW[L^J
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M6B8_+!S1;,U])[@26S@WR^N6NTZ6UIU>GVE]$S?1H<C+_^<Z+4>"J?9SZB-
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M=C0GC##7>\>9.X&66LO[,[S)917CE*?-R01L&INNBI&HMRB*Z,T-=RV!/TL
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MA-!K'8LF4../Z_Z%YDIRA7()<U+YGB:#4MV^:+ZU_Q+N1UEMC,W7:EW[2C'
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MK4TMY?%=9\'S2Z(^NV>2;9S\&L/J0KW5QF9.[Z]0[FLFG@9F*'V*%E\'1F0
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M9:*D44.>H[S$W"+L(NNC-4%' MX]7.*KK.$1V*7:ZUVOVO$PLL$E7I3L^]<
M#S!-^P"?=*;AV9TUE-0IL-'K'\+-?*F:>_=#<TVF4;U-!H4'92]ZJ.\+:(DS
MX,4<3G6.*T7<SS:9MRNON:>IIE\V674T 9IF&\XUV,T-S@!UL5=.<KP4IBT[
M'Y;@>\:A5.($]E(P!GJ*#TQ<Q-AWFVBUX-D,7Q'TFR5^7 FHT?-D]5H3-9S>
M[?:R-^\UC@#!IAI#@>5S]J<(Y/FYV;MU!UD5QEL#] K^CY_XNV$9!]RT$Z$_
M-\BB^3>#+/$6RS33<#67U&3G#-X6SQYGF/5SE/OJO2O8P?]VIAS\W#'N[F%&
MWZ1AOH:1P%.3;!.#J'6[R4?4%.CNE\Q=BGM='K8E@YXLCGY+K3A$&+(M*W+&
MTXP<PM,S(N&47CH(,9E<+3@7F1\;E<YZO+?I8=Q)@1MV\LA" O$KTQ5Y]\NE
M7\FE;\;RKFM4A_2([3:EKH^".EC)%EQ>Q_'V-]!GG8C!1 :V0.K;*$O^MCFN
M]@I%E;M#7CFLV5TXI[V(+9A[V:K@^D>F;S>.0B]PN%-Q*20R,<=KI1N'!^.E
MB_OH899I:FS;[G>I?_@?MNZH"K#FEWJ8[I#XZA@)XY#4I0X=JM$&/02!@!^@
M/&:3[@00"XBM!.V60#NOT;!PT X @T"A6ZR15AR=04"T<[?X\:2#]Y36\D0X
MXJ2U4I485"O 3E$BDE24( LP(;(TLY>CP;-WL+%J'DK1?)[/&R2^F5:Q6U*\
MYNQ(^YIK-I'"8,/=6EZJRUSOY?[+C$K6;T/L$]!W0@P<[XF8DG>(Y<"MR:!!
MJ.VS3Q.J.?B8W@A";8?SN2?1"@,[*=[X.$*!S\=U$>\&O=Q2.,RP:<4C3>WL
MIZ6>":=$"C+VU>#O7*>F/1\A[8.:[MAB%$U-^CD@AU9^(+ABGYXQPGL;AP^#
M1<M,&/LC2R]C?)L]7M,TB!,Z)EB&F<-**GJWB@<>O$0T1T<7FPV,#U#D"58N
M6U7Z1+8-<0JKKGJV#S3CC'X2#/M.L+>EX?:Y1,9!P'DB6B7EQVA\I'5HG*"Z
M,L;HN7W>R]T#F?C[$H1]$P3^(K)QTEH;P!?1]D18W(-VP(=>:=5ST=$-!EC5
M3064QS3W'9#.AJ;()M/B38K$2@+O"U;';1A1.'F,A 9U9TL_#P^>6R[(#\LC
M6ONLW\P\$7.0;?]D+2H&.X+S&8O0T3?Z.S_4B.)J?8S'J(YY%;DILZB-*]"*
M:YA*2@+N -FT%Q57A:4LY::,*R3#$RW3U56$2OIROY.U1- ?I@[M#+E(:&>J
MMCY_B2,B9.D1XDCIOR\=-?*RO"9:(>[#O +)!$[W;*.U6&J?[X#)G ;X#B$R
M+\(<5'QKLU\A4(E$--F.B:M+]>G:_HFV;29;I3:=F3O$_8YUH*MQZJ>CW1,M
MQ6*DCN Q?]FG(0H>_CH?IY,@ABT>:!Z61^DN.8XK.P;Q4OQ&UK2@R[O);%#S
M3W&DQ27EO70PT:T%;Y%WJ;)"..P,U29WGQK&O65NUE0YQA1B;<V X7_3VW6-
M+13%<TC1V#LF&!S?ZN1D7;N#BW7A(_SE8[W'2/R:)-<QDN1&^AO5ZE*(!?%$
M"YT16;3VCXI%6_X L525L=+/[+K.*B"V\RR9=ZXT5<?#/0N\)DO?\"THC4+S
MN?E=:30$KH;1#)3BQ :%3Q],V;OR&W]-=NV0,5:SO;R7;\:K-)!'$?^V%%AB
M72Q<:1VDKDB; 84%/9#(H(_AV!=NS/2U[%V(!TFBS^.;<<IX&F%1?"LBH=S!
MR!,/;%ZFJGK*G]V*/3?JY1_H=*:025E)&0;+<6+1N'.'S2$E2*)TM.N\PR^I
MK"6#T%C#0*H$MG<_S-+<%S<<B$H.H%X.>U$P6,Q%OYT;-RRA$R'$6DL\!:]&
M\RV&'3;'A&^F(DJD9:/\Y\BI'>TP&LPMK$0.6/8XZ,23EYONW5=1I&CR7!7$
M-?5:R$'K0;5V"."N',,2(LSF[!,/0V*V2 9L3^F3>SOFQ<DU@-_DVQYP,2H\
MFV+=GQ2(8!T8!XO5D#=M>"PE_L1*.-[S_4.S3 V=%='F@;68E5/DB'HZG?Y#
M,Q&$7!G6.\*.S>!8D=ER1:@M[>OC*"8%I\.<&703'>'R*/P4^KN1RNHVAZFX
MM*3R(1 _9RQHE4BFFO']W<FJ2$$6T1G2HQ:=@XS:$L;GP\IR<K6&+*CW5IT1
M@OHK6HGK.>SI70GF4HF9_!?=7;UI&=]6]E/NH8Z'C4'&L<SZ@)Y6T[4C&V^2
MH:?^DZ#"KZ4\EU)B]&P2?B?TTN,I_DB(I;4;FI;I1L_&.PM19"AL3J.M/88K
M)*2?451LSF_5]C['5R;GM83/BMF]'.TO(S.[+H/<IM_X?#!LP^FQJ(]5%58:
MK/B1SBM6_;C?P4 B_JVD(H..8NQ[.8Z8!=+:^BP'E^+II\.E(1.*>_$:,.67
M>[B!/_0&T^PA\_P!Y+8X:Q==DNQ7D<FKRN%1MFWE(2L?N@6VA:DSF\?167QH
MB@;D(CX=-%4/O>W/VS8;<3SH8E4>V=8;(=K&Y7@@IE*&YG%PG!V%GJJ7;OBL
M?02Y5/[#HX\A@FWLOBGTR>M?HM?NJ'TL]W-6X.QCQ16<$F9VCE7VIM_1K8Q0
M'WQ.B^,?%.TY,TN#@:8!;?%C"*'HY$0HM6S!94_,AH^%L85J+;GTQ<C< 624
MMKHG<OU4%Y+D#2P=]RJ(X\U9@[]#.7IGYF+(XKSO9YO3LTMD/$L2!]J48'_A
M]# W,"0W>F:'DR<8#UJV%6L:SK3G$MP@B!^N0*%7:A>\-ZG*M\Y S"N/]*(P
M78_2.NJC>$Y>2=JG +UT!_'ZPTV2J/>8#(MU]!]'"(59%:L4]8S/^ ,3T8H_
M%/OM/VA&.NTV3LO.5.V9(Q3HI@Y+#_A: ;#B8N>HSAK3<'C?W?]P:$F(DPH)
M4A'(P"CO%.+GIRG"G]I<:*RT!ZN40K%^$@>JQAZ1@JRE>>Y+%93*U58" :W"
M/"&T'WO9'Q1/:5(OR^FLJH#1;,.=XGP-LJ4=;%EI)U%1,QO?V5T8IG:8-2#/
MAN?T]++YJ2A= V3B2&G&0PJ\%PF4:GPRU=:=S"X*QD4LR#PQPID>M& %I)C8
M*8V  L(Z&\<G"\:H-)]!U0<L;.B)I2M+/\H\*4[(ITN/-\Y@"_>OL((L&:T-
M9MOK$.7-J9E$.Y")S=N*(2?<"[0[.F9S\*0U,;*9XJ<;6@2P93Y!Z]DZP_.K
MYYF">9275(<IW><=+)4<V[I8#QZ1OWJ2MX6+X/ I!F',%4C983(90<7>66J@
M9Z1#,, .:X[6L7BH+AR#B^.&%3 7P#/$K@&:%@T1G6_NW8BQS69>KZ# VQN4
M2NEGRRYZ)P_C73RW5#@(>%\_HCK\/&3MKC7"4@E&UW"6%,\SZE=[+P8T6S3Z
M=@:-AG=SD%V@V3V(Y)0CD,PT$&CU"M=5:7F:.RVX)"/8*L'Y"H;A=<A+2R@H
M"UFV#4C%$7JY\E%JP%9#8/]-M-B@P0^W]SI?<X4.YD.6+*PPDVD%*KY,MJ6;
M[(^J38 ^FZM[<'[ER#H+<EJO+73Q^Y8SW[]%U&"(1MU\<<S>H:6^.FXP&O\6
M++".?2]5MIAI)ZK6D>-CMKJ(JT#:+D<=WCTDP5BJ5%=5A27,<CT3+Q_O+?G&
M"".R9R4E6LR8!SV@WMVC;!-PQM1KPJ_8RTQV.'7W?%SFR[<PU(L&;#-'Z9+:
M+8M63/./V0M2I@SQ))<ZUS)\4>L6J(1G+(8_C0ACIJ+1649%7'S:+FO940MJ
M3OBLKW)"D']EVT_O'>&:ML[911' 9]Y9]OX^:XOQ\CRIWBMGIK8<=3/:&$72
M#M[2\E6GG!*0V=0GH[3Q2JGV3\4Z7I2G_9J$/ V-X6<N3KIH1SEL_ALQ!EQU
M6_V%MI>@YAW9 0K/.0TR6P8A/FOAS&R5G@5:_-%M+.B"(NHL :I^!7>R3L$@
M1,N23Y.H.+ZY%,X2_?Q+4JDQ,EA@H,5"F>?^V])2+^'W(62<EAN01O!CT(1#
ML\3HI)@)319KGOH[,,A[C8\/:OW!]J'!M#4!\R*6((@1'S-5TNW%=JC]$1A5
M [OD4[19JP(E1N"BDKXW145)U#8AWK08A6O3$HEP\BA>WMR47!N;6@=*1VU1
M<<J6=?CL-0 $NW<4(/!I_&V%A_N;:P!=HG0W?R8U[?;C&"U:4[#OP<:C*--S
M4O\.FI2@1PBBVR9R"]),+"AF>/W+/1VGGP%B)T]50,N)R5-K'$PO!0Y*OM"^
ML<+]8MDRUR6=KF%X% JT-H-VW15TW-(0HW-]F!9CSD[C,M)K_TE7!599J5MD
M*+-4%^9F<]23*J2/%P1)(QXS8O8C>5 '."]@)PSZ#!6<8XR6^?(M(=A.]PQA
M&#JV7B'I#74 'D=BS2^V(A"I'ER"Q<5R%X5E+6$'Y7;[TI"5AI$M6P,]K$;1
MQN=EN%(L+*Y&?<:D?.@C6GH?W0&O:JF/L[!'HHCBDXVQE<Z"(I_7LUI\L QA
MNJ<X8$LO $:62-.81G'D_# AUGJ4-BG?=T#?SEE]]I"/26SVL1V)E[Z1E,:C
M.V[6TSF3T8*H*BJ-IMIQ1MZZ]I*3Z+7=&>K&'*^_DTL%+NG&/J>@OON$,S2^
M/:?--65CW#;]R&NTI*QT(8R^S/YB_:ETWFMVJN/AYON5<,UNG<@\'C>0K&KV
MW=.#+07MLKC1T+O];\1_R'Z&HCD6E]1T?_6282!&1)X1;R/DL<MY;DN;9CE8
M$;:3N8H''6IW(!NV+0O3Y;6:^ZS3 Y6>PQ][VC PI2[:OQFZS&!EJ3(>EZTG
M^!&:DURF5/96C\F*.UEXR!1:16MO1%^?LBTU2+*O@>QV=4;8GJ5HX1;OVS=F
M)#OAX'?^:A*C:+)1)7A#D8_M<1Y[OBY5Y:Y:6E\/NTA]W(O2DH'I'ID8DE<N
M:=RKSFZ.R:^&BD?-8=JV-KZ$';L?W+1[I+MS68*$U8WEJ^A&P)'IJ6-KNS/9
M37E=UI2[]2. CR<*/ I6L<Z*564^>O6,[=4?, 3[LT' .13\XG+OPZK6[J5[
MOKAG[XM&FC['D8<?=UB;D)V:QN[R$,B'!GT(4TG-/O=OWKN?CITUHNGBKQ@H
M$UJ$NRHBGIII++]>:F;-I=$"N'?U^(I]3-B%]*BV]'16W U,MX)[I@.UBIJZ
MP M,ICO:/94-K6M&<8YWJD^#=,6$D3-HZ.KW ;&Z ]D3_L18\[\. _'B5&?+
M@8G.A"5>I ,N^+;.I@EO\0$+7"M8?JGKH&)0 *Q#PFJOZP7+XB98AK5E2?[$
M0LM'&J*&OTAOQKQ>M2  &S8:+_7>)'O4X)2*HJ=8:!=O3IL;&S7=DBG5#RG.
M>;]QQCSH(GU7%H UXM+2BYXR7#2M-NE@( \9XV@PA2+O#;H+-N<?=NFO2([H
M5A;&/:PZP+<JKS_#*]69GSVCGU#ONC.U>"I*WKR-)'O8)6<IF=ALLT"966]W
M@ N=H!R"K7A_UYU"?0-^@""2AQ5LR3NEWL87_;K5G@ 5W:2BWQ;MJ71?^#BA
M,)>^7H= ORA[ -?Y2'F;#V3%?'%D0*UMWI6F[KWP)V8+4^HF^=*PGD84]V[1
M4>6[1W4YCA2%_3!:YW/7M].M%)W)'=^_;TR7"LPD #,[H,_WC*;Y'/&E04,P
MU^Y<F[-OG/;'1V>PRP"_.?W(KTD)S\M;-&&EMD].P-^A9K8OUK9QON1,>EH.
MK,DXV,OVRZVOR-:4B>8^MU)4>5J,EYV;%NLRH'$-L'B8BGAL^4#T@MH,>^#%
M.I,9.UA>IYYG9%P_2 IR#X*CO3A[9Y.KRQ*4=^%E[G/)]@+&1PXV2U\OE+2G
M:?1Z@&IE94(N$_QBT)PBH)2<X^5AS@J#(8Y"9L\KSDDH$%,)B5*-Y"K6)'NW
MU$M+-MB"(<*L(B8K^#CH1.Y$K;XGH[74WE!I3$I1>F\DI>G)2[P48RRA7S9H
MJLG[Z[49=SI5YE62%82PE-T!Z7T2&BW9B\_I,67^R5=H5FGMNL\P])>=&LF'
M7^_1DZ1"4>M_-1!.S2Q$@#5\#4!U*-HR3]^,('8YPIJ<F'QM^Z0#T<?_&(MP
MRZLFV5R[PI\GOK_<?E>CJZA@P%;LW>N+%^X\&J_E8 /T_L=R-%3'BX/ARE_6
ML7VM$?4(="W5FVH]WX;ZVM*N,7RPPCS(S<71\<2"4#R , $24!EQ&X/FUORH
M*)C&I8W+YQ;?])K6T^3*?* QTY&\&AJ(&^EDWB991(ZJ'QQ3:3 K*PTOFQ0!
M 8K4@P*Y)05QK@%!7CL[&K:Z&U$DP]B3CDU\$1C^M@EH.((+TX)Z]\NF]*X!
M!57:9AEE@@9?S?0WN7*'V7[T/>,>9U:$H?%,R!6?\[>;O^(YQKS_:4^\J+&P
M<2+,6WB\;L\N$RLN['G&.X,8,X4=2/(UX$%XJF&3*;N!:!""M+;2P<Z#EGNM
ME;5ESI4>K?2],F0K/G2@EH;=-Q?,<I8JFL]*U;(#C)^I9[=V]%3;50JHHS)J
M!PZ%)J^"QY0YY4ZG#>*6\IUEL+FL,Z735:8,*>V__=@*0BR !CTR6GB[&P M
M85+\;I&YH18A@.^YHBXI%K-T7US'T[BY'%X04U5'(B,_M$H2@]WT#P7ZC1[I
M=5+,2_L]X@N'N#--H#.C75W5NAENPH=8PY-C$@R11URYJ*;*!M_N*?<>4-E(
M6 47.!(L31ZGW,-XXN#*4!S&T5'BK/WMZ' ^=H[?^ERJ9W,@_]F'BYR'W[ER
M_7!PZHZ/L7JN ?5,!28B<L7EAO8<(*9J0]Q>Q+C!XF_+O[??SSZ2BLDX];?K
M"4:VGW.&BE4:(_"[9X76-"QSTFXLTH<6L4:NQ)ON73$?J?3,4IU;!)V/BYPB
M'] @:<9#"9I%XE>=P)^W^33N9^:HW?VQ0*,AU$(+.4!>>C'(^&R>'@:9+"LQ
M?,B,^".T%&IKDW+7NH>P^(DTZV8@>P>Q\9S>7GA>MB2%)G&_?P'I]\BA(+A6
M4GQ%ILY']*3L@>4R2^:9KM*TKQZ:=Y#)741D\KOQ<L)&Z7H?N.9R')8[CHN,
M?/ET8K.J:Y%773CGLRT>D3>3FSB7U0Z_ 9\=]KJ"6W.QK^X.7+T8;0.,'7T[
M*B.\!O1@:HABB,'@4X3B\Z!#C+>_/BD^M=V-_)A*3[(F ?J"*0M$1&[8,X^R
MU4+74,L[JZL<N)R[!@QWF<L]>D!R/!N8Y$'0XLE /GCQ'),EXWUT8J38,?FI
M$OM*@Z_2VE+?H1C=PI?%A)Z#W.D!Z:)\([SQNY];)^+?-4M#53'K6_#G=NX
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MFE^5A#WQE@ZW[$:$2IX]TSYB#<-7B%I'>Z\Q]MV!0[T^A(0;P4MBLMN ]!J
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M3NC]2>ZY[$ Q->5 HD%T.DJ,\TCL6K+TB+G'WOU:QNCX0W0^&-) U.&F;;=
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MID>ZN.,:D(B7C1KWMJ_-_]LDQTPJ:+AVD3\#/-)9>_8X2]&@73%4,39(9N1
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MU^W6JU%[PZ'%_HU%QT;*K"JZGID#B-+H]O(Z+@KE/==G!5?%--ZJ9OG11?E
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MP2Y.IJ+4"EOW *)%5(BG '70H B'XGLB#ZW9"6X^/*;2<P)277!R%NQ"OH;
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M\'V?SV#S(>=CRV;Q]/W9W<>&>CLJE\BW</#8SS,@Q P4\9TT+"PO6C\^Y;E
M-^C3*RIO;D%S<BGZ YIZ5#A1RQVXY/NKMO9DG8%C<D# VZCSB"ONWWNS,YIW
M%A&)^7-2&*ML3^L>8(/.LB;FO"G<.(%CQQ+0?1T3!M<M^LF-$42C^SW;VXJ5
M.+0YLIDGZIVAJ!!&BRL0#_W-.F; 4+G8<<*>T?O?Y&=>W<OY8+[-N;'8T2[K
M\OLLKRAE(XP2I$?R!3,BLT?LKJQ[3X(S4R\ ;\)6,$,OM).BOS7 *2JJ7-B"
M$:,!M -K!=K;#2AW9EVL]U$Y?L7_ C[FP[Z.ZT:5#X<5$^<W",:\<Y4H9+;(
MJ;"I;/1R+%/QLW8Z;JN08]J9SY_FB9+1?'JQ-T0WQ\YG?JW)RI6M/@X-QPFP
M%;T'?"W+HH69UQ%&E(R\4@U,)?<7L:V"L^@I((_2KB5=29/DV#D?H)@XPS$.
MR@SMY)R=699Z$\9?>UD(6(F,*IB7+.TD?-T_I"0!=%L>G9=-?WB7F'>5O'ES
M"U2;>8BU,$3W]-+%.6BO3X>2$=:+]62ZZ&0"0!2]$F*A*F$T7WCDJG+W@D7_
M 'YS "7+27_TC62@6#YT5J>SIBW^<'X'WI08?P+@[#TOTU U<;?C\TE>FSXR
MZ>2;-! T2$B.=7<$*Y4 YXM*7_3Y^=!,E@YJ=5$56JM*A1S0U:OXC0I1X>V1
MVG?&69<HX!LFFL1,:^#9S1[;T7\(WY5J%1AI'A*XGA%DJ+XMV(=XOS!8'/5R
MN21Z04+KHL!Q:"?(D!.ZX/DOQR7_#UIT<H_HX' &_+4"I\!K"WB[X.'VNV.>
MS/:<:B+/^!R/9]%^RK+\5=RU228=C:EW^R[E5#D"5<H(JC#<KZP5//JO+]+-
MPFN[HO%KMVD^RY[G9B7CJ20;)'>^:Q^V6>8[/IA9 I?4M4,,D6@YY!?]4BY9
M+R9F-:;G]3N3^Q=PJ2D?B)1/S+ZK/TZ.*U-!4X1;"*FCAR.FHK\WMRK)]-2"
M'%84[V!I\[I4OINOS0SK)A!GI8)V:I?YC#\YV;XV'.NOZ##C28>;.^ _6&X6
MP3$4I- B@7PXL&E+DLB(F[O1]D3PDCT.G[=J=6O1Z'4Z&%N+&P-^@G(WG_LI
M,Y&9AKD.C0$HVS3I<P<B@J+II=PGS@RQU"$(K4*OXBC615LSZII@'P/73PE'
M&MP4O%/2DQ!#VP.HKEE2/-ZKQ5P9929)3>GCK)C;U-RY)05/AMX41BR.2P&T
M>\",1KW:=4P@#]GSBMFXP9^1M^M=!VH>\_+ M,7!<G"/?252>LJ($+&@6(N>
MT=M$/(:# 2MN0-!]HY]R&R53"7]OM<"11AZODCO*><@[)4HB8>GRK;DI@9'$
M2%K?W<XFC5STQ60GA*XQ^?!.:KC".85I)](M1S4X4^'*S@(4TZ.%N\[=(!</
M6]9!#07\1(O'*)*R 95-*81U/>]()256+"M#DHAXIZWQ_ "_NU2/WU,-M[%,
MSVM)ZCKKKFS\((:PK4AD@$OUBQ8%H?,KS$M)CZS^1N?'9<)=1]KUF71[NAT*
M^AK,O2==3GDI<E '2/E&/>2=;LS(4L)R>V>//SGD^/9S#V80XSU ET[ 7*ZN
M$2/(?6FS&N3:DYQ%5:V3)V[I8!%[3M> $,??C<A6>"*-E?3T3Z=TSG_"WH"R
ME!4G/[NEO^!TI:>))06%8+QO_\D:NS+P-W(SP=<D>V8TH!9O<T"O2_EXX<VG
MST55ZM4L[\(9N;I%$RL>3FJ\@3'336].Y6<J39N\I/+57 N"AE;03,WI,>1%
MX/S-\<D?__>55E-G/22-P;HI6H#V'J!5T45XK1D9[O%B^O>=L?\9=OZC0%5+
M_SY6-I[!PC04(Y<RJ1(8B]"JG:>,<G8G'ME?-C!?//M3GQI; ;W86CZ1XZ90
M DM[$L>\HAHK;PQ&R8$6W)7<(IQ[T/GI&H5I\^T(\8;\2@V%4X@PGW[)>E&/
MDL@/<+ -'5P4:5XFYB1W811PXZ3(MTGVI@V?GZ=3+Q>X&?';DV_JQ%RQ(_6O
M$PMSUU6,(3T,ET2):]NJ3:$E(S_AQR.U/,25!Z0MSQ^$.-JZ]HFF &F;']-%
MH@] "UL:PT]@^EXI;FJ5LY1Y3=*3PJIKQ0'[<LGPOF@MNE>)J-WD+F]<"C%!
M.$27NAD95R2#0RH;6U_@05%W/<,1L+ZPMC$ )!=8'WG-3]D&6PE%<7/K6K1U
M-M](%SIW>WY$_.)ZIX4&^7N-BL!H]O;=3.@.4OUKR]R@F%='4?A?@'_#GS+0
MH_].\\C_MDCU[TPV>)CY!^U/V4[^@?YHS 9_!?O)?RR%/DSC]_UWAI7_K_6)
M/X#5^L[?\AXP$:75$"GGCNW0R1@GB=M?L6?\#VA+,&@BT3WF>J0]<24?/5.P
M/)#O*]G94AVF/'5@F =A_RR?85U-@F)*2.B=KT\C@2X;PIJ'K-2;8@X/SU!"
MVNJV<#"&/M2T!D%.2[GT[JLXO0?_.GF0)DH"3H73E\,:DS?//*A\Q#%U2&6<
M'K]\#]!+F"B[.J)57VKH2S5O//8,879\W?C9YZ8+-Y7;)Q27GUKD4Q_I4E)6
M?OX.Y:O/<_KCS(BOA)P  3'YPL?M^4!_RB YV(:/=@/UCTRSE2R_5G@J&)FM
MXN,G)C?%E\ZDJYIE]H2>HMJK2"^3OYCF##JXBY(K!X=]=6O5K&],5@@L9QI,
MO>*CQ"@TV[TCA;0AOSYKD:Y9&/ZL2^!SO;[KK"&L *?@4D4HI_C9"X!8OE=$
MFIM^)L[Z-KZI!LQBA5"^K9WAGN4:P >YOZJBDI3Z5JB7434"^P6[FZ]/Z+/N
M&5""W(W!\;[<N<B>EXN23=J[90(-&D'YR<2)@F$?G 0JBF=0="T]H$\.13XY
MK7U5R?['E$WP_$E?<RN'\XA,>:N0PQ0\.IAI)"4G RO/:Y)E#Y^?5X1M'/#T
M]'L 081*[<_"#G+&:')>#&576/,1Y>Z+962T#25_DGUJ$B8KEC6L%.2H&22/
M8-:>VAY:]GPNB':@ANSP8[W4 "X)(HIM=>K#)Y/F_1Z\B5_<2C+Z**3FO9C2
M/<]IO"QRNRP5E3WZ>F"9.I8)@N!9MS/&3=L>ML3N"AYXI9UE*TH_PZW@\;D?
MM"YM-H)M6C=02C!GA+RB/PZ(NZAVU]6V"!I:QZCZJ&ZY9@?5*&CP$)!S_T7V
M??+7BHD$)[NY<US"F)_(+?"I_R_J.:V-B#7$&FC$GOZB']'V\,8Y >G69QKM
MG+"0D)5(SIF8$*%X9DRIQ"S(&VZ:M,[R?$B:.B\\03S+WKB+-(-O!%J@<,)%
M"=JNFM:,R'3MUNO/MB0L=6:2>R0A/1WG)$[RBXG)$"$=9Y]+0=0S""?A]_(R
MGCYQ"1#$55;F2"C9SI<Z>HF+;)AWG D >]VEW@->ZXM='V9?/Z]Z'V9\G'04
M N9>TMJ5W&18+"</#$)B#DRK?+;/"S=DE5,:<966$!H#F,AM5Y$4-'#V0J/D
M&$M9,Y5[>CU:'EW&\9:7C]OR!YLQ;,]AGHY+'NEVT'VE^@Y[;EOGEZ_T(N\'
MUX_D>5G*C"D>)?6NM)GO!BN+\E-OGG1KQDF+!OJD#2,POM3+^O*W4(5-U^/\
M].@F8W==:>ZCK@3;T-+-0SHLJ[YHI_#RIKE'5<00=":U;GQTH)Y%758J_0YO
MN3P*GHT5.^\:#.>+47?".\;CN^8"24LX@RYM(X"Y+&I\HNI-^=[RFPG3">6$
M//V*+[TOJ>F7+J^:Z9?3!,I^I)Z6WC2P@2+NY$*_X5ZF5*T;.>X<,DVQ0(XP
M#9%:/Q1G',B_:3.7DT52^GS2$=P%";B5/HYA7OFX;F).7S)N)*@NK9/FG*:N
MUO%EHZ2 9#O2=<S6-LM3_W] DO;_U_I<S\QSH*\0E5?;D8QO'IL?*R8XGO<Y
MEU%BF?G7&T1'1Y9)_.FXS+M"2\5H/\  3Z!AQ-'X:,8V<4%>!-';VJQ:RU%)
MK8X9/;Z.)J\TCI!%C(?Y-9TM4ZQ2?8E%).+?:\_[M/,B7H[RL5J-'B&5A&7N
M 1*Z5^>8 876^G;7(9E[2PM+<N10\KHJDO/!W\S!K%#/_I3WSO('V%RUHRG:
MI[69-IX7W=,<8L,6Z?ON\629(K[;:D"(Z:14<-FT\LZA_C2/_H&:!.U!S\@P
M/TO,+T9CK<X$)4.10X-Y-B8B8@+E<&9Z-?VBWG58U8Z@U#+$MZ$A+KX7-5 ;
M8PPFE4[P!!L7%N:]&/&WVL]?66YO[<DB^XVKPOM>A'Z+69;U_I/V! F3ERMD
M[K.%"?/9YNA4?"BQE;W:$-&!K4  :M-&V]!W>)_KWR7')\?]2P+RG]O3H&JP
M+_]D09W0H"(QB_^-G5;C12] ,-XNW6[>FQ?6%DRE!&_;,^B<\07"Y=PHZ%P=
MS1U[3TJ[4/< E>^%QD'>7HJCI8MM6;E:C1_"C1#I+CZ4$<\.P /_#WO?&=#4
MLBT<1$5%P$*7IM*K($@GHM)%#)W05$":]%YC S1@0D<1B/0:BA)Z45HHTJM4
MZ;UW".%+L!S/O>=<S[WGW??>?=_YL9.]9]::56;VFC6S9];LO'XVM@]P>I2Z
M#WA3F\72X4UM:&9W;H]8+2S9?X(K^NFC!:ZW2WS/&:LBJ8-'&2V?SKV2_] \
MJCJ=N'@AGG7@E<_GLSCS:_/L+63\#9N$>[>WC97ZY_X;Q^9+M'R17=F>:FG3
M8'X.EOX>%[7Z1_N V<Q(OB?#K<8E72R649Z#VI^Q;)%=CL,>=4''IXW:-6<^
M]5DTGV;+ME/=!YRB7PV"KFQL76-2XPG/$2FX=7N>$)$R@2JAR9HY#K$;'K -
M\;"JE[_E M?K\FX2KPYK9HF7$;>6XN^WVP?PCDV4$BP@1ZV"5<YDSVEKP5SS
M01W<4LSZ]#P.+H+WF/<!IE*OD.*&3S>UEO?BM3H3=]41EWW.9:L4(MF4=43/
M)'--P6]3A2=\UKNAL ]XH)XQE:+_\@@A\R1TE7#)_9,T1WH3G:,XD6%%4LLB
MBH=(!T+LZJN"TM5C[;GO$!5@*[DU$O^I9L._4%%UQOV&*EK@Z//.CDVU2"\W
MV>=.P,<8!]X7MO-[T4X?66#JILGK69HSEZ,FWD6)RL;$C;QLIC,O[>>$C8U$
MN3NOU<T;&"$'FD?YSJ'C^N0K5=[=L3XV)3\&;WJF9J_%>>OC-.;Z\--NU(LK
M6P;'&E,'U78K^]J*[EQ)H9C$<@4K ZNQYZ"? A0*DL@_4XPB+5P7JU:V($JP
M<U(VF4VU[S?W 2+IMO9O;W#H7''BLSMLA9J0D?+Q$9X/+X$D5#?OWBLI:A_V
MC<_014YD92CFG_'LN]K4OS&1!"2Z2PCL.SO9P82]]CI9Q=(_1BXY(:BV.*C3
M+RVJ/;W>T5+_^@<&(50;>'F!VT;ZV'$1HFF## +"WKC;H)Z"O*ZX5AF*2/P$
M_ON#G7&&Q3+$;=#:CNL&D.43E%8DO.24E)LGYB1++5O(+&IP3O ,QYU7U^68
M."M"G"^_(GDQ)Q86Y:*YXA94&YO/HTW$%&4W.ZUWN(RT:^TY]19$S?AIW@WN
M/:E7"=CWRXF[U-;K@M"+W99WL*$9^0*\: $+X-GK?9=<Y\^;.!M,4F.=>C6!
M?AAQR^'9RW2B;L83"HA%?B3TU:63R\W4ZQDOU*J*-(,+"XJ5MX9/C3</@[;2
MVE5+6EG\%)QU0YHT\I;7LT3;25_%#8Q6B4G6(4K:'L\B9F_Q*Q,@4W&N8G'X
M.2^&VLI)D1<,=^ONV:$3+:8,*#IKTDG3,RRX5V+[+Q!=7!W=UK1YML[#!RIO
M(7W%;75B4.YEBQ7ZXI8[-FQ: FYP5#0]Y.VA];_=$Q>JW%4CO=NX+GC;>]5+
MF2+G/,YP,/WM*.T?7+\7"-0L#AK[AWN"KWL[1@[V=AS]G8@K?VBB R#6T;6'
MGV%6_7 PP\Q @(3\$(HC;0%54XR?8(Z&# K)"9G6=96CPA_)T,0+TLSV@#DN
MRYJ1>!R<R$60=0?#'B]X_V'Q'*,/SY>$Q(1&FC="<SQLP[+XY[OFP!-?$!2V
M0)&7KUKV@%4J EHC"0TJ)D*6\+C=V0<G>E%Y^>#/4/OV2+M!";UY '9PTI?E
MW]"]:_:5#/Y(L*.E?Z'^UZ(VET]?U<]\]'660U?W1@-CR4#$K&Q(PH"EUK2Y
MF<]+Q,M1'X;DMM+RRC*ZW*6]Q]5G""^?K&-S%GPMGNTJVN7BSK0TZ<?C";R7
M724L[XUY:J]LW7J5.D4J^-1MS6NMOS7)\3N3'>;F')8W[G^/DV"P]TEP-L*
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M6QD/IH)O#3EV4!Y\[+R^AKR <UNT@]$AW5TA;!U8QX-C3ZQBQ7Q54C%3=>O
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M=FM6NTU"6B@L._\2>F]J!1+M%.SZD.\)+#O1L_G=(IU=.>.HWM%\ZPC$&?!
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M+L^U)GHN59CN2XU!V5[B1\73LZI;P*I3E68/%C-/WY!SM+E($+6.=(MSOI;
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M#!F)4LS-I"*LZKU7L4IS./%0;%Z862@#[SM>3&X.VCW>QI3,8X5F-!T;!D/
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M]D(LP8UDM[L<U"(1BA$,=[UY'TC&;T&IK._DC/I[QEB:$/G>('X6Q0R,:J*
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M;2W;X!!:2-VA0N<?MN)#+#;U<8F"F]W)FANCT95_6>W%?:10,^1<F$$Q4-'
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M-_,Z<)5)5!O-0G-_N!QY2 OM@U0,K>".Q;U=+<ICN=P +)C9U,Q='2EF*YW
MVND8UN*J*5[[/HB78SI^1QE:@\%]]J!OQM)OMAC5P?C>R8\L@[M#'S\/KAH/
MH34<]ZQPT..6=][?Q"M_NF*5EZ_4:;_"H;ET0;[<3RA2=<02M8TMM%DI;W,E
MXRBJ]L)1L;)#XT=_PK*9>TH^/ %@[)_W&@GAR';2?'_"M/(7#1?[5_G97!JU
M1AC DY\5:@:A+,3@DC<_*[NPZM.!BZ8ZG^B(U"@5GF)2^Y/=510PVY%>T% A
M8%^\2_#ITJW70_X 7)V0^4\9EG)7J2WN/V@GVKPF4"W(=X&9]LX:JJ3>-/B%
MO5UHS,D:]!#O'JSVDQC=^@-01*U]%FI,P^E]MD+3H?4H(?(\ETMEFA-^.+AU
M<$B5M40T,7WX=S/S+>+<]B6XED4)\/X!5*MLOYY]L^ILJC)]AJ^FBHCI\:+N
MTB7C^EX5\JPU1?IW?&'%$LN+1DPBIW=YQ==)BN'@M?*ST.=^(L8\3Y,,O:V^
M4J://'#]0"8\4;O/7]%N[1B5;P=?=[>C6R"<RI(O]P@=3-X@S6,8@MA5KX;/
M:)!S?C%PUY>_U VO7 )]8<\?%RB&:3_'WHZ1\G_H9MBJ\"1I=L.1=6=3<"&P
M-O*\VFHW_;KS#EZ]P";>]@,OYZ*GQG'@]YX/*"3;N0)HT$?DI$O0F)*S8BLV
M^W?V?$&A46('GBI1N_(6#0H8HY'[_N/J5+5Q7%XC09+%]_%VAJN H8S+5'=4
M)X%T;DV'I+G[F[&11[R>R\1;AJ>_2)M(=!]H8+'&"P([Q,\L\H;@G0H?H+=8
M2;:V2V0Z!"OO-)^@_YY4_W'A=BK'O\M!:[C6=.Z:0FCCF3-KT0P_/YQA2L+;
ME38>7MO-[-Y@.:=VU$EF$@7X%D@7^3')1WSXRLEND6<;2Y*$>#59>*#KQ?54
M_Q?IC#%Z[ V/E9.DM^>!OHA"/Q W^!W'46&62Y%QMHYG.TU76L5J K&)7]2#
M&<I$I\'6*AH>1KEV@/TANB\@#1'@7&GT]/*K[FM*8>K=LO S#M;;7E2S7H W
M]!+OJ$V1[DD\U3IH\3B1J><F#_NN?FB7-:-O28S41HW<_NGD[588-Y0!<VVB
M$K!#N?X'0%4K?Q#?[VFB#1HOC3@6U&GO7'K[9F;#*">W>]78NJR?^OG)(:6^
MX?IX5K]]9AV/7P'>'\"7V1\H5,![ILL,CT??O;__ 9P_I"6X_D.>[1K/OD[+
M $$XE"VL4SV((033]20$C\'H>>/K%_.<B!1[2:];FNM[5EI"/R9U.'00887$
M7TZ5?AV1R/LSV?X7=LUV/(QX'"'@ U<3C?R*X<M41SQ$R=9-X6>K"IK5<!24
MTAG=V$@H),[W70D.X* !BCIK&_OOXUY_KL$NHX=C9LRZN/)_&T QXM4I"@P3
M76+6GM7:U&'NDPQU)^>V[IBHK'T+]AA3FX&X'E071C'URV Q,=W7.,X$B:&_
MV7/G*@EIRA2;?<EQ'B+ZCOQK7/'_56\K\8]$9JE6T;\$,['T_[,<+#(\2[*5
M<Z)<CZ?#ESL?\_P@!<GV1O1V//VS^/['\H.4$=1-^?P(R[C;IH3-CPI^W-P
M$P(PUWJ.UR3_A)_OH$CHE]S"+WQZK#P6H3O&9!LY/B6O5SZ)^Q54_@&02+[,
M1R4FBJZU=DH.')OZ%07C.Z%Y7UAN9?%0DATD! 1$12OGO9MO&6=$#@K4&N6)
MP-<QPQ5H$\ <\IY_3_?]!SKX*K0IF7F.?B&H5VIGGAA69DBI(K*TI)G,]X&H
M;AL$2R@7CX9@8F.7!N $1(6/;.2\.E+ :- 3;]TFEM5%'O ID[:W.[T6 GB/
M*X*7.<M*^_PIB SD]U^A$^V  &;,^)R\K1BA/P"" *'_2@DOSG]/TPI;E68*
M$YWMU=$K/^B<!)>!^08V'KV+/;\L.:.^M6EEB]/211Z5-,$!,4+Z$6\.%5!E
M<&]\"VJU?8I89Q;S?-Y8K@T1/9V/725F\PX[3K94<IO6KTII6H?*BR-V#)K1
MB_&YK^/M<3^$1F+I!\M)S.O NAO2 Q5Y8<]Z5N+%V0C,@?+K5J;0Z-XE\%UH
MX!\ #9'G7B)!P 8TX56)@)9 L=M)-TC;V>B C#JX"MS4V=P.)=7X@$=OZWYP
M7J;W3#._W:S,A-"0A'>0QRW0)F%[J5XAAJ]1,&-+Z+KIB.UD>T_WZ/R;N#"=
M_\)!RF$#7HP:@8Y0A=RNH&'VXM_E1!-Q4CPCWMUI='#TC8.N,>D@63Z%S'@D
M_'S<:(I?ND*?Q6-06\BC#_/W>96?$F)ME[^@V(0WG^.</YI:4O4L2P@_9<<@
M8 /]67>Z-)?<OL2)%%/TB<W.Y4U<31??7E627TU[\Y/!&2UE;$%%1+>'K6EZ
M$(1:&%,\ 6&3ZD..22SET 2II!;C#2[@/&H?VM:+>G=7]4PK&6JJI2..)BW[
MF%#C7_*=&B!FZ583V(>.&U]$GABKZLMOZ@E1CPLXR__R:T-/<Q+,S4E8D?5<
MJWC?*]6*1EO[6-6_$)'@W1?1M R'MSK+ZB%<O9EFSL+KAOJ41$.\TO70!U%E
MQ#4%49LV*]R ]9/*F\_[&TOMUTGGY:=V-=[^OWCAL>D](Q?"-8X&*$[TO1>$
M SLW'R0[8EB9$?(6?KA&FMD6HQ4;]ER273/^45 'W.'(5;KCHW^JYL^]!)FR
MG+-)ONXR>")5N5 /G5 QV&V.&F>^WV@[V<->DL(D-U1D^)@!<1$@E@(<UI22
M?XJ)T$VU%QZ7$9<3R4GTX#_.(P@U5!5(Q!)7 +MK$+P:MVN$G 'U24:L'Q.,
MU@#W?)M-R-I:?*U:OAP0 H0O=XQGQDJ2H2F!O""AEO82T-2NWR_ $(Q+>)+*
M5JA&JQ<]OK@P(^<OG)B&EQVV,Q& 4RC07B[YI3A&>,YY:>-M.68:-I%86U'.
M.KK/;UBH[ Y-/6G3\[V8RBP\'CFV)U):S%@#<LEY4%X7_1F>_\,B117A'4AM
MP.ZMM77=24DMR<DJV;A1L3AB&HAOD7;M?"J2++T2FS\1/N7&(XZMI"GYW#&S
MM1,!4[%PY!!Q=Z7"I#^8V.V-(D>E-,Y[&B"T]R$5,Y?K5' W'JD[J1I?Y5F;
M8)[]A7+';.D)H46#4+0(?*=[GO$8C_)XP_D@1W<,0[C9!SHUJ)\)S9KW?FVY
MC,[(\5"#>:*;VND%2**67XY[\3S[5=Q]6OKK=#G[A%+CT\W/&B#V$X*"DCJ>
M6/'B -+SS*:B^(2<#=O?)2L1]ZN#@;/"DA<'!_L/VN/6CV69#23N#7X?5O#?
M0ZL\I$&8T#K:@-0ZB"RZ+&0MSIMI%!G7P*,@H] D58S G*VKD=4^QN_;4S><
M&VG"8!R<G]CMK';0"T7KWEC'%@G3 SH^6T$TQW9W2A-,I8,=Q$F&9*=RW-1@
MCX\'CYPHMOF"E4[$=8.9U%,_[HPJQ]H23UL]5Y-&M>ZI>Y46<P2 >HMR7"*%
M)D(Y_?E\JX%Q%A^\;X%/3F()6<8"*.:,N$<3]1":53)>16 .3B'$Y\6B :H
MC5F8.H(_4/S=.K#4^O0Y47B2^KQ?M%I;)\F7PX97D0LM6/G(*B6::04I;_-
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MEO_WI^)J$DKG/EK#&IIC9!>UL&I.=Q(,#9EQ__'QOPD$F]XO'U<6@PT;=_\
M#O\ XG2H674W<>6(=/X56=/T>"Y],"$"GY:JMIDLM!?TN&[<:6H0WO9*^N1P
MT-DA4'?-_;Y>7OAI,>99A5T!NYR[(_X"!_X/>W8//.(D64U#0Z"^U.O&**$W
MY&_HU M>S8)5Y# L.4.?_YKE[9C924]6VN8\>,H01Q]",?TFR>J;4H/BBRB]
MEP#M^'LVW;\CJ:PB,/J]W=!0%B,E_6>8#1BT))II^&S-X*U+>0 %Z&\'1Q6)
MB5XN3O@2F]=B8GT![6CUZ;W(]-^7AFQE6Y<[D:;73=9M!O7C)Y0Z]+Z6T]:(
MU C#!FB5%[#_FRCMW]0]_\J4P+#X3ZA[G@NN&2/J_(RJG</9"TUI[OX E."_
MX]/L+5?;K:*8^U1H=IY+/ 0[F!+;Y<^C\9J^/K3@'].Z_P&@QMW0MK'GIGAS
M<7\-B[)_WILF'I[N=9 =^=+<E:MB/0+T@/JA(&J+1X Y&X\<9@17^[7W9P@(
M&'YN$M#]_.G8+5BRL&KI%;)#L=H!;F0\L+'33YN4\=C].W&"U24-UK'U?K/N
MC**YER^YI=%Z<BCD46LQV#&@-'IMNF#7E\N;J(!/LW5DPZ;U5M1QK/NKX-3/
MA6Q[LCI_A27<\!S=KFQ'][5)2D[8A3U=75A0_#K>!AY.=%]2RU55R"99Z=!U
M3-)/K9>6*HAS8X*A"-D.1%EW<Z+'R8F\'EUM%ZNQE@$2MDPJ$%%JPE_-G;"D
M3-YS^6!1L5O^!_"[^8U9;;-#T+S?;1YT[\HEB&F]@C_%Z=1^EF[+BGS0_8$6
M E#U%@?VTK# 9FIKEQXF?H4E"+*W"DUN.31_@7&8WP629%N6&\FGL$;BOD'S
MYN2K(HS\NX2/G6,O4#,*97.)AGIDBQ'M-UI'Q:%70 $Y[4B<8E%5;!/F1V7Q
M?+@'O+(&->=5[9NGCSZGWG5<[NFBG&7[\@D('] /]GG!WR@DWV),^*"6^P-9
M#N]XEFWE/9*Q7N/EX$Q,WTD3Y3T'^IUEU8:,QC3V#]E(3]*]/AL J,_0W&I'
MD4/_ ,B&9Q=(F]LMB&A6]$KF_?\ ;!(.."$"RYF%*[,)CIC2G<W8"G5=34A<
M_/)*F8I)21.)M%T3RI@36@(#\#7C!M,DZ*/=/P@;[[]QTR'^+_;>.JK-;EL7
M#]"6"H72XMX"Q:&X>X%"<(H%=T(*%'=HB[M#">Z:H,$I+18T%'<H[N[^X_OV
MWG=_YYR]S]EG_,Z]=XP[OC]61I*Q,M\UYYMWK6?-N>8S?Z.FTQ$51SH$-]X"
M(J<B+];F4$7=N5E.9#$YQC!]'^0V\MK1=E59\\>H<Z''L4A"3!-7A&3+J;*V
M@I>9_3I>GO'WN@ZQ6\"QQ@)DE,/*5TF&=8N#V$W5BP$:&>AX+=O:#2/S3;!$
M/;HZ5!IR?$+.$MI2P9D628TNLW3?'7_5OV &/+N#Y.93UPRO8J^R+ETH/JD5
MS%,).L5F7Y='G NI%,+JKOOC+JL=^VRL2)[F93+VWIAR1%2\'6=1U0;SU'M5
MM@*,5M#))SZ;7S/.\L37C>Q"M.(#762W(EQ:HZ4=A:4E/C5P4AD+A*GK:$2Y
MLJZK"<D>XJ[KJ2=$6AN9<5=9OY35JGPN+2TSF&J2/04>M0?EK;]T."QI6N^A
ME.UK.I:(P"]H=_\:@S07>AKS IW9]W/J2*S7-P5"F1=+"9Y/1P9*_8YV>9W7
M>W4JEW;/K99/0B$^)W8O39_QJ"CO:V(Y\8FZ--T"T 1>Q.@QO]]_S.AJ]589
M[[X^@#)5>V_WZA,,YV4UQG%Q(D^TWB1W52:4AU11R\=?<X@KR#'>Z0M8SR"\
M0D3BF@_.H!E6(&#=,+NR$:J.M_TS85>EJM)UH2XN&WCP27QU'VZLE3W@J?"A
M^NWGCP^=A-)O$([U <FVA:U+TPR+F9C11T6C%)0595][ [3-;PB2*D-*A*T<
M#;>.$; -?"/^?N-?$;T&-NAL"#3?SIG(7.W^&6$[[<T<'7B9TS,#%#68>'&P
M2DS($!?)!]>N/2P63!;G@EH>;G.**YA?G#4>2*BJI19ANW%SIT'K9<*L60:E
M8ZEIO_I40(J'CD*]>+27/N>P,/38'/?10*4:-O:M6 \>+>H590;@$!V5*EU*
MLZJ&NH,Z%[5D+)LYTP=8C8<\)0O$'1=>QUV5**+M7D-L]-Q;F-8^7/W<94.+
M77ERKH9@P>YYO^)H:G=EET(YFCW4R)V_/N16SAPC.]XMCERZ;Z:11U%Q$F-S
M<@4,LQJRP9UH2$)WW1*RLZ,=&(^-C$[._(4-L=HU**N(P7-[6_KR^[@D[HZ=
MZ@9(*J_X&=#O/% 6[U=(KMF\'D^W+?_;F!I;[L]W0K&K"8K4Z9QH8$M((HU\
M)A8UGA_3GQ/3.#BUE K./@G>&UADVGUS"R"917XP#IG/5I<^U12@?21+DQH&
M$]E53UNTWH$F[)OL/L)P4+_22]\BKENU7SW$;U#G)A=AD>N#Y;'B!G6IA0RF
M:A7MIU:_=EQ:KS5PB*C>FTWGCE&\*) V0_7UW'!I3U>Z0E2KSN4DQC4PB%<0
MMX#Y1T,\OX!VT]?S-_AY4'(H.$9+FMPX=I='6FE='Z;;$=KX/GG$D>]E8/((
MDS:9<25X5(-P/T*/_"&E/T,U.S"S[EYEK<-N8I]3Q9D[REJ E [L6:!#_STL
MW2:>I<,?XG@"7Q&SYCDW\HK$$^I(+1U337@.W&-WLLLSV#0P3YH=7!&)M?-5
MIKV>C2Z>FGJJ8)N9]'VJP0Y#- H>J/:SQ,D8QE'1*1JNB,U(+MHJX)WZ\;54
MC#2Y4 NVJ!R*KUL$-6AK'>)JE7("1"T#NSSEN#$)RF5.E!=M?M5=;31,Z8]#
MU'37-Y^VRJ<WAG6BJ0WO'\-+T@U:*A X=QB:4'H9JF6.9'EAXN1@5.ZXN(/H
MAL$25A"6"G#3W0LR5-C!5&N)7N<7A5#?:;(1GZT5 VS6#)M*BNTYBWY*]P8/
M/=;!P?ZM:.1E]09IS!RH[P[L )4..>N]DBN7;<\A1?SQ="R.[*[:.4:;;7I/
M7SLKL1(3V@S\="QVF&K-=RWZKD4OMN]OIHAYWNZ8Z&X&V\Y )+QY9F))V1I2
MG+]&X.ZXX@C.B;H%X(6G9D]F7THDYTT=:AQ3CBSW.XUV>#?!NL=$)]PM63ZN
M8B^>@4LAO(&-_*\F.P;UY.P[N.EB1TM$_3[DU$(BJW2#B6ML- &W ,:!H:K:
MHW8[LJ&^VL.5:CLU@2/P4!C53@+,A9'+2E$I61'YQ$7(CB<E&J0K;61LX!YE
M2A,1WUS0SC5VXIX:!SD)PSD"ZS)1>&V:WP)DJX=MK/.2EG#0NJVI,?,1) GA
MUH5?)QU>=1'/#]3AVR/5"A:V(39*(V;XM(<RW'E/"J^,S6K%:":UA\G\3N#5
M%\,&V@I66AGQ<C&8\L,"SM&0/*9SM)GI0YI %LTZ8:9(XN"3>./YK(A 18K8
M,$I>M7X;3WX\@6W$I]KH!$5@/+$^4]5@5=5@R4UO#%<&V8X9.NSK0.[A8R8^
M,G9]*5$HT^+&Z)=(P\S ,/*!;M=:S&]#RDL!GB;EQ'ASN(PR)>L2W(^?^>MB
MV4%GAKF2O:0A;N9N&!)3<0Q$FT=9E^^JF^N_+&A$@U[$ R+W8(4+F?CW+N@<
M2.+(9\*T?98\(VMV @^X)6[ 7"P:-]SW: ?-V.\@UR:\L"K9>413A8TMI0C/
MGGV((FX&^+9Z)"<$&,G)?JI_G,,^' \4+F$PRN_)]_AJ;<&2^'E:JBV&WN7J
M7:$V\]VS^$#H]3WM>VBG=?#X!=F7EMJ23%CXVUIS>R'@!;W+U8-3FS<)Y[(7
M[P<[)$!=$[.+:12R:W"825H3!R76NKZY:YPA12M^9I'= @M1VH/AI6N(B_*
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ME9]]NNK35$PIZI)XF-0GKB]^]W?SX7M+)'X*;0#J\)7,:RWHHHU%5&E/(BT
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M.2S6*T?=_PABM+( -D $<VLBZ"PH6;51PIM62'V?,^FTB\6G7!_>4QK P :
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MRPJ1%G?@2C:A]U+F0(?JA,I4M9+X02';24TPUZ6Z8'9-Z#9+1-+V5?$38-/
M<LR)M<:H3M)R4APE5:TZ9@:51O-G:UKH[,;%6@ 8)^Y;=_--/5"EX,QJ86,8
M;.UQ+TR?0)$G=K.=Z0T'[I+/_8UG]^*-M?<)O^:^T_]N7C/6VH,90 O![[L:
MO>I6ZIW-2G(Q*YX]TS!M$!M3[21ZZTLJ92.DV;P7>:Y10MUP(*X;P8$I9TF,
MG+@%M C;&6&GNEE-.FW@7B(#,5T*K':]4>'&+*F-(PQEE92-M7!.E?3W(T?S
M^0J9? W&&-//WWQ;C-S4TW5690UB#LNE??8!6\ WY)Z#Y+NQ1B&:FZY45ABO
M#<_N,(Z)\D8:C;5F2VR%].@IA=4/#HOX)0P-:R<]'YD:'E[0^[&PG'.';$/<
MW7;-P):Q4Q!%QB$CTL.)+:UP'64GUN74C+V></,LYATLFC;B38>4+D%_88$U
M\DKIBO?[+2"2/;([J6@#BN@/R*],E(_!(#,$<M;T(//QF4?'RMHS-PF<^^RI
M/JLOJ'01;8L1<K>F$Z\%?B.[@]R=D:&4^';IL^S(4GROQ1%N)3QPX@%XUQ9"
ML66S%+8(8^<JWJUP#59H"*AU9L?RVN'+P%R_(1NBV?O215LAM(*^8*ZL(PKJ
M\-P *04:U]'< G+P/KACA(S4U(^Q<-$,*H8SR7>5FV,N8TRKL3F2R_4K#!A7
MAO9!9ZZZ'JZG+(4 DMLF%1(BG_H?ASVZ5ZY8H$UH\PM2&5[34>*]KZRTK.NT
M/^(I*YR;O!X#^H'U>3EZZF70T4(##9HFX&C![[5@I!Q]5D'LWP[G8 Q6VL 6
MZ@/>F8OMUTY*8B-RW#5I%YHH54<6/CMNSE54?0"2.?59\.@J>AL -@0<#W@#
M$8D(_XBWBEMX7NPJ=[<??T%8\E$))!=VB22M?E?0/(^Y+_+&\^VT!^5^B;#S
MT/N?A(04-& ZZN4 $:7#//BV.5!81W;0F@M"6UD9Q@P</C79L!H^9&E\KO 2
M305H.H:V=X%L8[&W/68PO>1\/2R+#?08@Y2TC0FP##.,+!@R\7N"*H9^_MJJ
M"KZATE<HM')Y_AH:@__EF?OGGZ.'GOQ[B\C*K?Y:G*85LH&]BPWB1B8LC.4$
M]*Y7+IC""DY?ER(5\V+CTS[%6!Y^I6K8(V@R(]%MG)3:W$+KGW[=1$3V.4(&
M9B?Z+%?V%E!QM'0.SZV75J=LP>2'HYYIX*D-HZ5W!T^VA@XW_$>GA,[O>3F6
MZU)T5G\A"!7[[[3_[,S)PW^UK!O#[\2@'+^SA/[D:/^/98=-_?_5(?UV4IMR
MOQ!6CY"O]O;5^8/'0>_31TE'(9+RO_L=Q V>J,F%75C)[<DAB4Q&/+F]!'5T
M2$.UDYW9HQA78NU@&P*ED[E/K:VR'W"\P?FIJ73V6!0%R5T\S]QC.GVCY9SK
MQ$0=9UK_D[LG-!/"/%HCO*#7BZ.&'$W-T];3FYW=&./9QDDF9;:4?@3/,75$
M#D,%,(;2K0B$J^,T8-IE6N_KU\>7/47O#5B2?!&R9^(*1\BE+%JN,9*SR4,W
M6WDUX)%DN37T3J\:L'\M[<L(/_!Y ;R4L.9)V#VX[R=+.[Y(<G"C0'U)!1XB
MWE].>GR50>F32Y*7R V+2+2*;@PGW?$J3B'9VGNT>[[P>4@H%L3<E5=G,A/+
MS*SK=6*Z63VHN\:!)"'T^O2+PO6DH)';CGJ]V):V<5\6@-;8]MTVUWJQANSX
M=<3WPQC^/@=FN1,;@IGIF8'K5>'>5+6W-X/U 8O;JA+[7C-?ZC:M*;8]E;O'
M>*4T[Z'>+]?!9R,+-]@'JS(CBQ592?.""@/58N*WS%FS'9UVRTGEQ:O2!<%+
M$?$Y8JY[$ZUL7-]N 9V#V'Q':Y $-55(M-8H;G4BWR T/\#V-<])LV554D6&
MYUP/M"ZG'[8!*IVTT*Q!*(N'!]YSAJ<X_09T#04<TA 30BY"'WZ53K?P:6*:
MB49WKE]\3&X;ZW, UQ,L Y&?%2^%QP*=_"Z%5($FHLK%J77PRCK1T2@<HSZ<
M-]8(8768H=:[FWS&$^/-#L'<:@N$Z4:G\PUB0&=\$K0,VS8*2L-N?W)5]!TE
ML#B;2"S:70X+B7\;HU$#3%3">3A39>_NGY>9O?G<*N'-^4_9\*[=HSR=.4C]
MM]Q'[R@&B5 Z_(#(COJ;\]W-6\!H-OF[_E6=:R<^CSV%4^J-+H]N>;!RIWJ$
M).O09+G//.X@9S16$AW=:4 -/?R=9K'B%7PVX"#_$6@--70D2,ZC$3-"Q$[4
MP\\MTUX.%(FLII\9KSU_;WH,NQ!PV=S6Q)*/?X=27(BG[>EZ$1K:)E#"\V4:
MC/W^=6^<SW)(!#G/P5Q+8MZ[5-/4D80W'';1DPV1AZ.)0BOUL\8E=2\A#2GE
M/]9MS#^ZIR5]G.1)&)"D@Q:H?%)+[X#-:@&Q\[/\0B0*26P9'V&,1>L%*HH)
M>?SD(]K>ECG)U2_?4?OQ=MF) 9%*IP[Y>J]&X\">NDO0AS'7Q-:C>#-J)EP(
M)//"QAX/OEOJH%=W87><PR_*>^\RY.L*-KN='W?U8@(N?\W/[L16T(<Q%ON!
MKA5.&T%3*O-R1)OTB(O>.LZ;#NJ8Y[*VI0?PAES!4G(F>I-\@ES!BE4)%IH(
M2:6?.[&MIT'%RPH?Q;4NGCUPO;:**W5RRI+,AB<RHL+]H_+P'(9)=E "AT>W
M@,V!J;J+T;E)5>L& YT=\ST5!-P>]"W6Y?'Z:?E+*%#]R2OLYFMW+S]-DIJ@
M@*R3"G$L2!4FD;'=NI[R*:62%3^R65_82L-(1%''S3/$5;W/>^L76W[ML%.D
MP$GW_K8)G2F8>$GC4I(RJ&J72LK)."J*T'Y;R%U3\JA_5?9L*,UP&L^(E+NZ
MWJLE@/CU,G7 ")=.+4+G+:&F6N$M(,'/-!<,J;Z4JN+58/-X7/# M"NFWONF
MRI&_?UGF)*R4\*HYB)E,U=N":1[&$I#)D\4R.8F>2QT>@+.HI[R8ORQ3CKD)
M94K&#7):1?45#(5S]TQW>;W6V'^^(?$6UV_RO843!-N+0P$/&^>@9%5#3</K
ML3_?CP:R_B"C!&L+>=?%Z'B=%4:_Q6AIQ+W2!2]6J>!434N+)RU7R$)X\M"]
M/6&PS.%*O5%X'#715&>WEA-3,V=B"'%@.&U<VX)PCNU4N\H^1:+H27U3%C\P
M'ET>&^T4/G9TH7+FC;#KI2,NA+<!GQ"+M_8BAZLBJ]8D.J;GL\4K14:"678R
M'7+@L=?I'"CICNC$9>HQ[HGT#S^Q<3 NA@<[)D4NOM7H2RGA$ N3UY/9P'+[
M(-:Y4U*D=?Z)#HRQ&MP%-BS<4\+23&ZO@Y5M<</2F(K[O1V.<ZY$R49DWL2"
M$7/[+UJ9N'OM"?H=/!8N/3JJH/3:BH-KKJ1*:I,Y/ZU7([6&9Q:B\0/O1WUR
M/SJ&E\2B!"\BXLAPD0:Y.)2HNO?N6M3^*E8'A_RB.#I]!,G%CS*CM8,Q[./I
M?'^J>P!)ZX0H[=!;-ME2&R"OGV#=+?C31_Q"*[&;Z1VQO62Q-L(VE.H:->RK
M8_I>J$AK:]N<OF?^OG*S&KRX:X*C =6)"E[Y2O>K8O##GO-0L.M%DEG4R.'<
M G3X8&907IISYY>&8X<V]FK)S<\V"9(J$QX:&?::$:&P(26 ^]^WV]D*B)#-
M>*E-PL6QN$$GU=)'!9>\=I99(2L>R7=+X;O_VR'8N];.A29%JUM6EG!A]EN\
M-1G?L5 N!_;<C/:^,XEW.LO5+ B+2I13$P*VP,]Y0F8($+@<@-R]92(#?KK;
M!E<::'_Z(8-#[DW=UF9,KIGW_0&#95;#P&]QV#?_,$3R;Y.SY:+"P@PI3:18
M+.$6'E:&/BU,$ )XO7].N,V4[[O@@1M$XX/[+/AJJ9/2"$9%9[7'\EZ<Z7(@
M1JS6\M64@9^&CMO]<O09K!@1XC\Z^'*^(P%VVV.;P+M-O:Z\/3V2[/!X)2&$
MF? %17JZ._]Q.PO>%B&.W8_C[&K.HSM (V^2;P#Z<C(^,]%G0VO95O0^>AA#
M@[Z=JDY)?FAQB)FZ*FA9V6MQ^!:0,H+R!:1X66;CW6\C>^;%X/9CM51E4XHH
M@Y5.=&D Y;ZZ"90"T/'_BCX;3!_][>+YA>.L^?D*%M3QV@\>;:IJ3X8*\EE'
MASZ,HC(9_F5<HB+U90&[[OL)>MQ1A^P%E#[KA]T;SC3.+089>>>3K# 5PUH/
MLL5-*3SC3[\7)H:4RM'KQVE(9T $W+(^DVC/F 2[L2)S+<=(%T5Q],Y"!A^R
MP&]0Y76L1*:\N19<R<,Y,U5OCI6(YS9.P_-<C0D2Y+<A*89HQT+JNSAGSV>[
M;6LVX+9.F(*A[-V%5^XWW,$6>[> -A)/;[V\JJB(_ ^N*S"<AZZ50F=AAS=]
MCYA "PIS)C^O:Z_*SU5]<(B.?L U6Z'8=7D&YQ<))399$Y\I9N-';O!]-<P+
M9\AX8/,L<DBU6+6]]LZ:&+4D*I-/R.9S;LUM'UR=-UXA,UJW@!XQZG7]8"G5
MKRF*HJVSS]-F;P&7.KIUO"Y]W?9R^8/U-[+\5-=,86?A7&7KDW8A,A*VS\A+
MI*6<1F\!^[NXMP!#'T;: BFMYG\6N4N:3(A%L'PP_8?.E_^D/?G'('GQOQ>X
M^TOJIK7 [X$[L]#?^=\DU71O :57C(Q??F-0[/I7HXDX<M"IXO<BZ2#HW"Y)
M$E-[#M^_+:4\_2W2= <UN@$DBTVKFMM2$+WQ2CSD/HSG<*](CO%(:V0?"%,M
M;U/1:SYYG7X+$.DYAXJ6<]T"SD\,>H=]C$=V0F]^1IH$937X_/6G7#[&X%O
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M;BR+G&]GPEZ%6V"4KF#["+!'7'M=:$:=&7><:HR6.LH,[VB@ICG?:)PG/XU
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M[R'TNFP#D"E!_'9-=N!-2.F/DF3_A*=@$0&PZ-71&G5!)[*%HO^:L:"&])\
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M[<6)LR!8(*H(JIRZXW\G>TU\ VI9.\APS>)(O31 4-K:B#PP(K9.5_\]H>B
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MEE2+Z%Y.#.^GR";J)W[4[Q\/X[7OKR@[&6B7]%@R4Y5?>^1?_)(D@W/<Z%A
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M944M^K5IDZLQOOQ'O2_]CPE_=J@F$0%A^.M].P+<_OOSO29X)\5BM7%RDJ_
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MG -.A^-AL.1EOVS-G"^-V=NM48OF4@%!8%)/G#OFQB%3WHIM7XS*]U*I_,X
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MMW<O\%U_X/N@O:S[V$Y>5-G/KF?%<,J%0^*GJ"1&@:L%GSCU.Q9/2]YY^/@
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M^[!PN))8=)(C+BDA3-*F/S,G@F@?C[$O&?9(G ^O-\>K&G>1QDQES0D\B I
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M_26R1O]P6BS3R>E.$3IFU/8 A[W)ZS5.:1<P.]KJWDC'W0QB;+#S]EYW\IW
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M.R.8@B?\G[K.&&U?SR/$\)]^C*OGPXV+ 9_D*USYK<0'V0SM>D7L+U,$DNI
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M3DZ^@@Y1E*])-O+?W.C.@V^*6ZX5C!T,?ZD+]&/MC#XBU(04NLR6@_GSAQF
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M[%>VJ5 ;NG%R-5KH0VH5VU,"!Y :OSX B@SF[FW. N]/34ORX'U7 ?^..T?
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M+(@*;EW@@.KG,.KG G5L9T:W)V%CME]X3=8-XKC;M@# -9G"KN\8XV63\LC
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M0EYZZ2HY63_!$H=9L["E%?#F9\)/D6+,XCZ.=V3=BE1T3+NO!FE%A(0K2Q0
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MX,1@A K\:R"+1'LAJ%2:NU?7TU*)RB";D$K?:?W467)D4P!A."<?IY83[_-
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MZ4W*'_2><_3>XZGOO?'^,5X<4]E)W&3M-==7YIK9QP/''P'G%6459 $X.#B
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M 0IS+8<;<BG7=]KD(/]W\#]XH%<6/6; =Y$'RA:0LW\,>%/4;2H% 6J2:T"
M@-\('-59J()=H62CS,E)U*J/ 8:[VL"&;T_)<]'M9):[3I[2Z)+\GSI"WW<6
ML&, :U]_JX[;B#X&;/3F3<[>WYN'5>3  <^Y&(\!R8_][:\?;/(3@>_Z,/^:
MP,O_&Z;A_Z\#:.J=SCS3R%NE&;9':58\Z7HLZ<_>P%E23_U[Y(_*SV- @>\*
M=!1W/A5U(P@@WYR+5^$$:"Q/9B)W/O7T_QU\/8"QHF:E?.:88M*2'*IK67#J
MK"NQN8M4O1Q+N]&;7WF/%2>5Y [&>P^#GG"^<; )RS\KJ(Z?4JIR#! [2PM+
M.'*G+&ICLCSEZ"J!?=&J)N7(O512!8P =(;.ZDHJ(5Q/+K[4Y?W2?:WY4VJ_
MPCW+_]0!KO1@_&0+52*Z%S]G/Z4I)X^%)1T.8&-/V3JKB89*8"A]^'+3X>G2
M/^>0?S><Y53Q(IQUI>(^D@_X^D%6]MU8L(^7E:-R&T4JH3,_(P\A14XG#@2H
M_M\3(&#$DB N A #]V_E7%:E .-P@FC.(8D'/B( $7!)J7DK2T ZG.7G..6A
MMG4,"##.)TM9/ 80URF$X ,UY$U^<'I\DKJM\0 IK=%C .J C3@-^UY)O]]:
M2M]&1K@'.LI4S/)4G2*?9LGMS>R]NSZ7P#/3W42U*O( 7#A [Q^I@DS3 "8?
M,H0!<4%%<3L,"_I<QP#8C1[)G$F?2ZTT4?O!<,E&RU-ZK/D3>>C_( G=D/+]
M@$),5]DQ0+TDKHOS1V/7+O+:/V1;UJS]O+B9[1N-G7*S .S8\;\+33+<O%3\
M](P-,7SF.,M3RKY*B6@*9B0+ R4  9=\W?WW9EU^RN'"HA($H"Y*I:G=DWV%
MOE86"K]]%;P*$S;HQ*O.>[2ATL8(X++$Y<!GH=)^SF60H@AXGD%,F,4)U/QV
MIG\4IPZ_)'8NIP3ZB%],0>KD=VH8' -R83'IV+6LCL9)@@!U+@(U(("?@[_?
M;C+#W&0H.]V'77,RA^T<['X,RRDV]VPW_JOJ(II_;9P&32^GV&UY%Y>ZF)/8
M#C])[?9#G*^'6W/4C6CV3N.<'=W<H'%]I[:H0A\)TM/NUAA-JBT*74KTSOII
MC79;&S%<VE\R7!^WHF[Q\ME9M]WN<EE287A'U0ON,KDS(G .QT+#FP>*<\_]
MR,W.2ZVP6D>L"J39.YISUBP9?Q ZXQUMLRB\C'I*Y/:BW0N#^S[35;;0G-0U
MG9\%)7N.9DAQ(*+[YI.\V]9W^QOTS,?PH.R1 \$:MT/<'081)5HZO4T:_N?4
M'553T2>0\*.0O5T0J7-Z;#"/BW97;DJ#&!!OKTE:"N"G0P!B2V6M7+5.I^++
M/,G+SQ/D-U>=(? A^V;IG%Z6Z#\">>7J>1<=L!TR@;'7_MI_IMW7 &+3OM\+
MA*_F>E2]FLOV"/O>4_]CLKP(G+A,&Z+:"E+@EV,HL\29S-+2(+8#XW"+]FRH
M^ZN-2A);Y63A]7P=*B8-.U12[%"I_ST5] 3&,60O"V2'#Z6[37\J^=%HOZS"
M@M)_D;1N.IPUXMOL!/;;9L"=)9<K<P'OMS*S3CYB5BJ V$"=%0V(2@V796D$
M2 BE)W0G_>9U_*,XZT3*#:MY]B)4" 2# SK2426*HQ#I3M",6RJ1?".C<C%?
MLBR^:C'=)A#GC-VE%CNV-[D:ODK??+I?0H67Y9,D:7HZ[SZQ=B06'A7_[:I>
M'_+..X"Y^_4<JDUIH:-._A,(U+'_. ]VPCZ2%&@-B,:U_P+.(+@.1QTUIZH.
M-AT#1H^<7UO9K6: NA^LSSW5EWS@G1B65EA+QU'U68>^I>$5K&_I/@=QS*!8
M@"-E_)7$?IT'8X;%^U!:SWCC%FJ#C^H64&OJ%#];T9#+K28;[Z:/J OBU[!8
M8KM&TIP82/#A$X<IF3N#4C#P"?,B?$,[<CEV8R3YA3A&?OS"2G<(KR7X&,##
M!_>;?=U4V<2>TX.L?\*@ZU7DXQ**;K=081FQ\"^]$LAO<M>@A(L;N,T_WSLW
M1EQVT?J2ZMMKEW '^E.[+=+\ZUZ<+$<Y]1]9 EV3,N5]]*W9PA$NJ'BTK@\#
M0?)9&<0#&"!2,#M2A;.1#PR8A*&-,?T+VFBRVVRKY !W]5-=WYQ [*OSZ"7Y
M2IR935@"S.3^$;@&C.]_>I.:M_)U<:J?D*74K]?>S/TO<@(H&F5M-U^6;./O
M6/SFZHHE,#,=U:;'_HA&HDH,C&X^=)*8D%H[[#P&Q,&\Q]\> 9<<#^^%.5:G
M5ZI<:@K'N/KU3>+@A=K%">'U:ZX4-W7SO,E]+XX.2=/D@SZEAMA#DT7740@1
M?1XPS+XR+A@ML9IBZ-W)+_%I BL-.,S6G")+VU?@'_LGJ9ZR!2V!Z#LXJ"+8
M2U[4P(^Z1>+T6:;H_!;Z M0"8K 3<%;Z!W* B(NOQ%U;] [R'>\C'4J '9;'
MV.S KZ,H#7J /2\;KUX&=UN=SHZ4Q.&_>V[+61U1>;[AC@_M?P]2\,J^;I11
M=8S)[L1!Z"GJ ?3T6"UQ("S9<+M4_*ST&)\KBBR9J80:*GK.O[%\_TDHAS^/
MP@&&5!8GLU;,)J@" :G:OE892'D6 )76 H^\<"=N[C<44F=UE+.6A\$FG$2(
MFN:7S-8^D9Y9N2AO-#_ 0@,"^NE'M/#G0XLQ_$Y04BA(5@7@5A>4\]DX<!3G
M0^-K)#4EERM4[,J5A(7L>TI"1\[]5N%+_OQRX9<[;M")Z:D4+[<Y[C]DVC H
M#W0L]4]YW9=<?+U5+HN&I)P/MCYJ&AA5-"<GE=6A0Y^[1MTQL"DTJDK*C>]V
ME$"+.U;E36UP9VAH5&W<L4*7*Y[L%H2H1FFVX%XSQ.:589EG07QO5FNHHZ'8
M6R*D6G=%K;3*NNW1QIU'%CJ#-Y<>GK.>L7)0?AMO;"<^@,K.M>P;-^M:OMU$
MS'36.$],6&/&[V296?YH"JY1D.<'5RO@Z7R0QB&G\V'1T*49KT($ILEL$-_F
MC7+.*81T4+,Y!6@E9S\[&T"ZW*"]^?WENC3TA9+52XX!QKLZ^\J6V'F2^1$]
MLAA^E<O)GPY=)]1UB+#OQ<,*354"2QP*OYXS3TK!9?I@UU3\$35W O=.UDD?
MX VD< *<$ C _%D"GA!UR-HB,>^X(NS%/]I_84HJ277XL&-1A6J@;H*/IOV=
M0A.;-1+,\-,D<B%CQZ\(8XE'I24(O,S9+MY^_;KQ"_JP,?CFJ'F<I>,S-Y[P
M?6CB&Q[4H'>_AM'3PF/ .]+[^W.'K'P/F9[%S[JX3$39Z[-G%5P5S!>@G];#
M+'=>L?FL)917S_>XE_.1AP\U^ZM5 >^)*\K'@ [9H^BF1=-85//K\74NYD.G
M^PL*"2:@ @F9+.Q*I$G] 40#=(0BK3]35FJT!O2'IONPW8E(=LC NQ.O+..;
M-:J<[@M7 ]]&*#J8)>(@ #<[7_I"82P9[!'NB)AG_Y'4EL/>N7KMR"OWMT@4
M0BYB4?SQ;R4#Z L^H'K9QU_5*5I2Z,%9LN5__BQ:AL]9T>\)*5*)BA54,\&
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MW8'[$7 PX%)$OW"M"PWA,2#<WGLQPUMQ:JN]R/")[S%@VL!X?WZ\.Q+\YAA
ML4_-B%5,F[]9MO^S46);A^:T^%+QRVP*LOR18,ORV.E?@,*B/XT;9X'/("%
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M<LU*L=]F&OG$3S,:-5A?8.ZH:;7=X9T__)9RCI3BE<\&=+GF6L&'"89AXF/
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MCCVV?JN:,$BV2J,NNNZ#J(7U:;Q(]\:ZD,L=1"GY!UL8N#N.'2UN>EGO5!1
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MV%RMD>UY8G>"P8(UJ\K)HC6)28P\?\GW\'"YKI?G.QZN"TNDQ\H.QZJMY1[
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MVMQNJ9&>%>MCE>_'*KK9G]HS\J_I&Z?#3L>*Y(H0=./2N=,D0UEN%F_,$Q'
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M6_F?!;(>7M?U ^,G'S?;D$73$XT>@1>^[FK$IV^L)L_[&'=VC!74S4BU@\Y
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M22-QE%*MPF]-,^)B[0]LZE^\6=1@3#15O['E'O!2;\(/MC%;+_)X7<+N6U.
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MY>*[]54)ST1%,[4)&W:3Y82$4$//T[2Z-/;2;PKI2U>^VHZ3GS;-2<3KB4'
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M8UJ8,PQB]GZ6,[TN&DPTWF0HM;3V8$.M>-%6JD(:>%'DN9FY',Y\^W$ IFO
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M)"H>REP#I'4&-H-&'''[UDT1!&\AXKL%M! TC+/DU<R!]<5W:J/+&NM S9V
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MR9MNXC,H1$]IVG N!+_DW&D@3 ]LU^J&VP\;.3LE$>NQW->!EUHDW:*ET'H
MHXP&CMJI//N]':"!0C&#+W%.GH;<M["Y($3-]F4&Y4-*"28EKGX0VAEV-<N&
MC=.9<+66M;@9U.)(3:/",4 BIE"0 $&SQQO)?W;>=/H=*WHAZJ9,VL'<V&MJ
M"7E6VL(&:!UEM[S/E6*7"D+,R;[;=?XX5_T%>,94_F*NWO-,);T,TA(=K*4C
MHWGHOFEK'T5@6Q<S4-N%O1JYF4\K'X1V^IMFH7ZL71&.,Y#WLI5VAPJE\ 6*
M^*C]B!AT 44T!']T+),O*%[=A.ZS?T4VO>KE6*0?"/_HH?U;V#(:%A&)IU2#
M1<E'K&) B6UT$%4H@&]UA.^$,7P(/R(RB[D<.R+X&3[^SO6QZ"G3L.6-M&=#
MP<=C0A<0>IH"=U=51/^L/UMO704N2J%*?@&\Y1_,SM=?YDN7TEM4!I9\NW3%
M]H8J3M M:0K3CZ60M-MW1N2\(WQ]?TE]DN=(O<C-<0Q,%\7$FY/W'Z[W?ZQH
MF!!^9U"82 [TGY#3Y2*+GP>GAE-_G.C1(N*_&(._,?!8&ZMR 4<(OC8\F?:F
MXW*[G[2,$C718^CM:C;P'Q<3PGGQG:@9'M+KF;XN8(A7L5K5H8=3]!/,KT&3
MZCDW;6JE;0ZV$0SQG9SQ@>N;NBT]/L*DLWEG=%I'=M!=A(.!XZCGB47D>MAE
M+XZ^19R8(U;\_CP@3^+IJ2%\__O$6VO8F=I3U[%<H-A2+$29?LB6[B!?/Q2@
MP=>22Y+!1Q'[!Q=]A5%<2%.M?FY'AL[7S#A%ITYX&AH&:GL8<<.5%[3P",09
M7TGRV<?&\?>V7%X0"H<Y]C;7F^Y+OLI R@#4XLFI&W&:9)3'-Y>]\A5]<?(C
MYOP8; SYOMG@5)2^3?UIDPZ9X9N\N331T\]8> 1I*(Q;Q%_-$WS$'7P)-'4A
MUOX:[(([O?KPQZ<73)D>I')=\J(0*[)C%R%E@ 3KF!JNP^5A7T?4N6P-/Q.B
MR(J%+_AQ^2TLPBJ?*19/*4*-MBJB5'&\T<.GQ25"3*=+H@6@9P<AGZM8[8,6
M(ZEPO'1A<<Z?C9I"+J7Z1W=4&[?)/!NZ= $</K*B2GOD!7 :?G[<";NM8'QW
MM-3AK/+2^1%]%_6C57<^][O%?^"&!0E=<,*9IAK-'=USG1Y7ML(J^%Y>L<V<
M 0L),G7DQ&4KTQDD_:6X_O7S*#D9\_R^O3USJDT.<*EIHWJU=[O/7]:GONDN
M6Q3D3]@RR)I,6^?* 7FQFF]/Y#TLL1RH:E?!\98*VOR>CJ""T#QHK"XQS"E)
M>S$0F/WNR23M!UG^1Z-.>FO-V\B5^$G43=:0,IW2NPQ@:0,=0X9"+.?#5.=-
MNXOP5S=:7^S<Y9E]@-&#.>NH3^L[Y\5:-)P\G>B\HTNEBO%]7'Q@KHI5^UJD
MI_VHPJ[P8\:=S*+565P9I8>>S9;PPC<7AK+7.CUB:^;'3)5%))BAU=;^;M I
M38@F.I+)&U&]>AO]".^ACB:1N,#1*[QZEKR6:.+(G_98\,]Z[ZL4DXZN,V5D
M(VKQ907)\K!%%-KL]MN#<KFR;QJ_ '%6'Z),",?,X*PO4JI<][$O/#\8'.E)
ML14C<D:K>WD]J66\5RO=]JAP7=??R^%FUHLM6Y4<!P$[REH<66L(P4?7*:'-
M?KYK;C1=6:Y,;["FGCO SR4:=T5M'."XK\>/IWNYJ8:D1GTR=\7O_?3,_P6(
MB(W_^=D^(S=_[2:SD'W$%2(VZ%%!9]Z:5&D$>I::;-"0A6#)0+OX2=JZY-CE
M7)XF$%HU'M=;@:V5BJJ]4QVC$+^QR3XA$Q*U*87N&@>%5HYR1%]OO#?#AF*+
M^@6X>_QB ^-T'/5RO8:X@>BGLL5(3 J31*_6*RT>K9&G-P..?XQQ;*-O/<*#
ML??C.^YQC4=>FL7L6%>C/:E"@%3:P'NDN25BDEV*<"]894DN%UTMK^\+[3 G
MQ<="V<:?X\)*E?(<3Y_%@Q?:Q!,J6+X3BZO8O;AAAEI[G,'E[635S!E$0GS_
M,Z*?O$?$I4KLV[/RFMY%8FKG$^_]=F'/PF)YQ,.2DB<S,]W$,DR13*Z@"T+P
MA@O#/-1(EV,O4HF8_">\EA L_VT8VJH '3ETMQJB+$+\*.1RC@5.. \D8Q!D
M8(V!*K$B%?E:8H=$V?G"\N"1>&IF"$4'<T27>XK,NRT-PI4W]6J%6%()B?;)
M#QC]^,A$=#W!=%U/_A?@H_4.=2L;H8+EC8#5T)*6ZU3@^9=]TXS,EHX&0:E]
M^?E98V:=:?#>L8"6O^$Y-N)+KBQRJ$ O$Y?O!%%Q%^4M=YW[M\MU?3-;_<*L
MAU=N2-(S-W1@TH,@TZ/0,"QQ?*P:3)JW#+I]CJ@7W50\O%RD7"4Y"@&5'WAP
M_UYAWI0>TUU<'$7HE3JB(EG2TB>^ N6K"47*  6!:W>VY5!:)0PL)0.RV$>C
M6GISMQKXM#7M]34#TQ]GEEYY0@@KS,08V#!@E1^_%A<T8?TC&X] Y*^35#F[
M+,(H7%DN$8I/'O"=&DO%JZ6^>7C<W3V%"&'5<T7JKEM%I.7$*S>[>5(]'UJ9
M&$L/7:LC9KG$?E"">K+.X%-44G4X7+M3QB+HC\S1FA$C!W/FX<0OXO!B*BWF
M5JFXT5IW+S3F#5HM$*WZG\K/J!3'WPOB=W'=*5J_63PLSQ:<;ZYS/PC?S0]Z
M_Z.SU*UJ??P(:(U>F[EN"!Z#W=X5J/U!7N>R\ /.GEQM/^(RV;9Q0'F_1Q"@
MG;1:^?59:ZG=,7SL6N^89D22,E%V68B>WCDCLXHO*;+[^RLAYZ4$4D<B-.3%
MC<4/-'Q/2\.1-R<4/Z@_H]N"^D=GYJY57EUY12_+#ADKUOH%X$"^&->P9*1=
M-HVQT?=Q1-GY.5J>=XS@F+DRR%[QC_./957$*#2F36**4VY%+7IAI<1_O+EX
M['*93VOF+I-.J9[%7HRU6;* G5,;H3JS<OV-R_69V!^XRBG[Y%P3@>1AOX&9
MF%+NZIZ,.]6"^ =SJI&0*3)6!2##8@Q&(V$I)D6;3T/G74S>VE13<*9.3,\3
MN=6#HPM-0?58P>T%I[AN2;"[, $[1^>[R>TS=\W684W7-Q"%ZWW9) JO28B)
MNZ\MDISR9(U)+E,@QG>8<G%35>:26=,*ZK#[65".X!>AV;?8#!YO)_/@WP%J
M6Y1S%><-+.6>C^,%?;V(OT^$E/@0;9(<DG2TO/H%@TZ/V <C86$72?J1(I-5
M 9-5EI(6%PG2FAQ% A09P]!17DC!?/(XN(H,^44DALAW113V:Q 8\]FY\TE%
MZIZH-:\#50K?VEHG)KC!I*^8IT^.?%ZG5:J84A)XZ*[UU'2ZTX/M>$#9M<:G
M'\:3("XBKK1F>FC\Q@'X8V%S]WG8!X_KEM2A;3\M;VQG]!T6,!D6!6CX@SQ!
M>OS\A79W0J;UQAM<0__W7:"_/&WT.2_T]*ZP(6L_9!3L^#2Q4#IOD]C]R/_5
M43S-IO<AQ"#G(AGRHAN2JNW[C-I"MV=QT9(R^)MYT&%^!DE)Z8JO^BUX(PS=
MI2OO!$+B54>*P"%$J)1/^Z5B$)SF*XM5#)]@"N3.A*0UC*P92PF1*(XT,,PI
M>9B:T @TF[[FNT>(43 Y]VIE.2FIW^2;PDID"!;V"?N3E[,TIB+XC/;9WT<Z
MP3/P*,>X9@OWY0IK_FXKJ^4*3UGU+6BQ^R562FOUJ' P%I%9E1_(_XP8-K"3
MT/2FM;\QWX3D3W&^'UUI-K*<VR\$N\0-$_M#:\W#\D9HM7ZK(+S"'VKW8FR<
MO^@W5<?8-?5V%%02-'B)AIS*"EY0I4P9B6[Q^/@O6!I\:.2G;^_M9K1"P3<$
M'RP:/M@&N^Z\*-,Y"G6@:\J]G_I\@,>D9*W&^U14B[Z!,_PX%/*]/;UI<5>P
MC?\.41"AJIS/Y7H1)(UBQT"&]9H+6H]J-C%G/W81]UJA],DOP*M$TQ/-Q6\<
M#O#)4<^MVUI>=6CJZDBR1*^2CHNT7/WB WP\4OWGIZV:-XT/L?R]BJO#^^G:
MW0ZU$8I-ZA;O#6Y"5L5OD70[!<>Z-85#,Q4OGG'Z!9AYL6%V&'*1"2<^SN8G
MOY_7]$:B0AZ/R'47Y=W8Y3K+J7E1N=_$UFWW(6; GI52J.XB)"OL5Q]T)+2O
M#CH1%7*1FAGLR1GH(_42-CE@4L[EUO@)U<7*_<M%OA[:+^?7'<LN$F$',\[1
M5YU5P,Y[CLH-#2(Q'KO'Z$_C9EB%Z$KESN69MMPLO:TM&HB;GYT$EOG[&PNZ
MVIP]RM"]+/M%2,JZU#=T\L!/G,:5A!^L=4.KS!X8]4<H?H??^8>A&)R/UKM(
MBJ_ C 7H/T+QHO8Q*,0Q;.@A25X3R^@3J^$XV(COTLTI9-D^-+#'_,Z)U!>1
MV/".\TFT*CQV5%N4K"C>_8WZ!/L(K I3.\H=D5L=IJ:VF$&H(F[S$?D658EK
M,;'$56<\_-$V<QWC>=/XC1VPR&JQRW<%\VR;Z0,'9<1I#8?!H0-.8@2K.84?
MZ5109J]L"-,CDVT7#"@@^Y<LKG.0P-?4?[CE\Z<2O"H76Y^Z-EV#E,$Q$Y\5
MO_">M?F4D(^(K/<!#59#.1/BW;4NQR.'/J'@\G!Z\!U0F :E&J4\I;37W?B;
MA=VYH!%8$!Z"DT!'HJ]PT4$>*9F&6N<*(COX71G?//01Z7<:-COXOEZIWOBX
M!\,EEV^.>97AF_%\YM8(SD-=V1PH@F%[C"+CY;\[B>D718Y6G.2">G@O3>8/
M_PUK#$%]D?Q.G).I/O:2)R$4'F8_Z=!:)M&B;CX*YC?3YU]400,SUHE$J4@H
M/:IU"82WW/@&*=\?AG1BY7$.2ZTSMQC!R7+%\1OLQP^;E9P_9R!$D1I\THDK
MW"7]Z2ZF,89J+8K#FPR+R_DC/Y1N9A: L?+;VL^?M#8]@:@"<2$9QO7N'0=.
M8+H&6P'ZJFJFVM*-J\7=M)VTJN]\)$N0?).P12&'\I2A2=_4GIH;%@HK60Q$
M2*_QU\VUPA.?KWEQ9* &(.KM(L7Q&AUE4=BR%/<]=6;UQJ%Y+#P96V@);LF6
M;\T&:R.]C>OJTTOHLD8@C^+E89]&Y?'!6;;UF'X52B$8X,<PVMZQGXCU H0I
M>;]9HU5#Z_[;WPMAH?2\8$I9+2)NDCR2[ N^N9M I !F<^R_B]12@;5=E$>4
M8.JBJX7](A2>QALG^,0Z(J&VZ%=HWD+/KXOY8X5P=TV4+.4,#]3QK9+KI-(G
MFZD&.SLOBH([^^ 55&,./%_<%!;3]7Q-MDA#%E(JE<Z('U:F3ZF7_7-IA7#M
MSS/+>1TOD7_O<?A/O0[?'3@Y*E+<7[RU/9O8,%NTR%<;\6/1/9 _F3,AP9CA
MP)[^_[1S]>%,[GU\YSBI1,A;6!S2DD5BBLR1=V)65F0HCK?6S-ND\Z \*$52
M:$UW3AR:6:A8DY=3F2=':&:SY"V5$PEUD:A4=N[-VW25_NAYKG.NZ^F/>W_<
MUV_?U\_W\_O^OO=VZWA8PZOL>[O2ZVC@*;'8.=R&ML@2!!WH'%IJ>X(S2TP+
MEHF"@1SZG90MKV>_ >XX07YZG+7KBG6V;T329D-)[UV CK^:7S-067+TA\T2
M\>;:+XH=X2$_*AWV"^$6<3QYH:$4/4([:8ML0CD88'^%UB!3,+SS'PAM6;9!
MU@9/434,'JHSU_=)Q4/&6&ODBZZ$56Q*'XK8$I)TLQ$_'ITI><=XI9'!+Y>T
M _9JWK63'M'^ T64=PE#=5%<'';?/^2C[N'!AZPK2WQ 1W) _!0B@](0T>(F
M('ZT>['_6HQDC&Y9IBYK@Z.H;KH>Z9N=J5\;\(P\Z!-S7?)HM=EWEQ"8LN*,
MNT-D7S?W>V1,A4/>R;S. :);<8RS8IM5=)">O.1R$&6.)&PML>%]G55T3\BF
M-F;@XO;F%-F=KPCN$55GS]IWH+J/*9!L)-8M95VG'=QYT\MR[+*"Q/=;Y'8R
M+^8"#G"-39U5:E)(E>/@6:":C*@H8%)8/ZH#ADXLY1Q?NCVX<7T$/$W>SC&$
M9.;,&"%3Q9/GS0&LY $?"MAL;I0T4AY$P_(02_#:8?&&EO%YJIE7O-';L#K^
MSBMP]5[%B50M $W$.-U[0@]-7\$!B=G]AY$N:ZV3<9@]L=@HY_Q6EZ.^F9FC
MSZWS#NV(&/"PC41@-$FP%&20,CH,791Z^BL&-,Q[C!+%?MTFCZHHET& FI[?
MH?B6W;V:0=1*#X\"RNL*-])<.C2\VMOH*QP&4)N2X9BLM!GV<P)C=$0E$B=Y
MFJ$/GG0=\K]72:(]X?DU:Y0K-YD4>62^4'E+V2A37MU75E"$Y^S*:WB0<@F#
M<37X^=K9@^(6C,4[!K$Y$,BJ1;KRVW^3T.%(1/ 4XQR!;7"BA9 "(8?W"3XC
M<88.\YNG"/TWR=K7$OP(767<S<$K+\= H2"/N>_Y,YRPIJU_*&:[!EWQ=63?
M 3&Q-"[E1&V8A?'+HG&+U!VAR_'DW(SDX%X=D(+.W9,9U'S72*BB7T?R*KM+
M@9)3?KIJS%1GO%JRB>L%"[9N3%,">D32%>N!-:JBR]@^^@^T->#7F#)LO&>I
MH@3QF@K%QA0?1C35VC^(K1P@RS9""8*O[Q^C)M5T+@DA'!DP7@7/RB7K,(ZQ
MX5W](4C4S2ZF?[!N<XH:R<VF5<Z1U&T/"*"8)H!BDW/M#=OG(5?V'+#\K4IN
MEP6(1%=72\+U2'NP;SH!PBI.#T?<D> (;#5'!)P##+?6!0!@X2_-V8K2YV:@
M\@73:PT;^_Q<*BW'K[J%61!'%;/WJP:[+?$4[LJ++5+KP.WIN$\!"\D+B)/R
M7ZYO([%2BI(DEK.6HJM@0%4V@C&L,.FHM16%^?@56/U42^SJ"3=W>1K"ISD^
M__<)!N(DJJA/M@(&,S/3/A-R"4%UZ3"\FINVVR 1<SK*I=7.XK-;K1,)>:<A
M(:59W-]O?\?OVRTYULR+P<;/L0<G4+T-0XG/-3'W>TV*$AY5Q8>'^&KQ(:5X
M^T[:F;=E]KWUZQW6:G'==O A2W;R(:-OU3\,[P/;,YWIZ1H5Z61VYAWTA@(O
MMD;!?'I2:_Y8(GLR=C4?<E,*.B+M_U/=!K1XY=XWEM299P1V[S6(? C[2>QK
M9MX%C:&G;4^M7/HJ-[RQTC-_^M+\W1,NR.>J87R(>1H?\A!&1EBULTN: @ L
M*,0J>'I);(WRS KQU'W'Z-F^F;#S7J*2)V5H?(A@\:.6I\>C3<9-HN %<Z8C
M1 PVZ5%K.)2Z)WE Q'+UX:/H6?F_'"O-]B7G5IZ:[P1&Q EJ6V__91&='-&(
M@?K7?=/_M^OWO(_^-(X1Q-MF6>^@?^"(7IM%Q$[*5,Q(8\N,$X>([GE&+;$U
M2G- 7R8"],"?ZC8"3D(5GI]5\:5*L3D@ZO@\?Y%6[>B21FZ"E_D\$VDB)F*&
MB-XMS,LG)F4:3TUIO36<R)XM)*2PD/K(1IS8FE7F[S_4@38 8$T)'MZ5@SHR
M[)!V0[UM?:,HF*#4J#.W'4"7@J9<>KEOJI;B<20>6*6SH4"+6(J^H D&*_S5
MYUA#$ H!:6AK05.77,Y>*&<ZN(EWUHKPN H[U<+<Q![X$6FY1/%2D;#M9@S?
M&+L8EWLK)9I@;"1-&L(O/Y!G^V"Z)?3 !QY)/"@9EA#G6@@+$OQ+;^%WV 0^
M]-*E%-ZQ[UHLQFMEU-*WU9+^;5Q]IV@96_+AGOI*Q_Z1=DOH+O@!3;>R8QJ(
M8D3Q:F@Z&(A/9Y3 ECL/QKN1XV6W0,+"7PWC*?/*0DFD+)H.I88:F0KR-<=V
MY$F93F%VWR(J<@4KB CNO?F4F3$' **U ';UB(8!$;2*8BQ;B(HO6OFE9'XM
MKK_I_R?K)RI36!$/YTMX*BJ!7<(*2+F/^HC[]#ZB5T,!=WUB@YZBUZ]V<IM4
M!!^R@)N@D0E@*[+AC>4+81?Q2%@UT_( 3R&%FP*>]VU *T!)HZ]!OL/%/I;.
MGCS\)Z@&!1U1IY-]S[,0P+/8Q\MG[JY]KT&?<JE^JIOI6YH/B%;;VKG 4MFR
M_X5.Y/O6R1[.J&I6E,JS]49MP:$9,>F'24KSTE<U5?Y&NK4D!1<SJ:L6RHLU
MKQ7?XNGZXB9TGY_K7-/CH)[? G0F(<MK,K)<G?I/3IS*35XGO\"@E*<D@[BM
MX*UOFBRC7+HM32/0.R<*8-X:6:*:QU#K/+FO^TWXQ%A]='_-^':J GHNN:TG
MR+24K.X[?5X==GIUZZ, PF>QB"7>KONG4"83T?&-,K_I_U]3IJ,(98)<\S<T
ME,G/^)"%V.:\^ 6IB+W#1]DBU=0^Y>H3[E0WV,45'M]F&T:!4S'3! HV<A^R
MJJ#=N(M"7V=Y53HA<-J2C*EHW)5S,N)E+YI5DS'O '?CZWV]REJ&P2BUY\<8
M?. >@L<6_RPM[BF6%KUR]8<,[+@*JK=T"'BVQJ(%/ GW$CC73-+IMK\*?SA1
M\#BE5HU+9#FXG__2V^*_7?\_ESJ__2]02P,$%     @ ZX!84HF)O91/C@
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M#O=T)VX.)@8C<.H<!N8Y#%0M0 \ &%@8WW_ CQ_&*<S36-@XN'CX!&B$HK/
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MY?7*)_3AY"LH8#$HCV'7DM-J=]*U@)TG')'_,>O5%U^+0+O$+(BQ)J1M!':
MH)^4VO:.0!P,H67P)R0_5J0H'PH(4MHY&-S0?X[F-?RZD#XFQ&([PL#%%$E>
MH5+J_28/N(.7)[PKCP*85/O0/9N-/P+YTC6#$"Z?D>-(U8U7D50MDS>2K,/,
M"G 1<FZTQP6I@>@J%?1;NY#(1%IQEZ11V#A-%VAV ')1"L$49838YYGB4(/Z
M11A UP0\[(9:>#6Y)@:$/#_.ON)H<3V7T9+L&$MMH]WL=/U=F^EVBYER4==F
MLT^L*J5X_",C9G7O7=-1.?EZ\J7STZ[#(?-:4JH9;PN=Z<63?,#6[?Y=&:_3
M(O O(L]!W0R-#78#]?UJRAS+P\G#9 U,WZK075B[+<I2$FQL/GJ.$G@AV&*
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ME=,:JE,/KHYXVEG^\6,&2WN?6-HN1'?M<A)1:S$M5Z+@;7>QS/Z8-LF.C8,
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M#I%\OB-!VBI00!C]:KZ=/'PG;CWQT]*#$=J&H<2M)#1>'S$*(*"XC0+BG%
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M/KISG=RYS+$:>$&M&C.):,V&!8P6S[;P'I?D_7J!7[!T2@(J'ACEF5136SD
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MU4(_<3(:<G^)*+Q4-6:S7&B\T>M=[R"373F1<\'P&W5XN&WM>^]C,/<WT5I
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MRO06_)_+LZ/Y(TDKFT8T1%?[=0&QX!"W-_EXQ)_XREEGQHK=&41,>WU:D93
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MH;+/=S\D6QW-D63Z7+]LQ&=?<)RI,(#;\IXBNVW.JSGS%B?<G<N=!G:!O8Y
M.3C]_-R1\38W">W"LO91!W)Q/XW^E!+0,;<X*\E3#)]"<PT3=OBKRPM<'9UU
MBO3F:\FR$.R=%+ST^;./S7M8]D14*M;=J$X44U"#=GRMLZI_VVA2E2U,2?1@
M#,J6H7J=-XZRXR2R/=F!]K96(;7>#;H[<9EWTO0G6MR['7F)D-0]XVD_1^O,
M#$M)Q#J[GW9OD.INL-#05"<2I:69[6UQO#E[CSF:I]+!EOZBX\!;5I:TA9:S
MYZGU]*?YYZZY=C&SMRZ?DRR5&!^UEQ-)%6Y]<SQ4Y\#]=)'A?O96<U0%TE+J
M05!&&P LTH(>6I\OX[DY/TM^0F.ZW*.UD;'O?:@JO9O+J<OV&1<879IL="==
M/)YZ6\1,<:_#W>O\\T$')\5O41F9F4F;S>Z 0PZX&<]=ZKX6)_$BXK5?3^)E
MF W]^6@)][&@'MHH2S+Z@ BIS"-EMH,=86_M- Y_K!4RA 07V#YN,CM$2^;Y
MLJG@O8,^;<7>EDMQ&:OGW[T-K:G;^Y@_P=6+8JAMI7_]"%]^)@OS ZWE+WBF
MTLBJ"D%QU1[)3WK  \J6.\L-&>_*>ZCH6O?ZH VBY>DN[G=8O)Y3)DKGGV0-
MR6$Z%NHZ<VZNR;B; /AR"(0IJ/+D)P#T7/&+$'':2GO-(F:6MLL+E0+FBR?%
MG)O[1+0]K0='(QOI8]@7 ZZ7578KA^FB[Z?IK66%"+_337\S3-.!]G\M[OS*
M7^K=P2GA4T6,RR(Z%TJE=AY/BA-DNWQ\?SW+BVR&0=_>;GV:U\_?'DO^0":5
M69QN\^[%+!1<HA*1*%/\X!QS03UZN*K' O8 8>G3RPLMHY^=BD3[$@ LV@0
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M9.CAX:J]R<"P]M';5T#B O$&&G!_/Z<I>ZK*4%N\\Y#H>GFLBD>9[2L1PS'
M@>$R@<_.;?P5G]Q/1DV=.U3**O*Q+8Q1_3F" *BGAZS:^J&-\+ESN%&\\[AX
M;&;_!\6=AX_[[1!I0HM6=GLSNS>]"T$^4V3P>F]EL$L_II"(2K^D3@*76PF
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M 6Q^^Y%^C(#3Y=]=WDRHQ^]V7J83CL#5'U1> K&(6Z.C^I)VCJ(V5=MJO$7
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M"RN8R2X<J5WS;J2N^21N4[PY>(DS#C<FBI0[S.*8QEWN5VSE]Z,I/;1_L($
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M@CWK2K"SZ@FH+=]Y6XA3=S9)K>M:)].#1U3Q>E\<Z1$/M?W\J["V\*KAT!-
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M:61?"#@'K[2HXS47+,S7<"PM$-*Q-FNX'7'J"96O6G\MJ3U*=]ZH/I'DE)^
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M9DQM_&YQ^U6%?S^_LJN/_;OFXCB*ZP*.'EQE5WZ>:%.MC^4N0 O,P6<[GCB
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M S_L>A/4COWD\3TM_V;/#6P0U?^;P-_O @/Q&RU&"="VSEZ-_LG $#\NUE2
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M!+7[D[&8^:SZ9 UA$?O*N,HKIFM*^;3Y)V.L=&';-"=.O//=+A=2>2["FKD
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MT&4MM:Y1PH%A7H-*93$H?":>_ZE"#$QX]JDY:<@JRROS.A%G6)(V%D%-X][
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MZG]%PA+O+0M@:P_ =UH=MFWQP6]8U;OXO'*Q5#02Y,GOD"/AA/(1TRZ0NU@
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MHT^GB@'$+EW;ZML2B$W#;L.N5:H5GNG]=J6<2"Z:H$!S_C]ZS'-9N3G(#_)
M.62DS+526EDJV5N^TOHC*JZ+TJ+_2=&9_Y' ??E[.KW)_YUSQ>OYY.[?D !U
M01&"+)N%D4H[(MHW@?8/C%#C4PO!.1XE^/A8@O!H,#Z#7E<K<0RCS6=/%&]+
M6%O:> U&R7.\<UZ]*_$XJ:_!L9]P*.MO!0-/DJM3]F&UG#P_74X+.+41[K_Z
M;LHF:A$1>!T*E4U<T#M1O7LM;VM<9P+8"E.6@F19"027:VGU@JW>8*"\1:$N
MM("D.C-5[S(&2X&<- OH_WB F"YEYDX+G%67:'OZ4_N\=*'0,UG*Z&'_M39.
M<'77S(5'J<@/:]DY(7=E$<YJ=)SY WM<WQ<D.]9@^YL;0H&I(RK]@NQ8<,@4
MGR!C^CJR1RDW8G@""N!N?R32U*UU0/]C%)\]PG2JKZ4>AA5Y\VFX$*FE]9"S
M\T^,):&X=]]B>H2Q^I>OY+I<77^\EZRP7HIT"(UKK[-B3)P^LM?O.)-:R"#4
M^5>2\S'?:10Q)F3*<OQ@N9;8T.5> R-,W4F]9E[,DATYAZ2O>U=L:TL8$AA+
M#J#;@B76@B)):SQ^ZEV$^:4;ZB8(+JXM-E8-%-_^D Y^YT[.0L^< _ZIHJ^\
MF]4\,?G/%'WX4_[_R3]1< -ND-T8'2JH:()'Q]U;!]OD@RGZ9OE-ZQDF804+
MT=2V9F!/5;;KAE)S97FBF'EEZ=8F$:W',:YKUDT/&#1!OD"+Q14$F2'E)23N
MN( 3M4?0-BGQE 9<N;Z>3?%6[=C%/PYA)V"S@4^F43Y ,Y\__N0I!='P2O)B
M56@=74^MJ2_+C5(Z^2R .>%S\*DTJ>^DV@8]B'UW4R2RW%<E4@P\R3^@]4=Z
M)WCOVF[VL%C!G60?VC,& HU)G\KQ":F(\,T/<_+2YT-V,F8_27Q&.!Y4AST%
M*D(92&3+<>QB)8NT$'/7'@&8%APWT>73+C8VC=J3RV3W.V'5D_RLYIYV5F]
M'"#)3+UAU;Z"FEB)3^=?D^LI?7G!@0BR3H^ /-=[NI@3WB?EJ!)5'H\^WKB0
M""?K?+BU<PZ1:3](OE<2'NU'WY.R1+#1GL[=X$5E/2S=,D;)AV_47'5:@1TJ
MLE#2+@F%JW5CIW."UWD$!(;D/@*\?'B^04%AEDX1[%I"[0U.?%[F;2<E^8^
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MA3[XP]R,^P+:<;&&"[KE4RXI(@IID0)FG_SOR8W_TA:Q RK>0!26*T6YMIW
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MF(NR1?IN8QII[0F ]879W&8!G0 $/37\IM$._P7%^S+89*Z6F;_;R^"7LJA
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M_J0I=-^ ,G*0.(!;:[JY@P#T<AT>3@WY/#.(2"3>FOH@= !3*>4B99I8-:6
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M1+.Z]"B8[ 9^)T\ Z<?A,=Q%.\H8AP-@OR/0DNOXE205<5AX M<Q= P,3K,
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MEXQYRH_.>![3"?=I-PJI7\GCT83>2TE^3!1"TZD(7]=87( ^-Q :W13\\ 0
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M5X#.($<INZ8%3/']0U?[\XZ3IF5' ]+3IK\ K4GR?HIBMI.WXG+A\-C^3LQ
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MD@)'JA2)]^JC*8?867S\2C &Z^L]:Y+?"'=.>S%AAV[%\F88X5-E?UNT=U"
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M-6DY9'M.(7(5-QK? QSH21NDRT #JU>Q0'_1W_N'=*[%F#=*3#04/MB"8HS
MDIQO8QM<)9:KS 8[8=K]<,>@:]>W0MP+&"SCY%)>54YO0"*U(&'_\H2/C_W<
M$7K-$X(V ZL)60(8W(IT9,?,CLZ&*-84/7-Y,MZ^H M9Q@RM_I][CAT(DD(L
M#@G>2&.EK;/6$TO5Y!/6S$$4@5*K&CNEU"HJB^E8!2\/OB+G9/M=X%0J_T.Z
M$D"%(UBEE -#1X?N67A$K&5!9?@7 @UG)GF#;) ,]8]-6EIG'&4)]O_J)++_
MQLEJ  W2HE428NU&'DUHMLPWE :A0!M-K+5((KT=][H*T-2&DE_-R[[]/[M5
MB2VK^C? 1T_$7Y=Z/J&>Q"99!*Q@I9<\J^M7N":/>-;'#S=]3P#O<%.@ >7D
M@Q[YQ/CP>Y6'3*:(*DN!J+GJX.(=#@F6 ',JQFKN,%Q2_TJ@B%@E$ U]>.KQ
M0CF0*^M?I3[_ORY?"5>V]TT[ K!O@+*V*%&5B16/^$9W@"S=?3FL2C1_!Q^5
M^!4'2=7:G,)L%1)+OB!JL]?==(Y?8&SA"">90)4\\=WBSM@#SY>\]W:,1=KE
M>EM^^<)%1;!E^5GZL%<QFL*5O**26X3">FM9HL)\WNZ\ZB^',\7RLJ*!F8ES
M<]PIF<6#<*\OJJ*O+*^"\4["<TA>EGGV59Y"@^T59#8F#ID-]C[FY+MQG24'
M"21>JUU[9&K&FAK,_@)B-DW]I)DXH)T\@O).EM/&ZL<E0@WPR\^8^YO&R-A)
M)#[)%+9ESZ4"E8CLV8YWO,+M:Z8CVO*B!]@ON3:ZK4"53K$/& 7Q],8Z6^,H
M!?:'4X?=1<[:,PWLN_IXJ:LM%,N'FBUO*#=4]_5: KBDF2\[[[5>< MUN2]5
MO7XUTT/QHVT#X%4B$?1KLKC&V2B\LS]N78RA[Y(381(IET MO,L/W,1]-VLM
M%JRD]FF:D:U&2]7(^F:;2U]_^JB<L$Q'ZW8TQ5E1CM3S9*R(+'G*X,:?MTU:
M<GT/S>&:_^OU!Q<^\HF//S,V3XK=CD'+,"^]"(-O>U1]F3#"V]"/.RO(P RA
M*>Z:Z=D;J]__S"=RR+2:?@*\KU#0X6T]DL8-*+Y9EYL0Q^#TP#@Z-RC#IOFJ
MOU&7W/%M4+_F)S^=]?H?7UX + ;M<[#C^'X-H9UZI-4?23H8$R/=^#A-[ *V
MPA])9J'B.ZR='E,9V+1VE K59/>_<1+R4+^)S)]]H6M?\6-]TVK5R?!;??S1
MIM\<M1"" UZ]_N%%EHF_Y(A7 >[TK@@::YDO,+PP_=$&6*22):7].J*:HJ%2
M@6/K;N]*?T)ZL&<)HN7Z174RZ:5U[D<//X.6W!M$N0E?XWS)XT:S2B?@/1G:
MC-NC;#'D6J,B@Y]1FF+=UWFK>!A#^D:?\3#F2BFG'K=L6>'$.;Z@8.!9PF7^
MLNM/:)_UAV0R"P9$TJH<NS++JY,O'H7UCNB<>NKLN+0- I9*.62!I-JGB+*5
M/R9Y=.-19_K1ISHUQ==^*3O)V\CD?.[Q17"8VAV7%]7;X7($>Y]+RTA4!KJ4
M\98*E"1#RI8LDRK8^V@*RORWV]L<X8K:N^IM"(^ P>R-]'4]#B7PLKAV6.%2
M68...$J2Z'20..%#JOCH25>!SJ$L*W@/[\U>M!%19=>*3L6R/>H.[UU7Y91M
MNI*KF(V-':-+*^_I>5V5Q]@BN;SE+@<L/O$TY#MXT:GLJ8O>[7 _7KCFJO-
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MP:$$P6UP6+S:BGD5Z#(#3?I>JWO%MFIMK#C'GE^QS]CSFV=NFOX,?P)58_3
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MQ!Y\N'Q?$^G\,Z1K;11L9"HIFLP]K5S5A>>TI=9"S/$TDZ'.K7WQ-+L0JR.
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M6^T9/;%0[WON1J$IJV+]&BD!P;G/=3:UE2:\ _ WNAEYB'WWMF'-,&-!'XL
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MT.VE!)GF2S4?O&%57K)),*(M"/[>G:7L%]L&Y_"Z!<A3^V@(^S]?'X2=+-P
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M7GHW)BTN4JN%O%#D=:K(WEWH6C0AZ<%=Y'W6L=,X2>Y+0DC2CP_IMA>OC[2
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MY>J&5[4+84ED[J:Q!FD3? [/IE=&3:H9JO;.M=+.88NG"$3'D&209_4*&<)
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M)$5_:E<?3J;4II'NNF.B9-+R\MN74FZ&PSQ+;PX*M'V!?KP U'@]V_JY4[[
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MI3Z 4NG1<I 7F6"W_]"Z,LVX@81BH*I?!S?JEK+U\2I35.^4^QA8+\5C^1Y
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M':3.>2H8X?-.4 LVKX/ID0?1M%V_12O7E-.MG]]>D&B99K5WZ.7M*O'.)6>
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M:D&>#4-5/=V)Z:.:24A5102'/C_%,>E5\0V1O1:AS&',D<52:$6+\L)W,T\
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MXF^,F65U+OLY,9B'#-A]K[=A60/<=5$V-+[X4:$>9#$775W4N/WQW5#@0YE
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M98&[V]''J/Q/L!MYN@;8[H\TQ,[[0VJT6N;+LQ-_$Y&2JNGAF-G!_!:.K]"
M[H06FZC"90S!?"66F/,%8='9/T @X7]R3F^NC#-[_3[GHD!)B/1M %I%9+E6
M/-K.=U+OV>1(ET9[EPU^5-GQZ 34 ^Q%W(2ARD+GZ<\CDD.$1L'"QY9K2IH7
M@SX&_NZ&G'FUCFPD:.;UTB?W]/E<J3D]5>C20V@/UF(NS6^21_"AI]=+&@"
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MWT"<9FS10%>D,9$*@9]L"S4DDDX/_%AYW (R-BX:\27VNQ#BB)U,,7]C\UY
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MTSY'GRMNVVNWXAXXR[\D,;5R88P8LJ5G'L'96>SAYR&R4QFKS[%!)EP3C<.
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M9_NB;/M9<ZCQ^L[&>1EXL"^[ASMA]9%5Q5X?FUM-[UO?;C\!IK@>U?:TZ<+
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MUF]:<MYM(1"G0^"==Y\ N <<'OX&-G O? ]^S55Z(/? :TT82_"D@'X=8E'
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M.6%1AAJ$Q:LT?>I'-V?P"P$=@3_6C/H-8SW\QJ,6(S5&@;2?1J@T[3/K[U%
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M?HNTVW=OU!O>W1;[O$B9[DO'I# 9EMEBYI_?@#G(&WZ5-V7L,EHD>^(O).J
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M96[PV17!1JC[:/[R7\G=P/0]8'M.8KA*0^:'VT"-W V-VCT@1_>/X@\U9_>
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M:!_SUMIUX/GC]+84<0=!!VVOX_+7VOV"N2=:> 3&ZK-QO(+0H^N=GU!)K3.
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MV37W;%=#ILCZ2A:DAFOQ'MST*@R[@34MG;,P7N7AMGEI8/WHG[0OY==MF[@
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MD'$&9CGE<LO'Z+TC#^WE9V1BL* LQ]-?/T2^7+\AO!&#]@9)KEDY259I_GD
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M9*!SJSQTOS/!JWF1C%TR+TH@M*>'A1]O]D"GI38%/$-(D<Z>;-$<5><DH4W
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MPU\8V?+P<!#EG%56/0M8X9J6VK28P%#P+_YVC=+SB_,9?"! AS.D\)VCN]T
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MA83M8V5K"@EPN<R#=?5]S4N"OWGN^0UB "N.J.2S,;Z^8$C'!X>_6VF))T>
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M?D)-H@0(!DGIY5WD?^/8!J@F25OBU-L-C!U@M-L&.E@[<KAUD#;#5;.*-U3
M=,]K'.KUA$3/(1N];LMJQ^<%[0##6I07*"A\G5]_LD?$.Q-DUY33E!)E;208
M=*=)/E:C?/IE.<6>[OTQ3;C'LMO0KU80>W/'[H#?02?,8.?%[5#P4=DP0C>F
MQ>'+I_CTEGB_,T7ZY6X6W>%I4;%B6SG^"8Y W<=VY]M(GZ7@>?X[;3$IWWL
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M+1U#B(QZ)B;M1<"7"M2?Z70=D?6DVIIH/K\BD9^8'G0FF,=X]!ZPM[ACWW]
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M3'M(JI=1JI4NM'(!6@$\(V'B5MS\\Y5#.4[0AZ&O6'V9A_@V-0(#=A)-#=X
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M(WW*>4ZD\DV."[%$PVH5TK*:/IH_O2O^A6<;J&)OIS%8^?OB+>#Q27[J\<S
M!H9QICI^@:X-9HZG8>$;'0T<6BJMYLRLYD=XB.1U%J,G;N>E.7E1+)F890#]
M+0W/!Z.EH'S,22'&.VPME:.'5L@YE]>Z]6=I<Z$8.IT9)D738F<C$B01+@_
M0(?H?7S. *RPREI-*3H>\3-7T(=]<""<5[2W.!D^$/_0W#FAI?_<]F&8G,Q"
M_"-3U5)U-,+O:#Y9FTY9&>,2O/Y>+S0-ZUOYJ&5/?%[= NYE\D(6:1T(<+%'
M8KLC..Q.,G.8Q,L,%8$/$6F+T7!7QTIK" N,&OE]:B'20TE#%IBXGU'09/.L
M;U 39 M58E:5)#3UT01:G5YLEF'J&TXC\H<A=Z,_83*N9FD4I.?=<]1,_O14
M]-5B2J3STH?QJNML6?5UGC[P>42.BW6[*=YR&*ZRCE\5?"*F-7;/,"?BP"C5
M@<C2%,&0M56YGWE*=D0W0H:E47;17-)$^H3_77)2V1=+QD$E+A1ZLV^)6Z,5
M8+QS#T&/LIGG=D?WM%:$'.Y/3TD\ SC1$0XK^7Q]:Z@>EH.(;3W[:-1Z3C>B
M2.:^P1A4F^^YQ;,6AIS0%?Z'KB.IR>;BJ8A< M#7W>@TEI#^U48E2R;,F6<#
M(L!^I__4ENF#>2-81M9,7F0"0Z_U_=!+.<1(=^$1SZ&L[Z$:((P>]7.+[ N(
MA5Y/\TK.A^'=F,,;M:_+D>Q,']Q'\;^RTK5_NW>])6DB<L(7V(+_H*IV)_8B
MH?+C87=P"O!AOF],NT[PYLRI( 4IG&=,PMBZ7"6TRY_,5U;>-I<H\S>:_OPC
M\'L:!B&T$(,*]J^A]:%2&;M)?.:1LK!3!7%,2;E,F<>,:GMZ,;> %O-8MV1U
M6BIZ'/:9V7.(5.70Y(2%GF+Y/1\OLQ*-\)SQX*8AP;%$G% APMA*2I76] 1S
MO6J+122^G%[W1X<;\93#]A]74B2L6>R"[FDG2*RS9_ZR6TE!ZT#?3!J$WP%]
MLH'6&C,@P5XH A"QL@+F"G(JT:/Y5,P1W!$D)GT+<!^STEP+..8JU<B1H"!%
M4@T/E[9$&9U8-9E"/! *&:PD>31#%9GFIOL"><%+SKS<!\PTR]FWG_FHHA[3
M671U]2*_9(.W$G>E[JW<>Z'%ZM2Z,0N&)!Y8!]Q&]B"& -3#OT="*; +_BB]
M$/)8UM#1RFKYB)H"X>N8"-STQ1:^?63?<##J<]*Z$8OPYAYP]//^@Y-6 V=D
M["NJUB&4Q^//<W&O,7)J%F<U?"S>&1/TO3Z6?MG$][()9-*.5)&T[E6NN9HR
MOP-6J#+_$"KYHA,># O]ZG\-V@'=N#"OJ/*#]M."0].?Q-K++0S;G.1+__H8
M=>I,J[[^OZ7#6W\\$T;_^]/B3W=)30\C%J"/#EP%IN=-O5F_SCJ60_BW@; )
MFF!(5]QO5U[8DLOE4&D^)\R01/## ,9_&! K0.T]E2YI[]W//@8H#/SV#ZD1
M$U,0^A4&!!Y[K].9_!=_[BB%_DKRWTVQ(?D[]EB5<!R[G2S[ZV=TWRD."!#^
M43*,)/OY)?D7R_41#L>*U<!@H1O@:<1=]!=UF(/M^7@H%Z[@'"I$UP&/AS&U
MO]GYY>1+:L,Q5HG</>6UPO)*RNZG;R]'8+1/-#NM4#=D%B8')!$^F4L))S,S
MH#"G\<,>)$>VX[GM+TG4Q*V^R#3FHL$RN06@YY9X*/",?['U)[VG%8>U:[A-
M-WO*<K+SHE2+<4?^%/N!,7"Y^)IFF(*F.S1AO71G6"[.%X*.##_D9/:_P:WM
M1TDP$]7T>20B<@"6JAVVF+]+P*(5/_&7KBN-"D-KDNJ2 S?1T4D,MT?;ORF8
MX*>"/4=&JZ*5?=.^RCSO2L0X'RLOC<CQV'+N&Q%QH:Z(Y15C\47VL0005<#?
M*M4.A[!B^)[2;^S:QK,H/BI<H1; R%K:4%-7.OHH^% -U[#]*#])HWG2,N6!
M;0]R,18@+H6//G.?.IA&384%3T84E,Y(.SXR;[3R[4MQ;<I \]H#830H\O[4
M+0"X13*%X[CE>*-R^&)'^X2QJM.D'_I8JW3!$S2P4Y)G>.W'8$ 52\/)MNBH
MDD'W^N4$[MO6Z$(NFCSD5M7GFVBFM#GLW+AU9)NNAE4:*64C&SVNB%XUL@Z+
MN$2[CSDI[;0E3%-?%KH0E;Q-FIXW6*QU:HC'J=S?1BLNBFL)+1GN:F=05M:Y
M2M7F/Y">\_>MGR@^6N-D;\IO950J((@]@I^U>V)5'>"^V]Y.,;(+UQ2\IAMN
M1J@#7VV&%4:2Z?&E+(\79TW7?H^+3R)MB4*P4\*)YQ]F^X YBFV1=&]+W?4F
M9E(F/%VMXU48&UFAZM:\QMY3YBDR@R=G+OP1G3)=U6*LRLHJ294O$PY8%2MK
M@ZF-R(*YQ_*E;3M3"4+/WM\M[X20<--;P),3D/GXBG$(LJVGV4E6WI?CE+?\
M!P$T&UHR[9Y E>)3_Q ==^D1TMI(*J.F,D3VRODYPKDMUZSRKX6::.E%S'4X
M9A"<HJY\8KPB?K.I?:C77@F?W+14AY)W_U#_6GHA_X"==KO6$JJZ!4[SX>RK
MN,T&%,CG!)@ZW//(TV&+F'&0:O08[VT2*<]S"NJ:DFO:$=:SI5M 7:8*>RO]
M]2V@>GR/%V%1,O_IA"QCKVV(=T*:RKGW8DX]6EIA&:5+\*O&TYSXA_L][?X,
MZ;#Y+*8K/U3(P=[[W1KQR,7IS,/Q\/ =2<D8L/D)=(\0WUUA1-*[LI*_="L>
M;]APA(V6:;7W;"OF,.)<,2LG:XX$\6ID\X9@*'6P1)QAA;3(H95#[WG\U)<K
MZ1#^ TC("2J-BKFSY$/BDX34:XGA/7;.-XYZ\''>T0P8/_'<YF6.9DL'UF5,
M4IH[R_#;4EI+HJ7)C^'O1/U85!-,TW;L1HPJ[0?QEST6,*!WJ6 Y^-F)>(8!
M2C/B:&VPN4JXA+GN69 &^/4A*,0WYFMQL7_(@UN :UCA .QTTHW5KI&8HV[,
MP:_L:Z' E^4QC<7OVA8$0C&[*'NOVD"1^SK>5O:H:G!C WI%0OS-:XV4[KSU
M<'5! 6-</#93F\'3NM8C2Q>)\XSLM3V.-6W_>6:,Z7._01<FUL^D*&,/;P'(
M*4I]<R$WE_!;0$,=?L7^3NI!KU+4W?)IV<9I&' :?]-*0NQ<M-=\2#X5=H\B
M"4X/AG'GB&>K57)N:;4'NU,X+-)AY$V(HMMI&D"1'=A#-=S=";]O GVU?NAP
M;8CZ_O?CF.!0X+=ZEZJQZ//J5J?!V1G32EWD.NY+2/IZI'3:^D$C'9Y,>HU&
M*T-(_DR1W1=4C.D=,VGA-AH:-CKZAN#$07D5^1UBP C_1$HNRH^S 0XG2_QW
M?[;F!*@5%#^M&2OR0>I8-^=BE!0<^-6!I?^FK0'$2%,G# WWUR/$$.0ZJ.(Q
M<#UA2H7D:+^TU9P$+6W8(2?G?!?%TVYWH2,;NI]K!5Z[E+VZ-)OY@KSNWWQ6
MMG& J/0E]?[+KY^@][1#OI?JW@+ 3[0=^8&]<"W+Z!>;PO[4"7<R:SNZ@:;>
M NK3_8V0UX_7[S(.B%"$[B?3$=G7)>:H3+,#T<7"L1(T7#D1#__F,4!;DJ?U
MRPBW  N<BS$=36@+:PAZX;$#.(^]@E7_CV7S+ON^ ,&F)AXH0US]]DC]N=K2
MC0O)U6I<--Q5"[B:L%_<?GT$/NLA^3$XO!LPJ>"(I0UH__ MO- ^BKL@:^!7
MPZZF]>,J4 ]XP3CD8AFZ%_.G 9>J%G&4B$O&-</!W7(8\OU([,\CT).4P?5\
MMKL\/QZ\%OIC8^)7PQ5=^S\A<OAK1 ASF4(DDVN&;K"=[U)@L9N+E#^/(GP'
M-NPA,="F/I*CCEO '-N?1[8%57Q,L"/97P@-^640_#^=,.-_5<+^&27V)YLX
M^A<C[)])8GW_JH3],TIL]5^5L'\FB27\-Q'F(A9(]GPKK:-M;0;RIU<VC]9(
M$-?S6C[-26R74L$-X'CRU7G\2*%JW17N:\UD'YVJ&!JD$N$B&K'$Q28)+#=D
M2 SC[-'\\ZO--OA-J*T$D^/8^L2C"WQA*&6<P&7U]O>E/4(*\7:6*VJ=.FEF
MMX!?,:=7YP\3CU!_U JVNGDJ;7SCH1UR_HH]X>+$=>,.+^9?6!_U;T'.>,D+
M^UL HKDC9$"3L=A/Z)/Y6!YO7Y$P%:YUBM-HS=X-MNTMX"]Y.&A:H/+O6!]U
M@VUY"XC0XP)O#Q8+V4K*QW-7J#FP!Q!&=SZJ)D$6?#,@+]XF8]YU0B0\JR/A
M\M+3J!/8WWA QC@O'DGA"_"87$[\NKKL,@[I4U%&E_UM58#7J;AR_.-R[?N?
MIK#_*4LTCPXZ'11&XT QJOAP0]C,NP?2=/]FZZF>])L_&9)(K&*$-A67W^%T
M"SC?(=G/W;D%K-7?\"A#_P-[^!9,3";=>6&#FUR#T"]H8MU:-;3ZOD^_[N#V
MN-3_ABT(20?_%49K_K]B"^L_LX/Z5_.\"7]!F,12_07VRI]+Y_ GF@?]HVRK
M)4BBBURM3G6H/TKL)&<?7^:^^_']#9#BI\N76= ,#3.5U2>9D>*=O:@:R5Y<
M>^>")>"+_<##E)NG>4]NW,FO<Y*2X\95CT+PSJTDATKZ7DZ.<L[%"^1H8^^7
MA7NDYA9/BN[:= *=%M&OO>L1(.XXMP!2RFNZN5<.1+< )!7?6P _AJ<2M F8
M!.U[KQ-ASZ90313L]LO+?^QD@P1O 0E(]?3K)LG;#'9S^[XF.D<+."MBUV3J
M.-?G(A<0(1$<7?WX7ST)7D#NKU]K8NZJPJ>M?D)X]LN3\G^>4;E_0&1<=:W^
MER=#[NAB_D$7W _&U-3.]]NXR3MB_X$#S'_)@<""PKX_/4?R"XI:J%A:OO\-
MQ%3*XI\[20^]5=ZQ"'M):8M8ZVIH0X(!7B9,V&,^2H]/UEWH0S;%B6%@E38F
MJ':@5"G_Y9U*=9AW.N.*WE9.][+AKS"G_7]9_7N(X2UO5W\4ES8UQ9Y6):HN
M1912:L]-\][>/(YXU/1MBK%])Z5#-OB.^TNC0S=5MX#7F]=</]KN@2]7?]@*
MW6]2#/]?6?R#Q,!)VF.(_**H,DO*Q<].)KF/M(NUK0Y8OSM$7>Q)\PGWS( ;
M)QG*GHJ?RF,;*,CP98_]@H8*/.)./-U6EZOU77"%:H2_BOK_.K/?1<RA+.YZ
M)+YCH05JR6-\+DTO[B.MB(1W]A*,^HZ% 6%<G'"W]EO (7'Q+< %'.>*EG +
M();WH"M/K(J^!?P6'J#"\7\I_OR_)2;GW0%UH+[Q(BWCO#?F2W?@_5K'FN[6
MN4/V*>B8[,:=H?3&C#7&4$RV].AC4+VB 7+\R4Q&$JY=A&[FLS:T@O[OH"P&
M]BF!4M7$BB^Y6S= )$5HLHN?P<R^'4CL8+8K'<(7T?'+7I<+@FJ'W#D69EX/
M&,&Z,,67]=-D%Q/0TE,LAYHJOHC*\(QAI&Z6JZ.>JW$\1'PH;=,F$Y1[RMO1
MN6!FV[U@[/9;Z)F85O6DIR'7V-+J7U,>J;./ISG8N\K;A%7]-LIQ$RJ_^1_I
M$O3"L<MOLGEBF!A1T.\>(!MM8^ZJZ,-27Q^U9-QFU%>[UVFXI7%#<V!@^FQR
MHDQU7Q7"EV@"P6_=CWPSJ\H3R.&ZDJ/</>V]M@BJK#>4ZM]/\'LSK&N:KX>.
MUZBL.UIE]<ND>=WF)GEO5)/E@*(/)344_2G?.O2G9KT2_FVI#&Y/_AZQ+.//
M?M2W6#1A3/96H=Y,=(/M4>QK^^DKO-5;1AOI/ ^Y$2.P.IJ&I(O<9(%GL*8P
MGT-_:W*(_O]O]O5?0LS&OHK_NQMOG!5M-X]4-9&E@&T%(/8R7+&<?=MX-R'-
M127E%D!%SIP-53?]$)?_VY2_WG;\[R;CGULF0O-YZ(C?[]\10R]ZE7XWT=+
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MY;TP&\&J\IDWGGY>V'^VWE[N_GLB[%H:NP5@(9E?F37=$_KOJW<ON&>2[C(
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M/SXW[5[@';5;Z9!TPI>X<F9T'&Y;<_GVX6%H $:&*^A65B[WN(/4@J6F\%H
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MX JT31WW4$ 8;68QFW/#&+A;RN2K6IK9GW7=W#_,JP9Z=P0<>8!]>I 7*S[
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M9[4=;E_^CB=>W(DQZS"ZXJ;4$J(Z)JQAO+^4_&,:/>!TOBD !@3\B<SSPU\
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MC4W-G5W=/;U]_0.#8^,3DU/PG],S2XCEE=6U]8W-K<.CXY/3L_.+RZO?],(
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M+_)I6N93)A,0=Y/JQ]43%6W$W<0))DN:0U(6#00(73.D3P2W$!:B/SZ:M2@
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MSYE;I9F--WC/OVT -XQ#M3U-I5*$0($E;K%;B+__/C>5Y-THT /I,<07F[B
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MQ5L49L20235)0(I]7G?8-3/7?>'Y*BP\<>3PO94;G0+8^@3A]<]3T^Z> '>
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M$):9)==9+X6C@L*0O>30]%>?SIC@'[<L:+DMQ"#^)NOVD=A@.ZII+YJEERB
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M)(17U9B;8TWM^G4V'+++#P382VHJ=?2_92>RY(DRJA&?\=>-7&*.G- /5TN
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M44[ND^NZ]W8/UO7Q 4B&J*"U8D+'>4$H=V,H0K<0)[NR![LV_%$03X3VBO/
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MFU$-S%=W<;YF=CVJ=PV&;.1-3H8PY96-"(5WI+3U=*;.AG7:)"X8(=IP!L=
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M2]NJ.C=]W]TM:.#M4]7M2SBA2&@>^EE9W#@,95 4"H5&:^%"DH^V7+4A#B@
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M.C8X,_^5MFWLJ"?F7M=LG<=KUD.6W/P+B-H$IPFOJWA)DR76RV)),$''1:$
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M"G"@Q#OM[!]^=,,DPPC!Z;CL9JX<5GA=*8#V!VN/TM6'DJ>J7L0X:!<-V_>
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MU:KN[L,9<:\7L2[^/D3 3,W.:97H6VN!7&*]KC+".'=8.BDC\\7K5>I[0!C
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MX$5INFJ^[77I])Y2!T?' P7BC+\V=1+ZP#;E9K].?:V/UO%\8_HYA,]^+#;
M4#H\:&1M3DDX*_/0DO=:N]ID9ZN*#04J:@+O 3+#SK?[Y=H]2T\/SK/L%_M5
MR1D,U;'9"15(+5LD,:)/#Y\BY%HG/%MC'N]9)%K28[RCSQBF(^6N&TU'$9'
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ME<3J0:?=>FIU#\B.0IT.3[X=!V65[MP8&0$KHRM_#_4=IYS= Z12WJ-8?M$
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M6%?D(#NAZJF/FO"DIDWU,9.GI.-XJ3K$9;FC/1Y_7C92P$3>5LEHA:$L5DZ
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M_!IC."DY:-.V!:XH>RC%RPDTH751R4JB?>UR]XH>FFW8$J R*,H0_C1,'T?
MFZ0!JU\%\S$&D,SG_K[(Y1+[M[F3P3V@PKE0]V\E+?]2K%_N^\=Q4&C<]B>6
M^>9/+/.OLOQCNL>@BVR:V8.#*D*]N%6[;U&RHO/X;I+L<^7]$M@%!B IQK90
M32A1;PU_&(<BWA%_UZ7 >/:F'"1 8:*!AO1@E-SY8;*BKJIBKBWRI@C!@J)H
MH'O Y< )2>D*/L95T)A,>Q-T2NM%_//!;B41Z2P;!/,__D(,? MR3SV*;WZ;
MNZOO3?F!FT.#ZOD'F5Z:;Y<,D] VI=5 3.U)IH;ZJ0)^91X(HWUKX-6+6@1F
M_D^0T=T>95A3AF!8EJPECS=:-GZ[ZDH.KO2'!A%/*B9"PSJ76D"71MY%<6&/
M,54G7EZ:RCCWN7B]9V@:=KPR>M(C&Y^I?C_;2('(?8[59D-2S;6A8!R+&R+3
MB[#27SY?9'">:\9WF(S'/[B)%]>G6UW"WA;3BR&^\0R.MN)YHYO>U'7^(DW3
MG]#':J!%/>?K]HWUA"G%^./O.F^:F7</]3I>J%M#I\X&KY-\W92@SK"BH^(/
M'JHY>-N7:6)N#5,O+MSV\&0EZW0%\:\R$3KU4'*[/1W>L]4-9+TGW<N(WE;K
MNJFS+]:W-5P35T_:"P*4)AP\OA@;OFWCDW]O4 &*O0<LZ6+V);06WZDY; 7A
M')W#HFPE;NPE:A6QA3\C<D:S4Z=-/42X"4&I+?> J/V#?5+=V$<FRKG4FS\S
MMI#L9U/W ,J>XZ TFP*?QL7%?C0< T4XEL3F/&RS+R@#O*ID<:!2>'7;T^AG
MVM!VH8_+84<2^?XQ\VEEJ.RQ4TRE/9U-37VJ:$CJ_#%;++Z+FON-:7&PL6HC
MJ+_N5E9VPRGK_=BF<<OS*[XI+>T"53NHDQ"+2GK4F .12IS);X22)VY"KW=+
MEJH"\> HX#N]98MQ3F0V91)<WE3(^YW)(SM-]*N-YGTO.%5GU))MEG ?XU9E
MP2K]2D. S6]5?W;I?1K:YR%<UA'BX9**P"W.U_> "#WM!9\BXZL5.\A'7@G7
M[\N@FIAO7J&]"14F)O6W:T")M(1@#75W>#E"^IA:+.M]39)(7DNPAP)VF]\J
MK/QJME]Q5*X .%EF4C/'T7M,"P2Y;EMA#M3 [6F9ZFHG5^7<AU37X]=B@TQF
MRPQ[+6J@41TGBF5!N99-YCCXV'; B_3S&-4XV6N@X2ETV_1&[#OE8"P%.<8;
M\5"YAV[@IPWL(]QR\2"JB! YED<?3Z,W' X0H$J[<E^@Q_/PAUV!/WV5=_P\
M(6/1TB=</?< TS#3(R5$Y#&X:6DH_OWTCR/,:.=SE4H'SQ>GM"3SM;0=OV=H
M]/O\8- JE8(K\*5]K/X/&G6QS N2K-^ D16( EFY OT=L.-Q<XS2<=PTV<%S
M+TYR[@%1@3ZWA47("NHD->EY42JV,-=JD37W_F(4 ]>#EOOXX=)1F/%.AFE/
M]]2KS]82P;*#=VPYO0MO1NI]*I)TDI;7<1O477A\*]K?P8W-/\"P6.#]R\:8
MU>(E@)K6X\K. NPO[(G$/)7"J3U#2F;S,&C/$M'2SB69$&5HNAGC*>E+T1T,
M_$VC10 *D](.(^'@+4<3\YYNI=C*8.9/#D@/M-V4$9]AG1F!?4'I6HB9BK4(
MD-C6XD:?N=1'KF^6,J47=NE0W9H4NF]M$<B:@2R'7(%DIP0BFE@]!D<$NJ!)
MV)DX.?9Z-(."6&V@ N#WT@7[G%8'(K+T4ZY 1?8@,.&2&4(T\(TH#IG]'/;
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MVG^-K>KW%T=S\QB]I .#M81W!#H6^Z(0[J=;O#XQJK<X4Q*J&Y@H6?8'!C5
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M.=9&WD\XY^\]7O[:<C#?:EDP[$/2ZN$A$A7S[=>T LTJ(*A&/F1]_P.L+#9
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M,*[_&5WN?UB,8?7]\RMQ'>&[]TP2X<2A :2I)V=ENEI&=?8A_PJ9XJEB2FX
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M\JE=!L2+9'>Y@[:S=?GGSA4QD+L8I@5X;<L;V^,+PI>-=\W$[7,= "=/<0'
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M%PWFS33'-S/Q+\O-,=K6BND[6@O;S ^87]>UIM\MB KLB/$US?GB3S<^&77
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M37> 2-^',9!'-ZZ7ZFZC'S^<_:-5/*^N3>X M DY=P#=GEL_%N&5X>L0VSO
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M?[]RE(1M$N7GH5V:T\@=AQ*61AA[Q%R9D#N 3U%)DVS)UNUS7VD$=?SS^CN
MLB.9_^,KGWO0LKD/)0/^B\A4=77'LNIXQP+I^,\U5^I-H79HE-*@:IG7SWU'
MQE__=&.6S>&4T:RUBBCY^??&6_WOA"7X_,MO$>%GG]]4Y=!--5IM7IOGMI2O
M# 09ZXV_.,!UIK>/[$[!9W>!/!/'VM[QAN!R*.99:5(NB^-*N.8""^1I\Q:^
M_:J(P$ :IZJ>7%AH,_EX1LS%:ON\[X, P2/&PLT(P<P8P3B27S*&;L9U!AA6
M#0FML,:!R73E?)KG4HH#X\B1TXBB:WL8$XWZ* \,=+B)?N56*-I*QDHL<HF
MT$QO5 3L2.95_YB75CSJ*[<97ZFI_?:9Y57V@M+''MM=W3BJ1S5W #_Y$E/E
MT\V;[;@(R4LH<X&/XZ]2:U/X?NZ[00S"H%J#@G-5MV +YW(>Y2\BA04CWPA8
M$<(06>7(3$-P\O0UECD,2V9QV%E$08U] ID":ME [,-Z3"EOD]64KHFN"?:)
M\(P+<(S_<3YN )'H":R*^E"7_+E_H!=Y_-IRD19!N%_TE1IG2_!($?]]:\<.
M]PW8OD.,L!I^TB+%T&A[U1>TN25:B,RM/A80#!_:Z>73ID49+B8B+15_G*F(
MMMWF5=<C#J?3N);[,'U+T5*CG.!21ZW@E6?L(3P!JX,?:B4\<M<P>^FV_&7S
M)"?3D=E#!;"E44 1?'Y=+-S]=H ZP+=VD8[^1J/4 UBG]^9 891MSN'@)2MQ
M#/>/X:,B,1HM'I!4JC/9=8W=2T-AG#N 5K[?T"$OQK.7@DBO"3<;>@80*C_*
M'_L-K^O5Q'JA9N7I+$C05D%(^M"RD%-@;'J\!R$X]DA+$(NFNC533"\AF8^A
MFLE-O @L7F%_QJ%EPSI*[EN@8^(BV^CR>(I#4X3*P"$MQ7?J=\6E8)!:RD\0
M:I%Y\P= 27EXYNDEV<=T,OAT8.G:1$M_\'IX6ZY=A^BWIYG8SBM?8OI*K09I
M(:S\KT13G6F;N>H4 _G&^ALBRI_3[=ESZIYMOC@IVP^L8_O\IXSI/^9A[YD<
M,9!N"?("2 4(BVR(XTDHAQEC36020EX6LOYE+TA?A1]_C8?\$3/P,!+\P:BN
MR;#J131_#A)FK*T)L:DBQMK [YYW@UJ\6UZ(J DYY#C7:<BX08:('^3? <BF
MX,.=X#W[3KX&ARF^T1[.CPU$O>VQ2]N*\:')5)%  I5_:]64Z4%7S"RC:T\7
M:$2@-O+Z346]#<KSI1$4>&@AGO\/94M:Z8P(MMJ CT0PET4II]F@YB'FQ<#"
MFM+L.8/*Q]Q,D)Q:^GL0R/J;D%UIZF!);M2Z/ ?H[,^/8AU0MR#>M<@^R9K3
M5#4",?W\?L]P;P@;Q\OJ'M$DLNM"%<D-_A=[[QW49-3M"T=!4&FB]-Z4#B*$
M#@$1$)#>NW0()=([493>I L(2*\)4D,'Z8CT*IT@O08(A!8^?-]S[KQS[IDS
M]]ZOW6_F^V,_LV;VD\Q^=EOKM];:OVVT_=D \U'EDK1>PBK>O2:[IPZ]H*\]
MOL^CK3X^.._>^O1M>4!EK^1?E?/?/N2_%3O'V:@M<?*UJ]?P0P43;@^A.WGR
MMC[^VHD&(WL5:S%6OJE/];_!Q/^+G2A]KTK88N:)#'%NP_!]GT@HZ>_Y04G2
M+LO4@3L/_@0!1T?NR)-_:F4A6<4?T6*PBO+O4R_NZP:XC!I 2L&.R-KQ5#5V
M=0$\$7_C.RV"8XC_8B*\O85:FCK?_T*M%W[_ COQ0&";U]<E2?_P7.*PQ=A$
MY$$:VS^:! 0]3(9TUG;9S@OONC<VB7,63G4X2/64AFCD?:,BJZG1HOKK%*2[
M 80#G?6&?)Q.,H'PHC3W=8$.]HFI-V:$+9,+=BB^_#/Z[AJV\*G: /D5"^2#
ME:1M2KU6H[TN_AH&_RG^*VZ=&\"W_8(; #1&JY)OP\JJR,@A!4G [1$J<,4A
MH.=XJY,9:7 ?=_&[\#7WX L*(Z63:[4THY!+Y^1 _HOER>S# ^RK)OX>!# *
MI]2!4IA%ECK]14;?D.">[I58'CW^JX]J#ET]/%<K7AN'_44CIJJWF 7R>'O:
MC".01"9XWN25(-MQ[#UOW;Z=H ?^>W:7YBH3V6HMK,0K(GA7''KX[DFHNDPD
M-Y1$Z&*HDC#<Y XNT_O>;*/:U=R*Y0J2S[*X"B#4)$RE+2R5IB _3W?:KJF1
ME?2U!J[<3HWGU?9^V7*#)XAXJ]&P3<?QQ8/4GWT!_G:19;E.0Y6:FG>YWG][
M^Q"5*<UI@_%',C]B=^YC(U'M:<EM:"/RT?3@IMTQW*?8EBCBZ1R8!8BMEJ!+
MU+J!;KV?;".A#QWV".[F,A%+D$XUM' 9V&(0I4*XY(^XOD)] "0[VC> #AQ_
M&Z&!/)]@?UHQ-2,<JH! 8I^R((9#<0S4-%4S%EVHQ/)0<WJ=-];8RS\;[$>@
M#2NGM^N@4:MYDRB[9N*5Q9]<%E3?=!"VX^\/[)_RO'_5LU#YE(FD@$U8_M2<
MPL<.*Y5O:MD-7<O(K"J^<JRLK'=LHG*A80_O^Q#M(F9N96+WK^/JY4719O$]
M>/J7KV0^0<N0BG\Z_0>3X>DK.<>5.7LXWVIR7OPI#A4^_M(SV*"#58E190I5
M8:@-;L(+*JM(56/EVJF:+9Z*)QYJ$I[X$_HLK3A3+ AA#4RNQW=)7VD]8X:,
MZI??P7H8]\L8.Y/J6J] :4ZHA[_GZ@D<NX&5LOTGJ4E>CKVP&>-WBA3P##O?
MKMM0H*KYK3D29]@V#_H9NO^#F_4CQI0';USWTR-V2J=?$O$[;S 1$>AADKF7
MBK.M8^7/?7&D'"E_!-'53S)-0,J!8D[\ELW6C[GVM>KQXS'3#CD8 8_KU]OI
MR2?IL3G1//!Z@A-RM?[Y9*_RMZ79&!-EV@1>O\OUVB#V&T!?*O^U=]SYY T
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M[+;,C,UP+C2(,J::(M/LP?-%2]=&%?B(TQ+9FNJM[QWP9;,)?J-5.IAJ!',
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M)^"4:"FVV/BX=Q[Z0-2$]8Z5N"AY&]_891<X_2>L5BHDBR#ER(*P \:"9R_
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MF,^:[YK;\?]9MI+PNYB"QKA8)/9@:1$*>/:9O]NW[_2 XHOBSGEV;@!F,3>
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M>A:&S#17HTGT"74T3M-1HJ]A"V^7?'_;D@-[N'J[.'H1D?>3O\\QPT&R#G(
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MS6&R]Z2!&3*OGW^?JX%Q2B;<IV+,U!GE"5 OVAXW7#*MW4\?S4Q5Z_2KDVZ
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MB7%G%8%,L#H&?-XU^CC^*[<+S4&/O]C8)P6Y[:/3=ZBLI'"[$HP@='$8F1L
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M^==SD_;?1O\A$'D8DL:'ZH;>1\,M0;AS3V]5!X\E4;T\XF*],?V?3#)=  X
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M(Z;J=9^_O?"H[-.1?4H2>V,('E42^+A$94(YX79 I06ARI Y:%(TZF:"/@V
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M>5H=.4WRDX7B-[C>?_WXD;3?IN#B0G2Z^2%B3T]"0'E!,C29S<UMRYC^*]^
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MN2N:>@.6LR,V?1U+VQ*S:CX3790D;,C'M)Q+)@+L]&PO#-*3']N\^/9KP>B
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M?6<\/WTB?R)O][<L"60SWYI4S'+#E)=*QL90E6C).#N]N\KO?F] S7OJFKZ
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M0<_M8?IE0;^UA9T(]PEX6YT(Y3^&_MY]/S3];B0]ZTG1SE,E8 0RMGAE1T>
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MR>%,K2ER[WCSB6_P;69U12. :<>Q$?)?Z9-P?[1$OYD]2.7:!9KK3'.<^0F
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M;?J+"2-S/OJIM*-#3*JAX#[\2W1#K<:4+UWV;E.+=]Y2<^NBCWM#8L"5JCP
M7N= '[.[K,!,$2,[WRD$3_#!XQAE10K> >A2DV]=3+?T:2G;:\?1C$9JA>_J
M$, ^7$D Y7D&04>3?)B)[N0'SU3UL"5& 3"O=JWD@_L_OPTTV,PQV3C(HS#8
M<//G5"W%R C:=W(_VL(;-&?P^XR,FH4N'<+N16=\\=VN>=;.!O/H.T#=T0KX
M..<%\/S*LURO\1B=[)'76V!DP)14&<50<=,NHW?L*WC<0O185XW]US\MO&[J
M>1Q@XQ RHE-U$DU"[EJTD3J>AU_.1A6CYXUA"'YR!UA_9WI]>&_V=96+K+W]
MR_+!5L;2:2;<E(0_>E6_']#)58V5^G<7](S_(J^;Z&Z4V-I1NM9SAVW%>S:C
ME88DSV%TZZ]ZNXQ57=:40;C-X=F3S^3TY)R^.37<S&2;($5EI_@3IZ$<2^7$
M)3B$%10T0B.B6M<SH7RQS[#0XS6$57XPK!*"+A>U%-Q$B,R:30L734AM05B.
M_.>%C93'X@U8J6?E^+M)\[J=@\";^.6W[^.['ZII:K(&M BE^B8I%P02?R$5
M'3F-O6B:7C\>2:$-FG\9(?-1FE8_,1QP.B.<53,=R)+1*86@"0OGR&V8',H7
M6@!YA==LUNYQO3U&9ZSN>=%/FEFOQ=6_MN(873-(Y.JK(5:7I?_/X)?_%>'Y
MF_]T!SBBC,EK(,] UY)81\W^9U,:="&^ZCLYX!G=.\ <:&QO5.+EV7C[7LD=
M8+\&!O>A.2A >77> 8QFKG2!"%:TK/D=P%BGJ40->1KVMP(.J@M70T7THIO*
M<#]O2[NMGL_XXEA4!G!F1?JJK.QH((FZ., ?YRW7GON 3E:;JF*/=PPA%'>
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M8^>4_1!CK?[OL3VGQ6>22[S7?NZ?G=]\5YJ8-"6RMA45O/]'\";A_Y&+UM]
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M!@DK92-S2)DD4H1VFM:=@'FK;='V$\79C@ T"M,R2*<\YNR.WF('_$Q@(,K
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M,WNKC:X,[KQ[S"[^+'"6\?Q[XXK&GU:C1Z<N?6 LSN;Y\?+9,6GYN?ZN#,[
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M':9X'O+;JKU$IJ^-7M96;P@4!!(^"?2+IT*?[1M%;R?=.F%X9\$D:\5,3E/
MH6O)R)1MYLPS8:TGNS8UT$R> TK/ .J&N*HB9\7>\:X^[FLTSX@(^F*\=0H^
M*!X0UK\[S:GJ5(]ZB%(BC5A_%=O>HZ3J4S\U+WE)4>)6W!>;\KBBURY*"+.X
MMB:^8()972Z6V8))PERH'0=QR]2,TG2GW@=;[&Z!VN'R%#P+2C<P?-2B<G?B
MT 2J_/AI@H%Q(A7Q!THYT8M'F1>LHUKLD6EM(V<HH+X8P#/4\+ 6M9B$)$"]
MR( ,6\[HW.8?Y953$2JM!LF_#'JQ.+;V.;VBL"(2C/V9LW-N(Q.<2&]6)(>
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M47G8(?-R1GUU7W:S+LT;C^#.;,W"TH=/-_>F ^P9$EGRKE"VJZ.'LC! 5%7
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M?Y5*/E?PYZ1SQ?RSM[G^CHN#,XL6SF9/&9+F1SE/3^\K+WMY3,P_F=0[0?+
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MV/29R^J"/.9S)%$?PO_+?!<JNISD4&#*TU*P*C+@_A-T[1JB_"O(]">UVVS
M?<K.L:$Q1=^K[$;ZHL\4K%6@YT\)D*@?5%Y*,/:%L-'WW6#PQPVCR)',RL_T
MYV!&_=M(963/CM6.2?3NNLK+VFF>9X96L0LW<F6IY-\;7W-I"L:!_A1)M&$
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MW8.N6D5P#0 RY4;Y$AQ;2NVB@^W900(\8,S;'X"JY^;C/M[7_*;AHY;'%58
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M>0HGSLI]9HF#^\(3RU'$OH)UP8CEC-:?]WL08A[IR)"^!0ZJ#E&3H_4,U],
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M/=76Z5::$VLX8AS >5+\G/ >D2US^.]D4.[R)&_6\V9R:)S:=+J+Y15@X0I
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M@47?!O],4TXCZ&\[,$\K%<\.-!0*ZT-//N!>]7B*%.;B_^88_M<=BJB;0U>
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M!_<_95Q?0::V<I+\(]B^ ]ZAZ-[_YEXYO.5_?TV%8G;X/1'=O[V-Z^?/MXE
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MH C^[;C*E/5G7&5)BC],Q]H;2K"B2[Y8I=2H1*H/YWP+PS.XW6<(Y-V/6HF
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MUT>K$&HO[P4FO)L1_L'+<Z1$W^\+BV>N=2)5_1OR'OR7T6)L0OT()SF9I''
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M=-S#6JXX"N&?;FFYXU_QFY!L5!\PL[12>Z//'E?5Q)W'DL!)1I+Y24I !);
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M5^CY08^>\6"390X-BP V8^NAI9Y^0.GM&FXRHLV$;)/#/7HG_RT'8*H+WK+
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MZPYO_<A Z*!Z#$<!U@"FVJ'7PR^F'L?;\^<BNMN$E![D/180PG1W2P4]0S5
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MS>ZVVY1\5XZ6:1#$0/SYZ%-TUF_#^MH7;7E(G/X6PUIC9(*'MVW?PDX8/4#
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M9<SA)!!>6AN5KHEBK0>YK1C'^92X NU-3K>93Q)3J"V5L*OVY!VRR&&3=PI
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M\E#JO!00&[(Z[8C;AEZ\"O%W'^\'+?4*G?)H<'5%5Y;-_%@,ZJJ_="@$#XR
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MO$+IKIHNO$_UKH2*'&W_6^W"JEVB .M^&,\#)O"GG%P!'Q")6P80JWQ?KU/
MOR17\/V0N#_$:=M:B^(@<QA^)Y'P@")*X4D="\<,NH^FB-B])6J-+]7?M:)\
ML_R] $</,6GN%(@E?R"QN1VS;-N.TS'C(U:]V=.J)N#M3,@]P*-0LX/L:>4D
M,]'^O UP4(N9?<SL1Z59R3SJX>U>II2%$_=";.SUF"?V85SFTDRM^GZ<-,GM
M;+2WEA$",\3^S;K&($],4P@_Z/WB HFVSC9:]O;+P$!4@A29]%S]'+BK!*Z2
MHMK_U[CY_X_T$"M(QHBO "/KF$<@B!WVZ[8ZR6R>9!=]W!'R9?U^WGHV&6T2
MS]0C%IFJT46_Y8@R9DS.Q( .8DKS7E,KAH]M: O(=5:78C=\]P#1)*_NT97#
M,&\TRW Y;X4\Y.1E!NF3A:>;\1KA@=03#SY>U<"%8 "2=NFWU,,"S6@J^VSY
M1B#<_2M#K?\\@UF[=9H$*2"W!#T+*\)L?6*I-SN<]_"B_07, GOTB_^'. I\
MVB!MPV7!J#W?#]X(6Q>#>C]'?#+\8>;9ABM[=K9MZ5R-2RO),NMSA#M;R::R
MDCV>,;'R.)?N*YZ9'TQM\*42:!=RC0CF9=A)ZU7,^579Q^%H/\.SBV(=P!-O
M9:L*>9[/T,DXFSX/-<4?G#:N&^$5U\GLTC ]]KX5@!Z7U&&79$W9M?SI9L]&
MR'-*TA-M>V&<(3WK87 $)<8BT6089^#3MWY*0ZC,,",\IWI!TXY@FM@5WF+:
MT) /T1%"':[^?L4(B")FN>FJ4HKY^%UX[K;S-;3(;L6[1BEW\\HS/K4$T86\
MC_%KPG]4-/ICHUK3XZ!FA0<?#:>I*A (=H;#YE\."7YB_>V*]5EI(Q6E>17%
MXQZ@'7!<+%7@ZAAKF-4^K*9)]6*#\;4#EVV2DX%L]Z(PE;/5WOG;N^=/S6H6
M/;E 2]6!H>VOLK6J!_'G!NT23\$&,IELW>DQ9\CET :>S.E9E_,K=[;>G_M*
M_0);^IJ:F0.",ED+SI#V%?4R27M;N3W";4AVU65T#E==0N2$*-]G2%G*/,./
MD"\4]D+*$W*7(FW'PA<CL%ZR2TYMH=9^"YNV+J*!8I@4<B3RC,5-W]%&H\7E
M<9=BXY"!FY,-HU[YBQ["%40=A(FF3>$>$"ZG''"+J/E-*%O2+6365/>\8NS$
M"^-&-&A004[H$Q^>VE=%S:">H_#O7]J7B9G8QQ.J;:_?%TO7'%8%.+V)\N F
M)#BC4H[S)!^Q(.&"A2BQ/@B 0XWZKET)V"K[DC C^J#,*/S3*Y<%GQLI8>^\
M@77\J+D!<K--#IV.9:L_3V:]ZKPBBX4NC0VA'M0W(,6B_.K]ZHE$5S:N@M+2
M@AOI<C?DL$XZ(A?D(?ZS/&'22U?GM23E1K%BECET/I))7?QOIP14V!(YHG"!
MKQ!]%26QO!;2YPR%ZA@#%Z:)-^\/QW_5!X!*/VLP6BJ-G2169[E+5^+)X67B
M9+>B\^A!FNS5<1]B\VV&MU8O-T$8.E!V%,.Q"+.ZRA_J"^+]#3*P.>>!8P%2
MX7G=<DOB0$(2H@.#A\"A] ;(E'I!2?M'M3$N/'=KX6@#0B*R'U3-*,,I3Q)$
M2*#G.^__B_*W,/&#^VZSNSL!Y9F+'&.DWB*"!C^,VO])U)3C78ZL9<R$:3\F
MDX7D;]/Q.'(6A;\YQ+P)Y]$%P13(-<T=$[.(8C-EAPM7"W#"8N<US%R-0T>U
M9M0[</O'QVS-5X>D; C#E#$"\CC_5-;4VI>V@^\!6*<+)9W5+W;HX00X8Y.4
M!;VTP3=**%,P=:;Q7W/55Y.Y(M\$12@//)B?=M4B%T]O<1,YWP,^5$DWS^%J
M,_GT[]O.,QZVF9,1!O%Z\[#2+UZCMAXVAR9)5=X-CNM%?G1'"@'E.Q 4U3=C
M@/$'=-9;Z=3.&-\I9")7UO$QZ2Y_U#4]/LW3WE<[M(G41OEVX.!V*ZAEGJ[R
MPSK=,5)5[T%8S)<61_4E25M@#HI!0$G GDSE$%@X8\*Q_AY (=!\M:'!V6,@
MDV&VJMC=]HSLU-]%H4WW#Z:V5\/XEX[F8Z6T!WW,_$-TILF$+S^Z!H8R4?K-
M%+[;D:\9LJ\O_.4D%*-@C?'AFYU*/ZQ[;:2C4.3R).!V6$=^Y> /,:QY)_>T
M6%?E1;JR'H9/GO:FAO%9ZZ"=*6Y9?K<)29#,=,SX,'/\PRKJK:[6Z>>XL PE
M/@#H0P "7_+1&2@[1(X9%Q[\-J7&&<FAA!U2&SM*:">A@K@HF?&_@O6\J0=#
M\D-M6J,+8R6ZPJ%P;*8>6U4J]'+F4]V(NSQ&&B6[>$2[]T\[;>/J]F3&Z<(?
MJ\PHLRB)N\R[T.*,8WBZNN*Y>9_N"V</<M<M:V320_"<4(=)2D#$9;UB\\3^
MRIBIWW*5%*IW/(E)HX*$WCSJYRRL\CR86RB^?'T5W@E"BHKRV1L2FR^_#"%0
M,R9]O\]/6MZ/!# ]D>P[$0GP.F;7N0<TG6U5._8Z@:GK;R<)N)ZGA.:J?1S5
M0$CAAMCV9<+4:R.7JYU">6H(T79DZDNSC9SW&JI34(X^1LF@-69&>2KM:!MO
MM"=1&BT8!,ZOAD=@N!3TK BQ?!FC+IMD- RA!#Y;W0 ::!8_VRJM;.<N>8EK
M;)U[8YZ:P-#S$]_/)'&CL]/E%R:-FB_B@=??A4FBE4=7ZJN>]0/FO,<F^1;=
M\,8%U;ESUZ!5Q#Y'796NZT^TL#JP'?6!]B[- 0V><:IRI@6M6XSB9KPM+;D0
M$6S"(8F,E@.^16P>U%U+=XZ,>3ZW4/Y'*Z0$74HFZF^;V3KL;$M7DMUT-!3D
MLLO7!D.X<RL^3E'0KSQM&&RW0$BUKX[32G+OO+,(SW:C * _^4H?>AZ<L^UU
M= TFF;H[3!=@-=\,_C )XYHQ21D[Q'A!4TD?EYJE!I;^W#G!B_LSP@<^%F/=
M#+P'K"J(G$V+)-N1H1[!4]/!<E;686H8G8T/Y_VI?)SI;M#-,KKCYYYG0E'S
MO_GI<1J8B=RG"TGR&R8F\CL7N3\3&P$-*L;+D@E0I8"8)] QKU;\I<&K9S-W
MDL5;")JDK'AN/)N9^*4JC(ID;ZV35T[RS8>I@?> 2HL5TR#Q> 3'V(GV!W)L
M^ZJOA%CC1[^C^QUY\(;F/ABDL+TEZRPC_G5'[C2/4*DU7$!.'IUEG.AZ@QE:
MV6BJ*6V?YZBQL<Y"YG8UD=M._$KL0#),#F1#)1J'%<7Q!P0RS5;;6L&+Z\&_
MKH3&\,?J1[@&L<"]H5R".Z*7?L^;4N+J8FP9AT-K+?E5R4.XQH^4(Z:WXHJZ
MJ/ 1KUR5[X!#^UDLPDE(I=O27%PIWMG@7:*1W^_4[.G?U<TRGO/U<$Z,"F+H
M>S48]I#]5.5I541W2@L)P=S0B19J "D1Y(;PDQ68-_I'YF[I^X4665M>SZ!H
ML*1I?OE]ELRA>!@>&%9H[K<4638CZ4R;N&UX&9]]&^_617/(]_%$.[FC@L?F
MX0G2 06)/?> ;R)M:Q?W &/-_;-?&5O[>!##?L.JIJ/FP)5Z9VVF#+[/;4B^
MB:>81)VESL1*$@1/253/8,F-(3HJ%7+87@Y@2YA>8Y6;VX\):2W]R#HL<5>?
ML("7_Q6H'QH][66BQWD56O>>D(\^F>.+EF:' ])[_K_9"IE&2\Z*TG4OM'AW
M'ED,]C[ZY-N!W"4K?.($]RW&X T?Z0Y7O["'W29< XNL5U?W@-3KJ6 O\GB'
MI[^;0A62E&PW;=G=)4>,*BPD^]:<O_CVV\[CE-9.N)O>ENF998#0A;60=+XW
M81X>5RUE:_J?_8)I0N3<>-L=CQC-!)CPY?3*W:*')8#4_ZW96?^D_S%ZK:,A
MX6$Q]!&CDX"7*R']4O?3X?7O"08*=H^]_D1$1O!C7OG_XTQ"##?E0Y/(0EFC
MFD!?LJ/D2C$1_SITJQHT_W.P#'!*Z=.NJH0FJ?#,IZ\25@0J9./F_Z$PX)_T
M3_HG_=^EPH7!<\C+C7M BIG&UW<[9&]*A_?FUB($@T> (FQ7JEA'?Y29[4G%
M]0CGJD-4\;\QCG80K>WG>UVWAXD:2J[J3>;\R#1SSTCK"JWW*$B.I-_M'SZ[
M)C69X-.+8 QC-Z!=US54OZ,X2BX..,!&:()S(H\JI!:X4E&^&8_>?+S*CJ3#
MN_F#M%^I=[E!V\D/ID3I"W_[+?97M6'&@Z/<NP=LZHYY'22J"5-H-&YK:FU=
M<(>L DP60?I:*!T$>D0?\9\H:[U$)G!(5R]QDCY0FOB $4*H(,: KWXD'Q8!
ME#E9IR7[:+I>=,NB$JUPZ0'U8IU[VS:PW7J($557V _3S4L49WBV<,,KJ*37
M;*BA\)WLLU6\V!@6BJI^"SSZXP3CF=F'N)%";'9E,@F-FNJ@;61_(XP0/N2:
M6_+6>'Z::NK^BM!5Z4^&N^Q@,Z%/$T$;Q>Z0C*V+*(U9>8HX#O^G["X%]X##
M$G>1>X#0VCV@63*8M8X_L6_<88;I+0UX59<5_?NO/Z'O]9=#.93]32MBNT/L
M:MFT6 +2'_9>W@'"!RTT!&&+,=CRTGRK]_4(\Q/TU$:"^^8!!7WPJBH4L*=V
M;'!P7&Q]W@<.]C&HOY5>QLKP$V4%P-E7?AW@!R-GYZ[/8R.??0J82/$9)ZT$
M^BTKX&@Z>T[AMPW< [97SHK4W966(<[/^Q"X#-#0CO8  0^P>MCF7D)5ON&4
M2>TM3D=5XMK->83X6T&^'LL %*"AY.2>PQY;CK?_82K_%0D(\_#@3A(JM7T/
MN,+*A3Z;WN8$T<*<NW9=?;:N+- <G)W?M7]]I9S4233Q0S]:;>1M556DSP&(
M\:^7;!9!%72#)MOZ"S7\$@6?IJ5DU":1DT#XR^)'[;_GA'J>X+]]."R!*X:X
M\0:=.NY(*Z8Q699U+5@-'V&_8E*')W6EMZ6E_;O/4P\+_Q8A9%:.EEF345:A
M[3BI48K/RO,^GBS6UVU%,Y"+NW28<>3\P_5,($%&'W/80!F7UVN$V8E&VSL6
MZG8?U@(7PGT(,B:1KJ8Y&P+BZNX(I7$$&MAIA0<?./"Y?S&F5*?0?_O#_Z!Y
M2UY*B<_,C13XK6[WG/]C/&*N3L/B#@@=#X8NIV)O8R7LVO,:5S.*U4:$C)3L
M.YX-ZCC7C0RVRV4*LA-^_]) QE?01'X4<!Z7R9WD]71&5W+&O9+*5ZNI\1Y
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MG$$-7#;H%4I&A#MK^P38GL&]NV3K(01,1=,;EH#*A%EZ^%= TEAP^G<[\D%
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M66N#!R,@/PK/JE$G/]<FY?8PO#'XF;JR)"OU>FO&UL=-TRH(B6F38W,X=)X
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MHSZZ*-F#5V2W6NZQ]9$_6Z5,ATN5UISD$=&.'I,FIA1WO!1/IHY<9O65TEG
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MNP5+,55(4VQ<5M6%"6J@UKT0TM 7:MP48=QDKT"+W-/V;H.",%M@%7[5N'#
M!TGQ3A^HVT5T^^\6EW.AJ@*(Q8=)MWO OKV]9)*<W!M8H_DDFODHX8^=U@Y"
M10;T7H!BF<9[W)7,YF,Q/W>6D^5+GL0%OX0-NF>*5*855U>J]3*'I;/M=+S3
M@L=%HT4*GR,4MR>,ZX%Y$ZT"CH6V]D5Y/A/L!*QB&XD#WC5IJ ? IS,<O?-
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M@N$L\EA*B\&[8K-X'D+5ZPUT9V8+^"<D2%+6!:E<)U%\0L"BYCOBA7/.3*&
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MX/+;DY5(\C$N:VOY;#M<Y L/[W(#J8'(D"0*#G6>0&E-*CM<]NX5Y]2YHYG
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M5OO[1K%/R)+D4Q+RT0H8&-8'L>8\Z@5!A:*HF;NP!"N=$7W#I'WW@"[2XGO
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MJ2/)<*-KCVGX(;>M,P-<6LGL"R>K88Z1CBY(;ZS@Y2M%A75]9!D(H9C%UF,
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M7CJBGPWC^6WP3T82:3J+E81KJ9PA[NXN\PKV1(D@4D(WZ^T/9CU4<F^JZW,
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M=AA22M]U7$(Y!*F0\ZX_2FPH030Z<D-4HND7/Z>>+6#)1\O")R;8#16T(H>
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M^..BG_=2253'-[0A70*8_C4G=]#'/Q6?*9XUYRNV12H_PK8=(B8<"1%=3<%
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M'E[YI6RK#>G*5\,8\HB4P 2 WP!I_<L]<GWA!S1/(6O'N2PL0B+C^)7EK6O
M=;H&8:ALQ>CN-'-2'77H!\AMUL7U_U1/%V'FMI8GC&JJL5MS2*E]YX[P@E<2
MAUZIL:81YG:D).CSA@A^%4*[GP'[C0/8:301U1%>\N:E[>C[I>>.5VIY69-D
M(K/@!CL4Y)(1K>?B<08BV2&AS@1C3O:Q!J\#DZ20_\.U_S^ K?!+57;U-=GW
MR^:S[?Q?3_F\EVPYZ<-@(/5_I1#\$_\WP#?X5O_HCN@^9F*+_A&F=]&S0ZQK
ML>[OBRIN6-?B"B?Y&VPYVF "U5"&=!C@MUAK5#%^98\?W;>/U WJ[%YJ@LK$
M?*I5\K%'-!GX2&#TY#^$@Y*6(@]2Z3].6\*Z'Z)W/$<Y6_$_+J!?8HWC,T[)
MTF@X]S06)+S/^1U-B0*'E=>1^WW.7F F+\6]3Q0;WT0#S&\ MMOUR]\4<S'=
M-F%;.XUW#:W$9[7)T^L?6?.,CXF%$Q#M$8:D5C!N$,;SC$NQ>8\;)T/UPM_]
M=7-_BXY?3_?ZDC]WAJVXMBT/5@*EWRPU?^)?"2BAO^5UHZ*_R0#%?EO.E4I@
MJ;:_&D(9[V)RR@-2T=+KOJMTNFA!@32"N"UCNM1=+A=5,T^C.'>5I[AWT-7
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M)V>S#<[XM -ON IC!Q 15"KI)1PMCL/O,=+@5F[]VO-^K/HBT9LX+:,)V%8
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M) 5ZFUE9]!P^=T&]7Q3<EW <9*5,37XY :R>E5?A%5?[$<?BG#@H8J'J/E3
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MVM3!>+Y/M=?N4>EG(5(_,3!8AWF*V5OY*-O=^&X0H3#E?BK@"+ZYXM/+*Q)
MYSZ<;%[-?I+<B7Q1(AH-&N6[(]X++H7(?(@G-P25W%:TU>DR:NG>(85(F'$8
MN] @<XOTL@I+<:!.K58#XAI:;(G3&47DHFJ^I6H2?S0\@2KX'O>R1<P$.R/6
M"Q__[85W9K]?>:%.&9A>\,8)1 !#K$W.][;F3SM7AM.\N+N'[97;FU!"8\KW
M5UAN,<*IEX%N<"ZA!EB:V>0J/*0!JPK[X3):S+Y#I@N.68S"%\98<\?C^6\<
MRN.\]K,@++D2%G'Z.<=OP504!POYGJS1@N".W-^^9:%!@($\PA!_XB3B=U"$
M\0%*(18%0P_&GB/K2]5./R?[+:RRD7,^<(B\(RY[PUSC( MG.5?B=^B0WW/]
MAIL<X+A ^G;>-+?+*ZK\%E^@]E\-T_S=T:X$T7TJW2S!3RG_&*Q7E<EL14VP
MX"'*4I[(W,S(E?6*^MI_Y\G?#<N$J[#-X\LNWBN0R;I1^J=S,]3)ZIMCW6TA
ME_5)JV7F= ;/3272M^4RRK*"URLCR(Y:.83)_";?RZY^3MMQ"XOK?%Q>,5'L
M_+@V?'-3NV-,4YM=P<&0A_KKNI(31Y=W=N[@2-R<6E7*^@1?D(\C4;;GT_>B
M-LGE%3:I,X1MV1XFXJQ:K#BH!AI08+*F)$RZ[D.C6J%25.;*2+9LY-7F5$G6
M_04]PIU,E+Q(QG=A3A F[EG?%@T/8G_E:F?JSE$>^_;N0N0)6Q3F'HD  C?#
M_WQ :V2^RA5N*;!'*((-.WDXD0KT,7WJOE<6SO;;,!6\\H 2,*/ (,>*>D_&
MVSF+K)MC;)$8Y20;?@=MQ\6W#^#Y8F.-SQXB0D[E)+"!F2 >B7Q8I7F"HUJS
MKML:>3<#10.^UCH@N7KK.^Y MP@^U@-(-RER=_78N4JQJ(;X$]4^<-[X&4E$
MND[V.".!W8__MPN<#X#?UH'5Y/?<QJZA7\]?(2@D;M_0.XLRXN].20]TX)W'
M48Q3(7G ]S8:GOF[+Y>WHJX0!]CU4=4L=%"3*UI@['D6[^1?A$,U&&:?\4T6
M#.9K!$Z H7\0BNO[0%40)K;QK0?ZY<__"*RC'%EC)FX!VD7[*?C_E*9A.V0V
M=@V+5Z9P2?LG_XIM8%5):!V SCDPX-(L?R&ZHAL&JW>>_R&.C$L%DEZC&0[@
M-TBTC,%ZVQ]6>G9EUZO*S#]GVBI[6U)LQM&F]5,8_M$N?CXR>9Z??R*IOV1;
MF9HP'"?L<RS62*J4?B18\^K@,?X>)H4/_OTPN3%Y+:=]EK_C7P\24P#.58=T
MLEYK[X8B]AD<LVA9_\;1DK]PM%3=L9-!)PKRVR5"KGB2S%:T-+9'O$MDKL-1
MCWY)C3P<D/B[*A;3^X]_LB ,\#<9(DG^=*14X"^9\6?85G/TR2CB7HT2@?X[
M#SE5_GB:WX*U*PO60ADI#M?]GB^B?:]&J<@U3S@:.-MY^HS?.(G3 MNJQ_5@
MPTI1U3O@)V&?DP.<$/_#SED[NDKO>U\NMM'B?WS"M=B[^P\.8)2 %3T]X'TF
M7#Q;RI9_ONXJT,T7A)_Y^*WHWIGHQY1+0#+_!:TBZ0:>A-;4U21 $>_<L9^.
MSN)(,,&RH./'STO EX4!E\J-@F"*I?PWM$GI[/2095)8I'N(KG!K;O0S/!P*
MK7UO M\#A:\7-3=)*/F0__YC@X#L \'1D9_78A1S*6O5E(R8[/TT/X:SX$0,
M>TD[^+J/^21]2]I-E>O?W@I,+VKI[L)-VNTRK=(0!>6-3_!UX9")[<+J2T2E
M+P&B\Y> KV$JS+X>Y(B..1WJ\,%&=SV3XIT[>ZHT-:DX$@$NXC05=8&3 :N1
MS3LQ&EA&$) =MZP[^F#W267 '%]D3ZI:53B-N*&.=]-49?W-EZ88K2TZ3IEN
MR3&I.M]R*O\H1KSHVP5=+_H9^ZW]01VKLCG%.%"TOF;V?DG#8]<O#2V:&5EF
MU#YT%EE+2V<K$C-Z*_4;%RZC*HKK4-$MG6V%@+AXIIVMB:^?TX[>6(?;JE\"
M"'["#/[-ZR^191K%K77B-YB=5L9GZ!]JRR@*ZB]YZ$"D> -9G7;&VX?A0X(]
MX%=24JSF:?C=)O<%%"WJ7X=,Y?>!&YM4KG/>Y-5X8+"K7JI\4^D+>$L5;!DE
M ,W)"'D;^I20,L_:D)E9=#"7Y3JRZ /U+A0B&8JOQ7*=PJ;?:%==WP K9)AG
MUO=^4]8X+RB"/P@P 'ORF_$S<!%;#8W1U-R:/@SE!G5LVMKN3[YP,DD(YQ96
MG="Y6EBDJ%'CW.WIYN_%2.-/X."86L>X^25W9(<*%8XRR5*A\S^C B81B'7Z
M'"(+:C6:*[^M0)_A W  ZFYD/%K-QK'ER%5+*BSE-\!2?KI?K<GV-QWU'N]P
MI*3DI>]RR35A27UC8$7IZ\E@X%)VP;YV:'2/D@XB;J^FCUHCR5%IM'_HY5A<
MD4MNCZ/B[3G@&[GM4_E@6T']?"4K$ZO/THLZ3[?P#-GBT@OD'4XKGT%68@M@
MJMF^CN%1FTZGPNZ^4[.I?#6^"15N>5H6D1X"E;N -H:JXN'JNAZ H<9!#T@-
MO%UV4,A6DWGUB7/5DR[ A@\9OW!WY()>E\^\T:_4[;Y&J'.A&./(O-?3GR3C
MIE]UW&;K*/M;"5C\'1C>XNFH+:90R50(X6=4;CBUE9>_B^X;DJ8)LT"+9%*2
MRR2#=\<: V63 &)K <.B9A8 \[QQ3L%Y& 7J*/P4\NELO4H,!Q+&W*@5B'KH
M%E9;,IB;;]-#67D2F\IQPTQWM6(L*2D.Z_-WK8RDMG4/LM:8@D]+AOF7A9G]
MK/?FH0YU=>0P%6J>QC0I>)HGOJ(N/#.N4PE1(E3'W.#ZX%:>>OP68CJ\E?S#
M6&5;&II//:6451)1JFP4"O'@8(PJMFPA?:!^>D-O7U2%_06!JLHSPFB>ATT0
M7ZQC09?3\%?,J&TJS?B-J WA+-=+1J76-9805TX'16;\Y!5LMBI5E2?IY!Y\
M1'I-#>O/ W.EX0+M:%(5^_O4ANBRC]:.3E"L!Z=B?3?C*X9CK\M1M_HN6US9
M+#G?\B?0^\>"N+6KEP"UZD%;AYA=6@!_@-:J,$>/J!0;WUYX7D6!>Z"-HJE,
M[^9N*^L8<^ BQIA$)J>KEQ\U<PFX71I@6JV:F>\6J2UM1RZ# 8C=-,%735Q,
MZ):^(UR8@E)2[.?8._H6YK&%^,'(2%H*TX)"I5'D2#1#B>;+-M%^[T NSS*P
M2*@E"_@;<J%"MJBF3 $,^&T(=NC*[4X,1ODZ;R YO\9(LZ('6EWYIHK1O8>[
M+9K*I*]5^Y[=Z[*.3BH#']RJ6YTDU;EE6*'Q=4.FD_KU #(-_VJ@QEIGJ$4A
M2L!DUP#?6EX\RG,4T,K)>,OF[<?EB6"!$@>@S--PJV^366Q!+IK(ZK0RWH(X
M/EJ.4J %YTA#&Z1D9XOM:E\8F6;Q9=IOR'9P='S,!+IV_=)JW:C*3>X=R5=S
MCACX,4R/<A_2Y(W,C=T']M0-'F1R B>B/4VK%H+E99+X>7YH/==9+_32M;'.
MYM!F%P,[C@5]L"O#>?\C9=!.:3M[8P W@4+]L*!"<3LV/XVPS6'/0',L7XF1
M5@?LO2>-8Y$Q;7GG(UZJUJKS] WDV/"SI9%A,V >]UL2?O(](+\5H2CT))GT
M"W=X,2;=(DMKM&#D!QT2E=+)>KLSW#NW&U@M:^V*S,H+QVGY>AO^ZW%EF=+4
M\+6L(\7-2X#*+TI>4H$[;U:N!=YJ1QJ5^#%/1#&4.T6"4CY3/HGG69W9U2JU
M$'YSP+MG=W=L)<Z*,J<[(A'>=]4QEO!EN I4.E&HJ@NA'7OE:IV8HSG24C6F
MO"&5$N/%&*P'8H&O\LY+XH*^_@1V I:FOS%2VHI:&J36!_XFR<NS!@D+?3F_
MF*_R#.B#Q5M-R*VTNYA2Y1N\XUG3GAE7-=G" 8$@XP\+EE#EKO?R8 !$@.=^
MBOD#'IP4RT%2'78&I,H[%?DK%_C+9_B4V25<LS/>4B[3V%O6CS <7KF,27&P
M-J,HY"TW#U;$<XY<N5'+B"L5JUDJB<'7F[E+#Y^MO9]*QHK'BMA#FY DA0XB
M6"KQK"%NI>%2'6C2/W17:R%IKM2*A@.,HX+)K)Q_QX@KEWF49-X0Z,C6*MC"
M07I-=WW.=<+IU1_*<^(PADIQLSX*-B&W]'B=^1C5BQI_<9A%@4R6:=(4 9(+
MF4=N804KRKL;V'R[*(MPFB4T?GD-&".>([J$TD\O%"ZWD:*4AKJH?</$%;Y
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MNC86>@GP2O&^^8QD<WD^;FE-LQ9F;+A+<,:R5W6F9';7XT[$"TV8N%"%'HE
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M%+X$A-F4UKR[_E6#&X\:T^/@5\.?*>62W773J3"CQ#G,<!I:3M+8-'%?2WU
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MG&U$YV&__YMN9!@K"V;$B1,5JJY=A_R[%D??WT]4_BSG:F\0Q)#*@E]%('W
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M\O_8-"+L$WR2J$0^RX#457,&[],GF9&-X!\#:4SX;CM*$LGI*A8$__;5&]U
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ML5^[E2#: >$J<G[^.>NX8R)]VB)NPJF/ZVW6\Q30QC-;[6OITCSJ8YK8JE,
M5(0]U "-#QZ8KQK-+E.E4#39(F*.(/U5>^17I'G<V^AZ^LN3)NZ'/F46Q):.
M'!K ^JZ.MC]%)%?*L'!<2!=\S&U;W.+2 ^ZC.*YEI \SWYRVTWN'7<;")+1?
M7&EU*D]W-<Y,[$8Z&*<.CN%<3?9VLURF'2U>UY'!?P4&-_NP;WP3;.O%JW2,
M=DE4J"#V'R4^!4NL=-GS=;R,#I>3=[;/\3/V:Z:7*?GHKH],P\3U6_40SE?A
M2=-W9]5A%:&L\ZUN/]_.2S,I0NYS3K:#S2]:T^E\1:REH(BJG.05LO(:3U6I
M"N*@EQ]90N]?AY,'6DT<%GLMM$/CT6*-!_/@[OI([R8YF*Z?0[(A^IC<ZISX
ME[0?8P=#V7,&QIA/P0G7<9E."ZPCGJ]U^YM]K3*[$X"%$#R\K<-PM@GNNS!9
MCW<E!1.IG;2_(=WJM:)VTOUZU8?9JQVN@3L)IY-[U"'[U$ 13K6??87<X?I4
M%?LV3DTH:*BR@>>=5MHN<N/8UM,/ &5=(+ @$V5H,YSPFY,4L4,(4P#AUI7Z
MMVH_D5T+D5@V8(8L&5-VV9^<'?\GP _^;P%S2,X;P9I3I].5==OH#Y-IK2K3
MUHBBB8J:A;[KB;B(U=YFEBBX&T/:9%X0U]#!DWLE_#^(3?@?QBC\>^)R#".E
MD'M*8M<>I6>:9SY!JC"%3(DK_K0QN!QL14,A-Q<UD?H>A(E0.]-.<DEBR:O-
MK.US\>Z0M?,9.=P0>FH./L#,RK,N:EL,3;'76<_/UC&',E+G;:,7A[2G,))K
MZSX/]P7WK) 63HV!V']O+YGV,=C%5<>["2_T:MJX]I1(#'M(616TO?Q^?Q@N
MNYP(O[1;4/LZ"+B*$(*FZFC-;1%I6/7VNI.NW.UCZBY[>M^(&"M5A-]H''XC
MLC"J?$]^T6^CY1]C:\@,E?!L*6YO;V+7?-KJU,(KMUW,"G<4]/[.#*$0*Y%@
M2:$1&IJ]>N>ELM7;KYG"(HZ:4UT?-ZVP.4E3UP]K/9;0DC>F=TN:H ?7M[Z$
MJJ 7T6.(;[NH,RO&(':YO4ED"1'U']NGZ]W9%.?/7QW5G4PF'#GJG.Y 6<_(
M$C&0:"D%\;55.^0$D]5LR_VCQRA'I6P31$.CQ4KG?J*EM1178>45OQ>R1 =/
M848E#)TQC_M)N919,&44(22>;+,477O@^S9:S &YOIK Z6V[% 4R4VL/+ZFO
MJ/'@1DJY2E9)/K:;H.J<,A"N&E5;P_24 FE"M[3C:!<B/$(U,/AZ>V8_FG,;
M!)GI0+%AH+L#J6S(^BR2AWJ"*#?$HER_FN[H<."%M<,4YBA$)O"TER$F<TVY
M*"V+*]L6B\;"Q%3IQ83:L!##$R/#(<2AQ03A93?M?%5V8DV3UG!ITB'SCD)R
M-M#/JJ3+AH%/9*P09_5U:"8T7QXH5](RP#^<)$*GD;?JSX]*(I[/A0,<,C:D
MV6BO\^P17/X%#G!>#$P4-7W?K*J;#$S*E]#.)%G:&G1P=5SP/8#_HLY'&BE+
MF#_OO(2N#"NX,ZL+JU'EY=&7^1BW2Z=>]!09^^L;)Y7WK3101+!5'U'F6HCA
MBE&FC?>7A-E^<8P[:RD./FASXN5GI+Z!H"Q\Z=W874S-SUN%X_R(+^L8O=3]
MM7]V1^K.&Y5IU6+24 UMTB[L-K.C9?P,T^](4%^/KS1&!CFT%D,:DU (EO88
M*@7R<IE.%"P>U6 W&3'(1@ [=77]":.*&/]RN=4N0ZVT Q7+&1P$^\1D2,59
MC.W%P)U?<V;*PU"72^8H$*:O3V2^-O.T]!P9@MIM'YEU#QS:%"&+4;$Y9GY.
M>38]XR+=!A Y$CD[V?ZV;3$HPN=6>;?NFL3L(-T9=N@]!7;#P3S?/$0?S"M1
M\7U7]1FG-+^[(+B")LQ-.O,0'D=4+V 87U(QR/]H^.U^9_\5/%E]^ 84(2Q^
M3;K["DU<7JL;#]E!!DU.&%O>&VMK")=FO2*CM/JK 3[0)'A8BBUJF-0FO$<L
MS>%I7#!+R/](OH?_G_[CQ#?X]QN\DG\O-0HVV?]YU U31IF09%ZRZ+LXJ9L9
M.R8D">V>EWS.3S/O1RL>S<*,!K5M@?%"FWZDWRWG% 7>92X!(]Z]A=^@PJ$6
MD*Q%.9:1G\;(#N 5PJJZRQK=-@]/T(3#T(K25]GD)6E[V<*GQG7_(%58JM)!
M[8:ONS ^U +>(SN[P9.#'@!OO]-+?BK9JE8J(_O\VQV*G[O%>WV?-JK;<]0E
M,V<1WT%)%B-;SAM73889U39:!AR41'[UV"S*V"XAK,X9$X3?=ITYMU4T$O.]
M!3EA;3^K[@BWD;["GDL*:_'ZN93/AA518$7M@I$SB_9()="W6&V5=,F1 ZT2
MGIXP[UF<RDGMV*EW^+@(CN5&"1)&:80FL*)I_\W+[G_&B^Z?$*I7;K9DWDR9
M0&C*90G7V*E[&/OJ3V1V+U6]>C5'"AX*"509Y7IR_.G20BD%76N[CS:]!76S
MR[>\RX8DVN[^*VET$ZIY6SQUG<5K2(R1+="4'2VZ:^-?1LAY0L] T'8]1IBS
M!CL&:)1N0LBH.>!]-T9HOH1'M)-9QUB%()S!;KOHF3?0PL6[4T5+H%W0&&.U
M=$OW]OR\#E[]4N?5CI[[,AZ6O,D>*Z LQ28SVQ;2KM8N/ZT\>?-.A"N.B[*W
M:2-3:Z[5&V#T$A'<-W;+:^45JB[!J_\-FFIV?380SR?#JD95K_<C>P=R_8VE
MMY?\3Z;M:KS@W, (UFJA(B^-+>L2_'ZP$MZ<^3%^:4/I?'FT^ 4Y'MQ=JK.(
M]RU$#1L/;CN]X-MNG3#[Y;Z'0*V]LD@I >[S37C;E-@JZ&J);F6T4G?T;*91
MX#W6ZR>3";FLO) 7L0[&@(L#U:Y#W>(NS+"[E?F?4"4%DE^$HZ/2SM=*P? 2
M(,14S7ZZCLXQRIFY![RBHMEO>;-$__G^I=:T4G"QI09K9Q;@E*$N/; J1G#+
M,.'"@C)3RFBK[@Q^C+3.4KJ7,(;\/-(.E,\]-KS991M=1QC,E/,G[^(3_)E.
MZJLHI27-:@%RU:=J>]>8$QFE^0&YZEIF(T!3M/WRR-IAT\!U,)M:Q+35=^,?
MM@>Z4X"S@N/)UE=7F<@3\5"F\-/D\![#E%$H?Z&5G=E/]%GA'9,%;9]WKJ$$
M8[#D)_K?)SDJC73,XPDWUB"6SL#!/<Y)_1 U6%\ O"ITU_ OSST5*&8\%+)W
M\>./93A]PP!$5#<Z#O=OR<L%_V[+085I;#N<JF-YJF $L!=XLFSWA',5X;C9
M%&(4=LZN?*.G&-IFRJB@6VEPS:H\"XPE8@#WNS245EBK^Z.79&<',01E.J)H
M?/#5(0H4 L3;<8_OT_X:& )5X^A*V?4H4,K("4RH>BYN%4561#]#RRNJX=Z5
M'>0#5UI:L<CM)9W!VJ(1Y;F$X:@ZGML['L)+M1S&FMDJS\@CW+S]&[@FV,M^
MURLK20A,9,YHR\">A8,!>'*'5\9:UED#<MST6GHC.6U:TU+FCQ>0*'UR,X*W
MM"@39$%_TC/]?\>O1[UD7VN@5W;D-2UUC_)\PP'D*.RN52IZ6D%8?&GR[MI<
M1V'R=!KT>?C6P//KYTE9(:.5/8J('=UMGLNQP"XQOO3"I\X44N).G59)^:U/
M&^SW$L;SE]T3^2IE#<09T"HQ=,A*]]2@2 \ =*5 T4W#F.,'P Y$?>/\XNLG
MJ<[.U8DA7/0]Q;;:;0<(;\#9IF.]$N<K8AOHXR3,2OO'/;G%6]MELA 2J[1J
MUJ^]3V@;N8L9=IV_09R"7@_FTO9T?K\ 9[[]Y^L>L/^R&QHC/[S.^92\6!(7
M06TJ*V4WC]E<@^!>BW/%BJY=SZH; O.?535&J#M4TWVD;#_--=#9,LMZKTZ
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M8!<E6\0;/ZOTOMG?K_SXIV%^A[YH1_5 <HS$JS$%J,IGE[[?#;A'[;QBK[7
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M$QVH*3KP>8XG10DT T0C.7W$4.*!/E26Y_"1[]6^'C,J4[-"^QUU)$OBNMD
M@:&@>1=7CC&<\J(%JW_"\K&H"W -<?A-]3R4O$2,^M?55[8L:4 K<158OT?V
MGX:PVAO+17?BV]_I^MY">,<%Z*2(*0CTK)Y0,D5+$8G2$A,9ZI2Z-;R$H2/Y
MEZO0$UK6/ ?],VNVX!B?I'/>WHBX*G/8^/\%?C=\5IKD _6M#SY1L6K2Z@AQ
M&AH@&C&-O[/;<Y0*#/GGIII':'4- T]-XP@Z.Q_CHS?J82N(&[+8*TWY-H\7
M&]NY#X?EKX#U]'XQA&<]1&,N];A-Q49KR(Z5%IV4<U:PXFJZA5 )+VE&DP,\
ML!3G"$G_E53A?Y&<=+>]92LSV\(<AFD"EQ4#:<^MMV.[B;O2[L]2M(A<11ND
MA52]T6V&]\5L$;B@@3B5<4UR'?]]I@:;(4>=&XGIE#>OMO7?9EXY27TQH-#T
MX4XYZ7S0S9//LZ8'F9]FG$0$*240RMY>:$584486XW].M^1H&@AXR@3R."TU
MZDJZDD[&[3PW-G,9>+JG/I5;D-5HYE28_VEB&Q/J5JB3X.%<9M2^P-LRY?*Q
MNNXU)O^HA^9Z4O'W^J7SEI@' C'/U;W9_2Y][P'T'!F'W#NO='EKBT3P'[N-
MJ$P +]\;RP[:\<E13]N;\.OK2/+?;NBG'"N3WP-Z5VSNMNX2MF>4;_Q+6^9R
MISZEY\VPE- ]=DN9E0I)4GO^@1@>;P\V="<+NU'^D"\KH'*T$3QB/75X$+X"
MW[#1&_UF@#Y#?R:PVS4860-I/9)N9@JP9(KD68T,KB_FIMNFS/-_GF%::;"Q
M_MF56"=H;#->*[4V"AC&'J2HK*CG-J+)U-@L<4<C/<D4&F#ZP$%2\8%5XHZ@
MWF3VN, O9J?@&5=O&_FF%03C7>X3GM+\MP^7;RWE=ZDJ1'PQ=M1V9KAGN1Z$
M<,D,;!F@N<M\<K$U7Y1[W%;P*S$K](1=Z1K!V)583).CQT1NFB%O)Q*J(#G&
M4D8ZW67X-/V84426])@NX62F"MA"+I7WHOCX:UQ/HK>53N3F=B%,+*R;EB6%
M3EA Y=U.HWBQ4X<A5X N[9LND\9AL7)DW]*(D\BH3=I6-;HF(EY\PCG1US[*
M;W9W8#YWC:]L+5C[X $AK!,T&856/.]-NP<TY$YG,$>>*>A51VE,3/TD]XNU
MR9P\*Z[,!78GV''5<N&O_1XN5]QAZY,N^54H7M6.N2L+C2*'1KC6NJ5EE1PU
MKA+.W:KR'M33.9<AW8(BN,UA ^^S-O1["RZ5@4HBF_*)*6EI)!OE;HMZWU]<
M^7RIA.[CDM(]+@C3C!W0JU'@@\9DZ*9K:O&)8T&6<H]\&C\,7IDG<CVAZV;S
MQ;M<4)0_*CE8UG._L-4XRTD(X1.U9@=I3NY5A6DFNC](-7MYH*]N*#3-G<NL
M-#[EYLDC;BGWS99^S+*,3NFH<P?*F5YI5Q-+D*JE4&*=\?-*(.D(<"W]XBQ[
MD"M"A'V84X+>P# I$ONU50A6YIE K<3S(UP_Z>_CI"Q?ELH%?FG7QVSF+A%Z
M:E$5N;4KV!-*%NCML>S$Q2Q"QFN/'L&K3%Q,_74PZ2UAC' @KF*3#O6015A0
MK_:MM!3!2R;/YL;DMS+BVJ;PA*#EK_.OC@=N1:9[9R2,/.:AK/\SBAZ24!_F
M'E8Y C2",8&,9C87:KI6L0,H3R<=>5]0^]0O@9Z[ILRH9&8TH+WE]K?W6FSJ
M6"2ANV&:6?RBKO3SM V*'^YRR&<:1[>?,J'J+!*%[_:4PUQGGX'PL0>!P3A;
M-IKAI[=:X; (EWHJ;/ZX75Q+[<L-L+_+M8FLFI@_KH*BO^49A"TQJ5"F\*>,
MB._C(0,HR[_L/OZWTOF7,""9Y1M_8:Z3^9VRO_P/:@53Y#9LY$QR!EZ($^TI
MJ.:$Z$.*S_FWV0;EUC)U=0&B@12%W^'5#.5)Y"1&NQ9P<*:U4F6P$%3Y0;&,
MG8:?>%$;!7DN'VD=8-P;:E5JK7U&GG\;?@7QP%8=_V8<HQ@+IM/5GGB'2!:0
ML&/%L9])3(_#>*].9R*1G0N9RUF=&-6-B_-+"9PK!/+C#D"*IH*BP*\>O'3,
MA?=_Q)G4J&)SBM$$NY:QH%3(TPL!Z682$RW?A#S+OJ8X([:DC.OA<?)3Y6T=
MDL2AU>F#ZGSD8L4)V5-( 2-/-S(1WF;5A$.W63<Y%5ZLFN>X^U.K0YX7DN!\
M(WL?(/O.&VHMNT;H7'0/0#Y*7C ^6[H_/%9#,SR$0@VNA8:P1:'CGP7P.?D9
MG)2MT4\5 2,/)4W0LS^$3R8G6(.+J?C[!>:5-N3JJ;\!3F'*8V=?7-A=GG[R
M^5)FWVE(,A<AWO#))OY;2_TX5]O#LHDM?8?XPOX1D^' C: ,CAIQ[W4LF]BC
M]&;<ZM# QSIM-!X:C;:.V*7  @[4S%6B/AC'$>Y0=U:AK&OYBT5NDD5L.0/:
M7/-<&!'!CTI"JVKNGWGW@'3;7^!S*]^-KSX:F40Z1G,ZLCA\Q%=:4GC51;*9
M)>-T>8[W /.O=^ZU:P8P_T#"_E&#]AXQG&D\?FRV*0=7BQR_[NX@^(KS:V":
MMN^ .ZOO\M-)]7L ++:9Y=)& 73<JO'Q,#^]9RT0Q= 7SHMME9YTGDYR\&9)
M)K2:-H(^1B=I.GCK@B]U.B\#XT?&+U-6T#+.Q.=?6<3IV$0WG0,4GU*JH.GJ
M%16I_C:BX!.&^-[.U.ERD+_SC5=T84F:5JM?)A,@A^0['GDJIX9@D7#Q +?S
M8F5$\JJSYD+6\G68G'S\$[S+0H[3_,0U<"\@_>STJ'O4^J8GX SBW:]93Y0U
M&XWKX1JUPG)Z^US4OG+#W@NN28L6J:VQDOA,=E=*UQY%.9V&O6/003NELIID
M/V>^31*MSV.\T6SM:/6U$Q)A\*E;9:ZR?DVQNV$=B,DF8+OAW0/$Y!,V//4=
M-UVOJ:MO<W)I@;6@5I!(@I>QI6\#B')5V9^[V]>M)>&U%Y4/*-Q'_7MEN%ZG
M!/23YYM]#,CNR%'!ABH^T8^XNVJ0R,G)LNC8/6 [GPYG >5">4UYIRZA"?4:
MA'Z>O+G2Z<I\I\>\H9K?^';Q^(ANPU#?"^31M&M_O5YLH*W_L], 'BD*L:$S
M/%]E7'.S,5 7M2=WRR;G$&NTDN05$E5TIZZHBDUBCG52KDO+CXZUQCJ'+B8(
MV[F1J*O/1/9D7N)WHC]*'+=8GH7N&>8R1R0YUCW[[E";MI>O8R)D/#JM888H
M?=-)8B'TX%N7IKH6ORX-^1O^3H484?X?BN.HLES1TPGXQ(O07ZLFFEE' 5"J
M"\JU2+.7^RX#+)VE"2.JFG/\;V*-Z701I5[N=D6HW>MEONUZ)HXO?\C I\:Z
M59)F>-)1B6@0SBW6NK'"@2$/ZB^KPUA!H<B]$=5G^1\?Y6S<9NFQ52T,;CA;
M][BEO/G K_(U&O]9]-QL;QT1\^V9RI>8D:LN4(2N97!N U%8 C,)CS!%49AM
M0 =638XUPL]:^N2A4#Y2SYA]ZOU)0O9CI+ @LYI#AB<N3_RKY6\M  :REZUU
M/8V^A5I)]:>$[5K,)-AB[O,JO[36Q: '4@T3(W)1L=!>,M:[,M!6X4C JSD<
M'Z%+:5P3G)&\(V\JAPB0YLS[<RE*G>=!&10WI32?FUX06S[,7I;K4IXIXH0^
M=!0JUEXA1B%2*G)0O%8=EWNO?_2&U)3:GV44R)%S0%RV3,;TE=@,0T"![DM=
M+F^&M:Y&G>9[=:;!=$1J8J,^;P_Q*6E>45 9B1YZWAZDE!'ZD3G2"N?C3&*^
M#!X?6V$E?1;).Y:;ZBYQM,*R91&X$;(9M6^&$_1_QCK%2/M!^?394[&^BFE8
M[M4\5]2FIR<.?F6G3@T^3RB<&8U5IA['YA/]0^\^/^O-=7_@DBWPP\^JHFM=
ME7RDFE.<"<\:OSP#K"J#(CDDC@85%J(H5.R') >K0XIL'^VS(#EC-:=2P8<A
M=:1N);$BL_;;>A'<QQ)5*G.>5Z#X*"Y/$HD)OU^3H6V8=77)/ OR(").C6>N
M+I>/R#'SF(6,35%ZJJ2G,)<TD#8;J4MK\*2MA9DP/UAM-VJ1$(]24#V+[KQ6
MA<?T,VQIW'5[2RD@5383\KCDKY9]A3[P[#R7A;JB_,$XN,K#["4BR!?J\$F-
M:C8/2!4Z&3$*U>!C1/)Y7K:>XZZLN#4(^1K(UG@G_#H XL0#C@-WX,>S'C.=
M=3V-00X-J5:F/^!A[??9R-:8M@XJP')0C?Q2=&"GG4I;%<P]DY@GAQH.*?T-
M<F[OCJ>1G9(SW\ZE*(GL=3-E7EZ-B&3Q+DH4MCEV:@_X;5&1[MY;):'BAX74
MT:PH5/IH0@*+U9Q2;-UZR2KX3BJBLSU]Z:#K[; L)TK9Y6XIAMB'U%-RTQQ[
M?FCP6UP+0[>& ?(?/;3!67#_^1@V^$JC"'<URXY^2$33ZYH:97LBG\/P5<J1
MYJ-PMG"PMD.7^WDQ5 YJ0&$0NC=D("SMB462H[;,)O<T5M,)GIIRT/0( 7HF
M:<OO51#4!Q.'EEK8V 0F*#U/G2K5K]S,<@XI>)8GC5=/,N"F>6.=\M[TVPEO
M7)S!:ZMR!YV*:+DG\F%["LHIW/PQ4YE_!=#<MA&2I\B1\.Q3MSM0^#>0(SMS
M[#RO<"B+X9@5+8L&.12AMGJ._JQ1+/*.7)VHX\D<4E>4DA3(09';-LSVQXB2
MLE/Y9S@._6*G*FX-K6*NRWR$G&"_)[#_X!6DIKC:X06%X9-YKB@'+)Q&+G3V
M 6=N@MH@%ZW(];YRUAG]:=C<Z[J%01(9545C0S<;F6DJ?LP-^HP$O_R4;RD?
MJ:\60\["G!4:/U/(]4J+[^A.4;'KD9'*AQ$\O&EF'_$R6!(7&9#7.3V599*>
MKXN9*?,"P>VYG9.?U;U;UBYSZ*'(GK%\U+C]ULWCQ7?^^'O A(G>/8!P'=^$
M5!S7:8$N[&-XGM'5>QM/A&)]9#=W5M&VLJ1R6\NQDMI=O>!QF4RKZL,CAD#D
M%+D9<EG O0?$.F:<];4D.-RAA?<AA#&N%P?'YNA>?N>.%@S;D_W#\+H2\#LM
M]G*5/[8G>ZW6-36P77"E5;P9\WY\20(JKX<GFF01+XDMZQMHWF2O4W<W<]1(
M[UM$+JH\U0Q9)Q+#)[]["CDJOJ22/1HH265MG9\M)7A$6V^RVF%%[9 )_F9!
M)W\"HM9EBD!@BS;JTPL.NE[ Y"M##1<$M315,P^]BX=]GNCW>)=ISW:<?"-_
MZIXM&EC#Y99_5';#:L,>JQ,=JRBZG-?TV&IL+I#6!(=(Y3+E9^9A7M&W-DPW
MX,?EH?JXEX'7E-YH\-HC/!;&PQ7%;Q2H>%:+^/GT,M'EPYA=HHB'$EI!J;XU
M;-PA8[]2Q'+F5#=!5:YTUKJK-YX\WM0^0+@WD@*NB;G;J<G013#:1"RTWPC>
M V*$[@%-D^W;,;EWP%#J!P7"-UT?C9"MN:H$.@ ZD,5L]*C RGR_%.E5&/:>
M:9<95X\C'#_]LNIRUZZO@=]8.'#N;D?G?BKT2=@ZWMKCBJAVB$U8/??0B+LL
M0BRJA3DFM8X0YQCW;Y24-6=)VJSV> ->\7ZR&:P6;504[>:=LXI[&A[I2KM!
M,N_;WGP(CT%7D.KF3X6LP]Z+<>;M6!G3^*6\XZ/DS]AZ]4WT:\-=:LK^5^PA
MKYJC+]V(^:W1G090L+,;HCJ=*A3,XTJK6[](.WSXTL:*5/61R75!M9V;9^L5
MVG"4C0-C4567HS;!5 1GH8TWGF"7#ZNWZSB&+>L2U3&#^#U =[^)ZF-+^TC,
M\,1-<?KE9TX.YUE/*B] K#?2[E_T?\NYK/7!4_ X?\^8?6Z]Z=%(: 'H=+XE
MS=)+0YG/\Z%XVUUUVI*2F"+//2!_[V9'#?%I:#WMSMOR^N6Y4E3;V$N+3+V]
MERWVS%-UW'22)#VA&N<177"BR^DL-^O1FB [MRU]L@C$\8UTP%T*]TEN+4;Y
MMHA9+JF'/BN.,7%WKM\<HBD';%9[-%3Y^GG<TV'VZ5+WB:5[0)G"37$OT.T>
M@*BMIBVS_+RJL&*@ [/GV%M0+ _I(-HR@(6XX&(HC*^$VMM.AAC:C'CIY'\Y
M$]5,>Q2TNA$Y.;-Y]^BPZS;0"5OJW4*@FNNWA'V3FU<9<@VUURYY<ZKZP0!;
M,40I5^'T]X=U>(X:+];C.D4P JO(:_M,ZBLD-.A!_7EU_H.7S[<5V,W]^5 Z
M\*JLWDZMV[?OL+O;'>0EH#9$JZ?/L]<>O2=0S%%8?V);)#OD",*:OF@(*:<;
M;^0F]NVE]+W 93[" SWJN!&NMUQR.SF.F-,TSWLB(59K;W+3973Y$?]+K&]K
M,0@<1BM::X3\24O5@[;-U,F, ,FC,QC:1."N]*1@_',K\X!!8$PF$MEC&/&L
M6Y ,!)H=F-57D&DM/U3M:$U750@U^)AEI/L'IKZ0YU)/56]=-2_"YL,4T_C&
MP_OBF6#JTS8D@[%,F>O]67C7+>/P!Y))GA94VE(49H4,"(MORQ@,0"2?";*)
M0-#ZXR#A,Z3"#"HU0<K@_Y?%$)2KH@1U:<7^:$RDV<(QJN94H/9_&:/Q'0FK
MRCB&VDA.1+O_V!0.^DT?+L(U?'_CY:<WM2@1BAJQ/Z [73I[LJ:<0FH0I#46
MLQ?&^^0LW_LO%EN_D$MOMMQ#$Z:O.#ZZB-#L$RWB8/X]!26=#FIU$-).2D_L
MTB;T4!O53?14Y_Q ? I5?E8L7FXR#4$7W5-0HT>G(-%"6H@:7Y#V7L1#0EEZ
MZM\4QFO,_1.^?,#N;RJ%1)SM/4AT*LZDVUZ-Q(HF9B^2K'U-P"#&3F#*\50=
M2H6@96'\)G7"1I\Q7"&R=X?%M'^-[VJ)FK;[+'/]JN0O:QL%HR)IMO]:"LL2
M(R*#TK(X7G'Y(SV-"(2B..RT'HS"7>NGB-+I)B-5/5EFB%C"DY9FKTGJT/5L
M5RD@/X6Q5$YR-W&[]=7&M#V<FLL@Y,81(F"2[5)[$S^&=I;W/0 ABU#!X>#S
MO-*$09R_<N_F-H8;0^Q(AJU&%R[CM.72'M%F3H5 UM(69KJ?R6'7VEEN8X"7
M6'5V7>-:#=DKR^S;*6U^;,54A06;K3?()]7+_B-.7_]QGIG_'PG/BO?GPW6X
M8SQLGZ-7MFL1(OGQ1RHG2&B;HD[R9!YES%H,HLBL,K7GZ5N4-I*?EHF4T@68
MN!D\>$Y:8C++N0T1^7X^'T10] 7XY[8$OS 4LZZ:UQ/GO=+TI-6-/XRK_''J
M>_FZ:F2?TNCRM?/B/J4B1B>!M4H1/PJ7\(/:G1K^=2V9XD?=UD<\OLL$$[YU
MUGJ^.#_TY"ND<WF$22JE- 906K,AK']YVNE28A5T\[SL66O>F&<X&2_U\<J7
M;<*8^5ZW/-F G%&:=,?BB 33(BJ@TOS"Q<996MXC]!-G7X>XWJ((C0B7G<@>
M234?%\G^B&N6*KE4Q6X=?XWIDXFBS[C_U3-/,1'G$VU]F?T"V$<&=\?8L"'G
MAT9"MWJ 4NLI3&#,2P]8S*$6K09/.>  ZMF^XGD7S7M@(+#=[4ESZL!35#77
M[+?),M,R3Y? 20(=9>JZV[R!/F>^T#HN +_0-Y9M72,[AO$?K5?0W T\",_J
M,+:92/[(2EL],G<I/[SMFBC-^&7U2%&;RB*8?"ZCP9=-K.!NZZ9XUG?YT<2M
MKSSH+YOOIHI1A,<9UP7'I=X8 WJ;*VEZ)L_Q2;87#P.W[EKRA+W(WH:3$V*>
M0Y,X$G(A ?%T @;)&EY/\Q=>,7Y^3EFLL"3KNY:2,=Q(I6=65:L='TLV55 F
M_+9083>M?)"7X%HF56'))N:N!'^X<&!I3Q&_'V/#L%BNBC93DV_ LCGR\_IE
MT/>"J+[E/7GNYHS6E++WL$S0\<0)<+>;/$H;?D="I3-;JZUV]ZO$4(NNDMYM
M0_4:+.9B?Y )ZNE!6@,(<27NQHQ.RC-6@:]R(NT!=ZCJ:X=#\1GM&*/J8M^K
M?"A2.";PN2,Q</'#SQBN.WTT/+AI]/'/ GTT&@7]W^?>/:=[J7/BAH6_%#-$
MVT.%F]:S=[QU0(47UJ-B<A%XI^%!1V4U<I'<PM:6U#H.N_K6C7R'6SF)54Z%
M61/CACIO(^[T\?)Y&82WA%%#=VE/\4S?6,^&H>$=W=0ST/87E .-F0'UP)ON
ME_> !P+W@"IV&<2G=*V0I#:5<X;ZH!Y"[@WED\?W ,H[EY4'VW>H@Q6^B](%
M49T?HS.^*\,G2\9!UDSVC!D_$T:,Y\1E-A0,-<C"#W+N #[YL(Z5@8R5"';+
M=77:=:*^(VQ3#R!)I]1*-6CG.58+600'U<%@)M)@!B?-"*\E(>B;E+(AG6%=
M(OH9QX=L<QZ3X2V.[Z?ZJP4KA==>E7P,$V I)-PGNRY-^?+80R,_O=L66%<%
MEN+]%[]MDE!/,!#PU[>B H?U+D>4,U1)_<U&Y).5>.?&B2W @B2>-.+$G]M&
M^5+]^5BMP__/0G/9!)/IKWN(41A)Y!5UA[E;N-CB%U@FZ.\!B8B\879722A:
MX_/",DU[2AW853WQE/."B,-=J0I<9-3@C5E8'FV!2\PVJV#F]L"OZ>21%;V?
M0@2%M-V%"@C1OH9RBE/@UR[)K/!*+!N3R85M\AX^[@T-QJD2Q/7(+\KC' =O
M1[=$)=\9J,F$B\[=INN-HD)G;06_VR]0,'.6(F)/A!LA7/*SR=X:-!GW2XN?
M+!BH\_V4\]=4H 16_7OWPO:DJI+S5^>7R;NA^4=-&Q)@N@0+1<2MO'*#S)K>
MATM"ZG49!UV5R^?]W"O,VRRKI9P_/#G4+UR%Y%R:7]DW-V:\L,8_G8V[!W *
M7TU#I3)UNFZP?(JU"-M_BKS*N!BBTXJ;CWAKP0V1B>_*MB;RGE\,!3IR8VXK
M"0J1TYYM(3"3<JU!6)H1.E@K%"0VV+1Y/=PAFFY*S;:,>0-Z2ZL>FLSQOTMM
M)WBFC026[!?P]7:6GQ?^50EL^X>3Q$PKQ5N5::<SKH$NE-=D_GJP_<U3$5_8
MELQ?-EJ#8>4;A@139N,'\.=+$4%;AB/V?"-8#:?/ZL\.#?R%WLH^V<BSG]4K
MK7H&9/#;49DQ>0T'2SW]EV(D?@O)@2W]]ZK8&=570FUMZW4/#R]"JQ1?F8\E
M4Z(O>W6/D&R>JBFU6V\D;^O*1  +<VJ;C[W2EFHFAD6G;3(W26=(OY[K?? Q
M3AR!>4QG![?1#QZ(,9;IV#!=R!&LEIO43=YZOIQV&>)CV2#XU=^T,M4XPWK"
MZYB3>K@?X91_*>[\L_6DT\SM@B1@&?3(6D2ZXD+PZ6N+CY([A@%2[.4_3D8(
MW"15X4V2:*LH7KGDPL!Y[5=3YSR=]P!W,O22,<FW"?[U1L27\IQ67IMMU]*.
MN"[J*FG!DR-"E=^.NC,>^>,S]*3B]J1JC.!=<LD>S((G@^T"[/2I(?N;.5_T
M"_A7< DWM,NU;1^LXIVFXXQQ52DRB7IFHL+TM92ER,;;;.W>NK7(U4TY2U=7
M WJU::U!F);3(L" #D<D6'<Y.X.].4BGEG4\]N-H805RV!:N$Y4[NO&J%!NT
M=&-->MFM4Y9/K[GD:*MZ#NU*F4/?PLF9$W/6-UI(MM0UG/C<P21-YJ+.TMOH
MN(Z&3(?6VWS8Q2_#HC^Z] !_@N5$<8O3G>RM5HH]C2J98]:6(I6!6<OVZ-4)
M/>>1^8)&#QR&D7PF.RR$=="ML7UL9XI#Q3>W" &2WQ"X%>V^,FB8G?U%JXN#
MDW):Q%*G?3ROT'K572$Q[5XU7\N!@F@XP-PB2]$*F1D^16$=49;?8LGJ^P:6
M/;X'7+Z^D<RSAKGD?CX<UEL'YB! >#:ZB!^B@2?/Z)JN3@QNB7]]J0=G9.O*
MF>1VV',)9FZ0]%X6M*=$%I>4#M49<?"E*V>574'D?K@^\\-QC9%>=%=AO2GV
M:SD,SG- >'J>8J_FF)X8AD@]^D%9'U3BYHIKI/AXL*5)ZI?L69GT@.21ZV>O
M4L%^'OS&IO5F+@@1-JT3?F"UK8VF'NRQ[0S&:^#4CJZ"OIN'HL38"]LLS1K+
M[&63\$/!$.XJLD9!/YFO%Q]\$D9W7!T7K<8[2 7YHOEUU<'>=J3C/01+(SB+
MEEE!/\"Q'G2ZQ0A[3&NB'? VI8K!9DNGYQ%RL%$/7^!IV) ;4BI:B[HJ&IEK
M!<[J58'_C<P*_X613&CT)E;S$\V<[]Q2;DN<ZW4>X=;ZLSRH*;#-4MH8L=14
M6IU2M:*ET9JS,Z8?KQ-U@9_5__1S/4C50/:G-%!9\Z9H5W%$IKQNM.2PYOA5
MZ3;;/>#<(*(S[(.QC+CDNZ:&V0[=6*7<Q)OBR=/+&79,\/=#?<JDS#$S#?"K
MPE8:-,[_^$)W_PYY\!BSC8)DX#*LPV'A]7CG@[H-OZF&%,S>-FB\>D)RFKP#
ME%:'EJ_4)1?)G0GYTJ4\Z$)NI$ANV&(?5SAW,7_V$J6Y4620?Y@F=P83?[8A
MU]@[%UY0QAZUD,--/W!Q&'= ]-.OMS>[/@K?+5)T,U%8#T]H=?H-)OV352U3
MT]RR*,TT67B4@%3VWZ?1@KH7Z"T\U:%757;2W,R=[!RW'CP9LF_'?V1E>[RX
MZZ>_*ZC5H-&*EL8[T_P[3;[Q]@)538LT&Z2"-KB^Z'?$S\[;ZO6\''YG(S(9
M(0)]8\P5AK.R,M:5-$GI-K]]]GX@"'_>JM).1=O"'T,^2?Z(<2KCB9P.!'\9
M&O21;("/U801HT^#ME3*9,OCMB:+7-2?=U?1QA^S5[BLFF%R;$OZC\0Y[V,Y
M9 UZL43BY*BA;/O2..+0>(E_"_SC .-C+W!XI>?5*4-+;(T.7N67@.6Z>*'
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M"E%M]N75XMQF**-@_$+7*F-/>(+W#8#+PU>ZP+B= IJRL-M3X;67D_P)ZOZ
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MG6!Z@#= D.%/J6JU*7(XOH<QI(3\V=]D"25S9NI4%CF*&M4BVMQW@$>[7G<
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ML,K@OA^O-,<Q$S]'4?2H_4P,VO"KE+F/,.P0%(X/0 '>+G#N^3 ,;Z>;.PX
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MH[[%@,EC;11X2*'D+&/#O!BO?FW5E:[AFP\ABP(NUSN@G^"D+.:1&2-[,WK
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M1]^261F?(]3*H^8Z'(AA_H]"ED90%W$"Y-K8[BIQW!"U'<Q?%0FDU=;V$?F
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MTP!="1%LU)#T+DPFGN%6XX!@<CL)$=M8><RL99LX1'(9^%WY*U_@<7L4T1W
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MN4&(+%5[H(8Q6K@OB3K#O7EB$L(S$QXU7W6)ZOPM0 :/DP3M$3P@]7O' R3
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M \R"5ET,C:!"4,>+?ZT?&QLKT/Q8,4=@PA*Z>7MQ:E( L-AA>!GHF2^R_[6
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MC(&7D>4%.Q<7%R4]G]!+#L'GG%P<OS!!0D='Q\3 ),;"(N9X1O:,XT]?B#8
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MH_5]08?#HD.&-(DS3W@CHEWO5/:D!.>;WM&3)@3 %0&(+X%H0(X2SX/'I^I
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MYP,B?64E'*$4IS)2YCDT4[>59T6G2F4FXA B!&_ 6"$S@A(8Y!E\7Y;3\F%
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M!S.DW?L]_NX%BMGBWKS5,&A11"Z(3G+\AG]S"9EC,F2  7\&A7G#9^XD1@B
M4?A8F<<3*[C?>?CW*,Y[(-*MGZRK]7Y=5+ZY>5QS6NI%RX_:T]^1+2LAQT&)
MK^E:C=W:+B7]V$_ZLJ%TV5;.YI8/F@J9&]_[\_40C"W.S"VU&]2%ZL@;*K-Z
M<.?,RFYD-]B08_,KV!%QU;TEU6EBG51"J;\Q;3_7#(6F".0 J8FQ@8Y?%.R2
M'E_0G5!3UM0BP]THH04( ,X*SU7,][?VRF7#J[K^;%<Y5VJHRZ676(N@6Z/G
M^WB+K\ 50T:6_J_3Q?_ET';NM+DD:GT,*RPO$8#PPH*7@N#*4Q!W[ MG!(!J
M3>3GP]W=X2:,DNTI34SV85M<WS!FK_/N!.[LQKZS;!;4_I:<1#F(K/IRDT>.
M#8%F!F6B7:&N8)2&VMLRUL\S;["%?0O,G(XO&KNQ\GNSM&CBD<M0:H2IMZ/%
M8VL/[[43ZJ)6JRD';?V8V7+C+DG,[KC70<)41Y/'5T($$8XG2.ZJ2;?.X+O_
M65A78%IL98ETNU936\^L#IVC= C'8LW#N(0^B%O&'4OP,H]&47)_D":Y>]_0
MLE.5*.'@T],$P2JP7PSY+ILXM(E4MD%CA]\0\,E<6)URK"%90BWQV]6#,D*X
MU^1EA1VXD#!_A=5Z0M897]@0LXPZ/3/-$>N1BZGRE$@5JWJ7@^0SWN7')R5:
MD <7=5"AJL?EA%L<XG9)N,JP8-%5=Y41.6J\D#WB'LU1Z%3464)S]DVGL&?+
M".W".,VX5M">@VH*Q^%^<<'K,CK 3]0+-2+G@A]=JP+NS6Q,%:8NJ"%1S,55
MX6UJA /T/U@KPURXXZQ *]L>0/+8^+2Y?B219I)5_*>F^>US::'ACJ@GV;_8
M5]0(@&H=\;+=MMA-]Y6J26 D/>Q++ +@C0!PZK;J<K-^5VW%I9!*M/!N@M,U
M<\+QDJGA7E,E;]Y,Q</J='H.0Z:#^O+GI%9__'2D;B!>7Y$JU0S6'*\FGSK4
M1C$AAC157,M7C@G:,%L2%M)^J3 2"&-_\UI"AS<$)L!:*+I&-Z73?%L-MN7&
MBQ5H4LW4!Z\!%F\&>D&U-U 7="M-XZJ:E]H^GU1@SSRS]79E;Y+3.QZ*S\O5
M#T^%^4QD0NI0?%:?N%\0Q#+R%%+:6X)Z-&?"V]>?"2X\PP#7KNXS7XN]9@F^
M[OTJ+%'+O3$+G.P)*CUI%E8U)&,+.$NWS!/B$GK<SF\^UD0K$!D811=-7[K
MW>:BIC:>.5526JV_(>SU2M[C>KJBN620=E\IZ?4[+_52\E$KKE!*[?I*Z(.D
M#\0K)#W-Z(O+)^53%BDLAQOIN0/6AWG]259MFV0J./[.@ZP+IVD&!J'.#/03
MDP/091D!GG@6JV3O%5O7PA2D^HHFSF'3S"Z#;+MF],OZVW["M_00 >A[VX(
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MX[^64'I; B0@U.C**YZ@*H0DPAZHEP'^&:*L"!;\T3<D)Y^GJEJ=IKX;\?E
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MK&T_'9EWZGB?%,F?ATXN9ET9XH7Y<L#E@MOJ@\6==ZJ73N-I+?.:U6Y0?!'
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M5XIK2LCDV=N_!H:3:,%^Z)^-NZWB4;Q)N\X9W3Y/63>-_*V#B'/1BJ+==CC
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M[X^7+ W);OYJ!/S9O$9W^'- X5ZRP="T#(W2T75E[VBBH[J<1+&=I][_D>_
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M  ([9JMX+H<J1(X%*=IAM J8YE<'\3H>'XB7H6,>=CG9$);II:":V]4 +^U
M5K)F[+W5NK?L P1FI'<;H,?$+?-,VE=&Q!WW5IX,XM)\^S!?&[4)XYPXGC/A
M)S/AMNJOL@.HYXC1)^!^=C2,U&D(;X"F/!H !T:P MG!&$[T>(KW.X9XVF49
M,-.#&=#_; K1._S_E&_Y\[DW'/!TV],ROP"+P#Q."QPZ<1I,_-(-)]C23C!<
M 4IQ[3KGB>2F"ZQ,A&(1;\KTFH406M>]ZSS.7YB" QXID'0-WMSJ=-NJ7,XR
MSMKXC2P*[X=F7A5\,Y 7V6*2E!_-KMG'$7\:Y;RKM!/<,]I(OA4W>3"['5UG
ML.(S4Z:7A%1@J\52BE"B;BV88]WS/69ND&2?-2A]*XX;OS:=?:#)T:9#WK)1
M&%/@!0+MO [6I9DEA?X^3?>8?%I&UW"?O'/N=SSQ\B9R:8JH*;118%S*JIC+
M%IJ\_VI$@ "197Z;5:9^9=NTZA&[@[K3'B'$[.Q 4Q?"X=I &!E>?;O2H@*?
M',]D@'*D1G3)O:SMM/38]K]Z/?76>:X=V/'(6U9V2] J]:KHP89;GY"#:,HS
M8SR>(K8#B>!&O(E"KV:[LP%G'^!:[0-'?5(-K*<+9Y&8?EFWX\)GZLU%,J?$
MYM1-6/K5;P#ZIGQ+=C*M8DG3.+'9<%69L'W RZ=," ?4Q;A] [W.KQCG7&D<
M7BV%8!I--8ZOU2KX>6BFSM8[RQ1:]SVD?6TG;5' G5&S_4;ER3QE1-_5E<0>
MF#=[[)]8&CC+"F@6"9V!++L_EM2"7NS2E(S4)0D15)6$,R 327(I&,O,Q3?2
M#:5/'-<\?4?RG4:AP17D>Q*2@GX>N.EBK<9M4)C<TE!:O]ZIAU(WSCIR)BUB
M2AW7W8[M22CM)%'51J*2!Y0*%+6KYNE,!4M^;R3?/ZW(_E$GR2U]5D++U+ _
M%YO*265>()$N\@) (O"VAD7R>T)R2D[#O!\31B>_BQ7NZ 9M;>+>_EZK4IJI
MCTBJ<31#YC"G\$.MA;U1&K5JE2'IK^K<K!'+B6V'M$(ZIOG,];<JUI8'%?3!
M,2'$_$NW_?+:+)_BZ2S^%?8\L%<!-@/KJBWG?1_V0X+1?>_>AENH>'\-9BNC
MF&.>$,N^PFE]KZO)*JO*-YY^0]JXY:Z,0P)TWP]K>G872AODV3Q6U/L+H4]]
M!CS/W[[(%5#7/U![*<#[K<OMXD-*UYM&LGV6-JVXT]A\*H&+@1%[1N&0[VP!
M!1\V:#LWY<_,U$I-91?KSFT\.$RH;+5XOMMBB;VY!H$PP#X;/[B%1(C 3*_V
M)P.MRMUE=XA=#/ELS'IW\+PHD+8O^R'28)E>XJ\[6-7*I0V=+I;XC62;*A08
MLS87:DY(TG@!BY9MP]>&+D@+NV?XJ H>T7HUAD:8*:9D!8SWS9[QW)H?7BBZ
M\DKN!J_5Q0C1VA_.^14X?_=AQQ0'P@%M:.-CUTJ6YM8>WXG$K':Z\GVE#B#M
MI[8+='(P&^&>RGJV195W=J<W\A*Q&RFUL\%XL:F[QT\.DHJFZO%60,X<:EX$
M<$!7-1QP,E)^;9ZINTW,'#MA1OPR$R#/D(P\7,0I1U2XITCM=_3!00:VL;.'
M7V]^NVQX9<,!.@I'8'THCM7^ZK813YQP&KBSK5)E2XBTL:Q2<526?.S^,FUQ
M(]D&P25RA)U-CD3.H70U8'HIHI3"S.[ /\F]X$6$G9GJU$[O<H)7UB(9YBF!
M'8+F@RZK654L/"#9WIY$UK<:V50'[W9CUKCEAF1I1)/G=0/K%RK'!+G>6>*L
MOLO5/ZQ,V5_IBN'1$:X57HN,CBRT%<O9D1!2=[_EV=/5]ZM'O_2<;AHS-JT1
MC. !A[1YD5=-_M B MH*J2%&2KY(Z_EA. 7$:CFK5%+ M=[J85=3F<2-:T39
M]_SH7H00I.#R>0)=B.3 /^*+XQF[6#*B=+ P%/. ML(V9>9QZ4NL)_I.%,\N
MR." @(+R.HQG8IG/+'7;?$@$)BJ41\JGRO-Q*SYZY GRCT/\M7CA ,+;,6X2
MOLJ^4*?;CX8)[,)\ZO0?:PSF;#Z>F<DQ)WR$P ,&0?<"G,CN0:!LRV],$0G?
MC[-]C#L@-8(#ND4H]D!:IS%7&9MZ9O./Q@=#&N>?*)2M\\[MZ<7R* KF?'IU
M ,*YO<&9%6P?]K8A6?A$&K91]&)2X$G^_#F89,-0[%YDE/9\ PT"=HZ@"*ZL
M,?:L$ZZ2LI+W,ML%_JY0QN4DS7[^[JR7\$"=S4]2&V7:VCGF)*ET>(- M-;:
M</\RSUHNN>D.$L&MV+:&@:FO#$+C2_-LU='*![,OU#&59V.0I(LLP 0=7@\]
MWT)M?D@3&)'Q;+[2_2*M2W)IXW^<3TAU:*CB?1;!M:[_>*^0NLE_8O:;8BZ_
MN&[5B(!]26%94HEWV)(>*$8R[YJG*5HNW$QG5O\BWN;9<D0A5\:8@FHZ?Q,:
MJ"O[5DG5R?<]=X #J$PR8-<I?9.I0/N1K<'6B8DJN[S7D3L&F*Y@H^9DPK'C
MB$=ZNO.O\G$+5J7>G]#A%E5?D?F7O9]T>[U/>1%OR]0G1*Y+$Q$$MF+%BIWV
MP-_3JW=ST'-94D#B6DL[O2&WK:+*RT!XI2\2M>6&&T6M%$_FD[,2K<<@>*E_
M?J%+R)YAU74Y,7A*%P9.NV+IM0K<UY$=$&9<*R]D*;@V(JNMB>QD]3Q2Q7NK
M73-ZK3K:JZVIRXBO:']^W*Z[O_!1X'F!^:,^*N=HLX4@!:V="C+6!=716]5:
M5/VU*1G30(3OM63ZK/1-&), 32ENX["T(/.+BIJAV7.4ELI/\:Q4P&4R61D[
M+7+BD7I!8_ E4W[H=9N0*Y@5A %LU9CY_\:WX)F&_[W;:L6Q[]O^V/,U+N]0
M?MK'+61]J3K/=-_QV3\>_W-_7?]]^J_K:U[^9_C$W_[WUJ,_N0]^[XUZJ;_E
M7Y[(<Y;'2V,^M*[O>&M?OEJIXWJ#\[/V5:R+K:6>VQ0"<_W2^Q?"W2/N:6[8
M<>4+=W=T*J_V%Y9'D^[D)[?\"/RWK?Z'^.?U(>M%-WPH[_FRO3A3ZOB.^;OU
M[)?&_SOQH_GO^S^]_QFNK<IZ,^5-?_1ZD8^EK7OB[(U?<=Q/G1>S\9R1]HH/
MS^8^YC U^#6[[K'\Y\NF%RI6'[KV3VGSK?LZIX 9=I:WF_DJX[<VS ^[=Z?,
MLDA)3> 7FM7V^V =[P;FMSL[Y&8_M;DF8\7>:W+4X.;VF0*_=P,KY.6.#^:6
M1^SMBRU*BSAX[L+OAN6?Q4^\J;N\K"+?T?B&6^HV]D7;LM9-+UY<<>GBDNR
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M9&ZV_?RJ5RZFAY_W)$NN=U@TWV"G4Y?&2HV![N"-XE$\E/#_FP!02P,$%
M  @ ZX!84MLZQ&7TFP$ Q44" !8   !G>FMK-6HP8W5M;F0P,# P,3 N:G!G
M[+P'6%3+EC;<B(@DD8RD%B0C(#G3*I)%@N2H I($)&?:1$X"@@0)DH/DC$!+
MSCDT.30Y=Q,;:+K_]MRY]YP[<V>^>V:^F?G__[%]EL]N=O6J>JM6K?6N754;
M,XE9!-Q445!6 .#@X ">8?\!,#, .<#U:]?PK^%=Q\?')R"X3DA,24),1$1\
MBYR"E)*1#LC$2,? <)N5C^,VR]T[# R<8EQW[PD("PL#.21DQ 6E^82$!7\J
MP2$@(" F(J8E(:$59&9@%OS3'\P/ -EU/'K\*5P<%L 5,AQ<,AQ,&P ( .#@
MX?SV ?S+!^<*[E6\:_C7"0B)L 6J;@*NX.#B7KF*BX=W]2KVKA_V/N J&1XY
ML\"#:Q2:S_%9G"@%WT9_O7[G85DSE=8PG%7HA?,[ D)J&MI;=&SL')Q<W,(B
MHF+B$I)RC^05%)6459YJZ^CJZ1L8FEM8OK2RMK%U<75S]_#T\G[_(2 P*#@D
M-";V4US\YX3$I(S,K.R<W+S\@O**RJKJFMJZ^I;6MO:.SJ[NGI'1L?$)Z.34
M]!)L>65U;7UC<PMQ<'AT?'**/#O_B0L'@(OSU\\_Q$6&Q77EZE7<J_@_<>%<
M\?A9@.PJ'K/ -?('FOC/G2A8!-]>IWP8_;6LF>".D!:<ZH7S,"$UJ_ 2&^(G
MM-^0_7/ WOVGD/T-V.^XI@'$N#C8P<,E X  I^><&6\(?\DO^26_Y)?\DE_R
M2_Z!D(<:<N)P9O^Z^/_317PH)R C)O[_KJ'4@6YZ;I'@:EPPQ&L]GAQ8?0W*
M=JM:DV6.L$2&6$=^_;1\.[+AZ4/+0:1A/ 9P1)B&1I/",]'4V9#+*[D8 .0]
MBJ<:W5N* :0I@???JEY^?HX!R'[$ !:NI P9?%%$\:J"S_'4,0 P/E(3 R#2
M6D"_?8J]VXRFF@%;3H('LT"G/S(O^%K1?LP80!,>S8.73B!X%2\&L$$%ND0!
ME_Y.@Y[]'_1'[7PG/3L*0B,I3? 2VS" EK$:#"!=&P,XA8,#@'_485)S8A*$
M.I?# 'P)0>4[H/41X,6BIBNU%<7?M8@2_'<JW!>FW(&'FZ27<,[? <IC0:G_
M O4+U"]0OT#] O4+U"]0OT#] O4+U"]0OT#] O4+U"]0OT#] O4+U"]0OT#]
MKX(J1#R92M'8C"7IQ!4DA1=#?V_6:R#9+N_NRB@J04NZ1DI!:CB3.C?3J(^/
M=SF!&%]C\BC?-B<9 [@]XWB^!NDI&OM$J2D/^,^)SC[_\]*J&)@'$1UQ$J!,
M7G.D2DG$1\#-@5;AR;6MKX6>%>HC5@<,RL)SR\$6H7>O[5)%9"+C.PU?*JEV
M"AY'/@C,%P'?-+#.(VFE_G@Y.609(853*.\R;17NNJNR8K0;/Z][42BX[#%2
M3W?_9X54:]ZGJ$]AH-8SO1R]Q.V% \T=#(!T]0F+5?;(B-8(K:8\)>"7_+]3
M]%)03R[./2XP@(E&\H9]F,?"*'@!73D!LW+)P0"Z1&?0=24'A6Y/U3" C_8U
MER[ GJ+__( &UD(H-VJF/WC4T(A9OH)IF8>(#^![[]H)M8$.<!HP@&(U5'Y1
M<Z+IM3-? 9HR$=46#7F_ EN/499NCB_:0L3+^,"1$D_Z-.(.F7YMN!UOXU[N
MR_Z0JSLSZG7] F1V93F)RR2B6W,/O7Y\>ZL@INV^D135IIHF34!]M27P%FZV
M*NPEC2GO"*_Y6:)S?^0X8^",>C TA!EWX'&QS]#5)LF*4%I>QR5YY:\?G[]9
MIX).=Z]-RS.CV:[5J0.?0*;@1N\3V3X"> HJY*@^<7H7O%7>N==09R2ES,=
MGI<=R1,%(G<=4CK(6CS7LQ+FDE:C#*NC?1;:)4L^[((!,"F?:7SC?0Q"&A@Z
MH@YB#XJ?'R>X01BG9G]DZ[UFN.09@BR1#X/6NT'<2U5$1/8@&,D7T>'@Y2YQ
MH(IMBX>,5OQ'K?^*/_@E_]U"M0ZF:$(GHS& XY)')5+(E-.CA5,,H$BD-G%V
M$W) 4HTU;O,SG?K\OTZJJ%7=36+.C%# ?T:XJX[SFLKCIT(T6>)8?<:3.'&E
M%$9B%4<G1L3X"EQB#>JC/BQ]'Z-#3V_9J<9O(1A>UG,;\EV[%KT4+-Q;W1#O
MQ>>08-[_<67T.(W$R':4=S !;L(Q%R_TCL<A/NQMGZ&G+&M3Y-[YB<^4N80<
MUP!/3B=M]K^L7![*>*!5Y-.64(6C/'W'^V=<U&!-5$$&N[<)+QNO4DLH9_J5
M_Y2H&/X[8&/>4/^GE?[#BCAQK/]'*OK7PO7O5?P_)SP#: Z_2[%+#&#;-,34
M R&UOPG9QP ,[9R$ZD;!*_3V&(!QYS_A[._<T[G[!'"+'=MCA_QD*+W(CBU5
M$[XI*\_)0F5V=\1FZ#H&L.1@!SG<M#\30XYSBJHFR52'(OB11M[[J',C?S6T
MR#"2OW,Z-]BMV=+-D5"QM%J# 5TI+LPF/*B2$<JM^J<6TP]E?'Z:Y!B8^ZCG
M]VLG"AF^^)CXCW_6)*]UP<2G9C+"DY8MD&E+DRL6-I:S6>\O*M!4$_/@SD\+
M>\!54X+%7:9!8\2G>(_\)G(+5MS(Q()0=6?6:6^F1"P75&Q-.YPVNS@!MU0>
M+=!O2&9E<#IJ6LA<3>,#2PXX!LK2WPE["83?,0X*\Z<#6QI69V:IWF&5<^GP
MCG)Z,ORB(7KG_GJNBN$A.)")Y[-6M1_?<>_@];Y7WN47T$QJ0D$EW+&QJI>&
M'G)YW^H:Y#-GFKI%Z)_-IUJ+%U9#W:'19_&CG8+G'4N0..KGKNKR;"_G[,YU
MDG?2-&H4&*@.K\DS)[GJ2*D]Z4"]G-B[U1C=+.* '<0B-["-1?)>\8L \,QK
M[NR:8->P.NE:-R)WEV'?YGYJJN%\^=L2V>G/C0=1')*@$^B)7@(&8+-007]#
MR(374QP#B,G' !Q!(P7<*]V3IV]5Y9GS.0VYN"/6RG+U&4Q,FRG ;EFW4'E7
M+JD>#NJ/5N&&&4VR.>X5O@-S5XFTB0Z?Q?8S*%]NTG)>6A-E&'+3\J77/SPY
M[!1\_\[\=>M1OLO;+XC[1/*Z41KE\6;L4KT>GT%.EGB0NV,EW \#5MT>,1I$
M M().+]%(94K-?D_7^;:?P<=#KVHA"5)+)/+LW0%9?)8T &^%FW'>^-%S? ;
MQ/,V.U_S'DM2*+(KTF=;S:0@.F)]4<<?!CS@Q !F=- OBGU%,(!H42@"[:8[
MLK)@Q!A I2-"Q,5^8-Y08^,2$<8=CZK0+5#YS?BX.-/Q_MVM(;_=#.4$Y/$5
MIU>\S:V-8PE14!7X027CB0&T7:JL8?^GGF:]T2+"4Z?H+@MYFQ/7-A=9#PY)
M97BGEF;ML7Y+FU6W.@K6"#2VC_>P'@$[1=(??%.[LY039)?;\5DC.23Q@8?Y
M0I. ,6F$,!#Y\'C&J%%006FE-V]P[@Z#'W<1309S'>^@6T:%,,FCK7.2N$,
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M+Q]RQ+$\&$]Y TS,>>!CXZI44Q?XRNU@A22J)[V\'=M#8]1EM_@X(EF!;3N
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M@8&6B3A/<8U[OQ7KK>TA= /(]&]-^"'&S]^G@TQY%)=*4"'5D*>H+?]N.YB
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MMS" OQ3ZHS(G"#S(,PC]-@9MAQ8&MS#"@.?75+%M&][E/B$M7@/VH)?+,8"
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MS4"X_@7@WZ1"I)^PMXW.QV ^9T4ZGU'[/'04"R_#[,-G3:6%%^-]3K%#)1B
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M8_&&ABVYJ5($APY5\0+^;C4J*?QKXV9ER)/'1T;V#P>.7DZO<4%FG]GV^V(
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MG)H: RKUTKL8TRO Z7SAZXSQ=8K\)[\;]&H>M)PI*PL<>J%_&$F7LI;>\B&
MY6PLS!-/_,<=8VW0ZC/[;OZY7?Z!1HDFK^HTW1^H%]HES"M\X!E<D?VO>,89
M'-LOTGHD4,50)8D#WA J"Z#&@!G_2;OIR_JZOX+I)\W2O61(*9+U/*[/JQ/L
MG#[U2QC\>AM#OZ4:0V$F)$;TY%NQK+JFA2LRN1JRL*7MCY-(P!5B0Z3Z--6V
MTXNW(FH&%47/Q0L &+ZJ!:BO>!\GI/$[Y)4$]Y@P&A<Y#<']_-C&<]BZ#U/'
M6=LU4S0<:^V!. UVI:284H/:^=\0KTQ/\-PJQPZ-K(=-2_Y(8DJCP55158Y?
M->!-8VFE0MG@E=D,_W*+KM6DQ5;LCB,U4[YT<O!BX$[&1 ,_X:%87_8CG?L'
M^GN C!WRI8*IC2%^B>K/]4F*&-D?[P0>56NV01F/,.X!HPPB1U6:^S R=]<1
MR2B=$$+G4XS5:^*/VRWKOL>80?8N;5@@.^OG=7&16W8.ES]FJ]4HP;Q4VFOA
M*KCO&,,>*17:K8._P>/%'.7_]!WNG-PL7SX0Z=[#7$>,?BXZ NRT:!\O6/S&
M1[)CN\*UBX3388VPRF7F(.KD Q@[.VR@TF#)2B2SM"V0_?,Q=[8)4M+I/<"'
MN";G[5QSB4=Z;O8>").;\# S9<.AQE2B_8*;[;,W@TBX"TG*[?47W<"A2*AB
M;]UIV>U:M1SL^8*4W-NGT'#IXWCQ*Z#4H1G?G=6I5];F98F)>_:J2UI>//=6
MW(E'-.LZ2>HA'GD'BSFH1F\'N]48K?65%YD3-,"S>8 ,69,(2=&FJY4P1M"6
MXAY@!D?T*(OL->8E7N'_V]HK7!69H2*.+LQ2  ONM(M1/,4=@SP2$1TY$,!@
M5;2[[/+IAMCE]]CA'T[E*(!I[,3_Y80.M=\;I*L#_^R)^?\WY"#RW)L;M";/
M)%,BC@]6&*Y?#R/>;A8P84W+! *5(CGH.VHQ29D4$]+.*DI+.^ R^C^V&O/O
M4<F(_ 5J_/#3H#L7D;YI^R=7]P"I<4%V6R/7"91L9EWK7\4X^OE@* ,FV'85
M;+7$QE#WN&4O#AZ?", %5PRE3>FX6 $X-)SOE2W22\8_P7V$69.6(F/&BCE4
M7]",O.Y#UWF# S1(0DP9]"Y.GO[C==DPW(/$.T3:.Y&.M'4;U(F689ZK_-6U
M, 2%/MAJ&<FJ/S(D^]6V1KCS\G'^>] OF/TDE,FBTQ"3I9FG"&V[+">Z-K[3
M.#2G&DVV17$B(2:ABOMO%?3@?!W-_0"B"W8);2@_;"[E7ZQ%8O%5@D?0376W
MX6?EKX_+@I-S85GV^LF(:?< IU2$4[+JL:32W)V)'S:%M)$?ZHA-_*@U8@44
M) JOY^X!H2,)YJ95 8Z[^4?$;+9:G614E?P.[/-Z:>7XC@QSO$P03)5G4V62
M['@U+<Q7P).)>X!B],3C%7FR_:VF*U/LCAB,,$Z]\LA@6(^H$DT/4\YD.[$W
MX/P'@U"@-O6CF ^,(M42]P AM=."FJ=DNQV6QCX1NZ+V<J<7QQC5VAD'$OWG
MF=2<XQ\G,:'G2B/-\[HNH. +,^WGT6.W:O> 5<#,/6";'L3?'23?,"%H:V'O
M(I)&N^+V$4^64E<HYN$X$=P_6XG_;XB&Y;_ OMM_Z)[>WZ-? ,Q0,@#6B<!%
MCQ7%R"H$6M<2=(7:%.12K 3866_"W<?_?H,41>_]C4%QE@WG\HX#2Q=G:C-?
M+_?/<<451_Q&\]Q2&ZQ=_A)Y>]+ZK@^_Z(2K;8#"V?9E936Y =$=!^XA/;M[
ME?*2W28!]14S4 60_<6M655-0!WN8MIR=-FJ.B,2:2##E(I# -RA/?Y#<7T+
MQQ_^2?V]NNM_KOW^GT!_#Q_T2.=FK6^.9JT#):K+]1,0S^ Z1YYH[GG28]+L
M95P*"[ W>S*:/;X,6RZ[2$([PNLGT$A8BU<4A:]8GU"W]T[!#AEEZY1IH\]K
MR;A*OHA7;9%XGDOVI+JT7?R!8[SH77 M&N_94HF/],DM1X:-02[OA.\!&3V-
MH,>+5T6VWJRE%QE5[T7V^,US>[H9%LZ)&1BLY5&+?0J 5F-$9;]DLDE_3$UR
M,F-SH%>HBEYV>TA#*5LI(0F%-#U5G+H_J:*"?1[M,^0TQLSK$G"WA2I+,$GD
MS!/UK0]]#-K16UCBA:3G*$5%!'LB?@8):N58D6.>/:-#9]'T0(;(\7P,;#3U
MH_=]W@-&%GW"V)!5*[X9NYB.G;P<P;(\]&0/AMB ]W%^S3ZDA)SX,QIC1%/6
M3VB E^:8.X5QL;Y5 D^1YM8$D?J%\Y,(LQ]\ADZQQY==+73:75K2^TYGG7<S
M-\0'5-$THMOM<6%^F,"5\\@ 3\EM#^:D4G-!7SZ].T9,I#GW1/$9Q?@"NYA.
MQ)RD/G()V9P+Q(TZ(6*P'/!?'DKT6^7U_U/7_[[T=U%7&2MKDH:9F1F=Y<.>
M@,A543P7!0NE\:^G]F6J> >Q_65 0_ 22<A%8.-'SQ+1R%\&#I2[RUC-*I0]
MO>],_*'L>: [C26@-]4$U2?)H5-Y5F%SM6J+'2W3.L[F])[2Q*X,#(,^*@(V
M'+)TZP!8S8PTI0)Q/\D3*2)$MW(Z"'*'T;,JI>R1_6W.31&:UL",X[HN'GD/
MU@#WKB+T+I*B]/5KY8E:WYPC<\^6W_M?9600J%<PJJ>B:?3[VA.GE!$*LAI&
M7]BH;AL0UC=^JN1\3DPN[@3#97FS&"ZPZ"8_N6RV>,;.D\W#E0"\B"\0'M3=
M-G.",B[,QKJ#5A>/0DIF-=NFT&U$AAKTNX/*@1^;CN<N.R]L"W=N0F+[KH/1
MJLL$_)-;-2H%)Y9ZJ\;UZGQ=^FM&G_5R=]HETYXLMBBX:& ZQC;^EG#[[UV8
M1&ME"<B*;<$%5*NJ) . <IP*V#TC*GKXI%*6C\[B5*+XQQZ/O]51.:WT-RE[
MQN^+#Q87)>*:BJ<FDGIVQ@6X^;.[ ?Y,^BNFF\WZ0T(D>>'MH?-?.U;4_U"4
MY_S/0G:\I#4\B^.[D_RE5ZF::1QO=)Y']V@$/OU*M-'VE/4@J[&U.CI.KP')
M:>K3E%:95M!550=Q1F"-V]19)I-N5:)FL&F>USO7/"!4#8*7(\Y'Z6?\A$<N
M2"03+SO\7$I.KY%SP2R:\F'R=M9OD[=U.[[E_NKF*V,!354UH3MWFUD+LT/8
M0J1_XO)JK?3:!26?B02EH\6*!90?!=V8=CX"U=/7,4ZQ#9T)S-'GE@S+;$DP
M<TAAH#$0E9,W3PH:KLPWE)5L>(5*.6[0,[]2]" M_LE04C2@X4MQ_B39V/H7
MTNH] $QLGH5-*NH3LY[)_%$5E&M[U29S#_B<V'$R#VQLPJ8.]F^GXH6YR'>1
M8U:'V^JOB=DZ>V"2B_MT?SC1=6_[KAI"Y=;X#?DK22+9>D&1K%"P;2F1F@(D
M(UB0E'C'3=.WEP#U6R8BILF.XI2WRQHF7I?SH+PHO@&1L:IV9*FK)UOD&:E/
MS#.I)2:OV/;3.-O1J;.RF9F) 1I,&W0*LC"P2-KK@S%<^RIV09RO_5_=/06L
M(+_XEE9<N2<F5&=L%ZI+X#Q"^-<%X)\?6[;Z]SA)[^]%<O0((Q]IAJF!><%4
MT8D<+U;6Z\NE]IF&A)FI(SVR2Q1JI<Q1?3 D=>#\L.FY@ON-79AXT1PE6S'F
M<P5&J/H$E0[A2_4!__:M2AC-HJ'N5>OX?HX#]0=DU)QU/R6Y3^]==#%#@&^!
M-3\:OL2]_'Z0O C!9L[ /:LV6RA]BD@&32[%JK'<$V1:>RHHD=W[(0B'?IZ1
MK&AZL)NK[;AN,W+(GFW@MF']<,9E8/CXLH?)@4PQUON'V7[./2!UNDE6%11:
MRFS*(?@R+F(EEPFI"Q*P>5&\SF2(*>$Z4WOXR#&?I'Y8N_7* A'?5CBIP*!T
M]UF?P5N_CU]*#7&OY :[$IFH"?R653][EX1Q1CK,--1->GNMGG%TNM=5]/:K
M14A/EJ(I6X^JY1W;%1>*!)G&Z@5JF]?1L3'&+PAYE $'A-36: L%3_3E[;/?
MW&J8\+*<"=<4DX-UN\D0I^\!3AM+[2@Z5( (I?Q-+6&"]V3HD1:&?'4^[MFV
MTJV!FI7','W:X7*HB(\K:R826.!P 3G7>8E\ILS\N+)UZF#3S\O9A#Y:[G".
M,SIY.^21K/'C3_W<(^ZUSHW''[^^SY-E)^H/\0<(G.6Z7I+&3+^P2[0H\A9O
M3C\\N=#FJM]@C.[ZH+MMO52S(I^&L7PKW5DW:^ L6*TX7Q=IO73UGI(,Y=L)
MI#YP^7S!IMCUC?A(N[JCK" JR4R'++>KF;N%2N/4&2\KFVU.77T/*;5J3O1R
M!G"V8*7>;TWHXJ27TGGH_=,[1F#,V)_=:/-GT=^E>2N'JT9>L^&UI\9TQ]WV
M.K-P]2,M#0A&9"Z#OO@A==\FYA#HI5Y7.O,QXG##W&.?CT/+JP8.F9;\01'<
MQ4$>?7J),=)\/4IB^E%7/$_XII:%!Q]@59,7B2OL];%DYA!.-XEG:9/%M>9(
M[#HI)K#YEB9@->&]A7U"YS5X76158?X>,*:H=+NA.1L (^U>;=$ZZ/<\2<MU
MC0:3T]-1U<'A?0$7<1=C@A"@OYP2@AE:,PS2]V'JW*/LQ<&C06:61J8^*]=-
M0X^2\2]F0#@IQQ[GGCD6 ;L@3K&0)NB0;"&D6E" "[)H^S,ZTT5J)3[0Q,43
M4<CEW\S*KB@1ZEG/8EMZ#GDT2E(3Z-DA%%#-E,I##,6UT2B'CB)P\(;=7^FY
M1ZXAWJS-?[$-U(YZQ:'TN%BSAN[-F876FDC@C4%%GJ[8A4!Z9FSF#7C=>Y3
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MO+X'?([E%?GY_:"'[V:V8.<FH#77,O'U!')XC]B3+#P3'E.7M0_<%?W\H5+
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M(T<K=#<=":+14^C"Q0K3'1BJCXM *0+3*BYBJDR=#>-HT]MW-W<+'YKNW,R
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MRQ&P2%>)_H.Z'P!P@S Q0_Z U< ]>I(!B$%"0#%4^T,\#D/G'X./I() 6ES
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M<,P4JJ=W*8>/J _K586UMEG?4J&[_ZIQ%(FY-0U<;[\^UDVO*W 0W;3QIYU
M)ALR=0G5F8T!D]\!E"08X$W]MUU\&0\?='[>HO#%=@=NZ8JP9V7D@ZWGJ?4%
M]B0*&F"/EW2@T%]SIV00\9!4?*2CT]RMYI!HI=[-EH=6])"W97DI2E4FG0$J
M[C5=ZA$E>9AY ,P 92_V^U(4_\^KO?]'LY0JRI*@%"/L0.2^>83_,<V-*BO/
M1N><2N'E0,/Q)JZ=0.JZ6RF&_XMO^>4BOY8YTG#7(E\EA#\#=)DO7*LTLLD0
MV^9569<MVG(4TK\8P<&K=9O8%LQBNKV.:-.*.GIX[0=;L-*8XIVPG_:O3]\O
M@5N*)FUB '&;-N,4;?C.WAK95*F5;Z5VG-<GX,&)02P;/;[LGW]R"%;NYLQ\
MF(>+&K50O\,,61QR,+CF:W')*$U6.Q>&[C&<R8%->G3@S+.CS? ,C-ZZVOAL
MW1[X#.$RF&#1.TAVHZ2D.U"=M:T>;E?8,SC1Q[AER/Y3G&A.C ;Y23G*1CS(
MGJ 8,^K%=*R87Q%4HY223-8C?23(0T7 [<Q[J)/QHVFM7$?[W-!)?_!4@N):
M1DY%@&YHA=LL7R#YO+)@I*Z,5A51JD3*7LHP7*OC$=RU+U[@(E_8JSRJI4Q6
M5M/K/JBI_ \T\KD4*M!T_7)NG.?X101Z<;F6#CRT<,Y168>W5X1RBN>#93-7
M:23T_KVAM8*I8I?U#U"31W"2^"0H[EM?!7O;X71%D;50;Z11;DY?B:<IQ;1'
ML7\[V1*$\ZE0F8G?%I&/#J^7X$!X[+>9[38"ZA?0MRJTGF[CC60CCT#I"QG^
MWQ3$B9]"UDP<,P_&49%^E9.,N)NB>I)ZAA9N11#/H3[9]^%K9%'V?/9UQ87C
MU*H?PCK1 BRS5R75'U0 1STWR<HX.%:MPYPQR)(>T40#5:.,1XWSO8SK)]'!
M]*WU6M>MJZRMD:J4)C<'>TB5\FD89L6\S"V+K]&01?UO[:.B)YI.4+=ZAU><
M/V<4=*DTU#B]NW?\7A#_&XATI8N@&A_;G+.X'/,BBQ32Q:Z:[JU4*R"O/5S$
M,X@^.446:SK\0SA%D2+4E>?'#S,*Z/OJ;[(J3CG?C1_IHZ)?+8*&4ET,J]<Z
MM%YOZY,ZZY72/MOIHH"M")_RIPA P;XNC;WB25$+=0>=#T-8JZ=;6T-KBSHU
MWFA6&H31WU[ZE_8&_L!1#-P7M*% @P2X^\BA3,6^-H2;$*$X7T%RRJ/?C&K.
M6&&GX:D97(T,?BV0**LQ)(*=-"M;1"R9%9.4F@.$ %K%K).%2D13.66N2JY)
MS1;*LL"/3_\/-!99<X(^Y6GL[P2QJ>*A;K$K/W#+OFM,$E*O" GE?G6@+<@M
MG?]NM#@'&R0H_2KW/*3KI<H*!*_#W>'[C6!(2) S4S567E[1]/+C^.[$/*'M
MCV]H#TIT1=:SBXV'G.Q<$_L>H7X]&_(>3._:CUY9?*X>/NC]]-W#+V(.8EI*
MRZY5^Z?D;K(<OSAD @K102A1,+L -&@!_6)S6)S".3)K&-R!M<3[31^;[EYO
M7VY'XR:O<3M@<$*>ZFH750!K )1T%1V13WL5A^,C%UT(_NH%V];<GCDJD696
MV)OJ79%(\=(_L)H)(Z50[G SYHOZ*28:V7N]-?]1K*=HRN>7@T,<8T,4[^8^
MJEL@S:%8$^?;O,^)[/753#HQ9ZZB,Y)YWI@JGF,>DH],U>B.KW>>N+U%2S3I
M7ANCA.!T"F(UD21*;\?@L"7)8J 9X"/]=#3G-;4$+^VIM?M"8>NA]%U=^9 Z
M(_]5O"]3(U&$PN,G-@-/04$*Z+,:_>1SE%$8M-2KI"Q8E.Y7X,O5MOZ2G:9<
MVSGQH>/C-0ZI4_%B[$;^0>*=]P5QW+?S2(HX:[4CEXB>W@%<VBMX1EOX?59L
M,_1GG!@>]?YH>O/D)V:2X8')3!BQN%9'VF,TA5FG<!?14)T$L<%33):X) _Q
M]10G%S?\*!LI$SQ+O1+E_Y[#]M_\_(^D3,XL_SI#2K&KP#-$^++&#A>C?=,6
MI?L6"!*8<_SH5; H%*>8L<J^+=1%18PA03<1T7[A>TM3X3VPU-59/U)L&V0U
MO!'=X*1AS &%PM]O0*Z>31^N1EA@!WW LY\R:'[7#+7<%!UZ-J,R$3LT69*0
M^RH1U.M/P@N2)%B?I-&J3 7GE'7D>P]T#A:[ .<[\=",]X#;65@'_A)/JN@/
MSA,AWR5/B-(U*!;>3R&BAFGKC]*Y\:/HDLLC1//>9JK'JV8\-LM"QY,S:8J'
M1IT\HF(NG9&3@/<]*X:2Q.\+9MQW7F="P47E8_[,!7/><LH*#O&-(6GS ^0>
MI;K*6H*>)V(+_IJ'M-A%$6\6Y#4D.[,)30.7F8E$#P08A6%MH516C1D:$_L?
MXZ2X>DG<=K*W-*^?'[2(/ DW&7]D5..*LQT"(#^0U9GJJZ[=]T4/S3I2PYT3
M1\3*-2D#:3O3=:54'2(59SWA>YQX/]PO/N?6L0HVELPR_6>;4/XU@O3ZWZ9
M_ATAWN^ >3'Q(D*DDBH6N8E*49OC%";1:[V\S7=9:VD,/Y8-HDBZ"+^)LS=>
MKK?F[1P+[Z+S(+)NV?^U;$\+K*]F$U=>N=2E[^D4?_DZ8M"E(L?4GL*6-J[
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M8&\UGQCI\6>5U_/>]G-<V(V>L$$-DTD>?WYVP^9CX6W+4C58!'5U\,)+IJG
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M=R;KS7_\@9_QU?YU7+\W:?7TM,A%A7D]2:J.V>MIJYY(!\L'\FG\P_2PF^.
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M=P+\:0-E"?.M"TQ=!A<4WOE&O?H_)265EC^/%5%=;()_\ODT16._5&NW3_7
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MF_K.<&.L#(P?BU+E(:J'P['>[5:07O&!HIXM8^Q;LF0WE.([P*O3LHL:O\W
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MLA'C^!#5:*@GPWZ?]C/E>L180G"]_!/52L_T7<FPMR/C5 ]E_SBO<:83"6$
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M"5>:H "0GE91;&S4M*;G0_J&.#$V"6>6-(^P)X<,Y/WIUSR/&(+YA%6&AH:
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M;)&P7 @VRKS5MFDD$C_@_>!RZ\B5S'2KL&MK6>CGC;>O$B.WE&1*1/)%-!^
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MS\8B9! XQJ6T\^Z+<>]$DKR'*?N*?P>(H>NAZ\B;U:/K_!MI_/]3Z;?C ZW
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MQ)L7+.K=]ZC5:,XN^S*KP[>(SCV*B^ K&HUW-!IL*^)<L:2__*H+V6%D?F!
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MAC4&/G5&MDY0E)QWZIP.67I<'1H9,GH]QX[,?'4.0XMBPA\RN@@7?FR>8ZM
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MFP>#R<7W5]0^WM!^R',7S7+$G4%QI"Q3KNTZA<IO50NEZ>JZV'QH!(:5C]*
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MU 3_7"^DC,I.,V((R;A7]NXUE;?Q@*"';=#0C@6* G&K/SOG%K?V]!H/PT-
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M]:.D,]=T)39KJC]V*S%$QSZAR6^S_8#@-GUYG_<B;!+V;9BUU9!]!S%05OZ
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MPA_$FC2"^_2;E!NX'PT/XJTT5[A0,E)O9QNNV<?;;\M4'/F+?;O=S NLG&^
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M T9Y_WAB<\XW:)&W>Q&ZU/." 5MBXI"?>/_2I,:]K[1JW2&[?Z1">@$VJTA
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M__9KJ5I^?>WM'B.YMI/_]F2X"K=<275#\!ECRO_=0Q/G/"\ZS]5:0P(,6@T
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M^=.,'=@<1\*K8E*'U8?NSQ[I,^?P$SY2L[LGL?(O9S9&^6QSE5TYAU5QW;_
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M\RPK9"6&>-F,:OWQ<QLH.WQP_B7FLQ +[0TV\HEARA%3\CQ;78;'N_K771+
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M5T&F<%.=QK3E5*7 *.VW*6JBSPS!I" ;&]_P&906WHEOQMQH&WD:8^>9?,I
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M^XSR3S,]),N/\AU]@O'#UK:\WQ_X9')6H#$+K&A7HL=XY/R))I8/D;I" H^
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M(9K@*NQA1#EJ1#Y^DZEAV;109_ZHKM+1D^%[0@V]49G0#RU-[JTB*S8P1)O
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M%*PL"T YU/'B@E'%C9.:S?,/S(GHFSMB!?&$KJ>J3)PEJ_<G:OV>YSOGJLY
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MGA:)V9=SX#LX/YC[6:18I$\:ML7WPESMG;$<X#NQM @U-ZQ<M/Q\<5HL(L9
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MLYENZ)3*^E8O?A\(UG2A$J7)LRT+=*7"&&_8<UU[O<,W'5JQWUMJ:TTF?Q+
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M8!<74Q]YGL7D/@(ZQ5UXZ 5+<7MX<H <G2O5TFHLOL-6$L<H\F'P#U/UN18
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M;@[.#(%.Q-\HNT1(?FBFLTR50JZ"0')@!3F7L;!T:'4&R=1DA]#;GSZN1(^
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M_\]U$Q5_:6M/V9/6-,7C^Z$3!+7(\FS$\B\>E)>TB&E1SWJ*7@144?8U'F<
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M'\\"SZ\[O].\85=.U'X &,#V1J%N[Y\=>VR4N%]<IXCU.2TX&#ZN_;RZDBR
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M?^@E'>D+8' N9@?>F"F",>=&TF>,ZPVM.*[=8@ZRS7L!R(_)M1 ?X3>=1P^
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M/(GI)/NJU^6C'?Q;*IVL/XC7/B\;59F:D"J\L@,C>3;J]'*V,!,$K=D[OD/
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MU7'=2RDWOE^%0C)7-1FJM@T2SXYQ?%<O7:JRVKRV$3^X&@RQ2(@T9_$E"R!
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M7V3]9"3M, ZHR"UNQ7B>T/KR6RXN=;>:P4[&>;FTCB)=@O[%"8_1C_+\?34
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MA>.7/UU44;^>.N!H%W*&=*\O$"1-9BP=I03;NA3T!/B1M&1;#O*'\NMQN2-
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M4,M*.^X'?VO^2"V]DEQ%(XFE3!:^I824\41)EE<X_Y.5\/,'P(*I+95W_@-
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M#^?LWL#OUYXEJ#>&&/4OECW[Y>U4G]H@'$J-%.ZM#_0OEN_X# +Q.E?GM!X
M53D3Y=Y22H8[;T226*BA@(]4*WC/P1H]I<:%.BX =:]]X>M) ?,2;U=O+IC!
MV%<W.EAFO;JWWYL)9L2!_;F!NVU0/]X24VO4(<Z5C#*FX[[I1R%E.-+H5<?&
MRO;9;[KX"F6RI-!=R Z,&TO?-IA+[8>5.VJ4,%W+(>%3N:*2*'\?6F(K$7.Z
MMIO JXNHNV^W9>+A31@?PHF>/ZLS7V=JGERV(3.(RGFV:.UFQ9M( -#5+3<4
M*$X7V[Y,<&4/F8#MCA(IBTW/!OOIS:&A49A]$%1+W9OECJ(W(MOUQY=['ARP
MX,T/SJ#,]"Y^.IK>**>V),ZG53=1Z:_IA)M1FNLP3SQ-+P"%!O8O6-]?/P#8
M+++VLPIU!!/F9-H&H]]Y462LO:=[%%&,@;OY@2+[%9%740\ FD^/JQ9YNZ.S
M+@ZY'FF^  D4%>)7.G%->3H=Q+-U7J!')*E8B<0+!;N2J+CD%%E?Q8Z[E(RZ
M$>U:6>@PET@964@0'%4BS'9$64#X?.WNQ2H;7N$>40MRO0??2<>&L>PATKP\
M"F+,Q5T4<=#%'%@;/LD;+3<-H^&\K6N!A=ZP]<KQ&ISU<[0*FPPL<#J\H:*S
MT2 ,V.HR$9SNRSEH*\':"JMI/H5^CZ:<J]>0O5 V[Q8:WW6#*5*D13O][-&=
MG%9I.)[Z.GG!F8_:NQ@*]4CU!8;?RG-^[UG[LOC>FE*JF$&JT-O50%QI9+):
M^^Q"@U2)2%CB?,1.!#71>VFO:VA&6^_V=FTJ.4[MJ+@3+8<J=^(;RSP="J&U
M&F.[;[1O6OP8NI\MF#*K3HK(DV65F:G%B6S'2XW$GM.0?H0OD;V&DCWT>/3
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M.,!7('WS%07JI"[;]ZXV-U9 TA75<K<5M:,%O*[0R\K[-%E^B!T$ :R]^%J
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MPL=Y/X-D8.9V,1 #I/M%+G0+>\. RE<^%=] $J,=6HO$6PQN1%KE(]?4G6=
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M=Y=W$A634 9QZR+@(_*+$QH)L@<S2N;,QY:E:_N0*'WDVNO&JP9>(_T:HXW
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M62$CQ#_(&\J)Z4257%5PL\G=3JGG>%%D^%)/VMC;P8CO=!['.]7'%U0Z=LZ
M^F9*LBHLB.^+WJ%(LOV9[,KP6PM5IEUY(+L3U:495H?9=?\GR%E'O174S"Y
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M6Q>/_T1+@'-XCJ!7;.^UG:4E5^]^E8 CHRQ9,G@]9;.)N*L-57CF\S<,7%Q
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M'-D[FM3N6C*1H:;AYG >'%]NK?UL0#2+8H.@T;_,+F3^_U6ZN;^(6A1R-0*
MGW8@' &8 :^,( U/SG657T# Q/ W*B$5^8E/55A->8C2?V9V[+#5$%=F1[K,
ML&1=T@TT=.S*C[$NXGOA!9( NQ3\R9IKJ4U92NH/9F(QPWC8,<NHJLN[+N*G
MT@RD'9]C8%S!#AS;5S8Y?GZ,G>6/)\7ZJJ\%>8B3'!&1>\_LQB&%& ZN)683
M]\88FD9$25AD2DA[6HD(#1;]!6)V=MR3<>*L6X)?ZUF0V@:<D#<%_/N/D(Z+
M#!&]2R=;]K):IGP2%M%'/B?>KDIP+G=' QR&N8A2DIESUYC$YV5ZD67@_0F0
MB">KEE.OKQMO><XX4W">(X9^C2> AS(#=NF^;IL!&=1=(&$]+'X34T:WI<GM
M([.)+X^0MM@#P[=KGR< F8!2[D7)Z?"C8-H3H 1TGR\$T?VU%,:5<+X'<M?]
M(MA?S19AT?<$^/YV'LA@6U,C?A-O1VPWESH40?)AU()?O=^[$'/]SDX_MFF>
M0BY\(TL]*,>%^(>EG[.=!C%9RIE$?44=I9YN#'[%221<<6K@:2^+_VB6L_.9
M81R?$"AR7.4P2:4N#/T'4=?*R$5)YLK\*#H*_"(/8XG,^6;2N_G.NC-F#R>N
M0B7ZKK&U-^L:^C6!5ELGJ3.)[M\:0DSXAK%S"?-9.C1I6UL\9[/+MKJ?3:S7
M3TQ03;Q.225)X &E:0"GQE<D5!]88N):J]K.Z=P"T"4>G=*J;@HHBW0\J%%E
ME.LA%57"JQD(2'4[8F8^.#!&MZ/ORFW 3PZ(':(QF#RZ>+T/Y961+?D4K&7G
MMV_!I-1:FKU3Z&KFXGBE$CE K*H9WK0K4&<<V.WF-%Z+<_JNG\92$UBTU&J6
MI2#X'<N1'KU$&NL29XO(9?6UDQ)2< U6@CS=7+=<=@;XBZ=AN]V2OH$> _M7
MH>BHF[-/1<7K2J]E&>C>G ISZ'?[MZS+0I_[Q-$262WD^")[L<I=.,G!@;8J
M^!)'^Y6UT)Z8JM*;:ZBN[C!C]2#N<.)&N-)4_.^E4Z()[[VZ7' 1SHE]WJZQ
M,NTN\_?$V+/K&(,8!1Z0#<@FX.L[2TH2M]("X C8@*U@QRTA.7T]*Y[@[/IK
M'K!>(]EAM:'!2H<;Y?>K1TL3F+K3<@NRCG3S#@IP]]1.JGU^FS-,TDF(G\'G
M*D',IMBP0$>_*;8J(SL8D7B:K["*ZK\^9O^#(OO>+3PKI(F:4_[/VJB_@68Z
M.&)32?.(B;+C_TN2\O]IDFW82$>G^2^][;^\P4898?030E60!)C*8DJY8A.!
M*AA0,-1-*@]C+3[P_LC+QW^OF)'@MPT,DOL_C3'^-\EN/><$_/@4_+)%3",#
M^C)N3[*56@."&'F^6MKYIHO?017A#2]6%>H\M.B?67UI%HOHS/BJ5Z^V_Q'*
MFS"N=#F(2]]9Z.-@6<Y2#'%L]BHZNG2ICC1\M.7KD=7J[8S5<OF/XYGCG-/%
M%.M2#2YN4QHA*Z9C5/7>4#S!RZ^DX0DE$ @S$AF2[Q9T8G9W3@V<:5T.UUHX
M:QB F%2DO_MBN:[6\J!;;ML\UQF'[\"[G4*O+L#8UOBT6Y1_ZISM1KF;V*%<
M?&M'*2,2BTN??DFCTIQ&U%Y80Z1=KQ),H&+N-?C0Q%I%^*J,%2E7[O /R1-_
MOQ2T?+RY&TL..QY-^H1$9U/)A]FHSJ5\<KTJ^+;KVY<&MS^,7(Y+\$P!.?%=
M^[VD5@,R=Q,':JUC^KNCNSAN?K,R3<YH55,JBON,H41F[2J[91\^-*N/ 02/
M^7B+LH[5]RL[8+<3-;;IO<&_6Q\8*C-BV[JH2U<*A>05=3])^F?JE_.2V+IK
MD!X+G:>3-TYMU-:HHO_X;1S1UF!!-\]H;$%,['LDJ_M*QA_I2E(I>X="8?3+
M^'?_#E"-,_]4+-:W+4Z1-R5AGG;VS"@I#D==_&H7)"AA$KH*'^:QZ0$S$7+;
M?^[R%\R#!JV8T>6M_"4HB^_LASV(3Q#3E:N-2%H[[A3N*L.6U5ON@/:Y33]P
M5Y?-_"X7]_F$\OG3Q#_ .?[OR/__FZ(JN9B93WXDZ_//"D14^D<^Q1(V(0!Z
M\OX1"Q.=Z40D[**)1Q.DR^YO+TK #N)YQ+3!\Y^W"I\W$U:RL*Y[ E#4>S=Z
M)[N=LQ4E>IC_-LH /*KKD*O/](-YNH E4E;6C_(]75HI<+<:7QM6'U3;.X"F
MR&G?RY$8!ATT64MB3I@%S!$GV%E>GN0WJOTA4O8^2G36Q%Z(T(=&Y4 A4G<#
M:8FY)0;R1MF#@I1(ZI0FZLDBCV*73X##-T,G2O??2D3FN1#.!9N75M$AAV>7
MCMIV,!/M3KE%H1/3<G0GM)[6=:A6T? K<*L@V]91%8=K&AJZ7-.J(8GD*JI0
M,4YO^KST@,PJM+H!;TEA6'6D:MLIF>2@Y]4K88];GT$[ [)K?Y?+TDKS(!U)
M$;:Y!LX'VI*HY=?"W8X51\9U\=72Y(7W'./%FW&@! I4:G;T-373.DUWO-ZU
M)P"FCF)8GD0%\4T(]K:S 46$ZLCBZ?2W[4:_/4AJAP%)H.%XRD)UT7<CO8@&
M[:E'HIH101%!-H!6/E6@%RH3KD5H"SRX5!7&Y9X$ZI(@_'PP6WL(:BZENC9Z
M;B+4H[O<F\2+ JK:M3*5_R"8SO\1*;SRIZ)_6!'%H?U[L.:_$_C?0ODY6-89
MJ9( 42MRH3":Z=5SKB\0ER\5# _A+!+2_[#+W-93>LG;A$IB'#(R":%M0"9O
M>3[!Z?E\A09MQCXCY GP?&;TSR5:?^B!_N]O_X?\5O[/KI+D>R,3429CHC 9
M<LEMNG/5VGU<XA__;UQ'A,F2LBJ]L]_P)+'4_MM"E*NM'7W,[5[\1OGW2PCH
M^=S>1"?0R+U]NQJJ.OJ)C$V*SCP-'?.$JL.YF4T[VRJOR![48!@D3"Q/I>)Z
MUQD!L#J"Q&M<>V>#WG]=7=E$\ZZ?E'C$5@Q,O8CYPZN@^3&$T]Y-T &<V;6E
M$OQ:9II/>"*%-8'I7J>BQQ:R1=UD*#W*>"[/55TEYG/_P:/[I,C3[+>;08VC
M-;.!\OK6!J>A<K6_NT@0,1%D",M]GCT/WBI[4E R9T^':*0\=8"<FP:2_P1X
MDROQ!$B))[F:!.X\(HQS[KD:^6\PD,?R"4/-A92XCX6N HL>1Q^@4=6B,W4.
MNBGDDXT$PF&<;AZV(3%7SCFH5MYM^2-/@*WL[H<+T6OU] "D@52_AUT73>JA
M+B3?\_P+$M0%.L;J&_O,B;-/]S2K<"N>4B!],0^HH,D#",9H23I>K+$(CXR+
MV\4_)5RWO,!A0&^-U?5IB^U8@2%\(=RFXPGP=M]0$>R8T-^W=@3G2S\<6"4D
MH7K<-! ?!(9'I$D)R*VZ-L[0F6?L&V=3&PV7=#)3K+G#@'YZC:='E(FE[XBO
ME+_6C ACY%2P/]3=:81:?K,[!#W_XQ6C:YM';^^3V6%O?S>*GB&35$99$2Z:
M>_ID]$<W/>^E3P)L#)E5U;60TUF!(%U'>]0^3TEYB&_7F  RK=47RNYW!WJ3
MD.COG;C9&3[!$#9Y20 U;2<3%N!GYI]BRB^A?](I_[,/T_7_HV7'')7$IOC7
MGFT6)5K.-QR(K_P/N1)8J-<AW0QDNT4*Q#ATL)BP*7(5L:7T0Z^K61(/.ZJI
MI=&;GZ?F^9 TK0/^#9:)AM3EX\G]]N+2HD@R8?H :%TE2IM@[J[[+-/=&_SH
M:!_(5AHE)6EB8W-$,A1V\+!V,]I'^']5_5]5_[ZJC KXL.?3X]\/!?Y<4HR=
M4A/.OUHD[1C6NB<WX"()H8-#2L_.^F=\+CFRLZD?O:!PQ'\&0<=_H]'WO_UP
M5D03>TKR-MSYWX>9[(H_;DV2:5_0TYGGD/U+SJ^ 0^^*67EA'E<+76(H'!-V
MV^SUFN8$7G-G&K2OJ?W3&+A%!ZK$?R=FSM3:+J.;+<"F3Y2-K=-V2R0U:>;3
M3D>X5E[X*>#?PTG$3BHT--3.(!# =)0'B HA.6BNN(!CD[G9=H7^O#7XYYEI
M4["?3H3XV$;#9[Q($[(C4?P?FACOPZHX+)AS1C\Z;V4EU98D?9@4J3J_J#^]
M;XQF4QS0E K#@JKB_E-F6\W4FYG:P\Q\T,C<BY*_J]#3Y//IXV!$DA P:"DC
MKFY!NF.SN^-U]D.J\P9JBS 4;F14_%>><$9<9,<_D7 E<=PH]U)S5,D;[VCI
MH >C53IQ4J.S].,-N8UCM$@R.>##0D0JCW"&^N;U%UA[0HG-=7S&5?243ZH>
MBCN !4#J(1XRB4J7DK[7F;7!IL$U%([D86+:$<_Z)?ZAZ8L6Q!\?9S<HJLLX
MNA;TB&.SLGZH2KTFC) #_%O<;/U6$LKXE;JH0F%E7=3#.I/_"38Q];LVB,J5
M/T#A[U-)_R":*<M2K/PC+S<2C(DOI.0#'&"0L%]UO9RST"()H_^&OAD<HP/4
MS*_3 +)B0AQ022>!S8>56#O.35LP=470-;6G88%?_K<0^*/7Q*WQR,OGYOOY
M_;\!I]M_=",WU\V*C_9?#V#C\[17VW^]E[X&V#YC]FE.E)_[FQ8;!Z()<9GP
M3S"6@FN=S=/C0>0\^/5#KI9LK63A ?%NFOS-_.PO:BXLSZ-15EQ=2/=1C,?P
MHF=R-KO0NX=Z[[$.'][N"8"> ^']BD[.TL=?AEVWVM__X?A^4Q8#1N%/FKCZ
M!P:=R/1K]*J\/ZG9E3UV20D) ,C:5^$:KQ2QXBI+$JM6U5%J'.G*8NGQBICO
M^;-'+];:*JAQ% C5SJD(U&J:.(R=.#3W,P47BKPEDQ$4LB*TP-9P!, =,B@I
MB3^^H\^,#@2H-?M6YW(;/ &Z=-9'NNVHBI,S#Y8P/Y==Y96B'OEQY;VJ3]P=
M[,++$?15,#A&"28ZS'T96?$:,.N6@B!]0FX")H,:?#43!^R%CDZUCJV"0S0;
M)[G CNX\;*&,X=NVHEP2G?S<F2L+?-D5$]9F&B1\4<U'8TDY78Y/ ,+5C>:+
MQL^8YR7QJ_ GDBL[4=.(CF0.BV$_K4/#Q"]WO @\T\WLN"=OSH;=#-&V89JS
M]KLN;K%]@L8"+VU%\[C0;ZC6ME.GZJU0'5:D7^9_7WN\R4QSXBMG@D&<@$:@
M*6A5T(M2@N5$%H^C5TMSLC9Y3>OH RF@+9NQBGNFE06!3PTI##.YX:9;R'0&
M%^/#RRSHXGW6UF9X.YN*WL7XB$5]DU7 BV3[J?8#=!!\N0T[6>N@KB':;KW3
M/@<P\7M\GLPB54Q:L;YTNQM.@5%8"1NCW4%$?PP2]H">]IX7<B)?>KTT-.H2
ML&7W8/Y2NA,_>WYV,/R'"<@Q\?]A[BV#XHRZ=<$F6' )[A:LD1#< P2'X#0T
MEN#02/#& P0(;@$"!/= -]HX(3@$MR:XNQ,LZ)#OG#OW^^:<6S-SSIVJ^;&K
MNMY^J]ZW=Z^U]O.L]>RUU>.8:(B4I<,$@5AKV<I3SUNL=A,'NB'&O^RDV&MK
M(7]D-:9DI9!#;F)A">50\<&VJF8=!^K#G]UQ>[(8]E>;AZ?3&E4<0'G&E!<W
M&@U#RO"K8%]'J?&.Z<V&)BE#EE.1/8-[[C9_1?FJ+)G?E&LCM*<<@LDO]L34
MQG$5K&FR,MDKR>$MS"7@[0//],(YTV];/[E/-U.DB=4#5PS;S5-?B$0G2WP%
MN;EYH9&IN^X7$?)_/3'5>AO#FOG-F)U)J)$EH)9;9ML6ZJ4PV2)7+#AX'3.H
MVAB\'U"@'Q?*"]]'["TP;5JG]C/J?5U']G[HO=6)>@"84#4.:/SA\ F_<R=Q
MHHU3EA2!BQN,(V!F>K].,XP(&W\S^=%,F\]S2 6W7%^"D(@AE[-6(8/\CQP+
M+6Y'VI'67I_<^UO$N)W*SS.BPI9^,_=W"_<('06N^/J_48U %?"-?GM;E'/"
M&\8MX(OCY9MFNMTX3Z6MN &Z57P L%S,W3<$QFAA^-U3S*R('$G7PF,][_>S
M4]-GC\MQ<K>)=QV]N#Z&X5!GIS(5-3\ $C!X\_2$(C:.B?=Q7WFRT7W&]<PH
MGH?F&NFT3%G6&#8:K,:_U6UZ4^J2!VF;X3?VSZ.LUE=P^(I=L6+VU/:Z+M3Y
MO1//Z_)&2^5/O2M&9/=XQW<QUS_K7U(G8]IZ5]N.$ML(,TYZ9),)9>+-C_76
M?M>KZO;!C\G/9*4-.X2$Q%93K=V*Y?KY,]"B<:'[<+,*6.UESV*J)[C_FMIB
MWL!U&7*-6*$.J_>N."_[PO.4>Z,\Y$E]BPE<.<^.6!4#O=TXEYD!))9%.RFX
M'J<][?0CNCN94/0-WV)HY<NX,.N6YH;6<9OFA$21F8\9U1K@BN4[U)$3GIPV
MYP:SFGA7@J7KB5M2-*%%IDFFH(&<C\LI(S#(%?.]0HSSMG2F$(M70G$J59'R
MCQYU[\M/@>N!(?>-O&<5KRM$3UZP]6H%3?>3Y D9(,_%,S6,J;B>/66.0E\'
MM;=_FRU*<UGYU%-F5:;JM8[7(VI)(9B$GVSCNZ9:(BB<)LSTZ:>H<?JNDQ3]
MME:7>O?0S]XEORV2,]FI1%,S^Z;#B&=V2AE?>;_,5=5/D\I>=DC;5*:X52Q@
M(5_.X8; Q3P*IA $5XK<^96C&[*6/93#*YKJ*QRL$YMMT[S4PWPI9CS:90<]
MMBB+U">DIU<*QT,W_=Q,\Q1?4]8]2@1,&!%7+*T9X,9@1?&/]K<$]F: ;OM9
M_WW^!L*7@.XXAZE,N1^5_=3&MB"':O]#*W';7:I?C18%>]SY\[/V+ZL5FM.>
M*PX0\D=NW9+F_FD:K+B8F?XI7DFPN-7J<.5F,GE8T##A@1DSJ-GPD^"5W7>T
M!T!\X=9-&_*#^&Y72*=0Y>X#8%9^9F,+)5P-N>%FRGK"Y:,KI4:9N'&E9VJO
MI39X<CY4,S=GQ(XG^ODMRE>0<H[,\[H89Y)'UQ8<@OIVZBPL/ #L=WO]8)<@
M"8(WP 8 2I#<_O/YK19'B;I[\L9$<LMXHC"=(5<?_-#2JQ -2#-,81,3$&HP
M%[)CHA%[=5PX,JF;19C.X2Y@.Z-2@18)>5M7A!]2;K+S>V$;=&BXK#[ *&J1
MWCV>,REX1&@Z)WC>]9[ERW/J0J-'+U$Y6<P9]=NM*N5J%9]Z  !0[A#PQ^6,
M6_&4I$M_.K]Q#$%M9%M1[,%@6>.QKE=!M$=>LS2W?1$.(94]Q'^*IB/A_ !@
MW-/(N3?_MD"$&;>6*/?1EEE3 \[^Q-&BT^N:M'*R'"%>%L?@;)G0(&@!GLZZ
M63E+U3\5\.(D]S9] 2D\D3B16=GK9$;Y<H5V7B%ENQ! ;];W4[9O%\2,P-'T
MH:8C'SU$J"I5')X#"SR8G\+:29=*.H*FGU1)L$JO*A+<Y/_1/U#E8!Y & KB
M')'799!.5G5S92CK;P0D5_F9M5_+/3UZWM20\.&)Q82$GDC@>F[@G+U9!*'S
MBY:@VZ\EYFW@/+_ND$Y^8P/$0D^CA!<NSB>D5IS68M&HGP8W G%>.(?IR]+G
MM^6A;K<L2;PY+)JRN_,YAR4J)*A;SFO%G_K-V#ES\?"XL4#@BY=.DK:C7#_!
MIMDE4/CJZBYDYR /=/<KHBFR(.;;3A9O;,?FIG:&#*7#.DACF=)"S**WP5D6
M%1<IU2JA?2OS0:&]BK ?(S9W-//(*7!%,I% \C:G]-0F<J@M2;OMY..U@_#+
M@I?*M=7UP+,RU\!^^=2[R6*#!T"_3/9]LR:&4[USR96.5M!!Q58C?@,0Z)($
M.KJ5+C':D=,12^[[@K?YX@' (S:9322]=C&]VS8(4H4_ /K* _?"[P?D.WIH
M*R+7-3!D7-\[K<M]T* LX9(0YREVO-AK=8*R?'8^'=<*NI[F&:7T8RPFIA[0
M]$K>!\+')8CRS>S>OZD7?EUM%3P,S7\+>K<"LU\W-K$3QJ=-H$V^M(Q'Z3:W
M([0/8)@ZY 9?0%?B,OOFS^%EZL<]$07&QAH6XI(CB;MRJ@UK&#4M3Z57';WO
MC\YS!#G:+]KPKJK'AXY8&^HSC]5@?:2LN;Y"K:M?SK::$X>??#Q2:!<I@G;>
M*QSPWJT9U2_2C"%V&!.5?RX4&.G*LTY<:]+)X_ACZH\C+%,U6GWGW#XL.F1B
M^AS>@%+ZZ1J7TW*Z)UW! T)#Y5Y"6!7J=5^,?U27,+S8MN/+ W/8EK+_*YHL
MI(=JJ8A% E(BV?^9$BLXEB6](M)@C_'?$_Q2U5_*%M]W3@K69ZS\K^[8^<?X
M5E%JJ#!GNDOZ[E=#T6-(V'D _/Z#>7?!\:E17@9O ]'.1+F61.M99P]*8#89
M;M?U8HWOU=*4\X6\WV!LB%6@E:U3UW@$O-$_HQH_ ;P$=7=3 ,N+LD\?  XZ
M3Q9(-6Y &@^ [#[IHRH=.0_T8;^(1#6/6;=7$25Y94/^$*<;UH98H3/K)_$#
M)'KRD_LFP;!YEJP/(F6O@E_B*\)>D$66SX:F?^]I_"2L1D99)JD@S_#?K?N2
M$./+VQJIL1C3(3(U(GZ*,(7!!?8A6NH*N#F1'M8&_\@ATV6K^0 <2;349/Z_
M+ +^=\8;%<='(C[YSWR#[UIG)V[\/V;G=<GCJ<M$<S QY('9*EF1@!_'2^'9
M,K'R=DB33AKLI4<;Z#[A"9L]_^@Y\.)3>="I8J'I!%=,:*11#09P7N_GWSHP
MPOFI.D\![YDOHCHS=L<@^E @Q92@P5^9%Y'1W9J,0;)&03JM]69?7Y%^51VH
M/NEL$4G]"X9@[V/XND5;EGX2$%4J5T0VA1!L?DOP.8<HQ"2L=>7I>4:N!^W
M[#QNP FFA)YJ(.I/GOR4&_VL<\*M@<^X.FKJ6,XY4K!E55\B]IA"><<N]VYW
ML/Y7]SM)1Y/.Y;<)((L(QAB+&-F\:("X3JFQI\B=3GOB0(E_O4JSD6C_GPS*
M(98 PDF>P[4D\&3*A<@(5K (O.=OF63=0P.#TFFM:1RN/VP[;6N.M9HC13A5
M4?#)_KK:I/T9ANZLHN#LF/PO0QIXQ?+V86&POY@>HN'C(4CBMV[A<5A]P&N?
MHNI4H0= -]W$D.>9EB>9(C<,*N,!I/:%>.N3AHXUTKI$MI9<>2YICZ<@'2B9
MZ9L##[/!<W^K+B(6RW>>JAI5&K#\F34,R>)"1^FP=R8X-V*_R@W;K<\%V_[6
M8JR@@<J.Y&ID,0SQ8=P-!."A\(Y$^=6H3+,#;'WKA1J:R)WMO)5W3_O:CXQ3
M<E>H*PXL O,789]#W[OR9X/W2@HRPRU"FHZ?WQ=$S\86)0W%)5]DX=DN72D8
M+>%V%E(7$M#XXGY\#RG+R_Q5'LU[I5AOBU/4\B$>L!"[^FV;CNK[!'/Z[.F=
MD\,\(1-.M'63#WLS#HW&+6-Z<NC^N&UZ^DP[F])%4A!((/ IHG5@8;<>Q]LK
M._$57RU([^_+N_DXARYV=G&7IDU]SC7YX&;RG$2[83 S4"[<9&)Q40V#&;L7
MX?8 .(Z$?NRH&X+G(K2"Z"8FQO\6_?5%[LC;V12F"ILC5_Q*GT$4,'7FQXL_
M'AT(_CG'D]8T8$RK/G&4B%/9V\[;YPKKH;30/&C\L'X]+5X*?7?4(D]7PD.J
MI\G3(0DLR$ON<1.[_)@_]3QR=U8^^)0_@8,TF^WC^< JT^1Y84.==(!D@27(
M45Z\RI"FKGAYP @FRE@+1.^P<"C^:EXJ_1$QT- 2=6=G_0$7;192]X\_[@[X
M8^>=H[<CUP +/WQ*4^I /Z2#ZCSV:M^C-FP^ZYG=,LCM'S^_B3QT0B5,/TL^
M?5>]O1 563)SI:HY@2AJKIW4%_>4%C#2^'OH0C,. QQ3ZYBUV*N<5I9;C]DE
MLU'G!_PZ\EFEH%NL!L$5S#/N2BG)]J!R6NL=7A>92Z^'<.8+>OXUF&%>5&@L
MI#=?ZEDC70&(?V4)?X^@8$U]*@6Y<']FI=PO"6E"GB4C:QNYLN2H&NE?%-N)
MF>_HR\X8-] .D8]REV;D04VY.8=?#5:;J@CUOSA2#/<3NGY^<-?YIAJG"!=
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MC^_FQ_OSQ25[2.F53+'^P%NGZ^4I@@BB,KN3*DTEG9 =0RDZ:V?4Q?4M8MP
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MP_J</(Y(MKMMIAP/[H?BJ7]2"DZ!(?KU/EIM"G>S<*/I6(2%5EWD;H_MAN9
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MMFS;S=@Q9 L!'[[\Z*NO&X(OKZL</_N_O;7-%^M/-)2$])XD94S2\Q[.N4,
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MGCAO5A>$S:2OJ@<%+8-D_EV#"B+GC3/85;>Q*]1PU;JH45 D :_XTA:2DK;
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M$]XP%L71%2MF6YJOTTQ=&B?$&BQ.,^R+H$* !=1+H3FI&\0'+WY9ZQH_"!@
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M2DZ-7DI8%RV%HI@J<?GQ\. TWQ0AS[DU$&-=$\X3(9W:BHN6@,UF4Y12"5\
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M6DBI3WF.>#ZX*J84:76 Y9A(X-O5YL<HZW,Y+XX!L9#LECK;[EDS\LNORXG
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M+I#8D-$O1']LL@6)CH;N1KW!"XX_PUI2C(E\CQWX46%G4C,-QIE]\%W;O:+
M\\572HE/>?J@TWX9S@HK?]2,B8RP=;OVN,NU]&51R[::O1378G7=]Z_'5L2
M)0 1S(G1:TD,>M4ZMT<'OY=?:5FQP5?T05\;AA_$/)#7SR5SI8EHJSG6B<QK
M&FC=7/;F9%SD8IIPFZ/ [/L(%YA*;38L'HK,J!QU>"OHWY_X<NO;&V(VG0D5
M2/W;9(_K/-:/P?*/E8CZ0%#GMT2X[D>:,8@-W-+FM.S[_MQ+>:5$6]5O[5@_
M"BL[MBW2=!GF3['%N1BI1UD(XQC^EW-4WAVP24 5U;+6344P.85K]H4SADH4
MTTT/?14*,A(7F#XYT:O9H@J6WRL_DJ.F/])YL*/CJSR>N?B56#GZ%)E@U0^;
MZIN&I-Y35[L[/E*%!U/NW\HNLIY.WGOZ&_W]P=);"9SEIDJ+1=9ZR 87\M>2
M4YUEP=E'E@_];4=]6)*$S(6K0T0[1B(^)[+P[^8]V%E>?:CGTP@Q36\87?!K
M+()<70XI*HQ22'YJ97G2VDBYA1_ID)DQ5KE$ *J^YMMRZQY<'S8X2%I.]#L1
M=DJ-;V2LS=O:WKS.:+CN&F*\J=.5ERG>SZ@D]5%:HZ3\Z@]A,3PP/;JU+\=^
M;L;-C8$'E]T!&*7G?UO7TU]K&ED6##JA24I +5,]_A+W)29UJS]4^HRAD"+2
M>&3;0FP*>H<GLN6H0$8_X4#K""E>J!T0\0662K%:N+:_>>V;5C_\##FK<;5A
MZ61$K)%O5G'ZQ46YOG"M<TG7/J84/,T]XR""2N9TE[;SW'I2&=XCG\<6N?4U
ME<*FL%M>*6.Z__N]W*F&E%<;OUU4OM/_5RJ-*7A'IFMR(*Z8#Y%:.W/6S[)S
M.$4<W!EG*QD8/_@DO;2!IX0_N$'6/O<,E>I[YU5[]WRU'"MU#WW*:Y4SGR-'
M/"*07E=XR&J:W^!YQ^35LJ"07'4+6+&AE.)+LRRYJM"J1+E)0=9Q,@-_G"9)
M '7>66\V,Z;0N^OLMD\H-I,@8C(.L_6-$K<OI(?:JX8<?M1?MR$9TSESOELV
MBY<DK@-@>*AW'UZW[A?XD9CW@]+BSWE_.W;,N03TW&0 *A[*?]WYN!$PFN2N
M+)$B0&*371C<1;D.^51LW[%B2F&/"Q'O]&E9WNKB?GG+ZQH+1U&#F37T1NZ@
M@J:JQ>TIC5S%]ZGDVD0/TF^+EXRA7G(J7;X2>.>LMW;C/8?K,EY6+YE";6*H
M'"[4[O53KS9[OO75!&Z%2L3$:%H_8K6BVK])O%BUL/A/W5$%H*W$\%?(LSK8
ME0 $QV[0-\7DWV%\#ZY7YGAUI--4Q1FEEM[D$] .OB0B;R :E*@7MJD=GB"T
M2P"N;54(08.9/**DJ_/:I/(['XQSK.SFC":GUGW=2Q(:]&/!9&COT#1E'H>?
M8,/\@Q^0D3.N7EM?O-;2%)BL1Q6F)./E.%7KX66=Y'R9.B[T-L._V"C*>.3]
M10YF[93WQ(9"D.I:>"RPS_?&\FG\$Y5/J>?2HZ/)U #O$:$,W(3>,<<0:6ZF
ME2ZK%>"==(];1'Q=8I2/:)PK3XCG>"W_\:+/V86?/K76Q?VP(=G[N_J:OX\8
MS_T8/!?^\W[RDNJW>%]5#LJ4L@:-_(_T;<@Z_^R#0#Y++@PJVW'XF;.^+9=Y
M#LRCDTO,/@P'U:L97?C)HN08K@_0;^M*FD!,T/#V,#"MR?J*5EDCN8UPO344
M;F?]I@)^T>?^:+)!_0[U1'0/SSG_Z4W@C._Y0N:1'Y+0\$G&CUG8ZM@KBBX]
M5\S8:=8AE;;G^G3$O.!M]/PPM8PA10',/=VQDNMN."H:7XMO7^'!U'I2B9V^
M&AK<M!<Q7ILF,%OSN\Q'>H?!6%_?!40P4Y(O1G7/_O7GM[DG77.[Q0OI(U+>
M8A)7*]NI)6IR>1CIZB(F)N.%7 RV7$P9)N1Y4$5*^[[B-YLK/IVT]@6!)FJ\
ML]A6-L]&&V.')MO>/ER7&%S3%=Y\]@Q_<[)K(1MD?3DY*QB;.G_LQ^C4>18#
M7J2)"K8Z]\PQKM?C!\4&=CT5*27KX(U#Q?J41YG0.I("))-E;E#JM5OC,XWC
MN \N&HXN[#<&:&P,35J\'3@[&@IX'X@7Y@28^BY"@N/63'E&737I^VKJDV[S
MF=;K)4YJY HGK[H@F!_/P0;;O.1 >^X?-43->Y%EDW<3#J+;6%JYSP&^0MU^
M8E^G)_O3,/'FP@>";_LCVWBP-%[PH/UZ!0^5ZH:*CQ;Z=SYP!7&$7L%*U\L0
M (!_AW^D;?\C^0/DIMZ43I4:2F^:,="S1&X'CRC@A"@-2[[?3*NPU@OEBY)3
M-R]1D"V:"YZ5@U+8?LI*SDQZ.\ D$,5?Y+A:VI3W-&<]Z6-=$29,07'K=K]
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MQXQ9#$,P$0>_Z6"$9S+>A74(+D##CK^/?ITV"3IROYT9,SK$]D/$3[(A6MP
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MCUXO0WOC]VHVBR*K0E$\.U89>3TY!@93O#+Z6IXCK!*O6<BC!BH;I(J-[5Y
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MU?7II+JZ_ QV_U[18]Y7TP3^=_"H8,Q_44U@B"4"!*@(".3T4D@!:13( NF
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M#DNYU3IY,ZBFRG- Z+3OTC"V>UWYD'5NX8-$Z<-=@9(_!E.56<D-6=2\KQY
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MQ/2E-R^M*R_Z! L_\*PQQ^_!(L6]$$!86E (9UQ+_;UIO&E(_[2_L#*GZ3=
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M(;NF.]L2CJY I1?8$H)$I2QP,E'"9U9\Q!KPX5=2VOSE,Z]%7TB^$ZP:7YH
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M=CD%T&?*8",,WE2585UB:/%!#U_L0'_E1(%/3NR"8TS+47QT:JF/C>$])$<
MJ,&.%ZP(/.08.X:AU$F1Y&;<\/T6-RS%"Z+Y^/GS9FAM\&*Q#6K9+&H(\. 4
M::7:SE*_$WM-2W2G 20];3CROG3-)"2UG\.G5'C.>%RK#3U\ #(?>E$K6D]*
MP))*S")$ZC.HTJ!4 7JQ'F+/%KBIT@N0R6%8\1NL64.4-5^P-IS=7<<=3R/T
MD%-VT0<G@<.JTF"<1#A?,,6__-0:PA;]6PID(U0P"O/W4;.L9<#'A== 3?JD
M_,_T72 W C]_9AP#G\?;I?]\=MF1S'X>]T6QB:S&OZA(3-O_(]B@-B1"&CB%
MN'4I]0C>'_]A'CT&S?^3C)#09Q.?6M6DEK+YK5ORYQ\D/Q7U\U9J$NCC4EYE
MS<PPV[KZ(?>!\VCN>"Q2@(!],BV VFJNE(P-WS@3T,SD/FL0[M8#BB? B:ZT
MLTP[NI>>G<+88XY?,6%@\,1,Z(V3;))3$/KZ-X!6+8BRI+RO84T5B<A^2Y&%
M5-*2*-A,,@$E]^!FU"G*<PM7"IJP_!_?U/.5GJPOOR@+B%@](359RJT*6MN;
MB)N>5Y</*X4,QB%_0S)8 $N-4V(RQ;$2_ )JCK@)0$HE@Z4"<-PGHS*U5E!L
M@';6%G+L7B0F="V$3E8&\&0J&O)SL^L9Q[].M>[YBGA[U9^8^ H.E:[S/Q-0
M^__Y+''[()B!=N5+.?[0)ZPVTZS#KLRN8S_K=,OQ);\C[US-3>9RX@B<-2["
M7](QN[OE >MT@0?G7B;-R#R,0&W?WZI24 AVAI2FLB[-3'E&#HN)#\SNMF#^
ME#)1L+G_Q"VN;5U9SZ[.80)OMF6^PJC=\3VJ-N0X;!*S&-^<]5BB3%E/U0M.
MJ7+J(L)I,.*5Q8T_\I8')G:5!G+J5.D'*;(.MQ=S;\B-='W5G&&U@=6P>,N$
MFI058Z[SX4!55P1$2384\HEY$()UZ^FI+'CL:E))]\+4>2W# )W1V95Y=S=S
M4WI</Z;?L"%P G)BD\ALF4=GVN&3I=Q!,R)#:"_$]W.RR<O/%E+<:ID;V2]S
MS;U:W6T0K6L_)+EKUG 6^?U15'9U+?O>@D&S36'2]QCZC@;7N'/UX_I1T0=:
M5S^TBILSW]ZY[<RR[*9#V8^Y]XZ7 -L0&"? $?AV!%=%,.S*%LZT:0JWD*K0
M5\\%8P$ZB45PCC)A#]U-UO'(&#229[\F/"3YQN?@E[D>W'Y$U+J'7?T.:0S%
MU<5>OR1$:#U/,=W@"M=HG-:NV-7=>M9-S"O-2]QE:&^K :C.RK/\8[)$<!ZT
MI<OQ&?.LHY^/_7S)_I;K5Y.YV*W+<(FRT+N)4RI1YWVYV.%V0F\=(A6X"=#I
MZK8.=N3J9EX8Z2K8^CHG1L9:"\>496F9\(C/;<AH!S\GA;=,ESLLE3[NJ$J^
M*K<>LG@+:[2"P*2+^8BL6M!'0O ^$O_J'B6T^C.UIY-RY1ZGA^^?(V8%<UJI
MMB23$LWVF^W78E"Z2$=N-SQFY[87BVDXO.4]LPXO>Z%6]]T%+!*BP1I<'DO>
M8W-94[J<JTS+F!4C_/M"_8TOQ(!46;?)7@DTSXQ@2IOILU= XQ% 8:2:>]74
MB5/!?@0X5SC'R3UG%[,=6>B\&MG9/BR58,@RB;8^- 769Z#INVO G:^-+APJ
M&'K*JW[MM0=1L?UVW<XZ?%"KH4Z^6*7OMW!<$'AN+YG[%.:";I&Z"69 &,JT
M@S%E^YRV!GUL?F2^V_X>69"NY5K0)<O@U8E4C\]6OW<U>3%ES_MC"+IFFFCY
MA02E%_S1U[^/Q).]JY6;/6_ONE<W*?4GP=N#A(9_1!X:1!&AV?62M=)VI.%P
MD B+W-#ED_$''%:+:H=^&F*&KOBW-'&3J-YSQG,9>C^=!'SCH14LNK$6W%%V
M<BIT<1GQ1E5!R<=I!7-$F]**OWAWD.L\R(<//)3CL].Z&1Y_FE!^%ZP]JHR%
M*'M(W/:H[KCOL-'MX7>1S5EY4$5X<VK?9;$E0;:N>"+(CO-"&?G'( \AW[N+
MZ5:+\&&?+(YK:Q:N:CVS/Z6VF_[!0FOR5?."D,2I<N[]]MYA$_/OX^4I[;7T
M] '+$P:I7)XG9_/>I9FCRI^>R3^*MI5K[0C5G+L:[>K(2#DQ;'A12EX]^.VJ
MZHVB48XC.=ZRA*]"Y:8W.3#[GXDWZ#QISXB8MKPR-1K>%["455(+;B_$^=KJ
M\G/W7BIZ>5EBGNDJ\M[BV-0:8HLVA?.IOI( [A[CTP&'33;S)JT4WOKJVQ;,
MFFT/LB<&WK!=C'P4^+[\4,C1IY2$S34Q(BBR>5Y3U[=D#WY^AEL:S;XPFEPO
M9:8_R7-3XZ!7?YF2_*W8SU7 9RSZ;&R*:K)269;]R&*T>1[/L3(_MZ-CE4[N
M!T/I'Z8Y<>U?RHY!.V#(?#RS/EO]*Y?G^?NO7?-+3L@.U6^OM M!$W4Z!"P7
M>6)2.O+ (J3LPWU9VFIJ]["7&5#=0M&XB2AMU=?:PH#HJ^44$<!4!SL:J'BR
M(#<<%QY\&G?4BE(WL9OB.7%=XC#D^RSXR2#D:Z19T]*$^&X[N%OFY]12(-^#
M)A#T2(*H#.GV X,ORQY3]S;N()C9QJ!;DN#H$?F^@]FE(C6ZNA'WXB=5H6(B
MNWC.D%0#"CJX)JL?/UC:293CN@D'C$,OKCJO(7(Z]2.'!18W@(W4])ZW *%[
MRF[;Q,?IZ</@[IO/BAXH4JX\:@LF*8L)06B-#XZP=:>LUFD-X>!DB]U1(-DO
M,C?)$2@Z!I($IW'&/B^_4*?Q@<Z.VJMI*S$2)D!&R4OO*F%IJGM<&&9:8 C]
M-4^=Y&.=1I)#+]#2$2D-K7(;A4J&:X^!K:H8TG8-%/-O$LD#K.(2W7CR)B<N
MNG&>J5R7RM;,4["L3FYZX^\9/ @',HC?=%7DH!]DDZ&:N#VD*:[*=NYGD"5O
M0.^7J&8[^% -%_V34D+_C!NQ@\-(G'*81/RBL4HOY>S9K3$5H5]5;6JU^G[W
M%' XAC:TL7\K;$W];[,,T<=Q+:PS!)"=V!0FR8]Z>$/EI-$V!#O;#X--JR_]
M;>:-.QUI(<2.[&5>?L*(6!?'0>4 =]0%AJ=;*2?<:MF2"?<@1V )O["9]A//
MKZK6[[Z,!F?+S/_D)&!-EUKB+C= (CQ(D)<H'(J'W-#ZNY)WXR\,I7G1G 2'
M=>0??02W*$[(FD6>_:H2RMC_0BW\2OK'G1('Y-(=@F:U@C4C&(HX'YS8^X5N
M8EIC#3&@B:,RF%!J2=H)_MP>&YF\!1Z]/UQ /S.&"D0X]A54Y/JKYY0\NQZI
M:GGVX\X03T^,PD+FP1OZP62'4#AS"U&Y*YZ]> ,NVF7VU4LJMGL0XL;!^Q$M
M&5'!*]L,G2?8:/SKU)-IK05TY:O>UY0(]U-FF'DF3^H[K<FD2)ODB\!GUGON
M9R"1^^W4:PAOF^E8KR'HG#K@-#B\QY57-D[. SO;^-CFNA<SX2C+*G1<Y'SR
M_EF0*2>8?OZMT:1;,A@I>!\)9I8_*<$^UFK^]"7"Y&#>QR]K"/P==W$VFD<>
M( IID9*QK(?6$/&53:ME=L??']^Q!;+LA3BDY&]P>+,S[I9QZ/2FC1P;;Y2?
M(=RYC,(%IZXA;G7&T3JT=.S=Z:/@:<(-ZPZ'6E#$ B>DROX9Y9SYRT#['@UZ
MM=\PNWJ"HDL# S]&Y)O#A\;YTIEW0W\>Y\(O<UL2OJHZ 4SX"LC:_X ^D&@U
MLDNBPC>_YRSAG#7^P]9_]P1'7]I:MFT_[]& ]H>!C]4/X$-W>^<ACZ9AR-^?
M.BVR81-4470I+OI YVHEK"-[1%#%VG/0&V\0VNV:-J["+NL/@3Q(:$, VZ!F
M0+ *'8Y0HCUYO_P$R=ILT-)Y56/R;,][HVL^%T]+-A:4V0&0$Q')GZ2U6@:W
M/Z5!Q:6Y-Z6^NH_#9 VQS0D/>MJCEYO@#9L#RA W:+HW!I)1 P81D%^\#SM(
MR1R?37O1W&\SP0+#E1?)<)2_<V+.-1),^7//*GN>?REV?A*YQ'7GP;D/?L/J
M,_PM9<"@EH=M*NE2S\3KE6?;3UXZ95WQ^GBITPC_7>D,0D]&2$".XY#]B$&0
MMI^7H+#JC/T-WIJ#O;,/%# 0XPFIE"?CYEG#+8626KX6O=%U_5"VH_$U*\4B
M?J[?,]W08HDMW?* CG1AKB_WS>YBPO-NP=/S ;?31<Z<3[-)./K"RWQ+Y#(G
M: !'</UT/86O+\:Y=ZDX#!@:3<[Z>N!9^\!X4*D@-<!U6[?W]]BN/$V=4@LN
M(O?OGT0NL%ZD^DTL;[0+#)[0$>D-R!P@U?99L-1.A>A=^T U#_G@B^LX$9X"
M$5^K4[5Q*5,[@0%V@A5#^!7GN6]KUQG7WN/G@DC)X L(DGII/P[=AC*??RU,
MKK:PA_JLL<*P1V,1)7\723GJQ,7.SS O4)28]Z#\<+,[R/L:.6R!W3^R"!/@
M]-5]3JC+55,C7!]%G#H GZ-2 U.4X@5Z^Z7TTY\O9<NY.^AM:R P8>@=G%9Y
MHU\+H7E(0Z-79=80?RQH3\6N#\/V<0-E3QE]K >.*-)#LK793]I^6;T$;<*0
MB+#;K6F57QE P=O;]TTK+M6]5O[TME$!D2VC+?PZ@#IS!O.L(SA?IK'_BT=K
MA_M)54VP![EJZ&S5E[AZ2\]U1IY=G'N#$T]AV>.A T4-YXD)TR$[D9_JZ@;A
MGY;W,)U;<.W#V^?Q&E3$AI9X8$HD]W"GC<X?ZXONM1WT=-QYE+U7J#^,SL@/
MNU3W)C@JHJ>U#&7I$[)<=/Z@RB8_J%B?H5F;F/XPUWS^I:)]$_#3:PA+?VK6
MBPFI,A^3V?MT$U.T(I<.8\IJ#;A7;TF&+-RW(\9NWZUI[<A\?J5\J3]ZG"WD
MH+$]%[T?W"C=KFL;A!^<:PF=?CV$%N[K6W96V13)@^LQ>H<6IA?G%L[>\:W-
MM*9^9D,[/V)0UI& VJQO1^V&"_BCV6S9!UUG;(*@]E>S&DZ'W$!%A814<_7<
MK'&S*BF968K=@=\+U&'@.+0EV@<&<"MTND")OI7_*1;#;>8A6?8'; +\ADK%
MSQ[WO<?T@"U&?'*@Z(,?256W!D,+ZHJ= J@[M--TX!-',\@1 ^W!6?Q$Q#C&
MP>#M58?QP;*S+?/\.14XH?MLR2ZJXK40>S?\A;T?=$BH,/S&S_.&2@H3V\3$
M]X>63#_^$KRDI$%Z'$=1'C@$C+W!4#?'3HBSLMOQ0Y+60G.8*L=>ZD*LJ _2
M>M;S8B8_P][?(:NK'__5+LC_PCX[@69$8< \%I0 >77.&)$AXE_<2Q; &?MS
M!646NQ__AL)IED[FI:1G$,VC!=#7*OS.[6A8@(;\FXP@SQM@3*(!\'4H>G7W
M-4YV64;(ZKX,*J1"?O>;QX8-H?32^:*A5(9YF&YBJHM_ OT0AH! /R B=7MG
M3^V5(<)/9 ()8?ZAV&JN+B,BVOX7!+$YQ]>C;O*,5([/3-VDXSJ^1YG<9<)\
MX=U(@<K)P8T''UJVT0G]U&$;SHL]A!CFF5I)N;%?&091_(S<MV[[J9<A3T3H
MA,,\07_;1G^O/ZV[((0B1G,HWO=68K<6_*@[(L?'F#Y9 4)!" 8IOY\XLJO?
M26-49;XGA(&,4ZJ_^QEK-]1M*Y^8PSQO W\CHK]&3NG _G8JH)-]((4%/XCT
M43OCKK5K#1$4B<!^V4Q?U<];3T\];8O^RN>TF?;"L9A-'L<)PG[+]B7T:XB#
M.K.,84HO@UZAWO_:WZV% A@C_R DPT\T*&[U(.1N0U=:(!AX?N+E+QR)YHOA
MD9^@B)K^@JGN#MLB5.[&0X[UPD_.%AIVWP9D?Q_$NG="COQW*:-58\/[PT%(
M=NYOXJORNS>%^P%R[66B\)L:V67_D*+O;M:F5L\MC 93;7X%HDW4Z39(9H-$
M#C:M+TWR9/S>+X06C]L[$<:QOW?UMRI R!/FD4UWXP\1VHQ^AQ"T\C:_/]X@
MI\;(WS5(G&'\[LU_QP$0@+Z0^+VOFC;V_ 0#K-\-H3,ABA@DLN.7-NTM0WM;
MTHI5V?0K N*"8"?T*J[SDSTIZX'NX^N7MIP?MX'H\-ZAQ.]5O^/@=XD#!2?J
M2NC/VL[]Y/SXE@P<\\2<L/?L@Z(JN=UT#![H8;4W:PA[<J>\7J?[6\,MG^F:
M^!>S(G[,@B>F>UL>&;\48_R\H9TS-3W/@#PCNGU?%N2AM5DBS%_HAO=:]UV;
MFSZKS&[*=_;:Y[K?2B*V:>SDM;E*8*C:9WO@5E'>3?K+\=(CP24QSEK.YF[\
MA,2V5K. &V]D#UNW9)F"G 0VK[P/KFC#S8K.3[8$.>_29FRO/I4O[F'SVB3K
M0N(KK1T>WA?/GC#;\'N-=N8$O4*F9BE7EY_5WRP8U'+8VKI,VMU!\MJ.R*[V
M7&Y;,T['HP^Y3PM%#B]BO/EM;S^(L)\_^>9REOW\>0B=*N@$7ON,(QSK[,G(
M[=G"/)-U9.%:]H L ZD=RV31,OG)T=)FI]]DB^13GI@+^U")MQ4',F5KP$K5
M[!?'"A_MVOW((. T S$3M6/\F<C=SN6"C*31)<F97;%OWZ:US(ZM3)!V93[[
M &YU6ZC2D<5<>#0#<M]FU_3]9%W,2,U*)%CH%+Z)OO.X^RT]]HJ78-^GY.N]
M\J-*E@>R9V2L]XN7:N'9%@L' E4EZNDJ($-_.,;S'TQQ,] 1M$&I_8;4Q['P
M8LVS.9#5?A!+>22 6]T*+Z=I\@]0>,?.X0:EFV8K7$XN6#&M(>IEVM%3 VN(
M<'LG/,5]%ICR!W@&Q/YNV=4?7E_E5 "VKT3C(+FYVKJ&Z$5_["C_*45<R!?E
ME5VY:XAEY((@-AVHV[\*EL%IVY1<G;H6D.B_B^]NL>%O$@TG,>C^AQVP&>TK
M4!)H<D7$Y=Q>X^>#VNH-_4.$C':2ZP!AH*,Y\M,.IL([M1^5LYQ&B].XZ1O$
MY!,:8RDG.QZ.1B<5^ GN?,-Q<=: -RP;8E?<0!_K^!J"!4)DT5/HQ7J *(@]
M__N-A96QKI684:4E4(8?^D5='IQ$<W.:$XKBG1=,'H?G,\9\@6&=-F#*4U,<
M"4IWUU(?*E/WA%?+46N2TT1Y_W=Y]/_&\NCZCZ&P&6I^90UA>!88ERT/P>[R
M'NCTM3Q>Q)SW1G9!-$NJ82M79[_[.=[C0^!%>%F<H0A4U <HA\JYUQ#)AG5K
MB$ 3/(E3KS4SSU*'&KNS.DF98^?!80\(PCQ+ NI$D,N;=-,B32B>D*+=URQ&
MU(:"DI&UU,>9:");IBGM\'+.+8AM'X=Z\":O,G73E YZT8(8NT%YT9(H.(YB
M0 ]#3*D 8K]$8VU,/<RKR^B_C%%\\$N+:## '$'<OSYT24GD^BMW'A(2E$/M
M 3JK /)6K#16[->ESC^.;_^[#X-!'J29NW*IHLIEN679>2Q3:N5=7^B/2.$Y
MY['7TI02N^6!I<]'M%_>SZA,1#C@?6]WW,8H>%>):*B8Y;R^?LS#4;7KX=XQ
MUJGN.U'&2:93FQZ;OWZ\8HWW*[(UL7+<ZC=X+ 1I="*[YUBB[Z/#CR\=EHN-
M149:XH8&5\'R41K!2^O $PBNT$#9 .-W,CJ[;ZPA(&D,3JD$-DMX6?[E&F;C
M7RYX9IVT6NW;]8P5)%QYY,>-O4:4@?H^Q+X:/Y,\S[H;/;EK0JT+TM62P=EE
M]95M?JC%K40L%QU(T.VD-(HR4,S+7X6M6\E4_->;E/^TD.GVZV*GX5Z7=Y4_
MTJ59N9R7D:!KV4I/E<Q@^^OL:KOIVAS-X-,0(\G?=M(=H'V1B\#T[9[DIBO7
M 1ZZ:3A:4)M_ND7;GF<%?6$_TQ+,A_ZV)1!/^R*6"XXO3OS^:ZP"?$W;Y>8"
M?TF9;_V^0X_V)>&#\O?-?;0O/Q4E[K2N3K$@\[<J)BO\]*:_*3G^+RHU$10V
MR4V_O7HRH4(D%4&_9)<E6NG'Y&T90D%WE*#_3+NT&1NN&%;X&9Q=>1AE5(HJ
MH-F^1=Y+ACG2\\&%R D#W2'E;^?P%W'@$]YV/O10 VJ983[>.1PB5N=JFP_A
MYJ8VT95WR5J#]6GH?Q'#H $^_<HI]W@- 9^1_YK'(#_^89EM0O$RSMHM+/=_
M9%%2FQ6R&?67" RKO\&[$$IT?LI'U;0)_?-*J. 8_N?3S*:(WU<#_YM/1N-.
M6'AA*0PTZ_BQ3NI^KO3G!$U_&:I5/]M24;KTC?23R"/QN>9/\JRMS1+T>W6R
M)H8"<I#JZJ(/2L(/+/!R2 \$'RAX=#/J<OO)EW=M\K(#FE.F"E#,+O))[XQ-
MZRTMN>T>B-<X4GCCYYZD&@]MN0?D3T^7M^^.NO_^K$71Z]<MN0/Y#=R<7,%A
M.R);TQZ,*]NR4$Z,5/A2VS=@9%@/_=C@)OM]T?;=!'[^VB*.3(07SI7LPW^^
M1MB'_8/$]XYKB&KO:T3],WV/TB9/L\A_<6EOP+!,;)C3<2U&G4[Z.KN7,I5.
M\HW%3T8Z]5[O/719PO%PB)16[4"UHVGH.\]*K)@_?\^EJ(\>#DP2^F5.VIB
MMW*LQXY/&SMI1@M:[!8[=T2)P*#V5)@I4/2W]P^0K'B+'R@KN.5A>B:Z1JM%
M3T!2^=XQ39_[=)_L]O\!S^8(<\-5->(9MLWV29][2+O 2].T,*,6Z^-47N?X
MVX.2[9G! NL.2JXA=D "AC$S7/P(AX5XS8<;]C?'+<X*6L&YFYZZ)@*=Y^#
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MN(K9LVE;DL0R(SNY[\IDZXW"\>YDNO9X@P86R+9N-\W.(D(36L5.&49\3>)
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M!F8<VMEA)'-5E04"WX4(Y$HUV"-)'^9!U?T-H@GR2?K89>A!?0S/^FOG"E;
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M&?BZF,@.WIPZ]8#63N1V-)-MTWRJW5L?;#ZTA DH3ZT/-MA$7-],B@X&SN&
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M4AFQ)?ZG&ZO'YL%AXH8)2'>Z1*T\N-WM"J?-C=:/W83>'69K/):\6A&$<LE
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MG\$LMW+3 @#SM5_<2/ZJZ2?C'P__3SZ<UO:Q.8H]>"]P.Q<];)&#',8VV"M
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MRA+=3 G#65&F P!T,!&D'M&E9KRNA#.35UY_^UGOL$Y884+ 90BJG*P:3P?
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M7!#V@2VE&5K,%#5U??"5@?+3/G#=TQ_H'Q3"I&UB1'#_!\GQ7Y1]6LOB(DM
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MO]$12VP^@JBI*D(DKWED<ZQ8)*<8+MDJ[8,G]_!OBAU"\,PUY0R[,ZU;77/
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M/T\<+[!6 %?\VL2'4MN^O@(E.9KP-U$E0.BJ^9_E)2'2_,Q ,$-XJ]3O#.1
MUSNXU2@0(_3"-IB]OT1RM3 Y3>MU)L-C(:GI=!,\R&S,C#S[QG$ EE5K3"9G
M057FCJ2VD;-T553$7>0T1VWV6,]-ANJRL:,& XNF]##N0%:'?/W.#/4R00U<
M5&WVD%K((Q.3?!VT&%CV4LE,4^VKL37Y# A2G4.-XVI*TJLI0UAB4(:9(4M
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MW-&_P4.748#]11P#K@J^Z JX6\NW,_ NUB0O0FH\.GW:,3R\P0G!.4I<0 @
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M&P1BIK&XR-:[@_#%Y-X?YF<3*"QZ#5J9$Z@F43)#HUHF(_,//\]@@WQC #>
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M-B3'5;+X.S47_L8ZNDBN!1W/ GK3 -7(9<XS&,<C#U4]3W"Y;Z!,PD6U,PV
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M/NF'9(^/.W4KRU76!6" %M*R93PP3-EK-K+S&2.(D/6#>_+!4PC]@)<:E)R
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M]ULG_G!3I"[Z'/#/=_X5IC=)]7#,-"B8RWMP?.G0,6^(C-IV"#&Y_&>=_.D
M^"K6A7,L#:UY-\AKV9HZ4,E?N3'QU%,0#12VXY'.P;U_EP@NDAW__Y5I_4[C
M#E97W"RM!W+P0=*_S(/NJWN\JF#.6G(F(UR;)GUAPF. ^8S&V441-;/[%ZP7
MRO':T7(Z;MI 7F4+( -\WH&KWCAN4XUK[7#'YZ#2V*..+<VC2U>O]YBQZ>64
M7?<.*41TSF35@D!MK!+%^G@>B;0V]Y8PVX;$Q'3D#8^U,)U^FT&**W1J9=7Y
ME2X.I8P&2*5(^/_JA!XI/:%$-AC)-/]>1]7U&(1EME,"^:V:P\K*Z'P<W%$\
M?WG>\RDY,[4*LDVY&6FOGQ1]I/.UP$U&#B>"A0HQZ?V-JOVE[=-8I/X>;LM]
MJ55>XA4XJ*AJA.RKU#L/5"= MF,!SV'G?ZB_?S]8P73T;U;?GS=VJ7-&*9Z^
M+%N:-#@G=JDO%\36K,&TL**#\[\*OP0SPI3KNX69XZ:*U;XL^)K:%50;'=A_
MKYO]>=M\5]$?WE.05[_8(7IX?T3S0VN  2RN)\(#;7Q4E(;=M.>M/6/]R&8\
M9I2C.FR*O$^N.^&AQUK9O" ZQL@^ZST_YUM4&.66\5JB4UN) >]ES.EVLLST
M@/@_DEQ!DI6)ATF_31D.LM_6N.HT"5'^6D];*?@0VYMR2KO37Y /8OS,2H[2
ME\Z6)H$=&SXH&_^MH6/4S K3B?6041N.D6.&B;\UO%\KGQHSD^G;+E?=0%YF
M)7\;R]LD5+EDYXBJ044)V.C?'[$0U^J'^RC8\KM] -8GE']/*PCMH9#0/-+@
M_#^HV?^H;<.&WJL="-)=GN[]YU,C'4&"9!Y7+VWOQ>-H)50LCM2450QTM[I*
M6EU.$ZJN2_XW6;0.;-\O',(;^!K\);^TB[)R93M;Y8]EMS1RIU=/EM]64WSW
M<?DS<_PQ0LG@NT7<$:M-HV0)87MNF:%_W[RJ3::P9,;)@R'MUW?.\>_UC]NR
MTP1-+/+WX^J.JE])PS.AF(F=7FF*W1V8WCV5;LQ?$Q<N@28;.WK76YL%FM%%
M=LL]E0Z$/H6!6SUYSM\ VTRLOYX K.P<PP/GGMO+?D"BK19\B/E0'QA,<4+%
M^!FHEJ01\K*QYCS$W<<6P$E67)]XN1-C)B4+W<"JN_;X-MM0",#@<OY1!A?B
MF%E?-N#]Z%*#.U6)+<W"-6RPG^?V'J3D7UZ&\ V7_TE:30#UL4]S?802("C*
M)\WLNC)J/RJ96FCQ/V35HE,Y.$N:0^43T^B]S1\2B:"\-,[J/\[I;U[O1>7L
MRS[HL3-94VG@P>SV\H("%Z4KZ1HE[?/<[^,L=TG9(*C[H,A&YD ITU>P+I%N
MR;('IPO XHL>J>27W5?:@&7K*YZ!XBNJ4_?5(*CUTHFZ.KJ<*UR-'6.KXZ,8
MH+IUSL=@_/TLG(-CO1,$LXIL93U4\WZ6M:PUW;'L:$%/!UZD0X B$O6!YUE9
MX1KKZ]86.K=:AY1J07TXS<W\]_48B:7/3N8$WB*)ON-SJZ*:1R5S82LK6C_)
MX*];!K;WU(J96A\7D\,&\B*SD;$7+)K,67WO+^A%+JS&N4RB_0R$3@X%Q4X
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M8@FI\[CUK8B> .:Z),F6>2+![ZD\Z,@RICVWT(/SJ  %,+UG9P$)J'G2$$3
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MX[3T"62YOE$UU-VQ\C$=&9<!.]D]A9XX(#T?.'R@DR$)PD5L/?FJ3M4E]6Q
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M.I\[601W?R4?1+'YGQA<<=3$MSVPY5=)67K(S#A<.#'C%[BGI>[U#AF<2_3
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MQ+35%5]"B5^_]8T( CXHT.&.N/YO0PC-OG]5JW];2;,LVB"$$?.B> GDH>N
MU5>K("\EJ\RWW-&*DN(UI?9,9'8QT(H!BX(A?PRZ\K3^Z?BAE]'RSUB&"^RG
M#?DG,M,#<<JGR3.^CC_E/UX[)['X*[[)MM@@:(-;U)R?DB"G2F@ :\?(T#KU
M\=][6@3J_)9=O3]2JD^.?PF"NP#KT1R#& Z:UV84\_=K-JVR+%!H8T(K>SR=
MG(OR<H3>N[/\VB@PDAO:/D\Y>,=X(QTU<R#V4H5_&-2^SSY5V"^ .\[D+SRN
M[-[DZV:;FA__J\C^029UQ#XM^2*ZJ-\6+#5&C\LW0SUQFDI<H#[IX&,4Q=7.
MO2A7T]S#1&XG7]>40!^^KD7R.$L;J*.E(8$0P%6PT+-07VQ"K\X(R4I A1W@
M[>:'$9>4VF*5(/@&$"3+F-\M/@OUR;2*9R5ZCX"($H66(W)\1^P=O"\&*'P<
M39_!K;6W-GWS?'Z-?_VKTA$OO15 L]!*H0O?6$P<1A U\)(YRHQ+6!-+:>@K
MKB<:QMPNF7;-LB2OL8,K;;_$-RZ::/7+%V"D].+SU%&S4 >(72N(Q$=ME[W0
M_-.N!XM" X90X?E&:\CJ0_E:1IU<J0'^4X]]K<SY.X<P#NZ9&?5]$C_L'_B%
MSRZ%2LXR6B?[TBE#-MI?;TT'2]ZPO@;&P8><3!^#3W=D:JN[)_).N6#_8M@J
M!<;O.A.O*9YK>SWB"-\S,PZ/088$G";8ASLT_3:'6CL[9S6RZFJ?">L;&-2_
MK4\E-#G8^'T[*ZALKITX,]=075_[&O@Q?K=J2JVE(>A$@F.#/EYRG*3%;(/=
MO'^'\EB$#3C:)2WWH4F\P5[[C*UFM2JWN&MW&7]I8:]@)0S-\)W<)0 PJ;@C
MBUZQQB'_O? !JVJ!<%"EEJQYP&#W\O=;.XSRJMQR@_?>;S1E*)FKGM?_Z<C=
MP=G9-4)3Q9%WRGA5N:8><@J4B_*)8PZ3G\X($$3(68Y[FE>.N6#5GF1H1_OK
MUWPBA$/?QCO2,JF^>D,TQMK1(]DD#,Y>6:T'%F9Z$9.SZ+'G-43)O[8GP1Z1
M7I(F96F/(&Y]Z0,W3MX040$<G!,M2S;&Y8VXW^09???@78&C,5P8TX.0%INO
M^JAJ&PEVEJ0Z%9^;_;3%#-MVZDC, 4' 2=AKF'B!%2Z-<JGVUR#B7P4:*;@$
MO*@1+V.^Z.C"*BWCM^SU1GZN"!YJ-8RBX61,4\4^](4R4[4UM;SNXH6\F+-_
M;FJ1'WV5O?'XO))3/B2]=BMUY*W *!-]=F*/*YH<=PQN@23'/+P 3Z\Q)<9O
M(]MH[P??>.QF/7L'FPL==W"T5.D>LFXS[,AQZX*#O2"^0Z'L\ZQ3&(/E"_$S
M-L'"H'/$5OSKLT%Y]4HLDA,2S$35NA3D(.7_*:BXKTCOX\&907]E 5(@H#">
M1NI<N#RF* 99%GF[88@&;3,N)D^/A*-'$CFZM(D+]=VPF!:9%GM]&ZD IQ.8
MS.'Y-DR4Z@]01Y_D80N7N63X&$G2!BNJUQ C4>0_-]WDY?B&I@PCGA6^UL^N
MASKM'_*S:8;^+)&&I[4'^\";FX/K8OEX<GUSDLD,0K)@WB[+4K\?9YU5>)<S
MWL1G;D33J-BKQ"!X>!CDA2XQT2H:#72RXP 1RW@?F]F0%>ZCD\ -)WD %"(.
M%-[U %LK7(RTJ+#\W\2\#,>6V'-M-*D*TSN9XPDP_L2J#596]=.#E=L@^/$4
MR0H=B_HC*\2WS=<4\W\Z9GHP^IE4>S>5-K_&9?95"FP7N+#'CT%JKS?J+/4M
MK/05]".O$2^WF0V!XM &M/Z,MKP^@OAICQ$J\W_?&=;J2:R0LHL/+S^?FMT>
MJA='%I<LUWU[AKV5'[,6I?J5*QHMP8J/RYN\#/=OOII\JDW08EV4LZ1%KH&G
M&/&/>P&(P5,%DB&:PEH['0V-5"HN[[WW6[Y4'CL!C7A@*UZ-@[6C\5MD,:I,
MNAZ2>9^?[86(!/5XRMRI_;M["5]V6W=U/8N%UC-R 8R3H=G2VNWUS+%UR;MS
M5"3PC!U2J^5_G%CW0F79$7T9#0G)U W_Y3RB8/#PY9O4WUG^!SY&P!'"C$2Y
M9WXD,B^(5*_+'I9U?5=]5(565-KEP(ZW>'3X$M7GZ%6$(N^AD %_PC)QP4-P
M3%+^T^30=F1:TU^DY^M_I5X':H]W14M\R.NWG3' 5A:Q7;/%P\<5T'GU55,>
M3YHHA@_]B^D+1-W:S(6W.]DQB?P[)&BSCT[S#RACW #^J.KFK4X7KWYH*';R
MNI=9>T?&-='V11%'^A&/O0^05/_[VZ&7O!;Y\7WO3 R S8I5YG)BZ;]X:XV!
MO?B%.7Q8DRE$O(L.;%4\6,+CL\1433( (BKL^L'Z:''B]KUC6OT/V;^T_B+5
M5_K]_'#L?#S^H5U[GU=3?H<N8NAQS:O(@P27/:1\*3,Y\/5 1>!0&6,0:UJ4
M*Y6;F/:,8NF"(F=2JGK=7R0WP3'] HVD-5@E>]&%64,TY<,OK7_LF_3,OJEB
MS]3"#GG0J3-U ,,5NK?#*XUP>A'PJG#!.LD7=-SW.DQ#%4LIL,D#H%*U%P%!
M0U1_!R$YBP(;.SB?N^<EC8 ZBL$N+R6Q;/FAKH]EV?8(1K*F#S_S?6I$1O^A
M=K!L;DTO'<4=TN0F>]L!H8E+$T5L28] -GFA/:/1+^WH$@27\R3UBJ< N0H$
M8P,*8M-5S^A3J7I!Y]YGOWI;C&'$@CA@0BARU&S+"?][H]E^L^++!&N$ 7"
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MQ7M^G$J9![Z( 8E*@$0-.O.<(  1P-?=;T(B/A=&,17Y^H>H0=NJ6P]5';*
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M7F]#H?KBAB :PXB\<OQ4O:O@-*?O^=F8=,3BAS0>:+^>N ME>E&GKMWU5#%
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MR5H:=S^#J&F$,0V7(WZ+9A81[M7FE,-;UA!*\0HSS&W#CV8*LF9*XDXK^#S
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ML;0(Z79?!!X5+OP>$:Q/IV!&-\@NS+KE:9JSZZ6^'X<&ID>I9F/(R23[DG[
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M_Z\(+A[PV/S@ATB07D5,=5'D2C'DFAW=4$=="6@6)RFJ;;>/!QO*PH!]6$X
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METJ<6K*I?: 6;9."^V^BORKD? QE+U']?_PUY/\?_Y\.Z9O)_P-02P,$%
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M6C*%M. SUZCH1@$=E6/0[3T4@$2RHP 29007#R72OQP%'*U!CRGFM)2G[5
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M<Y2<H8&F^X=SG^?<V?O>???,N3-GYOX.?[S/T[VJ:ZUO55=]H>JMKR+V"(K
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MW././O\@S&6^4U"2^;ES96(Z+,0$;^ KZU/LY)4[(M M")GB#B20QX=H+N?
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M(WWPT&KSN87EPD3 "F<\Z/2'Q-0N2=#&^&%W]-BD$H-=,]@L<"\2F=>WT:.
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M05)C>=P92RO^<-HL'C?N9#CMI[.61%<<"\OSN79\F[&_)-[$[D/?O+!&\1C
MU# *W6>X^$=$N)!=6("/PGQ7& WSK=*B0+7::^6YI'&UKT)A[H9)&K0YG*G
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M*O @S]DQLEJ9HMK&Y>% GJL*W\RC0=[T\A*$2LR#P""6[EAG):E8):FD2CF
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M=$N)X%K79T6!OMUT8--7X93A<>=X:B!@OM+B:>=>P]'.*+Z&T4 ]"G=- X&
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MPP!R<H;9?C7J+Q=X^=8-$P8D5?B\@U5$V 2Y'Z1P*['CL7,$DJ225'N5WRV
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M/LGNS3F\ 1*<I*U)JWJRTXB%:6IQB$;=WC&<8[*RHJ&M(_)Q<U](22$GF8]
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M\9FW84P%).:D''J?NR:Q\LP<>XKUQ_$S-Z8$:RC.'7V:W?";H3FU"6]#<L7
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M1*&3LU(_J9COPL)E-1I<$DSNM>PZTV!O=L+YQ_A[I?6K2 V5&VQ>FJ??\DE
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MZE[OGC-=_X[AJML1_!/_A?"K2,OQ5VTNBV8'<LN3E"=YR7]HY=78_I&42"Z
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M683C]HR]05&*:S(0A<.PM5N\\9JO?/LDN@+_-*CRB++=7@\8C*:;T2F9-5^
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MIEL11<+HQT+8V$7]XK+LI8-BHMGF7%LE03PT.TG/B4))C.V'?1N7(G1&\ZW
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M,BVM[?JWK;^2FZT_,**BP61X0( MT\%3Y\QFTB3_J;K/5=:\!UQ\PBEPF;=
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MV%ZE2.>H'#!+28QP^']5/BM^W;$71:2TX:#3M,5''"MQ>"<CJ:>Z>S7JE=5
M11^)3;_RR )6(*E]@77"'$FF&HF?;LSSJRYJ'X7Y4)#OF!OQM.P/&W]$/Q)P
MW/Y9%4<FJ =[/6Y]JB8I\.LXLR)"G.E@V*N.2W-  )RQ)4$]HL9/DN0193[;
M0$3+=E6'@WYI!2HH^(\\@%)2''*4!@ZB*D@6*(Z:S7_PGY")TPD\3KA(4T9/
MVU?0S8" )%-FZ/,5_@/W1DU-Q^,,>GY)E9W 94Z'PK_*Y1C2QK)T]&LU-%L#
MO\_$%K< =X*=QQ2A 2<35E2X_78K^)HYB2()8!%5F3(>%_DGQF08^&W09?6H
MZ3-GGA3$^?>VXY-V-E4%!R^E^-N".^YHB;/NOL<?'EK+4DB:9@ELG!C_ 2V!
MN,"XQERK([.8^D2M)NH"-NB6E^-Q-:7!_3NJWU>_QX6[&A],]UFM4OI(JF!%
M!DF1.AUJ'/4:G'P5[;\DLYGC\M:XRY1JV_%<_+[U"6#L(X)Y5'^Z:,F7S*7R
M.#%_9\3"05LI+MVT]5T+?ZH%6X<%[S6C/ YZT5TSEM>\%T,<4**=CNFI=%AW
MW?@"BV/<;-_UZIK;H#53MKK=F&XIA<Z HLD)H0M=:JNWUHOGO/V;M)0AYM&W
MRZB*2\NM#M1:GCSV'&S'6QZ&@%BR;EP0L<5'CATX@L16?D*Z/Y/JJR0ITA#U
MR^)G87J5$=WF*,"B3/PAA=O-OML$WZY)KJ:*'OY+L 75@6)RTI/9][L)6)_H
M.P;6RGX.V.2X3C-]YJ^^\ *OUO#D$3.F$SI]F'I&GTI-W0[Q2U(4PW_=B#84
M!6'4^2\[I/U_JJ"?!>(9+#'%B"\HWCL+,5(=\<&G>Y.9N^M,F[6RBSX0R[U]
MOGJQ'QOCBQ&"YV"LQN%,B;CVH4MX+;,AJQ'=G!>30-;M!C3>Y:(3CEL#<J+6
M=G/ @[1S/^921F:KH?T/56\.Q4W>9[_&DM$4?FV1NA#JY 0!;-(GEYP*FLL,
MPM/J*J<Y)H],E\6BC(N"IJE?:Q[<I3/B(8V[#QA(+CX)>;09LSW;IB/@XRS^
ML=+3@=93)>#EZBPI)/<6)N4R9IP-9]9K#'SH/&Q<>+A^2+\ZP6B7^\$/4Z:U
MJN#;57/% A+=@95=2I0>GF)W\SKI?+;F& ,<=6/N?1"P$FN*' GTO+O@R3^
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M2, 1 SC("L5 ?O_?68<2[=IODB_S;'()S*C ]&Y2'HE.@SJ9I^8'+_1&G;K
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ME$YN5<X;E)UXW;<6.;UY_DLNA7+4IT^J(S-;0Y)W^U># 8$..U*DUKM:_J)
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MS40<FE;8KXY]"DJ%/<I3H2/8Q.--XT<[(']J#QE[K#T=&#90;:3\0#_.@9L
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M>0"WHJBJ'_&>\* OW!]" KYZB2(!/^M\$>@9L''TK/Z7?60FJ6K5!D'X\4C
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M32-2#S\\PJ.B<E)Q6ZMK$NX\GH=>K7%/1W^STDP.'+?<,;:;<QGX[!U7\/,
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MY8N8N?("A4],F49WU)S/8PH(")X4VZ_"FS*MT3CE21UG!H:5U;<_V0O,N*
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M-D9>!]C\]TJ_$1N6\$^J>[\]FE&NF*6K]J4LMZX+A_!C. MA/C ^]J<<B%7
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M5O#7M$^]N'2:V?^8R9CB;)-\-")8@[BW4N.OS>P$M]"F^LXQP\=))$[.2KI
MQKFT_9^C<&CKVOT/0-*Y?':W_O8H*NO#_AP,;ABAM-"9":EL:.+IT*F<*#Q
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ML@7KPR.:@SFTR7&-CG8ELTA%+!DBY0'&%O7&L9.BH#XL0)*CO@:^M+[VK4*
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MQ#!:6S.(7R"' \Q72O!_PR'+POTG/"55^''DWV)#+1_&MA20/?.[(S+DT8+
MS?I6M6(KW*FA>A:R_Q!W,$S]Z:='=X5O@*H3/+\YSZ<B++&&WI33!YM!W/9K
M/ 7Y.VE6$D,?]W@&/FH0J*%1ZR)[46)G);I_S\0#FN.N[*ZI-#WO:K0I\.>A
M!RS:  'YY!-<K(B5R^2CD7^%78=EH9Z_0VZF[(@]:L"N#GGH7N,/(1;R>N=<
M%R?ZZH,*5=F;;53O\ JG<0<#U?@U2V9'MB6)A\;1\>!"8[%G0]J^X^6MA0<P
MRO0QD!6W.J&[Y>SWK4ZPU-_Z+O]=R:X@9W$.HMK"=:XQ));8ML+1^Y%N_<L9
MV+GG,\I]]5'#:@G%(A0^TZVF#'/_Z9.MFHT9[Q%95T[Q.OH3SH7"SLZM_UXF
M:[SG27S-ZDN9+CMI;QZ.>,WE?N\'X\.4&(B%[0^--FR5PX38^.G:&X# 6_Q(
M,Y@YJ-=;KCGI571T17$ZJ2N&6WY6O\F/+/SC#U%$P+ %2/)0#CWZ.\?&E5Z"
MZ?C7(KM27F] +$NHL:P1[F5[X4><-O9&!VS/+O/MRT>I&;--Q2GV&SVL)>"<
MU&P/$V.XN]O#U.@",B@H@SSS7YA2\.?J(J^T'(8<[OKB)'=+6\GKBD6(P*XF
MKE\!,XESE/./HQ$&\]7E6]T9U AQ78,84,L(_E[^?!8K&7-7^:?0SUYM.4E#
MVDV6W&^R@&?7O]+X/SQM_BX9_+"J. N[^-L1%J7_C"?+4=TT\PV@B]E#9^[V
MQ#MM9B4ZE.OV=)1=JT[97E_H>#1^,E'ED[L:_I$.%Z&^-8(,F>^MLU"\[6?3
M, O_@5>EH48GQ?0L^AEV;JON_'3QW=I->]&HBI][4L@H* \Q&&9O!4+(<0?\
MIJ #M_"[O$]\_V&X72)2@G&5H<!VC5!8;:;1^;MU-9P2<X>K&*[\31W7V-]4
MA*.3X<M*U,<91>*/AX]0!<YKBS+[^M.$$C8NVW%\X\4J6[&AJY"'D[:[)<.B
MO;CO9<G;MGT)CV#!Q3RR+=&LDUP;;A8K4_N$ _)Q3Z_:.,J8"%SQ^\1E!#"&
MKM7&)&>/K%>'AE*;KW9X1I+GCSX90C>W5235QM-$17O =\_N=HR#!8E2\_7V
MA#7)#/8H+<H&7-D!>:I;B*M6<ET1[@:Q4V3=_!PM6"?-@'&E#!LLN@'L85=R
M3>C&DA[&NX(EC O: P70\G'6"CDMHZKQEWE<<C_%O['&!](['D=@#/N 7E1-
M%W%?%YFK5T[JO29_&-0[7\;D/7@#-!HJKEQG2F]%08&U&\!K32I:ZGA!"Z6I
M>@,8\LX5:QZ9O24]ZY"?EQ+.UF1$W@#M[FG4%5-VKN9E\9I357?LB].&^4C=
M&5@(EOG9+T)&E#>\4J/O[21_*\L<>I]M+35+><^[R*W4HSAT@6VP0>N6PQ?G
M"#H2C %4Z@$8YB'\\1>D#U$YX.%FG9R A1'A;$G=MOB@=TD>3\1V/DS3XF2G
M7K IIV' TA@DIC/7/5CVV.8]BTSK,.Y="9$2EC(4RYHRW["X.''H95%.H<<L
M 4D?#8\BVUVVUCY6M. H].VJ#SIT+=S'6??(]3S$I#+L1:52&=,Q?2O!RF=(
M_H8Q?=LN-N#,P%&F2N [SD!SA%4V?%;?_6"!6O5PT&P9<'CFAXQ/U^CV)#:>
MJF)WL:6Y>E>K38//Z<'#JM7*I7Z_#,1*L.(9EKL&([#TY1G].2X(!<][B&KH
M,[#1TQ.;4?]68/*7Z6E$!GU?(Z1WL;]O76JPDSO GY,3/)M=Q][?JO!3'D-1
M-R8L6*3M=8RT2,OLC+2M5-O,W&0!<_-W!PIP>:+%U_X@P(GH+.'6NW9Q7+AD
M^U,E48$3WH.JFK"E)?95?]8[=(YYZK(@ ! !B*9&4 W/IAME<Q9WW&BFOJ6:
MN]L9?JI.,T\BC)F'#*H#W^?/%>EBG", !UA%]'7\T'-T>SEL.Z^ 99T[.UFU
M2PH'58S<'V>&+SW^]L[L..+M9UHW7%<C:>I;\]SEYHN!<B^"8BXIT:K>T]';
M.='E.NX0@C\'^=$:A]9R91 ]Q_!SG)$P#[U^FH-J>)ZB,+5R8KNQJ0V%?G%Q
MD?AD?LKD?P<+9-1X;Y4H8?3:YJCQ##[6E3O;-%3,<K> VCK&6#JK^L=\1NO\
M?-@O*/CAFK@!<=?J%8Q"GBB%#!^Z%:TZ[PE?66%*4"P548V'):6O=7L4C?Q+
M'A^ T_5W<:6&?HUUD=[\A8Y0@66N.$O!@&!LK:'"A;84-(.T[R( U$/GA+&6
M_C]+\PN6]_JOB9%9.DCLKHUZU7#NATJ=ZLF<1:SE<=F(]]6&,M3O9QB?]H*-
M&X\D/^=;T]!-T\A5_(YU%.Z?L<9-WDYM]QZHBCZOZQ%I:P/H6D*7UGO.XZ&J
MLHUI\Z]JDLSJODM+4_4(Q7ZA'Z>+W' ("%JLS7&+EDS)@LQ!&JOA3_ASB@IM
M!LC@W60"= 0K#ED38<?BC/Z2K!-<ZQ6EJ/3\.9V>U)@V@MBO&W$.7[T)XE37
M]7 #)2F7M]/8:V8$1R@-H$%*"ME*+QK(B!\L ,-W$NN+Y9XN,&2H8:P3"W=*
MD7NSK.9='UGG'LS8W[4!;3PT9$I3H2-G(HI&)/X*6[_F7Q4?$N].8SL2RCOC
MT[.*RW9K7^+_9+M.J\FU<&!XSRF*SV\#B?L:9GV&$/LY@K@W?W$DH._:L!\G
MT1K9N_C)G.E, ,.H$?9Z3&J=W25EGA-V$2B(.#F\ <RT0(;IEQNU!L5BR;M@
MB55[FFT*6RNT2,"[:!113HY U)<X7T>Q"G.I3I4G0&MQ@ QR,^W#69]1G%?!
MWH[W7L/>-T(!Q/6#$ #[]7%^WMVLC(V-VPT&6DN__L+KWX+HN0%>+C4=./)#
M^JN/Y>DV\2(WGNT61=U1DV&1*.??Y>R_ED7&ZQWQAMMZ*[FNLS]HJ3Q&#S*-
M PK>U0NUA(]'!I6\.T]_W<(LK1)A)"QEC3&LF>>(*PU:-7&VK?'^#..89,(?
MEXT(A*DJ?]9^%LK01!'I5N+^;6$WA6ZN?AY,@C-_C&OP]$?DHH($,2C*"<V
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MMQ)7"N^,NI =5;U*&'/P@J98(G(L:5)H<[7*QGKT:?F2_;]K#-UV>/]GA0C
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M9K#FY:N,"B. 4I":K)B$F[G?;6'.ER<-0>RZ7- L9A%)B))1GR'',?_ZL#Y
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M,. -4X61N7PG4_\%4$L! A0#%     @ ZX!84M,-_ NA= 0 (PI! !4
M         ( !     &-T;7@M,3!K7S(P,C Q,C,Q+FAT;5!+ 0(4 Q0    (
M .N 6%+#]=RTW!P  *94 0 1              "  =1T! !C=&UX+3(P,C Q
M,C,Q+GAS9%!+ 0(4 Q0    ( .N 6%)OQD;>+1,  .LH 0 5
M  "  =^1! !C=&UX+3(P,C Q,C,Q7V-A;"YX;6Q02P$"% ,4    " #K@%A2
M3J=FXXA%   I9 4 %0              @ $_I00 8W1M>"TR,#(P,3(S,5]D
M968N>&UL4$L! A0#%     @ ZX!84KSGIT@QH   $; ) !4
M ( !^NH$ &-T;7@M,C R,#$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( .N 6%($
M@74_#68  $Q9"  5              "  5Z+!0!C=&UX+3(P,C Q,C,Q7W!R
M92YX;6Q02P$"% ,4    " #K@%A27'NLJQ,A  "!UP  $P
M@ &>\04 8W1M>"UE>#$P,C1?.3DQ+FAT;5!+ 0(4 Q0    ( .N 6%+;,E*@
M3"H  $A> 0 3              "  >(2!@!C=&UX+65X,3 R-5\Y.3(N:'1M
M4$L! A0#%     @ ZX!84@D0@8#= @  L0D  !               ( !7ST&
M &-T;7@M97@R,S%?-BYH=&U02P$"% ,4    " #K@%A2;MVM.H8(  !R0@
M$               @ %J0 8 8W1M>"UE>#,Q,5\Y+FAT;5!+ 0(4 Q0    (
M .N 6%(J*"T BP@  %M"   0              "  1Y)!@!C=&UX+65X,S$R
M7S@N:'1M4$L! A0#%     @ ZX!84MRS*9U8!@  &"<  !
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M+FIP9U!+ 0(4 Q0    ( .N 6%(D.P9;R)$! #AU @ 6              "
M 0DA$ !G>FMK-6HP8W5M;F0P,# P,#@N:G!G4$L! A0#%     @ ZX!84IRF
MA;^5S@  TJ<! !8              ( !!;,1 &=Z:VLU:C!C=6UN9# P,# P
M.2YJ<&=02P$"% ,4    " #K@%A2VSK$9?2; 0#%10( %@
M@ '.@1( 9WIK:S5J,&-U;6YD,# P,#$P+FIP9U!+ 0(4 Q0    ( .N 6%($
M<8 [5)\!  OY 0 6              "  ?8=% !G>FMK-6HP8W5M;F0P,# P
M,3$N:G!G4$L! A0#%     @ ZX!84D]SSM[*$ ( (MX" !8
M ( !?KT5 &=Z:VLU:C!C=6UN9# P,# Q,BYJ<&=02P$"% ,4    " #K@%A2
M4Q9U>I]< 0 H80( %@              @ %\SA< 9WIK:S5J,&-U;6YD,# P
=,#$S+FIP9U!+!08     &0 9 'P&  !/*QD    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
